

Pen Out.

LIBRARY USE ONLY

LAW LIBRARY

JUN 9 1987
FACULTY OF LAW
UNIVERSITY OF TORONTO









ONTARIO REGULATIONS

1986

REGS. 547-763 (end)



Publications Under The Regulations Act

September 27th, 1986

HIGHWAY TRAFFIC ACT

O. Reg. 547/86. Parking. Made-August 28th, 1986. Filed-September 8th, 1986.

REGULATION TO AMEND **REGULATION 477 OF** REVISED REGULATIONS OF ONTARIO, 1980 MADE UNDER THE HIGHWAY TRAFFIC ACT

- 1. Schedule 6 of Appendix A to Regulation 477 of Revised Regulations of Ontario, 1980 is amended by adding thereto the following paragraph:
- 44. On the west side of that part of the King's Highway known as No. 11 and 169 in the Township of Morrison in the Town of Gravenhurst in the District Municipality of Muskoka beginning at a point situate at its intersection with the line between the Township of Muskoka and the Township of Morrison and extending southerly therealong for a distance of 950
 - 2.—(1) Paragraph 4 of Schedule 15 of Appendix A to the said Regulation, as made by section 1 of Ontario Regulation 214/85, is revoked and the following substituted therefor:
- 4. On the north side of that part of the King's Highway known as No. 5 in the Town of Oakville in The Regional Municipality of Halton beginning at a point situate 510 metres measured easterly from its intersection with the easterly limit of the King's Highway known as No. 25 and extending easterly therealong for a distance of 170 metres.
 - (2) Schedule 15 of the said Appendix A is amended by adding thereto the following paragraph:
- 7. On the south side of that part of the King's Highway known as No. 5 in the Town of Oakville in The Regional Municipality of Halton beginning at a point situate 470 metres measured easterly from its intersection with the easterly limit of the King's Highway known as No. 25 and extending easterly therealong for a distance of 130 metres.

- 3. Schedule 77 of Appendix A to the said Regulation, as made by section 1 of Ontario Regulation 694/84, is amended by adding thereto the following paragraph:
- 2. On the west side of that part of the King's Highway known as No. 169 and 11 in the Township of Morrison in the Town of Gravenhurst in the District Municipality of Muskoka beginning at a point situate at its intersection with the line between the Township of Muskoka and the Township of Morrison and extending southerly therealong for a distance of 950 metres.

EDWARD FULTON Minister of Transportation and Communications

Dated at Toronto, this 28th day of August, 1986.

(9378)

HIGHWAY TRAFFIC ACT

O. Reg. 548/86. Stop Signs at Intersections. Made-August 28th, 1986. Filed-September 8th, 1986.

REGULATION TO AMEND **REGULATION 493 OF** REVISED REGULATIONS OF ONTARIO, 1980 MADE UNDER THE HIGHWAY TRAFFIC ACT

- 1. Schedule 70 to Regulation 493 of Revised Regulations of Ontario, 1980 is revoked.
- 2. Schedule 84 to the said Regulation, as made by section 1 of Ontario Regulation 791/84, is revoked and the following substituted therefor:

Schedule 84

1. Highway 52 in the Town of Flamborough in The Regional Municipality of Hamilton-Wentworth at its intersection with the roadway known as Regional Road 97.

2. Southbound on Highway 52. O. Reg. 548/86,

EDWARD FULTON Minister of Transportation and Communications

Dated at Toronto, this 28th day of August, 1986.

(9379)

PLANNING ACT, 1983

O. Reg. 549/86. Zoning Areas-Territorial District of Kenora. Made-August 26th, 1986. Filed-September 11th, 1986.

ORDER MADE UNDER THE PLANNING ACT, 1983

ZONING AREAS—TERRITORIAL DISTRICT OF KENORA

1. In this Order, "mobile home" means a dwelling unit that is designed to be made mobile and constructed or manufactured to provide a residence for one or more persons but does not include a trailer. O. Reg. 549/86, s. 1.

- 2. This Order applies to land in the Territorial District of Kenora, being mining claims PA 781005, PA 781006 and PA 777905. O. Reg. 549/86, s. 2.
- 3. No land to which this Order applies shall hereafter be used and no building or structure shall hereafter be erected or used except in accordance with this Order, but nothing in this Order prevents the use of any land, building or structure for a purpose prohibited by this Order if such land, building or structure was lawfully used for such purpose on the day this Order comes into force. O. Reg. 549/86, s. 3.
- 4. The land to which this Order applies may be used for the location and use thereon of nine mobile homes and buildings and structures normally incidental or subordinate to the use of mobile homes. O. Reg. 549/86, s. 4.
- 5.—(1) Nothing in this Order prevents the reconstruction of any building or structure that is damaged or destroyed by causes beyond the control of the owner if the dimensions of the original building or structure are not increased or its original use altered.
- (2) Nothing in this Order prevents the strengthening or restoration to a safe condition of any building or structure or part of any such building or structure. O. Reg. 549/86, s. 5.

BERNARD GRANDMAÎTRE Minister of Municipal Affairs

Dated at Toronto, this 26th day of August, 1986.

(9404)

Publications Under The Regulations Act

October 4th, 1986

DEVELOPMENT CORPORATIONS ACT

O. Reg. 550/86. Innovation Ontario Corporation. Made—June 26th, 1986. Filed—September 15th, 1986.

REGULATION MADE UNDER THE DEVELOPMENT CORPORATIONS ACT

INNOVATION ONTARIO CORPORATION

- I.—(1) In this Regulation, "Corporation" means the Innovation Ontario Corporation constituted under subsection (2).
- (2) The Innovation Ontario Corporation is hereby constituted on behalf of Her Majesty in right of Ontario as a corporation without share capital with the following objects:
 - To encourage and assist in the acquisition, development and demonstration of technological products, processes and services in Ontario, including, without limiting the generality of the foregoing, the provision of financial assistance and incentives, subject to subsection (4), by way of loans, guarantees or the purchase of shares or other securities.
 - 2. To provide financial, technical, managerial and marketing expertise.
 - 3. To encourage commercial development of research activity based in Ontario.
 - To assist the development of enterprises so as to encourage investment in them by venture capitalists and institutional and other investors.
 - To provide technical and market information to facilitate innovation and technology transfers.
 - 6. To assist Ontario-based enterprises to acquire, through license or joint venture agreements or otherwise, access to foreign technology for the purpose of commercially developing products, processes and services in Ontario.
 - 7. To assist Ontario-based suppliers of technological products and services to meet

long-term procurement requirements of governments and public sector agencies and institutions.

- (3) For the purpose of carrying out its objects, and subject to the Act and this Regulation, the Corporation has the capacity and powers of a natural person.
- (4) The Corporation shall not provide financial assistance in an amount greater than \$250,000, including a guarantee for a loan greater than \$250,000, without the prior approval of the Lieutenant Governor in Council.
- (5) A guarantee of the Corporation is not valid unless it is executed under corporate seal of the Corporation and signed by the Treasurer of Ontario. O. Reg. 550/86, s. 1.
- 2.—(1) The Corporation shall have a board of directors consisting of not fewer than nine and not more than fifteen members to be appointed by the Lieutenant Governor in Council for a term of not more than three years, among whom one shall be a director of the Ontario Development Corporation, one shall be a director of the Northern Ontario Development Corporation, and one shall be a director of the Eastern Ontario Development Corporation.
- (2) The Lieutenant Governor in Council shall designate one of the directors as chairman and one of the directors as vice-chairman.
- (3) The Corporation may pay to those of its directors who are not public servants of Ontario such remuneration and allowances as may be fixed by the Lieutenant Governor in Council.
- (4) At the first meeting of the board of directors, and until otherwise provided for by by-law, a quorum shall be a majority of the directors appointed and, thereafter, a quorum shall be the number of directors that the board designates by by-law.
- (5) The board may make by-laws regulating its proceedings and generally for the conduct and management of the affairs of the Corporation.
- (6) The chairman shall preside at all meetings of the board and, in the chairman's absence or if the office of chairman is vacant, the vice-chairman has all the powers and shall perform all the duties of the chairman. O. Reg. 550/86, s. 2.
- 3. The chief executive officer of the Corporation shall be the person appointed by the Lieutenant Gov-

ernor in Council as chief executive officer of the Development Corporations under section 8 of the Act. O. Reg. 550/86, s. 3.

- 4.—(1) The fiscal year of the Corporation shall commence on the 1st day of April in each year and end on the 31st day of March in the following year.
- (2) Section 132 of the *Business Corporations Act*, 1982 applies with necessary modifications to the Corporation.
- (3) The *Corporations Act* does not apply to the Corporation. O. Reg. 550/86, s. 4.
- 5. The affairs of the Corporation shall be managed and supervised by its board, but the board shall comply with any directions respecting the policies of the Government of Ontario on technology and innovation given to it from time to time in writing by the Minister. O. Reg. 550/86, s. 5.
- 6. No member, officer or employee of the Corporation, or other person acting on behalf of the Corporation, is personally liable for anything done or omitted in good faith in the exercise or purported exercise of the powers conferred by this Regulation. O. Reg. 550/86, s. 6.
- 7.—(1) No act of the Corporation, including any transfer of property to or by the Corporation, is invalid by reason only that the act is not authorized by this Regulation.
- (2) No person is deemed to have notice of the contents of a document concerning the Corporation by reason only that the document is available to the public.
- (3) The Corporation or a guarantor of an obligation of the Corporation may not assert against a person dealing with the Corporation or with a person who has acquired rights from the Corporation that,
 - (a) this Regulation, an order in council, a direction of the Minister, the policies of the Government of Ontario or the by-laws of the Corporation have not been complied with;
 - (b) a person held out by the Corporation as a director, an officer or an agent of the Corporation has not been duly appointed or has no authority to exercise the powers and perform the duties that are the customary business of the Corporation or usual for such director, officer or agent; or
 - (c) a document issued by a director, officer or agent of the Corporation with actual or apparent authority to issue the document is not valid or not genuine,

except where the person has or ought to have, by virtue of a position with or relationship to the Corporation, knowledge to that effect. O. Reg. 550/86, s. 7.

- 8. The Lieutenant Governor in Council may authorize the Corporation to act as agent for the Province of Ontario in respect of programs, projects or matters undertaken or carried out by the Province for the advancement of technology in Ontario. O. Reg. 550/86, s. 8.
- 9. The Corporation may, within a reasonable time after it comes into existence, by any action or conduct signifying its intention to be bound thereby, adopt an oral or written contract made before it came into existence in its name or on its behalf, and upon such adoption,
 - (a) the Corporation is bound by the contract and is entitled to the benefits thereof as if the Corporation had been in existence at the date of the contract and had been a party thereto; and
 - (b) a person who purported to act in the name of or on behalf of the Corporation ceases to be bound by or entitled to the benefits of the contract. O. Reg. 550/86, s. 9.
- 10.—(1) Such employees may be appointed under the *Public Service Act* as are considered necessary for the proper conduct of the business of the Corporation.
- (2) The Corporation may engage persons other than those appointed under subsection (1) to provide professional, technical or other assistance to or on behalf of the Corporation, and may prescribe the duties and other terms of engagement and provide for payment of the remuneration and expenses of such persons. O. Reg. 550/86, s. 10.
- 11.—(1) The moneys required for the purpose of defraying the administrative expenses of the Corporation shall be paid out of the moneys appropriated by the Legislature for the purpose.
- (2) The moneys required for the purposes of subsection 1 (2) shall be paid out of the moneys appropriated therefor by the Legislature.
- (3) All moneys received by the Corporation shall be deposited in one or more accounts of the Corporation in the Province of Ontario Savings Office, one or more chartered banks, one or more trust companies registered under the *Loan and Trust Corporations Act*, and the moneys shall be applied soļely in carrying out the objects of the Corporation.
- (4) All or part of the moneys deposited in an account referred to in subsection (3) shall, on the order of the Lieutenant Governor in Council, be paid into and form part of the Consolidated Revenue Fund. O. Reg. 550/86, s. 11.
- 12. The accounts and financial transactions of the Corporation shall be audited annually by the Provincial Auditor and reports of the audit shall be made to the Corporation and to the Minister. O. Reg. 550/86, s. 12.

13.—(1) The Corporation shall make an annual report to the Minister of all financial assistance and incentives provided under subsection 1 (2) together with the names and addresses of the persons to whom the assistance or incentives are given, and the Minister shall submit the report to the Lieutenant Governor in Council and shall then lay the report before the Assembly if it is in session or, if not, at the next session.

- (2) The Corporation shall, in addition to making an annual report under subsection (1), make such other reports of its affairs and operations to the Minister as the Minister may require. O. Reg. 550/86, s. 13.
- 14.—(1) The Corporation shall terminate on the 30th day of June, 1991 or on such other day thereafter as the Lieutenant Governor in Council may designate.
- (2) On termination, the Corporation shall be wound up and its assets shall, at the direction of the Minister, be.
 - (a) liquidated or sold as a going concern and the proceeds paid into the Consolidated Revenue Fund;
 - (b) transferred to Her Majesty in right of Ontario or to an agency of the Crown. O. Reg. 550/86, s. 14.

PLANNING ACT, 1983

O. Reg. 551/86.

Zoning Areas—City of Cambridge in The Regional Municipality of Waterloo.

Made—September 11th, 1986. Filed—September 17th, 1986.

REGULATION TO REVOKE ONTARIO REGULATION 60/86 MADE UNDER THE PLANNING ACT, 1983

1. Ontario Regulation 60/86 is revoked.

BERNARD GRANDMAİTRE Minister of Municipal Affairs

Dated at Toronto, this 11th day of September, 1986.

(9405)

(9409)

40

40

LAND TRANSFER TAX ACT

O. Reg. 552/86. Forms. Made—September 18th, 1986. Filed—September 18th, 1986.

REGULATION TO AMEND REGULATION 566 OF REVISED REGULATIONS OF ONTARIO, 1980 MADE UNDER THE LAND TRANSFER TAX ACT

1. Forms 7 and 8 of Regulation 566 of Revised Regulations of Ontario, 1980, as made by section 4 of Ontario Regulation 607/83, are revoked and the following substituted therefor:

Form 7

Land Transfer Tax Act



Ministry Revenue Motor Fuels and Tobacco Tax Branch

P.O. Box 625 33 King Street West Oshawa, Ontario L1H 8H9

Statement of Disallowance - LT 104

Issued under section 7 of the Land Transfer Tax Act

Inquiries regarding this Statement of Disallowance should be made to: (416) 433-

| Date of Mailing or Delivery | | |
|-----------------------------|-------------------|--|
| File Number | Date of Statement | |

| in the n | natter of a conveyance or a di | sposition from _ | |
|----------|--------------------------------|------------------|---|
| | to | | |
| of | | | |
| | | | |
| on | day of | 19 | _ registered as Instrument Number (if applicable) |
| | Land | Registry Office | |
| Recond | ciliation of Claim | | |
| | Amount of Refund Claimed . | | \$ |
| Less: | Amount of Refund Disallowed | | \$ |
| | Amount of Refund Approved | | \$ |
| Plus: | Interest to Date of Statement | | \$ |
| | Total Amount Approved for P | avment | \$ |

The following are the reasons for the disallowance of the refund claim:

A cheque covering the "Total Amount Approved for Payment" will follow. Note:

NOTICE OF OBJECTION

NOTICE OF OBJECTION
You have the right to appeal this Statement of Disallowance of your claim by filing an objection with the Minister of Revenue in the prescribed form within 180 days from the date this notice was mailed. For more information or to obtain Notice of Objection forms contact:

Tax Appeals Branch
Ontario Ministry of Revenue
P.O. Box 627
Oshawa, Ontario
L1H 8H5
Phone: (416) 433-6029 in Oshawa
(416) 965-5836 in Toronto
(ask operator for Tax Appeals Branch)

T.M. Rus

T. M. RUSSELL Deputy Minister of Revenue

2296A (84-08)

O. Reg. 552/86, s. 1, part.

Form 8

Land Transfer Tax Act



Ministry of Revenue

Motor Fuels and Tobacco Tax Branch

P.O. Box 625 33 King Street West Oshawa, Ontario L1H 8H9

Notice of Assessment - LT 105

Issued under section 10 of the Land Transfer Tax Act

Inquiries regarding this Assessment should be made to: (416) 433-

| Assessment Number | Date of Mailing or Delivery |
|-------------------|--------------------------------|
| Due Date | |

| In the matter of a conveyance, or a conv | disposition by | | |
|--|--------------------------------|------------------------|---|
| to | | on | |
| of | | | |
| | | | |
| registered as Instrument Number (if | applicable) | Land Registry Office | |
| | | | |
| Value of the consideration/Fair Mar | ket Value of the land describe | ed above \$ | |
| You are hereby assessed the amount | of tax as shown below: | | |
| | Tax payable under subsection | on\$ | |
| | Credit for amount paid on a | ccount \$ | |
| | Unpaid tax | | - |
| | Penalty (if applicable) | \$ | |
| | Interest on unpaid tax and p | penalty to due date \$ | |
| | Amount Payable | s | |

NOTICE OF OBJECTION

You have the right to appeal this Notice of Assessment by filing an objection with the Minister of Revenue in the prescribed form within 180 days from the date this notice was mailed.

this Notice of Assessment to the date of payment.

Note: At the current interest rate, interest continues to accrue at \$

date this notice was mailed.

For more information or to obtain Notice of Objection forms contact:

Tax Appeals Branch
Ontario Ministry of Revenue
P.O. Box 627
Oshawa, Ontario L1H 8H5
Phone: (416) 433-6029 in Oshawa
(416) 965-836 in Toronto
(ask operator for the Tax Appeals Branch)

T.M. Rus

T. M. RUSSELL Deputy Minister of Revenue

2297B (86-05)

per diem from the due date of



Ministry

of Revenue Motor Fuels and Tobacco Tax Branch

P.O. Box 620 33 King Street West Oshawa, Ontario L1H 8E9

Remittance Advice

(Detach and return with payment.)

| Assessment Number | Due Date | |
|-------------------|-----------|--|
| Payment enclosed | Total Due | |
| Ministry use only | | |

O. Reg. 552/86, s. 1. part.

ROBERT NIXON Minister of Revenue

Dated at Toronto, this 18th day of September, 1986.

(9435)

ENVIRONMENTAL ASSESSMENT ACT

O. Reg. 553/86.

Exemption—The Township of Black
River-Matheson—BLAC-TWP-1.

Made—September 12th, 1986.

Filed—September 19th, 1986.

ORDER MADE UNDER THE ENVIRONMENTAL ASSESSMENT ACT

EXEMPTION—THE TOWNSHIP OF BLACK RIVER-MATHESON—BLAC-TWP-1

Having received a request from The Corporation of the Township of Black River-Matheson that an undertaking, namely:

the activity of establishing, operating and maintaining a sanitary sewage system by the Township of Black River-Matheson to serve the Community of Holtyre, and consisting of the repair or replacement of existing sanitary sewers; construction of two sewage pumping stations and a two-cell waste stabilization pond with an outlet to Black River, to be located in the south half of Lot 1, Concession 2, Township of Hislop, District of Cochrane,

be exempt from the application of the Act pursuant to section 29; and

Having been advised by The Corporation of the Township of Black River-Matheson that if the undertaking is subject to the application of the Act, the following injury, damage or interference with the persons and property indicated will occur:

- A. The health of local residents will be interfered with if the malfunctioning private systems are not replaced with the sewage collection and waste treatment system in the near future.
- B. The Township of Black River-Matheson and the Community of Holtyre will be interfered with and damaged by the undue delay required to prepare an environmental assessment for an undertaking which will not have significant adverse environmental effects.

Having weighed such injury, damage or interference against the betterment of the people of the whole or any part of Ontario by the protection, conservation and wise management in Ontario of the environment which would result from the undertaking being subject to the application of the Act;

The undersigned is of the opinion that it is in the public interest to order and orders that the undertak-

ing is exempt from the application of the Act for the following reasons:

- A. The undertaking will provide protection of the health of the residents of the Community of Holtyre.
- B. The undertaking will benefit the natural environment by reducing pollutants in an area where sources of potable water for community use are limited.

This exemption order is subject to the following terms and conditions:

- 1. Construction methods and schedules are to be implemented in consultation with the district and regional offices of the Ministry of the Environment, and will follow the "Environmental Considerations for Planning the Construction of Provincial Sewage and Water Projects" (January, 1985) referred to in Appendix 7 of the Ministry of the Environment Class Environmental Assessment document, Expansion or Upgrading of an Existing Sewage or Water System, which can be found in the public record file established by the Environmental Assessment Branch of the Ministry of the Environment.
- The proponent shall notify the Director of the Environmental Assessment Branch of the date construction commenced and this shall be done, in writing, within 30 days following that date.
- This Order expires on August 31, 1987, if construction has not been commenced. O. Reg. 553/86.

JAMES BRADLEY
Minister of the Environment

(9436)

40

ENVIRONMENTAL ASSESSMENT ACT

O. Reg. 554/86.

Exemption—Municipality of
Metropolitan Toronto and Toronto
Transit Commission—TTC-2.
Made—September 12th, 1986.
Approved—September 12th, 1986.
Filed—September 19th, 1986.

ORDER MADE UNDER THE ENVIRONMENTAL ASSESSMENT ACT

EXEMPTION—MUNICIPALITY OF
METROPOLITAN TORONTO AND TORONTO
TRANSIT COMMISSION—TTC-2

Having received a request from The Municipality of Metropolitan Toronto and the Toronto Transit Commission that an undertaking, namely:

The activity of designing, constructing and operating a 250 bus garage and maintenance facility to be known as Arrow Road Garage,

be exempt from the application of the Act pursuant to section 29; and

Having been advised by The Municipality of Metropolitan Toronto and the Toronto Transit Commission that if the undertaking is subject to the application of the Act, the following injury, damage or interference with the persons and property indicated will occur:

- A. The Toronto Transit Commission and the public will be interfered with by the preparation of an environmental assessment for an undertaking which will have insignificant adverse environmental effects;
- B. The public will be interfered with and possibly damaged in that the level of service available is restricted by existing inadequate garage facilities; and
- C. Employment opportunities which will arise out of the construction of the undertaking and the provision of equipment for it will be delayed by obtaining approval,

Having weighed such injury, damage or interference against the betterment of the people of the whole or any part of Ontario by the protection, conservation and wise management in Ontario of the environment which would result from the undertaking being subject to the application of the Act;

The undersigned is of the opinion that it is in the public interest to order and orders that the undertaking is exempt from the application of the Act for the following reasons:

- A. The undertaking will provide a needed transportation facility in an area designated as being appropriate for industrial development;
- B. The undertaking and the development expected to result from it will provide significant employment opportunities contributing to the economic well-being of the Region and the Province as a whole;
- C. An enclosed bus garage and maintenance facility is unlikely to have any detrimental effects on the environment;
- There is no significant public opposition to the project; and

E. The site of the proposed facility is owned by the Toronto Transit Commission, is zoned to permit the undertaking, and has adequate municipal services to accommodate the undertaking.

This exemption order is subject to the following terms and conditions:

- Where an activity which otherwise would be exempt under this order is being carried out as or is part of an undertaking for which an environmental assessment has been accepted and approval to proceed received, the activity shall be carried out in accordance with any terms or conditions in the approval to proceed as well as the conditions of this order.
- 2. Where any activity which is the subject of this order is being carried out as or is part of another undertaking which is the subject of an exemption order under the Act, the activity exempt under this order shall be carried out in accordance with any terms or conditions in the other exemption order as well as the conditions in this order.
- The Toronto Transit Commission shall advise the Director of the Environmental Assessment Branch in writing of the date construction commences, not more than 30 days after that date.
- This order shall expire on July 1, 1987 if construction of this facility has not begun by that date. O. Reg. 554/86.

JAMES BRADLEY
Minister of the Environment

(9437)

40

ONTARIO PLACE CORPORATION ACT

O. Reg. 555/86. Fees. Made—September 2nd, 1986. Approved—September 19th, 1986. Filed—September 19th, 1986.

REGULATION TO AMEND
REGULATION 732 OF
REVISED REGULATIONS OF
ONTARIO, 1980
MADE UNDER THE
ONTARIO PLACE CORPORATION
ACT

1. Clause 1 (e) of Regulation 732 of Revised Regulations of Ontario, 1980,

- as remade by section 1 of Ontario Regulation 398/85, is revoked and the following substituted therefor:
- (e) "winter season" means the period from and including the 8th day of September, 1986 to and including the 13th day of May, 1987.
- 2. Clauses 2 (10) (a) and (b) of the said Regulation, as remade by section 1 of Ontario Regulation 635/85, are revoked and the following substituted therefor:
 - (a) for each adult, \$5.00;
 - (b) for each junior, \$4.25;

ONTARIO PLACE CORPORATION:

V. J. COOPER General Manager

T. CURTIS Secretary Treasurer

Dated at Toronto, this 2nd day of September, 1986.

(9438)

HEALTH DISCIPLINES ACT

O. Reg. 556/86. Nursing. Made-August 20th, 1986. Approved-September 19th, 1986. Filed-September 19th, 1986.

REGULATION TO AMEND **REGULATION 449 OF** REVISED REGULATIONS OF ONTARIO, 1980 MADE UNDER THE HEALTH DISCIPLINES ACT

- 1. Subsection 25 (2) of Regulation 449 of Revised Regulations of Ontario, 1980 is revoked and the following substituted therefor:
- (2) On and after the 1st day of January, 1987 but before the 1st day of July, 1987, the fee for writing an examination set by the Canadian Nurses Association Testing Service for registration as a nurse is \$118.
- (3) On and after the 1st day of July, 1987, the fee for writing an examination set by the Canadian Nurses Association Testing Service for registration as a nurse is \$128. O. Reg. 556/86, s. 1.
 - 2. Section 26 of the said Regulation, as remade by section 2 of Ontario Regulation 144/85, is amended by adding thereto the following subsections:

- (2) On and after the 1st day of January, 1987 but before the 1st day of June, 1987, the fee for writing an examination set by the Canadian Nurses Association Testing Service for registration as a nursing assistant is
- (3) On and after the 1st day of June, 1987, the fee for writing an examination set by the Canadian Nurses Association Testing Service for registration as a nursing assistant is \$98. O. Reg. 556/86, s. 2.

COUNCIL OF THE COLLEGE OF NURSES OF ONTARIO:

> JOSELINE SIKORSKI President

MARGARET RISK Executive Director

Dated at Toronto, this 20th day of August, 1986.

(9439)40

HEALING ARTS RADIATION PROTECTION ACT

O. Reg. 557/86.

Hospitals Prescribed for the Installation and Operation of Computerized Axial Tomography Scanners. Made—September 19th, 1986. Filed—September 19th, 1986.

REGULATION TO AMEND **ONTARIO REGULATION 344/84** MADE UNDER THE HEALING ARTS RADIATION PROTECTION ACT

- 1.—(1) Item 39 of the Table to section 1 of Ontario Regulation 344/84, as remade by section 1 of Ontario Regulation 237/86, is revoked and the following substituted therefor:
- 39. Grey Bruce Regional Health Centre
- (2) The said Table, as remade by section 1 of Ontario Regulation 237/86, is amended by adding thereto the following items:
- 40. General Hospital, Sault Ste. Marie

York County Hospital, 41. Newmarket

40

(9440)

2178

Publications Under The Regulations Act

October 11th, 1986

HEALTH INSURANCE ACT

O. Reg. 558/86. General. Made—September 19th, 1986. Filed—September 22nd, 1986.

REGULATION TO AMEND REGULATION 452 OF REVISED REGULATIONS OF ONTARIO, 1980 MADE UNDER THE HEALTH INSURANCE ACT

- (1) Part I of Schedule 9 to Regulation 452 of Revised Regulations of Ontario, 1980 is amended by adding thereto the following item:
- 2a. Belleville Quinte Physiotherapy Clinic
- (2) Item 34 of Part I of the said Schedule 9 is revoked.
- (3) Part I of the said Shedule 9 is further amended by adding thereto the following item:

39a. North York North East Physiotherapy
Services

(4) Item 41 of Part I of the said Schedule 9, as remade by subsection 1 (2) of Ontario Regulation 78/86, is revoked.

(9441)

HEALTH INSURANCE ACT

O. Reg. 559/86. General. Made—September 19th, 1986. Filed—September 22nd, 1986.

REGULATION TO AMEND REGULATION 452 OF REVISED REGULATIONS OF ONTARIO, 1980 MADE UNDER THE HEALTH INSURANCE ACT 1. Item 1 of Part I of Schedule 9 to Regulation 452 of Revised Regulations of Ontario, 1980, as remade by subsection 1 (1) of Ontario Regulation 78/86, is revoked and the following substituted therefor:

1. Aurora Coxwell Physiotherapy
Centre

(9442)

4.1

PLANNING ACT, 1983

O. Reg. 560/86.
Restricted Areas—County of Simcoe,
Township of Nottawasaga.
Made—September 18th, 1986.
Filed—September 22nd, 1986.

REGULATION TO AMEND REGULATION 675 OF REVISED REGULATIONS OF ONTARIO, 1970 MADE UNDER THE PLANNING ACT, 1983

- Regulation 675 of Revised Regulations of Ontario, 1970 is amended by adding thereto the following section:
- 242.—(1) Notwithstanding any other provision of this Order, the building existing on the land described in subsection (2) on the day this Order comes into force may be used for a single-family dwelling, and buildings and structures accessory thereto may be erected and used on the land, if the following requirements are met:

Minimum front yard 7.6 m

7.6 metres

Minimum side yards

- 3 metres on one side and
- 1.2 metres on the other side

Maximum height of

9.1 metres

Minimum ground floor area of single-family dwelling

single-family dwelling

one storey—93 square metres one and one-half storeys or more—69.8 square metres

(2) Subsection (1) applies to that parcel of land in the Township of Nottawasaga in the County of Simcoe, being that part of Lot 19 in Concession III more particularly described as follows:

Commencing at the northeast corner of the said Lot 19;

Thence westerly along the northerly limit 264 feet to a point in the said northerly limit;

Thence southerly parallel with the easterly limit of the said Lot 165 feet to a point;

Thence easterly 264 feet to a point in the easterly limit of the said Lot;

Thence northerly along the said easterly limit 165 feet, more or less, to the point of commencement. O. Reg. 560/86, s. 1.

L. J. FINCHAM
Director
Plans Administration Branch
Central and Southwest
Ministry of Municipal Affairs

Dated at Toronto, this 18th day of September, 1986.

(9443)

PLANNING ACT, 1983

O. Reg. 561/86.
Restricted Areas—County of Simcoe,
Township of Nottawasaga.
Made—September 16th, 1986.
Filed—September 22nd, 1986.

REGULATION TO AMEND REGULATION 675 OF REVISED REGULATIONS OF ONTARIO, 1970 MADE UNDER THE PLANNING ACT, 1983

1. Regulation 675 of Revised Regulations of Ontario, 1970 is amended by adding thereto the following section:

243.—(1) Notwithstanding any other provision of this Order, a single-family dwelling and buildings and structures accessory thereto may be erected and used on the land described in subsection (2) if the following requirements are met:

Minimum front yard 7.6 metres

Minimum side yards 3 metres on one side

and 1.2 metres on the other

side

9.1 metres

Maximum height of

Minimum ground floor area of single-family dwelling

single-family dwelling

one storey—93 square metres one and one-half storeys or more—69.8 square metres

(2) Subsection (1) applies to that parcel of land in the Township of Nottawasaga in the County of Simcoe, being that part of Lot 23 in Concession I described as follows:

Commencing at a point on the easterly side of the Warrington Road, which Road is parallel with and adjoins the easterly limit of the Canadian National Railway distant 330 feet northwesterly from the northwest corner of Village Lot 28 on the east side of Front Street in the Village of Warrington as laid out by William Gibbard, P.L.S., on part of said Township Lot 23;

Thence northeasterly at right angles to said Warrington Road 330 feet;

Thence northwesterly parallel to said Warrington Road 264 feet;

Thence southwesterly at right angles to said Warrington Road 330 feet to the easterly limit of said Warrington Road;

Thence southeasterly along said costerly limit of Warrington Road 264 feet, more or less, to the point of commencement and containing two acres more or less. O. Reg. 561/86, s. 1.

L. J. FINCHAM
Director
Plans Administration Branch
Central and Southwest
Ministry of Municipal Affairs

Dated at Toronto, this 16th day of September, 1986.

(9444) 41

PARKWAY BELT PLANNING AND DEVELOPMENT ACT

O. Reg. 562/86.

County of Halton (now The Regional Municipality of Halton), City of Burlington.

Made—September 18th, 1986. Filed—September 22nd, 1986.

REGULATION TO AMEND ONTARIO REGULATION 482/73 MADE UNDER THE PARKWAY BELT PLANNING AND DEVELOPMENT ACT

1. Ontario Regulation 482/73 is amended by adding thereto the following section:

124.—(1) The land described in subsection (2) may be used for a single-family dwelling and buildings and structures accessory thereto if the following requirements are met:

Minimum distance of any building or structure from the centre line of Old York Road

23 metres

Minimum side yards

1.5 metres

Minimum rear vard

45 metres

Minimum floor area of single-family dwelling

one storey—112 square metres

one and one-half storeys
—126 square metres
two storeys—140 square
metres

split level—117 square

metres

Maximum height of single-family dwelling

two storeys

(2) Subsection (1) applies to that parcel of land in the City of Burlington in The Regional Municipality of Halton, formerly in the Township of East Flamborough in the County of Halton, being that part of Lot 13 in Concession II designated as Parts 1 and 2 on a Plan deposited in the Land Registry Office for the Registry Division of Halton (No. 20) as Number 20R-6126. O. Reg. 562/86, s. 1.

L. J. FINCHAM
Director
Plans Administration Branch
Central and Southwest
Ministry of Municipal Affairs

Dated at Toronto, this 18th day of September, 1986.

(9445) 41

NIAGARA ESCARPMENT PLANNING AND DEVELOPMENT ACT

O. Reg. 563/86.
Designation of Area of Development Control.
Made—September 15th, 1986.

Filed-September 22nd, 1986.

REGULATION TO AMEND REGULATION 683 OF REVISED REGULATIONS OF ONTARIO, 1980 MADE UNDER THE NIAGARA ESCARPMENT PLANNING AND DEVELOPMENT ACT

- Paragraph 19 of the Schedule to Regulation 683 of Revised Regulations of Ontario, 1980 is revoked and the following substituted therefor:
- 19. In the Township of Sarawak in the County of Grey, described as follows:

Beginning at the intersection of the southerly boundary of the Township of Sarawak and the southerly prolongation of the westerly limit of Park Lot 85 of the Town Plot of Brook;

Thence northerly to and along the westerly limit of Park Lots 85 to 102, both inclusive, of the said Town Plot to the southerly limit of Pennefather Street:

Thence westerly along the said southerly limit to the westerly limit of Park Street;

Thence northerly along the said westerly limit to the northerly limit of Park Lot 57 of the said Town Plot;

Thence westerly along the northerly limit of the said Park Lot 57 to the northwesterly angle of the said Park Lot;

Thence northerly and parallel with the westerly limit of Lot 10 in Concession II of the Township of Sarawak to the southerly limit of the right-of-way of the Canadian National Railways;

Thence westerly along the southerly limit of the said right-of-way to the westerly limit of the said Concession II;

Thence northerly along the westerly limit of Lots 11, 12, 13, 14 and 15 in the said Concession to the northwesterly angle of the said Lot 15;

41

Thence easterly along the northerly limit of Lot 15 in Concessions II and III to the westerly high-water mark of Owen Sound;

Thence northerly along the said westerly high-water mark to intersect the easterly prolongation of the southerly limit of Balmy Beach Road in Lot 17 of the said Concession III;

Thence westerly to and along the southerly limit of Balmy Beach Road and the said southerly limit prolonged to the westerly limit of Grey County Road Number 1;

Thence northerly along the westerly limit of the said County Road to the northerly limit of Lot 17 in Concession II;

Thence westerly along the northerly limit of the said Lot to the centre line of the said Concession;

Thence northerly along the said centre line to the northerly limit of Lot 22 in the said Concession;

Thence westerly along the northerly limit of the said Lot 22 to the northwesterly angle of the said Lot;

Thence northerly to and along the easterly limit of Concession I to the northeasterly angle of Lot 27 in the said Concession;

Thence westerly along the northerly limit of the said Lot 27 500 metres to a point;

Thence northerly to and along the easterly limit of the westerly half of Lot 28 in the said Concession to the northerly limit of the said Lot;

Thence westerly along the northerly limit of the said Lot and the westerly prolongation of the said northerly limit to the westerly boundary of the Township of Sarawak;

Thence southerly along the said westerly boundary to the southerly boundary of the said Township;

Thence easterly along the said southerly boundary to the place of beginning.

BERNARD GRANDMAÎTRE
Minister of Municipal Affairs

Dated at Toronto, this 15th day of September, 1986.

GENERAL WELFARE ASSISTANCE ACT

O. Reg. 564/86. Indian Bands. Made—September 19th, 1986. Filed—September 22nd, 1986.

REGULATION TO AMEND
REGULATION 442 OF
REVISED REGULATIONS OF
ONTARIO, 1980
MADE UNDER THE
GENERAL WELFARE ASSISTANCE
ACT

1. The Schedule to Regulation 442 of Revised Regulations of Ontario, 1980, as amended by section 1 of Ontario Regulation 122/82, subsection 1 (2) of Ontario Regulation 572/82, section 1 of Ontario Regulation 822/84 and section 1 of Ontario Regulation 352/85, is further amended by adding thereto the following items:

95. Pic Mobert Band

96. Sachigo Lake Band

(9447)

GAME AND FISH ACT

O. Reg. 565/86.

Hunting on Designated Crown Land and in Provincial Parks.

Made—September 19th, 1986.

Filed—September 22nd, 1986.

REGULATION TO AMEND REGULATION 422 OF REVISED REGULATIONS OF ONTARIO, 1980 MADE UNDER THE GAME AND FISH ACT

- 1. Section 2 of Regulation 422 of Revised Regulations of Ontario, 1980, as remade by section 1 of Ontario Regulation 516/85, is amended by striking out "2" in the third line and inserting in lieu thereof "3".
- 2. Clause 6 (1) (a) of the said Regulation is revoked.

(9446)

2182

- 3. Subsection 12 (1) of the said Regulation is amended by striking out "2" in the second line.
- 4. Section 13 of the said Regulation, as amended by section 2 of Ontario Regulation 10/86, is further amended by striking out "2" in the second line.
- 5. Schedule 2 to the said Regulation is revoked.

(9448)

PROVINCIAL PARKS ACT

O. Reg. 566/86.
Designation of Parks.
Made—September 19th, 1986.
Filed—September 22nd, 1986.

REGULATION TO AMEND REGULATION 821 OF REVISED REGULATIONS OF ONTARIO, 1980 MADE UNDER THE PROVINCIAL PARKS ACT

1. Schedule 28 of Appendix B to Regulation 821 of Revised Regulations of Ontario, 1980 is revoked.

(9449)

HIGHWAY TRAFFIC ACT

O. Reg. 567/86. Speed Limits. Made—September 15th, 1986. Filed—September 23rd, 1986.

REGULATION TO AMEND REGULATION 490 OF REVISED REGULATIONS OF ONTARIO, 1980 MADE UNDER THE HIGHWAY TRAFFIC ACT

I.—(1) Paragraphs 1 and 2 of Part 3 of Schedule 3 to Regulation 490 of Revised Regulations of Ontario, 1980 are revoked and the following substituted therefor: Middlesex-

Twp. of

London

That part of the King's Highway known
 as No. 4 in the Township of London in
 the County of Middlesex lying between a
 point situate 685 metres measured
 northerly from its intersection with the
 centreline of the roadway known as
 Fanshawe Park Road in the City of
 London and a point situate 305 metres
 measured southerly from its intersection
 with the southerly limit of the road
 allowance between concessions 6 and 7.

Middlesex-

41

Twps. of London and Biddulph

2. That part of the King's Highway known as No. 4 in the County of Middlesex lying between a point situate 610 metres measured northerly from its intersection with the northerly limits of the road allowance between concessions 6 and 7 in the Township of London and a point situate 600 metres measured southerly from its intersection with the northerly limit of the roadway known as Middlesex Road 47 in the Township of Biddulph.

(2) Paragraph 1 of Part 5 of the said Schedule 3 is revoked and the following substituted therefor:

Middlesex-

Twp. of London

41

1. That part of the King's Highway known as No. 4 in the Township of London in the County of Middlesex lying between a point situate 305 metres measured southerly from its intersection with the southerly limits of the road allowance between concessions 6 and 7 and a point situate 610 metres measured northerly from its intersection with the northerly limits of the said road allowance.

(3) Part 5 of the said Schedule 3 is amended by adding thereto the following paragraph:

Middlesex—
Twp. of
Biddulph

19. That part of the King's Highway known as No. 4 in the Township of Biddulph in the County of Middlesex lying between a point situate 185 metres measured southerly from its intersection with the northerly limit of the roadway known as Middlesex Road 47 and a point situate 600 metres measured southerly from its intersection with the northerly limit of the roadway known as Middlesex Road 47.

(4) Paragraph 2 of Part 6 of the said Schedule 3 is revoked and the following substituted therefor: Middlesex-

Twp. of

Biddulph

2. That part of the King's Highway known as No. 4 in the Township of Biddulph in the County of Middlesex beginning at a point situate at its intersection with the northerly limits of the roadway known as Middlesex Road 47 and extending southerly therealong for a distance of 185 metres.

2. Part 3 of Schedule 4 to the said Regulation is amended by adding thereto the following paragraphs:

Brant-Twp. of South **Dumfries**

Regional Municipality of Hamilton-Wentworth-Town of

7. That part of the King's Highway known as No. 5 in the Township of South Dumfries in the County of Brant lying between a point situate 1260 metres measured easterly from its intersection with the easterly limit of the roadway known as Brant County Road 13 and a point situate 585 metres measured westerly from its intersection with the easterly limit of the King's Highway known Flamborough as No. 6 in the Town of Flamborough in The Regional Municipality of Hamilton-Wentworth.

Regional Municipality of Hamilton-Wentworth-

Town of Flamborough

8. That part of the king's Highway known as No. 5 in the Town of Flamborough in The Regional Municipality of Hamilton-Wentworth lying between a point situate 545 metres measured easterly from its intersection with the easterly limit of the King's Highway known as No. 6 and a point situate 990 metres measured westerly from its intersection with the easterly limit of the roadway known as Mill Street.

3. Part 3 of Schedule 5 to the said Regulation is amended by adding thereto the following paragraph:

Regional Municipality of Hamilton-Wentworth-

Town of Flamborough

Wellington-

Twp. of Puslinch 27. That part of the King's Highway known as No. 6 in the Town of Flamborough in The Regional Municipality of Hamilton-Wentworth lying between a point situate 345 metres measured northerly from its intersection with the northerly limit of the King's Highway known as No. 5 and a point situate 550 metres measured southerly from its intersection with the northerly limit of the roadway known as Wellington County Road No. 36 in the Township of Puslinch in the County of Wellington.

4. Part 3 of Schedule 10 to the said Regulation is amended by adding thereto the following paragraphs:

Regional Municipality of Waterloo-City of Cambridge

Regional Municipality of Hamilton-Wentworth-

Town of Flamborough

10. That part of the King's Highway known as No. 8 in the Township of North Dumfries in The Regional Municipality of Waterloo lying between a point situate 2250 metres measured easterly from its intersection with the easterly limit of the roadway known as Waterloo Regional Road No. 97 and a point situate at its intersection with the west junction of the King's Highway known as No. 8 and 52 in the Town of Flamborough in The Regional Municipality of Hamilton-Wentworth.

Regional Municipality of Hamilton-Wentworth-

Town of Flamborough

11. That part of the King's Highway Known as No. 8 and 52 in the Town of Flamborough in The Regional Municipality of Hamilton-Wentworth lying between a point situate at its intersection with the west junction of the King's Highway known as No. 8 and the King's Highway known as No. 52 and a point situate at its intersection with the east junction of the said King's Highways.

Regional Municipality of Hamilton-Wentworth-

Town of Flamborough

12. That part of the King's Highway known as No. 8 in the Town of Flamborough in The Regional Municipality of Hamilton-Wentworth lying between a point situate at its intersection with the east junction of the King's Highway known as No. 8 and 52 and a point situate 145 metres measured westerly from its intersection with the westerly limit of the roadway known as Middleton Road.

5. Part 3 of Schedule 255 to the said Regulation is amended by adding thereto the following paragraphs:

Regional Municipality of Hamilton-Wentworth-

Town of Flamborough

2. That part of the King's Highway known as No. 52 in the Town of Flamborough Regional Municipality The Hamilton-Wentworth lying between a point situate at its intersection with the southerly limit of the roadway known as the Gore Road and a point situate at its intersection with the northerly limit of the roadway known as Hamilton-Wentworth Regional Road No. 97.

Regional Municipality of Hamilton-Wentworth-

Town of Flamborough

3. That part of the King's Highway known as No. 8 and 52 in the Town of Flamborough in The Regional Municipality of Hamilton-Wentworth lying between a point situate at its intersection with the west junction of the King's Highway known as No. 8 and the King's Highway known as No. 52 and a point situate at its intersection with the east junction of the said King's Highways.

Regional Municipality of Hamilton-Wentworth-

Town of

4. That part of the King's Highway known as No. 52 in the Town of Flamborough in The Regional Municipality of Hamilton-Wentworth lying between a point situate at its intersection with the east junction of the King's Highway Flamborough known as No. 8 and 52 and a point situate at its intersection with the roadway known as Hamilton-Wentworth Regional Road No. 299.

> EDWARD FULTON Minister of Transportation and Communications

Dated at Toronto, this 15th day of September, 1986.

(9451)41

EMPLOYMENT STANDARDS ACT

O. Reg. 568/86. Amending Certain Regulations. Made—September 24th, 1986. Filed—September 25th, 1986.

REGULATION TO REVOKE AND AMEND CERTAIN REGULATIONS MADE UNDER THE EMPLOYMENT STANDARDS ACT

- 1. Regulation 281 of Revised Regulations of Ontario, 1980 and Ontario Regulation 803/83 are revoked.
- 2.—(1) Section 3 of Regulation 283 of Revised Regulations of Ontario, 1980. as remade by section 1 of Ontario Regulation 39/85, is revoked and the following substituted therefor:
- 3.-(1) For the work week in which the 1st day of October, 1986 occurs and thereafter, a contract or arrangement for the services of a domestic or nanny shall provide that the wages for such service shall not be less than,
 - (a) \$35 a day;
 - (b) \$191 a week; or
 - (c) \$823 a month.
- (2) For the work week in which the 1st day of October, 1986 occurs and thereafter, in the absence of a contract or arrangement described in subsection (1), a householder shall pay a domestic or nanny not less than \$4.35 per hour. O. Reg. 568/86, s. 2 (1).

- (2) Section 4 of the said Regulation, as remade by section 1 of Ontario Regulation 75/84, is revoked and the following substituted therefor:
- 4. For the work week in which the 1st day of October, 1986 occurs and thereafter, where meals or room or both are taken into account by a householder in calculating the minimum wage of a domestic or nanny, the maximum amount at which meals or room or both shall be valued for the purposes of determining if the minimum wage prescribed has been paid to the person shall be as follows:
- 1. Room

\$20 a week where the room is private and \$10 a week where the room is not private.

2. Meals

\$1.70 a meal and not more than \$35 a week.

3. Both room and meals

\$55 a week where the room is private and \$45 a week where the room is not private.

O. Reg. 568/86, s. 2 (2).

- (3) Subsection 5 (5) of the said Regulation, as remade by section 2 of Ontario Regulation 39/85, is revoked and the following substituted therefor:
- (5) For the work week in which the 1st day of October, 1986 occurs and thereafter, where no compensating time is given as prescribed by subsection (4) and notwithstanding section 3, the householder shall pay to the domestic or nanny a minimum wage of not less than \$6.53 per hour for each hour duties are performed by the domestic or nanny during a free period. O. Reg. 568/86, s. 2 (3).
 - (4) Subsection 5a(1) of the said Regulation, as made by section 3 of Ontario Regulation 39/85, is revoked and the following substituted therefor:
- (1) For the work week in which the 1st day of October, 1986 occurs and thereafter, where a domestic or nanny who does not reside in the residence of the householder performs duties for the householder in excess of forty-four hours in a week, the householder, notwithstanding section 3, shall pay to the domestic or nanny a minimum wage of not less than \$6.53 per hour for each hour duties are performed in excess of fortyfour hours. O. Reg. 568/86, s. 2 (4).
 - (5) Notwithstanding subsections (1), (2), (3) and (4), Regulation 283 of Revised Regulations of Ontario, 1980, as it read on the 1st day of July, 1986, shall be deemed to continue to have effect to

and including the work week immediately preceding the work week in which the 1st day of October, 1986 occurs.

- 3.—(1) Section 3 of Regulation 284 of Revised Regulations of Ontario, 1980, as remade by section 1 of Ontario Regulation 307/85, is revoked and the following substituted therefor:
- 3. Subject to section 4, every employer shall pay a minimum wage of not less than,
 - (a) \$3.50 an hour to an employee who is a student under eighteen years of age where the weekly hours of the student are not in excess of twenty-eight hours or where the student is employed during a school holiday; and
 - (b) \$4.35 an hour to an employee other than an employee mentioned in clause (a). O. Reg. 568/86, s. 3 (1).
 - (2) Section 5 of the said Regulation, as amended by section 2 of Ontario Regulation 241/81, section 2 of Ontario Regulation 342/84 and section 2 of Ontario Regulation 307/85, is revoked and the following substituted therefor:
- 5. Where housing accommodation, room or meals are taken into account by an employer in calculating the minimum wage of an employee, the maximum amount at which such housing accommodation, room or meals shall be valued shall be as follows:
- Serviced housing accommodation

\$63 a week.

2. Housing accommodation

\$47 a week.

3. Room

\$20 a week where the room is private and \$10 a week where the room is not private.

4. Meals

\$1.70 a meal and not more than \$35 a week.

5. Both room and meals

\$55 a week where the room is private and \$45 a week where the room is not private.

O. Reg. 568/86, s. 3 (2).

- (3) This section comes into force on the 1st day of January, 1987.
 - 4.—(1) Section 6 of Regulation 285 of Revised Regulations of Ontario, 1980 is amended by striking out "or" at the

- end of clause (i), by inserting "or" at the end of clause (j) and by adding thereto the following clause:
- (k) as an ambulance driver, ambulance driver's helper or first-aid attendant on an ambulance.
- (2) Subsections 9 (1) and (2) of the said Regulation, as remade by section 1 of Ontario Regulation 802/83, are revoked and the following substituted therefor:
- (1) For the work week in which the 1st day of October, 1986 occurs and thereafter, an employer shall pay not less than the minimum wage hereinafter prescribed:
 - To an employee who is a student under eighteen years of age where the weekly hours of the student are not in excess of twentyeight hours or where the student is employed during a school holiday, \$3.50 an hour.
 - To an employee who is a learner during the first month of employment as a learner, \$4.25 an hour.
 - 3. To an employee who serves liquor directly to a customer, guest, member or patron in premises for which a licence or in a place for which a permit has been issued under the *Liquor Licence Act*, \$3.85 an hour.
 - 4. For the services of a hunting or fishing guide, \$21.75 for less than five consecutive hours in a day and \$43.50 for five or more hours in a day whether or not the hours are consecutive.
 - 5. To an employee other than one to whom paragraph 1, 2, 3 or 4 applies, \$4.35 an hour.
- (2) For the work week in which the 1st day of October, 1986 occurs and thereafter, where meals or room or both are taken into account by an employer in calculating the minimum wage of an employee, the maximum amount at which meals or room or both shall be valued for the purposes of determining if the minimum wage prescribed has been paid to the person shall be as follows:
- 1. Room

\$20 a week where the room is private and \$10 a week where the room is not private.

2. Meals

\$1.70 a meal and not more than \$35 a week.

Both room and meals

\$55 a week where the room is private and \$45 a week where the room is not private.

O. Reg. 568/86, s. 4 (2).

(3) Notwithstanding subsection (2), section 9 of Regulation 285 of Revised Regulations of Ontario, 1980, as it read on the 1st day of July, 1986, shall be deemed to continue to have effect to and including the work week immediately preceding the work week in which the 1st day of October, 1986 occurs.

(9472)

OCCUPATIONAL HEALTH AND SAFETY ACT

O. Reg. 569/86.
Mines and Mining Plants.
Made—September 24th, 1986.
Filed—September 25th, 1986.

REGULATION TO AMEND REGULATION 694 OF REVISED REGULATIONS OF ONTARIO, 1980 MADE UNDER THE OCCUPATIONAL HEALTH AND SAFETY ACT

- 1.—(1) Subsection 118 (1) of Regulation 694 of Revised Regulations of Ontario, 1980 is amended by striking out "and" at the end of clause (e) and by adding thereto the following clauses:
 - (g) under the control and direction of a competent person; and
 - (h) that is securely locked at all times when the competent person mentioned in clause (g) is not present.
- (2) Section 118 of the said Regulation is amended by adding thereto the following subsections:
- (3) Records shall be kept of explosives received and issued out of the magazine showing,
 - (a) the date of receipt or issue; and
 - (b) the quantity and type of explosives received or issued.
- (4) A weekly inspection of the magazine shall be carried out by a competent person who shall report in writing to a supervisor as to,
 - (a) the condition of the magazine and the explosives; and
 - (b) the quantities of each type of explosives stored therein.

- (5) Reports and records required by subsections (3) and (4) shall be kept for a period of at least three years. O. Reg. 569/86, s. 1 (2).
 - 2. The said Regulation is amended by adding thereto the following section:

118a. In sections 119 to 123a, "magazine" or "licensed magazine" includes an explosives storage area in the underground workings of a mine. O. Reg. 569/86, s. 2.

- 3. Subsection 119 (6) of the said Regulation is revoked.
- Section 121 of the said Regulation is revoked and the following substituted therefor:
- 121.—(1) A licensed magazine in an underground mine shall be under the control and direction of a competent person.
- (2) A weekly inspection of a magazine in an underground mine shall be carried out by a competent person who shall report in writing to a supervisor,
 - (a) as to the condition of the magazine and the explosives; and
 - (b) as to the quantities of explosives stored therein.
- (3) Reports required by subsection (2) shall be kept for a period of at least six months. O. Reg. 569/86, s. 4.
 - 5. The said Regulation is further amended by adding thereto the following section:

123a.—(1) A licence for a magazine shall be in the following form:

Mining Health

and Safety

STORAGE OF

EXPLOSIVES

Ontario

Ministry of

Labour Branch EXPLOSIVES

This licence is issued in accordance with the requirements of the Occupational Health and Safety Act and Regulations for Mines and Mining Plants.

Capacity

Explosives:

Blasting Caps:

Applicant

Location

Licence Date Engineer of the Ministry

This Licence is to be posted at the location set out herein.

- (2) A licence for a magazine is valid only for the location set out in the licence. O. Reg. 569/86, s. 5.
 - Section 234 of the said Regulation is amended by adding thereto the following subsection:
- (6) The person or persons designated to carry out the functions set out in subsection (4) shall be readily available to perform those functions. O. Reg. 569/86, s. 6.
 - Section 271 of the said Regulation is revoked and the following substituted therefor:

271.—(1) Where fifteen or more persons congregate to eat, a lunchroom shall be provided which,

- (a) is of sufficient size to accommodate all the persons therein;
- (b) is heated, lighted and ventilated;
- (c) has hand washing and drying facilities;
- (d) has hot and cold water;
- (e) has facilities for warming of food;
- (f) has suitable seating facilities; and
- (g) has a non-combustible, covered receptacle for waste disposal.
- (2) Where less than fifteen persons congregate to eat, an eating area shall be provided which has,
 - (a) suitable seating facilities; and
 - (b) fire retardant receptacles for waste disposal.
- (3) All lunchrooms and eating areas shall be kept sanitary, clean and dry. O. Reg. 569/86, s. 7.

(9473)

RENTAL HOUSING PROTECTION ACT, 1986

O. Reg. 570/86. General. Made—September 24th, 1986. Filed—September 25th, 1986.

REGULATION TO AMEND ONTARIO REGULATION 434/86 MADE UNDER THE RENTAL HOUSING PROTECTION ACT, 1986

- 1. Schedule 2 to Ontario Regulation 434/86 is amended by adding thereto the following paragraphs:
 - That parcel of land known municipally as 350 Front Street in the City of Belleville, more particularly described as follows:

In the City of Belleville in the County of Hastings, being composed of lots 61 and 62 and part of lots 54, 58, 59, 60 and 63 and part of the Island known as Lot 69 according to Haslett's Plan, registered in the Land Registry Office for the Registry Division of Hastings and part of the Bed of the Moria River, lying east of the Island known as Lot 69, being part of Lot 3 in Concession 1 of the Geographic Township of Thurlow, all designated as parts 1, 2, 3 and 4 on Reference Plan 21R-9366, deposited in the Land Registry Office for the Land Titles Division of Hastings.

SUBJECT to an easement, described in Instrument 166993, in favour of Her Majesty the Queen in right of the Province of Ontario as represented by the Minister of the Environment, its successors and assigns, on, in, across, under and through part of the said Island known as Lot 69 designated as Part 2 on Plan 21R-9366.

SUBJECT to an easement, described in Instrument 328539, in favour of The Corporation of the City of Belleville, its successors and assigns over part of the said Island known as Lot 69 designated as parts 2 and 3 on Plan 21R-9366.

3. The land known municipally as 211, 215 and 219 College Street in the City of Toronto and described as part of Park Lot 14 in the First Concession from the Bay in the City of Toronto, in The Municipality of Metropolitan Toronto more particularly described as follows:

Commencing at a point where the production easterly of the southerly limit of College Street would be intersected by the production northerly of the westerly limit of Beverley Street;

Thence westerly to and along the said southerly limit of College Street 252 feet 11 inches more or less to the easterly limit of Ross Street;

Thence southerly parallel with Beverley Street along the said easterly limit of Ross Street 200 feet;

41

Thence easterly parallel with College Street 253 feet ½ inch more or less to the westerly limit of Beyerley Street:

Thence northerly along the said westerly limit of Beverley Street and its production northerly 200 feet to the place of beginning.

Saving and Excepting therefrom that part of the said lands expropriated by The Corporation of the City of Toronto under By-law 16612 and being 25 feet on the west side of Beverley Street by 15 feet on the south side of College Street, as more particularly described in registered Instrument No. 56441 E.P.

(9470)

COURTS OF JUSTICE ACT, 1984

O. Reg. 571/86. Salaries and Benefits of Masters. Made—September 24th, 1986. Filed—September 25th, 1986.

O. Reg. 570/86

REGULATION TO AMEND REGULATION 539 OF REVISED REGULATIONS OF ONTARIO, 1980 MADE UNDER THE COURTS OF JUSTICE ACT, 1984

- 1. Section 1 of Regulation 539 of Revised Regulations of Ontario, 1980, as remade by section 1 of Ontario Regulation 672/85, is revoked and the following substituted therefor:
 - 1. The annual salary of a master in a position referred to in Column 1 of the Schedule is the salary set out opposite thereto in Column 2 for service on and after the 1st day of April, 1986. O. Reg. 571/86, s. 1.
- The Schedule to the said Regulation, as remade by section 2 of Ontario Regulation 672/85, is revoked and the following substituted therefor:

Schedule

| Column 1 | Column 2 |
|---------------|----------|
| Senior Master | \$82,540 |
| Master | 78,000 |

O. Reg. 571/86, s. 2.

(9475)

41

PROVINCIAL OFFENCES ACT

O. Reg. 572/86.
Proceedings Commenced by Certificate of Offence.
Made—September 24th, 1986.
Filed—September 25th, 1986.

REGULATION TO AMEND REGULATION 817 OF REVISED REGULATIONS OF ONTARIO, 1980 MADE UNDER THE PROVINCIAL OFFENCES ACT

1. Regulation 817 of Revised Regulations of Ontario, 1980 is amended by adding thereto the following Schedule:

Schedule 81

Regulation 704 of Revised Regulations of Ontario, 1980 under the Ontario Food Terminal Act

| Ітем | Column 1 | COLUMN 2 |
|------|---|-----------|
| 1. | Driving vehicle in excess of 15 km per hour | section 3 |
| 2. | Causing vehicle to be driven in excess of 15 km per hour | section 3 |

| ITEM | Column 1 | Column 2 |
|------------|--|---|
| 3. | Failing to obey traffic sign | clause 4(1)(a) |
| 4. | Failing to obey road markings | clause 4(1)(b) |
| 5. | Failing to obey stop sign | subsection 4(2) |
| 6. | Failing to obey officer's traffic direction | subsection 6(2) |
| 7. | Operating bicycle in prohibited area | section 7 |
| 8. | Operating vehicle in prohibited area | section 7 |
| 9. | Obstructing traffic | section 8 |
| 10. | Failing to obey officer's traffic direction | section 9 |
| 11. | Operating vehicle without driver's licence | section 10 |
| 12. | Careless driving | section 11 |
| 13. | Driving unsafe vehicle | clause 12(a) |
| 14. | Causing unsafe vehicle to be driven | clause 12(a) |
| 15. | Driving unlicenced vehicle | clause 12(b) |
| 16. | Causing unlicenced vehicle to be driven | clause 12(b) |
| 17. | Transferring fruit or produce outside Farmers' Mar- | |
| | ket section | subsection 14(4) |
| 18. | Transferring fruit or produce in buyer's court during | 1 |
| | prohibited hours | subsection 14(5) |
| 19. | Parking inoperative or unlicenced vehicle | subsection 14(9) |
| 20. | Storing inoperative or unlicenced vehicle | subsection 14(9) |
| 21. | Leaving inoperative or unlicenced vehicle | subsection 14(9) |
| 22. | Causing inoperative or unlicenced vehicle to be | |
| 2.2 | parked | subsection 14(9) |
| 23. | Permitting inoperative or unlicenced vehicle to be | subsection 14(9) |
| 2.4 | parked Causing inoperative or unlicenced vehicle to be | Subsection 14(9) |
| 24. | stored | subsection 14(9) |
| 25. | Permitting inoperative or unlicenced vehicle to be | Subsection 14(9) |
| 23. | stored | subsection 14(9) |
| 26. | Causing inoperative or unlicenced vehicle to be left | subsection 14(9) |
| 27. | Permitting inoperative or unlicenced vehicle to be | Subsection 14(7) |
| 27. | left | subsection 14(9) |
| 28. | Failing to report accident | section 15 |
| 29. | Selling fruit or produce other than by wholesale | section 16 |
| 30. | Unauthorized selling of goods | section 17 |
| 31. | Unlawful selling of goods | section 18 |
| 32. | Entering into (designate place) during prohibited | |
| | hours | subsection 20(1) |
| 33. | Releasing fruit or produce from cold storage | section 22 |
| 34. | Delivering fruit or produce during prohibited hours | subsection 23(1) |
| 35. | Receiving fruit or produce from prohibited vehicle | section 24 |
| 36. | Unauthorized entry from Parklawn Road | section 25 |
| 37. | Unauthorized entry from Queensway | section 26 |
| 38. | Damaging property | subsection 27(1) |
| 39. | Misusing public area of Food Terminal Building | clause 27(2)(a) |
| 40. | Creating a nuisance | clause 27(2)(b) |
| 41. | Removing barricade or traffic sign | clause 27(2)(c) |
| 42. | Damaging barricade or traffic sign | clause 27(2)(c) |
| 43. | Interfering with barricade or traffic sign | clause 27(2)(c) |
| 44. | Climbing fence | clause 27(2)(d) |
| 45. | Removing fence | clause 27(2)(d) |
| 46. | Damaging fence | clause 27(2)(d) |
| 47. | Interfering with use of gate | clause 27(2)(e) |
| 48. | Interfering with use of lock | clause 27(2)(e) |
| 49. | Interfering with use of equipment | clause 27(2)(e) |
| 50. | Interfering with use of supplies | clause 27(2)(e) |
| 51. 52. | Dumping garbage Causing garbage to be dumped | clause 27(3)(a) |
| 53. | Littering | clause 27(3)(a) clause 27(3)(b) |
| 54. | Permitting animal in terminal | subsection 27(4) |
| 55. | Permitting unsanitary conditions | section 29 |
| 33. | distance of the state of the st | Joedion 27 |

| ITEM | COLUMN 1 | COLUMN 2 |
|------|--|--------------|
| 56. | Maintaining equipment with steel or iron wheels on | |
| | Food Terminal Building docks or floors | clause 30(a) |
| 57. | Operating equipment with steel or iron wheels on | |
| | Food Terminal Building docks or floors | clause 30(a) |
| 58. | Allowing equipment with steel or iron wheels to be | |
| | operated on Food Terminal Building docks or floors | clause 30(a) |
| 59. | Maintaining damaging equipment | clause 30(b) |
| 60. | Operating damaging equipment | clause 30(b) |
| 61. | Allowing damaging equipment to be operated | clause 30(b) |
| 62. | Using docks of Food Terminal Building for storage | section 31 |
| 63. | Using docks or buyers' court for storage | section 32 |
| 64. | Keeping for sale merchandise in prohibited area | section 33 |
| 65. | Displaying merchandise in prohibited area | section 33 |

O. Reg. 572/86, s. 1.

(9476)

NIAGARA ESCARPMENT PLANNING AND DEVELOPMENT ACT

O. Reg. 573/86.

Designation of Area of Development Control.

Made—September 23rd, 1986. Filed—September 25th, 1986.

REGULATION TO AMEND REGULATION 683 OF REVISED REGULATIONS OF ONTARIO, 1980 MADE UNDER THE NIAGARA ESCARPMENT PLANNING AND DEVELOPMENT ACT

- 1. Paragraph 11 of the Schedule to Regulation 683 of Revised Regulations of Ontario, 1980, as remade by section 1 of Ontario Regulation 289/86, is revoked and the following substituted therefor:
- 11. In the Township of Collingwood in the County of Grey, described as follows:
 - Beginning at the southwesterly angle of the Township of Collingwood;

Thence easterly along the southerly boundary of the said Township to intersect the southerly prolongation of the westerly limit of Lot 1 in Concession IX:

Thence northerly to and along the westerly limit of lots 1, 2 and 3 in the said Concession to the northwesterly angle of that Lot 3;

Thence easterly along the northerly limit of that Lot 3 to the northeasterly angle of that Lot;

Thence northerly to and along the easterly limit of Lot 4 in the said Concession to the northeasterly angle of that Lot;

Thence easterly to and along the southerly limit of Lot 5 in Concession VIII to the southeasterly angle of that Lot;

Thence northerly along the easterly limit of that Lot 5 to the northeasterly angle of that Lot:

Thence easterly along the southerly limit of Lot 6 in Concession VII to the southeasterly angle of that Lot;

Thence northerly along the westerly limit of the road allowance between concessions VI and VII to the northeasterly angle of Lot 14 in the said Concession VII;

Thence easterly to and along the southerly limit of Lot 15 in concessions VI and V to the easterly limit of the westerly half of Lot 15 in the said Concession V;

Thence easterly along the northerly limit of that Lot to the northeasterly angle of that Lot:

Thence northerly along the easterly limit of lots 18 and 19 in the said Concession to the northeasterly angle of that Lot 19;

Thence westerly along the southerly limit of Lot 20 in concessions V and VI to the easterly limit of the westerly half of Lot 20 in Concession VI;

Thence northerly along the easterly limit of the westerly half of lots 20 and 21 in the said Concession to the northerly limit of that Lot 21:

Thence westerly along the northerly limit of that Lot to the northwesterly angle of that Lot; Thence southerly along the westerly limit of lots 21, 20 and 19 in the said Concession to the southwesterly angle of that Lot 19;

Thence westerly to and along the southerly limit of Lot 19 in Concession VII to the southwesterly angle of that Lot;

Thence southerly to and along the easterly limit of lots 18 and 17 in Concession VIII to the southeasterly angle of Lot 17;

Thence westerly along the northerly limit of Lot 16 in the said Concession to the westerly limit of the easterly half of that Lot;

Thence southerly along the westerly limit of the easterly half of lots 16, 15, 14 and 13 in the said Concession to the southerly limit of that Lot 13;

Thence southerly on the same course to the northerly limit of Lot 12 in the said Concession;

Thence westerly along the northerly limit of that Lot to the northwesterly angle of that Lot;

Thence southerly along the westerly limit of that Lot 12 to the southwesterly angle of that Lot;

Thence westerly to and along the southerly limit of Lot 12 in concessions IX, X and XI to the southwesterly angle of Lot 12 in the said Concession XI;

Thence northerly along the westerly limit of Lot 12 in the said Concession XI to the northwesterly angle of that Lot;

Thence westerly along the northerly limit of Lot 12 in Concession XII and the said limit prolonged to the westerly boundary of the Township of Collingwood;

Thence southerly along the westerly boundary of the said Township to the place of beginning.

ii. Beginning at the southwesterly angle of Lot 13 in Concession III;

Thence northerly along the westerly limit of that Lot to the northwesterly angle of that Lot:

Thence easterly along the southerly limit of Lot 14 in the said Concession to the westerly limit of the easterly half of that Lot;

Thence northerly along the westerly limit of the easterly half of lots 14 and 15 in the said Concession to the northerly limit of that Lot 15; Thence easterly along the said northerly limit 250 metres to a point;

Thence southerly and parallel with the westerly limit of the easterly half of lots 15 and 14 to the northerly limit of Lot 13 in the said Concession;

Thence easterly along that northerly limit to the easterly limit of that Lot;

Thence southerly along the easterly limit to the southerly limit of that Lot;

Thence westerly along that southerly limit to the place of beginning.

iii. Beginning at the southeasterly angle of the Township of Collingwood;

Thence northerly along the easterly boundary of the said Township to intersect the easterly prolongation of the southerly limit of Lot 8 in Concession I;

Thence westerly to and along the southerly limit of that Lot to the westerly limit of that Lot:

Thence northerly along the westerly limit of Concession I to the southwesterly angle of Lot 10 in the said Concession;

Thence easterly along the southerly limit of that Lot and the said southerly limit prolonged to the easterly boundary of the said Township;

Thence northerly along the said easterly boundary to intersect the southerly limit of the road allowance between lots 12 and 13 of the said Township;

Thence westerly along the northerly limit of Lot 12 in concessions I and II to the northwesterly angle of Lot 12 in Concession II of the said Township;

Thence southerly along the westerly limit of lots 12, 11, 10, 9 and 8 in the said Concession to intersect the easterly prolongation of the southerly limit of the northerly half of Lot 8 in Concession III of the said Township;

Thence westerly to and along the southerly limit of the said half Lot to the westerly limit of that Lot:

Thence northerly along the westerly limit of lots 8 and 9 in the said Concession to the northwesterly angle of that Lot 9;

Thence westerly along the southerly limit of the road allowance between lots 9 and 10 and the diversion thereof to the northwesterly angle of Lot 9 in Concession IV; Thence southerly along the westerly limit of lots 9 and 8 in the said Concession to the southwesterly angle of that Lot 8;

Thence easterly along the southerly limit of that Lot to the easterly limit of the said Concession;

Thence southerly along the easterly limit of the said Concession to the northerly limit of Lot 3;

Thence westerly along the northerly limit of that Lot to the westerly limit of the said Concession IV;

Thence southerly along the westerly limit of the said Concession to the southerly boundary of the Township of Collingwood;

Thence easterly along the southerly boundary of the said Township to the southeasterly angle of the said Township;

iv. Beginning at the intersection of the southerly limit of Lot 15 in Concession II and the westerly limit of Deviation Road;

Thence northerly along the said westerly limit to the southerly limit of Part 1 as shown on a Plan deposited in the Registry Division of Grey North (No. 16) as Number 16R-662;

Thence westerly along the southerly limit of the said Part to the westerly limit of the said Part;

Thence northerly along the said westerly limit to the northerly limit of the said Part;

Thence easterly along the said northerly limit to the westerly limit of Deviation Road;

Thence northerly along the said westerly limit to the southerly limit of Lot 16 in the said Concession;

Thence westerly along the said southerly limit 52 metres to a point;

Thence northwesterly in a straight line to a point in the southerly limit of Lot 17 in the said Concession distance 70 metres measured westerly therealong from the westerly limit of Winter Park Road;

Thence northwesterly in a straight line to a point on a line parallel with and distant 75 metres measured due south from the northerly limit of Lot 18 in the said Concession the said point being distant 130 metres measured easterly therealong from the westerly limit of that Lot;

Thence westerly along the said parallel line 130 metres to the westerly limit of that Lot;

Thence northerly along the easterly limit of the road allowance between concessions II and III to the southwesterly angle of Lot 19 in Concession II;

Thence westerly to and along the southerly limit of Lot 19 in Concession III 80 metres to a point;

Thence northwesterly in a straight line to a point in the northerly limit of Lot 19 in the said Concession distant 375 metres measured westerly from the northeasterly angle of that Lot;

Thence northwesterly in a straight line to the southerly angle of Lot 39 as shown on a Plan registered in the said Registry Office as Number 634;

Thence northwesterly along the southwesterly limit of the said Plan to the southerly limit of the road allowance between lots 21 and 22;

Thence northerly along the northerly prolongation of the westerly limit of the said Plan to the centre line of the said road allowance;

Thence westerly along the said centre line to the southwesterly angle of a Plan registered in the said Registry Office as Numbr 1045;

Thence northeasterly along the westerly and northerly limits of the said Plan to the westerly limit of Arrowhead Road;

Thence northerly along the said westerly limit to the northerly limit of the southerly half of Lot 23 in Concession IV;

Thence westerly along the said northerly limit and the -aid northerly limit prolonged to the easterly limit of Lot 23 in Concession V;

Thence northerly along the easterly limit of lots 23, 24 and 25 in the said Concession to the southerly limit of a Plan registered in the said Registry Office as Number 425;

Thence westerly along the said southerly limit to the westerly limit of the said Plan;

Thence northerly along the said westerly limit to the southerly limit of the right of way of the Canadian National Railways;

Thence westerly along the southerly limit of the said right of way to the northeasterly angle of a Plan registered in the said Registry Office as Number 903;

Thence southerly along the easterly limit of the said Plan to the northeasterly angle of Block A as shown on the said Plan;

Thence westerly along the northerly limit of the said Block A to the northwesterly angle of the said Block;

Thence northerly along a westerly limit of the said Plan to the southerly limit of Wensley Drive;

Thence westerly along the said southerly limit to the line between concessions V and VI;

Thence southerly along the said line 33.71 metres to the northerly limit of a Plan deposited in the said Registry Office as Number 16R-1929;

Thence easterly along the said northerly limit 11.48 metres to the easterly limit of the said Plan;

Thence southerly along the said easterly limit to the southerly limit of the said Plan;

Thence westerly along the said southerly limit 2.68 metres to the line between concessions V and VI;

Thence southerly along the said line 22.20 metres to the northerly limit of Part 15 as shown on a Plan deposited in the said Registry Office as Number 16R-1649;

Thence southwesterly along the northwesterly limits of the said Part to the northerly angle of Part 16 as shown on the said Plan;

Thence north 7° 20′ 10″ west 61.0 metres to a point;

Thence north 8° 34′ west 11 metres more or less to the northerly limit of Lot 25 in the said Concession;

Thence westerly along the said northerly limit to the westerly limit of Concession VI;

Thence southerly along the said westerly limit to the northerly limit of Lot 22;

Thence easterly along that northerly limit to the easterly limit of that Lot;

Thence southerly along that easterly limit to the southerly limit of that Lot;

Thence easterly along the southerly limit of Lot 22 in Concession V to the southeasterly angle of that Lot;

Thence southerly to and along the easterly limit of Lot 21 in the said Concession to the southeasterly angle of that Lot;

Thence easterly to and along the southerly limit of Lot 21 in Concession IV to the westerly limit of the easterly half of Lot 20 in the said Concession;

Thence southerly along the said westerly limit to the southerly limit of that Lot;

Thence easterly along the southerly limit of that Lot to the southeasterly angle of that Lot;

Thence easterly along the northerly limit of Lot 19 in Concession III 58 metres to a point;

Thence southeasterly in a straight line to the northeasterly angle of a Plan registered in the said Registry Office as Number 807, the said angle being on the northerly limit Lot 18 in the said Concession;

Thence southeasterly along the easterly limit of the said Plan to the northerly limit of Swiss Meadow Boulevard;

Thence southeasterly following the northeasterly limit of Swiss Meadow Boulevard and Scenic Caves Road to the northerly limit of Lot 15 in Concession II;

Thence easterly along that northerly limit 120 metres to a point;

Thence southerly and parallel with the westerly limit of that Lot to the northerly limit of Scenic Caves Road;

Thence easterly along the northerly limit of Scenic Caves Road to the southerly limit of Lot 15 in the said Concession;

Thence easterly along that southerly limit to the place of beginning.

> Bernard Grandmaître Minister of Municipal Affairs

> > 41

Dated at Toronto, this 23rd day of September, 1986.

(9477)

GAME AND FISH ACT

O. Reg. 574/86. Fishing Huts. Made—September 25th, 1986. Filed—September 25th, 1986.

REGULATION TO AMEND REGULATION 413 OF REVISED REGULATIONS OF ONTARIO, 1980 MADE UNDER THE GAME AND FISH ACT

- 1. Clause 2 (a) of Regulation 413 of Revised Regulations of Ontario, 1980, as remade by section 1 of Ontario Regulation 71/86, is amended by adding thereto the following subclause:
 - (iv) that part of Long Point Bay on Lake Erie in The Regional Municipality of Haldimand-Norfolk, lying westerly of a line drawn from the survey point at Turkey Point Marina, situate at approximate latitude 42° 42' North and longitude 80° 19' West to the control survey monument on the northerly extremity of Pottohawk Point situate at approximate latitude 42° 36' North and longitude 80° 17' West,
- 2. The Schedule to the said Regulation, as amended by section 2 of Ontario Regulation 753/81, section 1 of Ontario Regulation 24/82 and subsection 2 (2) of Ontario Regulation 71/86, is further amended by adding thereto the following paragraph:
- 27. That part of Long Point Bay on Lake Erie in The Regional Municipality of Haldimand-Norfolk, lying westerly of a line drawn from the survey point at Turkey Point Marina, situate at approximate latitude 42° 42′ North and longitude 80° 19′ West to the control survey monument on the northerly extremity of Pottohawk Point situate at approximate latitude 42° 36′ North and longitude 80° 17′ West.

VINCENT G. KERRIO Minister of Natural Resources

Dated at Toronto, this 25th day of September, 1986.

(9478)

PLANNING ACT, 1983

O. Reg. 575/86.

Restricted Areas—The Regional Municipality of York, Town of Markham.

Made—September 18th, 1986.

Filed—September 26th, 1986.

REGULATION TO AMEND ONTARIO REGULATION 104/72 MADE UNDER THE PLANNING ACT, 1983

- 1. Ontario Regulation 104/72 is amended by adding thereto the following section:
- 49.—(1) A single-family dwelling and buildings and structures accessory thereto may be erected and used on the land described in subsection (2) if the dwelling existing on the land on the day this section comes into force is demolished and if the new dwelling meets the following requirements:

Minimum distance of any building or structure from the centre line of 17th Avenue

30 metres

Minimum side yards

3.048 metres

Minimum rear yard

7.62 metres

Minimum total area of single-family dwelling

one storey—139.35 square metres one and one-half storeys—153.29 square metres two storeys—167.22 square metres

(2) Subsection (1) applies to that parcel of land in the Town of Markham in The Regional Municipality of York, being that part of Lot 21 in Concession VIII more particularly described as follows:

Commencing on the southern boundary or limit of said Lot at a point 3,300 feet from the southwest angle of said Lot;

Thence south 74° west along the southern boundary of said Lot 367.62 feet;

Thence northerly along the fence line dividing the lands hereby conveyed from the premises immediately to the west thereof a distance of 660 feet;

Thence easterly parallel with the south limit of said Lot a distance of 367.62 feet;

Thence southerly along the division line fence between the lands hereby conveyed and those immediately to the east thereof 660 feet more or less to the place of beginning, containing five and one-half acres more or less. O. Reg. 575/86, s. 1.

L. J. FINCHAM
Director
Plans Administration Branch
Central and Southwest
Ministry of Municipal Affairs

Dated at Toronto, this 18th day of September, 1986.

(9479) 41

O. Reg. 576/86

ENVIRONMENTAL ASSESSMENT ACT

O. Reg. 576/86. Exemption—Town of Hearst—HRST-T-1. Made—September 19th, 1986. Approved-September 19th, 1986. Filed-September 26th, 1986.

ORDER MADE UNDER THE ENVIRONMENTAL ASSESSMENT ACT

EXEMPTION—TOWN OF HEARST—HRST-T-1

Having received a request from The Corporation of the Town of Hearst that an undertaking, namely:

The activity of establishing a sanitary sewage system by The Corporation of the Town of Hearst to serve Cecile's Trailer Park, consisting of the construction, operation and maintenance of a sewage pumping station and a two-cell waste stabilization pond to be located on the north part of Lot 20, Concession X of the Township of Kendall with an outlet to the Mattawishkwia River,

be exempt from the application of the Act pursuant to section 29; and

Having been advised that if the undertaking is subject to the application of the Act, the following injury. damage or interference with the persons and property indicated will occur:

- A. The health of the residents of Cecile's Trailer Park will be interfered with by any delay in establishing the sewage collection and waste treatment system;
- B. The Town of Hearst will be interfered with and damaged by the undue delay required to prepare an environmental assessment for an undertaking which will have minimal adverse impact on the environment; and
- C. The water quality of the Mattawishkwia River will continue to be impaired due to the pollution from the existing sewage system,

Having weighed such injury, damage or interference against the betterment of the people of the whole or any part of Ontario by the protection, conservation and wise management in Ontario of the environment which would result from the undertaking being subject to the application of the Act;

The undersigned is of the opinion that it is in the public interest to order and orders that the undertaking is exempt from the application of the Act for the following reasons:

A. The undertaking is urgently needed to overcome severe problems associated with the (9481) existing malfunctioning treatment and disposal system;

B. The undertaking will have a beneficial effect on the environment by permitting closure of the existing unsatisfactory system.

This exemption is subject to the following terms and conditions:

- 1. Construction methods and schedules will follow the "Environmental Considerations for Planning the Construction of Provincial Sewage and Water Projects", (January, 1985) referred to in Appendix 7 of the Ministry of the Environment Class Environmental Assessment document, Expansion or Upgrading of an Existing Sewage or Water System, which can be found in the public record file established by the Environmental Assessment Branch of the Ministry of the Environment.
- 2. The proponent shall notify the Director of the Environmental Assessment Branch of the date construction commenced and this shall be done, in writing, within 30 days following that date.
- 3. This exemption shall terminate on July 31, 1987 if construction has not commenced. O. Reg. 576/86.

JAMES BRADLEY Minister of the Environment

(9480)

41

PETROLEUM RESOURCES ACT

O. Reg. 577/86. Spacing Units-Enniskillen-6-15-II. Made—September 24th, 1986. Filed-September 26th, 1986.

REGULATION TO AMEND **ONTARIO REGULATION 485/86** MADE UNDER THE PETROLEUM RESOURCES ACT

- 1. Section 3 of Ontario Regulation 485/86 is revoked and the following substituted therefor:
- 3. For the purpose of this Regulation, the area described in section 1 constitutes a single spacing unit of approximately one hundred acres. O. Reg. 577/86, s. 1.

41

GAME AND FISH ACT

O. Reg. 578/86. Game Birds-Captivity, Propagation or Sale. Made-September 24th, 1986. Filed-September 26th, 1986.

REGULATION MADE UNDER THE GAME AND FISH ACT

GAME BIRDS-CAPTIVITY, PROPAGATION OR SALE

1.—(1) A licence to,

- (a) keep game birds in captivity for more than ten days;
- (b) to propagate or sell game birds; or
- (c) to possess game birds for propagation or sale,

shall be in Form 1 and shall be valid for the species specified therein.

- (2) An application for a licence in Form 1 shall be in Form 2.
- (3) A licence in Form 1 expires with the 31st day of December next following the date on which it is issued.
 - (4) The fee for a licence in Form 1 is \$10.
- (5) The species of game birds specified in a licence in Form 1 may be varied at any time before the expiry of the licence, upon the request of the licensee and without payment of a fee, by the district manager of the administrative district of the Ministry of Natural Resources in which the licence was issued.
- (6) No holder of a licence in Form 1 shall possess more than fifty of each of the following species of live game birds at one time:
 - 1. Spruce grouse.
 - 2. Ruffed grouse.
 - 3. Sharp-tailed grouse.
 - 4. Rock ptarmigan.
 - 5. Willow ptarmigan.
 - 6. Hungarian partridge.
- (7) A licence in Form 1 of Regulation 404 of Revised Regulations of Ontario, 1980 issued after the 31st day of March, 1986 and before the day this Regulation comes into force is valid until the 31st day of March, 1987. O. Reg. 578/86, s. 1.

2.—(1) Subject to subsections (2) and (3), a licence in Form 1 authorizes its holder to,

5211

- (a) keep in captivity for more than ten days or to propagate or sell or to possess for propagation or sale live ruffed grouse, spruce grouse, Hungarian partridge, pheasant, sharp-tailed grouse, rock ptarmigan, willow ptarmigan, bob-white quail, wild turkey and their eggs:
- (b) sell the carcass of pheasant.
- (2) No holder of a licence in Form 1 shall sell, offer for sale or assist in the sale of live ruffed grouse, spruce grouse, Hungarian partridge, sharp-tailed grouse, rock ptarmigan, willow ptarmigan or their eggs, except to a holder of a licence in Form 1.
- (3) No person shall sell, offer for sale or assist in the sale of,
 - (a) a bob-white quail or a bob-white quail egg;
 - (b) a wild turkey or a wild turkey egg,

except to a holder of a licence in Form 1 or the holder of a licence to own or operate a game bird hunting preserve. O. Reg. 578/86, s. 2.

- 3.—(1) Subject to subsection (2), no holder of a licence in Form 1 shall sell live ruffed grouse, spruce grouse, Hungarian partridge, pheasant, sharp-tailed grouse, rock ptarmigan, willow ptarmigan, bob-white quail or wild turkey, or the carcass of a pheasant, unless at the time of sale the holder delivers to the purchaser an invoice showing.
 - (a) the vendor's name and address;
 - (b) the number of the vendor's licence;
 - (c) the date of the sale;
 - (d) the purchaser's name and address;
 - (e) the number of the purchaser's licence, if any; and
 - (f) the number and species of game birds sold.
- (2) Subsection (1) does not apply to pheasant that is sold in a dressed condition and in a container or package that clearly exhibits the name and address of the holder of the licence who sold the pheasant. O. Reg. 578/86, s. 3.
- 4.—(1) The purchaser named in an invoice referred to in subsection 3 (1) shall retain the invoice,
 - (a) where it relates to the purchase of a live bird. for two years after the purchase; and

(b) where it relates to the purchase of a carcass, until the carcass is consumed or disposed of or for two years after the purchase, whichever occurs first,

and shall produce and show the invoice upon an officer's request.

- (2) The vendor named in an invoice referred to in subsection 3 (1) shall retain a copy of the invoice for two years after the sale and shall produce and show it upon an officer's request. O. Reg. 578/86, s. 4.
- 5.—(1) The holder of a licence in Form 1 or a person authorized by the holder may kill at any time, by any method other than by shooting, a ruffed grouse, spruce grouse, Hungarian partridge, pheasant, sharp-tailed grouse, rock ptarmigan, willow ptarmigan, bob-white quail or wild turkey kept in captivity under the authority of the licence.
- (2) Any person may kill a pheasant by any method, other than by shooting, within ten days after purchasing it from the holder of a licence in Form 1. O. Reg. 578/86, s. 5.

Form 1

Game and Fish Act

LICENCE TO KEEP GAME BIRDS IN CAPTIVITY FOR MORE THAN TEN DAYS OR TO PROPAGATE OR SELL GAME BIRDS OR TO POSSESS GAME BIRDS FOR PROPAGATION AND SALE IN 19...

| Licence | Serial | No | |
|---------|--------|----|--|

Under the Game and Fish Act and the regulations, and subject to the limitations thereof, this licence is issued to:

| Mr. |
|------|
| Mrs. |
| Miss |

| Last Name | First Name | Middle Initial |
|------------------------------|----------------|----------------|
| Address, Street, No., RR # * | | |
| City, Town, Village | | Postal Code |
| *If RR, please specify: Lot | Conc. Township | |

to keep game birds in captivity for more than ten days or to propagate or sell game birds or to possess game birds for propagation or sale.

This licence is valid for the following species only:

| Species | Dat | te of Authorizat | ion | Issuer's Signature |
|--|------|------------------|-----|--------------------|
| | Year | Month | Day | |
| Pheasant Bob-white Quail Wild Turkey Spruce Grouse Ruffed Grouse Sharp-tailed Grouse Rock Ptarmigan Willow Ptarmigan Hungarian Partridge | | | | |

| This licence expires with the 31st day of De | cember next following th | ne date of issue. |
|--|--------------------------|------------------------|
| Signature of Issuer | Date of Issue | Signature of Licensee |
| | | O. Reg. 578/86, Form 1 |

Game and Fish Act

APPLICATION FOR A LICENCE TO KEEP GAME BIRDS IN CAPTIVITY OR TO PROPAGATE OR SELL GAME BIRDS OR TO POSSESS GAME BIRDS FOR PROPAGATION AND SALE IN 19...

Under the Game and Fish Act and the regulations, and subject to the limitations thereof:

| Mr. | | | |
|--------------|--|--|---|
| Mrs. Miss | Last Name | First Name | Middle Initial |
| | Address, Street, No., RR # * | | |
| | City, Town, Village | | Postal Code |
| | *If RR, please specify: Lot | Conc Township | • |
| game | birds for propagation or sale at: | came birds in captivity or to propagate of | or sell game birds or to possess |
| | oove address, []; or, | | |
| Lot . | Conc. | | |
| in the | Township of | in the County, District or Regional | Municipality of, and |
| furthe | er described in Instrument Numbe | r registered in the Land F | Registry Office for the Registry |
| | on (Land Titles Division) of | | |
| | | following species and number of game | birds**: |
| | GAME BI | RD* NUMBER | |
| | Bob-white Quail Pheasant Wild Turkey Spruce Grouse Ruffed Grouse Sharp-tailed Grouse | | |

Willow Ptarmigan Hungarian Partridge

^{*}Delete where not applicable.

^{**}NOTE: If this is an application for renewal you must also complete the table relating to last year's holdings.

PREVIOUS YEAR'S HOLDINGS*

| Game Bird | Quantity at start of previous Year | Quantity Bred | Quantity Acquired | Quantity Sold | Quantity Died | Quantity Traded | Balance at year end |
|------------------------|--|------------------|----------------------|------------------|------------------|--------------------|------------------------------|
| Bob-white Quail | | | | | | | |
| Pheasant | | | | | | | |
| Wild Turkey | | | | | | | - 4 |
| Spruce Grouse | | | | | | | |
| Ruffed Grouse | | | | | | | |
| Sharp-tailed Grouse | | | | | | | |
| Rock Ptarmigan | | | | | 1 | | |
| Willow Ptarmigan | | | | | | | |
| Hungarian Partridge | | | | | | | |

*To be completed only where application is for renewal.

Date of Application

Signature of Applicant

O. Reg. 578/86, Form 2.

6. Regulation 404 of Revised Regulations of Ontario, 1980, Ontario Regulation 446/81 and Ontario Regulation 517/86 are revoked.

(9482)

GAME AND FISH ACT

O. Reg. 579/86. Snares. Made—September 24th, 1986. Filed—September 26th, 1986.

REGULATION TO AMEND ONTARIO REGULATION 156/81 MADE UNDER THE GAME AND FISH ACT

- 1. Items xxi and xxvii of Schedule 1 to Ontario Regulation 156/81 are revoked and the following substituted therefor:
- xxi. Peterborough, except the townships of Anstruther, Burleigh, Cavendish, Chandos, Galway, Harvey and Methuen.

xxvii. Victoria, except the townships of Carden Dalton, Digby, Laxton, Longford and Somerville.

- Subparagraph iii of paragraph 4 of Schedule 2 to the said Regulation is revoked and the following substituted therefor:
 - iii. Carden, Dalton, Digby, Laxton, Longford and Somerville in the County of Victoria.
 - v. Anstruther, Burleigh, Cavendish, Chandos, Galway, Harvey and Methuen, in the County of Peterborough.

(9483)

41

Publications Under The Regulations Act

October 18th, 1986

PLANNING ACT, 1983

O. Reg. 580/86.
Zoning Areas—Part of the District of Nipissing.
Made—August 26th, 1986.
Filed—September 29th, 1986.

ORDER MADE UNDER THE PLANNING ACT, 1983

ZONING AREAS—PART OF THE DISTRICT OF NIPISSING

INTERPRETATION

1. In this Order,

- "accessory", when used to describe a use, building or structure, means a use, building or structure that is normally incidental or subordinate to the principal use, building or structure on the same lot;
- "boathouse" means a building used for the storage of one or more boats but does not include a boathouse used for commercial purposes;
- "camp" means an establishment which provides accommodation, recreation or instruction for a fee to individuals or groups and may include lodges, campgrounds and facilities for serving meals;
- "conservation" means the preservation, protection and improvement of the natural environment through a management and maintenance program;
- "height" means the vertical distance between the average elevation of the finished surface of the ground at the front of the building and the highest point of the roof surface;
- "home occupation" means any occupation for gain or support conducted entirely within a single dwelling or its accessory buildings by the residents;
- "lake lot line" means any lot line that divides a lot from a Crown shoreline reserve or high-water mark of a lake;
- "lot" means a parcel of land,
 - (a) described in a deed or other document legally capable of conveying land, or

- (b) shown as a lot or block on a registered plan of subdivision;
- "lot area" means the total horizontal area within the lot line of a lot;
- "lot frontage" means the straight line distance measured from the point of intersection of one side lot line and the high-water mark of the point of intersection of the other side lot line and the high-water mark;
- "lot line" means a boundary of a lot;
- "property line" means any lot line that is not a lake lot line;
- "public building" means a building or structure owned or leased by a municipal corporation, the Province of Ontario or the Government of Canada in which government activities are carried out;
- "public utility" means a public water works or water supply system, sewage works, electrical power or energy generating transmission or distribution system, street lighting system, natural or artificial gas works or supply system or a telephone system and includes any lands, buildings or equipment required for the administration or operation of the public works or system;
- "setback" means the minimum distance between a lot line and the nearest wall of any building or structure:
- "single dwelling" means a building containing one or more habitable rooms occupied or capable or being occupied as a single independent housekeeping establishment in which separate kitchen and sanitary facilities are provided;
- "unit" means a building or part of a building rented for a fee for the exclusive use of one or more guests. O. Reg. 580/86, s. 1.

APPLICATION

- 2. This Order applies to,
 - (a) all islands of Lake Temagami in the geographic townships of Canton, Aston, Le Roche, Cynthia, Belfast, Joan, Briggs, Phyllis, Yates and Vogt except those located in the municipality of the Township of Temagami and the Bear Island Indian Reserve;

- (b) those lands in the Township of Aston, District of Nipissing, described as Parcel 15316 and Location A, Parcel 14813, in the Nipissing Register in the Land Registry Office for the Land Titles Division of Nipissing (No. 36); and
- (c) those lands in the Township of Cynthia, District of Nipissing, described as Location B, Parcel 14813, in the Nipissing Register in the Land Registry Office for the Land Titles Division of Nipissing (No. 36). O. Reg. 580/86, s. 2.

PART I

GENERAL

- 3. No land to which this Order applies shall hereafter be used and no building or structure shall hereafter be erected or used except in accordance with the terms of this Order, but nothing in this Order prevents the use of any land, building or structure for a purpose prohibited by this Order if such land, building or structure was lawfully used for such purpose on the day this Order comes into force. O. Reg. 580/86, s. 3.
- 4. The lands affected by this Order are divided into the zones listed in the Table and shown on maps filed with the Plans Administration Branch, North and East, of the Ministry of Municipal Affairs at Toronto as Numbers 143 to 145, both inclusive, the said zones being designated on the maps as follows:

TABLE

| ZONE NAME | ZONE SYMBOL ON MAP |
|-------------------|-----------------------|
| Lake Residential— | Level 1L1 Level 2L2 |
| Camp/Lodge | CL |
| Wilderness | |
| | O. Reg. 580/86, s. 4. |

- 5. Any lands not indicated on the maps referred to in section 4 by one of the Zone Symbols therein or contained in a Hazard Land Zone as described in section 20 are hereby designated as Wilderness Zones. O. Reg. 580/86, s. 5.
- 6.—(1) Accessory uses, buildings and structures are permitted in every zone.
- (2) Unless this Order provides otherwise, accessory buildings and structures shall not,
 - (a) be erected, located or used within 5 metres of any lot line; and
 - (b) be erected, located or used closer to any lake lot line than the principal building, except that this shall not apply to any building or structure of less than 9.3 square metres in area.

- (3) Despite subsection (2), a boathouse, dock or wharf may be erected, located or used abutting a lake lot line if it is not within 5 metres of any property line. O. Reg. 580/86, s. 6.
- 7.—(1) Nothing in this Order prevents the reconstruction of any building or structure erected, located or used before the date this Order comes into force that is damaged or destroyed by causes beyond the control of the owner if,
 - (a) the dimensions of the original building or structure are not increased or its original use altered; and
 - (b) in Hazard Land Zones, no openings of any building or structure are constructed below the elevation of 295 metres Canadian Geodetic Datum.
- (2) Nothing in this Order prevents the strengthening or restoration to a safe condition of any building or structure. O. Reg. 580/86, s. 7.
- 8. Where a building has been erected, located or used before the date this Order comes into force on a lot having less than the minimum frontage or area, or having less than the minimum setbacks required by this Order, the building may be extended, enlarged, repaired or renovated if there is no further reduction in any standard so that it is less than the minimum required by this Order and all other requirements of this Order are met. O. Reg. 580/86, s. 8.
- 9. The height limitations of this order do not apply to water tanks, flag poles, television or radio antennae, power transmission towers, fire lookout towers, ventilators, skylights, chimneys, silos, windmills, devices used for receiving signals from space satellites or solar collectors. O. Reg. 580/86, s. 9.
- 10. Where a lot with less than the minimum lot frontage or area required by this Order existed before the day this Order came into force, this Order does not prohibit uses permitted in the relevant zone designation if all other requirements of this Order are met. O. Reg. 580/86, s. 10.
- 11. A tool shed, scaffold or other building or structure incidental to the construction of a building or structure may be erected, located or used until the construction is completed or has been discontinued for one year, whichever is earlier. O. Reg. 580/86, s. 11.
- 12. Home occupations are permitted in every zone if the use is subordinate to the principal use of the dwelling as a residence. O. Reg. 580/86, s. 12.
- 13. Despite the yard and setback requirements of this Order, unenclosed porches, balconies, steps, attached greenhouses and patios may project into the minimum setbacks a distance not exceeding 2 metres. O. Reg. 580/86, s. 13.

- 14. Public utilities are permitted in every zone. O. Reg. 580/86, s. 14.
- 15.—(1) Where the width of Crown land lying between a lake lot line and the high-water mark of Lake Temagami is greater than the required minimum building setback from the lake lot line, there shall be no required building setback from the lake lot line.
- (2) Where the width of Crown land lying between a lake lot line and the high-water mark of Lake Temagami is less than the minimum required building setback from the lake lot line, the required building setback may be reduced by a distance equal to the width of such Crown land. O. Reg. 580/86, s. 15.

PART II

- 16. This Part applies to the Lake Residential Zones. O. Reg. 580/86, s. 16.
- 17.—(1) Every use of land and every erection or use of buildings or structures is prohibited in the Lake Residential Zone except single dwellings.
- (2) No building or structure shall be erected or used unless the requirements respecting lot size, lot frontage, building setbacks and maximum height as set out in Table 1 are met.
- (3) Not more than one single dwelling and not more than one boathouse is permitted on a lot in the Lake Residential Zone. O. Reg. 580/86, s. 17.

PART III

18. This Part applies to the Camp/Lodge Zones. O. Reg. 580/86, s. 18.

- 19.—(1) Every use of land and every erection or use of buildings or structures is prohibited except camps.
- (2) No building or structure shall be erected or used unless the requirements respecting lot size, lot frontage, building setbacks and maximum height as set out in Table 1 are met. O. Reg. 580/86, s. 19.

PART IV

- 20. This Part applies to the Hazard Land Zones, which is all land below the 294.7 metres C.G.D. flood elevation for Lake Temagami. O. Reg. 580/86, s. 20.
- 21. Every use of land and every erection or use of buildings or structures is prohibited except,
 - (a) campsites used for temporary camping;
 - (b) conservation; and
 - (c) flood and erosion control. O. Reg. 580/86, s. 21.

PART V

- This Part applies to the Wilderness Zones.
 Reg. 580/86, s. 22.
- 23. Every use of land and every erection or use of buildings or structures is prohibited except,
 - (a) conservation; and
 - (b) campsites used for temporary camping. O. Reg. 580/86, s. 23.

TABLE 1

| Zone | Min. Lot Size (square metres) | Min. Lot Frontage (metres) | Min. Bldg. Setback From Lot Lines (metres) | Maximum Height (metres) |
|---------------|-------------------------------------|----------------------------------|--|-------------------------------|
| Residential: | | | | |
| L1 | 4,200 | 45 | 5 | 11 |
| L2 | 8,400 | 100 | 5 | 11 |
| Commercial CL | 12,500 | 200(*1) | 5 | 15 |

(*1) or 15 metres frontage per unit; whichever is greater.

O. Reg. 580/86, Table 1.

Bernard Grandmaître
Minister of Municipal Affairs

Dated at Toronto, this 26th day of August, 1986.

(9485)

MUNICIPAL BOUNDARY NEGOTIATIONS ACT, 1981

O. Reg. 581/86. City of Chatham, Township of Chatham Boundary. Made—September 24th, 1986. Filed—September 29th, 1986.

ORDER IN COUNCIL

R.O.C. 363/86

WHEREAS The Corporation of the City of Chatham and The Corporation of the Township of Chatham have entered into an agreement dated the 8th day of July, 1986 for the resolution of certain boundary issues:

AND WHEREAS public notice was given by the Clerk of the Executive Council under subsection 17 (1) of the Municipal Boundary Negotiations Act, 1981 of the intention to make an order implementing the intermunicipal agreement;

AND WHEREAS no objections to the proposed issuance of the Order were filed with the Clerk of the Executive Council within the filing period;

Now Therefore, on the recommendation of the undersigned, the Lieutenant Governor, by and with the advice and concurrence of the Executive Council, orders under section 14 of the Municipal Boundary Negotiations Act, 1981 that,

- 1. On the 1st day of October, 1986, the portion of the Township of Chatham described in the Schedule is annexed to the City of Chatham.
- 2. All real property of The Corporation of the Township of Chatham situate in the annexed area vests in The Corporation of the City of Chatham on the 1st day of October, 1986.
- 3. On the 1st day of October, 1986, the by-laws of The Corporation of the City of Chatham extend to the annexed area and the by-laws of The Corporation of the Township of Chatham cease to apply to such area, except,
 - (a) by-laws that were passed,
 - (i) by the council of The Corporation of the Township of Chatham under section 34 or 41 of the *Planning Act, 1983* or a predecessor of those sections, or
 - (ii) by the council of The Corporation of the Township of Chatham that are kept in force by subsection 13 (3) of The Municipal Amendment Act, 1941,

which shall remain in force until repealed by the council of The Corporation of the City of Chatham; and

- (b) by-laws conferring rights, privileges, franchises, immunities or exemptions that could not have been lawfully repealed by the council of The Corporation of the Township of Chatham.
- 4. The clerk of The Corporation of the Township of Chatham shall forthwith prepare and furnish to the clerk of The Corporation of the City of Chatham a special collector's roll showing all arrears of taxes or special rates assessed against the lands in the annexed area up to and including the 30th day of September, 1986 and the persons assessed therefor.
- 5.—(1) All real property taxes levied under any general or special Act and uncollected in the annexed area that are due and unpaid on the 1st day of October, 1986 shall be deemed on that date to be taxes due and payable to The Corporation of the City of Chatham and may be collected by The Corporation of the City of Chatham.
- (2) On or before the 31st day of December, 1986, The Corporation of the City of Chatham shall pay to The Corporation of the Township of Chatham an amount equal to the amount of all real property taxes that The Corporation of the City of Chatham is entitled to collect in the annexed area under subsection (1) that were due but unpaid on the 1st day of October, 1986.
- 6. All business taxes levied and uncollected in the annexed area that are due and unpaid on the 30th day of September, 1986 shall continue after that date to be taxes due and payable to The Corporation of the Township of Chatham and may be collected by The Corporation of the Township of Chatham.
- 7.—(1) The assessment of land in the annexed area upon which the taxes after the 30th day of September, 1986 shall be levied shall be determined by the Assessment Commissioner in accordance with the classes of real property and the factors prescribed for the City of Chatham by regulation.
- (2) Where the Assessment Commissioner makes an assessment in accordance with subparagraph (1), section 34 of the Assessment Act applies to such assessment.
- 8. The agreement between The Corporation of the City of Chatham and The Corporation of the Township of Chatham entered into on the 8th day of July, 1986 is hereby given effect. O. Reg. 581/86.

Recommended

BERNARD GRANDMAÎTRE
Minister of Municipal
Affairs

Concurred

JAMES BRADLEY
Chairman

Approved and Ordered, September 24th, 1986.

Lincoln M. Alexander
Lieutenant Governor

Schedule

AREA TO BE ANNEXED TO THE CITY OF CHATHAM

The portion of the Township of Chatham described as follows:

That parcel of land in the Township of Chatham in the County of Kent, being part of Lot 4 in Concession I of the said Township and being parts 3 and 4 as shown on a Plan deposited in the Land Registry Office for the Land Registry Division of Kent (No. 24) as Number 24R-1487. O. Reg. 581/86, Sched.

(9486)42

MUNICIPAL BOUNDARY **NEGOTIATIONS ACT, 1981**

O. Reg. 582/86.

O. Reg. 581/86

Township of South Plantagenet-Village of St. Isidore de Prescott. Made-September 24th, 1986. Filed-September 29th, 1986.

ORDER IN COUNCIL

R.O.C. 364/86

WHEREAS The Corporation of the Village of St. Isidore de Prescott and The Corporation of the Township of South Plantagenet have entered into an agreement dated the 5th day of August, 1986 for the resolution of certain boundary issues;

AND WHEREAS public notice was given by the Clerk of the Executive Council under subsection 17 (1) of the Municipal Boundary Negotiations Act, 1981 of the intention to make an order implementing the intermunicipal agreement;

AND WHEREAS no objections to the proposed issuance of the Order were filed with the Clerk of the Executive Council within the filing period;

Now THEREFORE, on the recommendation of the undersigned, the Lieutenant Governor, by and with the advice and concurrence of the Executive Council, orders under section 14 of the Municipal Boundary Negotiations Act, 1981 that,

- 1. On the 1st day of October, 1986, the portion of the Township of South Plantagenet described in the Schedule is annexed to the Village of St. Isidore de Prescott.
- 2. All real property of The Corporation of the Township of South Plantagenet situated in the annexed area vests in The Corporation of the Village of St. Isidore de Prescott on the 1st day of October, 1986.

- 3. On the 1st day of October, 1986, the by-laws of The Corporation of the Village of St. Isidore de Prescott extend to the annexed area and the by-laws of The Corporation of the Township of South Plantagenet cease to apply to such area, except,
 - (a) by-laws of The Corporation of the Township of South Plantagenet,
 - (i) that were passed under section 34 or 41 of the Planning Act, 1983 or a predecessor of those sections,
 - (ii) that were kept in force by subsection 13 (3) of The Municipal Amendment Act, 1941, or
 - (iii) that were passed under the Highway Traffic Act or the Municipal Act that regulate the use of highways by vehicles and pedestrians and that regulate the encroachment or projection of buildings or any portion thereof upon or over highways,

which shall remain in force until repealed by the council of The Corporation of the Village of St. Isidore de Prescott; and

- (b) by-laws of The Corporation of the Township of South Plantagenet passed under section 45, 58 or 61 of the Drainage Act, or a predecessor of those sections: and
- (c) by-laws conferring rights, privileges, franchises, immunities or exemptions that could not have been lawfully repealed by the council of The Corporation of the Township of South Plantagenet.
- 4. The clerk of The Corporation of the Township of South Plantagenet shall forthwith prepare and furnish to the clerk of The Corporation of the Village of St. Isidore de Prescott a special collector's roll showing all arrears of taxes or special rates assessed against the lands in the annexed area up to and including the 30th day of September, 1986 and the persons assessed therefor.
- 5.—(1) All real property taxes levied under any general or special Act and uncollected in the annexed area which are due and unpaid on the 1st day of October, 1986 shall be deemed on that date to be taxes due and payable to The Corporation of the Village of St. Isidore de Prescott and may be collected by The Corporation of the Village of St. Isidore de Prescott.
- (2) On or before the 31st day of December, 1986, The Corporation of the Village of St. Isidore de Prescott shall pay to The Corporation of the Township of South Plantagenet an amount equal to the amount of all real property taxes that The Corporation of the Village of St. Isidore de Prescott is entitled to collect in the annexed area under subsection (1) that were due but unpaid on the 1st day of October, 1986.

- 6. All business taxes levied and uncollected in the annexed area which are due and unpaid on the 30th day of September, 1986 shall continue after that date to be taxes due and payable to The Corporation of the Township of South Plantagenet and may be collected by The Corporation of the Township of South Plantagenet.
- 7. The assessment of land in the annexed area upon which the taxes after the 30th day of September, 1986 shall be levied shall be determined by the Assessment Commissioner, and the provisions of section 34 of the Assessment Act apply to the assessment.
- 8. The agreement between The Corporation of the Village of St. Isidore de Prescott and The Corporation of the Township of South Plantagenet entered into on the 5th day of August, 1986 is hereby given effect. O. Reg. 582/86.

Recommended

BERNARD GRANDMAÎTRE Minister of Municipal Affairs

Concurred

JAMES BRADLEY
Chairman

Approved and Ordered, September 24th, 1986.

Lincoln M. Alexander
Lieutenant Governor

Schedule

PORTION OF THE TOWNSHIP OF SOUTH PLANTAGENET TO BE ANNEXED TO THE VILLAGE OF ST. ISIDORE DE PRESCOTT

Beginning at the intersection of the easterly boundary of the Village of St. Isidore de Prescott and the northerly limit of Church Street;

Thence north 21° 19′ west along the easterly limit of a Plan, deposited in the Land Registry Office for the Registry Division of Prescott (No. 46) as Number 46R-3735, 149.35 metres to the northerly limit of the said Plan;

Thence south 68° 41' west along the northerly limit of the said Plan 128.16 metres to the easterly limit of a Plan deposited in the said Registry Office as Number 46R-1559;

Thence north 27° 24' west along the said easterly limit 5.61 metres to an angle in the said Plan;

Thence south 66° 15′ 30″ west along a northerly limit of the said Plan 11 metres, more or less, to the easterly boundary of the Village of St. Isidore de Prescott;

Thence southerly and easterly following the boundaries between the said Village and the Township of South Plantagenet to the place of beginning. O. Reg. 582/86, Sched.

(9487)

42

FARM PRODUCTS GRADES AND SALES ACT

O. Reg. 583/86. Grades—Fruit and Vegetables. Made—September 24th, 1986. Filed—September 29th, 1986.

REGULATION TO AMEND REGULATION 332 OF REVISED REGULATIONS OF ONTARIO, 1980 MADE UNDER THE FARM PRODUCTS GRADES AND SALES ACT

1.—(1) Item 1 of Table 2 of section 9 of Regulation 332 of Revised Regulations of Ontario, 1980, as amended by subsection 2 (1) of Ontario Regulation 460/85, is further amended by adding thereto the following:

Type of Package

Size or Volume

Half-bin

10 bushels, outside measurements 48 in. × 42 in. and inside depth 12¼ in. with sides and ends ½ in. minimum thickness and bottom 5% in. minimum thickness

- (2) Table 2 of the said section 9, as amended by section 2 of Ontario Regulation 764/81 and section 2 of Ontario Regulation 460/85, is further amended by adding thereto the following item:
- 3a. Cantaloupes
- Sound, suitable containers

5285

- (3) Section 9 of the said Regulation, as amended by section 2 of Ontario Regulation 764/81, section 1 of Ontario Regulation 433/84 and section 2 of Ontario Regulation 460/85, is further amended by adding thereto the following subsections:
- (5) Half-bin packages for apples shall be constructed of plywood and ends, sides and bottoms shall be padded with number 1 polyfoam or plastic bubble sheeting with a minimum thickness of one-quarter inch.
- (6) During shipment, half-bin packages of apples shall be level full and completely covered with corrugated material capable of withstanding a bursting test of 125 pounds per square inch. O. Reg. 583/86, s. 1 (3).
 - 2.—(1) Clause 11 (2) (e) of the said Regulation, as amended by section 4 of Ontario Regulation 460/85, is further amended by striking out "and" at the end thereof.
 - (2) Clause 11 (2) (f) of the said Regulation, as made by section 4 of Ontario Regulation 460/85, is revoked and the following substituted therefor:
 - (f) where potatoes of the Yukon Gold variety are packaged, the package shall be prominently marked "Yukon Gold" in letters no smaller than those of the grade name; and
 - (g) where potatoes of a yellow-flesh variety are packaged, the package shall be marked on the principal display surface of the package in bold face type in letters of not less than one-half inch in height with the words,
 - (i) "yellow fleshed", where the common name of the produce is shown elsewhere on the package, or
 - (ii) "yellow fleshed potatoes", where the common name of the produce is not shown elsewhere on the package.
 - 3. Clause 13 (c) of the said Regulation is revoked and the following substituted therefor:
 - (c) the price per unit of weight if sold by weight;
 - 4. Subsection 99 (2) of the said Regulation, as remade by section 7 of Ontario Regulation 764/81, is revoked and the following substituted therefor:

(2) Every contracted load delivered to a processor licensed under the Farm Products Marketing Act and the regulations made thereunder shall be graded by an inspector or grader or by a person employed by the Ministry. O. Reg. 583/86, s. 4.

(9488)

MILK ACT

O. Reg. 584/86. Grades, Standards, Designations, Classes, Packing and Marking. Made-August 20th, 1986. Approved-September 24th, 1986. Filed—September 29th, 1986.

REGULATION TO AMEND REGULATION 622 OF REVISED REGULATIONS OF **ONTARIO**, 1980 MADE UNDER THE MILK ACT

- 1.—(1) Subclause 5 (2) (e) (i) of Regulation 622 of Revised Regulations of Ontario, 1980, as remade by section 2 of Ontario Regulation 630/84, is revoked and the following substituted therefor:
 - (i) shall contain not less than 1.9 per cent nor more than 2.1 per cent milk-fat,
- (2) Subclause 5 (2) (h) (i) of the said Regulation, as remade by section 2 of Ontario Regulation 630/84, is revoked and the following substituted therefor:
 - (i) shall contain not less than 1.9 per cent nor more than 2.1 per cent milk-fat and not less than 8.25 per cent milk solids other than milk-fat, and
 - 2.—(1) Clause 12 (1) (a) of the said Regulation is amended by inserting after "processor" in the first line "of fluid milk products".
- (2) Subsection 12 (3) of the said Regulation, as amended by subsection 5(1) of Ontario Regulation 31/84 and subsections 6 (3) and (4) of Ontario Regulation 630/84, is revoked and the following substituted therefor:
- (3) The amount in litres of milk, partly-skimmed milk, skim-milk or cream that is equal to the amount,

O. Reg. 585/86

- (a) sold as,
 - (i) cream,
 - (ii) double cream,
 - (iii) table cream, or
 - (iv) whipping cream,

by a processor of fluid milk products;

- (b) included in the inventory of milk and fluid milk products of a processor of fluid milk products; or
- (c) used in the processing of,
 - (i) beverage yogurt,
 - (ii) cottage cheese,
 - (iii) egg nog,
 - (iv) kefir,
 - (v) sour cream,
 - (vi) yogurt, or
 - (vii) any milk product not referred to in this section.

is Class 3 milk. O. Reg. 584/86, s. 2 (2).

THE MILK COMMISSION OF ONTARIO:

KENNETH W. KNOX Chairman

GLORIA MARCO BORYS Secretary

Dated at Toronto, this 20th day of August, 1986.

(9490)

FARM INCOME STABILIZATION ACT

O. Reg. 585/86.

Fresh Market Potato Stabilization-1986-1989-Plan. Made-July 29th, 1986. Approved—September 12th, 1986. Filed-September 29th, 1986.

REGULATION MADE UNDER THE FARM INCOME STABILIZATION ACT

PLAN-FRESH MARKET POTATO STABILIZATION, 1986-1989

1. There is hereby established a voluntary plan for farm income stabilization respecting potatoes to be known as the "Ontario Fresh Market Potato Stabilization Plan, 1986-1989". O. Reg. 585/86, s. 1.

- 2. In this Regulation,
- "board" means The Ontario Fresh Potato Growers' Marketing Board established under the Farm Products Marketing Act;
- "plan" means the Ontario Fresh Market Potato Stabilization Plan, 1986-1989;
- "potatoes" means potatoes produced in Ontario and marketed during the term referred to in section 3;
- "production unit" means,
 - (a) one or more farms operated by an individual,
 - (b) one or more farms operated by two or more persons who, in the opinion of the Commission, have a common interest in the outcome of the operation;
- "sales year" means a period from the 1st day of July to the 30th day of June in the next year. O. Reg. 585/86, s. 2.
- 3. The term for this plan is three sales years commencing in 1986. O. Reg. 585/86, s. 3.
- 4. This plan applies only to potatoes in respect of which licence fees have been paid to the board. O. Reg. 585/86, s. 4.
- 5.—(1) A person who applies for enrolment in the plan in respect of a production unit is required, as a condition of acceptance for enrolment, to be,
 - (a) the owner and operator of a farm on which potatoes are produced;
 - (b) the tenant and operator of a farm on which potatoes are produced; or
 - (c) a person who is involved in the operation of a production unit.
- (2) A person who applies for enrolment in the plan shall disclose the name and address of every person who is involved in the operation of the production unit in respect of which application is made.
- (3) No payment shall be made under this plan in respect of a person whose name has not been disclosed on the application for enrolment.
- (4) An application for enrolment in the plan shall be in a form provided by the Commission.
- (5) No person shall be enrolled in the plan unless the application for enrolment is submitted to the Commission not later than the 15th day of October, 1986.

42

- (6) Notwithstanding subsection (5), a person may apply for enrolment in the plan for the sales year commencing in 1987 or 1988 where the prescribed fees are paid to the Commission together with an amount sufficient to place that person's account on a basis equivalent to those producers who enrolled for the sales year commencing in 1986.
- (7) The amount payable under the plan in respect of the first sales year to a person who,
 - (a) enrols under subsection (6); or
 - (b) is deemed to have withdrawn from enrolment under subsection 8 (3) of the Act and is subsequently accepted for re-enrolment,

shall be reduced by 20 per cent. O. Reg. 585/86, s. 5.

- 6.—(1) No payment shall be made in respect of potatoes not registered with the Commission or for which no fee has been paid.
- (2) No payment shall be made under the plan for potatoes marketed by a production unit in excess of 48,000 hundredweight in the aggregate in any sales year within the term of the plan.
- (3) No person is eligible to receive payments under the plan in respect of potatoes that were not grown by that person. O. Reg. 585/86, s. 6.
- 7. It is a condition of enrolment in the plan that to receive any payment thereunder the person enrolled,
 - (a) shall keep sales slips and weigh slips, signed by the buyer and the seller, and conforming to the records of the board through which the potatoes are marketed and shall submit such slips, or the equivalent record supplied by the board, to the Commission or to such person as it may direct, in respect of every lot of potatoes for which payment is claimed under the plan;
 - (b) shall not claim payment for potatoes under the plan unless it was marketed during the sales year with respect to which he or she has applied for payment;
 - (c) shall maintain a record of all sales of potatoes which shall include the names of the buying agent and seller, the date of sale, the date and location of delivery, the quantity and the price. O. Reg. 585/86, s. 7.
- 8.—(1) Each person enrolled in the plan shall, prior to the 1st day of September after each sales year, file with the Commission an annual registration form in a form provided by the Commission respecting potatoes that he or she intends to market subject to this plan during the forthcoming sales year and submit a fee of 10 cents per hundredweight.

- (2) Where a producer, at the end of the term referred to in section 3, has a credit in his or her account with the Commission, the Commission shall refund such moneys to the producer together with any interest earned thereon. O. Reg. 585/86, s. 8.
- 9. The final date for making a claim for payment under this plan shall be two years from the end of the sales year in respect of which the claim is being made. O. Reg. 585/86, s. 9.

FARM INCOME STABILIZATION COMMISSION:

HENRY EDIGER
Vice-Chairman

RUTH DAY Secretary

Dated at Toronto, this 29th day of July, 1986.

(9490) 42

FARM INCOME STABILIZATION ACT

O. Reg. 586/86. Grain Stabilization, 1985-1988—Plan. Made—July 14th, 1986. Approved—September 19th, 1986. Filed—September 29th, 1986.

REGULATION TO AMEND ONTARIO REGULATION 509/85 MADE UNDER THE FARM INCOME STABILIZATION ACT

- 1.—(1) The definition of "grain" in section 2 of Ontario Regulation 509/85 is amended by striking out "and" at the end of clause (a), by adding "and" at the end of clause (b) and by adding thereto the following clause:
 - (c) canola and oats produced in Ontario and marketed during the term referred to in subsection 3 (2);
- (2) The definition of "sales year" in the said section 2 is revoked and the following substituted therefor:

"sales year" means,

(a) in the case of canola, grain corn, soybeans and white beans, a period from the 1st day of September in one year to the 31st day of August in the next year,

- O. Reg. 586/86
- (b) in the case of barley and oats, a period from the 1st day of August to the 31st day of July in the next year, and
- (c) in the case of winter wheat, a period from the 1st day of July to the 30th day of June in the next year.
- 2. Section 3 of the said Regulation is amended by adding thereto the following subsection:
- (2) Notwithstanding subsection (1), the term for this plan in so far as it applies to canola and oats is for two sales years commencing in 1986. O. Reg. 586/86,
 - 3. Section 4 of the said Regulation is amended by adding thereto the following subsection:
- (4a) Notwithstanding subsection (4), a person submitting an application for enrollment for canola and oats on or before the 1st day of October, 1986 may be enrolled for that portion of the plan applied for. O. Reg. 586/86, s. 3.
 - 4.—(1) Subsection 5 (4) of the said Regulation is amended by striking out "3,600" in the second line and inserting in lieu thereof "5,000".
 - (2) Subsection 5 (5) of the said Regulation is amended by adding at the end thereof "plus accrued interest in the applicant's account".
 - 5. Table 1 of the said Regulation is revoked and the following substituted therefor:

Table 1

| Grain | FEE PER TONNE |
|--------------|---------------|
| Barley | \$ 2.15 |
| Canola | 5.00 |
| Corn | 2.25 |
| Oats | 2.15 |
| Soybeans | 4.80 |
| White Beans | 10.00 |
| Winter Wheat | 2.50 |
| | |

FARM INCOME STABILIZATION COMMISSION:

> M. HUFF Chairman

RUTH DAY Secretary

42

Dated at Toronto, this 14th day of July, 1986.

(9491)

FARM INCOME STABILIZATION ACT

O. Reg. 587/86. Grain Stabilization, 1985-1988-Plan. Made—August 6th, 1986. Approved—September 24th, 1986. Filed-September 29th, 1986.

REGULATION TO AMEND ONTARIO REGULATION 509/85 MADE UNDER THE FARM INCOME STABILIZATION ACT

- 1. Section 6 of Ontario Regulation 509/85 is amended by adding thereto the following clauses:
- (ba) shall not claim payment for barley, grain corn or oats marketed that have been replaced through purchases of grain or feed and, in the case of purchase of grain or feed, the amount of barley, grain corn or oats replaced shall be determined by the Commission:
- (bb) shall maintain a record of all barley, grain corn, oats and feed purchased during the sales year;

FARM INCOME STABILIZATION COMMISSION:

> HENRY EDIGER Vice-Chairman

> > RUTH DAY Secretary

Dated at Toronto, this 6th day of August, 1986.

LOCAL ROADS BOARDS ACT

O. Reg. 588/86.
Establishment of Local Roads Areas—
Northwestern Region.
Made—September 15th, 1986.
Filed—September 29th, 1986.

REGULATION TO AMEND REGULATION 599 OF REVISED REGULATIONS OF ONTARIO, 1980 MADE UNDER THE LOCAL ROADS BOARDS ACT

1. Schedules 12 and 16 to Regulation 599 of Revised Regulations of Ontario, 1980 are revoked and the following substituted therefor:

Schedule 12

LYON LOCAL ROADS AREA

All that portion of the Township of Lyon in the Territorial District of Thunder Bay shown outlined on Ministry of Transportation and Communications Plan N-741-2, filed with the Administrative Services Office of the Ministry of Transportation and Communications at Toronto on the 8th day of August, 1986. O. Reg. 588/86, s. 1, part.

Schedule 16

STIRLING LOCAL ROADS AREA

All that portion of the Township of Stirling in the Territorial District of Thunder Bay shown outlined on Ministry of Transportation and Communications Plan N-460-3, filed with the Administrative Services Office of the Ministry of Transportation and Communications at Toronto on the 8th day of August, 1986. O. Reg. 588/86, s. 1, part.

EDWARD FULTON

Minister of Transportation

and Communications

Dated at Toronto, this 15th day of September, 1986.

CORONERS ACT

O. Reg. 589/86. General. Made—September 24th, 1986. Filed—September 30th, 1986.

REGULATION TO AMEND REGULATION 185 OF REVISED REGULATIONS OF ONTARIO, 1980 MADE UNDER THE CORONERS ACT

- 1. Paragraph 3 of Schedule 9 to Regulation 185 of Revised Regulations of Ontario, 1980, as remade by section 2 of Ontario Regulation 302/84, is revoked and the following substituted therefor:
- 3. For each day of attendance of an expert witness, including the medical practitioner who performed the post mortem examination of the body, such fee not exceeding \$65 as the coroner considers proper or such greater fee as the Minister or the Deputy Solicitor General approves where, in the opinion of the Minister or the Deputy Solicitor General, as the case may be, the greater fee is justified having regard to the special circumstances of the
 - 2.—(1) Paragraphs 1 and 2 of Schedule 10 to the said Regulation, as remade by section 3 of Ontario Regulation 302/84, are revoked and the following substituted therefor:
- For a post mortem examination by a legally qualified medical practitioner, including necessary microscopic sections to prove diagnosis and the services of an assistant where necessary, a fee of\$323.00
- For any other examination or analysis, such fee not exceeding \$19 as the coroner considers proper or such greater fee as the Chief Coroner approves.
- (2) Paragraph 3 of the said Schedule 10, as remade by section 6 of Ontario Regulation 533/82, is revoked and the following substituted therefor:

(9493)

42

3. For the use of facilities for post mortem examination in a hospital or other place, for each post mortem examination, a fee of \$48.00

4. The fee mentioned in paragraph 3 may be increased by the Chief Coroner in an amount not exceeding \$15 in those cases where, in the opinion of the Chief Coroner, the increase is justified having regard to the special circumstances of the case.

(3) Paragraph 5 of the said Schedule 10 is revoked.

(9494)

42

SHORELINE PROPERTY ASSISTANCE ACT

O. Reg. 590/86. General. Made—September 19th, 1986. Filed-September 30th, 1986.

REGULATION TO AMEND REGULATION 912 OF REVISED REGULATIONS OF ONTARIO, 1980 MADE UNDER THE SHORELINE PROPERTY ASSISTANCE ACT

- 1. Subsection 1 (2) of Regulation 912 of Revised Regulations of Ontario, 1980, as remade by section 1 of Ontario Regulation 276/81, is revoked and the following substituted therefor:
- (2) No loan made under this Act for building raising, building relocation or building repairs shall exceed 75 per cent of the total cost of the raising, relocation or repairs or \$20,000, whichever is the lesser. O. Reg. 590/86, s. 1.
 - 2. The said Regulation is amended by adding thereto the following section:
 - 11.—(1) The rate of interest for the purposes of subsection 12 (7) of the Act is 8 per cent per annum.
- (2) The rate of interest for the purposes of clause 13 (1) (a) of the Act is 8 per cent per annum calculated on such amount of the annual payment of principal and interest as is in default. O. Reg. 590/86, s. 2.
 - 3. Form 6, as amended by section 5 of Ontario Regulation 276/81, Form 7, as remade by section 6 of Ontario Regulation 276/81, and Form 8 of the said Regulation are revoked and the following substituted therefor:

Shoreline Property Assistance Act

APPLICATION FOR LOAN

| To the Council of the | of enames of all owners) | | in name of mun | municipal organization, mark |
|---|---|---|---|--|
| (b) Owner's Address(es) | | | | |
| 2. Description of Work | | | | |
| Construction of Works | Building Raising | Building Relocation | Building Repairs | |
| 3. Description of Land | | | | |
| (a) Set out a description, sufficier building or structure is now si | | affected by the work. (If build | ing or structure is being rela | cated, describe land on which |
| Date Land Acquired Y M D Describe Build | ing or Structure Affected | | | |
| (b) If building or structura is being after the relocation. | ng relocated, set out a descrip | tion, sufficient for registration, | of the land on which the bu | ilding or structure will be situate |
| Date Land Acquired Y M D | | | | |
| (c) If work is to be done on Crow | vn Land, describe Crown Lan | d | | |
| 4. Estimated Cost | | | | |
| | | Estimate | ed Cost of | |
| | Works | Building Raising | Building Relocation | Building Repairs |
| Material | | | | |
| Other | | | | |
| Inspection Fees | | | | |
| Total Cost | | | | |
| Amount of Loan Request | | | | |
| 5. Total Amount of Loan Requested \$ | | ted must be a multiple of \$100, prescribed by the Regulations u | | |
| 6 Number of Metres of Shoreline of | the Property | 7. Anticrpated Date of Commit Y M | Anticipated Date | of Completion |
| 4. That the amount of the loan m 5. In the case of a loan by a muni in respect of which the loan is 6. In the case of a loan from the f | pplication is in the discretion he decision regarding the app ted, an inspector appointed be to the work has been satisfact and the same of the same of cipality, council shall levy an made, a special equal annual dinister of Municipal Affairs, cipal and interest of the loan, | of the council or the Minister, lication. y council or the Minister of Murity completed before any fund loan applied for herain and will dollact for the term set out in late sufficient to discharge the p I must repay the loan and interested to deliver to the Minister and to deliver to the Minister a | nicipal Affairs, as the case ms are advanced by way of lot be besed on actual complet the regulations over and abortincipal and interest of the last over a period of 10 years signed note for the amount | say be, will report to council an. tion costs. ove all other rates upon the land oan. tin equal annual payments |
| | | Signature of Owner | | |

Shoreline Property Assistance Act

DECLARATION AS TO OWNERSHIP

| Province of Onterio | | | |
|---|-----------------------------------|----------------------------------|--|
| TO WIT: | | | |
| I/WE, | | of the | |
| | | | |
| of in the | | of | |
| do solamnly declare that: | | | |
| I/Wa am/are the actual owner of: (Provide a | | | escribe the land on which the building or |
| structure is now situate) | | | |
| (b) the land to which a building or structur | e is being relocated and describe | ed as follows: (Delata if inappl | icable) |
| | | | |
| Strike out inapplicable paragraphs | | | |
| 2. The land described in subsection 1(e) of thi | s declaration is free from ancum | brance. | |
| Or 3. The land described in subsection 1(a) is end | umbered as follows: | | |
| Name and Address of Mortgagea(s | Neme and Addr | ass of Encumbrancer(s) | Name and Address of Assignee(s) |
| | | | |
| | | | |
| | | | |
| | /Asses Colone to 15 15 | | |
| | (Attach Schedula if n | nora space is raquirad) | |
| 4. The land described in subsection 1(b) of th | s declaration is frae from ancun | nbrence. | |
| Or 5. The land described in subsection 1(b) is and | umbered as follows: | | |
| | | · | |
| Name and Addrass of Mortgagee(s | Name and Addr | ess of Encumbrencer(s) | Name and Addrass of Assignee(s) |
| | | | |
| | | | |
| | | | |
| | (Attach Schodula if a | nore space is required) | |
| | (Attech ochedule ii ii | note space is required? | |
| 6. The application for loan is for a loan to con | struct works on Crown lands w | hich Crown lands are described | l as follows: |
| | | | |
| | | | |
| | | | |
| 7. AND I/WE, make this solemn declaration of | onsciantiously beliaving it to be | true, and knowing that it is of | the same force and effect as if made under oath. |
| Declared befora ma at the | | | |
| of | | | |
| | | | |
| this day of | , 19 | | |
| A Commissioner, atc. | | Signature | |
| | | | |

Shoreline Property Assistance Act

INSPECTION AND COMPLETION CERTIFICATE

| To the | | | | | | | |
|--------------------------------------|---|----------------------------|---|---------------------------------------|--------------------------------|--|--|
| Counci | l of the | | of | | | | |
| Or | | - | | | | | |
| Ministe | r of Municipal Affair | s | | | | | |
| 1 | | have inspected the | works, building raising, reloc | ation or repairs constructed or carr | ied out on the lands described | | |
| (nan | ne of Inspector) | | | | | | |
| as | (Lot No.) | (Plan/Concess | in the | nship, Town, etc.) | | | |
| and owned by | | | for which an application | for loan was made and dated | 19 | | |
| I certify that o | circumstances prevail | with respect to the work | s, building raising, building re | location or building repairs as indic | cated below: | | |
| | | | application for loan end are co | | | | |
| | The works are as de | scribed on the applicatio | n for loan and are completed | to my satisfaction. | | | |
| | The building raising | is as described on the ap | plication for loan and is comp | pleted to my satisfaction. | | | |
| | The building reloca | tion is as described on th | e application for loan and is o | ompleted to my satisfaction. | | | |
| | The works, building described on the ap | reising, building relocat | on or building repairs are con following respects: | pleted to my satisfaction but diffe | r significantly from that | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | The works, building following defects: | reising, building relocat | on or building repairs have be | en completed but are not satisfact | ory because of the | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| I confirm to t | he best of my knowle | edge and belief the shorel | ine length is approximately | metres. | | | |
| The actual cos | st of the completed w | orks, building raising, bu | ilding relocation or building r | epairs are as follows: | | | |
| | | | Actual (| Cost of Completed | | | |
| | | Works | Building Raising | Building Relocation | Building Repairs | | |
| Meterial | | | | | | | |
| Other | | | | | | | |
| Inspection | Fees | | | | | | |
| Total | | | | | - | | |
| Totel \$ | | | | | | | |
| | | | | | | | |
| Dated at this Signature of Inspector | | | | | | | |
| day of | | | | | | | |
| | | | | 0. 1 | Reg. 590/86, s. 3, part | | |
| | | | | | | | |

MINISTRY OF CORRECTIONAL SERVICES ACT

O. Reg. 591/86. General. Made—August 13th, 1986. Filed—October 1st, 1986.

REGULATION TO AMEND REGULATION 649 OF REVISED REGULATIONS OF ONTARIO, 1980 MADE UNDER THE MINISTRY OF CORRECTIONAL SERVICES ACT

- 1. Section 11 of Regulation 649 of Revised Regulations of Ontario, 1980 is amended by adding thereto the following subsection:
- (2a) The Superintendent is not required to give notice under subsection (1) in respect of money in an inmate's trust account amounting to less than \$5, and if that money remains unclaimed for ninety days after the inmate is paroled, discharged or transferred to a community resource centre, it shall be deposited in the Consolidated Revenue Fund. O. Reg. 591/86, s. 1.
 - 2. Subsection 14 (1) of the said Regulation is revoked and the following substituted therefor:
- (1) An inmate shall be permitted visits during reasonable hours from a minister of religion, a probation officer, a parole officer, a volunteer or the inmate's solicitor. O. Reg. 591/86, s. 2.
 - Section 17 of the said Regulation is amended by adding thereto the following subsections:
- (2) Subsection (1) does not apply to a letter sent by an inmate to, or to an inmate from,
 - (a) the inmate's solicitor;
 - (b) a member of the Legislative Assembly of Ontario;
 - (c) a member of the Parliament of Canada;
 - (d) the Deputy Minister of Correctional Services;
 - (e) the Ombudsman or the Correctional Investigator of Canada.
 - (3) A letter referred to in clause (2) (a),

- (a) shall not be opened by the Superintendent or the Superintendent's designate unless the inmate and a staff witness are present;
- (b) may be inspected for contraband; and
- (c) shall not be read by the Superintendent or the Superintendent's designate unless there are reasonable and probable grounds to believe that it contains material that is not privileged as a solicitor-client communication.
- (4) A letter referred to in clause (2)(b), (c) or (d) may be opened, read and inspected for contraband by the Superintendent or the Superintendent's designate.
- (5) A letter referred to in clause (2) (e) shall not be opened, read or inspected for contraband by the Superintendent or the Superintendent's designate. O. Reg. 591/86, s. 3.
 - Sections 18 and 19 of the said Regulation are revoked.
 - 5.—(1) Clause 21 (2) (a) of the said Regulation is revoked and the following substituted therefor:
 - (a) a fee of \$8 per day to be paid to the Ministry, unless the Minister waives the fee, as partial reimbursement for the cost of food, lodging and clothing supplied to the inmate by the institution;
 - (2) Subsection 21 (5) of the said Regulation is revoked and the following substituted therefor:
- (5) If the amount held in trust for an inmate exceeds \$100 throughout a quarter, the inmate shall be credited with simple interest on the amount at the end of the quarter.
- (6) The interest rate used for the purposes of subsection (5) is the average rate of interest earned on the trust account during the preceding quarter.
- (7) The three month periods ending on the 31st day of March, the 30th day of June, the 30th day of September and the 31st day of December are quarters.
- (8) All interest earned on the trust account that is not credited to inmates under subsection (5) shall be devoted to inmate recreation programs.
- (9) When an inmate is paroled, discharged or transferred to a community resource centre, the Superintendent shall, subject to subsection 11 (2a), pay to the inmate all moneys held in trust for the inmate less any disbursements or deductions authorized under subsection (2). O. Reg. 591/86, s. 5 (2).

- Clause 28 (1) (e) of the said Regulation is amended by striking out "wilfully" in the first line.
- 7.—(1) Subsections 30 (1) and (2) of the said Regulation are revoked and the following substituted therefor:
- (1) Where an inmate is alleged to have committed a misconduct, the Superintendent shall decide, as soon as possible, whether or not the inmate committed the misconduct.
- (2) Before making a decision under subsection (1), the Superintendent shall ensure that the inmate is notified of the allegation and is given an opportunity for an interview, which shall be held not later than ten days after the day on which the alleged offence became known to the Superintendent, to discuss the allegation with the Superintendent. O. Reg. 591/86, s. 7 (1).
 - (2) Section 30 of the said Regulation is amended by adding thereto the following subsection:
- (4a) The Superintendent may, during an interview held under subsection (2), adjourn the interview, but no such adjournment shall be for more than three clear days, except with the consent of the inmate. O. Reg. 591/86, s. 7 (2).
 - 8. Subsection 38 (1) of the said Regulation is revoked and the following substituted therefor:
- (1) Where an inmate's request for a temporary absence has been referred to the Temporary Absence Committee under subsection 37 (2) and has been denied by the Superintendent, the inmate may apply to the Minister in writing to conduct a further review of the inmate's request for a temporary absence permit and the inmate shall set out the reasons for the application and any new information or submissions in support of the request for a temporary absence. O. Reg. 591/86, s. 8.
 - 9. Section 39 of the said Regulation is revoked.
 - 10. Part II of the said Regulation is revoked and the following substituted therefor:

PART II

PAROLE

40.—(1) The portion of the term of imprisonment that an inmate must serve before parole may be granted is one-third of the total term of imprisonment imposed upon the inmate.

- (2) Notwithstanding subsection (1), the Board may parole an inmate at any time where, in the opinion of the Board, compelling or exceptional circumstances exist that warrant the inmate's parole.
- (3) Every inmate sentenced to imprisonment in an institution shall be notified in writing by the Ministry of the inmate's parole eligibility date no later than two months after the date on which the inmate was sentenced. O. Reg. 591/86, s. 10, part.
- 41.—(1) Where an inmate is serving a term of imprisonment of less than six months, the inmate may apply to the Board for parole at any time.
- (2) An inmate referred to in subsection (1) is not entitled to a hearing before the Board. O. Reg. 591/86, s. 10, part.
- 42.—(1) Where an inmate is serving a term of imprisonment of six months or more, the Board shall consider the inmate for parole before the parole eligibility date, whether or not the inmate has applied for parole.
- (2) An inmate referred to in subsection (1) is entitled to a hearing before the Board unless the inmate in writing waives the right to the hearing, but if the inmate withdraws the waiver before the Board makes a decision regarding the parole, the Board shall proceed to conduct a hearing of the matter. O. Reg. 591/86, s. 10, part.
- 43.—(1) Where the Board is considering whether or not an inmate is a suitable inmate to be granted parole the Board may obtain and consider any information that the Board considers useful and relevant regarding the character, abilities and prospects of the inmate, and in particular the Board may obtain and consider,
 - (a) particulars of the inmate's trial, conviction and sentence;
 - (b) particulars of the inmate's criminal record;
 - (c) information from persons knowledgeable about the inmate's background and living conditions before the inmate was confined in the institution;
 - (d) a report from the Superintendent of the institution assessing the progress made by the inmate towards rehabilitation; and
 - (e) a report from a health care professional concerning the inmate's physical condition and mental health.
- (2) Where the Board conducts a hearing to determine whether or not an inmate is a suitable inmate to be granted parole,
 - (a) the inmate shall be given at least forty-eight hours notice of the hearing;

- (b) the inmate shall be given an opportunity to attend before the Board and present arguments and submissions on his or her own behalf;
- (c) the Board may permit any person, including an interpreter, to assist in any manner that the Board considers appropriate; and
- (d) the Board shall, in the form and manner that it considers appropriate, inform the inmate of any information in the Board's possession that may affect its decision.
- (3) Upon consideration of the matters referred to in subsection (1) and the arguments and submissions of the inmate, the Board may,
 - (a) grant parole upon such terms and conditions as it considers necessary;
 - (b) defer its decision; or
 - (c) refuse to grant parole,

and the Board shall notify the inmate in writing of its decision and the reasons for the decision. O. Reg. 591/86, s. 10, part.

- 44.—(1) An inmate whose parole is reviewed under subsection 38 (2) of the Act is entitled to a hearing before the Board unless the inmate in writing waives the right to the hearing, but if the inmate withdraws the waiver before the Board makes a decision regarding the parole, the Board shall proceed to conduct a hearing of the matter.
- (2) Where the Board conducts a review of parole under subsection 38 (2) of the Act, the Board may obtain and consider any information that the Board considers useful and relevant, including any records relating to the decision to grant the inmate parole and information about the inmate's conduct while on parole.
- (3) Where the Board conducts a hearing in the course of a review of parole under subsection 38 (2) of the Act, subsection 43 (2) applies to the hearing with necessary modifications.
- (4) Upon consideration of the matters referred to in subsection (2) and the arguments and submissions, if any, of the inmate, the Board may,
 - (a) allow the inmate to continue on parole; or
 - (b) revoke parole,

and the Board shall notify the inmate in writing of its decision and the reasons for the decision. O. Reg. 591/86, s. 10, part.

45.—(1) An inmate who is aggrieved by a decision of the Board may request in writing that the chairman of the Board review the decision.

- (2) Upon receiving a request under subsection (1), the chairman or the chairman's delegate shall review the decision and shall.
 - (a) order a new hearing; or
 - (b) uphold the original decision of the Board,

and shall forthwith notify the inmate in writing of the results of the review with reasons. O. Reg. 591/86, s. 10, part.

- 46.—(1) An inmate who has received parole shall not be allowed to begin parole without signing a certificate of parole setting out the conditions of the parole.
- (2) Notwithstanding subsection (1), the Board may authorize an inmate to be allowed to begin parole before the certificate of parole has been completed and signed where the Board is of the opinion that compelling or exceptional circumstances warrant the authorization. O. Reg. 591/86, s. 10, part.
- 47. It is a condition of every grant of parole, unless the Board orders otherwise, that the parolee shall,
 - (a) remain within the jurisdiction of the Board;
 - (b) keep the peace and be of good behaviour;
 - (c) obtain the consent of the Board or the parole supervisor for any change of residence or employment;
 - (d) report as required to the parole supervisor and the local police force; and
 - (e) refrain from associating with any person who is engaged in criminal activity or, unless approved by the parole supervisor, with any person who has a criminal record. O. Reg. 591/86, s. 10, part.
- 48. A parolee shall on the first day of every month until the expiry of the parolee's full sentence provide the parole supervisor with a written report setting out,
 - (a) the parolee's address;
 - (b) where the parolee is employed, the nature of the parolee's employment, the amount earned and the employer's name and address;
 - (c) where the parolee is unemployed, an explanation of the failure to find employment;
 - (d) details of any arrests or convictions of the parolee that have occurred since the last preceding monthly report; and
 - (e) details of any difficulties the parolee is experiencing. O. Reg. 591/86, s. 10, part.

- 49. The warrant referred to in section 38 of the Act shall be in Form 1. O. Reg. 591/86, s. 10, part.
- 50. Where the Board has granted parole to an inmate to permit the deportation of the inmate, the Board may remit any remaining portion of the
- inmate's term of imprisonment. O. Reg. 591/86, s. 10, part.
 - 11. Forms 1, 2, 3 and 4 of the said Regulation are revoked and the following substituted therefor:

| To | all | peace | officers | and | to | the | superintendents | of | all | provincial | institutions: |
|----|-----|-------|----------|-----|----|-----|-----------------|----|-----|------------|---------------|
|----|-----|-------|----------|-----|----|-----|-----------------|----|-----|------------|---------------|

| Ministry of Corrects | ional Services Act | | | | | |
|---|--|--|--|--|--|--|
| WARR | ANT | | | | | |
| To all peace officers and to the superintendents of all p | provincial institutions: | | | | | |
| WHEREAS on the day of parole was granted, subject to the conditions a under section 34 of the Ministry of Correction | al Services Act to: | | | | | |
| (Name) | (Number) | | | | | |
| who was convicted of | •••••• | | | | | |
| on the day of | , 19, and | | | | | |
| was sentenced to | | | | | | |
| and was at the date of the certificate of parole | e confined in | | | | | |
| authorize the arrest and return to a correctional | AND WHEREAS I am a person having authority under the <i>Ministry of Correctional Services Act</i> to authorize the arrest and return to a correctional institution of a person on parole whenever I believe, on reasonable and probable grounds, that the person has failed to observe any condition of his or her parole, | | | | | |
| under the authority vested in me I hereby | NOW THEREFORE | | | | | |
| and return him or her to the nearest province | ial correctional institution, and I command you, the custody and to keep him or her there until duly dis- | | | | | |
| Dated at | Signature | | | | | |
| this day of, 19 To Peace Officer: | (A member of the Board of Parole or a person designated by the Board under section 38 of the Ministry of Correctional Services Act) | | | | | |
| This warrant is to be read to the subject at time of | Executed and read to the subject by the under- | | | | | |
| execution. | signed, this day of, 19 | | | | | |
| | (signature of Peace Officer) | | | | | |
| | No. (Badge) | | | | | |
| | O. Reg. 591/86, s. 11, part. | | | | | |

(9523)

42

O. Reg. 592/86 THE ON LOCAL SERVICES BOARDS ACT

O. Reg. 592/86.

Establishment of Local Services Board— Community of Savant Lake. Made—September 25th, 1986. Filed—October 1st, 1986.

ORDER MADE UNDER THE LOCAL SERVICES BOARDS ACT

IN THE MATTER OF the Local Services Boards Act; and

In The Matter Of the establishment of a Local Services Board for the community of Savant Lake situate in territory without municipal organization in the Territorial District of Thunder Bay.

ORDER

Under the provisions of section 4 of the Local Services Boards Act, IT IS ORDERED:

- 1. A Local Services Board is established under the name "The Local Services Board of Savant Lake". O. Reg. 592/86, s. 1.
- 2. The boundaries of the Board area are those described in the Schedule. O. Reg. 592/86, s. 2.
- 3. The Board shall be composed of five members. O. Reg. 592/86, s. 3.
- 4. The Board may exercise the powers set out in paragraphs 2 and 6 of the Schedule to the Act. O. Reg. 592/86, s. 4.
- 5.—(1) The election of the first members of the Board shall be held in the community of Savant Lake on the 6th day of October, 1986 and the members so elected shall hold office from the 6th day of October, 1986 to the 30th day of September, 1987 and until a new Board is elected.
- (2) Mr. Phil Mostow, Northern Affairs Officer, is appointed to conduct the election of the first members of the Board and for that purpose he has the general supervision of the election and the power to direct the manner of the election and to implement or to carry out any other act or thing that may be required for the effective undertaking of the election of the first members of the Board. O. Reg. 592/86, s. 5.

DAVID PETERSON for Minister of Northern Development and Mines

Dated at Toronto, this 25th day of September, 1986.

Schedule

The parcel or tract of land in the Territorial District of Thunder Bay described as follows:

Commencing at the northeast corner of the Township of Boucher;

Thence south along the east boundary of the said Township and the southerly prolongation thereof to a point distant thereon six miles southerly from the southeast corner of the said Township;

Thence west astronomic twelve miles;

Thence north astronomic twelve miles more or less to the intersection with the westerly prolongation of the north boundary of the Township of Boucher;

Thence easterly along the said westerly prolongation and along the said boundary to the point of commencement. O. Reg. 592/86, Sched.

(9524)

PLANNING ACT, 1983

O. Reg. 593/86.
Restricted Areas—County of Simcoe,
Township of Nottawasaga.
Made—September 26th, 1986.
Filed—October 1st, 1986.

REGULATION TO AMEND REGULATION 675 OF REVISED REGULATIONS OF ONTARIO, 1970 MADE UNDER THE PLANNING ACT, 1983

1. Regulation 675 of Revised Regulations of Ontario, 1970 is amended by adding thereto the following sections:

244.—(1) Notwithstanding any other provision of this Order, a single-family dwelling and buildings and structures accessory thereto may be erected and used on the land described in subsection (2) if the following requirements are met:

Minimum front yard

7.6 metres

Minimum side yards

metres on one side

1.2 metres on the other side

Maximum height of single-family dwelling

9.1 metres

Minimum ground floor area of single-family dwelling

one storey—93 square metres one and one-half storeys

or more—69.8 square metres

- (2) Subsection (1) applies to that parcel of land in the Township of Nottawasaga in the County of Simcoe, being that part of Lot 34 in Concession XII described as Part 1 on a Plan deposited in the Land Registry Office for the Registry Division of Simcoe (No. 51) as Number 51R-14765. O. Reg. 593/86, s. 1, part.
- 245.—(1) Notwithstanding any other provision of this Order, a store in which signs are made and sold may be operated in the vacant building situate on the land described in subsection (2) on the day this section comes into force.
- (2) Subsection (1) applies to that parcel of land in the Township of Nottawasaga in the County of Simcoe, being composed of Lot 63 according to a Plan registered in the Land Registry Office for the Registry Division of Simcoe (No. 51) as Number 1391. O. Reg. 593/86, s. 1, part.

L. J. FINCHAM
Director
Plans Administration Branch
Central and Southwest
Ministry of Municipal Affairs

Dated at Toronto, this 26th day of September, 1986.

9525)

RENTAL HOUSING PROTECTION ACT, 1986

O. Reg. 594/86. General. Made—October 2nd, 1986. Filed—October 3rd, 1986.

REGULATION TO AMEND ONTARIO REGULATION 434/86 MADE UNDER THE RENTAL HOUSING PROTECTION ACT, 1986

- 1. Schedule 2 to Ontario Regulation 434/86, as amended by section 1 of Ontario Regulation 570/86, is further amended by adding thereto the following paragraph:
 - 4. The land known municipally as 351, 354, 355, 356, 357, 358, 359, 360, 361, 362, 363, 364, 365, 366, 367, 368, 369, 371, 373, 375, 377 Claremont Drive; 1010, 1024 Peel Street; and 358, 362, 364, 366, 368, 370, 372, 374, 376, 378, 380, 382, 384, 388, 390, 392, 394, 396, 398, 400, 402, 404, 406, 408, 410 London Terrace, in The Regional Municipality of Ottawa-Carleton and being composed of,

- i. all that part of Peel Street, formerly Glasgow Street, Registered Plan 533, as closed by By-law 161-85, registered as Instrument N303490, designated as Part 1 on a plan of survey received and deposited in the Land Registry Office for the Registry Division of Ottawa-Carleton Number 5 as Plan 5R-9434.
- all that part of Block D, Registered Plan 533, designated as Part 2 on the said Plan 5R-9434,
- iii. all that part of Claremont Drive, Registered Plan 533, as closed by Bylaw 161-85, registered as Instrument N303490, designated as Part 3 on the said Plan 5R-9434,
- iv. all of Block E, registered Plan 533.

Subject to easements for public utilities in, over, along and upon all those parts of the said Peel Street and Claremont Drive, designated as the said Parts 1 and 3.

(9526)

42

EDUCATION ACT

O. Reg. 595/86. Calculation of Fees for Pupils. Made—September 25th, 1986. Approved—October 2nd, 1986. Filed—October 3rd, 1986.

REGULATION TO AMEND ONTARIO REGULATION 115/86 MADE UNDER THE EDUCATION ACT

- 1. Clauses 6 (1) (c), (d) and (e) of Ontario Regulation 115/86 are revoked and the following substituted therefor:
- (c) a program that includes technological studies that qualify for three or more credits toward the secondary school graduation diploma or Ontario secondary school diploma in the 1985-86 school year and for one or more credits toward the secondary school graduation diploma or the Ontario Secondary school diploma in the 1986-87 school year;
- (d) a program of instruction for which credit is granted that is offered in an elementary school to elementary school pupils as defined in paragraph 12 of section 1 of Ontario Regulation 116/86, (General Legislative Grants, 1986); and

(e) a program of instruction for which credit is granted that is offered to extended Roman Catholic separate school pupils as defined in paragraph 21a of section 1 of Ontario Regulation 116/86, (General Legislative Grants,

O. Reg. 595/86

SEAN CONWAY Minister of Education

Dated at Toronto, this 25th day of September, 1986.

(9527)

EDUCATION ACT

O. Reg. 596/86. General Legislative Grants, 1986. Made-September 25th, 1986. Approved—October 2nd, 1986. Filed—October 3rd, 1986.

REGULATION TO AMEND **ONTARIO REGULATION 116/86** MADE UNDER THE **EDUCATION ACT**

- 1.—(1) Paragraph 1 of section 1 of Ontario Regulation 116/86 is revoked and the following substituted therefor:
 - 1. "assessment" for a year means the sum of,
 - i. the residential and farm assessment as defined in clause 220 (b) of the Act, except in the case of The Sudbury Board of Education and The Sudbury District Roman Catholic Separate School Board as defined in section 68 of the Regional Municipality of Sudbury Act, and
 - ii. the quotient obtained by dividing by 0.85 the commercial assessment as defined in clause 220 (a) of the Act, except in the case of The Sudbury Board of Education and The Sudbury District Roman Catholic Separate School Board as defined in section 68 of the Regional Municipality of Sudbury Act,

that is rateable for the purposes of the board, except that reference to the last revised assessment roll in the said clauses 220 (a) and (b) of the Act and section 68 of the Regional Municipality of Sudbury Act shall, for the purposes of this Regulation, be deemed to be reference to the last revised assessment roll used for taxation purposes in the year;

(2) Paragraph 2 of the said section 1 is revoked and the following substituted therefor:

O. Reg. 596/86

- 2. "ADE.EB" means the product of the en-bloc transfer described in paragraph 16 of section 1 and 0.40 correct to two places of decimals;
- (3) Paragraph 4 of the said section 1 is revoked and the following substituted therefor:
 - 4. "A.E.F. for 1979" for a municipality or locality means the 1979 assessment equalization factor for the municipality or locality set out in Schedule B of Ontario Regulation 108/79 except that where such schedule provides factors in respect of parts of a municipality or locality, the assessment equalization factor for 1979 is the weighted average correct to two places of decimals of the factors for the parts of the municipality or locality in such Schedule B weighted with regard to the assessment for the board as defined in clauses 220 (a) and (b) of the Act, except in the case of The Sudbury Board of Education and The Sudbury District Roman Catholic Separate School Board as defined in section 68 of the Regional Municipality of Sudbury Act. according to the last revised assessment roll used for taxation purposes in 1979 that is in respect of such parts or as adjusted by the Minister;
- (4) Sub-subparagraphs a and b of subparagraph i of paragraph 9 of the said section I are revoked and the following substituted therefor:
 - a. in the case of a public or separate school board, the course is in the intermediate division and the A.D.E. in respect of such course conducted by the board is multiplied by 1.23, but does not include that portion of the A.D.E. in respect of a course offered by a Roman Catholic separate school board set out in Column 1 of Table 1 from and including the 1st day of January, 1986 to and including the 31st day of August, 1986 in the grade levels and languages of instruction set out in Columns 2 and 3 respectively of Table 1 or a course offered by a Roman Catholic separate school board set out in Column 1 of Table 1 from and including the 1st day of September, 1986 to and including the 31st day of December, 1986 in the grade

levels and languages of instruction set out in Columns 4 and 5 respectively of Table 1, and

- b. in the case of a Roman Catholic separate school board set out in Column 1 of Table 1. the course is offered from and including the 1st day of January, 1986 to and including the 31st day of August, 1986 in the grade levels and languages of instruction set out opposite thereto in Columns 2 and 3 respectively of Table 1 or the course is offered from and including the 1st day of September, 1986 to and including the 31st day of December, 1986 in the grade levels and languages of instruction set out opposite thereto in Columns 4 and 5 respectively of Table 1,
- (5) Subparagraph vi of paragraph 9 of the said section 1 is revoked and the following substituted therefor:
 - vi. a course described in subparagraph ii offered from and including the 1st day of September, 1986 to and including the 31st day of December, 1986 where the instructors are employed by and paid by the board or the course is provided under section 165 (a) (2) of the Act.
 - via. a course described in subparagraph ii offered from and including the 1st day of January, 1986 to and including the 31st day of August, 1986 or a course described in subparagraph iii or iv, or
- (6) Sub-subparagraphs a and b of subparagraph i of paragraph 11 of the said section I are revoked and the following substituted therefor:
 - a. the portion of the A.D.E. for 1986 calculated under section 2 of Ontario Regulation 127/85 (Calculation of Average Daily Enrolment) that is in respect of resident-internal pupils of the board other than extended Roman Catholic separate school pupils and other than pupils enrolled in schools or classes for trainable retarded pupils,
 - b the product of an enrolment weighting factor of 0.23 and

the portion of the A.D.E. for 1986 calculated under section 2 of Ontario Regulation 127/85 (Calculation of Average Daily Enrolment) that is in respect of elementary school pupils who are resident-internal pupils of the board and who are enrolled in grade 9 or 10 and are taking a program in which the majority of the courses of study are for credit toward the secondary school graduation diploma or Ontario secondary school diploma, and

(7) Sub-subparagraph c of subparagraph i of paragraph 11 of the said section 1 is amended by striking out,

> and where ADE 86. ADE 85 and ADE 84 means the average daily enrolment respectively for the board in respect of resident-internal and non-resident day school pupils, except pupils enrolled in schools or classes for trainable retarded pupils or pupils enrolled in a Roman Catholic separate school board set out in Column 1 of Table 1 in the grade levels and languages of instruction set out opposite in Columns 2 and 3 respectively of Table 1. and in the case of ADE 84 is calculated under clauses 2 (a) and (b) of Regulation 256 of Revised Regulations of Ontario, 1980 and in the case of ADE 86 and ADE 85 is calculated under clauses 2 (a) and (b) of Ontario Regulation 127/85 (Calculation of Average Daily Enrolment),

in the forty-eighth to the seventy-second lines and inserting in lieu thereof,

> and where ADE 86, ADE 85 and ADE 84 means the average daily enrolment respectively for the board in respect

of resident-internal and nonresident day school pupils, except pupils enrolled in schools or classes for trainable retarded pupils or pupils enrolled in a Roman Catholic separate school board set out in Column 1 of Table 1 in grades 9, 10, 11 and 12 and in the case of ADE 84 is calculated under clauses 2 (a) and (b) of Regulation 256 of Revised Regulations of Ontario, 1980 and in the case of ADE 86 and ADE 85 is calculated under clauses 2 (a) and (b) of Ontario Regulation 127/85 (Calculation of Average Daily Enrolment),

- (8) Sub-subparagraph b of subparagraph iii of paragraph 11 of the said section 1 is revoked and the following substituted therefor:
 - b. the portion of the A.D.E. for 1986 calculated under section 2 of Ontario Regulation 127/85 (Calculation of Average Daily Enrolment) that is in respect of extended Roman Catholic separate school pupils who are resident-internal pupils of the board;
- (9) Paragraph 12 of the said section 1 is revoked and the following substituted therefor:
 - 12. "elementary school pupil" means a pupil, other than a pupil referred to in paragraph 21a, who is enrolled in an elementary school and who at the beginning of the school year has completed fewer than eleven credits or their equivalent toward the secondary school graduation diploma or the Ontario secondary school diploma or a pupil who during the summer next following the completion of the eleven credits is enrolled in a summer school program operated by a public or separate school board;
- (10) Subparagraph i, exclusive of the subsubparagraphs, of paragraph 13 of the said section 1 is revoked and the following substituted therefor:
 - for a public or separate school board, in respect of elementary school pupils, the sum of,

- (11) Subparagraph ii, exclusive of the subsubparagraphs, of paragraph 13 of the said section 1 is revoked and the following substituted therefor:
 - ii. for a Roman Catholic separate school board in respect of extended Roman Catholic separate school pupils or a secondary school board, the sum of,
- (12) Subparagraph i, exclusive of the subsubparagraphs, of paragraph 14 of the said section 1 is revoked and the following substituted therefor:
 - for a public or separate school board, in respect of elementary school pupils, the sum of,
- (13) Subparagraph ii of paragraph 14 of the said section 1 is revoked and the following substituted therefor:
 - ii. for a secondary school board operating a program in a class established under section 261 of the Act or for a Roman Catholic separate school board operating a program in a class established under section 261 of the Act for extended Roman Catholic separate school pupils, the products obtained by multiplying the enrolment in the programs in which French is the language of instruction in a subject, by the number of credits that may be granted to a pupil for the subject or by one in the case of a subject offered in a day school in a course for which no credit may be granted and for which a minimum of 110 hours has been scheduled and by,
 - a. in the case of pupils enrolled in grade 9 or 10, \$71, or
 - b. in the case of pupils enrolled in grade 11, 12 or 13, \$77,

such that the maximum number of credits or courses for which no credit may be granted that may be taken into account for the purpose of this subparagraph in respect of any one pupil is five, and

(14) Paragraph 16 of the said section 1 is revoked and the following substituted therefor:

- 16. "en-bloc transfer" means, for a secondary school board set out in Column 1 of Table 2, the number of pupils identified by the Planning and Implementation Commission as having transferred, as an entire educational program, from a secondary school operated by the secondary school board to a Roman Catholic separate school board operating in the same area of jurisdiction in accordance with the board plan of the Roman Catholic separate school board and the impact statement of the secondary school board submitted to the Planning and Implementation Commission;
- (15) The said section 1 is amended by adding thereto the following paragraph:
 - 21a. "extended Roman Catholic separate school pupil" means,
 - i. from and including the 1st day of January, 1986 to and including the 31st day of August, 1986, a pupil enrolled in a grade level and language of instruction set out in Columns 2 and 3 respectively of Table 1 set out opposite a Roman Catholic separate school board set out in Column 1 of Table 1 and who at the beginning of the school year has completed fewer than nineteen credits or their equivalent toward the secondary school graduation diploma or the Ontario secondary school diploma or a pupil who during the summer next following the completion of the nineteen credits is enrolled in a summer school program operated by such Roman Catholic separate school board, or
 - ii. from and including the 1st day of September, 1986 to and including the 31st day of December, 1986, a pupil enrolled in a grade level and language of instruction set out in Columns 4 and 5 respectively of Table 1 set out opposite a Roman Catholic separate school board set out in Column 1 of Table 1 and who at the beginning of the school year has completed fewer than twenty-six credits or their equivalent toward the secondary school graduation diploma or the Ontario secondary school diploma;
- 16) Paragraph 25, exclusive of the subparagraphs, of the said section 1 is revoked and the following substituted therefor:

 "non-resident pupil" of a board means a pupil who is enrolled at a school operated by the board,

other than a pupil from outside Ontario enrolled at the school under a student exchange program approved by the board and other than a pupil enrolled at the school under subsection 1360 (2) of the Act;

- (17) Paragraph 29 of the said section 1 is revoked and the following substituted therefor:
 - 29. "P.A.C." means the pupil accommodation charge that for a pupil of A.D.E. is \$113 in the case of an elementary school pupil or a pupil enrolled in a class or school for trainable retarded pupils and \$226 in the case of a secondary school pupil or an extended Roman Catholic separate school pupil;
- (18) Sub-sub-subparagraphs I and II of subsubparagraph c of subparagraph ii of paragraph 31 of the said section 1 are revoked and the following substituted therefor:
 - I. the product of \$2,534 in the case of a public or separate school board or \$3,445 in the case of a secondary school board, the G.W.F. for 1986 for the board and the portion of the continuing education A.D.E. for grant purposes for 1986 that is not in respect of a course offered by a Roman Catholic separate school board set out in Column 1 of Table 1 from and including the 1st day of January, 1986 to and including the 31st day of August, 1986 in the language of instruction set out opposite thereto in Column 3 of Table 1 or from and including the 1st day of September, 1986 to and including the 31st day of December, 1986 in the language of instruction set out opposite thereto in Column 5 of Table 1, and
 - II. the product of \$3,445, the G.W.F. for 1986 for the board and the portion of the continuing education A.D.E. for grant purposes

for 1986 that is in respect of a course offered by a Roman Catholic separate school board set out in Column 1 of Table 1 from and including the 1st day of January, 1986 to and including the 31st day of August, 1986 in the language of instruction set out opposite thereto in Column 3 of Table 1 or from and including the 1st day of September, 1986 to and including the 31st day of December, 1986 in the language of instruction set out opposite thereto in Column 5 of Table 1,

- (19) Sub-subparagraph e of subparagraph ii of paragraph 31 of the said section 1 is revoked and the following substituted therefor:
 - e. in the case of a secondary school board or a Roman Catholic separate school board set out in Column 1 of Table 1, the product of \$3,445, the G.W.F. for 1986 for the board and the portion of the A.D.E. calculated under clause 3 (a) of Ontario Regulation 127/85 (Calculation of Average Daily Enrolment) in respect of pupils enrolled in a day school in the classroom instruction portion of a course in driver education, where in the case of a Roman Catholic separate school board from and including the 1st day of January, 1986 to and including the 31st day of August, 1986 the course is in the language of instruction set out opposite the name of the board in Column 3 of Table 1 or from and including the 1st day of September, 1986 to and including the 31st day of December, 1986, the course is in the language of instruction set out opposite the name of the board in Column 5 of Table 1, and
- (20) Sub-subparagraph b of subparagraph i of paragraph 32 of the said section 1 is revoked and the following substituted therefor:
 - b. \$195 in the case of an elementary school pupil or \$139 in the

case of a secondary school pupil, or an extended Roman Catholic separate school pupil, and

- (21) Sub-subparagraph b of subparagraph ii of paragraph 32 of the said section 1 is revoked and the following substituted therefor:
 - b. \$2,534 in the case of an elementary school pupil or \$3,445 in the case of an extended Roman Catholic separate school pupil or a secondary school pupil, and
- (22) Paragraph 33 of the said section 1 is revoked and the following substituted therefor:
 - 33. "resident-external pupil" of a board means a pupil whose fee is payable by the board, other than a pupil enrolled in a secondary school under subsection 1360 (2) of the Act;
- (23) Sub-subparagraph b of subparagraph i of paragraph 35 of the said section 1 is revoked and the following substituted therefor:
 - b. the portion of the A.D.E. for 1986 calculated under section 4 of Ontario Regulation 127/85 (Calculation of Average Daily Enrolment) that is in respect of resident-internal pupils of the board enrolled in summer schools established by the board, other than summer schools for extended Roman Catholic separate school pupils or for trainable retarded pupils, in a course for which credit is granted or in a course of study that the board is authorized or required to provide in its day school program in grades 1 to 8 and the course is approved by the Minister for grant' purposes,
- (24) Sub-subparagraph b of subparagraph iv of paragraph 35 of the said section 1 is revoked and the following substituted therefor:
 - the portion of the A.D.E. for 1986 calculated under section 4 of Ontario Regulation 127/85 (Calculation of Average Daily Enrolment) that is in respect of

extended Roman Catholic separate school pupils of the board who are resident-internal pupils of the board enrolled in summer schools established by the board;

- 2.—(1) Sub-subparagraph 2 of subparagraph A of paragraph iii of clause 8 (b) of the said Regulation is revoked and the following substituted therefor:
 - 2. the product of 0.23 and the portion of such A.D.E. that is in respect of elementary school pupils who are resident-external pupils of the board and who are enrolled in grade 9 or 10 and are taking a program in which the majority of the courses are for credit toward the secondary school graduation diploma or Ontario secondary school diploma,
- (2) Subparagraph C of paragraph iii of clause 8 (b) of the said Regulation is revoked and the following substituted therefor:
 - C. \$2,534 in the case of an elementary school pupil or a pupil enrolled in a school or class for trainable retarded pupils, or \$3,445 in the case of an extended Roman Catholic separate school pupil or a secondary school pupil.
- Clause 14 (b) of the said Regulation is revoked and the following substituted therefor:
- (b) \$195 in the case of an elementary school pupil or \$139 in the case of an extended Roman Catholic separate school pupil or a secondary school pupil; and

- Clause 15 (b) of the said Regulation is revoked and the following substituted therefor:
- (b) \$38,500 in the case of a program offered by a public or separate school board in respect of elementary school pupils or \$44,700 in the case of a program offered by a secondary school board or in the case of a program offered by a Roman Catholic separate school board in respect of extended Roman Catholic separate school pupils.
- Section 41, exclusive of the clauses, of the said Regulation is revoked and the following substituted therefor:
- 41. Where on or after the 1st day of January, 1982, as a result of the reorganization of a French-English mixed language school operated by the board prior to the 1st day of September, 1985, a secondary school board other than an isolate board or a board appointed under section 70 of the Act establishes a French-language secondary school under section 261 of the Act or on or after the 1st day of January, 1986, as a result of the reorganization of a French-English mixed language school operated by the board prior to the 1st day of September, 1985, a Roman Catholic separate school board set out in Column 1 of Table 1 establishes a French-language school for extended Roman Catholic separate school pupils under section 261 of the Act, a grant, subject to the approval of the Minister, is payable to the board as follows:
 - Section 42 of the said Regulation is revoked and the following substituted therefor:
- 42. Where a secondary school board set out in Column 1 of Table 2 has en-bloc transfer as defined in paragraph 16 of section 1, the board shall be paid a grant equal to the amount set out opposite thereto in Column 2 of Table 2. O. Reg. 596/86, s. 6.
 - 7. Table 1 of the said Regulation is revoked and the following substituted therefor:

Table 1

| | Januar | y 1, 1986 to | September 1, 1986 | | |
|---|--------------------------|-------------------------------------|------------------------------|-------------------------------------|--|
| | August | 31, 1986 | | 31, 1986 | |
| Column 1 | Column 2 | Column 3 LANGUAGE | Column 4 | Column 5 LANGUAGE | |
| NAME OF BOARD | CRADE LEVEL | OF INSTRUCTION French English | CRADE LEVEL | OF INSTRUCTION French English | |
| Brant County Roman Catholic Separate School Board | 9, 10 & 11 | X | 9,10,11 & 12 | х | |
| Bruce-Grey County Roman Catholic Separate School Board | 9, 10 & 11 | Х | 9,10,11 & 12 | х | |
| Carleton Roman Catholic Separate School Board | 9, 10 & 11 9, 10 & 11 | x x | 9,10,11 & 12 9,10,11 & 12 | X | |
| Cochrane-Iroquois Fails District Roman Catholic Separate School Board | 9 | x | 9, 10 | х | |
| Dufferin-Peel Roman Catholic Separate School Board | 9 9, 10 & 11 | x x | 9 & 10 9,10,11 & 12 | X X | |
| Durham Region Roman Catholic Separate School Board | 9, 10 & 11 | X | 9,10,11 & 12 9 & 10 | x x | |
| Elgin County Roman Catholic Separate School Board | 9, 10 & 11 | Х | 9,10,11 & 12 | x | |
| Essex County Roman Catholic Separate School Board | 9, 10 & 11 9, 10 & 11 | x x | 9,10,11 & 12 9,10,11 & 12 | X X | |
| Frontenac-Lennox and Addington County Roman Catholic Separate School Board | 9, 10 & 11 9, 10 & 11 | x | 9,10,11 & 12 9,10,11 & 12 | x x | |
| Haldimand-Norfolk Roman Catholic Separate School Board | 9, 10 & 11 | х | | | |
| Halton Roman Catholic Separate School Board | 9, 10 & 11 | x | 9,10,11 & 12 | X | |
| Hamilton-Wentworth Roman Catholic Separate School Board | 9, 10 & 11 | x | 9,10,11 & 12 | x | |
| Hastings-Prince Edward County Roman Catholic Separate School Board | 9, 10 & 11 | x | 9,10,11 & 12 | x | |
| Huron-Perth County Roman Catholic Separate School Board | | | 9 , | х | |
| Kenora District Roman Catholic Separate School Board | 9, 10 & 11 | х | 9,10,11 & 12 | х . | |

| | January 1, 1986 | September 1, 1986 | | |
|---|---|--|--|--|
| | to August 31, 1986 | December 31, 1986 | | |
| Column 1 | Column 2 Column 3 LANCUAGE | Column 4 Column 5 LÁNGUACE | | |
| NAME OF FOARD | CRADE OF LEVEL INSTRUCTION French English | GRADE OF LEVEL INSTRUCTION French English | | |
| Kent County Roman Catholic Separate School Board | 9, 10 & 11 X 9, 10 & 11 X | 9,10,11 & 12 X 9,10,11 & 12 X | | |
| Lakehead District Roman Catholic Separate School Board | 9, 10 & 11 X | 9,10,11 & 12 X | | |
| Lambton County Roman Catholic Separate School Board | 9, 10 & 11 X | 9,10,11 & 12 X | | |
| Lanark, Leeds and Grenville County Roman Catholic Separate School Board | 9, 10 & 11 X | 9,10,11 & 12 X | | |
| Lincoln County Roman Catholic Separate School Board | 9, 10 & 11 X | 9,10,11 & 12 X | | |
| London and Middlesex County Roman Catholic Separate School Board | 9, 10 & 11 X | 9,10,11 & 12 X 9 X | | |
| Metropolitan Separate School Board | 9 X 9, 10 & 11 X | 9 & 10 X 9,10,11 & 12 X | | |
| Nipissing District Roman Catholic Separate School Board | 9, 10 & 11 X | 9,10,11 & 12 X | | |
| Ottawa Roman Catholic Separate School Board | 9, 10 & 11 X 9, 10 & 11 X | 9,10,11 & 12 X 9,10,11 & 12 X | | |
| Oxford County Roman Catholic Separate School Board | 9, 10 & 11 X | 9,10,11 & 12 X | | |
| Peterborough-Victoria-Northumberland and Newcastle Roman Catholic Separate School Board | 9, 10 & 11 X | 9,10,11 & 12 X | | |
| Renfrew County Roman Catholic Separate School Board | 9, 10 & 11 X | 9,10,11 & 12 X | | |
| Sault Ste. Marie District Roman Catholic Separate School Board | 9, 10 & 11 X | 9,10,11 & 12 X | | |
| Simcoe County Roman Catholic Separate School Board | 9, 10 & 11 X | 9,10,11 & 12 X | | |
| Stormont, Dundas and Glengarry Roman Catholic Separate School Board | 9, & 10 X 9, 10 & 11 X | 9 & 10 X 9,10,11 & 12 X | | |

| | January August 3 | 1, 1986 to 1, 1986 | September 1, 1986 to December 31, 1986 | | |
|---|--------------------------|-------------------------------|--|-------------------------------|--|
| Column 1 | Column 2 | Column 3 LANGUAGE OF | Column 4 | Column 5 LANGUAGE OF | |
| NAME OF BOARD | LEVEL | INSTRUCTION French English | LEVEL | INSTRUCTION French English | |
| Sudbury District Roman Catholic Separate School Board | 9, 10 & 11 9, 10 & 11 | x x | 9,10,11 & 12 9,10,11 & 12 | x x | |
| Timmins District Roman Catholic Separate School Board | 9, 10 & 11 | Х | 9,10,11 & 12 | X | |
| Waterloo County Roman Catholic Separate School Board | 9, 10 & 11 | - X | 9,10,11 & 12 | Х | |
| Welland County Roman Catholic Separate School Board | 9, 10 & 11 | Х | 9,10,11 & 12 | X | |
| Wellington County Roman Catholic Separate School Board | 9, 10 & 11 | х | 9,10,11 & 12 | Х | |
| Windsor Roman Catholic Separate School Board | 9, 10 & 11 | Х | 9,10,11 & 12 | Х | |
| York Region Roman Catholic Separate School Board | 9, 10 & 11 | х | 9,10,11 & 12 9 & 10 | x | |

O. Reg. 596/86, s. 7.



SEAN CONWAY Minister of Education

Dated at Toronto, this 25th day of September, 1986.

(9528)

EDUCATION ACT

O. Reg. 597/86. Apportionment 1986 Requisitions. Made—October 2nd, 1986. Filed-October 3rd, 1986.

REGULATION TO AMEND **ONTARIO REGULATION 114/86** MADE UNDER THE **EDUCATION ACT**

1. Ontario Regulation 114/86 is amended by adding thereto the following sections:

1a.—(1) For the purposes of this Regulation, The Sudbury District Roman Catholic Separate School Board is deemed to be a divisional board.

(2) Subclause 1 (a) (i), clause 1 (b), clause 2 (2) (c), section 3 and subsection 4 (1) do not apply in the case of The Sudbury District Roman Catholic Separate School Board. O. Reg. 597/86, s. 1, part.

6. Subclauses 1 (a) (i) and 1 (b) (i), clauses 2 (2) (c) and 3 (2) (c) and subsection 4 (1) do not apply in the case of The Sudbury Board of Education. O. Reg. 597/86, s. 1, part.

(9529) 42

GAME AND FISH ACT

O. Reg. 598/86. Furs. Made—October 2nd, 1986. Filed—October 3rd, 1986.

REGULATION TO AMEND REGULATION 415 OF REVISED REGULATIONS OF ONTARIO, 1980 MADE UNDER THE GAME AND FISH ACT

- 1. Subsection 18 (1) of Regulation 415 of Revised Regulations of Ontario, 1980, as remade by section 1 of Ontario Regulation 521/85, is revoked and the following substituted therefor:
- (1) The royalties for taking or shipping to a point outside Ontario any fur-bearing animal or its pelt or sending or having sent any fur-bearing animal or its pelt to a tanner or taxidermist to be tanned, plucked or treated in any way are as follows:

| | 1. | Badger\$ | .45 |
|----|-------|-----------------|-------|
| | 2. | Beaver | 1.90 |
| | 3. | Bobcat | 6.70 |
| | 4. | Coyote | 1.35 |
| | 5. | Fisher | 9.75 |
| | 6. | Fox (Arctic) | .80 |
| | 7. | Fox (Coloured) | 1.55 |
| | 8. | Fox (Grey) | .75 |
| | 9. | Lynx | 27.30 |
| | 10. | Marten | 2.10 |
| | 11. | Mink | 1.75 |
| | 12. | Muskrat | .20 |
| | 13. | Opossum | .05 |
| | 14. | Otter | 2.50 |
| | 15. | Raccoon | 1.10 |
| | 16. | Skunk | .10 |
| | 17. | Timber Wolf | 2.50 |
| | 18. | Weasel | .10 |
| | 19. | Wolverine | 7.90 |
| (0 | 9530) | O. Reg. 598/86, | s. 1. |
| , | , | | |

2231



Publications Under The Regulations Act

October 25th, 1986

ONTARIO GUARANTEED ANNUAL INCOME ACT

O. Reg. 599/86. Guaranteed Income Limit. Made-October 2nd, 1986. Filed—October 6th, 1986.

REGULATION MADE UNDER THE ONTARIO GUARANTEED ANNUAL INCOME ACT

GUARANTEED INCOME LIMIT

- I. Commencing with the month of October, 1986, the guaranteed income limit for purposes of,
 - (a) subclause 1 (j) (i) of the Act is \$8,728.08;
 - (b) subclause 1 (j) (ii) of the Act is \$7,263.84;
 - (c) subclause 1 (j) (iii) of the Act is \$7,263.84; and
 - (d) subclause 1 (j) (iv) of the Act is \$14,527.68. O. Reg. 599/86, s. 1.
 - 2. Ontario Regulation 409/86 is revoked.
- 3. This Regulation comes into force on the 1st day of October, 1986.

(9531)

CROP INSURANCE ACT (ONTARIO)

O. Reg. 600/86. Crop Insurance Plan-Flue-Cured Tobacco. Made-September 8th, 1986. Approved-October 2nd, 1986. Filed-October 7th, 1986.

REGULATION TO AMEND **REGULATION 206 OF** REVISED REGULATIONS OF **ONTARIO**, 1980 MADE UNDER THE CROP INSURANCE ACT (ONTARIO)

- 1. Section 3 of the Schedule to Regulation 206 of Revised Regulations of Ontario, 1980, as amended by section 1 of Ontario Regulation 630/82, section 1 of Ontario Regulation 359/84, section 1 of Ontario Regulation 511/84 and section 1 of Ontario Regulation 524/85, is further amended by adding thereto the following clause:
 - (g) "price guarantee" means the average price received for the total crop marketed by The Ontario Flue-Cured Tobacco Growers' Marketing Board for the crop year less 5 per cent.
- 2. Section 9 of the said Schedule, as remade by section 4 of Ontario Regulation 524/85, is revoked and the following substituted therefor:
- 9. The coverage provided in each crop year under section A or B of the endorsement shall be computed by the Commission and shall not exceed 80 per cent of the average farm yield multiplied by 50 per cent of the final market average price less 5 per cent.
 - 3. Section 10 of the said Schedule, as remade by section 5 of Ontario Regulation 524/85, is revoked and the following substituted therefor:
- 10. The maximum amount for which the Commission is liable for a loss under a contract of insurance shall be the amount obtained by multiplying 80 per cent of the average farm yield by the final market average price less 5 per cent.
 - 4.—(1) Subparagraph 6 (5) of Form 1 of the said Regulation, as remade by subsection 7 (2) of Ontario Regulation 524/85, is revoked and the following substituted therefor:
- (5) Subject to subparagraph (6), where, upon completion of harvesting,
 - (a) one-half of the total gross income from the harvested acreage is less than the insurance coverage of the insured person, the amount of loss that shall be taken into account in the final adjustment of loss shall be calculated by subtracting one-half of the total gross income

43

from one-half of the amount arrived at by multiplying the price guaranteed per pound by the actual production harvested; or

- (b) the actual production from the harvested acreage multiplied by 45 per cent of the contract price per pound is less than the insurance coverage of the insured person, the amount of loss that shall be taken into account in the final adjustment of loss shall be calculated by subtracting the amount obtained by multiplying the actual production from the harvested acreage by 45 per cent of the contract price per pound from the insurance coverage.
- (2) Subparagraph 6 (6) of the said Form 1 is revoked and the following substituted therefor:
- (6) The amount of loss calculated under sub-sub-paragraph (5) (b) shall be reduced by an amount equal to the rental value of any poundage allotment in respect of which a production claim is paid to the insured person.
- (3) Subparagraph 8 (6) of the said Form I, as remade by subsection 7 (4) of Ontario Regulation 524/85, is revoked and the following substituted therefor:
 - (6) Where, upon completion of harvesting,
 - (a) one-half of the total gross income from the harvested acreage is less than the insurance coverge of the insured person, the amount of loss that shall be taken into account in the final adjustment of loss shall be calculated by subtracting one-half of the total gross income from one-half of the amount arrived at by multiplying the price guaranteed per pound by the actual production harvested; or
 - (b) the actual production from the harvested acreage multiplied by 30 per cent of the contract price per pound is less than the insurance coverage of the insured person, the amount of loss that shall be taken into account in the final adjustment of loss shall be calculated by subtracting the amount obtained by multiplying the actual production from the harvested acreage by 30 per cent of the contract price per pound from the insurance coverage.

THE CROP INSURANCE COMMISSION OF ONTARIO:

HENRY EDIGER Vice-Chairman

> J. MULDER Secretary

Dated at Toronto, this 8th day of September, 1986.

(9532)

PARKWAY BELT PLANNING AND DEVELOPMENT ACT

O. Reg. 601/86.
The Regional Municipality of York,
Town of Markham.
Made—September 26th, 1986.
Filed—October 8th, 1986.

REGULATION TO AMEND ONTARIO REGULATION 473/73 MADE UNDER THE PARKWAY BELT PLANNING AND DEVELOPMENT ACT

1. Ontario Regulation 473/73 is amended by adding thereto the following section:

75.—(1) A single-family dwelling and buildings and structures accessory thereto may be erected and used on the land described in subsection (2) if the dwelling existing on the land on the day this section comes into force is demolished and if the new dwelling meets the following requirements:

Minimum lot frontage 30 metres

Minimum lot area 0.4 hectares

Minimum front yard 9 metres

Minimum side yards 3 metres

(2) Subsection (1) applies to that parcel of land in the Town of Markham, in The Regional Municipality of York, being part of Lot 10, Registered Plan No. 2196 of the said Town of Markham, described as follows:

Commencing at a point in the south limit of Helen Avenue at the northwest angle of Lot 10;

Thence southerly along the westerly limit of Lot 10 a distance of 966.50 feet, more or less, to the southwest angle of Lot 10;

Thence east along the south limit of Lot 10 a distance of 113.50 feet to an iron bar;

Thence north along a line having a bearing of north 9° 02′ 30″ west a distance of 966.76 feet to a point in the north limit of Lot 10 being the south limit of Helen Avenue;

Thence westerly along the north limit of Lot 10 a distance of 113.47 feet to the place of beginning, which parcel contains 2.50 acres more or less. O. Reg. 601/86, s. 1.

L. J. FINCHAM
Director
Plans Administration Branch
Central and Southwest
Ministry of Municipal Affairs

Dated at Toronto, this 26th day of September, 1986.

(9555)

PLANNING ACT, 1983

O. Reg. 602/86.
Restricted Areas—District of Sudbury,
Township of Baldwin.
Made—September 26th, 1986.
Filed—October 8th, 1986.

REGULATION TO REVOKE ONTARIO REGULATION 270/74 MADE UNDER THE PLANNING ACT, 1983

- 1.—(1) Ontario Regulation 270/74 is revoked.
- (2) Section 2 of Ontario Regulation 334/76 is revoked.

BERNARD GRANDMAITRE
Minister of Municipal Affairs

Dated at Toronto, this 26th day of September, 1986.

(9556) 43

PLANNING ACT, 1983

O. Reg. 603/86.
Restricted Areas—District of Thunder
Bay, Geographic townships of
Pearson and Scoble.
Made—October 3rd, 1986.
Filed—October 9th, 1986.

REGULATION TO AMEND ONTARIO REGULATION 219/75 MADE UNDER THE PLANNING ACT. 1983

1. Section 11a of Ontario Regulation 219/75, as made by section 4 of Ontario Regulation 402/86, is amended by striking out "Minimum lot coverage" in the sixth line and inserting in lieu thereof "Maximum lot coverage".

PAULINE MORRIS
Director
Plans Administration Branch
North and East
Ministry of Municipal Affairs

Dated at Toronto, this 3rd day of October, 1986.

(9558) 43

LOCAL ROADS BOARDS ACT

O. Reg. 604/86.
Establishment of Local Roads
Areas—Northern and Eastern
Regions.
Made—October 2nd, 1986.
Filed—October 9th, 1986.

REGULATION TO AMEND REGULATION 598 OF REVISED REGULATIONS OF ONTARIO, 1980 MADE UNDER THE LOCAL ROADS BOARDS ACT

 Schedule 67 to Regulation 598 of Revised Regulations of Ontario, 1980 is revoked and the following substituted therefor:

Schedule 67

INGRAM LOCAL ROADS AREA

All those portions of the Township of Ingram in the Territorial District of Timiskaming shown outlined on Ministry of Transportation and Communications Plan N-801-4, filed with the Administrative Services Office of the Ministry of Transportation and Communications at Toronto on the 23rd day of September, 1986. O. Reg. 604/86, s. 1.

EDWARD FULTON

Minister of Transportation

and Communications

Dated at Toronto, this 2nd day of October, 1986.

(9559) 43

RENTAL HOUSING PROTECTION ACT, 1986

O. Reg. 605/86. General. Made—October 9th, 1986. Filed—October 9th, 1986.

REGULATION TO AMEND ONTARIO REGULATION 434/86 MADE UNDER THE RENTAL HOUSING PROTECTION ACT. 1986

- Subsection 2 (1) of Ontario Regulation 434/86 is revoked and the following substituted therefor:
- (1) A rental residential property is exempt from the Act if the number of residential units in the property, including the number of rental units, is four or less. O. Reg. 605/86, s. 1.
 - Section 3 of the said Regulation is revoked and the following substituted therefor:
- 3.—(1) A rental residential property or part thereof that is subject to demolition under subsection 10 (4) of the *Building Code Act*, an order for clearance of buildings and structures under clause 31 (7) (b) of the *Planning Act*, 1983 or an order for removal under clause 18 (2) (a) of the *Fire Marshals Act* is exempt from clause 4 (1) (a) of the Act.
- (2) A rental residential property or part thereof that is the subject of an order under section 10 of the *Building Code Act*, an order for repairs under clause 31 (7) (b) of the *Planning Act*, 1983 or an order for repairs under section 18 of the *Fire Marshals Act* is exempt from clause 4 (1) (c) of the Act. O. Reg. 605/86, s. 2.
 - Section 5 of the said Regulation is revoked and the following substituted therefor:
- **5.** A rental residential property is exempt from the Act in respect of an application under section 50 of the *Condominium Act*,
 - (a) if at the date of the application not more than half of the units in the property have ever been occupied as rental units other than by persons who have, in good faith, entered into an agreement or option to purchase their units; or
 - (b) if draft approval has been obtained under section 50 of the *Planning Act*, 1983.O. Reg. 605/86, s. 3.
 - 4. Section 6 of the said Regulation is amended by adding thereto the following subsection:
 - (2) A rental residential property is exempt,
 - (a) from clause 4 (1) (a) of the Act if demolished under the Non-Profit Housing Program

- administered by the Ontario Housing Corporation; or
- (b) from clause 4 (1) (c) of the Act if it is renovated or repaired under,
 - (i) the Low Rise Rehabilitation Program administered by the Ministry of Housing,
 - (ii) the Rental Residential Rehabilitation Assistance Program administered by the Canada Mortgage and Housing Corporation, or
 - (iii) the Non-Profit Housing Program administered by the Ontario Housing Corporation. O. Reg. 605/86, s. 4.
- 5. The said Regulation is amended by adding thereto the following section:
- 6a. A conveyance that consists only of an easement or right of way is exempt from clause 4 (1) (d) of the Act. O. Reg. 605/86, s. 5.
 - 6. Clause 7 (e) of the said Regulation is revoked and the following substituted therefor:
 - (e) the council of a municipality has approved the conversion of the rental residential property to a co-operative.
 - 7. Section 9 of the said Regulation is revoked and the following substituted therefor:
- 9. An application for a demolition under clause 4 (1) (a) of the Act shall contain the following information:
 - 1. Local municipality and municipal address.
 - 2. Location of property (abbreviated legal description).
 - 3. Name, address and telephone number of registered owner.
 - 4. Name, address and telephone number of agent and solicitor.
 - 5. Name and current address of tenants in the rental residential property.
 - 6. Nature of demolition sought (partial, complete).
 - 7. Reasons for demolition.
 - Application for building permit made and the date of application; date granted.

- Number of existing units on the property, specifying the number of units occupied for residential purposes and specifying the units that are the subject of the application.
- 10. Range of rents in the property—list by unit type (bachelor, one bedroom, etcetera).
- 11. If units vacant, dates of vacancy.
- 12. Date that the construction of the building was completed.
- 13. Gross floor area.
- 14. Number of storeys.
- 15. Height of building.
- A statement by the applicant certifying that all statements contained in the application are true. O. Reg. 605/86, s. 7.
- 8.—(1) Paragraph 1 of section 10 of the said Regulation is amended by adding at the end thereof "of the property".
- (2) Paragraph 2 of the said section 10 is revoked and the following substituted therefor:
 - 2. Location of property (abbreviated legal description).
- (3) Paragraph 6 of the said section 10 is amended by striking out "or" in the second line and inserting in lieu thereof "and".
- (4) The said section 10 is amended by adding thereto the following paragraph:
 - 7a. Name and current address of tenants in the rental residential property.
- (5) Paragraphs 8 and 9 of the said section 10 are revoked and the following substituted therefor:
 - 8. Proposed land use.
 - Number of existing units on the property specifying the number of units used for residential purposes that are occupied or vacant and the dates of vacancies, and specifying the units that are the subject of the application.
- (6) Paragraph 11 of the said section 10 is revoked and the following substituted therefor:

- Date that the construction of the building was completed.
- (7) Paragraph 23 of the said section 10 is amended by striking out "building" in the first line and inserting in lieu thereof "property".
- (8) Paragraph 25 of the said section 10 is revoked and the following substituted therefor:
 - 25. Available services and proposed services.
- (9) Paragraph 31 of the said section 10 is revoked and the following substituted therefor:
 - 31. A statement by the applicant certifying that all statements contained in the application are true.
- 9.—(1) Paragraph 2 of section 11 of the said Regulation is revoked and the following substituted therefor:
 - 2. Location of property (abbreviated legal description).
- (2) Paragraph 6 of the said section 11 is amended by striking out "or" in the second line and inserting in lieu thereof "and".
- (3) The said section 11 is amended by adding thereto the following paragraph:
 - 7a. Name and current address of tenants in the rental residential property.
- (4) Paragraphs 9 and 10 of the said section 11 are revoked and the following substituted therefor:
 - 9. Proposed land use.
 - 10. Number of existing units on the property specifying the number of rental residential units occupied and those vacant and the dates of vacancies, and specifying the units that are the subject of the application.
- (5) Paragraph 12 of the said section 11 is revoked and the following substituted therefor:
 - Date that the construction of the building was completed.

- (6) Paragraphs 25 and 26 of the said section 11 are revoked and the following substituted therefor:
 - Range of existing rents in the property list by unit type (bachelor, one bedroom, etcetera).
 - 26. Available services and proposed services.
- (7) Paragraph 32 of the said section 11 is revoked and the following substituted therefor:
 - A statement by the applicant certifying that all statements contained in the application are true.
- 10. Sections 12, 13 and 14 of the said Regulation are revoked and the following substituted therefor:
- 12. An application for renovation or repair under clause 4 (1) (c) of the Act shall contain the following information:
 - 1. Local municipality and municipal address.
 - Location of property (abbreviated legal description).
 - 3. Name, address and telephone number of registered owner.
 - Name, address and telephone number of agent and solicitor.
 - 5. Name and current address of tenants in the rental residential property.
 - Nature of renovation (interior or exterior alterations, additions, with details).
 - 7. Reasons for renovation or repair.
 - 8. Date of construction of building and type (combustible, non-combustible).
 - 9. Gross floor area.
 - 10. Number of storeys.
 - 11. Number of existing units on the property specifying the residential rental units occupied and those vacant and the dates of vacancies, and specifying the units that are the subject of the application.
 - 12. Number of kitchens and bathrooms.
 - Range of existing rents on the property list by unit type (bachelor, one bedroom, etcetera).

- 14. Number of units proposed.
- Estimates of range of rents following renovation.
- A statement by the applicant certifying that all statements contained in the application are true. O. Reg. 605/86, s. 10, part.
- 13. An application under subsection 5 (1) of the Act shall contain the following information:
 - 1. Local municipality and municipal address.
 - Location of property (abbreviated legal description).
 - Name, address and telephone number of owner of the share or interest.
 - Name, address and telephone number of tenant occupying unit and relationship to owner.
 - Name, address and telephone number of agent and solicitor.
 - 6. Name and current address of tenants in the rental residential property.
 - Date of original purchase of interest and purchase price.
 - 8. Estimated selling price.
 - A statement by the applicant certifying that all statements contained in the application are true.
 Reg. 605/86, s. 10, part.
- 14. An application under clause 4 (1) (d) of the Act for consent to sever any part of a rental residential property shall contain the following information:
 - 1. Local municipality and municipal address.
 - Location of property (abbreviated legal description).
 - Any prior application made for consent to sever the property, including the previous file number.
 - 4. Name, address and telephone number of registered owner.
 - Name, address and telephone number of agent, solicitor and planning consultant.
 - Name, address and telephone number of Ontario Land Surveyor.
 - 7. Name and current address of tenants in the rental residential property.
 - 8. Description of land to be severed and land to be retained.

- 9. Type of transaction (conveyance, mortgage, etcetera).
- 10. Any land in the vicinity previously severed by the applicant.
- 11. Name of grantees, mortgagees or lessees and relationship to owner.
- Any application made or application proposed for additional consents on the rental residential property.
- 13. Any application for minor variance or permission to extend or enlarge under section 44 of the *Planning Act*, 1983 in relation to any land that is the subject of application.
- 14. Proposed land use.
- 15. Number of existing units in the rental residential property specifying the number of units used for residential purposes that are occupied or vacant and the dates of vacancies and specifying the units that are the subject of the application.
- Date that the construction of the building was completed.
- 17. Gross floor area of individual units.
- 18. Number of storeys.
- Density proposed on parcel to be severed and parcel to be retained (specify units per hectare).
- 20. Internal roadways.
- 21. Parking provided.
- 22. Landscaping and recreational amenities.
- Land use designation for property in an approved regional or county official plan or amendment, and number of the amendment (if applicable).
- 24. Land use designation for property in an approved local official plan or amendment, and number of the amendment (if any).
- Zoning of the property in an approved zoning by-law or zoning order.
- Site plan approval (if applicable) and building permit.
- 27. Number of rental units that tenants in possession of the units wish to purchase.
- Range of existing rents in the property list by unit type (bachelor, one bedroom, etcetera).

- 29. Estimates of selling prices for severed units and whether any government sponsored financing has been sought or obtained.
- Access from property to publicly owned and maintained road.
- If lakefront without road access, types of docking and parking facilities existing and proposed, distance from property, and distance to nearest provincial highway.
- 32. Available services and proposed services.
- 33. Brief description of existing use, vegetation, topography and drainage.
- 34. Effects of the proposal on the environment (for example, traffic, noise, odours, pollution of waters) and proposed measures to deal with them.
- 35. Effects on the property from the surrounding area (for example, railways, highways, noise) and proposed measures to deal with them.
- Each copy of the application must be accompanied by a sketch showing,
 - (a) abutting land owned by the grantor, its boundaries and dimensions;
 - (b) the distance between the grantor's land and the nearest township lot line or appropriate landmark (for example, a bridge, railway crossing);
 - (c) the parcel of land that is the subject of the application, its boundaries and dimensions, the part of the parcel that is to be severed, the part that is to be retained and the location of all land previously severed;
 - (d) the approximate location of all natural and artificial features on the subject land (for example, buildings, railways, highways, watercourses, drainage ditches, banks, slopes, swamps, wooded areas, wells and septic tanks) and the location of any of these features on adjacent lands which may affect the application;
 - (e) the use of adjoining land (residential, agricultural, cottage, commercial, etcetera);
 - (f) the location, width and names of all road allowances, rights of way, streets or highways within or abutting the property, indicating whether they are public travelled roads, private roads, rights of way or unopened road allowances; and

- (g) the location and nature of any restrictive covenant or easement affecting the subject land.
- 37. A statement by the applicant certifying that all statements contained in the application are true. O. Reg. 605/86, s. 10, part.
- 11. Clause 15 (1) (a) of the said Regulation is amended by striking out "or" at the end of subclause (v), by adding "or" at the end of subclause (vi) and by adding thereto the following subclause:
 - (vii) "CU" for a conversion to another use;
- 12.—(1) Clause 17 (1) (b) is amended by adding after "to" in the first line "the applicant and to ".
- (2) Subsection 17 (2) of the said Regulation is revoked and the following substituted therefor:
- (2) The notice under clause (1) (a) shall be in Form 4.
- (3) The notice under clause (1) (b) shall be in Form 2. O. Reg. 605/86, s. 12 (2).
 - 13.—(1) Section 18 of the said Regulation, exclusive of the paragraphs, is revoked and the following substituted therefor:

TAKE NOTICE that the council of the

- 18. Where the application is for a conversion to a condominium under clause 4 (1) (b) or a consent to sever under clause 4 (12) (d) of the Act, the clerk of the municipality shall, within ten business days after the receipt of the application, give notice to each of the following by providing a copy of the application and a request for written comments:
 - (2) Paragraph 3 of the said section 18 is amended by striking out "Part VIII" in the fifth line and inserting in lieu thereof "Part VII".
 - 14. Section 19 of the said Regulation is amended by striking out "five" in the second line and inserting in lieu thereof "ten business".
 - 15. Form 1 of the said Regulation is amended by striking out "sale" in the tenth line and inserting in lieu thereof "consent, etc.".
 - 16. Forms 2 and 3 of the said Regulation are revoked and the following substituted therefor:

Form 2

Rental Housing Protection Act, 1986

NOTICE OF MEETING TO CONSIDER AN APPLICATION

| TARE NOTICE that the council of the | (name of municipal corporation) |
|--|---|
| will hold a public meeting to consider the | e application of |
| | (name of applicant) |
| | |
| (demolition; conversion | to a condominium, co-operative, apartment hotel, etc.; renovation; consent; etc.) |
| of the following property: | |
| Municipality | |
| Lot(s) No | |
| Part(s) No | |
| Geographic or Former Township | |
| Name of Street | Street No. |

| Unit(s) No. |
|--|
| |
| |
| On the day of , 19 |
| at o'clock (a.m., p.m.) |
| at |
| in |
| AND TAKE NOTICE that the application and the report prepared under section 7 of the said Act (if any) will be available for inspection at the office of the clerk of the said municipality until normal closing time of the municipal offices on the day of the meeting. |
| AND TAKE NOTICE that anyone attending the meeting may make comments with respect to the application. |
| AND TAKE NOTICE that if you do not attend the meeting, the council may proceed in your absence and you will not be entitled to any further notice in the proceedings. |
| AND TAKE NOTICE that any person who wishes to receive notice of council's decision should advise the clerk in writing. |
| Dated the day of , 19 . |
| Clerk |
| Name of the Municipal Corporation |
| O. Reg. 605/86, s. 16, part. |
| Form 3 |
| Rental Housing Protection Act, 1986 |
| CERTIFICATE OF APPROVAL |
| Under section 7 of the Rental Housing Protection Act, 1986, (For condominium add: "and section 50 of the Condominium Act" OR "and exempted under section 50 of the Condominium Act", as applicable) |
| (For severance add: "and section 52 of the Planning Act, 1983") I certify that the consent of |
| (municipal corporation) |
| was given onday of, 19, to a |
| (enter demolition, renovation, etc.) |
| of the following land (set out full description, unit numbers, etc.) |
| ······································ |
| (Add, as applicable, "Subsection |
| of the <i>Planning Act</i> , 1983 applies to any subsequent conveyance of or transaction involving the parcel of land that is the subject of this consent) |

(9560)

FAMILY LAW ACT, 1986

43

O. Reg. 606/86. Election of Surviving Spouse. Made—October 9th, 1986. Filed—October 10th, 1986.

REGULATION MADE UNDER THE FAMILY LAW ACT, 1986

ELECTION OF SURVIVING SPOUSE

1. An election made under section 6 of the Act shall be in Form 1. O. Reg. 606/86, s. 1.

REGLEMENT PRIS EN APPLICATION DE LA LOI DE 1986 SUR LE DROIT DE LA FAMILLE -CHOIX DU CONJOINT SURVIVANT

1. Le choix fuit en vertu de l'article 6 de la Loi est rédigé sur la formule 1. Règl. de l'Ont. 606/86, art. 1

ELECTION UNDER THE FAMILY LAW ACT, 1986

| - 1 | 1 | | | | | | |
|---|---|---|--|--|--|--|--|
| Formule | t'ourt File No./Dossier de la cour n ^o | | 3) | ville, etc. | | (s | stal Code/Code postal |
| CHOIX DU CONJOINT FAIT EN VERTU DE LA LOI DE 1986 SUR LE DROIT DE LA FAMILLE | | | Given name(s)/Prénom(s) | néro ou adresse posiale. City, town, etc./Cité, | | (iven nume(s)/Prénom(s) | e posiale City, town, ctc./Cité, ville, etc. Po |
| CHOIX DU CONJOINT LOI DE 1986 SUR LE L | | é par (procureurs) | ame/Nom de famille | Last address of deceased/Dernière adresse du défant. Street or postal address/Rue et numéro ou adresse postale. City, town, etc./Cité, ville, etc. | th, year/Jour, mois, anner | rname/Nom de fâmille | voltress of spouse/Adresse du conjoint. Street or postal address/rue et numéro ou adresse postale. City, town, etc./Cité, ville, etc. Postal Cocle/Code postal |
| | | This election is filed by (solicitors)/ $\!P\!$ flower par (procureurs) | Name of deceased/Nom du défunt. Surname/Nom de famille | Last address of deceased/Dernière adress | Date of death/Date du décès Day, month, year/Jour, mois, année | Surviving spouse/Conjoint survivant Surname/Nom de famille | veltress of spouse/Adresse du conjoint |

conjoint survivant, fais le choix suivant ; Je sonssignée(e) (Please print)/ecrire en caractères d'imprimerie) jonir du droit prévu à l'article 5 de la Loi de 1986 sur le droit de la famille; to receive the entitlement under section 5 of the Family Law Act, 1986;

the surviving spouse, elect:

| L Y | Ca |
|--------|---------|
| only | |
| pox | seule |
| one | une |
| (check | (cocher |
| OR | no |

1/ se) to receive the entitlement under the will, or under Part II of the Succession Law Reform Act, if there is an intestacy, or both, if there is a partial intestacy./

bénéficier des dispositions testamentaires; s'il n'y a pas de testament, jouir du droit prévu à la partie II de la Loi portant réforme du droit des successions; s'il s'agit d'une succession en partie testamentaire et en partie sans testament, se prévaloir de ces deux options.

Signature of surviving spouse/Signature du conjoint survivant

Date

NOTE:

REMAROUE:

YOU SHOULD HAVE LEGAL ADVICE **VOUS DEVRIEZ** LE PRÉSENT CHOIX ENTRAÎNERA DES EFFETS IMPORTANTS SUR VOS DROITS. THIS ELECTION HAS IMPORTANT EFFECTS ON YOUR RIGHTS. OBTENIR DES CONSEILS JURIDIQUES AVANT DE LE SIGNER. BEFORE SIGNING IT./

R43 (9/86)

(9561)

43

O. Reg. 606/86, Form 1.

2244

ADMINISTRATION OF JUSTICE ACT

O. Reg. 607/86. Fees-Unified Family Court. Made-October 9th, 1986. Filed-October 10th, 1986.

REGULATION TO AMEND **REGULATION 8 OF** REVISED REGULATIONS OF **ONTARIO, 1980** MADE UNDER THE ADMINISTRATION OF JUSTICE ACT

1. The Schedule to Regulation 8 of Revised Regulations of Ontario, 1980, as remade by section 1 of Ontario Regulation 609/85, is revoked and the following substituted therefor:

Schedule

FEES

PAYABLE IN THE UNIFIED FAMILY COURT

| 1. | Filing an application | \$50 |
|----|--|------|
| 2. | Filing of an answer | 25 |
| 3. | Placing of an application on the list for hearing | 85 |
| 4. | Issue of summons to a witness | 9 |
| 5. | Issue of certificate, including up to three pages of copies of Court documents | 9 |
| | For each additional page | .50 |
| 6. | Copies of documents, per page | .50 |
| 7. | Transmission of papers (postage or car- | |

NOTE:

The fees set out in items 1, 2 and 3 are not payable where the only claims made in the proceeding are under the Child and Family Services Act, 1984 or for support, custody of or access to a child and costs. O. Reg. 607/86, s. 1.

riage for not more than two kilograms

included)

2. This Regulation comes into force on the 1st day of November, 1986.

(9562)4.3

ADMINISTRATION OF JUSTICE ACT

O. Reg. 608/86. Fees-Supreme Court and District Court. Made-October 9th, 1986. Filed-October 10th, 1986.

REGULATION MADE UNDER THE ADMINISTRATION OF JUSTICE ACT

FEES—SUPREME COURT AND DISTRICT COURT

I. The following fees are payable in the Supreme Court and in the District Court:

| On the issue of, | |
|--|----|
| i. a statement of claim or notice of action | |
| ii. a petition for divorce | 50 |
| iii. a notice of application | 21 |
| iv. a third or subsequent party claim | 25 |
| v. a statement of defence and counterclaim or answer and counter-petition adding a party | 25 |
| vi. a summons to witness | 9 |
| vii. a certificate | 9 |
| viii. a commission | 16 |
| ix. writ of execution | 17 |
| x. a notice of garnishment | 30 |
| On the signing of, | |
| i. an order directing a reference, except | |

| i. | an order directing a reference, except |
|----|---|
| | an order on requisition directing the |
| | assessment of a solicitor and client bill |
| | of costs |

40

9

| ii. | an order on requisition directing the |
|-----|---|
| | assessment of a solicitor and client bill |
| | of costs |

| iii. | an order | for attendance of a witness i | n |
|------|----------|-------------------------------|---|
| | custody | | |

3. On the filing of,

| i. a notice of intent to defend | . 25 | | | defend | to | intent | of | notice | a | i. |
|---------------------------------|------|--|--|--------|----|--------|----|--------|---|----|
|---------------------------------|------|--|--|--------|----|--------|----|--------|---|----|

| 11. | a s | tater | nent | 10 | detend | e w | nere | no | |
|-----|-------|-------|-------|--------|--------|------|------|-----|----|
| | noti | ce o | fint | ent to | o defe | nd h | as b | een | |
| | filed | l by | the s | same | party | | | 2 | 25 |

| | 0 7 |
|--|--|
| iii. an answer\$25 | C. additional copies regardless of party ordering, if ordered con- |
| iv. a notice of appearance 11 | currently with A or B\$.50 |
| v. a notice of motion served on another party or a notice of motion for leave to | v. for handling costs, per invoice 4 |
| appeal, except a motion for a consent | vi. for attendance out of office, an al- |
| order 21 | lowance for travel in accordance |
| | with Ontario Regulation 283/82 |
| vi. a notice of motion for judgment in a | ("Kilometre Allowances"). |
| divorce action 85 | NOTEC |
| wii a nation of annual fram an interland | NOTES: |
| vii. a notice of appeal from an interlocu- tory order | 1. Solicitors charged at rates in excess of the above |
| tory order | or receiving a transcript that does not substantially |
| viii. a notice of appeal to an appellate | conform with rule 4.09 of Rules of Civil Procedure |
| court of a final order of the Provincial | should notify the Inspector of Legal Offices in writing. |
| Court (Civil Division) 21 | |
| | 2.—(1) Unless at least three days prior notice of |
| ix. a notice of appeal to an appellate | cancellation is given to the official examiner, where an |
| court of a final order of any court or | appointment is cancelled or not kept, the fee to the |
| tribunal other than the Provincial Court (Civil Division) 50 | official examiner shall be \$8 plus \$23 for each hour |
| Court (Civil Division) 30 | reserved for the appointment. |
| x. a request to redeem or request for sale 9 | (2) Saturdays and holidays shall not be counted in |
| | the computation of the three days referred to in sub- |
| 4. On the setting down of an action for trial, | note (1). |
| for the first time only | |
| , | (3) Where a party requires a transcript, |
| 5. For making up and forwarding papers, | (-) within five weating days of placing the order |
| documents and exhibits (the actual cost of | (a) within five working days of placing the order for the transcript, the party shall be charged |
| transportation to be paid in addition) 9 | an additional charge of 50 cents per page; |
| | and |
| 6. For making copies of documents not | |
| requiring certification, per page50 | (b) within two working days of placing the order |
| | for the transcript, the party shall be charged |
| 7. For the inspection of an index of proceed- | an additional charge of \$1.25 per page, |
| ings commenced 2.50 | but where more than one party requires such service, |
| | only the first party to order shall be charged the addi- |
| 8. For the inspection of a court file, except by | tional charge. O. Reg. 608/86, s. 1. |
| a solicitor or party in the proceeding, per | |
| file 2.50 | 2. Ontario Regulations 812/84 and 602/85 are |
| o m | revoked. |
| 9. To an official examiner, for each person | 2. This Doculation comes into force on the 1st days |
| examined, | 3. This Regulation comes into force on the 1st day of November, 1986. |
| i. for the appointment, oath and certifi- | or receitable, 1700. |
| cate | (9563) |
| | III |
| ii. for the provision of facilities per hour | A DAMAYOUND A MICCOLO |
| or part thereof 12 | ADMINISTRATION OF JUSTICE |
| iii. reporter's attendance, per hour or part | ACT . |
| thereof | O. Reg. 609/86. |
| 11 | Fees—Sheriffs. |
| iv. for the transcript of an examination, | Made—October 9th, 1986. |
| per page, | Filed—October 10th, 1986. |
| A 6 | |
| A. first party ordering 3 | |
| B. any additional copies if not | REGULATION MADE UNDER THE |
| ordered before transcript is | ADMINISTRATION OF JUSTICE |
| supplied to first party ordering 3 | ACT |
| | |

FEES-SHERIFFS

- 1. The following fees are payable to sheriffs:
- For postage and handling of a copy of a document where service is effected in the manner prescribed by subrule 16.03(5) of the Rules of Civil Procedure
- On the filing of any writ of execution or order, or renewal thereof, which a sheriff is liable or required to enforce 15

- For each attempt to enforce a writ of execution or order, exclusive of travelling allowance and reasonable and necessary actual disbursements.

 - ii. where a sale is held by the sheriff . . 44

- 7. For kilometres necessarily travelled in the county in which the service of a document is effected, or a writ or order is enforced or any other service performed, or an attempt to serve, enforce or perform is made, as set out in Ontario Regulation 283/82 ("Kilometre Allowances")
- 8. On a search for writs, per name searched
- Where a search for writs pursuant to any single requisition results in one or more abstracts, \$3 per writ listed on the abstract or abstracts, to a maximum of \$36
- 10. For preparation of a schedule of distribution under the *Creditor's Relief Act*, or a calculation for satisfaction of writs and garnishments, per writ or notice of garnishment....
- 11. A sheriff who is directed by the court to perform any service or do any act for which no fee is provided is entitled to be paid a travelling allowance and reasonable and actual disbursements, and may be allowed such fee as the court thinks fit, and it shall be payable as the court directs. O. Reg. 609/86, s. 1.
- 2. Ontario Regulations 811/84 and 608/85 are revoked.
- 3. This Regulation comes into force on the 1st day of November, 1986.

(9564)

43

HEALTH INSURANCE ACT

O. Reg. 610/86. General. Made—October 9th, 1986. Filed—October 10th, 1986.

REGULATION TO AMEND REGULATION 452 OF REVISED REGULATIONS OF ONTARIO, 1980 MADE UNDER THE HEALTH INSURANCE ACT

- 1.—(1) Schedule 15 to Regulation 452 of Revised Regulations of Ontario, 1980, as remade by section 3 of Ontario Regulation 215/86 and amended by section 1 of Ontario Regulation 342/86, is further amended by revoking:
 - 47. Non Elective Surgical Procedures, Obstetrics or Clinical Procedures Associated with Diagnostic Radiological Examination or Detention While in Attendance With Patient(s) in Ambulance:—when such procedures including fractures or dislocations or major invasive procedures contained in the list of Diagnostic and Therapeutic Procedures or elective procedures which

because of intervening emergency procedure(s) commence after 5:00 p.m. and before midnight or on Saturdays, Sundays and Holidays, increase the procedural fee(s) by 30% (E409). When the foregoing procedures commence after midnight and before 7:00 a.m. any night during the week, increase the procedural fee(s) by 50% (E410).

These premiums are not chargeable in addition to the obstetrical fee(s) if labour is induced by medical and/or surgical means by the same physician unless the reason for the induction is fetal distress, diabetes, premature rupture of membrane, severe pre-eclampsia—hypertension or abruption: However a forewater A.R.M. or oxytocin augmentation of labour carried out on a patient in desultory labour does not constitute induction. Major Invasive Procedures are considered to be the following:

| G211 | G266 | G275 | G288 | G294 | G323 | G330 | G349 | G412 | R843 | R853 |
|------|------|------|------|------|------|------|------|------|------|------|
| G246 | G267 | G277 | G290 | G295 | G324 | G331 | G380 | G418 | R849 | R854 |
| G254 | G268 | G280 | G291 | G302 | G327 | G332 | G398 | R833 | R850 | Z804 |
| G264 | G269 | G285 | G292 | G303 | G328 | G347 | G399 | R840 | R851 | Z805 |
| G265 | G270 | G287 | G293 | G304 | G329 | G348 | G411 | R841 | R852 | |

These premiums are not chargeable (during or after a "shift") by emergency or other physicians who have elected or are required to be physically and continuously present in the Emergency Department or environs for an arranged designated period of time.

E409 or E410 may not be claimed for procedures which mainly involve the interpretation of test results and are not applicable to assessments or consultations. Neither are they applicable to procedures listed in the Diagnostic Radiology, Nuclear Medicine or Diagnostic Ultrasound sections of the Schedule.

on page 593 under the heading "PREAMBLE" and subheading "Terms and Definitions" and substituting therefor:

47. Non Elective Surgical Procedures, Obstetrics or Clinical Procedures Associated with Diagnostic Radiological Examination or Detention While in Attendance With Patient(s) in Ambulance:—when such procedures including fractures or dislocations or major invasive procedures contained in the list of Diagnostic and Therapeutic Procedures or elective procedures which because of intervening emergency procedure(s) commence after 5:00 p.m. and before midnight or on Saturdays, Sundays and Holidays, increase the procedural fee(s) by 30% (E409). When the foregoing procedures commence after midnight and before 7:00 a.m. any night during the week, increase the procedural fee(s) by 50% (E410).

These premiums are not chargeable in addition to the obstetrical fee(s) if labour is induced by medical and/or surgical means by the same physician unless the reason for the induction is fetal distress, diabetes, premature rupture of membrane, severe pre-eclampsia—hypertension or abruption: However a forewater A.R.M. or oxytocin augmentation of labour carried out on a patient in desultory labour does not constitute induction. Major Invasive Procedures are considered to be the following:

| G211 | G266 | G275 | G288 | G294 | G323 | G330 | G349 | G412 | R843 | R853 |
|------|------|------|------|------|------|------|------|------|------|------|
| G246 | G267 | G277 | G290 | G295 | G324 | G331 | G360 | G380 | G418 | R849 |
| R854 | G254 | G268 | G280 | G291 | G302 | G327 | G332 | G398 | R833 | R850 |
| Z804 | G264 | G269 | G285 | G292 | G303 | G328 | G347 | G399 | R840 | R851 |
| Z805 | G265 | G270 | G287 | G293 | G304 | G329 | G348 | G411 | R841 | R852 |

These premiums are not chargeable (during or after a "shift") by emergency or other physicians who have elected or are required to be physically and continuously present in the Emergency Department or environs for an arranged designated period of time.

E409 or E410 may not be claimed for procedures which mainly involve the interpretation of test results and are not applicable to assessments or consultations. Neither are they applicable to procedures listed in the Diagnostic-Radiology, Nuclear Medicine or Diagnostic Ultrasound sections of the Schedule.

(2) The said Schedule is further amended by revoking:

on page 599 under the heading "CONSULTATIONS AND VISITS" and subheading "FAMILY PRACTICE AND PRACTICE IN GENERAL" and substituting therefor:

(3) The said Schedule is further amended by revoking:

T and P Columns should be interpreted in the spirit of the first two paragraphs on page 32, but without limiting the performance of these tests to suitably trained physicians of any one specialty. Furthermore, the physician must be physically available to approve, modify or intervene in the examination as required or the examination must be completely recorded by video/computer methods and reviewed in its entirety by the physician. No fee (either professional or technical) may be charged if the physician's only involvement is the interpretation of hard copy (films).

Notes: A-Mode—implies a one-dimensional ultrasonic measurement procedure.

M-Mode—implies a one-dimensional ultrasonic measurement procedure with movement of the trace to record amplitude and velocity of moving echo-producing structures.

Scan B-Mode—implies a two-dimensional ultrasonic scanning procedure with a two-dimensional display. All ultrasound examinations include a permanent record and interpretative report.

The total benefit is arrived at by adding T plus P. When coding the total benefit use suffix A; when coding the technical portion only use suffix B; when coding the professional portion only use suffix C.

on page 630 under the heading "DIAGNOSTIC ULTRASOUND" and substituting therefor:

T and P Columns should be interpreted in the spirit of the first two paragraphs on page 43, but without limiting the performance of these tests to suitably trained physicians of any one specialty. Furthermore, the physician must be physically available to approve, modify or intervene in the examination as required or the examination must be completely recorded by video/computer methods and reviewed in its entirety by the physician. No fee (either professional or technical) may be charged if the physician's only involvement is the interpretation of hard copy (films).

Notes: A-Mode—implies a one-dimensional ultrasonic measurement procedure.

M-Mode—implies a one-dimensional ultrasonic measurement procedure with movement of the trace to record amplitude and velocity of moving echo-producing structures. Scan B-Mode—implies a two-dimensional ultrasonic scanning procedure with a two-dimensional display. All ultrasound examinations include a permanent record and interpretative report.

The total benefit is arrived at by adding T plus P. When coding the total benefit use suffix A; when coding the technical portion only use suffix B; when coding the professional portion only use suffix C.

(4) The said Schedule is further amended by revoking:

E502 Following a caesarian section VBAC add to P020 15.75

on page 647 under the heading "OBSTETRICS" and subheading "OBSTET-RICAL CARE" and substituting therefor:

Z779 Chorionic villus sampling (I.O.P.) 75.60
P031 Suture of incompetent cervix in pregnancy (I.O.P.) cervical cerclage — any technique 3 118.15

| 5388 | THE ONTARIO GAZETTE | O. Reg. 610/ |
|-----------------|--|--------------------------------|
| (5) | The said Schedule is further amended by revoking: | |
| Z204 | Removal of plaster (not associated with fractures or dislocation within 8 weeks of initial treatment) | 8.40 |
| 4 | on page 658 under the heading "SURGICAL PROCEDURES" (OPERATIONS ON THE MUSCULOSKELETAL SYST) stituting therefor: | and subheading EM" and sub- |
| | emoval of plaster (not associated with fractures or dislocation within weeks of initial treatment) | |
| (6) | The said Schedule is further amended by revoking: | |
| R241 | | 7.90 8 |
| E570 | Revision, add 35% | 2 |
| | on page 671 under the heading "SURGICAL PROCEDURES" "OPERATIONS ON THE MUSCULOSKELETAL SYST stituting therefor: | and subheading EM" and sub- |
| R241 Re | evision total arthroplasty hip (includes acetabular reconstruction) 8 827.90 10 | |
| (7) | The said Schedule is further amended by revoking: | |
| R543 R562 | | 4.00 4 3.00 4 |
| | on page 674 under the heading "SURGICAL PROCEDURES" "OPERATIONS ON THE MUSCULOSKELETAL SYST stituting therefor: | and subheading EM" and sub- |
| R543 Te R562 | notomy of hamstrings — single | |
| (8) | The said Schedule is further amended by revoking: | |
| R266 | Tumour (foot) (see Preamble para B.32) | 4.80 4 |
| | on page 678 under the heading "SURGICAL PROCEDURES" "OPERATIONS ON THE MUSCULOSKELETAL SYST stituting therefor: | and subheading EM" and sub- |

2. This Regulation shall be deemed to have come into force on the 1st day of April, 1986.

3. A reference in this Regulation to any page number is a reference to that page (foot pagination) in *The Ontario Gazette* dated the 3rd day of May, 1986.

CONSERVATION AUTHORITIES ACT

O. Reg. 611/86.

Fill, Construction and Alteration to Waterways—Mattagami Region. Made—August 14th, 1986. Approved—October 9th, 1986. Filed—October 10th, 1986.

REGULATION MADE UNDER THE CONSERVATION AUTHORITIES ACT

FILL, CONSTRUCTION AND ALTERATION TO WATERWAYS—MATTAGAMI REGION

1. In this Regulation,

"Authority" means the Mattagami Region Conservation Authority;

"building" means a building or structure of any kind;

"fill" means any material used or capable of being used to raise, lower or in any way affect the contours of the ground;

"fill line" means any line designated as such on the maps referred to in the Schedules;

"regional storm" means,

- (a) for the main channel of the Mattagami River, the rainfall, snowmelt or the combination of rainfall and snowmelt, that would produce at Sandy Falls a peak flow of 807 cubic metres per second,
- (b) for rivers, streams and watercourses other than the main channel of the Mattagami River, a storm producing in a twelve hour period, on a drainage area of,
 - (i) twenty-five square kilometres or less, a rainfall that has the distribution set out in Table 1, or
 - (ii) more than twenty-five square kilometres, a rainfall such that the number of millimetres of rain referred to in each case in Table 1 shall be modified by the percentage amount shown in Column 2 of Table 2 opposite the size of the drainage area set out opposite thereto in Column 1 of Table 2;

"river", "lake", "creek", "stream" or "watercourse" means any river, lake, creek, stream or watercourse under the jurisdiction of the Authority.

TABLE 1

Distribution of Regional Storm Rainfall-

Watershed Area square kilometres or less

15 mm of rain in the first hour

20 mm of rain in the second hour

10 mm of rain in the third hour

3 mm of rain in the fourth hour 5 mm of rain in the fifth hour

20 mm of rain in the fifth hour

43 mm of rain in the seventh hour

20 mm of rain in the eighth hour

23 mm of rain in the ninth hour

13 mm of rain in the tenth hour
13 mm of rain in the eleventh hour

8 mm of rain in the twelfth hour

TABLE 2

| Drainage Area (square kilometres) | Percentage |
|--------------------------------------|------------|
| 26 to 50 both inclusive | 97 |
| 51 to 75 both inclusive | 94 |
| 76 to 100 both inclusive | 90 |
| 101 to 150 both inclusive | 87 |
| 151 to 200 both inclusive | 84 |
| 201 to 250 both inclusive | 82 |
| 251 to 375 both inclusive | 79 |
| 376 to 500 both inclusive | 76 |
| 501 to 750 both inclusive | 74 |
| 751 to 1000 both inclusive | 70 |
| 1001 to 1250 both inclusive | 68 |
| 1251 to 1500 both inclusive | 66 |
| 1501 to 1800 both inclusive | 65 |
| 1801 to 2100 both inclusive | 64 |
| 2101 to 2300 both inclusive | 63 |
| 2301 to 2600 both inclusive | 62 |
| 2601 to 3900 both inclusive | 58 |
| 3901 to 5200 both inclusive | 56 |
| 5201 to 6500 both inclusive | 53 |
| 6501 to 8000 both inclusive | 50 |

O. Reg. 611/86, s. 1.

2. The areas described in the Schedules are areas which, in the opinion of the Authority, are susceptible to flooding during a regional storm and may be affected by the placing or dumping of fill. O. Reg. 611/86, s. 2.

3. No person shall,

- (a) construct any building or permit any building to be constructed in or on a pond or swamp or in any area susceptible to flooding during a regional storm;
- (b) place or dump fill or permit fill to be placed or dumped in any area described in the Schedules whether the fill is already located

- in or upon the area, or brought to or on the area from some other place; or
- (c) straighten, change, divert or interfere in any way with the existing channel or a river, creek, stream or watercourse,

except in accordance with a permission issued under section 4. O. Reg. 611/86, s. 3.

- 4. Subject to the *Ontario Water Resources Act* or to any private interest, the Authority may permit in writing the construction of any building or the placing or dumping of fill or the straightening, changing, diverting or interfering with the existing channel of a river, creek, stream or watercourse to which section 3 applies if, in the opinion of the Authority, the site of the building or the placing or dumping and the method of construction or placing or dumping or the straightening, changing, diverting or interfering with the existing channel will not affect the control of flooding or pollution or the conservation of the land. O. Reg. 611/86, s. 4.
- 5.—(1) A signed application for permission to construct a building must be filed with the Authority and include,
 - (a) four copies of a plan of the property showing the proposed location of the building, its elevation and the proposed final grade plan;
 - (b) four copies of a complete description of the type of building to be constructed, including drainage details;
 - (c) four copies of a statement of the dates between which the placing or dumping will be carried out; and
 - (d) four copies of a statement of the proposed use of the building following completion of the construction.
- (2) A signed application for permission to place or dump fill must be filed with the Authority and include,
 - (a) four copies of a plan of the property on which the fill is to be placed, showing the proposed location of filling, the depth to which it is proposed to fill and the proposed final grade of the land when filling is completed;
 - (b) four copies of a complete description of the type of fill proposed to be placed or dumped;
 - (c) four copies of a statement of the dates between which the placing or dumping will be carried out; and
 - (d) four copies of a statement of the proposed use of the land following completing of placing or dumping.

- (3) A signed application for permission to straighten, change, divert or interfere in any way with the existing channel of a river, creek, stream or water-course must be filed with the Authority and include,
 - (a) four copies of a plan on which shall be shown in plan view and cross section the details of such straightening, change, diversion or interference;
 - (b) four copies of a description of the protective measures to be undertaken;
 - (c) four copies of a statement of the dates between which the straightening, changing, diverting or interfering will be carried out; and
 - (d) four copies of a statement of the purpose of the proposed work. O. Reg. 611/86, s. 5.
- 6. Members of the staff of the Authority are appointed officers to enforce this Regulation. O. Reg. 611/86, s. 6.
- 7. Regulation 169 of Revised Regulations of Ontario, 1980 is revoked.

Schedule 1

MATTAGAMI RIVER

1. That part of the Mattagami River watershed within the City of Timmins, in the Township of Mountjoy, commencing at Sandy Falls dam extending upstream to the Mountjoy Township — Ogden Township boundary and thence southerly into the Township of Ogden for a distance of 1.02 kilometres.

KRAFT CREEK

2. That part of the Kraft Creek watershed in the City of Timmins, in the Township of Mountjoy, from its confluence with the Mattagami River, upstream to a point 0.51 kilometres, north of Laforest Road.

TOWN CREEK

3. That part of the Town Creek watershed in the City of Timmins, in the Township of Mountjoy and the Township of Tisdale, from its confluence with the Mattagami River, upstream for a distance of 3.58 kilometres.

MOUNTJOY RIVER

4. That part of the watershed of the Mountjoy River, in the City of Timmins, in the Township of Mountjoy, from its confluence with the Mattagami River extending upstream for a distance of 4.83 kilometres and including the shoreline of Miller Lake.

GILLIES LAKE

5. The shoreline of Gillies Lake, in the City of Timmins, in the Township of Tisdale.

PEARL LAKE

6. The shoreline of Pearl Lake, in the City of Timmins, in the Township of Tisdale.

PORCUPINE RIVER (upstream Porcupine Lake)

7. That part of the Porcupine River watershed in the City of Timmins, in the Township of Tisdale, from its headwaters at Pearl Lake extending downstream to Porcupine Lake.

SOUTH PORCUPINE RIVER

8. That part of the South Porcupine River watershed in the City of Timmins, in the Township of Tisdale, from its confluence with the Porcupine River, upstream for a distance of 0.65 kilometres.

PORCUPINE LAKE

9. The shoreline of Porcupine Lake, and all tributaries to Porcupine Lake, in the City of Timmins, in the Townships of Tisdale and Whitney.

BOB'S LAKE

10. The shoreline of Bob's Lake, in the City of Timmins, in the Township of Whitney.

BOB'S CREEK

11. That part of the watershed of Bob's Creek in the City of Timmins, in the Township of Whitney, from its headwaters at Bob's Lake, extending downstream to Porcupine Lake.

PORCUPINE RIVER (downstream Porcupine Lake)

12. That part of the Porcupine River watershed in the City of Timmins, in the Township of Whitney, from Porcupine Lake and thence downstream for a distance of 4.19 kilometres.

THREE NATIONS LAKE

13. The shoreline of Three Nations Lake, in the City of Timmins, in the Township of Whitney, and that part of the watershed of an unnamed creek extending downstream from Three Nations Lake for a distance of 2.45 kilometres.

PORCUPINE RIVER (at Hoyle)

14. That part of the Porcupine River watershed in the City of Timmins, in the Township of Matheson,

commencing at a point 2.16 kilometres north of Highway No. 610 and thence southerly to a point 1.26 kilometres south of Highway No. 101.

KAMISKOTIA LAKE

15. The shoreline of Kamiskotia Lake, and its tributaries, in the City of Timmins, in the Township of Robb.

As shown delineated by the fill line on maps filed in the Regional Office of the Ministry of Natural Resources at Timmins, as Nos. MR-1 to MR-38, both inclusive. O. Reg. 611/86, Sched. 1.

THE MATTAGAMI REGION CONSERVATION AUTHORITY:

E. R. WHITE Chairman

BRIAN J. TEES General Manager

Dated at Timmins, this 14th day of August, 1986.

(9566)

43

PLANNING ACT, 1983

O. Reg. 612/86.

Restricted Areas—County of Ontario (now The Regional Municipality of Durham), Township of Pickering (now the Town of Pickering).

Made—October 8th, 1986. Filed—October 10th, 1986.

REGULATION TO AMEND ONTARIO REGULATION 102/72 MADE UNDER THE PLANNING ACT, 1983

 Ontario Regulation 102/72 is amended by adding thereto the following section:

63.—(1) A garage may be erected on the land described in subsection (2) as an accessory building to the single-family dwelling existing on the land if the following requirements are met:

Minimum distance of garage from lot line abutting the Eighth Concession Road

93 metres

Minimum distance of garage from lot line abutting unopened road allowance between lots 14 and 15

3.05 metres

Maximum height of garage 6.

6.4 metres

(2) Subsection (1) applies to that parcel of land in the Town of Pickering in The Regional Municipality of Durham, formerly the Township of Pickering in the County of Ontario, being that part of Lot 15 in Concession VII more particularly described as follows:

Commencing at the northeast angle of said Lot 15;

Thence south 72° 15′ west along the southerly limit of the road allowance between concessions VII and VIII in the said Township a distance of 815.62 feet to a point;

Thence south 72° 53' west continuing along the southerly limit of the said road allowance a distance of 88.72 feet to a point;

Thence south 18° 17′ east in a straight line parallel to the westerly limit of the road allowance between lots 14 and 15 in Concession VII of the said Township a distance of 627.14 feet to a point;

Thence north 72° 15′ east in a straight line parallel to that part of the said southerly limit of the said road allowance between said concessions VII and VIII a distance of 904.34 feet, more or less, to a point in the westerly limit of the said road allowance between said lots 14 and 15, which point is distant 626.16 feet measured southerly along the last-mentioned limit from the northeast angle of said Lot 15;

Thence north 18° 17′ west along the last-mentioned limit 626.16 feet to the point of commencement, the said lands containing by admeasurement 13 acres more or less. O. Reg. 612/86, s. 1.

L. J. FINCHAM
Director
Plans Administration Branch
Central and Southwest
Ministry of Municipal Affairs

Dated at Toronto, this 8th day of October, 1986.

(9567)

Publications Under The Regulations Act

November 1st, 1986

FARM PRODUCTS MARKETING ACT

O. Reg. 613/86. Tender Fruit—Marketing. Made—October 9th, 1986. Filed—October 14th, 1986.

REGULATION TO AMEND REGULATION 381 OF REVISED REGULATIONS OF ONTARIO, 1980 MADE UNDER THE FARM PRODUCTS MARKETING ACT

- 1. Section 13 of Regulation 381 of Revised Regulations of Ontario, 1980 is revoked and the following substituted therefor:
- 13.—(1) There shall be three advisory committees to be known as the "Processing Advisory Committee" and the "Fresh Market Advisory Committee", each composed of a chairman and six members, and the "Central Sales Policy Advisory Committee" composed of a chairman and nine members.
- (2) After the 1st day of April and before the 30th day of April in each year, appointments shall be made to the Processing Advisory Committee and the Fresh Market Advisory Committee as follows:
 - The Board shall appoint the chairman of each committee.
 - 2. The local board shall appoint three members to each committee.
 - The Ontario Food Processors' Association shall appoint three members to the Processing Advisory Committee.
 - The Canadian Fruit Wholesalers' Association shall appoint three members to the Fresh Market Advisory Committee.
- (3) After the 1st day of April and before the 30th day of April in each year, appointments shall be made to the Central Sales Policy Advisory Committee as follows:

- The local board shall appoint the chairman and four members.
- 2. The Niagara Fruit Shippers Association Inc. shall appoint five members.
- (4) The members of the advisory committees remain members thereof until the 30th day of April in the year following the year in which they are appointed.
- (5) Where for any reason a member of an advisory committee is unable or unwilling to act as a member, the body that appointed the member shall appoint a person to replace the member for the unexpired term.
- (6) Where there is a failure to make an appointment to an advisory committee in accordance with subsection (2), (3) or (5), the Board may appoint such members as are necessary to complete the committee.
- (7) The Processing Advisory Committee is empowered, respecting tender fruit that is sold for processing, to advise and make recommendations to the local board or to the Ontario Food Processors' Association in respect of,
 - (a) the promotion of harmonious relationships between persons engaged in the production and marketing of tender fruit;
 - (b) the promotion of greater efficiency in the production and marketing of tender fruit;
 - (c) the prevention and correction of irregularities and inequities in the marketing of tender fruit:
 - (d) the improvement of the quality and variety of tender fruit;
 - (e) the improvement of the circulation of market information respecting tender fruit; and
 - (f) any matter in respect of which the Board or the local board is empowered to make regulations under the Act.
- (8) The Fresh Market Advisory Committee is empowered, respecting tender fruit that is sold for a purpose other than processing, to advise and make recommendations to the local board or to the Canadian Fruit Wholesalers' Association in respect of,

- (a) the promotion of harmonious relationships between persons engaged in the marketing of tender fruit;
- (b) the promotion of greater efficiency in the production and marketing of tender fruit;
- (c) the prevention and correction of irregularities and inequities in the marketing of tender fruit;
- (d) the improvement of the quality and variety of tender fruit;
- (e) the improvement of the circulation of market information respecting tender fruit; and
- (f) any matter in respect of which the Board or the local board is empowered to make regulations under the Act.
- (9) The Central Sales Policy Advisory Committee is empowered, respecting tender fruit that is sold for a purpose other than processing, to advise and make recommendations to the local board regarding the operation of its central sales division in respect of,
 - (a) the promotion of harmonious relationships between persons engaged in the marketing of tender fruit;
 - (b) the promotion of greater efficiency in the production and marketing of tender fruit;
 - (c) the prevention and correction of irregularities and inequities in the marketing of tender fruit;
 - (d) the improvement of the quality and variety of tender fruit;
 - (e) the improvement of the circulation of market information respecting tender fruit; and
 - (f) any matter in respect of which the Board or the local board is empowered to make regulations under the Act.
- (10) All questions arising at a meeting of the Central Sales Policy Advisory Committee shall be decided by the majority of the votes of the members present, including the chairman, and in the event of a tie vote the chairman shall have the deciding vote. O. Reg. 613/86, s. 1.

THE FARM PRODUCTS MARKETING BOARD:

KENNETH W. KNOX Chairman

GLORIA MARCO BORYS
Secretary

Dated at Toronto, this 9th day of October, 1986.

(9568)

PLANNING ACT, 1983

O. Reg. 614/86.

Zoning Areas—Part of the Sioux Lookout Planning Area in the Territorial District of Kenora. Made—September 11th, 1986. Filed—October 15th, 1986.

REGULATION TO AMEND ONTARIO REGULATION 25/86 MADE UNDER THE PLANNING ACT, 1983

1. Ontario Regulation 25/86 is amended by adding thereto the following section:

66.—(1) Notwithstanding that the land described in subsection (2) is shown on the map referred to in section 2 as being in a Rural Zone, it shall be deemed to be in a Resort Commercial Zone to which Part VIII applies.

(2) Subsection (1) applies to that parcel of land in the geographic Township of Drayton in the District of Kenora described as part of Broken Lot 23, Concession III, which is part of Part 1 on Plan KR-239 deposited in the Land Registry Office for the Land Titles Division of Kenora (No. 23) and described as follows:

Beginning at a point in the southeasterly limit of the said Part 1, Plan KR-239, immediately northwest of the shoreline road allowance;

Thence inland west along the south lot line for a distance of 410 metres;

Thence northeast in a straight line to a point being 280 metres inland on the north lot line from the northeasterly limit of the said Part 1, Plan KR-239, immediately northeast of the shoreline road allowance;

Thence 280 metres east on the north lot line to a point being the easterly limit of the said Part 1, Plan KR-239, immediately northeast of the shoreline road allowance;

Thence in a general southwesterly direction in a line bordering the shoreline road allowance to the point of commencement. O. Reg. 614/86, s. 1.

PAULINE MORRIS Director Plans Administration Branch North and East Ministry of Municipal Affairs

Dated at Toronto, this 11th day of September, 1986.

PLANNING ACT, 1983

O. Reg. 615/86.

Restricted Areas-District of Manitoulin, Geographic townships of Campbell, Dawson, Mills and Robinson.

Made-October 14th, 1986. Filed-October 15th, 1986.

REGULATION TO AMEND **ONTARIO REGULATION 672/81** MADE UNDER THE PLANNING ACT, 1983

1. Ontario Regulation 672/81 is amended by adding thereto the following section:

78.—(1) Despite clause 5 (4) (d), sleeping accommodation is permitted in the largest of the utility buildings situate on the land described in subsection (2) on the day this Order comes into force if the minimum lot area is .16 hectares.

(2) Subsection (1) applies to that parcel of land in the Territorial District of Manitoulin being Summer Resort Location Island T.P. 2019 in MacGregor Bay, and shown as Parcel 538 in the Land Registry Office for the Land Titles Division of Manitoulin (No. 31). O. Reg. 615/86, s. 1.

> PAULINE MORRIS Director Plans Administration Branch North and East Ministry of Municipal Affairs

Dated at Toronto, this 14th day of October, 1986.

(9585)44

PLANNING ACT, 1983

O. Reg. 616/86.

Restricted Areas-District of Manitoulin, Geographic townships of Campbell, Dawson, Mills and Robinson.

Made-October 3rd, 1986. Filed-October 15th, 1986.

REGULATION TO AMEND ONTARIO REGULATION 672/81 MADE UNDER THE PLANNING ACT, 1983

1. Ontario Regulation 672/81 is amended by adding thereto the following section:

79. Despite subsection 47 (1), a seasonal dwelling and buildings and structures accessory thereto may be erected and used on that parcel of land in the geographic township of Mills in the Territorial District of Manitoulin, being the east half of Lot 14, Concession VI, if the following requirements are met:

O. Reg. 617/86

Maximum lot coverage 15 per cent

Minimum front yard 15 metres

Minimum side yards 15 metres

Minimum rear yard 15 metres

Maximum height of seasonal dwelling

9 metres

Minimum ground floor area of seasonal dwelling

55 square metres

O. Reg. 616/86, s. 1.

PAULINE MORRIS Director Plans Administration Branch North and East Ministry of Municipal Affairs

Dated at Toronto, this 3rd day of October, 1986.

(9586)

CONSERVATION AUTHORITIES ACT

O. Reg. 617/86. Fill, Construction and Alteration to Waterways-Hamilton Region. Made-August 21st, 1986. Approved-October 9th, 1986. Filed-October 16th, 1986.

REGULATION MADE UNDER THE CONSERVATION AUTHORITIES ACT

FILL, CONSTRUCTION AND ALTERATION TO WATERWAYS-HAMILTON REGION

1. In this Regulation,

"Authority" means the Hamilton Region Conservation Authority;

"building" means a building or structure of any kind;

"drainage area" means, for a point, the area that contributes runoff to that point;

"fill" means any material, whether originating on the site or elsewhere, used or capable of being used to raise, lower or in any way affect the contour of the ground;

"regional storm" means a storm producing in a fortyeight hour period, in a drainage area of,

- (a) twenty-five square kilometres or less, a rainfall that has the distribution set out in Table 1, or
- (b) more than twenty-five square kilometres, a rainfall such that the number of millimetres of rain referred to in each case in Table 1 shall be modified by the percentage amount shown in Column 2 of Table 2 opposite the size of the drainage area set out opposite thereto in Column 1 of Table 2;

"river", "lake", "creek", "stream" or "watercourse" means any river, lake, creek, stream or watercourse under the jurisdiction of the Authority.

TABLE 1

- 73 millimetres of rain in the first 36 hours
- 6 millimetres of rain in the 37th hour
- 4 millimetres of rain in the 38th hour
- 6 millimetres of rain in the 39th hour
- 13 millimetres of rain in the 40th hour
- 17 millimetres of rain in the 41st hour
- 13 millimetres of rain in the 42nd hour
- 23 millimetres of rain in the 43rd hour
- 13 millimetres of rain in the 44th hour
- 13 millimetres of rain in the 45th hour
- 53 millimetres of rain in the 46th hour
- 38 millimetres of rain in the 47th hour
- 13 millimetres of rain in the 48th hour

TABLE 2

| Column 1 | COLUMN 2 |
|--|--------------|
| Drainage Area (square kilometres) | Percentage |
| 26 to 45 both inclusive 46 to 65 both inclusive | 99.2 98.2 |
| 66 to 90 both inclusive | 97.1 |
| 91 to 115 both inclusive | 96.3 |
| 116 to 140 both inclusive | 95.4 |
| 141 to 165 both inclusive | 94.8 |
| 166 to 195 both inclusive | 94.2 |
| 196 to 220 both inclusive | 93.5 |
| 221 to 245 both inclusive | 92.7 |
| 246 to 270 both inclusive | 92.0 |
| 271 to 450 both inclusive | 89.4 |
| 451 to 575 both inclusive | 86.7 |
| 576 to 700 both inclusive | 84.0 |
| 701 to 850 both inclusive | 82.4 |
| 851 to 1000 both inclusive | 80.8 |
| 1001 to 1200 both inclusive | 79.3 |
| 1201 to 1500 both inclusive | 76.6 |
| 1501 to 1700 both inclusive | 74.4 |
| 1701 to 2000 both inclusive | 73.3 |
| 2001 to 2200 both inclusive | 71.7 |

TABLE 2-Con.

| Column 1 | Column 2 |
|--------------------------------------|------------|
| Drainage Area (square kilometres) | Percentage |
| 2201 to 2500 both inclusive | 70.2 |
| 2501 to 2700 both inclusive | 69.0 |
| 2701 to 4500 both inclusive | 64.4 |
| 4501 to 6000 both inclusive | 61.4 |
| 6001 to 7000 both inclusive | 58.9 |
| 7001 to 8000 both inclusive | 57.4 |
| | 1000 |

O. Reg. 617/86, s. 1.

- 2. The areas described in the schedules are areas in which, in the opinion of the Authority, the control of flooding or pollution or conservation of land may be affected by the placing or dumping of fill. O. Reg. 617/86, s. 2.
 - 3. No person shall,
 - (a) construct any building or permit any building to be constructed in or on a pond or swamp or in any area susceptible to flooding during a regional storm;
 - (b) place or dump fill or permit fill to be placed or dumped in the areas described in the schedules whether such fill is already located in or upon the area or brought to or on the area from some other place; or
 - (c) straighten, change, divert or interfere or permit the straightening, changing, diverting or interfering in any way with the existing channel of a river, creek, stream or watercourse,

except pursuant to a permit given under section 4. O. Reg. 617/86, s. 3.

- 4. Subject to the Ontario Water Resources Act or to any private interest, the Authority may permit in writing the construction of any building or the placing or dumping of fill or the straightening, changing, diverting or interfering with the existing channel of a river, creek, stream or watercourse to which section 3 applies if, in the opinion of the Authority, the site of the building or the placing or dumping and the method of construction or placing or dumping or the straightening, changing, diverting or interfering with the existing channel will not affect the control of flooding or pollution or the conservation of land. O. Reg. 617/86, s. 4.
- 5.—(1) A signed application for permission to construct a building must be filed with the Authority and include four copies of,
 - (a) a plan of the property showing the proposed location of the building, its elevation and the proposed final grade plan;

- (b) a complete description of the type of building to be constructed, including drainage details and the method of construction;
- (c) a statement of the dates between which the construction will be carried out; and
- (d) a statement of the proposed use of the building following completion of the construction.
- (2) A signed application for permission to place or dump fill must be filed with the Authority and include four copies of,
 - (a) a plan of the property on which the fill is to be placed, showing the proposed location of filling, the depth to which it is proposed to fill and the proposed final grade of the land when filling is completed;
 - (b) a complete description of the type of fill proposed to be placed or dumped and the method of placing or dumping the fill;
 - (c) a statement of the dates between which the placing or dumping will be carried out; and
 - (d) a statement of the proposed use of the land following completion of placing or dumping.
- (3) A signed application for permission to straighten, change, divert or interfere in any way with the existing channel of a river, lake, creek, stream or watercourse must be filed with the Authority and include four copies of,
 - (a) a plan on which shall be shown in plan view and cross section the details of such straightening, changing, diverting or interfering;
 - (b) a description of the protective measures to be undertaken and the method to be used to carry out such straightening, changing, diverting or interfering;
 - (c) a statement of the dates between which the straightening, changing, diverting or interfering will be carried out; and
 - (d) a statement of the purpose of the proposed work. O. Reg. 617/86, s. 5.
- 6. The Authority may, at any time, withdraw a permission given under section 4 if the representations contained in the application for permission are not being carried out. O. Reg. 617/86, s. 6.
- 7. The Authority may appoint officers to enforce this Regulation. O. Reg. 617/86, s. 7.
- 8. Regulation 165 of Revised Regulations of Ontario, 1980 is revoked.

Schedule 1

TOWN OF DUNDAS

That part of the Municipality of the Town of Dundas, The Regional Municipality of Hamilton-Wentworth within the fill line as outlined by a continuous solid line on maps HamR 1-1 to HamR 1-9, both inclusive, all maps dated December 5, 1985 of the maps entitled "Town of Dundas" filed in the Regional Office of the Ministry of Natural Resources at Richmond Hill, Ontario, more particularly described as follows:

- The valley containing Spencer Creek and its tributaries within the Town of Dundas.
- The valley containing Sydenham Creek and its tributaries within the Town of Dundas.
- 3. The valley containing Ann Street Creek and its tributaries within the Town of Dundas.
- The valley containing Sulphur Creek and its tributaries within the Town of Dundas.
- The valley containing Spring Creek and its tributaries within the Town of Dundas.
- The valley containing Borer's Creek and its tributaries within the Town of Dundas.
- The valley containing Cootes Paradise within the Town of Dundas. O. Reg. 617/86, Sched. 1.

Schedule 2

CITY OF STONEY CREEK

That part of the municipality of the City of Stoney Creek, The Regional Municipality of Hamilton-Wentworth within the fill line as outlined by a continuous solid line on maps HamR 2-1 to HamR 2-51, both inclusive, all maps dated March 10, 1974 of the maps entitled "City of Stoney Creek" filed in the Regional Office of the Ministry of Natural Resources at Richmond Hill, Ontario, more particularly described as follows:

- The valley containing Stoney Creek and Battlefield Creek and its tributaries within the City of Stoney Creek.
- The valleys containing Drainage Courses #3 to #15, both inclusive, and tributaries within the City of Stoney Creek.
- Certain sections of the Niagara Escarpment within the City of Stoney Creek. O. Reg. 617/86, Sched. 2.

Schedule 3

TOWN OF ANCASTER

That part of the Municipality of the Town of Ancaster, The Regional Municipality of Hamilton-Wentworth within the fill line as shown by a continuous solid line on maps HamR 3-1 to HamR 3-11, both inclusive, all maps dated December 5, 1985 of the maps entitled "Town of Ancaster" filed in the Regional Office of the Ministry of Natural Resources at Richmond Hill, Ontario, more particularly described as follows:

- 1. The valley containing Ancaster Creek and its tributaries in the Town of Ancaster.
- 2. The valley containing Tiffany Creek and its tributaries in the Town of Ancaster.
- 3. The valley containing Chedoke Creek and its tributaries in the Town of Ancaster.
- 4. The valley containing Sulphur Creek and its tributaries in the Town of Ancaster.
- 5. The valley containing Spring Creek and its tributaries in the Town of Ancaster. O. Reg. 617/86, Sched. 3.

Schedule 4

CITY OF HAMILTON

That part of the Municipality of the City of Hamilton, The Regional Municipality of Hamilton-Wentworth within the fill line as outlined by a continuous solid line on maps HamR 4-1 to HamR 4-25, both inclusive, all maps dated July 24, 1968 of the maps entitled "City of Hamilton" filed in the Regional Office of the Ministry of Natural Resources at Richmond Hill, Ontario, more particularly described as follows:

- 1. The valley containing Sulphur Creek and its tributaries within the City of Hamilton.
- 2. The valley containing Chedoke Creek within the City of Hamilton.
- 3. The valley containing Red Hill Creek and its tributaries within the City of Hamilton.
- 4. The valley containing Spencer Creek and its tributaries within the City of Hamilton.
- 5. The valley containing Sterling Creek ravine within the City of Hamilton.
- 6. The valley containing Cootes Paradise within the City of Hamilton.
- 7. Certain sections of the Niagara Escarpment within the City of Hamilton. O. Reg. 617/86, Sched. 4.

Schedule 5

HAMILTON HARBOUR

That part of the Hamilton Harbour within the Municipality of the City of Hamilton, The Regional Municipality of Hamilton-Wentworth located within the jurisdiction of the Hamilton Region Conservation Authority. O. Reg. 617/86, Sched. 5.

Schedule 6

TOWN OF FLAMBOROUGH

That part of the Municipality of the Town of Flamborough, The Regional Municipality of Hamilton-Wentworth within the fill line as outlined by a continuous solid line on maps HamR 6-1 to HamR 6-98, both inclusive, all maps dated March 10, 1977 of the maps entitled "Town of Flamborough" filed in the Regional Office of the Ministry of Natural Resources, Richmond Hill, Ontario, more particularly described as follows:

- 1. The valley containing Spencer Creek and its tributaries within the Town of Flamborough.
- 2. The valley containing Sydenham Creek and its tributaries within the Town of Flamborough.
- 3. The valley containing Borer's Creek and its tributaries within the Town of Flamborough.
- 4. The valley containing Spring Creek and its tributaries within the Town of Flamborough.
- 5. Certain sections of the Niagara Escarpment within the Town of Flamborough.
- 6. Certain sections of the Beverly Swamp within the Town of Flamborough. O. Reg. 617/86, Sched. 6.

HAMILTON REGION CONSERVATION AUTHORITY:

> A. H. McCoy Chairman

W. FULLER Secretary-Treasurer

Dated at Ancaster, this 21st day of August, 1986.

(9590)

PUBLIC COMMERCIAL VEHICLES ACT

O. Reg. 618/86. Carrying Goods in Bond. Made-October 2nd, 1986. Filed-October 17th, 1986.

5443

REGULATION TO AMEND
REGULATION 827 OF
REVISED REGULATIONS OF
ONTARIO, 1980
MADE UNDER THE
PUBLIC COMMERCIAL VEHICLES
ACT

 Subsection 4 (3) of Regulation 827 of Revised Regulations of Ontario, 1980 is revoked.

(9591)

44

COMMODITY BOARDS AND MARKETING AGENCIES ACT

O. Reg. 619/86. Levies or Charges—Tobacco. Made—October 17th, 1986. Filed—October 17th, 1986.

REGULATION MADE UNDER THE COMMODITY BOARDS AND MARKETING AGENCIES ACT

LEVIES OR CHARGES—TOBACCO

1. In this Regulation,

"Board" means The Farm Products Marketing Board constituted under the Farm Products Marketing Act:

"commodity board" means The Ontario Flue-Cured Tobacco Growers' Marketing Board constituted under the Farm Products Marketing Act;

- "tobacco" means unmanufactured flue-cured tobacco produced in Ontario, including flue-cured tobacco purchased or otherwise acquired by and readied for storage and sale by the commodity board. O. Reg. 619/86, s. 1.
- 2.—(1) The Lieutenant Governor in Council hereby grants to the commodity board, in relation to the marketing of tobacco locally within Ontario, authority to fix, impose and collect levies or charges from persons engaged in the production of tobacco in Ontario and for that purpose to classify such persons into groups and fix the levies or charges payable by the members of the different groups in different amounts, not exceeding in any case 2 cents per pound of tobacco, and to use the levies or charges for the purposes of the commodity board, including the creation of reserves. the payment of expenses and losses resulting from the sale or disposal of any tobacco, and the equalization or adjustment among producers of tobacco of moneys realized from the sale thereof during such period or periods of time as the commodity board may determine.
- (2) No regulation or order made or direction issued by the commodity board under subsection (1) takes effect until it is approved by the Board. O. Reg. 619/86, s. 2.
- 3. The commodity board shall, at any time during normal office hours, make available to such auditor as the Minister of Agriculture and Food may designate, all books of account, records and documents relating to the receipt of funds under this Regulation and expenditures made by the commodity board of moneys derived in whole or in part from funds received by the commodity board under this Regulation. O. Reg. 619/86, s. 3.

(9592)

44



Publications Under The Regulations Act

November 8th, 1986

SMALL BUSINESS DEVELOPMENT CORPORATIONS ACT

O. Reg. 620/86. General. Made—October 9th, 1986. Filed—October 20th, 1986.

REGULATION TO AMEND
REGULATION 915 OF
REVISED REGULATIONS
OF ONTARIO, 1980
MADE UNDER THE
SMALL BUSINESS
DEVELOPMENT CORPORATIONS
ACT

- 1.—(1) Subsection 3 (1) of Regulation 915 of Revised Regulations of Ontario, 1980, as amended by section 1 of Ontario Regulation 587/81, section 2 of Ontario Regulation 300/83, section 1 of Ontario Regulation 25/84 and section 2 of Ontario Regulation 410/86, is further amended by striking out "and" at the end of clause (d), by adding "and" at the end of clause (e) and by adding thereto the following clause:
 - (f) any business activity that involves the provision to business of services that are,
 - (i) computer services,
 - (ii) architectural, engineering or other professional scientific and related technical services, or
 - (iii) services ancillary to or in the nature of manufacturing,

is a prescribed business activity.

(2) Section 3 of the said Regulation, as amended by section 1 of Ontario Regulation 587/81, section 2 of Ontario Regulation 300/83, section 1 of Ontario Regulation 25/84 and section 2

- of Ontario Regulation 410/86, is further amended by adding thereto the following subsections:
- (3) For the purpose of subclause (1) (f) (i), "computer services" means the provision by the small business of,
 - (a) access to a computer database;
 - (b) access to computer hardware, software programs or related equipment and material directly controlled by the small business on a time-share, leased-time, rented-time or feefor-service basis;
 - (c) training in computer applications or operations;
 - (d) services of data entry personnel on a temporary or casual basis;
 - (e) services of trained technicians or other personnel for the identification and correction of computer and computer related malfunctions and for the repair and maintenance of computer systems;
 - (f) services of systems analysts or programmers on a temporary or casual basis;
 - (g) microfiche transfers, graphics, format conversions and other speciality services directly related to the computer industry;
 - (h) consultation, advice, analyses or reports with respect to the attributes of various computer hardware and software systems as they relate to the specific needs of individual computer users; or
 - (i) access to data and communications networks.

to users all of whom use the service in the ordinary course of carrying on business but does not include the sale, rental or lease of computer hardware, software or related materials and equipment, computer brokerage or any similar service.

- (4) For the purpose of subclause (1) (f) (ii), the provision by the small business of a service that is,
 - (a) the practice of architecture as defined in the Architects Act, 1984 where the small business

may perform that service under the provisions of that Act;

O. Reg. 620/86

- (b) the practice of professional engineering as defined in the *Professional Engineers Act*, 1984 under the authority of a certificate of authorization issued under that Act; or
- (c) research, analysis and reporting in any field of mathematical, physical or natural science, laboratory testing, hydrographic or land surveying, industrial designing or advising on energy conservation where the service is not,
 - (i) a business consulting or similar service, or
 - (ii) a legal or accounting service,

is an architectural, engineering or other professional scientific or related technical service.

(5) For the purpose of subclause (1) (f) (iii), a service ancillary to or in the nature of manufacturing means the provision by the small business to other commercial enterprises of a service that would constitute a prescribed manufacturing or processing activity but for the fact that the small business does not own the goods or materials on which an activity is performed. O. Reg. 620/86, s. 1 (2).

(9593) 45

HIGHWAY TRAFFIC ACT

O. Reg. 621/86. Vehicle Permits. Made—October 9th, 1986. Filed—October 22nd, 1986.

REGULATION TO AMEND ONTARIO REGULATION 744/82 MADE UNDER THE HIGHWAY TRAFFIC ACT

- Clause 1 (b) of Ontario Regulation 744/82 is revoked and the following substituted therefor:
- (b) "farmer" means a resident of Ontario who owns farm property that is used in a farming enterprise which, in a normal production year, produces farm products having a gross value of at least,
 - (i) \$5,000 where the farm property is located in that part of Ontario lying east of the westerly boundaries of the counties of Northumberland, Victoria and Peterborough or north of the southerly boundaries of the County of Haliburton and The District Municipality of Muskoka, and

- (ii) \$8,000 where the farm property is located elsewhere in Ontario other than that part described in subclause (i);
- (ba) "farm products" does not include products preserved by freezing, pickling, cooking, smoking or curing, other than cured tobacco leaves;
- Paragraph 2 of subsection 20 (1) of the said Regulation is revoked and the following substituted therefor:
 - For a commercial motor vehicle or a combination of a commercial motor vehicle and trailer or trailers, other than a bus, having a gross weight of more than 3,000 kilograms, where the permit holder is a farmer and the vehicle is used for,
 - (i) the farmer's personal transportation,
 - (ii) the uncompensated transportation of farm products, supplies or equipment, or
 - (iii) the compensated transportation of farm products, supplies or equipment in the months of September, October or November,

the applicable fee set out in Schedule 2.

(9606)

45

HEALTH PROTECTION AND PROMOTION ACT, 1983

O. Reg. 622/86. Rabies—Immunization. Made—October 23rd, 1986. Filed—October 24th, 1986.

REGULATION TO AMEND ONTARIO REGULATION 594/85 MADE UNDER THE HEALTH PROTECTION AND PROMOTION ACT, 1983

- 1. Table 1 to Ontario Regulation 594/85, as amended by section 1 of Ontario Regulation 120/86, section 3 of Ontario Regulation 287/86 and section 1 of Ontario Regulation 501/86, is further amended by adding thereto the following item:
- 8. Bruce County Health Unit

October 23, 1986

(9611)

Publications Under The Regulations Act

November 15th, 1986

TRANSBOUNDARY POLLUTION RECIPROCAL ACCESS ACT, 1986

O. Reg. 623/86. Reciprocating Jurisdictions. Made—October 23rd, 1986. Filed—October 27th, 1986.

REGULATION MADE UNDER THE TRANSBOUNDARY POLLUTION RECIPROCAL ACCESS ACT, 1986

RECIPROCATING JURISDICTIONS

- 1. The following provinces of Canada are declared reciprocating jurisdictions for the purposes of the Act:
 - 1. Manitoba.
 - Prince Edward Island. O. Reg. 623/86, s. 1.
- 2. The following states of the United States of America are declared reciprocating jurisdictions for the purposes of the Act:
 - 1. Colorado.
 - 2. Montana.
 - 3. New Jersev.
 - 4. Wisconsin. O. Reg. 623/86, s. 2.

(9612)

46

ENVIRONMENTAL ASSESSMENT ACT

O. Reg. 624/86.
Exemption—Ministry of Government Services—MGS-72.
Made—October 17th, 1986.
Approved—October 17th, 1986.
Filed—October 27th, 1986.

ORDER MADE UNDER THE ENVIRONMENTAL ASSESSMENT ACT

EXEMPTION—MINISTRY OF GOVERNMENT SERVICES—MGS-72

Having received a request from the Ministry of Government Services that an undertaking, namely:

The activities involving the renovation and the construction of an extension to the vacant Carnegie Library structure for the development of a Unified Family Court at a site referred to as all of Lot 69 and Part of Lots 50, 51, 52, 67 and 68, P.H. Hamilton Survey Unregistered Plan in the Block bounded by Charles Street, Main Street, MacNab Street, and Jackson Street in the City of Hamilton, Regional Municipality of Hamilton-Wentworth

be exempt from the application of the Act pursuant to section 29; and

Having been advised by the Ministry of Government Services that if the undertaking is subject to the application of the Act, the following injury, damage or interference with the persons and property indicated will occur:

- A. The Crown will be interfered with and damaged by the undue delay and expense required to prepare an environmental assessment for an activity for which adverse environmental impacts have not been identified
- B. The public will be interfered with and damaged in that the level of service available and the access to that service is restricted by the existing inadequate accommodations.

Having weighed such injury, damage or interference against the betterment of the people of the whole or any part of Ontario by the protection, conservation and wise management in Ontario of the environment which would result from the undertaking being subject to the application of the Act;

The undersigned is of the opinion that it is in the public interest to order and orders that the undertaking is exempt from the application of the Act for the following reasons:

 A. The proposed undertaking will have no significant adverse effects on the environment. B. The concerns of the Ministry of Citizenship and Culture regarding the renovation and restoration of the Carnegie Library structure and the redevelopment of the site shall be resolved to the mutual satisfaction of the Ministry of Citizenship and Culture and the Ministry of Government Services.

This exemption is subject to the following terms and conditions:

- Where any activity which otherwise would be exempt under this order is being carried out as or is part of an undertaking for which an environmental assessment has been accepted and approval to proceed received, the activity shall be carried out in accordance with any terms or conditions in the approval to proceed as well as the conditions of this order.
- 2. Where any activity which is the subject of this order is being carried out as or is part of another undertaking which is the subject of an exemption order under the Act, the activity exempt under this order shall be carried out in accordance with any terms or conditions in the other exemption order as well as the conditions in this order.
- 3. The heritage considerations associated with the renovation and restoration of the Carnegie Library structure and the redevelopment of the site shall be resolved to the mutual satisfaction of the Ministry of Citizenship and Culture and the Ministry of Government Services. The proponent shall inform the Director of the Environmental Assessment Branch of the agreement reached prior to commencement of construction.
- This order shall expire if construction and renovation has not commenced by December 31, 1987. O. Reg. 624/86.

JAMES BRADLEY
Minister of the Environment

(9613)

PARKWAY BELT PLANNING AND DEVELOPMENT ACT

O. Reg. 625/86.
The Regional Municipality of York,
Town of Markham.
Made—October 21st, 1986.
Filed—October 27th, 1986.

REGULATION TO AMEND ONTARIO REGULATION 473/73 MADE UNDER THE PARKWAY BELT PLANNING AND DEVELOPMENT ACT

1. Ontario Regulation 473/73 is amended by adding thereto the following section:

76.—(1) A track for testing a suspended light rail transit system may be installed on the land described in subsection (2), together with buildings and structures accessory thereto, if a minimum of thirty parking spaces are provided on the land.

(2) Subsection (1) applies to that parcel of land in the Town of Markham, in The Regional Municipality of York, being that part of Lot 7 in Concession VII designated as parts 1, 2 and 3 on a Plan deposited in the Land Registry Office for the Registry Division of Toronto Boroughs (No. 64) as Plan 64R-7807 and Part 1 on a Plan deposited in the said Land Registry Office as Number 64R-5888. O. Reg. 625/86, s. 1.

L. J. FINCHAM
Director
Plans Administration Branch
Central and Southwest
Ministry of Municipal Affairs

Dated at Toronto, this 21st day of October, 1986.

(9614) 46

PLANNING ACT, 1983

O. Reg. 626/86.
Restricted Areas—County of Simcoe,
Township of Nottawasaga.
Made—October 21st, 1986.
Filed—October 27th, 1986.

REGULATION TO AMEND REGULATION 675 OF REVISED REGULATIONS OF ONTARIO, 1970 MADE UNDER THE PLANNING ACT, 1983

1. Regulation 675 of Revised Regulations of Ontario, 1970 is amended by adding thereto the following section:

247.—(1) In this section,

"front lot line" means the lot line adjoining James Street;

"rear lot line" means the lot line opposite the front lot line:

"side lot line" means a lot line other than a front or rear lot line.

(2) Notwithstanding any other provision of this Order, a single-family dwelling and buildings and structures accessory thereto may be erected and used on the land described in subsection (3) if the following requirements are met:

Minimum distance between any building or structure and the front lot line

7.6 metres

Minimum distance between any building or structure and the rear lot line

7.6 metres

Minimum distance between any building or structure and the side lot lines

3 metres on one side

1.2 metres on the other side

Maximum height of single-family dwelling

9.1 metres

metres

Minimum ground floor area of single-family dwelling

one storey—93 square metres one and one-half storeys or more—69.8 square

(3) This section applies to that parcel of land in the Township of Nottawasaga in the County of Simcoe, being that part of Lot 22 in Concession I designated as Part 1 on a Plan deposited in the Land Registry Office for the Registry Division of Simcoe (No. 51) as Number 51R-14861. O. Reg. 626/86, s. 1.

L. J. FINCHAM
Director
Plans Administration Branch
Central and Southwest
Ministry of Municipal Affairs

Dated at Toronto, this 21st day of October, 1986. (9615)

PLANNING ACT, 1983

O. Reg. 627/86.
Restricted Areas—County of Simcoe,
Township of Nottawasaga.
Made—October 14th, 1986.
Filed—October 27th, 1986.

REGULATION TO AMEND REGULATION 675 OF REVISED REGULATIONS OF ONTARIO, 1970 MADE UNDER THE PLANNING ACT, 1983

 Regulation 675 of Revised Regulations of Ontario, 1970 is amended by adding thereto the following section:

246.—(1) In this section, "front lot line" means the lot line adjoining Mountain Road.

(2) Notwithstanding any other provision of this Order, a building may be erected on the land described in subsection (3) and used as a restaurant and a store in which skis and ski accessories are sold, rented and repaired, if the following requirements are met:

Minimum distance from the front lot line to the main wall of the build-

7.6 metres

Minimum side yards

metres on one side and

1.2 metres on the other side

(3) This section applies to the land in the Township of Nottawasaga in the County of Simcoe, being that part of the north half of Lot 44 and that part of the south half of Lot 45, Concession XI, designated as Part 4 on a Reference Plan deposited in the Land Registry Office for the Registry Division of Simcoe (No. 51) as Number 51R-14519. O. Reg. 627/86, s. 1.

L. J. FINCHAM
Director
Plans Administration Branch
Central and Southwest
Ministry of Municipal Affairs

Dated at Toronto, this 14th day of October, 1986.

(9616) 46

PLANNING ACT, 1983

O. Reg. 628/86.

Zoning Areas—Part of the Geographic Township of Southworth in the Territorital District of Kenora. Made—August 26th, 1986. Filed—October 29th, 1986.

ORDER MADE UNDER THE PLANNING ACT, 1983

ZONING AREAS—PART OF THE GEOGRAPHIC TOWNSHIP OF SOUTHWORTH IN THE TERRITORIAL DISTRICT OF KENORA

1. In this Order,

- "accessory", when used to describe a use, building or structure, means a use, building or structure that is normally incidental or subordinate to the principal use, building or structure located on the same lot;
- "agricultural use" means a use of land for forestry purposes, field crops, market gardening, poultry raising and other uses normally related to agriculture;
- "dwelling unit" means one or more habitable rooms occupied or capable of being occupied as an independent and separate housekeeping establishment in which separate kitchen and sanitary facilities are provided for the exclusive use of such unit with a private entrance from outside the building or from a common hallway or stairway inside the building;
- "front lot line" means the normal high-water mark of Dinorwic Lake;
- "guest cabin" means a building without cooking and sanitary facilities that is accessory to a dwelling and used for sleeping accommodation;

"lot" means a parcel of land,

- (a) described in a deed or other document legally capable of conveying land, or
- (b) shown as a lot or block on a registered plan of subdivision;
- "seasonal dwelling" means a single dwelling or mobile home not occupied as a permanent residence. O. Reg. 628/86, s. 1.
- 2. This Order applies to land in Lot 9, Concession I, in the Township of Southworth in the Territorial District of Kenora described as all of the lots and blocks shown on Plan Numbers 23M-839 and 23M-843 registered in the Land Registry Office for the Land Titles Division of Kenora (No. 23). O. Reg. 628/86, s. 2.
- 3. No land to which this Order applies shall hereafter be used and no building or structure shall hereafter be erected or used except in accordance with the terms of this Order, but nothing in this Order prevents the use of any land, building or structure for a purpose prohibited by this Order if such land, building or structure was lawfully used for such purposes on the day this Order comes into force. O. Reg. 628/86, s. 3.
- 4. One seasonal dwelling and building and structures accessory thereto may be erected and used on each of lots 1 to 12, inclusive, on Plan 23M-839 and lots 1 to 10, inclusive, on Plan 23M-843 if the following requirements are met:

- Not more than one guest cabin is permitted on a lot.
- Minimum distance between a dwelling unit or guest cabin and the front lot line:

Lots 2 and 3 on Plan 23M-839 9 metres

Lots 7 and 8 on Plan 23M-843 12 metres

Lots 1, 2, 3 and 4 on Plan 23M-843 15 metres

Lots 10 and 12 on Plan 23M-839 and Lot 10 on Plan 23M-843 18 metres

O. Reg. 628/86, s. 4.

5. Every use of land and every erection or use of buildings or structures on the land described as Blocks 11 and 12, Plan 23M-843, is prohibited except agricultural uses and outdoor sporting activities, excluding buildings or structures. O. Reg. 628/86, s. 5.

BERNARD GRANDMAÎTRE Minister of Municipal Affairs,

45

Dated at Toronto, this 26th day of August, 1986.

(9642)

HIGHWAY TRAFFIC ACT

O. Reg. 629/86. Stop Signs at Intersections. Made—October 27th, 1986. Filed—October 30th, 1986.

REGULATION TO AMEND REGULATION 493 OF REVISED REGULATIONS OF ONTARIO, 1980 MADE UNDER THE HIGHWAY TRAFFIC ACT

1. Regulation 493 of Revised Regulations of Ontario, 1980 is amended by adding thereto the following Schedules:

Schedule 86

- 1. Highway No. 130 in the Township of Paipoonge in the District of Thunder Bay at its intersection with the roadway known as Paipoonge Concession 1 Road.
- 2. Northbound on Highway No. 130. O. Reg. 629/86, s. 1, part.

Schedule 87

- 1. Highway No. 130 and Paipoonge 10th Line in the Township of Paipoonge in the District of Thunder Bay at its intersection with Highway No. 130 and the roadway known as Paipoonge Concession 1 Road.
- 2. Southbound on Highway No. 130 and northbound on Paipoonge 10th Line. O. Reg. 629/86, s. 1, part.

Schedule 88

- 1. Highway 511 in the Village of Lanark in the Township of Lanark in the County of Lanark at its east intersection with the roadway known as Lanark County Road 12.
- 2. Northbound on Highway 511. O. Reg. 629/86, s. 1, part.

EDWARD FULTON
Minister of Transportation
and Communications

Dated at Toronto, this 27th day of October, 1986.

(9643) 46

HIGHWAY TRAFFIC ACT

O. Reg. 630/86. Parking. Made—October 28th, 1986. Filed—October 30th, 1986.

REGULATION TO AMEND REGULATION 477 OF REVISED REGULATIONS OF ONTARIO, 1980 MADE UNDER THE HIGHWAY TRAFFIC ACT

- 1.—(1) Paragraph 8 of Schedule 2 of Appendix A to Regulation 477 of Revised Regulations of Ontario, 1980 is revoked and the following substituted therefor:
- 8. That part of the King's Highway known as No. 2 in the Town of Ajax in The Regional Municipality of Durham lying between a point situate at the easterly limit of its intersection with the roadway known as Elizabeth Street and a point situate at the westerly limit of its intersection with the roadway known as Rotherglen Road.
 - (2) Schedule 2 of Appendix A to the said Regulation is amended by adding thereto the following paragraph:

27. That part of the King's Highway known as No. 2 in the Town of Pickering in The Regional Municipality of Durham from a point situate at the westerly limit of its intersection with the roadway known as Rougemount Drive and extending westerly therealong for a distance of 215 metres.

O. Reg. 631/86

EDWARD FULTON
Minister of Transportation
and Communications

Dated at Toronto, this 28th day of October, 1986.

(9644)

46

HIGHWAY TRAFFIC ACT

O. Reg. 631/86. Parking. Made—October 27th, 1986. Filed—October 30th, 1986.

REGULATION TO AMEND REGULATION 477 OF REVISED REGULATIONS OF ONTARIO, 1980 MADE UNDER THE HIGHWAY TRAFFIC ACT

- 1. Paragraph 26 of Schedule 2 of Appendix A to Regulation 477 of Revised Regulations of Ontario, 1980, as made by subsection 1 (1) of Ontario Regulation 474/86, is revoked and the following substituted therefor:
- 26. That part of the King's Highway known as Nos. 2 and 53 in the Town of Ancaster, in The Regional Municipality of Hamilton-Wentworth and in the Township of Brantford, in the County of Brant, beginning at a point situate 215 metres measured westerly from its intersection with the westerly limit of Sunnyridge Road and extending westerly therealong for a distance of 215 metres.
 - 2. Schedule 16 of Appendix A to the said Regulation is amended by adding thereto the following paragraph:
- 5. The west side of that part of the King's Highway known as No. 10 in the Town of Caledon, in The Regional Municipality of Peel, lying between a point situate at the northerly limit of its intersection with the roadway known as Peel Regional Road 9, and extending northerly therealong for a distance of 160 metres.
 - 3. Paragraph 3 of Schedule 56 of Appendix A to the said Regulation, as made by subsection 1 (2) of Ontario Regula-

tion 474/86, is revoked and the following substituted therefor:

3. That part of the King's Highway known as Nos. 2 and 53 in the Town of Ancaster, in The Regional Municipality of Hamilton-Wentworth and in the Township of Brantford, in the County of Brant, beginning at a point situate 215 metres measured westerly from its intersection with the westerly limit of Sunnyridge Road and extending westerly therealong for a distance of 215 metres.

EDWARD FULTON
Minister of Transportation
and Communications

Dated at Toronto, this 27th day of October, 1986.

(9645) 46

OCCUPATIONAL HEALTH AND SAFETY ACT

O. Reg. 632/86. X-Ray Safety. Made—October 30th, 1986. Filed—October 30th, 1986.

REGULATION MADE UNDER THE OCCUPATIONAL HEALTH AND SAFETY ACT

X-RAY SAFETY

- 1. In this Regulation,
- "absorbed dose" means the mean energy per unit mass imparted by ionizing radiation to matter;
- "air kerma" means the sum of the initial kinetic energies per unit mass of all the charged particles liberated by uncharged ionizing radiation in air;
- "Director" means the Director of the Special Studies and Services Branch of the Ministry of Labour;
- "dose equivalent" means the product of absorbed dose and a quality factor where the quality factor is a measure of the biological effectiveness of the radiation, and is assigned the value 1.0 for x rays;
- "failsafe design" means a design in which any failure of safety indicators or components that can reasonably be anticipated causes the production or emission of x rays to cease;
- "gray" means,
 - (a) a unit of absorbed dose, and is realized when one joule of energy has been imparted per kilogram of material, or

- (b) a unit of air kerma, and is realized when one joule of energy has been liberated per kilogram of air;
- "redundant" when used with reference to a light means a light with two or more separate and equivalent bulbs so designed that the failure of one bulb will not affect the operation of the other bulb or bulbs;
- "shield" or "shielding" means radiation absorbing material or materials used to reduce the absorbed dose or absorbed dose rate imparted to an object;
- "sievert" means a unit of dose equivalent, and for x rays the dose equivalent measured in sieverts is numerically equal to the absorbed dose measured in grays;
- "x-ray machine" means an electrically powered device, the principal purpose of which is the production of x rays;
- "x-ray source" means any device, or that portion of any device, that emits x rays, whether or not the device is an x-ray machine;
- "x-ray worker" means a worker who, as a necessary part of the worker's employment, may be exposed to x rays and may receive a dose equivalent in excess of the annual limits set forth in column 4 of the Schedule;
- "x rays" means electrically-generated electromagnetic radiation of maximum photon energy not less than 5000 electron volts. O. Reg. 632/86, s. 1.
- 2. Subject to section 3, this Regulation applies to every owner, employer, supervisor and worker at a work place where,
 - (a) an x-ray machine is present or used; or
 - (b) an x-ray source that is not an x-ray machine is present or used, if the x-ray source is capable of producing an air kerma rate greater than 1.0 microgray per hour at any accessible point outside its surface. O. Reg. 632/86, s. 2.
- 3.—(1) This Regulation does not apply to an x-ray source that is licensable under the *Atomic Energy Control Act* (Canada).
- (2) Sections 5, 6, 7 and 8 of this Regulation do not apply in respect of an x-ray machine the installation, registration or operation of which is subject to the Healing Arts Radiation Protection Act. O. Reg. 632/86, s. 3.
- 4. Except as permitted under the *Healing Arts Radiation Protection Act*, an x-ray source shall not be operated for the irradiation of a worker. O. Reg. 632/86, s. 4.

- 5.—(1) An x-ray source shall not be used at a work place unless the employer who has possession of the x-ray source is registered with the Director.
- (2) An application for registration under this section shall be in Form 1 and shall be filed with the Director.
- (3) An employer who was registered under Ontario Regulation 263/84 or Regulation 855 of Revised Regulations of Ontario, 1980 or a predecessor thereof shall be deemed to be registered under this section if the registration was subsisting immediately before the coming into force of this Regulation.
- (4) If an employer who is registered under this section ceases to have possession of an x-ray source, the employer shall forthwith give a notice to the Director advising the Director of that fact.
- (5) An employer's registration under this section terminates when the employer notifies the Director that the employer no longer has possession of any x-ray sources. O. Reg. 632/86, s. 5.
- 6.—(1) An x-ray source shall not be installed or used in a permanent location and an x-ray source that is designed for portable or mobile use shall not be installed or used regularly in one location unless an application for review, together with plan location drawings, of the installation have been reviewed by and are acceptable to an inspector.
- (2) Subsection (1) does not apply to an x-ray source that.
 - (a) was in use in a permanent location before the 27th day of April, 1984, if it has remained continuously in that location since that time and so long as it remains in that location; or
 - (b) was installed after the 26th day of April, 1984, if the installation was made in compliance with Ontario Regulation 263/84 and there was compliance with that Regulation until the time this section came into force.
- (3) An application mentioned in subsection (1) shall be in Form 2 and shall be accompanied by the plan location drawings mentioned in that subsection, in duplicate.
- (4) Plan location drawings mentioned in subsection (1),
 - (a) shall bear the name of the applicant and the address of the location;
 - (b) shall be on a legible scale that is not less than 1:100 and that is suitable for microfilming;
 - (c) shall indicate the direction north;
 - (d) shall show the proposed location of the x-ray source and, where applicable, the range of its motion:

- (e) shall show the proposed location of the x-ray control panel, if the location of the control panel is different from that of the x-ray source;
- (f) shall indicate the use of rooms or areas that are adjacent, both horizontally and vertically, to the proposed location;
- (g) shall indicate the type and thickness of the shielding installed or to be installed on the boundaries of the proposed location; and
- (h) shall indicate the type and location of the safety devices such as warning lights, interlocks and cut-off switches.
- (5) An application under this section shall be filed with the Director.
- (6) Where an application under this section or a predecessor of this section has been found acceptable by an inspector, the x-ray source to which the application relates shall not be installed except in accordance with the application and the plan location drawings as accepted by the inspector.
- (7) An x-ray source to which subsection (1) applies or that is described in subsection (2) shall not be used, if after the installation of the x-ray source there is a change in,
 - (a) the installation or use of the x-ray source;
 - (b) the use of rooms or areas adjacent, horizontally or vertically, to the x-ray source; or
 - (c) any shielding of the x-ray source,

that may result in an increase in the exposure of a worker to x rays unless the change has been reviewed by and is acceptable to an inspector.

- (8) An employer shall request a review of a change described in subsection (7) by giving the request to the Director. O. Reg. 632/86, s. 6.
- 7.—(1) Where an employer comes into possession of an x-ray source that is designed for portable or mobile use and that is so used, notice thereof shall be given to the Director.
- (2) The notice required by subsection (1) shall be in writing and shall include,
 - (a) the name and address of the employer;
 - (b) the employer's registration number, if any, under section 5;
 - (c) the location where the x-ray source will normally be stored;
 - (d) the purpose for which the x-ray source will be used;

- (e) the make, model and serial number of the x-ray source; and
- (f) the maximum operating voltage and current of the x-ray source. O. Reg. 632/86, s. 7.
- 8. An employer shall designate a person, for each x-ray source, who is competent because of knowledge, training or experience in the use and operation of x-ray sources and in radiation safety practices, to exercise direction over the safe use and operation of the x-ray source, and shall advise the Director in writing of the name of the person designated. O. Reg. 632/86, s. 8.
- 9.—(1) An employer who employs a person as an x-ray worker shall, at the time that employment begins,
 - (a) inform the worker in writing that the worker is employed as an x-ray worker;
 - (b) inform the worker of the limits imposed by subsection 10 (1) on the dose equivalent that may be received by the worker; and
 - (c) if the worker is female, inform her of the dose equivalent limit mentioned in subsection 10(2) applicable to a pregnant x-ray worker.
- (2) An employer shall maintain a list of all x-ray workers in the employment of the employer. O. Reg. 632/86, s. 9.
- 10.—(1) The dose equivalent received or that may be received by a worker shall be as low as is reasonably achievable, and in any case,
 - (a) an x-ray worker shall not receive a dose equivalent in excess of the annual limits set out in column 3 of the Schedule; and
 - (b) a worker who is not an x-ray worker shall not receive a dose equivalent in excess of the annual limits set out in column 4 of the Schedule.
- (2) Notwithstanding subsection (1), an employer shall take every precaution reasonable in the circumstances to ensure that the mean dose equivalent received by the abdomen of a pregnant x-ray worker does not exceed five millisieverts during the pregnancy. O. Reg. 632/86, s. 10.
- 11. The following measures and procedures shall be carried out in a work place where an x-ray source is used:
 - X-ray warning signs or warning devices shall be posted or installed in conspicuous locations.
 - Every x-ray source capable of producing an air kerma rate greater than 5 micrograys per hour at any accessible point shall be labelled at its operating controls as a source of x rays.

- Where the air kerma in an area may exceed 100 micrograys in any one hour, access to the area shall be controlled by,
 - locks or interlocks if the x-ray source is one to which subsection 6 (1) applies or is described in subsection 6 (2), and
 - ii. barriers and x-ray warning signs if the x-ray source is portable or mobile and is being so used.
- 4. To ensure that the dose equivalent limits mentioned in section 10 are not exceeded,
 - i. structural or other shielding shall be installed as is necessary, and
 - ii. diaphragms, cones and adjustable collimators or other suitable devices shall be provided and used as are necessary to limit the dimensions of the useful x-ray beam. O. Reg. 632/86, s. 11.
- 12.—(1) An employer shall provide to each x-ray worker a suitable personal dosimeter that will provide an accurate measure of the dose equivalent received by the x-ray worker.
- (2) An x-ray worker shall use the personal dosimeter as instructed by the employer.
- (3) An employer shall ensure that the personal dosimeter provided to an x-ray worker is read accurately to give a measure of the dose equivalent received by the worker and shall furnish to the worker the record of the worker's radiation exposure.
- (4) An employer shall verify that the dose equivalent mentioned in subsection (3) is reasonable and appropriate in the circumstances, and shall notify an inspector of any dose equivalent that does not appear reasonable and appropriate.
- (5) An employer shall retain an x-ray worker's personal dosimeter records for a period of at least three years. O. Reg. 632/86, s. 12.
- 13. Where a worker has received a dose equivalent in excess of the annual limits set out in column 4 of the Schedule in a period of three months, the employer shall forthwith investigate the cause of the exposure and shall provide a report in writing of the findings of the investigation and of the corrective action taken to the Director and to the joint health and safety committee or health and safety representative, if any. O. Reg. 632/86, s. 13.
- 14. Where an accident, failure of any equipment or other incident occurs that may have resulted in a worker receiving a dose equivalent in excess of the annual limits set out in column 3 of the Schedule, the employer shall notify immediately by telephone, telegram or other direct means the Director and the joint

health and safety committee or health and safety representative, if any, of the accident or failure and the employer shall, within forty-eight hours after the accident or failure, send to the Director a written report of the circumstances of the accident or failure. O. Reg. 632/86, s. 14.

- 15.—(1) This section applies only to x-ray machines used for industrial radiography or industrial fluoroscopy but does not apply to an x-ray machine to which section 17 applies.
- (2) No x-ray machine to which this section applies shall be used except by or under the supervision of a competent person.
- (3) In addition to any other requirements of this Regulation, the following requirements apply with respect to every x-ray machine to which this section applies:
 - The control panel of the x-ray machine shall have a plainly visible warning light to indicate when x rays are being produced in the x-ray tube.
 - The x-ray machine, if installed in a permanent location or if designed for portable or mobile operation but used regularly in one location, shall be contained in an enclosure.
 - 3. No person shall be permitted in the enclosure required by paragraph 2 while x rays are being produced.
 - 4. The enclosure required by paragraph 2 shall be provided with,
 - reliable locks or interlocks to prevent any person from entering a radiation enclosure during an exposure, and where an exposure is terminated by an interlock, it shall only be possible to restart the exposure from the control panel, and
 - ii. conspicuous warning lights of failsafe or redundant design near each entrance to the enclosure that indicate when x rays are being produced,

and paragraph 3 of section 11 does not apply.

- If the enclosure required by paragraph 2 is of such a size or is so arranged that the operator cannot readily determine whether it is unoccupied, it shall be provided with,
 - i. suitable audible or visible pre-exposure warning signals within the enclosure that shall be actuated for not less than ten or more than thirty seconds immediately before the initiation of an x-ray exposure,

- suitable audible or visible warning signals within the enclosure that shall be actuated during the x-ray exposure, and
- iii. a suitable exit to enable any person to leave the enclosure without delay and without having to pass through the primary x-ray beam or an effective means, within the enclosure, that,
 - A. prevents or interrupts an x-ray exposure,
 - B. cannot be reset from outside the enclosure, and
 - C. can be reached without having to pass through the primary x-ray beam.
- An x-ray machine shall be operated, and, where an enclosure is required by paragraph
 the enclosure shall be shielded in such a manner that,
 - i. an x-ray worker is not likely to receive an effective dose equivalent in excess of 1 millisievert per week, and
 - ii. a worker who is not an x-ray worker is not likely to receive an effective dose equivalent in excess of 100 microsieverts per week.
- 7. The employer shall ensure that a direct reading dosimeter of a suitable type is provided to each x-ray worker who in the course of his or her work may be exposed to an air kerma rate in excess of 100 micrograys per hour.
- 8. An x-ray worker provided with a direct reading dosimeter shall use it and shall determine the amount by which its reading has increased during each work day and record that amount at the end of the work day.
- The employer shall retain the direct reading dosimeter records of each x-ray worker provided with such a dosimeter for a period of at least three years.
- 10. At least one radiation survey meter of a suitable type shall be provided for each portable or mobile x-ray machine and it shall be calibrated at least once every twelve months and kept in good working order. O. Reg. 632/86, s. 15.
- 16. In addition to any other requirement of this Regulation, the following requirements apply to every x-ray machine used for the diagnostic examination of animals:

- Where practicable, radiographic procedures shall be performed in a room designed for the purpose of performing x-ray examinations of animals.
- 2. The air kerma due to leakage radiation from the x-ray tube housing or from an attached beam-limiting device shall not exceed 1 milligray in one hour at a distance of one metre from the focal spot of the x-ray tube.
- 3. Exposure duration shall be controlled by a preset timing mechanism and shall be initiated by a switch that requires positive action by the operator to continue the exposure and that allows the operator to remain at least two metres from the tube housing.
- To the extent practicable, the dimensions of the useful beam shall be restricted to not more than those of the film.
- The film cassette shall not be held by hand during an exposure.
- The animal being x-rayed shall be restrained or supported by mechanical means where practicable.
- 7. If an animal is required to be restrained or supported by hand, a protective apron and gloves, providing shielding equivalent to at least 0.5 millimetre of lead, shall be worn by any person providing the restraint or support.
- A record of radiographic exposures, including the date, kilovoltage, tube current, and duration of each exposure, shall be maintained and kept for at least one year.
 O. Reg. 632/86, s. 16.
- 17. In addition to any other requirements of this Regulation, where an employer is in possession of an x-ray source in which the x-ray source, the object or the portion of the object being exposed to x rays and the detection device are enclosed in a cabinet that, independent of existing structures, provides radiation attenuation and prevents access to the x-ray beam, the employer shall comply with the following requirements:
 - A warning device that indicates when x rays are being produced shall be mounted on or near the cabinet in-such a way as to be conspicuous from any position from which the cabinet can be opened.
 - 2. Access doors and sample ports shall be interlocked with the x-ray source or with an adequately shielded shutter of failsafe design, and where operation has been interrupted by an interlock, it shall be possible to resume operation only from the control panel after the interlock has been reset.

- 3. The cabinet shall be so arranged and shielded as to prevent the air kerma rate from exceeding 5 micrograys per hour at any accessible point 5 centimetres from the external surface, under all possible operating conditions
- Cabinet x-ray equipment that is intended to permit the entry of a person shall also be provided with,
 - suitable audible or visible warning signals within the cabinet that shall be actuated for at least ten seconds immediately prior to the initiation of x-ray production after the closing of any door that is designed to permit human access into the cabinet,
 - suitable audible or visible warning signals within the cabinet that shall be actuated during x-ray production, and
 - iii. effective means within the enclosure to prevent or interrupt the production of x rays, that cannot be reset from outside the enclosure and that can be reached without having to pass through the primary x-ray beam. O. Reg. 632/86, s. 17.
- 18. In addition to any other requirements of this Regulation, where an employer is in possession of an x-ray source that consists of analytic x-ray equipment to which section 17 does not apply and that is primarily used to determine the structure or composition of a sample of a material, the employer shall comply with the following requirements:
 - 1. The control panel shall have an indicator, in close proximity to the x-ray "ON/OFF" switch, that clearly indicates when x rays are being produced in the x-ray tube.
 - A warning light shall be mounted near each x-ray tube in such a way as to be clearly visible from any direction from which the tube can be approached, that indicates when x rays are being produced.
 - 3. The condition of each shutter, open or closed, shall be clearly indicated at or near the x-ray tube.
 - 4. Each port shall be designed in such a way that the x-ray beam can emerge only when a camera or other recording device is in its proper position, wherever practicable.
 - At least one of the warning or safety devices mentioned in paragraphs 1 to 4 shall be of failsafe design.

- A guard or interlock which prevents entry of any part of the body into the primary beam path shall be used, wherever practicable.
- 7. A shield shall be provided to absorb the primary beam at the nearest practicable position beyond the point of intersection of the beam and the sample that it is intended to irradiate.
- 8. All unused ports shall be secured in such a

way as to prevent inadvertent opening. O. Reg. 632/86, s. 18.

- 19. In applying this Regulation, a procedure or device may vary from the procedure or device prescribed in this Regulation if the protection afforded thereby is equal to or greater than the protection afforded by the procedure or device prescribed. O. Reg. 632/86, s. 19.
 - 20. Ontario Regulation 263/84 is revoked.

Schedule

| PART OF BODY IRRADIATED | EXPOSURE CONDITIONS AND COMMENTS | DOSE EQUIVALENT ANNUAL LIMIT (millisieverts) | | |
|---|--|--|---------------|--|
| | | X-RAY WORKERS | OTHER WORKERS | |
| Column 1 | Column 2 | Column 3 | Column 4 | |
| Whole body or trunk of body | Uniform irradiation | 50 | 5 | |
| Partial or non- uniform irradia- tion of body | The Limit applies to the EFFECTIVE DOSE EQUIVALENT defined in Note (a) | 50 | 5 | |
| Lens of eye | Irradiated either alone or with other organs or tissues | | 50 | |
| Skin | The limit applies to the mean dose equivalent to the basal cell layer of the epidermis for any area of skin of 1 square centimetre or more | | 50 | |
| Individual organs or tissues other than lens of eye or skin | The limit on effective dose equivalent applies with an overriding limithe dose equivalent to individual organ or tis | it on the | 50 | |

Notes to the Schedule:

(a) The EFFECTIVE DOSE EQUIVALENT, H_E , is determined by the following formula:

$$H_E = \sum_T W_T H_T$$

where:

- (i) T is an index for tissue type;
- (ii) H_T is the annual dose equivalent in tissue T;
- (iii) $W_{\!\!\!\!T}$ is a weighting factor which has the following values:
 - 0.25 for the gonads,
 - 0.15 for the breast,
 - 0.12 for the red bone marrow,
 - 0.12 for the lungs,
 - 0.03 for the bone surfaces,
 - 0.03 for the thyroid,
 - 0.06 for each of the five other organs or tissues receiving the highest dose equivalents, but excluding the skin, extremities and eye lenses. The exposure of all other remaining tissues can be neglected. When the gastro-intestinal tract is irradiated, the stomach, small intestine, upper large intestine and lower large intestine shall be considered as four separate organs; and
- (iv) $\sum_T W_T H_T$ is the sum of the $W_T H_T$ values for all irradiated tissues which receive more than 1 millisievert in a given year.
- (b) The annual limits do not include any dose equivalent received by a worker from background sources or received as a patient undergoing medical diagnostic or therapeutic procedures.
- (c) The annual limits include any dose equivalent received by a worker, as a consequence of his or her occupation, from all sources of ionizing radiation.

O. Reg. 632/86, Sched.

Form 1

Occupational Health and Safety Act

APPLICATION FOR REGISTRATION

| | ario Ministry of Labour | Radiation Protection Service | Registration | | |
|------|---|---|---------------------|--|--|
| Onta | upational Health and Sa ario Regulation ay Safety | fety Act | | | |
| Note | e: Insert "X" in all a | pplicable boxes. | | | |
| app. | undersigned, as employ lies for registration w istry of Labour. | er or as agent for the rith the Radiation Protection | employer of the | | |
| A. | The employer is: | | | | |
| | Name | Telephone No. | | | |
| | Business Address | | | | |
| | City | Postal Code _ | | | |
| В. | The person to whom cor "A" \square , or is: | respondence should be addre | essed is as at | | |
| | Name | Telephone No. | | | |
| | Position or Title | | | | |
| | Address | | | | |
| | City | Postal Code | | | |
| c. | The general nature of the | e employer's business is (check | one category only): | | |
| | Industrial and Commerc | ial | | | |
| | Veterinarian | | | | |
| | Research and Development | | | | |
| - | Education and Training | | | | |
| | Other (Please specify) | | | | |

| D. | As of the date of this registration, the employer is in possession of the |
|----|--|
| | following x-ray sources at the locations indicated (for portable or mobile |
| | units indicate where normally stored): |
| | |

MAKE MODEL Building, Street, City)

DATE INSTALLED

| Dated at | , this | day of _ | 19 | |
|-----------------------|--------|----------|--------------------|-----------|
| | | | . 7 | |
| | | _ | | |
| Signature of Applican | t | Na | ame (please type o | or print) |

O. Reg. 632/86, Form 1.

Form 2

Occupational Health and Safety Act

APPLICATION FOR REVIEW OF PERMANENT X-RAY LOCATION

| | Ministry Labour | Radiation Protection Service | Registration No | | | |
|---------------------|---|---|------------------------|--|--|--|
| | tional Health and Safety Regulation Safety | Act | | | | |
| Note: | Insert "X" in all applicab | le boxes. | | | | |
| PART | A: GENERAL | | | | | |
| The unc | dersigned, as | Commence of the last | | | | |
| еп | ployer owner co | ontractor architect | engineer agent | | | |
| total of | x-ray sources in | rooms. It is accompa mpleted Part B for each | inied by related floor | | | |
| l. Th | 1. The name of the x-ray facility for which review is sought is | | | | | |
| 2. The employer is: | | | | | | |
| Na | me | Telephone t | No | | | |
| | mber, Street | | | | | |
| Ci | ty | Postal Code | · | | | |
| | e employer's registration | | OR | | | |
| the | e employer is not registe | red[] | | | | |
| 4. Th | is application is submitte | ed for the following reason | on: | | | |
| | Opening of a new facility | ty | | | | |
| | Relocation of sources | | | | | |
| | Replacement of old sources in existing facilities | | | | | |
| | Additional sources | | | | | |

THE ONTARIO GAZETTE O. Reg. 632/86

| Acquisition of existing facility from: | | | | | |
|---|--|---|--|--|--|
| Previous owner's name | | | | | |
| | Registration No. | | | | |
| | Change of shielding provisions, structure, or s | afety devices | | | |
| | Compliance with Inspector's direction | | | | |
| Operation is expected to commence on the following date: | | | | | |
| | | | | | |
| | 19 | | | | |
| - | | ated as at | | | |
| Nu | Number, street | | | | |
| Ci | City Postal Coo | de | | | |
| The person who exercises (or will exercise) direction over the safe use and operation of the x-ray source at the above location is the employer, or is: | | | | | |
| Na | Name Telephone | No. | | | |
| | | | | | |
| | Relevant Qualifications | | | | |
| | | | | | |
| Th | The drawings and specifications were prepared by | | | | |
| | The drawings and specifications were prepared by employer architect other (specify) | /: | | | |
| | employer architect other (specify) | <i>γ</i> : | | | |
| Na | employer architect other (specify) Name Telephone | <i>γ</i> : | | | |
| Na Nu | mane architect other (specify) Telephone Tumber, Street | /: No | | | |
| Na Nu Ci Th | employer architect other (specify) Name Telephone | Nodeeach Part B | | | |
| Na Nu Ci Th | me mployer architect other (specify) Name Telephone Number, Street City Postal Coo The information set out in this application and in | Nodeeach Part B | | | |
| Na Nu Ci Th | employer architect other (specify) Name Telephone Number, Street City Postal Coo The information set out in this application and in accompanying this application is accurate to the | deeach Part B best of my knowledge. | | | |
| Na Nu Ci Th | me mployer architect other (specify) Name Telephone Number, Street City Postal Coo The information set out in this application and in | deeach Part B best of my knowledge. | | | |
| Na Nu Ci Th | employer architect other (specify) Name Telephone Number, Street City Postal Coo The information set out in this application and in accompanying this application is accurate to the | deeach Part B best of my knowledge. | | | |
| | | Previous owner's name Registration No. Change of shielding provisions, structure, or some compliance with Inspector's direction Operation is expected to commence on the follow 19 The x-ray source(s) will be (or are at present) loc 2 , or at: Number, street City Postal Commence on the follow 19 The x-ray source(s) will be (or are at present) loc 2 operation of the x-ray source at the above location is: Name Telephone Position | | | |

PART B: SPECIFIC

| | ew is so | one copy of Fought. | art B is requ | ired for eac | h x-ray sour | ce for which |
|---|-----------|---|---------------------------------|----------------------------|---------------|------------------|
| 1. | This sh | This sheet refers to x-ray source number of | | | | |
| x-ray sources located in the room designated as | | | | | | |
| | | on the accomp | | | | |
| 2. | This x- | ray source is us | ed for | | | |
| | It is ide | entified by: | | | | |
| | Make/I | Model | | Serial No. | | and has |
| | | lowing operating | g characteris | | | and the |
| | (a) ti | he maximum ra | ted tube volt | age is | | kilovolts |
| | | he maximum ra | | | | |
| | (c) ti | he anticipated railliampere-min | naximum wor | kload is | | |
| | | | | | | |
| 3. | The co | mposition of the are (give materi | e boundaries of al types and | of the room thicknesses | , including v | windows and |
| | Floor | | | | | |
| | Ceiling | | | | | |
| | Walls: | North_ | | | | |
| | | | | | | |
| | | | | | | |
| | | West | | | | |
| | | | | | | |
| | | | | | | |
| | | Occupancy | (See Note 1) | | Usage Fac | tor (See Note 2) |
| Dire | ction | Туре | Per | Cent | P | er Cent |
| | | | | | | |
| | | | | | | |
| Dow | n | | | | _ | |
| Up Nort | -h | | | | - | |
| East | | | | | _ | |
| Sout | | | | | _ | |
| West | | | | | - | |

O. Reg. 632/86

- Note 1: Occupancy type is the nature of use of the area in the indicated direction relative to the x-ray source (e.g. office, waiting room, parking lot, etc.) Occupancy per cent is the fraction, expressed as a percentage, of the time the area will be occupied while the source is on (omit if unknown.)
- Note 2: The use factor is the fraction of the time the beam will be pointed in the direction indicated, as a percentage of the total time the source is on. For uncollimated, panoramic, or multiple beams, the sum may exceed 100%.

The information given in this Part must correspond with that given on the accompanying floor plans.

O. Reg. 632/86, Form 2.

46

(9646)

OCCUPATIONAL HEALTH AND SAFETY ACT

O. Reg. 633/86. Oil and Gas-Offshore. Made-October 30th, 1986. Filed-October 30th, 1986.

REGULATION MADE UNDER THE OCCUPATIONAL HEALTH AND SAFETY ACT

OIL AND GAS-OFFSHORE

INTERPRETATION

- 1. In this Regulation,
- "boom" means the projecting part of a backhoe, shovel, crane or similar lifting device from which a load is likely to be supported;
- "cathead" means a spool-shaped attachment on a winch around which rope for hoisting and pulling is wound:
- "Director" means the Chief Inspector of the Petroleum Resources Section, South-West Region, Ministry of Natural Resources;
- "drawworks" means the hoisting mechanism on a rig which raises or lowers the drill stem and bit;

- "flammable liquid" means a liquid having a flash point bėlow 37.8° Celsius, and a vapour pressure below 275 kilopascals absolute at 37.8° Celsius;
- "kelly" means the heavy steel pipe with four or six sides that is connected to the top of the drill pipe;
- "lifting device" means a device that is used to raise or lower any material or object and includes its rails and other supports;
- "prime mover" means an initial source of motive power;
- "professional engineer" means a person who is licensed as a professional engineer under the Professional Engineers Act, 1984;
- "rig" means any rotary drilling ship, cable tool ship, barge, platform or other rig used for offshore oil or gas exploration, development, production, maintenance, workover, capping, plugging or abandonment operations;
- "transmission equipment" means any object or objects by which the motion of a prime mover is transmitted to a machine that is capable of utilizing such motion and includes a shaft, pulley, belt, chain, gear, clutch or other device. O. Reg. 633/86, s. 1.

PART I

GENERAL

2. In applying this Regulation, the composition, design, size and arrangement of any material, object, device or thing may vary from the composition, design, size or arrangement prescribed if the factors of strength, health and safety are equal to or greater than the factors of strength, health and safety in the composition, design, size or arrangement prescribed. O. Reg. 633/86, s. 2.

- 3. This Regulation applies to all work done offshore on or from a rig. O. Reg. 633/86, s. 3.
- 4. The minimum age of a worker is eighteen years of age. O. Reg. 633/86, s. 4.
- 5. Prior to the start of the drilling season, the owner of the licence of occupation under the *Mining Act* shall provide a notice in writing to the Director, setting out,
 - (a) the contents of the operating manual required under section 14; and
 - (b) details of an emergency plan to rescue workers in the event of an emergency. O. Reg. 633/86, s. 5.
- 6. An emergency plan shall be prepared in writing and shall include,
 - (a) a suitable and rapid means of obtaining first aid help and transportation from the rig to a hospital for injured workers; and
 - (b) the measures and procedures to be used to,
 - (i) control a major fire,
 - (ii) react to serious damage to the rig,
 - (iii) evacuate the rig, and
 - (iv) notify rescue personnel. O. Reg. 633/86, s. 6.
- 7. The written report required by section 25 of the Act shall include.
 - (a) the name and address of the employer;
 - (b) the nature and the circumstances of the occurrence and the bodily injury sustained;
 - (c) a description of the machinery or equipment involved:
 - (d) the time and place of the occurrence;
 - (e) the name and address of the person who was killed or critically injured;
 - (f) the names and addresses of all witnesses to the occurrence; and
 - (g) the name and address of the physician or surgeon, if any, who is attending or has attended the injury. O. Reg. 633/86, s. 7.

- 8. For the purposes of section 26 of the Act, notice of,
 - (a) an accident, explosion or fire which disables a worker from performing his usual work; or
 - (b) an occupational illness,

shall include,

- (c) the name, address and type of business of the employer;
- (d) the nature and the circumstances of the occurrence and the bodily injury or illness sustained;
- (e) a description of the machinery or equipment involved;
- (f) the time and place of the occurrence;
- (g) the name and address of the person suffering the injury or illness;
- (h) the names and addresses of all witnesses to the occurrence;
- (i) the name and address of the physician or surgeon, if any, who is attending or has attended the injury or illness; and
- (j) the steps taken to prevent a recurrence. O. Reg. 633/86, s. 8.
- A record of an accident, explosion or fire causing injury requiring medical attention but not disabling a worker from performing his usual work shall be kept in the permanent records of the employer and include particulars of,
 - (a) the nature and circumstances of the occurrence and the injury sustained;
 - (b) the time and place of the occurrence; and
 - (c) the name and address of the injured person. O. Reg. 633/86, s. 9.
- 10. A record kept as prescribed by section 9 for the inspection of an inspector shall be notice to the Director. O. Reg. 633/86, s. 10.
- 11. A record of the qualifications of all workers appointed as competent persons shall be kept in the permanent records of the employer for as long as the worker is employed with the employer. O. Reg. 633/86, s. 11.

PART II

PREPARATION

12. Muster lists shall be posted in two conspicuous locations on the rig and in each cabin. O. Reg. 633/86, s. 12.

- 13. A muster list shall indicate,
 - (a) emergency signals or alarms;
 - (b) fire stations;
 - (c) survival craft stations;
 - (d) workers in charge of survival craft; and
 - (e) procedures outlined in the emergency plan. O. Reg. 633/86, s. 13.
- 14. An operating manual prescribing the procedures to be followed shall be,
 - (a) available for each drilling or related operation; and
 - (b) readily accessible to a worker on the drilling site. O. Reg. 633/86, s. 14.
- 15. The employer shall ensure that a rig and its equipment is inspected for compliance with this Regulation,
 - (a) in port, by an inspector prior to the drilling season; and
 - (b) by a worker who is a competent person at least once every thirty working days while in operation. O. Reg. 633/86, s. 15.
- 16. The employer shall ensure that the derrick or mast is inspected by a competent person,
 - (a) prior to being put into position, raised or lowered; and
 - (b) at least once every year while in port. O. Reg. 633/86, s. 16.
- 17. The employer shall ensure that firefighting and life saving equipment is inspected by a competent person at least once every two weeks. O. Reg. 633/86, s. 17.
- 18. The employer shall ensure that a lifting device is examined by a competent person to determine its capability of handling the maximum load as rated,
 - (a) prior to being used for the first time; and
 - (b) thereafter as often as necessary but not less frequently than recommended by the manufacturer and, in any case, at least once a year. O. Reg. 633/86, s. 18.
- 19. Written reports of inspections required by this Regulation shall be made by a competent person and shall be kept,
 - (a) on the rig for a period of one year; and

- (b) at the employer's principal office in Ontario for a period of five years,
- from the date of inspection. O. Reg. 633/86, s. 19.
- 20. The employer shall ensure that for each crew of workers on a working rig,
 - (a) a fire drill is held at least once every two weeks;
 - (b) an evacuation drill is held at least once every four weeks; and
 - (c) a man-over-board drill is held at least once every four weeks. O. Reg. 633/86, s. 20.

PART III

GENERAL REQUIREMENTS

- 21. A worker required to wear or use any protective clothing, equipment or device shall be instructed and trained in its care and use before wearing or using the protective clothing, equipment or device. O. Reg. 633/86, s. 21.
- **22.** Every worker who is exposed to the hazard of head injury shall wear head protection appropriate in the circumstances. O. Reg. 633/86, s. 22.
- 23. Every worker who is exposed to the hazard of eye injury shall wear eye protection appropriate in the circumstances. O. Reg. 633/86, s. 23.
- 24. Every worker who is exposed to the hazard of foot injury shall wear foot protection appropriate in the circumstances. O. Reg. 633/86, s. 24.
- 25. Long hair shall be suitably confined to prevent entanglement with any rotating shaft, spindle, gear, belt or other source of entanglement. O. Reg. 633/86, s. 25.
- 26. Every worker who is exposed to the hazard of skin injury by contact with,
 - (a) a noxious gas, liquid, fume or dust;
 - (b) a sharp or jagged object which may puncture, cut or abrade his skin;
 - (c) a hot object, hot liquid or molten metal; or
 - (d) radiant heat,

shall be provided with protection by the employer in the form of,

- (e) wearing apparel sufficient to protect the worker from injury; or
- (f) a shield, screen or similar barrier,

appropriate in the circumstances. O. Reg. 633/86, s. 26.

- 27. Where a worker is exposed to the hazard of falling and the surface to which the worker might fall is more than three metres below the position where the worker is situated.
 - (a) the employer shall provide and the worker shall wear a fall arrest system consisting of a serviceable safety belt or harness and lifeline adequately secured to a fixed support and so arranged that the worker cannot fall freely for a vertical distance of more than 1.5 metres; and
 - (b) the fall arrest system described in clause (a) shall.
 - (i) have sufficient capacity to absorb twice the energy and twice the load that under the circumstances of its use may be transmitted to it, and
 - (ii) be equipped with a shock absorber or other devices to limit the maximum arresting force to 8.0 kilonewtons to the worker. O. Reg. 633/86, s. 27.
- 28. Every worker who is exposed to the hazard of falling into water shall wear a life jacket. O. Reg. 633/86, s. 28.
 - 29. Material, articles or things,
 - (a) required to be lifted, carried or moved shall be lifted, carried or moved in such a way and with such precautions and safeguards, including protective clothing, guards or other precautions as will ensure that the lifting, carrying or moving of the material, articles or things does not endanger the safety of any worker;
 - (b) shall be transported, placed or stored so that the material, articles or things,
 - (i) will not tip, collapse or fall, and
 - (ii) can be removed or withdrawn without endangering the safety of any worker; and
 - (c) to be removed from a storage area, pile or rack shall be removed in a manner that will not endanger the safety of any worker. O. Reg. 633/86, s. 29.
- 30. Machinery, equipment or material that may tip or fall and endanger any worker shall be secured against tipping or falling. O. Reg. 633/86, s. 30.
- Cylindrical objects stored on their side shall be piled symmetrically with each unit in the bottom row

- chocked or wedged to prevent motion. O. Reg. 633/86, s. 31.
- **32.** Barrels, drums or kegs that are piled on their ends shall have two parallel planks placed on top of each row before another row is added. O. Reg. 633/86, s. 32.
 - 33. A storage cylinder for compressed gas shall,
 - (a) be secured in position during use;
 - (b) have the valve protection cap in position when the cylinder is not in use;
 - (c) when containing acetylene, be in an upright position; and
 - (d) be protected from physical damage. O. Reg. 633/86, s. 33.
- 34. A silo, bin, hopper, structure, container or thing used for storing or containing bulk material may be entered only where,
 - (a) the supply of material thereto is stopped and precautions are taken that will prevent any further supply;
 - (b) mechanical equipment that may endanger a worker is,
 - (i) disconnected from its power source,
 - (ii) locked out:
 - (c) the space is ventilated to provide a safe atmosphere;
 - (d) the space is tested for lack of oxygen and presence of combustible gases;
 - (e) the worker entering is wearing a safety harness or other similar equipment attached to a rope or lifeline; and
 - (f) at least one other worker equipped with a suitable alarm and capable of rendering any necessary assistance is keeping watch nearby. O. Reg. 633/86, s. 34.
- 35. Where the operator of a crane or similar material handling equipment does not have a full view of the intended path of travel of the crane or similar material handling equipment or its load, the crane or similar material handling equipment shall only be operated as directed by a signalman who is a competent person and who is stationed,
 - (a) in full view of the operator;
 - (b) with a full view of the intended path of travel of the crane or similar material handling equipment and its load; and

- (c) clear of the intended path of travel of the crane or similar material handling equipment and its load. O. Reg. 633/86, s. 35.
- 36. Except for the purpose of a test of the material handling equipment, no material handling equipment shall be loaded in excess of its maximum rated load. O. Reg. 633/86, s. 36.
- 37. A worker who may be exposed to a biological, chemical or physical agent that may endanger the worker's safety or health shall be trained,
 - (a) in the precautions and procedures to be followed in the handling, use and storage of the agent;
 - (b) in the proper use and care of required personal protective equipment; and
 - (c) in the proper use of emergency measures and procedures. O. Reg. 633/86, s. 37.
- 38. No food, drink or tobacco shall be taken into, left or consumed in any room, area or place where any substance that is poisonous by ingestion is exposed. O. Reg. 633/86, s. 38.
- 39. Containers used for handling or storage of corrosive, flammable or hazardous materials shall be,
 - (a) appropriate for their intended use;
 - (b) constructed to prevent spillage or leakage;
 - (c) labelled to identify the contents; and
 - (d) disposed of in a manner that will not endanger a worker's health or safety and complies with the requirements of the Ministry of the Environment. O. Reg. 633/86, s. 39.
- 40. A rig shall have an easily accessible eyewash station and deluge shower adjacent to the mud mixing facilities. O. Reg. 633/86, s. 40.
- 41.—(1) In this section, "decibel" means decibel measured on a type 2 sound level meter conforming to the standard Z107.1 of the Canadian Standards Association operating on the A-weighting network with slow meter response.
- (2) Where a worker is exposed to a sound level of ninety decibels or greater, measures shall be taken to reduce the sound level below ninety decibels and, where such measures are not practicable,
 - (a) the duration of exposure set out in Column 2 of the Table in subsection (5) shall not exceed the duration shown for the particular sound level set opposite thereto in Column 1 of the Table in subsection (5); or
 - (b) the person shall wear hearing protection.

- (3) Where a worker is exposed to a sound level of 115 decibels or greater, the worker shall wear hearing protection.
- (4) Clearly visible warning signs containing the information set out in subsection (5) shall be posted at the approaches to an area where the sound level is more than ninety decibels.
 - (5) Warning signs shall state,
 - (a) the daily exposure for the particular sound level permitted by the following Table; and
 - (b) that hearing protection must be worn when the daily exposure is more than that permitted for the particular sound level.

Table

| Column 1 | COLUMN 2 |
|------------------------------|-------------------------------------|
| Sound Level — in Decibels | Duration — Hours per 24 hour Day |
| 90 | 8 |
| 92 | 6 |
| . 95 | 4 |
| 97 | 3 |
| 100 | 2 |
| 102 | 11/2 |
| 105 | 1 |
| 110 | 1/2 |
| 115 | 1/4 or less |
| Over 115 | No exposure |

- (6) Where hearing protection is required by this section, the protection shall be sufficient to reduce the sound level below the sound level in Column 1 of the Table in subsection (5) for the exposure corresponding to that duration in Column 2 of the Table in subsection (5). O. Reg. 633/86, s. 41.
- 42. Where a machine or prime mover or transmission equipment other than a cathead, kelly or rotary table, has an exposed moving part that may endanger the safety of any worker, the machine or prime mover or transmission equipment shall be equipped with and guarded by a guard or other device that prevents access to the moving part. O. Reg. 633/86, s. 42.
- 43. An in-running nip hazard or any part of a machine, device or thing that may endager the safety of any worker shall be equipped with and guarded by a guard or other device that prevents access to the pinch point. O. Reg. 633/86, s. 43.
- 44. An emergency stop control on a power-driven machine shall,
 - (a) be conspicuously identified; and
 - (b) be located within easy reach of the operator. O. Reg. 633/86, s. 44.

- 45. An operating control that acts as a guard for a machine not otherwise guarded shall,
 - (a) be in a location where the safety of the operator is not endangered by moving machinery;
 - (b) be arranged so that it cannot be operated accidentally; and
 - (c) not be made ineffective by a tie-down device or other means. O. Reg. 633/86, s. 45.
 - 46. A grinding wheel shall be,
 - (a) marked with the maximum speed at which it may be used;
 - (b) checked for defects before mounting;
 - (c) mounted in accordance with the manufacturer's specifications;
 - (d) operated at a speed which does not exceed the manufacturer's recommendations;
 - (e) provided with protective hoods that enclose the wheel as closely as the work will permit;
 - (f) operated only by workers protected by eye protection; and
 - (g) stored where it will not be subjected to,
 - (i) extreme heat or cold, or
 - (ii) damage from impact. O. Reg. 633/86, s. 46.
 - 47. A work rest for a grinding wheel shall,
 - (a) have a maximum clearance of three millimetres from the grinding wheel;
 - (b) be in a position above the centre line of the grinding wheel; and
 - (c) not be adjusted while the grinding wheel is in motion. O. Reg. 633/86, s. 47.
- 48.—(1) A lifting device including a crane, pedestal or other mount shall,
 - (a) be capable of supporting the loads likely to be applied to it;
 - (b) have the maximum load rating clearly marked near the operating station;
 - (c) when the hoisting equipment is a crane, have,
 - (i) a load capacity chart that specifies boom angle and maximum working

- loads for each block, posted inside the control cab where load rating is more than five tons, and
- (ii) boom and block travel-limiting devices;
- (d) have hooks equipped with safety catches;
- (e) be equipped with suitable ropes, chains, slings and other fittings so as to adequately protect all workers;
- (f) have all operating controls clearly identified;
- (g) be plainly marked with sufficient information so as to enable the operator of the device to determine the maximum rated load that the device is capable of lifting under any operating condition;
- (h) have a cab, screen, canopy guard or other adequate protection for the operator where the worker may be exposed to the hazard of falling material;
- (i) when it is a pneumatic or hydraulic hoist, have controls that automatically return to their neutral position when released;
- (j) be operated only by,
 - (i) a competent person, or
 - (ii) a worker being instructed who is accompanied by a competent person; and
- (k) be operated in such a way that,
 - (i) no part of the load passes over any worker,
 - (ii) where a worker may be endangered by the rotation or uncontrolled motion of a load, one or more guide ropes is used to prevent rotation or other uncontrolled motion, and
 - (iii) when its load is in a raised position, the controls are attended by an operator.
- (2) Subclause (1) (k) (iii) does not apply to a hydraulic hoist that supports the load from below and is fixed in one location. O. Reg. 633/86, s. 48.
- 49. Hoisting controls operated from other than a cab or cage shall,
 - (a) be located so that they can be operated at a safe distance from a load being lifted; and
 - (b) automatically return to their neutral position when released. O. Reg. 633/86, s. 49.

- 50. Where a lifting device is equipped with limit switches, the switches shall,
 - (a) automatically cut off the power and apply the brake when the limit is reached; and
 - (b) when used as an operating control, have a second limit switch located beyond the control limit switch. O. Reg. 633/86, s. 50.
- 51. A crane, lift truck or similar equipment shall be used to support, raise or lower a worker only when,
 - (a) the worker is on a platform,
 - (i) equipped with adequate safety devices that will automatically prevent the platform and load from falling if the platform's normal support fails,
 - (ii) suspended from a boom, and the person is attached to a separate lifeline suspended from the boom or a fixed support capable of supporting at least four times the weight of the worker,
 - (iii) attached to a mast or boom that,
 - (A) is hydraulically or pneumatically operated, and
 - (B) is equipped with a safety device that will prevent free fall of the platform in the event of a pressure line failure;
 - (b) where the equipment is not designed for the specific purpose of hoisting personnel, the load applied to the crane, lift truck or similar equipment is less than one half the maximum rated load;
 - (c) the platform has a sign indicating the load described in clause (b);
 - (d) where controls are provided at more than one location,
 - (i) each control station is provided with means whereby the operator can shut off power to the equipment, and
 - (ii) interlocks have been provided so that only one station can be operative at any time; and
 - (e) except when the controls are operated from the platform, the controls are attended and operated by another worker. O. Reg. 633/86, s. 51.

- (a) at the perimeter of any area where there is a drop of more than one metre;
- (b) on a mud tank; and
- (c) where there is a hazard of falling into water or other hazardous material.
- (2) A guardrail shall consist of,
 - (a) a top rail not less than 107 centimetres above the surface, floor or platform;
 - (b) a mid rail located approximately mid way between the top rail and walking surface; and
 - (c) posts or uprights, supporting the top rail and spaced not more than three metres apart from centre to centre.
- (3) A guardrail shall,
 - (a) be capable of withstanding any load likely to be applied to it; and
- (b) where tools or other objects may fall on any worker, have a toe-board extending from the floor platform or other surface to a height of not less than 125 millimetres. O. Reg. 633/86, s. 52.
- 53. A cover on an opening in a floor, roof or other surface shall be,
 - (a) secured in place; and
 - (b) of sufficient strength to support,
 - (i) any load likely to be applied to it, or
 - (ii) 2.4 kilonewtons per square metre,

whichever is greater. O. Reg. 633/86, s. 53.

PART IV

RIGS ,

- 54. Where natural lighting is inadequate to ensure the safety of any worker, artificial lighting shall be provided and shadows and glare shall be reduced to a minimum. O. Reg. 633/86, s. 54.
- 55. A rig shall have emergency storage batteries or other system capable of supplying power for twenty-four continuous hours, sufficient to operate,
 - (a) the marine radio required under the Ship Station Radio Regulations made under the Canada Shipping Act for transmitting or receiving on the distress frequency;
 - (b) the navigation and obstruction lights; and

52.—(1) There shall be a guardrail,

- (c) the lighting required in communications and navigational control areas of the drill unit. O. Reg. 633/86, s. 55.
- 56. A rig shall have emergency lighting that,
 - (a) turns on automatically when the regular lighting fails;
 - (b) is independent of the regular lighting source;
 - (c) provides adequate lighting for evacuation of the area; and
 - (d) is tested at least once every three months, but not less frequently than recommended by the manufacturer to ensure the system will function in an emergency,

in work places that are,

- (e) a communication centre;
- (f) a drill floor;
- (g) a well control area;
- (h) a stairway;
- (i) an exit;
- (j) a machinery generator area;
- (k) an area where lighting is required for well control;
- (l) a passageway;
- (m) a navigation control area; or
- (n) a survival craft embarkation station. O. Reg. 633/86, s. 56.
- 57. The rig shall be kept clean, tidy and free from accumulation of waste materials, oil and mud in all areas used by a worker. O. Reg. 633/86, s. 57.
- 58. Walkways and the area around the base of a derrick ladder shall be clear of obstruction. O. Reg. 633/86, s. 58.
- 59. Each enclosed work place at or near which a worker regularly works on a rig shall have a least two exists. O. Reg. 633/86, s. 59.
 - 60. An exit shall,
 - (a) be located as distant from the next required exit as practicable;
 - (b) be suitably identified with a sign; and
 - (c) when the opening is covered by a door, have the door hinged to open in the direction of exit travel. O. Reg. 633/86, s. 60.

- 61. A diesel or gas powered engine shall,
 - (a) be located in an area where combustible gases are not likely to be present:
 - (b) be located as far as practicable from the centre line of the well bore;
 - (c) be equipped with an emergency stop control;
 - (d) be equipped with a fire extinguishing system when in an enclosed area; and
 - (e) be equipped with one fire extinguisher having a U.L.C. rating of twenty BC or higher in an open area. O. Reg. 633/86, s. 61.
- 62. No person shall smoke during emergencies or in any area except those,
 - (a) used for recreation;
 - (b) used for accommodation purposes; or
 - (c) designated by the employer as a smoking area. O. Reg. 633/86, s. 62.
- 63. Where welding or flame-cutting is planned, the worker shall, prior to starting work,
 - (a) inspect the working area for fire hazards;
 - (b) test for the presence of combustible gases;
 - (c) notify other workers that may be affected by this work; and
 - (d) ensure that fire fighting equipment is readily available. O. Reg. 633/86, s. 63.
- 64.—(1) No person under the influence of, or carrying, an intoxicating alcoholic beverage shall enter, or be on, or knowingly be permitted to enter, or be on, a rig.
- (2) Subject to subsection (3), no person under the influence of, or carrying, a drug or narcotic substance shall enter, or be on, or knowingly be permitted to enter, or be on, a rig.
- (3) A person required to use a drug for a medical purpose and able to perform work may enter and be on a rig upon establishing medical proof thereof. O. Reg. 633/86, s. 64.
 - 65. A rig shall have,
 - (a) emergency equipment and life-saving devices sufficient in number to provide for the escape of all workers;
 - (b) a light-weight manoeuverable rescue boat;
 - (c) a suitable means of launching all survival or life-saving craft;

- (d) at least four life buoys, of which at least two shall have self-igniting lights;
- (e) life-jackets sufficient in number to provide one for each worker, and in addition, a sufficient number of life-jackets at each survival craft embarkation station to provide one each for 25 per cent of the workers for whom accommodation is available on the survival craft;
- (f) personal floatation devices suitable for performing work which are sufficient in number to provide one each for every worker on shift at any one time;
- (g) a line throwing apparatus and twelve distress signals;
- (h) at least one buoyant personnel transfer basket, except where the drilling unit is not equipped with a crane or where there are fewer than three workers;
- (i) first-aid requirements specified under the Workers' Compensation Act; and
- (j) at least two workers per shift who possess a standard first-aid certificate from St. John Ambulance. O. Reg. 633/86, s. 65.

66. Life rafts shall be,

- (a) sufficient in number so that their combined capacity is capable of accommodating at least two workers more than the maximum number of workers present at any time;
- (b) so located that one half of the life rafts are on one side of the rig and the balance on another side; and
- (c) equipped with first aid supplies. O. Reg. 633/86, s. 66.

67. A life-buoy shall be,

- (a) equipped with a line approved by Canada Coast Guard whose length is at least one and one-half times the distance from the life-buoy station to the water line at shallow drafts;
- (b) located so as to be readily available to any worker; and
- (c) stored in a location which is clearly identified by a sign or other means. O. Reg. 633/86, s. 67.

68. A rig shall be equipped with,

 (a) self-contained breathing apparatus sufficient in number for the working crew, located in areas readily available to the working area;

- (b) at least two portable hydrogen sulphide gas detectors;
- (c) at least two portable combustible gas detectors; and
- (d) at least two portable oxygen gas detectors. O. Reg. 633/86, s. 68.
- 69. A rig shall be equipped with survival suits,
 - (a) approved by Canada Coast Guard;
 - (b) sufficient in number for at least two workers more than the maximum number of workers present at any time; and
 - (c) located in areas convenient to working, accommodation and survival craft embarkation areas. O. Reg. 633/86, s. 69.
- 70. A rig shall be equipped with fire protection and detection equipment. O. Reg. 633/86, s. 70.
- 71. A rig shall have a general alarm system consisting of a hailer or public address system that is audible in the work place. O. Reg. 633/86, s. 71.
- 72. A general alarm shall be sounded to alert workers when there is a danger to,
 - (a) the safety of the workers;
 - (b) the security of the drilling unit or the well; or
 - (c) the health of the workers due to the presence of toxic or combustible gases. O. Reg. 633/86, s. 72.
- 73. A rig shall have a radio communication system hat,
 - (a) includes a very high frequency marine radio telephone;
 - (b) includes a radio capable of communicating with any support craft used in connection with the drilling operations;
 - (c) has an emergency back-up system; and
 - (d) has a competent person available to,
 - (i) maintain a listening watch on the 156.8 MHz frequency, and
 - (ii) monitor all movements of any support craft operating between the rig and the shore. O. Reg. 633/86, s. 73.
- 74. A helicopter used in conjunction with an offshore rig shall carry a sufficient number of immersion suits to provide one for each crew member and passenger when surface water temperature is below 18° Celsius. O. Reg. 633/86, s. 74.

- 75. Where a helicopter deck on a rig is used it shall be,
 - (a) so located as to have an unobstructed approach path on at least a 210° sector;
 - (b) capable of supporting any type of helicopter than is likely to land on it;
 - (c) equipped with,
 - (i) tie-down devices for at least one helicoper,
 - (ii) internationally recognized markings,
 - (iii) deck lights suitable for night flying where night flights are made,
 - (iv) a non-skid deck surface, and
 - (v) safety nets around the perimeter of the deck;
 - (d) equal to or larger than the rotor diameter of any single-main rotor helicopter that is likely to land on the deck; and
 - (e) kept clear of obstructions. O. Reg. 633/86, s. 75.
- 76. Rigs shall not be used for helicopter refuelling. O. Reg. 633/86, s. 76.
 - 77. A personnel transfer basket shall.
 - (a) not be used to transfer cargo except in an emergency;
 - (b) only be used under conditions of good visibility and weather;
 - (c) be raised or lowered over water to the greatest extent practicable; and
 - (d) be operated by a competent person. O. Reg. 633/86, s. 77.
 - 78. Living quarters for the drilling crews shall be,
 - (a) equipped with at least four self-contained breathing apparatus;
 - (b) clean and sanitary;
 - (c) capable of being heated to at least 20° Celsius; and
 - (d) equipped with a smoke detector and alarm in each room. O. Reg. 633/86, s. 78.
 - 79. A rig shall have,

- (a) its hull, superstructure, bulkheads and decks constructed of material at least as resistant to fire as steel;
- (b) a means of embarking all workers so as not to endanger them;
- (c) a system of ventilation adequate to ensure that the gas, vapour, dust or fume does not reach a hazardous concentration;
- (d) ventilators, ports and other openings in any room so arranged that they can be closed;
- (e) its derrick or mast constructed to support any load likely to be applied to it without exceeding the maximum rated load; and
- (f) its drilling depth limited to comply with clause (e). O. Reg. 633/86, s. 79.
- **80.** Drilling equipment shall be constructed to withstand all loads or pressure applied to it without exceeding the maximum rated load. O. Reg. 633/86. s. 80.
 - 81. A cathead shall,
 - (a) be operated by a competent person;
 - (b) when a rope is manually operated on it, be,
 - (i) equipped with a blunt smooth-edged rope divider that has a clearance from the friction surface of the cathead of seven millimetres or less, and
 - (ii) operated only when the operating area is clear and the portion of the rope not in use is coiled or spooled;
 - (c) be located so that there is at least 500 millimetres of working area between the outer flanges and a substructure, guardrail or wall;
 - (d) have its controls attended while in use;
 - (e) when a rope or line is in use, have all other ropes and lines placed so that they cannot come in contact with,
 - (i) the cathead, or
 - (ii) the rope or line in use on the cathead;
 - (f) when automatic, have a separate control except where,
 - (i) dual purpose controls are used, and
 - (ii) a locking device prevents an automatic cathead from being accidentally engaged while the other is in operation;

- (g) have a key seat and projecting key covered with a smooth thimble or plate;
- (h) when unattended, be kept free of contact with any rope or line; and
- (i) have only ropes or lines free from splaces come in contact with the friction surface. O. Reg. 633/86, s. 81.
- 82. A travelling block shall,
 - (a) be equipped with securely attached sheave guards;
 - (b) be free of projecting bolts, nuts, pins or parts; and
 - (c) have any hook to which equipment is attached equipped with,
 - (i) a safety latch, or
 - (ii) a wire rope safety line. O. Reg. 633/86, s. 82.
- 83. A counterweight above a derrick floor, when not fully encased or running in permanent guides, shall be held to the frame of the derrick with a wire rope safety line that,
 - (a) is not less than sixteen millimetres in diameter; and
 - (b) will prevent the counterweight from coming within 2.4 metres of the floor. O. Reg. 633/86, s. 83.
- 84. A make-up or breakout tool shall have a safety device that prevents its uncontrolled movement. O. Reg. 633/86, s. 84.
- 85. A rotary drilling table shall not be used for final making up or initial breaking out of a pipe connection. O. Reg. 633/86, s. 85.
 - 86. Drilling shall occur only if,
 - (a) all workers and loose materials are clear of the drill;
 - (b) visual obstructions are removed; and
 - (c) other measures are taken to protect workers from hazards created by the cathead and tong lines. O. Reg. 633/86, s. 86.
 - 87. A hoisting rope, chain, sling or fitting shall,
 - (a) not be loaded beyond the safe-working load;
 - (b) not be used to raise or lower a worker, other than an injured worker in case of emergency; and

- (c) have the safe-working load established by,
 - (i) a professional engineer, or
 - (ii) the manufacturer. O. Reg. 633/86, s. 87.
- 88. A hoisting rope shall be,
 - (a) securely fastened to the winding drum with at least five full wraps remaining on the drum at any time;
 - (b) removed from a drum only when the travelling block is,
 - (i) lying on the derrick floor, or
 - (ii) supported by means of a separate wire rope; and
 - (c) equipped with a reliable weight indicator that, if hung above the floor, is secured by means of a safety line or chain. O. Reg. 633/86, s. 88.
- 89. Stairways shall be installed,
 - (a) beside the ramp to a derrick floor and extending from the deck to the derrick floor; and
 - (b) at the outer end of a walkway which is sixtyone centimetres or more above the deck and extending from the deck to the walkway. O. Reg. 633/86, s. 89.
- 90. Ladder platforms shall be,
 - (a) in place adjacent to a derrick ladder, other than where the ladder has a climbing device that protects the worker from falling; and
 - (b) located,
 - (i) at the crown of all drill rigs, and
 - (ii) approximately equidistant but nine metres or less apart. O. Reg. 633/86, s. 90.
- 91. Where a worker is stationed on an elevated platform on the derrick or mast, an auxiliary means of escape shall,
 - (a) be in place at the working platform; and
 - (b) consist of a specially rigged and securely anchored escape line or system. O. Reg. 633/86, s. 91.
- 92. A pipe, kelly hose, cable or rope shall not be used to slide down, other than the escape line in case of emergency. O. Reg. 633/86, s. 92.

93. A pipe rack shall,

- (a) be capable of supporting the loads to which it is to be subjected;
- (b) have a means of preventing pipes and other round material from falling out of the rack; and
- (c) be loaded or unloaded in such a way that no worker is,
 - (i) on top of the load, or
 - (ii) between the load and the pipe rack. O. Reg. 633/86, s. 93.

94. Drawworks shall,

- (a) have a reliable locking mechanism to hold down the brakes in the engaged position;
- (b) be tested for adequate brake function at the beginning of each shift;
- (c) except during drilling, be attended at all times while the hoisting drum is in motion;
- (d) except if equipped with an automatic feed control, when unattended have the brakes secured in the engaged position; and
- (e) be put in motion only when all workers are clear of machinery and lines. O. Reg. 633/86, s. 94.

95. Explosives and detonators shall be stored,

- (a) separately;
- (b) as far as practicable from,
 - (i) work areas.
 - (ii) living quarters,
 - (iii) sources of ignition, and
 - (iv) sources of physical damage;
- (c) in an area protected from lightning and other sources of electricity;
- (d) in quantities not exceeding fifty kilograms on a rig; and
- (e) in a magazine that,
 - (i) is conspicuously marked by "DANGER—EXPLOSIVES" signs,
 - (ii) is securely constructed and locked except when required to be opened for the issue or receipt of explosives,

- (iii) provides partitions to separate two or more explosives, and
- (iv) is constructed or lined or covered so as to prevent the exposure of the explosive to any grit, iron, steel or similar substance. O. Reg. 633/86, s. 95.
- 96. A competent person shall be placed in charge of the explosives magazine to,
 - (a) issue and receive explosives;
 - (b) inspect the condition and contents of the magazine once a week; and
 - (c) issue a report in writing to a supervisor as to the condition and contents of the magazine as identified during the inspection required in clause (b). O. Reg. 633/86, s. 96.

97. Electrical equipment shall,

- (a) comply with the Institute of Electrical and Electronics Engineers Recommended Practice for Electrical Installations on Shipboard Standard 45-1983;
- (b) be explosion proof,
 - (i) within four metres horizontally from the centre line of the well bore,
 - (ii) within three metres vertically above the drill floor,
 - (iii) within three metres vertically below the drill floor,
 - (iv) within three metres vertically and horizontally from a mud ditch, shale shaker, degasser and mud tank, and
 - (v) in any enclosed high fire hazard area;
- (c) be suitable for its intended use; and
- (d) be equipped with two manual shut off switches located distant from each other, which will disconnect the circuit from the power plant to the drilling equipment. O. Reg. 633/86, s. 97.
- 98. Well stimulation and similar operations shall,
 - (a) be equipped with a check valve as close as practicable to the well head riser, except where cementing or selective acidizing is being done;
 - (b) where liquid carbon dioxide is being used, be controlled from a position on the far side of the pumping unit when viewed from the well head riser:

5578

- (c) not be carried out until workers are removed a distance of three metres from the well head riser:
- (d) be equipped with fire protection positioned to control the increase hazard of fire where flammable fluids are being pumped by two or more pumping units, including blenders;
- (e) be equipped with bleed-off valves to release pressure before pipe connections are broken;
- (f) have controls readily operated from the rig floor when oil savers are used. O. Reg. 633/86, s. 98.
- 99. A system used to maintain drilling fluid shall,
 - (a) be equipped with a pressure relief device adequate to vent excess pressure in a controlled manner;
 - (b) vent excess pressure to an area which will not endanger workers;
 - (c) be designed by a professional engineer; and
 - (d) incorporate a testing and control procedure for hydrogen sulphide where oil, water or gas has been encountered. O. Reg. 633/86, s. 99.
- 100. A blow-out prevention system shall meet the requirements of Regulation 752 of Revised Regulations of Ontario, 1980 made under the Petroleum Resources Act and any regulations thereunder. O. Reg. 633/86, s. 100.

46 (9647)

OCCUPATIONAL HEALTH AND SAFETY ACT

O. Reg. 634/86. Diving Operations. Made-October 30th, 1986. Filed-October 30th, 1986.

REGULATION MADE UNDER THE OCCUPATIONAL HEALTH AND SAFETY ACT

DIVING OPERATIONS

INTERPRETATION

1. In this Regulation,

"ambient pressure" means the external pressure on the body of a diver;

- "atmospheric diving system" means a diving system in which the ambient pressure for the person using the system is normal atmospheric pressure;
- "bail-out system" means an independent breathing-gas supply carried by the diver, of sufficient quantity to return the diver to the surface, bell or emergency supply in the event of a malfunction of the primary gas supply;
- "bottom time" means the total elapsed time, measured in minutes, from the time a descending diver leaves the surface to the time the diver begins final ascent. rounded to the next whole minute;
- "buddy line" means a line consisting of polythene rope, seven millimetres in diameter and three metres in length, that can be securely attached to each diver;
- "closed bell" means a submersible compression chamber:
- "decompression sickness" means a disease caused by the formation of gas bubbles in the blood or body tissues as a result of pressure reduction;
- "decompression table" means the procedure that a diver follows during the ascent from depth in order to minimize the risk of decompression sickness;
- "deep diving operation" means any mode of diving to depths greater than fifty metres;
- "Director" means the Director of the Construction Health and Safety Branch of the Ministry of Labour;
- "diver" means a worker who performs work under
- "diver's tender" means a worker who tends divers:
- "diving bell" means a surface-tethered structure that can accommodate divers under water:
- "diving operation" means work performed underwater for commercial, industrial, construction or environmental purposes and includes the underwater inspection, alteration, repair or maintenance of equipment, machinery, structures or ships and the salvage of sunken property of a commercial or industrial nature:
- "diving plant and equipment" means all plant and equipment that form part of the life-support system of a diver;
- "diving supervisor" means a competent person having complete responsibility for a diving operation, including responsibility for the safety and health of all diving personnel;
- "free swimming" means diving while using S.C.U.B.A., with the diver supervised but not tethered to the surface by a lifeline or float;

- "hyperbaric chamber" means a pressure vessel and associated equipment designed for the purpose of applying greater than atmospheric pressure on the body of a diver;
- "lifeline" means a manilla rope nineteen millimetres in diameter having a breaking strength of not less than 2,454 kilograms;
- "life-support hose bundle" means a composite hose and cable or separate cables extending from the surface to the diver or to the pressure vessel of occupancy of the diver that supplies breathing gas, power, heat or communication as required;
- "liveboating" means the support of a surface-supplied diver from a vessel under way, but does not include towing the diver;
- "locked-out" means made inoperable by means of a padlock for which the key is held only by a person authorized by the diving supervisor;
- "lock-out submersible" means a self-propelled, tethered or untethered, submersible compression chamber from which a diving operation can be carried out, and that has a separate 1-atmosphere chamber from which the submersible is piloted;
- "mixed gas" means a respirable breathing mixture, other than air, that provides adequate oxygen to support life and does not cause detrimental physiological effects, particularly excessive breathing resistance or impairment of neurological function:
- "no decompression limit" means that, in accordance with the diving decompression table in use for the depth and duration of the dive, no decompression stop is required during the ascent;
- "open bell" means a surface-tethered structure that can accommodate divers underwater and is fitted with an onboard life-support system;
- "saturation diving" means a technique of diving in which the decompression table used allows a bottom time of unlimited duration;
- "S.C.U.B.A." means a self-contained underwater breathing apparatus and includes a self-contained open-circuit compressed air breathing apparatus;
- "stage" means a cage, basket or platform in which a diver may be lowered to or raised from a work site;
- "stand-by diver" means a diver who is fully equipped to dive and is ready to enter the water, with all life-support and communications equipment tested and at hand, but not necessarily with the helmet, face plate or face mask in place, trained and equipped to operate at the depths and in the circumstances in which the submerged diver is operating and prepared to render assistance to the submerged diver in the event of an emergency;

- "submersible compression chamber" means a hyperbaric chamber designed for transporting divers at atmospheric pressure or at an elevated pressure from the surface to the work site and vice versa, and includes untethered lock-out submersibles;
- "surface-supply diving" means a diving technique in which the diver is supplied from the dive location with a breathing mixture, by way of an umbilical;
- "therapeutic recompression" means the recompression treatment of a diver in accordance with appropriate tables and practices;
- "umbilical" means a life-support hose bundle;
- "vessel under way" means a vessel that is not at anchor, made fast to the shore or a fixed structure, or aground;
- "work site" means an underwater location where work is performed. O. Reg. 634/86, s. 1.

PART I

GENERAL

- 2. This Regulation applies to every employer, supervisor, worker and constructor engaged in a diving operation. O. Reg. 634/86, s. 2.
- 3. In applying this Regulation, a procedure and the composition, design, size and arrangement of any material, object, device or thing may vary from the procedures, composition, design, size or arrangement prescribed in this Regulation if the factors of strength, health and safety are equal to or greater than the factors of strength, health and safety in the procedure, composition, design, size or arrangement prescribed. O. Reg. 634/86, s. 3.
- **4.** The constructor of a project in which a diving operation is to take place and an employer who will be engaged in a diving operation shall, before commencing the diving operation,
 - (a) notify the Director by telephone of the location and duration of the diving operation and confirm this notification in writing to the Director;
 - (b) notify the Director in writing prior to the use of mixed gas diving operations, a copy of which shall be available on the dive site for inspection;
 - (c) notify harbour masters and, where it is necessary in the interests of safety, notify navigable water authorities, police departments, fire departments and upstream or adjacent industrial plants producing probable contamination, that a diving operation is to take place and the location thereof, a copy of which shall be available on the dive site for inspection;

- (d) appoint in writing a diving supervisor; and
- (e) set out in writing the operational procedures to be used on the diving operation and a contingency plan for emergencies, a copy of which shall be available on the dive site for inspection. O. Reg. 634/86, s. 4.
- 5.—(1) The diving supervisor shall be in direct control of the diving operation and shall take every precaution reasonable in the circumstances for the protection of a diver.
- (2) Without limiting the generality of subsection (1), the diving supervisor shall,
 - (a) establish a diving plan which shall be submitted in writing to the employer before commencement of the diving operation;
 - (b) advise the workers of the diving plan and of the emergency procedures that are to be followed in the event of a malfunction of the equipment or system;
 - (c) ensure that the diver is competent to perform the work;
 - (d) immediately before each dive, review the nature of the hazards in the work site and ensure that the diver fully understands the hazards involved as well as those likely to be encountered in the diving operation;
 - (e) ensure that,
 - (i) all necessary equipment and diving plant, including umbilicals, winches, cables, chambers and motors used in a diving operation are provided and maintained in good operating condition and examined daily by a competent person,
 - (ii) there are a sufficient number of competent persons at the dive site,
 - (iii) breathing gas is free of contamination,
 - (iv) the diving operation is conducted from a suitable and safe place;
 - (f) when diving operations are in progress, ensure that appropriate warning devices are displayed to define the area to be kept clear of any equipment other than that connected with the diving operation;
 - (g) ensure that a stand-by diver is present at all times when diving operations are in progress;
 - (h) except in the case of accident or unavoidable circumstances, ensure that a diver is not permitted to remain at any depth longer than

- the maximum time planned for the depth of the dive:
- (i) supervise all therapeutic recompressions;
- (j) while acting as supervisor, not dive except in an emergency; and
- (k) terminate or interrupt the diving operation if, in the diving supervisor's opinion, continuance of the operation is likely to endanger the health or safety of any worker engaged in the operation. O. Reg. 634/86, s. 5.
- 6.—(1) Every diver shall ensure and the diving supervisor shall be satisfied that the signals and procedures in use and, where applicable, the duties and instructions of the diving partner and all others with whom the diver works, are completely understood.
 - (2) A diver shall not dive unless,
 - (a) the diver has undergone a medical examination as prescribed in subsection 34 (1) and has submitted to the employer the written statement of the physician obtained in accordance with subsection 34 (4);
 - (b) the diver is not physically or emotionally fatigued;
 - (c) the diver has not consumed alcohol or drugs which would impair diving abilities; and
 - (d) the diving supervisor is satisfied that the diver is capable of functioning safely an effectively under water.
- (3) A diver shall inform the diving supervisor if he or she is unfit to dive.
- (4) Immediately before each dive, the diver shall check that all required equipment is in place and properly fastened and all apparatus is functioning.
- (5) Before descent, the same check as that required in subsection (4) shall be conducted in the water by the diver.
- (6) On completion of any dive that does not require decompression, the diver shall remain under observation for a period of time sufficient, in the opinion of the diving supervisor, to ensure the welfare of the diver.
- (7) On completion of any dive requiring decompression stops, the diver shall remain under observation in the general area of the hyperbaric chamber for a minimum period of one hour but this period of observation shall be extended if, in the opinion of the diving supervisor, it is necessary to ensure the safety of the diver.
- (8) A diver shall not fly in any aircraft at an altitude exceeding 300 metres above sea level for twenty-four hours after completion of any decompression.

- (9) A sturdy medical alert tag or bracelet displaying the words, "DIVER IN CASE OF EMERGENCY TAKE IMMEDIATELY TO A HYPERBARIC FACILITY", shall be worn by each diver for at least twenty-four hours after completing each dive. O. Reg. 634/86, s. 6.
 - 7. Every standy-by diver shall,
 - (a) be trained and equipped to operate at the depths and in the circumstances in which the submerged diver is operating;
 - (b) either at the surface diving base or in the diving bell, have a stand-by umbilical or a lifeline that shall be,
 - (i) of sufficient length to reach an operating diver in all cases, and
 - (ii) where the umbilical or lifeline attached to the operating diver has not become separated from the diver's tender, at least three metres longer than the umbilical or the lifeline of the operating diver;
 - (c) only enter the water in the event of an emergency; and
 - (d) be positioned so as to be capable of rendering immediate emergency assistance at all times.O. Reg. 634/86, s. 7.

PART II

EQUIPMENT

- 8.—(1) All diving equipment including breathing apparatus, compressors, compressed-gas cylinders, gas control valves, pressure gauges, reserve gas-supply devices, piping, helmets, winches, cables, diving bells or stages and all other accessories necessary for the safe conduct of the diving operation shall be,
 - (a) of sound construction, adequate strength and free from patent defect;
 - (b) maintained in a condition that will ensure its continuing operating integrity and suitability for its actual use;
 - (c) adequately protected against malfunction at low temperatures that may be caused by,
 - (i) ambient air or water, or
 - (ii) the expansion of gas; and
 - (d) examined, tested, overhauled and repaired in accordance with the manufacturer's recommended procedures.
- (2) Record books shall be kept for breathing apparatus, compressors, compressed gas cylinders, gas

- control valves, pressure gauges, reserve gas-supply devices, piping, helmets, winches, cables and diving bells or stages, and servicing and repairs thereto shall be entered in the records and dated and signed by the persons performing the examination, servicing and repairing.
- (3) The record books shall be kept for a period of one year after the equipment is no longer used. O. Reg. 634/86, s. 8.
- 9.—(1) When diving is in progress, a surface diving base shall be equipped with,
 - (a) if S.C.U.B.A. is being used, one complete spare set of underwater breathing apparatus with fully charged cylinders for emergency purposes only;
 - (b) an adequate quantity of oxygen for therapeutic purposes;
 - (c) one shot-line of weighted nineteen millimetre manilla of sufficient length to reach the bottom at the maximum depth of the work site;
 - (d) a first-aid kit appropriate for the size of the work crew and diving location;
 - (e) one complete set of decompression tables;
 - (f) a suitable heated facility for the use of workers that is located on or as near as possible to where the dive is to be made;
 - (g) a two-way communication system between the surface diving base and emergency services; and
 - (h) such other equipment as may be necessary to protect the health and safety of a worker.
- (2) All surface diving bases that are vessels shall be equipped with,
 - (a) a secondary means of propulsion; or
 - (b) a secondary means of transporting an injured diver. O. Reg. 634/86, s. 9.
 - 10. Lifelines shall,
 - (a) be free from patent defect, maintained in a condition that will ensure its continuing operating integrity and be free of knots and splices;
 - (b) when required to be used, be worn at all times by a submerged diver;
 - (c) fit snugly around the diver's waist under all of the diver's equipment except the exposure suit or be securely attached to the diver's safety harness;

- (d) be no longer than is necessary to perform the work;
- (e) be secured at the surface to a safe point of anchorage;
- (f) be secured in a manner that will prevent loss of contact with the diver; and
- (g) be tended at all times by a diver's tender or tethered to an identifiable float located on the surface. O. Reg. 634/86, s. 10.
- 11.—(1) Subject to subsection (2), the diving supervisor shall ensure that a two-way effective communication system by voice or by pre-arranged line signals is provided between every submerged diver and any person in control of plant and equipment that may assist the diving operation.
- (2) The two-way communication provided between the submerged diver and any person in control of plant and equipment shall be by voice when the depth of the dive exceeds or is intended to exceed thirty metres.
 - (3) A voice communication system shall provide,
 - (a) a standard of sound reproduction adequate to enable the diver's breathing to be clearly heard;
 - (b) a suitable means of voice-unscrambling when breathing mixtures containing helium or other gases that significantly distort sound transmission are being used; and
 - (c) a recording system for voice communications for depths exceeding fifty metres.
- (4) In addition to the primary communication system required under subsection (1) an emergency signal shall be established. O. Reg. 634/86, s. 11.
 - 12. Every diver shall be equipped with,
 - (a) diver's indicator devices, such as rescue beacons or strobes, where S.C.U.B.A. diving operations are to be carried on during the hours of darkness; and
 - (b) a strong, sharp knife. O. Reg. 634/86, s. 12.
- 13.—(1) A hoisting device used to lower a diver shall not be used for any other purpose until after the diver is in position.
- (2) All directions to the operator of the hoisting device shall be given by the diver, the diver's tender or the diving supervisor, but the signal to stop may be given by any person.
 - (3) A diver being hoisted shall be,

 (a) in continuous visual contact with the diving supervisor by the use of pre-arranged visual signals; or

O. Reg. 634/86

- (b) in contact with the diving supervisor by the use of a telecommunications system when visual signals are not practicable.
- (4) A hoisting device used to raise or lower a stage or submersible compression chamber shall,
 - (a) be so constructed that a brake is automatically applied when the control lever, handle or switch is not held in the operating position; and
 - (b) not be fitted with a pawl-and-ratchet gear on which the pawl must be disengaged before the commencement of raising or lowering operations. O. Reg. 634/86, s. 13.
 - 14. A stage shall,
 - (a) be large enough to carry at least two divers with their personal diving equipment and associated equipment in uncramped conditions;
 - (b) be secure against tipping or spinning;
 - (c) not contain any equipment that might interfere with an occupant's foothold or handhold and
 - (d) be so constructed or equipped that the occupants are secure against falling out of the stage. O. Reg. 634/86, s. 14.
 - 15. Open diving bells shall,
 - (a) be of sufficient size to accommodate all submerged divers;
 - (b) provide adequate emergency breathing gas for the safe decompression of divers in an emergency; and
 - (c) have a voice communication system which allows contact with surface supervisory personnel. O. Reg. 634/86, s. 15.
- 16.—(1) Subject to subsection (2), a hyperbaric chamber, Class A, of a double-lock type in operable condition shall be on site where a diving operation is to exceed,
 - (a) the no-decompression limit; or
 - (b) a depth of thirty metres.
- (2) A hyperbaric chamber shall be on site regardless of depth or decompression limits where it is reasonable in the circumstances for the protection of a diver.

- (3) Where a dispute arises between an employer, a diving supervisor or a diver as to the requirement for a hyperbaric chamber under subsection (2), the employer, diving supervisor or diver may notify an inspector who shall investigate and give a decision, to be confirmed in writing, to the employer, the diving supervisor or the diver, as appropriate, that shall determine the dispute. O. Reg. 634/86, s. 16.
- 17. The hyperbaric chamber shall be equipped with adequate fire prevention. O. Reg. 634/86, s. 17.
- 18.—(1) Where possible, sources of hyperbaric chamber illumination shall be mounted outside the pressure chamber and arranged so that the light is transmitted to the interior by fibre optic techniques.
- (2) Where externally mounted lamps are employed for illumination of hyperbaric chambers through view ports, suitable heat shields shall be incorporated to prevent the view ports from heating excessively during use. O. Reg. 634/86, s. 18.
- 19. All submersible compression chambers shall conform to the requirements of Canadian Standards Association Standard Z275.1-M1982, "Hyperbaric Facilities", and shall,
 - (a) be of a design that,
 - (i) enables divers to enter and exit without difficulty, and
 - (ii) allows at least two divers that are equipped and dressed for the diving operation to be seated within;
 - (b) be equipped to permit the transfer of personnel under pressure into or from the surface hyperbaric chamber;
 - (c) be used in association with lifting gear that enables the chamber to be lowered to the depth at which the diving operation is to be carried out, without excessive lateral, vertical or rotational movement taking place;
 - (d) be provided with a means whereby, in the event of a failure of the main lifting gear, the chamber can be returned to the surface and, where such means involve shedding of weights, the controls for such shedding shall be capable of operation from within the chamber and a means shall be incorporated to prevent accidental shedding of these weights; and
 - (e) be equipped with,
 - doors or hatches that act as pressure seals and may be opened from either side,
 - (ii) such valves, gauges and other fittings as are necessary to control the internal

- pressure and to clearly indicate the internal and external pressures inside the chamber and at the diving station,
- (iii) adequate equipment, protected against inadvertent operation, for supplying the appropriate breathing mixture to persons occupying or working from the chamber,
- (iv) a voice communication system whereby conversation may be maintained both with persons at the diving station and with divers outside the chamber,
- (v) appropriate lighting equipment,
- (vi) adequate first-aid equipment and lifting equipment sufficient to enable an unconscious or injured diver to be hoisted into the chamber by a person located within,
- (vii) a diver's umbilical which shall be limited to thirty metres,
- (viii) a strobe,
 - (ix) a location pinger of 37,000 Hz.,
 - (x) oxygen and carbon dioxide monitors, and
- (xi) primary and secondary carbon dioxide scrubbers. O. Reg. 634/86, s. 19.
- 20. A diving operation shall not be conducted from a lock-out submersible unless,
 - (a) the submersible is negatively buoyant on the bottom or positively secured to the work site;
 - (b) the diving supervisor is on board the submersible and present in the 1-atmosphere chamber during the diving operation;
 - (c) in addition to the diving supervisor there is at least one other diver monitoring the diving operation from the lock-out submersible and dressed and equipped to carry out emergency diving operations without prior notice; and
 - (d) the diver's umbilical is limited to thirty metres. O. Reg. 634/86, s. 20.
- 21. A diving operation shall not be undertaken unless,
 - (a) an adequate quantity of the appropriate breathing mixture, including a reserve supply 2.5 times that required for the operation, and suitable plant and equipment for supplying the mixture to a diver at a proper

- temperature, pressure and flow rate are available for use by every diver engaged in the operation;
- (b) an adequate quantity of an appropriate breathing mixture is available for therapeutic purposes; and
 - (c) when a submersible compression chamber is being used, an additional reserve supply of the appropriate breathing mixture, adequate for a duration of seventy-two hours, together with any necessary plant and equipment, is available. O. Reg. 634/86, s. 21.
- **22.** An appropriate breathing mixture shall be in the bail-out system carried by a diver. O. Reg. 634/86, s. 22.
- 23. The quantity of breathing mixture supplied for use by a diver shall be sufficient for the time needed by the stand-by diver to reach the diver and for both divers to,
 - (a) return to the surface and carry out the appropriate decompression procedures during the return; or
 - (b) return to a submersible compression chamber, if such is being used in the diving operation, and then to surface in that chamber and start the appropriate decompression procedures at the surface. O. Reg. 634/86, s. 23.
- 24.—(1) When gases mixed in proportions other than the normal proportions of respirable air are used, the employer shall ensure that the procedures and tables of decompression are appropriate for the mixture in use.
- (2) A diver shall not be given pure oxygen for breathing except for decompression or therapeutic purposes. O. Reg. 634/86, s. 24.
- 25. Breathing mixtures of air shall adhere to section 3.8 of Canadian Standards Association Standard Z275.2-M1982, "Occupational Safety Code for Diving Operations". O. Reg. 634/86, s. 25.
- 26. Compressed air supplied to a diver shall meet the requirements of Canadian Standards Association Standard Z180.1-M1978, "Compressed Breathing Air". O. Reg. 634/86, s. 26.
- 27.—(1) Compressors used to supply air to divers shall be capable of maintaining a supply of air equal to at least double the volume of air required and at a pressure 25 per cent greater than the maximum pressure requirement anticipated and shall operate automatically without undue fluctuation of pressure in the air-tank receiver.
- (2) Compressors supplying breathing gas or air to divers shall discharge the gas or air through adequate

- filters into a tank or receiver of suitable volume. O. Reg. 634/86, s. 27.
- 28.—(1) Compressors shall be operated by a competent person who may be the diver's tender.
 - (2) The operator of the compressor shall ensure,
 - (a) that all equipment necessary to supply an adequate quantity of air to the diver is in good working order; and
 - (b) that valves, stop-valves, drain-cocks, gauges and all parts liable to damage are operating properly. O. Reg. 634/86, s. 28.
- 29. Hoses and associated fittings shall be constructed of material that is compatible with oxygen at the operating pressure and temperature. O. Reg. 634/86, s. 29.
- 30. High flow velocities of oxygen through hoses shall be such that the differential pressure along a hose does not exceed 700 kPa. O. Reg. 634/86, s. 30.
- 31. Quick-opening valves such as ball valves shall not be used in oxygen systems except for emergency shut-off at the point of penetration of a hyperbaric chamber hull. O. Reg. 634/86, s. 31.
 - 32. An area where oxygen is stored shall be,
 - (a) adequately ventilated;
 - (b) properly identified with warning signs;
 - (c) equipped with a fire-suppression system; and
 - (d) kept clean and located as far as practical from combustible materials. O. Reg. 634/86, s. 32.
- 33.—(1) Gauges and metering equipment shall be checked at least once every six months and whenever a discrepancy is indicated.
- (2) Any malfunction of a gauge or metering equipment shall be rectified immediately or removed from service.
- (3) If a gauge or metering equipment is removed from service, it shall be identified as having a malfunction. O. Reg. 634/86, s. 33.

PART III

MEDICAL AND EMERGENCY PROCEDURES

- **34.**—(1) A diver shall undergo a medical examination annually or such shorter period as is specified by the examining physician.
- (2) A diver shall, at the expense of the employer, undergo a medical examination where the diving supervisor has reason to believe that the diver is unfit

to dive or where there are special hazards that the diving supervisor has reason to believe may endanger the health of the diver.

- (3) The medical examination required under subsection (1) or (2) shall meet the requirements of the Code for Medical Examination of Divers dated the 24th day of October, 1984 and issued by the Ministry.
- (4) The physician conducting the medical examination shall provide the diver with a written statement certifying that the examination was conducted in accordance with the Code for Medical Examination of Divers and that the diver is,
 - (a) fit;
 - (b) fit with limitations; or
 - (c) unfit for diving. O. Reg. 634/86, s. 34.
- 35.—(1) Every diver and at least one worker stationed at the surface shall be trained in cardio-pulmonary resuscitation, basic first aid and the emergency treatment of diving ailments.
- (2) Where deep water or remote diving operations are to be conducted, one member of the dive team shall,
 - (a) be trained as a medical attendant to divers; and
 - (b) be available to provide immediate medical assistance in the event of an emergency.O. Reg. 634/86, s. 35.
- 36. The employer shall arrange for a physician to be on call during a diving operation,
 - (a) to provide medical assistance in the event of an emergency; and
 - (b) to provide advice on the treatment of decompression sickness. O. Reg. 634/86, s. 36.
- 37. The employer shall identify the location of the nearest back-up hyperbaric facility suitable for the depth at which the diving operation is to be carried out and shall make arrangements for the use of this facility in the event of an emergency. O. Reg. 634/86, s. 37.
- 38. At the onset of any sign of malfunction of gear or sign or sympton of distress, the diver shall, when possible, notify the diver's tender and any diving partner by an appropriate signal and shall terminate the dive. O. Reg. 634/86, s. 38.
- 39. Diving operations, repetitive dives and treatment of divers shall be carried out in strict accordance with appropriate decompression procedures and tables. O. Reg. 634/86, s. 39.

- 40.—(1) The employer shall ensure that there is a second source of power for the diving system in the event of failure of the primary source.
 - (2) The second power source shall be capable of,
 - (a) being rapidly brought on line;
 - (b) operating the handling system for the submersible compression chamber;
 - (c) heating the diving plant and equipment, including heating for a diver in the water;
 - (d) sustaining life-support systems for compression chambers and any diver in the water;
 - (e) illuminating the work site of the diver and the interior of each compression chamber, dive station and other similar equipment; and
 - (f) operating communication and monitoring systems. O. Reg. 634/86, s. 40.
- 41.—(1) Where an atmospheric diving system is to be used, the employer shall locate the nearest back-up unit with sufficient depth capabilities to effect a rescue and shall arrange for its use in the event of an emergency.
- (2) An atmospheric diving system shall not be used unless the on-board reserve life-support system is capable of sustaining life for a period of time that would enable the back-up unit to reach the site of the diving operation and conduct rescue operations.
- (3) The employer shall provide a written contingency plan with methods for dealing with,
 - (a) deteriorating weather and ice conditions during a dive;
 - (b) the inability of the surface craft to maintain station;
 - (c) failure to any major component of diving plant and equipment; and
 - (d) any other hazard that may reasonably be anticipated. O. Reg. 634/86, s. 41.

PART IV

S.C.U.B.A. DIVING

- **42.**—(1) This Part applies to diving operations in which a diver uses S.C.U.B.A.
- (2) Where S.C.U.B.A. provides other than normal air mixtures or recirculating apparatus is used on a diving operation, written notice shall be given to the Director, a copy of which shall be available on the dive

site for inspection and the diver shall be competent and adequately trained in the use and hazards of the S.C.U.B.A. O. Reg. 634/86, s. 42.

- 43.—(1) Subject to subsection (2), a sufficient number of workers shall be present for each diving operation to ensure, so far as is reasonably practical, that the operation can be undertaken safely.
- (2) A minimum of three workers shall be present at each dive site, one of whom shall be a diver, one a stand-by diver and one a diver's tender. O. Reg. 634/86, s. 43.
- 44.—(1) A diver using S.C.U.B.A. shall use a lifeline tended at the surface or tethered to an identifiable float located on the surface and tended at the surface where.
 - (a) the diver is diving alone; or
 - (b) the buddy system of diving cannot be used safely.
- (2) Work that cannot be performed safely in a tethered mode shall be performed by a diver swimming free and accompanied by another diver who is tethered.
- (3) The buddy system of diving shall consist of two divers each of whom shall,
 - (a) be responsible for the other's safety;
 - (b) maintain constant visual contact of the other during the dive;
 - (c) know the hand signals being used and acknowledge each signal as given;
 - (d) not leave the other except in the case of emergency requiring the assistance of one of them; and
 - (e) abort the dive immediately if one becomes separated from the other, or one of them aborts the dive.
- (4) A lifeline tended from the surface shall be used at all times in a diving operation that is to be carried out under ice. O. Reg. 634/86, s. 44.
- 45. A S.C.U.B.A. diver shall not dive to depths greater than thirty metres except for the purpose of saving a life. O. Reg. 634/86, s. 45.
- 46. A diver using S.C.U.B.A. shall, for each dive, use or wear,
 - (a) except where a S.C.U.B.A. mentioned in subsection 42 (2) is used, an open-circuit S.C.U.B.A. complete with demand regulator and tank with quick-release harness and reserve device or bail-out system;

- (b) a face mask;
- (c) a suitable knife;
- (d) a submersible pressure gauge; and
- (e) an exposure suit or protective clothing appropriate for the condition of work and the temperature of the water. O. Reg. 634/86,
- 47.—(1) Each S.C.U.B.A. cylinder shall be hydrostatically tested as required by Transport Canada, for the specific type and construction, at a station licensed by the Canadian Transport Commission.
- (2) At least once a year each S.C.U.B.A. cylinder shall be visually inspected internally and externally by a competent person. O. Reg. 634/86, s. 47.

PART V

SURFACE-SUPPLY DIVING

- 48. This Part applies to surface-supply diving, O. Reg. 634/86, s. 48.
- 49.—(1) Subject to subsections (2) and (3), a sufficient number of workers shall be present for each diving operation to ensure, so far as is reasonably practical, that the operation can be undertaken safely.
- (2) Where the planned depth does not exceed thirty metres, a minimum of three workers shall be present for each diving operation, of whom one shall be a diver, one a stand-by diver and one a diver's tender.
- (3) Where the planned depth exceeds thirty metres, a minimum of four workers shall be present for each diving operation of whom one shall be a diver, one stand-by diver, one a diving supervisor and one a diver's tender. O. Reg. 634/86, s. 49.
- 50.—(1) A diver's tender shall be a competent person.
- (2) Except as permitted in section 28, a diver's tender shall, while working as a tender, devote his or her whole time and attention to the work as a tender.
- (3) Except in an emergency, each diver in the water shall have a separate diver's tender. O. Reg. 634/86, s. 50.
- 51.—(1) Stationary air-lines shall be properly safeguarded against injury or interference.
- (2) A valve shall be fitted in each diver's air-line, which valve shall be,
 - (a) readily accessible;
 - (b) guarded against interference;

- (c) clearly marked to identify the diver whose air supply it controls; and
- (d) under the care and control of a competent person.
- (3) Each air-line supplying air to a diver shall be fitted with a pressure gauge downstream of the supply valve and installed in such a position that its dial figures are in the clear and unobstructed view of the diver's tender
- (4) All hoses, pipes, couplings and other fittings in use in any air or gas supply line for divers shall be designed and suitable for their intended purposes.
- (5) Hoses shall be kink resistant and be capable of sustaining the required flow rates and pressures for the systems used. O. Reg. 634/86, s. 51.
- **52.** Where surface-supplied equipment is to be used, a bail-out system shall be worn by the diver. O. Reg. 634/86, s. 52.
 - 53. A non-return valve shall be,
 - (a) fitted to all diving helmets and surfacesupplied masks; and
 - (b) check daily, before the commencement of diving operations in accordance with the written instructions of the manufacturer. O. Reg. 634/86, s. 53.
- 54. Every umbilical shall incorporate a lifeline attached in a suitable manner to prevent stress on the hose. O. Reg. 634/86, s. 54.
- 55. When a diver is in the water, a vessel or platform shall be anchored at or near the operation or there shall be a diving platform, skip, pier or facility that shall be seaworthy, secure and of sufficient size to safely accommodate all workers and equipment without overcrowding. O. Reg. 634/86, s. 55.
- 56.—(1) Liveboating from a surface vessel shall not be conducted at night or in rough seas or from vessels with insufficient manoeuverability.
- (2) A procedure that prevents the diving umbilical from becoming entangled in the propellers shall be employed during a liveboating operation.
- (3) The diver's tender for a liveboating operation shall be competent to perform this type of tending and shall be in contact with the diver at all times by means of a voice communication system.
 - (4) A boat captain shall,
 - (a) be competent to perform the duties of a captain in a liveboating operation; and

(b) perform his or her duties in compliance with the instructions of the diving supervisor.O. Reg. 634/86, s. 56.

PART VI

DEEP DIVING

57. This Part applies to deep diving operations and includes bell, saturation, bounce (non-saturation) and submersible lock-out diving as well as sea bottom habitat dives. O. Reg. 634/86, s. 57.

58.—(1) The diver shall,

- (a) be tethered to the work base by a breathinggas umbilical; and
- (b) be provided with effective two-way voice communication.
- (2) Mixed gases shall be used as the breathing mixture in a deep diving operation.
- (3) A deep diving operation shall not be carried out unless,
 - (a) the divers are transported through the airwater interface by a suitable submersible compression chamber, open bell or stage;
 - (b) the stand-by diver is located,
 - (i) at the discretion of the diving supervisor, at the surface, in a stage or in an open bell, or
 - (ii) where a submersible compression chamber is used, in the chamber;
 - (c) every diver and stand-by diver is in voice communication with each other and with the attendants at the diving station; and
 - (d) the attendants at the diving station have a means of monitoring and controlling,
 - (i) the depth of the diver, and
 - (ii) the pressures of the breathing medium being supplied to each diver and stand-by diver.
- (4) Each submerged diver shall be tended by a diver's tender who shall,
 - (a) be located on a stage or open bell; or
 - (b) if a submersible compression chamber is used, be in the chamber.
- (5) Where a submersible compression chamber is used, at least one diver shall remain in the chamber to monitor the diver who has left the chamber. O. Reg. 634/86, s. 58.

- 59.—(1) Where bounce diving techniques are used in a deep diving operation, the diving supervisor shall ensure that no diver remains submerged for a total period of time in excess of three hours in a 24-hour period and that there is a rest period of at least twelve continuous hours after this limit has been reached.
- (2) Subject to subsection (3), where it is reasonable in the circumstances for the protection of a diver, a diving operation using bounce diving techniques shall be carried out at depths greater than fifty metres and a maximum bottom time of forty minutes only if a submersible compression chamber or lock-out submersible capable of mating to a Class A (double-lock type) hyperbaric chamber for the transfer of personnel under pressure to and from the work site is provided.
- (3) A diving operation using bounce diving techniques shall be carried out at depths greater than seventy metres and a maximum bottom time of forty minutes only if a submersible compression chamber or lock-out submersible capable of mating to a Class A (double-lock type) hyperbaric chamber for the transfer of personnel under pressure to and from the work site is provided.
- (4) Where a dispute arises between an employer, a diving supervisor or a diver under subsection (2), the employer, diving supervisor or diver may notify an inspector who shall investigate and give a decision in writing to the employer, the diving supervisor or the diver, as appropriate, that shall determine the dispute. O. Reg. 634/86, s. 59.
- 60.—(1) Where saturation diving techniques are used in a deep diving operation, the diving supervisor shall ensure that,
 - (a) where the dive is to a depth of 150 metres, no diver exceeds four hours in the water and four hours as attendant in the submersible compression chamber;
 - (b) where the dive is deeper than 150 metres, no diver exceeds three hours in the water and three hours as attendant in the submersible compression chamber; and
 - (c) in any 24-hour period, there is a rest period of at least twelve continuous hours after the time limits specified in clause (a) or (b) have been reached.
- (2) A diver shall not commence another dive within fourteen days of completion of decompression following a saturation dive unless authorized by a physician. O. Reg. 634/86, s. 60.
- 61.—(1) For all deep diving operations there shall be a sufficient number of competent persons to,
 - (a) operate the diving plant and equipment and other facilities while any diver is under, entering or leaving the water; and

- (b) operate any hyperbaric chamber and associated equipment required for the deep diving operation.
- (2) A minimum of five workers shall be present for a deep diving operation of whom one shall be a diving supervisor, two shall be divers and two shall be diver's tenders.
- (3) Except in an emergency, each diver in the water shall have a separate diver's tender.
- (4) A diver's tender shall be a competent person and shall, while working as a tender, devote his or her whole time and attention to the work as a tender.
- (5) A stand-by diver's tender shall be present on all deep diving operations.
- (6) A hyperbaric chamber operator who is a competent person shall be a member of the crew.
- (7) If more than one deep diving operation in a 24-hour period is planned, there shall be a sufficient number of competent crew to ensure that the diver and stand-by diver have not been exposed to pressure for a 12-hour period before commencing a dive.
- (8) At least two divers shall be used when diving from a closed bell, one of whom shall tend the diver from the bell in accordance with subsection (4).
 - (9) A diving supervisor shall,
 - (a) be on-site during all deep diving operations,
 - (b) be responsible for all aspects of safety in conducting deep diving operations;
 - (c) be familiar and experienced with the diving equipment and tools used during the diving operations, the appropriate decompression tables and techniques and emergency procedures; and
 - (d) ensure that the divers are rested and capable of performing their tasks. O. Reg. 634/86. s. 61.

PART VII

SPECIAL HAZARDS

- 62.—(1) When a diver is required to approach any underwater intake, pipe, tunnel or duct, the diver shall be equipped with means to identify an intake in such a manner as to differentiate it from any other similar intake in the area.
- (2) The diver shall not approach any intake until the flow through it is actively controlled and provisions are made so that the flow shall not be re-established until the diver leaves the water or until the diving supervisor has declared the diver clear of the hazardous location.

- (3) Facilities such as head gates, stop logs or turbine gates shall be used for protecting divers when they are working near penstock or turbine intakes or in draft tube chambers.
- (4) Where a diving operation is to be performed in a location in which the current is known to exceed 1.5 knots, the velocity of the water shall be determined.
- (5) Where a diving operation is to be performed in water in which the velocity of the current exceeds 1.5 knots, the dive shall only be carried out when notice of the dive and the water velocity has been given to the Director, a copy of which shall be available on the dive site for inspection. O. Reg. 634/86, s. 62.
- 63.—(1) Before a diver approaches a location that may be made hazardous by the operation of mechanisms, such mechanisms shall be,
 - (a) secured against inadvertent movement before the diver enters the water; and
 - (b) locked-out in a manner satisfactory to the diver and diving supervisor and adequate to protect the safety of the diver.
- (2) Where exceptional hazards exist or are predicted, a second diving crew, with independent equipment, shall be on the site of the diving operation and ready to effect a rescue.
 - (3) In subsection (2), exceptional hazards include,
 - (a) an exceptional risk of entrapment of a diver;
 - (b) a special hazard to a diver; or
 - (c) an exceptional risk of loss of the diver's essential life-support system.
- (4) Where explosives or blasting agents are to be handled in a diving operation, the explosive or blasting agent shall be transported, handled, used and stored in a manner that will not endanger the safety of a worker.
- (5) The initiation of all underwater charges shall be under the direct control of the diving supervisor. O. Reg. 634/86, s. 63.

PART VIII

DIVING RECORDS

- 64.—(1) A diver shall maintain a personal log book that,
 - (a) is permanently bound;
 - (b) has numbered pages;
 - (c) contains his or her name, signature and photograph; and

- (d) contains any factor relevant to the diver's safety or health.
- (2) A diver shall retain the personal log book for five years after its completion.
- (3) A diver shall have entered in or attached to his or her personal log book,
 - (a) a record of any certificates of qualification obtained that are currently valid;
 - (b) his or her diver's certificate or equivalent document;
 - (c) a certificate confirming successful completion of any diving courses; and
 - (d) a record of the diver's training and experience.
- (4) The personal log book shall show all entries in chronological order and shall include,
 - (a) an entry for each dive which shall be witnessed and signed by the supervisor for the dive;and
 - (b) any entries for medical recompressions or other exposure to hyperbaric environment which shall be witnessed and signed by a physician or diving supervisor.
- (5) The personal log book shall contain the following information for each dive, namely,
 - (a) the type of diving apparatus used;
 - (b) the gas media breathed;
 - (c) the time the diver left the surface;
 - (d) the time at the bottom;
 - (e) the maximum depth attained;
 - (f) the time the diver left the bottom;
 - (g) the time the diver reached the surface;
 - (h) the time of the surface interval, if a repetitive dive was undertaken;
 - (i) the decompression table and schedule used;
 - (j) the date;
 - (k) the name of the employer and unusual incidents;
 - (l) the dive location;
 - (m) the environmental conditions; and
 - (n) the signature of the diving supervisor.

- (6) In addition to the information required in subsection (5), for dives originating from a diving bell, habitat or other submerged base, the diver's personal log shall also record the depth at the base, the time of leaving the base, the greatest depth attained and the time of return to the base.
- (7) When a diver undergoes a medical examination, the name and address of the examining physician and the date of examination shall be recorded in the diver's personal log, along with a copy of the written statement of the physician obtained in accordance with subsection 34 (4). O. Reg. 634/86, s. 64.
- 65.—(1) A daily record of each dive shall be kept by the diving supervisor and filed with the employer.
- (2) The employer shall retain the daily record for at least five years.
- (3) The diving supervisor shall make a tape recording of all communications between divers or 1-atmosphere diving system pilots and members of the diving crew during the pre-dive systems checks and the diving operation itself.
- (4) The tape recording shall be retained by the diving supervisor for at least forty-eight hours after the completion of the diving operation. O. Reg. 634/86, s. 65.
- 66. This Regulation comes into force ninety days after the day it is filed with the Registrar of Regulations. O. Reg. 634/86, s. 66.

(9648) 46

OCCUPATIONAL HEALTH AND SAFETY ACT

O. Reg. 635/86. Construction Projects. Made—October 30th, 1986. Filed—October 30th, 1986.

REGULATION TO AMEND REGULATION 691 OF REVISED REGULATIONS OF ONTARIO, 1980 MADE UNDER THE OCCUPATIONAL HEALTH AND SAFETY ACT

- 1. Section 120 of Regulation 691 of Revised Regulations of Ontario, 1980 is amended by adding thereto the following subsection:
- (6) No person shall operate a crane upon a project unless the person holds a certificate of qualification as

a hoisting engineer under the *Apprenticeship and Tradesmen's Qualification Act* or is exempted under that Act. O. Reg. 635/86, s. 1.

(9649)

46

DRUGLESS PRACTITIONERS ACT

O. Reg. 636/86.
Physiotherapists.
Made—September 9th, 1986.
Approved—October 30th, 1986.
Filed—October 30th, 1986.

REGULATION TO AMEND REGULATION 253 OF REVISED REGULATIONS OF ONTARIO, 1980 MADE UNDER THE DRUGLESS PRACTITIONERS ACT

 Regulation 253 of Revised Regulations of Ontario, 1980 is amended by adding thereto the following section:

10a. For the purposes of section 11, "misconduct" means,

- (a) contravention of any provision of the Act or the regulations or of the *Health Insurance* Act;
- (b) failure to maintain the standards of practice of the profession;
- (c) failure to communicate with other health professionals concerned with the care of a patient where the condition or suspected condition of the patient is such that the communication is necessary to ensure the proper care of the patient;
- (d) accepting or performing professional responsibilities that the physiotherapist knows or has reason to know that the physiotherapist is not competent to perform;
- (e) failure to advise a patient to consult a qualified health practitioner when the physiotherapist recognizes or ought to recognize that the patient's condition is beyond the experience or competence of the physiotherapist;
- (f) providing treatment to a patient that the physiotherapist knows or ought to know would be harmful to the patient or that does not meet the needs of the patient given the patient's physical condition;

- (g) permitting, counselling or assisting any person to engage in the practice of physiotherapy whom the physiotherapist knows or ought to know is not registered as a physiotherapist under the *Drugless Practitioners Act*;
- (h) permitting, counselling or assisting a physiotherapist to engage in the practice of physiotherapy whom the physiotherapist knows or ought to know is incompetent to practise physiotherapy;
- (i) making a misrepresentation respecting a remedy, treatment or device;
- (j) contravening while engaged in the practice of physiotherapy any federal, provincial or municipal law, regulation or rule or a by-law of a hospital designed to protect the health of the public;
- (k) engaging in the practice of physiotherapy while the ability to perform any professional service is hindered in any way by alcohol or a drug;
- (1) sexual impropriety with a patient;
- (m) abusing a patient verbally or physically;
- (n) having been found guilty of an offence relevant to a physiotherapist's suitability to practise physiotherapy;
- (o) failure to carry out the terms of an agreement made by a physiotherapist with a patient;
- (p) making a record or signing or issuing a certificate, report, account or similar document that the physiotherapist knows or ought to know is false, misleading or otherwise improper;
- (q) giving indentifiable information concerning a patient's condition or any professional services performed for a patient to any person other than the patient or to another professional involved in the treatment of a patient,
 - (i) without the prior consent of the patient, or
 - (ii) unless required to do so by law;
- (r) failure to provide within a reasonable time in the circumstances and without cause any report or certificate requested in writing by a patient or the patient's authorized agent in respect of an examination or treatment performed by the physiotherapist;
- (s) charging a fee for services not performed or that is excessive in relation to the services performed;
- (t) where the services of a physiotherapist are not insured services under the Health Insurance Act, failure to advise the patient accordingly and to notify the patient of the

- fees charged by the physiotherapist for the physiotherapist's professional services prior to rendering the services to the patient;
- (u) failure to itemize an acount at the request of a patient or an agency making payment for the physiotherapy services of the physiotherapist;
- (v) selling a professional account to a third party;
- (w) sharing fees with any person who has referred a patient or receiving fees from any person to whom a physiotherapist has referred a patient or requesting or accepting a rebate or commission for the referral of a patient;
- (x) having a conflict of interest;
- (y) permitting directly or indirectly the publishing, display, distribution or use of any advertisement relating to the practice of physiotherapy that,
 - (i) is false, misleading or self-laudatory.
 - (ii) makes any claim or guarantee as to the quality or efficacy of physiotherapy services provided, or
 - (iii) promotes the excessive or unnecessary use of physiotherapy services;
- (z) breaching an undertaking provided to the Board;
- (za) refusing to allow an authorized representative of the Board to enter at a reasonable time the premises in which the physiotherapist is engaged in the practice of physiotherapy for the purposes of inspecting the physiotherapist's practice, professional records and equipment;
- (ab) failure to reply within thirty days to any written communication from the Board or its officers, employees or agents;
- (2c) conduct or an act relevant to the practice of physiotherapy that, having regard to all the circumstances, would reasonably be regarded by physiotherapists as disgraceful, dishonourable or unprofessional. O. Reg. 636/86, s. 1.

BOARD OF DIRECTORS OF PHYSIOTHERAPY

PATRICIA A. C. HARTNETT Chairman

RHONA WOLPERT
Registrar

Dated at Toronto, this 9th day of September, 1986.

(9650)

HEALTH DISCIPLINES ACT

O. Reg. 637/86.
Dentistry.
Made—September 24th, 1986.
Approved—October 30th, 1986.
Filed—October 30th, 1986.

O. Reg. 637/86

REGULATION TO AMEND REGULATION 447 OF REVISED REGULATIONS OF ONTARIO, 1980 MADE UNDER THE HEALTH DISCIPLINES ACT

1. Section 55 of Regulation 447 of Revised Regulations of Ontario, 1980, as remade by section 1 of Ontario Regulation 581/85, is revoked and the following substituted therefor:

55. The annual fee for a member is \$750 and is due and payable on or before the 1st day of January in each year for the year. O. Reg. 637/86, s. 1.

Council of the Royal College of Dental Surgeons of Ontario:

GARY E. PITKIN, D.D.S. President

KENNETH F. POWNALL, D.D.S. Registrar

Dated at Toronto, this 24th day of September, 1986.

FAMILY BENEFITS ACT

O. Reg. 638/86. General. Made—October 30th, 1986. Filed—October 30th, 1986.

(9651)

REGULATION TO AMEND REGULATION 318 OF REVISED REGULATIONS OF ONTARIO, 1980 MADE UNDER THE FAMILY BENEFITS ACT

I.—(1) Clauses 1 (1) (c) and (d) of Regulation 318 of Revised Regulations of Ontario, 1980 are revoked and the following substituted therefor:

- (c) "single person" means an adult person who is a widow or widower or who is unmarried, deserted, separated or divorced and who is not living with his or her spouse;
- (d) "spouse" means,
 - (i) a person to whom the applicant or recipient is legally married, or
 - (ii) a person of the opposite sex who is ordinarily resident with the applicant or recipient and who is providing an economic contribution to the applicant or recipient or a dependent child or children of the applicant or recipient and the relationship between the person and the applicant or recipient is of a social or familial nature.
- (2) Section 1 of the said Regulation, as amended by section 1 of Ontario Regulation 459/82, section 1 of Ontario Regulation 654/82, section 1 of Ontario Regulation 847/82, section 1 of Ontario Regulation 360/83, section 1 of Ontario Regulation 709/84, section 1 of Ontario Regulation 825/84 and section 1 of Ontario Regulation 396/86, is further amended by adding thereto the following subsection:
- (1a) In determining whether or not a person is a spouse within the meaning of this Regulation, sexual factors shall not be investigated or considered. O. Reg. 638/86, s. 1 (2).
 - 2. This Regulation comes into force on the 1st day of November, 1986.

40

(9652)

46

GENERAL WELFARE ASSISTANCE ACT

O. Reg. 639/86. General. Made—October 30th, 1986. Filed—October 30th, 1986.

REGULATION TO AMEND
REGULATION 441 OF
REVISED REGULATIONS
OF ONTARIO, 1980
MADE UNDER THE
GENERAL WELFARE ASSISTANCE
ACT

- 1.—(1) Subclause I(1)(n) (iii) of Regulation 441 of Revised Regulations of Ontario, 1980 is revoked and the following substituted therefor:
 - (iii) who is living with his or her spouse;
- (2) Clause 1 (1) (p) of the said Regulation is revoked and the following substituted therefor:
 - (p) "spouse" means, !
 - (i) a person to whom the applicant or recipient is legally married, or
 - (ii) a person of the opposite sex who is ordinarily resident with the applicant or recipient and who is providing an economic contribution to the applicant or recipient or a dependent child or children of the applicant or recipient and the relationship between the (9653)

person and the applicant or recipient is of a social or familial nature.

- (3) Section 1 of the said Regulation, as amended by section 1 of Ontario Regulation 655/82, section 1 of Ontario Regulation 786/82, section 1 of Ontario Regulation 691/83, section 1 of Ontario Regulation 402/84, section 1 of Ontario Regulation 708/84 and section 1 of Ontario Regulation 395/86, is further amended by adding thereto the following subsection:
- (1a) In determining whether or not a person is a spouse within the meaning of this Regulation, sexual factors shall not be investigated or considered. O. Reg. 639/86, s. 1 (3).
 - 2. This Regulation comes into force on the 1st day of November, 1986.

. 46

GENERAL WELFARE ASSISTANCE ACT

O. Reg. 640/86. General. Made-October 30th, 1986. Filed-October 30th, 1986.

REGULATION TO AMEND REGULATION 441 OF REVISED REGULATIONS OF ONTARIO, 1980 MADE UNDER THE GENERAL WELFARE ASSISTANCE ACT

1. Item 16 of Schedule E to Regulation 441 of Revised Regulations of Ontario, 1980, as made by section 1 of Ontario Regulation 441/86, is revoked and the following substituted therefor:

From and including the 1st day of August, 1986, up to and including the 31st day of October, 1986

From and including the 1st day of November, 1986

| \$20.02 | 48.48 | 77.00 | 41.25 |
|---------|-------|-------|-------|
| | | | |

\$20.23 48.48 77.00 41.25

CHARITABLE INSTITUTIONS ACT

O. Reg. 641/86. General. Made-October 30th, 1986. Filed-October 30th, 1986.

REGULATION TO AMEND REGULATION 95 OF REVISED REGULATIONS OF ONTARIO, 1980 MADE UNDER THE CHARITABLE INSTITUTIONS ACT

1. Item 35 of Table 1 of Regulation 95 of Revised Regulations of Ontario, 1980, as made by section 1 of Ontario Regulation 442/86, is revoked and the following substituted therefor:

| 35. | From and including the 1st day of August, 1986, up to and including the 31st day of October, 1986 | 20.02 | 48.48 | 34.38 | 77.00 | 33.50 |
|--------|---|-------|-------|-------|-------|-------|
| 36. | From and including the 1st day of November, 1986 | 20.23 | 48.48 | 34.59 | 77.00 | 33.50 |
| (9655) | | | | | | 46 |

HOMES FOR THE AGED AND REST HOMES ACT

O. Reg. 642/86. General. Made-October 30th, 1986. Filed-October 30th, 1986.

REGULATION TO AMEND REGULATION 502 OF REVISED REGULATIONS OF ONTARIO, 1980 MADE UNDER THE HOMES FOR THE AGED AND REST HOMES ACT

1. Item 35 of Table 1 of Regulation 502 of Revised Regulations of Ontario, 1980, as made by section 1 of Ontario Regulation 443/86, is revoked and the following substituted therefor:

| 35. | From and including the 1st day of August, 1986, up to and including the 31st day of October, 1986 | 20.02 | 46.48 | 34.38 | 77.00 |
|--------|---|-------|-------|-------|-------|
| 36. | From and including the 1st day of November, 1986 | 20.23 | 46.48 | 34.59 | 77.00 |
| (9656) | | | | | 4 |

FAMILY BENEFITS ACT

O. Reg. 643/86. General. Made-October 30th, 1986. Filed-October 30th, 1986.

REGULATION TO AMEND REGULATION 318 OF REVISED REGULATIONS OF **ONTARIO**, 1980 MADE UNDER THE FAMILY BENEFITS ACT

1. Subclause 12 (5) (e) (i) of Regulation 318 of Revised Regulations of Ontario, 1980, as remade by section 1 of Ontario Regulation 444/86, is revoked and the following substituted therefor:

(i) \$20.23 a day, or

2. This Regulation comes into force on the 1st day of November, 1986.

(9657)

46

46

NURSING HOMES ACT

O. Reg. 644/86. General Made-October 30th, 1986. Filed-October 31st, 1986.

O. Reg. 644/86

(9658)

REGULATION TO AMEND REGULATION 690 OF REVISED REGULATIONS OF ONTARIO, 1980 MADE UNDER THE NURSING HOMES ACT

1. Item 25 of Table 1 of Regulation 690 of Revised Regulations of Ontario, 1980, as made by section I of Ontario Regulation 439/86, is revoked and the following substituted therefor:

| 25. | On or after the 1st day of August, 1986, but before the 1st day of November, 1986. | \$608.96 | \$20.02 |
|-----|---|----------|---------|
| 26. | On or after the 1st day of November, 1986. | \$615.34 | \$20.23 |

HEALTH INSURANCE ACT

O. Reg. 645/86. General. Made-October 30th, 1986. Filed-October 31st, 1986.

REGULATION TO AMEND REGULATION 452 OF REVISED REGULATIONS OF ONTARIO, 1980 MADE UNDER THE HEALTH INSURANCE ACT

- 1. Item 1 of Table 1B of Regulation 452 of Revised Regulations of Ontario, 1980, as made by section 4 of Ontario Regulation 438/86, is revoked and the following substituted therefor:
- 1. On or after the 1st day of August, 1986, but before the 1st day of November, \$608.96 \$20.02 \$878.38 \$28,88 \$1,487.34 \$48,90 2. On or after the 1st day of November, 1986 615.34 20.23 872.00 28.67 1,487.34 48.90
- 2. Items 7x, 13x, 19x, 25x, 31x and 61 of Table 2 of the said Regulation, as made by section 5 of Ontario Regulation 438/86, are revoked and the following substituted therefor:

| Estimated income less \$77.00, divided by 30.4 | Estimated income less \$77.00, divided by 30.4 | Aggregate estimated incomes less \$2,078.00, divided by 91.2 | Aggregate estimated incomes less \$2,078.00, divided by 91.2 | Aggregate estimated incomes less \$2,375.00, divided by 91.2 | Aggregate estimated incomes less \$2,375.00, divided by 91.2 | Aggregate estimated incomes less \$2,645.00, divided by 91.2 | Aggregate estimated incomes less \$2,645.00, divided by 91.2 |
|--|---|--|--|--|---|--|---|
| Estimated income less \$77.00 | Estimated income less \$77.00 | Aggregate estimated incomes less \$2,078.00, divided by 3 | Aggregate estimated incomes less \$2,078.00, divided by 3 | Aggregate estimated incomes less \$2,375.00, divided by 3 | Aggregate estimated incomes less \$2,375.00, divided by 3 | Aggregate estimated incomes less \$2,645.00, divided by 3 | Aggregate estimated incomes less \$2,645.00, divided by 3 |
| Person with no dependants— maximum estimated income \$685.96 | Person with no dependants—maximum estimated income \$692.34 | Person with one dependant—maximum aggregate estimated incomes \$3,904.00 | Person with one dependant—maximum aggregate estimated incomes \$3,924.00 | Person with two dependants— maximum aggregate estimated incomes \$4,201.00 | Person with two dependants—maximum aggregate estimated incomes \$4,221.00 | Person with three dependants—maximum aggregate estimated incomes \$4,471.00 | Person with three dependants—maximum aggregate estimated incomes \$4,491.00 |
| On or after the 1st day of August, 1986, but before the 1st day of November, 1986. | On or after the 1st day of November, 1986. | On or after the 1st day of August, 1986, but before the 1st day of November, 1986. | On or after the 1st day of November, 1986. | On or after the 1st day of August, 1986, but before the 1st day of November, 1986. | On or after the 1st day of November, 1986. | On or after the 1st day of August, 1986, but before the 1st day of November, 1986. | On or after the 1st day of November, 1986. |
| 7x. | 73. | 13x. | 13y. | 19x. | 19 <i>y</i> . | 25x. | 25y. |

| Aggregate estimated incomes less \$2,887.00, divided by 91.2 | Aggregate estimated incomes less \$2,887.00, divided by 91.2 | \$20.02 | \$20.23 |
|--|--|--|--|
| Aggregate estimated incomes less \$2,887.00, divided by 3 | Aggregate estimated incomes less \$2,887.00, divided by 3 | 96.08.9€ | \$615.34 |
| Person with four or more dependants—maximum aggregate estimated incomes \$4,713.00 | Person with four or more dependants—maximum aggregate estimated incomes \$4,733.00 | Person not referred to in Items $1-31x$ | Person not referred to in Items 1-31y |
| 31x. On or after the 1st day of August, 1986, Person with four or more but before the 1st day of November, dependants—maximum ag 1986. | 31y. On or after the 1st day of November, 1986. | 61. On or after the 1st day of August, 1986, Person not referred to in Items 1-31x but before the 1st day of November, 1986. | On or after the 1st day of November, 1986. |
| 31x. | 31y. | .19 | 62. |

HEALTH INSURANCE ACT

O. Reg. 646/86. General. Made—October 30th, 1986. Filed—October 31st, 1986.

REGULATION TO AMEND REGULATION 452 OF REVISED REGULATIONS OF ONTARIO, 1980 MADE UNDER THE HEALTH INSURANCE ACT

- 1. Clause 43 (4) (a) of Regulation 452 of Revised Regulations of Ontario, 1980 is revoked.
- 2. Form 1 of the said Regulation, as remade by section 1 of Ontario Regulation 808/83, is revoked and the following substituted therefor:

| Health I | nsurance Act L- 1359 |
|--|--|
| | Type 1, 2 or 3 Care |
| of Health (EXTENDED CARE | INSURED SERVICE) |
| Ontario | tome Con |
| Applicant's Surname SECT | finitials Date of Birth Sex Ag |
| | day month year |
| OHIP Number Surname of Insurance Holder | Initials Applicant's relationship to Insurance molder |
| | 1 1 Holder Spouse Child Or Apr 3 |
| Present Location 4 Ac. 1 Nursing Home 5 Hor | The Licence of Regis |
| 2 Psychiatric bed 6 Chri | |
| 3 Home for the Aged 7 Oth | Telephone No where applicant or is applicant receiving |
| | responsible person can be contacted social assistance? |
| Street | Other Insurance (iplease specify) |
| City Posta: Code | _1 |
| Address where Erigibility Certificate should be mailed As above Other (Please specify) | , Drug Benefit Number Social Insurance Number |
| Street | 1 agree that application be made Date |
| City Posta Code | |
| | Signature of Applicant or Representative- |
| or function EATING DRESSING | bes the usual degree of Staff Assistance required in that daily activity GROOMING (mouth, hair care, etc.) Itub shower sponge include transfer |
| □ Nu assistance □ No assistance | ☐ No assistance ☐ No assistance |
| Assistance with one or two aspects of aabng or supervision aspects of supervision supervision | supervision supervision |
| Assistance with several aspects of eating Assistance with several aspects of dressing | Assistance with several Assistance with several aspects of grooming aspects of pathing |
| Total assistance Total assistance | Total assistance Transfer/Positionin |
| SKIN CARE BLADDER CONTROL Routine preventive care- Routine preventive care- | BOWEL CONTROL Ded/chair-whee/chair toilet/ |
| skin intact Needs reminding only | Needs reminding only One staff needed for |
| Routine plus special treatment: Needs requiar toileting one or two small areas involved catheter care occasional incommence. | Needs regular toileting transfers, positionings cotostomy care occasional incontinence |
| large and or many areas of skin Needs frequent attention- broken | Needs total care e.g. frequent inconfinence or enemas |
| LOCOMOTION/ ORIENTATION AMBULATION (time-prace person) | COMMUNICATION SOCIO-EMOTIONAL SUPPORT |
| No assistance even if crutches No assistance-well oriented canes, walker wheelchair etc | No assistance communicates Routine support le g |
| Used Some assistance reminding e.g. finding way knowing | with ease encouragement, discussion of fears, wornes output may need to be Some intervention for mild |
| specific problem locations e.g. time of day etc poor judgement | repeated or written behavioural problems e.g. Moderately severe difficulty depressed noisy resistive at |
| Considerable assistance with Considerable supervision assistance e.g. wanders | use of pictures objects gesture required Considerable intervention |
| Total assistance difficulty following directions etc | Severe difficulty raimost no comprehension of input and or no comprehensible outbut! Descriptive disruptive, host destructive etc or comprehensible outbut! |
| Person providing information: | MEDICATION toral drops suppositor es actives etc. |
| Comments: | None of occasionar pinn Including injections One or two medications |
| Primary. | once or twice daily inc injections! |
| Diagnosis | Several medications three times or more daily indirections: |
| Secondary: | ☐ IM or SC only ☐ IM or SC plus other |
| Name & address of physician completing form (please print) | medications medications |
| Street | Physician's GreiP Gare or Assessment Diagnostic from |
| City Posta Goor | Cam Number day morn year For Officia |
| 957 906 94 96 | 71277 |

| Applicant's Surname Given Name | |
|--|--|
| SECTION | N C |
| General Information: (To be completed by physician or designate) | |
| State of Consciousness: Conscious Semi-Conscious Unconsci | ous |
| Physical Abnormality: | |
| Psin: Mild Moderate Severe Describe | |
| Oedeme: Peripheral Other Describe | |
| Skin: Abrasions Rash Bruises Ulcerations | □ Pressure sores □ Other Describe |
| Appetite: Good Fair Poor | |
| Nutrition: Well Under nourished Overweight | HeightWeight |
| Other: Prosthesis Brace Splint Dentures | Eyeglasses Contact Lenses Hearing Aid |
| Pacemaker Other Describe | |
| Name of next of kin/responsible person | Talanhara Musahar |
| Name of next of kin/responsible person | Telephone Number |
| Address | |
| Present Maritel Status | parated |
| Type of Accomodation: Owns home Rents Home Boa | rds Rents Apartment |
| Living Arrangements: Lives with others Lives alone Financial Assistance Required: Yes No Describe | |
| Preferences: ☐ Smoker ☐ Non-Smoker ☐ Alcahal (specify) | Religion |
| Language: Other | er Social Information |
| Previous Occupation: | |
| Interests (please specify) | |
| Soci | iel Emergancy Admission (specify) |
| | |
| Professional Service Needs (check and specify) (To be completed | |
| Professional Service Meeds (check and specify) (to be completed | by physician or designate) |
| B W . | D |
| Dressing | Laboratory Tests Type |
| Tubeleeding | Туре |
| Intravenous feeding Tracheostomy care | Frequency |
| Irrigations | Radiology |
| Indwelling Catheter | Physiotherapy Occupational Therapy |
| Other Techniques | Occupational Therapy Speech Therapy |
| | Sociel Work |
| Nutrition Special diet | □ Community Support Services (Indicate under comments) |
| Special diet | Other |
| Present Medication | Comments (Sections C and D) |
| Drug Date Dosage Frequency Route | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| Patient Problems/Needs | |
| | |
| | |
| | |
| Person Providing Information: Name | Position or Relationship |

957-92E (84 06)

| Medical Assessment Medical Assessment 1. Brief Medical/Surgical History 2. Describe Patient's Present Cli | (This section to be complete y: | ECTION E d by physician. Please attac. | h additional information if n | ecessary) |
|---|--|--|--|-----------------------------|
| Medical Assessment 1. Brief Medical/Surgical History | у: | | | |
| | | | | |
| | | | | |
| . Describe Patient's Present Cli | nical Condition: | | | |
| . Describe Patient's Present Cli | nical Condition: | | | |
| . Describe Patient's Present Cli | nical Condition: | | | |
| . Describe Patient's Present Cli | nical Condition: | | | |
| P. Describe Patient's Present Cli | nical Condition: | | | |
| . Describe radent 5 rresent Cir | nical Condition: | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| Note any Drug Sensitivities or | r Allergies | | | |
| | | | | |
| | | | | |
| Diagnoses | | nt Status Three Mon isease Prognosis | th Purpose of Care | Rahabilitation Potential |
| List the diagnoses below in order of severity. | | 11/1/ | | 777 |
| | ACONINS Sinks Lines-Circes-Conto | ///// | 1/./// | /// |
| For each diagnosis check the appropriate boxes under the | Mooning Change C | Consequence of the Consequence o | 10000000000000000000000000000000000000 | /./// |
| headings to the right. | Siense Ciri | 000 000 000 000 000 000 000 000 000 00 | Cood In Cood I | Pale appropri |
| (3) | 2/2/3/3/4/ | 5/2/5/8/6/ | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| 100 | | | | |
| | | | | 1 |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| Accommodation | | | | |
| ype of Care Required: | Type 1 (Residential) | Type 2 (Extended) | Type 3 (Chronic) | |
| Proposed Placement; | ☐ Home for the Aged | Nursing Home | Chronic Unit or Ch | ronic Hospital |
| Accommodation Requested: | ☐ Ward | Semi-Private | Private | |
| Stimated Duration of Stay | Weeks | Months | Indeterminate | |
| | | | | |
| family Physician (please print) | | | | |
| Name | Address | | | |
| | | | | |
| | | | | |
| Attending Physician (please print) | | | | |
| Name | Address | | | |
| certify that the medical assessm | ant is portect to the heat of | ny professional knowledge | | |
| The tribulation assessing | construct to the best of f | ny professional knowledge. | | |
| | | | | |

O. Reg. 646/86, s. 2.

HEALTH INSURANCE ACT

O. Reg. 647/86. General. Made—October 30th, 1986. Filed—October 31st, 1986.

REGULATION TO AMEND REGULATION 452 OF REVISED REGULATIONS OF ONTARIO, 1980 MADE UNDER THE HEALTH INSURANCE ACT

 Item 53 of Part I of Schedule 9 to Regulation 452 of Revised Regulations of Ontario, 1980 is revoked.

(9661)

46

GASOLINE TAX ACT

O. Reg. 648/86. General. Made—October 30th, 1986. Filed—October 31st, 1986.

REGULATION MADE UNDER THE GASOLINE TAX ACT

GENERAL

- 1.—(1) The Minister may require a wholesaler or retailer of gasoline or aviation fuel who is not a collector to deliver a return to the Minister on or before the 15th day of every month showing the quantity of gasoline or aviation fuel sold by the wholesaler or retailer and the names and addresses of all persons to whom the gasoline or aviation fuel was sold during the preceding month.
- (2) The Minister may require a purchaser of gasoline or aviation fuel who is not a collector to deliver a return to the Minister on or before the 15th day of every month showing the quantity of gasoline or aviation fuel or both, purchased or received and the names and addresses of the persons from whom the gasoline or aviation fuel or both, was purchased or received during the preceding month. O. Reg. 648/86, s. 1.
- 2.—(1) A refund of tax may be made to a person who paid the tax where the person applies for the refund in a form provided by the Minister and,
 - (a) the tax was paid by the person in respect of a product that is excluded by regulation from the application of the Act; or
 - (b) the person is exempt under the regulations from the payment of tax under the Act.

- (2) No refund of tax shall be made under subsection (1) where the tax was paid more than three years before the date on which the application for a refund is mailed or delivered to the Minister. O. Reg. 648/86, s. 2.
- 3.—(1) In this section, "motor vehicle" means a machine operated, propelled or driven other than by muscular power.
- (2) The Minister may, upon application from a purchaser, refund the tax paid on gasoline where,
 - (a) the gasoline has been used in Ontario exclusively in a business, industry or institution and for business, industrial or institutional purposes that are not excluded by regulation from the application of this subsection; or
 - (b) the gasoline has been used in Ontario to operate the auxiliary equipment of a motor vehicle where the power from the auxiliary equipment is not used or designed for the propulsion of a motor vehicle on a highway, and the motor vehicle to which the equipment is auxiliary is not principally used by its owner or operator for the transportation of passengers, whether for hire or not, or for the pleasure or recreation of the owner or operator.
- (3) No refund of tax shall be made under subsection (2) with respect to gasoline used to operate a motor vehicle for which a permit issued under subsection 7 (3) of the *Highway Traffic Act* is required or in force, or with respect to gasoline used in the operation of any motor vehicle used or intended to be used principally for the recreation or pleasure of its owner or operator.
- (4) An application for a refund of tax under subsection (2) shall be accompanied by invoices covering the purchase of the gasoline in respect of the tax on which the applicant is claiming a refund.

- (5) Every invoice submitted in support of an application for refund under subsection (2) shall clearly show the invoice number, the name of the purchaser of the gasoline, the name and address of the person who sold the gasoline to the purchaser, the quantities of gasoline sold to the purchaser and the date upon which the gasoline was purchased.
- (6) No refund of tax shall be made under subsection (2) where the tax was paid more than three years before the date on which the application is mailed or delivered to the Minister.
- (7) The amount of a refund that may be granted by the Minister in respect of an application under subsection (2) shall be reduced by the greater of \$5 or 200 per cent of the amount of the refund of tax claimed if the applicant for the refund misrepresents a material fact on the application for the refund or on or in connection with any document used to support an application for a refund of tax, other than an invoice referred to in subsection (5).
- (8) No refund of tax shall be made under subsection (2) where the applicant has misrepresented a material fact on an invoice referred to in subsection (5). O. Reg. 648/86, s. 3.
- 4.—(1) The Minister may, upon application from a purchaser made within three years from the date on which the tax is paid, refund the tax paid on aviation fuel where the aviation fuel is delivered directly to the fuel tanks of an aircraft making a technical stop at Ottawa International Airport for the sole purpose of refuelling.
- (2) No refund of tax shall be made with respect to the fuel delivered to an aircraft that is not, at the time of making the stop, on a transoceanic flight entitling the aircraft to make the stop.
- (3) An application for a refund of tax referred to in subsection (1) shall be in a form provided by the Minister and shall be accompanied by invoices relating to the aviation fuel with respect to which the refund is claimed and by information that clearly sets out whether or not the aircraft was making a technical stop under the conditions set out in subsection (1). O. Reg. 648/86, s. 4.
- 5. For the purposes of subsection 15 (1) of the Act, every importer, wholesaler and retailer shall maintain a record of,
 - (a) the quantities of gasoline and aviation fuel imported, purchased or otherwise received from suppliers or the person's own production;
 - (b) the quantities of gasoline and aviation fuel sold, delivered or exported or consumed by the person including sales and deliveries to other collectors, importers, wholesalers, retailers and purchasers;

- (c) the person's inventory of gasoline and aviation fuel; and
- (d) the tax collectable and payable,

and shall retain each such record and all invoices, books of account and other documents related thereto for at least five years from the making of the record, invoice or document or the last entry in the book of account. O. Reg. 648/86, s. 5.

- 6.—(1) Every applicant for a refund of tax paid shall keep records and books of account in such form and containing such information as will enable an accurate determination to be made of the amount refundable to the applicant.
- (2) The records, invoices, books of account and other documents required to be kept by every wholesaler or retailer under subsection 15 (1) of the Act and section 5 of this Regulation and documents required to be kept under subsection (1) need not be maintained where,
 - (a) the records, invoices, books of account or other documents to be destroyed relate to a period for which all returns required under the Act and regulations have been filed and for which all taxes assessed under the Act or the regulations have been paid;
 - (b) the records, invoices, books of account or other documents to be destroyed relate to a period for which there is no outstanding dispute between the person retaining the records, invoices, books of account or other documents and the Minister with regard to any tax payable or to be remitted by the person;
 - (c) the time limit for filing a notice of objection to any assessment or statement of disallowance for the period referred to in clause (b) has expired without the filing of the notice of objection;
 - (d) no demand of the Minister for the production of the records, invoices, books of account or other documents that are to be destroyed has been made that remains unsatisfied:
 - (e) no written notice from the Minister has been given to the wholesaler or retailer requiring the retention of the records, invoices, books of account or other documents that are to be destroyed; and
 - (f) a period of five years has expired since the end of the calendar year to which the records, invoices, books of account or other documents relate. O. Reg. 648/86, s. 6.
- 7.—(1) A notice of assessment under section 11 of the Act shall be in Form 1.

- (2) An application for a refund under section 3 of Regulation 440 of Revised Regulations of Ontario, 1980 shall be in Form 2.
- (3) An application for a refund under section 3, 4 or 5 of this Regulation or under section 8 of Regulation 440 of Revised Regulations of Ontario, 1980 shall be in Form 3.
- (4) The return made by a collector under subsection 1 (1) of Regulation 440 of Revised Regulations of Ontario, 1980 shall be in Form 4.
- (5) The statement made by an importer under section 2 of Regulation 440 of Revised Regulations of Ontario, 1980 shall be in Form 5.
- (6) A statement of disallowance made under section 11 of the Act shall be in Form 6. O. Reg. 648/86, s. 7.
 - 8. Ontario Regulation 441/81 is revoked.

Gasoline Tax Act



Ministry Revenue Motor Fuels and Tobacco Tax Branch

P.O. Box 625 33 King Street West Oshawa, Ontario L1H 8H9

Notice of Assessment **GT 53**

| Date of Mailing or Delivery | Due Date | Please quote this ASSESSMENT NUMBER in all correspondence pertaining to this Notice of Assessment | |
|--------------------------------|----------|---|--|
|--------------------------------|----------|---|--|

Explanation of Assessment

Inquiries concerning this assessment may be made in writing or by telephoning (416) 433-

STATEMENT OF ACCOUNT

You have been assessed the amount indicated in respect of Gasoline Tax due and payable to the Treasurer of Ontario. If the tax due is not paid by the due date, interest will be charged to the date of payment.

| This liability is for t | the period | Gasoline Tax Due | Interest | Other/Penalty | TOTAL AMOUNT |
|-------------------------|------------|------------------|----------|---------------|--------------------|
| From | То | s | \$ | s | OF THIS ASSESSMENT |

as of

as of

Net account balance

Amount credited Net account balance

Total of above assessment

NOTICE OF OBJECTION

You have the right to appeal this Notice of Assessment by filing an objection with the Minister of Revenue in the prescribed form within 180 days from the date this notice was mailed.

For more information or to obtain Notice of Objection

forms contact:
Tax Appeals Branch
Ontario Ministry of Revenue P.O. Box 627

Oshawa, Ontario L1H 8H5

Phone: (416) 433-6029 in Oshawa (416) 965-5836 in Toronto (ask operator for the Tax Appeals Branch)

T.M. Ru

Deputy Minister of Revenue

DETACH BERE



Ministry

Mailing Address, if different from a

Motor Fuels and Tobacco Tax Branch

Remittance Advice Gasoline Tax Act

| bave (include Postal Code) | |
|----------------------------|--|
| | |
| | |
| | |
| | |
| | |
| | |

| ASSESSMENT NUM | BER | |
|----------------|--------------------------|---|
| CREDIT | \$ | • |
| on your next | the above amount will be | |
| PAYMENT DUE | \$ | |

DETACH AND RETURN THIS REMITTANCE ADVICE OETACH AND RETURN THIS REMITTANCE ADVICE
TOGETHER WITH YOUR CHEQUE OR MONEY ORDER
MADE PAYABLE TO THE TREASURER OF ONTARIO,
TO Ministry of Revenue
Taxation Data Centre
Motor Fuels and Tobacco Tax Branch
P.O. Box 620
33 King Street West
Oshawa, Ontario
L1H 8E9

0847F (86-01)

O. Reg. 648/86, Form 1

Gasoline Tax Act

| | Ministry Motor Fuels and P.O. Box 625 of Tobacco Tax Aperican Branch State West Oshawa, Ontario LIH 8H9 | Application for Refund - GT260 (Allowance to Retailers) |
|------------|---|---|
| | or use by Retail Vendors of Gasoline only | GTR Number |
| | Is this your first claim? Yes L No L | 1 2 |
| | | Branch Use Only Trans Code Name |
| | | 3 DO1 SE |
| | | G A 0 0 0 1 |
| Α | Gasoline Handling Licence Number 47 34 MUST be sho | |
| В | Complete Name and Address Section if above information is incorrect or if label is mis Trade or Business Name | sing. County or District in which business is operated |
| Þ11 | 28 | 51 |
| Þ12 | Address | C CLAIM |
| ⊳21 | 26 | PERIOD 931 |
| ⊳22 | 21 | Date of first Year Month Day Invoice 19 |
| ⊳23 | 26 | 53 |
| D24 | 23 | Date of last Year Month Day Invoice 19 |
| | Postal Code | 60 |
| D | | 200 |
| | Total tax paid on bulk gasoline purchases (as per attached receipted invoice | es) \$. |
| E | Less: Refund claimed on unlicensed equipment use | |
| | Tax on wholesale distribution | \$ |
| F | Tax on retail sales | \$ |
| - 9 | | |
| G | Total amount of claim ▷34 \$ X | 0.21% Þ35 \$ |
| J | DECLARATION | • |
| | I certify that gasoline tax was paid with respect to all invoices suppoin this application and in any documents attached in support thereof | |
| | Signature | Telephone No. (Area Code) |
| | | |
| | Warning: Fraudulent claims submitted may result in charges being laid under the | Criminal Code. |
| | Adj. Code Amount Sus. Code | Reas. Ind. Initials |
| | \$ | 0736N (85-11) |
| | | O. Reg. 648/86, Form 2 |

Adj. Code Amount

Ministry Motor Fuels and P.O. Box 625

Application for Refund of

Form 3

Gasoline Tax Act

| Ontari | of Tobacco Tax Revenue Branch | 33 King Street West Oshawa, Ontario L1H 8H9 | | Gasoline Tax - | GT255 |
|----------------|--|---|--|--|---------------------------------|
| s this | your first claim? Yes | No | GTR | Number | : |
| | | | | BRANCH US | E ONLY |
| | | | | Trans Code | Name |
| | | | | Act Type CI G 37 39 41 | 32 35 ass County 42 44 45 |
| 0 | omplete Name and Address Sec r if label is missing. | | correct | B County or District in operated | which business is |
| 26 | Name of Propriator or Business Nam Address | e | | Farm Claimant only Lot No | |
| 26 | | | | Concession No. | |
| | | Postal Códa 38 | | Township | |
| C ^D | Describe nature of business opera | ated and refundable use of gas | oline. | | |
| | oo you operate licensed asoline vehicles? | 26 No 26 | Do you fuel these ve your own storage? | hicles from Yes 20 | No 2a |
| | CLAIM Date of Invoice | irst Year Month | Day : s | Date of last Year Invoice 19 19 19 | Month Day |
| | urchases/Refundable use | Total purchases (as per attached in | tvoices) To | tal refundable use | Litro |
| 3 | NOTE: 1. If the worksheet information subm | n the guide is not completed, itted. | your refund will be calc | | the basis of the |
| R | 2. To calculate your EFUND CLAIMED | refund, the work sheet in the | guide should be comple | Refund \$ 25 | |
| I ve | ECLARATION hereby certify that none of the hereby dering the period covere ocument submitted in support to the hereby courners with the hereby | d by this application. I further | er certify that all inform | | |
| | ignature | Title | ,, | Telephone No. Area Code | |
| ١ | Narning: Fraudulent claims subi | mitted may result in charges be | eing laid under the Crim | inal Code. | |
| | | | | | |

O. Reg. 648/86, Form 3.

1251D (82-08)

Gasoline Tax Act



Ministry of Revenue Motor Fuels and Tobacco Tax Branch P.O. Box 620 33 King Street West Oshawa, Ontario L1H 8E9

Gasoline Tax Return-GT66

Month

Year

Collector's Name and Address

Γ

| | BRANCH | USE | ONLY |
|---------|---------|-----|------|
| Voucl | her No. | | |
| | | | |
| Initial | is. | | |
| Initial | ls | | |
| | | | |

TAX DUE

| 1 | Regular Gasoline | \$ |
|---|----------------------------|----|
| 2 | Regular Unleaded Gasoline | \$ |
| 3 | Premium Grades of Gasoline | \$ |
| 4 | Aviation Fuel | \$ |
| 5 | Total Tax for the Month | \$ |

DEDUCTIONS

| 6 | Authorized Adjustments: (Bad Debts/Bankruptcies, Product Losses as per attached approvals) | s |
|------|--|------------|
| 7 | Ontario Gasoline Tax paid on purchases | \$ |
| 8 | Refund claimed on sales to registered Indians per attached Vouchers | \$ |
| 9 | TOTAL CREDITS (Line 6 plus Lines 7 and 8) | s |
| 10 | NET TAX DUE (Line 5 minus Line 9) | s |
| | Other Adjustments (Please explain) | Plus Minus |
| (11) | | \$ |
| 12 | BALANCE DUE (Attach remittance) | \$ |

| CERTIFICATI | 10 | V |
|-------------|----|---|
|-------------|----|---|

| r certify | that to the b | est of my | knowieuge and i | seller the inform | nation included ne | erein or attached | nereto is correct. |
|-----------|---------------|-----------|-----------------|-------------------|--------------------|-------------------|--------------------|
| | | | | | | | |

Signature Title Date

0718K (83-01)

Gasoline Tax Act



Ministry of Revenue

try Motor Fuels and Tobacco Tax nue Branch

P.O. Box 620 33 King Street West Oshawa, Ontario L1H 8E9

Statement of Gasoline Imports - GT61

| Ontario | | | | | |
|--|---|-------------------|--------------------------------------|---|-----------------------|
| Name of Importer | | | | | |
| Postal Address — Number and Street or Rural Route | | | | Calendar Month | and Year |
| | | Postal Coo | 10 | | |
| City, Town and Province | | rostal Co. | 1 | | |
| ASTRUCTIONS Statement of Gasoline Imports must be received, together above. Submit one copy only of this Statement of Gasoline Imprat the address shown above. Quantities must be reported in litres. Imperial gallons to be converted to litres at the rate of 1. United States gallons to be converted to litres at the rate. | orts together with your cl | neque or money | | | |
| articulars of Gasoline Imported | | | | | |
| Name and Address from Whom Purchased | Date of Purchase/ Importation | Grade of Gasoline | Number of Litres | Tax Rate | Amount of Tax |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | - |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | - | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | Total Tax Du | e |
| | | | | | |
| I hereby certify that the financial and other state books of the importer and exhibit truly, correctly | ments of information y and completely all in | included here | in or attached he the period cove | ereto are in agre ered by this state | ement with the ement. |
| Signature of Proprietor or Signing Officer | Title | | | Date | |
| | | | | | |

0743K (82-08)

O. Reg. 648/86, Form 5.

Gasoline Tax Act



 Γ

Ministry Revenue

Branch

Motor Fuels and Tobacco Tax Branch P.O.Box 625 33 King Street Weet Oshawa, Ontario L1H 8H9

Statement of Disallowance - GT 262

| Date | of | Malling | or | Delh | rery | - | |
|------|----|---------|----|------|------|---|-------|
| | | | | | | | |
| | _ | | - | - | | | _ |

Piesse quote this DISALLOWANCE NUMBER on all corresponde pertaining to this tement of Dis

Refund of tax claimed by you in respect of Gasoline Tax has been disallowed in the amount and for the reason(s) indicated below.

Type of claim received

| Gasoline Tax Return(s) or Refund Claim | GTR No. | |
|--|------------------|---|
| | Refund Claim No. | |
| eriod covered by refund claim - From | То | |
| mount of refund claimed | \$ | • |
| mount of refund disallowed | \$ | • |
| mount of refund allowed | \$ | • |
| seson(s) for disallowance | | |
| | | |
| | | |

inquiries concerning this disallowance may be made in writing or by telephoning (416) 433-

NOTICE OF OBJECTION

You have the right to appeal this Statement of Disallowance of your claim by filing an objection with the Minister of Revenue in the prescribed form within 180 days from the date this notice was mailed. For more information or to obtain Notice of Objection forma contact:

Tax Appeals Branch Ontario Ministry of Revenue P.O. Box 627 Oshawe, Ontario L1H 6H5

Phone: (416) 433-6029 in Oshawa (416) 965-5836 in Toronto (ask operator for Tax Appeals Branch)

T.M. Rus

Deputy Minister of Revenue

0184 (86-01)

O. Reg. 648/86, Form 6.

ROBERT NIXON Minister of Revenue

Dated at Toronto, this 30th day of October, 1986.

46

FARM PRODUCTS MARKETING ACT

O. Reg. 649/86. Vegetables for Processing-Plan. Made-October 30th, 1986. Filed-October 31st. 1986.

REGULATION TO AMEND **REGULATION 387 OF** REVISED REGULATIONS OF ONTARIO, 1980 MADE UNDER THE FARM PRODUCTS MARKETING ACT

1. Section 10 of the Schedule to Regulation 387 of Revised Regulations of Ontario, 1980, as remade by section 4 of Ontario Regulation 560/85, is amended by striking out "forty" in the third line and inserting in lieu thereof "thirty".

(9663)

46

FARM PRODUCTS MARKETING ACT

O. Reg. 650/86. Sova Beans-Plan. Made-October 30th, 1986. Filed-October 31st, 1986.

REGULATION TO AMEND **REGULATION 378 OF** REVISED REGULATIONS OF ONTARIO, 1980 MADE UNDER THE FARM PRODUCTS MARKETING ACT

- 1. Section 1 of Regulation 378 of Revised Regulations of Ontario, 1980 is revoked and the following substituted therefor:
- 1. The plan in the Schedule is continued for the control and regulation of the producing and marketing of soya-beans within Ontario. O. Reg. 650/86, s. 1.
 - 2. Section 3 of the Schedule to the said Regulation is revoked and the following substituted therefor:
- 3. This plan applies to the control and regulation in all respects of the producing and marketing within Ontario of sova-beans, including the prohibition of such producing and marketing in whole or in part.

- 3. Section 5, sections 6 to 10, as remade by section 1 of Ontario Regulation 34/83, and sections 11 and 12 of the said Schedule, are revoked and the following substituted therefor:
- 5. The local board shall be composed of fifteen members who shall hold office until their successors take office.
 - 6.—(1) There shall be eight districts, as follows:
 - 1. District 1, comprising the County of Essex.
 - 2. District 2, comprising the County of Kent.
 - 3. District 3, comprising the County of Lambton.
 - 4. District 4, comprising the County of Elgin.
 - 5. District 5, comprising the County of Middlesex.
 - 6. District 6, comprising the counties of Brant and Oxford and the regional municipalities of Haldimand-Norfolk, Hamilton-Wentworth and Niagara.
 - 7. District 7, comprising the counties of Bruce, Grey, Huron, Perth and Wellington and The Regional Municipality of Waterloo.
 - 8. District 8, comprising the counties of Dufferin and Simcoe and the regional municipalities of Halton and Peel, and the area east thereof to the Quebec border.
- (2) A producer who resides in a district is a member of the group of producers for that district.
- (3) A producer who does not reside in a district is a member of the group of producers for the district nearest to his or her place of residence.
- 7. There shall be a committee in each district to be known as the "District Soya-Bean Growers' Committee".
- 8.-(1) On or before the 25th day of January in each year the members of each group of producers, except the group of producers for District 1, shall elect from among themselves one member for each 200 producers or fraction thereof to its District Soya-Bean Growers' Committee.
- (2) On or before the 25th day of January in each year the members of the group of producers for District 1 who do not reside on Pelee Island shall elect from among themselves one member for each 200 producers or fraction thereof to the District 1 Sova-Bean Growers' Committee.

- (3) On or before the 25th day of January in each year the members of the group of producers for District 1 who reside on Pelee Island shall elect from among themselves,
 - (a) one member for each 200 producers or fraction thereof; or
 - (b) two members,

whichever is greater, to the District 1 Soya-Bean Growers' Committee.

- 9. On or before the 31st day of January in each year each District Soya-Bean Growers' Committee shall elect members to the local board, as follows:
 - 1. District 1, three members.
 - 2. District 2, four members.

- 3. District 3, three members.
 - 4. Districts 4 to 8, one member each.
- 10.—(1) At its first meeting after the 31st day of January, the members elected to the local board shall appoint such members as are necessary to complete the local board.
- (2) Where a member elected or appointed to the local board dies, resigns or is unable or unwilling to act as a member, the other members of the local board may appoint a person to replace the member for the unexpired term.
- 11. No person is eligible for election or appointment to the local board from a district unless the person is a member of the group of producers for the district.

9664) 46

Publications Under The Regulations Act

November 22nd, 1986

LIOUOR LICENCE ACT

O. Reg. 651/86. General. Made-October 30th, 1986. Filed-November 3rd, 1986.

REGULATION TO AMEND **REGULATION 581 OF** REVISED REGULATIONS OF ONTARIO, 1980 MADE UNDER THE LIOUOR LICENCE ACT

- 1. Subsection 9 (24) of Regulation 581 of Revised Regulations of Ontario, 1980 is revoked.
- 2. Subsection 11 (6) and subsection 11 (7), as remade by section 1 of Ontario Regulation 353/82, of the said Regulation are revoked.
- 3. Subsection 13 (2) of the said Regulation is revoked.

(9665)

PARKWAY BELT PLANNING AND DEVELOPMENT ACT

O. Reg. 652/86.

County of Wentworth (now The Regional Municipality of Hamilton-Wentworth), Village of Waterdown (now the Township of Flamborough). Made-October 27th, 1986. Filed-November 3rd, 1986.

REGULATION TO AMEND **ONTARIO REGULATION 485/73** MADE UNDER THE PARKWAY BELT PLANNING AND DEVELOPMENT ACT

1. Ontario Regulation 485/73 is amended by adding thereto the following section:

15.—(1) Notwithstanding any other provision of this Order, a single-family dwelling and buildings and

structures accessory thereto may be erected and used on the land described in subsection (2) if the following requirements are met:

Minimum front yard

7.5 metres

Minimum side yards

3 metres on one side

and 1.2 metres on the other

Minimum rear yard

side 7.5 metres

Maximum height of garage accessory to singlefamily dwelling

5 metres

Minimum distance between the garage and single-family dwelling

1 metre

(2) Subsection (1) applies to that parcel of land in the Township of Flamborough in The Regional Municipality of Hamilton-Wentworth, formerly in the Village of Waterdown in the County of Wentworth, being that part of Lot 6 in Concession III more particularly described as Parcel 24-2, Section M-10, and designated as Part 1 on a Plan deposited in the Land Registry Office for the Registry Division of Wentworth (No. 62) as Number 62R-4018. O. Reg. 652/86, s. 1.

> L. J. FINCHAM Director Plans Administration Branch Central and Southwest Ministry of Municipal Affairs

Dated at Toronto, this 27th day of October, 1986.

(9666)

47

PLANNING ACT, 1983

O. Reg. 653/86. Restricted Areas-County of Simcoe, Township of Nottawasaga. Made-October 29th, 1986. Filed-November 3rd, 1986.

REGULATION TO AMEND **REGULATION 675 OF** REVISED REGULATIONS OF ONTARIO, 1970 MADE UNDER THE PLANNING ACT, 1983

1. Regulation 675 of Revised Regulations of Ontario, 1970 is amended by adding thereto the following section:

248.—(1) Notwithstanding any other provision of this Order, a single-family dwelling and buildings and structures accessory thereto may be erected and used on the land described in subsection (2) if the following requirements are met:

Minimum front yard

7.6 metres

Minimum side yards

- metres on one side
- 1.2 metres on the other side

Maximum height of single-family dwelling

9.1 metres

Minimum ground floor area of single-family dwelling

one storey—93 square metres one and one-half storeys or more—69.8 square metres

(2) Subsection (1) applies to that parcel of land in the Township of Nottawasaga in the County of Simcoe, being that part of Lot 39 in Concession X described as follows:

Premising that bearings herein are astronomic and are derived from Department of Highway's Plan P-2574-4 registered in the Land Registry Office for the Registry Division of the County of Simcoe (No. 51) as Instrument Number 21407;

Commencing at an iron survey bar set in the northerly limit of the said Lot 39 and distant 2,242.02 feet measured easterly therealong from the northwest angle thereof;

Thence south 16° 25′ 30″ east, and being along the easterly limit of the lands owned by the Baptist Cemetery Trust, a distance of 660 feet to an iron survey bar;

Thence south 73° 34′ 30″ west, and being along the southerly limit of the said Cemetery lands, a distance of 231 feet to an iron survey bar;

Thence south 16° 25′ 30″ east a distance of 340.75 feet to an iron survey bar set in the existing line between the north and south halves of the said Lot 39:

Thence north 73° 41′ 30″ east, along the said existing half lot line, a distance of 462 feet to an iron survey bar;

Thence north 16° 25′ 30″ west, a distance of 1,001.56 feet to an iron survey bar set in the northerly limit of the said Lot 39;

Thence south 73° 34′ 30″ west, along the said northerly limit, a distance of 231 feet to the point of commencement. O. Reg. 653/86, s. 1.

L. J. FINCHAM
Director
Plans Administration Branch
Central and Southwest
Ministry of Municipal Affairs

Dated at Toronto, this 29th day of October, 1986.

(9667)

47

OCCUPATIONAL HEALTH AND SAFETY ACT

O. Reg. 654/86.
Control of exposure to Biological or Chemical Agents.
Made—November 6th, 1986.
Filed—November 6th, 1986.

REGULATION MADE UNDER THE OCCUPATIONAL HEALTH AND SAFETY ACT

CONTROL OF EXPOSURE TO BIOLOGICAL OR CHEMICAL AGENTS

- 1. In this Regulation, "exposure" means exposure by inhalation, ingestion or skin contact. O. Reg. 654/86, s. 1.
- 2. This Regulation does not apply at a project to an employer who primarily carries on the business of contruction or to the workers of such an employer. O. Reg. 654/86, s. 2.
- 3.—(1) Every employer shall take all measures reasonably necessary in the circumstances to protect workers from exposure to a hazardous biological or chemical agent because of the storage, handling, processing or use of such agent in the work place.
- (2) The measures referred to in subsection (1) shall include the provision and use of engineering controls, work practices, hygiene facilities and practices and, subject to section 6, personal protective equipment. O. Reg. 654/86, s. 3.
- 4. Without limiting the generality of section 3, but subject to section 9, every employer shall take the measures prescribed in that section to limit the daily and weekly exposure of workers to a biological or chemical agent listed in the Schedule to the concentration limit expressed as a time-weighted average exposure value, a short-term exposure value or a ceiling exposure value set out for the agent in the Schedule as determined in accordance with the methods set out in the Schedule. O. Reg. 654/86, s. 4.

- 5. In determining the exposure of workers to a hazardous biological or chemical agent under section 3 or 4, no regard shall be had to the wearing and use of personal protective equipment. O. Reg. 654/86, s. 5.
- 6. Except in the circumstances set out in sections 7 and 9, an employer shall protect workers from exposure to a hazardous biological or chemical agent without requiring the workers to wear and use personal protective equipment. O. Reg. 654/86, s. 6.
- 7. Where engineering controls required by this Regulation,
 - (a) are not in existence or are not obtainable;
 - (b) are not reasonable or not practical to adopt, install or provide because of the duration or frequency of the exposures or because of the nature of the process, operation or work;
 - (c) are rendered ineffective because of a temporary breakdown of such controls; or
 - (d) are ineffective to prevent, control or limit exposure because of an emergency,

the employer shall provide, and workers shall wear and use, personal protective equipment appropriate in the circumstances to protect the workers from exposure to a hazardous biological or chemical agent. O. Reg. 654/86, s. 7.

- 8.—(1) Where a worker has been exposed to a hazardous biological or chemical agent and,
 - (a) the worker or the worker's physician has reason to believe that the worker's health has been affected by exposure to the agent and the worker or the worker's physician has so notified the employer;
 - (b) the employer believes that the worker has been exposed to the agent, and the worker's health is likely to be affected thereby and the employer has so notified the worker; or
 - (c) the Chief Physician of the Occupational Health Medical Service of the Ministry so requires,

the worker, subject to subsection (2), shall at the expense of the employer undergo medical examinations and clinical tests to determine whether the worker has an occupational illness because of the exposure and whether the worker is fit, fit with limitations or unfit to continue working in such an exposure.

(2) A notice under clause (1) (a) or (b) shall be in writing and a notice under clause (1) (b) shall notify the worker that the worker may dispute whether he or she must undergo medical examinations and clinical tests by giving notice of the dispute to an inspector.

- (3) Where a dispute arises between an employer and a worker under clause (1) (a) or (b) as to whether a worker must undergo medical examinations or clinical tests, the employer or the worker may notify an inspector thereof who shall cause an investigation to be made and give a decision in writing to the employer and the worker.
- (4) The employer shall provide the physician who examines the worker or under whose supervision clinical tests are performed with a copy of the records, if any, of the exposure of the worker to the hazardous biological or chemical agent. O. Reg. 654/86, s. 8.
 - 9.—(1) In this section,
- "fibrous reinforcing agent" means an agent such as glass fibre or other fibrous substance used to strengthen a plastic material;
- "plastic material" means a synthetic resinous polymeric substance that can be shaped or molded.
- (2) Every employer using styrene-based polyester resin in conjunction with a fibrous reinforcing agent to make or repair any goods, substance, article or thing, or part thereof, shall take all necessary measures and procedures by means of engineering controls, work practices and hygiene facilities and practices to ensure that the time-weighted average exposure of a worker to airborne styrene shall not exceed 100 parts styrene per million parts of air by volume, or 426 milligrams styrene per cubic metre of air.
- (3) Where subsection (2) applies, the employer shall provide a worker with respiratory equipment which shall be used by the worker if the time-weighted average exposure of a worker to airborne styrene is greater than 50 but less than 100 parts styrene per million parts of air by volume.
- (4) Notwithstanding subsection (2), an employer shall ensure that the exposure of a worker to styrene shall not exceed a short-term exposure concentration, measured over fifteen minutes, of 200 parts styrene per million parts of air by volume or 852 milligrams styrene per cubic metre of air. O. Reg. 654/86, s. 9.
 - Section 145 of Regulation 692 of Revised Regulations of Ontario, 1980 is revoked.
 - 11.—(1) Clause 242 (1) (b) of Regulation 694 of Revised Regulations of Ontario, 1980, as remade by section 67 of Ontario Regulation 569/83, is revoked and the following substituted therefor:
 - (b) except as provided by a regulation made in respect of a designated substance, dilute and remove contaminants from all work places therein to prevent exposure of a worker to contaminants in excess of the values,

- (i) prescribed under section 4 of Ontario Regulation 654/86, or
- (ii) if no values are prescribed under the said section 4, adopted as criteria or guides under section 279 of this Regulation.
- (2) Clause 243 (1) (b) of the said Regulation, as amended by section 68 of Ontario Regulation 569/83, is revoked and the following substituted therefor:
 - (b) except as provided by a regulation made in respect of a designated substance, dilute and remove contaminants from all work places therein to prevent exposure of a worker to contaminants in excess of the values,
 - (i) prescribed under section 4 of Ontario Regulation 654/86, or
 - (ii) if no values are prescribed under the said section 4, adopted as criteria or guides under section 279 of this Regulation.
- (3) Subsection 244 (1) of the said Regulation, as amended by section 69 of Ontario Regulation 569/83, is revoked and the following substituted therefor:
- (1) In an underground mine,
 - (a) subject to clause (b), a development, exploration or production work place shall be ventilated throughout by an auxiliary ventilation system for any advance in excess of sixty metres from a mechanical mine ventilation system; and
 - (b) a continuous supply of fresh air shall be provided and used to dilute and remove contaminants,
 - (i) in a raise, and
 - (ii) in a sub-drift for any advance in excess of ten metres from a mechanical mine ventilation system,

to prevent exposure of a worker to contaminants in excess of the values.

- (iii) prescribed under section 4 of Ontario Regulation 654/86, or
- (iv) if no values are prescribed under the said section 4, adopted as criteria or guides under section 279 of this Regulation. O. Reg. 654/86, s. 11 (3).
- (4) Section 279 of the said Regulation is revoked and the following substituted therefor:
- 279. As a factor to be considered under clause 20 (8) (f) of the Act, the threshold limit values for chemical substances and physical agents set out in "TLVs Threshold Limit Values and Biological Exposure Indices for 1986-87" issued by the American Conference of Governmental Hygienists are adopted as criteria or guides. O. Reg. 654/86, s. 11 (4).
 - (5) Section 282 of the said Regulation is revoked and the following substituted therefor:
- 282. Where a local exhaust ventilation system recirculates air to the work place, provision shall be made for a make-up air supply system having sufficient volume to keep any contaminants below the values,
 - (a) prescribed under section 4 of Ontario Regulation 654/86; or
 - (b) if no values are prescribed under the said section 4, adopted as criteria or guides under section 279 of this Regulation,

and the contaminant level in the recirculated air shall not exceed 20 per cent of such values. O. Reg. 654/86, s. 11 (5).

12. This Regulation comes into force on the day thirty days after it is filed with the Registrar of Regulations.

O. Reg. 654/86

SCHEDULE

Exposure Values for

Biological and Chemical Agents in Work Places

NOTE: Use of the Index to Find an Agent

Agents have been assigned to tables given in Parts 4 through 11 of the Schedule and reference should be made to the Index for the location of an agent.

Also, many of the agents' names in the Schedule are based on the naming rules of the International Union of Pure and Applied Chemistry (IUPAC). Reference should be made to the Index for the cross-referencing of common names with IUPAC names.

TABLE OF CONTENTS

| | | | | Page |
|------|---------------|---------|---|------|
| Biol | ogical and Cl | hemical | Agents | |
| | Part 1 | - | Index of Biological and Chemical Agents | 11 |
| | Part 2A | - | Calculation of Exposure Values | 31 |
| | Part 2B | - | Calculation of Exposure Values Where a STEV or CEV is Not Indicated | 33 |
| | Part 3 | | Explanatory Notes on Chemical Names, CAS Reg. Nos., and Other Notations | 34 |
| | Part 4 | | Time-Weighted Average Exposure Values (TWAEV) and Short-Term Exposure Values (STEV) for Biological and Chemical Agents | 37 |
| | Part 5 | - | Ceiling Exposure Values (CEV) for Biological and Chemical Agents | 77 |
| | Part 6 | - | Time-Weighted Average Exposure Values (TWAEV) for Mineral Dusts | 81 |
| | Part 7 | _ | Time-Weighted Average Exposure Values (TWAEV) for Nuisance Particulates | 82 |
| | Part 8 | - | Time-Weighted Average Exposure Values (TWAEV) and Short-Term Exposure Values (STEV) for Chemical Agents of Variable Composition | 85 |
| | Part 9 | - | Exposure Values for Simple Asphyxiants | 87 |
| | Part 10 | | Known Toxic Agents for Which Exposure Values Have Not Been Established, and to Which Any Exposure Should be Avoided | 88 |
| | Part 11 | - | Exposure Values for Acrylonitrile, | 89 |

PART 1. INDEX OF BIOLOGICAL AND CHEMICAL AGENTS

| ABATE ^R , see Temephos | 71 | Aluminium, alkyl derivatives | 38 |
|---|----|---|----|
| Acetaldehyde | 37 | Aluminium, metal and oxide dust | 38 |
| Acetic acid | 37 | | 00 |
| Acetic anhydride | 77 | Aluminum, water-soluble compounds of | 38 |
| Acetone | 37 | Aluminum welding fume or particulate, see | |
| Acetonitrile | 37 | Welding, | 86 |
| Acetylene | 87 | ALUNDUM ^R , see alpha- Alumina | 82 |
| Acetylene dichloride, see 1,2-Dichloroethene | 48 | 4-Aminobiphenyl, see (1,1'-Biphenyl)-4-amine | 88 |
| Acetylene tetrabromide, see 1,1,2,2-Tetrabromoethane | 71 | Aminodimethylbenzenes, see ar, ar-Dimethylbenzenamine | 50 |
| 2-(Acetyloxy) benzoic acid | 37 | 2-Aminoethanol | 38 |
| Acetylsalicylic acid, see 2-(Acetyloxy) benzoic acid | 37 | 2-Aminopyridine | 38 |
| Acrolein | 37 | 3-Amino-1H-1,2,4-triazole | 38 |
| Acrylamide | 37 | 4-Amino-3,5,6-trichloro-2- pyridinecarboxylic acid | 38 |
| Aerylic acid | 37 | Amitania and 2 Amino 111 | |
| Acrylonitrile | 89 | Amitrole, see 3-Amino-1H- 1,2,4-triazole | 38 |
| Aldrin | 37 | AMMATE ^R , see Ammonium sulfamate | 38 |
| Allyl alcohol | 37 | Ammonia | 38 |
| Allyl chloride | 37 | Ammonia | 30 |
| | | Ammonium chloride fume | 38 |
| Allyl glycidyl ether, see ((2-Propenyloxy)methyl) oxirane | 68 | Ammonium persulfate, see Persulfates | 66 |
| Allyl propyl disulfide | 37 | Ammonium perfluorooctanoate | 38 |
| alpha-Alumina | 82 | Ammonium sulfamate | 38 |
| Aluminum-powder | 37 | n-Amyl acetate | 38 |

| sec-Amyl acetate | 39 | 1,4-Benzoquinone, see Quinone | 69 |
|---|----|--|----------|
| Aniline and homologues | 39 | Benzoyl peroxide | 40 |
| Anisidine (sum of isomers) | 39 | | |
| Antimony and its compounds | 39 | Benzyl chloride | 40 |
| Antimony hydride | 39 | Beryllium and its compounds | 40 |
| ANTU, see alpha-Naphthyl- thiourea | 63 | Biphenyl (1,1'-Biphenyl)-4-amine | 40 88 |
| | | | 00 |
| Argon | 87 | Bis(chloromethyl) ether, see Oxybis(chloromethane) | 65 |
| Arsine | 39 | Bis(eta-cyclopentadienyl)iron | 40 |
| Asphalt, fumes | 85 | | 10 |
| Aspirin, see | | 2,6-Bis(1,1-dimethylethyl)- 4-methylphenol | 40 |
| 2-(Acetyloxy) benzoic acid | 37 | Bis (dimethylthiocarbamoyl) | |
| Atrazine | 39 | disulfide | 40 |
| Azinphos-methyl | 39 | Bis(2-ethylhexyl) phthalate see 1,2-Benzenedicarboxylic acid | |
| Barium carbonate, chloride, nitrate, or oxide | 39 | bis(2-ethylhexyl) ester | 39 |
| Barium sulfate | 82 | Bismuth telluride | 40 |
| BAYGON ^R , see Propoxur | 68 | Bismuth telluride, selenium-doped | 40 |
| Benomyl | 39 | Borates, tetra, sodium | 40 |
| Benzene | 89 | 3333 | |
| 1,2-Benzenedicarboxylic | | Boron oxide | 41 |
| acid bis(2-ethylhexyl) ester | 39 | Boron tribromide | 77 |
| | | Boron trifluoride | 77 |
| 1,4-Benzenediol, see 1,4-Dihydroxybenzene | 50 | Bromacil | 41 |
| Benzenethiol | 40 | Bromine | 41 |
| Benzidine | 88 | Bromine pentafluoride | 41 |
| Benzo(a)pyrene | 88 | Bromochloromethane | 41 |
| | | | |

| 1 | 3 | | |
|---|---|--|--|

| Bromoform | 41 | Cadmium-containing fume | 77 |
|--|----|---|----|
| Bromotrifluoromethane | 41 | Cadmium oxide, production | 42 |
| 1,3-Butadiene | 41 | Calcium carbonate | 82 |
| Butane | 41 | Calcium cyanamide | 42 |
| 1-Butanethiol | 41 | Calcium hydroxide | 43 |
| 2-Butanone | 41 | Calcium oxide | 43 |
| 2-Butoxyethanol | 41 | Calcium silicate | 82 |
| (Butoxymethyl)oxirane | 41 | Calcium sulfate | 82 |
| n-Butyl acetate | 42 | Camphor | 43 |
| sec-Butyl acetate | 42 | Caprolactam | 43 |
| tert-Butyl acetate | 42 | Captafol | 43 |
| n-Butyl acrylate | 42 | Captan | 43 |
| n-Butyl alcohol | 77 | Carbaryl, see 1-Naphthyl | CO |
| sec-Butyl alcohol | 42 | N-methylcarbamate | 63 |
| tert-Butyl alcohol | 42 | Carbofuran | 43 |
| n-Butylamine | 77 | Carbon black | 43 |
| Butylated hydroxytoluene, see | | Carbon dioxide | 43 |
| 2,6-Bis(1,1-dimethylethyl)- 4-methylphenol | 40 | Carbon disulfide | 43 |
| | 77 | Carbon monoxide | 43 |
| tert-Butyl chromate | " | Carbon tetrabromide | 43 |
| n-Butyl glycidyl ether, see (Butoxymethyl)oxirane | 41 | Carbon tetrachloride | 43 |
| n-Eutyl lactate | 42 | Carbonyl chloride | 44 |
| n-Butyl mercaptan, see | 41 | Carbonyl fluoride | 44 |
| o-sec-Butylphenol | 42 | Catechol, see 1,2-Dihydroxybenzene | 50 |
| | | | 30 |
| p-tert-Butyltoluene | 42 | CELLOSOLVE ^R acetate, see 2-Ethoxyethyl acetate | 53 |
| Cadmium and its compounds | 42 | | |

| Cellulose | 82 | p-Chloronitrobenzene | 44 |
|--|----|--|----|
| Cesium hydroxide | 44 | 1-Chloro-1-nitropropane | 44 |
| Chlordane | 44 | Chloropentafluoroethane | 45 |
| Chlorinated camphene, see Toxaphene | 86 | 2-Chloro-1-phenylethanone | 45 |
| Chlorinated diphenyl oxides | 85 | Chloropicrin, see Trichloronitromethane | 73 |
| Chlorine | 44 | Chloroplatinates, see | |
| Chlorine dioxide | 44 | Platinum, water-soluble compounds of | 68 |
| Chlorine trifluoride | 77 | beta-Chloroprene, see 2-Chloro-1,3-butadiene | 44 |
| Chloroacetaldehyde | 77 | o-Chlorostyrene | 45 |
| alpha-Chloroacetophenone, see 2-Chloro-1-phenylethanone | 45 | o-Chlorotoluene | 45 |
| Chloroacetyl chloride | 44 | 2-Chloro-6-(trichloro- methyl)pyridine | 45 |
| Chlorobenzene | 44 | | |
| o-Chlorobenzylidene | | Chlorpyrifos | 45 |
| malononitrile | 77 | Chromates | 45 |
| Chlorobromomethane, see Bromochloromethane | 41 | Chromium divalent compounds, see Chromium metal, | 45 |
| 2-Chloro-1,3-butadiene | 44 | | 40 |
| Chlorodifluoromethane | 44 | Chromium hexavalent compounds, see Chromates | 45 |
| Chlorodiphenyls, see Polychlorinated biphenyls | 86 | Chromium metal | 45 |
| 1-Chloro-2,3-epoxypropane | 44 | Chromium trivalent com- | |
| 2-Chloroethanol | 77 | pounds, see Chromium metal, | 45 |
| Chloroform, see Trichloromethane | 73 | Chromyl chloride | 45 |
| Chloromethyl ether, see | | Chrysene | 88 |
| Oxybis (chloromethane) | 65 | Clopidol | 45 |
| Chloromethyl methyl ether | 88 | Coal dust | 81 |

15

| Coal tar pitch volatiles | 85 | Cyclopentane | 47 |
|---|----|--|----|
| Cobalt metal and fume | 45 | Cyclotrimethylenetrini- tramine, see Hexahydro-1,3,5- | |
| Cobalt carbonyl | | trinitro-1,3,5-triazine | 56 |
| and hydrocarbonyl | 45 | | |
| Copper fume | 46 | Cyhexatin | 47 |
| Copper fume | 40 | 2,4-D, see (2,4-Dichloro- | |
| Copper dust and mists | 46 | phenoxy) acetic acid and its esters | 49 |
| Corundum, see alpha- | | | |
| Alumina | 82 | DDT, see 1,1,1-Trichloro-2,2- | 73 |
| Cotton dust, raw | 46 | bis (p-chlorophenyl) ethane | 13 |
| ootton dust, raw | 10 | Decaborane | 47 |
| Cresol (sum of isomers) | 46 | VIII- | |
| Cratanaldahada | AC | Demeton | 47 |
| Crotonaldehyde | 46 | Diacetone alcohol, see | |
| Crufomate | 46 | 4-Hydroxy-4-methyl- | |
| | | 2-pentanone | 57 |
| Cumene | 46 | 1,2-Diaminoethane | 47 |
| Cyanamide | 46 | 1,2-Diaminioethane | 41 |
| - Januari | | Diatomaceous earth, | |
| Cyanide, potassium and sodium | 46 | uncalcined | 82 |
| Cyanide, sodium; see Cyanide, | | Diazinon, see Phosphorothionic | |
| potassium and sodium | 46 | acid 0,0-diethyl 0- | |
| 1 | | (6-methyl-2-(1-methylethyl) | |
| Cyanogen | 46 | -4-pyrimidinyl)ester | 67 |
| Cyanogen chloride | 77 | Diazomethane | 47 |
| | | | |
| Cyclohexane | 46 | Diborane | 47 |
| Cyclohexanol | 46 | Dibromodifluoromethane | 47 |
| Getonekanor | 10 | 21310modifiaoi omethane | |
| Cyclohexanone | 47 | 1,2-Dibromoethane | 88 |
| Cyclohexene | 47 | 2-(Dibutylamino)ethanol | 48 |
| Cyclonexene | 41 | 2 (Dioutylamino)ctnanor | 10 |
| Cyclohexylamine | 47 | 2,6-Di-tert-butyl-p-cresol | |
| Cualanita and Hamabudan 1 9 5 | | see 2,6-Bis- | |
| Cyclonite, see Hexahydro-1,3,5 -trinitro-1,3,5-triazine | 56 | (1,1-dimethylethyl)-4- methylphenol | 40 |
| The Light Clubin | 30 | 5 4.1.5 | |
| Cyclopentadiene | 47 | Dibutyl phosphate | 48 |
| | | Dibutyl phthalate | 48 |

| Dichloroacetylene, see Dichloroethyne | 78 | (2,4-Dichlorophenoxy) acetic acid and its esters | 49 |
|--|----|--|----|
| o-Dichlorobenzene | 77 | 2-(2,4-Dichlorophenoxy) | |
| p-Dichlorobenzene | 48 | ethanol hydrogen sulfate sodium salt | 49 |
| 3,3'-Dichlorobenzidine | 88 | 1,2-Dichloropropane | 49 |
| Dichlorodifluoromethane | 48 | 1,3-Dichloropropene | 49 |
| 1,3-Dichloro-5,5-dimethyl- hydantoin | 48 | 2,2-Dichloropropionic acid | 49 |
| 1,1-Dichloroethane | 48 | 1,2-Dichloro-1,1,2,2-tetra- fluoroethane | 49 |
| 1,2-Dichloroethane | 48 | Dichlorvos | 49 |
| 1,1-Dichloroethene | 48 | Dichromates, see Chromates, | 45 |
| 1,2-Dichloroethene | 48 | Dicrotophos | 49 |
| 1,1-Dichloroethylene, see 1,1-Dichloroethene | 48 | 1,3-Dicyanobenzene, see m-Phthalodinitrile | 67 |
| 1,2-Dichloroethylene, see 1,2-Dichloroethene | 48 | Dicyclopentadiene | 49 |
| 2,2'-Dichloroethyl ether, see 1,1'-Oxybis (2-chloroethane) | 65 | Dicyclopentadienyl iron, see Bis(eta-cyclopentadienyl) iron | 40 |
| sym-Dichloroethyl ether, see | | Dieldrin | 49 |
| 1,1'-Oxybis (2-chloroethane) | 65 | Diethanolamine | 49 |
| Dichloroethyne | 78 | Diethylamine | 49 |
| Dichlorofluoromethane | 48 | 2-(Diethylamino)ethanol | 50 |
| Dichloromethane | 48 | Diethylenetriamine | 50 |
| Dichloromonofluoromethane, see Dichlorofluoromethane | 48 | Diethyl ether, see Ethoxyethane | 53 |
| sym-Dichloromethyl ether, see Oxybis (chloromethane) | 65 | Di-2-ethylhexylphthalate, see 1,2-Benzenedicarboxylic acid bis(2-ethylhexyl) ester | 39 |
| 1,1-Dichloro-1-nitroethane | 48 | Diethyl ketone, see 3-Pentanone | 66 |
| | | Diethyl phthalate | 50 |

| Difluorodibromomethane, see Dibromodifluoromethane | 47 | N,N-Dimethylformamide | 50 |
|--|------|--|-----|
| | | 2,6-Dimethyl-4-heptanone | 51 |
| Diglycidyl ether, see 2,2'- (Oxybis-(methylene))- bisoxirane | 65 | 1,1-Dimethylhydrazine | 51 |
| | | 2-(2,2-Dimethyl-1-oxopropyl)- | |
| 1,2-Dihydroxybenzene | 50 | H-indene-1,3(2H)-dione | 51 |
| 1,4-Dihydroxybenzene | 50 | Dimethyl phthalate | 51 |
| Diisobutyl ketone, see | | Dimethyl sulfate | 51 |
| 2,6-Dimethyl-4-heptanone | 51 | Dimpylate, see Phosphorothionic | c |
| Diisopropylamine | 50 | acid 0,0-diethyl 0-(6-methyl- 2-(1-methylethyl)- | |
| Diisopropyl ether, see | 0.5 | 4-pyrimidinyl) ester | 67 |
| 2,2'-Oxybis (propane) | 65 | Dinitolmide, see 2-Methyl- | |
| Dimethoxymethane | 50 | 3,5-dinitrobenzamide | 61 |
| N,N-Dimethylacetamide | 50 | Dinitrobenzene (sum of | |
| | 4. | isomers) | 51 |
| Dimethylamine | 50 | Dinitro-o-cresol | 51 |
| ar, ar-Dimethylaniline, see | | | |
| ar, ar-Dimethylbenzenamine | 50 | 3,5-Dinitro-o-toluamide, see 2-Methyl-3,5-dinitro- | |
| N,N-Dimethylaniline | 50 | benzamide | 61 |
| | F.O. | Dinitro taluana (aum of | |
| ar,ar-Dimethylbenzenamine | 50 | Dinitrotoluene (sum of isomers) | 51 |
| Dimethylbenzene (sum of | | | |
| isomers) | 50 | Di-sec-octyl phthalate, see 1,2-Benzenedicarboxylic acid | |
| 3,3'-Dimethylbenzidine, see | | bis(2-ethylhexyl)ester | 39 |
| 3,3'-Dimethyl-(1,1'-biphenyl) | 88 | 1,4-Dioxane | 51 |
| -4,4-'diamine | 00 | 1,4-Dioxane | 01 |
| 3,3'-Dimethyl-(1,1'-biphenyl)- | 00 | Dioxathion | 51 |
| 4,4'-diamine | 88 | Diphenyl, see Biphenyl | 40 |
| 1,3-Dimethylbutyl acetate, | | | F-1 |
| see sec-Hexyl acetate | 56 | N,N-Diphenylamine | 51 |
| Dimethylcarbamoyl chloride | 88 | Diphenyl ether, see 1,1'-Oxybisbenzene | 65 |
| Dimethyl-1, 2-dibromo-2- 2-dichloroethyl phosphate, | | Dipropylene glycol | |
| see Naled | 63 | monomethyl ether | 51 |

| Dipropyl ketone, see 4-Heptanone | 56 | Ethoxyethane | 53 |
|-------------------------------------|----|---|----|
| | | 2-Ethoxyethanol | 53 |
| Diquat | 52 | 2-Ethoxyethyl acetate | 53 |
| Disulfiram | 52 | Ethyl acetate | 53 |
| Disulfoton | 52 | | 10 |
| Diuron | 52 | Ethyl acrylate | 53 |
| m-Divinylbenzene | 52 | Ethyl alcohol, see Ethanol | 52 |
| • | | Ethylamine | 53 |
| Emery | 82 | Ethyl sec-amyl ketone, see | |
| Endosulfan | 52 | 5-Methyl-3-heptanone | 61 |
| Endrin | 52 | Ethylbenzene | 53 |
| Enflurane | 52 | Ethyl bromide | 53 |
| Epichlorohydrin, see | | Ethyl butyl ketone, see | |
| 1-Chloro-2,3-epoxypropane | 44 | 3-Heptanone | 55 |
| EPN, see 0-Ethyl 0-p-nitropheny | | Ethyl chloride | 53 |
| phenylphosphonothioate | 54 | Ethylene | 87 |
| 1,2-Epoxy-4-(epoxyethyl)- | 52 | Ethylene chlorohydrin, see | |
| cyclohexane | | 2-Chloroethanol | 77 |
| 1,2-Epoxypropane | 52 | Ethylenediamine, see | |
| 2,3-Epoxy-1-propanol | 52 | 1,2-Diaminoethane | 47 |
| Ethane | 87 | Ethylene dibromide, see | |
| 1,2-Ethanediamine, see | | 1,2-Dibromoethane | 88 |
| 1,2-Diaminoethane | 47 | Ethylene dichloride, see 1,2-Dichloroethane | 48 |
| Ethanedinitrile, see | | | |
| Cyanogen | 46 | Ethylene glycol, vapour | 78 |
| Ethanethiol | 52 | Ethylene glycol dinitrate | 53 |
| Ethanol | 52 | Ethylene glycol monomethyl | 50 |
| Ethanolamine, see | | ether, see 2-Methoxyethanol | 59 |
| 2-Aminoethanol | 38 | Ethylene glycol monomethyl ether acetate, see | |
| Ethion | 53 | 2-Methoxyethyl acetate | 59 |

| Ethylene oxide | 53 | Formamide | 55 |
|---|------|---|----------|
| Ethylenimine | 54 | Formic acid | 55 |
| Ethyl ether, see Ethoxyethane | 53 | Furfural | 55 |
| Ethyl formate | 54 | Furfuryl alcohol | 55 |
| Ethylidene chloride, see 1,1-Dichloroethane | 48 | Gasoline | 85 |
| 5-Ethylidene-2-norbornene | 78 | Germane, see Germanium tetrahydride | 55 |
| Ethyl mercaptan, see Ethanethiol | 52 | Germanium tetrahydride | 55 |
| N-Ethylmorpholine | 54 | Glass, fibrous or dust | 55 |
| O-Ethyl O-p-nitrophenyl phenylphosphonothioate | 54 | Glutaraldehyde Glycerin mist | 78 82 |
| Ethyl silicate | 54 | Glycidol, see 2,3-Epoxy-1-propanol | 52 |
| Fenamiphos | 54 | Glycol monoethyl ether, see | |
| Fensulfothion | 54 | 2-Ethoxyethanol | 53 |
| Fenthion | 54 | Grain dust | 55 |
| Ferbam | 54 | Graphite, natural | 81 |
| Ferric chloride and sulfate, see Iron salts, water-soluble | 57 | Graphite, synthetic | 82 |
| Ferrocene, see Bis(eta- cyclopentadienyl) iron | 40 | Gypsum Hafnium | 83 55 |
| Ferrovanadium dust | 54 | Halothane | 55 |
| Fibrous glass, see Glass | 55 | Helium | 87 |
| Fluorides | 54 | Hemimellimellitene, see Trimethylbenzene | 74 |
| Fluorine | 54 | Heptachlor | 55 |
| Fluorotrichloromethane, see Trichlorofluoromethane | 79 | n-Heptane | 55 |
| Fonofos | 54 | 2-Heptanone | 55 |
| Formaldehyde | 55 | 3-Heptanone | 55 |
| | 2242 | 4-Heptanone | 56 |

| Hexachloro-1,3-butadiene | 56 | Hydrogen peroxide | 56 |
|--|----|--|----------|
| Hexachlorocyclopentadiene | 56 | Hydrogen selenide | 57 |
| Hexachloroethane | 56 | Hydrogen sulfide | 57 |
| Hexachloronaphthalene | 56 | Hydroquinone, see 1,4-Dihydroxybenzene | 50 |
| Hexafluoroacetone | 56 | 4-Hydroxy-4-methyl-2- | |
| Hexahydro-1,3,5-trinitro- 1,3,5-triazine | 56 | pentanone 2-Hydroxypropyl acrylate | 57 57 |
| Hexametapol, see | | | |
| Hexamethylphosphoric triamide | 88 | Indene | 57 |
| Hexamethylphosphoramide, | | Indium and its compounds | 57 |
| see Hexamethylphosphoric triamide | 88 | Iodine | 78 |
| | | Iodoform | 57 |
| Hexamethylphosphoric triamide | 88 | Iron pentacarbonyl | 57 |
| n-Hexane | 56 | Iron salts, water-soluble | 57 |
| Hexane, other isomers of | 56 | | • |
| 2-Hexanone, | 56 | Iron welding fume or particulate, see Welding, | 86 |
| Hexone, see 4-Methyl-2- pentanone | 62 | Isoamyl acetate | 57 |
| • | | The second second | |
| sec-Hexyl acetate | 56 | Isoamyl alcohol | 57 |
| Hexylene glycol | 78 | Isobutyl acetate | 58 |
| HMPA or HMPT, see Hexa- methylphosphoric triamide | 88 | Isobutyl alcohol | 58 |
| Hydrazine | 56 | Isohexane, see Hexane | 56 |
| | | Isooctyl alcohol | 85 |
| Hydrogen | 87 | Isophorone, see 3,5,5- | |
| Hydrogenated terphenyls | 85 | Trimethyl-2-cyclohexen-1 | 80 |
| Hydrogen bromide | 78 | Isophalodinitrile, see | |
| Hydrogen chloride | 78 | m-Phthalodinitrile | 67 |
| Hydrogen cyanide | 78 | 2-Isopropoxyethanol | 58 |
| Hydrogen fluoride | 78 | Isopropyl acetate | 58 |

| Isopropylacetone, see | | MEK, see 2-Butanone | 41 |
|-------------------------------|-----|--|----|
| 4-Methyl-2-pentanone | 62 | men, see 2-butanone | 41 |
| Isopropyl alcohol | 58 | Mercaptoacetic acid, see | 70 |
| Isopropyi areonoi | 30 | Thioglycolic acid | 72 |
| Isopropylamine | 58 | Mercury, compounds of | 89 |
| N-Isopropylaniline | 58 | Mesitylene, see | |
| Isopropyl ether, see | | Trimethylbenzene | 74 |
| 2,2'-Oxybis(propane) | 65 | Mesityl oxide | 59 |
| Isopropyl glycidyl ether, see | | Methacrylic acid | 59 |
| ((1-Methylethoxy) methyl)- | 0.1 | | |
| oxirane | 61 | Methacrylonitrile, see 2-Methyl-2-propenenitrile | 62 |
| Kaolin | 83 | 2 methyr 2 propenentiale | 02 |
| Vatana | 5.0 | Methane | 87 |
| Ketene | 58 | Methanethiol | 59 |
| Limestone | 83 | | |
| Lindane | 58 | Methanol | 59 |
| Lindane | 30 | Methomyl | 59 |
| Liquified petroleum gas, | | | |
| see L.P.G. | 85 | Methoxychlor | 59 |
| Lithium hydride | 58 | 2-Methoxyethanol | 59 |
| L.P.G. (Liquified petroleum | | 2-Methoxyethyl acetate | 59 |
| gas) | 85 | | |
| Magnesite | 83 | 4-Methoxyphenol | 60 |
| | 00 | 1-Methoxy-2-propanol | 60 |
| Magnesium oxide fume | 58 | Mathyl agatata | 60 |
| Malathion | 58 | Methyl acetate | 00 |
| | | Methylacetylene, see Propyne | 69 |
| Maleic anhydride | 58 | Methylacetylene - propadiene | |
| Manganese, dust and compounds | 59 | mixture (MAPP) | 85 |
| Manganese-containing fume | 59 | Methyl acrylate | 60 |
| manganese containing rune | 00 | methyl acrylate | 00 |
| Manganese cyclo- | 50 | alpha-Methylacrylonitrile, see | co |
| pentadienyltricarbonyl | 59 | 2-Methyl-2-propenenitrile | 62 |
| Manganese tetroxide | 59 | Methylal, see Dimethoxy- | |
| Marble, see Calcium | | methane | 50 |
| carbonate | 82 | Methyl alcohol, see Methanol | 59 |

| Methylamine | 60 | 4,4'-Methylenedianiline | 61 |
|--|----|--|----|
| Methyl amyl alcohol, see 4-Methyl-2-pentanol | 62 | ((1-Methylethoxy)methyl)- oxirane | 61 |
| Methyl n-amyl ketone, see 2-Heptanone | 55 | Methyl ethyl ketone or MEK, see 2-Butanone | 41 |
| N-Methylaniline, see N-Methylbenzenamine | 60 | Methyl ethyl ketone peroxides | 78 |
| N-Methylbenzenamine | 60 | Methyl formate | 61 |
| Methylbenzene | 60 | 5-Methyl-3-heptanone | 61 |
| Methyl bromide | 60 | 5-Methyl-2-hexanone | 61 |
| 3-Methyl-2-butanone | 60 | Methylhydrazine | 78 |
| Methyl n-butyl ketone, see 2-Hexanone | 56 | Methyl iodide | 61 |
| Methyl CELLOSOLVE ^R acetate, see 2-Methoxyethanol | 59 | Methyl isoamyl alcohol, see 4-Methyl-2-pentanol | 62 |
| Methyl chloride | 60 | Methyl isoamyl ketone, see 5-Methyl-2-hexanone | 61 |
| Methylchloroform, see 1,1,1-Trichloroethane | 73 | Methyl isobutyl carbinol, see 4-Methyl-2-pentanol | 62 |
| Methyl 2-cyanoacrylate | 60 | Methyl isobutyl carbinol | |
| Methylcyclohexane | 60 | acetate, see sec-Hexyl acetate | 56 |
| 2-Methylcyclohexanol | 60 | Methyl isobutyl ketone, see 4-Methyl-2-pentanone | 62 |
| 2-Methylcyclohexanone | 61 | Methyl isopropyl ketone, see 3-Methyl-2-butanone | 60 |
| 2-Methylcyclopentadienyl- manganese tricarbonyl | 61 | | 00 |
| Methyl demeton | 61 | Methyl mercaptan, see Methanethiol | 59 |
| 2-Methyl-3,5-dinitrobenzamide | 61 | Methyl methacrylate | 61 |
| 4,4'-Methylenebis- (2-chloroaniline) | 61 | Methyl parathion | 62 |
| Methylene chloride, see | | 2-Methylpentane, see Hexane | 56 |
| Dichloromethane | 48 | 4-Methyl-2-pentanol | 62 |

| | _ | _ | - |
|----|---|---|---|
| | | | |
| 23 | | | |
| 40 | | | |

| 4-Methyl-2-pentanone | 62 | Morpholine | 63 |
|--|----------|---|----------|
| 2-Methyl-2-propenenitrile | 62 | Naled | 63 |
| Methyl propyl ketone, see 2-Pentanone | 66 | Naphtha, varnish makers' and painters', see V.M. & P. Naphtha | 86 |
| Methyl silicate, see Tetramethoxysilane | 72 | Naphthalene | 63 |
| ar-Methylstyrene, see Vinyltoluene | 75 | beta-Naphthylamine 1-Naphthyl N-methyl- carbamate | 88 63 |
| alpha-Methylstyrene | 62 | alpha-Naphthylthiourea | 63 |
| 1-Methyl-2,4,6-trinitro- benzene | 62 | Neohexane, see Hexane | 56 |
| Metribuzin | 62 | Neon | 87 |
| Mevinphos | 62 | Nickel | 63 |
| Mica | 81 | Nickel carbonyl | 63 |
| Mineral oil, see Oil, mineral | 85 | Nickel oxides, see Nickel, | 63 |
| Mineral wool fibre | 83 | Nickel sulfides, see Nickel, | 63 |
| MOCA ^R , see 4,4-Methylenebis-(2-chloroaniline) | 61 | Nickel, water-soluble compounds of | 63 |
| Molybdates, see Molybdenum trioxide | 62 | Nicotine | 63 |
| Molybdenum dioxide, see Molybdenum metal, | 62 | Nitramine | 63 |
| Molybdenum disulfide, see Molybdenum metal, | 62 | Nitrapyrin, see 2-Chloro- 6-(trichloromethyl) pyridine | 45 |
| Molybdenum metal, dioxide | 22 | Nitric acid | 63 |
| and disulfide Molybdenum trioxide | 62 62 | Nitric oxide | 63 |
| Monocrotophos | 62 | p-Nitroaniline | 64 |
| Monomethylaniline, see N-Methylbenzenamine | 60 | Nitrobenzene | 64 |
| Monomethylhydrazine, see Methylhydrazine | 78 | 4-Nitrobiphenyl | 88 |

| p-Nitrochlorobenzene, see p-Chloronitrobenzene | 44 | 2,2'-(Oxybis(methylene))- bisoxirane | 65 |
|---|----|--|----------|
| Nitroethane | 64 | 2,2'-Oxybis (propane) | 65 |
| Nitrogen | 87 | Oxygen difluoride | 78 |
| Nitrogen dioxide | 64 | Oxygen fluoride, see Oxygen difluoride | 78 |
| Nitrogen fluoride, see Nitrogen trifluoride | 64 | Ozone | 65 |
| Nitrogen trifluoride | 64 | PAHs, see Coal tar pitch volatiles | 85 |
| Nitroglycerine | 64 | Paper fibre, see Cellulose | 82 |
| Nitromethane | 64 | Paraffin wax fume | 85 |
| 1-Nitropropane | 64 | | |
| 2-Nitropropane | 64 | Paraquat | 65 |
| N-Nitrosamines | 88 | Parathion | 65 |
| N-Nitrosodimethylamine, see N-Nitrosamines | 88 | Particulate polycyclic aromatic hydrocarbons, see Coal tar pitch volatiles | 85 |
| Nitrotoluene (sum of isomers) | 64 | PCBs, see Polychlorinated biphenyls | 86 |
| Nitrous oxide | 64 | Pentaborane | 65 |
| Nonane | 64 | | 66 |
| Octachloronaphthalene | 65 | Pentachloronaphthalene | 0 |
| Octane | 65 | Pentachlorophenol | 66 |
| Oil, mineral - mist | 85 | Pentaerythritol | 83 |
| Osmium tetroxide | 65 | Pentane | 66 |
| Oxalic acid | 65 | 2-Pentanone 3-Pentanone | 66 66 |
| 1,2-Oxathiolane 2,2-dioxide | 88 | Perchloroethylene, see Tetrachloroethylene | 71 |
| 1,1'-Oxybisbenzene | 65 | | |
| 1,1'-Oxybis(2-chloroethane) | 65 | Perchloromethyl mercaptan, see Trichloromethanesulfenyl | 73 |
| Ovybis (chloromethane) | 65 | chloride | 13 |

| Perchloryl fluoride | 66 | Phosphorothionic acid 0,0-diethyl 0-(6-methyl)- | |
|---|----|--|----|
| Perlite | 81 | 2-(1-methylethyl) -4-pyrimidinyl)ester | 67 |
| Persulfates, alkali metal | 66 | Phosphorus (yellow or white) | 67 |
| Phenacyl chloride, see 2-Chloro-1-phenylethanone | 45 | Phosphorus oxychloride | 67 |
| Phenol | 66 | Phosphorus pentachloride | 67 |
| Phenothiazine | 66 | Phosphorus pentasulfide | 67 |
| (Phenoxymethyl)oxirane | 66 | Phosphorus trichloride | 67 |
| p-Phenylenediamine | 66 | Phosphotungstic acids and salts, see Tungsten, water- | |
| Phenyl ether, see 1,1'-Oxybisbenzene | 65 | soluble compounds of | 75 |
| Phenylethylene, see | 00 | Phthalic anhydride | 67 |
| Ethenylbenzene | 53 | m-Phthalodinitrile | 67 |
| Phenyl glycidyl ether, see (Phenoxymethyl) oxirane | 66 | Picloram, see 4-Amino 3,5,6-trichloro-2- pyridinecarboxylic acid | 38 |
| Phenylhydrazine | 66 | Picric acid, see 2,4,6- | 00 |
| Phenyl mercaptan, see Benzenethiol | 40 | Trinitrophenol | 74 |
| N-Phenyl-beta-naphthylamine | 88 | Pindone, see 2-(2,2-Dimethyl- 1-oxopropyl)-H-indene- | |
| Phenylphosphine | 79 | 1,3(2H)-dione | 51 |
| 2-Phenylpropene, see alpha- | | Piperazine dihydrochloride | 67 |
| Methylstyrene Methylstyrene | 62 | PIVAL ^R , see 2-(2,2-Dimethyl- 1-oxopropyl)-H-indene- | |
| Phorate | 67 | 1,3(2H)-dione | 51 |
| PHOSDRIN ^R , see Mevinphos | 62 | 2-Pivaloyl-1,3-indandione, see 2-(2,2-Dimethyl- | |
| Phosgene, see Carbonyl chloride | 44 | 1-oxopropyl)-H-indene- 1,3(2H)-dione | 51 |
| Phosphine | 67 | Plaster of Paris, see Calcium sulphate | 82 |
| Phosphoric acid | 67 | Platinum metal | 68 |
| | | Platinum, water-soluble compounds of | 68 |

| Polychlorinated biphenyls (PCBs) | 86 | Propylene oxide, see 1,2-Epoxypropane | 52 |
|---|----|---|----------|
| Polycyclic aromatic hydro- carbons, see Coal tar | | Propylenimine | 68 |
| pitch volatiles | 85 | n-Propyl nitrate | 68 |
| Portland cement | 83 | Propyne | 69 |
| Potassium cyanide, see Cyanide, | 46 | Pseudocumene, see Trimethylbenzene | 74 |
| Potassium hydroxide | 79 | Pyrethrum | 69 |
| Potassium persulfate, see Persulfates | 66 | Pyridine | 69 |
| Precipitated silica | 83 | Pyrocatechol, see 1,2-Dihydroxybenzene | 50 |
| Propane | 87 | Quinone | 69 |
| 1,3-Propane sultone, see 1,2-Oxathiolane 2,2-dioxide | 88 | RDX ^R , see Hexahydro- 1,3,5-trinitro-1,3,5-triazine56 | |
| Propargyl alcohol | 68 | Resorcinol | 69 |
| ((2-Propenyloxy)methyl) oxirane | 68 | Rhodium, metal and water-insoluble compounds of | 69 |
| beta-Propiolactone | 68 | Rhodium, water-soluble compounds of | 69 |
| Propionic acid | 68 | Ronnel | 69 |
| Propoxur | 68 | Rosin core solder | 00 |
| n-Propyl acetate | 68 | pyrolysis products | 86 |
| n-Propyl alcohol | 68 | Rotenone | 69 |
| Propylene | 87 | Rouge | 83 |
| Propylene dichloride, see 1,2-Dichloropropane | 49 | Rubber solvent | 86 |
| 1,2-Propylene glycol dinitrate | 68 | Selenium and its compounds Selenium hexafluoride | 69 70 |
| Propylene glycol monomethyl ether, see 1-Methoxy-2-propanol | 60 | SESONE ^R , see 2-(2,4-Dichloro- phenoxy)ethanol hydrogen sulfate sodium salt | 49 |

| Silane | 70 | Styrene | 70 |
|---|----------|---|----------|
| Silica gel | 83 | Subtilisins | 79 |
| Silicon | 83 | Sucrose | 83 |
| Silicon carbide | 83 | Sulfotep, see Tetraethyl dithionopyrophosphate | 72 |
| Silicon tetrahydride, see Silane | 70 | Sulfur dioxide | 70 |
| Silver, metal | 70 | Sulfur hexafluoride | 70 |
| Silver, water-soluble compounds | 70 | Sulfuric acid | 70 |
| Soapstone | 81 | Sulfur monochloride | 79 |
| Sodium azide | 79 | Sulfur pentafluoride | 79 |
| Sodium bisulfite | 70 | Sulfur tetrafluoride | 79 |
| Sodium cyanide, see Cyanide, potassium and sodium | 46 | Sulfuryl fluoride Sulprofos | 71 71 |
| Sodium 2,4-dichloro- phenoxyethyl sulfate, see 2-(2,4-Dichloro- phenoxy)ethanol hydrogen | 10 | SYSTOX ^R , see Demeton 2,4,5-T, see (2,4,5-Trichloro- phenoxy)acetic acid and esters of | 74 |
| sulfate sodium salt Sodium fluoroacetate | 49 70 | Talc, containing no asbestos | 81 |
| Sodium hydroxide | 79 | Tantalum, metal and oxide | 84 |
| Sodium metabisulfite | 70 | TEDP, see Tetraethyl dithionopyrophosphate | 72 |
| Sodium persulfate, see Persulfates | 66 | Tellurium and its compounds | 71 |
| Starch | 83 | Tellurium hexafluoride | 71 |
| Stearates | 83 | Temephos | 71 |
| Stibine, see Antimony hydride | 39 | TEPP, see Tetraethyl pyrophosphate | 72 |
| Stoddard solvent | 86 | Terphenyls (sum of isomers) | 79 |
| Strychnine | 70 | to phony to toom of toom of o | |

| Terphenyls, 40% hydrogenated, see Hydrogenated terphenyls | 85 | Thiram, see Bis(dimethylthiocarbamoyl) disulfide | 40 |
|---|----|--|----|
| 1,1,2,2-Tetrabromoethane | 71 | Tin, metal, oxide and inorganic compounds of | 72 |
| 1,1,1,2-Tetrachloro-2,2- difluoroethane | 71 | Tin, organic compounds of | 73 |
| 1,1,2,2-Tetrachloro- 1,2-difluoroethane | 71 | Titanium dioxide | 84 |
| 1,1,2,2-Tetrachloroethane | 71 | TNT, see 1-Methyl-2,4,6- trinitrobenzene | 62 |
| Tetrachloroethylene | 71 | o-Tolidine, see 3,3'-Dimethyl- (1,1'-bipheny1)-4,4'- | |
| Tetrachloronaphthalene | 71 | diamine | 88 |
| Tetraethyl dithiono- pyrophosphate | 72 | Toluene, see Methylbenzene | 60 |
| Tetraethyl pyrophosphate | 72 | Toluidine (sum of o-,m-and p-isomers) | 73 |
| Tetrahydrofuran | 72 | Toluol, see Methylbenzene | 60 |
| Tetramethoxysilane | 72 | Toxaphene | 86 |
| Tetramethylsuccino- dinitrile | 72 | Tributyl phosphate | 73 |
| Tetramethylthiuram disulfide, see Bis- (dimethylthiocarbamoyl) | 40 | Tricarbonyl(eta-(2- methylcyclopentadienyl))- manganese, see 2-Methyl- cyclopentadienyl manganese | 01 |
| disulfide | 40 | tricarbonyl | 61 |
| Tetranitromethane | 72 | Trichloroacetic acid | 73 |
| Tetrasodium pyrophosphate | 72 | 1,2,4-Trichlorobenzene | 79 |
| Tetryl, see Nitramine | 63 | 1,1,1-Trichloro-2,2- bis(p-chlorophenyl)ethane | 73 |
| Thallium, water-soluble compounds of | 72 | 1,1,1-Trichloroethane | 73 |
| 4,4'-Thiobis(6-tert-butyl-m-cresol) | 72 | 1,1,2-Trichloroethane | 73 |
| Thioglycolic acid | 72 | Trichloroethylene | 73 |
| Thiophenol, see Benzenethiol | 40 | Trichlorofluoromethane | 79 |
| Thionyl chloride | 79 | Trichloromethane | 73 |

| Trichloromethanesulfenyl chloride | 73 | Triphenyl phosphate | 74 |
|---|------|--|----|
| Trichloronaphthalene | 73 | Tungsten, water-insoluble compounds of | 75 |
| Trichloronitromethane | 73 | Tungsten, water-soluble compounds of, including | |
| (2,4,5-Trichlorophenoxy) acetic acid and esters of | 74 | tungstic acids, phospho- tungstic acids and their salts | 75 |
| 1,2,3-Trichloropropane | 74 | Tungstic acids and salts, | |
| 1,1,2-Trichloro-1,2,2- trifluoroethane | 74 | see Tungsten, water- soluble compounds of | 75 |
| Tri-ortho-cresyl phosphate | 74 | Turpentine | 86 |
| Tricyclohexyltin hydroxide, see Cyhexatin | 47 | Uranium (natural) and its compounds | 75 |
| Triethylamine | 74 | n-Valeraldehyde | 75 |
| Trifluorobromomethane, see Bromotrifluoromethane | : 41 | Vanadium respirable dust and fume | 75 |
| Trimellitic anhydride | 74 | Vegetable oils, mists | 84 |
| Trimethylamine | 74 | Vinyl acetate | 75 |
| Trimethylbenzene (sum of isomers) | 74 | Vinyl benzene, see Ethenylbenzene | 53 |
| 3,5,5-Trimethyl-2-cyclo- hexen-1-one | 80 | Vinyl bromide | 75 |
| Trimethyl phosphite | 74 | 4-Vinylcyclohexené dioxide, see 1,2-Epoxy-4- (epoxyethyl)cyclohexane | 52 |
| 2,4,6-Trinitrophenol | 74 | Vinylidene chloride, see | 02 |
| 2,4,6-Trinitrophenylmethyl- nitramine, see Nitramine | 63 | 1,1-Dichloroethene | 48 |
| 2,4,6-Trinitrotoluene, see 1-Methyl-2,4,6-trinitro- | | Vinyltoluene (m-and p- isomers) | 75 |
| benzene Triorthocresyl phosphate, | 62 | V.M. & P. Naphtha | 86 |
| see Tri-ortho-cresyl | 7.4 | Warfarin | 75 |
| phosphate | 74 | Welding fume or particulate | 86 |
| Triphenyl amine | 74 | Wood dust | 76 |

THE ONTARIO GAZETTE

| Xenylamine, see (1,1'-Biphenyl)-4-amine | 88 | Yttrium, metal and compounds | 76 |
|--|----|------------------------------|----|
| | | Zinc chloride fume | 76 |
| Xylene (sum of isomers), see . Dimethybenzene | 50 | Zinc chromates | 76 |
| m-Xylene-alpha, alpha'-diamine | 80 | Zinc oxide dust | 84 |
| | 00 | Zinc oxide fume | 76 |
| Xylidene (sum of isomers), see ar,ar-Dimethylbenzenamine | 50 | Zinc stearate, see Stearates | 83 |
| | | Zirconium compounds | 76 |

PART 2A Calculation of Exposure Values

- The time-weighted average exposure value (TWAEV) is the average
 of the airborne concentrations of a biological or chemical agent
 determined from air samples of the airborne concentrations to
 which a worker is exposed in a work day or a work week.
- 2. The short-term exposure value (STEV) is the maximum airborne concentration of a biological or chemical agent to which a worker is exposed in any fifteen minute period determined from a single sample or a time-weighted average of sequential samples taken during such period.
- The ceiling exposure value (CEV) is the maximum airborne concentration of a biological or chemical agent to which a worker is exposed at any time.
- 4. The airborne concentrations of the agent are expressed as parts of the agent per million parts of air by volume (ppm) or as milligrams of the agent per cubic metre of air (mg/m³).
- 5. Air sampling of the airborne concentrations of an agent is not required for the full period of a work day or a work week where the air sampling is representative of airborne concentrations of an agent likely to be present during the period.
- 6. The method of air sampling, the number and volume of the air samples and the method of analyses of the air samples shall be determined according to the nature of the operations or processes and the characteristics of the agent in accordance with recognized industrial hygiene practice.

- 7. In determining exposure to airborne concentrations of a biological or chemical agent, no regard shall be had or taken to the wearing or use by a worker of respiratory equipment.
- 8. The daily and weekly time-weighted exposure values shall be calculated as follows:
 - (a) $C_1T_1 + C_2T_2 + + C_nT_n =$ cumulative daily or weekly exposure, where C_i is the concentration found in an air sample and T_i is the total time in hours to which the worker is taken to be exposed to concentration C_i in a work day or a work week for i taking on the values of 1, 2, ..., n.
 - (b) The time-weighted average exposure shall be calculated by dividing the cumulative daily exposure by 8 and the weekly exposure by 40 respectively.
- 9. For mixtures of airborne chemical agents which exert an additive health effect and when analytical results of individual airborne agents are available, the following formula shall be used:

$$\frac{C_1}{L_1} + \frac{C_2}{L_2} + \cdots + \frac{C_n}{L_n} = E$$

where $\mathbf{C_1},\ \mathbf{C_2},\ \dots$, $\mathbf{C_n}$ are the concentrations found in the air sample;

and L_1 , L_2 , ..., L_n are the respective exposure values for the agents set out in the Schedule.

The sum of these ratios, E, shall not exceed 1.

When calculating E for time-weighted average exposures, C shall be taken to be the time-weighted average exposure value calculated for each agent.

10. Paragraph 9 does not apply where the agents have widely different health effects. In such circumstances, independent exposure values for each agent shall be used and calculated in accordance with paragraph 8.

PART 2B Calculation of Exposure Values Where a STEV or a CEV is Not Indicated

Where a STEV or a CEV is not set out for a biological or chemical agent listed in Part 4, 6, 7 or 8 of this Schedule, a worker shall not be exposed to a concentration of the biological or chemical agent that exceeds,

- (a) three times the TWAEV set out in the Schedule for the agent for any period of 30 minutes, and
- (b) five times the TWAEV set out in the Schedule for the agent for any period of time.

PART 3 Explanatory Notes on Chemical Names, CAS Reg. Nos., and Other Notations

Parts 4 to 11 of this Schedule deal with biological and chemical agents and contain names of the agents, Chemical Abstracts Service Registry Numbers, and some notations.

Chemical Names

The chemical names used in this Schedule conform with nomenclature rules of the International Union of Pure and Applied Chemistry or with common usage. An agent will only be listed under one name and its other names (i.e.: generic, chemical, common, and trade) will be cross-referenced in the index.

Numerals and italicized prefixes (e.g.: o-, p-, n-, O-, N-, sec-, tert-) are disregarded when listing the main entries in alphabetical order, but are used to assign the order when main entry names are identical. For example, "N-methylaniline" is listed under "m", and "sec-butyl acetate" precedes "tert-butyl acetate".

Chemical Abstracts Service Registry Number

The Chemical Abstracts Service Registry Number (CAS Reg. No.) is a unique numerical identifier assigned to a chemical substance in the CAS registry system by the Chemical Abstracts Service (P.O. Box 3012, Colombus, Ohio, 43210). The CAS Reg. No. itself has no chemical or structural significance; it is merely a computer-verifiable number assigned in sequential order to each agent as it is entered in the CAS registry system. Some of the CAS Reg. Nos. listed in this guide were assigned by the CAS under contract for the United States Environmental Protection Agency (U.S. EPA). CAS Reg. Nos. have been used as chemical or biological identifiers in inventories and computer literature-retrieval systems.

The CAS Reg. No. has the format (xxxxxx-xx-x) and consists of up to 9 digits, separated by hyphens into 3 groups: (1) the first group has up to 6 digits; (b) the second always contains 2 digits; and (c) the third contains 1 digit.

Under the CAS Reg. No. heading some entries other than the CAS Reg. No. have been inserted; e.g., (a), (b), (c), as shown below:

Example: Agent

Symbol Comment CAS Reg. No.

(a) A CAS Reg. No. has not been assigned.

Cotton dust, raw
(a)

(b) The CAS Reg. No. is for the parent substance only. In the example given, cobalt is a parent compound. CAS Reg. Nos. have been assigned to individual compounds; e.g.: cobalt chloride. Cobalt and its compounds (as cobalt) (7440-48-4), (b)

(c) A CAS Reg. No. exists but has not been included here because reference to the CAS Reg. No. data base could be misleading. Glass, fibrous or dust
(c)

Notations

The notation "skin" following the name of an agent in this Schedule indicates that direct or airborne contact with the agents may result in significant absorption of the agent through the skin, mucous membranes or eyes. Vehicles, such as certain solvents, may enhance the rate of skin absorption. Inclusion of this notation is intended to suggest that

preventative action should be taken against absorption of the agent through the skin, mucous membranes or eyes.

(As...) - In the lists of biological and chemical agents, the notation "(as...)", e.g.: "nickel carbonyl (as nickel)", is used to indicate that the agent is to be analyzed for the substance indicated in parentheses, nickel in this example, rather than nickel carbonyl.

PART 4 Time-Weighted Average Exposure Values (TWAEV) and Short-Term Exposure Values (STEV) for Biological and Chemical Agents

| AGENT (CAS Reg. No.) | TW. | MEV mg/m ³ | ppm | rev mg/m ³ |
|--------------------------------------|-----|--------------------------|----------|--------------------------|
| Acetaldehyde (75-07-0) | 100 | 180 | : 150 | 270 |
| Acetic acid (64-19-7) | 10 | 25 | 15 | 37 |
| Acetone (67-64-1) | 750 | 1,780 | 1,000 | 2,375 |
| Acetonitrile (75-05-8) — Skin | 40 | 67 | 60 | 100 |
| 2-(Acetyloxy) benzoic acid (50-78-2) | - | 5 | 1 | _ |
| Acrolein (107-02-8) | 0.1 | 0.23 | 0.3 | 0.7 |
| Acrylamide (79-06-1) — Skin | - | 0.03 | PA. | The re- |
| Acrylic acid (79-10-7) | 10 | 29 | | - |
| Aldrin* (309-00-2) Skin | - | 0.25 | - | - |
| Allyl alcohol (107-18-6) — Skin | 2 | 5 | 4 | 10 |
| Allyl chloride (107-05-1) | 1 | 3 | 2 | , 6 |
| Allyl propyl disulfide (2179-59-1) | 2 | 12 | 3 | 18 |
| Aluminum-powder (7429-90-5) | - | 5 | - | - 1 |

^{*} Not licenced for use in Ontario as a pesticide.

PART 4 Time-Weighted Average Exposure Values (TWAEV) and Short-Term Exposure Values (STEV) for Biological and Chemical Agents

| AGENT (CAS Reg. No.) | TWA ppm | EV mg/m ³ | STEV ppm mg/m ³ |
|--|------------|-------------------------|----------------------------|
| Aluminum, alkyl derivatives of (7429-90-5), (b) | | 2 | |
| Aluminum, metal and oxide dust (7429-90-5), (b) | - | 10 | I I I I I I |
| Aluminum, water-soluble compounds of (7429-90-5), (b) | - | 2 | |
| 2-Aminoethanol (141-43-5) | 3 | 7.5 | 6 15 |
| 2-Aminopyridine (504-29-0) | 0.5 | 2 | |
| 3-Amino-1H-1,2,4-triazole (61-82-5) | - | 0.2 | 1======= |
| 4-Amino-3,5,6-trichloro- 2-pyridinecarboxylic acid (1918-02-1) | _ | 10 | - 20 |
| Ammonia (7664-41-7) | 25 | 17 | 35 24 |
| Ammonium chloride fume (12125-02-9) | - 1 | 10 | - 20 |
| Ammonium perfluoro- octanoate (3825-26-1) | - | 0.1 | 1, 15, 1-2 |
| Ammonium sulfamate (7773-06-0) | - | 10 | 0 - 1 |
| n-Amyl acetate (628-63-7) | 100 | 530 | 1 - 1 - 1 |

PART 4 Time-Weighted Average Exposure Values (TWAEV) and Short-Term Exposure Values (STEV) for Biological and Chemical Agents

| AGENT (CAS Reg. No.) | TW/ | MEV mg/m ³ | STEV ppm mg/m ³ |
|--|------|-----------------------|----------------------------|
| sec-Amyl acetate (53496-15-4) | 125 | 660 | |
| Aniline and homologues (62-53-3) — Skin | 2 | 8 | - 11 |
| Anisidine (sum of o-and p-isomers), (29191-52-4) — Skin Antimony and its com- | 0.1 | 0.5 | |
| pounds, including antimony trioxide handling and use, but excluding stibine (as antimony) (7440-36-0), (b) | 4 | 0.5 | |
| Antimony hydride (7803-52-3) | 0.1 | 0.5 | 10-55 |
| Arsine (7784-42-1) | 0.05 | 0.16 | |
| Atrazine (1912-24-9) | - | 5 | - 11- |
| Azinphos-methyl (86-50-0) — Skin | - | 0.2 | |
| Barium carbonate, chloride, nitrate, or oxide (as barium) | | | |
| (7440-39-3), (b) | - | 0.5 | |
| Benomyl (17804-35-2) | 0.8 | 9 | |
| 1,2-Benzenedicarboxylic acid bis(2-ethylhexyl) ester (117-81-7) | - 1 | 5 | - 10 |

PART 4 Time-Weighted Average Exposure Values (TWAEV) and Short-Term Exposure Values (STEV) for Biological and Chemical Agents

| AGENT (CAS Reg. No.) | TW. | AEV mg/m ³ | STEV ppm mg/m ³ |
|---|-----|--------------------------|-------------------------------|
| Benzenethiol (108-98-5) | 0.5 | 2.2 | - 1/- |
| Benzoyl peroxide (94-36-0) | - | 5 | |
| Benzyl chloride (100-44-7) | 1 | 5 | 712 |
| Beryllium and its compounds (as beryllium) (7440-41-7), (b) | _ | 0.002 | - F |
| Biphenyl (92-52-4) | 0.2 | 1.3 | - 1 |
| Bis(eta-cyclopentadienyl) iron (102-54-5) | - 1 | 10 | |
| 2,6-Bis(1,1-dimethylethyl)- 4-methylphenol (128-37-0) | _ | 10 | -0-011 |
| Bis(dimethylthiocarbonyl) disulfide (137,-26-8) | _ | 5 | Armi |
| Bismuth telluride (1304-82-1) | - | 10 | . i |
| Bismuth telluride, selenium-doped (1304-82-1), (b) | - | 5 | |
| Borates, tetra, sodium salts (1303-96-4), (b) Anhydrous) Decahydrate Pentahydrate | | 1 5 1 | |

PART 4 Time-Weighted Average Exposure Values (TWAEV) and Short-Term Exposure Values (STEV) for Biological and Chemical Agents

| | | | |
|--------------------------------------|-------|-------------------------|-------------------------------|
| AGENT (CAS Reg. No.) | TWA: | EV mg/m ³ | STEV ppm mg/m ³ |
| Boron oxide (1303-86-2) | 10 | - | -11 - |
| Bromacil (314-40-9) | 1 | 11 | |
| Bromine (7726-95-6) | 0.1 | 0.7 | 0.3 2 |
| Bromine pentafluoride (7789-30-2) | 0.1 | 0.7 | -1 |
| Bromochloromethane (74-97-5) | 200 | 1,060 | 250 1,320 |
| Bromoform (75-25-2) — Skin | 0.5 | 5 | |
| Bromotrifluoromethane (75-63-8) | 1,000 | 6,085 | |
| 1,3-Butadiene (106-99-0) | 10 | 22 | 3.77 |
| Butane (106-97-8) | 800 | 1,900 | |
| 1-Butanethiol (109-79-5) | 0.5 | 1.8 | 1- 1- |
| 2-Butanone (78-93-3) | 200 | 590 | 300 885 |
| 2-Butoxyethanol (111-76-2) — Skin | 25 | 120 | |
| (Butoxymethyl)oxirane (2426-08-6) | 25 | 133 | |
| | | | |

PART 4 Time-Weighted Average Exposure Values (TWAEV) and Short-Term Exposure Values (STEV) for Biological and Chemical Agents

| AGENT (CAS Reg. No.) | TWA | EV mg/m ³ | STEV mg/m ³ |
|---|-----|-------------------------|------------------------|
| n-Butyl acetate (123-86-4) | 150 | 710 | 200 950 |
| sec-Butyl acetate (105-46-4) | 200 | 950 | |
| tert-Butyl acetate (540-88-5) | 200 | 950 | |
| n-Butyl acrylate (141-32-2) | 10 | 52 | - 1 - 2 |
| sec-Butyl alcohol (78-92-2) | 100 | 303 | 150 454 |
| tert-Butyl alcohol (75-65-0) | 100 | 303 | 150 454 |
| n-Butyl lactate (138-22-7) | 5 | 30 | - 1-1-1- |
| o-sec-Butylphenol (89-72-5) Skin | 5 | 31 | - |
| p-tert-Butyltoluene (98-51-1) | 10 | 60 | 20 120 |
| Cadmium and its compounds (as cadmium) (7440-43-9), (b) | - | 0.05 | |
| Cadmium oxide, production (as cadmium) (1306-19-0) | - | 0.05 | |
| Calcium cyanamide (156-62-7) | - | 0.5 | - |

PART 4 Time-Weighted Average Exposure Values (TWAEV) and Short-Term Exposure Values (STEV) for Biological and Chemical Agents

| AGENT (CAS Reg. No.) | TW ppm | AEV mg/m ³ | S' ppm | rev mg/m ³ |
|--|-----------|-----------------------|--------|--------------------------|
| Calcium hydroxide (1305-62-0) | - | 5 | - | - |
| Calcium oxide (1305-78-8) | - | 2 | - | - |
| Camphor (76-22-2) | 2 | 12 | 3 | 19 |
| Caprolactam, vapour and aerosol (105-60-2) | 0.25 | 1 | - | - |
| Captafol (2425-06-1) — Skin | - | 0.1 | - | - |
| Captan (133-06-2) | - | 5 | - | - |
| Carbofuran (1563-66-2) | - | 0.1 | - | - |
| Carbon black (1333-86-4) | - | 3.5 | - | - |
| Carbon dioxide (124-38-9) | 5,000 | 9,000 | 30,000 | 54,000 |
| Carbon disulfide (75-15-0) Skin | 10 | 31 | - | - |
| Carbon monoxide (630-08-0) | 35 | 40 | 400 | 460 |
| Carbon tetrabromide (558-13-4) | 0.1 | 1.4 | 0.3 | 4.1 |
| Carbon tetrachloride (56-23-5) — Skin | 5 | 31 | - | _ |

PART 4 Time-Weighted Average Exposure Values (TWAEV) and Short-Term Exposure Values (STEV) for Biological and Chemical Agents

| AGENT (CAS Reg. No.) | TW ppm | MEV mg/m ³ | ST ppm | mg/m ³ |
|--|-----------|-----------------------|-----------|-------------------|
| Carbonyl chloride (75-44-5) | 0.1 | 0.4 | - | _ |
| Carbonyl fluoride (353-50-4) | 2 | 5.4 | 5 | 13 |
| Cesium hydroxide (21351-79-1) | - | 2 | - | - |
| Chlordane (57-74-9) Skin | - | 0.5 | | 2 |
| Chlorine (7782-50-5) | 1 | 3 | 3 | 9 |
| Chlorine dioxide (10049-04-4) | 0.1 | 0.3 | 0.3 | 0.9 |
| Chloroacetyl chloride (79-04-9) | 0.05 | 0.23 | - | - |
| Chlorobenzene (108-90-7) | 75 | 345 | - | - |
| 2-Chloro-1,3-butadiene (126-99-8) Skin | 10 | 36 | -0 | - |
| Chlorodifluoromethane (75-45-6) | 1,000 | 3,535 | 1,250 | 4,415 |
| 1-Chloro-2,3-epoxypropane (106-89-8) Skin | 2 | 7.6 | - | - |
| p-Chloronitrobenzene (100-00-5) | 0.1 | 0.6 | - | - |
| 1-Chloro-1-nitro- propane (600-25-9) | 2 | 10 | - | |

PART 4 Time-Weighted Average Exposure Values (TWAEV) and Short-Term Exposure Values (STEV) for Biological and Chemical Agents

| AGENT | TW. | TWAEV ppm mg/m ³ | | rev mg/m ³ |
|--|-------|-----------------------------|-----|--------------------------|
| (CAS Reg. No.) | ppm | mg/m | ppm | mg/m |
| Chloropentafluoroethane | | | | |
| (76-15-3) | 1,000 | 6,315 | - | - |
| 2-Chloro-1-phenylethanone (532-27-4) | 0.05 | 0.32 | _ | |
| o-Chlorostyrene (2039-87-4) | 50 | 283 | 75 | 425 |
| o-Chlorotoluene (95-49-8) | 50 | 260 | 75 | 388 |
| 2-Chloro-6-(trichloro- methyl)pyridine | | | | |
| (1929-82-4) | - | 10 | - | 20 |
| Chlorpyrifos (2921-88-2) - Skin | _ | 0.2 | _ | 0.6 |
| Chromates, dichromates and other hexavalent chromium | | | | |
| compounds (as chromium) (7440-47-3), (b) | - | 0.05 | - | |
| Chromium metal, and divale | nt | | | |
| and trivalent chromium compounds (as chromium) | | | | |
| (7440-47-3), (b) | - | 0.5 | - | - |
| Chromyl chloride (14977-61-8) | 0.025 | 0.16 | - | |
| Clopidol (2971-90-6) | - | 10 | - | 20 |
| Cobalt carbonyl and hydrocarbonyl | | | | |
| (as cobalt) (7440-48-4), (b) | - | 0.1 | - | 1 |
| Cobalt metal, dust | | | | |
| (as cobalt) (7440-48-4), (b) | - | 0.05 | - | 0.1 |
| | 2369 | | | |

PART 4 Time-Weighted Average Exposure Values (TWAEV) and Short-Term Exposure Values (STEV) for Biological and Chemical Agents

| | (DI) | ADV | CMEN |
|--|------|-------------------|-----------------------|
| AGENT (CAS Reg. No.) | ppm | mg/m ³ | ppm mg/m ³ |
| Copper fume (as copper) (7440-50-8), (b) | _ | 0.2 | 34-7 |
| Copper dust and mists (as copper) (7440-50-8), (b) | _ | 1 | - 1- |
| Cotton dust, raw (a) | - | 0.2 | |
| Cresol (sum of o-,m-, and p-isomers), (1319-77-3) Skin | 5 | 22 | 100 |
| Crotonaldehyde (4170-30-3) | 2 | 5.7 | - |
| Crufomate (299-86-5) | - | 5 | - 20 |
| Cumene (98-82-8) — Skin | 50 | 245 | |
| Cyanamide (420-04-2) | - | 2 | g |
| Cyanide, potassium and sodium (as cyanide) (57-12-5), (b) — Skin | | 5 | PERM. |
| Cyanogen (460-19-5) | 10 | 21 | |
| Cyclohexane (110-82-7) | 300 | 1,030 | - 1 - |
| Cyclohexanol (108-93-0) Skin | 50 | 200 | |

PART 4 Time-Weighted Average Exposure Values (TWAEV) and Short-Term Exposure Values (STEV) for Biological and Chemical Agents

| AGENT (CAS Reg. No.) | TWA ppm | mg/m ³ | STEV ppm mg/m ³ | |
|------------------------------------|------------|-------------------|-------------------------------|--|
| Cyclohexanone (108-94-1) — Skin | 25 | 100 | | |
| Cyclohexene (110-83-8) | 300 | 1,010 | | |
| Cyclohexylamine (108-91-8) | 10 | 40 | - 1-110 | |
| Cyclopentadiene (542-92-7) | 75 | 200 | | |
| Cyclopentane (287-92-3) | 600 | 1,720 | | |
| Cyhexatin (13121-70-5) | - | 5 | | |
| Decaborane (17702-41-9) — Skin | 0.05 | 0.25 | 0.15 0.75 | |
| Demeton (8065-48-3) Skin | 0.01 | 0.11 | | |
| 1,2-Diaminoethane (107-15-3) | 10 | 25 | | |
| Diazomethane (334-88-3) | 0.2 | 0.34 | | |
| Diborane (19287-45-7) | 0.1 | 0.11 | | |
| Dibromodifluoromethane (75-61-6) | 100 | 860 | | |

PART 4 Time-Weighted Average Exposure Values (TWAEV) and Short-Term Exposure Values (STEV) for Biological and Chemical Agents

| | TW | AEV | STEV |
|---|-------|-------------------|-----------------------|
| AGENT (CAS Reg. No.) | ppm | mg/m ³ | ppm mg/m ³ |
| 2-(Dibutylamino)ethanol (102-81-8) Skin | 2 . | 14 | |
| Dibutyl phosphate (107-66-4) | 1 | 8.6 | 2 17 |
| Dibutyl phthalate (84-74-2) | - | 5 | |
| p-Dichlorobenzene (106-46-7) | 75 | 450 | 110 660 |
| Dichlorodifluoromethane (75-71-8) | 1,000 | 4,940 | - |
| 1,3-Dichloro-5,5-dimethyl- hydantoin (118-52-5) | - | 0.2 | - 0.4 |
| 1,1-Dichloroethane (75-34-3) | 200 | 810 | 250 1,010 |
| 1,2-Dichloroethane (107-06-2) | 10 | 40 | |
| 1,1-Dichloroethene (75-35-4) | 5 | 20 | 20 80 |
| 1,2-Dichloroethene (540-59-0) | 200 | 790 | 250 990 |
| Dichlorofluoromethane (75-43-4) | 10 | 42 | |
| Dichloromethane (75-09-2) | 50 | 175 | - " - |
| 1,1-Dichloro-1-nitroethane (594-72-9) | 2 | 12 | |

PART 4 Time-Weighted Average Exposure Values (TWAEV) and Short-Term Exposure Values (STEV) for Biological and Chemical Agents

| A CIPNITO | TWAEV 3 | | | STEV 3 | |
|--|---------|-------------------|-----|-------------------|--|
| AGENT (CAS Reg. No.) | ppm | mg/m ³ | ppm | mg/m ³ | |
| (2,4-Dichlorophenoxy) acetic acid and its esters (as 2,4-D) (94-75-7),(b) | - | 10 | _ | - | |
| 2-(2,4-Dichlorophenoxy) ethanol hydrogen sulfate sodium salt (136-78-7) | _ | 10 | - | | |
| 1,2-Dichloropropane (78-87-5) | 75 | 350 | 110 | 510 | |
| 1,3-Dichloropropene (542-75-6) — Skin | 1 | 5 | - | - | |
| 2,2-Dichloropropionic aci (75-99-0) | d 1 | 6 | - | - | |
| 1,2-Dichloro-1,1,2,2-tetra fluoroethane (76-14-2) | 1,000 | 6,985 | _ | | |
| Dichlorvos (62-73-7) — Skin | 0.1 | 0.9 | - | | |
| Dicrotophos (141-66-2) Skin | - | 0.25 | - | - | |
| Dicyclopentadiene (77-73-6) | 5 | 27 | - | - | |
| Dieldrin (60-57-1) — Skin | 0. | 0.25 | - | | |
| Diethanolamine (111-42-2) | 3 | 13 | _ | - | |
| Diethylamine (109-89-7) | 10 | 30 | 25 | 75 | |

PART 4 Time-Weighted Average Exposure Values (TWAEV) and Short-Term Exposure Values (STEV) for Biological and Chemical Agents

| AGENT (CAS Reg. No.) | TW ppm | AEV mg/m ³ | STEV ppm mg, | /m ³ |
|---|-----------|--------------------------|-----------------|-----------------|
| 2-(Diethylamino)ethanol (100-37-8) Skin | 10 | 48 | | 4_ |
| Diethylenetriamine (111-40-0) — Skin | 1 | 4 | I Laboratoria | - |
| Diethyl phthalate (84-66-2) | - | 5 | -10 3 | - |
| 1,2-Dihydroxybenzene (120-80-9) | 5 | 22 | - | - |
| 1,4-Dihydroxybenzene (123-31-9) | - | 2 | | - |
| Diisopropylamine (108-18-9) Skin | 5 | 20 | - 7- | -12 |
| Dimethoxymethane (109-87-5) | 1,000 | 3,110 | 4 | _ |
| N,N-Dimethylacetamide (127-19-5) — Skin | 10 | 36 | - 1700 | -11 |
| Dimethylamine (124-40-3) | 10 | 18 | - | - |
| N,N-Dimethylaniline (121-69-7) Skin | 5 | 25 | 10 | 50 |
| ar,ar-Dimethylbenzenamine (sum of all isomers) (1300-73-8) — Skin | 2 | 10 | _ | - |
| Dimethylbenzene (sum of o-, m- and p-isomers) (1330-20-7) | 100 | 435 | 150 | 650 |
| N,N-Dimethylformamide (68-12-2) — Skin | 10 | 30 | - 11-1 | 14 |

PART 4 Time-Weighted Average Exposure Values (TWAEV) and Short-Term Exposure Values (STEV) for Biological and Chemical Agents

| AGENT (CAS Reg. No.) | TWA ppm | MEV mg/m ³ | STEV ppm mg/m ³ |
|--|------------|--------------------------|----------------------------|
| 2,6-Dimethyl-4-heptanone (108-83-8) | 25 | 145 | - ,, ' |
| 1,1-Dimethylhydrazine (57-14-7) Skin | 0.5 | 1.2 | |
| 2-(2,2-Dimethyl-1- oxopropyl)-H-indene- 1,3(2H)-dione | | 0.1 | |
| (83-26-1) Dimethyl phthalate | - | 0.1 | |
| (131-11-3) | - | 5 | 1,35 |
| Dimethyl sulfate (77-78-1) Skin | 0.1 | 0.5 | |
| Dinitrobenzene (sum of m-, and p-isomers: (99-65-0), (528-29-0), and (100-25-4)) Skin | | 1.0 | |
| Dinitro-o-cresol (534-52-1) — Skin | - | 0.2 | |
| Dinitrotoluene (sum of all isomers) | | | |
| (25321-14-6) — Skin | - | 1.5 | |
| 1,4-Dioxane (123-91-1) — Skin | 25 | 90 | |
| Dioxathion (78-34-2) — Skin | - | 0.2 | |
| N,N-Diphenylamine (122-39-4) | .13 | 10 | |
| Dipropylene glycol monome ether | thyl | | |
| (34590-94-8) | 100 | 605 | 150 910 |

PART 4 Time-Weighted Average Exposure Values (TWAEV) and Short-Term Exposure Values (STEV) for Biological and Chemical Agents

| AGENT (CAS Reg. No.) | TWA ppm | AEV mg/m ³ | STEV ppm mg/m ³ |
|---|------------|--------------------------|-------------------------------|
| Diquat (85-00-7) | _ | 0.5 | |
| Disulfiram (97-77-8) | -11 | 2 | 1 - 1 1 |
| Disulfoton (298-04-4) | - | 0.1 | |
| Diuron (330-54-1) | - | 10 | _ |
| m-Divinylbenzene (108-57-6) | 10 | 53 | 1 million |
| Endosulfan (115-29-7) Skin | - | 0.1 | |
| Endrin* (72-20-8) Skin | - | 0.1 | 1-1-10- |
| Enflurane (13838-16-9) | 2 | 16 | - |
| 1,2-Epoxy-4-(epoxyethyl)- cyclohexane (106-87-6) Skin | 10 | 57 | Total of |
| 1,2-Epoxypropane (75-56-9) | 20 | 47 | |
| 2,3-Epoxy-1-propanol (556-52-5) | 25 | 76 | |
| Ethanethiol (75-08-1) | 0.5 | 1.3 | |
| Ethanol (64-17-5) | 1,000 | 1,900 | |
| | | | |

Not licenced for use in Ontario as a pesticide.

PART 4 Time-Weighted Average Exposure Values (TWAEV) and Short-Term Exposure Values (STEV) for Biological and Chemical Agents

| | TWA | EV 3 | | rev 3 |
|--|-------|-------------------|-----|-------------------|
| AGENT (CAS Reg. No.) | ppm | mg/m ³ | ppm | mg/m ³ |
| Ethion (563-12-2) — Skin | - | 0.4 | - | _ |
| Ethoxyethane (60-29-7) | 400 | 1,210 | 500 | 1,515 |
| 2-Ethoxyethanol (110-80-5) — Skin | 5 | 18 | - | - |
| 2-Ethoxyethyl acetate (111-15-9) — Skin | _ 5 | 27 | - | - |
| Ethyl acetate (141-78-6) | 400 | 1,440 | - | - |
| Ethyl acrylate (140-88-5) — Skin | 5 | 20 | - | _ |
| Ethylamine (75-04-7) | 10 | 18 | - | - |
| Ethylbenzene (100-41-4) | 100 | 435 | 125 | 540 |
| Ethyl bromide (74-96-4) | 200 | 890 | 250 | 1,110 |
| Ethyl chloride (75-00-3) | 1,000 | 2,635 | - | - |
| Ethylene glycol dinitrate (628-96-6) — Skin | 0.05 | 0.31 | - | - |
| Ethylene oxide (75-21-8) | 1 | 1.8 | _ | - |

PART 4 Time-Weighted Average Exposure Values (TWAEV) and Short-Term Exposure Values (STEV) for Biological and Chemical Agents

| . CDVM | | VAEV mg/m ³ | 3 STEV | |
|---|-----|------------------------|--------|-------|
| AGENT (CAS Reg. No.) | ppm | mg/m | ppm | mg/m³ |
| Ethylenimine (151-56-4) Skin | 0.5 | 0.9 | _ | - |
| Ethyl formate (109-94-4) | 100 | 300 | - | - |
| N-Ethylmorpholine (100-74-3) Skin | 5 | 23 | - | - |
| O-Ethyl O-p-nitrophenyl phenylphosphonothioate (2104-64-5) Skin | - | 0.5 | - | - |
| Ethyl silicate (78-10-4) | 10 | 85 | - | - |
| Fenamiphos (22224-92-6) Skin | - | 0.1 | - | - |
| Fensulfothion (115-90-2) | - | 0.1 | - | _ |
| Fenthion (55-38-9) Skin | _ | 0.2 | - | - |
| Ferbam (14484-64-1) | _ | 10 | - | - |
| Ferrovanadium dust (12604-58-9) | _ | 1 | - | 3 |
| Fluorides (as fluoride) (16984-48-8),(b) | - | 2.5 | - | - |
| Fluorine (7782-41-4) | 1 | 1.6 | 2 | 3.1 |
| Fonofos (944-22-9) Skin | _ | 0.1 | - | - |

PART 4 Time-Weighted Average Exposure Values (TWAEV) and Short-Term Exposure Values (STEV) for Biological and Chemical Agents

| | | AEV | STEV |
|---------------------------------------|-----|-------------------|-----------------------|
| AGENT (CAS Reg. No.) | ppm | mg/m ³ | ppm mg/m ³ |
| Formaldehyde (50-00-0) | 1 | 1.6 | 2 3 |
| (50-00-0) | 1 | 1.5 | 2 3 |
| Formamide (75-12-7) — Skin | 10 | 15 | |
| Formic acid (64-18-6) | 5 | 9.4 | |
| Furfural (98-01-1) — Skin | 2 | 8 | - |
| Furfuryl alcohol (98-00-0) — Skin | 10 | 40 | 15 60 |
| Germanium tetrahydride (7782-65-2) | 0.2 | 0.63 | 0.0 |
| Glass, fibrous or dust (a) | | 10 | V- 17- |
| Grain dust (oats, wheat, barley), (a) | - | 4 | 0-0-0 |
| Hafnium | | | |
| (7440-58-6) | - | 0.5 | |
| Halothane (151-67-7) | 2 | 16 | |
| Heptachlor (76-44-8) — Skin | - | 0.5 | |
| n-Heptane (142-82-5) | 400 | 1,635 | 500 2,045 |
| 2-Heptanone (110-43-0) | 50 | 233 | |
| 3-Heptanone (106-35-4) | 50 | 230 | |

PART 4 Time-Weighted Average Exposure Values (TWAEV) and Short-Term Exposure Values (STEV) for Biological and Chemical Agents

| AGENT (CAS Reg. No.) | TW ppm | AEV mg/m ³ | STEV ppm mg/m ³ |
|--|-----------|-----------------------|----------------------------|
| 4-Heptanone (123-19-3) | 50 | 233 | 7-1-0 |
| Hexachloro-1,3-butadiene (87-68-3) Skin | 0.02 | 0.21 | -1-1 |
| Hexachlorocyclopentadiene (77-47-4) | 0.01 | 0.11 | |
| Hexachloroethane (67-72-1) | 10 | 97 | -1:0000 |
| Hexachloronaphthalene (1335-87-1) Skin | 1.1 | 0.2 | |
| Hexafluoroacetone (684-16-2) Skin | 0.1 | 0.7 | |
| Hexahydro-1,3,5-trinitro- 1,3,5-triazine (121-82-4) Skin | - | 1.5 | - 3 |
| n-Hexane (110-54-3) | 50 | 176 | |
| Hexane, other isomers of | 500 | 1,760 | 1,000 3,520 |
| 2-Hexanone (591-78-6) | 5 | 20 | 200 |
| sec-Hexyl acetate (142-92-7) | 50 | 294 | |
| Hydrazine (302-01-2) Skin | 0.1 | 0.13 | |
| Hydrogen peroxide (90%) (7722-84-1) | 1 | 1.4 | |

PART 4 Time-Weighted Average Exposure Values (TWAEV) and Short-Term Exposure Values (STEV) for Biological and Chemical Agents

| | TW | AEV 3 | STEV | |
|--|------|-------------------|------|-------------------|
| AGENT (CAS Reg. No.) | ppm | mg/m ³ | ppm | mg/m ³ |
| Hydrogen selenide | | | | |
| (as selenium) (7783-07-5) | 0.05 | 0.16 | - | |
| Hydrogen sulfide (7783-06-4) | 10 | 14 | 15 | 21 |
| 4-Hydroxy-4-methyl- 2-pentanone (123-42-2) | 50 | 240 | 75 | 360 |
| 2-Hydroxypropyl acrylate (999-61-1) — Skin | 0.5 | 2.7 | - | |
| Indene (95-13-6) | 10 | 47 | - | _ |
| Indium and its compounds (as indium) | | | | |
| (7440-74-6),(b) | - | 0.1 | | - |
| Iodoform (75-47-8) | 0.6 | 10 | -1 | 111- |
| Iron pentacarbonyl (as iron) | 0.1 | 0.0 | 0.0 | 1.0 |
| (13463-40-6) Iron salts, water- | 0.1 | 0.8 | 0.2 | 1.6 |
| soluble (as iron) | | 1 | | |
| (7439-89-6), (b) Isoamyl acetate | _ | 1 | - | |
| (123-92-2) | 100 | 530 | - | - |
| Isoamyl alcohol (123-51-3) | 100 | 360 | 125 | 450 |

PART 4 Time-Weighted Average Exposure Values (TWAEV) and Short-Term Exposure Values (STEV) for Biological and Chemical Agents

| AGENT (CAS Reg. No.) | TW ppm | MAEV mg/m ³ | ppm | rev mg/m ³ |
|---|-----------|---------------------------|------|--------------------------|
| Isobutyl acetate (110-19-0) | 150 | 710 | 187 | 887 |
| Isobutyl alcohol (78-83-1) | 50 | 150 | | - |
| 2-Isopropoxyethanol (109-59-1) | 25 | 105 | | -11- |
| Isopropyl acetate (108-21-4) | 250 | 1,040 | 310 | 1,295 |
| Isopropyl alcohol (67-63-0) | 400 | 980 | 500 | 1,225 |
| Isopropylamine (75-31-0) | 5 | 12 | 10 | 24 |
| N-Isopropylaniline (768-52-5) — Skin | 2 | 11 | 1 | - |
| Ketene (463-51-4) | 0.5 | 0.9 | 1.5 | 2.6 |
| Lindane (58-89-9) — Skin | | 0.5 | - 1- | |
| Lithium hydride (7580-67-8) | - | 0.025 | 0- | |
| Magnesium oxide fume (1309-48-4) | | 10 | - | - iči |
| Malathion (121-75-5) Skin | | 10 | 1/2 | - T- |
| Maleic anhydride (108-31-6) | 0.25 | 1 | _ | len - |

PART 4 Time-Weighted Average Exposure Values (TWAEV) and Short-Term Exposure Values (STEV) for Biological and Chemical Agents

| AGENT (CAS Reg. No.) | TW ppm | AEV mg/m ³ | ST ppm | EV mg/m ³ |
|---|-----------|-----------------------|-----------|----------------------|
| Manganese, dust and compounds (as manganese (7439-96-5), (b) | e) - | 5 | _ | - |
| Manganese-containing fume (as manganese) (7439-96-5),(b) | - | 1 | - | 3 |
| Manganese cyclo- pentadienyltricarbonyl (as manganese) (12079-65-1) — Skin | 1.2 | 0.1 | Ti | _ |
| Manganese tetroxide (as manganese) (1317-35-7) — Skin | - | 1 | - | |
| Mesityl oxide (141-79-7) | 15 | 60 | 25 | 100 |
| Methacrylic acid (79-41-4) | 20 | 70 | - | - |
| Methanethiol (74-93-1) | 0.5 | 1 | - | - |
| Methanol (67-56-1) — Skin | 200 | 260 | 250 | 325 |
| Methomyl (16752-77-5) | - | 2.5 | | - |
| Methoxychlor (72-43-5) | - | 10 | - | - |
| 2-Methoxyethanol (109-86-4) Skin | 5 | 16 | - | - |
| 2-Methoxyethyl acetate (110-49-6) — Skin | 5 | 24 | - | - |

PART 4 Time-Weighted Average Exposure Values (TWAEV) and Short-Term Exposure Values (STEV) for Biological and Chemical Agents

| AGENT (CAS Reg. No.) | TW. | AEV mg/m ³ | S' ppm | rev mg/m ³ |
|--|-----|--------------------------|----------|--------------------------|
| 4-Methoxyphenol (150-76-5) | - | 5 | | - |
| 1-Methoxy-2-propanol (107-98-2) | 100 | 365 | 150 | 550 |
| Methyl acetate (79-20-9) | 200 | 605 | 250 | 755 |
| Methyl acrylate (96-33-3) Skin | 10 | 35 | 10.70 | - 11 - |
| Methylamine (74-89-5) | 10 | 13 | - 1 | - |
| N-Methylbenzenamine (100-61-8) Skin | 0.5 | 2.2 | - | Loren |
| Methylbenzene (108-88-3) | 100 | 376 | 150 | 564 |
| Methyl bromide (74-83-9) — Skin | 5 | 19 | A I Toma | 1 -14 |
| 3-Methyl-2-butanone (563-80-4) | 200 | 705 | - | - |
| Methyl chloride (74-87-3) | 50 | 103 | 100 | 205 |
| Methyl 2-cyanoacrylate (137-05-3) | 2 | 9 | 4 | 18 |
| Methylcyclohexane (108-87-2) | 400 | 1,600 | - | |
| 2-Methylcyclohexanol (583-59-5) | 50 | 233 | - 1 | - |

PART 4 Time-Weighted Average Exposure Values (TWAEV) and Short-Term Exposure Values (STEV) for Biological and Chemical Agents

| AGENT (CAS Reg. No.) | TW/ppm | AEV mg/m ³ | ST: ppm | EV mg/m ³ |
|--|----------|--------------------------|------------|-------------------------|
| 2-Methylcyclohexanone (583-60-8) — Skin | 50 | 230 | 75 | 345 |
| 2-Methylcyclopentadienyl- manganese tricarbonyl (as manganese) | | | | |
| (12108-13-3) — Skin | - | 0.2 | - | - |
| Methyl demeton (8022-00-2) — Skin | - | 0.5 | | - |
| 2-Methyl-3,5-dinitrobenzami (148-01-6) | ide - | 5 | - | 10 |
| 4,4'-Methylenebis- (2-chloroaniline) (101-14-4) — Skin | 0.02 | 0.22 | =1 | - |
| 4,4'-Methylene- dianiline (101-77-9) — Skin | - | 0.04 | v | _ |
| ((1-Methylethoxy)methyl)- oxirane (4016-14-2) | 50 | 237 | 75 | 356 |
| Methyl formate (107-31-3) | 100 | 245 | 150 | 370 |
| 5-Methyl-3-heptanone (541-85-5) | 25 | 130 | - | - |
| 5-Methyl-2-hexanone (110-12-3) | 50 | 233 | _ | - |
| Methyl iodide (74-88-4) — Skin | 2 | 12 | - | - |
| Methyl methacrylate (80-62-6) | 100 | 410 | - | - |

PART 4 Time-Weighted Average Exposure Values (TWAEV) and Short-Term Exposure Values (STEV) for Biological and Chemical Agents

| AGENT (CAS Reg. No.) | TWAE ppm n | V ng/m ³ | STE ppm | CV mg/m ³ |
|---|------------|------------------------|------------|-------------------------|
| Methyl parathion (298-00-0) Skin | 143 | 0.2 | | -62 |
| 4-Methyl-2-pentanol (108-11-2) — Skin | 25 | 104 | 40 | 167 |
| 4-Methyl-2-pentanone (108-10-1) | 50 | 205 | 75 | 305 |
| 2-Methyl-2-propenenitrile (126-98-7) Skin | 1 | 2.7 | | - |
| alpha-Methylstyrene (98-83-9) | 50 | 241 | 100 | 482 |
| 1-Methyl-2,4,6-trinitrobenzen (118-96-7) — Skin | e - | 0.5 | -0 | -1112 |
| Metribuzin (21087-64-9) | - | 5 | 12.0 | a Y |
| Mevinphos (7786-34-7) Skin | 0.01 | 0.1 | 0.03 | 0.3 |
| Molybdenum metal, dioxide and disulfide (as molybdenum) | | | | |
| (7439-98-7), (b) | - | 10 | 11-11- | - |
| Molybdenum trioxide and molybdates (as molybdenum) | | | - 1 | |
| (7439-98-7),(b) | - | 5 | | 1 |
| Monocrotophos (6923-22-4) | - | 0.25 | -0 | 1 |

PART 4 Time-Weighted Average Exposure Values (TWAEV) and Short-Term Exposure Values (STEV) for Biological and Chemical Agents

| AGENT (CAS Reg. No.) | TWAI | EV mg/m ³ | STEV ppm mg/m ³ |
|---|------|-------------------------|----------------------------|
| Morpholine (110-91-8) — Skin | 20 | 70 | 30 105 |
| Naled (300-76-5) — Skin | - | 3 | |
| Naphthalene (91-20-3) | 10 | 52 | 15 78 |
| 1-Naphthyl N-methyl- carbamate (63-25-2) | ŧ. | 5 | 300 |
| alpha-Naphthylthiourea (86-88-4) | 211 | 0.3 | |
| Nickel, metal and oxides and sulfides of (as nickel) (7440-02-0), (b) | | 1 | alt-talt- |
| Nickel carbonyl (as nickel) (13463-39-3) | 0.05 | 0.35 | - |
| Nickel, water-soluble compounds of (as nickel) (7440-02-0),(b) | 200 | 0.1 | 7,000 |
| Nicotine (54-11-5) — Skin | - | 0.5 | |
| Nitramine (479-45-8) Skin | _ | 1.5 | - |
| Nitric acid (7697-37-2) | 2 | 5 | 4 10 |
| Nitric oxide (10102-43-9) | 25 | 31 | |

PART 4 Time-Weighted Average Exposure Values (TWAEV) and Short-Term Exposure Values (STEV) for Biological and Chemical Agents

| | mr. | ATTI | |
|---|------------|-------------------|-----------------------|
| AGENT (CAS Reg. No.) | T W ppm | mg/m ³ | ppm mg/m ³ |
| p-Nitroaniline (100-01-6) Skin | - | 3 | -207-00 |
| Nitrobenzene (98-95-3) — Skin | 1 | 5 | |
| Nitroethane (79-24-3) | 100 | 306 | 2 15. |
| Nitrogen dioxide (10102-44-0) | 3 | 5.6 | 5 9.4 |
| Nitrogen trifluoride (7783-54-2) | 10 | 29 | |
| Nitroglycerine (55-63-0) Skin | 0.05 | 0.5 | |
| Nitromethane (75-52-5) | 100 | 250 | 1-1-11 |
| 1-Nitropropane (108-03-2) | 25 | 90 | Lo mo. |
| 2-Nitropropane (79-46-9) | 10 | 35 | 20 70 |
| Nitrotoluene (sum of m-,o-,and p-isomers: (99-08-1), (88-72-2), | | | |
| and (99-99-0)) Skin | 2 | 11 | |
| Nitrous oxide (10024-97-2) | 25 | 45 | There was |
| Nonane (111-84-2) | 200 | 1,050 | To the same |

PART 4 Time-Weighted Average Exposure Values (TWAEV) and Short-Term Exposure Values (STEV) for Biological and Chemical Agents

| 100 | TW | AEV | S' | rev . |
|--|--------|-------------------|--------|-------------------|
| AGENT (CAS Reg. No.) | ppm | mg/m ³ | ppm | mg/m ³ |
| Octachloronaphthalene (2234-13-1) Skin | - | 0.1 | - | 0.3 |
| Octane (111-65-9) | 300 | 1,400 | 375 | 1,750 |
| Osmium tetroxide (as osmium) (20816-12-0) | 0.0002 | 0.002 | 0.0006 | 0.006 |
| Oxalic acid (144-62-7) | 1 _ | 1 | - | . 2 |
| 1,1'-Oxybisbenzene (101-84-8) | 1 | 7 | 2 | 14 |
| 1,1'-Oxybis (2-chloroethane) (111-44-4) Skin | 5 | 29 | 10 | 58 |
| Oxybis (chloromethane) (542-88-1) | 0.001 | 0.005 | - 0 | = 10 |
| 2,2'-(Oxybis(methylene))- bisoxirane (2238-07-5) | 0.1 | 0.53 | | ₹. |
| 2,2'-Oxybis(propane) (108-20-3) | 250 | 1,045 | 310 | 1,295 |
| Ozone (10028-15-6) | 0.1 | 0.2 | 0.3 | 0.6 |
| Paraquat (1910-42-5) | _ | 0.1 | _ | |
| Parathion (56-38-2) — Skin | - | 0.1 | -1-2- | |
| Pentaborane (19624-22-7) | 0.005 | 0.013 | 0.015 | 0.039 |

PART 4 Time-Weighted Average Exposure Values (TWAEV) and Short-Term Exposure Values (STEV) for Biological and Chemical Agents

| AGENT (CAS Reg. No.) | TW/ | AEV mg/m ³ | STI ppm | EV mg/m ³ |
|--|-----|--------------------------|-------------|-------------------------|
| Pentachloronaphthalene (1321-64-8) | - | 0.5 | 75 | - SS |
| Pentachlorophenol (87-86-5) — Skin | - | 0.5 | 0.45 | - Car |
| Pentane (109-66-0) | 600 | 1,770 | 750 | 2,210 |
| 2-Pentanone (107-87-9) | 200 | 700 | 250 | 880 |
| 3-Pentanone (96-22-0) | 200 | 705 | - | 30 |
| Perchloryl fluoride (7616-94-6) | 3 | 13 | 6 | 25 |
| Persulfates, alkali metal, and including ammonium (7727-54-1), sodium (7775-27-1) and potassium persulfate | | | | |
| $(7727-21-1)$ (as S_2O_8) | - | 5 | (Final | - |
| Phenol (108-95-2) Skin | 5 | 19 | | - |
| Phenothiazine (92–84–2) — Skin | | 5 | | |
| (Phenoxymethyl) oxirane (122-60-1) | 1 | 6 | (5.00 | |
| p-Phenylenediamine (106-50-3) — Skin | _ | 0.1 | - | 70. |
| Phenylhydrazine (100–63–0) — Skin | 5 | 22 | 10 | 44 |

PART 4 Time-Weighted Average Exposure Values (TWAEV) and Short-Term Exposure Values (STEV) for Biological and Chemical Agents

| AGENT (CAS Reg. No.) | TWA | EV mg/m ³ | STEV ppm mg/m | 3 |
|---|-----|-------------------------|------------------|---|
| Phorate (298-02-2) Skin | _ | 0.05 | - 0. | 2 |
| Phosphine (7803-51-2) | 0.3 | 0.4 | 1 . 1. | 4 |
| Phosphoric acid (7664-38-2) | - | 1 | 40.00 | 3 |
| Phosphorothionic acid 0,0-diethyl 0-(6-methyl- 2-(1-methylethyl)- | 1.1 | | | |
| 4-pyrimidinyl) ester (333-41-5) — Skin | - | 0.1 | - | - |
| Phosphorus (yellow or white) (7723-14-0) | | 0.1 | -021- | _ |
| Phosphorus oxychloride (10025-87-3) | 0.1 | 0.6 | 0.5 | 3 |
| Phosphorus pentachloride (10026-13-8) | 0.1 | 0.85 | | - |
| Phosphorus pentasulfide (1314-80-3) | - | 1 | - | 3 |
| Phosphorus trichloride (7719-12-2) | 0.2 | 1.1 | 0.5 2. | 8 |
| Phthalic anhydride (85-44-9) | 1 | 6 | | _ |
| m-Phthalodinitrile (626-17-5) | - | 5 | | _ |
| Piperazine dihydrochloride (142-64-3) | | 5 | - 10 - | _ |
| | | | | |

PART 4 Time-Weighted Average Exposure Values (TWAEV) and Short-Term Exposure Values (STEV) for Biological and Chemical Agents

| AGENT (CAS Reg. No.) | TW. | AEV mg/m ³ | ST ppm | EV mg/m ³ |
|--|------|--------------------------|-----------|-------------------------|
| Platinum metal (7440-06-4) | - | 1 | - | _ |
| Platinum, water-soluble compounds of, including chloroplatinates (as | | | | |
| platinum) (7440-06-4),(b) | _ | 0.002 | - | - |
| Propargyl alcohol (107-19-7) Skin | 1 | 2.3 | | =0- |
| ((2-Propenyloxy)methyl) oxirane | | | | |
| (106-92-3) Skin | 5 | 23 | 10 | 47 |
| beta-Propiolactone (57-57-8) | 0.5 | 1.5 | - | -11 |
| Propionic acid (79-09-4) | 10 | 30 | - | - 11- |
| Propoxur (114-26-1) | | 0.5 | j= 0 | 1/- |
| n-Propyl acetate (109-60-4) | 200 | 830 | 250 | 1,040 |
| n-Propyl alcohol (71-23-8) Skin | 200 | 490 | 250 | 615 |
| 1,2-Propylene glycol dinitrate (6423-43-4) — Skin | 0.05 | 0.34 | - | - |
| Propylenimine (75-55-8) — Skin | 2 | 4.7 | - | 1-1 |
| n-Propyl nitrate (627-13-4) | 25 | 105 | 40 | 170 |
| | | | | |

PART 4 Time-Weighted Average Exposure Values (TWAEV) and Short-Term Exposure Values (STEV) for Biological and Chemical Agents

| AGENT (CAS Reg. No.) | TWA ppm | EV mg/m ³ | ppm | mg/m ³ |
|--|------------|-------------------------|-------|-------------------|
| Propyne (74-99-7) | 1,000 | 1,635 | 1,250 | 2,045 |
| Pyrethrum (8003-34-7) | | 5 | 1, | - |
| Pyridine (110-86-1) | 5 | 16 | 75 | 257 |
| Quinone (106-51-4) | 0.1 | 0.44 | - | |
| Resorcinol (108-46-3) | 10 | 45 | 20 | 90 |
| Rhodium, metal and water-insoluble compounds of (as rhodiu (7440-16-6),(b) | um) - | 1 | - | |
| Rhodium, water-soluble compounds of, including chloride, nitrate, and sulfate (as rhodium) (7440-16-6),(b) | - | 0.01 | | |
| Ronnel (299-84-3) | - 44 | 10 | | . · |
| Rotenone (commercial) (83-79-4) | h 11 | 5 | 11 | balair. |
| Selenium and its com- pounds except selenium hexafluoride and hydrog | | | | |
| selenide (as selenium) (7782-49-2),(b) | - | 0.2 | _ | 77- |

PART 4 Time-Weighted Average Exposure Values (TWAEV) and Short-Term Exposure Values (STEV) for Biological and Chemical Agents

| AGENT (CAS Reg. No.) | TW/ | AEV mg/m ³ | STEV ppm mg/m ³ |
|--|-------|--------------------------|----------------------------|
| Selenium hexafluoride (as selenium) (7783-79-1) | 0.05 | 0.16 | |
| Silane (7803-62-5) | 5 | 6.6 | 100000 |
| Silver, metal (7440-22-4) | - | 0.1 | .0 = 7 |
| Silver, water-soluble compounds of (as silver) (7440-22-4),(b) | - | 0.01 | 15-11 |
| Sodium bisulfite (7631-90-5) | 1 | 5 | • , - |
| Sodium fluoroacetate (62-74-8) — Skin | _ | 0.05 | - 0.15 |
| Sodium metabisulfite (7681-57-4) | - | 5 | 7.75 |
| Strychnine (57-24-9) | - | 0.15 | 20 000 |
| Styrene * (100-42-5) | 50 | 213 | 100 425 |
| Sulfur dioxide (7446-09-5) | . 2 | 5.2 | 5. 10.4 |
| Sulfur hexafluoride (2551-62-4) | 1,000 | 5,970 | 1 2 2 |
| Sulfuric acid (7664-93-9) | - | 1 | 7-12 |

^{*} Special exceptions may apply to this substance; see section 9 of the Regulation.

PART 4 Time-Weighted Average Exposure Values (TWAEV) and Short-Term Exposure Values (STEV) for Biological and Chemical Agents

| AGENT (CAS Reg. No.) | TW. | MEV mg/m ³ | S71 ppm | rev mg/m ³ |
|--|------|--------------------------|------------|--------------------------|
| Sulfuryl fluoride (2699-79-8) | 5 | . 21 | 10 | 42 |
| Sulprofos (35400-43-2) | - | 1 | - | _ |
| Tellurium and its com- pounds except tellurium hexafluoride (as tellurium) (13494-80-9),(b) | | 0.1 | | |
| Tellurium hexafluoride (as tellurium) (7783-80-4) | 0.02 | 0.20 | | |
| Temephos (3383-96-8) | - | 10 | | |
| 1,1,2,2-Tetrabromoethane (79-27-6) | 1 | 14 | | |
| 1,1,1,2-Tetrachloro-2,2- difluoroethane (76-11-9) | 500 | 4,165 | - | |
| 1,1,2,2-Tetrachloro- 1,2-difluoroethane (76-12-0) | 500 | 4,165 | | - |
| 1,1,2,2-Tetrachloroethane (79-34-5) — Skin | 1 | 7 | - | _ |
| Tetrachloroethylene (127-18-4) | 50 | 340 | 200 | 1,355 |
| Tetrachloronaphthalene (1335-88-2) | _ | 2 | | - |

PART 4 Time-Weighted Average Exposure Values (TWAEV) and Short-Term Exposure Values (STEV) for Biological and Chemical Agents

| AGENT (CAS Reg. No.) | TW. | AEV mg/m ³ | STEV ppm mg/m ³ |
|---|---------|--------------------------|----------------------------|
| Tetraethyl dithiono- pyrophosphate (3689-24-5) Skin | - | 0.2 | -07-11 |
| Tetraethyl pyrophosphate (107-49-3) Skin | 0.004 | 0.047 | 11 114 |
| Tetrahydrofuran (109-99-9) | 200 | 590 | 250 735 |
| Tetramethoxysilane (681-84-5) | 1 | 6.2 | -1-1 |
| Tetramethylsuccino- dinitrile (3333-52-6) Skin | 0.5 | 2.8 | |
| Tetranitromethane (509-14-8) | 1 | 8 | |
| Tetrasodium pyrophosphate (7722-88-5) | - | 5 | - ministra |
| Thallium, water-soluble compounds of (as thallium) (7440-28-0),(b) Skin | _ | 0.1 | - T |
| 4, 4'-Thiobis | | 111 | |
| (6-tert-butyl-m-cresol) (96-69-5) | - | 10 | - 1- |
| Thioglycolic acid (68-11-1) Skin | 1 | 3.8 | |
| Tin, metal, oxide and inorgan compounds of, except stannane (as tin) (7440-31-5),(b) | ie - | 2 | 5 - di |

PART 4 Time-Weighted Average Exposure Values (TWAEV) and Short-Term Exposure Values (STEV) for Biological and Chemical Agents

| AGENT (CAS Reg. No.) | TWA | MEV mg/m ³ | STEV ppm mg/m ³ |
|--|-----|--------------------------|----------------------------|
| Tin, organic compounds of (as tin) (7440-31-5) — Skin | _ | 0.1 | |
| Toluidine (sum of o-,m- and p-isomers: (95-53-4), (108-44-1), and (108-49-0)) — Skin | . 2 | 9 | |
| Tributyl phosphate (126-73-8) | 0.2 | 2.2 | 1000 |
| Trichloroacetic acid (76-03-9) | 1 | 6.7 | |
| 1,1,1-Trichloro-2,2-bis- (p-chlorophenyl) ethane (50-29-3) | _ | 1 | The same party |
| 1,1,1-Trichloroethane (71-55-6) | 350 | 1,910 | 450 2,455 |
| 1,1,2-Trichloroethane (79-00-5) — Skin | 10 | 55 | |
| Trichloroethylene (79-01-6) | 50 | 268 | 200 1,075 |
| Trichloromethane (67-66-3) | 10 | 49 | The second |
| Trichloromethanesulfenyl chloride (594-42-3) | 0.1 | 0.8 | |
| Trichloronaphthalene (1321-65-9) — Skin | - | 5 | 200- |
| Trichloronitromethane (76-06-2) | 0.1 | 0.67 | 0.3 2 |

PART 4 Time-Weighted Average Exposure Values (TWAEV) and Short-Term Exposure Values (STEV) for Biological and Chemical Agents

| | | | • | |
|--|-----------|---------------------------|--------------------|---------------------------|
| AGENT (CAS Reg. No.) | T' ppm | WAEV mg/m ³ | ppm | STEV mg/m ³ |
| (2,4,5-Trichlorophenoxy) acetic acid and esters (as 2,4,5-T) (93-76-5), (b) | | 10 | - | 127 |
| 1,2,3-Trichloropropane (96-18-4) Skin | 10 | 60 | n _e = 1 | 111-11- |
| 1,1,2-Trichloro-1,2,2- trifluoroethane (76-13-1) | 1,000 | 7,650 | 1,250 | 9,560 |
| Tri-ortho-cresyl phosphate (78-30-8) — Skin | | 0.1 | - | more) |
| Triethylamine (121-44-8) | 10 | 41 | 15 | 62 |
| Trimellitic anhydride (552-30-7) | 0.005 | 0.039 | - | 18 76 |
| Trimethylamine (75-50-3) | 10 | 24 | 15 | 36 |
| Trimethylbenzene (sum of isomers) (25551-13-7) | 25 | 123 | - | 314- |
| Trimethyl phosphite (121-45-9) | 2 | 10 | - | |
| 2,4,6-Trinitrophenol (88-89-1) Skin | - | 0.1 | - | 0.3 |
| Triphenyl amine (603-34-9) | - | 5 | - | - |
| Triphenyl phosphate (115-86-6) | _ | 3 | _ | Universal Park |

PART 4 Time-Weighted Average Exposure Values (TWAEV) and Short-Term Exposure Values (STEV) for Biological and Chemical Agents

| AGENT (CAS Reg. No.) | TW. | AEV mg/m ³ | ST: ppm | EV mg/m ³ |
|---|-----|--------------------------|------------|-------------------------|
| Tungsten, water-insoluble compounds of (as tungsten) (7440-33-7),(b) | - | 5 | _ | 10 |
| Tungsten, water-soluble compounds of, including tungstic acids, phosphotungstic acids and their | | | | |
| salts (as tungsten) (7440-33-7),(b) | _ | 1 | - | 3 |
| Uranium (natural) and its compounds (as uranium) (7440-61-1),(b) | - | 0.2 | _ | 0.6 |
| n-Valeraldehyde (110-62-3) | 50 | 175 | - | - 4 |
| Vanadium respirable dust and fume (as vanadium pentoxide) (1314-62-1),(b) | _ | 0.05 | - | _ |
| Vinyl acetate (108-05-4) | 10 | 35 | 20 | 70 |
| Vinyl bromide (593-60-2) | 5 | 22 | - | - |
| Vinyltoluene (mixture of m- and p-isomers) (25013-15-4) | 50 | 241 | 100 | 482 |
| Warfarin (81-81-2) | _ | 0.1 | - | _ |

PART 4 Time-Weighted Average Exposure Values (TWAEV) and Short-Term Exposure Values (STEV) for Biological and Chemical Agents

| AGENT (CAS Reg. No.) | TWAI ppm i | EV mg/m ³ | STEV ppm mg/m ³ |
|---|------------|-------------------------|----------------------------|
| Wood dust -certain hard | | | |
| woods as beech and oak, (a) -soft wood, (a) | - | 1 5 | - - 10 |
| Yttrium, metal and compounds (as yttrium) (7440-65-5),(b) | - " | 1 | |
| Zinc chloride fume (7646-85-7) | | 1 | - 2 |
| Zinc chromates (as chromium) (sum of (13530-65-9), (1103-86-9), and | | | |
| (37300-23-5)) Zinc oxide fume | | 0.01 | - |
| (1314-13-2) | - | 5 | - 10 |
| Zirconium compounds (as zirconium) (7440-67-7),(b) | <u> </u> | 5 | - 10 |

PART 5 Ceiling Exposure Values (CEV) for Biological and Chemical Agents

| | | CEV |
|---|------|-------------------|
| AGENT (CAS Reg. No.) | ppm | mg/m ³ |
| Acetic anhydride (108-24-7) | 5 | 21 |
| Boron tribromide (10294-33-4) | 1 | 10 |
| Boron trifluoride (7637-07-2) | 1 | 2.8 |
| n-Butyl alcohol (71-36-3) — Skin | 50 | 150 |
| n-Butylamine (109-73-9) Skin | 5 | 15 |
| tert-Butyl chromate, (as chromate) (1189-85-1) — Skin | _ | 0.1 |
| Cadmium-containing fume (as cadmium) (1306-19-0) | _ | 0.05 |
| Chlorine trifluoride (7790-91-2) | 0.1 | 0.4 |
| Chloroacetaldehyde (107-20-0) | 1 | 3 |
| o-Chlorobenzylidene malononitrile (2698-41-1) — Skin | 0.05 | 0.4 |
| -Chloroethanol (107-07-3) — Skin | 1 | 3.3 |
| Cyanogen chloride (506-77-4) | 0.3 | 0.75 |
| -Dichlorobenzene (95-50-1) | 50 | 300 |

PART 5 Ceiling Exposure Values (CEV) for Biological and Chemical Agents

| | CEV | |
|---|------|-------------------|
| AGENT (CAS Reg. No.) | ppm | mg/m ³ |
| Dichloroethyne (7572-29-4) | 0.1 | 0.4 |
| Ethylene glycol, vapour (107-21-1) | 50 | 127 |
| 5-Ethylidene-2-norbornene (16219-75-3) | 5 | 25 |
| Glutaraldehyde (111-30-8) | 0.2 | 0.8 |
| Hexylene glycol (107-41-5) | 25 | 120 |
| Hydrogen bromide (10035-10-6) | 3 | 10 |
| Hydrogen chloride (7647-01-0) | 5 | 7.4 |
| Hydrogen cyanide (74-90-8) Skin | 10 | 11 |
| Hydrogen fluoride (as fluoride) (7664-39-3) | 3 | 2.5 |
| Iodine (7553-56-2) | 0.1 | 1 |
| Methyl ethyl ketone peroxides (a) | 0.2 | 1.5 |
| Methylhydrazine (60-34-4) Skin | 0.2 | 0.38 |
| Oxygen difluoride (7783-41-7) | 0.05 | 0.1 |

PART 5 Ceiling Exposure Values (CEV) for Biological and Chemical Agents

| | | CEV | |
|---|-------|-------------------|--|
| AGENT (CAS Reg. No.) | ppm | mg/m ³ | |
| Phenylphosphine (638-21-1) | 0.05 | 0.23 | |
| Potassium hydroxide (1310-58-3) | | 2 | |
| Sodium azide (26628-22-8) | 0.1 | 0.26 | |
| Sodium hydroxide (1310-73-2) | _ | 2 | |
| Subtilisins (proteolytic enzymes as 100% pure crystalline enzyme) (9014-01-1) | - | 0.00006 | |
| Sulfur monochloride (10025-67-9) | 1 | 6 | |
| Sulfur pentafluoride (5714-22-7) | 0.01 | 0.1 | |
| Sulfur tetrafluoride (7783-60-0) | _ 0.1 | 0.4 | |
| Terphenyls (sum of o-, m-, and p-isomers; (84-15-1) (92-06-8), (92-94-4)) | 0.5 | 4.7 | |
| Thionyl chloride (7719-09-7) | 1 | 5 | |
| 1,2,4-Trichlorobenzene (120-82-1) | 5 | 37 | |
| Trichlorofluoromethane (75-69-4) | 1,000 | 5,600 | |

PART 5 Ceiling Exposure Values (CEV) for Biological and Chemical Agents

| | CEV | |
|---|-----|-------------------|
| AGENT (CAS Reg. No.) | ppm | mg/m ³ |
| 3,5,5-Trimethyl-2- cyclohexen-1-one (78-59-1) | 5 | 28 |
| m-Xylene-alpha,alpha'- diamine (1477-55-0) Skin | _ | 0.1 |

PART 6 Time-Weighted Average Exposure Values (TWAEV) for Mineral Dusts

| Management. | TWAEV-mg/m ³ | |
|---|-------------------------|-----------------|
| AGENT (CAS Reg. No.) | Total Dust | Respirable Dust |
| Coal dust (c) | 4 | 2 |
| Graphite, natural (7782-42-5) | 5 | 2.5 |
| Mica (12001-26-2) | 6 | 3 |
| Perlite (a) | 10 | 0 |
| Soapstone (a) | 6 | 3 |
| Talc (containing no asbestos fibres) (14807-96-6) | -1- | 2 |

^{*} Crystalline silica in a respirable form could be present in mineral dusts and, when it is, the Regulation respecting Silica, O. Reg. 769/83, shall also be consulted.

PART 7 Time-Weighted Average Exposure Values (TWAEV) for Nuisance Particulates

| AGENT (CAS Reg. No.) | TWAEY mg/m ³ |
|---|----------------------------|
| alpha-Alumina (total dust) (1344-28-1) | 10 |
| Barium sulfate (total dust) (7727-43-7) | 10 |
| Calcium carbonate, including marble (total dust) (471-34-1) | 10 |
| Calcium silicate (total dust) (1344-95-2) | 10 |
| Calcium sulfate, including plaster of Paris (total dust) (10101-41-4) | 10 |
| Cellulose (paper fibre, total dust) (9004-34-6) | 10 |
| Diatomaceous earth, uncalcined (total dust) (68855-54-9) | 10 |
| Emery (total dust) (57407-26-8) | 10 |
| Glycerin mist (56-81-5) | 10 |
| Graphite, synthetic (total dust) (a) | 10 |

^{*} Crystalline silica in a respirable form could be present in nuisance particulates and, when it is, the Regulation respecting Silica, O. Reg. 769/83, shall also be consulted.

PART 7 Time-Weighted Average Exposure Values (TWAEV) for Nuisance Particulates

| AGENT (CAS Reg. No.) | TWAEV mg/m ³ |
|--|-------------------------|
| | |
| Gypsum (total dust) (10101-41-4) | 10 |
| Kaolin (total dust) | |
| (1332-58-7) | 10 |
| Limestone (total dust) | 40 |
| (1317-65-3) | 10 |
| Magnesite (total dust) (546-93-0) | 10 |
| Mineral wool fibre (total dust) | |
| (a) | 10 |
| Pentaerythritol (total dust) | 10 |
| (115-77-5) | 10 |
| Portland cement (total dust) (65997-15-1) | 10 |
| Precipitated silica (total dust) | 10 |
| Rouge (total dust) | |
| (1309-37-1) | 10 |
| Silica gel (total dust) | 10 |
| Silicon (total dust) | |
| (7440-21-3) | 10 |
| Silicon carbide (total dust) (409-21-2) | 10 |
| Starch (total dust) | |
| (9005-25-8) | 10 |
| Stearates (total dust) (a) | 10 |
| | 10 |
| Sucrose (total dust) (57-50-1) | 10 |

PART 7 Time-Weighted Average Exposure Values (TWAEV) for Nuisance Particulates

| AGENT (CAS Reg. No.) | TWAEY mg/m ³ |
|--|-------------------------|
| Tantalum, metal and oxide (total dust) (7440-25-7), (b) | 10 |
| Titanium dioxide (total dust) (13463-67-7) | 10 |
| Vegetable oils (mists) except mists of irritant oils such as oils of castor and cashew nut | |
| (a) Zinc oxide dust (total dust) | 10 |
| (1314-13-2) | 10 |

PART 8 Time-Weighted Average Exposure Values (TWAEV) and Short-Term Exposure Values (STEV) for Chemical Agents of Variable Composition

| AGENT (CAS Reg. No.) | TWAEV mg/m ³ | STEV mg/m ³ |
|--|----------------------------|---------------------------|
| Asphalt fumes (as total benzene- soluble compounds) (8052-42-4) | 5 | W. 3 = 5 |
| Chlorinated diphenyl oxides (55720-99-5) | 0.5 | 2 |
| Coal tar pitch volatiles ¹ (as total benzene-soluble compounds) (8007-45-2),(b) | 0.2 | |
| Gasoline (8006-61-9) | 900 | 1,500 |
| Hydrogenated terphenyls ¹ (61788-32-7) | 5 ` | - |
| Isooctyl alcohol (26952-21-6) — Skin | 270 | |
| L.P.G. (Liquified petro- leum gas) (68476-85-7) | 1,800 | -1,- |
| Methyl acetylene-propadiene mixture (MAPP) (a) | 1,800 | 2,250 |
| Oil, mineral - Mist (8012-95-1) | 5 | 10 |
| Paraffin wax fume (8002-74-2) | 2 | |

As sum of components assayed by chromatographic procedure with reference to the bulk sample.

PART 8 Time-Weighted Average Exposure Values (TWAEV) and Short-Term Exposure Values (STEV) for Chemical Agents of Variable Composition

| AGENT (CAS Reg. No.) | TWAEV mg/m ³ | STEV mg/m ³ |
|---|-------------------------|---------------------------|
| Polychlorinated biphenyls (PCBs) ¹ (1336-36-3) — Skin | 0.05 | |
| Rosin core solder pyrolysis products (as formaldehyde) | 0.1 | 0-12-7 |
| Rubber solvent ¹ (a) | 1,600 | |
| Stoddard solvent ¹ (8052-41-3) | 525 | |
| Toxaphene ¹ (8001-35-2) Skin | 0.5 | 1 |
| Turpentine (8006-64-2) | 560 | 1000 |
| V.M.& P. Naphtha ¹ , (8030-30-6) | 1,350 | 1 |
| Welding fume or particulate, Aluminum-containing (as aluminum) (7429-90-5), (b) | 5 | |
| Iron-containing (as iron) (7439-89-6), (b) | 5 | |
| Other, not otherwise classified (total weight, oil-free) (a) | . 5 | 11-2-11/2 01-1-2-1-2 |

As sum of components assayed by chromatographic procedure with reference to the bulk sample.

PART 9 Exposure Values for Simple Asphyxiants

The agents listed below are examples of simple asphyxiants which have not been assigned any definite exposure values. These agents cause asphyxiation by diluting the atmospheric oxygen level below that required to maintain normal respiratory function. If any of the listed gases and vapours is present in the air, the minimal oxygen content should not be less than 18 per cent by volume at any time. A number of the simple asphyxiants can form explosive mixtures in air; therefore, the explosive hazard should be considered when limiting the airborne concentration of these asphyxiants.

| Agent | (CAS Reg. No.) |
|-----------|----------------|
| | |
| Acetylene | (74-86-2) |
| Argon | (7440-37-1) |
| Ethane | (74-84-0) |
| Ethylene | (74-85-1) |
| Helium | (7440-59-7) |
| Hydrogen | (1333-74-0) |
| Methane | (74-82-8) |
| Neon | (7440-01-9) |
| Nitrogen | (7727-37-9) |
| Propane | (74-98-6) |
| Propylene | (115-07-1) |

PART 10 Known Toxic Agents for Which Exposure Values Have
Not Been Established, and to Which Any Exposure
Should be Avoided

| Agent (C | AS Reg. No.) |
|---|--------------|
| | |
| Benzidine Skin | (92-87-5) |
| Benzo(a)pyrene | (50-32-8) |
| (1,1'-Biphenyl)-4-amine Skin | (92-67-1) |
| Chloromethyl methyl ether | (107-30-2) |
| Chrysene | (218-01-9) |
| 1,2-Dibromoethane - Skin | (106-93-4) |
| 3,3'-Dichlorobenzidine Skin | (91-94-1) |
| 3,3'-Dimethyl-(1,1'-biphenyl)-4,4'-diamine Skin | (119-93-7) |
| Dimethylcarbamoyl chloride | (79-44-7) |
| Hexamethylphosphoric triamide Skin | (680-31-9) |
| beta-Naphthylamine | (91-59-8) |
| 4-Nitrobiphenyl | (92-93-3) |
| N-Nitrosamines Skin (e.g. N-Nitrosodimethylamine) | (a) |
| 1,2-Oxathiolane 2,2-dioxide | (1120-71-4) |
| N-Phenyl-beta-naphthylamine | (135-88-6) |

89

PART 11 Exposure Values* for Acrylonitrile, Benzene and Mercury

| Agent (CAS Reg. No.) | TW ppm | MAEV mg/m ³ | STEV ppm mg/m ³ | CEV ppm mg/m | 3 |
|---|-----------|------------------------|-------------------------------|-----------------|---|
| Acrylonitrile (107-13-1) | 2 | 4.3 | 150 200 | 10 21.5 | |
| Benzene (71-43-2) | 5 | 16 | 1 4 | 15 48 | |
| Mercury - all forms of except alkyl (as mercury) | | | | | |
| (7439-97-6), (b) - alky compounds of (as mercury) | - | 0.05 | - 0.15 | | |
| (7439-97-6), (b) | - | 0.01 | - 0.03 | | |

The values listed in this part apply to work places to which the designated substance regulation does not apply.

O. Reg. 654/86, Sched.

RETAIL SALES TAX ACT

O. Reg. 655/86. General. Made-October 30th, 1986. Filed-November 6th, 1986.

REGULATION TO AMEND **REGULATION 904 OF** REVISED REGULATIONS OF ONTARIO, 1980 MADE UNDER THE RETAIL SALES TAX ACT

- 1. Clause 2 (a) of Regulation 904 of Revised Regulations of Ontario, 1980, as made by section 2 of Ontario Regulation 232/86, is revoked and the following substituted therefor:
 - (a) "install" includes the erection or assembly of tangible personal property, but does not include the erection or assembly of scaffolding, formwork, hoarding, construction cranes or temporary power or utilities used in the construction, renovation, maintenance, restoration or repair of real property; and
- 2. This Regulation shall be deemed to have come into force on the 14th day of June, 1982.

47 (9693)

APPRENTICESHIP AND TRADESMEN'S QUALIFICATION ACT

O. Reg. 656/86. Horticulturist. Made—October 23rd, 1986. Filed—November 6th, 1986.

REGULATION MADE UNDER THE APPRENTICESHIP AND TRADESMEN'S **OUALIFICATION ACT**

HORTICULTURIST

- 1. In this Regulation, "cértified trade" means the trade of horticulturist. O. Reg. 656/86, s. 1.
- 2. The trade of horticulturist is designated as a certified trade for the purposes of the Act. O. Reg. 656/86, s. 2.
- 3. The certified trade is composed of two branches as follows:

- 1. Branch 1, nursery-greenhouse worker.
- 2. Branch 2, landscaper-greenskeeper. O. Reg. 656/86, s. 3.
- 4. An apprentice training program is established for the certified trade and shall consist of,
 - (a) training and instruction at a location approved by the Director in the units of study listed in items 1 to 24 of Schedule 1 for Branch 1 and in the units of study listed in items 1 to 15 and in items 25 to 36 of Schedule 1 for Branch 2; and
 - (b) work experience training provided by the employer of the apprentice in the units of study listed in items 1 to 10 of Schedule 2 for Branch 1 and in the units of study listed in items 10 to 20 of Schedule 2 for Branch 2. O. Reg. 656/86, s. 4.
 - 5.—(1) An apprentice in the certified trade shall,
 - (a) for Branch 1, complete related training and work experience training of 4,500 hours; and
 - (b) for Branch 2, complete related training and work experience training of 4,500 hours.
- (2) The holder of a certificate of qualification in Branch 1 of the certified trade is entitled to a certificate of qualification in Branch 2 of the certified trade upon completion of a further period of related training and work experience training of 1,500 hours approved by the Director.
- (3) The holder of a certificate of qualification in Branch 2 of the certified trade is entitled to a certificate of qualification in Branch 1 of the certified trade upon completion of a further period of related training and work experience training of 1,500 hours approved by the Director. O. Reg. 656/86, s. 5.
- 6. The subjects of examination for an apprentice in the certified trade are based upon the units of study contained in Schedules 1 and 2. O. Reg. 656/86, s. 6.
- 7. Notwithstanding subsection 8 (2) of Regulation 36 of Revised Regulations of Ontario, 1980 (General), every hour worked by an apprentice in excess of the apprentice's regular daily hours of work experience training shall be included in computing the hours spent by the apprentice in work experience training. O. Reg. 656/86, s. 7.
- 8. The Director shall issue a progress record book to an apprentice in the certified trade for the purpose of recording the progress of the apprentice in respect of related training and work experience and the apprentice shall be responsible for keeping the progress record up to date and for its safe keeping. O. Reg. 656/86, s. 8.

9. Section 10 of Regulation 36 of Revised Regulations of Ontario, 1980 (General) does not apply to an apprentice in the certified trade. O. Reg. 656/86, s. 9.

10.—(1) Section 9 and subsection 11 (2) of the Act do not apply to any person who works or is employed in the certified trade.

(2) Section 10 and subsection 11 (3) of the Act do not apply to any employer in the certified trade. O. Reg. 656/86, s. 10.

11. A certificate of qualification in the certified trade is not required to be renewed. O. Reg. 656/86, s. 11.

Schedule 1 IN-SCHOOL TRAINING

| ITEM | COLUMN 1 | COLUMN 2 |
|------|-----------------------------------|---|
| LILL | UNIT OF STUDY | INSTRUCTION TO BE GIVEN |
| 1. | SAFETY | Safety rules and safe operating procedures. Protective clothing and equipment. First aid. Fire prevention; use and maintenance of fire fighting equipment. Handling and storing toxic solvents and materials. Occupational Health and Safety Act. Workers' Compensation Act. Ontario Pesticides Act. |
| 2. | TRADE CALCULATIONS AND BLUEPRINTS | Addition, substraction, multiplication and division of whole numbers, fractions and decimals, ratio and proportion, areas. Lines, planes and angles; application to layout. Basic drafting and interpretation of blueprints. Site restrictions. Layout control stakes for grading operations. Layout lines of control for patios, walks, retaining walls. |
| 3. | TRADE COMMUNICATIONS | Effective communication. Reports, forms, work orders, instruction manuals, periodicals, trade journals. |
| 4. | BOTANY | Basic plant development from seed to mature plant. Germination, plant cells, osmosis, diffusion, transpiration, evaporation. Cell division, photosynthesis. Effects of temperature, soil conditions and oxygen. Parts and functions of a leaf, stem and root. |
| 5. | PORTABLE HAND AND POWER TOOLS | Care and use of all trade portable hand and power tools. Importance of proper tool selection. |
| 6. | PLANT MATERIAL I | Identification of hardy woody, herbaceous and annual plant materials commonly used within the industry. Cultural requirements of woody and herbaceous plant materials as they pertain to moisture, soil type, hardness, light and nutrient requirements. |

| ITEM | COLUMN 1 | ° COLUMN 2 |
|------|-----------------------------|---|
| LIBN | UNIT OF STUDY | INSTRUCTION TO BE GIVEN |
| 7. | SOILS AND FERTILIZERS | Soil characteristics and identification Sampling and testing for pH. Identification and application of common fertilizers. Growth regulators. |
| 8. | BASIC TURF MANAGEMENT | Identification of common turf varieties: blue grass, fescue, perennial rye, bent grass. Seeding and sodding procedures to establish and maintain healthy turf. |
| 9. | PLANTING TECHNIQUES I | Hand and machine planting methods and procedures. Preparation of planting beds and pits. Replanting and transplanting methods and procedures. |
| 10. | PRUNING | Use and care of: pruning knives, budding knives, secateurs, loppers, pole pruners, hedge trimmers, pruning saws. Root pruning techniques. Methods of pruning shrubs, fruit trees, shade trees and evergreens. |
| 11. | DISEASE AND PEST CONTROL | Recognition and control of weeds, insects and disease. Selection, mixing and application of fungicides, repellents and poisons. Ministry of Environment standards, manufacturer's specifications, Ontario Pesticides Act. |
| 12. | BASIC GRADING | Interpretation of grading plan. Setting grades. Rough grading. Cut and fill procedures. Stripping, conservation and reapplication of topsoil. |
| 13. | BASIC CARPENTRY | Identification and selection of timber for landscape applications. Familiarity with lumber mill grade stamps. Construction of screens, fences, decks and forms. |
| 14. | SMALL ENGINE MAINTENANCE | Care and use of all small internal combustion engines. Maintenance procedures, non-scheduled repairs, use of manufacturer's manuals and specification charts. |

| ITEM | COLUMN 1 | COLUMN 2 |
|------|----------------------------|--|
| ITEM | UNIT OF STUDY | INSTRUCTION TO BE GIVEN |
| 15. | DRY MASONRY | Care and use of masonry tools. Preparation of base and foundation for laying paving stones and bricks, pre-cast units. Cutting and shaping as required. |
| 16. | PROPAGATION AND PRODUCTION | Methods of propagating nursery stock. Production of annuals and herbaceous perennials, woody shrubs and trees, aquatic plants and vines, by grafting, budding, seeding or from cuttings, using container and row cultures. Preparation of seed beds and flats. |
| 17. | GREENHOUSE GROWING | Producing and maintaining greenhouse plant materials. Care and operation of greenhouse. Control of: humidity, light ventilation, carbon dioxide, water, temperature, periodicity. Use of artificial growing mediums and hydroponic systems. Spraying and fumigating. |
| 18. | ADVANCED BOTANY | Recognition and identification of mature plant materials and scope of application, including botanical names and their meaning. Plant hardiness and cultural requirements. Handle, store, protect and grade nursery stock in accordance with requirements of Canadian Nursery Trades Association Guide Specifications. |
| 19. | ADVANCED SOILS | Cultivation and grading by hand and machine. Sub-soiling. Sterilization and reconditioning. |
| 20. | FERTILIZERS | Selection and application of fertilizers. The importance of: nitrogen, phosphorus, potassium and trace elements. Storing of fertilizers. |
| 21. | IRRIGATION | Care and use of manual and automatic irrigation systems for nursery stock and greenhouse crops. |

| | | e e |
|-------|------------------------------|---|
| ITEM | COLUMN 1 | COLUMN 2 |
| 11150 | UNIT OF STUDY | INSTRUCTION TO BE GIVEN |
| 22. | PLANTING TECHNIQUES II | Preparation and transplanting of all nursery stock by hand and machine. Staking and guying. Large material planting. Balled and burlap/bare root materials. Bedding. |
| 23. | POWER TOOLS AND EQUIPMENT | Care and use of all trade power tools and equipment, including: chain saws, tractors/loaders, sod cutters, rototillers, hedge trimmers, spreaders, seeders, tree spades, planting machines, sprayers, sterilizers, potting machines, slings and cultivators. |
| 24. | PLANT MATERIAL II | Methods and application of winter protection for plant materials including: wrapping/screening, mulching/hilling, traps, baits, spraying and wire screen protection. Winter storage requirements for harvested and container-grown nursery stock. |
| 25. | PLANT MATERIAL III | Identification of at least eighty hardy herbaceous and annual plants. Methods of providing winter protection when required. Methods of repairing and salvaging damaged plant material such as: pruning, bark tracing, bracing and guying, bridging and grafting, wood dressing applications. Identification and grading of plant material. Interpretation of C.N.T.A. guide specifications. |
| 26. | PLANTING I | Methods of installing nursery stock. Staking out plant bed locations. Preparation of planting pits and beds: - excavation - drainage - backfilling - fine grade, mulching and irrigation. |
| 27. | LANDSCAPE DESIGN | Preparation of basic residential land- scape sketches. Determination of design requirements and landscape features. |

| ITEM | COLUMN 1 | COLUMN 2 |
|-------|--|--|
| TIEFI | UNIT OF STUDY | INSTRUCTION TO BE GIVEN |
| 28. | ADVANCED GRADING | Preparation of grading plans. Use of levels, batter boards, cross heads and boning rods. Establishing areas of cut and fill. Care and use of grading equipment to strip and stockpile topsoil, establish sub-grade, replace topsoil and fine grade. |
| 29. | LANDSCAPE CONSTRUCTION I | Constructing timber landscape structures by: estimating material requirements, laying out structure, excavating as required, cutting and securing components, finishing surface as required. Methods of mixing and placing concrete using appropriate materials and equipment. Constructing simple masonry structures and walls. Asphalt applications, physical properties and base preparations. Finishing methods. |
| 30. | ESTIMATING I | From prepared plans, methods of calculating quantities of: materials, labour, equipment. Determination of unit prices, allowance for overhead factors, profit. Tendering procedures. |
| 31. | EQUIPMENT III | Care and use of all hand and power tools and equipment, including: trimmers, scythes, edgers, mowers, sod cutters, rollers, spreaders, shredders, tractors plows, augers, rotavators, harrows, blowers, sprayers, mixers, compaction, grading and soil equipment, chain saws, aerifiers, seeders, dressers, thatchers, lawn sweepers and trap rakes. |
| 32. | TURF MANAGEMENT | Selecting, developing and maintaining the standard fine turf species in Ontario. Selecting appropriate turf as required for tees, fairways and greens. |
| 33. | GOLF COURSE RENOVATION AND RECONSTRUCTION | Principles of golf course design and lay-out, including: tees, greens, fairways and traps. Preparation of soil mixtures and additives. Selection and installation of common drainage components. |

| ITEM | COLUMN 1 | COLUMN 2 |
|------|-------------------------|--|
| 1150 | UNIT OF STUDY | INSTRUCTION TO BE GIVEN |
| 34. | FERTILIZERS II | Selection and use of fertilizers to produce quality of turf desired. Importance of nitrogen, phosphorus, and potassium to plant growth. Identification of trace element deficiencies. Selection, identification and application of fertilizers as required. Proper storage procedures for fertilizers. |
| 35. | IRRIGATION | Identification of water requirements in new and existing landscapes. Operation and maintenance of manual and automatic irrigation systems. |
| 36. | GOLF COURSE MAINTENANCE | Maintaining fine turf on golf courses. Methods of de-thatching, overseeding, aerating, brushing, spraying, fertilizing and rolling of fine turf. Changing cup holes and markers. Sand trap maintenance. Proper mowing procedures. |

O. Reg. 656/86, Sched. 1,

Schedule 2

WORK EXPERIENCE TRAINING

| ITEM | COLUMN 1 | COLUMN 2 |
|------|----------------------------|--|
| | UNIT OF STUDY | INSTRUCTION TO BE GIVEN |
| 1. | PROPAGATION AND PRODUCTION | Methods of producing and propagating nursery stock including: annuals, herbaceous perennials, woody shrubs, trees, aquatic plants and vines. Methods of grafting, budding, seeding using container and row cultures, preparation of seed beds and flats. |
| 2. | GREENHOUSE GROWING | Methods of producing and maintaining greenhouse plant materials. Methods of operating a greenhouse through proper control of: humidity, light, ventilation, water, temperature, carbon dioxid and photo-periodicity. Use of artificial growing media. Methods of spraying and fumigating. |
| 3. | ADVANCED BOTANY | Identification and features of woody an herbaceous plant material commonly encountered in the industry. Selection of plants for specific landscape applications. Cultural and hardiness factors including light, soil and moisture. Methods of harvesting plant material. Handling, storing, protectin and grading nursery stock. Application of Canadian Nursery Trades Association Guide Specifications. |
| 4. | ADVANCED SOILS | Preparation of soil for nursery production. Identification of soil structure and type. Sterilization and reconditioning procedures. Proper drainage and cultivation methods. |
| 5. | FERTILIZERS | Selection and application of fertil- izers. The importance of potassium, nitrogen and phosphorus to plant growth Identification and remedies for trace element deficiencies. |
| 6. | IRRIGATION | Proper use of manual and automatic irrigation systems for nursery stock an greenhouse crops. |

| | | 0 |
|------|------------------------------|---|
| ITEM | COLUMN 1 | COLUMN 2 |
| TIEM | UNIT OF STUDY | INSTRUCTION TO BE GIVEN |
| 7. | PLANTING TECHNIQUES | Preparation of plants for transplanting: balling, potting, bare-rooting. Methods of staking and guying transplanted stock. Care and use of machines used to plant stock: tree spades, tree planters and potting machines. |
| 8. | GREENHOUSE MAINTENANCE | Maintenance and repair of greenhouses and related equipment. Proper installation of valves and pipe fittings. Glass cutting and reglazing techniques. Polyhouse construction. |
| 9. | POWER TOOLS AND EQUIPMENT | Care and use of power tools and equipment including: chain saws, tractors, sod cutters, rototillers, hedge trimmers, spreaders, seeders, tree spades, planting machines, sprayers, sterilizers and posting machines. |
| 10. | PLANT MATERIALS | Determination of winter protection requirements for plant material. Winter storage requirements for harvested and container-grown nursery stock. Methods of: wrapping/screening, mulching/ hilling, spraying and wire screen protection. Recognition of damaged plant material and methods of repair: pruning, bark tracing, bracing and guying, bridging and grafting, wood dressing applications. |
| 11. | PLANTING II | Methods of installing nursery stock. Staking out plant/bed locations. Preparation of planting pits and beds: excavation and removal of excess fill, provision of drainage where required, backfilling with planting mixture and nursery stock, fine grading, mulching and irrigation. |
| 12. | LANDSCAPE DESIGN | Preparation of basic residential land- scape sketches. Determination of design requirements. Selection and delineation of the required landscape features. |

| | COLUMN 1 | COLUMN 3 |
|------|--------------------------------|--|
| ITEM | COLUMN 1 | COLUMN 2 |
| | UNIT OF STUDY | INSTRUCTION TO BE GIVEN |
| 13. | ADVANCED GRADING | Laying out grading plans. Use of survey level, batter boards, cross heads and boning rods to establish areas of cuts and fill according to plan. Grading operations and selection of appropriate equipment. Stripping and stockpiling topsoil, establishing sub-grade, fine grading. |
| 14. | LANDSCAPE CONSTRUC- TION II | Construction of lumber and/or timber landscape structures, from drawings or specifications. Estimating material requirements. Layout procedures and preparation of base. Cutting and securing components. Mixing and placing of concrete. Finishing techniques. Construction of masonry surface/wall. Preparation of base for asphalt application. Care and use of proper equipment. |
| 15. | ESTIMATING II | From landscape drawings and/or plans, methods of: calculating quantities of materials, labour and equipment requirements. Methods of determining unit prices, overheads, profit margins. Tendering procedures. |
| 16. | EQUIPMENT IV | Care and use of all hand tools including: slings, chains, rigging, ropes and tree spurs. Care and use of all power tools and equipment including: trimmers, chain saws, mowers, tractors, cutters, rototillers, spreaders, plows, seeders, rollers, augers, mixers, spades, compactors, edgers, loaders and shredders. |
| 17. | TURF MANAGEMENT III | Selecting, developing and maintaining the standard fine turf species in Ontario. Selecting appropriate turf as required for tees, fairways and greens. Methods of cutting, rolling and staking nursery turf. |

| ITEM | COLUMN 1 | COLUMN 2 |
|------|---|---|
| TTEM | UNIT OF STUDY | INSTRUCTION TO BE GIVEN |
| 18. | GOLF COURSE RENOVATIONS AND RECONSTRUCTION | Principles of golf course layout and design. Preparation of soil mixtures and additives for greens, tees and fairways. Proper selection, installation and maintenance of drainage components. |
| 19. | FERTILIZERS III | Methods of fertilizing fine turf. Identification of cultural requirements. Application and storage of quality fertilizers. Soil test procedures. |
| 20. | IRRIGATION III | Methods of installing and maintaining irrigation components as determined by landscape characteristics. Use of manual and automatic systems. |

O. Reg. 656/86, Sched. 2.

(9694)

47

ENVIRONMENTAL ASSESSMENT ACT

O. Reg. 657/86.

Exemption—Ministry of Natural Resources—MNR-30/7. Made—October 30th, 1986. Approved—October 30th, 1986. Filed—November 7th, 1986.

ORDER MADE UNDER THE ENVIRONMENTAL ASSESSMENT ACT

EXEMPTION—MINISTRY OF NATURAL RESOURCES—MNR-30/7

Having received a request from the Minister of Natural Resources that an undertaking, namely:

The carrying out of the Provincial Parks Program including:

- (a) implementing:
 - 1. Park Management Plans,
 - 2. Resource Management Strategies,
 - 3. Operations Strategies and Maintenance Schedules,
 - 4. Development Strategies,
 - 5. Site Plans,

- Visitor Service and Interpretive Programs,
- Capital Construction and Lease Purchase Projects,

in Provincial Parks:

- (b) developing sewage or water works within or for Provincial Parks;
- (c) acquiring land to amend the boundaries of existing Provincial Parks, to complete land acquisition for an existing Provincial Park or for a sewage lagoon in or for a Provincial Park; and
- (d) establishing, amending and rescinding boundary regulations for existing Provincial Parks;

be exempted from the application of the Act pursuant to section 29; and

Having been advised that if the undertaking is subject to the application of the Act, the following injury, damage or interference with the persons and property indicated will occur:

A. The Ministry of Natural Resources has included a schedule for completion of an Environmental Assessment (EA) for Provincial Park Management with its request for exemption. Pre-submission consultation and completion of the EA for formal submission

will be hampered by having to prepare separate exemptions or assessments for all Provincial Park projects at the same time.

- B. Park environmental and recreational features could be damaged in the absence of Provincial Park projects that address existing park management problems.
- C. Public enjoyment of recreational features may be reduced in the absence of the implementation of Provincial Park projects.
- D. The realization of the Government's Outdoor Recreation Program Objective and economic benefits to local communities would be limited.

Having weighed such injury, damage or interference with the betterment of the people of the whole or any part of Ontario by the protection, conservation and wise management of the environment which would result from the undertaking being subject to the application of the Act;

The undersigned is of the opinion that it is in the public interest to order and orders that the undertaking is exempt from the application of the Act for the following reasons:

- A. This interim exemption will allow Provincial Park plans and projects to continue while the Environmental Assessment for Provincial Park Management undergoes pre-submission consultation.
- B. The Provincial Parks Program is carried out within a context of conservation, protection and wise management of the environment. A major feature of the Provincial Parks Program is the preservation of significant, natural and cultural features in the Ontario landscape.
- C. The conditions to which this undertaking is subject will ensure that affected Government agencies and the public are informed of MNR's intentions to implement components of the Provincial Parks Program during the period of this exemption order.
- D. A number of activities that make up this undertaking are similar to activities that are covered by approved MNR Class Environmental Assessments. The Minister of Natural Resources will apply such parts of the procedures specified in the Class Environmental Assessments as are appropriate to the activities that make up this undertaking until such procedures or other procedures are made directly applicable by the Environmental Assessment referred to in reason A.

This exemption order is subject to the following rms and conditions:

- This exemption order does not apply to any plan or project:
 - (a) for any provincial park designated by regulation under the *Provincial Parks* Act after June 1, 1983;
 - (b) where development is likely to affect the habitat of a species designated under the Endangered Species Act (except for protecting the species);
 - (c) where the estimated completion cost of a sewage or water works or a capital construction or lease purchase project is in excess of \$2 million, not including any land acquisition costs.
- This exemption order does not apply to any plan or project which includes the disposition of property or interests in property to the private sector for:
 - (a) the development of a new commercial recreation facility or the upgrading of an existing commercial recreational facility;
 - (b) mineral exploration or development;

both of which will be done pursuant to Exemption Order MNR-26/4, as amended from time to time.

- 3. MNR will continue to provide the Environmental Assessment Branch as well as the Regional Office of the Ministry of the Environment (MOE) with a list of proposed plans and projects (e.g., capital development and facility upgrading projects, resource management activities, preparation or review of management plans) for the Provincial Parks Program no less than 30 days prior to the implementation of any project. The lists will specify the nature, scope and location of all plans and projects and will specify which plans and projects will be carried out pursuant to another exemption order. MNR will notify the above offices of revisions to the lists no less than 30 days prior to the implementation of any such plans or projects.
- 4. A copy of all plans prepared for projects specified in the lists noted in Condition 3 shall be available to the public for examination at the appropriate District Office of MNR at least 30 days before implementation commences.
- Any activity exempt under this order that would be approved under a MNR Class Environmental Assessment, except that the approval does not apply to Provincial Parks, shall be carried out in accordance with the

appropriate Class EA procedures, as though the activity was not in a Provincial Park by:

- (a) following the appropriate Class EA procedures, including notification, if there is no Park Management Plan; and
- (b) following the environmental quality guidelines and Construction and Mitigation Handbook, if there is a Park Management Plan.
- 6. Where the Minister of the Environment determines, after consultation with the Minister of Natural Resources, that a proposed plan or project:
 - (a) may generate an unusual amount of public or Government concern; or
 - (b) may have unusual or significant potential environmental impacts not adequately treated in the pertinent planning exercise,

the Minister of the Environment may, by written notice to the Minister of Natural Resources, direct that an environmental assessment be prepared for the plan or project in which event the plan or project will not be exempt under this order.

- 7. Where the Minister of the Environment has given written notice to the Minister of Natural Resources that he is considering the application of Condition 6 to a plan or project, MNR shall not implement the plan or project until 45 days have elapsed from the giving of notice or the Minister of the Environment gives written notice to the Minister of Natural Resources that it is not proposed to require an environmental assessment.
- 8. During the period covered by this order, the Provincial Parks Program shall be planned, implemented and managed according to the following Provincial Parks' guidelines and policies:
 - o Ontario Provincial Parks Policy
 - o Ontario Provincial Parks Planning and Management Policies
 - o Provincial Park Management Planning Guidelines - 1983
 - o Provincial Park Management Planning Reference - 1986
 - o Ontario Provincial Parks Provincial Operating Standards
 - o Ontario Provincial Parks Capital Maintenance Standards
 - o Ontario Provincial Parks Development Manual

- o Ontario Provincial Parks Development Standards
- o Parks and Recreational Areas Branch Policies and Procedures
- o Visitor Services Interim Policy
- 9. The guidelines and policies specified in Condition 8 and any revisions or additions to these guidelines and policies will be made available by MNR for public inspection upon request and will be forwarded to the Environmental Assessment Branch of the Ministry of the Environment.
- 10. Those plans and projects planned under the previous exemption (MNR-30/6), filed as Ontario Regulation 576/85, but not implemented by the date of its expiry, may continue to proceed in accordance with the conditions of this exemption.
- 11. Those plans and projects planned under this exemption, but not fully implemented by the date of expiry of this exemption, will have their status under the Environmental Assessment Act reviewed in connection with the review of the Class Environmental Assessment for Provincial Park Management and, if provided for in conditions of approval issued in connection with the undertaking, may continue to proceed in accordance with such conditions.
- 12. This order expires on April 30, 1987 except that the Minister of the Environment, taking into consideration the progress of the Ministry of Natural Resources on pre-submission consultation and any related drafting of the Class Environmental Assessment for Provincial Park Management and upon the request of the Minister of Natural Resources, may extend this expiry date but this extention shall not be beyond October 31, 1987.
- 13. If the Ministry of Natural Resources has submitted a Class Environmental Assessment under this Act for the Provincial Park Management undertaking prior to the expiry of this order, this order shall remain in effect until a final decision on the approval of the Class Environmental Assessment has been made.
- 14. Where an Environmental Assessment has been done and approval to proceed issued for an individual Provincial Parks plan or project, that plan or project shall be deemed to be a separate undertaking not exempt by this order. O. Reg. 657/86.

JAMES BRADLEY

Minister of the Environment

ENVIRONMENTAL ASSESSMENT ACT

O. Reg. 658/86.

O. Reg. 658/86

Exemption-The Corporation of the Township of Marathon-MARN-

Made-October 30th, 1986. Approved-October 30th, 1986. Filed-November 7th, 1986.

ORDER MADE UNDER THE ENVIRONMENTAL ASSESSMENT ACT

EXEMPTION—THE CORPORATION OF THE TOWNSHIP OF MARATHON—MARN-TP-1

Having received a request from The Corporation of the Township of Marathon that an undertaking, namely:

The activity of construction, operating and maintaining a deep well, well pumphouse and water distribution system to service the Marathon Industrial Park, located in the Township of Marathon, District of Thunder Bay,

be exempt from the application of the Act pursuant to section 29; and

Having been advised by The Corporation of the Township of Marathon that if the undertaking is subject to the application of the Act, the following injury, damage or interference with the persons and property indicated will occur:

- A. The four occupants of the newly established industrial park will be interfered with by having to use trucked-in water.
- B. The Corporation of the Township of Marathon will be damaged and interfered with by being required to prepare an environmental assessment for an undertaking which will not have adverse effects on the environment.

Having weighed such injury, damage or interference against the betterment of the people of the whole or any part of Ontario by the protection, conservation and wise management in Ontario of the environment which would result from the undertaking being subject to the application of the Act;

The undersigned is of the opinion that it is in the public interest to order and orders that the undertaking is exempt from the application of the Act for the following reasons:

> A. The proponent has advised that the environmental effects of the construction and operation of the water system will not be adverse nor are there any adjacent owners which it will affect.

This exemption is subject to the following terms and conditions:

- 1. Within 30 days after construction commences, the proponent shall notify in writing the Director of the Environmental Assessment Branch of the Ministry of the Environment of the date when construction commenced.
- 2. This order shall expire if construction has not commenced by June 30, 1987. O. Reg. 658/86.

JAMES BRADLEY Minister of the Environment

(9696)

ENVIRONMENTAL ASSESSMENT ACT

O. Reg. 659/86. Exemption-Ministry of Government Services-MGS-73. Made-October 30th, 1986. Approved-October 30th, 1986. Filed-November 7th, 1986.

ORDER MADE UNDER THE **ENVIRONMENTAL ASSESSMENT ACT**

EXEMPTION-MINISTRY OF GOVERNMENT SERVICES-MGS-73

Having received a request from the Ministry of Government Services that an undertaking, namely:

The activity of providing the Ministry of Transportation and Communications' Freeway Traffic Management System Control Centre and Central Region Office Building at 1201 Wilson Avenue, Downsview.

be exempt from the application of the Act pursuant to section 29; and

Having been advised by the Ministry of Government Services that if the undertaking is subject to the application of the Act, the following injury, damage or interference with the persons and property indicated will occur:

> A. The Crown will be interfered with by the expense required to prepare an environmental assessment for an undertaking which will have insignificant environmental effects.

Having weighed such injury, damage or interference against the betterment of the people of the whole or any part of Ontario by the protection, conservation and wise management in Ontario of the environment which would result from the undertaking being subject to the application of the Act;

The undersigned is of the opinion that it is in the public interest to order and orders that the undertaking is exempt from the application of the Act for the following reasons:

A. The proposed undertaking will have insignificant adverse effects on the environment.

This exemption is subject to the following terms and conditions:

- Where any activity which otherwise would be exempt under this order is being carried out as or is part of an undertaking for which an environmental assessment has been accepted and approval to proceed received, the activity shall be carried out in accordance with any terms or conditions in the approval to proceed as well as the conditions of this order.
- 2. Where any activity which is the subject of this order is being carried out as or is part of another undertaking which is the subject of an exemption order under the Act, the activity exempt under this order shall be carried out in accordance with any terms or conditions in the other exemption order as well as the conditions in this order.
- This exemption shall cease to apply unless construction has commenced by December 31, 1992. O. Reg. 659/86.

JAMES BRADLEY
Minister of the Environment

(9697)

17

HEALTH PROTECTION AND PROMOTION ACT, 1983

O. Reg. 660/86.
Rabies—Immunization.
Made—November 6th, 1986.
Filed—November 7th, 1986.

REGULATION TO AMEND ONTARIO REGULATION 594/85 MADE UNDER THE HEALTH PROTECTION AND PROMOTION ACT, 1983

1. Table 1 of Ontario Regulation 594/85, as amended by section 1 of Ontario Regulation 120/86, section 3 of Ontario Regulation 287/86, section 1 of Ontario Regulation 501/86 and section 1 of Ontario Regulation 622/86, is further amended by adding thereto the following item:

9. Middlesex-London District Health Unit

November 1, 1986

(9698)

November 1, 1986

PLANNING ACT, 1983

O. Reg. 661/86.

Delegation of Authority of Minister under Section 4 of the Planning Act, 1983— Official Plans—Hamilton-Wentworth. Made—November 3rd, 1986. Filed—November 7th, 1986.

ORDER MADE UNDER THE PLANNING ACT, 1983

DELEGATION OF AUTHORITY OF MINISTER UNDER SECTION 4 OF THE PLANNING ACT, 1983—OFFICIAL PLANS—HAMILTON-WENTWORTH

- 1. Subject to sections 2 and 3, all authority of the Minister under section 17, except subsections 17 (19) and (21), subsection 20 (1), subsections 22 (1) and (3) and section 64 of the *Planning Act*, 1983 is delegated to the council of The Regional Municipality of Hamilton-Wentworth in respect of official plans for the local municipalities within that regional municipality. O. Reg. 661/86, s. 1.
- 2.—(1) The delegation in section 1 does not apply to an official plan or official plan amendment submitted to the Minister for approval prior to the day this Order comes into force.
- (2) The delegation in section 1 does not apply to an official plan adopted by the council of The Corporation of the Town of Flamborough in 1986 or 1987 but does apply to amendments thereto and to amendments to an official plan that is in effect in the Town on the day this Order comes into force. O. Reg. 661/86, s. 2.
- 3.—(1) The council, in exercising the authority delegated by section 1, shall comply with the following conditions:
 - The council shall send to the Ministry of Municipal Affairs one copy of each official plan or official plan amendment received by the council for approval not later than ten days after the receipt of the application for approval.
 - 2. The council shall request comments for those departments or ministries of the public service, commissions and authorities that, in the council's opinion, have an interest in an official plan or official plan amendment as well as from such other public authorities and agencies as the Minister may direct, and shall submit to the Ministry of Municipal Affairs a list thereof, and shall not make a decision in

2428

respect of the official plan or official plan amendment until thirty days after all requests for comments have been sent or until all comments have been received, whichever period of time is shorter.

- 3. Where the council has not approved or referred to the Ontario Municipal Board an official plan or an official plan amendment within ninety days of the receipt of the application for approval, the council shall forthwith provide the clerk of the local municipality and the Ministry of Municipal Affairs with a report on the status of the application.
 - 4. The council shall send to the Ministry of Municipal Affairs one copy of each comment received under paragraph 2 as well as one copy of all modifications that are proposed for an official plan or official plan amendment and shall likewise send a copy of all modifications that are proposed to such other public authorities and agencies that the council considers are affected thereby.
 - 5. Where the council makes a decision on an application, written notice of the decision shall be sent to the Ministry of Municipal Affairs and the clerk of the local municipality within fifteen days of making the decision.
 - The original of the official plan or official plan amendment as approved shall be sent to the clerk of the local municipality.
 - One certified copy of the official plan or official plan amendment as approved shall be sent to the Ministry of Municipal Affairs, Plans Administration Branch, Central and Southwest.
 - One certified copy of the official plan or official plan amendment as approved shall be retained in the office of the clerk of the Regional Municipality.
 - One certified copy of the official plan or official plan amendment as approved shall be sent to each of the Ministry of the Environment, the Ministry of Natural Resources, the Ministry of Transportation and Communications and Ontario Hydro.
 - One certified copy of the official plan or official plan amendment as approved shall be sent to such other Ministries of the Government of Ontario as request it.
- (2) The delegation of authority set out in this Order is not terminated by reason only that the council has failed to comply with a condition set out in subsection (1). O. Reg. 661/86, s. 3.
- 4. This Order comes into force on the 3rd day of November, 1986.

BERNARD GRANDMAİTRE Minister of Municipal Affairs

Dated at Toronto, this 3rd day of November, 1986.

(9699) 47

PLANNING ACT, 1983

O. Reg. 662/86.
Restricted Areas—Territorial District of Sudbury.
Made—October 10th, 1986.
Filed—November 7th, 1986.

REGULATION TO AMEND ONTARIO REGULATION 834/81 MADE UNDER THE PLANNING ACT, 1983

- 1. Schedule 1 to Ontario Regulation 834/81 is amended by adding thereto the following section:
- 73.—(1) A second single dwelling and buildings and structures accessory thereto may be erected and used on the land described in subsection (2).
- (2) Subsection (1) applies to that parcel of land in the geographic Township of Cleland in the Territorial District of Sudbury, being that part of Lot 8, Concession VIII, shown as Parcel 14433, Sudbury East Section, in the Land Registry Office for the Land Titles Division of Sudbury (No. 53).

PAULINE MORRIS Director Plans Administration Branch North and East Ministry of Municipal Affairs

Dated at Toronto, this 10th day of October, 1986.

(9700) 4

PLANNING ACT, 1983

O. Reg. 663/86.
Restricted Areas—Territorial District of Sudbury.
Made—October 3rd, 1986.
Filed—November 7th, 1986.

REGULATION TO AMEND ONTARIO REGULATION 834/81 MADE UNDER THE PLANNING ACT, 1983

- 1. Schedule 1 to Ontario Regulation 834/81 is amended by adding thereto the following section:
- 74. Notwithstanding that the parcel of land in the geographic Township of Cartier, Territorial District of Sudbury, being Part 1, Plan 53R-10814, deposited in the Land Registry Office for the Land Titles Division of Sudbury (No. 53) is shown on a map referred to in

subsection 4 (1) as being in a Rural Zone, it shall be deemed to be in a General Industrial Zone to which Part VII applies.

PAULINE MORRIS
Director
Plans Administration Branch
North and East
Ministry of Municipal Affairs

Dated at Toronto, this 3rd day of October, 1986.

(9701)

47

Publications Under The Regulations Act

November 29th, 1986

LOCAL SERVICES BOARDS ACT

O. Reg. 664/86. Establishment of Local Services Board-Community of Moose Factory. Made-November 10th, 1986. Filed-November 10th, 1986.

ORDER MADE UNDER THE LOCAL SERVICES BOARDS ACT

IN THE MATTER OF the Local Services Boards Act; and

IN THE MATTER OF the establishment of a Local Services Board for the community of Moose Factory situate in territory without municipal organization in the Territorial District of Cochrane.

ORDER

Under the provisions of section 4 of the Local Services Boards Act, IT IS ORDERED:

- 1. A Local Services Board is established under the name "The Local Services Board of Moose Factory". O. Reg. 664/86, s. 1.
- 2. The boundaries of the Board areas are those described in the Schedule. O. Reg. 664/86, s. 2.
- 3. The Board shall be composed of five members. O. Reg. 664/86, s. 3.
- 4. The Board may exercise the powers set out in paragraphs 4 and 5 of the Schedule to the Act. O. Reg. 664/86, s. 4.
- 5.—(1) The election of the first members of the Board shall be held in the community of Moose Factory on the 12th day of November, 1986 and the members so elected shall hold office from the 12th day of November, 1986 to the 30th day of September, 1987 and until a new Board is elected.
- (2) Mr. Roy Cheechoo, Northern Affairs Officer, is appointed to conduct the election of the first members of the Board and for that purpose he has the general supervision of the election and the power to direct the manner of the election and to implement or to carry out any other act or thing that may be required for the

effective undertaking of the election of the first members of the Board. O. Reg. 664/86, s. 5.

> DAVID PETERSON Premier and Acting Minister of Northern Development and Mines

Dated at Toronto, this 10th day of November, 1986.

Schedule

All that parcel or tract of land in the Territorial District of Cochrane and Province of Ontario and being that part of Moose Factory Island described as follows:

Commencing at the northwesterly corner of Lot 2 as shown on Registered Plan M-140 C:

Thence southeasterly along the southwesterly limit of the said Lot 2 to the intersection with the most northerly limit of Lot 1 as shown on Registered Plan M-376 Coch.;

Thence southwesterly along said most northern limit to the northwesterly corner of the said Lot 1;

Thence southeasterly along the southwesterly limit of the said Lot 1 and the southwesterly limit of Centre Street as shown on the said Registered Plan M-376 Coch. to the southwesterly corner of Centre Street:

Thence northeasterly along the southeasterly limit of Centre Street to the northwesterly corner of Lot 71 as shown on Registered Plan M-376 Coch.;

Thence southeasterly along the southwesterly limit of lots 71, 70, 69 and 68 as shown on the said Plan to the southwesterly corner of the said Lot 68;

Thence southwesterly along the northwesterly limit of lots 74, 73 and 72 as shown on the said Plan to the northwesterly corner of the said Lot 72;

Thence southeasterly along the southwesterly limit of the said lot to the southwesterly corner thereof;

Thence southwesterly along the northwesterly limit of Horden Street, as shown on the said Registered Plan M-376 Coch. to the northwesterly corner thereof;

Thence southeasterly along the southwesterly limit of the said street and its southeasterly prolongation to the intersection with the southerly limit of the road between lots 4 and 10 as shown on Registered Plan M-140 C;

Thence southwesterly along said southerly limit to the southwesterly corner of Lot 10 as shown on Registered Plan M-140 C;

Thence in a generally southeasterly and northeasterly direction along the southeasterly limits of lots 10 and 8 as shown on the said Registered Plan M-140 C to the southeasterly corner of Lot 8 south of the road as shown on the said registered Plan;

Thence northwesterly along the northeasterly limit of the said Lot 8 south of the road to the northeasterly corner thereof;

Thence in a straight line to the southeasterly corner of Lot 8 north of the road as shown on the said Registered Plan M-140 C;

Thence northwesterly along the northeasterly limit of the said Lot 8 of the road, the road between lots 8 and 7, and Lot 7, all as shown on the said Registered Plan M-140 C, to the northeasterly corner of the said Lot 7;

Thence in a generally southwesterly direction along the northwesterly limit of lots 7 and 2 to the point of commencement. O. Reg. 664/86, Sched.

(9702)

48

HIGHWAY TRAFFIC ACT

O. Reg. 665/86.

Motor Vehicle Inspection Stations.

Made—October 30th, 1986.

Filed—November 12th, 1986.

REGULATION TO AMEND REGULATION 474 OF REVISED REGULATIONS OF ONTARIO, 1980 MADE UNDER THE HIGHWAY TRAFFIC ACT

 Form 3 of Regulation 474 of Revised Regulations of Ontario, 1980, as made by section 9 of Ontario Regulation 525/84, is revoked and the following substituted therefor:



Ministry of Transportation and Communications

MVIS Group 1201 Wilson Ave. Downsview, Ontario M3M 1J8.

Propane Fuel System Inspection Report

FORM 3 Highway Traffic Act

Instructions: • Complete and mail all inspection reports, whether the vehicle is rejected or accepted, within 30 days to M.V.i.S. Group, 1201 Wilson Ave., Downsview, Ontario M3M 138.

- Suggest vehicle owner to record the sticker serial number and place it on the inside surface of the glove compartment door.
- . Ensure information is PRINTED and LEGIBLE.

| Vehicle Owner | | Defect Rep | ort & Check List | |
|--|--|----------------|--|-------|
| venicle Owner | | DE | Description | c S |
| Surname Given Name(s) | Initial | 1 6 | | MOMIN |
| | | I S | | R % |
| Address Street Number, Name, P.O. Box No. RR. No. | or Lot Con & Two Apt. No. | 10 | Tank | |
| Address Street Number, Name, P O Box No. PM. No. | or Lot, Cont a two | 1.1 | Valves - Fittings - Gauges | |
| 1 1 1 1 1 1 1 1 1 1 1 1 1 1 | | 1.2 | Damage | |
| City Town or Village | Postal Code | 1 13 | Ground clearance | |
| | | 14 | Location | |
| | | 15 | Mounting - Attachment | |
| Vehicle Dans Oct | | 1.6 | Corresion | |
| Propane Only | Dual Fuel | 1.7 | Compartment Vent - Seal | |
| | Month Year | 1 16 | Canadian registration no | |
| A. Onginal Equipment Manufacturer | Date Manufactured | 19 | Design Pressure | |
| | | 1 10 | | |
| | Conversion Date Day Month Year | 1 111 | | |
| B. After Market Conversion | Day Month Year | 20 | Lines and Fitting | |
| | | 21 | Fuel Line | |
| Name of Contractor | | 22 | Fill Line | |
| | | 23 | Fixed liquid level line | |
| Contractor's Registration No | Installing Fitter's | 24 | Relief valve lines | |
| | S6A or S6B Certificate No | 25 | Filler cap | |
| | | 26 | Fittings | |
| Vehicle Identification Number | Plate No. | 27 | Installation | |
| 1 | | 26 | Mounting - Attachment | |
| Make , Model | , Year Odometer Reading | 29 | Corrosion – Damage | |
| | | 2 10 | Corresponding Co | |
| | | 2 11 | | |
| Tank Manufacturer | Senal Number Senal Number Vear | 2.12 | | |
| 1. | | 30 | Equipment | |
| | | 31 | Fuel filter | |
| 2. | | 32 | Fuel lock-off | |
| | | 33 | Vaporizer | |
| Data not visible | Equipped with automatic stop fill valve | 34 | Mixer | |
| Location Inside Outside | Fill Location On tank Remote | 35 | Hydrostatic relief | |
| | | 36 | Back check valves | |
| Fuel Lines | Components Make Model | 37 | Remote fill | |
| Steel | Fuel Lock | 38 | Gasoline lock-off | |
| Type III Hose - Year Installed | Vaponzer | 39 | G-300 G-001-01 | |
| | 1400.00 | 310 | | |
| Type II Hose Green Black | Moxer | 40 | Testing | |
| | | 1 41 | Tank leakage | |
| Inspection | Inspection Date | 42 | Fitting leakage | |
| | Day Month Year | 43 | Fuel lines leakage | |
| | Other | 44 | Components leakage | |
| Initial SCC Periodic | | | - a . An - a . randle | - |
| | | 1 45 | Excess flow value | |
| Results | Inspection Sticker Number Issued | 45 | Excess flow valve VAC/OIL fuel lock-off | |
| | Inspection Sticker Number Issued | 45 46 47 | Excess flow valve VAC/OIL fuel lock-off | |
| Results Rejected Repaired Accepted We hereby submit the information contain propane fuelled vehicle made under the Name of inspection Station | the herein in accordance with the inspection Highway Traffic Act. Signature of Licensee/Agent | 46 47 | VACOIL flue! lock-off Motor Vehicle Inspection State Licence Number | |
| Results Rejected Repaired Accepted We hereby submit the information contain propane fuelled vehicle made under the least of the least | Inspection Socker Number Issued U med herein in accordance with the inspection Highway Traffic Act. | 46 47 | VAC/OIL flue! lock-off | |

| List and | descri | be all | del | ect | S |
|----------|--------|--------|-----|-----|---|
|----------|--------|--------|-----|-----|---|

| Item Number | | Description |
|-------------|----|-------------|
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | Comments |
| | | |
| | | |
| | | |
| | | |
| | | |
| | _= | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | - 12 |
| | | |
| | | |

PLANNING ACT, 1983

O. Reg. 666/86.

Restricted Areas—District of Algoma, Sault Ste. Marie North Planning Area. Made—November 10th, 1986. Filed—November 12th, 1986.

REGULATION TO AMEND ONTARIO REGULATION 279/80 MADE UNDER THE PLANNING ACT, 1983

1. Ontario Regulation 279/80 is amended by adding thereto the following section:

93. Notwithstanding that the land in the geographic Township of Hodgins in the District of Algoma described as lots 11, 12 and 13, Plan M-55, registered in the Land Registry Office for the Land Titles Division of Algoma (No. 1), is shown on a map referred to in clause 4 (b) as being in an Urban Residential Zone, it shall be deemed to be in a General Commercial Zone to which Part VI applies. O. Reg. 666/86, s. 1.

PAULINE MORRIS
Director
Plans Administration Branch
North and East
Ministry of Municipal Affairs

Dated at Toronto, this 10th day of November, 1986.

(9705)



Publications Under The Regulations Act

December 6th, 1986

MUNICIPAL BOUNDARY NEGOTIATIONS ACT, 1981

O. Reg. 667/86.
Town of Picton—Township of Hallowell Boundary.
Made—November 13th, 1986.
Filed—November 19th, 1986.

ORDER IN COUNCIL

R.O.C. 411/86

WHEREAS The Corporation of the Township of Hallowell and The Corporation of the Town of Picton have entered into an agreement dated the 2nd day of July, 1986 for the resolution of certain boundary issues;

AND WHEREAS public notice was given by the Clerk of the Executive Council under subsection 17 (1) of the Municipal Boundary Negotiations Act, 1981 of the intention to make an Order implementing the intermunicipal agreement;

AND WHEREAS no objections to the proposed issuance of the Order were filed with the Clerk of the Executive Council within the filing period;

Now Therefore on the recommendation of the undersigned, the Lieutenant Governor, by and with the advice and concurrence of the Executive Council, orders under section 14 of the Municipal Boundary Negotiations Act, 1981 that,

- 1. On the 1st day of January, 1987, the portion of the Township of Hallowell described in Schedule A is annexed to the Town of Picton.
- 2. All real property of The Corporation of the Township of Hallowell situate in the annexed area vests in The Corporation of the Town of Picton on the 1st day of January, 1987.
- 3. On the 1st day of January, 1987, the by-laws of The Corporation of the Town of Picton extend to the annexed area and the by-laws of The Corporation of the Township of Hallowell cease to apply to such area, except,
 - (a) by-laws of The Corporation of the Township of Hallowell.
 - (i) that were passed under section 34 or 41 of the *Planning Act*, 1983 or a predecessor of those sections,

- (ii) that were kept in force by subsection 13 (3) of The Municipal Amendment Act, 1941, or
- (iii) that were passed under the Highway Traffic Act or the Municipal Act that regulate the use of highways by vehicles and pedestrians and that regulate the encroachment or projection of buildings or any portion thereof upon or over highways,

which shall remain in force until repealed by the council of The Corporation of the Town of Picton;

- (b) by-laws of The Corporation of the Township of Hallowell passed under section 45, 58 or 61 of the *Drainage Act* or a predecessor of those sections; and
- (c) by-laws conferring rights, privileges, franchises, immunities or exemptions that could not have been lawfully repealed by the council of The Corporation of the Township of Hallowell.
- 4. The clerk of The Corporation of the Township of Hallowell shall forthwith prepare and furnish to the clerk of The Corporation of the Town of Picton a special collector's roll showing all arrears of taxes or special rates assessed against the lands in the annexed area up to and including the 31st day of December, 1986 and the persons assessed therefor.
- 5.—(1) All real property taxes levied under any general or special Act and uncollected in the annexed area that are due and unpaid on the 1st day of January, 1987 shall be deemed on that date to be taxes due and payable to The Corporation of the Town of Picton and may be collected by The Corporation of the Town of Picton.
- (2) On or before the 31st day of March, 1987, The Corporation of the Town of Picton shall pay to The Corporation of the Township of Hallowell an amount equal to the amount of all real property taxes that The Corporation of the Town of Picton is entitled to collect in the annexed area under subsection (1), that were due but unpaid on the 1st day of January, 1987.
- 6. All business taxes levied and uncollected in the annexed area that are due and unpaid on the 31st day of December, 1986 shall continue after that date to be taxes due and payable to The Corporation of the Township of Hallowell and may be collected by The Corporation of the Township of Hallowell.

- 7. For the purposes of the assessment roll to be prepared for the Town of Picton under subsection 13 (1) of the Assessment Act in 1986, the annexed area shall be deemed to be a part of the Town of Picton.
- 8. The land described in Schedule B is established as a special area for municipal tax purposes and, for properties in that area,
 - (a) in the year 1987, each property shall pay an amount of taxes calculated by multiplying the 1987 total mill rate for the Town of Picton for all purposes by the assessment for that property, as shown on the last revised assessment roll for the Town of Picton for the 1987 taxation year and subtracting therefrom 50 per cent of the tax differential calculated under section 10; and
 - (b) in the year 1988, and subsequently, each property shall pay an amount of taxes calculated by multiplying the 1988 and subsequent total mill rates for the Town of Picton for all purposes by the assessment for that property, as shown on the last revised assessment roll for the Town of Picton for the 1988 and subsequent taxation years.
- 9. The land described in Schedule C is established as a special area for municipal tax purposes and, for properties in that area,
 - (a) in the year 1987, each property shall pay an amount of taxes calculated by multiplying the 1987 total mill rate for the Town of Picton for all purposes by the assessment for that property, as shown on the last revised assessment roll for the Town of Picton for the 1987 taxation year and subtracting therefrom 80 per cent of the tax differential established under section 10;
 - (b) in the year 1988, each property shall pay an amount of taxes calculated by multiplying the 1988 total mill rate for the Town of Picton for all purposes by the assessment for that property, as shown on the last revised assessment roll for the Town of Picton for the 1988 taxation year and subtracting therefrom 60 per cent of the tax differential established under section 10;
 - (c) in the year 1989, each property shall pay an amount of taxes calculated by multiplying the 1989 total mill rate for the Town of Picton for all purposes by the assessment for that property, as shown on the last revised assessment roll for the Town of Picton for the 1989 taxation year and subtracting therefrom 40 per cent of the tax differential established under section 10;
 - (d) in the year 1990, each property shall pay an amount of taxes calculated by multiplying the 1990 total mill rate for the Town of

- Picton for all purposes by the assessment for that property, as shown on the last revised assessment roll for the Town of Picton for the 1990 taxation year and subtracting therefrom 20 per cent of the tax differential established under section 10; and
- (e) in the year 1991 and subsequently, each property shall pay an amount of taxes calculated by multiplying the 1991 and subsequent total mill rates for the Town of Picton for all purposes by the assessment for that property, as shown on the last revised assessment roll for the Town of Picton for the 1991 and subsequent taxation years.

10.—(1) In this section,

"town assessment" means the assessment on a property as shown in the last returned assessment roll for the 1987 taxation year;

"township assessment" means,

- (a) in the case of a township property entirely included in the annexed area, the assessment on that property prepared by the assessment commissioner in 1985 for the 1986 taxation year, as adjusted by such additional assessments as have been made under section 32 or 33 of the Assessment Act in respect of the 1986 tax year, as it exists on the day prior to the date of annexation.
- (b) in the case of a township property divided by the annexation, the assessment of the entire property prepared by the assessment commissioner in 1985 for the 1986 tax year, as adjusted by such additional assessments as have been made under section 32 or 33 of the Assessment Act in respect of the 1986 tax year, as it exists on the day prior to the date of annexation, minus the assessment as shown on the last returned assessment roll for the 1987 tax year for that portion of the property remaining in the township, and
- (c) in the case of a property consolidated by the annexation, the town assessment minus the assessment on that portion of the property previously in the Town of Picton prepared by the assessment commissioner in 1985 for the 1986 tax year, as adjusted by such additional assessments as have been made under section 32 or 33 of the Assessment Act in respect of the 1986 tax year, as it exists on the day prior to the date of annexation,
- (2) In the year 1987, the treasurer of The Corporation of the Town of Picton shall establish a tax differential for each property in the annexed area by calculating the product of the 1987 mill rate for the Town of Picton for all purposes and the town assessment for that property and subtracting therefrom the product of the 1987 total mill rate for the Township of Hallowell

for all purposes and the township assessment on that property.

- 11.—(1) In this section, "phase-in period" means,
 - (a) for lands located in Schedule B, 1987; and
 - (b) for land located in Schedule C, 1987, 1988, 1989 and 1990.
- (2) If two or more properties in the annexed area are consolidated during the phase-in period, the tax differentials for those properties shall be consolidated to establish a new tax differential for the consolidated property.
- (3) If the total assessment of the consolidated property is less than the aggregate of the assessments on the constituent properties, the new tax differential shall be diminished in the same proportion and at the same time as the total assessment is diminished.
- (4) If a property in the annexed area is severed or subdivided during the phase-in period, the tax differential shall be allocated to each of the divided parts of the property in the same proportion as the assessment of each part bears to the aggregate of all of the assessments making up the original property at the time of the division of that property but in no case shall the total of the tax differential be increased.
- (5) If for any reason taxes on a property are reduced in any year during the phase-in period, the tax differential established under section 10 shall not exceed the taxes payable and the treasurer of The Corporation of the Town of Picton shall reduce the tax differential in that year by the amount by which the tax differential exceeds the taxes payable.
- 12. The agreement between The Corporation of the Town of Picton and The Corporation of the Township of Hallowell dated the 2nd day of July, 1986 is hereby given effect. O. Reg. 667/86.

Recommended

BERNARD GRANDMAÎTRE Minister of Municipal Affairs

Concurred

JAMES BRADLEY
Chairman

Approved and Ordered, November 13th, 1986.

Lincoln M. Alexander
Lieutenant Governor

Schedule A

AREA TO BE ANNEXED TO THE TOWN OF PICTON

That part of the Township of Hallowell described as follows:

Beginning at the intersection of the westerly boundary of the Town of Picton and the southerly limit of Talbot Street, being also known as County Road Number 4;

Thence north 14° 56′ 50″ east along the prolongation of the said westerly boundary to the centre line of the said Talbot Street;

Thence westerly along the said centre line to the easterly limit of the right of way of the Canadian National Railways;

Thence northerly along the easterly limit of the said right of way to an angle of the Town of Picton, being on the line between the east and west halves of Lot 4 in Concession I Northwest of Carrying Place of the Township of Hallowell;

Thence easterly and southerly following the westerly boundaries of the said Town to the place of beginning. O. Reg. 667/86, Sched. A.

Schedule B

WATER SERVICES AREA

 Beginning at the intersection of the westerly boundary of the Town of Picton and the northerly limit of Talbot Street;

Thence westerly along the said northerly limit to the westerly limit of Part 1 as shown on a Plan deposited in the Land Registry Office for the Registry Division of Prince Edward (No. 47) as Number 47R-1562;

Thence northerly along the said westerly limit to the southwesterly angle of Part 5 as shown on a Plan deposited in the said Registry Office as Number 47R-247;

Thence easterly along the southerly limit of the said Plan Number 47R-247 to the westerly boundary of the Town of Picton;

Thence southerly along the said westerly boundary to the place of beginning.

Beginning at the intersection of the southerly limit of Johnson Street and the westerly boundary of the Town of Picton;

Thence southerly along the westerly boundaries of the said Town to a point distant 39.62 metres measured southerly therealong from the southerly limit of Paul Street:

Thence westerly and parallel with the southerly limit of Paul Street to the southwesterly angle of Part 2 as shown on a Plan deposited in the Land Registry Office for the Registry Division of Prince Edward (No. 47) as Number 47R-3164;

Thence northerly along the westerly limit of the said Part 2 to the southerly limit of Part 3 as shown on a Plan deposited in the said Registry Office as Number 47R-2464;

Thence westerly along the southerly limit of the said Part 3 to the westerly limit of the said Plan Number 47R-2464;

Thence northerly along the westerly limit of the said Plan to the northerly limit of the said Plan;

Thence easterly along the said northerly limit of the said Plan to the northeasterly angle of the said Plan;

Thence northerly along the northerly prolongation of the easterly limit of the said Plan to the southerly limit of Johnson Street;

Thence easterly along the said southerly limit to the place of beginning. O. Reg. 667/86, Sched. B.

Schedule C

AREA WITHOUT SEWER AND WATER SERVICE

Beginning at the intersection of the northerly limit of Talbot Street and the westerly limit of Part 1 as shown on a Plan deposited in the Land Registry Office for the Registry Division of Prince Edward (No. 47) as Number 47R-1562;

Thence northerly along the said westerly limit to the southwesterly angle of Part 5 as shown on a Plan deposited in the said Registry Office as Number 47R-247;

Thence easterly along the southerly limit of the said Plan Number 47R-247 to the westerly boundary of the Town of Picton;

Thence northerly along the said westerly boundary to the southerly limit of Lot 11 as shown on a Plan registered in the said Registry Office as Number 32—Town of Picton;

Thence westerly along the southerly limit of the said Lot to the westerly limit of the said Lot;

Thence northerly along the said westerly limit to the southerly limit of Downes Avenue;

Thence easterly along the said southerly limit to the westerly boundary of the Town of Picton;

Thence northerly along the said westerly boundary to a point distant 39.62 metres measured southerly therealong from the southerly limit of Paul Street;

Thence westerly and parallel with the southerly limit of Paul Street to the southwesterly angle of Part 2 as shown on a Plan deposited in the said Registry Office as Number 47R-3164;

Thence northerly along the westerly limit of the said Part 2 to the southerly limit of Part 3 as shown on a Plan deposited in the said Registry Office as Number 47R-2464;

Thence westerly along the southerly limit of the said Part 3 to the westerly limit of the said Plan Number 47R-2464;

Thence northerly along the westerly limit of the said Plan to the northerly limit of the said Plan;

Thence easterly along the said northerly limit of the said Plan to the northeasterly angle of the said Plan;

Thence northerly along the northerly prolongation of the easterly limit of the said Plan to the southerly limit of Johnson Street;

Thence easterly along the said southerly limit to the westerly boundary of the Town of Picton;

Thence northerly and westerly following the boundaries of the said Town to the easterly limit of the right of way of the Canadian National Railways;

Thence southerly along the easterly limit of the said right of way to the northerly limit of Talbot Street;

Thence easterly along the said northerly limit to the place of beginning. O. Reg. 667/86, Sched. C.

(9727)

49

EDUCATION ACT

O. Reg. 668/86. Supervisory Officers. Made—November 12th, 1986. Approved—November 19th, 1986. Filed—November 20th, 1986.

REGULATION TO AMEND REGULATION 276 OF REVISED REGULATIONS OF ONTARIO, 1980 MADE UNDER THE EDUCATION ACT

1. Section 1 of Regulation 276 of Revised Regulations of Ontario, 1980 is revoked and the following substituted therefor:

1.—(1) In this Part,

- "acceptable university degree" means a degree from an Ontario university or post-secondary institution that is an ordinary member of the Association of Universities and Colleges of Canada or a degree that is equivalent thereto from a university other than such Ontario university or post-secondary institution;
- "architect" means a person who is an architect within the meaning of the Architects Act, 1984;
- "certified general accountant" means a member of the Certified General Accountants Association of Ontario:
- "certified management accountant" means a registered or certified member of The Society of Management Accountants of Ontario;
- "chartered accountant" means a member of The Institute of Chartered Accountants of Ontario;
- "Principal's Certificate" means a permanent principal's certificate;
- "professional engineer" means a person who is a professional engineer within the meaning of the Professional Engineers Act, 1984;
- "program in school board management" means two compulsory graduate courses approved by the Minister that are offered by a university one of which is a course in school board finance and the other in school board administration and four optional graduate courses approved by the Minister that are offered by a university in education, public administration or political science;

"university" means,

- (a) an Ontario university or post-secondary institution that is an ordinary member of the Association of Universities and Colleges of Canada.
- (b) a Canadian university in a province other than Ontario that is an ordinary member of the Association of Universities and Colleges of Canada,
- (c) a university in the United States that is recognized by,
 - Middle States Association of Colleges and Schools,
 - (ii) New England Association of Schools and Colleges,
 - (iii) North Central Association of Colleges and Schools,
 - (iv) Northwest Association of Schools and Colleges,

- (v) Southern Association of Colleges and Schools,
- (vi) Western Association of Schools and Colleges, or
- (d) a university that is located in a country other than Canada or the United States and that is a member of the Association of Commonwealth Universities or the International Association of Universities.
- (2) A person who holds or who under this Regulation is deemed to hold a Supervisory Officer's Certificate is, subject to subsection 5a (1), qualified as a supervisory officer for the purposes of the Act and this Regulation.
- (3) A person referred to in subsection 3 (4) who is employed by a board is qualified as a business supervisory officer for the purposes of the Act and this Regulation for the period during which the person is employed by the board in a position referred to in that subsection.
- (4) For the purposes of this Regulation, a person who is the holder of a Master's degree that is an acceptable university degree and who successfully completes a graduate course, either as part of or in addition to the courses necessary to obtain the degree, in each of school board finance and school board administration at a university shall be deemed to have completed a program in school board management.
- (5) For the purposes of this Regulation, a person who is the holder of an acceptable university degree and who is a certified general accountant, a certified management accountant or a chartered accountant shall be deemed to be a person who has completed the four optional graduate courses as part of a program in school board management. O. Reg. 668/86, s. 1.
 - (1) Subsection 2 (1) of the said Regulation is revoked and the following substituted therefor:
- (1) A person who wishes to be a candidate for a Supervisory Officer's Certificate or a Business Supervisory Officer's Certificate shall apply to the Minister before the 1st day of December in 1986 and before the 1st day of November in each subsequent year, to take, in the year next following, the written and oral examinations approved by the Minister. O. Reg. 668/86, s. 2 (1).
 - (2) Subclauses 2 (2) (a) (i) and (iii) of the said Regulation, as remade by section 1 of Ontario Regulation 473/84, are revoked and the following substituted therefor:
 - (i) an acceptable university degree,

- (iii) a master's degree in education from a university, and
- (3) Clauses 2 (2) (b) and (c) of the said Regulation are revoked.
- (4) Subsection 2 (2a) of the said Regulation, as made by subsection 1 (3) of Ontario Regulation 473/84, is revoked and the following substituted therefor:
- (2a) Notwithstanding subsections (2) and (2b), a person who,
 - (a) on the 1st day of July, 1984 was eligible to be a candidate for a Supervisory Officer's Certificate, continues to be so eligible until the 1st day of July, 1987; and
 - (b) on the 1st day of September, 1986 was eligible to be a candidate for a Supervisory Officer's Certificate and is not a person referred to in clause (a), continues to be so eligible until the 31st day of October, 1988.
- (2b) A candidate for a Business Supervisory Officer's Certificate under subsection (1) shall submit with the application evidence that he or she,
 - (a) has completed a program in school board management;
 - (b) has seven years of experience in business administration; and
 - (c) is,
 - (i) the holder of an acceptable university degree, or
 - (ii) an architect, certified general accountant, certified management accountant, chartered accountant or professional engineer. O. Reg. 668/86, s. 2 (4).
 - (5) Subsection 2 (4) of the said Regulation is revoked and the following substituted therefor:
- (4) Where a candidate obtains standing of at least 60 per cent on each of the written and oral examinations referred to in subsection (1), the Minister shall grant the candidate a Supervisory Officer's Certificate or a Business Supervisory Officer's Certificate, as the case requires. O. Reg. 668/86, s. 2 (5).
 - 3.—(1) Subsection 3 (2) of the said Regulation, exclusive of the clauses, is revoked and the following substituted therefor:

(2) A senior business official who,

shall, subject to subsections (4) and (5), be a person who holds, or who under this Regulation is deemed to hold, a Business Supervisory Officer's Certificate.

- (2) Subsection 3 (3) of the said Regulation, exclusive of the clauses, is revoked and the following substituted therefor:
- (3) A business official who,

shall, subject to subsection (4), be a person who holds, or who under this Regulation is deemed to hold, a Business Supervisory Officer's Certificate.

- (3) Subsection 3 (4) of the said Regulation is revoked and the following substituted therefor:
- (4) A board may appoint a person who does not hold or who under this Regulation is not deemed to hold a Business Supervisory Officer's Certificate as a senior business official referred to in subsection (2) or as a business official referred to in subsection (3) for a term of not more than two years where the person,
 - (a) is an architect, certified general accountant, certified management accountant, chartered accountant or professional engineer or the person is the holder of an acceptable university degree; and
 - (b) has entered into an agreement in writing with the board that sets out that the person will,
 - (i) within a period of time not to exceed two years, complete a program in school board management, and
 - (ii) make application at the first opportunity available under subsection 2 (1) to be a candidate for a Business Supervisory Officer's Certificate.
- (5) Notwithstanding subsection (4), a board may employ a person for an additional period of two years provided that the person continues to make progress towards obtaining the qualifications referred to in subclause (4) (b) (i).
- (6) A person who was appointed as a senior business official with the approval of the Minister before the 1st day of October, 1986 and whose agreement with the board is inconsistent with the requirements of subsection (4) may, by agreement with the board, amend the agreement to be consistent with the provisions of subsection (4). O. Reg. 668/86, s. 3 (3).

4. Part I of the said Regulation is amended by adding thereto the following section:

5a.—(1) A person who,

O. Reg. 668/86

- (a) holds a Supervisory Officer's Certificate and who has submitted evidence of experience other than experience as a teacher to the Minister under subsection 2 (2):
- (b) is deemed to hold a Supervisory Officer's Certificate under section 5; or
- (c) holds a Business Supervisory Officer's Certificate.

is qualified as a supervisory officer under this Regulation for business administration purposes only.

- (2) A supervisory officer other than a supervisory officer referred to in subsection (1) who, on the 30th day of September, 1986, was performing the duties,
 - (a) of a senior business official referred to in clause 3 (2) (c) and who reports as referred to in clauses 3 (2) (a) and (b); or
 - (b) of a business official referred to in clause 3 (3) (c) who reports to a senior business official referred to in subsection 3 (2),

is deemed to hold a Business Supervisory Officer's Certificate. O. Reg. 668/86, s. 4.

> SEAN CONWAY Minister of Education

Dated at Toronto, this 12th day of November, 1986.

(9752)49

EDUCATION ACT

O. Reg. 669/86. North of Superior District Roman Catholic Separate School Board. Made-November 19th, 1986. Filed-November 20th, 1986.

REGULATION TO AMEND **REGULATION 267 OF** REVISED REGULATIONS OF **ONTARIO**, 1980 MADE UNDER THE **EDUCATION ACT**

1. Paragraph 2 of subsection 2 (1) of Regulation 267 of Revised Regulations of Ontario, 1980, as remade by section 1 of Ontario Regulation 418/82, is revoked and the following substituted therefor:

- 2. The geographic townships of Atikameg, Bomby, Brothers, Bryant, Byron, Cecil, Cecile, Coldwell, Cotte, Davies, Flood, Foote, Grain, Grenville, Herbert, Homer, Killraine, Knowles, Laberge, Lahontan, Lecours, Lyon, McCron, McGill, Mikano, Nickle, O'Neill, Pic, Priske, Roberta, Shabotik, Spooner, Stirling, Strey, Syine, Tuuri, Walsh, Wiggins and Yesno.
- 3. All lands except St. Ignace Island in unsurveyed territory within an area described as follows:
 - i. on the north side, the extension of the north side of the geographic Township of Davies westerly to intersect with the boundary formed by extending the west side of the geographic Township of Wiggins northerly until it meets the said extension,
 - ii. on the east side, the extension of the east side of the geographic Township of Spooner southerly until the Canada-United States border,
 - iii. on the south side, the Canada-United States border, and
 - iv. on the west side, the extension of the west side of the geographic Township of Wiggins southerly until the Canada-United States border.

(9753)

49

PLANNING ACT, 1983

O. Reg. 670/86. Zoning Areas-District of Timiskaming. Made-November 12th, 1986. Filed-November 20th, 1986.

ORDER MADE UNDER THE PLANNING ACT, 1983

ZONING AREAS—DISTRICT OF TIMISKAMING

- 1. In this Order, "mobile home" has the same meaning as in clause 45 (1) (a) of the Planning Act, 1983. O. Reg. 670/86, s. 1.
- 2. In addition to the mobile home existing on the land described in section 3 on the day this Order comes into force, a second mobile home may be erected,

located and used thereon if the minimum distance between the second mobile home and any road is 7.5 metres. O. Reg. 670/86, s. 2.

3. This Order applies to that part of Lot 1, Concession V, in the geographic Township of Robillard in the District of Timiskaming, being Parcel 3969 in the Land Registry Office for the Land Titles Division of Timiskaming (No. 56). O. Reg. 670/86, s. 3.

Bernard Grandmaître
Minister of Municipal Affairs

Dated at Toronto, this 12th day of November, 1986.

HEALTH DISCIPLINES ACT

(9754)

O. Reg. 671/86.
Pharmacy.
Made—September 19th, 1986.
Approved—November 19th, 1986.
Filed—November 20th, 1986.

REGULATION TO AMEND REGULATION 451 OF REVISED REGULATIONS OF ONTARIO, 1980 MADE UNDER THE HEALTH DISCIPLINES ACT

- 1.—(1) Clauses 79 (1) (a) and (b) of Regulation 451 of Revised Regulations of Ontario, 1980, as remade by section 1 of Ontario Regulation 817/84, are revoked and the following substituted therefor:
 - (a) for a pharmacist under sixty-five years of age \$210; or
 - (b) for a pharmacist sixty-five years of age or over, \$105.
- (2) Clause 79 (5) (c) of the said Regulation, as remade by section 1 of Ontario Regulation 817/84, is revoked and the following substituted therefor:
 - (c) for the year 1987, \$410,

Council of the College of Pharmacists:

J. A. Monaghan President

> A. J. Dunsdon Registrar

Dated at Toronto, this 19th day of September, 1986. (9755)

RENTAL HOUSING PROTECTION ACT, 1986

> O. Reg. 672/86. General. Made—November 19th, 1986. Filed—November 20th, 1986.

REGULATION TO AMEND ONTARIO REGULATION 434/86 MADE UNDER THE RENTAL HOUSING PROTECTION ACT, 1986

- 1. Schedule 2 to Ontario Regulation 434/86, as amended by section 1 of Ontario Regulation 570/86 and section 1 of Ontario Regulation 594/86, is further amended by adding thereto the following paragraphs:
- 5. The parcel of land known municipally as 13 Admiral Road in the City of Toronto in The Municipality of Metropolitan Toronto, being the south half of Lot 100, Plan M-6, registered in the Land Registry Office for the Land Titles Division of Metropolitan Toronto (No. 66) and shown as Parcel 100-2, Section M-6.
- 6. The parcel of land known municipally as 80 Pembroke Street in the City of Toronto in The Municipality of Metropolitan Toronto, being part of Lot 32, Plan 150, registered in the Land Registry Office for the Registry Division of Toronto (No. 63), described as follows:

Commencing at a point in the westerly limit of Pembroke Street at the existing northeasterly angle of the said Lot and where the old fence line of the property intersects the westerly limit of Pembroke Street, being distant 156 feet 9 inches measured northerly from the southeasterly angle of Lot 33 on the said Plan;

Thence westerly along the old fence line being the existing northerly limit of the said Lot, 138 feet, more or less, to the rear of the said Lot at a point distant 157 feet 5 inches measured northerly from the southwesterly angle of the said Lot 33;

Thence southerly along the westerly limit of the said Lot, 62 feet 2 inches, more or less, to the old fence that divides the property now described from the property adjoining to the south;

Thence easterly along the said last-mentioned old fence line and prolongation thereof and parallel to the northerly wall of the house on the property to the south of the property now described 138 feet, more or less, to the westerly limit of Pembroke Street;

Thence northerly along the westerly limit of Pembroke Street 61 feet 6 inches, more or less, to the point of commencement.

7. The parcel of land known municipally as 182 Walmer Road in the City of Toronto in The Municipality of Metropolitan Toronto, being part of Lot 127, Plan 698, registered in the Land Registry Office for the Registry Division of Toronto (No. 63), described as follows:

Commencing at a point in the westerly limit of Walmer Road distant 75 feet measured northerly from the southeasterly angle of Lot 126, according to the said Plan;

Thence westerly parallel to the southerly limit of Lot 126, in all a distance of 100 feet to a point in a line drawn parallel to the westerly limit of Walmer Road and distant 100 feet measured westerly therefrom, the said point being distant 75 feet measured northerly along the said line from the southerly limit of Lot 126;

Thence northerly along the said line 25 feet to a point in the northerly limit of Lot 127;

Thence easterly along the northerly limit of Lot 127, 100 feet to the northeasterly angle of said Lot and the westerly limit of Walmer Road;

Thence southerly along the westerly limit of Walmer Road 25 feet more or less to the place of beginning.

8. The parcel of land known municipally as 80 Beverley Street in the City of Toronto in The Municipality of Metropolitan Toronto, being part of Park Lot No. 14 in the First Concession from the Bay in the Township of York, described as follows:

Commencing at a point in the westerly limit of Beverley Street (formerly known as St. George's Terrace) where the same is intersected in February, 1923 by the centre line of a double fence running westward, the said point being distant 215 feet 8 inches measured southerly along the said limit of Beverley Street from the southerly limit of Grange Avenue (formerly called Charles Street) taken at a width of 60 feet measured southerly from the northerly limit thereof, the said point of commencement being also distant 90 feet 5½ inches northerly from the intersection of the said limit of Beverley Street with the northerly limit of Sullivan Street;

Thence westerly along the said centre line of fence, 22 feet 9 inches, more or less, to the northeasterly angle of the brick veneering on the northerly wall of the old rough cast building standing at the date last-mentioned upon the lands immediately to the south of the lands hereby conveyed, being at a distance of 215 feet 10½ inches measured on a course parallel to the said limit of Beverley Street from the said southerly limit of Grange Avenue;

Thence westerly along the said northerly face of a brick veneering 34 feet 1½ inches to an angle in the same, being at a distance of 216 feet 1 inch measured southerly on a course parallel to the said limit of Beverley Street from the said southerly limit of Grange Avenue;

Thence northerly and parallel to the said limit of Beverley Street 3½ inches to the northerly face of the brick veneering on the westerly part of the said building;

Thence westerly along the northerly face of the last-mentioned brick veneering 18 feet $6\frac{1}{2}$ inches to the westerly end of the same being at a point distant 216 feet $2\frac{1}{2}$ inches measured southerly on a course parallel to the said limit of Beverley Street from the said limit of Grange Avenue;

Thence southerly and parallel to the said limit of Beverley Street 5½ inches to the line of a fence running westerly;

Thence westerly along the line of the last-mentioned fence 66 feet 4 inches to a point in the southerly production of the easterly face of the rough cast building standing at the date last-mentioned upon the southwesterly part of the lands hereby conveyed which point is distant 217 feet 8 inches measured southerly on a course parallel to the said limit of Beverley Street from the said southerly limit of Grange Avenue;

Thence northerly and parallel to the said limit of Beverley Street, 5 inches to the southerly face of the southerly wall of the last-mentioned building;

Thence westerly along the last-mentioned face of wall 11 feet 3 inches, more or less, to the point of intersection with the easterly limit of a lane as shown on a plan registered as Number D-91 in the Registry Office for the City of Toronto, which limit is distant 153 feet westerly from the said limit of Beverley Street and parallel thereto which point of intersection is distant 217 feet 3 inches measured southerly on a course parallel to the said limit of Beverley Street, from the said limit of Grange Avenue, and distant also 89 feet 1½ inches measured northerly on the same course from the said northerly limit of Sullivan Street;

Thence northerly along the said limit of a lane 40 feet;

Thence easterly 153 feet to the point of intersection with the westerly limit of Beverley Street;

Thence southerly along the said limit of Beverley Street 40 feet to the point of commencement.

Together with a right-of-way over, along and upon the most southerly 4 feet of the most easterly 100 feet of the lands lying immediately adjacent to and to the north of the lands herein described.

And subject to a right-of-way over, along and upon the most northerly 3 feet of the most easterly 100 feet of the lands herein described.

49 (9756)

GAME AND FISH ACT

O. Reg. 673/86. Game Birds-Captivity, Propagation or Made-November 19th, 1986. Filed-November 20th, 1986.

REGULATION TO AMEND **ONTARIO REGULATION 578/86** MADE UNDER THE GAME AND FISH ACT

- 1. Subsection 1 (4) of Ontario Regulation 578/86 is amended by striking out "\$10" and inserting in lieu thereof "\$15".
- 2. This Regulation comes into force on the 1st day of January, 1987.

(9757)

49

PROVINCIAL OFFENCES ACT

O. Reg. 674/86. Proceedings Commenced by Certificate of Offence. Made-November 19th, 1986. Filed-November 20th, 1986.

REGULATION TO AMEND REGULATION 817 OF REVISED REGULATIONS OF ONTARIO, 1980 MADE UNDER THE PROVINCIAL OFFENCES ACT

- 1.—(1) Items 8, 9, 12, 13, 14, 17, 34, 35, 36, 44, 45 and 46 of Schedule 55 to Regulation 817 of Revised Regulations of Ontario, 1980, as made by section 4 of Ontario Regulation 382/82, are revoked and the following substituted therefor:
 - Operate incineration site-fail to dispose of 35. incinerator waste at landfilling site

section 9 paragraph 2

(2) Schedule 55 to the said Regulation, as made by section 4 of Ontario Regulation 382/82, is amended by adding thereto the following items:

| Ітем | COLUMN 1 | COLUMN 2 |
|------|--|-------------|
| 68. | Operate waste management system —vehicle val- | section 13 |
| | ves not capable of being locked | paragraph 4 |
| 69. | Operate waste management system—vehicle val- | section 13 |
| | ves not locked with driver absent | paragraph,4 |
| 70. | Waste transferred to vehicle without driver, | section 13 |
| | generator or receiver present | paragraph 5 |
| 71. | Waste transferred from vehicle without driver, | section 13 |
| | generator or receiver present | paragraph 5 |
| 72. | Operate waste management system—fail to | section 13 |
| | clearly mark vehicle | paragraph 6 |
| 73. | Operate waste management system—fail to keep | section 13 |
| | certificate of approval in vehicle | paragraph 7 |
| 74. | Fail to construct vehicle in accordance with the | section 13 |
| | Transportation of Dangerous Goods Act (Canada) | paragraph 8 |
| 75. | Fail to maintain vehicle in accordance with the | section 13 |
| | Transportation of Dangerous Goods Act (Canada) | paragraph 8 |
| 76. | Fail to operate vehicle in accordance with the | section 13 |
| | Transportation of Dangerous Goods Act (Canada) | paragraph 8 |

| TEM | COLUMN 1 | COLUMN 2 |
|------|--|---------------------------------|
| 77. | Fail to mark or placard vehicle in accordance with | section 13 |
| | the Transportation of Dangerous Goods Act | paragraph 8 |
| | (Canada) | |
| 78. | Fail to train driver in operation of vehicle and | section 13 |
| | equipment | paragraph 9 |
| ~n | Fail to train driver in wests management legisle | subparagraph i section 13 |
| 79. | Fail to train driver in waste management legisla- tion and guidelines | paragraph 9 |
| | uon and guidennes | subparagraph ii |
| 80. | Fail to train driver in major environmental con- | section 13 |
| 00. | cerns of waste to be handled | paragraph 9 |
| | | subparagraph iii |
| 81. | Fail to train driver in occupational health and | section 13 |
| | safety concerns of waste to be handled | paragraph 9 |
| | | subparagraph iv |
| 82. | Fail to train driver in emergency management | section 13 |
| | procedures for waste to be handled | paragraph 9 |
| | | subparagraph v |
| 83. | Cause asbestos waste to leave location without | subsection 14(1) |
| 0.4 | obtaining acceptance from waste disposal site | paragraph 1 |
| 84. | Permit asbestos waste to leave location without obtaining acceptance from waste disposal site | subsection 14(1) paragraph 1 |
| 85. | Cause asbestos waste to leave location in | subsection 14(1) |
| 05. | inadequate container | paragraph 1 |
| | madequate container | subparagraph i |
| 86. | Permit asbestos waste to leave location in | subsection 14(1) |
| | inadequate container | paragraph 1 |
| | | subparagraph i |
| 87. | Cause transportation of asbestos waste in bulk | subsection 14(1) |
| | without certificate of approval for same | paragraph 1 |
| | | subparagraph ii |
| 88. | Permit transportation of asbestos waste in bulk | subsection 14(1) |
| | without certificate of approval for same | paragraph 1 |
| | | subparagraph ii |
| 89. | Fail to have external surfaces of container free | subsection 14(1) |
| 90. | from asbestos waste Fail to have transportation vehicle external sur- | paragraph 4 subsection 14(1) |
| 90. | faces free from asbestos waste | paragraph 4 |
| 91. | Fail to have transportation vessel external surfaces | subsection 14(1) |
| / 4. | free from asbestos waste | paragraph 4 |
| 92. | Asbestos waste—fail to have vehicle properly | subsection 14(1) |
| | signed | paragraph 5 |
| 93. | Asbestos waste—fail to have container properly | subsection 14(1) |
| | signed | paragraph 5 |
| 94. | Asbestos waste—fail to transport by driver trained | subsection 14(1) |
| | in management of asbestos waste | paragraph 6 |
| 0.5 | A.1 | subparagraph i |
| 95. | Asbestos waste—fail to transport to disposal site | subsection 14(1) paragraph 6 |
| | as directly as practicable | subparagraph i |
| 96. | Asbestos waste transferred to unauthorized site | subsection 14(1) |
| , , | The state of the s | paragraph 6 |
| | | subparagraph ii |
| 97. | Asbestos waste transported with other cargo in the | subsection 14(1) |
| | same vehicle | paragraph 6 |
| | | subparagraph iii |
| 98. | Asbestos waste transported in compaction type | subsection 14(1) |
| | waste haulage vehicle | paragraph 6 |
| | | subparagraph iv |
| 99. | Asbestos waste in cardboard boxes not in enclosed vehicle | subsection 14(1) paragraph 6 |
| | | |

| Ітем | Column 1 | COLUMN 2 |
|------------------------------|---|--|
| 100. | Asbestos waste not properly secured | subsection 14(1) |
| | | paragraph 6 |
| | | subparagraph vi |
| 101. | Asbestos waste not covered with suitable tarpaulin | subsection 14(1) |
| | or net in unenclosed vehicle | paragraph 6 |
| | | subparagraph vi |
| 102. | Asbestos waste transportation vehicle not | subsection 14(1) |
| | adequately equipped with emergency clean-up | paragraph 6 |
| 103 | equipment | subparagraph vii |
| 103. | Fail to properly package loose asbestos waste immediately upon discovery | subsection 14(1) paragraph 7 |
| 104. | Asbestos waste—fail to properly package dam- | subsection 14(1) |
| 104. | aged container immediately upon discovery | paragraph 7 |
| 105. | Asbestos waste—unloading carried out so that | subsection 14(1) |
| 105. | loose waste is landfilled | paragraph 8 |
| 106. | Asbestos waste—unloading carried out so that | subsection 14(1) |
| | damaged container is landfilled | paragraph 8 |
| 107. | Fail to deposit asbestos waste at authorized loca- | subsection 14(1) |
| | tion within disposal site | paragraph 9 |
| 108. | Asbestos waste deposited at landfill site without | subsection 14(1) |
| | proper supervision | paragraph 10 |
| 109. | Fail to properly cover asbestos waste with suitable | subsection 14(1) |
| | material forthwith | paragraph 11 |
| 110. | Asbestos waste—fail to wear protective clothing | subsection 14(1) |
| | A.1. 4. 6.11.4 | paragraph 12 |
| 111. | Asbestos waste—fail to wear respiratory equip- | subsection 14(1) |
| 112. | ment Asbestos waste—fail to properly deal with protec- | paragraph 12 subsection 14(1) |
| 112. | tive clothing | paragraph 13 |
| 113. | Asbestos waste—reuse disposable protective clo- | subsection 14(1) |
| 113. | thing | paragraph 14 |
| 114. | Allow asbestos waste to become airborne | subsection 14(1) |
| /- | | paragraph 15 |
| 115. | Generator—fail to submit Generator Registration | 1 0 1 |
| | Report to Director in Form 2 | subsection 15(1) |
| 116. | Generator—Generator Registration Report not | - Table 2 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 |
| | containing sufficient data | subsection 15(2) |
| 117. | Generator—fail to submit supplementary | |
| | Generator Registration Report to Director within | 1 7 10 10 10 10 10 10 10 10 10 10 10 10 10 |
| | 15 days | subsection 15(4) |
| 118. | Generator—transfer waste without having | |
| | generator registration document with waste | 1000 |
| 110 | number | subsection 15(5) |
| 119. | Generator—fail to use registration number in transfer of waste | subsection 15(7) |
| 120. | Generator—fail to use waste numbers in transfer | Subsection 15(1) |
| 120. | of waste | subsection 15(7) |
| 121. | Generator—fail to keep record of waste disposed | Subsection 10(1) |
| | at waste generation facility | subsection 15(8) |
| | | |
| 122. | | |
| 122. | Generator—fail to submit report to Regional Director | subsection 15(10) |
| 122. 123. | Generator—fail to submit report to Regional | |
| | Generator—fail to submit report to Regional Director Generator—fail to submit report with necessary information | subsection 15(10) |
| | Generator—fail to submit report to Regional Director Generator—fail to submit report with necessary information Generator—fail to orally report to Director inabil- | subsection 15(10) |
| 123. 124. | Generator—fail to submit report to Regional Director Generator—fail to submit report with necessary information Generator—fail to orally report to Director inability to confirm waste delivery | |
| 123. | Generator—fail to submit report to Regional Director Generator—fail to submit report with necessary information Generator—fail to orally report to Director inability to confirm waste delivery Generator—permit subject waste to pass from his | subsection 15(10) |
| 123. 124. 125. | Generator—fail to submit report to Regional Director Generator—fail to submit report with necessary information Generator—fail to orally report to Director inability to confirm waste delivery Generator—permit subject waste to pass from his control to an unapproved facility | subsection 15(10) |
| 123. 124. | Generator—fail to submit report to Regional Director Generator—fail to submit report with necessary information Generator—fail to orally report to Director inability to confirm waste delivery Generator—permit subject waste to pass from his control to an unapproved facility Generator—permit subject waste to pass from his | subsection 15(10) subsection 15(11) subsection 16(1) |
| 123. 124. 125. 126. | Generator—fail to submit report to Regional Director Generator—fail to submit report with necessary information Generator—fail to orally report to Director inability to confirm waste delivery Generator—permit subject waste to pass from his control to an unapproved facility Generator—permit subject waste to pass from his control without completing manifest | subsection 15(10) |
| 123. 124. 125. | Generator—fail to submit report to Regional Director Generator—fail to submit report with necessary information Generator—fail to orally report to Director inability to confirm waste delivery Generator—permit subject waste to pass from his control to an unapproved facility Generator—permit subject waste to pass from his | subsection 15(10) subsection 15(11) subsection 16(1) |

| ITEM | Column 1 | Column 2 |
|-------|--|-------------------------------------|
| 128. | Generator—transfer subject waste—markings not | |
| | in accordance with the Transportation of Danger- | |
| | ous Goods Act (Canada) | subsection 16(2) |
| 129. | Carrier—fail to report manifest numbers of lost, | |
| | spoiled or improperly used manifests | section 17 |
| 130. | Carrier—possession of subject waste without a | 1 |
| . , . | manifest completed by generator | subsection 18(1) |
| 131. | Carrier—permit subject waste to pass from his | 10(1) |
| 132. | control not in accordance with this Regulation Carrier—fail to promptly transport subject waste | subsection 19(1) |
| 1.72. | to proper receiving facility | subsection 19(3) |
| 133. | Carrier—fail to complete section B of intact man- | Subsection 19(5) |
| | ifest | clause 20(2)(a) |
| 134. | Carrier—fail to give manifest to generator at time | |
| | of transfer | clause20 (2)(a) |
| 135. | Generator—fail to complete section A of manifest | subclause 20(2)(b)(i) |
| 136. | Generator—fail to return Copy 1 of manifest to | |
| | Director within 3 working days after transfer | subclause 20(2)(b)(ii) |
| 137. | Generator—fail to retain Copy 2 of manifest for 2 | |
| | years | subclause 20(2)(b)(iii) |
| 138. | Generator—fail to return proper copies of man- | 1 1 22/2/11/1 |
| 120 | ifest to carrier at time of transfer | subclause 20(2)(b)(iv) |
| 139. | Carrier—fail to give proper copies of manifest to receiver at time of transfer | |
| 140. | Receiver—fail to complete Section C of manifest | subsection 20(4) clause 20(5)(a) |
| 141. | Receiver—fail to return Copy 3 of manifest to | ciause 20(3)(a) |
| | Director within 3 working days after transfer | clause 20(5)(b) |
| 142. | Receiver—fail to return Copy 4 of manifest to car- | ciaase 20(0)(0) |
| | rier at time of transfer | clause 20(5)(c) |
| 143. | Receiver—fail to retain Copy 5 of manifest for 2 | |
| | years | clause 20(5)(d) |
| 144. | Receiver—fail to return Copy 6 of manifest to | |
| | generator within 3 working days after transfer | clause 20(5)(e) |
| 145. | Carrier—fail to retain Copy 4 of manifest for 2 | |
| | years | subsection 20(6) |
| 146. | Carrier/Operator—dust suppression site—fail to | |
| | complete Section C of manifest at time of deposit | 1 00/80/) |
| 147. | completion Carrier/Operator—dust suppression site—fail to | clause 20(7)(a) |
| 147. | return Copy 3 of manifest to Director within 3 | 10001000 |
| | working days after deposit | clause 20(7)(b) |
| 148. | Carrier/Operator—dust suppression site—fail to | ciadse 20(1)(b) |
| | retain Copy 4 of manifest for 2 years | clause 20(7)(c) |
| 149. | Carrier/Operator—dust suppression site—fail to | |
| | return Copy 6 of manifest to generator within 3 | |
| | working days after deposit | clause 20(7)(d) |
| 150. | Carrier—fail to complete Section B of intact man- | |
| | ifest | clause 21(4)(a) |
| 151. | Carrier—fail to give manifest to generator at time | |
| | of transfer | clause 21(4)(a) |
| 152. | Generator—fail to complete Section A of manifest Generator—fail to return Copy 1 of manifest to | subclause 21(4)(b)(i) |
| 153. | Director within 3 working days of transfer | subclause 21(4)(b)(ii) |
| 154. | Generator—fail to retain Copy 2 of manifest for 2 | 540Clau5C 21(4)(0)(11) |
| :JT. | years | subclause 21(4)(b)(iii) |
| 155. | Generator—fail to return proper copies of man- | 2 1 (1)(0)(III) |
| | ifest to carrier at time of transfer | subclause 21(4)(b)(iv) |
| 156. | Carrier—transport subject waste to receiver out- | |
| | side Ontario without reasonable belief of receiver's | |
| | willingness to complete Section C of manifest | subsection 21(5) |
| | | |
| 157. | Carrier—fail to give proper copies of manifest to receiver at time of transfer | subsection 21(6) |

| TEM | COLUMN 1 | COLUMN 2 |
|------|--|-------------------|
| 158. | Carrier—fail to return Copy 3 of manifest to | |
| | Director within 3 working days after transfer | clause 21(7)(a) |
| 159. | Carrier—fail to retain Copy 4 of manifest for 2 | |
| | years | clause 21(7)(b) |
| 160. | Carrier—fail to return Copy 6 of manifest to generator within 3 working days after transfer | clause 21(7)(c) |
| 161. | Carrier—bring subject waste to a receiver in | ciause 21(7)(c) |
| 101. | Ontario without appropriate generator registration | |
| | document | clause 22(3)(a) |
| 162. | Carrier—fail to complete Section B of intact man- | 0.0000 12(0)(0) |
| | ifest | clause 22(3)(b) |
| 163. | Carrier—fail to give manifest to generator at time | |
| | of transfer | clause 22(3)(b) |
| 164. | Carrier—fail to have manifest accompany the | 1 |
| | subject waste load | clause 22(3)(c) |
| 165. | Carrier—fail to return Copy 1 of properly completed manifest to Director within 3 working days | |
| | after transfer | subsection 22(4) |
| 166. | Carrier—fail to give proper copies of manifest to | . absection ss(4) |
| | receiver at time of transfer | subsection 22(6) |
| 167. | Receiver—fail to complete Section C of manifest | clause 22(7)(a) |
| 168. | Receiver—fail to return Copy 3 of manifest to | |
| | Director within 3 working days after transfer | clause 22(7)(b) |
| 169. | Receiver—fail to return Copy 4 of manifest to car- | |
| | rier at time of transfer | clause 22(7)(c) |
| 170. | Receiver—fail to retain Copy 5 of manifest for 2 | -1 22(7)(3) |
| | years Receiver—fail to return Copy 6 of manifest to | clause 22(7)(d) |
| 171. | generator within 3 working days after transfer | clause 22(7)(e) |
| 172. | Carrier—fail to retain Copy 4 of manifest for 2 | ciaqse 22(1)(0) |
| 1,2. | years | subsection 22(8) |
| 173. | Carrier/Operator—dust suppression site—fail to | |
| | complete Section C of manifest at time of deposit | |
| | completion | clause 22(9)(a) |
| 174. | Carrier/Operator—dust suppression site—fail to | |
| | return Copy 3 of manifest to Director within 3 | 1 00(0)(1) |
| | working days after deposit | clause 22(9)(b) |
| 175. | Carrier/Operator—dust suppression site—fail to | -1 22(0)(-) |
| 176 | retain Copy 4 of manifest for 2 years Carrier/Operator—dust suppression site—fail to | clause 22(9)(c) |
| 176. | return Copy 6 of manifest to generator within 3 | |
| | working days after deposit | clause 22(9)(d) |
| 77. | Carrier—transporting subject waste through | |
| | Ontario without an accompanying, properly com- | |
| | pleted manifest | subsection 23(1) |
| 178. | Receiver—fail to properly complete a refusal | |
| | report | subsection 24(1) |
| 179. | Receiver—fail to return refusal report to Director | subsection 24(1) |
| | within 3 working days after refusal Carrier—fail to obtain instructions from generator | Subsection 24(1) |
| 180. | following a refusal by designated receiver | subsection 24(2) |
| 181. | Carrier—fail to give proper copies to generator at | Subsection 24(2) |
| 101. | time of transfer after refusal of waste by desig- | |
| | nated receiver | subsection 24(3) |
| 182. | Generator—fail to accept return of subject waste | |
| | after refusal of waste by designated receiver | subsection 24(4) |
| 183. | Generator—fail to complete Section C of manifest | |
| | where subject waste returned | clause 24(5)(a) |
| 184. | Generator—fail to return Copy 3 of manifest to | |
| | Director within 3 working days after return of | |

| ITEM | Column 1 | Column 2 |
|------|---|------------------|
| 185. | Generator—fail to return Copy 4 of manifest to | clause 24(5)(c) |
| 186. | Generator—fail to retain Copy 6 of manifest for 2 years | clause 24(5)(d) |
| 187. | Carrier—fail to retain Copy 4 of manifest for 2 years | subsection 24(6) |

(9758)

Man and 12

49



Publications Under The Regulations Act

December 13th, 1986

CROP INSURANCE ACT (ONTARIO)

O. Reg. 675/86. Crop Insurance Plan—Apples. Made—October 28th, 1986. Approved—November 19th, 1986. Filed—November 24th, 1986.

REGULATION TO AMEND REGULATION 198 OF REVISED REGULATIONS OF ONTARIO, 1980 MADE UNDER THE CROP INSURANCE ACT (ONTARIO)

- 1. Subsection 9 (4) of the Schedule to Regulation 198 of Revised Regulations of Ontario, 1980, as amended by section 2 of Ontario Regulation 768/81 and subsection 4 (1) of Ontario Regulation 647/85, is revoked and the following substituted therefor:
- (4) Where the insured crop is damaged by hail or frost and the actual harvested yield exceeds the average yield, the coverage provided shall be the sum of percentage of the average yield determined under this section and the same percentage of the excess yield harvested, but in no case shall the maximum indemnity exceed that for which the Commission is otherwise liable.
 - 2. Subsection 12 (1a) of the said Schedule, as remade by subsection 6 (1) of Ontario Regulation 647/85, is revoked and the following substituted therefor:
- (1a) Notwithstanding subsection (I), where the guaranteed production exceeds 600,000 pounds, the premium payable shall be reduced as follows:

| GUARANTEED PRODUCTION | PREMIUM DISCOUNT |
|-------------------------------|---------------------|
| Up to 600,000 pounds | 0% |
| 600,001 to 1,200,000 pounds | 10% |
| 1,200,001 to 1,800,000 pounds | 20% |
| 1,800,001 to 2,400,000 pounds | 30% |
| 2,400,001 to 2,500,000 pounds | 33% |
| 2,500,001 to 2,600,000 pounds | 36% |
| 2,600,001 to 2,700,000 pounds | 39% |
| 2,700,001 to 2,800,000 pounds | 42% |
| 2,800,001 to 2,900,000 pounds | 45% |
| 2,900,001 to 3,000,000 pounds | 48% |
| over 3,000,000 pounds | 50% |

3. Paragraph 2a of Form 4 of the said Regulation, as made by subsection 1 (3) of Ontario Regulation 6/85, is amended by striking out "the 1st day of August preceding" in the second line and inserting in lieu thereof "the 20th day of December during".

THE CROP INSURANCE COMMISSION OF ONTARIO:

HENRY EDIGER Vice-Chairman

JACK MULDER
Secretary

Dated at Toronto, this 28th day of October, 1986.

(9759) 50

CROP INSURANCE ACT (ONTARIO)

O. Reg. 676/86. Crop Insurance Plan—Peaches. Made—October 28th, 1986. Approved—November 19th, 1986. Filed—November 24th, 1986.

REGULATION TO AMEND **REGULATION 215 OF** REVISED REGULATIONS OF ONTARIO, 1980 MADE UNDER THE CROP INSURANCE ACT (ONTARIO)

- 1. Clause 6 (b) of the Schedule to Regulation 215 of Revised Regulations of Ontario, 1980 is amended by striking out "in Form 2".
- 2. Clause 6 (c) of the said Schedule is amended by striking out "in Form 3" in the first line.
- 3. Clause 7 (a) of the said Schedule is revoked.
- 4. Subsection 10 (1) of the said Schedule, as remade by section 1 of Ontario Regulation 794/82, is revoked and the following substituted therefor:
- (1) The established price for peaches is,
 - (a) 14 cents:
 - (b) 18 cents; or
 - (c) 20 cents,

per pound.

- 5. Section 14 of the said Schedule is amended by striking out "in Form 3" in the second line.
- 6. Clause 6 (1) (a) of Form 1 of the said Regulation is revoked and the following substituted therefor:
 - (a) loss of damage to the insured crop occurs; or
- 7. Form 2, as amended by section 5 of Ontario Regulation 794/83, and Form 3 of the said Regulation are revoked.

THE CROP INSURANCE COMMISSION OF ONTARIO:

HENRY EDIGER Vice-Chairman

JACK MULDER Secretary

Dated at Toronto, this 28th day of October, 1986.

PLANNING ACT, 1983

O. Reg. 677/86.

Zoning Areas—Territorial District of Sudbury. Made-October 10th, 1986.

Filed-November 25th, 1986.

REGULATION TO AMEND **ONTARIO REGULATION 834/81** MADE UNDER THE PLANNING ACT, 1983

- 1. Subsection 4 (2) of Ontario Regulation 834/81, as remade by section 1 of Ontario Regulation 450/82, is revoked and the following substituted therefor:
- (2) All of the lands in the geographic townships of Awrey, Bigwood, Burwash, Cascaden, Cherriman, Cleland, Curtin, Delamere, Dill, Haddo, Loughrin and Secord are divided into the zones listed in the following Table as shown on maps filed with the Plans Administration Branch, North and East, of the Ministry of Municipal Affairs at Toronto as numbers 115 to 135, both inclusive:

TABLE

| Name of Zone | Symbol of Map |
|----------------------|---------------|
| Rural | RU |
| Hamlet Residential | HR |
| Seasonal Residential | SR |
| General Commercial | CG |
| Resort Commercial | CR |
| General Industrial | M |
| Institutional | I |
| Open Space | os |
| Mobile Home Park | MPH |
| Hazard | Н |

O. Reg. 677/86, s. 1.

- 2. The said Regulation is amended by adding thereto the following sections:
- 60. Notwithstanding any other provision of this Order, any building or structure erected in the geographic townships of Bigwood, Delamere, Cherriman 50 and Haddo,

(9760)

- O. Reg. 678/86
- 6023

- (a) along the west arm of Lake Nipissing below the 196.75 metre C.G.D. elevation;
- (b) along Ranger's Bay and Eighteen Mile Bay below the 184.51 metre C.G.D. elevation; or
- (c) along Dry Pine Bay below the 182.90 metre C.G.D. elevation.

shall have a minimum elevation for any opening of 0.3 metres above the respective metre C.G.D. elevations. O. Reg. 677/86, s. 2, part.

PART XII

- 61. This Part applies to the Hazard Land Zones. O. Reg. 677/82, s. 2, part.
- 62.—(1) Every use of land and every erection or use of buildings or structures within the Hazard Land Zones is prohibited except,
 - (a) agricultural uses excluding farm dwellings;
 - (b) horticultural nurseries;
 - (c) golf courses, excluding club houses;
 - (d) docks, marine gasoline pumps and boat storage:
 - (e) parkland, playing fields and playgrounds;
 - (f) works for the protection and management of,
 - (i) lands subject to flooding or high water table, and
 - (ii) steep slopes subject to erosion; and
 - (g) uses existing on the day this section comes into force.
- (2) No guest cabins are permitted in Hazard Land Zones.
- (3) Notwithstanding section 20, no public utilities shall be permitted in the Hazard Land Zones except for,
 - (a) water works or water supply systems;
 - (b) electrical power or energy transmission or distribution systems;
 - (c) street lighting systems;
 - (d) natural or artificial gas works or supply systems; and
 - (e) telephone systems.
- (4) Buildings or structures permitted under subsection (1) shall have a minimum setback of 20 metres from the higher of either the high water mark or the

top of the bank of any watercourse, lake or pond. O. Reg. 677/86, s. 2, part.

PAULINE MORRIS
Director
Plans Administration Branch
North and East
Ministry of Municipal Affairs

Dated at Toronto, this 10th day of October, 1986.

(9761)

50

PLANNING ACT, 1983

O. Reg. 678/86.
Restricted Areas—County of Simcoe,
Township of Nottawasaga.
Made—November 24th, 1986.
Filed—November 25th, 1986.

REGULATION TO AMEND REGULATION 675 OF REVISED REGULATIONS OF ONTARIO, 1970 MADE UNDER THE PLANNNG ACT, 1983

- Regulation 675 of Revised Regulations of Ontario, 1970 is amended by adding thereto the following section:
- 249.—(1) Notwithstanding any other provision of this Order, one seasonal dwelling and buildings and structures accessory thereto may be erected and used on the lands described in subsection (3) if the following requirements are met:

Minimum front yard 7.6

7.6 metres

Minimum side yards

3 metres on one side

1.2 metres on the other side

Maximum height of sea-

sonal dwelling

9.1 metres

Minimum ground floor area of seasonal dwelling

one storey—93 square metres one and one-half storeys or more—69.8 square

netres

(2) In this section, "front yard" is the distance between any building or structure and the lot line abutting King's Highway No. 26. (3) This section applies to that parcel of land in the Township of Nottawasaga in the County of Simcoe, being Lot 7 according to a Plan registered in the Land Registry Office for the Registry Division of Simcoe (No. 51) as Number 1096. O. Reg. 678/86, s. 1.

L. J. FINCHAM
Director
Plans Administration Branch
Central and Southwest
Ministry of Municipal Affairs

Dated at Toronto, this 24th day of November, 1986.

(9762) 50

PLANNING ACT, 1983

O. Reg. 679/86.
Restricted Areas—County of Simcoe,
Township of Nottawasaga.
Made—November 24th, 1986.
Filed—November 25th, 1986.

REGULATION TO AMEND REGULATION 675 OF REVISED REGULATIONS OF ONTARIO, 1970 MADE UNDER THE PLANNING ACT, 1983

 Regulation 675 of Revised Regulations of Ontario, 1970 is amended by adding thereto the following sections:

250.—(1) The building existing on the land described in subsection (2) on the day this section comes into force may be used for a restaurant and for a store for the sale of crafts, gifts and antiques and buildings and structures accessory thereto may be erected and used on the land.

- (2) Subsection (1) applies to that parcel of land in the Township of Nottawasaga in the County of Simcoe, being composed of Lot 4 on a Plan registered in the Land Registry Office for the Registry Division of Simcoe (No. 51) as Number 92. O. Reg. 679/86, s. 1, part.
- 251.—(1) A building in which automobiles, recreational vehicles and related equipment are sold and serviced, together with buildings and structures accessory thereto, may be erected and used on the land described in subsection (2).
- (2) Subsection (1) applies to that parcel of land in the Township of Nottawasaga in the County of Simcoe, being that part of Lot 37 in Concession V described as follows:

Premising that the bearing of the southerly limit of the said Lot 37 is north 73° 12′ east (astronomic) and relating all bearings herein thereto;

Commencing at an iron survey bar defining the southeast angle of the said Lot 37;

Thence south 73° 12' west along the southerly limit of the said Lot a distance of 61.56 metres to an iron survey bar;

Thence north 11° 51′ 30″ west a distance of 101.79 metres to an iron survey bar set in the southwesterly limit of the King's Highway No. 26;

Thence south 56° 11′ 20″ east along the said southwesterly limit of highway a distance of 89.48 metres to an iron survey bar marking the intersection with the easterly limit of the said Lot;

Thence south 9° 44′ 50″ east along the last-mentioned limit a distance of 32.55 metres, more or less, to the point of commencement. O. Reg. 679/86, s. 1, part.

L. J. FINCHAM
Director
Plans Administration Branch
Central and Southwest
Ministry of Municipal Affairs

Dated at Toronto, this 24th day of November, 1986.

(9763) 50

VOCATIONAL REHABILITATION SERVICES ACT

O. Reg. 680/86. General. Made—November 19th, 1986. Filed—November 26th, 1986.

REGULATION TO AMEND REGULATION 943 OF REVISED REGULATIONS OF ONTARIO, 1980 MADE UNDER THE VOCATIONAL REHABILITATION SERVICES ACT

- 1.—(1) Item 19 of Schedule 1 to Regulation 943 of Revised Regulations of Ontario, 1980 is revoked and the following substituted therefor:
- 19. Central Seven Association for the Developmentally Handicapped

- (2) Item 25 of the said Schedule 1 is revoked and the following substituted therefor:
- 25. Community Living Mississauga
- (3) The said Schedule 1 is amended by adding thereto the following item:
- 25a. Community Sheltered Workshops
 - (4) Item 28 of the said Schedule 1 is revoked and the following substituted therefor:
- 28. COSTI-ILAS Immigrant Services
- (5) The said Schedule 1 is further amended by adding thereto the following item:

39a. Goodwill Industries of Toronto

- (6) Items 69 and 98 of the said Schedule 1 are revoked.
 - (1) Item 85a of Schedule 2 to the said Regulation, as made by subsection 2 (17) of Ontario Regulation 335/84, is revoked.
- (2) Item 86 of the said Schedule 2 is revoked and the following substituted therefor:
- 86. Atlaz Industrial Centre, 55 Ameer Drive, Toronto
 - (3) Item 99 of the said Schedule 2 is revoked and the following substituted therefor:
- C.N.I.B. Caterplan
 Occupational Units Program,
 1929 Bayview Avenue, Toronto
- (4) The said Schedule 2 is amended by adding thereto the following item:
- 99a. C.N.I.B. Vocational Rehabilitation Activity Centre,1929 Bayview Avenue, Toronto
 - (5) Item 107a of the said Schedule 2, as made by subsection 2 (22) of Ontario Regulation 335/84, is amended by striking out,

771 St. Clair Avenue West, Toronto

in the forty-seventh and forty-eighth lines and inserting in lieu thereof:

1611 Wilson Avenue, Toronto

and

1508-1510 Danforth Avenue, Toronto

and

230 Richmond Street, Toronto

- (6) Item 139 of the said Schedule 2, as remade by subsection 1 (2) of Ontario Regulation 763/84, is revoked and the following substituted therefor:
- The Salvation Army Booth Industries,
 Lakeshore Boulevard East, Toronto
 - (7) Item 141 of the said Schedule 2 is revoked.
 - (8) Item 141a of the said Schedule 2, as made by subsection 2 (2) of Ontario Regulation 247/81, is revoked and the following substituted therefor:
- 141a. Scarbrook Enterprises, 2220 Midland Avenue, Units 14-22, Scarborough

GENERAL WELFARE ASSISTANCE ACT

O. Reg. 681/86. General. Made—November 19th, 1986. Filed—November 26th, 1986.

REGULATION TO AMEND
REGULATION 441 OF
REVISED REGULATIONS
OF ONTARIO, 1980
MADE UNDER THE
GENERAL WELFARE ASSISTANCE
ACT

 Section 15 of Regulation 441 of Revised Regulations of Ontario, 1980, as amended by section 4 of Ontario Regulation 361/83, section 6 of Ontario Regulation 691/83, section 1 of Ontario Regulation 495/84, section 6 of Ontario Regulation 708/84 and section 4 of Ontario Regulation 824/84, is further amended by adding thereto the following subsection:

(5a) Notwithstanding subsection (5) and subject to section 20, the Province of Ontario shall pay by way of reimbursement to the municipality or to the council of the approved band, as the case may be, 80 per cent of any amount paid in the month of October or November in 1986 as special assistance to provide winter clothing for one or more eligible dependants referred to in subsection 28 (1) of any applicant or recipient. O. Reg. 681/86, s. 1.

2. The said Regulation is amended by adding thereto the following section:

28.—(1) In this section, "eligible dependant" means,

(a) a dependant child;

6026

- (b) a foster child referred to in clause 12 (3) (c);and
- (c) a dependant adult other than a spouse who,
 - (i) where this section applies in 1986, has not attained twenty-one years of age on the 1st day of November, 1986, and
 - (ii) where this section applies in any year subsequent to 1986, has not attained twenty-one years of age on the 1st day of October in that year.
- (2) Subject to subsection (3), an applicant or recipient who is eligible for general assistance, other than emergency assistance paid under subsection 8 (10) in the month of November in 1986 or in the month of October in any year subsequent to 1986 and who has one or more eligible dependants in that month shall be paid in that month, in addition to the amount of general assistance, an amount equal to \$80 for each of his or her eligible dependants.
- (3) Where an applicant or recipient was paid in October or November in 1986 an amount of special assistance to provide winter clothing for one or more eligible dependants, any amount otherwise payable under subsection (2) in the month of November in 1986 shall, for each eligible dependant, be reduced by the amount already paid on behalf of that eligible dependant as special assistance for winter clothing.
- (4) For the purposes of subsection 11 (6), a payment made in accordance with this section shall be deemed to be general assistance paid in accordance with subsection 11 (1) or (5). O. Reg. 681/86, s. 2.

PARKWAY BELT PLANNING AND DEVELOPMENT ACT

O. Reg. 682/86.

County of Halton (now The Regional Municipality of Halton), City of Burlington.

Made—November 20th, 1986. Filed—November 26th, 1986.

REGULATION TO AMEND ONTARIO REGULATION 482/73 MADE UNDER THE PARKWAY BELT PLANNING AND DEVELOPMENT ACT

1. Ontario Regulation 482/73 is amended by adding thereto the following section:

125.—(1) A one-storey woodworking shop may be erected and used as an accessory building to the single-family dwelling existing on the lands described in subsection (2) on the date this Regulation comes into force if the following requirements are met:

Minimum distance between woodworking shop and,

(i) Sumach Drive

30 metres

(ii) Unsworth Avenue

6 metres

(iii) easterly lot line

1.5 metres

Maximum floor area of workshop

340 metres

(2) Subsection (1) applies to the parcel of land in the City of Burlington in The Regional Municipality of Halton, formerly in the Township of East Flamborough in the County of Halton, being that part of Lot 9 in Concession I, described as follows:

Commencing at an iron bar planted in the northern corner of the herein described parcel of land and being in the southeastern limit of the right-of-way lands of the Canadian National Railway Company (Toronto-Hamilton main line) which point of commencement may be arrived at as follows:

Beginning at a point in the northeastern limit of Lot 9 where it is intersected by the said railway limit;

Thence along the said railway limit on a course of south 48° 53' west 669 feet 5 inches to an iron bar planted at an angle therein;

Thence continuing thereon on a course of south 51° 05′ west 509 feet 1½ inches to an iron bar planted in the said railway limit at

(9765)

50

the point of commencement of the herein described parcel of land;

Thence south 44° 40' west 234 feet 9¾ inches, more or less, to a point in the northwestern limit of a given road through said Lot 9, sometimes known as Old York Road;

Thence south 51° 54′ 30″ west along the said limit of Old York Road, 75 feet to an iron pipe planted at the point of intersection of the said limit of Old York Road with the northeastern limit of said Old York Road;

Thence north 44° 40' west along the northeastern limit of the Old York Road 226 feet 9 inches, more or less, to a point in the southeastern limit of the said right-of-way of the Canadian National Railway Company;

Thence along the said railway limit on a course of north 51° 05′ east 75 feet, more or less, to the point of commencement. O. Reg. 682/86, s. 1.

L. J. FINCHAM
Director
Plans Administration Branch
Central and Southwest
Ministry of Municipal Affairs

Dated at Toronto, this 20th day of November, 1986.

(9766)

50

CROP INSURANCE ACT (ONTARIO)

O. Reg. 683/86. Crop Insurance Plan—Tomatoes. Made—April 23rd, 1986. Approved—June 6th, 1986. Filed—November 26th, 1986.

REGULATION TO AMEND REGULATION 226 OF REVISED REGULATIONS OF ONTARIO, 1980 MADE UNDER THE CROP INSURANCE ACT (ONTARIO)

- 1. Clause 3 (d) of the Schedule to Regulation 226 of Revised Regulations of Ontario, 1980 is revoked and the following substituted therefor:
 - (d) "processor" means a person who is licensed as a processor of vegetables under the Farm Products Marketing Act and the regulations made thereunder:

- 2. Subsection 11 (4) of the said Schedule, as remade by subsection 4 (2) of Ontario Regulation 292/85, is revoked and the following substituted therefor:
- (4) The premium prescribed by subsection (1) is subject to a surcharge of,
 - (a) \$10 per acre where the insured person is eligible for a lost plants benefit of \$148 per acre;
 - (b) \$13.50 per acre where the insured person is eligible for a lost plants benefit of a maximum of \$197.50 per acre; or
 - (c) \$18.75 per acre where the insured person is eligible for a lost plants benefit of more than \$276.50 per acre.
 - 3. Subparagraph 4 (2) of Form 1 of the said Regulation is amended by striking out "application" in the second and third lines and inserting in lieu thereof "final acreage report".
 - 4. Subparagraph 4 (3) of the said Form 1 is amended by striking out "application, unless the processor increases the contract acreage or tonnage accordingly" in the third and fourth lines and inserting in lieu thereof "final acreage report".
 - 5. Clause 9 (2) (b) of the said Form 1, as remade by subsection 5 (1) of Ontario Regulation 356/84, is revoked and the following substituted therefor:
 - (b) an amount calculated at the rate of \$148 for each replanted acre.
 - 6. Clause 9 (4) (a) of the said Form 1, as remade by subsection 6 (2) of Ontario Regulation 292/85, is revoked and the following substituted therefor:
 - (a) the original cost to the producer of the plants or seed in respect of which loss or damage was suffered; or
 - 7. Clauses 9 (5) (a) and (b) of the said Form 1, as remade by subsection 5 (2) of Ontario Regulation 356/84, are revoked and the following substituted therefor:
 - (a) a maximum of \$197.50 per acre where he has planted up to 10,000 plants per acre; or

(b) a maximum of \$276.50 per acre where he has planted in excess of 10,000 plants per acre.

THE CROP INSURANCE COMMISSION OF ONTARIO:

M. Huff Chairman

JACK MULDER Secretary

Dated at Toronto, this 23rd day of April, 1986.

(9767)

ASSESSMENT ACT

O. Reg. 684/86.

Pipe Line Rates in Part of the District of
Algoma and Part of The Regional
Municipality of Ottawa-Carleton.

Made—November 19th, 1986.

Filed—November 26th, 1986.

REGULATION MADE UNDER THE ASSESSMENT ACT

PIPE LINE RATES IN PART OF THE DISTRICT OF ALGOMA AND PART OF THE REGIONAL MUNICIPALITY OF OTTAWA-CARLETON

1.—(1) In lieu of the rates contained in the Schedule to Regulation 71 of Revised Regulations of Ontario, 1980, commencing with the year 1985, the rates contained in the Schedule to this Regulation shall apply to the assessment for taxation of all pipe lines liable to assessment and taxation under section 24 of the Act and located in or on the boundary of the Township of West Carleton in The Regional Municipality of Ottawa-Carleton.

(2) In lieu of the rates contained in the Schedule to Regulation 71 of Revised Regulations of Ontario,

1980, commencing with the year 1986, the rates contained in the Schedule to this Regulation shall apply to the assessment for taxation of all pipe lines liable to assessment and taxation under section 24 of the Act and located in or on the boundary of the Town of Bruce Mines, the Town of Thessalon, the Village of Hilton Beach, the Township of Hilton, the Township of Jocelyn, the Township of Johnson, the Township of Laird, the Township of Macdonald, Meredith and Aberdeen Additional, the Township of St. Joseph, the Township of Tarbutt and Tarbutt Additional, the Township of Thessalon and the Locality of the Central Algoma Board of Education in the District of Algoma. O. Reg. 684/86, s. 1.

2. For the purpose of clause 24 (16) (b) of the Act,

- (a) where two or more pipe lines occupy the same right of way, the second and subsequent pipe lines occupying that right of way are designated to be each pipe line occupying that right of way, except that which bears the higher or highest assessed value computed by applying the rates in the Schedule to this Regulation without the reduction in rates for the second and subsequent pipe lines occupying the same right of way provided for in clause (b), and where two or more pipe lines occupying the same right of way have the same assessed value so computed and that assessed value is the higher or highest assessed value or is the assessed value for the pipe lines occupying that right of way, each of such pipe lines is designated as a second and subsequent pipe line except that one that was first in use as a pipe line; and
- (b) where a right of way occupied by a pipe line that is not designated to be a second or subsequent pipe line under clause (a) is occupied by a pipe line that is so designated, each pipe line so designated shall be assessable and taxable at 75 per cent of the rate in the Schedule that is applicable to each pipe line so designated. O. Reg. 684/86, s. 2.

| Sched |
|-------|
| ,98/ |
| 684 |
| Reg |
| 0 |

| | 7. |
|---|----------------------------------|
| 되다 | a ther |
| اد | 0 -1 |
| Ö | d and Gath Pipe Line |
| 1900 Market Value in Dollars Per Foot of Lergth | Field and Gathering Pipe Line |
| Per | |
| Ars | c |
| 110 | sto |
| u u | Oil Transmission Pipe Line |
| 9 | Pipe |
| Valu | 4- |
| ke t | |
| Har | ton |
| 0061 | Gas Fransmission Pipe Line |
| | Gas Transmission Pipe Line |
| | |

| Plastic | 6 | 1.45 | 1.95 | 2.90 | 3.75 | | | | | | | | | | | | | | | | | | | | | |
|---------|-------------------------|-----------------|-------------------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|------------------|------------------|------------------|------------------|------------------|------------------|------------------|------------------|------------------|------------------|------------------|------------------|------------------|------------------|------------------|-----|
| Steel | \$ 2.40 | 2.65 | 3.25 | 4.15 | 5.00 | 5,85 | 6.65 | 9.25 | 12.45 | 15.65 | | | | | | | | | | | | | | | | - 0 |
| | 43 | 3.40 | 4.25 | 5.35 | 6.55 | 7.50 | 8.55 | 11.80 | 15.60 | 19.40 | 23.25 | 26.90 | 30.45 | 34.65 | 38.30 | 41.95 | 45.45 | 48.90 | 52.20 | 55.45 | 58.60 | 61.65 | 64.60 | | | |
| | \$ 3.25 | 3,55 | 4.35 | 5.55 | 6.70 | 7,80 | 8.90 | 12.40 | 16.55 | 20.90 | 25.25 | 29.55 | 34.20 | 38.90 | 43.55 | 48.20 | 52.85 | 57.50 | 62.10 | 66.80 | 71.45 | 76.10 | 79.65 | 85.45 | 90.10 | |
| | Nominal Inside Diameter | Inside Diameter | Nominal Ineide Diameter | Inside Diameter | Outside Dismeter | Outside Diameter | |
| | Nominal Ins | Nominal Inst | Nominal Ine | | Nominal Inst | Nominal Insi | Out | Outs | Outa | Outs | |

1980 PIPE LINE RATES Schedule

| | | - | 3 | - | 5 | 5 | | | | | | | | | | | | | | | | | | |
|--------|------|------|------|------|------|------|------|---|----|---|----|----|----|----|----|----|----|----|----|----|----|----|----|----|
| | /5 | ~ | ~ | 4 | 50 | 9 | 8 | | | | | | | | | | | | | | | | | |
| | _ | Over | Over | Over | Over | OVER | OVer | | | | | | | | | | | | | | | | | |
| | Over | Not | Noc | Not | Not | Not | Not | | | | | | | | | | | | | | | | | |
| | Not | and | and | and | and | and | and. | | | | | | | | | | | | | | | | | |
| Over 1 | and | 1/2 | 1/5- | 3/4" | 1/5 | 2/8" | 2/8" | | | | | | | | | | | | | _ | | | | |
| o ve | - | - | ~ | ~ | 4 | S | 9 | 0 | 12 | 4 | 16 | 18 | 20 | 22 | 24 | 26 | 28 | 30 | 32 | 34 | 36 | 38 | 40 | 42 |
| Not | Over | Over | Over | Over | Over | Over | Over | | | | | | | | | | | | | | | | | |

Size of Pipe

2 4 7 8 8

O. Reg. 685/86

GASOLINE TAX ACT

O. Reg. 685/86. General. Made—November 19th, 1986. Filed—November 26th, 1986.

REGULATION TO AMEND REGULATION 440 OF REVISED REGULATIONS OF ONTARIO, 1980 MADE UNDER THE GASOLINE TAX ACT

- 1. Section 2 of Regulation 440 of Revised Regulations of Ontario, 1980 is revoked and the following substituted therefor:
- 2. Every importer shall, on or before the 15th day of the month following the month in which the gasoline or aviation fuel was imported into or received in Ontario, deliver to the Minister a statement showing the quantity of gasoline or aviation fuel or both imported by the importer into Ontario or received by the importer in Ontario and the names and addresses of the person from whom the gasoline or aviation fuel or both was purchased and the date of each purchase and shall remit with the statement the tax collectable by the importer and the tax payable by the importer in respect of the gasoline and aviation fuel. O. Reg. 685/86, s. 1.
 - 2.—(1) Subsection 3 (1) of the said Regulation, as amended by section 1 of Ontario Regulation 626/81, is revoked and the following substituted therefor:
 - (1) A person who applies to the Minister and,
 - (a) who is not a collector but is licensed under the Gasoline Handling Act; or
 - (b) is an employee of a collector who by reason of an agreement between the employee and the collector is held responsible for and must pay the collector for all losses and shortages incurred with respect to gasoline delivered to the person and sold by the person for the account of the collector,

and collects and pays over the tax under the Act may be paid a refund of 0.21 per cent of the amount by which the amount of tax paid by the person to the supplier of the person on gasoline sold by the person at retail exceeds any amount of tax with respect to which the person is or was or will be entitled to make an application for refund under any other section of the Act or regulations. O. Reg. 685/86, s. 2 (1).

- (2) Subsection 3 (2) of the said Regulation is revoked and the following substituted therefor:
- (2) An application for a refund under subsection (1) shall be accompanied by properly receipted invoices covering the gasoline in respect of which the applicant is claiming a refund.
- (2a) No refund shall be paid if the tax has been paid more than three years before the date on which the application for refund is mailed or delivered to the Minister. O. Reg. 685/86, s. 2 (2).
 - 3.—(1) Clause 5 (1) (e) of the said Regulation is revoked and the following substituted therefor:
 - (e) subsections 16 (1) and (5);
 - (2) Clause 5 (2) (f) of the said Regulation is revoked and the following substituted therefor:
 - (f) subsections 16 (1) and (5);
 - 4. Section 6 of the said Regulation is revoked.
 - Section 7 of the said Regulation, as amended by section 1 of Ontario Regulation 547/81, is revoked.
 - 6. Clause 8 (1) (c) of the said Regulation, as amended by section 1 of Ontario Regulation 254/85, is revoked and the following substituted therefor:
 - (c) the application for the refund in the form required by the Minister is mailed or delivered to the Minister not more than three years after the date on which the tax was paid on the exported gasoline or aviation fuel and is supported by,
 - (i) invoices showing the purchase of the gasoline or aviation fuel, and
 - (ii) documentary evidence sufficient to satisfy the Minister that the gasoline or aviation fuel was exported from Ontario and was not subsequently imported into Ontario in bulk.
 - 7. Section 9 of the said Regulation is revoked.
 - 8. Section 10 of the said Regulation, as amended by section 1 of Ontario Regulation 179/81, is revoked and the following substituted therefor:

- 10. For the purpose of subsection 15 (1) of the Act, every collector shall maintain a record of,
 - (a) the quantities of gasoline and aviation fuel imported, purchased or otherwise received from suppliers or the collector's own production;
 - (b) the quantities of gasoline and aviation fuel sold, delivered or exported or consumed by the collector including sales and deliveries to other collectors, importers, wholesalers, retailers and purchasers;
 - (c) the collector's inventory of gasoline and aviation fuel; and
 - (d) the tax collectable and payable by the collector.

and shall retain each such record and all invoices, books of account and other documents related thereto for at least five years from the date of the making of the record, invoice or document or last entry in the book of account. O. Reg. 685/86, s. 8.

- 9. Paragraph 3 of section 12 of the said Regulation is revoked.
- Section 14 of the said Regulation is revoked.
- 11. Form 1 of the said Regulation, as remade by section 1 of Ontario Regulation 542/86, is revoked.
- 12. Form 2 of the said Regulation, as remade by subsection 1 (2) of Ontario Regulation 386/83, is revoked.

(9769)

MUNICIPAL ACT

O. Reg. 686/86. Small Business Programs. Made—November 19th, 1986. Filed—November 26th, 1986.

REGULATION MADE UNDER THE MUNICIPAL ACT

SMALL BUSINESS PROGRAMS

1. The maximum amount that may be expended by a municipality under a program referred to in subsection 112a (2) of the Act is \$5 per person based on the latest census made by the assessor under the Assessment Act. O. Reg. 686/86, s. 1.

2. For the purposes of section 112a of the Act, "small business" means a business that has less than 100 employees. O. Reg. 686/86, s. 2.

(9770)

50

GAME AND FISH ACT

O. Reg. 687/86. Open Seasons—Game Birds. Made—November 26th, 1986. Filed—November 27th, 1986.

REGULATION TO AMEND ONTARIO REGULATION 501/81 MADE UNDER THE GAME AND FISH ACT

1. Ontario Regulation 501/81 is amended by adding thereto the following section:

OPEN SEASON FOR WILD TURKEY

13a. The holder of a licence that is a licence issued to a resident in Form 5 of Regulation 420 of Revised Regulations of Ontario, 1980 may hunt a wild turkey with a beard in any wildlife management unit specified in Column 1 of Schedule 6 during the open seasons specified opposite thereto in Column 2 during the hours specified in Column 3 upon condition that,

- (a) the holder's name is drawn by a lot in a draw administered by the Ministry;
- (b) the holder affixes a tag in Form 12 of Regulation 420 of Revised Regulations of Ontario, 1980 to the licence before the hunt:
- (c) the holder does not shoot or attempt to shoot more than one wild turkey with a beard;
- (d) the holder uses,
 - (i) a shotgun not larger than number 10 gauge and not smaller than number 20 gauge loaded with shot sizes number 4, 5 or 6, or
 - (ii) a cross-bow, long-bow, arrow or bolt specified in section 1 of Regulation 405 of Revised Regulations of Ontario, 1980;
- (e) the holder does not use decoys; and
- (f) the holder who has killed wild turkey with a beard takes the intact carcass within six hours of the kill to a person designated at the time of the hunt for registration of wild turkeys by the Ministry. O. Reg. 687/86, s. 1.

2. The said Regulation is further amended by adding thereto the following Schedule:

Schedule 6

WILD TURKEY

| Item | COLUMN 1 Wildlife Management Units | Column 2 Open Seasons | COLUMN 3 Hours |
|------|---|--|--|
| 1. | 68, 71 | From the first Monday in May to the Saturday next following, | ½ hr. before sunrise to 12 o'clock noon |
| | | and | |
| | | from the second Monday in May to the Saturday next following, in any year. | |

s. 1.

O. Reg. 687/86, s. 2.

50

(9794)

(13) An application for a tag in Form 12 shall be in the form furnished by the Ministry. O. Reg. 688/86,

O. Reg. 688/86. Hunting Licences.

GAME AND FISH ACT

Made-November 26th, 1986. Filed—November 27th, 1986.

REGULATION TO AMEND **REGULATION 420 OF** REVISED REGULATIONS OF ONTARIO, 1980 MADE UNDER THE GAME AND FISH ACT

- 1. Section 2 of Regulation 420 of Revised Regulations of Ontario, 1980, as remade by section 1 of Ontario Regulation 138/83 and amended by section 1 of Ontario Regulation 376/83, is further amended by adding thereto the following subsections:
- (10) A licence in Form 5 is not valid for hunting wild turkey unless a tag in Form 12 is affixed to the licence before the hunt.
- (11) A non-resident is not entitled to be issued a tag in Form 12.
- (12) Where tags are issued on the basis of a lottery, no person whose name is drawn by lot shall receive a tag in Form 12 unless the person has obtained a certificate issued by the Ministry indicating that the person has successfully completed a wild turkey hunter education course held by the Ministry.

- 2.—(1) Section 9 of the said Regulation. as remade by section I of Ontario Regulation 499/82 and amended by section 1 of Ontario Regulation 683/82, section 3 of Ontario Regulation 138/83, section 3 of Ontario Regulation 186/84 and section I of Ontario Regulation 219/85, is further amended by adding thereto the following subsection:
- (3a) Every holder of a licence in Form 5 who has killed a wild turkey shall,
 - (a) immediately after the kill and at the site of the kill, attach the seal provided with the tag in Form 12 to the leg of the turkey in the manner indicated on the seal; and
 - (b) keep the seal attached to the leg of the turkey at all times until it is prepared for consumption. O. Reg. 688/86, s. 2 (1).
 - (2) Subsection 9 (5) of the said Regulation, as made by subsection 3 (2) of Ontario Regulation 138/83, is amended by inserting after "4" in the first line "5".
 - (3) The said section 9 is further amended by adding thereto the following subsections:

2464

- (6a) No holder of a licence in Form 5 shall attach the seal provided with the tag in Form 12 to a wild turkey that has been killed by another person.

 O. Reg. 688/86, s. 2 (3), part.
- (7a) Except as otherwise provided in this Regulation, the holder of a licence in Form 5 shall, at the time of the hunt, have a seal provided with the tag in Form 12 on his or her person and shall produce and show it to any officer on request by the officer. O. Reg. 688/86, s. 2 (3), part.
 - 3. The said Regulation is amended by adding thereto the following section:

9a. Subsections 2 (10) and 9 (3a) do not apply to a holder of a licence in Form 5 when hunting wild tur-

keys on a game bird hunting preserve as authorized under Regulation 416 of Revised Regulations of Ontario, 1980. O. Reg. 683/86, s. 3.

- 4. Schedule 3 to the said Regulation, as remade by section 3 of Ontario Regulation 519/86 and amended by section 1 of Ontario Regulation 520/86, is further amended by inserting under "11" in Column 1 "12" and by inserting opposite thereto in Columns 2 and 3 "12,00" and "NIL" respectively.
- The said Regulation is further amended by adding thereto the following Form:

Form 12

Game and Fish Act

RESIDENT'S WILD TURKEY

VALIDATION TAG 19...

| Tag Serial Number | |
|---|--|
| This tag authorizes | |
| | |
| (Last Name) | |
| (First Name) | (Middle Initial) |
| to take a wild turkey with a beard | |
| in WMU(WMU Number) | |
| (during the open season specified above) | |
| Remove the backing from this tag and stick the tag to 688/86, s. 5. | the back of your licence to hunt small game. O. Reg. |

(9795)

50

6. Section 4 of this Regulation comes into force on the 1st day of January, 1987.

ONTARIO DRUG BENEFIT ACT, 1986

O. Reg. 689/86. General. Made—November 26th, 1986. Filed—November 27th, 1986.

REGULATION MADE UNDER THE ONTARIO DRUG BENEFIT ACT, 1986

GENERAL

1. In this Regulation,

"extemporaneous preparation" means a drug or combination of drugs prepared or compounded in a pharmacy according to a prescription;

"modified release dosage form" means a dosage form of a product that is formulated to control the level of the drug in the blood over a shorter or longer period of time than a conventional dosage form;

"resident of Ontario" means a person who is legally entitled to remain in Canada and makes his or her home and is ordinarily resident in Ontario for at least four uninterrupted months in any one year but does not include a person who is a tourist, transient or visitor to Ontario;

"unit" means a gram, millilitre, tablet, capsule or other appropriate unit of a listed drug product in a particular dosage form and strength. O. Reg. 689/86, s. 1.

- 2.—(1) Subject to subsections (3) and (4), the following classes of persons who are residents of Ontario are designated as eligible classes of persons for the purposes of section 2 of the Act:
 - Persons who are receiving extended care services within the meaning of clause 43 (1) (b) of Regulation 452 of Revised Regulations of Ontario, 1980 (General) for which payment is made under the *Health Insurance Act*.
 - 2. Persons who are receiving home care services within the meaning of clause 44 (1) (b) of Regulation 452 of Revised Regulations of Ontario, 1980 (General) for which payment is made under the *Health Insurance Act*.
 - 3. Persons who reside in homes licensed under section 5 of the *Homes for Special Care Act*.
 - 4. Persons who are eligible for a pension under Part I of the *Old Age Security Act* (Canada).
 - Persons who have attained sixty-five years of age and have been residents of Ontario for twelve consecutive months immediately preceding the date of the Minister's confirmation referred to in subsection (4).

- (2) Subsection (1) does not apply to a person who is eligible to receive drug benefits under section 24 of Regulation 318 of Revised Regulations of Ontario, 1980 (General).
- (3) A person is not a member of the class of persons referred to in paragraph 4 of subsection (1) until the first day of the month for which the person first receives payment of the pension.
- (4) A person is not a member of the class of persons referred to in paragraph 5 of subsection (1) until the first day of the month following the month in which the Minister receives all the information required by the Minister to confirm that the person is a member of the class.
- (5) Any information referred to in subsection (4) that is submitted before the person attains sixty-five years of age shall be deemed to have been submitted when the person attains sixty-five years of age.
- (6) Any information referred to in subsection (4) that is submitted after the person attains sixty-five years of age shall be deemed to have been received,
 - (a) when the person attained sixty-five years of age; or
 - (b) on the day that is five years earlier than the day on which the Minister receives the information,

whichever is the later day. O. Reg. 689/86, s. 2.

- 3.—(1) The drug products listed in Column 2 of Part B of Schedule 1 are designated as listed drug products.
- (2) For the purposes of subsections 5 (1) and (2) of the Act, the amount in Column 3 of Part B of Schedule 1 that is set out opposite each drug in Column 1 of Part B of Schedule 1 is the best available price of the drug.
- (3) For the purposes of subsection 5 (3) of the Act, the Minister shall pay to a physician for dispensing a listed drug product for an eligible person the amount provided for by this Regulation with respect to the listed drug product and a dispensing service fee that shall be,
 - (a) in the case of a physician whose office is located 20 kilometres or more from an accredited pharmacy, \$4.17; and
 - (b) in the case of a physician whose office is located less than 20 kilometres from an accredited pharmacy, \$3.51.
- (4) For the purposes of subsection 6 (1) of the Act and subsection 3 (3) of this Regulation, the amount the Minister shall pay in respect of each listed drug product in Column 2 of Part B of Schedule 1 is the lesser of,

- (a) the sum of the dispensing fee referred to in subsection 6 (2) of the Act or subsection 3 (3) of this Regulation, the amount in Column 3 of Part B of Schedule 1 set out opposite the drug in Column 1 of Part B of Schedule 1 and the amount referred to in subsection (11); or
- (b) the usual and customary amount charged by the operator of the pharmacy or the physician to persons who are not eligible persons.
- (5) Subsection (4) does not apply to listed drug products referred to in subsection (8).
- (6) For the purposes of subsection 6 (1) of the Act and subsection 3 (3) of this Regulation, the amount the Minister shall pay in respect of each listed drug product that is designated as "otc" in Part B of Schedule 1 is the lesser of the amount in Column 3 of Part B of Schedule 1 set out opposite the drug in Column 1 of Part B of Schedule 1 or the usual and customary amount charged by the operator of the pharmacy or the physician to persons who are not eligible persons.
- (7) For the purposes of clause 6 (2) (a) of the Act, the dispensing fee the Minister shall pay to a pharmacy operated in a hospital approved as a public hospital under the *Public Hospitals Act* for dispensing a listed drug product for an eligible person is \$2.65.
- (8) Listed drug products that are designated as "otc" in Part B of Schedule 1 are listed drug products to which clause 6 (2) (b) of the Act applies.
- (9) For the purposes of subclause 6 (2) (c) (i) of the Act, the amount determined under section 7 of the Act for the dispensing of a listed drug product for an eligible person is \$5.32.
- (10) For the purposes of subsection 8 (1) of the Act, the Minister shall pay to a physician or a pharmacy, in addition to the dispensing fee, for dispensing a drug for which there is not a listed drug product and to the supplying of which the Minister has made the Act apply, the cost of the drug dispensed calculated under section 4.
- (11) For the purposes of subsection 18 (2) of the Act, the percentage of the best available price that is to be added to the price of a listed drug product is that percentage set out in Part A of Schedule 1. O. Reg. 689/86, s. 3.
- 4.—(1) For the purposes of subsection 6 (5) of the Act, the cost to the operator of a pharmacy of purchasing a listed drug product is the amount calculated by,
 - (a) deducting from the total amount paid or payable, exclusive of shipping charges, by the operator or the physician to purchase the product dispensed, the value of any price reduction granted by the manufacturer or wholesaler or an agent or representative of the manufacturer or wholesaler in the form of

- rebates, allowances, discounts, refunds, free goods or any other benefits of a like nature paid or credited to the operator or to the physician in respect of the purchase of the product that included the units dispensed;
- (b) dividing the result obtained under clause (a) by the number of units purchased by the operator or the physician; and
- (c) multiplying the unit cost determined under clause (b) by the number of units dispensed pursuant to a prescription.
- (2) For the purposes of clause (1) (a),
 - (a) a discount for prompt payment that is made within thirty days of the sale of the product to the operator or physician shall be deemed not to be a price reduction if the discount does not exceed 2 per cent of the net price of the product; and
 - (b) delayed payment by the operator or physician shall be deemed not to be a price reduction unless the payment is made in excess of 120 days after the product is delivered to the operator or physician.
- (3) Where payment is delayed by the operator or physician in excess of 120 days after the product is delivered to the operator or physician, the delayed payment terms shall be considered to be a price reduction of 1.5 per cent of the net purchase price per month. O. Reg. 689/86, s. 4.
- 5.—(1) For the purposes of subsection 17 (1) of the Act,
 - (a) extemporaneous preparations that do not duplicate the formulation of a manufactured drug product are designated pharmaceutical products; and
 - (b) substances that are designated as "dpp" in Schedule 1 are designated pharmaceutical products.
- (2) For the purposes of subsections 5 (1) and (3) of the Act, the Minister shall pay to an operator of a pharmacy or a physician for dispensing an extemporaneous preparation,
 - (a) the acquisition cost of the ingredients used to make the extemporaneous preparation;
 - (b) in the case of an operator of a pharmacy, the dispensing fee referred to in subsection 6 (2) of the Act and in the case of a physician, the dispensing service fee provided for in subsection 3 (3) of this Regulation; and
 - (c) an amount that shall not exceed 50 cents per minute for compounding the extemporaneous preparation. O. Reg. 689/86, s. 5.

- 6. The substances listed in Schedule 2 are designated as listed substances. O. Reg. 689/86, s. 6.
- 7.—(1) An operator of a pharmacy that supplies a listed drug product to an eligible person pursuant to a prescription may charge the eligible person,
 - (a) an amount in respect of the listed drug product dispensed that is not greater than the difference between the cost of the product actually dispensed as determined in accordance with section 4 and the amount provided for in Part B of Schedule 1 plus the amount referred to in subsection 3 (11) in respect of the product dispensed where,
 - (i) the person dispensing the product is authorized under the Prescription Drug Cost Regulation Act, 1986 to dispense an interchangeable product, and
 - (ii) the person presenting the prescription or the person for whom the product was prescribed, before having the prescription filled, insists upon receiving a product the cost of which to the operator of the pharmacy as determined in accordance with section 4 is greater than the amount provided for in Part B of Schedule 1 and the person is advised by the operator of the pharmacy that a listed drug product is available free of charge; or
 - (b) the total amount charged in respect of the listed drug product dispensed, where the person presenting the prescription or the person for whom the product was prescribed elects before having the prescription filled to pay for the product dispensed or where another person pays for the product dispensed on account of the eligible person and the person is advised by the operator of the pharmacy that a listed drug product is available free of charge.
 - (2) A physician who supplies a listed drug product to an eligible person may charge the eligible person,
 - (a) an amount in respect of the listed drug product supplied that is not greater than the difference between the cost of the product actually dispensed as determined in accordance with section 4 and the amount provided for in Part B of Schedule 1 plus the amount referred to in subsection 3 (11) in respect of the product dispensed where,
 - (i) the physician dispensing the product is authorized under the Prescription Drug Cost Regulation Act, 1986 to dispense an interchangeable product, and

- (ii) the person for whom the product is dispensed, before having the product dispensed, insists upon receiving a product the cost of which to the physician as determined in accordance with section 4 is greater than the amount provided for in Part B of Schedule 1 and the person is advised by the physician that a listed drug product is available free of charge; or
- (b) the total amount charged in respect of the listed drug product dispensed, where the eligible person elects before having the product dispensed to pay for the product dispensed or where another person pays the charge for the product dispensed on account of the eligible person and the eligible person is advised by the physician that a listed drug product is available free of charge.
- (3) The operator of the pharmacy or the physician prior to charging or accepting payment under subsection (1) or (2), as the case may be, shall advise the person that the payment is not recoverable from the Minister. O. Reg. 689/86, s. 7.
- 8.—(1) Where the Minister pays an amount in respect of supplying a listed drug product for an eligible person, the amount paid shall be for the quantity of the product that is supplied to the eligible person as directed by the prescriber but shall not exceed payment for a quantity greater than,
 - (a) in the case of a person who is eligible for general assistance under the General Welfare Assistance Act or who is a "dependant" of such a person within the meaning of clause 1
 (1) (e) of Regulation 441 of Revised Regulations of Ontario, 1980, the quantity sufficient for a thirty-five day course of treatment; or
 - (b) in the case of a person, other than a person referred to in clause (a), the quantity sufficient for a 250 day course of treatment.
- (2) Where the Minister makes a payment referred to in subsection (1) and the quantity of the listed drug product supplied is sufficient for a course of treatment,
 - (a) that does not exceed 100 days, the Minister shall pay the operator of the pharmacy or the physician an amount that does not exceed one dispensing fee as is provided for under subsection 5 (1) or (3) of the Act, as the case may be; or
 - (b) that exceeds 100 days but does not exceed 250 days, the Minister shall pay the operator of the pharmacy or the physician an amount that does not exceed one dispensing fee as is provided for under subsection 5 (1) or (3) of the Act, as the case may be, and in addition not more than i/3 of one dispensing fee for each additional course of treatment of fifty

days or part thereof to a maximum of two dispensing fees. O. Reg. 689/86, s. 8.

- 9.—(1) Each operator of a pharmacy or a physician submitting a claim under subsection 5 (1) or (3) of the Act shall include in the claim,
 - (a) the drug benefit account number of the pharmacy or physician as assigned by the Minister;
 - (b) the name and address of the pharmacy or physician submitting the claim;
 - (c) the month, year and day on which the listed drug product was supplied;
 - (d) the Ontario Drug Benefit Eligibility Number of the eligible person for whom the listed drug product was supplied;
 - (e) the Drug Identification Number of the listed drug product supplied;
 - (f) the quantity of the listed drug supplied;
 - (g) where the claim is submitted by the operator of a pharmacy, the total amount claimed;
 - (h) the prescription number or identification number recorded on the prescription for the listed drug product supplied;
 - (i) where the claim is on paper, the signature of the operator of the pharmacy or physician submitting the claim or the signature of an employee of the operator or physician who is authorized by the operator or physician to sign such claims; and
 - (j) any other information that is necessary to process the amount payable on the claim.
- (2) Where a claim referred to in subsection (1) is on a medium other than paper,
 - (a) the following information shall be sent to the Minister within thirty days from the receipt by the operator of the pharmacy or physician of the bi-monthly statement of the Minister that relates to the claim: The signature of the operator of the pharmacy or physician submitting the claim or the signature of an employee of the operator or physician who is authorized by the operator or physician to sign such claims on a statement that sets out that to the best knowledge and belief of the operator, physician or person, the claims referred to on the bi-monthly statement of the Minister are true and accurate; and
 - (b) the claim shall be in a form that is compatible with equipment used by the Minister.
- (3) A claim referred to in subsection (1) that relates to an extemporaneous preparation shall also include,

- (a) the formula of the preparation in a manner that clearly indicates all the ingredients and the quantities of those ingredients;
 - (b) the acquisition cost of each ingredient; and
 - (c) the length of time in minutes that was spent compounding the ingredients, not including the time required to dispense the preparation.
- (4) A claim referred to in subsection (1) to which subsection 6 (3) of the Act applies shall also include,
 - (a) a copy of the supplier's invoice for the listed drug product;
 - (b) a calculation of the cost to the operator of the pharmacy of purchasing the listed drug product in accordance with section 4;
 - (c) any other information that is necessary to calculate the cost to the operator of the pharmacy of the listed drug product; and
 - (d) a statement signed by the operator or an employee of the operator who is authorized by the operator to sign such statement attesting to the validity of the information.
- (5) Where, subsequent to the submission of a claim referred to in subsection (4), the cost referred to in clause (b) of that subsection is varied as a result of a price reduction given to the operator of the pharmacy in respect of the listed drug product to which the claim relates, the operator of the pharmacy shall submit a revised calculation of the cost of the listed drug product to the Minister forthwith. O. Reg. 689/86, s. 9.
- 10. Every operator of a pharmacy and every physician shall retain the following records in or readily available to each pharmacy or dispensary of each pharmacy operated by the operator or in or readily available to the dispensary of the physician, as the case may be, for the periods indicated:
 - In the case of a claim on a medium other than paper, a copy of each bi-monthly statement received from the Minister, for at least two years from the date on which the statement is received.
 - A copy of each claim made to the Minister under subsection 5 (1) or (3) of the Act, for at least two years from the date on which the claim is submitted.
 - 3. The monthly Ontario Drug Benefit Eligibility Card or a copy thereof with respect to each eligible person for whom a drug is dispensed in the pharmacy, for at least two years from the date that the first drug is dispensed for the eligible person.

- Records that relate to the cost of a drug for which the operator has made a claim to the Minister, for at least two years from the date on which the claim was submitted to the Minister.
- 5. Each special authorization form provided by the Minister indicating that the Minister has made the Act apply in respect of the supplying of a particular drug under subsection 8 (1) of the Act, for at least two years from the date on which the special authorization was received. O. Reg. 689/86, s. 10.
- 11.—(1) An eligible person who purchases and pays for a listed drug product and who at the time of the purchase is unable to identify himself or herself as an eligible person may apply to the Minister for reimbursement of the amount paid for the listed drug product.
- (2) Section 9 applies with necessary modifications to an application under subsection (1).
- (3) The Minister may reimburse a person who makes a claim under subsection (1) in an amount that does not exceed the amount the Minister would pay the operator of the pharmacy or the physician under section 6 of the Act in respect of the listed drug product. O. Reg. 689/86, s. 11.
- 12.—(1) The conditions set out in this section apply only with respect to each strength and dosage form of each product for which a submission to the Minister to be designated as a listed drug product is made on and after the 31st day of July, 1986.
- (2) It is a condition for each strength and dosage form of a product to be designated as a listed drug product that the manufacturer of the product submit to the Minister within the time limit set out in Schedule 3,
 - (a) evidence that the manufacturer meets the standards contained in Good Manufacturing Practices for Drug Manufacturers and Importers, second edition, published by the Health Protection Branch of Health and Welfare (Canada);
 - (b) if,
- (i) the product is a new drug within the meaning of the Food and Drugs Act (Canada).
- (ii) the Health Protection Branch of Health and Welfare (Canada) has issued a Notice of Compliance to the manufacturer of the product in respect of a new drug submission within the meaning of the said Act, or
- (iii) where the manufacturer has filed with the said Health Protection Branch a

new drug submission that relates to the drug product,

- a Notice of Compliance with respect to the product issued under section C.08.004 of Division 8, Part C of the Food and Drug Regulations and a product monograph with respect to the product that has been approved by the Health Protection Branch for the purpose of the issuing of the Notice of Compliance;
- (c) a statement that sets out all the representations that are intended to be made by the manufacturer for the promotion of the product with respect to,
 - (i) the recommended route of administration of the product,
 - (ii) the proposed dosage of the product,
 - (iii) the claims for the product, and
 - (iv) the contra-indications and side effects of the product;
- (d) the Drug Identification Number of the product;
- (e) the formula of the product in a manner that clearly indicates all the ingredients and the quantities of those ingredients;
- (f) specifications of a pharmacopoeial or equivalent standard for the active raw materials used to make the product and for the finished product;
- (g) documentation with respect to the manufacturing and quality control of the product;
- (h) a sample of the product packaged and labelled as it is being sold at the time of the submission:
- (i) proof of the availability of the product for sale as shown by,
 - (i) an invoice or invoices detailing the sale of the product to a drug wholesaler or pharmacy in Ontario, or
 - (ii) a copy of a completed Drug Notification Form issued under section C.01.014 of Division 1, Part C, of the Food and Drug Regulations;
- (j) a list that sets out the cost to the pharmacist or wholesaler for each package size of the product that is offered for sale;
- (k) evidence that the manufacturer is able to supply the product at the price quoted to the Minister in a quantity that is sufficient to meet the demands for the product;

- (l) clinical evidence of the product's therapeutic use and safety;
- (m) information that relates to the use of the drug as prescribed by physicians, including adverse drug reactions and side effects, if any;
- (n) where applicable, evidence of the therapeutic need for an additional strength of the drug product;
- (o) studies that show that the product is stable under the storage conditions specified by the manufacturer for the intended shelf life of the product;
- (p) dissolution studies or other studies that show the consistency of the manufacturing process of the product;
- (q) evidence of the therapeutic need for a modified release dosage form;
- (r) evidence of the rate and extent of absorption for a solid oral dosage form; and
- (s) a consent that sets out that the Minister may have access to all information given to the Health Protection Branch of Health and Welfare (Canada) with respect to the product that is in connection with a new drug submission or a supplement relating to the product within the meaning of the Food and Drugs Act (Canada) or any other submission that is necessary for the lawful sale of the product in Canada.
- (3) Clause (2) (b) does not apply where the Health Protection Branch gives an opinion in writing that states that a new drug submission or a supplement relating to the product is not required by the Branch and that a Notice of Compliance is not required for the lawful sale of the product.
- (4) Notwithstanding subsection (2), a product that meets the requirements of section 6 of Ontario Regulation 690/86 (General) and that is designated as an interchangeable product shall be deemed to meet the requirements of subsection (2). O. Reg. 689/86, s. 12.
- 13.—(1) For the purposes of clause 16 (1) (b) of the Act, the following information is prescribed:

- The name, dosage form and strength of the drug product.
- The Drug Identification Number assigned by the Health Protection Branch of Health and Welfare (Canada).
- 3. Whether or not the drug product is subject to tax under the *Excise Tax Act* (Canada).
- The percentage of units of each package size
 of the drug product that are sold directly to
 retail pharmacies in Ontario, excluding sales
 to hospitals.
- 5. The package size or sizes in which the drug product is sold.
- (2) In addition to the information required under subsection (1), the following information is prescribed with respect to data that relates to the drug product for the period set out in Schedule 4:
 - The best available price for each unit of the drug product within the meaning of subsection 18 (4) of the Act.
- (3) In addition to the information required under subsection (1), the following information is prescribed with respect to data that relates to the drug product for the period set out in Schedule 5:
 - The total number of units of the drug product that were sold.
 - The total sales in dollars for the drug product.
 - The average unit price of the drug product calculated by dividing the total sales for the drug product by the total number of units of the drug product.
 - The best available price for each unit of the drug product within the meaning of subsection 18 (4) of the Act.
 - The percentage of sales of a drug product at the best available price referred to in paragraph 4. O. Reg. 689/86, s. 13.
- 14. This Regulation comes into force on the day that section 18 of the Act is proclaimed in force.

Schedule 1

PART A

10 per cent

PART B

| COLUMN 1 | COLUMN 2 | COLUMN 3 |
|------------------------------------|-----------------------|--------------|
| 04:00 Antihistaminics | | |
| Astemizole | | .2986 |
| 2mg/ml O/L | 610070 Hismanal | JAN |
| Astemizole 10mg Tab | 610089 Hismanal | .5936 JAN |
| • | | |
| Azatadine Maleate lmg Tab | 355666 Optimine | SCH .1902 |
| Brompheniramine Maleate | | .0157 |
| 0.4mg/mL O/L | 026395 Dimetane | ROB |
| Brompheniramine Maleate | | .0616 |
| 4mg Tab | 026484 Dimetane | ROB |
| Chlorpheniramine Maleate | | 1.9380 |
| 10mg/mL Inj Sol-1mL Pk | 027995 Chlor-Tripolom | SCH |
| Chlorpheniramine Maleate | 000010 ChlassTaisslas | 6.0500 |
| 200mg/2mL -Inj Sol-2mL Pk | 028010 Chlor-Tripolon | SCH |
| Chlorpheniramine Maleate | 028124 ChloraTrinolon | .0258 SCH |
| 0.5mg/mL O/L | 028134 Chlor-Tripolon | aca |
| * Chlorpheniramine Maleate 4mg Tah | 021288 Novopheniram | .0065 NOP |
| 1162 Ten | 028193 Chlor-Tripolon | SCH |
| Clemastine | | .1411 |
| lmg Tab | 349046 Tavist | ANC |
| Cyproheptadine HCl | | .0312 |
| 0.4mg/mL 0/L | 009989 Vimicon | FRS MSD |
| | 016314 Periactin | עבוו |
| * Cyproheptadine HC1 | 010073 Vimicon | .1395 FRS |
| 4mg Tab | 016454 Periactin | MSD |
| Dexchlorpheniramine Maleate | | .0249 |
| 0.4mg/mL O/L | 225533 Polaramine | SCH |
| Dexchlorpheniramine Maleate | | .0936 |
| 2mg Tab | 028207 Polaramine | SCH |
| * Diphenhydramine HC1 | | .0535 |
| 50mg Cap | 022764 Benadryl | PDA ICN |
| | 271411 Allerdryl | ICA |
| * Diphenhydramine HCl | 022756 Benadryl | .04GG PDA |
| 25mg Cap | 370517 Allerdryl | ICN |
| Diphenhydramine HCl | | 2.7216 |
| 50mg/mL Inj Sol-1mL Pk | 023205 Benadryl | PDA |

04:00 Antihistaminics

| Diphenhydramine HC1 | | | | 6.4400 |
|---|---------|-------------------------------|------------|--------|
| 100mg/10mL Inj Sol-10mL Pk | 023191 | Benadryl | PDA | |
| Diphenhydramine HCl 2.5mg/mL O/L | 022918 | Benadryl | PDA | .0240 |
| Methdilazine HCl 0.8mg/mL O/L | #003158 | Dilosyn | АНА | .0622 |
| Promethazine HCl 50mg/2mL Inj Sol-2mL Pk | 025046 | Phenergan | RPP | 1.0483 |
| Promethazine HCl 2mg/mL O/L | | Phenergan PMS-Promethazine | RPP PMS | .0179 |
| Promethazine HCl 12.5mg Sup | #025380 | Phenergan | RPP | .6222 |
| Promethazine HCl 25mg Tab | #213896 | Phenergan | RPP | .0717 |
| Promethazine HCl 10mg Tab | 025712 | Phenergan | RPP | .0687 |
| Terfenadine 6mg/mL Susp | +614394 | Seldane | MER | .0498 |
| Terfenadine 60mg Tab | 590908 | Seldane | MER | .3470 |
| Trimeprazine Tartrate 10mg Tab | #025801 | Panectyl | RPP | .1595 |
| Trimeprazine Tartrate 5mg Tab | 025798 | Panectyl | RPP | . 1622 |
| Trimeprazine Tartrate 2.5mg Tab | 025771 | Panectyl | RPP | .1368 |
| Tripelennamine HCl 50mg Tab | 623504 | Pyribenzamine | CIB | .0800 |
| Triprolidine HCl 0.25mg/mL O/L | #235768 | Actidil | BWE | .0246 |
| Triprolidine HCl 2.5mg Tab | #004812 | Actidil | BWE | .0801 |

| 08:08:00 Anthelmintics | | |
|------------------------------------|---------------------|----------------|
| Mebendazole 100mg Tab | 556734 Vermox | 2.0833 JAN |
| Piperazine Adipate Gran-2g Pk | 002739 Entacyl | .6944 AHA |
| Piperazine Adipate 120mg/mL O/L | 003131 Entacyl | .055G AHA |
| Pyrantel Pamoate 50mg/mL O/L | 425869 Combantrin | .1304 PFI |
| Pyrantel Pamoate 125mg Tab | 316296 Combantrin | .5264 PFI |
| Pyrvinium Pamoate 10mg/mL O/L | 023477 Vanquin | .0909 PDA |
| Pyrvinium Pamoate 50mg Tab | 023841 Vanquin | .3692 PDA |
| Quinacrine HCl 100mg Tab | 033804 Atabrine | .1926 WIN |
| Thiabendazole 500mg Chew Tab | #140228 Mintezol | .7297 MSD |
| 08:12:04 Antibiotics Antifungals | | |
| Amphotericin B Inj Pd-50mg Pk | 029149 Fungizone | 24.4000 SQU |
| Flucytosine 500mg Cap | 384895 Ancotil | .7855 HLR |
| Griseofulvin 500mg Tab | 012262 Grisovin FP | GLA .2765 |
| Griseofulvin 500mg Tab | 028282 Fulvicin U/F | SCH .3233 |
| Griseofulvin 330mg Tab | 513237 Fulvicin P/G | .2907 SCH |
| Griseofulvin 250mg Tab | 012254 Grisovin FP | GLA .1535 |
| Griseofulvin 250mg Tab | 028274 Fulvicin U/F | SCH .1910 |
| Griseofulvin 165mg Tab | 513229 Fulvicin P/G | .1719 SCH |

| Griseofulvin 125mg Tab Griseofulvin 125mg Tab Ketoconazole 200mg Tab Nystatin 100,000U/mL O/L Nystatin 500,000U Tab O8:12:12 Antibiotics Erythromycins Erythromycin Base 250mg Ent Pel Cap Erythromycin Base 250mg Tab Erythromycin Estolate 250mg Cap | 028266 +633836 014850 248169 282219 014974 029416 270113 607142 | | GLA SCH JAN LED SQU NDA LED SQU NDA | .0865 .1111 1.3600 .0437 .0600 |
|--|---|--|--|--|
| 125mg Tab Ketoconazole 200mg Tab Nystatin 100,000U/mL O/L Nystatin 500,000U Tab 28:12:12 Antibiotics Erythromycins Erythromycin Base 250mg Ent Pel Cap Erythromycin Base 250mg Tab Erythromycin Estolate | +633836 014850 248169 282219 014974 029416 270113 607142 | Nilstat Mycostatin Nadostine Nilstat Mycostatin Nadostine ERYC | JAN LED SQU NDA LED SQU NDA | .0437 |
| Retoconazole 200mg Tab Nystatin 100,000U/mL O/L Nystatin 500,000U Tab Resile: 12 Antibiotics Erythromycins Erythromycin Base 250mg Ent Pel Cap Erythromycin Base 250mg Tab Erythromycin Estolate | +633836 014850 248169 282219 014974 029416 270113 607142 | Nilstat Mycostatin Nadostine Nilstat Mycostatin Nadostine ERYC | JAN LED SQU NDA LED SQU NDA | .0437 |
| 200mg Tab Nystatin 100,000U/mL O/L Nystatin 500,000U Tab N8:12:12 Antibiotics Erythromycins Erythromycin Base 250mg Ent Pel Cap Erythromycin Base 250mg Tab Erythromycin Estolate | 014850 248169 282219 014974 029416 270113 607142 | Nilstat Mycostatin Nadostine Nilstat Mycostatin Nadostine | LED SQU NDA LED SQU NDA | .0600 |
| Nystatin 100,000U/mL O/L Nystatin 500,000U Tab 08:12:12 Antibiotics Erythromycins Erythromycin Base 250mg Ent Pel Cap Erythromycin Base 250mg Tab Erythromycin Estolate | 014850 248169 282219 014974 029416 270113 607142 | Nilstat Mycostatin Nadostine Nilstat Mycostatin Nadostine | LED SQU NDA LED SQU NDA | .0600 |
| Nystatin 500,000U/mL 0/L Nystatin 500,000U Tab 08:12:12 Antibiotics Erythromycins Erythromycin Base 250mg Ent Pel Cap Erythromycin Base 250mg Tab Erythromycin Estolate | 248169 282219 014974 029416 270113 607142 | Mycostatin Nadostine Nilstat Mycostatin Nadostine | SQU NDA LED SQU NDA | .0600 |
| Systatin 500,000U Tab 28:12:12 Antibiotics Erythromycins Erythromycin Base 250mg Ent Pel Cap Erythromycin Base 250mg Tab Erythromycin Estolate | 248169 282219 014974 029416 270113 607142 | Mycostatin Nadostine Nilstat Mycostatin Nadostine | SQU NDA LED SQU NDA | .3099 |
| 500,000U Tab 28:12:12 Antibiotics Erythromycins Erythromycin Base 250mg Ent Pel Cap Erythromycin Base 250mg Tab Erythromycin Estolate | 282219 014974 029416 270113 607142 | Nadostine Nilstat Mycostatin Nadostine ERYC | NDA LED SQU NDA | .3099 |
| 500,000U Tab 08:12:12 Antibiotics Erythromycins Erythromycin Base 250mg Ent Pel Cap Erythromycin Base 250mg Tab Erythromycin Estolate | 014974 029416 270113 607142 | Nilstat Mycostatin Nadostine ERYC | LED SQU NDA | .3099 |
| 500,000U Tab 08:12:12 Antibiotics Erythromycins Erythromycin Base 250mg Ent Pel Cap Erythromycin Base 250mg Tab Erythromycin Estolate | 029416 270113 607142 030899 | Mycostatin Nadostine ERYC | SQU NDA PDA | .3099 |
| 500,000U Tab 08:12:12 Antibiotics Erythromycins Erythromycin Base 250mg Ent Pel Cap Erythromycin Base 250mg Tab Erythromycin Estolate | 029416 270113 607142 030899 | Mycostatin Nadostine ERYC | SQU NDA PDA | .3099 |
| 28:12:12 Antibiotics Erythromycins Erythromycin Base 250mg Ent Pel Cap Erythromycin Base 250mg Tab Erythromycin Estolate | 029416 270113 607142 030899 | Mycostatin Nadostine ERYC | SQU NDA PDA | |
| Erythromycin Base 250mg Ent Pel Cap Erythromycin Base 250mg Tab Erythromycin Estolate | 270113 607142 030899 | Nadostine ERYC | NDA PDA | |
| Erythromycin Base 250mg Ent Pel Cap Erythromycin Base 250mg Tab Erythromycin Estolate | 607142 | ERYC | PDA | |
| Erythromycin Base 250mg Ent Pel Cap Erythromycin Base 250mg Tab Erythromycin Estolate | 030899 | | | |
| 250mg Ent Pel Cap Erythromycin Base 250mg Tab Erythromycin Estolate | 030899 | | | |
| 250mg Ent Pel Cap Erythromycin Base 250mg Tab Erythromycin Estolate | 030899 | | | |
| Erythromycin Base 250mg Tab Erythromycin Estolate | | | | |
| 250mg Tab Erythromycin Estolate | | | | |
| 250mg Tab Erythromycin Estolate | | m 14 4 | | .0738 |
| Erythromycin Estolate | 000= | E-Mycin | UPJ | |
| | 244635 | Erythronid | ABB | |
| | +640263 | Erythromycin | KNR | |
| | | | | .0816 |
| 25Umg Cap | 015000 | ** | 7 71 | .0816 |
| | | Ilosone | LIL | |
| | 020966 | Novorythro Estolate | NOP | |
| Erythromycin Estolate | | | | .0341 |
| 50mg/mL O/L | 210641 | Ilosone | LIL | .0541 |
| Jong/ ML O/ L | | Novorythro Estolate | NOP | |
| | 202000 | Movely this Estatate | 1101 | |
| Erythromycin Estolate | | | | .0170 |
| 25mg/mL 0/L | 015474 | Ilosone | LIL | |
| | 021172 | Novorythro Estolate | NOP | |
| Erythromycin Estolate | | | | . 3382 |
| 500mg Tab | +244384 | Ilosone | LIL | |
| | 211001 | 11030110 | 212 | |
| Erythromycin Ethylsuccinate | | | | .1012 |
| 80mg/mL 0/L | 453617 | EES-400 | ABB | |
| Erythromycin Ethylsuccinate | | | | .0475 |
| 40mg/mL O/L | 000299 | EES-200 | ABB | |
| | | Novorythro Ethyl | NOP | |
| | 000000 | Succinate | | |
| Erythromycin Ethylsuccinate | | | | .5844 |
| 600mg Tab | 583782 | | ABB | |

| 40mg & 120mg/mL O/L Erythromycin Stearate 50mg/mL O/L Erythromycin Stearate 25mg/mL O/L Erythromycin Stearate 25mg/mL O/L O00302 Erythrocin ABB 266515 Erythrocin ABB 266515 Erythrocin ABB Erythromycin Stearate 500mg Tab 266515 Erythrocin ABB 266515 Erythrocin ABB 266515 Erythrocin ABB 281673 Erythromycin Stearate 250mg Tab O00434 Erythrocin ABB 281673 Erythromycin Stearate 3065: APX 281216 Antibiotics Penicillins Amoxicillin 500mg Cap 30531 Amoxil 406716 Novamoxin NOP 628123 Apo-Amoxi APX Amoxicillin 250mg Cap 288497 Amoxil 406724 Novamoxin APX Amoxicillin 50mg/mL O/L 288519 Amoxil 406724 Novamoxin NOP 628158 Apo-Amoxi APX Amoxicillin 50mg/mL O/L 288500 Amoxil 47E 452130 Novamoxin NOP 628158 Apo-Amoxi APX Amoxicillin 25mg/mL O/L 288500 Amoxil 47E 452149 Novamoxin APX Amoxicillin 25mg/mL O/L 288500 Amoxil 47E 452149 Novamoxin APX Amoxicillin 50mg/mL Ped O/L 288500 Amoxil APX Amoxicillin 50mg/mL Ped O/L 353035 Amoxil APX Amoxicillin & Clavulanic Acid 50mg & 12.5mg/mL O/L 617520 Clavulin BEE | Erythromycin Ethylsuccinate & Sulfisoxazo | le Acetyl | | | .0723 |
|---|---|-----------|---------------|-------|--------|
| 273023 Erythrosin | | | Pediazole | ABB | .0723 |
| Erythromycin Stearate 25mg/mL 0/L 25mg/mL 0/L 266515 Erythrocin 266515 Erythrocin 27mg/mL 0/L 266515 Erythrocin 27mg/mL 0/L 266515 Erythrocin 27mg/mL 0/L 27mg/mL | Erythromycin Stearate | | | | .0535 |
| 25mg/mL O/L 000302 Erythrocin ABB 150mg Tab 266515 Erythrocin ABB 1638568 Apo-Erythro-S APX 250mg Tab 266515 Erythrocin ABB 281573 Erythromycin Stearate 250mg Tab 000434 Erythrocin ABB 281573 Erythromycin Stearate SAP 391581 Noverythro-S tearate NOP 545678 Apo-Erythro-S APX 28:12:16 Antibiotics Penicillins Amoxicillin ATE 406716 Novamoxin NOP 628123 Apo-Amoxi APX Amoxicillin APX 406724 Novamoxin NOP 628115 Apo-Amoxi APX Amoxicillin AVE 406724 Novamoxin NOP 628158 Apo-Amoxi APX APX Amoxicillin AVE 452130 Novamoxin NOP 628158 Apo-Amoxi APX APX Amoxicillin AVE 452149 Novamoxin NOP 628131 Apo-Amoxi APX APX Amoxicillin AVE 452149 Novamoxin NOP 628131 Apo-Amoxi APX APX Amoxicillin AVE 452149 Novamoxin NOP 628131 Apo-Amoxi APX APX Amoxicillin AVE AVE 452149 Novamoxin APX APX AMoxicillin AVE 50mg/mL O/L | 273023 | Erythrocin | ABB | |
| ### Stooms | Erythromycin Stearate | 000000 | F - 43 | 4 m m | .0633 |
| 266515 Erythrocin | 25mg/mL U/L | 000302 | Erythrocin | ABB | |
| +688568 Apo-Erythro-S APX 250mg Tab 250mg Tab 200434 Erythronycin Stearate SAP 391581 Novorythro Stearate SAP 391581 Novorythro-S APX 28:12:16 Antibiotics Penicillins Amoxicillin 500mg Cap 330531 Amoxil 47E 406716 Novamoxin NOP 628123 Apo-Amoxi APX Amoxicillin 250mg Cap 28497 Amoxil 406724 Novamoxin NOP 628115 Apo-Amoxi APX Amoxicillin 50mg/mL O/L 288519 Amoxil 452130 Novamoxin NOP 628158 Apo-Amoxi APX Amoxicillin 25mg/mL O/L 288500 Amoxil 452130 Novamoxin NOP 628131 Apo-Amoxi APX Amoxicillin 25mg/mL O/L 353035 Amoxil AYE 452149 Novamoxin NOP 628131 Apo-Amoxi APX Amoxicillin 25mg/mL O/L 45019 Novamoxin NOP 628131 Apo-Amoxi APX Amoxicillin 50mg/mL Ped O/L 353035 Amoxil AYE 452149 Novamoxin APX Amoxicillin & Clavulanic Acid 50mg & 12.5mg/mL O/L 617520 Clavulin BEE Amoxicillin & Clavulanic Acid 25mg & 6.25mg/mL O/L Amoxicillin & Clavulanic Acid | | | | | .3950 |
| ### Erythromycin Stearate | 500mg Tab | | | | |
| 250mg Tab | | +688568 | Apo-Erythro-S | APX | |
| 281573 Erythromycin Stearate SAP 391581 Novorythro Stearate NOP 545678 Apo-Erythro-S APX | Erythromycin Stearate | | | | .0657 |
| 391581 Novorythro Stearate NOP 545678 Apo-Erythro-S APX | 250mg Tab | 000434 | Erythrocin | ABB | |
| S45678 Apo-Erythro-S APX | | | | | |
| Amoxicillin ATE | | | | | |
| Amoxicillin | | 545678 | Apo-Erythro-S | APX | |
| 330531 Amoxil | 08:12:16 Antibiotics Penicillins | | | | |
| 406716 Novamoxin NOP | Moxicillin | | | | .1520 |
| APX Amoxicillin APX Amoxicillin APX Amoxicillin AYE After Af | 500mg Cap | | | | |
| 250mg Cap 288497 Amoxil AYE 406724 Novamoxin NOP 628115 Apo-Amoxi APX | | | | | |
| 250mg Cap 288497 Amoxil AYE 406724 Novamoxin NOP 628115 Apo-Amoxi Amoxicillin 50mg/mL O/L 288519 Amoxil 452130 Novamoxin NOP 628158 Apo-Amoxi ANOX Canoxicillin 25mg/mL O/L 288500 Amoxil AYE 452149 Novamoxin NOP 628131 Apo-Amoxi APX Amoxicillin 50mg/mL Ped O/L 353035 Amoxil AYE Amoxicillin & Clavulanic Acid 50mg & 12.5mg/mL O/L Amoxicillin & Clavulanic Acid 25mg & 6.25mg/mL O/L 288500 Amoxil AYE 452149 Novamoxin NOP 628131 Apo-Amoxi APX Amoxicillin 50mg/mL Ped O/L 353035 Amoxil BEE Amoxicillin & Clavulanic Acid 25mg & 6.25mg/mL O/L Amoxicillin & Clavulanic Acid 39854 | | 628123 | Apo-Amoxi | APX | |
| 406724 Novamoxin 628115 Apo-Amoxi Amoxicillin 50mg/mL 0/L 288519 Amoxil 452130 Novamoxin NOP 628158 Apo-Amoxi Amoxicillin 25mg/mL 0/L 288500 Amoxil 452149 Novamoxin NOP 628131 Apo-Amoxi Amoxicillin 50mg/mL Ped 0/L 353035 Amoxil AYE Amoxicillin & Clavulanic Acid 50mg & 12.5mg/mL 0/L 617520 Clavulin BEE Amoxicillin & Clavulanic Acid 25mg & 6.25mg/mL 0/L 617512 Clavulin BEE Amoxicillin & Clavulanic Acid 25mg & 6.25mg/mL 0/L 617512 Clavulin BEE | Amoxicillin | | | | .0780 |
| ## Amoxicillin | 250mg Cap | 288497 | Amoxil | AYE | |
| Amoxicillin 50mg/mL O/L 288519 Amoxil AYE 452130 Novamoxin NOP 628158 Apo-Amoxi APX Amoxicillin 25mg/mL O/L 288500 Amoxil AYE 452149 Novamoxin NOP 628131 Apo-Amoxi APX Amoxicillin 50mg/mL Ped O/L 353035 Amoxil AYE 353035 Amoxil AYE 4520mg & 12.5mg/mL O/L 617520 Clavulin BEE Amoxicillin & Clavulanic Acid 50mg & 12.5mg/mL O/L 617512 Clavulin BEE Amoxicillin & Clavulanic Acid 52mg & 6.25mg/mL O/L 617512 Clavulin BEE | | | | | |
| Somg/mL O/L 288519 Amoxil AYE 452130 Novamoxin NOP 628158 Apo-Amoxi APX | | 628115 | Apo-Amoxi | APX | |
| 288519 Amoxil | Amoxicillin | | | | .0236 |
| 452130 Novamoxin NOP 628158 Apo-Amoxi APX Amoxicillin 25mg/mL O/L 288500 Amoxil AYE 452149 Novamoxin NOP 628131 Apo-Amoxi APX Amoxicillin 50mg/mL Ped O/L 353035 Amoxil AYE Amoxicillin & Clavulanic Acid 50mg & 12.5mg/mL O/L 617520 Clavulin BEE Amoxicillin & Clavulanic Acid 25mg & 6.25mg/mL O/L 617512 Clavulin BEE Amoxicillin & Clavulanic Acid 25mg & 6.25mg/mL O/L 617512 Clavulin BEE | | 288519 | Amoxil | AYE | |
| Amoxicillin 25mg/mL O/L 288500 Amoxil AYE 452149 Novamoxin NOP 628131 Apo-Amoxi APX Amoxicillin 350mg/mL Ped O/L 353035 Amoxil AYE Amoxicillin & Clavulanic Acid 50mg & 12.5mg/mL O/L 617520 Clavulin BEE Amoxicillin & Clavulanic Acid 50mg & 6.25mg/mL O/L 617512 Clavulin BEE Amoxicillin & Clavulanic Acid .0750 Amoxicillin & Clavulanic Acid .0750 Amoxicillin & Clavulanic Acid .07512 Clavulin BEE .0750 Amoxicillin & Clavulanic Acid .9854 | | | | NOP | |
| 25mg/mL O/L 288500 Amoxil AYE 452149 Novamoxin NOP 628131 Apo-Amoxi APX Amoxicillin 50mg/mL Ped O/L 353035 Amoxil AYE Amoxicillin & Clavulanic Acid 50mg & 12.5mg/mL O/L 617520 Clavulin BEE Amoxicillin & Clavulanic Acid 25mg & 6.25mg/mL O/L 617512 Clavulin BEE Amoxicillin & Clavulanic Acid 25mg & 6.25mg/mL O/L 617512 Clavulin BEE | | 628158 | Apo-Amoxi | APX | |
| 25mg/mL O/L 288500 Amoxil AYE 452149 Novamoxin NOP 628131 Apo-Amoxi APX Amoxicillin 50mg/mL Ped O/L 353035 Amoxil AYE Amoxicillin & Clavulanic Acid 50mg & 12.5mg/mL O/L 617520 Clavulin BEE Amoxicillin & Clavulanic Acid 25mg & 6.25mg/mL O/L 617512 Clavulin BEE Amoxicillin & Clavulanic Acid 25mg & 6.25mg/mL O/L 617512 Clavulin BEE | tuenieillie | | | | 0161 |
| 452149 Novamoxin NOP 628131 Apo-Amoxi APX Amoxicillin | | 299500 | Amovil | | .0161 |
| ### Amoxicillin ### Amoxicillin ### Amoxicillin ### Amoxicillin ### Amoxicillin ### Amoxicillin ### Amoxicillin ### Clavulanic Acid ### Amoxicillin ### Clavulanic Acid ### Amoxicillin ### Clavulanic Acid ### Amoxicillin ### Clavulanic Acid ### Amoxicillin ### Clavulanic Acid ### Amoxicillin ### Clavulanic Acid #### Amoxicillin ### Clavulanic Acid #### Amoxicillin #### Clavulanic Acid ##### Amoxicillin ################################## | 25mg/mL 0/L | | | | |
| Somg/mL Ped O/L 353035 Amoxil AYE | | | | | |
| 50mg/mL Ped O/L 353035 Amoxil AYE Amoxicillin & Clavulanic Acid .1260 50mg & 12.5mg/mL O/L 617520 Clavulin BEE Amoxicillin & Clavulanic Acid .0750 25mg & 6.25mg/mL O/L 617512 Clavulin BEE Amoxicillin & Clavulanic Acid .9854 | | | | | 4700 |
| Amoxicillin & Clavulanic Acid .1260 50mg & 12.5mg/mL 0/L 617520 Clavulin BEE Amoxicillin & Clavulanic Acid .0750 25mg & 6.25mg/mL 0/L 617512 Clavulin BEE Amoxicillin & Clavulanic Acid .9854 | | 353035 | Amovil | AVE | .4/20 |
| 50mg & 12.5mg/mL O/L 617520 Clavulin BEE Amoxicillin & Clavulanic Acid .0750 25mg & 6.25mg/mL O/L 617512 Clavulin BEE Amoxicillin & Clavulanic Acid .9854 | Song/me red o/e | 303030 | AMUATI | ALL | |
| Amoxicillin & Clavulanic Acid .0750 25mg & 6.25mg/mL O/L 617512 Clavulin BEE Amoxicillin & Clavulanic Acid .9854 | | | | | .1260 |
| 25mg & 6.25mg/mL O/L 617512 Clavulin BEE Amoxicillin & Clavulanic Acid .9854 | 50mg & 12.5mg/mL O/L | 617520 | Clavulin | BEE | |
| Amoxicillin & Clavulanic Acid .9854 | Amoxicillin & Clavulanic Acid | | | | .0750 |
| | 25mg & 6.25mg/mL O/L | 617512 | Clavulin | BEE | |
| | Amoricillin & Classicanic Acid | | • | | 985 |
| | | 617504 | Claunlin | RFF | . 3634 |
| | | | | | |

| moxicillin & Clavulanic Acid | 217100 | 63 31 | 200 | .6327 |
|-------------------------------|--------|-----------------|-----|--------|
| 250mg & 125mg Tab | 617490 | Clavulin | BEE | |
| mpicillin | | | | .1200 |
| 500mg Cap | | Penbritin | AYE | |
| | | Novo-Ampicillin | NOP | |
| | | Ampicillin | SAP | |
| | 603295 | Apo-Ampi | APX | |
| mpicillin | | | | .0620 |
| 250mg Cap | 002003 | Penbritin | AYE | |
| | 020877 | Novo-Ampicillin | NOP | |
| | | Ampicillin | SAP | |
| | 603279 | Apo-Ampi | APX | |
| npicillin | | | | 1.8500 |
| Inj Pd-1000mg Pk | 002127 | Penbritin | AYE | |
| | 004065 | Ampicin | BRI | |
| | | | | 1.3000 |
| mpicillin Inj Pd-500mg Pk | 002119 | Penbritin | AYE | 1.3000 |
| Tity tu-soomg tk | | Ampicin | BRI | |
| | | Ampiein | DRI | |
| mpicillin | | | | .0217 |
| 50mg/mL 0/L | 002429 | Penbritin | AYE | |
| | | Novo-Ampicillin | NOP | |
| | | Ampicillin | SAP | |
| | 603287 | Apo-Ampi | APX | |
| mpicillin | | | | .0135 |
| 25mg/mL O/L | 002410 | Penbritin | AYE | .0.55 |
| 3 | 021121 | Novo-Ampicillin | NOP | |
| | | Ampicillin | SAP | |
| | 603260 | Apo-Ampi | APX | |
| acampicillin HCl | | | | .9424 |
| 800mg Tab | 627135 | Penglobe | AST | |
| - 191 HILLS | | | | |
| acampicillin HCl | | | | .4618 |
| 400mg Tab | 627127 | Penglobe | AST | |
| arbenicillin Indanyl (Sodium) | | | | .7970 |
| 500mg Tab | 328235 | Geopen | PFI | .,,,, |
| | 1 | | | |
| loxacillin | | | | .1470 |
| 500mg Cap | | Orbenin | AYE | |
| | | Novocloxin | NOP | |
| | 618284 | Apo-Cloxi | APX | |
| loxacillin | | | | .0750 |
| 250mg Cap | | Orbenin | AYE | .0750 |

| 08:12:16 Antibiotics Penicillins | | | | |
|--|---------|-------------------------|------------|--------|
| Cloxacillin | | | | .0750 |
| 250mg Cap | | Novocloxin | NOP | |
| | 618292 | Apo-Cloxi | APX | |
| Cloxacillin | | | | 2.9000 |
| Inj Pd-2000mg Pk | | Orbenin | AYE | |
| | | Tegopen Bactopen | BRI | |
| | 417230 | bactopen | DEE | |
| Cloxacillin | | | | 1.0500 |
| Inj Pd-250mg Pk | | Orbenin | AYE BRI | |
| | | Tegopen Bactopen | BEE | |
| | 717203 | bactopen | BLL | |
| Cloxacillin | | | | 1.3500 |
| Inj Pd-500mg Pk | | Orbenin | AYE BRI | |
| | | Tegopen Bactopen | BEE | |
| | 71.211 | bactopen | DEL | |
| Cloxacillin | | | 1 | .0207 |
| 25mg/mL O/L | | Orbenin | AYE | |
| | | Novocloxin Apo-Cloxi | NOP APX | |
| | +044033 | Apo-Clux1 | | |
| Dicloxacillin | | | | .3220 |
| 250mg Cap | 003964 | Dynapen | BRI | |
| Dicloxacillin | | | | .0429 |
| 12.5mg/mL O/L | #004286 | Dynapen | BRI | |
| W. 41 * 122 * | | | | 3.8000 |
| Methicillin Inj Pd-1g Pk | 004081 | Staphcillin | BRI | 3.8000 |
| 111) 14 1g 17 | 007001 | Staphellin | 2.1.1 | |
| Oxacillin | | | 2.7. | 4.0150 |
| Inj Pd-500mg Pk | #004111 | Prostaphlin | BRI | |
| Penicillin G (Benzathine) | | | | 5.2000 |
| 1,200,000IU/2mL Inj Sol-2mL Pk | 036315 | Bicillin 1200 L-A | WYE | |
| B | | | | .0474 |
| Penicillin G (Benzathine) 100.000IU/mL O/L | 000038 | Megacillin 500 | FRS | .0474 |
| 100,000107 M2 07 2 | 000000 | Megaellin doo | - 110 | |
| Penicillin G (Potassium) | | | | .0566 |
| 100,000 IU/mL O/L | 013633 | P-50 | HOR | |
| Penicillin G (Potassium) | | | | .0305 |
| 500,000IU Tab | | Megacillin 500 | FRS | |
| | 116726 | | HOR | |
| | 151432 | Novopen-500 | , NOP | |
| Penicillin G Crystalline | | | | 1.0320 |
| Inj Pd 1,000,000IU-Pk | 002208 | Penicillin G (Pot) | AYE | |
| | | | | |

| Penicillin G Crystalline Inj Pd 1,000,000IU-Pk | 011983 | Crystapen (Sod) | GLA | 1.0320 |
|---|---------|--------------------|---------|--------|
| Penicillin G Crystalline | | | | 2.2400 |
| Inj Pd 5,000,000IU-Pk | 002216 | Penicillin G (Pot) | AYE | |
| | 011991 | Crystapen (Sod) | GLA | |
| Penicillin G Procaine Aqueous Suspension | on | | | 3.9000 |
| 5,000,000IU/10mL Inj Susp-10mL Pk | 355615 | Wycillin 5 Million | WYE | |
| Penicillin G Procaine Aqueous Suspensio | on | | | 3.9300 |
| 3,000,000 IU/10mL Inj Susp-10mL Pk | 002402 | Ayercillin | AYE | |
| Penicillin V (Benzathine) | | | | .0376 |
| 60mg/mL O/L | 034045 | Pen-Vee | WYE | |
| | 248835 | PVF 500 | FRS | |
| Penicillin V (Potassium) | | | | .0250 |
| 60mg/mL O/L | 331945 | VC-K 500 | LIL | .0230 |
| | | Novopen-VK-500 | NOP | |
| | | Apo-Pen V-K | APX | |
| enicillin V (Potassium) | | | | .0185 |
| 25mg/mL O/L | 015563 | V-Cillin K | LIL | .0203 |
| | | Nadopen-V | NDA | |
| | | Apo-Pen V-K | APX | |
| Penicillin V (Potassium) | | | | .0300 |
| 300mg Tab | 018740 | Nadopen-V | NDA | |
| | 021202 | Novopen-VK-500 | NOP | |
| | | Penicillin V (Pot) | SAP | |
| | | PVF-K 500 | FRS | |
| | | Ledercillin VK | LED | |
| | +642215 | Apo-Pen V-K | APX | |
| 'ivampicillin | | | | .0884 |
| 32.4mg/mL 0/L | 582239 | Pondocillin | LEO | |
| Pivampicillin Pivampicillin | | | | .4720 |
| 500mg Tab | 582247 | Pondocillin | LEO | |
| Sodium Flucloxacillin | | | | .7807 |
| 500mg Cap | 486809 | Fluclox | AYE | |
| odium Flucloxacillin | | | | .4260 |
| 250mg Cap | 486795 | Fluclox | ATE | . 4200 |
| Cadima Flantana (11) | | | | |
| Sodium Flucloxacillin | FORECA | Flucton | 4.97.50 | .1617 |
| 50mg/mL O/L | 525561 | Fluciox | AYE | |
| Sodium Flucloxacillin | | | | .1080 |
| 25mg/mL 0/L | 486817 | Fluclox | AYE | |

| 08:12:24 Antibiotics Tetracyclines | | • |
|--|-------------------------------------|---------------|
| Tetracycline | 24/22 | .0182 |
| 250mg Cap | 014605 Achromycin V | LED |
| | 021059 Novotetra 024422 Tetracyn | NOP PF I |
| | 210765 Tetracycline | SAP |
| | 580929 Apo-Tetra | APX |
| | po 2001 | |
| Tetracycline | 014790 Ashmannsis | 8.7083 LED |
| Inj Pd-250mg Pk | 014729 Achromycin | LED |
| Tetracycline | | .0130 |
| 25mg/mL O/L | 151416 Novotetra | NOP |
| 08:12:28 Antibiotics Other Antibiotics | | |
| | | Tillianes |
| Cefaclor | | 1.4675 |
| 500mg Cap | 465194 Ceclor | LIL |
| Cefaclor | | .7468 |
| 250mg Cap | 465186 Ceclor | LIL |
| | | |
| Cefaclor | 465216 Ceclor | .1464 LIL |
| 50mg/mL O/L | 405216 CeC10F | LIL |
| Cefaclor | | .0802 |
| 25mg/mL 0/L | 465208 Ceclor | LIL |
| Cefadroxil | | .8850 |
| 500mg Cap | 507245 Duricef | BRI |
| Joomg Cap | 30.210 24.100. | 2.1.2 |
| Cefadroxil | | .1650 |
| 50mg/mL O/L | +674826 Duricef | BRI |
| Cefazolin Sodium | | 5.7160 |
| Inj Pd-1000mg Pk | 319112 Ancef | SKF |
| , | 322296 Kefzol | LIL |
| | | - 17 29990 |
| Cefazolin Sodium | 010100 1 6 | 2.9330 |
| Inj Pd-500mg Pk | 319139 Ancef | SKF LIL |
| | 322288 Kefzol | LIL |
| Cephalexin Monohydrate | | .2692 |
| 500mg Cap | 253146 Ceporex | GLA |
| market to the | 342114 Novolexin | NOP |
| Cephalexin Monohydrate | | .1367 |
| 250mg Cap | 253154 Ceporex | GLA |
| | 342084 Novolexin | NOP |
| | | |
| Cephalexin Monohydrate | | .0520 |
| 50mg/mL O/L | 035645 Keflex | LIL |

| Cephalexin Monohydrate | | | .0520 |
|--|--|------|---|
| 50mg/mL O/L | 321443 Ceporex | GLA | .0020 |
| | 342092 Novolexin | NOP | |
| Cephalexin Monohydrate | | | .0260 |
| 25mg/mL 0/L | 015547 Keflex | LIL | . 0200 |
| 2018 | 321435 Ceporex | GLA | |
| | 342106 Novolexin | NOP | |
| ephalexin Monohydrate | | | .2692 |
| 500mg Tab | 244392 Keflex | LIL | . 2032 |
| Journal of the state of the sta | 583421 Novolexin | NOP | |
| ephalexim Monohydrate | | | * 705 |
| | 403628 Keflex | LIL | .1367 |
| 250mg Tab | 583413 Novolexin | | |
| | 583413 NOVOIEXIR | NOP | |
| ephalothin Sodium | | | 3.7420 |
| Inj Pd-1g Pk | 015369 Keflin | LIL | |
| ephalothin Sodium | | | 7.2700 |
| Inj Pd-2g Pk | 244406 Keflin | LIL | ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,, |
| ephradine | | | 1 0456 |
| 500mg Cap | 301639 Velosef | sou | 1.0450 |
| occas cap | 001000 VC103E1 | 200 | |
| ephradine | | | .5330 |
| 250mg Cap | 301620 Velosef | squ | |
| ephradine | | | 4.0000 |
| Inj Pd-1000mg Pk | #348295 Velosef | squ | |
| ephradine | | | 2.7500 |
| Inj Pd-500mg Pk | #348287 Velosef | SOU | ,500 |
| | en. | | |
| ephradine | #001017 W 1 | 2011 | .1180 |
| 50mg/mL O/L | #301647 Velosef | SQU | |
| lindamycin HCl | | | .5731 |
| 150mg Cap | 030570 Dalacin C | UPJ | |
| lindamycin Palmitate | | | .0810 |
| 15mg/mL O/L | 225851 Dalacin C | UPJ | |
| lindamycin Phosphate | | | - 1100 |
| 300mg/2mL Inj Sol-2mL Pk | 260436 Dalacin C | UPJ | 5.1100 |
| Sound, The This Source IX | 200430 Dalacin C | CLA | |
| olistimethate Sodium | The state of the s | | 3.1400 |
| Inj Pd-150mg Pk | 476420 Coly-Mycin | PDA | |
| | | | |
| entamicin Sulfate | | | 4.0900 |

| 08:12:28 Antibiotics Other Antibiotics | | | | |
|---|------------------|--------------------|------------|---------|
| Gentamicin Sulfate 80mg/2mL Inj Sol-2mL Pk | 259179 | Cidomycin | ROU | 4.0900 |
| Kanamycin Sulfate 500mg Cap | #003980 | Kantrex | BRI | 1.3624 |
| Kanamycin Sulfate 0.5g/2mL Inj Sol-2mL Pk | #004227 | Kantrex | BRI | 8.8550 |
| Kanamycin Sulfate 1g/3mL Inj Sol-3mL Pk | #004235 | Kantrex | BRI | 15.1800 |
| Lincomycin 500mg Cap | 030589 | Lincocin | UPJ | .5285 |
| Lincomycin 600mg/2mL Inj Sol-2mL Pk | 030732 | Lincocin | UPJ | 3.8500 |
| Neomycin Sulfate 25mg/mL O/L | 030805 | Mycifradin | UPJ | .0550 |
| Neomycin Sulfate 500mg Tab | 030996 | Mycifradin | UPJ | .1755 |
| Polymyxin B Sulfate Inj Pd-500,000UPk | 004421 | Aerosporin | BWE | 20.8000 |
| Spectinomycin Inj Pd-2g Pk | 210196 | Trobicin | UPJ | 11.3000 |
| Tobramycin Sulfate 60mg/1.5mL Inj Sol-1.5mL Pk | 375764 | Nebcin | LII | 4.8230 |
| Tobramycin Sulfate 80mg/2mL Inj Sol-2mL Pk | | Nebcin Nebcin | LIL | |
| Tobramycin Sulfate 20mg/2mL Inj Sol-2mL Pk | 325457 | Nebcin | LII | 2.5930 |
| 08:16:00 Antitubercular Agents | | | | |
| Aminosalicylate Sodium 500mg Tab | 236691 | Nemasol | ICA | .1374 |
| Ethambutol HCl 400mg Tab | 127965 247979 | Myambutol Etibi | LEI ICN |) |
| Ethambutol HCl 100mg Tab | 127957 | Myambutol | LEI | .0718 |

| thambutol HCl | | | .0718 |
|---------------------------------------|------------------------------------|------|--------|
| 100mg Tab | 247960 Etibi | ICN | |
| | | | 0.470 |
| soniazid | 272655 Isotamine-300 | ICN | .0470 |
| 300mg Tab | 310247 Isoniazid | SAP | |
| | 310247 13081821G | SAL | |
| soniazid | | | .0177 |
| 100mg Tab | 013323 Rimifon | HLR | |
| | 261270 Isotamine-100 | ICN | |
| | 440108 Isoniazid | SAP | |
| | | | |
| yrazinamide | | | .3692 |
| 500mg Tab | 283991 Tebrazid | ICN | |
| | | | |
| ifampin | 010/00 84 | 6.00 | .7233 |
| 300mg Cap | 210463 Rimactane 249483 Rifadin | CIB | |
| | 343617 Rofact | ICN | |
| | 343017 KOTACT | ICA | |
| ifampin | | | . 4668 |
| 150mg Cap | 210471 Rimactane | CIB | . 4000 |
| 20028 | 249475 Rifadin | MER | |
| | 393444 Rofact | ICN | |
| | | | |
| 8:20:00 Plasmodicides (Antimalarials) | | | |
| hloroquine Phosphate | | | .0475 |
| 250mg Tab | 021261 Novochloroquine | NOP | |
| 1 | 033642 Aralen | WIN | |
| | | | |
| lydroxychloroquine Sulfate | | | .2740 |
| 200mg Tab | 033669 Plaquenil | WIN | |
| | | | |
| uinine Sulfate | | Non | .1197 |
| 300mg Cap | 021016 Novoquinine | NOP | |
| | 093750 Quinine | DIC | |
| uinine Sulfate | | | .0779 |
| 200mg Cap | 021008 Novoquinine | NOP | .0773 |
| 200mg Cap | 093742 Quinine Sulfate | DTC | |
| | 333112 Q 212103 | | |
| 8:24:00 Sulfonamides | | | |
| ulfamethoxazole | | | .0675 |
| 500mg Tab | 013412 Gantanol | HLR | .0073 |
| | | - | |
| Storing 188 | 47 4XII ADO-SHITAMATROVA7 | | |
| 00045 | 421480 Apo-Sulfamethoxaz | | |
| | 42148U Apo-Sulfamethoxaz | | |
| Sulfapyridine 500mg Tab | #155470 Sulfapyridine | PDA | .098 |

| Sulfasalazine | | | | | |
|--|--|---------|-------------------|------|-------|
| 158528 Salazopyrin | 08:24:00 Sulfonamides | | | | |
| 158528 Salazopyrin | Sulfaculating | | | | 1144 |
| Sulfasalazine | | 158526 | Salazonyrin | PHD | |
| Soung Tab O24856 Salazopyrin PHD 263869 S.A.S. 500 ICN 1598461 PMS-Sulfasalazine PMS | | | | | |
| Soung Tab O24856 Salazopyrin PHD 263869 S.A.S. 500 ICN 1598461 PMS-Sulfasalazine PMS | | | | | |
| Sulfisoxazole | Sulfasalazine | | | | .0790 |
| Sulfisoxazole 115487 Gantrisin HLR .0298 | 500mg Tab | | | | |
| Sulfisoxazole | | | | | |
| 100mg/ml O/L | | +598461 | PMS-Sulfasalazine | PMS | |
| 100mg/ml O/L | Sulfinavarala | | | | 0208 |
| Sulfisoxazole | | 115487 | Gantrisin | HI B | .0290 |
| 13420 Gantrisin HLR NOP 210730 Sulfisoxazole SAP | TOOME OF L | 110404 | Ganti 1311 | IILI | |
| 021792 Novosoxazole NOP SAP | Sulfisoxazole | | | | .0280 |
| | 500mg Tab | 013420 | Gantrisin | HLR | |
| Dapsone | | 021792 | Novosoxazole | NOP | |
| Dapsone | | 210730 | Sulfisoxazole | SAP | |
| Dapsone | | | | | |
| 100mg Tab | 08:26:00 Sulfones | | | | |
| 100mg Tab | Control of the Contro | | | | |
| 08:32:00 Trichomonacides Metronidazole .6719 500mg Cap 489891 Flagyl RPP Metronidazole .0237 250mg Tab 021555 Novonidazol NOP 025615 Flagyl RPP 545066 Apo-Metronidazole APX *584339 PMS-Metronidazole PMS 08:36:00 Urinary Germicides Methenamine Hippurate .4144 1g Tab 026379 Hip-Rex RIK Methenamine Mandelate .0875 500mg Ent Tab 499013 Mandelamine PDA Methenamine Mandelate .1340 1000mg Ent Tab 499021 Mandelamine PDA Nalidixic Acid .0556 50mg/mL O/L 036250 NegGram WIN Nalidixic Acid .3361 500mg Tab 033723 NegGram WIN | • | 000506 | Au-116 | AVE | .1344 |
| Metronidazole 189891 Flagyl 189891 189891 Flagyl 189891 | luumg lab | 002526 | AVIOSUITOR | AIL | |
| Metronidazole 189891 Flagyl 189891 18989 | 08.32.00 Trickemanacides | | | | |
| Source | OU.32.00 If tenomonatiaes | | | | |
| Source | Metronidazole | | | | .6719 |
| 250mg Tab | | 489891 | Flagyl | RPP | |
| 250mg Tab | | | | | |
| 025615 Flagy RPP 545066 Apo-Metronidazole APX +584339 PMS-Metronidazole PMS | | | | | .0237 |
| 545066 Apo-Metronidazole | 250mg Tab | | | | |
| #584339 PMS-Metronidazole PMS #684339 PMS-Metronidazole #68434 PMS-Metronidazole #684339 PMS-Metronidazole #684330 PMS-Metronidazole #684330 PMS-Metronidazole #684330 PMS-Metron | | | | | |
| 08:36:00 Urinary Germicides Methenamine Hippurate .4144 1g Tab 026379 Hip-Rex RIK Methenamine Mandelate .0875 500mg Ent Tab 499013 Mandelamine PDA Methenamine Mandelate .1340 1000mg Ent Tab 499021 Mandelamine PDA Nalidixic Acid .0556 500mg/mL O/L .036250 NegGram WIN Nalidixic Acid .033723 NegGram WIN Nitrofurantoin .2332 | | | | | |
| Methenamine Hippurate .4144 1g Tab 026379 Hip-Rex RIK Methenamine Mandelate .0875 500mg Ent Tab 499013 Mandelamine PDA Methenamine Mandelate .1340 1000mg Ent Tab 499021 Mandelamine PDA Nalidixic Acid .0556 50mg/mL O/L 036250 NegGram WIN Nalidixic Acid .3361 500mg Tab 033723 NegGram WIN Nitrofurantoin .2332 | | +584339 | PMS-Metronidazole | PMS | |
| Methenamine Hippurate .4144 1g Tab 026379 Hip-Rex RIK Methenamine Mandelate .0875 500mg Ent Tab 499013 Mandelamine PDA Methenamine Mandelate .1340 1000mg Ent Tab 499021 Mandelamine PDA Nalidixic Acid .0556 50mg/mL O/L 036250 NegGram WIN Nalidixic Acid .3361 500mg Tab 033723 NegGram WIN Nitrofurantoin .2332 | 08.36.00 Uringry Carmicidae | | | | |
| 1g Tab 026379 Hip-Rex RIK Methenamine Mandelate 500mg Ent Tab 499013 Mandelamine .0875 Methenamine Mandelate 1000mg Ent Tab 499021 Mandelamine .1340 Nalidixic Acid 500mg/mL 0/L 036250 NegGram WIN Nalidixic Acid 500mg Tab 033723 NegGram WIN Nitrofurantoin .2332 | OS:36:00 OF THAT Y GET MICIAES | | | | |
| 1g Tab 026379 Hip-Rex RIK Methenamine Mandelate 500mg Ent Tab 499013 Mandelamine .0875 Methenamine Mandelate 1000mg Ent Tab 499021 Mandelamine .1340 Nalidixic Acid 50mg/mL 0/L 036250 NegGram WIN Nalidixic Acid 500mg Tab 033723 NegGram WIN Nitrofurantoin .2332 | Methenamine Hippurate | | | | .4144 |
| Methenamine Mandelate .0875 500mg Ent Tab 499013 Mandelamine PDA Methenamine Mandelate .1340 1000mg Ent Tab 499021 Mandelamine PDA Nalidixic Acid .0556 50mg/mL O/L 036250 NegGram WIN Nalidixic Acid .3361 500mg Tab 033723 NegGram WIN Nitrofurantoin .2332 | · · · · · · · · · · · · · · · · · · · | 026379 | Hip-Rex | RIK | |
| 500mg Ent Tab 499013 Mandelamine PDA Methenamine Mandelate .1340 1000mg Ent Tab 499021 Mandelamine PDA Nalidixic Acid .0556 50mg/mL O/L 036250 NegGram WIN Nalidixic Acid .3361 500mg Tab 033723 NegGram WIN Nitrofurantoin .2332 | | | • | | |
| Methenamine Mandelate .1340 1000mg Ent Tab 499021 Mandelamine PDA Nalidixic Acid .0556 50mg/mL O/L 036250 NegGram WIN Nalidixic Acid .3361 500mg Tab 033723 NegGram WIN Nitrofurantoin .2332 | Methenamine Mandelate | | | | .0875 |
| 1000mg Ent Tab 499021 Mandelamine PDA Nalidixic Acid 50mg/mL 0/L .0556 Nalidixic Acid 500mg Tab 036250 NegGram WIN Nalidixic Acid 500mg Tab .3361 Nitrofurantoin .2332 | 500mg Ent Tab | 499013 | Mandelamine | PDA | |
| 1000mg Ent Tab 499021 Mandelamine PDA Nalidixic Acid 50mg/mL 0/L .0556 Nalidixic Acid 500mg Tab 036250 NegGram WIN Nalidixic Acid 500mg Tab .3361 Nitrofurantoin .2332 | Annual Control of the | | | | |
| Nalidixic Acid 036250 NegGram .0556 50mg/mL O/L 036250 NegGram WIN Nalidixic Acid .3361 500mg Tab 033723 NegGram WIN Nitrofurantoin .2332 | | 100001 | | 22. | .1340 |
| 50mg/mL 0/L 036250 NegGram WIN Nalidixic Acid .3361 500mg Tab 033723 NegGram WIN Nitrofurantoin .2332 | 1000mg Ent Tab | 499021 | Mandelamine | PDA | |
| 50mg/mL 0/L 036250 NegGram WIN Nalidixic Acid .3361 500mg Tab 033723 NegGram WIN Nitrofurantoin .2332 | No lidivio Acid | | | | 0556 |
| Nalidixic Acid .3361 500mg Tab 033723 NegGram WIN Nitrofurantoin .2332 | | 036250 | NegGram | WIN | .0555 |
| 500mg Tab 033723 NegGram WIN Nitrofurantoin .2332 | | 00000 | | | |
| 500mg Tab 033723 NegGram WIN Nitrofurantoin .2332 | Nalidixic Acid | | | | .3361 |
| Nitrofurantoin .2332 | 500mg Tab | 033723 | NegGram | WIN | |
| | The second second | | | | |
| 50mg Cap 452505 Macrodantin EAT | | 11 | | | .2332 |
| | 50mg Cap | 452505 | Macrodantin | EAT | |

C8:00 Anti-Infective Agents

| 08:36:00 Urinary Germicides | | | | |
|--|---------|--------------------|------|--------|
| Nitrofurantoin | | | | .143 |
| 25mg Cap | 452491 | Macrodantin | EAT | |
| Nitrofurantoin | | | | .410 |
| 100mg Cap | 452483 | Macrodantin | EAT | |
| Nitrofurantoin | | | | .015 |
| 5mg/mL O/L | 232971 | Novofuran | NOP | |
| Mitrofurantoin | | | | .007 |
| 50mg Tab | 021563 | Novofuran | NOP | |
| | 092800 | Nitrofurantoin | DTC | |
| | 319511 | Apo-Nitrofurantoin | APX | |
| Nitrofurantoin | | | | .009 |
| 100mg Tab | 021571 | Novofuran | NOP | .005 |
| | | Nitrofurantoin | DTC | |
| | | Apo-Nitrofurantoin | APX | |
| 21 111 1103 | | | | |
| Phenazopyridine HCl 200mg Tab | 454583 | Phenazo | ICN | .104 |
| | | Pyridium | PDA | |
| 21 | | | | |
| Phenazopyridine HCl | 071 400 | DI | 7.00 | .062 |
| 100mg Tab | | Phenazo | ICN | |
| | 4/6/14 | Pyridium | PDA | |
| Pivmecillinam HCl | | | | .500 |
| 200mg Tab | +657212 | Selexid | LEO | |
| 08:40:00 Miscellaneous Anti-Infectives | | | | |
| Sulfamethoxazole & Trimethoprim | | | | .0300 |
| 40mg & 8mg/mL O/L | 270644 | Septra | BWE | |
| | | Bactrim Sugar Free | HLR | |
| Sulfamethoxazole & Trimethoprim | | | | .1000 |
| 800mg & 160mg Tab | 368040 | Septra DS | BWE | . 1000 |
| | | Bactrim-DS | HLR | |
| | | Apo-Sulfatrim-DS | APX | |
| | | Novotrimel DS | NOP | |
| | | Sulfamethoxazole & | DTC | |
| | | Trimethoprim | DIC | |
| Sulfamethoxazole & Trimethoprim | | | | .0635 |
| 400mg & 80mg Tab | 270636 | Septra | BWE | |
| | 272469 | Bactrim | HLR | |
| | 445274 | Apo-Sulfatrim | APX | |
| | | Novotrimel | NOP | |
| | 516759 | Sulfamethoxazole & | DTC | |
| | | Trimethoprim | | |
| frimethoprim | | | | . 4000 |
| 200mg Tab | +677590 | Proloprim | BWE | |

08:00 Anti-Infective Agents

| 20. 40. 00 Minnellanen Andi Tudad | Nima a | |
|--|-----------------------------------|-----------------|
| 08:40:00 Miscellaneous Anti-Infect | tives | |
| Trimethoprim | 675229 Proloprim | .1870 BWE |
| 100mg Tab | 073223 FroTopFin | BWE ; |
| Trimethoprim & Sulfadiazine | 478717 Coptin | .3638 |
| 90mg & 410mg Tab | Troite coptin | 300 |
| | | |
| 10:00 Antineoplastic Agents | | |
| | | 117 717 400 |
| Amethopterin 2.5mg Tab | 014915 Methotrexate | .3750 LED |
| | | |
| Amethopterin (Sodium) 50mg/2mL Inj Sol-2mL Pk | 321397 Methotrexate | 10.7500 LED |
| | | |
| Amethopterin (Sodium) 5mg/2mL Inj Sol-2mL Pk | 321400 Methotrexate | 6.2500 LED |
| *-iTutthinide | | 7770 |
| Aminoglutethimide 250mg Tab | 587729 Cytadren | .7730 CIB |
| AAlii | | 5000 |
| Azathioprine 50mg Tab | 004596 Imuran | .5880 BWE |
| Plannein Culfata | | 121 5000 |
| Bleomycin Sulfate Inj Pd-15U Pk | 258482 Blenoxane | 121.5000 BRI |
| Busulfan | FREE PROPERTY. | .8800 |
| 2mg Tab | 004618 Myleran | BWE |
| Carmustine (BCNU) | | 36.5000 |
| Inj Pd-100mg Pk | 297763 BiCNU | BRI |
| Chlorambucil | | .8800 |
| 2mg Tab | 004626 Leukeran | BWE |
| Cyclophosphamide | | 10.8500 |
| Inj Pd-1000mg Pk | 013552 Procytox | HOR |
| Cyclophosphamide | and the same | 4.3600 |
| Inj Pd-200mg Pk | 013544 Procytox | HOR |
| | 344907 Cytoxan | BRI |
| Cyclophosphamide | 044047 0 | 5.4500 |
| Inj Pd-500mg Pk | 344915 Cytoxan | BRI |
| Cyclophosphamide | 010740 B | .3380 |
| 50mg Tab | 013749 Procytox 344885 Cytoxan | HOR BRI |
| Cualanhaanhanida | | .2510 |
| Cyclophosphamide 25mg Tab | 262676 Procytox | HOR |
| | 344877 Cytoxan | BRI |
| Cyproterone Acetate | | 1.6250 |
| 50mg Tab | +704431 Androcur | BER |
| Cytarabine | | 7.0000 |
| Inj Pd-100mg Pk | 386715 Cytosar | UPJ |
| Cytarabine | | 31.5000 |
| Inj Pd-500mg Pk | 194727 Cytosar | UPJ |
| | 2486 | |
| | | |

10:00 Antineoplastic Agents

| Dacarbazine Inj Pd-200mg Pk | 521183 DTIC | 13.9667 MIT |
|--|---------------------------------------|----------------------|
| Dactinonycin Inj Pd-0.5mg Pk | 213071 Cosmegen | 6.3700 MSD |
| Daunorubicin Inj Pd-20mg Pk | 163899 Cerubidine | 59.7500 RPP |
| Dihydroxybusulfan 250mg Cap | #452122 Treosulfan | .7040 LEO |
| Doxorubicin HCl Inj Pd-10mg Pk | 357391 Adriamycin | 31.9500 ADI |
| Doxorubicin HCl Inj Pd-50mg Pk | 353078 Adriamycin | 152.3500 ADI |
| Estramustine Phosphate Disodium 140mg Cap | 461830 Encyt | 2.2500 HLR |
| Fluorouracil 500mg/10mL Inj Sol-10mL Pk | 012882 Fluorouracil 428493 Adrucil | 2.0800 HLR ADI |
| Flutamide 250mg Tab | +637726 Euflex | 1.5756 SCH |
| L-Asparaginase | 285463 Kidrolase | 90.1000 |
| Inj Pd-10,000IUPk Leuprolide Acetate | | RPP 140.0000 |
| 5mg/mL Inj Sol-2.8mL Pk Lomustine (CCNU) | +642932 Lupron | ABB 5.0000 |
| 40mg Cap Lomustine (CCNU) | 360422 CeeNU | BRI 8.2550 |
| 100mg Cap Lomustine (CCNU) | 360414 CeeNU | BRI 3.0800 |
| 10mg Cap Mechlorethamine HCl | 360430 CeeNU | BRI 5.5500 |
| Inj Pd-10mg Pk | 016063 Mustargen | MSD |
| Megestrol Acetate 40mg Tab | 386391 Megace | .8170 BRI |
| Melphalan 2ng Tab | 004715 Alkeram | .9840 BWE |
| Mercaptopurine 50mg Tab | 004723 Purinethol | 1.2800 BWE |

10:00 Antineoplastic Agents

| Methotrexate Sodium | 12.50 | 000 |
|--------------------------|---------------------------------|-----|
| 20mg/2mL Inj Sol-2mL Pk | +614335 Methotrexate Sodium HOR | |
| Mutamycin | 60.60 | 000 |
| Inj Pd-5mg Pk | 381799 Mitomycin BRI | |
| Procarbazine HCl | .29 | 33 |
| 50mg Cap | 012750 Natulan HLR | |
| Streptozocin | 25.00 | 000 |
| Inj Pd-1g Pk | +622141 Zanosar UPJ | |
| Tamoxifen Citrate | 2.41 | 67 |
| 20mg Tab | +638706 Nolvadex D ICI | 0, |
| Tamoxifen Citrate | 1.27 | 110 |
| 10mg Tab | 419052 Nolvadex ICI | 12 |
| | | |
| Thio-Tepa Inj Pd-15mg Pk | 237035 Thio-Tepa LED | 00 |
| | | |
| Thioguanine 40mg Tab | 282081 Lanvis BWE | 40 |
| TOING 160 | 202001 Lanvis B#L | |
| Vinblastine Sulfate | 37.76 | 00 |
| Inj Pd-10mg Pk | 015431 Velbe LIL | |
| Vincristine Sulfate | 28.62 | 00 |
| 1mg/mL Inj Sol | 611182 Oncovin LIL | |

| 12:04:00 Parasympathomimetic (Chol | inergic) Agents | | |
|-------------------------------------|------------------------------------|------|--------|
| Bethanechol Chloride | | | 2.3650 |
| 5mg/mL Inj Sol-1mb Pk | 349747 Urecholine | FRS | |
| Bethanechol Chloride | | | . 5365 |
| 50mg Tab | 453013 Duvoid | EAT | |
| Bethanechol Chloride | | | .3315 |
| 25mg Tab | 349739 Urecholine 453005 Duvoid | FRS | |
| | 200000 221012 | 2.12 | |
| Bethanechol Chloride 10mg Tab | 349720 Urecholine | FRS | .2072 |
| | 452998 Duvoid | EAT | |
| Carbachol | | | 3.2704 |
| 0.25mg/mL Inj Sol-1mL Pk | 341622 Carbachol | AHA | 3.2/04 |
| Carbachol | | | .3007 |
| 2mg Tab | 003212 Carbachol | AHA | .3007 |
| Edrophonium Chloride | | | 9.4584 |
| 100mg/10mL Inj Sol-10mL Pk | 013064 Tensilon | HLR | 9.4364 |
| Neostigmine Bromide | | | .1058 |
| 15mg Tab | 013382 Prostigmin | HLR | . 1036 |
| Neostigmine Methylsulfate | | | .6496 |
| 0.5mg/mL Inj Sol-1mL Pk | 012955 Prostignin | HLR | .0450 |
| Pyridostigmine Bromide | | | .2610 |
| 180mg LA Tab | 035890 Mestinon | HLR | |
| Pyridostigmine Bromide | | | .1103 |
| 60mg Tab | 013404 Mestinon | HLR | |
| | | | |
| 12:08:00 Parasympatholytic ICholine | ergic Blocking) Agents | | |
| Atropine Sulfate | | | |
| 0.6mg/mL Inj Sol-1mL Pk | 012076 Atropine | GLA | .4547 |
| | # 535699 Atropine Sulfate | SQU | . 3024 |
| | | | |
| Atropine Sulfate | | | |
| 0.4mg/ml Inj Sol-1ml Pk | 061697 Atropine | GLA | .4547 |
| | #535680 Atropine Sulfate | SQU | .2968 |
| | | | |
| Benztropine Mesylate | 010100 0 | ИСВ | 3.8005 |
| 2mg/2mL Inj Sol-2mL Pk | 016128 Cogentin | MSD | |

| Benztropine Mesylate | 12:08:00 Parasympatholytic (Cholinergic | Blocking) Agents | | |
|--|---|-----------------------|-------|--------|
| 10mg Cap | | 426857 Apo-Benztropin | e APX | .0067 |
| 20mg/2mL Inj Sol-2mL Pk | · | | | .0245 |
| Dicyclomine HCl 282529 Bentylol MER .1451 | | 133965 Bentylol | MER | 4.2388 |
| 20mg Tab 282529 Bentylol MER | | 018023 Bentylol | MER | .0439 |
| Comparison | | 282529 Bentylol | MER | .1451 |
| O.2mg/mL Inj Sol-1mL Pk O26425 Robinul ROB | | 025550 Parsitan | RPP | .1383 |
| 2mg Tab | | 026425 Robinul | ROB | 1.4336 |
| lmg Tab 026514 Robinul ROB Hyoscyamine Sulfate #608807 Levsin ROR 0.125mg/mL 0/L #608807 Levsin ROR Hyoscine Butylbromide 363839 Buscopan BOE Hyoscine Butylbromide 363820 Buscopan BOE 10mg Sup 363812 Buscopan BOE Hyoscine Butylbromide 363812 Buscopan BOE 10mg Tab 608777 Levsin ROR 0rphenadrine Citrate 608777 Levsin ROR 0rphenadrine Citrate 171468 Norflex RIK 0rphenadrine Citrate 171476 Norflex RIK 0rphenadrine HCl .4928 0rphenadrine HCl .3354 | | 026522 Robinul Forte | ROB | .1456 |
| No. 125mg/mL 0/L | | 026514 Robinul | ROB | .0806 |
| 20mg/mL Inj Sol-1mL Pk 363839 Buscopan BOE Hyoscine Butylbromide 10mg Sup 363820 Buscopan BOE Hyoscine Butylbromide 10mg Tab 363812 Buscopan BOE Hyoscyamine Sulfate 0.125mg SL Tab 608777 Levsin ROR Orphenadrine Citrate 60mg/2mL Inj Sol-2mL Pk 171468 Norflex RIK Orphenadrine Citrate 100mg Tab 171476 Norflex RIK Orphenadrine HCl .3354 | | #608807 Levsin | ROR | .4723 |
| 10mg Sup 363820 Buscopan BOE Hyoscine Butylbromide 10mg Tab 363812 Buscopan BOE Hyoscyamine Sulfate 0.125mg SL Tab 608777 Levsin ROR Orphenadrine Citrate 60mg/2mL Inj Sol-2mL Pk 171468 Norflex RIK Orphenadrine Citrate 100mg Tab 171476 Norflex RIK Orphenadrine HCl .3354 | | 363839 Buscopan | BOE | 2.6264 |
| 10mg Tab 363812 Buscopan BOE Hyoscyamine Sulfate 0.125mg SL Tab 608777 Levsin ROR Orphenadrine Citrate 60mg/2mL Inj Sol-2mL Pk 171468 Norflex RIK Orphenadrine Citrate 100mg Tab 171476 Norflex RIK Orphenadrine HCl .3354 | | 363820 Buscopan | ВОЕ | 1.1760 |
| 0.125mg SL Tab 608777 Levsin ROR Orphenadrine Citrate 60mg/2mL Inj Sol-2mL Pk 171468 Norflex RIK Orphenadrine Citrate 100mg Tab 171476 Norflex RIK Orphenadrine HCl .3354 | | 363812 Buscopan | вое | .1534 |
| 60mg/2mL Inj Sol-2mL Pk 171468 Norflex RIK Orphenadrine Citrate .4928 100mg Tab 171476 Norflex RIK Orphenadrine HC1 .3354 | | 608777 Levsin | ROR | .1159 |
| 100mg Tab 171476 Norflex RIK Orphenadrine HC1 .3354 | | 171468 Norflex | RIK | 5.9827 |
| 0. 5.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0 | | 171476 Norflex | rik | .4928 |
| | | 026387 Disipal | RIK | .3354 |

| Oxybutynin Chloride lmg/mL O/L | 548332 Ditropan | .0630 EAT |
|-------------------------------------|--|--------------|
| Oxybutynin Chloride | | .2805 |
| 5mg Tab | 530921 Ditropan | EAT |
| Procyclidine HCl | | .0168 |
| 0.5mg/mL 0/L | 004405 Kemadrin | BWE |
| | 485012 Procyclid | ICN |
| Procyclidine HCl | | .0226 |
| 5mg Tab | 004758 Kemadrin | BWE |
| 3 | 306290 Procyclid | ICN |
| | | |
| Propantheline Bromide | 028592 Pro-Banthine | .0225 |
| 15mg Tab | 294837 Propanthel | SEA ICN |
| | 233007 Propantite | ICA |
| Propantheline Bromide | | .1366 |
| 7.5mg Tab | 028584 Pro-Banthine | SEA |
| | | |
| Scopolamine | | 1.3944 |
| 1.5mg Transderm Syst | 623547 Transderm-V | CIB |
| Trihexyphenidyl HCl | | .0208 |
| 0.4mg/mL O/L | 014656 Artane | LED |
| | | 000 |
| Trihexyphenidyl HCl | the second secon | .0092 |
| 5mg Tab | 015059 Artane | LED |
| | 021938 Novohexidyl | NOP |
| | 271314 Aparkane 545074 Apo-Trihex | ICN APX |
| | 343074 Apo-IFINEX | APA |
| Trihexyphenidyl HCl | | .0072 |
| 2mg Tab | 015040 Artane | LED |
| | 021911 Novohexidyl | NOP |
| | 280445 Aparkane | ICN |
| | 545058 Apo-Trihex | APX |
| 12:12:00 Sympathomimetic (Adrenergi | c) Agents | |
| Ephedrine HCl | | .1637 |
| 30mg Tab | 304069 Ephedrine | AHA |
| | | |
| Epinephrine | | 9.5600 |
| Aero Sol-15mL Pk | 282286 Bronkaid Mistometer | WIN |
| Epinephrine Bitartrate | | 13.0480 |
| Aero Susp-15mL Pk | 026271 Medihaler-Epi | RIK |
| | | |
| Epinephrine HCl | | 7.4256 |
| 30mg/30mL Inj Sol-30mL Pk | 155357 Adrenalin | PDA |

| 12:12:00 Sympathomimetic (Adrenergic | c) Agents | |
|--|------------------------------------|---------------------|
| Epinephrine HCl (Racemic) 2.25% Inh Sol 30mL Pk | 480363 Vaponefrin | 18.0660 ROR |
| Fenoterol HBr Inh Pd-200dosePk | 371807 Berotec | 9.3000 BOE |
| Fenoterol HBr 0.17 Inh Sol-20mL Pk | 541389 Berotec | 10.4000 BOE |
| Fenoterol HBr 2.5mg Tab | 454796 Berotec | .1625 BOE |
| Ipratropium Bromide Inh 200 dose Pk | 576158 Atrovent | 11.1000 BOE |
| Isoproterenol HC1 Aero Sol-15mL Pk | 033219 Isuprel Mistometer | 9.3495 WIN |
| Isoproterenol HCl 0.5% Inh Sol-10mL Pk | 033227 Isuprel | 6.0500 WIN |
| Isoproterenol HCl 10mg SL Tab | 033820 Isuprel | .1300 WIN |
| Isoproterenol Sulfate Aero Susp-15mL Pk | 026301 Medihaler-Iso | 11.6500 RIK |
| Orciprenaline Sulfate Inh Pd-300dosePk | 254134 Alupent | 9.0000 BOE |
| Orciprenaline Sulfate 5% Inh Sol-10mL Pk | 003859 Alupent | 6.5000 BOE |
| Orciprenaline Sulfate 2mg/mL O/L | 249920 Alupent | .0416 BOE |
| Orciprenaline Sulfate 20mg Tab | 003891 Alupent | .1690 BOE |
| Pseudoephedrine HC1 Gmg/mL O/L | 004561 Sudafed 425516 Robidrine | .0160 BWE ROB |
| Pseudoephedrine HCl 60mg Tab | 004766 Sudafed 342726 Robidrine | .0655 BWE ROB |
| Salbutamol 400mcg/Cart Inh Pd | 622079 Ventolin Rotacaps | .1810 AHA |
| Salbutamol 200mcg/Cart Inh Pd | 622060 Ventolin Rotacaps | .1280 AHA |

| Salbutamol | 224227 V4-1:- | | 6.7000 |
|--|---------------------------------------|------------|--------|
| 5mg/mL Inh Sol-10mL Pk | 334227 Ventolin | AHA | |
| Salbutamol | | | 9.5000 |
| Inh-200 dose Pk | 303569 Ventolin | AHA | |
| Salbutamol | | | .8100 |
| 2.5mg/5mL Inj Sol | 602922 Ventolin | AHA | |
| Salbutamol | | | .7700 |
| 0.25mg/5mL Inj Sol | 602914 Ventolin | AHA | |
| Salbutamol | | | .0880 |
| 4mg Tab | 332267 Ventolin | AHA | .0000 |
| | +620963 Novosalmol | NOP | |
| | | | |
| albutamol | 004407 !! | | .0528 |
| 2mg Tab | 361135 Ventolin +620955 Novosalmol | AHA NOP | |
| | +020333 NOVOS21801 | AUP | |
| erbutaline Sulfate | | 1 | 0.4500 |
| Inh 200 dose Pk | 444774 Bricanyl Spacer | AST | |
| Cerbutaline Sulfate | | | .1610 |
| 5mg Tab | 335363 Bricanyl | AST | .1010 |
| erbutaline Sulfate | | | 1070 |
| 2.5mg Tab | 335355 Bricanyl | AST | .1230 |
| | obobbo Bi icaay i | 101 | |
| | | | |
| and the same of th | | | |
| 12:16:00 Sympatholytic (Adrenergic Bloc | king) Agents | | |
| ergotamine & Pentobarbital Compound | | | 1.5470 |
| Sup | 176214 Cafergot-PB | SAN | |
| rgotamine & Pentobarbital Compound | | | .4420 |
| Tab | 176222 Cafergot-PB | SAN | .4420 |
| | | | |
| rgotamine Tartrate | | | .5008 |
| 2mg SL Tab | 328952 Ergomar | FIS | |
| rgotamine Tartrate | | | .3820 |
| lmg Tab | 027405 Gynergen | SAN | . 5020 |
| | | | |
| rgotamine Tartrate & Caffeine | | | .3820 |
| lmg & 100mg Tab | 176095 Cafergot | SAN | |
| -41 -11 -1 -1 | | | . 4580 |
| ethysergide Bimaleate | | | |
| | 027499 Sansert | SAN | |
| 2mg Tab | 027499 Sansert | SAN | |
| letbysergide Bimaleate 2mg Tab Pizotyline lmg Tab | 027499 Sansert 511552 Sandomigran DS | SAN | .4090 |

| 12:16:00 Sympatholytic (Adrenergic | Blocking) Agents | | |
|------------------------------------|---------------------|-----|-------|
| Pizotyline 0.5mg Tab | 329320 Sandomigran | SAN | .2470 |
| 12:20:00 Skeletal Muscle Relaxants | | | |
| Baclofen 20mg Tab | +636576 Lioresal DS | GEI | .7150 |
| Baclofen 10mg Tab | 455881 Lioresal | GEI | .3460 |
| Cyclobenzaprine HCl 10mg Tab | 417300 Flexeril | MSD | .4237 |
| Dantrolene Sodium 25mg Cap | 452513 Dantrium | EAT | .2524 |
| Dantrolene Sodium 100mg Cap | 452521 Dantrium | EAT | .5140 |

16:00 Blood Derivatives

| Immune Human Serum Globulin 16.5% Inj Sol-10mL Pk | 990515 Immune Human Serum Globul CNG | 9.8600 |
|--|--------------------------------------|--------|
| Immune Human Serum Globulin 16.5% Inj Sol-2mL Pk | 075280 Immune Human Serum Globul CNG | 3.1900 |
| Immune Human Serum Globulin 16.5% Inj Sol-5mL Pk | 990523 Immune Human Serum Globul CNG | 5.5100 |
| Tetanus Immune Human Globulin Inj Sol-250U Pk | 074942 Tetanus Immune Human Glob CNG | 2.7800 |

20:00 Blood Formation and Coagulation

| 20:04:00 Antianemia Drugs | | | | |
|---|---------|-------------------------|-----|--------|
| Ferrous Fumarate (OTC) | *445492 | Palafer | BEE | 8.7000 |
| 300mg Cap 30 Pk | *440463 | ralater | BEE | |
| Ferrous Fumarate | | | | .0690 |
| 60mg/mL O/L | 437018 | Palafer | BEE | |
| Ferrous Fumarate (OTC) | | | | 1.7500 |
| 200mg Tab 100 Pk | | Fersanal | GLA | |
| | | Novofumar | NOP | |
| | 094706 | Ferrous Fumarate | DTC | |
| Ferrous Fumarate (Pediatric) | | | | .1085 |
| 60mg/mL O/L | 590630 | Palafer Pediatric Drops | BEE | |
| Ferrous Glucomate (OTC) | | | | 1.7000 |
| 300mg Tab 100 Pk | 021458 | Novoferrogluc | NOP | |
| 3 | | Ferrous Gluconate | WAM | |
| | | Fergon | WIN | |
| | | Ferrous Gluconate | LEA | |
| | 094714 | Ferrous Gluconate | DTC | |
| | 545031 | Apo-Ferrous Gluconate | APX | |
| errous Succinate (OTC) | | | | 6.9000 |
| 100mg Tab 30 Pk | 677981 | Cerevon | BWE | |
| Ferrous Sulfate (OTC) | | | | 1.7000 |
| 300mg Ent Tab 100 Pk | 232998 | Novoferrosulfa | NOP | |
| | | Apo-Ferrous Sulfate | APX | |
| errous Sulfate | | | | .1413 |
| 125mg/mL O/L | 017841 | Fer-in-Sol | MJO | .1413 |
| | | | | |
| Iron Dextran | 000500 | T-F | FIC | 2.3990 |
| 100mg/2mL Inj Sol-2mL Pk | 009598 | Imferon | FIS | |
| | | | | |
| 20:12:00 Coagulants and Anti-Coagulants | | | | |
| Heparin Calcium | | | | |
| 25,0001U/mL Inj Sol-0.8mL Pk | 562122 | Calcilean | ORG | 6.9664 |
| Heparin Sodium | | | | |
| 10,000USP U/10mL Inj Sol-10mL Pk | 304042 | Heparin | AHA | 1.7250 |
| Heparin Sodium | | | | |
| 10,000USP U/10mL Inj Sol-10mL Pk | 562262 | Hepalean | ORG | 2.7664 |
| Heparin Sodium | | | | |
| 25,000USP U/mL Inj Sol-2mL Pk | +562289 | Hepalean | ORG | 11.631 |
| Heparin Sodium | | | | |
| 50,000USP U/5mL Inj Sol-5mL Pk | 204050 | Heparin | AHA | 4.3120 |

20:00 Blood Formation and Coagulation

| 20:12:00 Coagulants and Anti-Coagulants | | |
|--|--------------------|------------|
| Heparin Sodium 50,000USP U/5mL Inj Sol-5mL Pk | 562270 Hepalean | ORG 4.9056 |
| Nicoumalone 4mg Tab | 010391 Sintrom | GEI .2950 |
| Nicoumalone 1mg Tab | 010383 Sintrom | GEI .0940 |
| Warfarin 10mg Tab | 585637 Coumadin | DUP .3115 |
| Warfarin 5mg Tab | 010308 Warfilone | FRS .1334 |
| Warfarin 5mg Tab | 026174 Athrombin-K | PFR .0770 |
| Warfarin 5mg Tab | 585629 Coumadin | DUP .1705 |
| Warfarin 2.5mg Tab | 585645 Coumadin | DUP .1560 |

| 24-24-22 Cardias Drugs | | | |
|--------------------------------------|------------------------------------|------------|--------|
| 24:04:00 Cardiac Drugs | | | |
| Digoxin 0.05mg/mL Inj Sol-1mL Pk | 004456 Lanoxin | BWE | 2.2200 |
| Digoxin 0.50mg/2mL Inj Sol-2mL Pk | 004464 Lanoxin | BWE | 2.2200 |
| Digoxin 0.05mg/mL 0/L | 242713 Lanoxin | BWE | .1070 |
| Digoxin 0.25mg Tab | 004685 Lanoxin | BWE | .0550 |
| Digoxin 0.125mg Tab | 035319 Lanoxin | BWE | .0550 |
| Diltiazem HCl 60mg Tab | 587761 Cardizem | NRD | .4507 |
| Diltiazem HCl 30mg Tab | 587753 Cardizem | NRD | .2569 |
| Disopyramide 150mg Cap | 396389 Norpace | SEA | .2500 |
| Disopyramide | 439363 Rythmodan | ROU | .1770 |
| 100mg Cap | 382876 Rythmodan 396370 Norpace | ROU SEA | |
| Disopyramide 250mg LA Tab | 619760 Rythmodan I | L.A. ROU | .5215 |
| Disopyramide 150mg LA Tab | 584231 Norpace CR | SEA | .3825 |
| Labetalol HC1 200mg Tab | 603643 Trandate | AHA | .2970 |
| Labetalol HCl | 603651 Trandate | АНА | .1680 |
| 100mg Tab Metoprolol Tartrate | | | |
| 200mg LA Tab Metoprolol Tartrate | 497827 Betaloc Dur | | .5186 |
| 200mg LA Tab Metoprolol Tartrate | 534560 Lopresor SI | R GEI | .4270 |
| 100mg LA Tab | +658855 Lopresor SI | R GEI | .2500 |
| Metoprolol Tartrate 50mg Tab | 397423 Lopresor | GEI | .0970 |

| 24:04:00 Cardiac Drugs | | | | |
|-----------------------------|----------|----------------|-----|--------|
| Metoprolol Tartrate | | | | .0970 |
| 50mg Tab | | Betaloc | AST | |
| | | Apo-Metoprolol | APX | |
| | +648035 | Novometoprol | NOP | |
| Metoprolol Tartrate | | | | :1780 |
| 100mg Tab | 397431 | Lopresor | GEI | |
| | 402540 | Betaloc | AST | |
| | 618640 | Apo-Metoprolol | APX | |
| | +648043 | Novometoprol | NOP | |
| (| | | | 1770 |
| lexiletine HCl 200mg Cap | . 500064 | Mexitil | BOE | .4780 |
| 200mg Cap | *099904 | Mexicii | BUE | |
| Mexiletine HCl | | | | .3570 |
| 100mg Cap | +599956 | Mexitil | BOE | |
| | | | | |
| iadolol | | | | .5100 |
| 80mg Tab | 463256 | Corgard | SQU | |
| | | | | |
| adolol | | | | .3415 |
| 40mg Tab | 607126 | Corgard | SQU | |
| adolol | | | | .9110 |
| 160mg Tab | 592279 | Corgard | SQU | .9110 |
| Tooms Tab | 023312 | Corgana | 200 | |
| ifedipine | | | | .3851 |
| 10mg Cap | 557633 | Adalat | MIT | |
| | | | | |
| indolol | | | | .3070 |
| 5mg Tab | 417270 | Visken | SAN | |
| indolol | | | | .7580 |
| 15mg Tab | 417289 | Visken | SAN | .7500 |
| IOME IND | 711200 | 7 ISACH | SAN | |
| indolol | | | | .5230 |
| 10mg Tab | 443174 | Visken | SAN | |
| | | | | |
| rocainamide HCl | | | | .3440 |
| 500mg Cap | 353523 | Pronestyl | SQU | |
| rocainamide HCl | | | | .2585 |
| 375mg Cap | 205021 | Pronestyl | sou | .2303 |
| Srong Cap | 250031 | Fronestyl | 260 | |
| rocainamide HCl | | | | .1726 |
| 250mg Cap | 029076 | Pronestyl | SQU | |
| | | • | | |
| rocainamide HCl | | | | 7.6000 |
| 100mg/10mL Inj Sol-10mL Pk | 029181 | Pronestyl | SQU | |
| | | | 1 | |
| rocainamide HCl | . 000004 | Procan SR | PDA | 4501 |
| 750mg LA Tab | +038084 | rrucan an | rua | .4501 |

| 24:04:00 Cardiac Drugs | | | |
|-----------------------------|-------------------------|-----|-------|
| Procainamide HCl | | | |
| 500ng LA Tab | +638676 Procan SR | PDA | .3333 |
| Procainamide HCl | | | |
| 500mg LA Tab | +639885 Pronestyl SR | squ | .3450 |
| Proceinamide HCl | COOCOO P. CD | | |
| 250mg LA Tab | +638692 Procam SR | PDA | .1818 |
| Propranolol 160mg LA Cap | 511668 Inderal L.A. | AYE | .7896 |
| | olioo lacial p.n. | AIL | |
| Propranolol 120mg LA Cap | 587931 Inderal L.A. | AYE | .6270 |
| | | | |
| Propranolol 80mg LA Cap | 566950 Inderal L.A. | AYE | .4408 |
| Propranolol | | | .0560 |
| 80mg Tab | 313602 Inderal | AYE | .0560 |
| | 402761 Apo-Propranolol | APX | |
| | 496502 Novopranol | NOP | |
| | 523380 Propranolol | DTC | |
| | 582271 PMS-Propranolol | PMS | |
| Propranolol | | | .0332 |
| 40mg Tab | 002666 Inderal | AYE | |
| | 402753 Apo-Propranolol | APX | |
| | 496499 Novopranol | NOP | |
| | 523399 Propranolol | DTC | |
| | 582263 PMS-Propranolol | PMS | |
| Propranolol | | | .0275 |
| 20mg Tab | 489859 Inderal-20 | AYE | .02/5 |
| | +663719 Apo-Propranolol | APX | |
| Propranolol | | | .1120 |
| 120mg Tab | 456578 Inderal | AYE | |
| | 504335 Apo-Propranolol | APX | |
| | 549657 Novopranol | NOP | |
| | 582298 PMS-Propranolol | PMS | |
| Propranolol | | | .0184 |
| 10mg Tab | 002658 Inderal | AYE | |
| | 402788 Apo-Propranolol | APX | |
| | 496480 Novopranol | NOP | |
| | 523402 Propranolol | DTC | |
| | 582255 PMS-Propranolol | PMS | |
| Quinidine Bisulfate | | | .3164 |
| 250mg Tab | 249580 Biquin Durules | AST | |

| Quinidine Gluconate | ====== | | | .5765 |
|-----------------------------|---------|-----------------------|-----|---------|
| 324mg LA Tab | 704644 | Quinaglute-Duratabs | BER | |
| Quinidine Gluconate | | | | .2960 |
| 325mg Tab | 311731 | Quinate | ROG | |
| Quinidine Polygalacturonate | | | | .3600 |
| 275mg Tab | 026131 | Cardioquin | PFR | |
| Quinidine Sulfate | | | | .3000 |
| 300mg LA Tab | 346837 | Quinidex Extentabs | ROB | |
| Ouinidine Sulfate | | | | .0539 |
| 200mg Tab | 003611 | Quinidine | AHA | . 0000 |
| | | Ouinidine | BWE | |
| | | Novoquinidine | NOP | |
| | | Quinidine | PDA | |
| | | Quinidine | ROG | |
| | | Quinidine | DTC | |
| | | Apo-Quinidine Sulfate | APX | |
| Sotalol HCl | | | | .7350 |
| 160mg Tab | +483923 | Sotacor | BRI | . / 550 |
| Timolol Maleate | | | | .1789 |
| 5mg Tab | 353914 | Blocadren | FRS | .1705 |
| | | | | |
| Timolol Maleate | | | | .5763 |
| 20mg Tab | 495611 | Blocadren | FRS | |
| Timolol Maleate | | | | .2941 |
| 10mg Tab | 353922 | Blocadren | FRS | |
| Verapamil HCl | | | | .5870 |
| 120mg Tab | 554324 | Isoptin | SEA | |
| Verapamil HCl | | | | .3845 |
| 80mg Tab | 554316 | Isoptin | SEA | |
| 24:06:00 Antilipemic Drugs | | | | |
| | | | | |
| Cholestyramine Resin | | _ | | 22.9446 |
| 440mg/g Oral Pd-378g Pk | 634093 | Questran | BRI | |
| Cholestyramine Resin | | | | .7353 |
| 440mg/g Oral Pd 9g Pouch Pk | 464880 | Questran | BRI | |
| Clofibrate | | | | .0312 |
| 500mg Cap | 002038 | Atromid-S | AYE | |
| • | | Novofibrate | NOP | |
| | | Claripex | ICN | |

| Colestipol HCl Gran | +642975 Colestid | *** | .6000 |
|--|--|------------|--------|
| Gran | *642975 Colestia | UPJ | |
| Gemfibrozil | | | .3073 |
| 300mg Cap | +599026 Lopid | PDA | .5075 |
| • | • | | |
| Sodium Dextrothyroxine | | | .5615 |
| 4mg Tab | 009636 Choloxin | FLI | |
| Sodium Dextrothyroxine | | | .4800 |
| 2mg Tab | 273015 Choloxin | FLI | .4000 |
| | | | |
| | | | |
| | | | |
| 24:08:00 Hypotensive Drugs (For Diureti | cs See 40:281 | | |
| Amiloride HCl & Hydrochlorothiazide | | | .2641 |
| 5mg & 50mg Tab | 487813 Moduret | MSD | .2041 |
| | | ,,,,, | |
| Atenolol | | | .4018 |
| 50mg Tab | 520683 Tenormin | ICI | |
| | | | |
| Atenolol | 486833 Tenormin | ICI | .6554 |
| 100mg Tab | 480833 lendrmin | 101 | |
| Captopril | | | 1.3830 |
| 100mg Tab | 546305 Capoten | SQU | |
| The state of the s | 2012 | | |
| Captopril | | | .7435 |
| 50mg Tab | 546291 Capoten | squ | |
| Captopril | | | .3995 |
| 25mg Tab | 546283 Capoten | SQU | |
| | | | |
| Chlorthalidone | | | .0187 |
| 50mg Tab | 010413 Hygroton | GEI | |
| | 298964 Uridon | ICN | |
| | 337447 Novothalidone 360279 Apo-Chlorthalido | NOP APX | |
| | 398365 Chlorthalidone | DTC | |
| | 00000 0.10. 1.0.110.10 | | |
| Chlorthalidone | | | .0305 |
| 100mg Tab | 010421 Hygroton | GEI | |
| | 293881 Uridon | ICN | |
| | 337455 Novothalidone | NOP APX | |
| | 360287 Apo-Chlorthalido 398373 Chlorthalidone | DTC | |
| | 555575 CHIUFTHEIIGONE | DIC | |
| Clonidine HCl | | | .3430 |
| 0.2mg Tab | 291889 Catapres | BOE | |
| | • | | |
| Clonidine HCl | | | .1920 |
| 0.1mg Tab | 259527 Catapres | BOE | |

| 24:08:00 Hypotensive Drugs (For Di | #/ titts 5tt 10120 | <u>~</u> | | |
|------------------------------------|--------------------|------------------|-----|---------|
| Debrisoquine Sulfate | | | | .1070 |
| 10mg Tab | 255432 | Declinax | HLR | |
| Diazoxide | | | | 35.1300 |
| 300mg/20mL Inj Sol-20mL Pk | 269271 | Hyperstat | SCH | |
| Ethacrynic Acid | | | | .2274 |
| 50mg Tab | 016497 | Edecrin | MSD | |
| Furosemide | | | | .8800 |
| 20mg/2mL Inj Sol-2mL Pk | 217743 | | HOE | |
| | #467766 | Uritol | HOR | |
| Furosemide | | | | .1508 |
| 10mg/mL O/L | 432342 | Lasix | HOE | |
| Furosemide | | | | .0067 |
| 40mg Tab | 012580 | Lasix | HOE | |
| - | 332275 | Furoside | ICN | |
| | | Novosemide | NOP | |
| | 344079 | | HOR | |
| | | Apo-Furosemide | APX | |
| | 396249 | Furosemide | DTC | |
| Furosemide | | | | .0048 |
| 20mg Tab | 289590 | Lasix | HOE | |
| | | Novosemide | NOP | |
| | | Furoside | ICN | |
| | | Apo-Furosemide | APX | |
| | 489131 | Furosemide | DTC | |
| Guanethidine Monosulfate | | | | .0759 |
| 25mg Tab | | Ismelin | CIB | |
| | 396753 | Apo-Guanethidine | APX | |
| Guanethidine Monosulfate | | | | .0397 |
| 10mg Tab | | Ismelin | CIB | |
| | 396745 | Apo-Guanethidine | APX | |
| Hydralazine HCl | | | | 3.0520 |
| 20mg/mL Inj Sol-1mL Pk | 005274 | Apresoline | CIB | |
| Hydralazine HCl | | | | .2720 |
| 50mg Tab | 005541 | Apresoline | CIB | |
| | | p. sacottina | | |
| Hydralazine HCl | | | | .1740 |
| 25mg Tab | 005533 | Apresoline | CIB | |
| Hydralazine HCl | | | | .1010 |
| 10mg Tab | 005525 | Apresoline | CIB | |
| Hadaaah lanathiani la | | | | .0040 |
| Hydrochlorothiazide 50mg Tab | #005576 | Esidrix | CIB | .0040 |
| | #UU00110 | 20.41.1/2 | 010 | |

| 24:08:00 Hypotensive Drugs (For Diureti | | 4.4 | | |
|---|---------|-------------------------|-----|--------|
| Hydrochlorothiazide | | | | .0040 |
| 50ng Tah | | HydroDIURIL | MSD | |
| | 021482 | Novohydrazide | NOP | |
| | | Hydrochlorothiazide | DTC | |
| | 209821 | Hydrochlorothiazide | SAP | |
| He Doe | 263907 | Urozide | ICN | |
| | 312800 | Apo-Hydrochlorothiazide | APX | |
| lydrochlorothiazide | | | | .0033 |
| 25mg Tab | #005568 | Esidrix | CIB | |
| | 016500 | HydroDIURIL | MSD | |
| | 021474 | Novohydrazide | NOP | |
| | | Hydrochlorothiazide | DTC | |
| | 263893 | Urozide | ICN | |
| | 326844 | Apo-Hydrochlorothiazide | APX | |
| lydrochlorothiazide & Spironolactone | | | | .2502 |
| 50mg & 50mg Tab | 594377 | Aldactazide-50 | SEA | |
| Hydrochlorothiazide & Spironolactone | | | | .0919 |
| 25mg & 25mg Tab | 180408 | Aldactazide | SEA | |
| | | Novo-Spirozine | NOP | |
| | | optioning | | |
| lydrochlorothiazide & Triamterene | | | | .0317 |
| 25mg & 50mg Tab | 181528 | Dyazide | SKF | |
| | | Apo-Triazide | APX | |
| | | Novotriamzide | NOP | |
| Indapamide | | | | .3280 |
| 2.5mg Tab | 564966 | Lozide | SEV | . 5250 |
| abetalol HCl | | | | .2970 |
| 200mg Tab | 602642 | Trandate | AHA | .2370 |
| 200mg 120 | 003043 | Irandate | ADA | |
| abetalol HCl | | | | .1680 |
| 100mg Tab | 603651 | Trandate | AHA | |
| lethyldopa | | • | | .0946 |
| 500mg Tab | | Aldomet | MSD | |
| | | Novomedopa | NOP | |
| | 353639 | Dopamet | ICN | |
| | 426830 | Apo-Methyldopa | APX | |
| | 456020 | Methyldopa | DTC | |
| fethyldopa | | | | .0473 |
| 250mg Tab | 016578 | Aldomet | MSD | |
| | 250392 | Dopamet | ICN | |
| | | Novomedopa | NOP | |
| | | Apo-Methyldopa | APX | |
| | | Methyldopa | DTC | |
| dethyldopa | | | | .0280 |
| 125mg Tab | 016551 | Aldomet | MSD | |
| | | | | |

| 24:08:00 Hypotensive Drugs (For Diure | tics See 40:281 | | |
|---------------------------------------|-------------------------|------|-------|
| Methyldopa | | | .0280 |
| 125mg Tab | 337463 Novomedopa | NOP | .0200 |
| 120% | 353620 Dopamet | ICN | |
| | 360252 Apo-Methyldopa | APX | |
| | 456012 Methyldopa | DTC | |
| Methyldopa & Hydrochlorothiazide | | | .0619 |
| 250mg & 25mg Tab | 140597 Aldoril-25 | MSD | |
| | 363634 Novodoparil-25 | NOP | |
| | #403490 Dopazide-25 | ICN | |
| | 441716 Apo-Methazide-25 | APX | |
| | 584975 PMS-Dopazide-25 | PMS | |
| Methyldopa & Hydrochlorothiazide | | | .0599 |
| 250mg & 15mg Tab | 140589 Aldoril-15 | MSD | |
| | 363642 Novodoparil-15 | NOP | |
| | #403482 Dopazide-15 | ICN | |
| | 441708 Apo-Methazide-15 | APX | |
| | 584967 PMS-Dopazide-15 | PMS | |
| Metolazone | | | .1765 |
| 10mg Tab | 301671 Zaroxolyn | PWC | |
| Metolazone | | | .1341 |
| 5mg Tab | 301698 Zaroxolyn | PWC | |
| Metolazone | | | .1024 |
| 2.5mg Tab | 301663 Zaroxolyn | PWC | |
| | | | |
| Metoprolol Tartrate | | | |
| 200mg LA Tab | 497827 Betaloc Durules | AST | .5186 |
| Metoprolol Tartrate | | - 33 | |
| 200mg LA Tab | 534560 Lopresor SR | GEI | .4270 |
| Metoprolol Tartrate | | | |
| 100mg LA Tab | +658855 Lopresor SR | GEI | .2500 |
| Metoprolol Tartrate | | | .0970 |
| 50mg Tab | 397423 Lopresor | GEI | |
| | 402605 Betaloc | AST | |
| | 618632 Apo-Metoprolol | APX | |
| | +648035 Novometoprol | NOP | |
| Metoprolol Tartrate | | | .1780 |
| 100mg Tab | 397431 Lopresor | GEI | |
| | 402540 Betaloc | AST | |
| | 618640 Apo-Metoprolol | APX | |
| | +648043 Novometoprol | NOP | |
| Minoxidil | | | .4630 |
| 10mg Tab | 514500 Loniten | UPJ | |

| Minoxidil 2.5mg Tab | 514497 Loniten | .2100 UPJ |
|---|------------------------|--------------|
| Nadolol 80mg Tab | 463256 Corgard | .5100 SQU |
| Nadolol 40mg Tab | 607126 Corgard | .3415 SQU |
| Nadolol 160mg Tab | 523372 Corgard | .9110 squ |
| Oxprenolol HCl 80mg LA Tab | 534579 Slow-Trasicor | CIB ,2970 |
| Oxprenolol HCl 160mg LA Tab | 534587 Slow-Trasicor | CIB .5980 |
| Oxprenolol HCl 80mg Tab | 402583 Trasicor | .2910 CIB |
| Oxprenolol HCl 40mg Tab | 402575 Trasicor | .1940 CIB |
| Oxprenolol HCl 20mg Tab | 402567 Trasicor | .1090 |
| Pindolol 5mg Tab | 417270 Visken | .3070 SAN |
| Pindolol 15mg Tab | 417289 Visken | .7580 SAN |
| Pindolol 10mg Tab | 443174 Visken | .5230 SAN |
| Pindolol & Hydrochlorothiazide 10mg & 50mg Tab | 568635 Viskazide 10/50 | .5200 SAN |
| Pindolol & Hydrochlorothiazide 10mg & 25mg Tab | 568627 Viskazide 10/25 | .5200 SAN |
| Prazosin HCl 5mg Tab | 560979 Minipress | .3280 PFI |
| Prazosin HCl 2ng Tab | 560960 Minipress | .2387 PFI |
| Prazosin HCl lng Tab | 560952 Minipress | .1757 PFI |
| Propranolol 160mg LA Cap | 511668 Inderal L.A. | AYE .7896 |

| Propranolol | | | | |
|---|---------|----------------------------|-----|--------|
| 120mg LA Cap | 587931 | Inderal L.A. | AYE | .6270 |
| | | | | |
| Propranolol | | | | |
| 80mg LA Cap | 566950 | Inderal L.A. | AYE | .4408 |
| Propranolol | | | | .0560 |
| 80mg Tab | 313602 | Inderal | AYE | |
| | 402761 | Apo-Propranolol | APX | |
| | | Novopranol | NOP | |
| | | Propranolol | DTC | |
| | 582271 | PMS-Propranolol | PMS | |
| Propranolol | | | | .0332 |
| 40mg Tab | 002666 | Inderal | AYE | |
| | | Apo-Propranolol | APX | |
| | | Novopranol | NOP | |
| | 523399 | Propranolol | DTC | |
| | 582263 | PMS-Propranolol | PMS | |
| Propranolol | | | | .0275 |
| 20mg Tab | 489859 | Inderal-20 | AYE | .0275 |
| 2018 | | Apo-Propranolol | APX | |
| | | | | |
| ropranolol | 450570 | | AYE | .1120 |
| 120mg Tab | | Inderal Apo-Propranolol | APX | |
| | | Novopranol | NOP | |
| | | PMS-Propranolol | PMS | |
| | | | | |
| Propranolol | | to the second | | .0184 |
| 10mg Tab | | Inderal | AYE | |
| | | Apo-Propranolol | APX | |
| | | Novopranol | NOP | |
| | | Propranolol | DTC | |
| | 582255 | PMS-Propranolol | PMS | |
| ropranolol & Hydrochlorothiazide | | | | .5123 |
| 80mg & 25mg Tab | 465321 | Inderide 80 | AYE | |
| June 1 & Hudwerhlauethiagide | | | | .3308 |
| Propranolol & Hydrochlorothiazide 40mg & 25mg Tab | 465212 | Inderide 40 | AYE | . 3300 |
| 40mg & 25mg 1sb | 400010 | Inder ide 40 | ALL | |
| auwolfia Serpentina | | | | .1830 |
| 50mg Tab | 029440 | Raudixin | SQU | |
| laumalfia Camantina | | | | .2980 |
| Rauwolfia Serpentina 100mg Tab | 020450 | Raudixin | SQU | . 2500 |
| TOOMS 190 | 023439 | Naudixin | 240 | |
| Reserpine | | , | | 3.2710 |
| 5mg/2mL Inj Sol-2mL Pk | #436917 | Serpasil | CIB | |
| | | | | |
| | | | | |

| 021784 093238 005657 093211 336459 +483923 028606 613215 285455 544477 | Serpasil Novoreserpine Reserpine Serpasil Reserpine Nipride Sotacor Aldactone Novo-Spiroton Aldactone Sincomen Novo-Spiroton | CIB NOP DTC CIB DTC HLR BRI SEA NOP | .0081 .0197 10.6750 .7350 .0729 |
|---|---|---|---|
| 021784 093238 005657 093211 336459 +483923 028606 613215 285455 544477 | Novoreserpine Reserpine Serpasil Reserpine Nipride Sotacor Aldactone Novo-Spiroton Aldactone Sincomen | NOP DTC CIB DTC HLR BRI SEA NOP | .7350 .0729 |
| 093238 005657 093211 336459 +483923 028606 613215 285455 544477 | Reserpine Serpasil Reserpine Nipride Sotacor Aldactone Novo-Spiroton Aldactone Sincomen | DTC CIB DTC HLR BRI SEA NOP | .7350 .0729 |
| 005657 093211 336459 +483923 028606 613215 285455 544477 | Serpasil Reserpine Nipride Sotacor Aldactone Novo-Spiroton Aldactone Sincomen | CIB DTC HLR BRI SEA NOP | .7350 .0729 |
| 093211 336459 +483923 028606 613215 285455 544477 | Reserpine Nipride Sotacor Aldactone Novo-Spiroton Aldactone Sincomen | DTC HLR BRI SEA NOP SEA BER | .7350 .0729 |
| 093211 336459 +483923 028606 613215 285455 544477 | Reserpine Nipride Sotacor Aldactone Novo-Spiroton Aldactone Sincomen | DTC HLR BRI SEA NOP SEA BER | .7350 |
| 336459 +483923 028606 613215 285455 544477 | Nipride Sotacor Aldactone Novo-Spiroton Aldactone Sincomen | HLR BRI SEA NOP SEA BER | .7350 |
| +483923 028606 613215 285455 544477 | Sotacor Aldactone Novo-Spiroton Aldactone Sincomen | HLR BRI SEA NOP SEA BER | .7350 |
| +483923 028606 613215 285455 544477 | Sotacor Aldactone Novo-Spiroton Aldactone Sincomen | HLR BRI SEA NOP SEA BER | .7350 |
| 028606 613215 285455 544477 | Aldactone Novo-Spiroton Aldactone Sincomen | SEA NOP SEA BER | .0729 |
| 028606 613215 285455 544477 | Aldactone Novo-Spiroton Aldactone Sincomen | SEA NOP SEA BER | .0729 |
| 028606 613215 285455 544477 | Aldactone Novo-Spiroton Aldactone Sincomen | SEA NOP SEA BER | |
| 613215 285455 544477 | Novo-Spiroton Aldactone Sincomen | NOP SEA BER | |
| 613215 285455 544477 | Novo-Spiroton Aldactone Sincomen | NOP SEA BER | .2250 |
| 285455 544477 | Aldactone Sincomen | SEA BER | .2250 |
| 544477 | Sincomen | BER | .2250 |
| 544477 | Sincomen | BER | |
| | | | |
| 613223 | Novo-Spiroton | NOP | |
| | | | |
| | | | .1789 |
| 353914 | Blocadren | FRS | .1703 |
| | | | |
| | | 71.00 | .5763 |
| 495611 | Blocadren | FRS | |
| | | | .2941 |
| 353922 | Blocadren | FRS | |
| | | | .3240 |
| 509353 | Timolide | FRS | .3240 |
| | | | |
| 000745 | | 0.000 | .1117 |
| 299715 | Dyrenium | SKF | |
| | | | .1372 |
| 027138 | Dyrenium | SKF | |
| | | | |
| | | | |
| | | | |
| | | | .1290 |
| 299790 | Cardilate-10 | BWE | .1250 |
| | | | |
| | | | .0470 |
| | | | |
| 446661 | Coronex | AYE | |
| | | | .0403 |
| 279536 | Isordil | WYE | |
| | 495611 353922 509353 299715 027138 299790 243116 446661 | 495611 Blocadren 353922 Blocadren 509353 Timolide 299715 Dyrenium 027138 Dyrenium 299790 Cardilate-10 243116 Isordil 446661 Coronex | 495611 Blocadren FRS 353922 Blocadren FRS 509353 Timolide FRS 299715 Dyrenium SKF 027138 Dyrenium SKF 299790 Cardilate-10 BWE 243116 Isordil WTE 446661 Coronex AYE |

| 24:12:00 Vasodilating Drugs | | | | |
|------------------------------|---------|---------------------|------------|---------|
| Isosorbide Dinitrate | | | | .0403 |
| 30mg Tab | 441694 | Apo-ISDN | APX | |
| | 446696 | Coronex | AYE | |
| | 458694 | Novosorbide | NOP | |
| | | | | 0100 |
| Isosorbide Dinitrate | 000073 | T127 | WVF | .0188 |
| 10mg Tab | | Isordil | WYE | |
| | | Apo-ISDN Coronex | AYE | |
| | | Novosorbide | NOP | |
| | 400000 | NOVOSOI DI GE | NOI | |
| Nitroglycerin | | | | |
| 5mg LA Tab | 590746 | Nitrogard-SR | SYN | .2423 |
| OME 211 140 | | | | |
| Nitroglycerin | | | | |
| 3mg LA Tab | 590738 | Nitrogard-SR | SYN | .1886 |
| | | | | |
| Nitroglycerin | | | | |
| 2mg LA Tab | 590681 | Nitrogard-SR | SYN | .1616 |
| | | | | |
| Nitroglycerin | | | | |
| ing LA Tab | 590673 | Nitrogard-SR | SYN | .1346 |
| | | | | |
| Nitroglycerin | E05500 | N2 Assessed | RPP | 3.1200 |
| 2% Oint-30g Pk | 525529 | Nitrong | KFF | 3.1200 |
| Nitroglycerin | | | | |
| 2% Oint-30g Pk | 608785 | Nitrol | ROR | 4.8990 |
| 2% Offit-Sog 1k | 000100 | | NO. | 4.0000 |
| Nitroglycerin | | | | |
| 2% Oint-60g Pk | 442925 | Nitro-Bid | ROU | 5.7000 |
| | | | | |
| Nitroglycerin | | | | |
| 2% Oint-60g Pk | 990973 | Nitrong | RPP | 9.9300 |
| | | | | |
| Nitroglycerin | | | | |
| 2% Oint-60g PK | 990914 | Nitrol | ROR | 8.8500 |
| | | | | |
| * Nitroglycerin | "000000 | N | 4 27 4 | 2.3400 |
| 0.6mg SL Tab-100 Pk | | Nitrostabilin | AHA LIL | |
| | | Nitroglycerin | PDA | |
| | 990620 | Nitrostat | FUA | |
| Nitroglycerin | | | | 2.3400 |
| 0.3mg SL Tab-100 Pk | 015954 | Nitroglycerin | LIL | 3.0.400 |
| 0.0mg 02 100 100 10 | | Nitrostat | PDA | |
| | | | | |
| Pentaerythritol Tetranitrate | | | | .1908 |
| 80mg Tab | 476579 | Peritrate Forte | PDA | |
| | | | , | |
| Pentaerythritol Tetranitrate | | | | .1017 |
| 20mg Tab | 476609 | Peritrate | PDA | |

| 24:12:00 | Vasodilat | ing Drugs |
|----------|-----------|-----------|

Pentaerythritol Tetranitrate 10mg Tab

476595 Peritrate

.0740 PDA

| | | | .2218 |
|--|--|------------|--------|
| ecetaminophen 90mg/mL O/L | #221627 Tempra | MJO | .5519 |
| | and the second second | | |
| cetaminophen | | | . 1523 |
| 80mg/mL O/L | +631353 Atasol | HOR | |
| | +642401 Tempra | MJO | |
| cetaminophen | | | 0070 |
| 24mg/mL O/L | #330884 Robigesic | ROB | .0270 |
| | nooco noolgeste | KOD | |
| cetaminophen | | | .0269 |
| 16mg/mL 0/L | +658049 Robigesic | ROB | |
| AND PARTY OF THE P | | | |
| cetaminophen | FF0000 | | .6608 |
| 650mg Sup | 553336 Acetaminophen | BEE | |
| cetaminophen | | | . 4555 |
| 120mg Sup | 553328 Acetaminophen | BEE | . 4333 |
| | | DLL | |
| Acetaminophen | | | .0143 |
| 500mg Tab | 013668 Atasol Forte | HOR | |
| | #292486 Campain | WIN | |
| | 446114 Exdol Strong | FRS | |
| | 482323 Novogesic Forte 545007 Apo-Acetaminophen | NOP | |
| | 566802 Acetaminophen Extra | APX | |
| | 567663 Acetaminophen | WAM | |
| | 589233 Acetaminophen Extra | | |
| A STATE OF THE STA | | | |
| Acetaminophen | | 2 | .0107 |
| 325mg Tab | #229229 Campain | WIN | |
| | 277193 Rounox 293482 Atasol | ROG HOR | |
| | 330876 Robigesic | ROB | |
| | 373710 Exdol | FRS | |
| | 374148 Acetaminophen | WAM | |
| | 389218 Novogesic | NOP | |
| | 467065 Acetaminophen | CLK | |
| | 544981 Apo-Acetaminophen | APX | |
| | 589241 Acetaminophen | DPC | |
| | | | |
| cetaminophen with Codeine | | | .1870 |
| cetaminophen with Codeine | | MCN | |
| 60mg Tab | 396516 Tylenol No. 4 | MCN | |
| 60mg Tab | 396516 Tylenol No. 4 666149 Empracet-60 | BWE | |
| cetaminophen with Codeine | | | .0380 |

| | 202512 3: 3 22 | .03 |
|-------------------------------------|--|--------------|
| Acetaminophen Compound with Codeine | 293512 Ataso1-30 | HOR |
| 30mg Tab | 372358 Exdol-30 | FRS |
| | 425389 Tylenol No.3 653276 Lenoltec No. | MCN 3 TCH |
| cetaminophen Compound with Codeine | 033270 Lenoitee No. | .02 |
| 15mg Tab | 293504 Atasol-15 | HOR |
| TOME 180 | 372331 Exdol-15 | FRS |
| | 425370 Tylenol No.2 | MCN |
| | Total | |
| | | |
| cetylsalicylic Acid | 410509 F-41 | .069 |
| 975mg Ent Tab | 419508 Entrophen | FRS |
| Acetylsalicylic Acid | | .018 |
| 650mg Ent Tab | 010340 Entrophen | FRS |
| | 229296 Novasen | NOP |
| | 343889 Ecotrin-10 | SKF |
| Acetylsalicylic Acid | 010000 7 | .011 |
| 325mg Ent Tab | 010332 Entrophen 027189 Ecotrin | FRS SKF |
| | 216666 Novasen | NOP |
| | 210000 Novasen | HOE |
| cetylsalicylic Acid | | .63 |
| 650mg Sup | 451746 Sal-Adult | BEE |
| | | 0.00 |
| cetylsalicylic Acid | 215122 5 | . 660 NRD |
| 640mg Sup | 315133 Supasa | NKU |
| cetylsalicylic Acid | | .568 |
| 320mg Sup | 315117 Supasa | NRD |
| | | |
| cetylsalicylic Acid | | . 498 |
| 160mg Sup | 377961 Supasa | NRD |
| cetylsalicylic Acid | | .500 |
| 150mg Sup | 451738 Sal-Infant | BEE |
| | | |
| Acetylsalicylic Acid (OTC) | | 1.50 |
| 325mg Tab 100 Pk | +040851 ASA | LEA |
| | 453897 ASA | CLK |
| Acetylsalicylic Acid (OTC) | | 3.45 |
| 325mg Tab 300 Pk | 092754 ASA | DTC |
| Acetylsalicylic Acid (OTC) | The state of the s | 4.60 |
| 325mg Tab 500 Pk | 036145 ASA | WAM |
| | | |
| cetylsalicylic Acid & Codeine | | .25 |
| 650mg & 30mg Tab | 406104 Coryphen 650-30 | ROG |

| 28:08:00 Analgesics | | |
|------------------------------------|--------------------------|--------------|
| Acetylsalicylic Acid & Codeine | | .1860 |
| 325mg & 30mg Tab | 406112 Coryphen 325-30 | ROG |
| Acetylsalicylic Acid Compound with | | .0469 |
| 30mg Tab | 095516 AC & C | DTC |
| | 219843 292 | FRS |
| | 604518 Ancasal 30 | SAN |
| Acetylsalicylic Acid Compound with | Codeine | .0327 |
| 15mg Tab | 095508 AC & C | DTC |
| | 108103 282 | FRS |
| | 604496 Ancasal 15 | SAN |
| Anileridine HCl | | .2671 |
| 25mg Tab | 010014 Leritine | FRS |
| Anileridine Phosphate | | 1.4424 |
| 25mg/mL Inj Sol 1mL Pk | 009857 Leritine | FRS |
| | | |
| Choline Salicylate & Magnesium Sal | | .1475 |
| Tab | 449636 Trilisate | PFR |
| Codeine Phosphate | | .5160 |
| 30mg/mL Inj Sol-1mL Pk | 303879 Codeine | AHA |
| Calaina Phanaha | | 0100 |
| Codeine Phosphate 5mg/mL O/L | 018678 Codeine | .0160 NDA |
| Jug/ mt O/ t | 093114 Codeine | DTC |
| | 000114 Codeline | Die |
| Codeine Phosphate | | .1552 |
| 60mg Tab | 003247 Codeine | AHA |
| | 093149 Codeine | DTC |
| Codeine Phosphate | | .0630 |
| 30mg Tab | 003239 Codeine | AHA |
| | 018694 Codeine | NDA |
| | 093130 Codeine | DTC |
| | +593451 Codeine Phosphat | te TCH |
| Codeine Phosphate | | .0430 |
| 15mg Tab | 003220 Codeine | AHA |
| | 018686 Codeine | NDA |
| | 093122 Codeine | DTC |
| | +593435 Codeine Phosphat | te TCH |
| Colchicine | | .1770 |
| ing Tab | . 206032 Colchicine | ROG |
| 0.11. | | |
| Colchicine | | .0493 |
| 0.6mg Tab | 000396 Colchicine | ABB |
| | 094382 Colchicine | DTC |

| 28:08:00 Analgesics | | |
|--|---------------------|--------------|
| Colchicine | | .0493 |
| O.6mg Tab | 287873 Colchicine | ROG |
| | | (700 |
| Diclofenac Sodium | 514012 Voltaren | .4500 GEI |
| 50mg Ent Tab | 014012 VOITALEN | OL1 |
| Diclofenac Sodium | | .2250 |
| 25mg Ent Tab | 514004 Voltaren | GEI |
| D: 1 6 C. 1/- | | |
| Diclofenac Sodium 100mg LA Tab | +590827 Voltaren SR | GEI .9000 |
| TOOMS LA 125 | TOUGHT TOTAL ON | |
| Diclofenac Sodium | | .7500 |
| 50mg Sup | +632724 Voltaren | GEI |
| Diclofenac Sodium | | 1.0100 |
| 100mg Sup | +632732 Voltaren | GEI 1.0100 |
| 20018 019 | | |
| Diflunisal | | .5248 |
| 500mg Tab | 576131 Dolobid | FRS |
| Diflunisal | | .4288 |
| 250mg Tab | 587699 Dolobid | FRS |
| | | |
| Fenoprofen Calcium | | .2088 |
| 300mg Cap | 328642 Nalfon | LIL |
| Fenoprofen Calcium | | .3828 |
| 600mg Tab | 345504 Nalfon | LIL |
| • | | |
| Flurbiprofen | .500046 Funkan | ORG .2905 |
| 50mg Tab | +593346 Froben | ORG .2905 |
| Flurbiprofen | | , |
| 50mg Tab | +647942 Ansaid | UPJ .3515 |
| | | |
| Flurbiprofen | +593354 Froben | ORG .3875 |
| 100mg Tab | +033304 Flobell | 0.0 .50/5 |
| Flurbiprofen | | |
| 100mg Tab | +600792 Ansaid | UPJ .4750 |
| W 1 2 2001 | | .9300 |
| Hydromorphone HCl 2mg/mL Inj Sol-1mL Pk | +627100 Dilaudid | KNL .9300 |
| Zmg/mb Inj Sol Imb Ix | 021200 21200210 | |
| Hydromorphone HC1 | | 2.4000 |
| 10mg/mL Inj Sol-1mL Pk | +622133 Dilaudid-HP | KNL |
| Hydromorphone HC1 | | 2.0250 |
| Hydromorphone HCl 3mg Sup | +125105 Dilaudid | KNL |
| | | |
| Hydromorphone HC1 | | .2475 |
| 4mg Tab | +125121 Dilaudid | KNL |

| T I WALL TO HELD | | | 1010 |
|----------------------------|-------------------------|-----|--------|
| Hydromorphone HCl 2mg Tab | +125083 Dilaudid | KNL | .1615 |
| Ibuprofen | | | .1825 |
| 400mg Cap | 443204 Amersol | HOR | |
| Ibuprofen | | | .1380 |
| 300mg Cap | 443190 Amersol | HOR | |
| Ibuprofen | | | .1131 |
| 200mg Cap | 443182 Amersol | HOR | |
| Ibuprofen | | | .0737 |
| 600mg Tab | 484911 Motrin | UPJ | |
| | 606227 Ibuprofen | KNR | |
| | +629359 Novoprofem | NOP | |
| Ibuprofen | | | .0528 |
| 400mg Tab | 364142 Motrin | UPJ | |
| | 606219 Ibuprofen | KNR | |
| Ibuprofen | | | .0407 |
| 300mg Tab | 327794 Motrin | UPJ | .0407 |
| | 606200 Ibuprofen | KNR | |
| Ibuprofen | | | 0007 |
| 200mg Tab | 252409 Motrin | UPJ | .0287 |
| Loong Ind | 606197 Ibuprofen | KNR | |
| | | | |
| Indomethacin | | | .1410 |
| 50mg Cap | 016047 Indocid | MSD | |
| | 337439 Novomethacin | NOP | |
| | 611166 Apo-Indomethacin | APX | |
| Indomethacin | | | .0814 |
| 25mg Cap | 016039 Indocid | MSD | |
| | 337420 Novomethacin | NOP | |
| | 611158 Apo-Indomethacin | APX | |
| Indomethacin | | | |
| 75mg LA Cap | 463248 Indocid SR | MSD | .8094 |
| To James Albert | | | |
| Indomethacin 50mg Sup | 594466 Indocid | MSD | .7997 |
| Jung Sup | 334400 Indoc1a | MSD | |
| Indomethacin | | | 1.0747 |
| 100mg Sup | 016233 Indocid | MSD | |
| Ketoprofen | | | .2467 |
| 50mg Cap | 336440 Orudis | RPP | |
| Vatarrafar | | | 0.77 |
| Ketoprofen 50mg Ent Tab | 566888 Orudis E | RPP | .2467 |
| - Line Lan | JUDGOO OFUEIS E | KFF | |

| 28:08:00 Analgesics | | | | |
|---|-------------------|----------------------|------------|---------|
| Ketoprofen 100mg Sup | 499544 | Orudis | RPP | 1.1003 |
| Levorphanol Tartrate 2mg/mL Inj Sol-1mL Pk | 012904 | Levo-Dromoran | HLR | 1.1100 |
| Levorphanol Tartrate 2mg Tab | 013366 | Levo-Dromoran | HLR | .1670 |
| Mefenamic Acid 250mg Cap | 155225 | Ponstan | PDA | .3395 |
| Meperidine HCl 75mg/mL Inj Sol-1mL Pk | 033294 | Demerol | WIN | .2340 |
| Meperidine HCl 50mg/mL Inj Sol-1mL Pk | 036242 | Demerol | WIN | .2160 |
| Meperidine HCl 100mg/mL Inj Sol-1mL Pk | 033308 | Demerol | WIN | .2480 |
| Meperidine HCl 100mg/2mL Inj Sol-2mL Pk | 990477 | Demerol | MIN | .2780 |
| Meperidine HCl 1500mg/30mL Inj Sol-30mL Pk | 990493 | Demerol | WIN | 4.5990 |
| Meperidine HCl 50mg Tab | 003506 | Pethidine | АНА | .0742 |
| | 033685 | Demerol | WIN | |
| Morphine HC1 | | | v 400 | .0763 |
| 5mg/mL O/L | 514217 +607770 | MOS-5 Morphitec-5 | ICN TCH | |
| Morphine HC1 | | | | .4760 |
| 20mg/mL O/L | +632481 | M.O.S. | ICN | |
| Morphine HCl | | | | .1872 |
| 10mg/mL O/L | +632503 | M.O.S. | ICN | |
| Morphine HCl | | , | | .0137 |
| 1mg/mL O/L | 486582 +607762 | MOS Morphitec-1 | ICN TCH | |
| Morphine HCl | | | | .1.6467 |
| 30mg Sup | - +636681 | M.U.S. | ICN | |
| Morphine HC1 | | | | 1.4733 |
| 20mg Sup | +624276 | M.O.S. | , ICN | 1-1-0 |
| Morphine HCl | +624268 | M O S | ICN | 1.2567 |
| 10mg Sup | ₹0 242 08 | 11.0.5. | ICA | |

| 28:08:00 Analgesics | | |
|---------------------------------------|---------------------|--------------|
| Morphine Sulfate | | .4730 |
| 15mg/mL Inj Sol-1mL Pk | 335371 Morphine | АНА |
| orphine Sulfate | +665150 MS Contin | DED. |
| 60mg LA Tab | +665150 MS CORTIN | PFR 1.4400 |
| forphine Sulfate | +665142 MS Contin | PFR 8200 |
| 30mg LA Tab | .000132 %5 002012 | PFR .8200 |
| orphine Sulfate 15mg LA Tab | +665134 MS Contin | PFR .5400 |
| | | ••• |
| forphine Sulfate 100mg LA Tab | +665169 MS Contin | PFR 2.2000 |
| | | .0560 |
| forphine Sulfate 5mg/mL O/L | 591475 Statex | PMS |
| | | .0205 |
| orphine Sulfate Ing/mL O/L | 591467 Statex | PMS |
| | | .3200 |
| orphine Sulfate 20mg/mL Oral Drops | +621935 Statex | PMS . 3200 |
| | | 0577 |
| iaproxem 500mg Sup | 531022 Naprosyn | .9537 SYN |
| | | .2580 |
| aproxen 500mg Tab | 525537 Naprosyn | SYN |
| | 589861 Novonaprox | NOP |
| | 592277 Apo-Naproxen | APX |
| | 615331 Naxen | SYP |
| aproxen | | .1780 |
| 375mg Tab | 583367 Naprosym | SYN |
| | 600806 Apo-Naproxen | APX |
| | 615323 Naxen | SYP |
| | 627097 Novo-Naprox | NOP |
| aproxen | | .1300 |
| 250mg Tab | 335193 Naprosyn | SYN |
| | 522651 Apo-Naproxen | APX |
| | 565350 Novonaprox | NOP |
| | 615315 Naxen | SYP |
| aproxen | | .0640 |
| 125mg Tab | 299413 Naprosyn | SYN |
| | 522678 Apo-Naproxes | APX |
| | 565369 Novonaprox | NOP |
| | 615307 Naxen | SYP |

| 28:08:00 Analgesics | | | | .1400 |
|--|--------|--------------------------------|------------|--------|
| Oxycodone HCl & Acetaminophen 5mg & 325mg Tab | | l Percocet Oxycocet | DUP TCH | .1400 |
| Oxycodone HCl & Acetylsalicylic Acid | Eonnac | Percodan | DUP | .1700 |
| 5mg & 325mg Tab | | Oxycodan | TCH | |
| Oxymorphone HC1 | E05300 | N | 200 | 2.1250 |
| 1.5mg/mL Inj Sol-1mL Pk | 585688 | Numorphan | DUP | |
| Oxymorphone HCl 5mg Sup | 585661 | Numorphan | DUP | 2.4417 |
| Pentazocine | | | | 4.5000 |
| 300mg/10mL Inj Sol-10mL Pk | 036277 | Talwin | WIN | 4.3000 |
| Pentazocine | | | -1002 | .2217 |
| 50mg Tab | 033731 | Talwin | WIN | |
| Phenylbutazone 100mg Ent Tab | 258377 | Intrabutazone | ORG | .1763 |
| Phenylbutazone | | | | |
| 100mg Tab | 001000 | W | Nan | .0077 |
| | | Novobutazone Phenylbutazone | NOP | - |
| | 312789 | Apo-Phenylbutazone | APX | |
| Piroxicam 20mg Cap | 505619 | Feldene | PFI | 1.0033 |
| And the second of | 020018 | retuene | FFI | |
| Piroxicam 10mg Cap | 525596 | Feldene | PFI | .5985 |
| Propoxyphene | | | | .0225 |
| Cap | | Novopropoxyn Darvon-N | NOP | |
| Account the same of the same o | 201432 | Darvon-N | LIL | |
| Propoxyphene 65mg Tab | 010081 | 642 | FRS | .0830 |
| Sulindac | | | | .5468 |
| 200mg Tab | 432369 | Clinoril | FRS | |
| Sulindac | 450000 | 01: 11 | EDG | .4315 |
| 150mg Tab | 456888 | Clinoril | FRS | 100 |
| Tolmetin Sodium 400mg Cap | 484938 | Tolectin DS | MCN | .3885 |
| Tolmetin Sodium | | • | | .2640 |
| 200mg Tab | 364126 | Tolectin | MCN | |

| 12 1 To 4 | | | |
|---|--|-------------|--------|
| evallorphan Tartrate lmg/mL Inj Sol-1mL Pk | #115584 Lorfan | HLR | 1.3373 |
| aloxone HCl | | | 6.7850 |
| 0.4mg/ml Inj Sol-1mL Pk | 589020 Narcan | DUP | |
| 8:12:00 Anticonvulsants | | | |
| arbanazepine | | | .1620 |
| 200mg Chew Tab | +665088 Tegretol Chew Tabs | GEI | |
| arbamazepine | | | .0810 |
| 100mg Chew Tab | +369810 Tegretol Chew Tabs | GEI | |
| arbamazepine | 010405 T | | .0699 |
| 200mg Tab | 010405 Tegretol 402699 Apo-Carbamazepine | GE I APX | |
| | 504742 Mazepine | ICN | |
| | 304742 Mazepine | ICA | |
| lonazepam | | | .2330 |
| 2mg Tab | 382841 Rivotril | HLR | |
| lonazepam | | | .1340 |
| 0.5mg Tab | 382825 Rivotril | HLR | |
| ivalproex Sodium | | | .5747 |
| 500mg Ent Tab | 596434 Epival | ABB | |
| ivalproex Sodium | | | .2873 |
| 250mg Ent Tab | 596426 Epival | ABB | |
| ivalproex Sodium | | | .1599 |
| 125mg Ent Tab | 596418 Epival | ABB | |
| thosuximide | | | .1913 |
| 250mg Cap | 022799 Zarontin | PDA | |
| thosuximide | | | .0383 |
| 50mg/mL 0/L | 023485 Zarontin | PDA | |
| ephenytoin | | | .0920 |
| 100mg Tab | 027421 Mesantoin | SAN | |
| ephobarbital | | | .2025 |
| 200mg Tab | #033715 Mebaral | WIN | |
| ephobarbital | | | .1405 |
| 100mg Tab | 033707 Mebaral | WIN | |
| ethsuximide | | | .2110 |
| 300mg Cap | 022802 Celontin | PDA | |

| 28:12:00 Anticonvulsants | | |
|---|--------------------------|---------------|
| Phenobarbital | 00000 | .5450 |
| 120mg/mL Inj Sol-1mL Pk | 033367 Luminal | WIN |
| Phenobarbital | | .0107 |
| 4mg/mL O/L | 588180 Phenobarbital | DTC |
| | 604585 Phenobarbital | SAN |
| Phenobarbital | | .0110 |
| 60mg Tab | 023817 Phenobarbital | PDA |
| | 093556 Phenobarbital | DTC |
| | 320714 Phenobarbital-ICN | ICN |
| Phenobarbital | | .0050 |
| 30mg Tab | 023809 Phenobarbital | PDA |
| | 093521 Phenobarbital | DTC |
| | 293903 Phenobarbital-ICN | ICN |
| | 604550 Phenobarbital | SAN |
| Phenobarbital | | .0044 |
| 15mg Tab | 023795 Phenobarbital | PDA .0044 |
| Tomg Tab | 093505 Phenobarbital | DTC |
| | 271276 Phenobarbital-ICN | ICN |
| | 604542 Phenobarbital | SAN |
| | | |
| Phenobarbital | | .0137 |
| 100mg Tab | 093564 Phenobarbital | DTC |
| | 344036 Phenobarbital-ICN | ICN |
| | 604577 Phenobarbital | SAN |
| Phensuximide | | .2034 |
| 500mg Cap | 022810 Milontin | PDA |
| | 022010 | |
| Phenytoin (Diphenylhydantoin) | | .0255 |
| 6mg/mL O/L | 023442 Dilantin | PDA |
| Phenytoin (Diphenylhydantoin) | | .0302 |
| 25mg/mL O/L | 023450 Dilantin | PDA |
| | | |
| Phenytoin (Diphenylhydantoin) | | .0464 |
| 50mg Tab | 023698 Dilantin | PDA |
| Discount (Districtly Coding | | .0322 |
| Phenytoin (Diphenylhydantoin) Sodium 30mg Cap | 022772 Dilantin | PDA PDA |
| Song Cap | OZZ77Z DITARLIR | I DA |
| Phenytoin (Diphenylhydantoin) Sodium | | |
| 100mg Cap | 022780 Dilantin | PDA .0365 |
| D) (D) 1 | | 0.0000 |
| Phenytoin (Diphenylhydantoin) Sodium | 245453 Dilantin | 2.2620 PDA |
| 100mg/2ml Inj Sol-2ml Pk | 240403 Dilantin | FUA |
| Phenytoin (Diphenylhydantoin) Sodium | | 4.7180 |
| 250mg/5mL Inj Sol-5mL Pk | 271705 Dilantin | PDA |
| | | |

| 28:12:00 Anticonvul | sants | | | | |
|---------------------|------------------------|-----------|-------------------|-----|-------|
| Primidone | | | | | .0397 |
| 250mg Tab | | | Mysoline | AYE | |
| | | #294985 | | ICN | |
| | | 396761 | Apo-Primidone | APX | |
| Primidone | | | | | .0248 |
| 125mg Tab | | 002623 | Mysoline | AYE | |
| | | 399310 | Apo-Primidone | APX | |
| alproate Sodium | | | | | .0608 |
| 50mg/mL 0/L | | 443832 | Depakene | ABB | |
| alproic Acid | | | | | .2736 |
| 250mg Cap | | 443840 | Depakene | ABB | |
| alproic Acid | | - | | | .5473 |
| 500mg Ent Cap | | 507989 | Depakene | ABB | |
| 8:16:04 Psychother | apeutic Agents Antides | bressants | | | |
| mitriptyline | | | | | .0303 |
| 2mg/mL O/L | | 016306 | Elavil | MSD | |
| mitriptyline | | | | | .0115 |
| 50mg Tab | | 016349 | Elavil | MSD | |
| | | 037427 | Novotriptyn | NOP | |
| | | 271152 | Levate | ICN | |
| | | 335088 | Apo-Amitriptyline | APX | |
| | | 377899 | Amitriptyline | DTC | |
| | | 398462 | Amitriptyline | SAP | |
| mitriptyline | | | | | .0051 |
| 25mg Tab | | 016330 | Elavil | MSD | |
| | | 037419 | Novotriptyn | NOP | |
| | | 251275 | Amitriptyline | SAP | |
| | | 306320 | Levate | ICN | |
| | | 335061 | Apo-Amitriptyline | APX | |
| | | 377880 | Amitriptyline | DTC | |
| mitriptyline | | | | | .0040 |
| 10mg Tab | | 016322 | | MSD | |
| | | | Novotriptyn | NOP | |
| | | | Amitriptyline | SAP | |
| | | | Levate | ICN | |
| | | | Apo-Amitriptyline | APX | |
| | | 377872 | Amitriptyline | DTC | |
| moxapine | | | | | .1375 |
| 50mg Tab | | 527092 | Asendin | LED | |
| moxapine | | | | | .1375 |
| 25mg Tab | | 527084 | Asendin | LED | |

| 28:16:04 Psychotherapeutic Ag | ents Antidepressants | | | |
|-------------------------------|----------------------|-------------------------|---------------|-------|
| Amoxapine 150mg Tab | 527114 | Asendin | LED | .6150 |
| Amoxapine 100mg Tab | 527106 | Asendin | LED | .4350 |
| Clomipramine HCl 50mg Tab | 402591 | Anafranil | GEI | .4860 |
| Clomipramine HCl 25mg Tab | 324019 | Anafranil | GEI | .2640 |
| Clomipramine HCl 10mg Tab | 330566 | Anafranil | GEI | .1940 |
| Desipramine 75mg Tab | 425265 | Norpramin | MER | .7480 |
| Desipramine 50mg Tab | 353876 | Norpramin | MER | .4965 |
| Desipramine 25mg Tab | | Pertofrane Norpramin | GE I MER | .2499 |
| Doxepin HCl 75mg Cap | | Sinequan Triadapin | PFI PWC | .4336 |
| Doxepin HCl 50mg Cap | | Sinequan Triadapin | PFI PWC | .2089 |
| Doxepin HCl 25mg Cap | 024333 | Sinequan | PFI PWC | .1314 |
| Doxepin HCl 150mg Cap | | Triadapin Sinequan | PWC | .9637 |
| Doxepin HCl 100mg Cap | 326925 | Sinequan | PFI | .5705 |
| Doxepin HCl | | Triadapin Sinequan | PWC - PF I | .1070 |
| 10mg Cap | | Triadapin | PWC | .0126 |
| Imipramine 50mg Tab | | Tofranil Novopramine | GEI NOP | .0120 |

| Imipramine | | | .0126 |
|-----------------------|-----------------------|-----|-------|
| 50mg Tab | 209848 Imipramine | SAP | |
| | 236721 Impril | ICN | |
| | 326852 Apo-Imipramine | APX | |
| | 377929 Imipramine | DTC | |
| | | | |
| mipramine | | | .0073 |
| 25mg Tab | 010472 Tofranil | GEI | |
| | 021512 Novopramine | NOP | |
| | 209864 Imipramine | SAP | |
| | 236756 Impril | ICN | |
| | 312797 Apo-Imipramine | APX | |
| | 377910 Imipramine | DTC | |
| | | | 00.40 |
| mipramine 10mg Tab | 010464 Tofranil | CET | .0040 |
| 10mg 120 | | GEI | |
| | 021504 Novopramine | NOP | |
| | 209856 Inipramine | SAP | |
| | 236748 Impril | ICN | |
| | 360201 Apo-Imipramine | APX | |
| | 377902 Imipramine | DTC | |
| * Isocarboxazid | | | .1490 |
| 10mg Tab | 013307 Marplan | HLR | .1450 |
| Tong 180 | 013507 Mat plan | nLn | |
| aprotiline HCl | | | .5340 |
| 75mg Tab | 360511 Ludiomil | CIB | .5540 |
| 5 | JOOGIA Ladiomii | CIB | |
| protiline HCl | | | .3910 |
| 50mg Tab | 360503 Ludiomil | CIB | .0310 |
| | 300003 Lautomii | CIB | |
| protiline HCl | | | .2070 |
| 25mg Tab | 360481 Ludiomil | CIB | .2070 |
| | 000101 20010011 | 015 | |
| aprotiline HCl | | | .1520 |
| 10mg Tab | +641855 Ludiomil | CIB | |
| | | | |
| ortriptyline | | | .2934 |
| 25mg Cap | 015237 Aventyl | LIL | |
| | | | |
| ortriptyline | | | .1451 |
| 10mg Cap | 015229 Aventyl | LIL | |
| | | | |
| * Phenelzine Sulfate | | | .1949 |
| 15mg Tab | 476552 Nardil | PDA | |
| | | | |
| rotriptyline | | | .1783 |
| 5mg Tab | 322261 Triptil | MSD | |
| | | | |
| rotriptyline | | | .2587 |
| 10mg Tab | 322741 Triptil | MSD | |

| 28:16:04 Psychotherapeutic Agents | Antidetressants | | |
|-------------------------------------|--|------------|-------|
| ** Tranylcypromine Sulfate | | | .1886 |
| 10mg Tab | 027111 Parnate | SKF | |
| m 1 11 11 11 | | | 22.47 |
| Trazodone Hydrochloride 50mg Tab | 579351 Desyrel | BRI | .2247 |
| | , | | |
| Trazodone Hydrochloride | 570279 Decree 1 | BRI | .4455 |
| 100mg Tab | 579378 Desyrel | I NA | |
| Trimipramine | | | .5534 |
| 75mg Cap | 442437 Surmontil | RPP | |
| Trimipramine | | | .7043 |
| 100mg Tab | 025852 Surmontil | RPP | |
| To be described. | | | .3873 |
| Trimipramine 50mg Tab | 025844 Surmontil | RPP | .30/3 |
| 33.19 | TV | | |
| Trimipramine | 025836 Surmontil | RPP | .2012 |
| 25mg Tab | U25836 Surmontil | KPP | |
| Trimipramine | | | .1587 |
| 12.5mg Tab | 025828 Surmontil | RPP | |
| 28:16:08 Psychotherapeutic Agents | Tranquilizers | | |
| | 1 | | |
| Alprazolam | 548367 Халах | UPJ | .1540 |
| 0.5mg Tab | J40507 ASIBA | 010 | |
| Alprazolam | the state of the s | | .1286 |
| 0.25mg Tab | 548359 Xanax | UPJ | |
| Bromazepam | | | .1499 |
| 6mg Tab | 518131 Lectopam | HLR | |
| Bromazepam | | | .1028 |
| 3mg Tab | 518123 Lectopam | HLR | |
| | | | |
| Chlordiazepoxide 5mg Cap | 012629 Librium | HLR | .0085 |
| omg cap | 013463 Solium | HOR | |
| | 020915 Novopoxide | NOP | |
| | 398403 Chlordiazepoxide 522724 Apo-Chlordiazepoxide | DTC APX | |
| | 022124 Apo-Chiordiazepoxide | AI A | |
| Chlordiazepoxide | | | .0135 |
| 25mg Cap | 012645 Librium 013498 Solium | HLR HOR | |
| | 020931 Novopoxide | NOP | |
| | 398438 Chlordiazepoxide | DTC | |
| | 522996 Apo-Chlordiazepoxide | APX | |

| Chlordiazepoxide | | | | .0099 |
|----------------------------|--------|----------------------|------|--------|
| 10mg Cap | 012637 | Librium | HLR | |
| | 013471 | Solium | HOR | |
| | 020923 | Novopoxide | NOP | |
| | | Chlordiazepoxide | SAP | |
| | | Chlordiazepoxide | DTC | |
| | | Apo-Chlordiazepoxide | APX | |
| Chlormezanone | | | | .2175 |
| 200mg Tab | 033626 | Trancopal | WIN | |
| Chlorpromazine | | | | 1.1590 |
| 50mg/2mL Inj Sol-2mL Pk | 163953 | Largactil | RPP | 111000 |
| Chlorpromazine | | | | .0159 |
| 5mg/mL O/L | 025151 | Largactil | RPP | .0103 |
| Chlorpromazine | | | | .2247 |
| 40mg/mL O/L | 025186 | Largactil | RPP | |
| Chlorpromazine | | | | .0291 |
| 20mg/mL 0/L | 025178 | Largactil | RPP | |
| | | Chlorpromanyl 20 | TCH | |
| hlorpromazine | | | | 1.4300 |
| 100mg Sup | 025283 | Largactil | RPP | 1.4300 |
| hlorpromazine | | | | .0118 |
| 50mg Tab | 025488 | Largactil | RPP | .0110 |
| | | Chlorpromazine | SAP | |
| | | | NOP | |
| | 232601 | Novochlorpromazine | .1UP | |
| hlorpromazine | | | | .0078 |
| 25mg Tab | 025461 | Largactil | RPP | .0070 |
| | | Chlorpromazine | SAP | |
| | | Novochlorpromazine | NOP | |
| | 232023 | ovocatorpromazine | AUF | |
| hlorpromazine | | | | .0866 |
| 200mg Tab | 025518 | Largactil | RPP | .0000 |
| | 020010 | 20.80011 | NI I | |
| Chlorpromazine | | | | .0179 |
| 100mg Tab | 025496 | Largactil | RPP | .01/5 |
| | | Chlorpromazine | SAP | |
| | | Novochlorpromazine | NOP | |
| hlorpromazine | | | | .0067 |
| 10mg Tab | 025452 | Largactil | RPP | .0007 |
| | | Novochlorpromazine | NOP | |
| hlonoughius | | | | |
| hlorprothixene 50mg Tab | 012242 | Tarasan | HLR | .1945 |
| - ONE 1811 | 013242 | larasan | HLK | |

| 28:16:08 Psychotherapeutic Agents Tran | quilizers | |
|--|------------------------|--------------|
| Chlorprothixene | | .0960 |
| 15mg Tab | 013234 Tarasan | HLR |
| | | |
| Clorazepate Dipotassium | | .1880 |
| 15mg Cap | 264911 Tranxene | ABB |
| | +628212 Novo-Clopate | NOP |
| Clorazepate Dipotassium | | .1100 |
| 7.5mg Cap | 264946 Tranxene | ABB |
| • | +628204 Novo-Clopate | NOP |
| Clorazepate Dipotassium | | .0500 |
| 3.75mg Cap | 264938 Tranxene | ABB |
| o.romg cap | +628190 Novo-Clopate | NOP |
| | TOZOTO NOVO OTOPOTO | |
| Diazepam | 010074 V-1: | .9500 HLR |
| 10mg/2ml Inj Sol-2mL Pk | 012874 Valium | HLK |
| Diazepam | | .0335 |
| lmg/mL O/L | 013110 Valium | HLR |
| Diazepam | | .0020 |
| 5mg Tab | 013285 Valium | HLR |
| | 013765 Vivol | HOR |
| | 272442 Novodipam | NOP |
| | 280429 E-Pam | ICN |
| | 303461 Diazepam | SAP |
| | 362158 Apo-Diazepam | APX |
| | 396230 Diazepam | DTC |
| Diazepam | | .0020 |
| 2mg Tab | 013277 Valium | HLR |
| | 013757 Vivol | HOR |
| | 272434 Novodipam | NOP |
| | 272647 E-Pam | ICN |
| | 405329 Apo-Diazepam | APX |
| | 466905 Diazepam | DTC |
| Diazepam | | .0029 |
| 10mg Tab | 013293 Valium | HLR |
| | 013773 Vivol | HOR |
| | 272450 Novodipam | NOP |
| | 272639 E-Pam | ICN |
| | 405337 Apo-Diazepam | APX |
| | 466891 Diazepam | DTC |
| Flupenthixol Decanoate | | 50.6500 |
| 200mg/10mL Inj Sol-10mL Pk | 524522 Fluanxol Depot | MER |
| 200mg/10mL Inj Sol-10mL ik | 024022 I Induati Debot | 10201 |
| Flupenthixol Decanoate | | 50.6500 |
| 200mg/2mL Inj Sol-2mL Pk | 524530 Fluanxol Depot | MER |

| Supenthixol Dihydrochloride Smg Tab | 585157 Fluanxol | MER | .3640 |
|--|--|------------|---------|
| | | | .1680 |
| lupenthixol Dihydrochloride 0.5mg Tab | 580619 Fluanxol | MER | .1000 |
| luphenazine Decanoate 125mg/5mL Inj Susp-5mL Pk | 349917 Modecate | squ | 30.9500 |
| luphenazine Enanthate 125mg/5mL Inj Sol-5mL Pk | 029173 Moditen Enanthate | squ | 30.8500 |
| luphenazine HCl | #471518 Moditen HCl | sou | 9.0000 |
| 25mg/10mL Inj Sol-10mL Pk | #4/1518 Moditen nci | Sér | |
| luphenazine HCl 0.5mg/mL O/L | 245240 Moditen HCl | sou | .0254 |
| luphenazine HCl | | | .1039 |
| 5mg Tab | 029408 Moditen HCl | sou | |
| | 405361 Apo-Fluphenazine 504459 Permitil | APX SCH | |
| | JUSTICA LEUMICIT | 5011 | |
| luphenazine HCl | | | .0693 |
| 2mg Tab | 029386 Moditen HCl | SQU | |
| | 410632 Apo-Fluphenazine 504432 Permitil | APX SCH | |
| luphenazine HCl | | | .0577 |
| lmg Tab | 029378 Moditen HCl | SQU | .03// |
| | 405345 Apo-Fluphenazine | APX | |
| | 504424 Permitil | SCH | |
| luspirilene | | | 11.5200 |
| 10mg/mL Inj Susp-1mL Pk | 542903 IMAP Forte | MCN | |
| luspirilene | | | 14.4000 |
| 12mg/6ml Inj Susp-6ml Pk | 368393 IMAP | MCN | |
| laloperidol | | | 2.1100 |
| 5mg/ml Inj Sol-1ml Pk | 017574 Haldol | MCN | |
| aloperidol | | | .1000 |
| 2mg/mL O/L | 017582 Haldol | MCN | |
| | 552429 Peridol | TCH | |
| | 587702 Apo-Haloperidol | APX | |
| aloperidol | | | .8710 |
| 20mg Tab | 499579 Haldol | MCN | |
| Laloperidol | | | .4710 |
| 10mg Tab | 381772 Haldol | MCN | |

| 28:16:08 Psychotherapeutic Agents Tr | ranqui l izers | |
|---|---|----------------|
| Haloperidol | | .1521 |
| 5mg Tab | 017698 Haldol 363650 Novo-Peridol | MCN NOP |
| Haloperidol | | .2030 |
| 2mg Tab | 017671 Haldol | MCN |
| Haloperidol | | .0615 |
| 1mg Tab | 017663 Haldol 396818 Apo-Haloperidol | MCN APX |
| | 552143 Peridol | тсн |
| Haloperidol | 0.5055 7. 11. 1 | .0380 |
| 0.5mg Tab | 017655 Haldol 396796 Apo-Haloperidol | MCN APX |
| | 552135 Peridol | тсн |
| Haloperidol Decanoate | 500005 W 11.1 V | 7.2400 |
| 50mg/mL Oily Inj Sol-1mL Pk | 599085 Haldol-LA | MCN |
| Haloperidol Decanoate 100mg/mL Oily Inj Sol-1mL Pk | 599093 Haldol-LA | 14.3100 MCN |
| Hydroxyzine HCl | 004000 | .1139 PFI |
| 50mg Cap | 024392 Atarax 557900 Multipax | ROR |
| Hydroxyzine HCl | | .0923 |
| 25mg Cap | 024384 Atarax 557919 Multipax | PFI ROR |
| | 307313 Martipas | |
| Hydroxyzine HCl 10mg Cap | 024376 Atarax | PFI .0G13 |
| | 557927 Multipax | ROR |
| Hydroxyzine HCl | | 9.5200 |
| 500mg/10mL Inj Sol-10mL Pk | 024589 Atarax | PFI |
| Hydroxyzine HCl 2mg/mL O/L | 024694 Atarax | .0323 |
| | 021001 Ntal 67 | |
| Ketazolam 30mg Cap | 514527 Loftran | .527G BEE |
| Ketazolam | | .3565 |
| 15mg Cap | 514519 Loftran | BEE |
| Lorazepam | | .0617 |
| 2mg Tab | 348333 Ativan +637750 Novolorazem | WYE NOP |
| | +655767 Apo-Lorazepam | APX |

| Lorazepam | | | .0380 |
|--------------|------------------------|------|-------|
| lng Tab | 348325 Ativan | WYE | .0500 |
| | +637742 Novolorazem | NOP | |
| | +655759 Apo-Lorazepan | APX | |
| | | | |
| Lorazepan | | | .0399 |
| 0.5mg Tab | 399124 Ativan | WYE | |
| | +655740 Apo-Lorazepam | APX | |
| | | | |
| Meprobamate | | | .0127 |
| 400mg Tab | 013846 Miltown | HOR | |
| | 021547 Novomepro | NOP | |
| | 034142 Equanil | WYE | |
| | 092738 Meprobamate | DTC | |
| | 337943 Apo-Meprobamate | APX | |
| | | | |
| Mesoridazine | | | .2510 |
| 25mg/mL O/L | 259489 Serentil | SAN | |
| | | | |
| Mesoridazine | | | .3720 |
| 50mg Tab | 027464 Serentil | SAN | |
| | | | |
| Mesoridazine | 007450 0 | 2.17 | .2700 |
| 25mg Tab | 027456 Serentil | SAN | |
| Mesoridazine | | | 2222 |
| 10mg Tab | 027448 Serentil | 0.00 | .2200 |
| long lab | U2/448 Serentil | SAN | |
| Oxazepam | | | .0099 |
| 30mg Tab | 231363 Serax | WYE | .0055 |
| Jong 120 | 402737 Apo-Oxazepam | APX | |
| | 414263 Oxpan | ICN | |
| | 483907 Oxazepam | DTC | |
| | 496537 Novoxapam | NOP | |
| | apam | 101 | |
| Oxazepam | * | | .0075 |
| 15mg Tab | 295698 Serax | WYE | .0075 |
| | 402745 Apo-Oxazepam | APX | |
| | 414255 Oxpam | ICN | |
| | 483915 Oxazepam | DTC | |
| | 496529 Novoxapan | NOP | |
| | , cools no one par | | |
| Oxazepam | | | .0071 |
| 10mg Tab | 295701 Serax | WYE | |
| | 402680 Apo-Oxazepam | APX | |
| | 414247 Oxpam | ICN | |
| | 483893 Oxazepam | DTC | |
| | 500852 Novoxapam | NOP | |
| | • | | |
| Pericyazine | | | .1100 |
| 5mg Cap | 024880 Newleptil | RPP | |

| Pericyazine | 004900 | Nami anddi | Pan | .1650 |
|---------------------------|---------|----------------------------------|-------------|--------|
| 10mg Cap | 024899 | Neuleptil | RPP | |
| Pericyazine | | | | .1952 |
| 10mg/mL O/L | 379301 | Neuleptil | RPP | |
| Perphenazine | | | | 1.5820 |
| 5mg/mL Inj Sol-1mL Pk | 028002 | Trilafon | SCH | |
| Perphenazine | | | | .1395 |
| 3.2mg/mL O/L | 028169 | Trilafon Conc. | SCH | |
| | | | | 0.467 |
| Perphenazine 0.4mg/mL O/L | 028150 | Trilafon | SCH | .0467 |
| O. Amg/ ML O/ L | 020100 | ********** | 5011 | |
| Perphenazine | | | | .0145 |
| 8mg Tab | | Trilafon | SCH | |
| | | Phenazine | I CN APX | |
| | | Apo-Perphenazine Perphenazine | DTC | |
| | 100000 | i ei piienazzne | 2.0 | |
| Perphenazine | | | | .0125 |
| 4mg Tab | | Trilafon | SCH | |
| | | Phenazine | ICN APX | |
| | | Apo-Perphenazine Perphenazine | DTC | |
| | 400011 | i ci piiciazine | 210 | |
| Perphenazine | | | | .0115 |
| 2mg Tab | | Trilafon | SCH | |
| | | Phenazine | ICN | |
| | | Apo-Perphenazine Perphenazine | APX | |
| | 100000 | rer phenazine | DIC | |
| Perphenazine | | | | .0210 |
| 16mg Tab | | Trilafon | SCH | |
| | | Phenazine | ICN | |
| | | Apo-Perphenazine Perphenazine | APX | |
| | 101320 | rer phenazine | DIC | |
| Pimozide | | | | .3760 |
| 4mg Tab | 313823 | Orap | MCN | |
| Pimozide | | | | .2080 |
| 2mg Tab | 313815 | Oran | MCN | |
| | | | | |
| Pimozide | | | | .8200 |
| 10mg Tab | 573817 | Orap | MCN | |
| Piperacetazine | | | | .3036 |
| 50mg Tab | #279447 | Quide . | MER | |
| • | | | | |
| Piperacetazine | 12.0 | | | .1265 |
| 10mg Tab | #037370 | Quide | MER | |

| 28:16:08 Psychotherapeutic Agents | Tranquilizers | |
|---|---|---------------------|
| Pipotiazine Palmitate 50mg/mL Inj Sol-1mL Pk | 990507 Piportil L4 | 14.4733 RPP |
| Pipotiazine Palmitate 25mg/mL Inj Sol-1mL Pk | 427918 Piportil L4 | 8.5333 RPP |
| Pipotiazine Palmitate 100mg/2mL Inj Sol-2mL Pk | 427926 Piportil L4 | 23.5600 RPP |
| Prochlorperazine 10mg/2mL Inj Sol-2mL Pk | 578185 Stemetil | 1.2350 RPP |
| Prochlorperazine lng/mL O/L | 025216 Stemetil | .0361 |
| Prochlorperazine 5mg Sup | #025356 Stemetil | .3817 RPP |
| Prochlorperazine 10mg Sup | 025364 Stemetil | .8120 |
| Prochlorperazine 5mg Tab | 025682 Stemetil | .1245 RPP |
| Prochlorperazine 10mg Tab | 025690 Stemetil | .1521 RPP |
| Promazine 50mg Tab | 034185 Sparine | .0449 WYE |
| Promazine | 093599 Promazine | .0358 |
| 25mg Tab | 034177 Sparine 093580 Promazine | DTC |
| Thioridazine 30mg/mL O/L | 027359 Mellari1 | .1130 SAN |
| Thioridazine 2mg/mL O/L | 027375 Mellaril 238775 Thioridazine | .0141 SAN SAP |
| Thioridazine 50mg Tab | 027545 Mellaril | .0381 |
| | 037486 Novoridazine 238805 Thioridazine 360236 Apo-Thioridazine | NOP SAP APX |
| | 456098 Thioridazine +575135 PMS-Thioridazine | DTC PMS |
| Thioridazine 25mg Tab | 027537 Mellaril | .0209 SAN |

| Thioridazine | 027404 | Novoridazine | Non | .0209 |
|--|---------|-------------------------|------------|--------|
| 25mg Tab | | Thioridazine | NOP SAP | |
| | | Apo-Thioridazine | APX | |
| | | Thioridazine | DTC | |
| | | PMS-Thioridazine | PMS | |
| Thioridazine | | | | .0744 |
| 100mg Tab | 027553 | Mellaril | SAN | 4 |
| | | Novoridazine | NOP | |
| | 360244 | Apo-Thioridazine | APX | |
| | | Thioridazine | DTC | |
| | +575143 | PMS-Thioridazine | PMS | |
| Thioridazine | | | | .0111 |
| 10mg Tab | | Mellaril | SAN | |
| | | Novoridazine | NOP | |
| | | Thioridazine | SAP | |
| | | Apo-Thioridazine | APX | |
| | | Thioridazine | DTC | |
| | +575119 | PMS-Thioridazine | PMS | |
| Thiothixene | 224442 | N. | | .2164 |
| 5mg Cap | 024449 | Navane | PFI | |
| Thiothixene | | | | .1259 |
| 2mg Cap | 024430 | Navane | PFI | |
| Thiothixene | | | | .2787 |
| 10mg Cap | 024457 | Navane | PFI | |
| Tuifluorene in a | | | | 1.3033 |
| Irifluoperazine 1mg/mL Inj Sol-1mL Pk | 026999 | Stelazine | SKF | 1.3033 |
| | | | | 0.0550 |
| Trifluoperazine 20mg/10mL Inj Sol-10mL Pk | #027006 | Stelazine | SKF | 9.8560 |
| | | | | .1560 |
| Trifluoperazine | 007000 | C+ 1 - ! | CVT | .1560 |
| 10mg/mL O/L | | Stelazine Terfluzine | SKF | |
| | 298212 | leriluzine | ICA | |
| Trifluoperazine | | | | .0070 |
| 5mg Tab | 013919 | Solazine | HOR | |
| | 021873 | Novoflurazine | NOP | |
| | | Stelazine | SKF | |
| | | Trifluoperazine | DTC | |
| | | Terfluzine | ICN | |
| | 312746 | Apo-Trifluoperazine | APX | |
| Trifluoperazine | | | | .0050 |
| 2mg Tab | 013900 | Solazine | HOR | |
| | | | | |

| 28:16:08 Psychothe: | rapeutic Agents Tranquilizers | | | |
|--|--|--|-------------------------|---|
| Trifluoperazine | | | | .0050 |
| 2mg Tab | 021865 | Novoflurazine | NOP | |
| | 027154 | Stelazine | SKF | |
| | 249076 | Trifluoperazine | DTC | |
| | 303453 | Terfluzine | ICN | |
| | 312754 | Apo-Trifluoperazine | APX | |
| rifluoperazine | | | | -0115 |
| 10mg Tab | 013927 | Solazine | HOR | |
| | 021881 | Novoflurazine | NOP | |
| | | Stelazine | SKF | |
| | 249092 | Trifluoperazine | DTC | |
| | | Terfluzine | ICN | |
| | | Apo-Trifluoperazine | APX | |
| rifluoperazine | | | | .0045 |
| Img Tab | 012907 | Solazine | HOR | .0045 |
| Ing 120 | | Novoflurazine | NOP | |
| | | Stelazine | | |
| | | | SKF | |
| | | Trifluoperazine | DTC | |
| | | Terfluzine Apo-Trifluoperazine | ICN APX | |
| 8:16:12 Psychother | apeutic Agents Other Psychotrop | ics | | |
| | | carbolith | ICN | .0520 |
| ithium Carbonate 300mg Cap | | | ICN | .0520 |
| ithium Carbonate 300mg Cap ithium Carbonate | 236683 | Carbolith | | |
| ithium Carbonate 300mg Cap | 236683 | | ICN TCH | .0520 |
| ithium Carbonate 300mg Cap ithium Carbonate 300mg Cap | 236683 +328790 | Carbolith Lithizine | | |
| ithium Carbonate 300mg Cap ithium Carbonate 300mg Cap | 236683 +328790 | Carbolith | | |
| ithium Carbonate 300mg Cap ithium Carbonate 300mg Cap ithium Carbonate 300mg Cap | 236683 +328790 | Carbolith Lithizine | тсн | .1249 |
| ithium Carbonate 300mg Cap ithium Carbonate 300mg Cap ithium Carbonate 300mg Cap | 236683 +328790 406775 | Carbolith Lithizine | тсн | .1249 |
| ithium Carbonate 300mg Cap ithium Carbonate 300mg Cap ithium Carbonate 300mg Cap ithium Carbonate 150mg Cap | 236683 +328790 406775 | Carbolith Lithizine Lithane | TCH PFI | .1249 |
| ithium Carbonate 300mg Cap ithium Carbonate 300mg Cap ithium Carbonate 300mg Cap | 236683 +328790 406775 - 461733 | Carbolith Lithizine Lithane | TCH PFI | .1249 |
| ithium Carbonate 300mg Cap ithium Carbonate 300mg Cap ithium Carbonate 300mg Cap ithium Carbonate 150mg Cap ithium Carbonate 300mg LA Tab | 236683 +328790 406775 - 461733 | Carbolith Lithizine Lithane Carbolith | TCH PFI ICN | .1249 |
| ithium Carbonate 300mg Cap ithium Carbonate 300mg Cap ithium Carbonate 300mg Cap ithium Carbonate 150mg Cap ithium Carbonate 300mg La Tab | 236683 +328790 406775 | Carbolith Lithizine Lithane Carbolith | TCH PFI ICN | .1249 |
| ithium Carbonate 300mg Cap ithium Carbonate 300mg Cap ithium Carbonate 300mg Cap ithium Carbonate 150mg Cap ithium Carbonate 300mg LA Tab ithium Carbonate 300mg LA Tab ithium Carbonate 300mg Tab | 236683 +328790 406775 | Carbolith Lithizine Lithane Carbolith Duralith | TCH PFI ICN MCN | .1249 .0640 .0499 |
| ithium Carbonate 300mg Cap ithium Carbonate 300mg Cap ithium Carbonate 300mg Cap ithium Carbonate 150mg Cap ithium Carbonate 300mg LA Tab ithium Carbonate 300mg LA Tab | 236683 +328790 406775 461733 +590665 024406 | Carbolith Lithizine Lithane Carbolith Duralith | TCH PFI ICN MCN | .1249 .0640 .0499 .1320 |
| ithium Carbonate 300mg Cap .ithium Carbonate 300mg Cap .ithium Carbonate 300mg Cap .ithium Carbonate 150mg Cap .ithium Carbonate 300mg LA Tab .ithium Carbonate 300mg LA Tab .ithium Carbonate | 236683 +328790 406775 461733 +590665 024406 | Carbolith Lithizine Lithane Carbolith Duralith Lithane | TCH PFI ICN MCN PFI | .1249 .0640 .0499 .1320 |
| ithium Carbonate 300mg Cap ithium Carbonate 300mg Cap ithium Carbonate 300mg Cap ithium Carbonate 150mg Cap ithium Carbonate 300mg LA Tab ithium Carbonate 300mg LA Tab ithium Carbonate 300mg Tab oxapine HCl 25mg/mL O/L oxapine Succinate | 236683 +328790 406775 461733 +590665 024406 361364 | Carbolith Lithizine Lithane Carbolith Duralith Lithane | TCH PFI ICN MCN PFI | .1249 .0640 .0499 .1320 .0640 |
| ithium Carbonate 300mg Cap ithium Carbonate 300mg Cap ithium Carbonate 300mg Cap ithium Carbonate 150mg Cap ithium Carbonate 300mg LA Tab ithium Carbonate 300mg LA Tab oxapine HCl 25mg/mL O/L | 236683 +328790 406775 461733 +590665 024406 361364 | Carbolith Lithizine Lithane Carbolith Duralith Lithane Loxapac | TCH PFI ICN MCN PFI LED | .1249 .0640 .0499 .1320 .0640 |

| Loxapine Succinate 25mg Tab | 346802 | Loxapac | LED | .3421 |
|------------------------------------|---------|----------------|-----|--------|
| Loxapine Succinate 10mg Tab | 346799 | Loxapac | LED | .2134 |
| 28:20:00 C.N.S. Stimulants | | | | |
| Dexamphetamine Sulfate 5mg Tab | 027065 | Dexedrine | SKF | .1600 |
| Methylphenidate HCl 20mg LA Tab | +632775 | Ritalin SR | CIB | .3640 |
| Methylphenidate HCl 10mg Tab | 005606 | Ritalin | CIB | . 1970 |
| Pemoline 75mg Tab | +397520 | Cylert | ABB | .9800 |
| Pemoline 37.5mg Tab | +397512 | Cylert | ABB | .5100 |
| 28:24:00 Sedatives and Hypnotics | | | | |
| Amobarbital 30mg Tab | 015628 | Amytal | LIL | .0593 |
| Amobarbital 15mg Tab | 015601 | Amytal | LIL | .0485 |
| Amobarbital 100mg Tab | 015636 | Amytal | LIL | .1006 |
| Amobarbital Sodium 60mg Cap | 015148 | Amytal Sodium | LIL | .0650 |
| Amobarbital Sodium 200mg Cap | 015156 | Amytal Sodium | LIL | .1497 |
| Butabarbital 30mg Tab | 604607 | Day-Barb | SAN | .0410 |
| Butabarbital 15mg Tab | 604674 | Day-Barb | SAN | .0330 |
| Butabarbital 100mg Tab | 604615 | Day-Barb | SAN | .0890 |
| Butabarbital Sodium 30mg Tab | 581291 | Butisol Sodium | HOR | .0680 |

| 28:24:00 Sedatives and Hypnotics | | |
|--|--|-------------|
| Butabarbital Sodium | The second secon | .05 |
| 15mg Tab | 581305 Butisol Sodium | HOR |
| utabarbital Sodium | | .13 |
| 100mg Tab | 581313 Butisol Sodium | HOR |
| 2007 | | |
| hloral Hydrate | | .02 |
| 500mg Cap | 020893 Novochlorhydrate 029041 Noctec | NOP |
| | 092886 Chloral Hydrate | SQU |
| | 032000 CHIOFAI Hydrate | DIC |
| hloral Hydrate | | .01 |
| 100mg/mL O/L | 029327 Noctec | SQU |
| | | |
| lurazepan | 012718 Dalmane | HLR .03 |
| 30mg Cap | 414239 Som-Pam | ICN |
| | 496553 Novoflupam | NOP |
| | 521701 Apo-Flurazepam | APX |
| | • | |
| lurazepam | | .02 |
| 15mg Cap | 012696 Dalmane 414220 Som-Pam | HLR ICN |
| | 496545 Novoflupam | NOP |
| | 521698 Apo-Flurazepam | APX |
| | | |
| lurazepam | | .00 |
| 30mg Tab | 483818 Somnol | HOR |
| lurazepan | | .00 |
| 15mg Tab | 483826 Sonnol | HOR |
| | | |
| dethotrimeprazine | 005002 N: | 1.68 RPP |
| 25mg/mL Inj Sol-1mL Pk | 025003 Nozinan | KFF |
| dethotrimeprazine | | .03 |
| 5mg/mL 0/L | 025194 Nozinan | RPP |
| | | |
| dethotrimeprazine | 025208 Nozinan | RPP .29 |
| 40mg/mL 0/L | U252U8 NOZIRAR | KPF |
| (ethotrimeprazine | | .28 |
| 50mg Tab | 025607 Nozinan | RPP |
| | | 0.5 |
| lethotrimeprazine | 025585 Nozinan | RPP .OT |
| 5mg Tab | U25585 NOZIRAR | VLL |
| ethotrimeprazine | | .19 |
| 25mg Tab | 025593 Nozinan | RPP |
| The State of the S | | |
| dethotrimeprazine | | .05 |
| 2mg Tab | 025577 Nozinan | RPP |

| 28:24:00 Sedatives and Hypnotics | | |
|----------------------------------|--|---------------|
| Nitrazepam | | .1095 |
| 5mg Tab | 511528 Mogadon | HLR |
| Nitrazepam | | .1635 |
| 10mg Tab | 511536 Mogadon | HLR |
| 4 | | 1 0740 |
| Paraldehyde | 012149 Paraldehyde | 1.2740 GLA |
| Inj Sol-5mL Pk | 012140 Taratuenyue | OLA |
| Paraldehyde | | .0360 |
| 0/L | 002755 Paraldehyde | AHA |
| Pentobarbital Sodium | | .0265 |
| 100mg Cap | 000086 Nembutal | ABB |
| 100mg cup | 020990 Novopentobarb | NOP |
| | 093572 Pentobarbital | DTC |
| Phenobarbital | | .5450 |
| 120mg/mL Inj Sol-1mL Pk | 033367 Luminal | WIN .3430 |
| , | | |
| Phenobarbital | | .0107 |
| 4mg/mL O/L | 588180 Phenobarbital 604585 Phenobarbital | DTC SAN |
| | 604585 Phenobarbitai | SAN |
| Phenobarbital | | .0110 |
| 60mg Tab | 023817 Phenobarbital | PDA |
| | 093556 Phenobarbital | DTC |
| | 320714 Phenobarbital-ICN | ICN |
| Phenobarbital | | .0050 |
| 30mg Tab | 023809 Phenobarbital | PDA |
| | 093521 Phenobarbital | DTC |
| | 293903 Phenobarbital-ICN | ICN |
| | 604550 Phenobarbital | SAN |
| Phenobarbital | | .0044 |
| 15mg Tab | 023795 Phenobarbital | PDA |
| | 093505 Phenobarbital | DTC |
| | 271276 Phenobarbital-ICN | ICN |
| | 604542 Phenobarbital | SAN |
| Phenobarbital | | .0137 |
| 100mg Tab | 093564 Phenobarbital | DTC |
| | 344036 Phenobarbital-ICN | ICN |
| | 604577 Phenobarbital | SAN |
| Promethazine HCl | | 1.0483 |
| 50mg/2mL Inj Sol-2mL Pk | 025046 Phenergan | RPP |
| | | - |
| Promethazine HCl | 00m 100 Pl | .0179 RPP |
| 2mg/mL O/L | 025429 Phenergan | KFF |

| 28:24:00 Sedatives and Hypnotics | <u>5</u> | | | |
|----------------------------------|----------|-------------------------|-----|-------|
| Promethazine HCl 2mg/mL O/L | +583979 | PMS-Promethazine | PMS | .0179 |
| Promethazine HCl 12.5mg Sup | #025380 | Phenergan | RPP | .6222 |
| Promethazine HCl 25mg Tab | #213896 | Phenergan | RPP | .0717 |
| Promethazine HCl 10mg Tab | 025712 | Phenergan | RPP | .0687 |
| Secobarbital Sodium 50mg Cap | 015261 | Seconal | LIL | .0639 |
| Secobarbital Sodium 100mg Cap | | Seconal Novosecobarb | LIL | .0352 |
| Temazepam 30mg Cap | 604461 | Restoril | SAN | .1500 |
| Temazepam 15mg Cap | 604453 | Restoril | SAN | .1300 |
| Triazolam 0.5mg Tab | 443131 | Halcion | UPJ | .1762 |
| Triazolam 0.25mg Tab | 443158 | Halcion | UPJ | .1479 |
| Triazolam 0.125mg Tah | 512559 | Halcion | UPJ | .1195 |

36:00 Diagnostic Agents

36:04:00 Adrenal Insufficiency

| Cosyntropin Inj Pd-0.25mg | Pk | 022381 Cortrosym | ORG | 6.5800 |
|------------------------------|----|------------------|-----|--------|
| | | | | |

Cosyntropin Zinc Hydroxide 15.9300 lng/nL Inj Susp-1mL Pk 253952 Synacthen Depot CIB

36:00 Diagnostic Agents

| 36:26:00 Diabetes Mellitus | | | | |
|---|-------------------|------------------------------|-----|---------|
| Glucose Oxidase Reagent Stick-20 Pk | +980684 | Glucoscan/GM | LIF | 9.5900 |
| Glucose Oxidase Reagent Stick-25 Pk | 990280 | Visidex II | AME | 11.7500 |
| Glucose Oxidase Reagent Stick-25 Pk | 990906 | Chemstrip bG | ВОМ | 13.2000 |
| Glucose Oxidase Reagent Stick-25 Pk | 990922 | Dextrostix | AME | 11.7250 |
| Glucose Oxidase Reagent Stick-50 Pk | +980676 | Glucoscan | LIF | 23.9750 |
| Glucose Oxidase Reagent Strip-100 Pk | +980706 | Reflocheck | ВОМ | 39.6000 |
| Glucose Oxidase Reagent Strip-50 Pk | 990027 | Chemstrip bG | ВОМ | 26.8000 |
| 36:56:00 Myasthenia Gravis | | | | |
| Edrophonium Chloride 100mg/10mL Inj Sol-10mL Pk | 013064 | Tensilon | HLR | 9.4584 |
| Neostigmine Methylsulfate O.5mg/mL Inj Sol-ImL Pk | 012955 | Prostigmin | HLR | .6496 |
| 36:88:00 Urine Contents | | | | |
| * Cupric Sulfate Reagent Tab-100 Pk | 980420 | Clinitest | AME | 6.0000 |
| * Glucose Oxidase Reagent (Qualitative) Stick-50 Pk | 980633 | Clinistix | AME | 3.3000 |
| Glucose Oxidase Reagent (Semi-Quantitative) Stick-50 Pk | | Diastix | AME | 3.4000 |
| Glucose Oxidase Reagent (Semi-Quantitative) Strip-50 Pk | | Chemstrip uG5000 | вом | 3.5000 |
| Glucose Oxidase/Sodium Nitroprusside Reagen Stick-100 Pk | | Keto-Diastix | AME | 8.7500 |
| 36:88:00 Urine Contents | | | | |
| Semiquantitative Glucose Ketones Reagent Ana Strip-50 Pk | lysis I 980692 | Paper Chemstrip UG 5000 K | вом | 3.9000 |
| Sodium Nitroprusside Reagent Stick-50 Pk | 980595 | Ketostix | AME | 4.5500 |
| Sodium Nitroprusside Reagent Tab-100 Pk | 980560 | Acetest | AME | 10.5000 |
| Urine-Ketone Analysis Paper Strip-100 Pk | 990698 | Chemstrip K | вом | 7.6450 |
| * Urine-Sugar Analysis Paper Strip-100Pk | 980609 | Tes-Tape | LIL | 5.9500 |
| | | | | |

| 40.09.00 Albelinizing Agente | | | | |
|--|---------|---------------------------------------|-----|--------|
| 40:08:00 Alkalinizing Agents | | 7 | | |
| Sodium Bicarbonate (OTC) 600mg Tab 100 Pk | 221619 | Sodium Bicarbonate | DTC | 3.7000 |
| Sodium Bicarbonate (OTC) | | | | 3.4000 |
| 300mg Tab 100 Pk | | Sodium Bicarbonate Sodium Bicarbonate | DTC | |
| | #302280 | Souram Bicar sonate | CLA | |
| 40:12:00 Replacement Agents | | | | |
| Calcium Carbonate | | | | .1064 |
| 500mg Chew Tab | +648345 | Calsan | SAN | |
| Calcium Carbonate | 0.10050 | 0.1 | ~ | .1064 |
| 500mg S. G. Cap | +648353 | Calsan | SAN | |
| Calcium Carbonate | | Caltrate 300 | LED | .0710 |
| 750mg Tab | +623469 | Caltrate 300 | LED | |
| Calcium Carbonate | E4101E | 0s-Cal 250 | AYE | .0856 |
| 625mg Tab | 541915 | US-Ca1 250 | AIL | |
| Calcium Carbonate 1500mg Tab | A626241 | Caltrate 600 | LED | .0670 |
| 1300mg 120 | +020341 | Caltrate 000 | LED | |
| Calcium Carbonate 1250mg Tab | 541907 | 0s-Cal 500 | AYE | .1018 |
| 1200mg 180 | +618101 | | MIT | |
| Calcium Carbonate & Calcium Gluconolactate | | | | .3002 |
| 0.3g & 2.94g Eff Tab | | Calcium-Sandoz Forte | SAN | |
| Calcium Carbonate & Calcium Gluconolactate | | | | .5040 |
| 1.5g & 3.08g Eff Tab | 259497 | Gramcal | SAN | |
| Calcium Gluconate | | | | 1.4000 |
| 1000mg/10ml Inj Sol-10ml Pk | | Calcium-Sandoz Calcium Gluconate | SAN | |
| | +333702 | Calcium Gluconate | 260 | |
| Calcium Gluconate (OTC) 650mg Tab 100 Pk | 023574 | Calcium Gluconate | PDA | 3.2000 |
| 000mg 120 100 FK | 094773 | Calcium Gluconate | DTC | |
| | | Calcium Gluconate | WAM | |
| | | COLCIUM GIGCOMATC | NOI | |
| Calcium Gluconate & Calcium Glucoheptonate 58.7mg & 172.1mg/mL O/L | | Calcium-Rougier | ROG | .0146 |
| | 100120 | nought | | - |
| Calcium Gluconogalactogluconate 200mg/mL O/L | 027383 | Calcium-Sandoz | SAN | .0202 |
| | 12.100 | | | |
| Calcium Lactate (OTC) 650mg Tab 100 Pk | +021253 | Calcium Lactate | NOP | 3.2000 |
| | | | | |

| 40:12:00 Replacement Agents | | | |
|---|--|--------------------------|--------|
| Calcium Lactate (OTC) 650mg Tab 100 Pk | 023590 Calcium Lactate 094765 Calcium Lactate | PDA DTC | 3.2000 |
| Potassium Chloride 12mEq Eff Tab | 027596 Potassium-Sandoz | SAN | .1994 |
| Potassium Chloride 20mEq/10mL Inj Sol-10mL Pk | 511978 Potassium Chloride | squ | .7390 |
| * Potassium Chloride 10mEq LA Cap | +632759 Micro-K-10 | ROB | .0818 |
| * Potassium Chloride 8nEq LA Cap | 516244 Micro-K Extencaps | ROB | .0683 |
| Potassium Chloride 10mEq LA Tab | 471496 Kalium Durules | AST | .0623 |
| * Potassium Chloride 8mEq LA Tab | 074225 Slow-K | CIB | .0515 |
| * Potassium Chloride 8mEq LA Tab | 554308 Slo-Pot 600 | ICN | .0151 |
| * Potassium Chloride 8mEq LA Tab | 602876 Novolente-K | NOP | .0158 |
| * Potassium Chloride 8mEq LA Tab | 602884 Apo-K | APX | .0146 |
| * Potassium Chloride 6.7mEq LA Tab | 501972 K-Long | ADI | .0710 |
| * Potassium Chloride 2.66mEq/mL O/L | 208604 Kaochlor-20 Concentrate | ADI | .0209 |
| * Potassium Chloride 1.33mEq/mL O/L | 208590 Kaochlor 436984 K-10 485284 Roychlor 704504 Kay Ciel | ADI BEE ROY BER | .0122 |
| Potassium Chloride 25mEq/Pouch Oral Pd 7.8g Pk | 464813 K-Lyte/Cl | BRI | . 4237 |
| Potassium Chloride 20mEq/Pouch Oral Pd-3g Pk | 481211 K-Lor | ABB | .3010 |
| * Potassium Gluconate 1.33mEq/mL O/L | 026700 Potassium-Rougier | ROG | .0136 |

| 40:12:00 Replacement Agents | | | | |
|-------------------------------------|---------|--------------------------------|-------|---------|
| * Potassi n Gluconate | | | | .0136 |
| 1.33mEq/mL O/L | 208701 | Kaon | ADI | |
| | 485357 | Royonate | ROY | |
| | | | | |
| Potassium Gluconate | | | | .0806 |
| 5mEq Tab | 215503 | Kaon | ADI | |
| Desiration Desiration | | | | |
| Sodium Chloride | | | | .9410 |
| 0.9% Inj Sol-10mL Pk | 990167 | Sodium Chloride | SQU | |
| | | | | |
| Sodium Chloride Bacteriostatic | | | | 1.0860 |
| 0.9% Inj Sol-30mL Pk | 511943 | Bacteriostatic Sodium | SQU | |
| | | Chloride | | |
| 40:18:00 Potassium-Removing Resins | | | | |
| D-1 | | | | 48.3351 |
| Polystyrene Sodium Sulfonate | 022107 | Kayexalate | WIN | +0.3331 |
| 1mEq/g Oral Pd-454g Pk | 033137 | hayexarate | W 174 | |
| 40:28:00 Diuretics | | | | |
| 40:28:00 Diareties | | | | |
| Acetazolamide | | | | |
| 500mg LA Cap | 127930 | Diamox | LED | .5140 |
| 50015 2 V-P | | | | |
| Acetazolamide | | | | .0204 |
| 250mg Tab | 014907 | Diamox | LED | |
| | 295019 | Acetazolam | ICN | |
| | +488275 | Novozolamide | NOP | |
| | 545015 | Apo-Acetazolamide | APX | |
| | | | | |
| Amiloride HCl | | | | .2131 |
| 5mg Tab | 487805 | Midamor | MSD | |
| | | | | |
| Amiloride HCl & Hydrochlorothiazide | | | | .2641 |
| 5mg & 50mg Tab | 487813 | Moduret | MSD | |
| | | | | |
| Aminophylline | | | 0.011 | .8000 |
| 500mg/10mL Inj Sol-10mL Pk | +535672 | Aminophylline | Sốn | |
| 4 | | | | .8000 |
| Aninophylline | 010000 | 4-1 | GLA | . 8000 |
| 250mg/10mL Inj Sol-10mL Pk | | Aminophylline Aminophylline | SQU | |
| | +333004 | Aminophylline | 300 | |
| Aminophylline | | | | .0346 |
| 21mg/mL O/L | 379603 | Palaron | FIS | .0040 |
| 7776, 72 0, 2 | 5.000 | | | |
| Aminophylline | | | | .5423 |
| 500mg Sup | 451673 | Corophyllin | BEE | |
| | | | | |
| Aminophylline | | | | . 4555 |
| 250mg Sup | 451665 | Corophyllin | BEE | |
| | | - | | |
| Aminophylline | | | | .0600 |
| 200mg Tab | 014931 | Aminophylline | LED | |
| | | | | |

| 40:28:00 Diuretics | | | | |
|-------------------------|---------|-------------------------|-----|-------|
| Aminophylline | | | | .0215 |
| 100mg Tab | 014923 | Aminophylline | LED | |
| | | Aminophylline | DTC | |
| | | | | |
| Chlorthalidone | | | | .0187 |
| 50mg Tab | | Hygroton | GEI | |
| | 298964 | Uridon | ICN | |
| | 337447 | Novothalidone | NOP | |
| | 360279 | Apo-Chlorthalidone | APX | |
| | 398365 | Chlorthalidone | DTC | |
| C1 3 41 3 1 2 | | | | .0305 |
| Chlorthalidone | 010401 | Unguntan | GEI | .0303 |
| 100mg Tab | | Hygroton Uridon | ICN | |
| | | | NOP | |
| | | Novothalidone | | |
| | | Apo-Chlorthalidone | APX | |
| | 398373 | Chlorthalidone | DTC | |
| Ethacrynic Acid | | | | .2274 |
| 50mg Tab | 016497 | Edecrin | MSD | |
| | | | | .8800 |
| furosemide | 217743 | T | HOE | .0000 |
| 20mg/2mL Inj Sol-2mL Pk | #467766 | | HOR | |
| | #401100 | Uritoi | nok | |
| Furosemide | | | | .1508 |
| 10mg/mL O/L | 432342 | Lasix | HOE | |
| | | | | |
| Furosemide | | | | .0067 |
| 40mg Tab | 012580 | | HOE | |
| | 332275 | Furoside | ICN | |
| | | Novosemide | NOP | |
| | 344079 | Uritol | HOR | |
| | 362166 | Apo-Furosemide | APX | |
| | 396249 | Furosemide | DTC | |
| Furosemide | | | | .0048 |
| 20mg Tab | 289590 | lasiv | HOE | .0040 |
| Zong 180 | | Novosemide | NOP | |
| | | Furoside | ICN | |
| | | Apo-Furosemide | APX | |
| | | Furosemide | DTC | |
| | | | | |
| Hydrochlorothiazide | | | | .0040 |
| 50mg Tab | | Esidrix | CIB | |
| | | HydroDIURIL | MSD | |
| | | Novohydrazide | NOP | |
| | | Hydrochlorothiazide | DTC | |
| | | Hydrochlorothiazide | SAP | |
| | | Urozide | ICN | |
| | 312800 | Apo-Hydrochlorothiazide | APX | |

| 40:28:00 Diuretics | | | | |
|--------------------------------------|---------|-------------------------|-----|--------|
| Hydrochlorothiazide | | | | .0033 |
| 25mg Tab | #005568 | Esidrix | CIB | |
| | 016500 | HydroDIURIL | MSD | |
| | | Novohydrazide | NOP | |
| | | Hydrochlorothiazide | DTC | |
| | | Urozide | ICN | |
| | 326844 | Apo-Hydrochlorothiazide | APX | |
| Hydrochlorothiazide & Spironolactone | | | | .2502 |
| 50mg & 50mg Tab | 594377 | Aldactazide-50 | SEA | . 2002 |
| Walanchlausthianida & Cuinaualantana | | | | 0010 |
| Hydrochlorothiazide & Spironolactone | 100400 | 411-41-11 05 | 05. | .0919 |
| 25mg & 25mg Tab | | Aldactazide-25 | SEA | |
| | 613231 | Novo-Spirozine | NOP | |
| Hydrochlorothiazide & Triamterene | | | | .0317 |
| 25mg & 50mg Tab | 181528 | Dyazide | SKF | |
| | 441775 | Apo-Triazide | APX | |
| | 532657 | Novotriamzide | NOP | |
| Indapamide | | | | .3280 |
| 2.5mg Tab | 564966 | Lozide | SEV | . 3250 |
| | 00.000 | 302140 | 52. | |
| Methyldopa & Hydrochlorothiazide | | | | .0619 |
| 250mg & 25mg Tah | | Aldoril-25 | MSD | |
| | | Novodoparil-25 | NOP | |
| | | Dopazide-25 | ICN | |
| | | Apo-Methazide-25 | APX | |
| | 584975 | PMS-Dopazide-25 | PMS | |
| Methyldopa & Hydrochlorothiazide | | | | .0599 |
| 250mg & 15mg Tab | 140589 | Aldoril-15 | MSD | |
| | 363642 | Novodoparil-15 | NOP | |
| | | Dopazide-15 | ICN | |
| | | Apo-Methazide-15 | APX | |
| | | PMS-Dopazide-15 | PMS | |
| Metolazone | | | | .1765 |
| 10mg Tab | 301671 | Zaroxolyn | PWC | .1765 |
| | 001011 | 22.0.0192 | | |
| Metolazone | | | | .1341 |
| 5mg Tab | 301698 | Zaroxolyn | PWC | |
| Metolazone | | | | .1024 |
| 2.5mg Tab | 301663 | Zaroxolyn | PWC | |
| S-1 | | | | |
| Spironolactone | 000000 | 414-44-6 | CEA | .0729 |
| 25mg Tab | | Aldactone | SEA | |
| | 613215 | Novo-Spiroton | NOP | |
| Spironolactone | | | | .2250 |
| 100mg Tah | 285455 | Aldactone | SEA | |
| 5 | 200300 | | Can | |
| | | | | |

30mg Tab

40:00 Electrolytic, Caloric and Water Balance

| 40:28:00 Diuretics | | | | |
|----------------------------|--------|--------------------|------|-------|
| Spironolactone | | | | .2250 |
| 100mg Tab | 544477 | Sincomen | BER | |
| TOOMS 120 | | Novo-Spiroton | NOP | |
| | 0.0220 | | | |
| Triamterene | | | | .1117 |
| 50mg Tab | 299715 | Dyrenium | SKF | ***** |
| JOME 180 | 200120 | 271 011 1111 | O.M. | |
| Triamterene | | | | .1372 |
| 100mg Tab | 027138 | Dyrenium | SKF | *10,2 |
| Tooms 180 | 021100 | Dyrenium | OM | |
| 10:40:00 Uricosuric Drugs | | | | |
| | | | | |
| Probenecid | | | | .1019 |
| 500mg Tab | | Benemid | MSD | |
| | 294926 | Benuryl | ICN | |
| | | | | |
| Sulfinpyrazone | | | | .0507 |
| 200mg Tab | | Anturan | GEI | |
| | | Apo-Sulfinpyrazone | APX | |
| | 463051 | Zynol | HOR | |
| | 475076 | Novopyrazone | NOP | |
| | 481181 | Antazone | ICN | |
| | 481947 | Sulfinpyrazone | DTC | |
| | | | | .0309 |
| Sulfinpyrazone | 010510 | A. A | GEI | .030: |
| 100mg Tab | | Anturan | | |
| | | Apo-Sulfinpyrazone | APX | |
| | 463043 | | HOR | |
| | | Novopyrazone | NOP | |
| | | Antazone | ICN | |
| | 481955 | Sulfinpyrazone | DTC | |
| | | | | |
| 48:00 Cough Preparations | | | | |
| 18:04:00 Antitussives | | | | |
| | | | | |
| Clophedianol Hydrochloride | | | | .0291 |
| 5mg/mL O/L | 026328 | Ulone | RIK | |
| | | | | |
| Codeine Phosphate | | | | .5160 |
| 30mg/mL Inj Sol-1mL Pk | 303879 | Codeine | AHA | |
| | | | | |
| Codeine Phosphate | | | | .0160 |
| 5mg/mL O/L | 018678 | Codeine | NDA | |
| | 093114 | Codeine | DTC | |
| | | | | |
| Codeine Phosphate | | | | .1552 |
| 60mg Tab | 003247 | Codeine | AHA | |
| | | Codeine | DTC | |
| | | | | |
| Codeine Phosphate | | | | .0630 |
| | | | | |

003239 Codeine

018694 Codeine

093130 Codeine

+593451 Codeine Phosphate

AHA

NDA

DTC

TCH

48:00 Cough Preparations

48:04:00 Antitussives

| Codeine Phosphate | | .0430 |
|--|-----------------------------|-----------|
| 15mg Tab | 003220 Codeine | AHA |
| | 018686 Codeine | NDA |
| | 093122 Codeine | DTC |
| | +593435 Codeine Phosphate | TCH |
| | . coorso coderne i nospuate | ich |
| Dextromethorphan (as Polistirex) | | .0276 |
| 6mg/mL O/L | 589888 Delsym | PWC |
| | | |
| Dextromethorphan HBr | | .0067 |
| 3mg/mL O/L | 391069 DM-Syrup | PDA |
| | 436895 Koffex | ROG |
| | 454389 Robidex | ROB |
| Hydrocodone Bitartrate | | .0240 |
| lmg/mL O/L | #307858 Corutol DH | DOW .0240 |
| 195/ 82 0/ 2 | 316970 Robidone | ROB |
| | 585580 Hycodan | DUP |
| | 383360 HyCouan | Del |
| Hydrocodone Bitartrate | | .2635 |
| 5mg Tab | 585572 Hycodan | DUP |
| | ., | |
| 48:08:00 Expectorants | | |
| Acetylcysteine | | 5,8240 |
| 20% Aero Sol-10mL Pk | 606235 Mucomyst | BRI |
| | oosaoo maaay sa | 2 |
| Acetylcysteine | | 14,2230 |
| 20% Aero Sol-30mL Pk | 990833 Mucomyst | BRI |
| | , | |
| * Guaifenesin | | .0258 |
| 40mg/mL O/L | #296228 Corutol Expectorant | DOW |
| | | |
| * Guaifenesin | | .0058 |
| 20mg/mL 0/L | 026468 Robitussin | ROB |
| | 026794 Guaifenesin | ROG |
| | | |
| Guaifenesin (Sugar Free) | | .0069 |
| 20mg/mL 0/L | 990930 Guaifenesin Sugar F | ree ROG |
| | | |
| Organically bound Iodine (as Iodinated | Glycerol) | .0161 |
| 6mg/mL O/L | 354910 Organidin | HOR |
| Maria A | | |
| Organically bound Iodine (as Iodinated | Glycerol) | .0684 |
| 15mg Tab | 354902 Organidin | HOR |
| | | |

| 52:04:04 Anti-Infectives Antibiotics | | |
|--|--|---------------------|
| Bacitracin 500U/g Oph Oint-3g Pk | 327476 Baciguent | UPJ 1.2432 |
| Chloramphenicol 1% Oph Oint-3.5g Pk | 001058 Fenicol 024066 Chloromycetin | ALC PDA |
| Chloramphenicol 0.5% Oph Sol | 001082 Chloroptic 221678 Chloromycetin 403474 Isopto Fenicol | ALL PDA ALC |
| Chloramphenicol 0.25% Oph Sol | #239879 Isopto Fenicol 704598 Pentamycetin | .3900 ALC BER |
| Chloramphenicol 0.5% Ot Sol | 349615 Chloromycetin | .4483 PDA |
| Colistin Base & Neomycin Base & Hydrocort 3mg & 3.3mg & 10mg/mL Ot Susp | isone Acetate 476439 Coly-Mycin Otic | 1.2070 PDA |
| Framycetin Sulfate 0.5% Oph Oint-5g Pk | 026964 Soframycin | 3.9000 ROU |
| Framycetin Sulfate 0.5% Oph Sol | 026921 Soframycin | .7125 |
| Framycetin Sulfate & Gramicidin & Dexamet 5mg & 50mcg & 0.5mg/mL Ot Sol | hasone 228052 Sofracort | .9810 ROU |
| Gentamicin & Betamethasone Sodium Phospha 3mg & 1mg/mL Ot Drops | te +614270 Garasone | 1.3160 SCH |
| Gentamicin Sulfate 0.3% Oph Oint-3.5g Pk | 028339 Garamycin | 4.9284 SCH |
| Gentamicin Sulfate 0.3% Oph Sol | 436771 Alcomicin 512192 Garamycin | .6000 ALC SCH |
| Gentamicin Sulfate 0.3% Ot Sol | 512184 Garamycin | 1.0733 SCH |
| Polymyxin B Sulfate & Bacitracin (Zinc) 10,000U & 500U/g Oph Oint-3.5g Pk | 299219 Polysporin | 2.9400 BWE |
| Polymyxin B Sulfate & Gramicidin 10,000U & 0.025mg/mL Oph/Ot Sol | 035343 Polysporin | .3120 BWE |
| Polymyxin B Sulfate & Neomycin Sulfate & 1 10000U & 5mg & 400U/g Oph Oint-3.5g Pk | Bacitracin (Zinc) 522422 Neosporin | 4.5000 BWE |
| | | |

| 52:04:04 Anti-Infectives Antibiotics | <u>.</u> | |
|--|---|----------------------|
| Polymyxin B Sulfate & Neomycin Sulfa 10000U & 5mg & 0.25mg/mL Ot Sol | | 1.3000 SYP |
| Polymyxin B Sulfate & Neomycin Sulfa 10000U & 2.5mg & 0.025mg/mL Oph/Ot | | .5250 BWE |
| Polymyxin B Sulfate & Neomycin Sulfa 10,000U & 5mg & 10mg/ml Ot-Sol | ted Hydrocortisone 694401 Cortisporin | .9640 BWE |
| Tobranycin 0.3% Oph Oint | 614254 Tobrex | 1.8000 ALC |
| Tobranycin 0.3% Oph Sol | 513962 Tobrex | 1.2900 ALC |
| 52:04:08 Anti-Infectives Sulfonamide | <u>s</u> | |
| Sulfacetamide (Sodium) 10% Oph Oint-3.5g Pk | 028347 Sulamyd 252522 Cetamide | 1.6485 SCH ALC |
| Sulfacetamide (Sodium) 30% Oph Sol | 028061 Sulamyd | .2347 SCH |
| Sulfacetamide (Sodium) 10% Oph Sol | 000965 Isopto Cetamide 001287 Bleph-10 028053 Sulamyd | ALC ALL SCH |
| 52:04:12 Anti-Infectives Other Anti- | Infectives | |
| Idoxuridine 0.5% Oph Oint-4g Pk | 027200 Stoxil | 13.0000 SKF |
| Idoxuridine 0.1% Oph Sol | 001120 Herplex 027014 Stoxil | .6390 ALL SKF |
| Trifluridine 1% Oph Sol | 589055 Viroptic | 2.5330 BWE |
| Vidarabine 3% Oph Oint-3.5g Pk | 381780 Vira-A | 11.4400 PDA |
| 52:08:00 Anti-Inflammatory Agents | | |
| Beclomethasone Dipropionate Nas Sp 200-dose Pk | 359688 Becomase 422053 Vancenase | AHA SCH |
| Dexamethasone 0.1% Oph Oint-3.5g Pk | 042579 Maxidex | 5.0700 ALC |

| 52:08:00 Anti-Inflammatory Agents | | |
|--|-----------------------------------|----------------|
| Dexamethasone 0.1% Oph Sol | 042560 Maxidex | 1.3500 ALC |
| Dexamethasone 0.1% Oph/Ot Sol | 016217 Decadron | 1.4180 MSD |
| Flumethasone Pivalate & Iodochlorhydroxyq 0.02% & 1% Ot Sol | orin 074454 Locacorten-Vioform | .9320 CIB |
| Flunisolide 0.025% Nas Sp-25mL Pk | 421456 Rhinalar | 14.5500 SYP |
| Fluorometholone 0.1% Oph Susp | 247855 FML | 1.0610 ALL |
| Hydrocortisone & Atropine Sulfate 2.5% & 1% Oph Oint-3g Pk | 062251 HC-Atropine 17 | 13.3500 AHA |
| Methylprednisolone 0.1% Oph Oint-3g Pk | #358711 Medrol | 2.3500 UPJ |
| Methylprednisolone 0.1% Oph/Ot Sol | 030791 Medrol | .9000 UPJ |
| Prednisolone Acetate 1% Oph Sol | 301175 Pred Forte | 1.0200 ALL |
| Prednisolone Acetate 0.12% Oph Sol | 299405 Pred Mild | .9240 ALL |
| Prednisolone Acetate & Atropine Sulfate 0.25% & 1% Oph Sol | 411124 Mydrapred | 1.8500 ALC |
| Prednisolone Sodium Phosphate 17 Oph Sol | +526460 Inflamase Forte | 1.2240 CEV |
| Prednisolone Sodium Phosphate 0.125% Oph Sol | +526452 Inflamase Mild | 1.0900 CEV |
| 52:16:00 Local Anesthetics Benzydamine HCl | | .0505 |
| 0.15% Oral Rinse | 574171 Tantum | RIK .0650 |
| 2% 0/L | 001686 Xylocaine Viscous | AST |
| 52:20:00 Miotics Carbachol | 000000 1 | .6574 |
| 3% Oph Sol | 000663 Isopto Carbachol | ALC |

| 52:20:00 Miotics | | |
|--|--|---------------------|
| Carbachol 1.5% Oph Sol | 000655 Isopto Carbachol | .5454 ALC |
| Echothiophate Iodide 0.25% Oph Sol | 002348 Phospholine Iodide | 3.2460 AYE |
| Echothiophate Iodide 0.125% Oph Sol | 002313 Phospholine Iodide | 2.8660 AYE |
| Echothiophate Iodide 0.06% Oph Sol | 052817 Phospholine Iodide | 2.4980 AYE |
| Pilocarpine HCl 4% Oph Gel | +575240 Pilopine HS | 2.1280 ALC |
| Pilocarpine HCl 6% Oph Sol | 000892 Isopto Carpine 526738 Miocarpine | .2688 ALC CEV |
| Pilocarpine HCl 4% Oph Sol | 000884 Isopto Carpine 527572 Miocarpine | ALC CEV |
| Pilocarpine HCl 3% Oph Sol | #000876 Isopto Carpine | .3080 |
| Pilocarpine HCl 2% Oph Sol | 000868 Isopto Carpine 527556 Miocarpine | .1665 ALC CEV |
| Pilocarpine HC1 1% Oph Sol | 000841 Isopto Carpine 527548 Miocarpine | ALC CEV |
| Pilocarpine HCl 0.5% Oph Sol | 000833 Isopto Carpine | .2576 ALC |
| Pilocarpine HCl & Epinephrine Bitartrate 6% & 1% Oph Sol | 526428 E-Pilo 6 | .7157 CEV |
| Pilocarpine HC1 & Epinephrine Bitartrate 4% & 1% Oph Sol | 526401 E-Pilo 4 | .6776 CEV |
| Pilocarpine HCl & Epinephrine Bitartrate 2% & 1% Oph Sol | 526371 E-Pilo 2 | .6037 CEV |
| Pilocarpine HCl & Epinephrine Bitartrate 17 & 17 Oph Sol | 526363 E-Pilo 1 | .5992 CEV |
| 52:24:00 Mydriatics | | |
| Atropine Sulfate 1% Oph Oint-3.5g Pk | 252484 Atropine Sulfate | 3.3600 ALC |

| 52:24:00 Mydriatics | | | |
|--|--|------------|--------|
| tauruing Sulfata | | | .8042 |
| Atropine Sulfate 27 Oph Sol | 527955 SMP Atropine | CEV | .0042 |
| 2% Opii 301 | ozvos s.asprac | 021 | |
| Atropine Sulfate | | | .5264 |
| 1% Oph Sol | 035017 Isopto Atropine | ALC | |
| | 527947 SMP Atropine | CEV | |
| I - Comment - I - Comment | | | |
| Dipivefrin HCl | 500117 B | | 1.3574 |
| 0.1% Oph Sol | 529117 Propine | ALL | |
| Epinephrine Bitartrate | | | 1.3335 |
| 2% Oph Sol | 002356 Epitrate | AYE | 1.5555 |
| 2% Opin 501 | oozooo aprerate | HIL | |
| Epinephrine HCl | | | .6149 |
| 2% Oph Sol | 001112 Epifrin | ALL | |
| | 358223 Glaucon | ALC | |
| | | | |
| Epinephrine HCl | | | .7045 |
| 1% Oph Sol | 001104 Epifrin | ALL | |
| | 358231 Glaucon | ALC | |
| | | | |
| Epinephrine HC1 | 001000 F : C : | | .7291 |
| 0.5% Oph Sol | 001090 Epifrin | ALL | |
| Epinephryl Borate | | | .6000 |
| 1% Oph Sol | 323659 Eppy/N 1% | вні | .0000 |
| 1% Opn 301 | obooo bpp//// in | 241 | |
| Epinephryl Borate | | | .5590 |
| 0.5% Oph Sol | #323640 Eppy/N 1/2% | BHI | |
| | | | |
| Homatropine HBr | | | .5667 |
| 5% Oph Sol | 000787 Isopto Homatropin | e ALC | |
| A company of the comp | | | |
| Homatropine HBr | 000770 7 + 11 + 1 | | .4782 |
| 2% Oph Sol | 000779 Isopto Homatropin | e ALC | |
| Phenylephrine HCl | | | .8064 |
| 2.5% Oph Sol | 465763 Mydfrin | ALC | .0004 |
| 2.0% Opn 501 | 100100, 411 1 | | |
| Phenylephrine HCl | | | .2834 |
| 0.12% Oph Sol | 395161 Prefrin | ALL | |
| | | | |
| 52:32:00 Vasoconstrictors | | | |
| | | | |
| Naphazoline HCl (OTC) | | | 5.4000 |
| 0.1% Oph Sol 15mL Pk | 001147 Albalon | ALL | |
| | 343978 Opcon | HCI ALC | |
| | 390283 Naphcon Forte 528005 Vasocon | CEV | |
| | 320003 VaSucun | CEV | |
| Oxymetazoline HCl | | , | .2860 |
| 0.025% Oph Sol | 543454 Ocuclear | SCH | |
| | | | |

| 12:32:00 Vasoconstrictors | | | | |
|--|---|---|-------------------|--|
| Phenylephrine HCl (OTC) | | | | 3.7000 |
| 0.25% Nas Sol 25mL Pk | #561819 | Neo-Synephrine | STP | |
| (vlometazoline HCl (OTC) | | | | 2.0000 |
| 0.1% Nas Sol 25mL Pk | 537411 | Sustaine | WIN | |
| | 650854 | Otrivin | CIB | |
| (ylometazoline HCl (OTC) | | | | 1.9000 |
| 0.05% Nas Sol 25mL Pk | | Sustaine | WIN | |
| | 623458 | Otrivin | CIB | |
| 52:36:00 Other Eye, Ear, Nose and Throa | t Agents | | | |
| Acetazolamide | 405000 | | | |
| 500mg LA Cap | 127930 | Diamox | LED | .514 |
| Acetazolanide | 014007 | Diamox | LED | .0204 |
| 250mg Tab | | Acetazolam | ICN | |
| | | Novozolamide | NOP | |
| | | Apo-Acetazolamide | APX | |
| | | | | |
| Dextram 40/Hydroxypropyl Methylcellulos | | v | 1107 | .2554 |
| Oph Sol | 544787 | Muro Tears | HCI | |
| Dextran 70/Hydroxypropyl Methylcellulos | | | | .2912 |
| Oph Sol | 390291 | Tears Naturale | ALC | |
| lydroxyethylcellulose & Polyvinylpyrrol | | | | .2912 |
| Oph Sol | 656216 | Adsorbotear | ALC | |
| Indomethacin | | | | |
| | | | | 3.3600 |
| 1% Oph Susp | 594458 | Indocid | MSD | 3.3600 |
| 1% Oph Susp .evobunolol HCl | 594458 | Indocid | | 3.3600 |
| | | Indocid Betagan | MSD | |
| evobunolol HCl 0.5% Oph Sol | +637661 | Betagan | ALL | 1.5560 |
| .evobunolol HCl 0.5% Oph Sol | +637661 | Betagan Isopto Tears | ALL | 1.5560 |
| evobunolol HCl 0.5% Oph Sol | +637661 | Betagan | ALL | 1.5560 |
| evobunolol HCl 0.5% Oph Sol | +637661 | Betagan Isopto Tears | ALL | 1.5560 |
| evobunolol HCl 0.5% Oph Sol Methylcellulose 1% Oph Sol | +637661 000817 514705 | Betagan Isopto Tears | ALL | 1.5560 |
| evobunolol HCl 0.5% Oph Sol Methylcellulose 1% Oph Sol | +637661 000817 514705 | Betagan Isopto Tears Murocel | ALC HCI | .2949 |
| evobunolol HCl 0.5% Oph Sol Methylcellulose 1% Oph Sol Methylcellulose 0.5% Oph Sol | +637661 000817 514705 000809 | Betagan Isopto Tears Murocel | ALC HCI | .2949 |
| evobunolol HCl 0.5% Oph Sol Methylcellulose 1% Oph Sol Methylcellulose 0.5% Oph Sol Petrolatum & Mineral Oil (DPP) 94% & 3% Oph Oint-3.5g Pk | +637661 000817 514705 000809 | Betagan Isopto Tears Murocel Isopto Tears | ALC HCI ALC | 1.5560 .2949 .2722 |
| evobunolol HCl 0.5% Oph Sol Methylcellulose 1% Oph Sol Methylcellulose 0.5% Oph Sol Petrolatum & Mineral Oil (DPP) 94% & 3% Oph Oint-3.5g Pk Petrolatum & Mineral Oil (DPP) | +637661 000817 514705 000809 469688 | Betagan Isopto Tears Murocel Isopto Tears Duratears | ALC HCI | 1.5560 .2949 .2722 |
| evobunolol HCl 0.5% Oph Sol Methylcellulose 1% Oph Sol Methylcellulose 0.5% Oph Sol Petrolatum & Mineral Oil (DPP) 94% & 3% Oph Oint-3.5g Pk Petrolatum & Mineral Oil (DPP) 80% & 20% Oph Oint-3.5g Pk | +637661 000817 514705 000809 469688 | Betagan Isopto Tears Murocel Isopto Tears | ALC HCI ALC | 1.5560 .2949 .2722 2.9265 2.8798 |
| evobunolol HCl 0.5% Oph Sol Methylcellulose 1% Oph Sol Methylcellulose 0.5% Oph Sol Petrolatum & Mineral Oil (DPP) 94% & 3% Oph Oint-3.5g Pk Petrolatum & Mineral Oil (DPP) | +637661 000817 514705 000809 469688 514691 | Betagan Isopto Tears Murocel Isopto Tears Duratears | ALC HCI | |

| 52:36:00 Other Eye, Ear, Nose and Throat | Aranto | | | |
|---|---------|-----------------|-----|---------|
| 52:36:00 Other Eye, Ear, Nose and Inroal | Agents | | | |
| Polyvinyl Alcohol 3% Oph Sol | 368911 | Liquifilm Forte | ALL | .3461 |
| Polyvinyl Alcohol 1.4% Oph Sol | 045616 | Liquifilm Tears | ALL | .2341 |
| Polyvinyl Alcohol 1% Oph Sol | +606391 | Hypotears | CEV | .1717 |
| Polyvinyl Alcohol 0.1% Oph Sol | 469033 | Neo-Tears | вні | . 2300 |
| Polyvinyl Alcohol & Polyvinylpyrrolidone Oph Sol | 579408 | Tears Plus | ALL | .2341 |
| Sodium Carboxymethylcellulose & Gelatin & Oral Top Oint | | Orabase | squ | .3453 |
| Sodium Chloride 5% Oph Oint-3.5g Pk | 514675 | Muro-128 | нсі | 3.7917 |
| Sodium Chloride 5% Oph Sol | 514667 | Muro-128 | нсі | .2949 |
| Sodium Cromoglycate 2% Nas Sol-26mL Pk | 605255 | Rynacrom | FIS | 16.6010 |
| Sodium Cromoglycate 2% Oph Sol | 394300 | Opticrom | FIS | 1.1470 |
| Sodium Cromoglycate 10mg/Cart Pd Inh | 328944 | Rynacrom | FIS | .2112 |
| Timolol Maleate 0.5% Oph Sol | 451207 | Timoptic | MSD | 2.2960 |
| Timolol Maleate 0.25% Oph Sol | 451193 | Timoptic | MSD | 1.9400 |

| 56:04:00 Antacids and Adsorbents | | | | |
|---|---------|------------------------|-----|--------|
| | | | | |
| * Aluminum Hydroxide | | | | .0090 |
| 60mg/mL O/L | 034002 | Amphojel | WYE | |
| | | | | |
| Aluminum Hydroxide | | | | .0805 |
| 600mg Tab | 208965 | Amphojel | WYE | |
| | | | | |
| Aluminum Hydroxide (Dried Gel) | | | | .0892 |
| 600mg Tab | 313297 | Alu-Tab | RIK | |
| | | | | |
| Aluminum Hydroxide & Magnesium Hydroxide | (DPP) | | | .1001 |
| 600mg & 300mg Chew Tab | 541125 | Maalox TC | ROR | |
| | 621544 | Diovol Ex | HOR | |
| | | | | |
| Aluminum Hydroxide & Magnesium Hydroxide | (DPP) | | | .0138 |
| 130mg & 70mg/mL 0/L | 531154 | Gelusil Extra Strength | PDA | |
| | | | | |
| Aluminum Hydroxide & Magnesium Hydroxide | (DPP) | | | .0143 |
| 120mg & 60mg/mL 0/L | 491217 | Diovol Ex | HOR | |
| | 497037 | Maalox TC | ROR | |
| | | | | |
| Aluminum Hydroxide & Magnesium Hydroxide | (DPP) | | | .0131 |
| 100mg & 100mg/mL 0/L | 515655 | Amphojel 500 | WYE | |
| | | | | |
| Aluminum Hydroxide & Magnesium Hydroxide | (DPP) | | | .0131 |
| 80mg & 80mg/mL O/L | 420646 | Mylanta-2 Plain | PDA | |
| | | | | |
| * Aluminum Hydroxide & Magnesium Hydroxid | e (DPP) | | | .0085 |
| 40mg & 40mg/mL O/L | 013625 | Univol | HOR | |
| | 026530 | Maalox | ROR | |
| | 261173 | Neutralca-S | DES | |
| | 476471 | Gelusil | PDA | |
| | | | | |
| Aluminum Hydroxide & Magnesium Hydroxide | (DPP) | | | .0632 |
| 400mg & 400mg Tab | 026549 | Maalox | ROR | |
| | 483605 | Gelusil 400 | PDA | |
| | | | | |
| Aluminum Hydroxide & Magnesium Hydroxide | (DPP) | | | .0607 |
| 200mg & 200mg Tab | 476455 | Gelusil | PDA | |
| | | | | |
| Magaldrate | | | | .0521 |
| 480mg Chew Tab | 571229 | Riopan | AYE | |
| | | | | |
| Magaldrate | | | | .0085 |
| 96mg/mL O/L | 571202 | Riopan | AYE | |
| | | | | |
| Magaldrate | | | | .0122 |
| 1080mg/mL 0/L | +640476 | Riopan Extra Strength | AYE | |
| | | | | |
| * Magnesium Hydroxide (OTC) | | | | |
| 80mg/mL O/L 450mL Pk | 036218 | Milk of Magnesia | WAM | 3.1500 |
| | | | | |
| * Magnesium Hydroxide (OTC) | | | | |
| 80mg/mL O/L 500mL Pk | 093807 | Milk of Magnesia | DTC | 2.9000 |
| | | | | |

| 56:04:00 Antacids and Adsorbents | | | | |
|--|---------|-----------------------|------------|--------|
| Magnesium Hydroxide (OTC) 300mg Tab 100 Pk | 093815 | Milk of Magnesia | DTC | 2.3000 |
| 56:08:00 Antidiarrhea Agents | | | | |
| Camphorated Tincture of Opium (Paregoric $0/L$ | | Camphor Co. Tincture | DTC | .0176 |
| Diphenoxylate HCl O.5mg/mL O/L | 399353 | Lomotil | SEA | .1480 |
| Diphenoxylate HCl 2.5mg Tab | 399345 | Lomotil | SEA | .2478 |
| Kaolin & Pectin & Paregoric O/L | 346756 | Donnagel-PG | ROB | .0260 |
| * Kaolin & Pectin Compound O/L | 030864 | Kaopectate | UPJ | .0076 |
| Loperamide HCl 2mg Cap | 579343 | Imodium | JAN | .4130 |
| Loperamide HCl 0.2mg/mL O/L | 610062 | Imodium | JAN | .0717 |
| 56:12:00 Cathartics | | | | |
| Bisacodyl (OTC) 2mg/mL Enema 5mL Pk | 286265 | Dulcolax | BOE | 4.1000 |
| * Bisacodyl (OTC) | | | | 1.5000 |
| 5mg Ent Tab 30 Pk | | Dulcolax Bisacolax | BOE | |
| | | Apo-Bisacodyl | APX | |
| Bisacodyl (OTC) | | | | 1.6800 |
| 10mg/5mL Rect Sol 5mL Pk | #067369 | Dulcolax | BOE | |
| Bisacodyl (OTC) 5mg Sup 3 Pk | 003867 | Dulcolax | BOE | 4.1000 |
| Bisacodyl (OTC) | 000075 | D-11- | DOE | 1.6500 |
| 10mg Sup 6 Pk | | Dulcolax Bisacolax | BOE | |
| | | Bisacodyl | TCH | |
| Cascara Sagrada (OTC) | | | | 4.4500 |
| 300mg Tab 100 Pk | | Cascara Sagrada | PDA DTC | |
| Castor Oil (OTC) | | | | 8.3000 |
| Emuls 115mL Pk | 127922 | Neoloid | LED | |

| 56:12:00 Cathartics | | | | |
|--|--------|---|-------------------|---------|
| Castor Oil (OTC) O/L 50mL Pk | 094080 | Castor Oil | DTC | 1.6000 |
| Danthron (OTC) 7.5mg/mL O/L 114mL Pk | 323810 | Modane | ADI | 9.5500 |
| Danthron (OTC) 75mg Tab 100 Pk | | Dorbane Modane | RIK | 19.5000 |
| Docusate Calcium (Dioctyl Calcium Sulfosuce 50mg Cap 100 Pk | | (OTC) Surfak | ное | 20.6000 |
| Docusate Calcium (Dioctyl Calcium Sulfosuco 240mg Cap 30 Pk | 012491 | (OTC) Surfak pms-Docusate Calcium | HOE PMS | 7.2000 |
| * Docusate Sodium (Dioctyl Sodium Sulfosuco 100mg Cap 100 Pk | 464767 | (OTC) Colace Regulex | BRI AYE | 8.3000 |
| Docusate Sodium (Dioctyl Sodium Sulfosuccin | 473111 | Docusate Sodium | KLP | 11.3000 |
| 4mg/mL O/L 250mL Pk Docusate Sodium (Dioctyl Sodium Sulfosuccir | | Colace | BRI | 8.3000 |
| 10mg/mL O/L 25mL Pk | | Colace | BRI | |
| * Glycerin (OTC) 2.7g Sup 24 Pk | 990825 | Glycerin Glycerin Glycerin | PDA ROG DTC | 2.1000 |
| * Glycerin (OTC) 1.8g Sup 24 Pk | | Glycerin Glycerin | ROG PDA | 2.2000 |
| A Creative & City on Fill (1970) | | Glycerin | DTC | 4 4000 |
| * Grain & Citrus Fibre '(OTC) Tab 100 Pk | | Fibyrax Novo-Fibre | ROU | 4.4000 |
| * Magnesium Hydroxide (OTC) 80mg/mL O/L 450mL Pk | 036218 | Milk of Magnesia | WAM | 3.2000 |
| * Magnesium Hydroxide (OTC) 80mg/mL O/L 500mL Pk | 093807 | Milk of Magnesia | DTC | 2.9000 |
| dagnesium Hydroxide (OTC) 300mg Tab 100 Pk | 093815 | Milk of Magnesia | DTC | 2.3000 |
| lineral Oil (OTC) Enema 130mL Pk | 107875 | Fleet | FRS | 4.9000 |

| 56:12:00 Cathartics | | |
|--|--|---|
| * Mineral Oil (OTC) O/L 500mL Pk | 093947 Mineral Oil | 3.8000 DTC |
| Psyllium Mucilloid (OTC) Gran 100g Pk | 536695 Prodiem Plain | 4.6000 ROR |
| * Psyllium Mucilloid (OTC) Oral Pd 340g Pk | 242438 Metamucil 387177 Karacil 545465 Dispensalax 551546 Novo-Mucilax 599875 Natural Source Laxat | 4.2000 SEA ICN DPP NOP ive LEA |
| * Psyllium Seed Husks (OTC) Oral Pd 450g Pk | 990078 Siblin | 19.0000 PDA |
| Sennosides A & B (OTC) 15mg/3g Gran 200g Pk | 026042 Senokot | 11.7000 PFR |
| Sennosides A & B (OTC) 5mg/mL O/L 250mL Pk | 367729 Senokot | 11.1000 PFR |
| Sennosides A & B (OTC) 30mg Sup 6 Pk | 026107 Senokot | 4.8000 PFR |
| * Sennosides A & B (OTC) 12mg Tab 100 Pk | 027502 Glysennid | 12.5000 SAN |
| * Sennosides A & B (OTC) 8.6mg Tab 100 pk | 026158 Senokot 604402 Glysennid | 9.2000 PFR SAN |
| Sodium Biphosphate & Sodium Phosphate (160mg & 60mg/mL Ped Rect Sol 65mL Pk | 0TC) 108065 Fleet | 3.2500 FRS |
| * Sodium Biphosphate & Sodium Phosphate 160mg & 60mg/mL Rect Sol 130mL Pk | (OTC) 009911 Fleet | 3.5000 FRS |
| Sodium Citrate & Sodium Lauryl Sulfoacet Micro Enema 4 Pk | ate (OTC) +024848 Microlax | 4.5000 PHD |
| 56:16:00 Digestants | | |
| Aprotinin 100,000KIU/10mL Inj Sol-10mL Pk | 513954 Trasylol | 23.0160 MIT |
| Glutamic Acid HCl 340mg Cap | 015210 Acidulin | .1569 LIL |
| Pancreatin Oral Pd-115g Pk | 651672 Viokase | 28.8512 ROB |

| 56:16:00 Digestants | | | |
|---|--|--------|--------|
| Pancreatin | | | .1075 |
| 325mg Tab | 651680 Viokase | ROB | .10/5 |
| | | | |
| Pancrelipase equivalent to Lipase & Anylase 8,000 & 30,000 & 30,000USP U Cap | 263818 Cotazym | ORG | .1317 |
| 8,000 & 30,000 & 30,000csr v cap | 203010 COLAZYA | UKG | |
| Pancrelipase equivalent to Lipase & Amylase | & Protease | | .2734 |
| 8,000 & 30,000 & 30,000USP U | Market Comment and | | |
| Ent Microsph Cap | 502790 Cotazym ECS | ORG | |
| Pancrelipase equivalent to Lipase & Amylase | & Protease | | .2132 |
| 4,000 & 20,000 & 25,000USP U | | | |
| Ent Microsph Cap | 591548 Pancrease | MCN | |
| | | | |
| 56:22:00 Antiemetics and Antinauseants | | | |
| Dimenhydrinate | | | .9397 |
| 50mg/5ml Inj Sol-5ml Pk | 013560 Gravol | HOR | |
| | 511986 Dimenhydrinate | SQU | |
| | | | |
| Dimenhydrinate | 013579 Gravol | HOR | 1.4000 |
| 250mg/5mL Inj Sol-5mL Pk | 511994 Dimenhydrinate | SOU | |
| | 311334 Dimensydi Inate | 266 | |
| * Dimenhydrinate | | | .0367 |
| 3mg/mL O/L | 230197 Gravol | HOR | |
| A Dib-dui | | | .2489 |
| * Dimenhydrinate 50mg Sup | 013595 Gravol | HOR | .2407 |
| down out | 0.0000 | 20021 | |
| * Dimenhydrinate | | | .2620 |
| 100mg Sup | 013609 Gravol | HOR | |
| A Dihadainada | | | .0060 |
| * Dimenhydrinate 50mg Tab | 013803 Gravol Filmkote | HOR | .0000 |
| oung sau | 021423 Novodimenate | NOP | |
| | 209783 Dimenhydrinate | SAP | |
| | 272671 Travamine | ICN | |
| | 363766 Apo-Dimenhydrinate | APX | |
| | 398381 Dimenhydrinate | DTC | |
| | 457515 Dimenhydrinate 586331 PMS-Dimenhydrinate | PMS | |
| | Journal of Menny di Inate | 1 1112 | |
| * Dimenhydrinate | | | .1299 |
| 15mg Tab | 511196 Gravol Filmkote | HOR | |
| W1:-: PC | | | 1007 |
| Meclizine HCl 25mg Tab | 220442 Bonamine | PFI | .1803 |
| 2008 120 | 220772 DUNAMINE | LLI | |
| Nahilone | | | 4.5300 |
| lng Cap | 548375 Cesamet | LIL | |

| 01 4111 | | | | .1289 |
|----------------------------------|---------|----------------|-------|--------|
| Cimetidine 60mg/mL O/L | 397482 | Tagamet | SKF | .1289 |
| Cimetidine | | | | .2406 |
| 800mg Tab | 618616 | Peptol | HOR | |
| Cimetidine | | | | .1481 |
| 600mg Tab | | Tagamet | SKF | |
| | | Peptol | HOR | |
| | | Apo-Cimetidine | APX | |
| | 603686 | Novocimetine | NOP | |
| Cimetidine | | | | .1160 |
| 400mg Tab | 563579 | Tagamet | SKF | |
| | 568449 | Peptol | HOR | |
| | | Apo-Cimetidine | APX | |
| | 603678 | Novocimetine | NOP | |
| Cimetidine | | | | .0750 |
| 300mg Tab | 397474 | Tagamet | SKF | |
| Joons 125 | | Apo-Cimetidine | APX | |
| | | Peptol | HOR | |
| | 582417 | Novocimetine | NOP | |
| Cimetidine | | | | .0630 |
| 200mg Tab | 546232 | Peptol | HOR | |
| 200mg 1ab | | Tagamet | SKF | |
| | | Novocimetine | NOP | |
| | 584215 | Apo-Cimetidine | APX | |
| D | | | | .1900 |
| Domperidone | +6428E1 | Motilium | JAN | .1500 |
| 10mg Tab | +042831 | MOCITION | o n.v | |
| Lactulose | | | - | .0388 |
| 666.7mg/mL O/L | 444316 | Cephulac | MER | |
| Metoclopramide HCl | | | | 1.2200 |
| 10mg/2mL Inj Sol-2mL Pk | 314706 | Maxeran | NRD | |
| | 386006 | Reglan | ROB | |
| Mataglaryanida UCl | | | | .0242 |
| Metoclopramide HCl lmg/mL O/L | 314714 | Maxeran | NRD | 10240 |
| Img/ mt 0/ L | | Reglan | ROB | |
| | | | | 0755 |
| Metoclopramide HCl | E70040 | Marraman | NRD | .0755 |
| 5mg Tab | | Maxeran | ROB | |
| | +631671 | vegiau | KOB | |
| Metoclopramide HCl | | | | .0820 |
| 10mg Tab | 314722 | Maxeran | NRD | |
| | | Reglan | ROB | |
| | +60377 | 5 Fmey | BEE | |

56:00 Gastrointestinal Drugs

| Pirenzepine Dihydrochloride 50mg Tab | 608998 Gastrozepin | .4620 BOE |
|---|--------------------|---------------|
| Ranitidine HC1 50mg/2mL Inj Sol-2mL Pk | 603791 Zantac | 1.9060 GLA |
| Ranitidine HCl 300mg Tab | +641790 Zantac | 1.5625 GLA |
| Ranitidine HCl 150mg Tab | 553379 Zantac | .8223 GLA |
| Sucralfate 1g Tab | 506346 Sulcrate | .3248 NRD |

60:00 Gold Compounds

| Auranofin 3mg Cap | +600733 Ridaura | 1.1000 SKF |
|---|--------------------|----------------|
| Sodium Aurothiomalate 50mg/mL Inj Sol-1mL Pk | 025089 Myochrysine | 12.8576 RPP |
| Sodium Aurothiomalate 25mg/mL Inj Sol-1mL Pk | 025070 Myochrysine | 8.2805 RPP |
| Sodium Aurothiomalate 10mg/mL Inj Sol-1mL Pk | 025062 Myochrysine | 6.8280 RPP |

64:00 Heavy Metal Antagonists

| Calcium | Disc | dium | Edetate |
|---------|------|-------|-------------|
| 1000mg/ | Sml. | Ini : | Sol-5ml. Pk |

13.8507 026239 Calcium Disodium Versenat RIK

| 68:04:00 Corticosteroids | |
|--|--|
| Beclomethasone Dipropionate 200mcg/Cart Pd Inh | 545333 Beclovent Rotacaps AHA |
| Beclomethasone Dipropionate 100mcg/Cart Pd Inh | .17 545325 Beclovent Rotacaps AHA |
| Beclomethasone Dipropionate Aero Pd-200 dose Pk | 10.90 334243 Beclovent AHA 374407 Vanceril SCH |
| Betamethasone 0.5mg Tab | .25 012211 Betnelan GLA 028185 Celestone SCH |
| Betamethasone Acetate & Betamethason 3mg & 3mg/mL Inj Susp-1mL Pk | e Disodium Phosphate 3.44 028096 Celestone Soluspan SCH |
| Cortisone Acetate 5mg Tab | .08 016438 Cortone MSD |
| Cortisone Acetate 25mg Tab | .08 016446 Cortone MSD 249963 Cortisone UPJ 280437 Cortisone-ICN ICN |
| Dexamethasone 4mg Tab | .11 349100 Hexadrol ORG |
| | 354309 Decadron MSD 489158 Dexasone ICN 504416 Deronil SCH |
| Dexamethasone 0.75mg Tab | .05. 285471 Dexasone ICN 501069 Deronil SCH |
| Dexamethasone 0.5mg Tab | .03: 016462 Decadron MSD |
| | 295094 Dexasone ICN 501050 Deronil SCH |
| Dexamethasone Tertiary-Butylacetate 20mg/5mL Inj Susp-5mL Pk | #016268 Decadron T.B.A. MSD |
| Dexamethasone 21-Phosphate 20mg/5mL Inj Sol-5mL Pk | 12.900 213624 Decadron MSD 269026 Hexadrol ORG |
| Fludrocortisone Acetate 0.1mg Tab | 029351 Florinef SQU |
| Hydrocortisone 20mg Tab | 030929 Cortef UPJ |

| 68:04:00 Corticosteroids | | |
|---|--|---------------|
| Hydrocortisone Sodium Succinate | | 1.4400 |
| Inj Pd-100mg Pk | 030600 Solu-Cortef | UPJ |
| Hydrocortisone Sodium Succinate | | 5.1100 |
| Inj Pd-1000mg Pk | 030635 Solu-Cortef | UPJ |
| Hydrocortisone Sodium Succinate | | 2.2300 |
| Inj Pd-250mg Pk | 030619 Solu-Cortef | UPJ |
| Hydrocortisone Sodium Succinate | | 3.7300 |
| Inj Pd-500mg Pk | 030627 Solu-Cortef | UPJ |
| Methylprednisolone | | .2485 |
| 4mg Tab | 030988 Medrol | UPJ |
| Methylprednisolone Acetate | | 6.9000 |
| 80mg/mL Inj Susp-1mL Pk | 030767 Depo-Medrol | UPJ |
| Methylprednisolone Acetate | | 3.5900 |
| 40mg/mL Inj Susp-1mL Pk | 030759 Depo-Medrol | UPJ |
| Methylprednisolone Acetate | | 6.0500 |
| 100mg/5ml Inj Susp-5ml Pk | 030740 Depo-Medrol | UPJ |
| Methylprednisolone Sodium Succinate | | 8.9600 |
| Inj Pd-125mg Pk | 030651 Solu-Medrol | UPJ |
| Methylprednisolone Sodium Succinate Inj Pd-40mg Pk | 030643 Solu-Medrol | 3.7800 UPJ |
| Inj Id-30mg IK | 030043 S01E-MedF01 | UPS |
| Methylprednisolone Sodium Succinate | 030678 Soln-Medrol | 22.4600 |
| Inj Pd-500mg Pk | USU678 Solf-Medrol | UPJ |
| Prednisone | 020220 1 | .0825 |
| 50mg Tab | 232378 Novoprednisone 252417 Deltasone | NOP UPJ . |
| | 550957 Apo-Prednisone | APX |
| Prednisone | | .0086 |
| 5mg Tab | 021695 Novoprednisone | NOP |
| | 093629 Prednisone | DTC |
| | 210188 Deltasone | UPJ |
| | 232092 Prednisone | SAP |
| | +271381 Winpred | ICN |
| | 312770 Apo-Prednisone 610623 Prednisone | APX KNR |
| B 1 | | |
| Prednisone | 971979 WiI | .0624 |
| lmg Tab | 271373 Wimpred | ICN |
| | 598194 Apo-Prednisone | APX |
| Triamcinolone | | .3900 |
| 4mg Tab | 015024 Aristocort | LED |

| 68:04:00 Corticosteroids | | |
|--|--------------------------|----------------|
| Triamcinolone 4mg Tab | 029475 Kenacort | .3900 SQU |
| Triamcinolone 2mg Tab | 015016 Aristocort | .2050 LED |
| Triamcinolone Acetonide 40mg/mL Inj Susp-1mL Pk | 990876 Kenalog-40 | 3.1200 SQU |
| Triamcinolone Acetonide 50mg/5mL Inj Susp-5mL Pk | 460761 Kenalog-10 | 6.7200 SQU |
| Triamcinolone Acetonide 200mg/5mL Inj Susp-5mL Pk | 029300 Kenalog-40 | 10.5600 Sọu |
| Triamcinolone Hexacetonide 20mg/mL Inj Susp-1mL Pk | 297151 Aristospan | 3.9000 LED |
| 68:08:00 Androgens | | |
| Fluoxymesterone 5mg Tab | 030902 Halotestin | .1132 UPJ |
| Methyltestosterone 25mg Tab | 005630 Metandren | .7000 |
| Methyltestosterone 10mg Tab | 005622 Metandren | .2790 CIB |
| Nandrolone Phenpropionate 100mg/2mL Oily Inj Sol-2mL Pk | 022489 Durabolin | 15.9300 ORG |
| Nandrolone Phenpropionate 125mg/5mL Oily Inj Sol-5mL Pk | 022470 Durabolin | 19.3000 ORG |
| Oxymetholone 50mg Tab | 189421 Amapolon-50 | 1.2238 SYN |
| Stanozolol 2mg Tab | 033812 Winstrol | .2060 WIN |
| Testosterone Cypionate 100mg/mL Oily Inj Sol-1mL Pk | 030783 Depo-Testosterone | 3.4000 UPJ |
| Testosterone Enanthate 1000mg/5mL Oily Inj Sol 5mL Pk | 029246 Delatestryl | 10.0800 SQU |
| 68:16:00 Estrogens | | |
| Chlorotrianisene | | .8216 |

| 68:16:00 Estrogens | | | | |
|--|---------|-----------------------|------------|-------|
| Chlorotrianisene | | | | .3875 |
| 12mg Cap | 017965 | Tace | MER | |
| Conjugated Estrogens | | | | |
| 2.5mg Tab | 002593 | Premarin | AYE | .3233 |
| | #252611 | l Oestrilin | DES | .2100 |
| | | | | |
| | | | | |
| Conjugated Estrogens 1.25mg Tab | 002585 | Premarin | AYE | .0746 |
| 1.20mg 100 | | Oestrilin | DES | |
| | | C.E.S. | ICN | |
| and the second s | | | | |
| Conjugated Estrogens | 000577 | | | .0452 |
| 0.625mg Tab | | Premarin Oestrilin | AYE | |
| | | C.E.S. | DES ICN | |
| | 200770 | U.E.S. | ICH | |
| Conjugated Estrogens | | | | |
| 0.3mg Tab | | Premarin | AYE | .0617 |
| | #252603 | 3 Oestrilin | DES | .0450 |
| | | | | |
| Contract I Francis | | | | |
| Conjugated Estrogens 0.625mg/g Vag Cr | กกวกรด | Premarin | AYE | .2478 |
| o.ozomg/g vag ci | 002083 | 11 Cmai In | ALE | |
| Dienestrol | | | | .0760 |
| 0.1mg/g Vag Cr | 441295 | Dienestrol | ORT | |
| Dienestrol | | | | 0017 |
| 0.1mg/g Vag Cr-App | #519360 | DV Cream | MER | .0813 |
| 5 tag | | Dienestrol | ORT | |
| | _ | | | |
| Ethinyl Estradiol | | | | .2146 |
| 0.5mg Tab | 028231 | Estinyl | SCH | |
| Ethinyl Estradiol | | | | .0986 |
| 0.05mg Tab | 028223 | Estinyl | SCH | .0986 |
| | 020220 | 200111, 1 | 000 | |
| Ethinyl Estradiol | | | | .0599 |
| 0.02mg Tab | 028215 | Estinyl | SCH | |
| Piperazine Estrone Sulfate (Estropipate) | | | | .3000 |
| 3mg Tab | 282677 | Ogen | ABB | .5000 |
| | | | | |
| Piperazine Estrone Sulfate (Estropipate) | 00000 | 0 | | .1896 |
| 1.5mg Tab | 282685 | Ugen | ABB | |
| Stilboestrol | | | | .1874 |
| 5mg Tab | 003379 | Stilboestrol | AHA | |
| | | | | |

| 68:16:00 Estrogens | | |
|--|--|---------------|
| Stilboestrol Img Tab | 003360 Stilboestrol | .1402 AHA |
| Stilboestrol 0.5mg Tab | 003352 Stilboestrol | .1492 AHA |
| Stilboestrol O.lmg Tab | 003336 Stilboestrol | .1148 AHA |
| Stilboestrol Sodium Diphosphate 250mg/5mL Inj Sol-5mL Pk | 013587 Honvol | 4.6640 HOR |
| Stilboestrol Sodium Diphosphate 100mg Tab | 013781 Honvol | . 4807 HOR |
| Sulfanilamide & Allantoin & Aminacrine HO Vag Cr | Cl & Dienestrol 134198 AVC/Dienestrol | .2065 |
| 68:20:01 Anti-Diabetic Agents Insulins | | |
| Insulin (Isophane) Beef & Pork (OTC) 1000U/10mL Inj Susp 10mL Pk | 446572 Iletin NPH | LIL 11.9000 |
| Insulin (Isophane) Beef & Pork (OTC) 1000U/10mL Inj Susp 10mL Pk | 612235 NPH Insulin | NOO 12.4000 |
| Insulin (Isophane) Human Biosynthetic (rI 1000U/10mL Inj Susp 10mL Pk | ONA Origin) (OTC) 587737 Humulin NPH | LIL 18.6500 |
| Insulin (Isophane) Human Semi-Synthetic 1000U/10mL Inj Susp 10mL Pk | (OTC) +612197 Novolin-NPH | NOO 18.1000 |
| Insulin (Isophane) Human Semi-Synthetic 1000U/10mL Inj Susp 10mL Pk | (OTC) +632651 Insulatard Human | HOR 18.9000 |
| Insulin (Isophane) Pork (OTC) 1000U/10mL Inj Susp 10mL Pk | 514551 Iletin II NPH | LIL 20.4000 |
| Insulin (Isophane) Pork (OTC) 1000U/10mL Inj Susp 10mL Pk | 552275 Insulatard | HOR 18.9000 |
| Insulin (Isophane) Pork (OTC) 1000U/10mL Inj Susp 10mL Pk | 612170 Protaphane MC (Pork) | NOO 19.9000 |
| Insulin (Lente) Beef & Pork (OTC) 1000U/10mL Inj Susp 10mL Pk | 446580 Iletin Lente | LIL 11.9000 |
| Insulin (Lente) Beef & Pork (OTC) 1000U/10mL Inj Susp 10mL Pk | 612278 Lente Insulin | NOO 12.4000 |
| Insulin (Lente) Human Semi-Synthetic (OT 1000U/10mL Inj Susp 10mL Pk | C) +612200 Novolin-Lente | NOO 18.1000 |

| 68:20:01 Anti-Diabetic Agents Insulins | |
|---|-------------|
| Insulin (Lente) Pork (OTC) 1000U/10mL Inj Susp 10mL Pk 514535 Iletin II Lente | LIL 20.4000 |
| Insulin (Lente) Pork (OTC) 1000U/10mL Inj Susp 10mL Pk 612359 Monotard MC (Pork) | NOO 19.9000 |
| Insulin (Neutral) Human Semi-Synthetic (OTC) 1000U/10mL Inj Sol 10mL Pk +632686 Velosulin Human | HOR 18.9000 |
| Insulin (Neutral) Pork (OTC) 1000U/10mL Inj Sol 10mL Pk 552267 Velosulin | HOR 18.9000 |
| Insulin (Protamine Zinc) Beef & Pork (OTC) 1000U/10mL Inj Susp 10mL Pk 446610 Iletin Protamine Zinc | LIL 11.9000 |
| Insulin (Protamine Zinc) Beef & Pork (OTC) 1000U/10mL Inj Susp 10mL Pk 612219 Protamine Zinc Insulin | NOO 12.4000 |
| Insulin (Semilente) Beef & Pork (OTC) 1000U/10mL Inj Susp 10mL Pk 446602 Iletin Semilente | LIL 11.9000 |
| Insulin (Semilente) Beef & Pork (OTC) 1000U/10mL Inj Susp 10mL Pk 612251 Semilente Insulin | NOO 12.4000 |
| Insulin (Sulfated) Beef (OTC) 1000U/10mL Inj Susp 10mL Pk 648094 Sulfated Insulin | N00 45.3500 |
| Insulin (Ultralente) Beef & Pork (OTC) 1000U/10mL Inj Susp 10mL Pk 446599 Iletin Ultralente | LIL 11.9000 |
| Insulin (Ultralente) Beef & Pork (OTC) 1000U/10mL Inj Susp 10mL Pk 612243 Ultralente Insulin | N00 12.4000 |
| Insulin (Zinc Crystalline) Beef & Pork (OTC) 1000U/10mL Inj Sol 10mL Pk 446564 Iletin Regular | LIL 11.9000 |
| Insulin (Zinc Crystalline) Beef & Pork (OTC) 1000U/10mL Inj Sol 10mL Pk 612227 Insulin-Toronto | NOO 12.4000 |
| Insulin (Zinc Crystalline) Human Biosynthetic (rDNA Origin) (OTC) 1000U/10mL Inj Sol 10mL Pk 586714 Humulin Regular | LIL 18.6500 |
| Insulin (Zinc Crystalline) Human Semi-Synthetic (OTC) 1000U/10mL Inj Susp 10mL Pk +612189 Novolin-Toronto | N00 18.1000 |
| Insulin (Zinc Crystalline) Pork (OTC) 1000U/10mL Inj Sol 10mL Pk 513644 Iletin II Regular | LIL 20.4000 |
| Insulin (Zinc Crystalline) Pork (OTC) 1000U/10mL Inj Sol 10mL Pk 612162 Actrapid MC (Pork) | N00 19.9000 |
| Insulin (30% Neutral and 70% Isophane) Human Semi-Synthetic (CTC) 1000U/10mL Inj Susp 10mL Pk +632694 Mixtard Human | HOR 18.9000 |

| 68:20:01 Anti-Diabetic Agents Insulins | | |
|--|---------------------------------|-------------|
| Insulin (30% Neutral and 70% Isophane) Por | ek (OTC) | |
| 1000U/10mL Inj Susp 10mL Pk | 552259 Mixtard | HOR 18.9000 |
| Insulin (50% Neutral & 50% Isophane) Human | Semi-Synthetic (OTC) | |
| 1000U/10mL Inj Susp 10mL Pk | +632678 Initard Human | HOR 18.9000 |
| Insulin (50% Neutral & 50% Isophane) Pork | (OTC) | |
| 1000U/10mL Inj Susp 10mL Pk | 614416 Initard | HOR 18.9000 |
| Insulin Injection (30%) & Insulin Isophane | (70%) Human Semi-Synthetic (OTC |) |
| 1000U/10mL Inj Susp 10mL Pk | +650935 Novolin 30/70 | NOO 18.1000 |
| Insulin Zinc Suspension Medium Human Biosy | onthetic (rDNA Origin) (OTC) | |
| 1000U/10mL Inj Susp 10mL Pk | +646148 Humulin L Lente | LIL 18.6500 |
| Insulin Zinc Suspension Prolonged, Human S | Semi-Synthetic (OTC) | |
| 1000U/10mL Inj Susp 10mL Pk | +644358 Novolin-Ultralente | NOO 18.1000 |
| 68:20:02 Anti-Diabetic Agents Oral Anti-Di | abetic Agents | |
| | | |
| Acetohexamide | | .2977 |
| 500mg Tab | 015598 Dimelor | LIL |
| Chlorpropamide | | .0140 |
| 250mg Tab | 021350 Novopropamide | NOP |
| | 024716 Diabinese | PFI |
| | 209937 Chlorpropamide | SAP |
| | 312711 Apo-Chlorpropamide | APX |
| | 377937 Chlorpropamide | DTC |
| Chlorpropamide | | .0159 |
| 100mg Tab | 024708 Diabinese | PFI |
| 100% | 399302 Apo-Chlorpropamide | APX |
| | ossessa inpo suitoi propaintae | |
| Glyburide | | .1110 |
| 5mg Tab | 012599 Diabeta | HOE |
| | 720941 Euglucon | ВОМ |
| Glyburide | | .0680 |
| 2.5mg Tab | 454753 Diabeta | HOE. |
| 2.0% 100 | 720933 Euglucon | BOM |
| | 720000 Lagracon | DOM |
| Metformin HCl | | .1368 |
| 500mg Tab | 314552 Glucophage | NRD |
| Tolbutamide | | .0152 |
| 500mg Tab | 012602 Orinase | HOE |
| • | 013889 Mobenol | HOR |
| | 021849 Novobutamide | NOP |
| | 093033 Tolbutamide | DTC |
| | 209872 Tolbutamide | SAP |
| | 312762 Apo-Tolbutamide | APX |
| | | 111 |
| | | |

| 0.25mg/mL O/L 0.2ng Tab 0. | 68:24:00 Parathyroid Agents | | |
|--|---|----------------------------|--------------|
| 0.125mg Cap 0.33057 Hytakerol 0.25mg/mL O/L 0.25mg/mL O/L 0.35mg/mL O/L 0.25mg/mL O/L 0.25mg Tab #569186 Dihydrotachysterol 0.2mg Tab #569186 Dihydrotachysterol 0.2mg Tab #569186 Dihydrotachysterol 0.2mg Tab #569186 Dihydrotachysterol #569186 Dihydrota | Dibudrotschusterol | | 6754 |
| 0.25mg/mL O/L 0.2ng Tab 0. | | 033057 Hytakerol | |
| Dihydrotachysterol 0.2mg Tab #569186 Dihydrotachysterol 80E #569186 Dihydrotachysterol 815.9300 #618 #6000 #618 #618 #6000 #618 #618 #6000 #618 #6000 #618 #6000 #618 #6000 #618 #6000 #618 #6000 #618 #6000 #618 #6000 #618 #6000 #618 #6000 #618 #6000 #618 #6000 #618 #618 #6000 #618 #618 #6000 #618 #6 | Dihydrotachysterol | | 2.2140 |
| #569186 Dihydrotachysterol BOE #8228:00 Pituitary Agents Cosyntropin Zinc Hydroxide Img/mL Inj Susp-ImL Pk Cosmopressin Acetate 0.1mg/mL Nas Sol-2.5mL Pk #8232:00 Progestogens and Oral Contraceptives Chinyl Estradiol & Ethynodiol Diacetate 0.05mg & Img Tab-21 Pk #8327 Demulen 30 SEA 8.3250 Chinyl Estradiol & Ethynodiol Diacetate 0.05mg & 2mg Tab-21 Pk #8332 Demulen 30 SEA 8.9100 SEA 8.9100 SEA 8.9100 SEA 8.9100 SEA 8.5000 SEA 8.500 | 0.25mg/mL 0/L | 033553 Hytakerol | WIN |
| 15.9300 18.28:00 Pituitary Agents 15.9300 18g/mL Inj Susp-ImL Pk 253952 Synacthen Depot CIB 34.6000 18g/mL Nas Sol-2.5mL Pk 402516 DDAVP RIC 34.6000 R | Dihydrotachysterol | | .5877 |
| 15.9300 15.9 | 0.2mg Tab | #569186 Dihydrotachysterol | BOE |
| Ing/mL Inj Susp-ImL Pk 253952 Synacthen Depot CIB | 68:28:00 Pituitary Agents | | |
| 34.6000 36.6000 36.6 | Cosyntropin Zinc Hydroxide | | 15.9300 |
| 0.1mg/mL Nas Sol-2.5mL Pk | ing/mL Inj Susp-imL Pk | 253952 Synacthen Depot | |
| Statinyl Estradiol & Ethynodiol Diacetate 0.05mg & Img Tab-21 Pk 0.28630 Demulen 50 SEA 8.3250 SEA 8.3250 SEA 8.3250 SEA 8.3250 SEA 8.3250 SEA 8.3250 SEA 8.3250 SEA 8.3250 SEA 8.3250 SEA 8.3250 SEA 7.9400 SEA 7.9400 SEA 7.9400 SEA 7.9400 SEA 7.9400 SEA 8.9100 SEA 7.9400 SEA 8.9100 SEA 8. | Desmopressin Acetate | | 34.6000 |
| thinyl Estradiol & Ethynodiol Diacetate 0.05mg & Img Tab-21 Pk 028630 Demulen 50 SEA 8.3250 thinyl Estradiol & Ethynodiol Diacetate 0.03mg & 2mg Tab-21 Pk 469327 Demulen 30 SEA 7.9400 thinyl Estradiol & Ethynodiol Diacetate 0.05mg & Img Tab-28 Pk 343536 Demulen 50 SEA 8.9100 thinyl Estradiol & Ethynodiol Diacetate 0.03mg & 2mg Tab-28 Pk 471526 Demulen 30 SEA 8.5000 thinyl Estradiol & Norethindrone 3 Phase Tab-21 Pk 602957 Ortho 7/7/7 ORT 7.1528 thinyl Estradiol & Norethindrone 0.035mg & Img Tab-21 Pk 372846 Ortho 1/35 ORT 7.1528 thinyl Estradiol & Norethindrone 0.035mg & Img Tab-21 Pk 317047 Ortho 0.5/35 ORT 7.1528 thinyl Estradiol & Norethindrone 0.035mg & 0.5mg Tab-21 Pk 373265 Brevicon SYN 7.5000 thinyl Estradiol & Norethindrone 0.035mg & 0.5mg Tab-21 Pk 373265 Brevicon SYN 7.5000 | 0.1mg/mL Nas Sol-2.5mL Pk | 402516 DDAVP | RIC |
| 0.05mg & 1mg Tab-21 Pk 0.28630 Demulen 50 SEA 8.3250 Sthinyl Estradiol & Ethynodiol Diacetate 0.03mg & 2mg Tab-21 Pk 469327 Demulen 30 SEA 7.9400 SEA 7.9400 SEA 7.9400 SEA 7.9400 SEA 7.9400 SEA 8.9100 68:32:00 Progestogens and Oral Contracept | ives | |
| 0.05mg & 1mg Tab-21 Pk 0.28630 Demulen 50 SEA 8.3250 Sthinyl Estradiol & Ethynodiol Diacetate 0.03mg & 2mg Tab-21 Pk 469327 Demulen 30 SEA 7.9400 SEA 7.9400 SEA 7.9400 SEA 7.9400 SEA 7.9400 SEA 8.9100 Ethinyl Estradiol & Ethynodiol Diacetate | | |
| 0.03mg & 2mg Tab-21 Pk | | 028630 Demulen 50 | SEA 8.3250 |
| 0.03mg & 2mg Tab-21 Pk | Ethinyl Estradiol & Ethynodiol Diacetate | | |
| 0.05mg & 1mg Tab-28 Pk 343536 Demulen 50 SEA 8.9100 Sthinyl Estradiol & Ethynodiol Diacetate 0.03mg & 2mg Tab-28 Pk 471526 Demulen 30 SEA 8.5000 | 469327 Demulen 30 | SEA 7.9400 |
| thinyl Estradiol & Ethynodiol Diacetate 0.03mg & 2mg Tab-28 Pk 471526 Demulen 30 SEA 8.5000 thinyl Estradiol & Norethindrone 3 Phase Tab-21 Pk 602957 Ortho 7/7/7 ORT 7.1528 thinyl Estradiol & Norethindrone 0.035mg & 1mg Tab-21 Pk 372846 Ortho 1/35 ORT 7.1528 thinyl Estradiol & Norethindrone 0.035mg & 1mg Tab-21 Pk 531006 Brevicon 1/35 SYN 7.5000 thinyl Estradiol & Norethindrone 0.035mg & 0.5mg Tab-21 Pk 317047 Ortho 0.5/35 ORT 7.1528 thinyl Estradiol & Norethindrone 0.035mg & 0.5mg Tab-21 Pk 373265 Brevicon SYN 7.5000 thinyl Estradiol & Norethindrone 0.035mg & 0.5mg Tab-21 Pk 373265 Brevicon SYN 7.5000 | Ethinyl Estradiol & Ethynodiol Diacetate | | |
| 0.03mg & 2mg Tab-28 Pk | 0.05mg & 1mg Tab-28 Pk | 343536 Denulen 50 | SEA 8.9100 |
| thinyl Estradiol & Norethindrone 3 Phase Tab-21 Pk 602957 Ortho 7/7/7 0RT 7.1528 thinyl Estradiol & Norethindrone 0.035mg & 1mg Tab-21 Pk 372846 Ortho 1/35 0RT 7.1528 thinyl Estradiol & Norethindrone 0.035mg & 1mg Tab-21 Pk 531006 Brevicon 1/35 SYN 7.5000 thinyl Estradiol & Norethindrone 0.035mg & 0.5mg Tab-21 Pk 317047 Ortho 0.5/35 0RT 7.1528 thinyl Estradiol & Norethindrone 0.035mg & 0.5mg Tab-21 Pk 373265 Brevicon SYN 7.5000 thinyl Estradiol & Norethindrone 0.035mg & 0.5mg Tab-21 Pk 373265 Brevicon SYN 7.5000 | Ethinyl Estradiol & Ethynodiol Diacetate | | |
| 3 Phase Tab-21 Pk 602957 Ortho 7/7/7 ORT 7.1528 thinyl Estradiol & Norethindrone 0.035mg & Img Tab-21 Pk 372846 Ortho 1/35 ORT 7.1528 thinyl Estradiol & Norethindrone 0.035mg & Img Tab-21 Pk 531006 Brevicon 1/35 SYN 7.5000 thinyl Estradiol & Norethindrone 0.035mg & 0.5mg Tab-21 Pk 317047 Ortho 0.5/35 ORT 7.1528 thinyl Estradiol & Norethindrone 0.035mg & 0.5mg Tab-21 Pk 373265 Brevicon SYN 7.5000 thinyl Estradiol & Norethindrone 0.035mg & 0.5mg Tab-21 Pk 373265 Brevicon SYN 7.5000 | 0.03mg & 2mg Tab-28 Pk | 471526 Demulen 30 | SEA 8.5000 |
| thinyl Estradiol & Norethindrone 0.035mg & Img Tab-21 Pk 2372846 Ortho 1/35 ORT 7.1528 Chinyl Estradiol & Norethindrone 0.035mg & Img Tab-21 Pk 231006 Brevicon 1/35 SYN 7.5000 Chinyl Estradiol & Norethindrone 0.035mg & 0.5mg Tab-21 Pk 2317047 Ortho 0.5/35 ORT 7.1528 Chinyl Estradiol & Norethindrone 0.035mg & 0.5mg Tab-21 Pk 2373265 Brevicon SYN 7.5000 Chinyl Estradiol & Norethindrone 0.035mg & 0.5mg + 0.035mg & 1mg | Ethinyl Estradiol & Norethindrone | | |
| 0.035mg & 1mg Tab-21 Pk 372846 Ortho 1/35 ORT 7.1528 thinyl Estradiol & Norethindrone 0.035mg & 1mg Tab-21 Pk 531006 Brevicon 1/35 SYN 7.5000 thinyl Estradiol & Norethindrone 0.035mg & 0.5mg Tab-21 Pk 317047 Ortho 0.5/35 ORT 7.1528 thinyl Estradiol & Norethindrone 0.035mg & 0.5mg Tab-21 Pk 373265 Brevicon SYN 7.5000 thinyl Estradiol & Norethindrone 0.035mg & 0.5mg + 0.035mg & 1mg | 3 Phase Tab-21 Pk | 602957 Ortho 7/7/7 | ORT 7.1528 |
| thinyl Estradiol & Norethindrone 0.035mg & Img Tab-21 Pk 531006 Brevicon 1/35 SIN 7.5000 thinyl Estradiol & Norethindrone 0.035mg & 0.5mg Tab-21 Pk 317047 Ortho 0.5/35 ORT 7.1528 thinyl Estradiol & Norethindrone 0.035mg & 0.5mg Tab-21 Pk 373265 Brevicon SIN 7.5000 thinyl Estradiol & Norethindrone 0.035mg & 0.5mg + 0.035mg & 1mg | Ethinyl Estradiol & Norethindrone | | |
| 0.035mg & 1mg Tab-21 Pk 531006 Brevicon 1/35 SYN 7.5000 thinyl Estradiol & Norethindrone 0.035mg & 0.5mg Tab-21 Pk 317047 Ortho 0.5/35 ORT 7.1528 thinyl Estradiol & Norethindrone 0.035mg & 0.5mg Tab-21 Pk 373265 Brevicon SYN 7.5000 thinyl Estradiol & Norethindrone 0.035mg & 0.5mg + 0.035mg & 1mg | U.U35mg & Img Tab-21 Pk | 372846 Ortho 1/35 | ORT 7.1528 |
| thinyl Estradiol & Norethindrone 0.035mg & 0.5mg Tab-21 Pk 317047 Ortho 0.5/35 ORT 7.1528 Thinyl Estradiol & Norethindrone 0.035mg & 0.5mg Tab-21 Pk 373265 Brevicon SYN 7.5000 Thinyl Estradiol & Norethindrone 0.035mg & 0.5mg + 0.035mg & 1mg | Ethinyl Estradiol & Norethindrone | | |
| 0.035mg & 0.5mg Tab-21 Pk 317047 Ortho 0.5/35 ORT 7.1528 thinyl Estradiol & Norethindrone 0.035mg & 0.5mg Tab-21 Pk 373265 Brevicon SYN 7.5000 thinyl Estradiol & Norethindrone 0.035mg & 0.5mg + 0.035mg & 1mg | U.U.Song & Ing 125-21 Pk | 531006 Brevicon 1/35 | SYN 7.5000 |
| thinyl Estradiol & Norethindrone 0.035mg & 0.5mg Tab-21 Pk 373265 Brevicon SYN 7.5000 thinyl Estradiol & Norethindrone 0.035mg & 0.5mg + 0.035mg & 1mg | Ethinyl Estradiol & Norethindrone | 017017 0 11 0 5 105 | |
| 0.035mg & 0.5mg Tab-21 Pk 373265 Brevicon SYN 7.5000 thinyl Estradiol & Norethindrone 0.035mg & 0.5mg + 0.035mg & 1mg | U.U35mg & U.5mg 1ab-21 Pk | 317047 Ortho 0.5/35 | ORT 7.1528 |
| thinyl Estradiol & Norethindrone 0.035mg & 0.5mg + 0.035mg & 1mg | Ethinyl Estradiol & Norethindrone | 272265 Provide | CVV 7 FAAA |
| 0.035mg & 0.5mg + 0.035mg & 1mg | | 3/3203 brevicon | 31.7 / .3000 |
| | Ethinyl Estradiol & Norethindrone | | |
| 538590 Ortho 10/11 ORT 7.1528 | Tab-21 Pk | 538590 Ortho 10/11 | ORT 7.1528 |

| 68:32:00 Progestogens and Oral Contracepti | ves | | |
|---|--------------------------|-----|--------|
| Ethinyl Estradiol & Norethindrone 3 Phase Tab-28 Pk | 602965 Ortho 7/7/7 | ORT | 7.6400 |
| Ethinyl Estradiol & Norethindrone 0.035mg & 1mg Tab-28 Pk | 372838 Ortho 1/35 | ORT | 7.6400 |
| Ethinyl Estradiol & Norethindrone 0.035mg & 1mg Tab-28 Pk | 531014 Brevicon 1/35 | SYN | 7.5000 |
| Ethinyl Estradiol & Norethindrone 0.035mg & 0.5mg Tab-28 Pk | 340731 Ortho 0.5/35 | ORT | 7.6400 |
| Ethinyl Estradiol & Norethindrone 0.035mg & 0.5mg Tab-28 Pk | 373273 Brevicon | SYN | 7.5000 |
| Ethinyl Estradiol & Norethindrone 0.035mg & 0.5mg + 0.035mg & 1mg Tab-28 Pk | 538582 Ortho 10/11 | ORT | 7.6400 |
| Ethinyl Estradiol & Norethindrone Acetate 0.05mg & 2.5mg Tab-21 Pk | 024015 Norlestrin 2.5/50 | PDA | 8.0000 |
| Ethinyl Estradiol & Norethindrone Acetate 0.05mg & 1mg Tab-21 Pk | 024007 Norlestrin 1/50 | PDA | 8.0000 |
| Ethinyl Estradiol & Norethindrone Acetate 0.03mg & 1.5mg Tab-21 Pk | 297143 Loestrin 1.5/30 | PDA | 8.0000 |
| Ethinyl Estradiol & Norethindrone Acetate 0.02mg & 1mg Tab-21 Pk | 315966 Minestrin 1/20 | PDA | 8.0000 |
| Ethinyl Estradiol & Norethindrone Acetate 0.05mg & 2.5mg Tab-28 Pk | 340804 Norlestrin 2.5/50 | PDA | 8.0000 |
| Ethinyl Estradiol & Norethindrone Acetate 0.05mg & 1mg Tab-28 Pk | 340790 Norlestrin 1/50 | PDA | 8.0000 |
| Ethinyl Estradiol & Norethindrone Acetate 0.03mg & 1.5mg Tab-28 Pk | 353027 Loestrin 1.5/30 | PDA | 8.0000 |
| Ethinyl Estradiol & Norethindrone Acetate 0.02mg & 1mg Tab-28 Pk | 343838 Minestrin 1/20 | PDA | 8.0000 |
| Ethinyl Estradiol & Norgestrel 3 Phase Tab-21 Pk | 579386 Triphasil | WYE | 7.9000 |
| Ethinyl Estradiol & Norgestrel 0.05mg & 0.25mg Tab-21 Pk | 034207 Ovral | WYE | 7.5500 |
| Ethinyl Estradiol & Norgestrel 0.03mg & 0.15mg Tab-21 Pk | 300640 Min-Ovral | WYE | 7.5500 |

| 68:32:00 Progestogens and Oral Contrac | ept ives | |
|---|-------------------------|-------------|
| Ethinyl Estradiol & Norgestrel 3 Phase Tab-28 Pk | 586609 Triphasil | WYE 7.9000 |
| Ethinyl Estradiol & Norgestrel 0.05mg & 0.25mg Tab-28 Pk | 340766 Ovral | WYE 7.5500 |
| Ethinyl Estradiol & Norgestrel 0.03mg & 0.15mg Tab-28 Pk | 342815 Min-Ovral | WYE 7.5500 |
| Hydroxyprogesterone Caproate 250mg/2mL Oily Inj Sol-2mL Pk | 029211 Delalutin | SQU 5.6400 |
| Medroxyprogesterone Acetate 400mg/4mL Inj Susp-4mL Pk | 030856 Depo-Provera | UPJ 24.2900 |
| Medroxyprogesterone Acetate 5mg Tab | 030937 Provera | UPJ .1975 |
| Medroxyprogesterone Acetate 100mg Tab | 030945 Provera | UPJ .9310 |
| Mestranol & Ethynodiol Diacetate 0.1mg & 1mg Tab-21 Pk | 028703 Ovulen 1 | SEA 11.0450 |
| Mestranol & Ethynodiol Diacetate 0.lmg & 0.5mg Tab-21 Pk | 028681 Ovulen 0.5 | SEA 10.3100 |
| Mestranol & Ethynodiol Diacetate 0.1mg & 1mg Tab-28 Pk | #340774 Ovulen 1 | SEA 10.0540 |
| Mestranol & Ethynodiol Diacetate 0.1mg & 0.5mg Tab-28 Pk | #341533 Ovulen 0.5 | SEA 9.2180 |
| Mestranol & Norethindrone 0.1mg & 2mg Tab-21 Pk | 022640 Ortho-Novum 2 | ORT 8.2833 |
| Mestranol & Norethindrone 0.1mg & 2mg Tab-21 Pk | 030368 Norinyl 2 | SYN 8.5100 |
| Mestranol & Norethindrone 0.1mg & 0.5mg Tab-21 Pk | 022632 Ortho-Novum 0.5 | ORT 8.2833 |
| Mestranol & Norethindrone 0.08mg & 1mg Tab-21 Pk | 022659 Ortho-Novum 1/80 | ORT 8.2833 |
| Mestranol & Norethindrone 0.08mg & 1mg Tab-21 Pk | 030341 Norinyl 1 + 80 | SYN 8.5100 |
| Mestranol & Norethindrone 0.075mg & 5mg Tab-21 Pk | #022616 Ortho-Novum 5 | ORT 12.7050 |
| Mestranol & Norethindrone 0.05mg & 1mg Tab-21 Pk | 022608 Ortho-Novum 1/50 | ORT 7.1523 |

| 68:32:00 Progestogens and Oral Con | ntraceptives | |
|--|-----------------------------|---------|
| | | |
| Mestranol & Norethindrone | | |
| 0.05mg & 1mg Tab-21 Pk | 030333 Norinyl 1 + 50 SYN | 7.5000 |
| Mestranol & Norethindrone | | |
| 0.1mg & 2mg Tab-28 Pk | 340839 Norinyl 2 SYN | 8.5100 |
| Mestranol & Norethindrone | | |
| 0.08mg & 1mg Tab-28 Pk | 340855 Norinyl 1 + 80 SYN | 8.5100 |
| Mestranol & Norethindrone | | |
| 0.05mg & 1mg Tab-28 Pk | 340758 Ortho-Novum 1/50 ORT | 7.6400 |
| Mestranol & Norethindrone | | |
| 0.05mg & 1mg Tab-28 Pk | 340847 Norinyl 1 + 50 SYN | 7.5000 |
| Mestranol & Norethynodrel | | |
| 0.1mg & 2.5mg Tab-21 Pk | 028665 Enovid-E SEA | 15.4800 |
| Norethindrone | | |
| 0.35mg Tab-28 Pk | 037605 Micronor ORT | 8.2900 |
| 68:36:00 Thyroids | | |
| | | 70 7700 |
| Calcitonin Salmon 400IU/2mL Inj Sol-2mLPk | 584703 Calcimar ROR | 32.7700 |
| 100107 Zill III DOZ Zill I | OSTION ON TOTAL | |
| Levothyroxine (Sodium) | | .0353 |
| 0.3mg Tab | 009695 Synthroid FLI | |
| | 012319 Eltroxin GLA | |
| Levothyroxine (Sodium) | | .0258 |
| 0.2mg Tab | 009687 Synthroid FLI | |
| | 012300 Eltroxin GLA | |
| | | |
| Levothyroxine (Sodium) | | .0242 |
| 0.15mg Tab | 212164 Synthroid FLI | |
| | 295582 Eltroxin GLA | |
| Levothyroxine (Sodium) | | .0212 |
| 0.1mg Tab | 009660 Synthroid FLI | |
| | 012297 Eltroxin GLA | |
| Levothyroxine (Sodium) | | .0169 |
| 0.05mg Tab | 009652 Synthroid FLI | |
| | 012289 Eltroxin GLA | |
| Levothyroxine (Sodium) | | .0330 |
| 0.025mg Tab | +009644 Synthroid FLI | |
| Liothyronine (Sodium) | | .0485 |
| 5mcg Tab | 027081 Cytomel SKF | |
| | | |

| Liothyronine (Sodium) | #012327 Tertroxin | | .0590 |
|------------------------------------|-------------------------------------|------------|--------|
| 25mcg Tab | #UI2327 Tertroxin 027103 Cytonel | GLA SKF | |
| _ | 02/103 Cytomer | SAF | |
| Ihyroid | | | .0370 |
| 125mg Tab | 023965 Thyroid | PDA | |
| | 483559 Proloid | PDA | |
| Thyroid | | | .0290 |
| 60mg Tab | 023957 Thyroid | PDA | |
| | 483540 Proloid | PDA | |
| Thomaid | | | 0007 |
| Thyroid 30mg Tab | 023949 Thyroid | PDA | .0223 |
| | 483583 Proloid | PDA | |
| | | | |
| 68:38:00 Anti-Thyroids | | | |
| Methimazole | | | .0831 |
| 5mg Tab | 015741 Tapazole | LIL | .0001 |
| | | | |
| Propylthiouracil | 010200 B1 TI1 | FDC | .0865 |
| 50mg Tab | 010200 Propyl-Thyracil | FRS | |
| Propylthiouracil | | | .1354 |
| 100mg Tab | 010219 Propyl-Thyracil | FRS | |
| | | | |
| | | | |
| | | | |
| | | | |
| 76:00 Oxytocics | | | |
| | | | _ |
| | | | |
| Ergonovine Maleate 0.2mg Tab | 015709 Ergotrate | LIL | .1872 |
| U.Zmg 13b | 013703 Ergotrate | LIL | |
| Oxytocin | | | .4930 |
| 5IU/mL Inj Sol-1mL Pk | 282316 Syntocinon-5 | SAN | |
| 0 | | | .6060 |
| Oxytocin 10IU/mL Inj Sol-1mL Pk | 035998 Syntocinon-10 | SAN | . 0000 |
| | 000000 07 1100211011 10 | - Jul | |

| 84:04:04 Anti-Infectives Antibiotics | | |
|--------------------------------------|---------------------------------------|---------------------|
| Bacitracin 500U/g Oint | 012351 Bacitracin 031046 Baciguent | GLA UPJ |
| Erythromycin 1.5% Lot | 512591 Staticin | .1135 WSD |
| Erythromycin 1% Oint | 015997 Ilotycin | .3327 LIL |
| Fusidic Acid 2% Cr | 586668 Fucidin | .4100 LEO |
| Neomycin Sulfate 0.5% Oint | 031070 Myciguent | .1300 UPJ |
| Neomycin Sulfate 500mg/mL Top Sol | 030813 Mycifradin | .4320 UPJ |
| Sodium Fusidate 2% Oint | 586676 Fucidin | .4100 LEO |
| 84:04:06 Anti-Infectives Antivirals | | |
| Acyclovir 5% Oint 4g Pk. | 569771 Zovirax | 9.9000 BWE |
| Idoxuridine 0.1% Top Sol | 001317 Herplex-D | 1.0240 ALL |
| 84:04:08 Anti-Infectives Fungicides | | |
| Clotrimazole 10mg/g Cr | 513903 Canesten 516805 Myclo | .2366 MIT BOE |
| Clotrimazole 10mg/mL Top Sol | 513911 Canesten 516821 Myclo | .2889 MIT BOE |
| Clotrimazole 20mg/g Vag Cr-App | 576492 Canesten 3 | .4732 MIT |
| Clotrimazole 10mg/g Vag Cr-App | 513938 Canesten 516813 Myclo | MIT BOE |
| Clotrimazole 500mg Vag Tab | 629243 Canesten 1 | 10.8300 MIT |
| Clotrimazole 200mg Vag Tab | 567388 Canesten 3 | 3.9433 MIT |

| lotrimazole 100mg Vag Tab | 513946 Canesten | MIT | 1.611 |
|------------------------------|---|------------|---------|
| loone vag las | 516848 Myclo | BOE | |
| | | 202 | |
| conazole Nitrate | | | .3010 |
| 1% Cr | 561002 Ecostatin | SQU | |
| conazole Nitrate | | | 4.0500 |
| 150mg Vag Sup | 452114 Ecostatia | SQU | |
| aloprogia | | | .2373 |
| 1% Cr | 291048 Halotex | WSD | |
| | | | |
| aloprogin | | | .2130 |
| 1% Top Sol | 291021 Halotex | WSD | |
| iconazole Nitrate | | | .3657 |
| 2% Cr | 326968 Micatin | MCN | |
| | 497797 Monistat Derm | ORT | |
| iconazole Nitrate | | | .3890 |
| 27 Lot | 471534 Micatin | MCN | . 5050 |
| | | | |
| iconazole Nitrate | | | 2.4500 |
| 100mg Tamp | 504203 Monistat 5 | ORT | |
| iconazole Nitrate | | | .1976 |
| 27. Vag Cr | 980625 Monistat | ORT | |
| | | | |
| iconazole Nitrate | Annual Control | | .2606 |
| 2% Vag Cr-App | 321036 Monistat 7 | ORT | |
| iconazole Nitrate | | | 4.0830 |
| 400mg Vag Sup | 530999 Monistat 3 | ORT | 4.0050 |
| | | | |
| iconazole Nitrate | *************************************** | | |
| 100mg Vag Sup-15 Pk | #980617 Monistat | ORT | 14.9600 |
| iconazole Nitrate | | | |
| 100mg Vag Sup-7 Pk | 387193 Monistat 7 | ORT | 13.0500 |
| ystatin | | | .0700 |
| 100,000U/g Cr | 029092 Mycostatin | SOU | .0700 |
| 200,00007 g 0. | 288217 Nadostine | NDA | |
| | 382639 Nyaderm | KLP | |
| | 449792 Nilstat | LED | |
| | | | |
| retatio | | | |
| ystatin | 029556 Nucostatia | con | .0783 |
| ystatin 100,000U/g Oint | 029556 Mycostatin 288195 Nadostine | SQU NDA | .0783 |

| 84:04:08 Anti-Infectives Fungicides | | | |
|--|-------------------------------------|------------|--------|
| Nystatin | | | .0783 |
| 100,000U/g Oint | 522864 Nyaderm | KLP | |
| Nystatin | | | .0416 |
| 25,000U/g Vag Cr | 288209 Nadostine | NDA | |
| | 295973 Mycostatin 480819 Nyaderm | SQU KLP | |
| | 450515 Ayaderm | KLF | |
| Nystatin | | | .1770 |
| 100,000U/g Vag Cr | 278793 Nilstat | LED | |
| Nystatin | | | .0900 |
| 100,000U Vag Tab | 015067 Nilstat | LED | |
| | 029491 Mycostatin | sou | |
| | 270091 Nadostine | NDA | |
| 84:04:12 Anti-Infectives Parasiticides | | | |
| Benzyl Benzoate | | | .0661 |
| 25% Cr | 604437 Scabanca | SAN | |
| | | | |
| Crotamiton | 600077 F | CIB | .1982 |
| 10% Cr | 623377 Eurax | CIR | |
| Lindane (Gamma Benzene Hexachloride) | | | .0474 |
| 1% Cr | 026204 Kwellada | RCA | |
| Lindane (Gamma Benzene Hexachloride) | | | .0430 |
| 1% Lot | 026212 Kwellada | RCA | |
| Lindane (Gamma Benzene Hexachloride) | | | .0627 |
| 1% Shampoo | 026220 Kwellada | RCA | .0027 |
| 276 Oldings C | 351105 gBh | ROR | |
| n 41 1 9 n1 - 3 n-4/1- | | | .0670 |
| Pyrethrins & Piperonyl Butoxide Top Sol | 480150 A-200 Pyrinate | BEE | .0670 |
| 10p 301 | 100100 200 1)1111200 | 111 | |
| 84:04:16 Anti-Infectives Other Anti-Infe | ctives. | | |
| Chlorhexidine Gluconate (OTC) | | | 2.1000 |
| 4% Top Sol 110mL Pk | 245097 Hibitane | AYE | |
| Have all anombors | | | .0393 |
| Hexachlorophene 3% Top Emuls | 205389 PhisoHex | WIN | .0355 |
| on top make to | 200000 1 210011011 | " | |
| * Iodochlorhydroxyquin | | | .1669 |
| 3% Cr | 005142 Vioform | CIB | |
| Iodochlorhydroxyquin | | | .1669 |
| 3% Oint | 005797 Vioform | CIB | |
| Metronidazole | | | .1433 |
| 10% Vag Cr-App | 024929 Flagyl | RPP | . 1433 |
| | | **** | |

| Metronidazole | #000007 T :1 | 7.011 | 2145 |
|---|---|------------|--------|
| 500mg Vag Tab App | #283967 Trikacide 025887 Flagyl | ICN RPP | .3230 |
| | 11000 | | |
| | | | |
| Metronidazole & Nystatin | | | .2798 |
| 500mg & 100,000U/g Vag Cr-App | 338338 Flagystatin | RPP | |
| Metronidazole & Nystatin | | | 1.5390 |
| 500mg & 100,000U Vag Sup | 439134 Flagystatin | RPP | |
| Metronidazole & Nystatin | | | 1.5390 |
| 500mg & 100,000U Vag Tab-App | 250724 Flagystatin | RPP | |
| N'benzoylsulfanilamide & Sulfathiazol | le & Sulfacetamide & Urea | | .1788 |
| Vag Cr-App | 153605 Sultrin | ORT | |
| * Povidone - Iodine | | | .0050 |
| 10% Top Sol | #062081 Bridine Sol | AHA | |
| | 158348 Betadine | PFR | |
| | 172944 Proviodine | ROG | |
| Povidone - Iodine | | | .0564 |
| 10% Vag Gel | #002720 Bridine | AHA | |
| | 026034 Betadine | PFR | |
| | 026611 Proviodine | ROG | |
| Povidone - Iodine | | | .0199 |
| 10% Vag Sol | #003115 Bridine | AHA | |
| | 026093 Betadine | PFR | |
| | 252824 Proviodine | ROG | |
| Povidone - Iodine | | | .4787 |
| 200mg Vag Sup | 026050 Betadine | PFR | |
| Silver Sulfadiazine | | | .1710 |
| 1% Cr | 323098 Flamazine | SNE | , |
| Culfanilanida & Allanania & Animania | ucl e Dissession | | .2065 |
| Sulfanilamide & Allantoin & Aminacrin Vag Cr | 134198 AVC/Dienestrol | DOW | .2005 |
| | | | |
| Sulfanilamide & Aminacrine HCl & Alla Vag Cr | ntoin 134120 AVC | DOW | .1730 |
| vag Cr | 134120 AVC | DOW | |
| Sulfanilamide & Aminacrine HCl & Alla | ntoin | | 1.2400 |
| Vag Sup | 134139 AVC | DOW | |
| Iriclosan | | | .0142 |
| 0.5% Top Sol | 632317 Tersaseptic | TCD | |

| 84:06:00 Anti- | Inflammatory Agents | | | | |
|----------------|----------------------|-------------------|------------------|-----|-------|
| Amcinonide | | | | | .2920 |
| 0.1% Cr | | 443824 | Cyclocort | LED | |
| Amcinonide | | | | | .2420 |
| 0.1% Lot | | 571016 | Cyclocort | LED | |
| Amcinonide | | | | | .2917 |
| 0.1% Oint | | 559237 | Cyclocort | LED | |
| Beclomethasone | Dipropionate | | | | .1207 |
| 0.025% Cr | | 002712 | Propaderm | AHA | |
| Beclomethasone | Dipropionate | | | | .2792 |
| 0.025% Lot | | 270466 | Propaderm | AHA | |
| Beclomethasone | Dipropionate | | | | .1207 |
| 0.025% Oint | | 003697 | Propaderm | AHA | |
| Betamethasone | Benzoate | | | | .2837 |
| 0.025% Gel | | 335347 | Beben | PDA | |
| Betamethasone | Dipropionate | | | | .3229 |
| 0.05% Cr | | 323071 | Diprosone | SCH | |
| Betamethasone | Dipropionate | | | | .2740 |
| 0.05% Lot | | 417246 | Diprosone | SCH | |
| Betamethasone | Dipropionate | | | | .3229 |
| 0.05% Oint | | 344923 | Diprosone | SCH | |
| | Dipropionate in a ba | se containing pro | opylene glycol | | .4978 |
| 0.05% Oint | | +629367 | Diprolene | SCH | |
| Betamethasone | Valerate | | | | .0244 |
| 0.1% Cr | | | Betnovate | GLA | |
| | | | Celestoderm-V | SCH | |
| | | | Betaderm | KLP | |
| | | +535435 | Ectosone Regular | тсн | |
| Betamethasone | Valerate | | | | .0161 |
| 0.05% Cr | | 011916 | Betnovate-1/2 | GLA | |
| | | 027898 | Celestoderm-V/2 | SCH | |
| | | 458147 | Betaderm | KLP | |
| | | +535427 | Ectosone Mild | тсн | |
| Betamethasone | Valerate | | | | .2417 |
| 0.1% Lot | | 011940 | Betnovate | GLA | |
| Betamethasone | Valerate | | | | .1917 |
| 0.05% Lot | | 011932 | Betnovate-1/2 | GLA | |
| | | | | | |

| 012386 Betnovate 028363 Celestoderm-V 509701 Betaderm 012378 Betnovate-1/2 028355 Celestoderm-V/2 509698 Betaderm 027944 Valisone +653217 Ectosone | GLA SCH KLP GLA SCH KLP | .0161 |
|--|---|--|
| 509701 Betaderm 012378 Betnovate-1/2 028355 Celestoderm-V/2 509698 Betaderm 027944 Valisone | GLA SCH KLP | |
| 012378 Betnovate-1/2 028355 Celestoderm-V/2 509698 Betaderm | GLA SCH KLP | |
| 028355 Celestoderm-V/2 509698 Betaderm 027944 Valisone | SCH KLP | |
| 028355 Celestoderm-V/2 509698 Betaderm 027944 Valisone | SCH KLP | |
| 028355 Celestoderm-V/2 509698 Betaderm 027944 Valisone | SCH KLP | .0926 |
| 509698 Betaderm 027944 Valisone | KLP | .0926 |
| | SCH | .0926 |
| | SCH | .0926 |
| | SCH | |
| +653217 Ectosone | | |
| | ICH | |
| | | .2267 |
| 441147 Norfemac | NRD | |
| | | |
| | | .2218 |
| 441155 Norfemac | AKD | |
| | | .4550 |
| 359718 Dermovate | GLA | |
| | | |
| | | .4550 |
| 359726 Dermovate | GLA | |
| | | .4058 |
| 479012 Dermovate | GLA | |
| | | |
| | | .2565 |
| 456543 Eumovate | GLA | |
| | | .2565 |
| 456551 Eumovate | GLA | |
| | | |
| | | .1978 |
| 521248 Tridesilon | MIT | |
| | | .3163 |
| 521264 Tridesilon | MIT | .0100 |
| 021207 1.1400110- | | |
| | | .3208 |
| 420271 Topicort | HOE | |
| | | 1000 |
| 100450 Torione Wild | HOE | .1908 |
| 486450 Topicort Mila | HUE | |
| | | .2025 |
| 481807 Florone | UPJ | |
| 530956 Flutone | ROR | |
| | | |
| | | .2025 |
| | | |
| | 441147 Norfemac 441155 Norfemac 359718 Dermovate 359726 Dermovate 479012 Dermovate 456543 Eumovate 456551 Eumovate 521248 Tridesilon 521264 Tridesilon 420271 Topicort 486450 Topicort Mild | 441147 Norfemac NRD 441155 Norfemac NRD 359718 Dermovate GLA 359726 Dermovate GLA 479012 Dermovate GLA 456543 Eumovate GLA 456551 Eumovate GLA 521248 Tridesilon MIT 521264 Tridesilon MIT 420271 Topicort HOE 486450 Topicort Mild HOE 481807 Florone UPJ 530956 Flutone ROR 481793 Florone UPJ |

84:06:00 Anti-Inflammatory Agents

| Diflucortolone Valerate, 0.1% Cr | +587826 | Nerisone | STI | .2654 |
|--|---------|---|-------------------|-------|
| Diflucortolone Valerate 0.1% Oily Cr | +587818 | Nerisone | STI | .2687 |
| Diflucortolone Valerate 0.1% Oint | +587834 | Nerisone | STI | .2689 |
| Flumethasone Pivalate 0.03% Cr | 005134 | Locacorten | CIB | .4710 |
| Flumethasone Pivalate 0.03% Oint | 005789 | Locacortem | CIB | .4710 |
| Fluocinolone Acetonide 0.025% Cr | 385220 | Synalar Regular Fluoderm Fluonide Regular | SYP KLP TCH | .0442 |
| Fluocinolone Acetonide 0.01% Cr | 385239 | Synalar Mild Fluoderm Fluonide Mild | SYP KLP TCH | .0369 |
| Fluocinolone Acetonide 0.01% Emol Cr | 424927 | Synamol Mild | SYP | .1150 |
| Fluocinolone Acetonide 0.025% Emol Cr | 424935 | Synamol Regular | SYP | .1834 |
| Fluocinolone Acetonide 0.025% Oint | 030406 | Synalar Regular | SYP | .1834 |
| Fluocinolone Acetonide 0.025% Oint | +509655 | Fluoderm | KLP | .0486 |
| Fluocinolone Acetonide 0.01% Oint | 030392 | Synalar Mild | SYP | .1860 |
| Fluocinolone Acetonide 0.01% Oint | +509647 | Fluoderm | KLP | .0406 |
| Fluocinolone Acetonide 0.01% Top Sol | 030260 | Synalar Solution | SYP | .2826 |

| 84:06:00 Anti-Inflammatory Age | ents ents | | |
|---|---------------------------------|-----|-------|
| Fluocinonide 0.05% Cr | 036099 Lidex 589896 Lyderm | SYP | .1932 |
| Fluocinonide 0.01% Cr | 274453 Lidex Mild | SYP | .2406 |
| Fluocinonide 0.05% Emol Cr | 424943 Lidemol 598933 Tiamol | SYP | .1600 |
| Fluocinonide 0.05% Gel | 281913 Topsyn | SYN | .3535 |
| Fluocinonide 0.05% Oint | 274437 Lidex | SYP | .2643 |
| Fluocinonide 0.01% Oint | 274445 Lidex Mild | STP | .2406 |
| Fluocinonide & Procinonide & C Enol Cr | Ciprocinonide +552283 Trisyn | SYP | .2458 |
| Flurandrenolide 0.05% Cr | 015326 Dremison | LIL | .3532 |
| Flurandrenolide 0.0125% Cr | 015318 Dremison-1/4 | LIL | .1626 |
| Flurandrenolide 0.05% Oint | 016012 Drenison | LIL | .3532 |
| Flurandrenolide 0.0125% Oint | 016004 Drenison-1/4 | LIL | .1756 |
| Halcinonide 0.1% Cr | 326941 Halog | squ | .2958 |
| Halcinonide 0.025% Cr | #404179 Halog | sęu | .1842 |
| Halcinonide 0.1% Oint | 403075 Halog | sęu | .2958 |
| Halcinonide 0.1% Sol | 404187 Halog | sou | .2958 |
| Hydrocortisone 2.5% Cr | 595799 Emo-Cort | TCD | .1271 |

| 84:06:00 Anti-Inflammatory Agents | | |
|---|-----------------------------------|------------|
| W-1 | 102507 Fmg Comb | .0206 |
| Hydrocortisone 1% Cr | 192597 Emo-Cort 303895 Unicort | TCD AHA |
| 1% CF | 502200 Cortate | SCH |
| | 551945 Hydrocortisone | DTC |
| | 301340 hydrocor tisone | DIC |
| Hydrocortisone | | .0148 |
| 0.5% Cr | 303887 Unicort | AHA |
| 0.0% 01 | 513288 Cortate | SCH |
| | 551953 Hydrocortisone | DTC |
| | | |
| Hydrocortisone | | .1350 |
| 2.5% Lot | 595802 Emo-Cort | TCD |
| | | |
| Hydrocortisone | | .1125 |
| 1% Lot | 192600 Emo-Cort | TCD |
| | | |
| Hydrocortisone | | .0697 |
| 0.5% Lot | +192589 Emo-Cort | TCD |
| | 513253 Cortate | SCH |
| | | |
| Hydrocortisone | | .0206 |
| 1% Oint | 093645 Hydrocortisone | DTC |
| | 502197 Cortate | SCH |
| | 509639 Cortoderm | KLP |
| | | |
| Hydrocortisone_ | | .0181 |
| 0.5% Oint | 093637 Hydrocortisone | DTC |
| | 509620 Cortoderm | KLP |
| | 513261 Cortate | SCH |
| | | |
| Hydrocortisone & Urea | | .2450 |
| 1% & 10% Cr | 364134 Calmurid-HC | PHD |
| | | |
| Hydrocortisone Acetate | | .0226 |
| 1% Cr | 458155 Hyderm | KLP |
| | 477699 Corticreme | ROG |
| | | 0176 |
| Hydrocortisone Acetate | #00#00 N 1 | .0176 |
| 0.5% Cr | 539538 Hyderm | KLP |
| | | .1620 |
| Hydrocortisone Acetate | 001074 5 | UPJ |
| 1% Oint | 031054 Cortef | UPJ |
| W. 1 | | .1218 |
| Hydrocortisone Acetate & Urea 17 & 107 Cr | 503134 Uremol-HC | TCD |
| 1% & 10% CF | 503134 Uremo1-nC | ICD |
| Hydrocortisone Acetate & Urea | | .0663 |
| 1% & 10% Lot | 560022 Uremol-HC | TCD |
| 1% u 10% Lut | JUOUZZ UTEMUITAC | 100 |
| Hudrocontisone Valente | | .1753 |
| Hydrocortisone Valerate 0.2% Cr | 423165 Westcort | WSD |
| U. 2/6 CF | 423100 Westcort | MOD |

| 84:06:00 Anti-Inflammatory Agents | | | | |
|--|---------|---------------------------|------------|--------|
| Hydrocortisone Valerate | | | | .1753 |
| 0.2% Oint | 590800 | Westcort | WSD | |
| Methylprednisolone | | | | .1150 |
| 0.25% Cr | 031062 | Medrol | UPJ | |
| Triamcinolone Acetonide | | | | .0340 |
| 0.1% Cr | | Aristocort R | LED | |
| | | Kenalog | SÓN | |
| | | Triaderm Trianide Regular | KLP | |
| | | | | |
| Triamcinolone Acetonide | #000100 | F 1 P | CON | .0170 |
| 0.025% Cr | | Kenalog-E Aristocort D | SQU LED | |
| | | Triaderm | KLP | |
| | | Trianide Mild | TCH | |
| Triamcinolone Acetonide | | | | .0378 |
| 0.1% Oint | 029572 | Kenalog | SQU | .03/8 |
| O.I. Olit | | Aristocort R | LED | |
| | | | | |
| Triamcinolone Acetonide | | 2000 | | .0583 |
| 0.025% Oint | | Kenalog-E | SQU | |
| | 282456 | Aristocort D | LED | |
| Triancinolone Acetonide 0.1% in Orabase | | | | .8933 |
| Oral Top Oint | 029505 | Kemalog-Orabase | SQU | |
| 84:08:00 Antiprurities and Topical Anesthe | etics | | | |
| Cinchocaine HCl | | | | .0795 |
| 1% Oint | 623385 | Nupercainal | CIB | |
| | | | | |
| Pramoxine HCl 1% Cr | 000116 | Tronothane | ABB | .2313 |
| 1/e CF | 000116 | Tronotnane | ADD | |
| Tetracaine HC1 | | | | .2376 |
| 1% Cr | 205451 | Pontocaine | WIN | |
| 84:12:00 Astringents | | | | |
| Aluminum Acetate & Benzethonium Chloride | | | | . 4581 |
| 0.35% & 0.023% Pd | 579947 | Buro-Sol | TCD | .4301 |
| A COLUMN TO SERVICE ASSESSMENT TO SERVICE AS | | | | |
| 84:24:00 Emollients, Demulcents and Protect | tants | | | |
| * Dimethylpolysiloxane | | | | .0284 |
| 207 Cr | 253057 | Barriere | AHA | |
| Octyl Dimethyl PABA & Ethyl Dihydroxypropy | 1 PARA | | | .0249 |
| 6% & 4% Lot | | Sunstop | WAM | .0245 |
| | | - F | | |

| Octyl Dimethyl PABA & Oxybenzone 8% & 3.3% Lot | 539856 Presun 15 Cream | y WSD | .0372 |
|---|--|------------|--------|
| Octyl Dimethyl PABA & Oxybenzone | | | .0482 |
| 7% & 3% Lot | 544809 Pabafilm-15 +677094 Episun | ALC SCH | |
| 0 11 A 6 O colo company | | | .0487 |
| Pedimate & Oxybenzone 87 & 3.5% Cr | +626708 Ultrastop | CDM | .0467 |
| * Zinc Oxide | | | .0184 |
| 15% Oint | 093661 Zinc Oxide | DTC | |
| 84:28:00 Keratolytic Agents | | | |
| Anthralin | | | .1803 |
| 0.4% Cr | 537616 Anthranol | STI | |
| Anthralin | 537608 Anthranol | STI | .1551 |
| 0.2% Cr | 557608 ARTHRANCI | 211 | |
| Anthralin | 52750 A. A. Alvano . 3 | CTI | .1409 |
| 0.1% Cr | 537594 Anthranol | STI | |
| Anthralin | .526740 4 41 6 4 0 | 077 | .2753 |
| 2% Oint | +566748 Anthraforte 2 | STI | • |
| Anthralin | | C.T. | .2418 |
| 1% Oint | +566756 Anthraforte 1 | STI | |
| Anthralin | | C.T. | . 1033 |
| 0.2% Oint | #187682 Lasan-2 | STI | |
| Anthralin | | am. | .0984 |
| 0.1% Oint | #249858 Lasan-1 | STI | |
| Benzoyl Peroxide | | | .0442 |
| 5% Cl Lot | 503835 Benoxyl Wash | STI | |
| Benzoyl Peroxide | | | .0366 |
| 10% C1 Lot | 502669 Benoxyl Wash 542040 Desquam-X Wash | STI WSD | |
| | 012070 200420 | | |
| Benzoyl Peroxide 5% Lot | 236063 Benoxyl | STI | .0728 |
| on Lot | 374326 Oxyderm | ICN | |
| Benzoyl Peroxide | | | .0671 |
| 20% Lot | 187585 Benoxyl | STI | |
| | 374318 Oxyderm | ICN | |

| | | | .0711 |
|--|----------------------------------|-----|-------|
| Benzoyl Peroxide 10% Lot | 370568 Benoxyl 432938 Oxyderm | STI | |
| Benzoyl Peroxide in Acetone-containing | Ge1 | | .0757 |
| 5% Ge1 | 372692 Dermoxyl | ICN | |
| | 406821 Acet0xyl | STI | |
| | #530190 Persa-Gel | ORT | |
| Benzoyl Peroxide in Acetone-containing | Gel | | .1179 |
| 20% Gel | 399116 Dermoxyl | ICN | |
| | 406856 AcetOxyl | STI | |
| Benzoyl Peroxide in Acetone-containing | Ge1 | | .0910 |
| 10% Gel | 372706 Dermoxyl | ICN | .0313 |
| | 406848 Acet0xyl | STI | |
| | #530204 Persa-Gel | ORT | .0851 |
| | | | |
| | | | |
| Senzoyl Peroxide in Alcohol-containing | | | .0823 |
| 5% Gel | 263702 Panoxyl | STI | |
| | 426261 5-Benzagel | ROR | |
| Benzoyl Peroxide in Alcohol-containing | | | .1380 |
| 20% Gel | 373036 Panoxyl | STI | |
| Senzoyl Peroxide in Alcohol-containing | | | .1278 |
| 15% Gel | 403571 Panoxyl | STI | .10,0 |
| | | | |
| Senzoyl Peroxide in Alcohol-containing | | | .0728 |
| 10% Gel | 263699 Panoxyl | STI | |
| | 426288 10-Benzagel | ROR | |
| | 520772 Alquam-X10 | WSD | |
| Senzoyl Peroxide in Water-based Gel | | | .0600 |
| 5% Gel | 307564 Desquam-X5 | WSD | |
| | 512613 H20xyl | STI | |
| | 621048 Benzac W5 | ALC | |
| Benzoyl Peroxide in Water-based Gel | | | .1399 |
| 20% Gel | 512648 H20xyl | STI | |
| Benzoyl Peroxide in Water-based Gel | | | .0728 |
| 10% Gel | 307572 Desquam-X10 | WSD | |
| | 512621 H2Oxyl | STI | |
| | 621056 Benzac W10 | ALC | |
| | | | |
| Salicylic Acid | | - | .0719 |
| 6% Gel | 307580 Keralyt | WSD | |

| 84:28:00 Keratolytic Agents | | |
|---|--|--------------------------|
| Tretinoin 0.05% Cr | 493333 Vitamin A Acid 518182 StieVAA | .2780 ROR STI |
| Tretinoin 0.025% Cr | +578576 StieVAA | .2831 STI |
| Tretinoin 0.05% Gel | 419001 Vitamin A Acid | .2780 ROR |
| Tretinoin 0.025% Gel | +587966 StieVAA | .2871 STI |
| Tretinoin 0.01% Gel | +587958 StieVAA 590797 Vitamin A Acid | .2780 STI ROR |
| Tretinoin 0.025% Sol | +578568 StieVAA | .1417 STI |
| Tretinoin 0.05% Top Sol | 518174 StieVAA | .1431 STI |
| 84:32:00 Keratoplastic Agents | | |
| Coal Tar Extract (OTC) 2% Gel 85g Pk | 373222 Estar | 9.3000 WSD |
| Colloidal Crude Coal Tar (OTC) 1% Shampoo 250mL Pk | 426423 Zetar | 10.4500 ROR |
| Crude Coal & Salicylic Acid (OTC) 8% & 2% Top Sol 100mL Pk | 560448 P & S Plus Gel | 17.2500 DOR |
| Crude Coal Tar (OTC) 30% Emuls 125mL Pk | 426415 Zetar | 10.2000 ROR 8.7000 |
| Crude Coal Tar (OTC) 4.3% Susp 100mL Pk Crude Coal Tar (OTC) | 652326 Pentrax | SCJ |
| 2.5% Top Sol 230mL Pk Phenol (OTC) | 208132 Balmetar | WSD 11.7000 |
| 5% Top Sol 119mL Pk Tar (OTC) | 054232 P & S Liquid | DOR 5.4500 |
| 1% Shampoo 150mL Pk Tar Distillate (OTC) | 249866 Polytar | STI 9.5500 |
| 2% Emuls 250mL Pk Tar Distillate (OTC) | 579955 Doak-Oil | TCD 13.5500 |
| 10% Emuls 250mL Pk | 579971 Doak-Oil Forte | TCD |
| 84:32:00 Keratoplastic Agents | | 4.0000 |
| Tar Distillate (OTC) 3% Shampoo 150ml Pk | 632309 Tersa-Tar | TCD 4.0000 |

| Betamethasone Disodium Phosphate | | | 5.7900 |
|---|----------------------------------|------------|---------|
| 5mg/100ml Enema-100ml Pk | 012181 Betnesol | GLA | 3.7500 |
| Colloidal Oatmeal | | | 5.6215 |
| Pd-360g Pk | 652350 Aveeno | SCJ | |
| Colloidal Oatmeal (Oilated) | | | 5.6215 |
| Pd-180g Pk | 652342 Aveeno (Oilated) | SCJ | |
| tretinate | | | 2.1117 |
| 25mg Cap | +616419 Tegison | HLR | |
| tretinate | | | 1.2017 |
| 10mg Cap | +616400 Tegison | HLR | |
| ibrinolysin & Desoxyribonuclease | The same of | | .7251 |
| 1U & 666U/g Oint | 024082 Elase | PDA | |
| ibrinolysin & Desoxyribonuclease Pd 25U & 15,000U-Pk | 022079 Flag | DD. | 20.6080 |
| | 023078 Elase | PDA | |
| luorouracil 5% Cr | 330582 Efudex | HLR | .3040 |
| | 330362 Elidex | nuk | |
| ydrocortisone 100mg/60mL Enema-60mL Pk | 230316 Hycort | ICN | 5.6460 |
| | 200010 11,4011 | 10.1 | |
| ydrocortisone 40mg Sup | 406708 Cortiment | NRD | .8420 |
| | | | |
| ydrocortisone 10mg Sup | 407836 Cortiment | NRD | .6120 |
| ydrocortisone Acetate | | | 2.4685 |
| 10% Rect Aero | 579335 Cortifoam | RCA | 2.4003 |
| sotretinoin | | | 2.2217 |
| 40mg Cap | 582352 Accutane | HLR | , |
| sotretinoin | | | 1.0850 |
| 10mg Cap | 582344 Accutane | HLR | |
| ethoxsalen | | | .3500 |
| 10mg Cap | +007269 Oxsoralen | ICN | |
| elenium Sulfide | +646237 UltraMOP | CDM | .0377 |
| 2.5% Lot | 243000 Selsun | ABB | .03// |
| ulfasalazine | | | 4.5400 |
| 3g/100mL Enema-100mL Pk | 544442 Salazopyrin | PHD | |
| utilains | | | 1.9245 |
| 82,000U/g Oint | 265381 Travase | FLI | |
| inc Pyrithione (OTC) | | | 5.7000 |
| 27. Shampoo 125mL Pk | 507415 Dan-Gard | STI | |
| Zinc Sulfate 0.5% Oint | 504246 Anusol | PDA | .0700 |
| | +621447 Anuzinc | TCH | |
| Zinc Sulfate | | - | .1584 |
| 10mg Sup | 476315 Anusol +621439 Anuzinc | PDA TCH | |

86:00 Spasmolytics

| minophylline | | | | .8000 |
|-----------------------------|---------|-------------------|------|-------|
| 500mg/10mL Inj Sol-10mL Pk | +535672 | Aminophylline | รอุบ | |
| minophylline | | | | .8000 |
| 250mg/10mL Inj Sol-10mL Pk | 012033 | Aminophylline | GLA | |
| , | | Aminophylline | squ | |
| ninophylline | | | | .186 |
| 350mg LA Tab | 593230 | Phyllocontin-350 | PFR | |
| ninophylline | | | | .146 |
| 25mg LA Tab | 491179 | Phyllocontin | PFR | |
| | | | | |
| ninophylline Ning/mL O/L | 379603 | Palaron | FIS | .034 |
| .ing/ mt o/ t | 010000 | | | |
| inophylline | 451.050 | 0 1 111 | DEE | .542 |
| 600mg Sup | 451673 | Corophyllin | BEE | |
| ninophylline | | | | . 455 |
| 250mg Sup | 451665 | Corophyllin | BEE | |
| ninophylline | | | | .067 |
| 200mg Tab | 014931 | Aminophylline | LED | |
| ninophylline | | | | .024 |
| OOmg Tab | 014923 | Aminophylline | LED | .014 |
| | | Aminophylline | DTC | |
| triphylline | | | | .180 |
| 600mg LA Tab | 536709 | Choledyl SA | PDA | |
| ktriphylline | | | | .152 |
| 100mg LA Tab | 503436 | Choledyl SA | PDA | |
| rtuinkulling | | | | .021 |
| striphylline Omg/mL O/L | 476366 | Choledyl | PDA | .021 |
| | | • | | 0.00 |
| triphylline Omg/mL O/L | 40E210 | Rouphylline | ROG | .008 |
| ong/ mc o/ c | | Choledyl | PDA | |
| | | | | |
| striphylline 800mg Tab | 492501 | Choledyl | PDA | .024 |
| Jour 140 | | Apo-Oxtriphylline | APX | |
| | | Novotriphyl | NOP | |
| triphylline | | | | .021 |
| 200mg Tab | 346071 | Rouphylline | ROG | |
| <u> </u> | | Apo-Oxtriphylline | APX | |
| | | Novotriphyl | NOP | |
| | 476412 | Choledyl | PDA | |

86:00 Spasmolytics

| | | | .0175 |
|---------------------------------------|--------------------------|------|-------|
| Oxtriphylline | 441724 Apo-Oxtviphylline | APX | |
| 100mg Tab | 451282 Rouphylline | ROG | |
| | 458708 Novotriphyl | NOP | |
| | 476404 Choledyl | PDA | |
| heophylline Anhydrous | | | .1584 |
| 200mg Cap | 442283 Somophyllin-T | FIS | .1304 |
| acces of | 529109 Elixophyllin | BER | |
| | | | |
| heophylline Anhydrous | 4400000 0 1 111 0 | | |
| 100mg Cap | 442275 Somophyllin-T | FIS | .1711 |
| | #529095 Elixophyllin | BER | .161 |
| | | | |
| | | | |
| heophylline Anhydrous | | | |
| 50mg LA Cap | 551422 Somophyllin-12 | FIS | .1296 |
| | | | |
| Theophylline Anhydrous | C00001 C | | |
| 300mg LA Cap | 609021 Somophyllin-12 | FIS | .2011 |
| heophylline Anhydrous | | | |
| 250mg LA Cap | 551414 Somophyllin-12 | FIS | .1853 |
| • | | | .1055 |
| heophylline Anhydrous | | | |
| 200mg LA Cap | 609013 Somophyllin-12 | FIS | .1673 |
| Barrhulling Ashedurus | | | |
| heophylline Anhydrous 100mg LA Cap | 551430 Somophyllin-12 | FIS | 2 |
| Todag LA Cap | 331430 Somophy 111h-12 | F15 | .1446 |
| heophylline Anhydrous | | | |
| 500mg LA Tab | 502014 Theolair-SR | RIK | .2470 |
| | | | |
| heophylline Anhydrous | | | |
| 500mg LA Tab | #574945 Respbid | BOE | .2453 |
| heophylline Anhydrous | | | |
| 300mg LA Tab | 461008 Theo-Dur | AST | .2068 |
| | | .101 | |
| heophylline Anhydrous | | | |
| 300mg LA Tab | 545732 Theolair-SR | RIK | .1595 |
| | | | |
| heophylline Anhydrous 300mg LA Tab | FF0740 A :1 T/CB | 222 | 1000 |
| Soung LA 135 | 556742 Quibron-T/SR | BRI | .1890 |
| heophylline Anhydrous | | | |
| 300mg LA Tab | 599905 Theochron | FOR | .1656 |
| | | | |
| heophylline Anhydrous | | | |
| 250mg LA Tab | 461695 Theolair-SR | RIK | .1520 |
| basebullia A. I. I | | | |
| heophylline Amhydrous 250mg LA Tab | #F74027 B 1 · 1 | DOF | 1000 |
| TOORS IN 180 | #574937 Respbid | BOE | .1690 |

86:00 Spasmolytics

| Theophylline Anhydrous | | | | |
|--|---------|-------------------------|------|-------|
| 200mg LA Tab | 460990 | Theo-Dur | AST | .1718 |
| | | | | |
| Theophylline Anhydrous | | - | | |
| 200mg LA Tab | 631701 | Theochron | FOR | .1376 |
| 77 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 | | | | |
| Theophylline Anhydrous 100mg LA Tab | 460092 | Theo-Dur | AST | .1545 |
| Toung LA Tab | 100362 | THEO-DUP | NO. | .1343 |
| Theophylline Anhydrous | | | | |
| 100mg LA Tab | 631698 | Theochron | FOR | .1235 |
| 100% 20. 100 | | | | |
| Theophylline Anhydrous | | | | .0294 |
| 10mg/mL O/L | 547115 | Quibron-T | BRI | |
| 3 | | | | |
| Theophylline Anhydrous | | | | .0028 |
| 5.3mg/mL O/L | | Theophylline | DES | |
| | | Theolixir | ICN | |
| | | Theolair Alcohol Free O | | |
| | | Theophylline | TCH | |
| | | PMS-Theophylline | PMS | |
| | 704466 | Elixophyllin | BER | |
| The shalling Ashadusas | | | | .1623 |
| Theophylline Anhydrous 300mg Tab | #E21726 | Quibron-T | RRI | .1023 |
| 300mg 140 | #021750 | Quinion 1 | DILI | |
| Theophylline Anhydrous | | | | .2415 |
| 250mg Tab | 461687 | Theolair | RIK | |
| | | | | |
| Theophylline Anhydrous | | | | .1645 |
| 125mg Tab | 395218 | Theolair | RIK | |
| | | | | |
| Theophylline Calcium Aminoacetate | | | | .0874 |
| 325mg Tab | 263761 | Acet-Am | ORG | |
| | | | | |

88:30 Vitamins

| 88:04:00 Vitamin A | | | |
|----------------------------------|---------------------------|--------|--------|
| Vitamin A | | | |
| 50,000IU Cap | 021075 Vitamin A | Non | .0613 |
| 30,00010 Cap | 480169 Aquasol A | NOP | |
| | 400103 AquaS01 A | ROR | |
| itamin A | | | .0354 |
| 25,000IU Cap | 021067 Vitamin A | NOP | |
| | 480193 Aquasol A | ROR | |
| 8:08:00 Vitamins B | | | |
| Cyanocobalamin (OTC) | | | |
| ing/mL Inj Sol 10mL Pk | 002909 Anacobin | | 4.9000 |
| ING/ NE IN JOI TONE IN | | AHA | |
| | 029165 Rubranin | SQU | |
| | 211125 Cyanocobalamin | KLP | |
| | 314277 Cyanocobalamin | NRD | |
| | #571865 Cyanocobalamin | ORG | |
| Cyanocobalamin (OTC) | | | 2.7000 |
| .lmg/mL Inj Sol 10mL Pk | 029157 Rubramin | SQU | |
| olic Acid | | | 2055 |
| ing Tab | #003492 Folic Acid | 4.77.4 | .0052 |
| , | 014966 Folvite | AHA | |
| | 021466 Novofolacid | LED | |
| | | NOP | |
| | 094617 Folic Acid | DIC | |
| | 284149 Folic Acid-ICN | ICN | |
| | 426849 Apo-Folic | APX | |
| | +498777 Folic Acid | LEA | |
| eucovorin Calcium | | | 4.0600 |
| ing Tab | 482900 Calcium Leucovorin | LED | |
| icotinic Acid (DPP) | | | .0083 |
| 50mg Tab | 015768 Niacin | LII. | .0083 |
| | 268593 Niacin-ICN | ICN | |
| | 274496 Novoniacin | NOP | |
| | | **** | |
| icotinic Acid (DPP) 100mg Tab | A1777A VI. | | .0186 |
| 100mg Tab | 015776 Niacin | LIL | |
| | 268585 Niacin-ICN | ICN | |
| ridoxine HCl (DPP) | | | .0196 |
| 25mg Tab | 015865 Hexa-Betalin | LIL | |
| | +232475 Vitamin B6 | LEA | |
| | 268607 Vitamin B6-ICN | ICN | |
| | 416185 Vitamin B6 | WAM | |
| niamine HCl (DPP) | | | 9.6900 |
| 1000mg/10mL Inj Sol-10mL Pk | 033421 Betaxin | WIN | 3.0000 |
| THE THE THE TANK IN | USSMAI BELEXIN | WIN | |
| | | | |

88:00 Vitamins

| 88:08:00 Vitamins B | | | .0207 |
|--------------------------------------|--|-------------------|--------|
| Thiamine HCl (DPP) 50mg Tab | 023922 Thiamine 268631 Vitamin Bl-ICN +610267 Vitamin B1 | PDA ICN LEA | |
| * Vitamins B & C (OTC) Tab 100 Pk | 242934 Beminal | AYE | 8.8000 |
| 88:12:00 Vitamin C | | | |
| * Ascorbic Acid (OTC) | | | 3.2000 |
| 500mg Tab 100 Pk | 021997 Novo-C | NOP | |
| | 036188 Ascorbic Acid | WAM | |
| | 094668 Ascorbic Acid | DTC | |
| | 232122 Ascorbic Acid | SAP | |
| | +453951 Vitamin C | CLK | |
| * Ascorbic Acid (OTC) | | | 1.7000 |
| 250mg Tab 100 Pk | 021237 Novo-C | NOP | |
| | 036161 Vitamin C | WAM | |
| | 094641 Ascorbic Acid | DTC | |
| | 265012 Ascorbic Acid | SAP | |
| | +570397 Vitamin C | CLK | |
| * Ascorbic Acid (OTC) | | | 7.7000 |
| 1000mg Tab 100 Pk | 256862 Ascorbic Acid | WAM | 7.7000 |
| 1000mg 125 100 1K | 535907 Novo-C | NOP | |
| | | | |
| * Ascorbic Acid (OTC) | | | 1.5000 |
| 100mg Tab 100 Pk | 021970 Novo-C | NOP | |
| | 094633 Ascorbic Acid | DTC | |
| | #492752 Vitamin C | CLK | |
| 88:16:00 Vitamin D | | | |
| 00.10.00 VII amin D | | | |
| Alfacalcidol (DPP) | | | .9000 |
| 1mcg Cap | 474525 One-Alpha | LEO | |
| | | | |
| Alfacalcidol (DPP) | | 7.00 | .3000 |
| 0.25mcg Cap | 474517 One-Alpha | LEO | |
| Calcitriol (DPP) | | | 1.0075 |
| 0.5mcg Cap | 481815 Rocaltrol | HLR | 1.0075 |
| o.omeg oup | 102020 1100220102 | 11231 | |
| Calcitriol (DPP) | | | .6295 |
| 0.25mcg Cap | 481823 Rocaltrol | HLR | |
| | | | |
| Ergocalciferol | | 11.50 | .3226 |
| 10,360IU/mL O/L | 033545 Drisdol | WIN | |
| Ergocalciferol · | | | .1155 |
| 50,000IU Tab | #553050 Calciferol | ROR | |
| 20,00010 100 | #000000 VM1C11C1C1 | | |

88:00 Vitamins

O. Reg. 689/86

| 1697 | | | |
|--|--|--------------------|----------------|
| So,0001U Cap | 88:16:00 Vitamin D | | |
| ### ### ############################## | Vitamin D 50,000IU Cap | | |
| 1.1088 1 | Vitamin D (DPP) | | .1184 |
| Senadiol Sodium Diphosphate (DPP) | 400IU/0.6mL 0/L | +630934 D-Vi-Sol | MJO |
| Sing/mL Inj Sol-1mL Pk O12912 Synkavite HLR | 88:24:00 Vitamin K | | |
| Independent | Menadiol Sodium Diphosphate (DPP) | | .9408 |
| 10mg/mL Inj Sol-ImL Pk | 5mg/mL Inj Sol-1mL Pk | 012912 Synkavite | HLR |
| Marie Mari | | | 1.1088 |
| 5mg Tab 013374 Synkavite HLR 8:28:00 Multivitamins 3.4000 Hexavitamins USP (OTC) 3.4000 Tab 100 Pk 269034 Hexavitamins NOP 632082 Beminal Plus NYE Hexavitamins USP (OTC) 9.2000 Tab 120 Pk +629022 Revit ICN Vitamins A & D & C & B Complex (OTC) 156493 Pardec PDA itamins A & D & C & B Complex (OTC) 13.7000 | 10mg/mL Inj Sol-1mL Pk | 012920 Synkavite | HLR |
| ### 18:28:00 Multivitamins Hexavitamins USP (OTC) | | 013374 Sunkavite | .0543 |
| Hexavitamins USP (OTC) 3.4000 Tab 100 Pk 269034 Hexavitamins NOP 632082 Beminal Plus AYE | | Olddri Sylkavite | HLK |
| Tab 100 Pk 269034 Hexavitamins NOP 632082 Beminal Plus AYE Hexavitamins USP (OTC) 9.2000 Tab 120 Pk +629022 Revit ICN Vitamins A & D & C & B Complex (OTC) 6.2000 O/L 250mL Pk 156493 Pardec PDA itamins A & D & C & B Complex (OTC) 13.7000 | 8:28:00 Multivitamins | | • |
| 632082 Beminal Plus AYE Hexavitamins USP (OTC) Tab 120 Pk Vitamins A & D & C & B Complex (OTC) 0/L 250mL Pk 156493 Pardec 13.7000 | 10.07 | | 3.4000 |
| Hexavitamins USP (OTC) Tab 120 Pk +629022 Revit ICN Vitamins A & D & C & B Complex (OTC) 0/L 250mL Pk 156493 Pardec PDA itamins A & D & C & B Complex (OTC) 13.7000 | Tab 100 Pk | | |
| Tab 120 Pk +629022 Revit ICN Vitamins A & D & C & B Complex (OTC) 6.2000 O/L 250mL Pk 156493 Pardec PDA itamins A & D & C & B Complex (OTC) 13.7000 | | OSCOC BEHINGI 1182 | MIE |
| Vitamins A & D & C & B Complex (OTC) 0/L 250mL Pk 156493 Pardec 13.7000 | | +629022 Revit | |
| 0/L 250mL Pk 156493 Pardec PDA itamins A & D & C & B Complex (OTC) 13.7000 | | OLOULE NEVID | |
| itamins A & D & C & B Complex (OTC) | | 156493 Pardec | |
| | | 200300 181400 | |
| | /itamins A & D & C & B Complex (OTC) Ped O/L 50mL Pk | 477583 Poly-Vi-Sol | 13.7000 MJO |

92:00 Unclassified Therapeutic Agents

| Allopurinol | | .0335 |
|--|------------------------|---------|
| 300mg Tab | 294322 Zyloprim | BWE |
| | 363693 Novopurol | NOP |
| | 402796 Apo-Allopurinol | APX |
| | 415766 Purinol | HOR |
| | 454354 Alloprin | ICN |
| | | |
| Allopurinol | | .0270 |
| 200mg Tab | 415758 Purinol | HOR |
| | 479799 Apo-Allopurinol | APX |
| | 506370 Zyloprim | BWE |
| | 514209 Alloprin | ICN |
| | 565342 Novopurol | NOP |
| | | |
| Allopurinol | | .0137 |
| 100mg Tab | 004588 Zyloprim | BWE |
| | 364282 Novopurol | NOP |
| | 402818 Apo-Allopurinol | APX |
| | 415731 Purinol | HOR |
| | 449687 Alloprin | ICN |
| | | |
| Amantadine HCl | | .4860 |
| 100mg Cap | 589012 Symmetrel | DUP |
| | | |
| Amantadine HCl | | .0830 |
| 10mg/mL 0/L | 589004 Symmetrel | DUP |
| The same of the sa | | |
| Azathioprine | | .5880 |
| 50mg Tab | 004596 Imuran | BWE |
| Maria Caracteristics | | |
| Bromocriptine | | 1.1230 |
| 5mg Cap | 568643 Parlodel | SAN |
| | | |
| Bromocriptine | | .6610 |
| 2.5mg Tab | 371033 Parlodel | SAN |
| | | |
| Calcium Carbimide | | .3500 |
| 50mg Tab | 014958 Temposil | LED |
| | | |
| Clomiphene Citrate | | 2.7090 |
| 50mg Tab | 018031 Clomid | MER |
| | +640158 Serophene | PMS |
| | • | |
| Disulfiram | | .3642 |
| 500mg Tab | 002542 Antabuse | AYE |
| 3 | | |
| Disulfiram | | .1914 |
| 250mg Tab | 002534 Antabuse | AYE |
| - | | |
| Etidronate Disodium | | 1.0358 |
| 200mg Tab | 582522 Didronel | EAT |
| | | |
| Glucagon | | 18.8384 |
| Inj Pd-1mg Pk | 015377 Glucagon | LIL |
| • | , | |

92:00 Unclassified Therapeutic Agents

| Levodopa 500mg Tab | 013358 Larodopa | HLR | .2100 |
|---|------------------------|----------------|--------|
| Journa 185 | 010000 Lat Ottopa | HLK | |
| Levodopa | | | .1185 |
| 250mg Tab | 013331 Larodopa | HLR | |
| Levodopa & Benserazide | | | .5000 |
| 200mg & 50mg Cap | 386472 Prolopa 200-50 | HLR | |
| Levodopa & Benserazide | | | .2995 |
| 100mg & 25mg Cap | 386464 Prolopa 100-25 | HLR | |
| evodopa & Benserazide | | | . 1820 |
| 50mg & 12.5mg Cap | 522597 Prolopa 50-12.5 | HLR | |
| .evodopa & Carbidopa | | | .4286 |
| 250mg & 25mg Tab | 328219 Sinemet | MSD | |
| evodopa & Carbidopa | | | .4061 |
| 100mg & 25mg Tab | 513997 Sinemet | MSD | .4001 |
| evodopa & Carbidopa | | | |
| 100mg & 10mg Tab | 355658 Sinemet | MSD | .2712 |
| | | | |
| Penicillamine 250mg Cap | 016055 Cuprimine | MSD | .5758 |
| acong cap | 010035 Caprimine | MSD | |
| enicillamine | | | .3841 |
| 125mg Cap | 497894 Cuprimine | MSD | |
| enicillamine | | | .4695 |
| 250mg Tab | 511641 Depen | HOR | |
| entoxifylline | | | .4158 |
| 400mg LA Tab | 586625 Trental | HOE | . 4100 |
| odium Cromoglycate | | | .7043 |
| 100mg Cap | 500895 Nalcrom | FIS | .7043 |
| oline Consultant | | | |
| odium Cromoglycate 1% Inh Sol 2mL Pk | 534609 Intal | FIS | .5894 |
| | 001000 14681 | 1.12 | |
| odium Cromoglycate Inh 200 dose Pk | | | 9.2000 |
| INA 200 dose PK | 555649 Fivent | FIS | |
| odium Cromoglycate | | 1 | 8.5600 |
| Inh-112 dose Pk | 990981 Fivent | FIS | |
| odium Cromoglycate | | | .3435 |
| 20mg/Cart Pd Inh | 261238 Intal Spincaps | FIS | .0403 |
| -Aminosalicyclic Acid | | | 7015 |
| 400mg Tab | +634557 Asacol | EAT | .3815 |
| | | O. Reg. 689/86 | |

Schedule 2

OXYGEN

ALLERGENIC EXTRACTS

O. Reg. 689/86, Sched. 2.

PRESCRIPTION DRUG COST REGULATION ACT, 1986

O. Reg. 690/86. General. Made—November 26th, 1986. Filed—November 27th, 1986.

REGULATION MADE UNDER THE PRESCRIPTION DRUG COST REGULATION ACT, 1986

GENERAL

- 1. In this Regulation,
- "original product" means the original source of a drug product in a particular strength and dosage form that is designated as a listed drug product under Ontario Regulation 689/86 (General) or that was listed as a drug product in the Parcost C.D.I. prescribed under Ontario Regulation 839/84;
- "production size lot" means the amount of finished product that is made from the minimum quantity of raw materials specified in a formula that can be processed using full sized production equipment into a dosage form that meets the specifications for the finished product. O. Reg. 690/86, s. 1.
- 2. Each product that is listed in Schedule 1 of a particular strength and dosage form of a drug is interchangeable with each other such listed product. O. Reg. 690/86, s. 2.
- 3. For the purposes of section 7 of the Act, the best available price in respect of each product listed in Column 1 of Part B of Schedule 2 is the amount set out opposite thereto in Column 2 of Part B of Schedule 2. O. Reg. 690/86, s. 3.
- 4. The percentage of the base price that is prescribed for the purposes of clause 7 (3) (b) of the Act is that percentage set out in Part A of Schedule 2. O. Reg. 690/86, s. 4.
- 5. A person may charge more than the person's usual and customary dispensing fee for a product that is supplied pursuant to a prescription if the person explains why a fee in excess of the usual and customary fee is being charged prior to the dispensing of the prescription and the charging of the additional fee does not result in the person being in contravention of section 47 of Regulation 451 of Revised Regulations of Ontario, 1980. O. Reg. 690/86, s. 5.
- 6.—(1) The conditions set out in this section apply only with respect to each strength and dosage form of each product for which a submission to the Minister to be designated as interchangeable is made on and after the 31st day of July, 1986.

- (2) It is a condition for each strength and dosage form of a product to be designated as interchangeable with other products that the manufacturer of the product submits to the Minister within the time limit set out in Schedule 3.
 - (a) evidence that the manufacturer meets the standards contained in Good Manufacturing Practices for Drug Manufacturers and Importers, second edition, published by the Health Protection Branch of Health and Welfare (Canada);
 - (b) if,
- (i) the product is a new drug within the meaning of the *Food and Drugs Act* (Canada),
- (ii) the Health Protection Branch of Health and Welfare (Canada) has issued a Notice of Compliance to the manufacturer of the product in respect of a new drug submission within the meaning of the said Act, or
- (iii) the manufacturer has filed with the said Health Protection Branch a new drug submission that relates to the drug product,
- a Notice of Compliance with respect to the product issued under section C.08.004 of Division 8, Part C of the Food and Drug Regulations and a product monograph with respect to the product that has been approved by the Health Protection Branch for the purpose of issuing the Notice of Compliance;
- (c) a statement that sets out all the representations that are intended to be made by the manufacturer for the promotion of the product with respect to,
 - (i) the recommended route of administration of the product,
 - (ii) the proposed dosage of the product,
 - (iii) the claims for the product, and
 - (iv) the contra-indications and side effects of the product;
- (d) the Drug Identification Number of the product;
- (e) the formula of the product in a manner that clearly indicates all the ingredients and the quantities of those ingredients;
- (f) specifications of a pharmacopoeial or equivalent standard for the active raw materials used to make the product and for the finished product;

- (g) documentation with respect to the manufacturing and quality control of the product that shows at least,
 - (i) production work sheets of the manufacturer with respect to the two most current production size lots, and
 - (ii) the sources of the active raw materials used to manufacture the product;
- (h) a certificate of analysis that shows the results of the tests that were carried out on the active raw materials used to make the product and the finished product and that compares the results of those tests with the specifications for the active raw materials and the finished product;
- (i) studies that show that the product is stable under the storage conditions specified by the manufacturer for the intended shelf life of the product;
- (j) a sample of the product that is representative of the production size lots to which the documentation referred to in clause (g) relates packaged and labelled as it is being sold at the time of the submission and in a quantity that is sufficient to complete all the tests necessary to determine whether or not the product meets the manufacturer's specifications for the finished product;
- (k) a sample of the active raw materials used to make the product that is representative of the production size lots to which the documentation referred to in clause (g) relates in a quantity that is sufficient to complete all the tests necessary to determine whether or not the active raw materials meet the manufacturer's specifications for the active raw materials;
- (l) proof of the availability of the product for sale as shown by,
 - (i) an invoice or invoices detailing the sale of the product to a drug wholesaler or pharmacy in Ontario, or
 - (ii) a copy of a completed Drug Notification Form issued under section C.01.014 of Division 1, Part C, of the Food and Drug Regulations;
- (m) dissolution studies or other studies that show the consistency of the manufacturing process of the product;

- (n) comparative bioavailability studies or comparative clinical studies or both in humans or other in vivo studies that will show the interchangeability of the product with the original product;
- (o) evidence that the physical properties of the product do not adversely affect patient acceptance of the product to any greater degree than the original product;
- (p) a list that sets out the cost to the pharmacist or wholesaler for each package size of the product that is offered for sale;
- (q) evidence that the manufacturer is able to supply the product at the price quoted to the Minister in a quantity that is sufficient to meet the reasonably anticipated demand for the product; and
- (r) a consent that sets out that the Minister may have access to all information given to the Health Protection Branch of Health and Welfare (Canada) with respect to the product that is in connection with a new drug submission or a supplement relating to the product within the meaning of the Food and Drugs Act (Canada) or any other submission that is necessary for the lawful sale of the product in Canada.
- (3) Clause (2) (b) does not apply where the Health Protection Branch gives an opinion in writing that states that a new drug submission or a supplement relating to the product is not required by the Branch and that a notice of compliance is not required for the lawful sale of the product.
- (4) Clauses (2) (m) and (n) do not apply to a product that is the same as a listed drug product with respect to the dosage form, strength, formula and the manufacturing process and testing standards for both the raw materials and the finished product.
- (5) Clause (2) (n) does not apply to a submission that relates to an additional strength of a product of the manufacturer that is a listed drug product where the information previously submitted under clause (2) (n) with respect to the product is sufficient for the purpose of evaluating the interchangeability of the additional strength of the product. O. Reg. 690/86, s. 6.
- 7. Ontario Regulations 839/84, 63/85 and 224/86 are revoked.
- 8. This Regulation comes into force on the day that section 14 of the Act is proclaimed in force.

Schedule 1

04:00 Antihistaminics

| * Chlorpheniramine Maleate 4mg Tab | 021288 Novopheniram 028193 Chlor-Tripolon | NOP . |
|---------------------------------------|--|-------|
| Cyproheptadine HCl | 009989 Vimicon | FRS |
| 0.4mg/mL O/L | 016314 Periactin | MSD |
| * Cyproheptadine HCl | 010073 Vimicon | FRS |
| 4mg Tab | 016454 Periactin | MSD |
| * Diphenhydramine HCl | 022764 Benadryl | PDA |
| 50mg Cap | 271411 Allerdryl | ICN |
| * Diphenhydramine HCl | 022756 Benadryl | PDA |
| 25mg Cap | 370517 Allerdryl | ICN |
| Promethazine HCl | 025429 Phenergan | RPP |
| 2mg/mL 0/L | +583979 PMS-Promethazine | PMS |

APX

08:00 Anti-Infective Agents

| 08:12:04 Anti | biotics Antifungals | | | |
|----------------|-----------------------|---------|---------------------------|-----|
| Nystatin | | | | |
| 100.000U/mL | 0/L | 014850 | Nilstat | LED |
| 100,00007 AL | | 248169 | Mycostatin | SOU |
| | | | Nadostine | NDA |
| | | | | |
| Nystatin | | | | |
| 500,000U Tab | | 014974 | Nilstat | LED |
| , | | 029416 | Mycostatin | SQU |
| | | 270113 | Nadostine | NDA |
| 08:12:12 Ant i | biotics Erythromycins | | | |
| Erythronycin | Base | | | |
| 250mg Tab | | | E-Mycin | UPJ |
| | | 244635 | Erythromid | ABB |
| | | +640263 | Erythromycin | KNR |
| | | | | |
| Erythromycin | Estolate | | | |
| 250mg Cap | | | Ilosone | LIL |
| | | 020966 | Novorythro Estolate | NOP |
| Erythromycin | Estolate | | | |
| 50mg/mL 0/L | | 210641 | Ilosone | LIL |
| | | 262595 | Novorythro Estolate | NOP |
| | | | | |
| Erythromycin | Estolate | | | |
| 25mg/mL 0/L | | 015474 | Ilosone | LIL |
| • | | 021172 | Novorythro Estolate | NOP |
| | | | · | |
| Erythromycin | Ethylsuccinate | | | |
| 40mg/mL 0/L | | 000299 | EES-200 | ABB |
| | | 605859 | Novorythro Ethyl Succinat | NOP |
| | | | | |
| Erythromycin | Stearate | | | |
| 500mg Tab | | | Erythrocia | ABB |
| | | +688568 | Apo-Erythro-S | APX |
| Erythromycin | Stearate | | | |
| 250mg Tab | | | Erythrocin | ABB |
| | | | Erythromycin Stearate | SAP |
| | | | Novorythro Stearate | NOP |
| | | 545678 | Apo-Erythro-S | APX |
| 08:12:16 Anti | biotics Penicillins | | | |
| Amoxicillin | | | | |
| | | 220521 | Amoxil | AYE |
| 500mg Cap | | | Novamoxin | NOP |
| | | | AUVAMONTH | ADY |

628123 Apo-Amoxi

| moxicillin | | |
|-------------------|------------------------|-------|
| 250mg Cap | 288497 Amoxil | AYE |
| | 406724 Novamoxin | NOP |
| | 628115 Apo-Amoxi | APX |
| moxicillin | | |
| 50mg/mL O/L | 288519 Amoxil | AYE |
| | 452130 Novamoxin | NOP |
| | 628158 Apo-Amoxi | APX |
| moxicillin | | |
| 25mg/mL O/L | 288500 Amoxil | AYE |
| | 452149 Novamoxin | NOP |
| | 628131 Apo-Amoxi | APX |
| mpicillin | | |
| 500mg Cap | 002011 Penbritin | AYE |
| • | 020885 Novo-Ampicillin | NOP |
| | 348848 Ampicillin | SAP |
| | 603295 Apo-Ampi | APX |
| npicillin | | |
| 250mg Cap | 002003 Penbritin | AYE |
| 3 1 | 020877 Novo-Ampicillin | NOP |
| | 265047 Ampicillin | SAP |
| | 603279 Apo-Ampi | APX |
| mpicillin | | |
| Inj Pd-1000mg Pk | 002127 Penbritin | AYE |
| | 004065 Ampicin | BRI |
| mpicillin | | |
| Inj Pd-500mg Pk | 002119 Penbritin | AYE |
| • | 004057 Ampicin | BRI |
| mpicillin | | |
| 50mg/mL O/L | 002429 Penbritin | AYE |
| | 021148 Novo-Ampicillin | NOP |
| | 283185 Ampicillin | SAP |
| | 603287 Apo-Ampi | APX |
| npicillin | | |
| 25mg/mL O/L | 002410 Penbritin | AYE |
| The second second | 021121 Novo-Ampicillin | NOP |
| | 281565 Ampicillin | SAP |
| | 603260 Apo-Ampi | APX _ |
| loxacillin | | |
| 500mg Cap | 002054 Orbenin | AYE |
| | 337773 Novocloxin | NOP |
| | 618284 Apo-Cloxi | APX |

| 08:12:16 Antibiotics Penicillins | | |
|----------------------------------|-----------------------------------|------------|
| CO.IZ.IB ARTIVIOLES TERRETINS | | |
| Cloxacillin | | |
| 250mg Cap | 002046 Orbenin | AYE |
| | 337765 Novocloxin | NOP |
| | 618292 Apo-Cloxi | APX |
| | | |
| Cloxacillin | 000100 0 1 | 4 37 79 |
| Inj Pd-2000mg Pk | 002186 Orbenin | AYE |
| | 407615 Tegopen | BRI BEE |
| | 417238 Bactopen | DEE |
| Cloxacillin | | |
| Inj Pd-250mg Pk | 002151 Orbenin | AYE |
| Inj is soon in | 407593 Tegopen | BRI |
| | 417203 Bactopen | BEE |
| • | | |
| Cloxacillin | | |
| Inj Pd-500mg Pk | 002178 Orbenin | AYE |
| | 407607 Tegopen | BRI |
| | 417211 Bactopen | BEE |
| | | |
| Cloxacillin | | |
| 25mg/mL 0/L | 002445 Orbenin | AYE |
| | 337757 Novocloxin | NOP |
| | +644633 Apo-Cloxi | APX |
| | | |
| Penicillin G (Potassium) | 405404 14 4114 500 | FRG |
| 500,000IU Tab | 107484 Megacillin 500 | FRS |
| | 116726 P-50 | HOR NOP |
| | 151432 Novopen-500 | AUF |
| Penicillin G Crystalline | | |
| Inj Pd 1,000,000IU-Pk | 002208 Penicillin G (Pot) | AYE |
| inj 14 1,000,00010 1 K | 011983 Crystapen (Sod) | GLA |
| | 0.11000 0.7,50 2 pon (001) | |
| Penicillin G Crystalline | | |
| Inj Pd 5,000,000IU-Pk | 002216 Penicillin G (Pot) | AYE |
| | 011991 Crystapen (Sod) | GLA |
| | | |
| Penicillin V (Benzathine) | | |
| 60mg/mL O/L | 034045 Pen-Vee | WYE |
| | 248835 PVF 500 | FRS |
| | | |
| Penicillin V (Potassium) | 004047 1/0 1/ 700 | 1.71 |
| 60mg/mL O/L | 331945 VC-K 500 | LIL |
| | 391603 Novopen-VK-500 | |
| | +642231 Apo-Pen V-K | APX |
| Penicillin V (Potassium) | | |
| 25mg/mL O/L | 015563 V-Cillin K | LIL |
| SOME / ME O/ L | 018635 Nadopen-V | NDA |
| | +642223 Apo-Pen V-K | APX |
| | | |

| 08:12:16 Antibiotics Penicillins | | |
|--|---------------------------|-----|
| Penicillin V (Potassium) | | |
| 300mg Tab | 018740 Nadopen-V | NDA |
| | 021202 Novopen-VK-500 | NOP |
| | 210714 Penicillin V (Pot) | SAP |
| | 248843 PVF-K 500 | FRS |
| | 262447 Ledercillin VK | LED |
| | +642215 Apo-Pen V-K | APX |
| 08:12:24 Antibiotics Tetracyclines | | |
| Tetracycline | | |
| 250mg Cap | 014605 Achromycin V | LED |
| • • | 021059 Novotetra | NOP |
| | 024422 Tetracyn | PFI |
| | 210765 Tetracycline | SAP |
| | 580929 Apo-Tetra | APX |
| 08:12:28 Antibiotics Other Antibiotics | | |
| | | |
| Cefazolin Sodium | 010110 | |
| Inj Pd-1000mg Pk | 319112 Ancef | SKF |
| | 322296 Kefzol | LIL |
| Cefazolin Sodium | | |
| Inj Pd-500mg Pk | 319139 Ancef | SKF |
| | 322288 Kefzol | LIL |
| | | |
| Cephalexin Monohydrate | | |
| 500mg Cap | 253146 Ceporex | GLA |
| | 342114 Novolexin | NOP |
| | | |
| Cephalexin Monohydrate | 070474.0 | |
| 250mg Cap | 253154 Ceporex | GLA |
| | 342084 Novolexin | NOP |
| Cephalexin Monohydrate | | |
| 50mg/mL O/L | 035645 Keflex | LIL |
| 00.1167 1.12 0.12 | 321443 Ceporex | GLA |
| | 342092 Novolexin | NOP |
| | | |
| Cephalexin Monohydrate | · · | |
| 25mg/mL 0/L | 015547 Keflex | LIL |
| • | 321435 Ceporex | GLA |
| | 342106 Novolexin | NOP |
| Carla Lauin Vanahudus 4 | | |
| Cephalexin Monohydrate 500mg Tab | 244392 Keflex | LIL |
| Joung 180 | 583421 Novolexin | NOP |
| | 303421 NOVOIEXIN | NUP |
| Cephalexin Monohydrate | | |
| 250mg Tab | 403628 Keflex | LIL |
| = | 583413 Novolexin | NOP |
| | | NOF |

08:12:28 Antibiotics Other Antibiotics

| Gentamicin Sulfate | | |
|--|--|------------|
| 80mg/2ml Inj Sol-2ml Pk | 223824 Garamycin | SCH |
| SUNG/ZML IN SUI-ZML IN | 259179 Cidomycin | ROU |
| | 200110 01001,012 | NOU |
| Tobramycin Sulfate | | |
| 80mg/2mL Inj Sol-2mL Pk | 325449 Nebcin | LIL |
| | 381969 Nebcin | LIL |
| | | |
| 08:16:00 Antitubercular Agents | | |
| | | |
| Ethambutol HC1 | 1070CF Marchard | LED |
| 400mg Tab | 127965 Myambutol 247979 Etibi | ICN |
| | 24/3/3 Et101 | 10.1 |
| Ethanbutol HCl | | |
| 100mg Tab | 127957 Myambutol | LED |
| | 247960 Etibi | ICN |
| | | |
| Isoniazid | | |
| 300mg Tab | 272655 Isotamine-300 | ICN |
| | 310247 Isoniazid | SAP |
| | | |
| Isoniazid | 012202 B:-:6 | TIT D |
| 100mg Tab | 013323 Rimifon 261270 Isotamine-100 | HLR ICN |
| | 440108 Isoniazid | SAP |
| | 440108 ISOM14214 | SAI |
| Rifampin | | |
| 300mg Cap | 210463 Rimactane | CIB |
| | 249483 Rifadin | MER |
| | 343617 Rofact | ICN |
| | | |
| Rifampin | | |
| 150mg Cap | 210471 Rimactane | CIB |
| | 249475 Rifadin 393444 Rofact | ICN |
| | 393444 KOTACT | 10.1 |
| 08:20:00 Plasmodicides (Antimalarials) | | |
| OO.20.00 T tasmoutetaes Antimatar tass | | |
| Chloroquine Phosphate | | |
| 250mg Tab | 021261 Novochloroquine | NOP |
| | 033642 Aralen | WIN |
| | | |
| Quinine Sulfate | | |
| 300mg Cap | 021016 Novoquinine | NOP |
| | 093750 Quinine | DTC |
| Onining Sulfan | | |
| Quinine Sulfate 200mg Cap | 021008 Novoquinine | NOP |
| Zuong Cap | 093742 Quinine Sulfate | DTC |
| | 0,5,742 Quinino Dullace | 0.0 |

| 08:24:00 Sulfonamides | | |
|-----------------------------|---|--|
| Sulfamethoxazole | | |
| 500mg Tab | 013412 Gantanol 421480 Apo-Sulfamethoxazole | HLR APX |
| Sulfapyridine 500mg Tab | #155470 Sulfapyridine 163929 Dagenan | PDA RPP |
| | | |
| Sulfasalazine | | |
| 500mg Ent Tab | 15959C C- 1 | PHD |
| Soome Ent lab | 158526 Salazopyrin 445126 S.A.S. Enteric 500 | ICN |
| Sulfasalazine | | |
| 500mg Tab | 024856 Salazopyrin | PHD |
| | 263869 S.A.S. 500 | ICN |
| | +598461 PMS-Sulfasalazine | PMS |
| Sulfisoxazole | | |
| 500mg Tab | 013420 Gantrisin | HLR |
| | 021792 Novosoxazole | NOP |
| | 210730 Sulfisoxazole | SAP |
| | | 1 (1 (1 (1 (1 (1 (1 (1 (1 (1 (1 (1 (1 (1 |
| | | |
| 08:32:00 Trichomonacides | | |
| Metronidazole | | |
| 250mg Tab | 021555 Novonidazol | NOP |
| acomg xac | 025615 Flagyl | RPP |
| | 545066 Apo-Metronidazole | APX |
| | +584339 PMS-Metronidazole | PMS |
| 08:36:00 Urinary Germicides | | |
| Nitrofurantoin | | |
| 50mg Tab | 021563 Novofuran | NOP |
| | 092800 Nitrofurantoin | DTC |
| | 319511 Apo-Nitrofurantoin | APX |
| Nitrofurantoin | • | |
| 100mg Tab | 021571 Novofuran | NOP |
| | 092819 Nitrofurantoin | DTC |
| | 312738 Apo-Nitrofurantoin | APX |
| Phenazopyridine HCl | | |
| 200mg Tab | 454583 Phenazo | ICN |
| 3 | 476722 Pyridium | PDA |
| n | | |
| Phenazopyridine HCl | 971490 Phase | ICN |
| 100mg Tab | 271489 Phenazo | ICN |

476714 Pyvidium

PDA

DTC

08:00 Anti-Infective Agents

08:40:00 Miscellaneous Anti-Infectives

| Sulfamethoxazole & Trimethoprim 40mg & 8mg/mL O/L | 270644 Septra | BWE |
|---|--|-----|
| | 272485 Bactrim Sugar Free | HLR |
| Sulfamethoxazole & Trimethoprim | | |
| 800mg & 160mg Tab | 368040 Septra DS | BWE |
| Soung a loung 120 | | |
| | 371823 Bactrim-DS | HLR |
| | 445282 Apo-Sulfatrim-DS | APX |
| | 510645 Novotrimel DS | NOP |
| | 516767 Sulfamethoxazole & Trimethoprim | DTC |
| Sulfamethoxazole & Trimethoprim | | |
| 400mg & 80mg Tab | 270636 Septra | BWE |
| 3 | 272469 Bactrim | HLR |
| | 445274 Apo-Sulfatrim | APX |
| | 510637 Novotrimel | NOP |

516759 Sulfamethoxazole & Trimethoprim

10:00 Antineoplastic Agents

| Cyclophosphamide | | |
|----------------------------|---------------------|-----|
| Inj Pd-200mg Pk | 013544 Procytox | HOR |
| | 344907 Cytoxan | BRI |
| Cyclophosphamide | | |
| 50mg Tab | 013749 Procytox | HOR |
| | 344885 Cytoxan | BRI |
| Cyclophosphamide | | |
| 25mg Tab | 262676 Procytox | HOR |
| | 344877 Cytoxan | BRI |
| Fluorouracil | | |
| 500mg/10mL Inj Sol-10mL Pk | 012882 Fluorouracil | HLR |
| | 428493 Adrucil | ADI |

12:00 Autonomic Agents

| Bethanechol Chloride | | |
|--|---|------------|
| 25mg Tab | 349739 Urecholine | FRS |
| | 453005 Duvoid | EAT |
| ethanechol Chloride | | |
| 10mg Tab | 349720 Urecholine 452998 Duvoid | FRS |
| | 452998 Duvold | EAT |
| 2:08:00 Parasympatholytic (Cholinerg | ric Blocking) Agents | |
| hunning Culfota | 012076 34 | ar v |
| tropine Sulfate 0.6 mg/ml Inj Sol 1 ml Pk | 012076 Atropine #535699 Atropine Sulfate | GLA SOU |
| .6 mg/m1 111 301 1 m1 Pk | #333099 Attoptile Sufface | 200 |
| tropine Sulfate | 061697 Atropine | GLA |
| 0.4mg/ml Inj Sol lml Pk | #535680 Atropine Sulfate | SQU |
| enztropine Mesylate | | |
| 2mg Tab | 016357 Cogentin | MSD |
| | 426857 Apo-Benztropine | APX |
| | 428086 Bensylate | ICN |
| cyclomine HCl | | |
| 10mg Cap | 018007 Bentylol | MER |
| | 361933 Formulex | ICN |
| ocyclidine HCl | 004405 W | DIVE |
| 0.5mg/mL 0/L | 004405 Kemadrin 485012 Procyclid | BWE |
| | 400012 11 0Cyc11u | 10.1 |
| cocyclidine HCl | 004758 Kemadrin | BWE |
| Jug 1au | 306290 Procyclid | ICN |
| | | |
| ropantheline Bromide 15mg Tab | 028592 Pro-Banthine | SEA |
| TORK 140 | 294837 Propanthel | ICN |
| siboyumbanidul UCl | , | |
| hexyphenidyl HCl | 015059 Artane | LED |
| | 021938 Novohexidyl | NOP |
| | 271314 Aparkane | ICN |
| | 545074 Apo-Trihex | APX |
| ihexyphenidyl HCl | | |
| mg Tab | 015040 Artane | LED |
| | 021911 Novohexidyl | NOP ICN |
| | 280445 Aparkane 545058 Apo-Trihex | APX |
| | 010000 Apo II IBEN | A |
| | | |

12:00 Autonomic Agents

12:12:00 Sympathomimetic (Adrenergic) Agents

| Pseudoephedrine HC1 | | |
|--|--------------------|-------|
| 6mg/mL O/L | 004561 Sudafed | BWE |
| 5. A. S. | 425516 Robidrine | ROB |
| Pseudoephedrine HCI | | |
| 60mg Tab | 004766 Sudafed | BWE |
| | 342726 Robidrine | ROB |
| Salbutamol | 4. | |
| 4mg Tab | 332267 Ventolin | 477.4 |
| | +620963 Novosalmol | AHA |
| | 02000 .10 032 mol | NOP |
| Salbutamol | | |
| 2mg Tab | 361135 Ventolin | AHA |
| | +620955 Novosalmol | NOP |

20:00 Blood Formation and Coagulation

20:04:00 Antianemia Drugs

| * Ferrous Fumarate (OTC) | | | |
|---------------------------|---------|-----------------------|-----|
| 200mg Tab 100 Pk | #012238 | Fersanal | GLA |
| • | 021431 | Novofumar | NOP |
| | 094706 | Ferrous Fumarate | DTC |
| * Ferrous Gluconate (OTC) | | | |
| 300mg Tab 100 Pk | 021458 | Novoferrogluc | NOP |
| | 031097 | Ferrous Gluconate | WAM |
| | 033650 | Fergon | WIN |
| | +041157 | Ferrous Gluconate | LEA |
| | 094714 | Ferrous Gluconate | DTC |
| | 545031 | Apo-Ferrous Gluconate | APX |
| * Ferrous Sulfate (OTC) | | | |
| 300mg Ent Tab 100 Pk | 232998 | Novoferrosulfa | NOP |

520810 Apo-Ferrous Sulfate

APX

| 24:04:00 Cardiac Drugs | | |
|------------------------------|---|---------|
| Disopyramide | | |
| 150mg Cap | 396389 Norpace | SEA |
| 100mg Cap | 439363 Rythmodan | ROU |
| | | |
| Disopyramide | | |
| 100mg Cap | 382876 Rythmodan | ROU |
| | 396370 Norpace | SEA |
| Vitarial Tantusto | | |
| Metoprolol Tartrate 50mg Tab | 397423 Lopresor | GEI |
| Some 130 | 402605 Betaloc | AST |
| | 618632 Apo-Metoprolol | APX |
| | +648035 Novometoprol | NOP |
| | 1040000 Novome topi 01 | 1101 |
| Metoprolol Tartrate | | |
| 100mg Tab | 397431 Lopresor | GEI |
| | 402540 Betaloc | AST |
| | 618640 Apo-Metoprolol | APX |
| | +648043 Novometoprol | NOP |
| Propranolol | | |
| 80mg Tab | 313602 Inderal | AYE |
| COME TOO | 402761 Apo-Propranolol | APX |
| | 496502 Novopranol | NOP |
| | 523380 Propranolol | DTC |
| | 582271 PMS-Propranolol | PMS |
| | | |
| Propranolol | 200000 7 1 1 | . 77.57 |
| 40mg Tab | 002666 Inderal | AYE |
| | 402753 Apo-Propranolol | APX |
| | 496499 Novopranol | NOP |
| | 523399 Propranolol | DTC |
| | 582263 PMS-Propranolol | PMS |
| Propranolol | | |
| 20mg Tab | 489859 Inderal-20 | AYE |
| | +663719 Apo-Propranolol | APX |
| | | |
| Propranolol | 450550 7 1 1 | AYE |
| 120mg Tab | 456578 Inderal | APX |
| | 504335 Apo-Propranolol | NOP |
| | 549657 Novopranol 582298 PMS-Propranolol | PMS |
| | 22222 1.10 1.0p. 2.1022 | |
| Propranolol | | |
| 10mg Tab | 002658 Inderal | AYE |
| | 402788 Apo-Propranolol | APX |
| | 496480 Novopranol | NOP |
| | 523402 Propranolol | DTC |
| | 582255 PMS-Propranolol | PMS |

| 24:04:00 Cardiac Drugs | | |
|--|-----------------------------------|------|
| Quinidine Sulfate | 002613 0 : :1: | АНА |
| 200mg Tab | 003611 Quinidine 004782 Quinidine | BWE |
| 200113 143 | 021733 Novoquinidine | NOP |
| | 023868 Quinidine | PDA |
| | 026883 Quinidine | ROG |
| | 094412 Quinidine | DTC |
| | 441740 Apo-Quinidine Sulfate | APX |
| | 441740 Apo-Quinidine Sulfate | API |
| 24:06:00 Antilipemic Drugs | | |
| Clofibrate | | |
| 500mg Cap | 002038 Atromid-S | AYE |
| Stong Cap | 337382 Novofibrate | NOP |
| | 409472 Claripex | ICN |
| | 405472 Claripex | 10.1 |
| 24:08:00 Hypotensive Drugs (For Diuret | ics See 40:281 | |
| Chi al in | | |
| Chlorthalidone 50mg Tab | 010412 U | CET |
| 30mg 140 | 010413 Hygroton 298964 Uridon | GEI |
| | | ICN |
| | 337447 Novothalidone | NOP |
| | 360279 Apc-Chlorthalidone | APX |
| | 398365 Chlorthalidone | DTC |
| Chlorthalidone | | |
| 100mg Tab | 010421 Hygroton | GEI |
| 100% 130 | 293881 Uridon | ICN |
| | 337455 Novothalidone | NOP |
| | 360287 Apo-Chlorthalidone | APX |
| | 398373 Chlorthalidone | DTC |
| | 330373 Culti thallughe | DIC |
| Furosemide | | |
| 20mg/2mL Inj Sol-2mL Pk | 217743 Lasix | HOE |
| and the second | #467766 Uritol | HOR |
| | #201.00 U1101 | MOK |
| Furosemide | | |
| 40mg Tah | 012580 Lasix | HOE |
| | 332275 Furoside | ICN |
| | 337749 Novosemide | NOP |
| | 344079 Uritol | HOR |
| | 362166 Apo-Furosemide | APX |
| | 396249 Furosemide | DTC |
| | | |
| Furosemide | | |
| 20mg Tab | 289590 Lasix | HOE |
| | 337730 Novosemide | NOP |
| | 353612 Furoside | ICN |
| | 396788 Apo-Furosemide | APX |
| | 489131 Furosemide | DTC |
| | | |
| Guanethidine Monosulfate | | |
| 25mg Tab | 005517 Ismelin | CIB |
| | 396753 Apo-Guanethidine | APX |

24:08:00 Hypotensive Drugs (For Diuretics See 40:28)

| Guanethidine Monosulfate | | |
|--------------------------------------|--|---------------|
| 10mg Tab | 005509 Ismelin | CIB |
| | 396745 Apo-Guanethidine | APX |
| | • | |
| Hydrochlorothiazide | | |
| 50mg Tab | #005576 Esidrix | CIB |
| | 016519 HydroDIURIL | MSD |
| | 021482 Novohydrazide | NOP |
| | 092703 Hydrochlorothiazi | ide DTC |
| | 209821 Hydrochlorothiazi | |
| | 263907 Urozide | ICN |
| | 312800 Apo-Hydrochloroth | |
| | order in the injurious constitution of the | |
| Hydrochlorothiazide | | |
| 25mg Tab | #005568 Esidrix | CIB |
| | 016500 HydroDIURIL | MSD |
| | 021474 Novohydrazide | NOP |
| | 092681 Hydrochlorothiazi | |
| | 263893 Urozide | ICN |
| | 326844 Apo-Hydrochloroth | |
| | 020011po, u. 0011100011 | 102100 /// // |
| Hydrochlorothiazide & Spironolactone | | |
| 25mg & 25mg Tab | 180408 Aldactazide | SEA |
| Zong a Zong 140 | 613231 Novo-Spirozine | NOP |
| | order novo opriozrac | 1101 |
| Hydrochlorothiazide & Triamterene | | |
| 25mg & 50mg Tab | 181528 Dyazide | SKF |
| Long a comp 100 | 441775 Apo-Triazide | APX |
| | 532657 Novotriamzide | NOP |
| | ODEOG! NOVO DI IEMZICE | 1101 |
| Methyldopa | | |
| 500mg Tab | 016586 Aldomet | MSD |
| OCCURS 125 | 337498 Novomedopa | NOP |
| | 353639 Dopamet | ICN |
| | 426830 Apo-Methyldopa | APX |
| | 456020 Methyldopa | DTC |
| | 400020 Methy Idopa | D10 |
| Methyldopa | | |
| 250mg Tab | 016578 Aldomet | MSD |
| 230mg 120 | 250392 Dopamet | ICN |
| | 337471 Novomedopa | NOP |
| | 360260 Apo-Methyldopa | APX |
| | 456004 Methyldopa | DTC |
| | 430004 methy idopa | DIC |
| Methyldopa | | |
| • • | 016551 Aldomet | MSD |
| 125mg Tab | | NOP |
| | 337463 Novomedopa | ***** |
| | 353620 Dopamet 360252 Apo-Methyldop | ICN |
| | 456012 Methyldopa | |
| | 430012 Mechyluopa | DTC |

24:08:00 Hypotensive Drugs (For Diuretics See 40:28)

| Methyldopa & Hydrochlorothiazide | | | |
|----------------------------------|---------|-------------------------------|-----|
| 250mg & 25mg Tab | 140597 | Aldoril-25 | MSD |
| | 363634 | Novodoparil-25 | NOP |
| | #403490 | Dopazide-25 | ICN |
| | 441716 | Apo-Methazide-25 | APX |
| | 584975 | PMS-Dopazide-25 | PMS |
| Methyldopa & Hydrochlorothiazide | | | |
| 250mg & 15mg Tab | 140589 | Aldoril-15 | MSD |
| | | Novodoparil-15 | NOP |
| | | Dopazide-15 | ICN |
| | 441708 | Apo-Methazide-15 | APX |
| | 584967 | PMS-Dopazide-15 | PMS |
| Metoprolol Tartrate | | | |
| 50mg Tab | 397423 | Lopresor | GEI |
| | | Betaloc | AST |
| | 618632 | Apo-Metoprolol | APX |
| | +648035 | Novometoprol | NOP |
| | | | |
| Metoprolol Tartrate | | | |
| 100mg Tab | 397431 | Lopresor | GEI |
| | | Betaloc | AST |
| | 618640 | Apo-Metoprolol | APX |
| | | Novometoprol | NOP |
| | | • | |
| Propranolol | | | |
| 80mg Tab | 313602 | Inderal | AYE |
| | 402761 | Apo-Propranolol | APX |
| | 496502 | Novopranol | NOP |
| | 523380 | Propranolol | DIC |
| | 582271 | PMS-Propranolol | PMS |
| n | | | |
| Propranolol | | | |
| 40mg Tab | | Inderal | AYE |
| | | Apo-Propranolol | APX |
| | | Novopranol | NOP |
| | | Propranolol | DTC |
| | 582263 | PMS-Propranolol | PMS |
| Propranolol | | | |
| 20mg Tab | 400000 | 7 1 1 00 | |
| 20mg 140 | | Inderal-20 | AYE |
| | +663719 | Apo-Propranolol | APX |
| Propranolol | | | |
| 120mg Tab | 450570 | 71 | |
| 120115 100 | | Inderal | AYE |
| | | Apo-Propranolol Novopranol | APX |
| | | PMS-Propranolol | NOP |
| | 302230 | THO FIOPLANOIOI | PMS |

24:08:00 Hypotensive Drugs (For Diuretics See 40:28)

| Propranolol | | |
|-----------------------------|------------------------|------|
| 10mg Tab | 002658 Inderal | AYE |
| | 402788 Apo-Propranolol | APX |
| | 496480 Novopranol | NOP |
| | 523402 Propranolol | DTC |
| | 582255 PMS-Propranolol | PMS |
| | | 1110 |
| Reserpine | | |
| 0.25mg Tab | 005665 Serpasil | CIB |
| | 021784 Novoreserpine | NOP |
| | 093238 Reserpine | DTC |
| | | |
| Reserpine | | |
| 0.1mg Tab | 005657 Serpasil | CIB |
| | 093211 Reserpine | DTC |
| | | |
| Spironolactone | | |
| 25mg Tab | 028606 Aldactone | SEA |
| | 613215 Novo-Spiroton | NOP |
| C-11 | | |
| Spironolactone | 007.77 | |
| 100mg Tab | 285455 Aldactone | SEA |
| | 544477 Sincomen | BER |
| | 613223 Novo-Spiroton | NOP |
| 24:12:00 Vasodilating Drugs | | |
| critero vasouriating brags | | |
| Isosorbide Dinitrate | | |
| 5mg SL Tab | 243116 Isordil | WYE |
| 3 | 446661 Coronex | AYE |
| | 110001 COLONEX | AIE |
| Isosorbide Dinitrate | | |
| 30mg Tab | 279536 Isordil | WYE |
| | 441694 Apo-ISDN | APX |
| | 446696 Coronex | AYE |
| | 458694 Novosorbide | NOP |
| | | |
| Isosorbide Dinitrate | | |
| 10mg Tab | 208973 Isordil | WYE |
| | 441686 Apo-ISDN | APX |
| | 446688 Coronex | AYE |
| | 458686 Novosorbide | NOP |
| . N | | |
| * Nitroglycerin | | |
| 0.6mg SL Tab-100 Pk | #003662 Nitrostabilin | AHA |
| | 015962 Nitroglycerin | LIL |
| | 990620 Nitrostat | PDA |
| | | |
| Nitroglycerin | | |
| 0.3mg SL Tab-100 Pk | 015954 Nitroglycerin | LIL |
| | 037613 Nitrostat | PDA |
| | | |

| 28:08: | 00 4 | inalo | esics |
|--------|------|-------|-------|
| 20.00. | 00 / | 27000 | 00.00 |

| Acetaminophen | | |
|--|--|--------|
| 80mg/mL O/L | +631353 Atasol | HOR |
| | +642401 Tempra | MJO |
| * Acetaminophen | | |
| 500mg Tab | 013668 Atasol Forte | HOR |
| 334 | #292486 Campain | WIN |
| | 446114 Exdol Strong | FRS |
| | 482323 Novogesic Forte | NOP |
| | 545007 Apo-Acetaminophen | APX |
| | 566802 Acetaminophen Extra Str | en CLK |
| | 567663 Acetaminophen | WAM |
| | 589233 Acetaminophem Extra Str | en DPC |
| * Acetaminophen | | |
| 325mg Tab | #229229 Campain | WIN |
| | 277193 Rounox | ROG |
| | 293482 Atasol | HOR |
| | 330876 Robigesic | ROB |
| | 373710 Exdol | FRS |
| | 374148 Acetaminophen | WAM |
| | 389218 Novogesic | NOP |
| | 467065 Acetaminophen | CLK |
| | 544981 Apo-Acetaminophen | APX |
| | 589241 Acetaminophen | DPC |
| Acetaminophen with Codeine | | |
| 60mg Tah | 396516 Tylenol No. 4 | MCN |
| 332 | 666149 Empracet-60 | BWE |
| | | |
| Controller with Collins | 600000 Patrice 20 | |
| Acetaminophen with Codeine | 608882 Emtec-30 | TCH |
| 30mg Tab | 666130 Empracet 30 | BWE |
| The state of the s | | |
| Acetaminophen Compound with Codeine | 293512 Atasol-30 | HOR |
| 30mg Tab | | FRS |
| | 372358 Exdol-30 425389 Tylenol No.3 | MCN |
| | 653276 Lenoltec No. 3 | TCH |
| Acetaminophen Compound with Codeine | | |
| 15mg Tab | 293504 Atasol-15 | HOR |
| TONG 180 | 372331 Exdol-15 | FRS |
| | 425370 Tylenol No.2 | MCN |
| | ., | |
| * Acetylsalicylic Acid | | |
| 650mg Ent Tab | 010340 Entrophen | FRS |
| | 229296 Novasen | NOP |
| | 343889 Ecotrin-10 | SKF |
| * Acetylsalicylic Acid | | |
| 325mg Ent Tab | 010332 Entrophen | FRS |
| SLONG LIT 180 | 027189 Ecotrin | SKF |
| | 216666 Novasen | NOP |
| | | |

| * Acetylsalicylic Acid (OTC) 325mg Tab 100 Pk | +040851 ASA 453897 ASA | LEA CLK |
|--|---------------------------|------------|
| Acetylsalicylic Acid Compound with Codein | ie | |
| 30mg Tab | 095516 AC & C | DTC |
| | 219843 292 | FRS |
| | 604518 Ancasal 30 | SAN |
| cetylsalicylic Acid Compound with Codein | e | |
| 15mg Tab | 095508 AC & C | DTC |
| | 108103 282 | FRS |
| | 604496 Ancasal 15 | SAN |
| Codeine Phosphate | | |
| 5mg/mL O/L | 018678 Codeine | NDA |
| | 093114 Codeine | DTC |
| odeine Phosphate | | |
| 60mg Tab | 003247 Codeine | AHA |
| | 093149 Codeine | DTC |
| odeine Phosphate | | |
| 30mg Tab | 003239 Codeine | AHA |
| | 018694 Codeine | NDA |
| | 093130 Codeine | DTC |
| | +593451 Codeine Phospha | te TCH |
| odeine Phosphate | | |
| 15mg Tab | 003220 Codeine | AHA |
| | 018686 Codeine | NDA |
| | 093122 Codeine | DTC |
| | +593435 Codeine Phosphan | тсн |
| colchicine | | |
| 0.6mg Tab | 000396 Colchicine | ABB |
| | 094382 Colchicine | DTC |
| | 287873 Colchicine | ROG |
| buprofen | | |
| 600mg Tab | 484911 Motrin | UPJ |
| | 606227 Ibuprofen | KNR |
| | +629359 Novoprofen | NOP |
| buprofen | | |
| 400mg Tab | 364142 Motrin | UPJ |
| | 606219 Ibuprofen | KNR |
| buprofen | | |
| 300mg Tab | 327794 Motrin | UPJ |
| | 606200 Ibuprofen | KNR |

| 28:08:00 Analgesics | | |
|-------------------------------|------------------------------------|------------|
| Ibuprofen | 050400 W | |
| 200mg Tab | 252409 Motrin 606197 Ibuprofen | UPJ KNR |
| 20048 140 | ooder touproren | Aria |
| Indomethacin | | |
| 50mg Cap | 016047 Indocid | MSD |
| | 337439 Novomethacin | NOP |
| | 611166 Apo-Indomethacin | APX |
| | | |
| Indomethacin | | |
| 25mg Cap | 016039 Indocid | MSD |
| | 337420 Novomethacin | NOP |
| | 611158 Apo-Indomethacin | APX |
| Meperidine HCl | | |
| 50mg Tab | 003506 Pethidine | АНА |
| | 033685 Demerol | WIN |
| | | W 411 |
| Morphine HCl | | |
| 5mg/mL O/L | 514217 MOS-5 | ICN |
| | +607770 Morphitec-5 | TCH |
| | | |
| Morphine HC1 | 40.0000 400 | |
| ing/mL O/L | 486582 MOS | ICN |
| | +607762 Morphitec-1 | ТСН |
| Naproxen | | |
| 500mg Tab | 525537 Naprosyn | SYN |
| | 589861 Novonaprox | NOP |
| | 592277 Apo-Naproxen | APX |
| | 615331 Naxen | SYP |
| | | |
| Naproxen | | |
| 375mg Tab | 583367 Naprosyn | SYN |
| | 600806 Apo-Naproxen | APX |
| | 615323 Naxen 627097 Novo-Naprox | SYP |
| | 021097 NOVO-Naprox | NUP |
| Naproxen | | |
| 250mg Tab | 335193 Naprosyn | SYN |
| | 522651 Apo-Naproxen | APX |
| | 565350 Novonaprox | NOP |
| | 615315 Naxen | SYP |
| | | |
| Naproxen | | 1.0 |
| 125mg Tab | 299413 Naprosyn | SYN |
| | 522678 Apo-Naproxen | APX |
| | 565369 Novonaprox | NOP |
| | 615307 Naxen | SYP |
| Oxycodone HCl & Acetaminophen | | |
| 5mg & 325mg Tab | 580201 Percocet | DUP |
| 3 | +608165 Oxycocet | TCH |
| | • | |

28:08:00 Analgesics

| Oxycodone HCl & Acetylmalicylic Acid | | |
|--------------------------------------|------------------------|------------|
| 5mg & 325mg Tab | 580236 Percodan | DUP |
| | +608157 Oxycodan | тсн |
| | , | |
| Phenylbutazone | | |
| 100mg Tab | | *** |
| 100mg Tab | 021660 Novobutazone | NOP DTC |
| | 093041 Phenylbutazone | |
| | 312789 Apo-Phenylbutaz | one APX |
| Propoxyphene | | |
| Cap | 151351 Novepropoxyn | NOP |
| • | 261432 Darvon-N | LIL |
| | | |
| | | |
| 28:12:00 Anticonvulsants | | |
| Continuenta | | |
| Carbamazepine 200mg Tab | 010405 Tegretol | CEI |
| 200Mg 180 | 402699 Apo-Carbamazepi | |
| | 504742 Mazepine | ICN |
| | 004/42 Mazepine | 10.11 |
| Phenobarbital | | |
| 4mg/mL O/L | 588180 Phenobarbital | DTC |
| | 604585 Phenobarbital | SAN |
| | | |
| Phenobarbital | | |
| 60mg Tab | 023817 Phenobarbital | PDA |
| | 093556 Phenobarbital | DTC |
| | 320714 Phenobarbital-I | CN ICN |
| Phenobarbital | | |
| 30mg Tab | 023809 Phenobarbital | PDA |
| • | 093521 Phenobarbital | DTC |
| | 293903 Phenobarbital-I | CN ICN |
| | 804550 Phenobarbital | SAN |
| William Inc. I have be | | |
| Phenobarbital 15mg Tab | 023795 Phenobarbital | PDA |
| lows leb | 093505 Phenobarbital | DTC |
| | 271276 Phenobarbital-I | |
| | 604542 Phenobarbital | SAN |
| | | |
| Phenobarbital | | |
| 100mg Tab | 093564 Phenobarbital | DTC |
| • | 344036 Phenobarbital-I | |
| | 604577 Phenobarbital | SAN |

| 28:12:00 Anticonvulsants | | | |
|--|---------------------------|-------------------|-----|
| Primidone | | | |
| 250mg Tab | 002631 | Mysoline | AYE |
| 230mg 125 | #294985 | | |
| | | | ICN |
| | 396761 | Apo-Primidone | APX |
| Primidone | | | |
| 125mg Tab | 002622 | Mysoline | ATT |
| 125mg 120 | | , | AYE |
| | 355310 | Apo-Primidone | APX |
| 28.16.04 Poughathanataut | ic Agents Antidepressants | | |
| 20:10:04 FSychol herapeut | ic Agents Antiaepressants | | |
| Amitriptyline | | | |
| 50mg Tab | 016349 | Florit | MSD |
| 30mg 12b | | | |
| | | Novotriptyn | NOP |
| | 271152 | | ICN |
| | | Apo-Amitriptyline | APX |
| | | Amitriptyline | DTC |
| | 398462 | Amitriptyline | SAP |
| | | | |
| Amitriptyline | 0.4.0000 | | |
| 25mg Tab | 016330 | | MSD |
| | | Novotriptyn | NOP |
| | | Amitriptyline | SAP |
| | 306320 | | ICN |
| | | Apo-Amitriptyline | APX |
| | 377880 | Amitriptyline | DTC |
| | | | |
| Amitriptyline | | | |
| 10mg Tab | 016322 | | MSD |
| | | Novotriptyn | NOP |
| | | Amitriptyline | SAP |
| | 293911 | | ICN |
| | | Apo-Amitriptyline | APX |
| | 377872 | Amitriptyline | DTC |
| word to the same of the same o | | | |
| Desipramine | | | |
| 25mg Tab | | Pertoframe | GEI |
| | 353868 | Norpramin | MER |
| | | | |
| Doxepin HCl | | | |
| 75mg Cap | | Sinequan | PFI |
| | +629294 | Triadapin | PWC |
| | | | |
| Doxepin HCl | | | |
| 50mg Cap | | Sinequan | PFI |
| | +629286 | Triadapin | PWC |
| | | | |
| Doxepin HCl | | | |
| 25mg Cap | | Sinequan | PFI |
| | +629278 | Triadapin | PWC |
| | | | |

| oxepin HCl | 326925 | Sinequan Triadapin | PFI |
|-----------------------------|-------------------------|-----------------------|-------|
| 100mg Cap | +629308 | Triadapin | PWC - |
| oxepin HCl | The same of the same of | | |
| 10mg Cap | | Sinequan | PFI |
| | +629251 | Triadapin | PWC |
| mipramine | | | |
| 50mg Tab | 010480 | Tofranil | GEI |
| | | Novopramine | NOP |
| | | Imipramine | SAP |
| | 236721 | | ICN |
| | | Apo-Imipramine | APX |
| | 377929 | Imipramine | DTC |
| mipramine | | | |
| 25mg Tab | 010472 | Tofranil | GEI |
| | 021512 | Novopramine | NOP |
| | 209864 | Imipramine | SAP |
| | 236756 | Impril | ICN |
| | 312797 | Apo-Imipramine | APX |
| | 377910 | Imipramine | DTC |
| mipramine | | | |
| 10mg Tab | 010464 | Tofranil | GEI |
| TOME 120 | | Novopramine | NOP |
| | | Imipramine | SAP |
| | 236748 | | ICN |
| | | Apo-Imipramine | APX |
| | | Imipramine | DTC |
| 0.14.00.00 | | | |
| 8:16:08 Psychotherapeuti | c Agents tranquitizers | | |
| hlordiazepoxide | | | |
| 5mg Cap | 012629 | Librium | HLR |
| | 013463 | Solium | HOR |
| | 020915 | Novopoxide | NOP |
| | 398403 | Chlordiazepoxide | DTC |
| | 522724 | Apo-Chlordiazepoxide | APX |
| hlordiazepoxide | | | |
| 25mg Cap | 012645 | librium | HLR |
| | 013498 | | HOR |
| | | Novopoxide | NOP |
| | | Chlordiazepoxide | DTC |
| | | Apo-Chlordiazepoxide | APX |
| blandiana and b | | | |
| hlordiazepoxide 10mg Cap | 012637 | Lihuim | HLR |
| rong cap | 012637 | | HOR |
| | | | |

28:00 Central Nervous System Drugs

28:16:08 Psychotherapeutic Agents Tranquilizers

| | 3 Hanguitizers | |
|---------------------------|-----------------------------|-----|
| Chlordiazepoxide 10mg Cap | 071007 013 | |
| 10mg 00p | 251267 Chlordiazepoxide | SAP |
| | 398411 Chlordiazepoxide | DTC |
| | 522988 Apo-Chlordiazepoxide | APX |
| Chlorpromazine | | |
| 20mg/mL O/L | 025178 Largactil | RPP |
| | +580988 Chlorpromanyl 20 | TCH |
| Chlorpromazine | | |
| 50mg Tab | 025488 Largactil | 200 |
| | 209910 Chlorpromazine | RPP |
| | 232807 Novochlorpromazine | SAP |
| | | NOF |
| Chlorpromazine | | |
| 25mg Tab | 025461 Largactil | RPP |
| | 209902 Chlorpromazine | SAP |
| | 232823 Novochlorpromazine | NOP |
| Chlorpromazine | | |
| 100mg Tah | 025496 Largactil | 222 |
| | 210684 Chlorpromazine | RPP |
| | 232831 Novochlorpromazine | SAP |
| Chlorpromazine | | |
| 10mg Tab | | |
| 1005 120 | 025453 Largactil | RPP |
| | 232157 Novochlorpromazine | NOP |
| Clorazepate Dipotassium | | |
| 15mg Cap | 264911 Tranxene | ADD |
| | +628212 Novo-Clopate | NOP |
| Clorazepate Dipotassium | | |
| 7.5mg Cap | 264946 Tranxene | |
| | | ABB |
| | +628204 Novo-Clopate | NOP |
| Clorazepate Dipotassium | | |
| 3.75mg Cap | 264938 Tranxene | ABB |
| | +628190 Novo-Clopate | NOP |
| Diazepam | | |
| 5mg Tab | 013285 Valium | |
| | 013765 Vivol | HLR |
| | 272442 Novodipam | HOR |
| | 280429 E-Pam | NOP |
| | 303461 Diazepam | ICN |
| | 362158 Apo-Diazepam | SAP |
| | 396230 Diazepan | DTC |
| | · · | DIC |

| 28:16:08 Psychotherapeutic Agents | Tranquilizers | |
|--|-------------------------------|--------|
| Diazepam | 012277 Walium | HT D |
| 2mg Tab | 013277 Valium 013757 Vivol | HLR |
| Zing. 140 | 272434 Novodipam | NOP |
| | 272647 E-Pam | ICN |
| | 405329 Apo-Diazepam | APX |
| | | DTC |
| | 466905 Diazepam | DIC |
| The state of the s | | |
| Diazepam | 013293 Valium | HLR |
| 10mg Tab | | HOR |
| | 013773 Vivol | |
| | 272450 Novodipam | NOP |
| | 272639 E-Pam | ICN |
| | 405337 Apo-Diazepam | APX |
| | 466891 Diazepam | DTC |
| | | |
| Fluphenazine HCl | | |
| 5mg Tab | 029408 Moditen HCl | SQU |
| | 405361 Apo-Fluphenazine | APX |
| | 504459 Permitil | SCH |
| | | |
| Fluphenazine HCl | | |
| 2mg Tab | 029386 Moditen HCl | SQU |
| | 410632 Apo-Fluphenazine | APX |
| | 504432 Permitil | SCH |
| | | |
| Fluphenazine HCl | | |
| 1mg Tab | 029378 Moditen HCl | SOU |
| | 405345 Apo-Fluphenazine | APX |
| | 504424 Permitil | SCH |
| | | |
| Haloperidol | | |
| 2mg/mL O/L | 017582 Haldol | MCN |
| Zing/ ML O/ L | 552429 Peridol | TCH |
| | 587702 Apo-Haloperidol | APX |
| | | 714 75 |
| Haloperidol | | |
| | 017698 Haldol | MCN |
| 5mg Tab | 363650 Novo-Peridol | NOP |
| | 303030 1000-1 61 1001 | NOI |
| W-1 | | |
| Haloperidol | 017663 Haldol | MCN |
| 1mg Tab | | APX |
| | 396818 Apo-Haloperidol | TCH |
| | 552143 Peridol | ICH |
| | | |
| Haloperidol | OFFICE WALL | MCN |
| 0.5mg Tab | 017655 Haldol | MCN |
| | 396796 Apo-Haloperidol | APX |
| | 552135 Peridol | TCH |
| | | |
| Hydroxyzine HCl | | |
| 50mg Cap | 024392 Atarax | PFI |
| | 557900 Multipax | ROR |
| | | |

28:16:08 Psychotherapeutic Agents Tranquilizers

| Hydroxyzine HCl | | |
|-----------------|-------------------------|------|
| 25mg Cap | 024384 Atarax | PFI |
| | 557919 Multipax | ROR |
| | | NON. |
| Hydroxyzine HCl | | |
| 10mg Cap | 024376 Atarax | PFI |
| 2028 001 | 557927 Multipax | ROR |
| | | non |
| Lorazepam | | |
| 2mg Tab | 348333 Ativan | WYE |
| | +637750 Novolorazem | NOP |
| | +655767 Apo-Lorazepam | APX |
| | Octor hpo Lorazepan | ni a |
| Lorazepam | | |
| lmg Tab | 348325 Ativan | WYE |
| 145 100 | +637742 Novolorazem | NOP |
| | +655759 Apo-Lorazepam | APX |
| | The conscious | па |
| Lorazepam | | |
| 0.5mg Tab | 399124 Ativan | WYE |
| O.OMS IND | +655740 Apo-Lorazepam | APX |
| | Oct to Apo Lot azepan | na a |
| Meprobamate | | |
| 400mg Tab | 013846 Miltown | HOR |
| 100mg 140 | 021547 Novomepro | NOP |
| | 034142 Equanil | WYE |
| | 092738 Meprobamate | DTC |
| | 337943 Apo-Meprobamate | APX |
| | 557545 Apo-meprovama te | AL A |
| Oxazepam | | |
| 30mg Tab | 231363 Serax | WYE |
| Jones 125 | 402737 Apo-Oxazepam | APX |
| | 414263 Oxpam | ICN |
| | 483907 Oxazepam | DTC |
| | 496537 Novoxapam | NOP |
| | maqaxovon, veceee | NOF |
| Oxazepam | | |
| 15mg Tab | 295698 Serax | WYE |
| tong lau | 402745 Apo-Oxazepam | APX |
| | 414255 Oxpam | ICN |
| | 483915 Oxazepam | DTC |
| | | NOP |
| | 496529 Novoxapam | NOF |
| Oxazepam | | |
| 10mg Tab | 295701 Serax | WYE |
| TOME 180 | | APX |
| | 402680 Apo-Oxazepam | ICN |
| | 414247 Oxpam | DTC |
| | 483893 Oxazepam | |
| | 500852 Novoxapam | NOP |
| | | |

28:16:08 Psychotherapeutic Agents Tranquilizers

| Perphenazine | | | |
|---------------------|---------|---------------------------------------|------------|
| 8mg Tab | 028312 | Trilafon | SCH |
| | 294799 | Phenazine | ICN |
| | 335118 | Apo-Perphenazine | APX |
| | | Perphenazine | DTC |
| | | -1 | |
| Perphenazine | | | |
| 4mg Tab | 028304 | Trilafon | SCH |
| | 296317 | Phenazine | ICN |
| | 335126 | Apo-Perphenazine | APX |
| | | Perphenazine | DTC |
| | 1 | · · · · · · · · · · · · · · · · · · · | |
| Perphenazine | | | |
| 2mg Tab | 028290 | Trilafon | SCH |
| Zmg 140 | | Phenazine | ICN |
| | | Apo-Perphenazine | APX |
| | | Perphenazine | DTC |
| | 100000 | rer phenazine | <i>D10</i> |
| Perphenazine | | | |
| 16mg Tab | 028320 | Trilafon | SCH |
| Tomg Tab | | Phenazine | ICN |
| | | Apo-Perphenazine | APX |
| | | Perphenazine | DTC |
| | 481320 | rer phena21he | DIC |
| Promazine | | | |
| | 024195 | Sparine | WYE |
| 50mg Tab | | Promazine | DTC |
| | 093339 | rromazine | DIC |
| Promazine | | | |
| | 024177 | Sparine | WYE |
| 25mg Tab | | Promazine | DTC |
| | 093380 | rromazine | DIC |
| The desired desired | | | |
| Thioridazine | 007275 | Mellaril | SAN |
| 2mg/mL O/L | | Thioridazine | SAP |
| | 238775 | Inioridazine | SAF |
| 773 | | | |
| Thioridazine | 007545 | Mellaril | SAN |
| 50mg Tab | | | NOP |
| | | Novoridazine | |
| | | Thioridazine | SAP |
| | | Apo-Thioridazine | APX |
| | | Thioridazine | DTC |
| | +575135 | PMS-Thioridazine | PMS |
| | | | |
| Thioridazine | | | |
| 25mg Tab | | Mellaril | SAN |
| | | Novoridazine | NOP |
| | 238791 | Thioridazine | SAP |
| | | | |

Img Tab

HOR

NOP

28:00 Central Nervous System Drugs

| Thioridazine | | | |
|--------------------|---------|-------------------------------|------|
| 25mg Tab | 360198 | Apo-Thioridazine | APX |
| Zong 180 | | Thioridazine | DTC |
| | | PMS-Thioridazine | PMS |
| | 010121 | The later realine | r.no |
| Thioridazine | | | |
| 100mg Tab | 027553 | Mellaril | SAN |
| | | Novoridazine | NOP |
| | | Apo-Thioridazine | APX |
| | | Thioridazine | DTC |
| | +575143 | PMS-Thioridazine | PMS |
| This was done to a | | | |
| Thioridazine | 007700 | W 11 | |
| 10mg Tab | | Mellaril | SAN |
| | | Novoridazine | NOP |
| | | Thioridazine | SAP |
| | | Apo-Thioridazine Thioridazine | APX |
| | | PMS-Thioridazine | DTC |
| | +3/3113 | rab-inforidazine | PMS |
| Trifluoperazine | | | |
| 10mg/mL 0/L | 027022 | Stelazine | SKF |
| | 298212 | Terfluzine | ICN |
| | | | |
| Trifluoperazine | | | |
| 5mg Tab | | Solazine | HOR |
| | | Novoflurazine | NOP |
| | | Stelazine | SKF |
| | | Trifluoperazine | DTC |
| | | Terfluzine | ICN |
| | 312746 | Apo-Trifluoperazine | APX |
| rifluoperazine | | | |
| 2mg Tab | 013900 | Solazine | HOR |
| - 0 | | Novoflurazine | NOP |
| | | Stelazine | SKF |
| | | Trifluoperazine | DTC |
| | | Terfluzine | ICN |
| | 312754 | Apo-Trifluoperazine | APX |
| | | | |
| rifluoperazine | | | |
| 10mg Tab | | Solazine | HOR |
| | | Novoflurazine | NOP |
| | | Stelazine | SKF |
| | | Trifluoperazine | DTC |
| | | Terfluzine | ICN |
| | 326836 | Apo-Trifluoperazine | APX |
| rifluoperazine | | | |
| rii luoperazine | | | |

013897 Solazine

021857 Novoflurazine

| T. / Cluster mine | | |
|---------------------------------|--|--------|
| Trifluoperazine 1mg Tab | 027146 Stelazine | SKF |
| IMS 160 | | DTC |
| | | ICN |
| | | APX |
| | oreset inpo in interpolation | *** ** |
| 8:24:00 Sedatives and Hypnotics | | |
| | | |
| Chloral Hydrate 500mg Cap | 020893 Novochlorhydrate | YOP |
| ooomg our | | SÓN |
| | 092886 Chloral Hydrate | DTC |
| lywazanam | | |
| lurazepam 30mg Cap | 012718 Dalmane | HLR |
| | 414239 Som-Pam | ICN |
| | 100000 III. III. | NOP |
| | 521701 Apo-Flurazepam | APX |
| lurazepam | ald seems and a seems and | |
| 15mg Cap | 012000 241/12110 | HLR |
| | 11120 0011 1 111 | ICN |
| | 100010 1010111111111 | NOP |
| | 521698 Apo-Flurazepam | APX |
| entobarbital Sodium | | |
| 100mg Cap | 000000 !!!!! | ABB |
| • | 020000 110.0000011 | NOP |
| | 093572 Pentobarbital | DTC |
| henobarbital | | D.T.C. |
| 4mg/mL O/L | 000100 1 110110021 011021 | DTC |
| | 604585 Phenobarbital | SAN |
| henobarbital | and the same of th | |
| 60mg Tab | 020011 1110110001101101 | PDA |
| | 000000 I heliobal bittai | DTC |
| | 320714 Phenobarbital-ICN | ICN |
| henobarbital | - 1 | |
| 30mg Tab | 020000 1 1101100011 01 121 | PDA |
| | 000021 1.00.0001 01101 | DTC |
| | 293903 Phenobarbital-ICN | ICN |
| | 604550 Phenobarbital | SAN |
| henobarbital | 023795 Phenobarbital | PDA |
| 15mg Tab | 093505 Phenobarbital | DTC |
| | | ICN |
| | 604542 Phenobarbital | SAN |
| henobarbital | | |
| 100mg Tab | | DTC |
| | | ICN |
| | 604577 Phenobarbital | SAN |
| romethazine HCl | | |
| 2mg/mL O/L | | RPP |
| | +583979 PMS-Promethazine | PMS |
| ecobarbital Sodium | | |
| 100mg Cap | | LIL |
| | 021032 Novosecobarb | NOP |

40:00 Electrolytic, Caloric and Water Balance

| 40 00 00 Albalinining Assats | | |
|--|---|------------|
| 40:08:00 Alkalinizing Agents | | |
| Sodium Bicarbonate (OTC) | All blances and a second | |
| 300mg Tab 100 Pk | 093068 Sodium Bicarbonate #502286 Sodium Bicarbonate | DTC |
| | #502236 Sodium Bicarbonate | CLK |
| 40:12:00 Replacement Agents | | |
| 101.2.00 1000000000000000000000000000000 | | |
| Calcium Carbonate | | |
| 1250mg Tab | 541907 Os-Cal 500 | AYE |
| | +618101 BioCal | MIT |
| Calcium Gluconate | | |
| 1000mg/10mL Inj Sol-10mL Pk | 027219 Calcium-Sandoz | SAN |
| 100000 | +535702 Calcium Gluconate | SQU |
| | | • |
| Calcium Gluconate (OTC) | | |
| 650mg Tab 100 Pk | 023574 Calcium Gluconate | PDA |
| | 094773 Calcium Gluconate 241717 Calcium Gluconate | DTC |
| | +441473 Calcium Gluconate | NOP |
| | *111170 Calcium Giuconate | 101 |
| Calcium Lactate (OTC) | | |
| 650mg Tab 100 Pk | +021253 Calcium Lactate | NOP |
| | 023590 Calcium Lactate | PDA |
| | 094765 Calcium Lactate | DTC |
| * Potassium Chloride | | |
| 1.33mEq/mL O/L | 208590 Kaochlor | ADI |
| 1.35mEq/ME 0/E | 436984 K-10 | BEE |
| | 485284 Roychlor | ROY |
| | 704504 Kay Ciel | BER |
| | | |
| * Potassium Gluconate | | |
| 1.33mEq/mL O/L | 026700 Potassium-Rougier 208701 Kaon | ROG ADI |
| | 485357 Royonate | ROY |
| | 483337 Royonate | KUI |
| | | |
| | | |
| 40:28:00 Diuretics | | |
| Land Land | | |
| Acetazolamide | 014007 8: | LED |
| 250mg Tab | 014907 Diamox 295019 Acetazolam | ICN |
| | +488275 Novozolamide | NOP |
| | 545015 Apo-Acetazolamide | APX |
| | | |
| Aminophylline | | |
| 250mg/10mL Inj Sol-10mL Pk | 012033 Aminophylline | GLA |
| | +535664 Aminophylline | SQU |

40:00 Electrolytic, Caloric and Water Balance

| 40:28:00 Diuretics | | |
|----------------------------|--|------------|
| Aminophylline 100mg Tab | 014923 Aminophylline 092940 Aminophylline | LED DTC |
| Chlorthalidone 50mg Tab | 010413 Hygroton | GEI |
| | 298964 Uridon | ICN |
| | 337447 Novothalidone | NOP |
| | 360279 Apo-Chlorthalidone | APX |
| | 398365 Chlorthalidone | DTC |
| Chlorthalidone | | |
| 100mg Tab | 010421 Hygroton | GEI |
| | 293881 Uridon | ICN |
| | 337455 Novothalidone | NOP |
| | 360287 Apo-Chlorthalidone | APX |
| | 398373 Chlorthalidone | DTC |
| | | |
| Furosemide | | |
| 20mg/2mL Inj Sol-2mL Pk | 217743 Lasix | HOE |
| | #467766 Uritol | HOR |
| Furosemide | | |
| 40mg Tab | 012580 Lasix | HOE |
| 40mg Tab | 332275 Furoside | ICN |
| | 337749 Novosemide | NOP |
| | 344079 Uritol | HOR |
| | 362166 Apo-Furosemide | APX |
| | 396249 Furosemide | DTC |
| | | |
| Furosemide | | |
| 20mg Tab | 289590 Lasix | HOE |
| | 337730 Novosemide | NOP |
| | 353612 Furoside | ICN |
| | 396788 Apo-Furosemide | APX |
| | 489131 Furosemide | DTC |
| Hydrochlorothiazide | | |
| 50mg Tab | #005576 Esidrix | CIB |
| Joseph Lab | 016519 HydroDIURIL | MSD |
| | 021482 Novohydrazide | NOP |
| | 092703 Hydrochlorothiazide | DTC |
| | 209821 Hydrochlorothiazide | SAP |
| | 263907 Urozide | ICN |
| | 312800 Apo-Hydrochlorothiazide | APX |
| | | |
| Hydrochlorothiazide | W007700 P | 076 |
| 25mg Tab | #005568 Esidrix | CIB |
| | 016500 HydroDIURIL | MSD NOP |
| | 021474 Novohydrazide 092681 Hydrochlorothiazide | DTC |
| | 263893 Urozide | ICN |
| | 326844 Apo-Hydrochloro- | APX |
| | thiazide | |
| | | |

40:00 Electrolytic, Caloric and Water Balance

40:28:00 Diuretics

| Hydrochlorothiazide & Spironolactone | | |
|--|----------------------------|----------|
| 25mg & 25mg Tab | 180408 Aldactazide | -25 SEA |
| The state of the s | 613231 Novo-Spiroz | |
| | • | |
| Hydrochlorothiazide & Triamterene | | |
| 25mg & 50mg Tab | 181528 Dyazide | SKF |
| | 441775 Apo-Triazid | |
| | 532657 Novotriamzi | |
| | | |
| Methyldopa & Hydrochlorothiazide | | |
| 250mg & 25mg Tab | 140597 Aldori1-25 | MSD |
| | 363634 Novodoparil | -25 NOP |
| | #403490 Dopazide-25 | ICN |
| | 441716 Apo-Methazio | |
| | 584975 PMS-Dopazid | |
| | Dopation of the population | 1.45 |
| Methyldopa & Hydrochlorothiazide | | |
| 250mg & 15mg Tab | 140589 Aldoril-15 | MSD |
| | 363642 Novodoparil | |
| | #403482 Dopazide-15 | ICN |
| | 441708 Apo-Methazio | |
| | 584967 PMS-Dopazid | e-15 PMS |
| | oo loot the bopazia | 1.13 |
| Spironolactone | | |
| 25mg Tab | 028606 Aldactone | SEA |
| | 613215 Novo-Spiroto | |
| | ordere word opinous | .101 |
| Spironolactone | | |
| 100mg Tab | 285455 Aldactone | SEA |
| | 544477 Sincomen | BER |
| | 613223 Novo-Spiroto | |
| | order more opinous | |
| 40:40:00 Uricosuric Drugs | | |
| | | |
| Probenecid | | |
| 500mg Tab | 016616 Benemid | MSD |
| | 294926 Benuryl | ICX |
| | | 20.0 |
| Sulfinpyrazone | | |
| 200mg Tab | 010529 Anteran | GEI |
| | 441767 Apo-Sulfinpy | |
| | 463051 Zynol | HOR |
| | 475076 Novopyrazone | |
| | 481181 Antazone | ICN |
| | 481947 Sulfinpyrazo | |
| | | DIC |
| Sulfianusagona | | |
| Sulfinpyrazone | 010510 Anturan | GEI |
| 100mg Tab | 441759 Apo-Sulfinpy | |
| | 463043 Zyno1 | HOR |
| | 475068 Novopyrazone | |
| | 481173 Antazone | ICN |
| | 481955 Sulfinpyrazo | ne DTC |
| | | |

48:00 Cough Preparations

| 48:04:00 Antitussives | | |
|------------------------|-------------------------------|--|
| Codeine Phosphate | | |
| 5mg/mL O/L | 018678 Codeine NDA | |
| Sing/ Int. O/ L | 093114 Codeine DTC | |
| | | |
| Codeine Phosphate | | |
| 60mg Tab | 003247 Codeine AHA | |
| | 093149 Codeine DTC | |
| | | |
| Codeine Phosphate | | |
| 30mg Tab | 003239 Codeine AHA | |
| | 018694 Codeine NDA | |
| | 093130 Codeine DTC | |
| | +593451 Codeine Phosphate TCH | |
| | | |
| Codeine Phosphate | 003220 Codeine AHA | |
| 15mg Tab | D18686 Codeine NDA | |
| | 093122 Codeine DTC | |
| | +593435 Codeine Phosphate TCH | |
| | OSO 300 COUCTRE TROSPILLO | |
| Dextromethorphan HBr | | |
| 3mg/mL O/L | 391069 DM-Syrup PDA | |
| | 436895 Koffex ROG | |
| | 454389 Robidex ROB | |
| | | |
| Hydrocodone Bitartrate | | |
| 1mg/mL O/L | #307858 Corutol DH DOW | |
| | 316970 Robidone ROB | |
| | 585580 Hycodan DUP | |
| 40.40.44.7 | | |
| 48:08:00 Expectorants | | |
| . C | | |
| * Guaifenesin | 026468 Robitussin ROB | |
| 20mg/mL 0/L | 026794 Guaifenesin ROG | |
| | OZO107 GRATICHESIN NOO | |

52:00 Eye, Ear, Nose and Throat Preparations

| 52:04:04 Anti-Infectives Antibiotics | | |
|--|--|------------|
| 32:0:10:10:10:10:10:10:10:10:10:10:10:10:1 | | |
| Chloramphenicol | | |
| 1% Oph Oint-3.5g Pk | 001058 Fenicol | ALC |
| | 024066 Chloromycetin | PDA |
| Chloramphenicol | | |
| 0.5% Oph Sol | 001082 Chloroptic | ALI. |
| 0.0% Opa 001 | 221678 Chloromycetin | PDA |
| | 403474 Isopto Fenical | ALC |
| | | |
| Chloramphenicol | | |
| 0.25% Oph Sol | #239879 Isopto Fenicol | ALC |
| | 704598 Pentamycetin | BER |
| Gentanicin Sulfate | | |
| 0.3% Oph Sol | 436771 Alcomicin | ALC |
| | 512192 Garanycin | SCH |
| | | |
| 52:04:08 Anti-Infectives Sulfonamides | | |
| | | |
| Sulfacetamide (Sodium) | 200018 2 3 3 | |
| 10% Oph Oint-3.5g Pk | 028347 Sulamyd 252522 Cetamide | SCH |
| | 252522 Cetamide | ALC |
| Sulfacetamide (Sodium) | | |
| 10% Oph Sol | 000965 Isopto Cetamide | ALC |
| | 001287 Bleph-10 | ALL |
| | 028053 Sulamyd | SCH |
| | | |
| 52:04:12 Anti-Infectives Other Anti-In | fectives | |
| Idoxuridine | | |
| 0.1% Oph Sol | 001120 Herplex | ALL |
| over opin oo: | 027014 Stoxil | SKF |
| | | |
| 52:08:00 Anti-Inflammatory Agents | | |
| 2 1 2 1 2 2 2 2 | | |
| Nas Sp 200-dose Pk | 359688 Beconase | 477.4 |
| Nas Sp 200-dose PK | 422053 Vancenase | AHA SCH |
| | 422005 Vancenase | 304 |
| | | |
| | | |
| 52:20:00 Mietics | | |
| Pilosenia IICI | | |
| Pilocarpine HCl 6% Oph Sol | 000000 Icente Compie | ALC |
| 0.4 Opii 301 | 000892 Isopto Carpine 526738 Miocarpine | CEV |
| | 020730 Alucai pine | CL |
| Pilocarpine HCl | | |
| 4% Oph Sol | 000884 Isopto Carpine | ALC |
| | 527572 Miocarpine | CEV |
| | | |

52:00 Eye, Ear, Nose and Throat Preparations

| 52:20:00 Miotics | | |
|----------------------------------|--|---|
| Pilocarpine HCI | the second secon | - |
| 2% Oph Sol | 000868 Isopto Carpine ALC 527556 Miocarpine CEV | |
| | 327330 MIOCAPPINE CEN | |
| Pilocarpine HCl | | |
| 1% Oph Sol | 000841 Isopto Carpine ALC | |
| | 527548 Miocarpine CEV | ſ |
| 2:24:00 Mydriatics | | |
| | | |
| Atropine Sulfate 1% Oph Sol | 025017 Vacata Atmonia | |
| 1% Opn S01 | 035017 Isopto Atropine ALC 527947 SMP Atropine CEV | |
| | on the spine | |
| pinephrine HCl | | |
| 2% Oph Sol | 001112 Epifrin ALL | |
| | 358223 Glaucon ALC | |
| pinephrine HCl | | |
| 1% Oph Sol | 001104 Epifrin ALL | |
| | 358231 Glaucon ALC | |
| 2:32:00 Vasoconstrictors | | |
| 2:32:00 Vasoconstrictors | | |
| aphazoline HCl (OTC) | | |
| 0.1% Oph Sol 15mL Pk | 001147 Albalon ALL | |
| | 343978 Opcon HCI | |
| | 390283 Naphcon Forte ALC 528005 Vasocon CEV | |
| | OZOOO VESUCON | |
| ylometazoline HCl (OTC) | | |
| 0.1% Nas Sol 25mL Pk | 537411 Sustaine WIN | |
| | 650854 Otrivin CIB | |
| ylometazoline HCl (OTC) | Control of the Contro | |
| 0.05% Nas Sol 25mL Pk | 537381 Sustaine WIN | |
| | 623458 Otrivin CIB | |
| 2.24.00 Other For For Ness and | The set Assets | |
| 2:36:00 Other Eye, Ear, Nose and | inroal Agents | |
| cetazolamide | | |
| 250mg Tab | 014907 Diamox LED | |
| | 295019 Acetazolam ICN | |
| | +488275 Novozolamide NOP 545015 Apo-Acetazolamide APX | |
| | 040010 Apo-Acetazotamide Ara | |
| Methylcellulose | | |
| 1% Oph Sol | 000817 Isopto Tears ALC | |
| | 514705 Murocel HCI | |

56:00 Gastrointestinal Drugs

| me of on the side and Adamhanta | | | |
|--|---------|----------------------|------------|
| 56:04:00 Antacids and Adsorbents | | | |
| Aluminum Hydroxide & Magnesium Hydroxide | (DPP) | | |
| 600mg & 300mg Chew Tab | 541125 | Maalox TC | ROR |
| | 621544 | Diovol Ex | HOR |
| | | | |
| Aluminum Hydroxide & Magnesium Hydroxide | (DPP) | | |
| 120mg & 60mg/mL 0/L | | Diovol Ex | HOR |
| | 497037 | Maalox TC | ROR |
| * Aluminum Hydroxide & Magnesium Hydroxide | (DPP) | | |
| 40mg & 40mg/mL O/L | | Univol | HOR |
| | 026530 | Maalox | ROR |
| | 261173 | Neutralca-S | DES |
| | 476471 | Gelusil | PDA |
| | (222) | | |
| The state of the s | (DPP) | Maalox | non |
| 400mg & 400mg Tab | | Gelusil 400 | ROR PDA |
| | 103000 | 0614311 400 | FDA |
| *Magnesium Hydroxide | | | |
| 80mg/ml O/L (OTC) 450ml Pk | 03621 | 8 Milk of Magnesia | WAM |
| (OTC) 500ml Pk | 09380 | 7 Milk of Magnesia | DTC |
| 5(-12-00 Cathartics | | | |
| 56:12:00 Cathartics | | | |
| * Bisacodyl (OTC) | | | |
| 5mg Ent Tab 30 Pk | | Dulcolax | BOE |
| | | Bisacolax | ICN |
| | 545023 | Apo-Bisacodyl | APX |
| * Bisacodyl (OTC) | | | |
| 10mg Sup 6 Pk | 003875 | Dulcolax | BOE |
| | 261327 | Bisacolax | ICN |
| | 404802 | Bisacodyl | TCH |
| | | | |
| Cascara Sagrada (OTC) | | | 22. |
| 300mg Tab 100 Pk | | Cascara Sagrada | PDA DTC |
| | 093300 | Cascara Sagrada | DIC |
| Danthron (OTC) | | | |
| 75mg Tab 100 Pk | 026352 | Dorbane | RIK |
| | 323802 | Modane | ADI |
| | | | |
| Docusate Calcium (Dioctyl Calcium Sulfosuc | | (OTC) | *** |
| 240mg Cap 30 Pk | | Surfak | HOE PMS |
| | +664553 | pms-Docusate Calcium | rais |
| * Docusate Sodium (Dioctyl Sodium Sulfosuc | (OTC) | | |
| 100mg Cap 100 Pk | | Colace | BRI |
| | 472166 | Regulex | AYE |
| | 473111 | Docusate Sodium | KLP |
| | | | |

56:00 Gastrointestinal Drugs

| 56:12:00 Cathartics | | |
|--|--|------------|
| 30112:00 04412: | | |
| * Glycerin (OTC) | 990485 Glycerin | PDA |
| 2.7g Sup 24 Pk | 990825 Glycerin | ROG . |
| 41.00 | 990868 Glycerin | DTC |
| * Glycerin (OTC) | | |
| 1.8g Sup 24 Pk | 145416 Glycerin | ROG |
| 1,0g 24h 24 1K | 222801 Glycerin | PDA |
| | 094056 Glycerin | DTC |
| | The state of the s | C-3 |
| * Grain & Citrus Fibre (OTC) | 512656 Fibyrax | ROU |
| Tab 100 Pk | 595829 Novo-Fibre | NOP |
| | 353625 NOVO-FIBRE | NOF |
| * Psyllium Mucilloid (OTC) | | |
| Oral Pd 340g Pk | 242438 Metamucil | SEA |
| 0.01 74 0.05 7. | 387177 Karacil | ICN |
| | 545465 Dispensalax | DPP |
| | 551546 Novo-Mucilax | NOP |
| | 599875 Natural Source Laxative | LEA |
| | | |
| * Sennosides A & B (OTC) | | |
| 8.6mg Tab 100 pk | 026158 Senokot | PFR |
| | 604402 Glysennid | SAN |
| | | |
| | | |
| T(00 00 4 4 1 4 1 4 4 4 1 | | |
| 56:22:00 Antiemetics and Antinauseants | | |
| Dimenhydrinate | | |
| 50mg/5mL Inj Sol-5mL Pk | 013560 Gravol | HOR |
| dong/ one in our in | 511986 Dimenhydrinate | SOU |
| | | - 4- |
| Dimenhydrinate | | |
| 250mg/5mL Inj Sol-5mL Pk | 013579 Gravol | HOR |
| | 511994 Dimenhydrinate | SQU |
| | | |
| * Dimenhydrinate | | |
| 50mg Tab | 013803 Gravol Filmkote | HOR |
| | 021423 Novodimenate | NOP |
| | 209783 Dimenhydrinate | SAP |
| | 272671 Travamine | ICN APX |
| | 363766 Apo-Dimenhydrinate | DTC |
| | 398381 Dimenhydrinate | CLK |
| | 457515 Dimenhydrinate 586331 PMS-Dimenhydrinate | PMS |
| | 300331 FMS-Dimennydrinate | 1.40 |
| 56:40:00 Miscellaneous G.I. Drugs | | |
| | | |
| Cimetidine | | 100 |
| 600mg Tab | 563587 Tagamet | SKF |
| | 584282 Peptol | HOR |
| | | |

56:00 Gastrointestinal Drugs

| Cimetidine | | |
|-------------------------|-----------------------|-----|
| 600mg Tab | 600067 Apo-Cimetidine | APX |
| | 603686 Novocimetine | NOP |
| Cimetidine | | |
| 400mg Tab | 563579 Tagamet | SKF |
| | 568449 Peptol | HOR |
| | 600059 Apo-Cimetidine | APX |
| | 603678 Novocimetine | NOP |
| Cimetidine | | |
| 300mg Tab | 397474 Tagamet | SKF |
| | 487872 Apo-Cimetidine | APX |
| | 546240 Peptol | HOR |
| | 582417 Novocimetine | NOP |
| Cimetidine | | |
| 200mg Tab | 546232 Peptol | HOR |
| | 563560 Tagamet | SKF |
| | 582409 Novocimetine | NOP |
| | 584215 Apo-Cimetidine | APX |
| Metoclopramide HCl | | |
| 10mg/2mL Inj Sol-2mL Pk | 314706 Maxeran | NRD |
| | 386006 Reglan | ROB |
| Metoclopramide HCl | | |
| lmg/mL 0/L | 314714 Maxeran | NRD |
| | 386022 Reglan | ROB |
| detoclopramide HCl | | |
| 5mg Tab | 572268 Maxeran | NRD |
| | +631671 Reglan | ROB |
| detoclopramide HCl | | |
| 10mg Tab | 314722 Maxeran | NRD |
| | 386014 Reglan | ROB |
| | +603775 Emex | BEE |

68:00 Hormones and Substitutes

| Beclomethasone Dipropionate | | 0.000 |
|-----------------------------|-------------------------------------|------------|
| Aero Pd-200 dose Pk | 334243 Beclovent 374407 Vanceril | AHA SCH |
| | De 1300 Tuncci 11 | Sea |
| Betamethasone | | 1,140 |
| 0.5mg Tab | 012211 Betnelan 028185 Celestone | GLA SCH |
| | U28185 Celestone | SCH |
| Cortisone Acetate | | |
| 25mg Tab | 016446 Cortone | MSD |
| | 249963 Cortisone | UPJ |
| | 280437 Cortisone-ICN | ICN |
| Dexamethasone | | |
| 4mg Tab | 349100 Hexadrol | ORG |
| | 354309 Decadron | MSD |
| | 489158 Dexasone 504416 Deronil | ICN |
| | 5U4416 Deron11 | SCH |
| Dexamethasone | | |
| 0.75mg Tab | 285471 Dexasone | ICN |
| | 501069 Deronil | SCH |
| Dexamethasone | | |
| 0.5mg Tab | 016462 Decadron | MSD |
| | 295094 Dexasone | ICN |
| | 501050 Deronil | SCH |
| Dexamethasone 21-Phosphate | | |
| 20mg/5mL Inj Sol-5mL Pk | 213624 Decadron | MSD |
| | 269026 Hexadrol | ORG |
| D 3-1 | | |
| Prednisone 50mg Tab | 232378 Novoprednisone | NOP |
| John Land | 252417 Deltasone | UPJ |
| | 550957 Apo-Prednisone | APX |
| n 1 | | |
| Prednisone 5mg Tab | 021695 Novoprednisone | NOP |
| Sing 140 | 093629 Prednisone | DTC |
| | 210188 Deltasone | UPJ |
| | 232092 Prednisone | SAP |
| | +271381 Winpred | ICN |
| | 312770 Apo-Prednisone | APX |
| | 610623 Prednisone | KNR |
| Prednisone | | |
| 1mg Tab | 271373 Winpred | ICN |
| | 598194 Apo-Prednisone | APX |
| Triamcinolone | | |
| 4mg Tab | 015024 Aristocort | LED |
| | | |

68:00 Hormones and Substitutes

| 58:16:00 Estrogens | | |
|--|---|--|
| Conjugated Estrogens | 002593 Premarin | AYE |
| 2.5mg Tab | #252611 Oestrilin | DES |
| onjugated Estrogens | | |
| 1.25mg Tab | 002585 Premarin | AYE |
| | #006297 Oestrilin | DES |
| | 265489 C.E.S. | ICN |
| onjugated Estrogens | | |
| 0.625mg Tab | 002577 Premarin | AYE |
| | #006289 Oestrilin | DES |
| | 265470 C.E.S. | ICN |
| Conjugated Estrogens | 002569 Premarin | 3.1/22 |
| 0.3 mg Tab | #252603 Oestrilin | AYE |
| 0.5 mg Tab | #252003 Oestriin | DES |
| Dienestrol | | |
| 0.1mg/g Vag Cr-App | #518360 DV Cream | MER |
| | 990531 Dienestrol | ORT |
| | | |
| 68:20:03 Anti-Diabetic Agents Oral | Anti-Diabetic Agents | |
| Chlorpropamide. | | NOP |
| | O21350 Novopropamide | NOP PF I |
| Chlorpropamide. | 021350 Novopropamide 024716 Diabinese | |
| Chlorpropamide. | 021350 Novopropamide 024716 Diabinese 209937 Chlorpropamide | PFI |
| Chlorpropamide. | 021350 Novopropamide 024716 Diabinese | PFI SAP |
| Chlorpropanide. 250mg Tab | 021350 Novopropamide 024716 Diabinese 209937 Chlorpropamide 312711 Apo-Chlorpropamide | PFI SAP APX |
| Chlorpropanide . 250m ₅ Tab Chlorpropanide | 021350 Novopropamide 024716 Diabinese 209937 Chlorpropamide 312711 Apo-Chlorpropamide | PFI SAP APX |
| Chlorpropanide. 250mg Tab | 021350 Novopropamide 024716 Diabinese 209937 Chlorpropamide 312711 Apo-Chlorpropamide 377937 Chlorpropamide | PFI SAP APX DTC |
| Chlorpropanide. 250mg Tab Chlorpropanide 100mg Tab | 021350 Novopropamide 024716 Diabinese 209937 Chlorpropamide 312711 Apo-Chlorpropamide 377937 Chlorpropamide | PFI SAP APX DTC |
| Chlorpropanide . 250mg Tab Chlorpropamide 100mg Tab | 021350 Novopropamide 024716 Diabinese 209937 Chlorpropamide 312711 Apo-Chlorpropamide 377937 Chlorpropamide | PFI SAP APX DTC |
| Chlorpropanide 250mg Tab Chlorpropamide 100mg Tab | 021350 Novopropamide 024716 Diabinese 209937 Chlorpropamide 312711 Apo-Chlorpropamide 377937 Chlorpropamide 024708 Diabinese 399302 Apo-Chlorpropamide | PFI SAP APX DTC |
| Chlorpropanide . 250ng Tab Chlorpropanide 100mg Tab | 021350 Novopropamide 024716 Diabinese 209937 Chlorpropamide 312711 Apo-Chlorpropamide 377937 Chlorpropamide 024708 Diabinese 399302 Apo-Chlorpropamide | PFI SAP APX DTC |
| Chlorpropanide. 250mg Tab Chlorpropamide 100mg Tab Clyburide 5mg Tab | 021350 Novopropamide 024716 Diabinese 209937 Chlorpropamide 312711 Apo-Chlorpropamide 377937 Chlorpropamide 024708 Diabinese 399302 Apo-Chlorpropamide 012599 Diabeta 720941 Euglucon | PFI SAP APX DIC PFI APX HOE BOM |
| Chlorpropanide. 250mg Tab Chlorpropamide 100mg Tab Clyburide 5mg Tab | 021350 Novopropamide 024716 Diabinese 209937 Chlorpropamide 312711 Apo-Chlorpropamide 377937 Chlorpropamide 024708 Diabinese 399302 Apo-Chlorpropamide 012599 Diabeta 720941 Euglucon | PFI SAP APX DTC PFI APX HOE BOM |
| Chlorpropanide. 250mg Tab Chlorpropanide 100mg Tab Clyburide 5mg Tab | 021350 Novopropamide 024716 Diabinese 209937 Chlorpropamide 312711 Apo-Chlorpropamide 377937 Chlorpropamide 024708 Diabinese 399302 Apo-Chlorpropamide 012599 Diabeta 720941 Euglucon | PFI SAP APX DIC PFI APX HOE BOM |
| Chlorpropamide 250mg Tab Chlorpropamide 100mg Tab Glyburide 5mg Tab Glyburide 2.5mg Tab | 021350 Novopropamide 024716 Diabinese 209937 Chlorpropamide 312711 Apo-Chlorpropamide 377937 Chlorpropamide 024708 Diabinese 399302 Apo-Chlorpropamide 012599 Diabeta 720941 Euglucon 454753 Diabeta 720933 Euglucon | PFI SAP APX DTC PFI APX HOE BOM |
| Chlorpropanide . 250mg Tab Chlorpropamide 100mg Tab Clyburide 5mg Tab Clyburide 2.5mg Tab | 021350 Novopropamide 024716 Diabinese 209937 Chlorpropamide 312711 Apo-Chlorpropamide 377937 Chlorpropamide 024708 Diabinese 399302 Apo-Chlorpropamide 012599 Diabeta 720941 Euglucon 454753 Diabeta 720933 Euglucon | PFI SAP APX DTC PFI APX HOE BOM HOE BOM |
| Chlorpropanide . 250ng Tab Chlorpropamide . 100mg Tab Glyburide . 5mg Tab Glyburide 2.5mg Tab | 021350 Novopropamide 024716 Diabinese 209937 Chlorpropamide 312711 Apo-Chlorpropamide 377937 Chlorpropamide 024708 Diabinese 399302 Apo-Chlorpropamide 012599 Diabeta 720941 Euglucon 454753 Diabeta 720933 Euglucon 012602 Orinase 013889 Mobenol | PFI SAP APX DTC PFI APX HOE BOM HOE BOM |
| Chlorpropanide . 250ng Tab Chlorpropamide . 100mg Tab Clyburide . 5mg Tab Clyburide . 2.5mg Tab | 021350 Novopropamide 024716 Diabinese 209937 Chlorpropamide 312711 Apo-Chlorpropamide 377937 Chlorpropamide 024708 Diabinese 399302 Apo-Chlorpropamide 012599 Diabeta 720941 Euglucon 454753 Diabeta 720933 Euglucon 012602 Orinase 013889 Mobenol 021849 Novobutamide | PFI SAP APX DTC PFI APX HOE BOM HOE BOM |
| Chlorpropanide . 250ng Tab Chlorpropamide . 100mg Tab Clyburide . 5mg Tab Clyburide . 2.5mg Tab | 021350 Novopropamide 024716 Diabinese 209937 Chlorpropamide 312711 Apo-Chlorpropamide 377937 Chlorpropamide 024708 Diabinese 399302 Apo-Chlorpropamide 012599 Diabeta 720941 Euglucon 454753 Diabeta 720933 Euglucon 012602 Orinase 013889 Mobenol 021849 Novobutamide 093033 Tolbutamide | PFI SAP APX DTC PFI APX HOE BOM HOE HOR NOP DTC |
| Chlorpropamide 100mg Tab Glyburide 5mg Tab Glyburide 2.5mg Tab | 021350 Novopropamide 024716 Diabinese 209937 Chlorpropamide 312711 Apo-Chlorpropamide 377937 Chlorpropamide 024708 Diabinese 399302 Apo-Chlorpropamide 012599 Diabeta 720941 Euglucon 454753 Diabeta 720933 Euglucon 012602 Orinase 013889 Mobenol 021849 Novobutamide | PFI SAP APX DTC PFI APX HOE BOM HOE BOM |

68:00 Hormones and Substitutes

68:36:00 Thyroids

| Levothyroxine (Sodium) 0.3mg Tab | 009695 Synthroid 012319 Eltroxin | FLI GLA |
|--------------------------------------|-------------------------------------|------------|
| Levothyroxine (Sodium) 0.2mg Tab | 009687 Synthroid 012300 Eltroxin | FLI GLA |
| Levothyroxine (Sodium) 0.15mg Tab | 212164 Synthroid 295582 Eltroxin | FLI GLA |
| Levothyroxine (Sodium) 0.1mg Tab | 009660 Synthroid 012297 Eltroxin | FLI GLA |
| Levothyroxine (Sodium) 0.05mg Tab | 009652 Synthroid 012289 Eltroxin | FLI GLA |
| Liothyronine (Sodium) 25mcg Tab | #012327 Tertroxin 027103 Cytomel | GLA SKF |
| Thyroid 125mg Tab | 023965 Thyroid 483559 Proloid | PDA PDA |
| Thyroid 60mg Tab | 023957 Thyroid 483540 Proloid . | PDA PDA |
| Thyroid 30mg Tab | 023949 Thyroid 483583 Proloid | PDA PDA |

| 84:04:04 Anti-Infectives Antibiotics | | | |
|--------------------------------------|----------|---------------|------------|
| OT. CT. CT Ante Log | | | |
| Bacitracin | | | |
| 500U/g Oint | | Bacitracin | GLA |
| | 031046 | Baciguent | UPJ |
| 84:04:08 Anti-Infectives Fungicides | | | |
| | | | |
| Clotrimazole | 10.00 | | |
| 10mg/g Cr | | Canesten | MIT |
| | 516805 | Myclo | BOE |
| Clatrimazole | | | |
| 10mg/mL Top Sol | 513911 | Canesten | MIT |
| 1005, 207 | 516821 | Myclo | BOE |
| | | | |
| Clotrimazole | | | |
| 10mg/g Vag Cr-App | | Canesten | MIT |
| | 516813 | Myclo | BOE |
| | | | |
| Clotrimazole | E12046 | Canesten | MIT |
| 100mg Vag Tab | 516848 | | BOE |
| | 310040 | MyC10 | BOL |
| Miconazole Nitrate | | | |
| 27 Cr | 326968 | Micatin | MCN |
| 2/6 01 | 497797 | Monistat Derm | ORT |
| | | | |
| Miconazole Nitrate | 387193 | Monistat 7 | ORT |
| 100mg Vag Sup 7 Pk 15 Pk | | Monistat | ORT |
| 13 PK | # JOOOT, | 1101120000 | |
| | | | |
| | | | |
| Nystatin | 020002 | Mycostatin | SOU |
| 100,000U/g Cr | | Nadostine | NDA |
| | | Nyaderm | KLP |
| | | Nilstat | LED |
| | | | |
| Nystatin | | | |
| 100,000U/g Oint | | Mycostatin | SQU |
| | | Nadostine | NDA |
| | | Nilstat | LED KLP |
| | 522864 | Nyaderm | ALI |
| | | | |
| Nystatin | 288209 | Nadostine | NDA |
| 25,000U/g Vag Cr | | Mycostatin | sou |
| | | Nyaderm | KLP |
| | | | |
| Nystatin | | | LED |
| 100,000U Vag Tab | | Nilstat | LED |
| | | Mycostatin | SQU NDA |
| | 270091 | Nadostine | AUA |

| 84:04:12 Anti-Infectives Parasiticides | | |
|--|--|------------|
| Lindane (Gamma Benzene Hexachloride) | | |
| 1% Shampoo | 026220 Kwellada | RCA |
| | 351105 gBh | ROR |
| 84:04:16 Anti-Infectives Other Anti-Infe | ectives | |
| Metronidazole | #283967 Trikacide | ICN |
| 500mg Vag Tab App | 025887 Flagy1 | RPP |
| | | |
| * Povidone - Iodine | | |
| 10% Top Sol | #062081 Bridine Sol | AHA |
| | 158348 Betadine | PFR |
| | 172944 Proviodine | ROG |
| Povidone - Iodine | | |
| 10% Vag Gel | #002720 Bridine | AHA |
| | 026034 Betadine | PFR |
| | 026611 Proviodine | ROG |
| Povidone - Iodine | | |
| 10% Vag Sol | #003115 Bridine | AHA |
| 3 | 026093 Betadine | PFR |
| | 252824 Proviodine | ROG |
| 84:06:00 Anti-Inflammatory Agents | | |
| Betamethasone Valerate | | |
| 0.1% Cr | 011924 Betnovate | GLA |
| 0.17. | 027901 Celestoderm-V | SCH |
| | 458139 Betaderm | KLP |
| | +535435 Ectosone Regular | тсн |
| Betamethasone Valerate | | |
| 0.05% Cr | 011916 Betnovate-1/2 | GLA |
| 0.00% | 027898 Celestoderm-V/2 | SCH |
| | 458147 Betaderm | KLP |
| | +535427 Ectosone Mild | ТСН |
| D. A. C. Alberton, W. N. C. | | |
| Betamethasone Valerate 0.1% Oint | 010000 7 4 | G1 . |
| U.1% Uint | 012386 Betnovate 028363 Celestoderm-V | GLA SCH |
| | 509701 Betaderm | KLP |
| | 303701 Betaderm | VLL |
| Betamethasone Valerate | | |
| 0.05% Oint | 012378 Betnovate-1/2 | GLA |
| | 028355 Celestoderm-V/2 | SCH |
| | 509698 Betaderm | KLP |
| Betamethasone Valerate | | |
| 0.1% Scalp Lot | 027944 Valisone | SCH |
| - | +653217 Ectosone | TCH |
| | | |

| 84:06:00 Anti-Inflammatory Agent | <u>'s</u> | |
|----------------------------------|--------------------------------------|------------|
| Diflorasone Diacetate | | |
| 0.05% Cr | 481807 Florone 530956 Flutone | UPJ ROR |
| Diflorasone Diacetate | | |
| 0.05% Oint | 481793 Florone | UPJ |
| | 532630 Flutone | ROR |
| Fluocinolone Acetonide | | |
| 0.025% Cr | 030422 Synalar Regular | SYP |
| | 385220 Fluoderm | KLP |
| | +535281 Fluonide Regular | TCH |
| Fluocinolone Acetonide | | |
| 0.01% Cr | 030414 Synalar Mild | SYP |
| | 385239 Fluoderm | KLP |
| | +535338 Fluonide Mild | TCH |
| Fluocinonide | | |
| 0.05% Cr | 036099 Lidex | SYP |
| | 589896 Lyderm | KLP |
| | | |
| Fluocinonide | | |
| 0.05% Emol Cr | 424943 Lidemol | SYP |
| | 598933 Tiamol | TIC |
| Hydrocortisone | | |
| 1% Cr | 192597 Emo-Cort | TCD |
| | 303895 Unicort | AHA |
| | 502200 Cortate | SCH |
| | 551945 Hydrocortisone | DTC |
| Hydrocortisone | | |
| 0.5% Cr | 303887 Unicort | AHA |
| | 513288 Cortate | SCH |
| | 551953 Hydrocortisone | DTC |
| Hydrocortisone | | |
| 0.5% Lot | +192589 Emo-Cort | TCD |
| 0.000 | 513253 Cortate | SCH |
| | | 00 |
| Hydrocortisone | | |
| 17 Oint | 093645 Hydrocortisone | DTC |
| | 502197 Cortate | SCH |
| | 509639 Cortoderm | KLP |
| Hydrocortisone | | |
| 0.5% Oint | 093637 Hydrocortisone | DTC |
| 0.0 01110 | 509620 Cortoderm | KLP |
| | 513261 Cortate | SCH |
| | 0.020. 001 1810 | 3011 |
| Hydrocortisone Acetate | | |
| 17. Cr | 458155 Hyderm | KLP |
| | 477699 Corticreme | ROG |
| | | |

84:06:00 Anti-Inflammatory Agents

| Triamcinolone Acetonide | | |
|-------------------------|--------------------------|-----|
| 0.1% Cr | 014621 Aristocort R | LED |
| | 029114 Kenalog | SQU |
| | 385204 Triaderm | KLP |
| | +535273 Trianide Regular | тсн |
| Triamcinolone Acetonide | | |
| 0.025% Cr | #029106 Kenalog-E | SQU |
| | 282448 Aristocort D | LED |
| | 385182 Triaderm | KLP |
| | +535249 Trianide Mild | ТСН |
| Triamcinolone Acetonide | | |
| 0.1% Oint | 029572 Kenalog | SQU |
| | 127914 Aristocort R | LED |
| Triamcinolone Acetonide | | |
| 0.025% Oint | #029564 Kenalog-E | SQU |
| | 282456 Aristocort D | LED |
| | | |
| | | |

84:24:00 Emollients, Demulcents and Protectants

| 544809 Pabafilm-15 | ALC |
|-----------------------|---|
| +677094 Episun | SCH |
| | |
| | |
| 502669 Benoxyl Wash | STI |
| 542040 Desquam-X Wash | WSD |
| | |
| 236063 Benoxyl | STI |
| 374326 Oxyderm | ICN |
| | |
| 187585 Benoxyl | STI |
| 374318 Oxyderm | ICN |
| | |
| 370568 Benoxyl | STI |
| 432938 Oxyderm | ICN |
| | +677094 Episun 502669 Benoxyl Wash 542040 Desquam-X Wash 236063 Benoxyl 374326 Oxyderm 187585 Benoxyl 374318 Oxyderm |

| 84:28:00 Keratolytic Agents | | |
|---|---|------------|
| Benzoyl Peroxide in Acetone-containing | Gel 372692 Dermoyul | ICN |
| 5% Gel | 406821 Acet0xyl | STI |
| 5% Ge 1 | #530190 Persa-Gel | ORT |
| | #050100 Tel 34-061 | OKI |
| Benzoyl Peroxide in Acetone-containing | Gel | |
| 20% Gel | 399116 Dermoxyl | ICN |
| | 406856 AcetOxyl | STI |
| Benzoyl Peroxide in Acetone-containing | Gel | |
| 10% Gel | 372706 Dermoxyl | ICN |
| 10% 001 | 406848 AcetOxyl | STI |
| | #530204 Persa-Gel | ORT |
| Benzoyl Peroxide in Alcohol-containing | " 333237 2322 232 | |
| 5% Gel | 263702 Panoxyl | STI |
| | 426261 5-Benzagel | ROR |
| B1 B1 B1 | | |
| Benzoyl Peroxide in Alcohol-containing | 202000 2 | |
| 10% Ge1 | 263699 Panoxyl | STI |
| | 426288 10-Benzagel 520772 Alquam-X10 | ROR WSD |
| | 020772 Alquam-XIO | #3D |
| Benzoyl Peroxide in Water-based Gel | | |
| 5% Gel | 307564 Desquam-X5 | WSD |
| | 512613 H2Oxyl | STI |
| | 621048 Benzac W5 | ALC |
| Benzoyl Peroxide in Water-based Gel | | |
| 10% Gel | 307572 Desquam-X10 | WSD |
| | 512621 H20xyl | STI |
| | 621056 Benzac W10 | ALC |
| | | |
| Tretinoin | | |
| 0.05% Cr | 493333 Vitamin A Acid | ROR |
| | 518182 StieVAA | STI |
| Tretinoin | | |
| 0.01% Gel | +587958 StieVAA | STI |
| | 590797 Vitamin A Acid | ROR |
| | | |
| | | |
| 84:36:00 Miscellaneous Skin and Mucous | Membrane Agents | |
| 200 200 200 200 200 200 200 200 200 200 | 7,4,4,4,4 | |
| Methoxsalen | | |
| 10mg Cap | +007269 Oxsoralen | ICN |
| | +646237 UltraMOP | CDM |
| A 7i-a Calfan | | |
| * Zinc Sulfate | 70.00.0 | |
| 0.5% Oint | 504246 Anusol | PDA |
| | +621447 Anuzinc | ТСН |
| * Zinc Sulfate | | |
| 10mg Sup | 476315 Anusol | PDA |
| | +621439 Anuzinc | TCH |
| | | |

86:00 Spasmolytics

| Aminophylline | 0.40000 | | |
|----------------------------|---------|-----------------------|------------|
| 250mg/10mL Inj Sol-10mL Pk | | Aminophylline | GLA |
| | +535664 | Aminophylline | squ |
| Aminophylline | | | |
| 100mg Tab | 014923 | Aminophylline | LED |
| | 092940 | Aminophylline | DTC |
| Oxtriphylline | | | |
| 10mg/mL O/L | 405310 | Rouphylline | ROG |
| Tome, and of E | | Choledyl | PDA |
| Oxtriphylline | | | |
| 300mg Tab | 483591 | Choledyl | PDA |
| SOOME 182 | | Apo-Oxtriphylline | APX |
| | | Novotriphyl | NOP |
| Oxtriphylline | | | |
| 200mg Tab | 346071 | Rouphylline | ROG |
| 200118 120 | | Apo-Oxtriphylline | APX |
| | | Novotriphyl | NOP |
| | | Choledyl | PDA |
| Oxtriphylline | | | |
| 100mg Tab | 441724 | Apo-Oxtriphylline | APX |
| 100mg 1ab | | Rouphylline | ROG |
| | | Novotriphyl | NOP |
| | 476404 | Choledyl | PDA |
| Theophylline Anhydrous | | | |
| 200mg Cap | 442283 | Somophyllin-T | FIS |
| Looning Cup | | Elixophyllin | BER |
| Theophylline Anhydrous | 44227 | 5 Somophyllin-T | FIS |
| 100mg Cap | | 5 Elixophyllin | BER |
| | | | |
| Theophylline Anhydrous | | | |
| 5.3mg/mL O/L | 261203 | Theophylline | DES |
| J. Jing/ int O/ L | #452327 | Theolixir | ICN |
| | | Theolair Alcohol Free | e Ura KIK |
| | | Theophylline | TCH PMS |
| | | PMS-Theophylline | BER |
| | 704466 | Elixophyllin | DEN |

88:00 Vitamins

| 88:04:00 Vitamin A | | |
|------------------------|---|------------|
| 11/4 A | | |
| Vitamin A | 021075 Vitamin A | NOD |
| 50,000IU Cap | 480169 Agnasol A | NOP ROR |
| | 400100 Aquasut A | KUK |
| Vitamin A | | |
| 25,000IU Cap | 021067 Vitamin A | NOP |
| | 480193 Aquasol A | ROR |
| | and dealers in the con- | |
| 88:08:00 Vitamins B | | |
| | | |
| * Cyanocobalamin (OTC) | | |
| 1mg/mL Inj Sol 10mL Pk | 002909 Anacobin | AHA |
| | 029165 Rubramin | SQU |
| | 211125 Cyanocobalamin | KLP |
| | 314277 Cyanocobalamin #571865 Cyanocobalamin | NRD ORG |
| | #571865 Cyanocobalamin | UKG |
| Folic Acid | | |
| 5mg Tab | #003492 Folic Acid | AHA |
| 0.00 | 014966 Folvite | LED |
| | 021466 Novofolacid | NOP |
| | 094617 Folic Acid | DTC |
| | 284149 Folic Acid-ICN | ICN |
| | 426849 Apo-Folic | APX |
| | +498777 Folic Acid | LEA |
| | | |
| Nicotinic Acid (DPP) | | |
| 50mg Tab | 015768 Niacin | LIL |
| | 268593 Niacin-ICN | ICN |
| | 274496 Novoniacin | NOP |
| Nicotinic Acid (DPP) | | |
| 100mg Tab | 015776 Niacin | LIL |
| 100115 | 268585 Niacin-ICN | ICN |
| | 200000 1126211 2011 | 10.1 |
| Pyridoxine HCl (DPP) | | |
| 25mg Tab | 015865 Hexa-Betalin | LIL |
| | +232475 Vitamin B6 | LEA |
| | 268607 Vitamin B6-ICN | ICN |
| | 416185 Vitamin B6 | WAM |
| | | |
| Thiamine HCl (DPP) | | |
| 50mg Tab | 023922 Thiamine | PDA |
| | 268631 Vitamin B1-ICN +610267 Vitamin B1 | ICN LEA |
| | +610267 Vitamin Bi | LEA |
| 88:12:00 Vitamin C | | |
| over to vitality o | | |
| * Ascorbic Acid (OTC) | | |
| 500mg Tab 100 Pk | 021997 Novo-C | NOP |
| | 036188 Ascorbic Acid | WAM |
| | | |

88:00 Vitamins

| 88:12:00 Vitamin C | | |
|--------------------------|----------------------|-----|
| * Ascorbic Acid (OTC) | | |
| 500mg Tab 100 Pk | 094668 Ascorbic Acid | DTC |
| 1,9400 | 232122 Ascorbic Acid | SAP |
| | +453951 Vitamin C | CLK |
| * Ascorbic Acid (OTC) | | |
| 250mg Tab 100 Pk | 021237 Novo-C | NOP |
| | 036161 Vitamin C | WAM |
| | 094641 Ascorbic Acid | DTC |
| | 265012 Ascorbic Acid | SAP |
| | +570397 Vitamin C | CLK |
| | | |
| * Ascorbic Acid (OTC) | 256862 Ascorbic Acid | WAM |
| 1000mg Tab 100 Pk | 535907 Novo-C | NOP |
| | 330307 11040-0 | NOI |
| * Ascorbic Acid (OTC) | | |
| 100mg Tab 100 Pk | 021970 Novo-C | NOP |
| 1111 | 094633 Ascorbic Acid | DTC |
| | #492752 Vitamin C | CLK |
| 00 14 00 14:1 1 0 | | |
| 88:16:00 Vitamin D | | |
| Vitamin D | | |
| 50,000IU Cap | 002690 Radiostol | AHA |
| , | 009830 Ostoforte | FRS |
| | | |
| | | |
| 00 00 00 W 1.1 1. | | |
| 88:28:00 Multivitamins | | |
| * Hexavitamins USP (OTC) | | |
| Tab 100 Pk | 269034 Hexavitamins | NOP |
| | 632082 Beminal Plus | AYE |
| Tab 120 Pk | 264482 Revit | ICN |

92:00 Unclassified Therapeutic Agents

| Allopurinol | | |
|---|------------------------|-----|
| 300mg Tab | 294322 Zyloprim | BWE |
| | 363693 Novopurol | NOP |
| | 402796 Apo-Allopurinol | APX |
| | 415766 Purinol | HOR |
| | 454354 Alloprin | ICN |
| Allopurinol | | |
| 200mg Tab | 415758 Purinol | HOR |
| CONTRACTOR OF THE PARTY OF THE | 479799 Apo-Allopurinol | APX |
| | 506370 Zyloprim | BWE |
| | 514209 Alloprin | ICN |
| | 565342 Novopurol | NOP |
| Allopurinol | | |
| 100mg Tab | 004588 Zyloprim | BWE |
| | 364282 Novopurol | NOP |
| | 402818 Apo-Allopurinol | APX |
| | 415731 Purinol | HOR |
| | 449687 Alloprin | ICN |
| Clomiphene Citrate | | |
| 50mg Tab | 018031 Clomid | MER |
| | +640158 Serophene | PMS |

O. Reg. 690/86, Sched. 1.

Schedule 2

PART A

10 percent

PART B

COLUMN 1

COLUMN 2

| Product Name | Strength & Dosage | Manuf'r | DIN | Price | |
|-------------------------|----------------------------|---------|--------|----------|--|
| gBh | 1% Shampoo | ROR | 351105 | .0627 | |
| pms-Docusate Calcium | 240mg Cap 30 Pk | PMS | 664553 | 7.2000 | |
| A-200 Pyrinate | Top Sol | BEE | 480150 | .0670 | |
| Accutane | 40mg Cap | HLR | 582352 | 2.2217 | |
| Accutane | 10mg Cap | HLR | 582344 | 1.0850 | |
| Acet-Am | 325mg Tab | ORG | 263761 | .0874 | |
| Acetaminophen | 650mg Sup | BEE | 553336 | .6608 | |
| Acetaminophen | 120mg Sup | BEE | 553328 | . 4555 | |
| Acetaminophen | 500mg Tab | WAM | 567663 | .0234 | |
| Acetaminophen | 325mg Tab | WAM | 374148 | .0142 | |
| Acetaminophen | 325mg Tab | CLK | 467065 | .0113 | |
| Acetaminophen | 325mg Tab | DPC | 589241 | .0168 | |
| Acetaminophen Extra Str | ength | | | | |
| | 500mg Tab | CLK | 566802 | .0143 | |
| Acetaminophen Extra Str | ength | | | | |
| | 500mg Tab | DPC | 589233 | .0218 | |
| Acetazolam | 250mg Tab | ICN | 295019 | .0499 | |
| Acetest | Tab-100 Pk | AME | 980560 | 10.5000 | |
| Acet0xyl | 5% Gel | STI | 406821 | .0867 | |
| Acet0xyl | 20% Gel | STI | 406856 | . 1383 | |
| Acet0xyl | 10% Gel | STI | 406848 | .1085 | |
| Achromycin | Inj Pd-250mg Pk | LED | 014729 | 8.7083 | |
| Achromycin V | 250mg Cap | LED | 014605 | .0355 | |
| Acidulin | 340mg Cap | LIL | 015210 | . 1569 | |
| Actidil | 0.25mg/mL 0/L | BWE | 235768 | .0246 | |
| Actidil | 2.5mg Tab | BWE | 004812 | .0801 | |
| Actrapid MC (Pork) | 1000U/10mL Inj Sol 10mL Pk | NOO | 612162 | 19.9000 | |
| Adalat | 10mg Cap | MIT | 557633 | .3851 | |
| Adrenalin | 30mg/30mL Inj Sol-30mL Pk | PDA | 155357 | 7.4256 | |
| Adriamycin | Inj Pd-10mg Pk | ADI | 357391 | 31.9500 | |
| Adriamycin | Inj Pd-50mg Pk | ADI | 353078 | 152.3500 | |
| Adrucil | 500mg/10mL Inj Sol-10mL Pk | ADI | 428493 | 3.4500 | |
| Adsorbotear | Oph Sol | ALC | 656216 | .2912 | |
| Aerosporin | Inj Pd-500,000UPk | BWE | 004421 | 20.8000 | |
| Albalon | 0.1% Oph Sol 15mL Pk | ALL | 001147 | 7.4000 | |
| Alcomicin | 0.3% Oph Sol | ALC | 436771 | .6000 | |
| Aldactazide | 25mg & 25mg Tab | SEA | 180408 | .0919 | |
| Aldactazide-50 | 50mg & 50mg Tab | SEA | 594377 | .2502 | |
| Aldactone | 25mg Tab | SEA | 028606 | .0740 | |
| Aldactone | 100mg Tab | SEA | 285455 | .2721 | |
| Aldomet | 500mg Tab | MSD | 016586 | . 1964 | |
| Aldomet | 250mg Tab | MSD | 016578 | . 1185 | |
| Aldomet | 125mg Tab | MSD | 016551 | .0682 | |
| Aldoril-15 | 250mg & 15mg Tab | MSD | 140589 | . 1674 | |
| Aldoril-25 | 250mg & 25mg Tab | MSD | 140597 | . 1829 | |
| Alkeran | 2mg Tab | BWE | 004715 | .9840 | |
| Allerdryl | 50mg Cap | ICN | 271411 | .0535 | |
| Allerdryl | 25mg Cap | ICN | 370517 | .0466 | |
| Alloprin | 300mg Tab | ICN | 454354 | .0354 | |
| Alloprin | 200mg Tab | ICN | 514209 | .0302 | |
| Alloprin | 100mg Tab | ICN | 449687 | .0146 | |
| Alguam-X10 | 10% Gel | WSD | 520772 | .0728 | |
| Alu-Tab | 600mg Tab | RIK | 313297 | .0892 | |
| Alupent | Inh Pd-300dosePk | BOE | 254134 | 9.0000 | |
| Alupent | 5% Inh Sol-10mL Pk | BOE | 003859 | 6.5000 | |
| Alupent | 2mg/mL O/L | BOE | 249920 | .0416 | |
| | 20mg Tab | BOE | 003891 | . 1690 | |
| Alupent | Tour Isn | BUE | 000001 | . 1000 | |
| | | | | | |

| Product Name | Strength & Dosage | Manuf' | r DIN | Price |
|-----------------------|----------------------------------|--------|------------------|--------|
| Amersol | 400mg Cap | HOR | 443204 | . 1825 |
| Amersol | 300mg Cap | HOR | 443190 | .1380 |
| Amersol | 200mg Cap | HOR | 443182 | .1131 |
| Aminophylline | 500mg/10mL Inj Sol-10mL Pk | SQU | 535672 | .8000 |
| Aminophylline | 250mg/10mL Inj Sol-10mL Pk | GLA | 012033 | .9620 |
| Aminophylline | 250mg/10mL Inj Sol-10mL Pk | SQU | 535664 | .8000 |
| Aminophylline | 200mg Tab | LED | 014931 | .0600 |
| Aminophylline | 100ng Tab | LED | 014923 | .0215 |
| Aminophylline | 100mg Tab | DTC | 092940 | .0256 |
| Amitriptyline | 50mg Tab | DTC | 377899 | .0129 |
| Amitriptyline | 50mg Tab | SAP | 398462 | .0129 |
| Amitriptyline | 25mg Tab | SAP | 251275 | .0069 |
| Amitriptyline | 25mg Tab | DTC | 377880 | .0060 |
| Amitriptyline | 10mg Tab | SAP | 251283 | .0049 |
| Amitriptyline | 10mg Tab | DTC | 377872 | .0046 |
| Amoxil | 500mg Cap | AYE | 330531 | .3059 |
| Amoxil | 250mg Cap | AYE | 288497 | . 1529 |
| Amoxil | 50mg/mL 0/L | AYE | 288519 | .0542 |
| Amoxil Amoxil | 25mg/mL 0/L | AYE | 288500 | .0356 |
| | 50mg/mL Ped O/L | AYE | 353035 | .4720 |
| Amphojel | 60mg/nL O/L | WYE | 034002 | .0090 |
| Amphojel | 600mg Tab | WYE | 208965 | .0805 |
| Amphojel 500 | 100mg & 100mg/ml. O/L | WYE | 515655 | .0131 |
| Ampicillin | 500mg Cap | SAP | 348848 | .1375 |
| Ampicillin | 250mg Cap | SAP | 265047 | .0691 |
| Ampicillin | 50mg/ml 0/L | SAP | 283185 | .0272 |
| Ampicillia Ampicin | 25mg/nL 0/L | BRI | 281565 004065 | .0168 |
| Ampicin | Inj Pd-1000mg Pk Inj Pd-500mg Pk | BRI | 004065 | 1.9000 |
| Amytal | 30mg Tab | LIL | 015628 | .0593 |
| Amytal | 15mg Tab | LIL | 015601 | .0485 |
| Amytal | 100mg Tab | LIL | 015636 | .1006 |
| Amytal Sodium | 60mg Cap | LIL | 015148 | .0650 |
| Amytal Sodium | 200mg Cap | LIL | 015156 | .1497 |
| Anacobin | 1mg/mL Inj Sol 10mL Pk | AHA | 002909 | 9.0000 |
| Anafranil | 50mg Tab | GEI | 402591 | .4860 |
| Anafranil | 25mg Tab | GEI | 324019 | .2640 |
| Anafranil | 10mg Tab | GEI | 330566 | .1940 |
| Anapolon-50 | 50mg Tab | SYN | 189421 | 1.2238 |
| Ancasal 15 | 15mg Tab | SAN | 604496 | .0540 |
| Ancasal 30 | 30mg Tab | SAN | 604518 | .0770 |
| Ancef | Inj Pd-1000mg Pk | SKF | 319112 | 5.7160 |
| Ancef | Inj Pd-500mg Pk | SKF | 319139 | 2.9330 |
| Ancotil | 500mg Cap | HLR | 384895 | . 7855 |
| Androcur | 50mg Tab | BER | 704431 | 1.6250 |
| Ansaid | 50mg Tab | UPJ | 647942 | .3515 |
| Ansaid | 100mg Tab | UPJ | 600792 | .4750 |
| Antabuse | 500mg Tab | AYE | 002542 | .3642 |
| Antabuse | 250mg Tab | AYE | 002534 | .1914 |
| Antazone | 200mg Tab | ICN | 481181 | .0541 |
| Antazone | 100mg Tab | ICN | 481173 | .0328 |
| Anthraforte 1 | 1% Oint | STI | 566756 | .2418 |
| Anthraforte 2 | 2% Oint | STI | 566748 | .2753 |
| Anthranol | 0.4% Cr | STI | 537616 | .1803 |
| Anthranol | 0.2% Cr | STI | 537608 | .1551 |
| Anthranol | 0.1% Cr | STI | 537594 | .1409 |
| Anturan | 200mg Tab | GE I | 010529 | . 2370 |

| Product Name | Strength & Dosage | Manuf'r | DIN | Price |
|-----------------------|----------------------|------------|------------------|--------|
| Anturan | 100mg Tab | GEI | 010510 | .1780 |
| Anusol | 0.5% Oint | PDA | 504246 | .0780 |
| Anusol | 10mg Sup | PDA | 476315 | . 1584 |
| Anuzinc | 0.5% Oint | ТСН | 621447 | .0700 |
| Anuzinc | 10mg Sup | ТСН | 621439 | . 1952 |
| Aparkane | 5mg Tab | ICN | 271314 | .0092 |
| Aparkane | 2mg Tab | ICN | 280445 | .0075 |
| Apo-Acetaminophen | 500mg Tab | APX | 545007 | .0182 |
| Apo-Acetaminophen | 325mg Tab | APX | 544981 | .0107 |
| Apo-Acetazolamide | 250mg Tab | APX | 545015 | .0220 |
| Apo-Allopurinol | 300mg Tab | APX | 402796 | .0335 |
| Apo-Allopurinol | 200mg Tab | APX | 479799 | .0270 |
| Apo-Allopurinol | 100mg Tab | APX | 402818 | .0137 |
| Apo-Amitriptyline | 50mg Tab | APX | 335088 | .0115 |
| Apo-Amitriptyline | 25mg Tab | APX | 335061 | .0051 |
| Apo-Amitriptyline | 10mg Tab | APX | 335053 | .0040 |
| Apo-Amoxi | 500mg Cap | APX | 628123 | . 1520 |
| Apo-Amoxi | 250mg Cap | APX | 628115 | .0780 |
| Apo-Amoxi | 50mg/mL O/L | APX | 628158 | .0236 |
| Apo-Amoxi | 25mg/mL O/L | APX | 628131 | .0161 |
| Apo-Ampi | 500mg Cap | APX | 603295 | . 1200 |
| Apo-Ampi | 250mg Cap | APX | 603279 | .0620 |
| Apo-Ampi | 50mg/mL O/L | APX | 603287 | .0217 |
| Apo-Ampi | 25mg/mL O/L | APX | 603260 | .0135 |
| Apo-Benztropine | 2mg Tab | APX | 426857 | .0067 |
| Apo-Bisacodyl | 5mg Ent Tab 30 Pk | APX | 545023 | 1.5000 |
| Apo-Carbamazepine | 200mg Tab | APX | 402699 | .0699 |
| Apo-Chlordiazepoxide | 5mg Cap | APX | 522724 | .0087 |
| Apo-Chlordiazepoxide | 25mg Cap | APX | 522996 | .0138 |
| Apo-Chlordiazepoxide | 10mg Cap | APX | 522988 | .0104 |
| Apo-Chlorpropamide | 250mg Tab | APX | 312711 | .0169 |
| Apo-Chlorpropamide | 100mg Tab | APX | 399302 | .0159 |
| Apo-Chlorthalidone | 50mg Tab | APX | 360279 | .0187 |
| Apo-Chlorthalidone | 100mg Tab | APX | 360287 | .0310 |
| Apo-Cimetidine | 600mg Tab | APX | 600067 | .1500 |
| Apo-Cimetidine | 400mg Tab | APX | 600059 | .1160 |
| Apo-Cimetidine | 300mg Tab | APX | 487872 | .0750 |
| Apo-Cimetidine | 200mg Tab | APX | 584215 | .0630 |
| Apo-Cloxi | 500mg Cap | APX | 618284 | .0750 |
| Apo-Cloxi | 250mg Cap | APX | 618292 | .0210 |
| Apo-Cloxi | 25mg/mL 0/L | APX | 644633 362158 | .0020 |
| Apo-Diazepam | 5mg Tab | APX | 405329 | .0020 |
| Apo-Diazepam | 2mg Tab | APX APX | 405325 | .0029 |
| Apo-Diazepam | 10mg Tab | APX | 363766 | .0066 |
| Apo-Dimenhydrinate | 50mg Tab | APX | 688568 | .3950 |
| Apo-Erythro-S | 500mg Tab | APX | 545678 | .0657 |
| Apo-Erythro-S | 250mg Tab | APX | 545031 | 1.7000 |
| Apo-Ferrous Gluconate | 300mg Tab 100 Pk | APX | 520810 | 1.7000 |
| Apo-Ferrous Sulfate | 300mg Ent Tab 100 PK | APX | 405361 | .1039 |
| Apo-Fluphenazine | 5mg Tab | APX | 410632 | .0693 |
| Apo-Fluphenazine | 2mg Tab | APX | 405345 | .0577 |
| Apo-Fluphenazine | 1mg Tab | APX | 521701 | .0317 |
| Apo-Flurazepam | 30mg Cap | APX | 521701 | .0278 |
| Apo-Flurazepam | 15mg Cap | APX | 426849 | .0059 |
| Apo-Folic | 5mg Tab | APX | 362166 | .0039 |
| Apo-Furosemide | 40mg Tab | ALY | 302100 | .0007 |

| Product Name | Strength & Dosage | Manuf'r | DIN | Price |
|-------------------------|-------------------|---------|--------|--------|
| Apo-Furosemide | 20mg Tab | APX | 396788 | .0048 |
| Apo-Guanethidine | 25mg Tab | APX | 396753 | .0759 |
| Apo-Guanethidine | 10mg Tab | APX | 396745 | .0397 |
| Apo-Haloperidol | 2mg/mL O/L | APX | 587702 | .1000 |
| Apo-Haloperidol | ing Tab | APX | 396818 | .0615 |
| Apo-Haloperidol | 0.5mg Tab | APX | 396796 | .0380 |
| Apo-Hydrochlorothiazide | 50mg Tab | APX | 312800 | .0040 |
| Apo-Hydrochlorothiazide | 25mg Tab | APX | 326844 | .0033 |
| Apo-Imipramine | 50mg Tab | APX | 326852 | .0126 |
| Apo-Imipramine | 25mg Tab | APX | 312797 | .0073 |
| Apo-Imipramine | 10mg Tab | APX | 360201 | .0040 |
| Apo-Indomethacin | 50mg Cap | APX | 611166 | .1410 |
| Apo-Indomethacin | 25mg Cap | APX | 611158 | .0814 |
| Apo-ISDN | 30mg Tab | APX | 441694 | .0403 |
| Apo-ISDN | 10mg Tab | APX | 441686 | .0188 |
| Аро-К | 8mEq LA Tab | APX | 602884 | .0146 |
| Apo-Lorazepam | 2mg Tab | APX | 655767 | .0617 |
| Apo-Lorazepam | 1mg Tab | APX | 655759 | .0380 |
| Apo-Lorazepam | 0.5mg Tab | APX | 655740 | .0399 |
| Apo-Meprobamate | 400mg Tab | APX | 337943 | .0148 |
| Apo-Methazide-15 | 250mg & 15mg Tab | APX | 441708 | .0599 |
| Apo-Methazide-25 | 250mg & 25mg Tab | APX | 441716 | .0619 |
| Apo-Methyldopa | 500mg Tab | APX | 426830 | .0960 |
| Apo-Methyldopa | 250mg Tab | APX | 360260 | .0489 |
| Apo-Methyldopa | 125mg Tab | APX | 360252 | .0290 |
| Apo-Metoprolol | 50mg Tab | APX | 618632 | .0970 |
| Apo-Metoprolol | 100mg Tab | APX | 618640 | .1780 |
| Apo-Metronidazole | 250mg Tab | APX | 545066 | .0237 |
| Apo-Naproxen | 500mg Tab | APX | 592277 | .2580 |
| Apo-Naproxen | 375mg Tab | APX | 600806 | . 1780 |
| Apo-Naproxen | 250mg Tab | APX | 522651 | . 1300 |
| Apo-Naproxen | 125mg Tab | APX | 522678 | .0640 |
| Apo-Nitrofurantoin | 50mg Tab | APX | 319511 | .0079 |
| Apo-Nitrofurantoin | 100mg Tab | APX | 312738 | .0096 |
| Apo-Oxazepam | 30mg Tab | APX | 402737 | .0099 |
| Apo-Oxazepam | 15mg Tab | APX | 402745 | .0075 |
| Apo-Oxazepam | 10mg Tab | APX | 402680 | .0071 |
| Apo-Oxtriphylline | 300mg Tab | APX | 511692 | .0475 |
| Apo-Oxtriphylline | 200mg Tab | APX | 441732 | .0212 |
| Apo-Oxtriphylline | 100mg Tab | APX | 441724 | .0175 |
| Apo-Pen V-K | 60mg/mL O/L | APX | 642231 | .0250 |
| Apo-Pen V-K | 25mg/mL O/L | APX | 642223 | .0185 |
| Apo-Pen V-K | 300mg Tab | APX | 642215 | .0300 |
| Apo-Perphenazine | 8mg Tab | APX | 335118 | . 3145 |
| Apo-Perphenazine | 4mg Tab | APX | 335126 | .0125 |
| Apo-Perphenazine | 2mg Tab | APX | 335134 | .0115 |
| Apo-Perphenazine | 16mg Tab | APX | 335096 | .0210 |
| Apo-Phenylbutazone | 100mg Tab | APX | 312789 | .0089 |
| Apo-Prednisone | 50mg Tab | APX | 550957 | .0950 |
| Apo-Prednisone | 5mg Tab | APX | 312770 | .0086 |
| Apo-Prednisone | lmg Tab | APX | 598194 | .0825 |
| Apo-Primidone | 250mg Tab | APX | 396761 | .0397 |
| Apo-Primidone | 125mg Tab | APX | 399310 | .0248 |
| Apo-Propranolol | 80mg Tab | APX | 402761 | .0560 |
| Apo-Propranolol | 40mg Tab | APX | 402753 | .0332 |
| Apo-Propranolol | 20mg Tab | APX | 663719 | .0275 |

| Apo-Propranolol 120mg Tab APX 504335 .1120 Apo-Propranolol 10mg Tab APX 402788 .0184 Apo-Quinidine Sulfate 200mg Tab APX 41740 .0539 Apo-Sulfamethoxazole 500mg Tab APX 421480 .0675 Apo-Sulfatrim 400mg & 80mg Tab APX 441824 .0635 Apo-Sulfatrim 58 800mg & 160mg Tab APX 445282 .1230 Apo-Sulfatrim-DS 800mg & 160mg Tab APX 445282 .1230 Apo-Sulfinpyrazone 200mg Tab APX 441789 .0365 Apo-Sulfinpyrazone 100mg Tab APX 441789 .0365 Apo-Thioridazine 50mg Tab APX 441789 .0365 Apo-Thioridazine 50mg Tab APX 360236 .0381 Apo-Thioridazine 100mg Tab APX 360238 .0110 Apo-Thioridazine 25mg Tab APX 360238 .0111 Apo-Triptuperazine 5mg Tab APX 360238 .0111 Apo-Triptuperazine 5mg Tab APX 360238 .0111 Apo-Triptuperazine 5mg Tab APX 312762 .0180 Apo-Triftuoperazine 5mg Tab APX 312764 .0070 Apo-Triftuoperazine 10mg Tab APX 312764 .0070 Apo-Triftuoperazine 10mg Tab APX 312764 .0070 Apo-Triftuoperazine 10mg Tab APX 328836 .0015 Apo-Trihex 2mg Tab APX 328836 .0015 Apo-Trihex 5mg Tab APX 328836 .0015 Apo-Trihex 5mg Tab APX 328836 .0015 Apo-Trihex 5mg Tab APX 345539 .0045 Apresoline 50mg Tab APX 345539 .0045 Apresoline 50mg Tab APX 3456074 .0092 Apo-Trihex 2mg Tab APX 3456074 .0092 Apo-Trihex 2mg Tab APX 345088 .0072 Apresoline 50mg Tab CIB 0055525 .1010 Aquasol A 50,0001U Cap ROR 480189 .1298 Aristocort 4mg Tab LED 015016 .2050 Aristocort 5mg Tab LED 015016 .2050 Aristocort 6mg Tab LED 015016 .2050 Aristocort 7mg Tab LED 016021 .3300 Aristocort 2mg Tab LED 015016 .2050 Aristocort 8mg Tab LED 015016 .2050 Aristocort 9mg Tab DOPk MAN 03648 .3.2000 Aristocort 10mg Tab DOPk MAN 03688 .3.2000 Aristocort 2mg Tab DOPk MAN 03688 .3.2000 Aristocort 2mg Tab DOPk MAN 036888 .3.2000 Ascorbic Acid 500mg Tab 100 P | Product Name | Strength & Dosage | Manuf'r | DIN | Price |
|--|-----------------------|--|---------|--------|--------|
| Apo-Quinidine Sulfate 200mg Tab APX 441740 .0539 Apo-Sulfartrim 400mg & 80mg Tab APX 4418274 .0635 Apo-Sulfatrim-DS 800mg & 160mg Tab APX 445282 .1230 Apo-Sulfinpyrazone 200mg Tab APX 441759 .0305 Apo-Sulfinpyrazone 100mg Tab APX 441759 .0305 Apo-Thioridazine 250mg Tab APX 441759 .0305 Apo-Thioridazine 25mg Tab APX 360236 .0381 Apo-Thioridazine 100mg Tab APX 360244 .0750 Apo-Thioridazine 100mg Tab APX 360228 .0111 Apo-Triduperazine 25mg & 50mg Tab APX 312754 .0070 Apo-Triduperazine 5mg Tab APX 312754 .0070 Apo-Triduperazine 5mg Tab APX 312754 .0050 Apo-Trifuoperazine 10mg Tab APX 312754 .0050 Apo-Trifuoperazine 10mg Tab APX | Apo-Propranolol | 120mg Tab | APX | 504335 | .1120 |
| Apo-Sulfamethoxazole 500mg Tab APX 421480 .0675 Apo-Sulfatrim 400mg & 80mg Tab APX 445282 .1230 Apo-Sulfinpyrazone 200mg Tab APX 441767 .0507 Apo-Thioridazine 250mg Cap APX 580929 .0182 Apo-Thioridazine 250mg Tab APX 580929 .0182 Apo-Thioridazine 25mg Tab APX 360198 .0209 Apo-Thioridazine 100mg Tab APX 360238 .0331 Apo-Thioridazine 100mg Tab APX 360228 .0111 Apo-Thioridazine 100mg Tab APX 360228 .0111 Apo-Triduoperazine 200mg Tab APX 312746 .0075 Apo-Trifuoperazine 20mg Tab APX 411775 .0317 Apo-Trifuoperazine 10mg Tab APX 312746 .0070 Apo-Trifuoperazine 10mg Tab APX 345539 .0045 Apo-Trifuoperazine 10mg Tab APX 34 | Apo-Propranolol | 10mg Tab | APX | 402788 | .0184 |
| Apo-Sulfatrim | Apo-Quinidine Sulfate | 200mg Tab | APX | 441740 | .0539 |
| Apo-Sulfatrian-DS | Apo-Sulfamethoxazole | 500mg Tab | APX | 421480 | .0675 |
| Apo-Sulfinpyrazone Apo-Sulfinpyrazone Apo-Itra Apo-Sulfinpyrazone Apo-Tetra 250mg Cap Apo-Thioridazine Apo-Thioridazine Apo-Thioridazine Apo-Thioridazine Apo-Thioridazine Apo-Thioridazine Apo-Thioridazine Apo-Thioridazine Apo-Thioridazine Apo-Thioridazine Apo-Thioridazine Apo-Thioridazine Apo-Thioridazine Apo-Thioridazine Apo-Thioridazine Apo-Thioridazine Apo-Thioridazine Apo-Tribuoperazine Apo-Tribuoperazine Apo-Trifluoperazine Apo-Trifluope | • | 400mg & 80mg Tab | APX | 445274 | .0635 |
| Apo-Sulfinpyrazone 200mg Tab APX 441767 .0557 Apo-Sulfinpyrazone 100mg Tab APX 441767 .0557 Apo-Thioridazine 50mg Tab APX 580929 .0182 Apo-Thioridazine 25mg Tab APX 360198 .0209 Apo-Thioridazine 100mg Tab APX 360198 .0209 Apo-Thioridazine 100mg Tab APX 360244 .0750 Apo-Trioridazine 10mg Tab APX 360244 .0750 Apo-Triduoperazine 500mg Tab APX 312762 .0180 Apo-Trifluoperazine 50mg Tab APX 41275 .0317 Apo-Trifluoperazine 10mg Tab APX 312762 .0180 Apo-Trifluoperazine 10mg Tab APX 34539 .0045 Apo-Trifluoperazine 10mg Tab APX 345074 .0092 Apo-Trifluoperazine 10mg Tab APX 34539 .0045 Apo-Trifluoperazine 10mg Tab APX 34507 | | 3 3 | APX | 445282 | |
| Apo-Sulfinpyrazone 100mg Tab APX 441759 .0305 Apo-Thioridazine 250mg Cap APX 580929 .0182 Apo-Thioridazine 25mg Tab APX 360198 .0209 Apo-Thioridazine 100mg Tab APX 360124 .0750 Apo-Thioridazine 10mg Tab APX 360228 .0111 Apo-Thioridazine 500mg Tab APX 312726 .0180 Apo-Triduoperazine 50mg Tab APX 312726 .0180 Apo-Trifluoperazine 2mg Tab APX 312736 .0070 Apo-Trifluoperazine 1mg Tab APX 32836 .0115 Apo-Trifluoperazine 1mg Tab APX 32836 .0115 Apo-Trifluoperazine 1mg Tab APX 345539 .0115 Apo-Triduoperazine 1mg Tab APX 345539 .0015 Apo-Triduoperazine 1mg Tab APX 345539 .0015 Apo-Triduoperazine 1mg Tab APX 345004 | A | 3 | APX | 441767 | |
| Apo-Tetra | | 5 | APX | 441759 | |
| Apo-Thioridazine | | | | 580929 | |
| Apo-Thioridazine 25mg Tab APX 360198 .0209 Apo-Thioridazine 10mg Tab APX 360244 .0750 Apo-Thioridazine 10mg Tab APX 360228 .0111 Apo-Trioridazine 500mg Tab APX 312762 .0180 Apo-Trifluoperazine 5mg Tab APX 312746 .0070 Apo-Trifluoperazine 10mg Tab APX 312746 .0070 Apo-Trifluoperazine 10mg Tab APX 312746 .0070 Apo-Trifluoperazine 10mg Tab APX 345539 .0045 Apo-Trihex 5mg Tab APX 345539 .0045 Apo-Trihex 2mg Tab APX 345539 .0045 Apo-Trihex 2mg Tab APX 345007 .0052 Apresoline 20mg/mL Inj Sol-ImL Pk C1B .00527 .0092 Apresoline 25mg Tab C1B .005533 .1740 Apresoline 25mg Tab C1B .005525 .010 <td>•</td> <td></td> <td></td> <td></td> <td></td> | • | | | | |
| Apo-Thioridazine 100mg Tab APX 360244 .0750 Apo-Thioridazine 10mg Tab APX 360228 .0111 Apo-Tolbutanide 500mg Tab APX 312762 .0180 Apo-Triazide 25mg & 50mg Tab APX 412775 .0317 Apo-Trifluoperazine 5mg Tab APX 312776 .0070 Apo-Trifluoperazine 2mg Tab APX 312774 .0050 Apo-Trifluoperazine 10mg Tab APX 312754 .0050 Apo-Trifluoperazine 10mg Tab APX 312754 .0050 Apo-Trifluoperazine 10mg Tab APX 328836 .0115 Apo-Trifluoperazine 1mg Tab APX 328836 .0115 Apo-Trihex 5mg Tab APX 545074 .0092 Apo-Trihex 5mg Tab APX 545074 .0092 Apo-Trihex 2mg Tab APX 545074 .0092 Apresoline 20mg/mL Inj Sol-lmL Pk CIB 005274 .0052 Apresoline 20mg/mL Inj Sol-lmL Pk CIB 005274 .0052 Apresoline 50mg Tab CIB 005531 .2720 Apresoline 10mg Tab CIB 005531 .7740 Apresoline 10mg Tab CIB 005532 .1740 Apresoline 10mg Tab CIB 005532 .1010 Aquasol A 50,0001V Cap ROR 480189 .1628 Aquasol A 25,0001V Cap ROR 480189 .1628 Aralen 250mg Tab WIN 033642 .2315 Aristocort 4mg Tab LED 015016 .2050 Aristocort 2mg Tab LED 015016 .2050 Aristocort D 0.025% Cr LED 282448 .0170 Aristocort R 0.1% Cr LED 282448 .0170 Aristocort R 0.1% Cr LED 014621 .0340 Aristocort R 0.1% Cr LED 014621 .0340 Arane 0.4mg/mL Inj Susp-lmL Pk LED 297151 .3,9000 Artane 2mg Tab LED 015090 .0258 Artane 2mg Tab LED 015090 .0258 Artane 2mg Tab LED 015090 .0258 Artane 2mg Tab LED 015090 .0258 Artane 2mg Tab LED 015090 .0258 Artane 2mg Tab LED 015090 .0258 Artane 2mg Tab LED 015090 .0258 Artane 2mg Tab LED 015090 .0258 Artane 2mg Tab LED 015090 .0258 Artane 2mg Tab LED 015090 .0258 Artane 2mg Tab LED 015090 .0180 Ascorbic Acid 500mg Tab 100 Pk SAP 285012 2.3000 Ascorbic Acid 500mg Tab 100 Pk SAP 285012 2.3000 Ascorbic Acid 500mg Tab 100 Pk SAP 285012 2.3000 Ascorbic Acid 100mg Tab 100 Pk SAP 285012 2.3000 Ascorbic Acid 100mg Tab 100 Pk SAP 285012 2.3000 Ascorbic Acid 100mg Tab 100 Pk SAP 285012 2.3000 Ascorbic Acid 100mg Tab 100 Pk SAP 285012 2.3000 Ascorbic Acid 100mg Tab 100 Pk SAP 285012 2.3000 Ascorbic Acid 100mg Tab 100 Pk SAP 285012 2.3000 Ascorbic Acid 100mg Tab 100 Pk SAP 285012 2.3000 Ascorbi | • | | | | |
| Apo-Thioridazine 10mg Tab APX 360228 .0111 Apo-Tolbutamide 500mg Tab APX 312762 .0180 Apo-Triazide 25mg & 50mg Tab APX 312762 .0180 Apo-Trifluoperazine 5mg Tab APX 312746 .0070 Apo-Trifluoperazine 2mg Tab APX 312746 .0070 Apo-Trifluoperazine 10mg Tab APX 312746 .0050 Apo-Trifluoperazine 10mg Tab APX 312754 .0050 Apo-Trifluoperazine 1mg Tab APX 312754 .0050 Apo-Trifluoperazine 1mg Tab APX 345539 .0045 Apo-Trifluoperazine 1mg Tab APX 345539 .0045 Apo-Triflex 5mg Tab APX 545074 .0092 Apo-Trihex 2mg Tab APX 545078 .0072 Apresoline 20mg/mL Inj Sol-ImL Pk C1B 005274 3.0520 Apresoline 50mg Tab C1B 005533 .1740 Apresoline 25mg Tab C1B 005533 .1740 Apresoline 10mg Tab C1B 005533 .1740 Apresoline 10mg Tab C1B 005535 .1010 Aquasol A 50,0001U Cap R0R 480169 .1628 Aquasol A 50,0001U Cap R0R 480169 .1628 Aquasol A 25,0001U Cap R0R 480189 .0945 Aralen 250mg Tab LED 015024 .3900 Aristocort 4mg Tab LED 015024 .3900 Aristocort 2mg Tab LED 015024 .3900 Aristocort 2mg Tab LED 015024 .3900 Aristocort B 0.025% Oint LED 282448 .0170 Aristocort B 0.1% Cr LED 282448 .0170 Aristocort R 0.1% Cr LED 282448 .0170 Aristocort R 0.1% Cr LED 282448 .0170 Aristocort R 0.1% Cr LED 282448 .0170 Aristocort B 0.4mg/mL Inj Susp-ImL Pk LED 197914 .0378 Aristospan 20mg/mL Inj Susp-ImL Pk LED 297151 3.9000 Artane 5mg Tab LED 015039 .0625 Artane 5mg Tab LED 015039 .0625 Artane 5mg Tab LED 015039 .0625 Artane 5mg Tab LED 015039 .0625 Artane 5mg Tab LED 015039 .0625 Artane 5mg Tab LED 015039 .0625 Artane 5mg Tab LED 015039 .0625 Artane 5mg Tab LED 01504 .2300 Ascorbic Acid 500mg Tab 100 Pk DTC 094631 3.9000 Ascorbic Acid 500mg Tab 100 Pk DTC 094633 1.5000 Ascorbic Acid 100mg Tab 100 Pk DTC 094633 1.5000 Ascorbic Acid 100mg Tab 100 Pk DTC 094631 1.570 Asendin 100mg Tab LED 527116 .4350 Atabrine 100mg Tab LED 527116 .4350 Atabrine 100mg Tab LED 527116 .4350 Atabrine 100mg Tab LED 527116 .4350 | • | | | | |
| Apo-Tolbutamide | • | | | | |
| Apo-Triazide | • | 3 | | | |
| Apo-Trifluoperazine | • | 3 | | | |
| Apo-Trifluoperazine | | | | | |
| Apo-Trifluoperazine lng Tab APX 326836 .0115 Apo-Trifluoperazine lng Tab APX 345339 .0045 Apo-Trihex 5mg Tab APX 545074 .0092 Apo-Trihex 2mg Tab APX 545058 .0072 Apresoline 20mg/ml Inj Sol-lml Pk CIB 005274 3.0520 Apresoline 25mg Tab CIB 005533 .1740 Apresoline 25mg Tab CIB 005533 .1740 Apresoline 10mg Tab CIB 005533 .1740 Apresoline 10mg Tab CIB 005533 .1740 Apresoline 25mg Tab CIB 005533 .1740 Apresoline 10mg Tab CIB 005533 .1740 Apresoline 25mg Tab CIB 005525 .1010 Aquasol A 50,0001U Cap ROR 480169 .1628 Aquasol A 25,0001U Cap ROR 480169 .1628 Aquasol A 25,0001U Cap ROR 480193 .0945 Aralen 250mg Tab WIN 033642 .2315 Aristocort 4mg Tab LED 015016 .2050 Aristocort 2mg Tab LED 015016 .2050 Aristocort D 0.025% Cr LED 282448 .0170 Aristocort D 0.025% Oint LED 282456 .0583 Aristocort R 0.1% Cr LED 282456 .0583 Aristocort R 0.1% Cint LED 297151 3.9000 Artane 0.4mg/ml 0/L LED 014621 .0340 Artane 5mg Tab LED 015059 .0625 Artane 5mg Tab LED 015069 .0208 Artane 2mg Tab LED 015069 .0625 Artane 2mg Tab LED 015069 .06 | | | | | |
| Apo-Trifluoperazine Apo-Trihex Apo-Trihex Apo-Trihex Apo-Trihex Apo-Trihex Apo-Trihex Apo-Trihex Apo-Trihex Apo-Trihex Apo-Trihex Apresoline Ap | | | | | |
| Apo-Trihex 5mg Tab APX 545074 .0092 Apo-Irihex 2mg Tab APX 545058 .0072 Apresoline 20mg/mL Inj Sol-lmL Pk CIB 005274 3.0520 Apresoline 50mg Tab CIB 005541 .2720 Apresoline 25mg Tab CIB 005523 .1010 Apresoline 10mg | 1 | | | | |
| Apo-Trihex 2mg Tab APX 545058 .0072 Apresoline 20mg/mL Inj Sol-1mL Pk C1B 005541 .2720 Apresoline 50mg Tab C1B 005541 .2720 Apresoline 25mg Tab C1B 005533 .1740 Apresoline 10mg Tab C1B 005525 .1010 Aquasol A 50,0001U Cap ROR 480169 .1628 Aquasol A 25,0001U Cap ROR 480193 .0945 Aralen 250mg Tab WIN 033642 .2315 Aristocort 4mg Tab LED 015024 .3900 Aristocort 2mg Tab LED 015024 .3900 Aristocort 2mg Tab LED 015024 .3900 Aristocort 0 0.0257 Cr LED 282448 .0170 Aristocort R 0.17 Cr LED 014621 .0344 Aristocort R 0.17 Oint LED 014621 .0344 Aristocort R | • | | | | |
| Apresoline | • | | | | |
| Apresoline | • | 3 | | | |
| Apresoline | • | | | | |
| Apresoline Aquasol A 50,0001U Cap ROR 480169 1628 Aquasol A 25,0001U Cap ROR 480193 .0945 Aralen 250mg Tab WIN 033642 .2315 Aristocort Amg Tab LED 015024 .3900 Aristocort D 0.025% Cr LED 282448 .0170 Aristocort R 0.1% Cr Aristocort R 0.1% Cr Aristocort R 0.1% Cr Aristocort R 0.1% Cr Aristocort R 0.1% Old Discord Aristocort R Aristocort R 0.1% Cr Aristocort R Aristocort R Aristocort R 0.1% Old Discord Aristocort R Aristocort A Aris | | | | | |
| Aquasol A Aquasol A Aquasol A Aquasol A Aralen Aralen Aristocort A | | | | | |
| Aquasol A 25,000 IU Cap ROR 480193 .0945 Aralen 250mg Tab WIN 033642 .2315 Aristocort 4mg Tab LED 015016 .2050 Aristocort 2mg Tab LED 015016 .2050 Aristocort D 0.025% Cr LED 282448 .0170 Aristocort R 0.1% Cr LED 014621 .0340 Aristocort R 0.1% Oint LED 014621 .0378 Aristocort R 0.1% Oint LED 014621 .0378 Aristocort | • | 3 | | | |
| Aralen 250mg Tab WIN 033642 .2315 Aristocort 4mg Tab LED 015024 .3900 Aristocort 2mg Tab LED 015016 .2050 Aristocort D 0.025% Cr LED 282448 .0170 Aristocort D 0.025% Oint LED 282456 .0583 Aristocort R 0.1% Cr LED 014621 .0340 Aristocort R 0.1% Oint LED 127914 .0378 Aristospan 20mg/mL Inj Susp-lmL Pk LED 297151 3.9000 Artane 0.4mg/mL O/L LED 014656 .0208 Artane 5mg Tab LED 015059 .0625 Artane 2mg Tab LED 015059 .0625 Artane 2mg Tab LED 015040 .0180 Asacol 400mg Tab LED 015040 .0180 Ascorbic Acid 500mg Tab 100 Pk WAM 036188 3.2000 Ascorbic Acid 500mg Tab 100 Pk WAM 036188 3.2000 Ascorbic Acid 500mg Tab 100 Pk SAP 232122 4.2000 Ascorbic Acid 500mg Tab 100 Pk SAP 232122 4.2000 Ascorbic Acid 250mg Tab 100 Pk SAP 232122 4.2000 Ascorbic Acid 250mg Tab 100 Pk SAP 232122 2.3000 Ascorbic Acid 250mg Tab 100 Pk DTC 094641 2.5000 Ascorbic Acid 1000mg Tab 100 Pk SAP 265012 2.3000 Ascorbic Acid 1000mg Tab 100 Pk DTC 094633 1.5000 Ascorbic Acid 1000mg Tab 100 Pk DTC 094633 1.5000 Ascorbic Acid 100mg Tab 100 Pk DTC 094633 1.5000 Ascorbic Acid 100mg Tab 100 Pk DTC 094633 1.5000 Ascorbic Acid 100mg Tab 100 Pk DTC 094633 1.5000 Ascorbic Acid 100mg Tab 100 Pk DTC 094633 1.5000 Ascorbic Acid 100mg Tab 100 Pk DTC 094633 1.5000 Ascorbic Acid 100mg Tab 100 Pk DTC 094633 1.5000 Ascorbic Acid 100mg Tab 100 Pk DTC 094633 1.5000 Ascorbic Acid 100mg Tab 100 Pk DTC 094633 1.5000 Ascorbic Acid 100mg Tab 100 Pk DTC 094633 1.5000 Ascorbic Acid 100mg Tab 100 Pk DTC 094633 1.5000 Ascorbic Acid 100mg Tab 100 Pk DTC 094633 1.5000 Ascorbic Acid 100mg Tab 100 Pk DTC 094633 1.5000 Ascorbic Acid 100mg Tab 100 Pk DTC 094633 1.5000 Ascorbic Acid 100mg Tab 100 Pk DTC 094633 1.5000 Ascorbic Acid 100mg Tab 100 Pk DTC 094633 1.5000 Ascorbic Acid 100mg Tab 100 Pk DTC 094633 1.5000 Ascorbic Acid 100mg Tab LED 527092 1.375 Asendin 150mg Tab LED 527094 1.375 | • | • | | | |
| Aristocort | | The state of the s | | | |
| Aristocort D 0.025% Cr LED 282448 .0170 Aristocort D 0.025% Oint LED 282448 .0170 Aristocort R 0.1% Cr LED 014621 .0340 Aristocort R 0.1% Oint LED 127914 .0378 Aristocort R 0.1% Oint LED 127914 .0378 Aristospan 20mg/mL Inj Susp-lmL Pk LED 297151 3.9000 Artane 0.4mg/mL 0/L LED 014656 .0208 Artane 5mg Tab LED 015059 .0625 Artane 2mg Tab LED 015040 .0180 Asacol 400mg Tab LED 015040 .0180 Asacol 400mg Tab LED 015040 .0180 Ascorbic Acid 500mg Tab 100 Pk WAM 036188 3.2000 Ascorbic Acid 500mg Tab 100 Pk DTC 094668 3.9000 Ascorbic Acid 500mg Tab 100 Pk DTC 094668 3.9000 Ascorbic Acid 250mg Tab 100 Pk DTC 094641 2.5000 Ascorbic Acid 250mg Tab 100 Pk SAP 232122 4.2000 Ascorbic Acid 250mg Tab 100 Pk DTC 094641 2.5000 Ascorbic Acid 1000mg Tab 100 Pk SAP 265012 2.3000 Ascorbic Acid 1000mg Tab 100 Pk DTC 094633 1.5000 Ascorbic Acid 100mg Tab 100 Pk DTC 094631 1.5000 Ascorbic Acid 100mg Tab 100 Pk DTC 094631 1.5000 Ascorbic Acid 100mg Tab 100 Pk DTC 094631 1.5000 Ascorbic Acid 100mg Tab 100 Pk DTC 094631 1.5000 Ascorbic Acid 100mg Tab 100 Pk DTC 094631 1.5000 Ascorbic Acid 100mg Tab 100 Pk DTC 094631 1.5000 Ascorbic Acid 100mg Tab 100 Pk DTC 094633 1.5000 Ascorbic Acid 100mg Tab 100 Pk DTC 094633 1.5000 Ascorbic Acid 100mg Tab LED 527092 1.375 Asendin 150mg Tab LED 527084 1.375 Asendin 150mg Tab LED 527114 .6150 Asendin 100mg Tab UNN 033804 1.926 Atarax 50mg Cap PFI 024384 1.1579 | | | | | |
| Aristocort D | | 3 | | | |
| Aristocort D | | 3 | | | |
| Aristocort R Aristocort R Aristocort R Aristospan Arist | Aristocort D | | | | |
| Aristocort R Aristospan 20mg/mL Inj Susp-lmL Pk LED 297151 3.9000 Artane 0.4mg/mL O/L LED 014656 .0208 Artane Smg Tab LED 015059 .0625 Artane 2mg Tab LED 015059 .0625 Artane Asacol Asacol Ascorbic Acid 500mg Tab 100 Pk MAM 036188 3.2000 Ascorbic Acid 500mg Tab 100 Pk DTC 094668 3.9000 Ascorbic Acid 500mg Tab 100 Pk DTC 094668 3.9000 Ascorbic Acid 500mg Tab 100 Pk DTC 094641 2.5000 Ascorbic Acid Ascorbic A | Aristocort D | | | | |
| Aristospan 20mg/mL Inj Susp-lmL Pk LED 297151 3.9000 Artane 0.4mg/mL O/L LED 014656 .0208 Artane 5mg Tab LED 015059 .0625 Artane 2mg Tab LED 015040 .0180 Asacol 400mg Tab LED 015040 .0180 Asacol 400mg Tab LED 015040 .0180 Ascorbic Acid 500mg Tab 100 Pk WAM 036188 3.2000 Ascorbic Acid 500mg Tab 100 Pk DTC 094668 3.9000 Ascorbic Acid 500mg Tab 100 Pk SAP 232122 4.2000 Ascorbic Acid 250mg Tab 100 Pk DTC 094641 2.5000 Ascorbic Acid 250mg Tab 100 Pk SAP 265012 2.3000 Ascorbic Acid 1000mg Tab 100 Pk WAM 256862 8.1000 Ascorbic Acid 100mg Tab 100 Pk DTC 094641 2.5000 Ascorbic Acid 100mg Tab 100 Pk DTC 094633 1.5000 Ascorbic Acid 100mg Tab 100 Pk DTC 094631 1.5000 Ascorbic Acid 100mg Tab 100 Pk DTC 094631 1.5000 Ascorbic Acid 100mg Tab 100 Pk DTC 094631 1.5000 Ascorbic Acid 100mg Tab 100 Pk DTC 094631 1.5000 Ascorbic Acid 100mg Tab 100 Pk DTC 094631 1.5000 Ascorbic Acid 100mg Tab LED 527092 .1375 Asendin 25mg Tab LED 527114 .6150 Asendin 150mg Tab LED 527114 .6150 Asendin 100mg Tab WIN 033804 .1926 Atarax 50mg Cap PFI 024392 .1948 Atarax 25mg Cap PFI 024384 .1579 | Aristocort R | | | | |
| Artane | Aristocort R | | | | |
| Artane | Aristospan | | | | |
| Artane 2mg Tab LED 015040 .0180 Asacol 400mg Tab EAT 634557 .3815 Ascorbic Acid 500mg Tab 100 Pk WAM 036188 3.2000 Ascorbic Acid 500mg Tab 100 Pk DTC 094668 3.9000 Ascorbic Acid 500mg Tab 100 Pk SAP 232122 4.2000 Ascorbic Acid 250mg Tab 100 Pk DTC 094641 2.5000 Ascorbic Acid 250mg Tab 100 Pk SAP 232122 2.3000 Ascorbic Acid 250mg Tab 100 Pk SAP 265012 2.3000 Ascorbic Acid 1000mg Tab 100 Pk WAM 256862 8.1000 Ascorbic Acid 100mg Tab 100 Pk DTC 094631 1.5000 Ascorbic Acid 100mg Tab 100 Pk DTC 094631 1.5000 Ascorbic Acid 100mg Tab 100 Pk DTC 094631 1.5000 Ascorbic Acid 100mg Tab 100 Pk DTC 094631 1.5000 Ascorbic Acid 100mg Tab LED 527092 .1375 Asendin 25mg Tab LED 527094 .1375 Asendin 150mg Tab LED 527114 .6150 Asendin 100mg Tab LED 527114 .6150 Asendin 100mg Tab WIN 033804 .1926 Atarax 50mg Cap PFI 024382 .1948 Atarax 25mg Cap PFI 024384 .1579 | | 0.4mg/mL 0/L | | | .0208 |
| Asacol 400mg Tab EAT 634557 .3815 Ascorbic Acid 500mg Tab 100 Pk WAM 036188 3.2000 Ascorbic Acid 500mg Tab 100 Pk DTC 094668 3.9000 Ascorbic Acid 500mg Tab 100 Pk DTC 094668 3.9000 Ascorbic Acid 500mg Tab 100 Pk DTC 094641 2.5000 Ascorbic Acid 250mg Tab 100 Pk DTC 094641 2.5000 Ascorbic Acid 250mg Tab 100 Pk SAP 265012 2.3000 Ascorbic Acid 1000mg Tab 100 Pk WAM 256862 8.1000 Ascorbic Acid 100mg Tab 100 Pk DTC 094633 1.5000 Ascorbic Acid 100mg Tab 100 Pk DTC 094633 1.5000 Ascorbic Acid 100mg Tab 100 Pk DTC 094633 1.5000 Ascorbic Acid 100mg Tab 100 Pk DTC 094633 1.5000 Ascorbic Acid 100mg Tab LED 527092 .1375 Asendin 25mg Tab LED 527084 .1375 Asendin 150mg Tab LED 527114 .6150 Asendin 100mg Tab LED 527114 .6150 Asendin 100mg Tab WIN 033804 .1926 Atarax 50mg Cap PFI 024392 .1948 Atarax 25mg Cap PFI 024384 .1579 | Artane | 5mg Tab | | | |
| Ascorbic Acid 500mg Tab 100 Pk DTC 094668 3.9000 Ascorbic Acid 500mg Tab 100 Pk DTC 094668 3.9000 Ascorbic Acid 500mg Tab 100 Pk SAP 232122 4.2000 Ascorbic Acid 250mg Tab 100 Pk DTC 094641 2.5000 Ascorbic Acid 250mg Tab 100 Pk SAP 265012 2.3000 Ascorbic Acid 1000mg Tab 100 Pk WAM 256862 8.1000 Ascorbic Acid 100mg Tab 100 Pk DTC 094633 1.5000 Ascorbic Acid 100mg Tab 100 Pk DTC 094633 1.5000 Ascorbic Acid 100mg Tab 100 Pk DTC 094633 1.5000 Ascorbic Acid 100mg Tab LED 527092 .1375 Asendin 25mg Tab LED 527084 .1375 Asendin 150mg Tab LED 527114 .6150 Asendin 100mg Tab LED 527114 .6150 Asendin 100mg Tab WIN 033804 .1926 Atarax 50mg Cap PFI 024392 .1948 Atarax 25mg Cap PFI 024384 .1579 | Artane | 2mg Tab | LED | 015040 | |
| Ascorbic Acid 500mg Tab 100 Pk SAP 232122 4.2000 Ascorbic Acid 250mg Tab 100 Pk DTC 094668 3.9000 Ascorbic Acid 250mg Tab 100 Pk DTC 094641 2.5000 Ascorbic Acid 250mg Tab 100 Pk SAP 265012 2.3000 Ascorbic Acid 1000mg Tab 100 Pk WAM 256862 8.1000 Ascorbic Acid 100mg Tab 100 Pk DTC 094633 1.5000 Ascorbic Acid 100mg Tab 100 Pk DTC 094633 1.5000 Asendin 50mg Tab LED 527092 .1375 Asendin 25mg Tab LED 527084 .1375 Asendin 150mg Tab LED 527114 .6150 Asendin 100mg Tab LED 527114 .6150 Asendin 100mg Tab WIN 033804 .1926 Atarax 50mg Cap PFI 024382 .1579 | Asacol | 400mg Tab | EAT | 634557 | .3815 |
| Ascorbic Acid 500mg Tab 100 Pk SAP 232122 4.2000 Ascorbic Acid 250mg Tab 100 Pk DTC 094641 2.5000 Ascorbic Acid 250mg Tab 100 Pk SAP 265012 2.3000 Ascorbic Acid 1000mg Tab 100 Pk WAM 256862 8.1000 Ascorbic Acid 100mg Tab 100 Pk DTC 094633 1.5000 Ascorbic Acid 100mg Tab 100 Pk DTC 094633 1.5000 Asendin 50mg Tab LED 527092 .1375 Asendin 25mg Tab LED 527084 .1375 Asendin 150mg Tab LED 527114 .6150 Asendin 100mg Tab LED 527114 .6150 Asendin 100mg Tab LED 527106 .4350 Atabrine 100mg Tab WIN 033804 .1926 Atarax 50mg Cap PFI 024382 .1948 Atarax 25mg Cap PFI 024384 .1579 | Ascorbic Acid | 500mg Tab 100 Pk | WAM | 036188 | 3.2000 |
| Ascorbic Acid 250mg Tab 100 Pk DTC 094641 2.5000 Ascorbic Acid 250mg Tab 100 Pk SAP 265012 2.3000 Ascorbic Acid 1000mg Tab 100 Pk WAM 256862 8.1000 Ascorbic Acid 100mg Tab 100 Pk DTC 094633 1.5000 Ascorbic Acid 100mg Tab 100 Pk DTC 094633 1.5000 Ascorbic Acid 250mg Tab LED 527092 .1375 Ascorbin 25mg Tab LED 527094 .1375 Ascorbin 150mg Tab LED 527114 .6150 Ascorbin 100mg Tab LED 527114 .6150 Ascorbin 100mg Tab LED 527106 .4350 Atabrine 100mg Tab WIN 033804 .1926 Atarax 50mg Cap PFI 024392 .1948 Atarax 25mg Cap PFI 024384 .1579 | Ascorbic Acid | 500mg Tab 100 Pk | DTC | 094668 | 3.9000 |
| Ascorbic Acid 250mg Tab 100 Pk SAP 265012 2.3000 Ascorbic Acid 1000mg Tab 100 Pk WAM 256862 8.1000 Ascorbic Acid 100mg Tab 100 Pk DTC 094633 1.5000 Ascorbic Acid 100mg Tab 100 Pk DTC 094633 1.5000 Ascordin 50mg Tab LED 527092 .1375 Ascordin 25mg Tab LED 527084 .1375 Ascordin 150mg Tab LED 527114 .6150 Ascordin 100mg Tab LED 527114 .6150 Ascordin 100mg Tab LED 527106 .4350 Atabrine 100mg Tab WIN 033804 .1926 Atarax 50mg Cap PFI 024392 .1948 Atarax 25mg Cap PFI 024384 .1579 | Ascorbic Acid | 500mg Tab 100 Pk | SAP | 232122 | 4.2000 |
| Ascorbic Acid 1000mg Tab 100 Pk WAM 256862 8.1000 Ascorbic Acid 100mg Tab 100 Pk DTC 094633 1.5000 Asendin 50mg Tab LED 527092 .1375 Asendin 25mg Tab LED 527084 .1375 Asendin 150mg Tab LED 527114 .6150 Asendin 100mg Tab LED 527114 .6150 Atabrine 100mg Tab WIN 033804 .1926 Atarax 50mg Cap PFI 024392 .1948 Atarax 25mg Cap PFI 024384 .1579 | Ascorbic Acid | 250mg Tab 100 Pk | DTC | 094641 | 2.5000 |
| Ascorbic Acid 100mg Tab 100 Pk DTC 094633 1.5000 Asendin 50mg Tab LED 527092 .1375 Asendin 25mg Tab LED 527084 .1375 Asendin 150mg Tab LED 527114 .6150 Asendin 100mg Tab LED 527106 .4350 Atabrine 100mg Tab WIN 033804 .1926 Atarax 50mg Cap PFI 024392 .1948 Atarax 25mg Cap PFI 024384 .1579 | Ascorbic Acid | 250mg Tab 100 Pk | SAP | 265012 | 2.3000 |
| Asendin 50 mg Tab LED 527092 .1375 Asendin 25 mg Tab LED 527084 .1375 Asendin 150 mg Tab LED 527114 .6150 Asendin 100 mg Tab LED 527106 .4350 Atabrine 100 mg Tab WIN 033804 .1926 Atarax 50 mg Cap PFI 024392 .1948 Atarax 25 mg Cap PFI 024384 .1579 | Ascorbic Acid | 1000mg Tab 100 Pk | WAM | 256862 | 8.1000 |
| Asendin 25mg Tab LED 527084 .1375 Asendin 150mg Tab LED 527114 .6150 Asendin 100mg Tab LED 527106 .4350 Atabrine 100mg Tab WIN 033804 .1926 Atarax 50mg Cap PFI 024392 .1948 Atarax 25mg Cap PFI 024384 .1579 | Ascorbic Acid | 100mg Tab 100 Pk | DTC | 094633 | 1.5000 |
| Asendin 25mg Tab LED 527084 .1375 Asendin 150mg Tab LED 527114 .6150 Asendin 100mg Tab LED 527106 .4350 Atabrine 100mg Tab WIN 033804 .1926 Atarax 50mg Cap PFI 024392 .1948 Atarax 25mg Cap PFI 024384 .1579 | Asendin | 50mg Tab | LED | 527092 | .1375 |
| Asendin 100mg Tab LED 527106 .4350 Atabrine 100mg Tab WIN 033804 .1926 Atarax 50mg Cap PFI 024392 .1948 Atarax 25mg Cap PFI 024384 .1579 | Asendin | | LED | 527084 | . 1375 |
| Atabrine 100mg Tab WIN 033804 .1926 Atarax 50mg Cap PFI 024392 .1948 Atarax 25mg Cap PFI 024384 .1579 | Asendin | 150mg Tab | LED | 527114 | .6150 |
| Atabrine 100mg Tab WIN 033804 .1926 Atarax 50mg Cap PFI 024392 .1948 Atarax 25mg Cap PFI 024384 .1579 | Asendin | | LED | 527106 | .4350 |
| Atarax 50mg Cap PFI 024392 .1948 Atarax 25mg Cap PFI 024384 .1579 | Atabrine | | WIN | 033804 | .1926 |
| Atarax 25mg Cap PFI 024384 .1579 | Atarax | | PFI | 024392 | |
| | Atarax | | PFI | 024384 | . 1579 |
| | Atarax | 10mg Cap | PFI | 024376 | . 1052 |
| Atarax 500mg/10mL Inj Sol-10mL Pk PFI 024589 9.5200 | | 9 . | | | |
| Atarax 2mg/mL O/L PFI 024694 .0323 | | | | | |
| Atasol 80mg/mL 0/L HOR 631353 , .1523 | | - | | | |

| Product Name | Strength & Dosage | Manuf'i | DIN | Price | |
|-------------------------|--|-------------------|----------------------------|---------------------------|--|
| Atasol | 325mg Tab | HOR | 293482 | .0208 | |
| Atasol Forte | 500mg Tab | HOR | 013668 | .0301 | |
| Atasol-15 | 15ng Tab | HOR | 293504 | .0279 | |
| Atasol-30 | 30ng Tab | HOR | 293512 | .0396 | |
| Athrombin-K | 5mg Tab | PFR | 026174 | .0770 | |
| Ativan | 2ng Tab | BTE | 348333 | .1296 | |
| Ativan | lng Tab | WYE | 348325 | .0828 | |
| Ativan | 0.5mg Tab | WYE | 399124 | .0666 | |
| Atromid-S | 500mg Cap | AYE | 002038 | .0993 | |
| Atropine | 0.6mg/mL Inj Sol-1mL Pk | GLA | 012076 | . 4547 | |
| Atropine | 0.4mg/nL Inj Sol-1mL Pk | GLA | 061697 | .4547 | |
| Atropine Sulfate | 0.6mg/mL Inj Sol-1mL Pk | SQU | 535699 | .3024 | |
| Atropine Sulfate | 0.4mg/mL Inj Sol-1mL Pk | SQU | 535680 | .2968 | |
| Atropine Sulfate | 1% Oph Oint-3.5g Pk | ALC | 252484 | 3.3600 | |
| Atrovent | Inh 200 dose Pk | BOE | 576158 | 11.1000 | |
| Aveeno | Pd-360g Pk | SCJ | 652350 | 5.6215 | |
| Aveeno (Dilated) | Pd-180g Pk | SCJ | 652342 | 5.6215 | |
| Aventyl | 25mg Cap | LIL | 015237 | .2934 | |
| Aventyl | 10mg Cap | LIL | 015237 | | |
| Avlosulfon | 100ng Tab | AYE | 015229 | .1451 | |
| Ayercillin | 100119 120 | ALL | 002326 | . 1344 | |
| | | 4 50 50 | 000400 | 0.0000 | |
| 3,000,000 IU/10mL Inj S | * | AYE | 002402 | 3.9300 | |
| AC & C | 30mg Tab | DTC | 095516 | .0469 | |
| AC & C | 15mg Tab | DTC | 095508 | .0327 | |
| ASA | 325mg Tab 100 Pk | LEA | 040851 | 1.5000 | |
| ASA | 325mg Tab 100 Pk | CLK | 453897 | 1.5000 | |
| ASA | 325mg Tab 300 Pk | DTC | 092754 | 3.4500 | |
| ASA | 325mg Tab 500 Pk | WAM | 036145 | 4.6000 | |
| AVC | Vag Cr | DOM: | 134120 | . 1730 | |
| AVC | Vag Sup | DOM | 134139 | 1.2400 | |
| AVC/Dienestrol | Vag Cr | DOM | 134198 | . 2065 | |
| Baciguent | 500U/g Oint | UPJ | 031046 | .0739 | |
| Baciguent | 500U/g Oph Oint-3g Pk | UPJ | 327476 | 1.2432 | |
| Bacitracia | 500U/g Oint | GLA | 012351 | .0784 | |
| Bacteriostatic Sodium C | | | | | |
| | 0.9% Inj Sol-30mL Pk | sou | 511943 | 1.0360 | |
| Bactopen | Inj Pd-2000mg Pk | BEE | 417238 | 6.2000 | |
| Bactopen | Inj Pd-250mg Pk | BEE | 417203 | 1.8000 | |
| Bactopen | Inj Pd-500mg Pk | BEE | 417211 | 2.6000 | |
| Bactrim | 400mg & 80mg Tab | HLR | 272469 | . 1744 | |
| Bactrim Sugar Free | 40mg & 8mg/mL O/L | HLR | 272485 | .0300 | |
| Bactrim-DS | 800mg & 160mg Tab | HLR | 371823 | .3128 | |
| Balmetar | 2.5% Top Sol 230mL Pk | WSD | 208132 | 10.6000 | |
| Barriere | 20% Cr | AHA | 253057 | .0284 | |
| Beben | 0.025% Gel | PDA | 335347 | .2837 | |
| Beclovent | Aero Pd-200 dose Pk | AHA | 334243 | 10.9000 | |
| Beclovent Rotacaps | 200mcg/Cart Pd Inh | AHA | 545333 | .2360 | |
| Beclovent Rotacaps | 100mcg/Cart Pd Inh | AHA | 545325 | . 1785 | |
| Beconase | Nas Sp 200-dose Pk | AHA | 359688 | 10.9000 | |
| Beminal | Tab 100 Pk | AYE | 242934 | 8.8000 | |
| Beminal Plus | Tab 100 Pk | AYE | 632082 | 9.4000 | |
| Benadryl | 50mg Cap | PDA | 022764 | .1286 | |
| Benadryl | 25mg Cap | PDA | 022756 | .0935 | |
| | Long Cap | 100 | | | |
| | 50mg/ml Ini Solatel Di- | PD4 | U333UE | 2 7216 | |
| Benadryl | 50mg/nL Inj Sol-InL Pk | PDA | 023205 | 2.7216 | |
| | 50mg/mL Inj Sol-1mL Pk 100mg/10mL Inj Sol-10mL Pk 2.5mg/mL O/L | PDA PDA PDA | 023205 023191 022918 | 2.7216 6.4400 .0240 | |

| Product Name | Strength & Dosage | Manuf'r | DIN | Price | |
|-------------------|--------------------------------|---------|---------|----------|--|
| Benoxyl | 5% Lot | STI | 236063 | .1110 | |
| Benoxy l | 20% Lot | STI | 187585 | .1388 | |
| Benoxyl | 10% Lot | STI | 370568 | .1471 | |
| Benoxyl Wash | 5% Cl Lot | STI | 503835 | .0442 | |
| Benoxyl Wash | 10% Cl Lot | STI | 502669 | .0529 | |
| Bensylate | 2mg Tab | ICN | 428086 | .0075 | |
| Bentylol | 10mg Cap | MER | 018007 | .0765 | |
| Bentylol | 20mg/2mL Inj Sol-2mL Pk | MER | 133965 | 4.2388 | |
| Bentylol | 2mg/mL O/L | MER | 018023 | .0439 | |
| Bentylol | 20mg Tab | MER | 282529 | .1451 | |
| Benuryl | 500mg Tab | ICN | 294926 | .1019 | |
| Benzac W10 | 10% Gel | ALC | 621056 | .0930 | |
| Benzac W5 | 5% Gel | ALC | 621048 | .0760 | |
| Berotec | Inh Pd-200dosePk | BOE | 371807 | 9.3000 | |
| Berotec | 0.1% Inh Sol-20mL Pk | BOE | 541389 | 10.4000 | |
| Berotec | 2.5mg Tab | BOE | 454796 | . 1625 | |
| Betaderm | 0.1% Cr | KLP | 458139 | .0332 | |
| Betaderm | 0.05% Cr | KLP | 458147 | .0332 | |
| | 0.1% Oint | KLP | | | |
| Betaderm | | | 509701 | .0332 | |
| Betaderm | 0.05% Oint | KLP | 509698 | .0216 | |
| Betadine | 10% Top Sol | PFR | 158348 | .0050 | |
| Betadine | 10% Vag Gel | PFR | 026034 | .0643 | |
| Betadine | 10% Vag Sol | PFR | 026093 | .0199 | |
| Betadine | 200mg Vag Sup | PFR | 026050 | .4787 | |
| Betagan | 0.5% Oph Sol | ALL | 637661 | 1.5560 | |
| Betaloc | 50mg Tab | AST | 402605 | .1770 | |
| Betaloc | 100mg Tab | AST | 402540 | .3022 | |
| Betaloc Durules | 200mg LA Tab | AST | 497827 | .5186 | |
| Betaxin | 1000mg/10mL Inj Sol-10mL Pk | WIN | 033421 | 9.6900 | |
| Betnelan | 0.5mg Tab | GLA | 012211 | .2515 | |
| Betnesol | 5mg/100mL Enema-100mL Pk | GLA | 012181 | 5.7900 | |
| Betnovate | 0.1% Cr | GLA | 011924 | .0244 | |
| Betnovate | 0.1% Lot | GLA | 011940 | .2417 | |
| Betnovate | 0.1% Oint | GLA | 012386 | .0244 | |
| Betnovate-1/2 | 0.05% Cr | GLA | 011916 | .0161 | |
| Betnovate-1/2 | 0.05% Lot | GLA | 011932 | . 1917 | |
| Betnovate-1/2 | 0.05% Oint | GLA | 012378 | .0161 | |
| Bicillin 1200 L-A | 1,200,000IU/2mL Inj Sol-2mL Pk | WYE | 036315 | 5.2000 | |
| BioCal | 1250mg Tab | MIT | 618101 | .1018 | |
| Biquin Durules | 250mg Tab | AST | 249580 | .3164 | |
| Bisacodyl | 10mg Sup 6 Pk | TCH | 404802 | 1.6500 | |
| Bisacolax | 5mg Ent Tab 30 Pk | ICN | 267066 | 1.5000 | |
| Bisacolax | 10mg Sup 6 Pk | ICN | 261327 | 1.9000 | |
| BiCNU | | BRI | 297763 | 36.5000 | |
| | Inj Pd-100mg Pk | BRI | | | |
| Blenoxane | Inj Pd-15U Pk | | 258482 | 121.5000 | |
| Bleph-10 | 10% Oph Sol | ALL | 001287 | .1660 | |
| Blocadren | 5mg Tab | FRS | 353914 | .1789 | |
| Blocadren | 20mg Tab | FRS | 495611 | .5763 | |
| Blocadren | 10mg Tab | FRS | 353922 | . 2941 | |
| Bonamine | 25mg Tab | PFI | 220442 | . 1803 | |
| Brevicon | 0.035mg & 0.5mg Tab-21 Pk | SYN | 373265 | 7.5000 | |
| Brevicon | 0.035mg & 0.5mg Tab-28 Pk | SYN | 373273 | 7.5000 | |
| Brevicon 1/35 | 0.035mg & 1mg Tab-21 Pk | SYN | 531006 | 7.5000 | |
| Brevicon 1/35 | 0.035mg & 1mg Tab-28 Pk | SYN | 531014 | 7.5000 | |
| Bricanyl | 5mg Tab | AST | 335363 | .1610 | |
| Bricanyl | 2.5mg Tab | AST | 335355 | .1230 | |
| Bricanyl Spacer | Inh 200 dose Pk | AST | 444774. | 10.4500 | |

| Product Name | Strength & Dosage | Manuf'r | DIN | Price |
|------------------------------------|-------------------------------|---------|--------|---------|
| Bridine | 10% Vag Gel | AHA | 002720 | .0713 |
| Bridine | 10% Vag Sol | AHA | 003115 | .0244 |
| Bridine Sol | 10% Top Sol | AHA | 062081 | .0180 |
| Bronkaid Mistometer | Aero Sol-15mL Pk | WIN | 282286 | 9.5600 |
| Buro-Sol | 0.35% & 0.023% Pd | TCD | 579947 | . 4581 |
| Buscopan | 20mg/mL Inj Sol-1mL Pk | BOE | 363839 | 2.6264 |
| Buscopan | 10mg Sup | BOE | 363820 | 1.1760 |
| Busconan | 10mg Tab | POE | 363812 | . 1534 |
| Butisol Sodium | 30mg Tab | HOR | 581291 | .0680 |
| Sutisol Sodium | 15mg Tab | HOR | 581305 | .0504 |
| Butisol Sodium | 100mg Tab | HOR | 581313 | .1372 |
| C.E.S. | 1.25mg Tab | ICN | 265489 | .0746 |
| C.E.S. | 0.625mg Tab | ICN | 265470 | .0452 |
| | lmg & 100mg Tab | SAN | 176095 | .3820 |
| Cafergot | | SAN | 176033 | 1.5470 |
| Cafergot-PB | Sup | | | |
| Cafergot-PB | Tab | SAN | 176222 | .4420 |
| Calciferol | 50,0001U Tab | ROR | 553050 | .1155 |
| Calcilean | 25,000 IU/mL Inj Sol-0.8mL Pk | ORG | 562122 | 6.9664 |
| Calcimar Calcium Disodium Verse | 400IU/2mL Inj Sol-2mLPk | ROR | 584703 | 32.7700 |
| | 1000mg/5mL Inj Sol-5mL Pk | RIK | 026239 | 13.8507 |
| alcium Gluconate | 1000mg/10mL Inj Sol-10mL Pk | SQU | 535702 | 1.4000 |
| alcium Gluconate | 650mg Tab 100 Pk | PDA | 023574 | 7.5000 |
| Calcium Gluconate | 650ng Tab 100 Pk | DTC | 094773 | 3.2500 |
| Calcium Gluconate | 650mg Tab 100 Pk | WAM | 241717 | 3.5000 |
| alcium Gluconate | 650mg Tab 100 Pk | NOP | 441473 | 3.2000 |
| Calcium Lactate | 650mg Tab 100 Pk | NOP | 021253 | 3.2000 |
| Calcium Lactate | 650mg Tab 100 Pk | PDA | 023590 | 8.0000 |
| Calcium Lactate | 650mg Tab 100 Pk | DTC | 094765 | 3.4000 |
| Calcium Leucovorin | 5mg Tab | LED | 482900 | 4.0600 |
| Calcium-Rougier | 58.7mg & 172.1mg/mL O/L | ROG | 466425 | .0146 |
| Calcium-Sandoz | 1000mg/10mL Inj Sol-10mL Pk | SAN | 027219 | 1.6464 |
| Calcium-Sandoz | 200ng/nL O/L | SAN | 027383 | .0202 |
| Calcium-Sandoz Forte | 0.3g & 2.94g Eff Tab | SAN | 027588 | .3002 |
| Calmurid-HC | 1% & 10% Cr | PHD | 364134 | .2450 |
| Calsan | 500mg Chew Tab | SAN | 648345 | . 1064 |
| Calsan | 3 | SAN | 648353 | .1064 |
| | 500mg S. G. Cap | | | |
| Caltrate 300 | 750mg Tab | LED | 625469 | .0710 |
| altrate 600 | 1500mg Tab | LED | 626341 | .0670 |
| ampain | 500mg Tab | WIN | 292486 | .0504 |
| Campain | 325mg Tab | WIN | 229229 | .0245 |
| Camphor Co. Tincture | 0/L | DTC | 095680 | .0176 |
| anesten | 10mg/g Cr | MIT | 513903 | .2366 |
| anesten | 10mg/mL Top Sol | MIT | 513911 | .3320 |
| anesten | 10mg/g Vag Cr-App | MIT | 513938 | .2366 |
| anesten | 100mg Vag Tab | MIT | 513946 | 1.9717 |
| anesten 1 | 500mg Vag Tab | MIT | 629243 | 10.8300 |
| Canesten 3 | 20mg/g Vag Cr-App | MIT | 576492 | .4732 |
| Canesten 3 | 200mg Vag Tab | MIT | 567388 | 3.9433 |
| Capoten | 100mg Tab | SQU | 546305 | 1.3830 |
| Capoten | 50mg Tab | SQU | 546291 | .7435 |
| apoten | 25mg Tab | SOU | 546283 | .3995 |
| Carbachol | 0.25mg/mL Inj Sol-1mL Pk | AHA | 341622 | 3.2704 |
| Carbachol | 2mg Tab | AHA | 003212 | .3007 |
| Carbolith | 300mg Cap | ICN | 236683 | .0520 |
| Carbolith | 150mg Cap | ICN | 461733 | .0499 |

| Product Name | Strength & Dosage | Manuf'r | DIN | Price |
|---------------------|------------------------------|---------|--------|---------|
| Cardilate-10 | 10mg SL Tab | BWE | 299790 | .1290 |
| Cardioquin | 275mg Tab | PFR | 026131 | .3600 |
| Cardizem | 60mg Tab | NRD | 587761 | . 4507 |
| Cardizem | 30mg Tab | NRD | 587753 | . 2569 |
| Cascara Sagrada | 300mg Tab 100 Pk | PDA | 023620 | 10.4000 |
| Cascara Sagrada | 300mg Tab 100 Pk | DTC | 093300 | 4.4500 |
| Castor Oil | O/L 50mL Pk | DTC | 094080 | 1.6000 |
| Catapres | 0.2mg Tab | BOE | 291889 | .3430 |
| • | O.lmg Tab | BOE | 259527 | . 1920 |
| Catapres Ceclor | 500mg Cap | LIL | 465194 | 1.4675 |
| | | LIL | 465186 | |
| Ceclor | 250mg Cap | | | .7468 |
| Ceclor | 50mg/mL 0/L | LIL | 465216 | .1464 |
| Ceclor | 25mg/mL 0/L | LIL | 465208 | .0802 |
| CeeNU | 40mg Cap | BRI | 360422 | 5.0000 |
| CeeNU | 100mg Cap | BRI | 360414 | 8.2550 |
| CeeNU | 10mg Cap | BRI | 360430 | 3.0800 |
| Celestoderm-V | 0.1% Cr | SCH | 027901 | .0575 |
| Celestoderm-V | 0.1% Oint | SCH | 028363 | .0575 |
| Celestoderm-V/2 | 0.05% Cr | SCH | 027898 | .0399 |
| Celestoderm-V/2 | 0.05% Oint | SCH | 028355 | .0399 |
| Celestone | O.5mg Tab | SCH | 028185 | .2709 |
| Celestone Soluspan | 3mg & 3mg/mL Inj Susp-1mL Pk | SCH | 028096 | 3.4420 |
| Celontin | 300mg Cap | PDA | 023802 | .2110 |
| Cephulac | 666.7mg/mL O/L | MER | 444316 | .0388 |
| • | | GLA | 253146 | .2810 |
| Ceporex | 500mg Cap | | | |
| Ceporex | 250mg Cap | GLA | 253154 | . 1584 |
| Ceporex | 50mg/mL 0/L | GLA | 321443 | .0590 |
| Ceporex | 25mg/mL O/L | GLA | 321435 | .0340 |
| Cerevon | 100mg Tab 30 Pk | BWE | 677981 | 6.9000 |
| Cerubidine | Inj Pd-20mg Pk | RPP | 163899 | 59.7500 |
| Cesamet | 1mg Cap | LIL | 548375 | 4.5300 |
| Cetamide | 10% Oph Oint-3.5g Pk | ALC | 252522 | 1.6485 |
| Chemstrip bG | Stick-25 Pk | BOM | 990906 | 13.2000 |
| Chemstrip bG | Strip-50 Pk | BOM | 990027 | 26.8000 |
| Chemstrip uG5000 | Strip-50 Pk | BOM | 990019 | 3.5000 |
| Chemstrip K | Strip-100 Pk | BOM | 990698 | 7.6450 |
| Chemstrip UG 5000 K | Strip-50 Pk | BOM | 980692 | 3.9000 |
| Chlor-Tripolon | 10mg/mL Inj Sol-1mL Pk | SCH | 027995 | 1.9380 |
| Chlor-Tripolon | 200mg/2mL Inj Sol-2mL Pk | SCH | 028010 | 6.0500 |
| Chlor-Tripolon | O.5mg/mL O/L | SCH | 028134 | .0258 |
| Chlor-Tripolon | 4mg Tab | SCH | 028193 | .0838 |
| Chloral Hydrate | 500mg Cap | DTC | 092886 | .0259 |
| • | | DTC | 398403 | .0085 |
| Chlordiazepoxide | 5mg Cap | | | |
| Chlordiazepoxide | 25mg Cap | DTC | 398438 | .0135 |
| Chlordiazepoxide | 10mg Cap | SAP | 251267 | .0118 |
| Chlordiazepoxide | 10mg Cap | DTC | 398411 | .0099 |
| Chloromycetin | 1% Oph Oint-3.5g Pk | PDA | 024066 | 2.5100 |
| Chloromycetin | 0.5% Oph Sol | PDA | 221678 | .2803 |
| Chloromycetin | 0.5% Ot Sol | PDA | 349615 | .4483 |
| Chloroptic | 0.5% Oph Sol | ALL | 001082 | .3070 |
| Chlorpromanyl 20 | 20mg/mL O/L | TCH | 580988 | .0325 |
| Chlorpromazine | 50mg Tab | SAP | 209910 | .0195 |
| Chlorpromazine | 25mg Tab | SAP | 209902 | .0150 |
| Chlorpromazine | 100mg Tab | SAP | 210684 | .0290 |
| Chlorpropamide | 250mg Tab | SAP | 209937 | .0189 |
| Chlorpropamide | 250mg Tab | DTC | 377937 | .0140 |
| propante | | 010 | 31.001 | .0210 |

| Product Name | Strength & Dosage | Manuf'r | DIN | Price |
|-------------------|-------------------------------|---------|--------|---------|
| Chlorthalidone | 50mg Tab | DTC | 398365 | .0211 |
| Chlorthalidone | 100mg Tab | DTC | 398373 | .0305 |
| Choledyl | 20mg/mL 0/L | PDA | 476366 | .0217 |
| Choledyl | 10mg/mL 0/L | PDA | 476390 | .0191 |
| Choledyl | 300mg Tab | PDA | 483591 | . 1050 |
| Choledyl | 200mg Tab | PDA | 476412 | .0308 |
| Choledyl | 100mg Tab | PDA | 476404 | .0450 |
| Choledyl SA | 600mg LA Tab | PDA | 536709 | . 1804 |
| Choledyl SA | 400mg LA Tab | PDA | 503436 | . 1521 |
| Choloxin | 4mg Tab | FLI | 009636 | .5615 |
| Choloxin | 2mg Tab | FLI | 273015 | .4800 |
| Cidomycin | 80mg/2mL Inj Sol-2mL Pk | ROU | 259179 | 5.1000 |
| Claripex | 500mg Cap | ICN | 409472 | .0312 |
| Clavulin | 50mg & 12.5mg/mL O/L | BEE | 617520 | .1260 |
| Clavulin | 25mg & 6.25mg/mL O/L | BEE | 617512 | .0750 |
| Clavulin | 500mg & 125mg Tab | BEE | 617504 | .9854 |
| Clavulin | 250mg & 125mg Tab | BEE | 617490 | .6327 |
| Clinistix | Stick-50 Pk | AME | 980633 | 3.3000 |
| Clinitest | Tab-100 Pk | AME | 980420 | 6.0000 |
| Clinoril | 200mg Tab | FRS | 432369 | .5468 |
| Clinoril | 150mg Tab | FRS | 456888 | .4315 |
| Clomid | 50mg Tab | MER | 018031 | 3.2350 |
| Codeine | 30mg/mL Inj Sol-1mL Pk | AHA | 303879 | .5160 |
| Codeine | 5mg/mL O/L | NDA | 018678 | .0227 |
| Codeine | 5mg/mL O/L | DTC | 093114 | .0160 |
| Codeine | 60mg Tab | AHA | 003247 | .1769 |
| Codeine | 60mg Tab | DTC | 093149 | . 1552 |
| Codeine | 30mg Tab | AHA | 003239 | .0910 |
| Codeine | 30mg Tab | NDA | 018694 | .1045 |
| Codeine | 30mg Tab | DTC | 093130 | .0741 |
| Codeine | 15mg Tab | AHA | 003220 | .0595 |
| Codeine | 15mg Tab | NDA | 018686 | .0550 |
| Codeine | 15mg Tab | DTC | 093122 | .0457 |
| Codeine Phosphate | 30mg Tab | TCH | 593451 | .0630 |
| Codeine Phosphate | 15mg Tab | TCH | 593435 | .0430 |
| Cogentin | 2mg/2mL Inj Sol-2mL Pk | MSD | 016128 | 3.8005 |
| Cogentin | 2mg Tab | MSD | 016357 | .1100 |
| Colace | 100mg Cap 100 Pk | BRI | 464767 | 18.8000 |
| Colace | 4mg/mL O/L 250mL Pk | BRI | 464783 | 11.3000 |
| Colace | 10mg/mL O/L 25mL Pk | BRI | 464775 | 8.3000 |
| Colchicine | lmg Tab | ROG | 206032 | .1770 |
| Colchicine | O.6mg Tab | ABB | 000396 | .2135 |
| Colchicine | 0.6mg Tab | DTC | 094382 | .0623 |
| Colchicine | O.6mg Tab | ROG | 287873 | .0493 |
| Colestid | Gran | UPJ | 642975 | .6000 |
| Coly-Mycin | Inj Pd-150mg Pk | PDA | 476420 | 23.1400 |
| Coly-Mycin Otic | 3mg & 3.3mg & 10mg/mL Ot Susp | PDA | 476439 | 1.2070 |
| Combantrin | 50mg/mL O/L | PFI | 425869 | . 1304 |
| Combantrin | 125ng Tab | PFI | 316296 | .5264 |
| Coptin | 90mg & 410mg Tab | JOU | 478717 | .3638 |
| Corgard | 80mg Tab | SOU | 463256 | .5100 |
| Corgard | 40mg Tab | SQU | 607126 | .3415 |
| Corgard | 160mg Tab | SOU | 523372 | .9110 |
| Coronex | 5mg SL Tab | AYE | 446661 | .0558 |
| Coronex | 30mg Tab | AYE | 446696 | .0971 |
| Coronex | 10mg Tab | AYE | 446688 | .0410 |

| Product Name | Strength & Dosage | Manuf'r | DIN | Price |
|----------------------|----------------------------------|------------|--------|---------|
| Corophyllin | 500mg Sup | BEE | 451673 | .5423 |
| Corophyllin | 250mg Sup | BEE | 451665 | . 4555 |
| Cortate | 1% Cr | SCH | 502200 | .0269 |
| Cortate | 0.5% Cr | SCH | 513288 | .0244 |
| Cortate | 0.5% Lot | SCH | 513253 | .0697 |
| Cortate | 1% Oint | SCH | 502197 | .0269 |
| Cortate | 0.5% Oint | SCH | 513261 | .0244 |
| Cortef | 1% Oint | UPJ | 031054 | .1620 |
| Cortef | 20mg Tab | UPJ | 030929 | . 1790 |
| Corticreme | 1% Cr | ROG | 477699 | .2142 |
| Cortifoam | 10% Rect Aero | RCA | 579335 | 2.4685 |
| Cortiment | 40mg Sup | NRD | 406708 | .8420 |
| Cortiment | 10mg Sup | NRD | 407836 | .6120 |
| Cortisone | 25mg Tab | UPJ | 249963 | .1030 |
| Cortisone-ICN | 25mg Tab | ICN | 280437 | .0835 |
| | 10,000U & 5mg & 10mg/ml Ot-Sol | BWE | 694401 | .9640 |
| Cortisporin | 1% Oint | KLP | 509639 | .0249 |
| Cortoderm | 0.5% Oint | KLP | 509620 | .0249 |
| Cortoderm | | | | |
| Cortone | 5mg Tab | MSD MSD | 016438 | .0838 |
| Cortone | 25mg Tab | | 016446 | .3129 |
| Cortrosyn | Inj Pd-0.25mg Pk | ORG | 022381 | 6.5800 |
| Corutol DH | 1mg/mL O/L | DOM | 307858 | .0260 |
| Corutol Expectorant | 40mg/mL O/L | DOW | 296228 | .0258 |
| Coryphen 325-30 | 325mg & 30mg Tab | ROG | 406112 | . 1860 |
| Coryphen 650-30 | 650mg & 30mg Tab | ROG | 406104 | .2500 |
| Cosmegen | Inj Pd-0.5mg Pk | MSD | 213071 | 6.3700 |
| Cotazym | 8,000 & 30,000 & 30,000USP U Cap | ORG | 263818 | . 1317 |
| Cotazym ECS | | | | |
| 8,000 & 30,000 & 30, | 000USP U Ent Microsph Cap | ORG | 502790 | .2734 |
| Coumadin | 10mg Tab | DUP | 585637 | .3115 |
| Coumadin | 5mg Tab | DUP | 585629 | . 1705 |
| Coumadin | 2.5mg Tab | DUP | 585645 | . 1560 |
| Crystapen (Sod) | Inj Pd 1,000,000IU-Pk | GLA | 011983 | 1.0320 |
| Crystapen (Sod) | Inj Pd 5,000,000IU-Pk | GLA | 011991 | 2.6560 |
| Cuprimine | 250mg Cap | MSD | 016055 | .5758 |
| Cuprimine | 125mg Cap | MSD | 497894 | .3841 |
| Cyanocobalamin | Img/mL Inj Sol 10mL Pk | KLP | 211125 | 4.9000 |
| Cyanocobalamin | 1mg/mL Inj Sol 10mL Pk | NRD | 314277 | 7.5500 |
| Cyanocobalamin | 1mg/mL Inj Sol 10mL Pk | ORG | 571865 | 4.9000 |
| Cyclocort | 0.1% Cr | LED | 443824 | .2920 |
| Cyclocort | 0.1% Lot | LED | 571016 | .2420 |
| Cyclocort | 0.1% Oint | LED | 559237 | .2917 |
| Cylert | 75mg Tab | ABB | 397520 | .9800 |
| Cylert | 37.5mg Tab | ABB | 397512 | .5100 |
| Cytadren | 250mg Tab | CIB | 587729 | .7730 |
| Cytomel | | SKF | 027081 | .0485 |
| • | 5mcg Tab | SKF | 027103 | .0590 |
| Cytomel | 25mcg Tab | | | 7.0000 |
| Cytosar | Inj Pd-100mg Pk | UPJ UPJ | 386715 | 31.5000 |
| Cytosar | Inj Pd-500mg Pk | | 194727 | |
| Cytoxan | Inj Pd-200mg Pk | BRI | 344907 | 4.3600 |
| Cytoxan | Inj Pd-500mg Pk | BRI | 344915 | 5.4500 |
| Cytoxan | 50mg Tab | BRI | 344885 | .3380 |
| Cytoxan | 25mg Tab | BRI | 344877 | .2510 |
| D-Vi-Sol | 400IU/0.6mL O/L | MJO | 630934 | .1184 |
| Dagenau | 500mg Tab | RPP | 163929 | .2337 |
| Dalacin C | 150mg Cap | UPJ | 030570 | .5731 |
| Dalacin C | 300mg/2mL Inj Sol-2mL Pk | UPJ | 260436 | 5.1100 |

| Product Name | Strength & Dosage | Manuf' | DIN | Price | |
|-------------------|--------------------------------|--------|--------|---------|--|
| Dalacin C | 15mg/mL 0/L | UPJ | 225851 | .0810 | |
| Dalmane | 30mg Cap | HLR | 012718 | . 1066 | |
| Dalmane | 15mg Cap | HLR | 012696 | .0910 | |
| Dan-Gard | 27 Shampoo 125mL Pk | STI | 507415 | 5.7000 | |
| Dantrium | 25mg Cap | EAT | 452513 | .2524 | |
| Dantrium | 100mg Cap | EAT | 452521 | .5140 | |
| Darvon-N | Сар | LIL | 261432 | .1560 | |
| Day-Barb | 30mg Tab | SAN | 604607 | .0410 | |
| Day-Barb | 15mg Tab | SAN | 604674 | .0330 | |
| Day-Barb | 100mg Tab | SA.N | 604615 | .0890 | |
| Decadron | 20mg/5mL Inj Sol-5mL Pk | MSD | 213624 | 13.7200 | |
| Decadron | 0.1% Oph/Ot Sol | MSD | 016217 | 1.4180 | |
| Decadron | 4mg Tab | MSD | 354309 | .9204 | |
| Decadron | 0.5mg Tab | MSD | 016462 | .2363 | |
| Decadron T.B.A. | 20mg/5mL Inj Susp-5mL Pk | MSD | 016268 | 13.0600 | |
| Declinax | 10mg Tab | HLR | 255432 | .1070 | |
| Delalutin | 250mg/2mL Oily Inj Sol-2mL Pk | Sõu | 029211 | 5.6400 | |
| Delatestryl | 1000mg/5mL Oily Inj Sol 5mL Pk | SQU | 029246 | 10.0800 | |
| Delsym | 6mg/nL O/L | PWC | 589888 | .0276 | |
| Deltasone | 50mg Tab | UPJ | 252417 | .0825 | |
| Deltasone | 5mg Tab | UPJ | 210188 | .0095 | |
| Demerol | 75mg/mL Inj Sol-1mL Pk | WIN | 033294 | .2340 | |
| Demerol | 50mg/mL Inj Sol-1mL Pk | WIN | 036242 | .2160 | |
| Demerol | 100mg/mL Inj Sol-1mL Pk | WIN | 033308 | .2480 | |
| Demerol | 100mg/2mL Inj Sol-2mL Pk | WIN | 990477 | .2780 | |
| Demerol | 1500mg/30mL Inj Sol-30mL Pk | WIN | 990493 | 4.5990 | |
| Demerol | 50mg Tab | WIN | 033685 | .0756 | |
| Demulen 30 | 0.03mg & 2mg Tab-21 Pk | SEA | 469327 | 7.9400 | |
| Demulen 30 | 0.03mg & 2mg Tab-28 Pk | SEA | 471526 | 8.5000 | |
| Demulen 50 | 0.05mg & 1mg Tab-21 Pk | SEA | 028630 | 8.3250 | |
| Demulen 50 | 0.05mg & 1mg Tab-28 Pk | SEA | 343536 | 8.9100 | |
| Depakene | 250mg Cap | ABB | 443840 | .2736 | |
| Depakene | 500mg Ent Cap | ABB | 507989 | .5473 | |
| Depakene | 50mg/mL O/L | ABB | 443832 | .0608 | |
| Depen | 250mg Tab | HOR | 511641 | . 4695 | |
| Depo-Medrol | 80mg/ml Inj Susp-1ml Pk | UPJ | 030767 | 6.9000 | |
| Depo-Medrol | 40mg/ml Inj Susp-1ml Pk | UPJ | 030759 | 3.5900 | |
| Depo-Medrol | 100mg/5mL Inj Susp-5mL Pk | UPJ | 030740 | 6.0500 | |
| Depo-Provera | 400mg/4mL Inj Susp-4mL Pk | UPJ | 030856 | 24.2900 | |
| Depo-Testosterone | 100mg/mL Oily Inj Sol-1mL Pk | UPJ | 030783 | 3.4000 | |
| Dermovate | 0.05% Cr | GLA | 359718 | .4550 | |
| Dermovate | 0.05% Oint | GLA | 359726 | .4550 | |
| Dermovate | 0.05% Scalp Lot | GLA | 479012 | .4058 | |
| Dermoxyl | 5% Ge1 | ICN | 372692 | .0757 | |
| Dermoxyl | 20% Gel | ICN | 399116 | .1179 | |
| Dermoxyl | 10% Gel | ICN | 372706 | .0910 | |
| Deronil | 4mg Tab | SCH | 504416 | .4928 | |
| Deronil | 0.75mg Tab | SCH | 501069 | .1214 | |
| Deronil | 0.5mg Tab | SCH | 501050 | .0857 | |
| Desquam-X Wash | 10% Cl Lot | #SD | 542040 | .0366 | |
| Desquam-X10 | 10% Gel | WSD | 307572 | .0728 | |
| Desquam-X5 | 5% Ge1 | WSD | 307564 | .0600 | |
| Desyrel | 50mg Tab | BRI | 579351 | .2247 | |
| Desyrel | 100mg Tab | BRI | 579378 | . 4455 | |
| Dexasone | 4mg Tab | ICN | 489158 | . 1976 | |
| Dexasone | 0.75mg Tab | ICN | 285471 | .0551 | |
| Dexasone | 0.5mg Tab | ICN | 295094 | .0354 | |
| | | | | | |

| Product Name | Strength & Dosage | Manuf'r | DIN | Price | |
|--------------------------------|--------------------------|---------|--------|---------|--|
| Dexedrine | 5mg Tab | SKF | 027065 | . 1600 | |
| Dextrostix | Stick-25 Pk | AME | 990922 | 11.7250 | |
| Diabeta | 5mg Tab | HOE | 012599 | .1110 | |
| Diabeta | 2.5mg Tab | HOE | 454753 | .0680 | |
| Diabinese | 250mg Tab | PFI | 024716 | .1278 | |
| Diabinese | 100mg Tab | PFI | 024708 | .0641 | |
| Diamox | 500mg LA Cap | LED | 127930 | .5140 | |
| Diamox | 250mg Tab | LED | 014907 | .0750 | |
| Diastix | Stick-50 Pk | AME | 980641 | 3.4000 | |
| Diazepam | 5mg Tab | SAP | 303461 | .0027 | |
| Diazepam | 5mg Tab | DTC | 396230 | .0025 | |
| Diazepam | 2mg Tab | DTC | 466905 | .0026 | |
| Diazepam | 10mg Tab | DTC | 466891 | .0038 | |
| Didronel | 200mg Tab | EAT | 582522 | 1.0358 | |
| Dienestrol | 0.1mg/g Vag Cr | ORT | 441295 | .0760 | |
| Dienestrol | 0.1mg/g Vag Cr-App | ORT | 990531 | .0813 | |
| | 0.2mg Tab | BOE | 569186 | .5877 | |
| Dihydrotachysterol Dilantin | | PDA | 022772 | .0322 | |
| | 30mg Cap | PDA | | | |
| Dilantin | 100mg Cap | | 022780 | .0365 | |
| Dilantin | 100mg/2mL Inj Sol-2mL Pk | PDA | 245453 | 2.2620 | |
| Dilantin | 250mg/5mL Inj Sol-5mL Pk | PDA | 271705 | 4.7180 | |
| Dilantin | 6mg/mL O/L | PDA | 023442 | .0255 | |
| Dilantin | 25mg/mL 0/L | PDA | 023450 | .0302 | |
| Dilantin | 50mg Tab | PDA | 023698 | .0464 | |
| Dilaudid | 2mg/mL Inj Sol-1mL Pk | KNL | 627100 | .9300 | |
| Dilaudid | 3mg Sup | KNL | 125105 | 2.0250 | |
| Dilaudid | 4mg Tab | KNL | 125121 | .2475 | |
| Dilaudid | 2mg Tab | KNL | 125083 | .1615 | |
| Dilaudid-HP | 10mg/mL Inj Sol-1mL Pk | KNL | 622133 | 2.4000 | |
| Dilosyn | 0.8mg/mL 0/L | AHA | 003158 | .0622 | |
| Dimelor | 500mg Tab | LIL | 015598 | .2977 | |
| Dimenhydrinate | 50mg/5mL Inj Sol-5mL Pk | SQU | 511986 | .9397 | |
| Dimenhydrinate | 250mg/5mL Inj Sol-5mL Pk | SQU | 511994 | 1.4000 | |
| Dimenhydrinate | 50mg Tab | SAP | 209783 | .0068 | |
| Dimenhydrinate | 50mg Tab | DTC | 398381 | .0072 | |
| Dimenhydrinate | 50mg Tab | CLK | 457515 | .0134 | |
| Dimetane | 0.4mg/mL 0/L | ROB | 026395 | .0157 | |
| Dimetane | 4mg Tab | ROB | 026484 | .0616 | |
| Diovol Ex | 600mg & 300mg Chew Tab | HOR | 621544 | . 1001 | |
| Diovol Ex | 120mg & 60mg/mL 0/L | HOR | 491217 | .0143 | |
| Diprolene | 0.05% Oint | SCH | 629367 | . 4978 | |
| Diprosone | 0.05% Cr | SCH | 323071 | .3229 | |
| Diprosone | 0.05% Lot | SCH | 417246 | . 2740 | |
| Diprosone | 0.05% Oint | SCH | 344923 | .3229 | |
| Disipal | 50mg Tab | RIK | 026387 | .3354 | |
| | 9 | DPP | 545465 | 4.5500 | |
| Dispensalax | Oral Pd 340g Pk | EAT | 548332 | .0630 | |
| Ditropan | Img/mL O/L | | | .2805 | |
| Ditropan | 5mg Tab | EAT | 530921 | | |
| Doak-Oil | 2% Emuls 250mL Pk | TCD | 579955 | 9.5500 | |
| Doak-Oil Forte | 10% Emuls 250mL Pk | TCD | 579971 | 13.5500 | |
| Docusate Sodium | 100mg Cap 100 Pk | KLP | 473111 | 11.6000 | |
| Dolobid | 500mg Tab | FRS | 576131 | .5248 | |
| Dolobid | 250mg Tab | FRS | 587699 | .4288 | |
| Donnagel-PG | 0/L | ROB | 346756 | .0260 | |
| Dopamet | 500mg Tab | ICN | 353639 | .0946 | |
| Dopamet | 250mg Tab | ICN | 250392 | .0473 | |
| Dopamet | 125mg Tab | ICN | 353620 | .0280 | |

| Product Name | Strength & Dosage | Manuf'r | DIN | Price | |
|-------------------|-------------------------------|------------|--------|---------|--|
| Dopazide-15 | 250mg & 15mg Tab | ICN | 403482 | .1144 | |
| Dopazide-25 | 250mg & 25mg Tab | ICN | 403490 | .1051 | |
| Dorbane | 75mg Tab 100 Pk | RIK | 026352 | 19.5000 | |
| Drenison | 0.05% Cr | LIL | 015326 | .3532 | |
| Drenison | 0.05% Oint | LIL | 016012 | .3532 | |
| Drenison-1/4 | 0.0125% Cr | LIL | 015318 | .1626 | |
| Drenison-1/4 | 0.0125% Oint | LIL | 016004 | . 1756 | |
| Drisdol | 10,360IU/mL O/L | WIN | 033545 | .3226 | |
| Dulcolax | 2mg/mL Enema 5mL Pk | BOE | 286265 | 4.1000 | |
| Dulcolax | 5mg Ent Tab 30 Pk | BOE | 254142 | 5.4000 | |
| Dulcolax | 10mg/5mL Rect Sol 5mL Pk | BOE | 067369 | 1.6800 | |
| Dulcolax | 5mg Sup 3 Pk | BOE | 003867 | 4.1000 | |
| Dulcolax | 10mg Sup 6 Pk | BOE | 003875 | 6.1000 | |
| Duolube | 80% & 20% Oph Oint-3.5g Pk | HCI | 514691 | 2.8798 | |
| Durabolin | 100mg/2mL Oily Inj Sol-2mL Pk | ORG | 022489 | 15.9300 | |
| Durabolin | 125mg/5mL Oily Inj Sol-5mL Pk | ORG | 022470 | 19.3000 | |
| Duralith | 300mg LA Tab | MCN | 590665 | .1320 | |
| Duratears | 94% & 3% Oph Oint-3.5g Pk | ALC | 469688 | 2.9265 | |
| Duricef | 500mg Cap | BRI | 507245 | .8850 | |
| Duricef | 50mg/nL O/L | BRI | 674826 | . 1650 | |
| Duvoid | 50mg Tab | EAT | 453013 | .5365 | |
| Duvoid | 25mg Tab | EAT | 453005 | .3315 | |
| Duvoid | 10mg Tab | EAT | 452998 | .2072 | |
| Dyazide | 25mg & 50mg Tab | SKF | 181528 | .0518 | |
| Dynapen | 250mg Cap | BRI | 003964 | .3220 | |
| Dynapen | 12.5mg/mL O/L | BRI | 004286 | .0429 | |
| Dyrenium | 50mg Tab | SKF | 299715 | .1117 | |
| Dyrenium | 100mg Tab | SKF | 027138 | . 1372 | |
| DDAVP | 0.1mg/mL Nas Sol-2.5mL Pk | RIC | 402516 | 34.6000 | |
| DM-Syrup | 3mg/mL O/L | PDA | 391069 | .0158 | |
| DTIC | Inj Pd-200mg Pk | MIT | 521183 | 13.9667 | |
| DV Cream | 0.1mg/g Vag Cr-App | MER | 518360 | .0843 | |
| E-Mycin | 250mg Tab | UPJ | 030899 | .0781 | |
| E-Pam | 5mg Tab | ICN | 280429 | .0022 | |
| E-Pan | 2mg Tab | ICN | 272647 | .0023 | |
| E-Pam | 10mg Tab | ICN | 272639 | .0033 | |
| E-Pilo 1 | 1% & 1% Oph Sol | CEV | 526363 | .5992 | |
| E-Pilo 2 | 2% & 1% Oph Sol | CEV | 526371 | .6037 | |
| E-Pilo 4 | 4% & 1% Oph Sol | CEV | 526401 | .6776 | |
| E-Pilo 6 | 67. & 17. Oph Sol | CEV | 526428 | .7157 | |
| Ecostatin | 1% Cr | SOU | 561002 | .3016 | |
| Ecostatin | 150mg Vag Sup | SQU | 452114 | 4.0500 | |
| Ecotrin | 325mg Ent Tab | SKF | 027189 | .0259 | |
| Ecotrin-10 | 650mg Ent Tab | SKF | 343889 | .0389 | |
| Ectosone | 3 | TCH | 653217 | .0926 | |
| | 0.1% Scalp Lot | TCH | 535427 | .0266 | |
| Ectosone Mild | 0.05% Cr | | | .0317 | |
| Ectosone Regular | 0.1% Cr | TCH MSD | 535435 | .2274 | |
| Edecrin Efudex | 50mg Tab | | 016497 | .3040 | |
| | 5% Cr | HLR | 330582 | | |
| Elase | 10 & 6660/g Oint | PDA | 024082 | .7251 | |
| Elase | Pd 25U & 15,000U-Pk | PDA | 023078 | 20.6080 | |
| Elavil | 2mg/mL O/L | MSD | 016306 | .0303 | |
| Elavil | 50mg Tab | MSD | 016349 | .1762 | |
| Elavil | 25mg Tab | MSD | 016330 | .0909 | |
| Elavil | 10mg Tab | MSD | 016322 | .0498 | |
| Elixophyllin | 200mg Cap | BER | 529109 | .2425 | |
| Elixophyllin | 100mg Cap | BER | 529095 | . 1616 | |

| Product Name | Strength & Dosage | Manuf'r | DIN | Price |
|----------------------|-------------------------|---------|----------|---------|
| Elixophyllin | 5.3mg/mL O/L | BER | 704466 | .0110 |
| Eltroxin | 0.3mg Tab | GLA | 012319 | .0395 |
| | 0.2mg Tab | GLA | 012310 | .0259 |
| Eltroxin | 0.15mg Tab | GLA | 295582 | .0242 |
| Eltroxin | 3 | GLA | 012297 | .0212 |
| Eltroxin | O. Img Tab | GLA | 012289 | .0174 |
| Eltroxin | 0.05mg Tab 140mg Cap | HLR | 461830 | 2.2500 |
| Emcyt | | BEE | 603775 | .0820 |
| Emex | 10mg Tab | TCD | 595799 | .1271 |
| Emo-Cort | 2.5% Cr | TCD | 192597 | .1244 |
| Emo-Cort | 1% Cr | TCD | 595802 | .1350 |
| Emo-Cort | 2.5% Lot | TCD | | |
| mo-Cort | 1% Lot | | 192600 | .1125 |
| Emo-Cort | 0.5% Lot | TCD | 192589 | .0833 |
| Impracet-30 | 30mg Tab | BWE | 666130 | .0680 |
| Empracet-60 | 60mg Tab | BWE | 666149 | .1870 |
| Emtec-30 | 30mg Tab | TCH | 608882 | .0380 |
| Enovid-E | 0.1mg & 2.5mg Tab-21 Pk | SEA | 028665 | 15.4800 |
| intacyl | Gran-2g Pk | AHA | 002739 | .6944 |
| intacyl | 120mg/mL O/L | AHA | 003131 | .0556 |
| Introphen | 975mg Ent Tab | FRS | 419508 | .0691 |
| introphen | 650mg Ent Tab | FRS | 010340 | .0225 |
| introphen | 325mg Ent Tab | FRS | 010332 | .0203 |
| phedrine | 30mg Tab | AHA | 304069 | . 1637 |
| pifrin | 2% Oph Sol | ALL | 001112 | .6149 |
| pifrin | 1% Oph Sol | ALL | 001104 | .7045 |
| pifrin | 0.5% Oph Sol | ALL | 001090 | .7291 |
| pisun | 7% & 3% Lot | SCH | 677094 | .0482 |
| pitrate | 2% Oph Sol | AYE | 002356 | 1.3335 |
| pival | 500mg Ent Tab | ABB | 596434 | .5747 |
| pival | 250mg Ent Tab | ABB | 596426 | .2873 |
| pival | 125mg Ent Tab | ABB | 596418 | .1599 |
| ppy/N 1/2% | 0.5% Oph Sol | ВНІ | 323640 | .5590 |
| Eppy/N 1% | 1% Oph Sol | BHI | 323659 | .6000 |
| iquanil | 400mg Tab | WYE | 034142 | .0435 |
| | 2mg SL Tab | FIS | 328952 | .5008 |
| rgomar | 0.2mg Tab | LIL | 015709 | .1872 |
| rgotrate | | ABB | 273023 | .0535 |
| rythrocin | 50mg/mL 0/L | ABB | 000302 | .0633 |
| rythrocin | 25mg/mL O/L | ABB | 266515 | .6144 |
| rythrocin | 500mg Tab | | | .2100 |
| rythrocin | 250mg Tab | ABB | 000434 | .0791 |
| rythromid | 250mg Tab | ABB | 244635 | |
| Erythromycin | 250mg Tab | KNR | 640263 | .0738 |
| rythromycin Stearate | 250mg Tab | SAP | 281573 | .0746 |
| sidrix | 50mg Tab | CIB | 005576 | .0643 |
| sidrix | 25mg Tab | CIB | 005568 | .0510 |
| star | 2% Gel 85g Pk | WSD | 373222 | 9.3000 |
| Stinyl | 0.5mg Tab | SCH | 028231 | .2146 |
| stinyl | 0.05mg Tab | SCH | 028223 | .0986 |
| Estinyl | 0.02mg Tab | SCH | 028215 | .0599 |
| tibi | 400mg Tab | ICN | 247979 | .2075 |
| tibi | 100mg Tab | ICN | 247960 | .0718 |
| luflex | 250mg Tab | SCH | 637726 | 1.5756 |
| uglucon | 5mg Tab | BOM | 720941 | .1190 |
| Euglucon | 2.5mg Tab | BOM | 720933 | .0720 |
| umovate | 0.05% Cr | GLA | 456543 | .2565 |
| Eumovate | 0.05% Oint | GLA | 456551 | . 2565 |
| Eurax | 10% Cr | CIB | 623377 , | .1982 |

| Product Name | Strength & Dosage | Manuf' | r DIN | Price | |
|----------------------------------|-------------------------------|--------|--------|---------|--|
| Exdol | 325mg Tab | FRS | 373710 | .0281 | |
| Exdol Strong | 500mg Tab | FRS | 446114 | .0391 | |
| Exdol-15 | 15mg Tab | FRS | 372331 | .0303 | |
| Exdol-30 | 30mg Tab | FRS | 372358 | .0406 | |
| EES-200 | 40mg/mL O/L | ABB | 000299 | .0659 | |
| EES-400 | 80mg/mL O/L | ABB | 453617 | .1012 | |
| EES-600 | 600mg Tab | ABB | 583782 | .5844 | |
| ERYC | 250mg Ent Pel Cap | PDA | 607142 | .3099 | |
| Feldene | 20mg Cap | PFI | 525618 | 1.0033 | |
| Feldene | 10mg Cap | PFI | 525596 | .5985 | |
| Fenicol | 1% Oph Oint-3.5g Pk | ALC | 001058 | 2.1490 | |
| Fer-in-Sol | 125mg/mL 0/L | MJO | 017841 | .1413 | |
| Fergon | 300mg Tab 100 Pk | WIN | 033650 | 3.2000 | |
| Ferrous Fumarate | 200mg Tab 100 Pk | DTC | 094706 | 3.0000 | |
| Ferrous Gluconate | 300mg Tab 100 Pk | WAM | 031097 | 2.4000 | |
| Ferrous Gluconate | 300mg Tab 100 Pk | LEA | 041157 | 3.1000 | |
| Ferrous Gluconate | 300mg Tab 100 Pk | DTC | 094714 | 3.0000 | |
| Fersamal | 200mg Tab 100 Pk | GLA | 012238 | 9.5000 | |
| Fibyrax | Tab 100 Pk | ROU | | | |
| | lnh 200 dose Pk | FIS | 512656 | 8.7000 | |
| Fivent | | FIS | 555649 | 29.2000 | |
| Fivent | Inh-112 dose Pk | | 990981 | 18.5600 | |
| Flagyl | 500mg Cap | RPP | 489891 | .6719 | |
| Flagyl | 250mg Tab | RPP | 025615 | .0255 | |
| Flagyl | 10% Vag Cr-App | RPP | 024929 | . 1433 | |
| Flagyl | 500mg Vag Tab-App | RPP | 025887 | .3230 | |
| Flagystatin | 500mg & 100,000U/g Vag Cr-App | RPP | 338338 | .2798 | |
| Flagystatin | 500mg & 100,000U Vag Sup | RPP | 439134 | 1.5390 | |
| Flagystatin | 500mg & 100,000U Vag Tab-App | RPP | 250724 | 1.5390 | |
| Flamazine | 17. Cr | SNE | 323098 | .1710 | |
| Fleet | Enema 130mL Pk | FRS | 107875 | 4.9000 | |
| Fleet | | | | | |
| 160mg & 60mg/mL Ped Rec Fleet | t Sol 65mL Pk | FRS | 108065 | 3.2500 | |
| 160mg & 60mg/mL Rect So | 1 130mL Pk | FRS | 009911 | 3.5000 | |
| Flexeril | 10mg Tab | MSD | 417300 | . 4237 | |
| Florinef | O.lmg Tab | SOU | 029351 | . 1590 | |
| Florone | 0.05% Cr | UPJ | 481807 | .2025 | |
| Florone | 0.05% Oint | UPJ | 481793 | .2025 | |
| Fluanxol | 3mg Tab | MER | 585157 | .3640 | |
| Fluanxol | 0.5mg Tab | MER | 580619 | .1680 | |
| Fluanxol Depot | 200mg/10mL Inj Sol-10mL Pk | MER | 524522 | 50.6500 | |
| Fluanxol Depot | 200mg/2mL Inj Sol-2mL Pk | MER | 524530 | 50.6500 | |
| Fluclox | 500mg Cap | AYE | 486809 | .7807 | |
| Fluclox | 250mg Cap | AYE | 486795 | .4260 | |
| Fluciox | 50mg/mL O/L | AYE | 525561 | .1617 | |
| Fluclox | | AYE | 486817 | .1080 | |
| Fluoderm | 25mg/mL O/L 0.025% Cr | KLP | 385220 | .0442 | |
| Fluoderm | 0.01% Cr | KLP | 385239 | .0369 | |
| Fluoderm | | KLP | | | |
| | 0.025% Oint | | 509655 | .0486 | |
| Fluoderm | 0.01% Oint | KLP | 509647 | .0406 | |
| Fluonide Mild | 0.01% Cr | TCH | 535338 | .0550 | |
| Fluonide Regular | 0.025% Cr | TCH | 535281 | .1276 | |
| Fluorouracil | 500mg/10mL Inj Sol-10mL Pk | HLR | 012882 | 2.0800 | |
| Flutone | 0.05% Cr | ROR | 530956 | .3000 | |
| Flutone | 0.05% Oint | ROR | 532630 | .3000 | |
| Folic Acid | 5mg Tab | AHA | 003492 | .0622 | |
| Folic Acid | 5mg Tab | DTC | 094617 | .0065 | |

| Product Name | Strength & Dosage | Manuf'r | DIN | Price |
|------------------------|--------------------------|---------|--------|---------|
| Folic Acid | 5mg Tab | LEA | 498777 | .0205 |
| Folic Acid-ICN | 5mg Tab | ICN | 284149 | .0065 |
| Folvite | 5mg Tab | LED | 014966 | .0247 |
| Formulex | 10mg Cap | ICN | 361933 | .0245 |
| Froben | 50mg Tab | ORG | 593346 | .2905 |
| Froben | 100mg Tab | ORG | 593354 | .3875 |
| Fucidin | 2% Cr | LEO | 586668 | .4100 |
| Fucidin | 2% Oint | LEO | 586676 | .4100 |
| Fulvicin P/G | 330mg Tab | SCH | 513237 | .2907 |
| Fulvicin P/G | 165mg Tab | SCH | 513229 | .1719 |
| Fulvicin U/F | 500mg Tab | SCH | 028282 | .3233 |
| Fulvicin U/F | 250mg Tab | SCH | 028274 | . 1910 |
| Fulvicin U/F | 125mg Tab | SCH | 028266 | .1111 |
| Fungizone | Inj Pd-50mg Pk | SQU | 029149 | 24.4000 |
| Furosemide | 40mg Tab | DTC | 396249 | .0077 |
| Furosemide | 20mg Tab | DTC | 489131 | .0058 |
| Furoside | 40mg Tab | ICN | 332275 | .0071 |
| Furoside | 20mg Tab | ICN | 353612 | .0053 |
| FML | 0.1% Oph Susp | ALL | 247855 | 1.0610 |
| Gantanol | 500mg Tab | HLR | 013412 | .1280 |
| Gantrisin | 100mg/mL 0/L | HLR | 115487 | .0298 |
| Gantrisin | 500mg Tab | HLR | 013420 | .0565 |
| Garamycin | 80mg/2ml Inj Sol-2ml Pk | SCH | 223824 | 4.0900 |
| Garamycin | 0.3% Oph Oint-3.5g Pk | SCH | 028339 | 4.9284 |
| Garamycin | 0.3% Oph Sol | SCH | 512192 | 1.0440 |
| Garamycin | 0.3% Ot Sol | SCH | 512184 | 1.0733 |
| Garasone | 3mg & 1mg/mL Ot Drops | SCH | 614270 | 1.3160 |
| Gastrozepin | 50mg Tab | BOE | 608998 | .4620 |
| Gelusil | 40mg & 40mg/mL O/L | PDA | 476471 | .0106 |
| Gelusil | 200mg & 200mg Tab | PDA | 476455 | .0607 |
| Gelusil Extra Strength | 130mg & 70mg/mL 0/L | PDA | 531154 | .0138 |
| Gelusil 400 | 400mg & 400mg Tab | PDA | 483605 | .0965 |
| Geopen | 500mg Tab | PFI | 328235 | .7970 |
| Glaucon | 2% Oph Sol | ALC | 358223 | .8680 |
| Glaucon | 1% Oph Sol | ALC | 358231 | .8288 |
| Glucagon | Inj Pd-1mg Pk | LIL | 015377 | 18.8384 |
| Glucophage | 500mg Tab | NRD | 314552 | .1368 |
| Glucoscan | Stick-50 Pk | LIF | 980676 | 23.9750 |
| Glucoscan/GM | Stick-20 Pk | LIF | 980684 | 9.5900 |
| Glycerin | 2.7g Sup 24 Pk | PDA | 990485 | 2.9000 |
| Glycerin | 2.7g Sup 24 Pk | ROG | 990825 | 2.1000 |
| Glycerin | 2.7g Sup 24 Pk | DTC | 990868 | 2.1000 |
| Glycerin | 1.8g Sup 24 Pk | ROG | 145416 | 2.2000 |
| Glycerin | 1.8g Sup 24 Pk | PDA | 222801 | 2.7000 |
| Glycerin | 1.8g Sup 24Pk | DTC | 094056 | 2.3000 |
| Glysennid | 12mg Tab 100 Pk | SAN | 027502 | 12.5000 |
| Glysennid | 8.6mg Tab 100 Pk | SAN | 604402 | 10.5000 |
| Gramcal | 1.5g & 3.08g Eff Tab | SAN | 259497 | .5040 |
| Gravol | 50mg/5mL Inj Sol-5mL Pk | HOR | 013560 | 1.2900 |
| Gravol | 250mg/5mL Inj Sol-5mL Pk | HOR | 013579 | 2.3457 |
| Gravol | 3mg/mL O/L | HOR | 230197 | .0367 |
| Gravol | 50mg Sup | HOR | 013595 | .2489 |
| Gravol | 100mg Sup | HOR | 013609 | .2620 |
| Gravol Filmkote | 50mg Tab | HOR | 013803 | .0883 |
| Gravol Filmkote | 15mg Tab | HOR | 511196 | . 1299 |
| Grisovin FP | 500mg Tab | GLA | 012262 | .2765 |
| Grisovin FP | 250mg Tab | GLA | 012254 | |
| Grisovin rr | 200mg 1ab | GLA | 012254 | , .1555 |

| Product Name | Strength & Dosage | Manuf'r | DIN | Price |
|------------------------|----------------------------------|---------|--------|---------|
| Grisovin FP | 125ng Tab | GLA | 012246 | .0865 |
| Guaifenesin | 20mg/mL O/L | ROG | 026794 | .0058 |
| Guaifenesin Sugar Free | 20mg/mL 0/L | ROG | 990930 | .0069 |
| Gynergen | lmg Tab | SAN | 027405 | .3820 |
| Halcion | 0.5mg Tab | UPJ | 443131 | .1762 |
| Halcion | 0.25mg Tab | UPJ | 443158 | .1479 |
| Halcion | 0.125mg Tab | UPJ | 512559 | .1195 |
| Haldol | 5mg/mL Inj Sol-1mL Pk | MCN | 017574 | 2.1100 |
| Haldol | 2ng/nL 0/L | MCN | 017582 | .2079 |
| Haldol | 20mg Tab | MCN | 499579 | .8710 |
| Haldol | 10mg Tab | MCN | 381772 | .4710 |
| Haldol | 5mg Tab | MCN | 017698 | .3230 |
| Haldol | 2ng Tab | MCN | 017671 | .2030 |
| Haldol | lmg Tab | MCN | 017663 | . 1355 |
| Haldol | 0.5mg Tab | MCN | 017655 | .0902 |
| Haldol-LA | 50mg/mL Oily Inj Sol-1mL Pk | MCN | 599085 | 7.2400 |
| Haldol-LA | 100mg/mL Oily Inj Sol-1mL Pk | MCN | 599093 | 14.3100 |
| Halog | 0.1% Cr | SQU | 326941 | .2958 |
| Halog ' | 0.025% Cr | SOU | 404179 | .1842 |
| Halog | 0.1% Oint | SOU | 403075 | .2958 |
| Halog | 0.1% Sol | SOU | 404187 | .2958 |
| Halotestin | 5mg Tab | UPJ | 030902 | .1132 |
| Halotex | 17 Cr | WSD | 291048 | .2373 |
| Halotex | 1% Top Sol | WSD | 291021 | .2130 |
| Hepalean | 10,000USP U/10mL Inj Sol-10mL Pk | | 562262 | 2.7664 |
| Hepalean | 25,000USP U/mL Inj Sol-2mL Pk | ORG | 562289 | 11.6312 |
| Hepalean | 50,000USP U/5mL Inj Sol-5mL Pk | ORG | 562270 | 4.9056 |
| Heparin | 10,000USP U/10mL Inj Sol-10mL Pk | | 304042 | 1.7250 |
| Heparin | 50,000USP U/5mL Inj Sol-5mL Pk | AHA | 304050 | 4.3120 |
| Herplex | 0.17 Oph Sol | ALL | 001120 | .6390 |
| Herplex-D | 0.1% Top Sol | ALL | 001317 | 1.0240 |
| Hexa-Betalin | 25mg Tab | LIL | 015865 | .1104 |
| Hexadrol | 20mg/5mL Inj Sol-5mL Pk | ORG | 269026 | 12.9000 |
| Hexadrol | 4mg Tab | ORG | 349100 | .1185 |
| Hexavitamins | Tab 100 Pk | NOP | 269034 | 3.4000 |
| Hibitane | 4% Top Sol 110mL Pk | AYE | 245097 | 2.1000 |
| Hip-Rex | lg Tab | RIK | 026379 | .4144 |
| Hismanal | 2mg/mL O/L | JAN | 610070 | .2986 |
| Hismanal | 10mg Tab | JAN | 610089 | .5936 |
| Honvol | 250mg/5mL lnj Sol-5mL Pk | HOR | 013587 | 4.6640 |
| Honvol | 100mg Tab | HOR | 013781 | .4807 |
| Humulin L Lente | 1000U/10mL Inj Susp 10mL Pk | LIL | 646148 | 18.6500 |
| Humulin NPH | 1000U/10mL Inj Susp 10mL Pk | LIL | 587737 | 18.6500 |
| Humulin Regular | 1000U/10mL Inj Sol 10mL Pk | LIL | 586714 | 18.6500 |
| Hycodan | lng/mL O/L | DUP | 585580 | .0382 |
| Hycodan | 5mg Tab | DUP | 585572 | .2635 |
| Hycort | 100ng/60mL Enema-60mL Pk | ICN | 230316 | 5.6460 |
| Hydern | 1% Cr | KLP | 458155 | .0226 |
| Hydern | 0.5% Cr | KLP | 539538 | .0176 |
| Hydrochlorothiazide | 50mg Tab | DTC | 092703 | .0045 |
| Hydrochlorothiazide | 50mg Tab | SAP | 209821 | .0047 |
| Hydrochlorothiazide | 25mg Tab | DTC | 092681 | .0037 |
| Hydrocortisone | 1% Cr | DTC | 551945 | .0206 |
| Hydrocortisone | 0.5% Cr | DTC | 551953 | .0181 |
| Hydrocortisone | 1% Oint | DTC | 093645 | .0206 |
| Hydrocortisone | 0.5% Oint | DTC | 093637 | .0181 |
| a, a. ocor traone | O.O. UIRC | DIC | 033031 | .0101 |

| Product Name | Strength & Dosage | Manuf'r | DIN | Price |
|--------------------------|-----------------------------|---------|-------------|---------|
| HydroDIURIL | 50mg Tab | MSD | 016519 | .0618 |
| HydroDIURIL | 25mg Tab | MSD | 016500 | .0446 |
| Hygroton | 50mg Tab | GEI | 010413 | .0980 |
| Hygroton | 100mg Tab | GEI | 010421 | . 1310 |
| Hyperstat | 300mg/20mL Inj Sol-20mL Pk | SCH | 269271 | 35.1300 |
| Hypotears | 1% Oph Sol | CEV | 606391 | . 1717 |
| Hytakerol | 0.125mg Cap | WIN | 033057 | .6754 |
| Hytakerol | 0.25mg/mL 0/L | WIN | 033553 | 2.2140 |
| HC-Atropine 1% | 2.5% & 1% Oph Oint-3g Pk | AHA | 062251 | 13.3500 |
| H20xy1 | 5% Gel | STI | 512613 | .0965 |
| H20xy1 | 20% Gel | STI | 512648 | . 1399 |
| H20xy1 | 10% Gel | STI | 512621 | .1093 |
| Ibuprofen | 600mg Tab | KNR | 606227 | .0800 |
| Ibuprofen | 400mg Tab | KNR | 606219 | .0528 |
| Ibuprofen | 300mg Tab | KNR | 606200 | .0407 |
| Ibuprofen | 200mg Tab | KNR | 606197 | .0287 |
| Iletin II Lente | 1000U/10mL Inj Susp 10mL Pk | LIL | 514535 | 20.4000 |
| Iletin II NPH | 1000U/10mL Inj Susp 10mL Pk | LIL | 514551 | 20.4000 |
| Iletin II Regular | 1000U/10mL Inj Sol 10mL Pk | LIL | 513644 | 20.4000 |
| Iletin Lente | 1000U/10mL Inj Susp 10mL Pk | LIL | 446580 | 11.9000 |
| Iletin NPH | 1000U/10mL Inj Susp 10mL Pk | LIL | 446572 | 11.9000 |
| Iletin Protamine Zinc | 1000U/10mL Inj Susp 10mL Pk | LIL | 446610 | 11.9000 |
| Iletin Regular | 1000U/10mL Inj Sol 10mL Pk | LIL | 446564 | 11.9000 |
| Iletin Semilente | 1000U/10mL Inj Susp 10mL Pk | LIL | 446602 | 11.9000 |
| Iletin Ultralente | 1000U/10mL Inj Susp 10mL Pk | LIL | 446599 | 11.9000 |
| Ilosone | 250mg Cap | LIL | 015202 | .1606 |
| Ilosone | 50mg/mL O/L | LIL | 210641 | .0573 |
| Ilosone | 25mg/mL O/L | LIL | 015474 | .0296 |
| Ilosone | 500mg Tab | LIL | 244384 | .3382 |
| Ilotycin | 1% Oint | LIL | 015997 | .3327 |
| Imferon | 100mg/2mL Inj Sol-2mL Pk | FIS | 009598 | 2.3990 |
| Imipramine | 50mg Tab | SAP | 209848 | .0141 |
| Imipramine | 50mg Tab | DTC | 377929 | .0146 |
| Imipramine | 25mg Tab | SAP | 209864 | .0082 |
| Imipramine | 25mg Tab | DTC | 377910 | .0084 |
| Imipramine | 10mg Tab | SAP | 209856 | .0047 |
| Imipramine | 10mg Tab | DTC | 377902 | .0049 |
| Immune Human Serum Globi | 9 | | | |
| Immune Human Serum Globi | 16.5% Inj Sol-10mL Pk | CNG | 990515 | 9.8600 |
| Immune Human Serum Globi | 16.5% Inj Sol-2mL Pk | CNG | 075280 | 3.1900 |
| | 16.5% Inj Sol-5mL Pk | CNG | 990523 | 5.5100 |
| Imodium | 2mg Cap | JAN | 579343 | .4130 |
| Imodium | 0.2mg/mL 0/L | JAN | 610062 | .0717 |
| Impril | 50mg Tab | ICN | 236721 | .0134 |
| Impril | 25mg Tab | ICN | 236756 | .0079 |
| Impril | 10mg Tab | ICN | 236748 | .0042 |
| Imuran | 50mg Tab | BWE | 004596 | .5880 |
| Inderal | 80mg Tab | AYE | 313602 | . 1534 |
| Inderal | 40mg Tab | AXE | 002666 | .0924 |
| Inderal | 120mg Tab | AYE | 456578 | .2520 |
| Inderal | 10mg Tab | AYE | 002658 | .0520 |
| Inderal L.A. | 160mg LA Cap | AYE | 511668 | .7896 |
| | acome with very | TAL | 3 1 2 0 0 0 | |
| Inderal L.A. | 120mg LA Cap | AYE | 587931 | .6270 |

| Product Name | Strength & Dosage | Manuf'r | DIN | Price |
|--------------------|-----------------------------|---------|--------|---------|
| Inderal-20 | 20mg Tab | AYE | 489859 | .0834 |
| Inderide 40 | 40mg & 25mg Tab | AYE | 465313 | .3308 |
| Inderide 80 | 80mg & 25mg Tab | AYE | 465321 | .5123 |
| Indocid | 50mg Cap | MSD | 016047 | .3519 |
| Indocid | 25mg Cap | MSD | 016039 | .2165 |
| Indocid | 1% Oph Susp | MSD | 594458 | 3.3600 |
| Indocid | 50mg Sup | MSD | 594466 | .7997 |
| Indocid | 100mg Sup | MSD | 016233 | 1.0747 |
| Indocid SR | 75mg LA Cap | MSD | 463248 | .8094 |
| Inflamase Forte | 1% Oph Sol | CEV | 526460 | 1.2240 |
| Inflamase Mild | 0.125% Oph Sol | CEV | 526452 | 1.0900 |
| Initard | 1000U/10mL Inj Susp 10mL Pk | HOR | 614416 | 18.9000 |
| Initard Human | 1000U/10mL Inj Susp 10mL Pk | HOR | 632678 | 18.9000 |
| Insulatard | 1000U/10mL Inj Susp 10mL Pk | HOR | 552275 | 18.9000 |
| Insulatard Human | 1000U/10mL Inj Susp 10mL Pk | HOR | 632651 | 18.9000 |
| Insulin-Toronto | 1000U/10mL Inj Sol 10mL Pk | NOO | 612227 | 12.4000 |
| Intal | 1% Inh Sol 2mL Pk | FIS | 534609 | .5894 |
| Intal Spincaps | 20mg/Cart Pd Inh | FIS | 261238 | .3435 |
| Intrabutazone | 100mg Ent Tab | ORG | 258377 | . 1763 |
| Ismelin | 25mg Tab | CIB | 005517 | .2930 |
| Ismelin | 10mg Tab | CIB | 005509 | . 1630 |
| Isoniazid | 300mg Tab | SAP | 310247 | .0470 |
| Isoniazid | 100mg Tab | SAP | 440108 | .0205 |
| Isoptin | 120mg Tab | SEA | 554324 | .5270 |
| Isoptin | 80mg Tab | SEA | 554316 | .3845 |
| Isopto Atropine | 1% Oph Sol | ALC | 035017 | .6048 |
| Isopto Carbachol | 3% Oph Sol | ALC | 000663 | .6574 |
| Isopto Carbachol | 1.5% Oph Sol | ALC | 000655 | .5454 |
| Isopto Carpine | 6% Oph Sol | ALC | 000892 | .4334 |
| Isopto Carpine | 4% Oph Sol | ALC | 000884 | .3282 |
| Isopto Carpine | 3% Oph Sol | ALC | 000876 | .3080 |
| Isopto Carpine | 2% Oph Sol | ALC | 000868 | .2800 |
| Isopto Carpine | 1% Oph Sol | ALC | 000841 | .2576 |
| Isopto Carpine | 0.5% Oph Sol | ALC | 000833 | .2576 |
| Isopto Cetamide | 10% Oph Sol | ALC | 000965 | .0790 |
| Isopto Femicol | 0.5% Oph Sol | ALC | 403474 | . 1750 |
| Isopto Fenicol | 0.25% Oph Sol | ALC | 239879 | .7370 |
| Isopto Homatropine | 5% Oph Sol | ALC | 000787 | .5667 |
| Isopto Homatropine | 2% Oph Sol | ALC | 000779 | .4782 |
| Isopto Tears | 17. Oph Sol | ALC | 000817 | .3326 |
| Isopto Tears | 0.5% Oph Sol | ALC | 000809 | .2722 |
| Isordil | 5mg SL Tab | WYE | 243116 | .0470 |
| Isordil | 30mg Tab | WYE | 279536 | .0540 |
| Isordil | 10mg Tab | WYE | 208973 | .0236 |
| Isotamine-100 | 100mg Tab | ICN | 261270 | .0177 |
| Isotamine-300 | 300mg Tab | ICN | 272655 | .0520 |
| Isuprel | 0.5% Inh Sol-10mL Pk | WIN | 033227 | 6.0500 |
| Isuprel | 10mg SL Tab | WIN | 033820 | . 1300 |
| Isuprel Mistometer | Aero Sol-15mL Pk | WIN | 033219 | 9.3495 |
| IMAP | 12mg/6ml Inj Susp-6ml Pk | MCN | 368393 | 14.4000 |
| IMAP Forte | 10mg/mL Inj Susp-1mL Pk | MCN | 542903 | 11.5200 |
| K-Long | 6.7mEq LA Tab | ADI | 501972 | .0710 |
| K-Lor | 20mEq/Pouch Oral Pd-3g Pk | ABB | 481211 | .3010 |
| K-Lyte/Cl | 25mEq/Pouch Oral Pd 7.8g Pk | BRI | 464813 | .4237 |
| K-10 | 1.33mEq/mL O/L | BEE | 436984 | .0122 |
| Kalium Durules | 10mEq LA Tab | AST | 471496 | .0623 |
| Kantrex | 500mg Cap | BRI | 003980 | 1.3624 |
| | 3 1 | | | |

| Kantrex 1g Kaochlor 1. Kaochlor-20 Concentrate 2. Kaon 5m Kaopectate 0 Karacil 0 Kay Ciel 1. Kayexalate 1m Keflex 25 Keflex 25 Keflex 50 | .5g/2ml Inj Sol-2ml Pk 4/3ml Inj Sol-3ml Pk 33mEq/ml O/L 66mEq/ml O/L 33mEq/ml O/L teq Tab 1/1 1/2 1/3 1/3 1/4 1/4 1/4 1/4 1/4 1/4 1/4 1/4 | BRI BRI ADI ADI ADI UPJ ICN BER WIN | 004227 004235 208590 208604 208701 215503 030864 387177 704504 | 8.8550 15.1800 .0161 .0209 .0207 .0806 .0076 4.3000 |
|--|---|---|--|--|
| Kaochlor 1. Kaochlor-20 Concentrate 2. Kaon 5m Kaopectate 0 Karacil 0 Kay Ciel 1. Kayexalate 1m Keflex 50 Keflex 25 Keflex 50 | 33mEq/mL O/L 66mEq/mL O/L 33mEq/mL O/L iEq Tab i/L iPral Pd 340g Pk 33mEq/mL O/L iEq/g Oral Pd-454g Pk img/mL O/L | ADI ADI ADI ADI UPJ ICN BER WIN | 208590 208604 208701 215503 030864 387177 704504 | .0161 .0209 .0207 .0806 .0076 4.3000 |
| Kaochlor-20 Concentrate 2. Kaon 5m Kaopectate 0 Karacil 0 Kay Ciel 1. Kayexalate 1m Keflex 50 Keflex 25 Keflex 50 | 66mEq/mL O/L 33mEq/mL O/L LEq Tab O/L Oral Pd 340g Pk 33mEq/mL O/L LEq/g Oral Pd-454g Pk Dmg/mL O/L | ADI ADI ADI UPJ ICN BER WIN | 208604 208701 215503 030864 387177 704504 | .0209 .0207 .0806 .0076 4.3000 |
| Kaon 1. Kaon 5m Kaopectate 0 Karacil 0 Kay Ciel 1. Kayexalate 1m Keflex 50 Keflex 25 Keflex 50 | 33mEq/mL O/L LEq Tab J/L J/L J/L J/L J/L J/L J/L J/ | ADI ADI UPJ ICN BER WIN | 208701 215503 030864 387177 704504 | .0207 .0806 .0076 4.3000 |
| Kaon 5m Kaopectate 0 Karacil 0 Kay Ciel 1 Kayexalate 1m Keflex 50 Keflex 25 Keflex 50 Keflex 50 | nEq Tab N/L Nral Pd 340g Pk 33mEq/mL O/L nEq/g Oral Pd-454g Pk Nmg/mL O/L | ADI UPJ ICN BER WIN | 215503 030864 387177 704504 | .0806 .0076 4.3000 |
| Kaopectate C Karacil C Kay Ciel 1. Kayexalate 1m Keflex 50 Keflex 25 Keflex 50 | D/L Dral Pd 340g Pk 33mEq/mL O/L nEq/g Oral Pd-454g Pk Dmg/mL O/L | UPJ ICN BER WIN | 030864 387177 704504 | .0076 4.3000 |
| Karacil C Kay Ciel 1. Kayexalate 1m Keflex 50 Keflex 25 Keflex 50 | oral Pd 340g Pk 33mEq/mL O/L nEq/g Oral Pd-454g Pk ng/mL O/L | ICN BER WIN | 387177 704504 | 4.3000 |
| Kay Ciel 1. Kayexalate 1m Keflex 50 Keflex 25 Keflex 50 | .33mEq/mL O/L nEq/g Oral Pd-454g Pk ng/mL O/L | BER WIN | 704504 | |
| Kayexalate 1m Keflex 50 Keflex 25 Keflex 50 | nEq/g Oral Pd-454g Pk Omg/mL O/L | WIN | | |
| Keflex 50 Keflex 25 Keflex 50 | mg/mL O/L | | | .0124 |
| Keflex 25 Keflex 50 | | | 033197 | 48.3351 |
| Keflex 50 | img/ml O/L | LIL | 035645 | .0758 |
| | , o, a | LIL | 015547 | .0380 |
| | Omg Tab | LIL | 244392 | .4352 |
| | iOmg Tab | LIL | 403628 | .2011 |
| Keflin I | inj Pd-1g Pk | LIL | 015369 | 3.7420 |
| Keflin I | inj Pd-2g Pk | LIL | 244406 | 7.2700 |
| Kefzol | nj Pd-1000mg Pk | LIL | 322296 | 6.0640 |
| Kefzol . | inj Pd-500mg Pk | LIL | 322288 | 3.1500 |
| Kemadrin 0. | 5mg/mL O/L | BWE | 004405 | .0330 |
| Kemadrin 5m | g Tab | BWE | 004758 | .0400 |
| Kenacort 4m | g Tab | SQU | 029475 | .4715 |
| Kenalog 0. | 1% Cr | SQU | 029114 | .1106 |
| Kenalog 0. | 1% Oint | SQU | 029572 | .1106 |
| Kenalog-E 0. | 025% Cr | SQU | 029106 | .0553 |
| Kenalog-E 0. | 025% Oint | SQU | 029564 | .1167 |
| Kenalog-Orabase 0 | ral Top Oint | SQU | 029505 | .8933 |
| Kenalog-10 50 | mg/5mL Inj Susp-5mL Pk | SQU | 460761 | 6.7200 |
| Kenalog-40 40 | mg/mL Inj Susp-1mL Pk | SQU | 990876 | 3.1200 |
| Kenalog-40 20 | Omg/5mL Inj Susp-5mL Pk | SOU | 029300 | 10.5600 |
| | Gel | WSD | 307580 | .0719 |
| Keto-Diastix S | Stick-100 Pk | AME | 990647 | 8.7500 |
| Ketostix | Stick-50 Pk | AME | 980595 | 4.5500 |
| Kidrolase I | nj Pd-10,000IUPk | RPP | 285463 | 90.1000 |
| Koffex 3m | g/mL O/L | ROG | 436895 | .0067 |
| Kwellada 17 | Cr | RCA | 026204 | .0474 |
| Kwellada 17 | Lot | RCA | 026212 | .0430 |
| Kwellada 17 | Shampoo | RCA | 026220 | .0668 |
| Lacri-Lube 55 | 7% & 42.5% Oph Oint-3.5g Pk | ALL | 210889 | 3.0342 |
| Lanoxin 0. | O5mg/mL Inj Sol-1mL Pk | BWE | 004456 | 2.2200 |
| Lanoxin 0. | 50mg/2mL Inj Sol-2mL Pk | BWE | 004464 | 2.2200 |
| Lanoxin 0. | 05mg/mL 0/L | BWE | 242713 | .1070 |
| Lanoxin 0. | 25mg Tab | BWE | 004685 | .0550 |
| Lanoxin 0. | 125mg Tab | BWE | 035319 | .0550 |
| Lanvis 40 | Img Tab | BWE | 282081 | 2.7040 |
| Largactil 50 | mg/2mL Inj Sol-2mL Pk | RPP | 163953 | 1.1590 |
| Largactil 5m | g/mL O/L | RPP | 025151 | .0159 |
| Largactil 40 | lmg/mL O/L | RPP | 025186 | .2247 |
| Largactil 20 | lmg/mL O/L | RPP | 025178 | .0291 |
| Largactil 10 | Omg Sup | RPP | 025283 | 1.4300 |
| Largactil 50 | mg Tab | RPP | 025488 | .0276 |
| Largactil 25 | img Tab | RPP | 025461 | .0189 |
| Largactil 20 | Omg Tab | RPP | 025518 | .0866 |
| Largactil 10 | Omg Tab | RPP | 025496 | .0527 |
| Largactil 10 | mg Tab | RPP | 025453 | .0299 |
| | Omg Tab | HLR | 013358 | .2100 |
| | Omg Tab | HLR | 013331 | .1185 |
| Lasan-1 0. | 1% Oint | STI | 249858 | .0984 |

| Product Name | Strength & Dosage | Manuf'i | DIN | Price |
|-------------------------|-----------------------------|---------|------------------|----------------|
| Lasan-2 | 0.2% Oint | STI | 187682 | .1033 |
| Lasix | 20mg/2mL Inj Sol-2mL Pk | HOE | 217743 | .8800 |
| Lasix | 10mg/mL O/L | HOE | 432342 | .1508 |
| Lasix | 40mg Tab | HOE | 012580 | .0750 |
| Lasix | 20mg Tab | HOE | 289590 | .0487 |
| Lectopam | 6mg Tab | HLR | 518131 | .1499 |
| Lectopam | 3mg Tab | HLR | 518123 | .1028 |
| Ledercillin VK | 300mg Tab | LED | 262447 | .0740 |
| Lenoltec No. 3 | 30mg Tab | TCH | 653276 | .0310 |
| Lente Insulia | 1000U/10mL Inj Sasp 10mL Pk | NOO | 612278 | 12.4000 |
| Leritine | 25mg/mL Inj Sol ImL Pk | FRS | 009857 | 1.4424 |
| Leritine | 25mg Tab | FRS | 010014 | .2671 |
| Leukeran | 2mg Tab | BWE | 004626 | .8800 |
| Levate | 50mg Tab | ICN | 271152 | .0122 |
| Levate | 25mg Tab | ICN | 306320 | .0052 |
| Levate | 10mg Tab | ICN | 293911 | .0043 |
| Levo-Dromoran | 2mg/mL Inj Sol-1mL Pk | HLR | 012904 | 1.1100 |
| Levo-Dromoran ' | 2mg Tab | HLR | 013366 | .1670 |
| Levsin | 0.125mg/mL O/L | ROR | 608807 | .4723 |
| Levsin | 0.125mg SL Tab | ROR | 608777 | .1159 |
| Librium | 5mg Cap | HLR | 012629 | .0412 |
| Librium | 25mg Cap | HLR | 012645 | .0852 |
| Librium | 10mg Cap | HLR | 012637 | .0554 |
| Lidemol | 0.05% Emol Cr | SYP | 424943 | .2643 |
| Lidex | 0.05% Cr | SYP | 036099 | .2643 |
| Lidex | 0.05% Oint | SYP | 274437 | .2643 |
| Lidex Mild | 0.01% Cr | SYP | 274453 | .2406 |
| Lidex Mild | 0.01% Oint | SYP | 274445 | .2406 |
| Lincocin | 500mg Cap | UPJ | 030589 | .5285 |
| Lincocin | 600mg/2mL Inj Sol-2mL Pk | UPJ | 030732 | 3.8500 |
| Lioresal | 10mg Tab | GEI | 455881 | .3460 |
| Lioresal DS | 20mg Tab | GEI | 636576 | .7150 |
| Liquifilm Forte | 3% Oph Sol | ALL | 368911 | .3461 |
| Liquifilm Tears Lithage | 1.4% Oph Sol | ALL | 045616 | .2341 |
| Lithane | 300mg Cap | PFI | 406775 | .0640 |
| Lithizine | 300mg Tab 300mg Cap | TCH | 024406 328790 | .0640 |
| Locacorten | 0.03% Cr | | | |
| Locacorten | 0.03% Cr 0.03% Oint | CIB | 005134 | .4710 |
| Locacorten-Vioform | 0.02% & 1% Ot Sol | CIB | 005789 074454 | .4710 .9320 |
| Loestrin 1.5/30 | 0.03mg & 1.5mg Tab-21 Pk | PDA | 297143 | 8.0000 |
| Loestrin 1.5/30 | 0.03mg & 1.5mg Tab-28 Pk | PDA | 353027 | 8.0000 |
| Loftran | 30mg Cap | BEE | 514527 | .5276 |
| Loftran | 15mg Cap | BEE | 514527 | .3565 |
| Lomotil | 0.5mg/mL O/L | SEA | 399353 | .1480 |
| Lomotil | 2.5mg Tab | SEA | 399345 | .2478 |
| Loniten | 10mg Tab | UPJ | 514500 | .4630 |
| Loniten | 2.5mg Tab | UPJ | 514497 | .2100 |
| Lopid | 300mg Cap | PDA | 599026 | .3073 |
| Lopresor | 50mg Tab | GEI | 397423 | .1340 |
| Lopresor | 100mg Tab | GEI | 397431 | .2420 |
| Lopresor SR | 200mg LA Tab | GEI | 534560 | .4270 |
| Lopresor SR | 100mg LA Tab | GEI | 658855 | .2500 |
| Lorfan | lmg/mL Inj Sol-1mL Pk | HLR | 115584 | 1.3373 |
| Loxapac | 25mg/mL O/L | LED | 361364 | .4910 |
| Loxapac | 50mg Tab | LED | 346810 | .4650 |
| Loxapac | 5mg Tab | LED | 346780 | .1485 |
| | | | 010100 | |

| Product Name | Strength & Dosage | Manuf'r | DIN | Price |
|----------------|-------------------------|---------|--------|-----------|
| Loxapac | 25mg Tab | LED | 346802 | .3421 |
| Loxapac | 10mg Tab | LED | 346799 | .2134 |
| Lozide | 2.5mg Tab | SEV | 564966 | .3280 |
| Ludiomil | 75mg Tab | CIB | 360511 | .5340 |
| Ludiomil | 50mg Tab | CIB | 360503 | .3910 |
| Ludiomil | 25mg Tab | CIB | 360481 | .2070 |
| Ludiomil | 10mg Tab | CIB | 641855 | . 1520 |
| Luminal | 120mg/mL Inj Sol-1mL Pk | WIN | 033367 | .5450 |
| Lupron | 5mg/mL 1nj Sol-2.8mL Pk | ABB | 642932 | 140.0000 |
| Lyderm | 0.05% Cr | KLP | 589896 | . 1932 |
| M.O.S. | 20mg/mL O/L | ICN | 632481 | .4760 |
| M.O.S. | 10mg/mL O/L | ICN | 632503 | . 1872 |
| M.O.S. | 30mg Sup | ICN | 636681 | 1.6467 |
| M.O.S. | 20mg Sup | ICN | 624276 | 1.4733 |
| M.O.S. | 10mg Sup | ICN | 624268 | 1.2567 |
| | 40mg & 40mg/mL O/L | ROR | 024200 | .0085 |
| Maalox | | ROR | 026549 | |
| Maalox | 400mg & 400mg Tab | ROR | | .0632 |
| Maalox TC | 600mg & 300mg Chew Tab | | 541125 | .1033 |
| Maalox TC | 120mg & 60mg/mL 0/L | ROR | 497037 | .0148 |
| Macrodantin | 50mg Cap | EAT | 452505 | .2332 |
| Macrodantin | 25mg Cap | EAT | 452491 | .1430 |
| Macrodantin | 100mg Cap | EAT | 452483 | .4104 |
| Mandelamine | 500mg Ent Tab | PDA | 499013 | .0875 |
| Mandelamine | 1000mg Ent Tab | PDA | 499021 | . 1340 |
| Marplan | 10mg Tab | HLR | 013307 | . 1490 |
| Maxeran | 10mg/2mL Inj Sol-2mL Pk | NRD | 314706 | 1.2200 |
| Maxeran | img/mL O/L | NRD | 314714 | .0242 |
| Maxeran | 5mg Tab | NRD | 572268 | .0755 |
| Maxeran | 10mg Tab | NRD | 314722 | . 1251 |
| Maxidex | 0.1% Oph Oint-3.5g Pk | ALC | 042579 | 5.0700 |
| Maxidex | 0.1% Oph Sol | ALC | 042560 | 1.3500 |
| Mazepine | 200mg Tab | ICN | 504742 | .0801 |
| Mebaral | 200mg Tab | WIN | 033715 | .2025 |
| Mebaral | 100mg Tab | WIN | 033707 | .1405 |
| Medihaler-Epi | Aero Susp-15mL Pk | RIK | 026271 | 13.0480 |
| Medihaler-Iso | Aero Susp-15mL Pk | RIK | 026301 | 11.6500 |
| Medrol | 0.25% Cr | UPJ | 031062 | .1150 |
| Medrol | 0.1% Oph Oint-3g Pk | UPJ | 358711 | 2.3500 |
| Medrol | 0.1% Oph/Ot Sol | UPJ | 030791 | .9000 |
| Medrol | 4mg Tab | UPJ | 030988 | .2485 |
| Megace | 40mg Tab | BRI | 386391 | .8170 |
| Megacillin 500 | 100,000IU/mL O/L | FRS | 009938 | .0474 |
| Megacillin 500 | 500,000IU Tab | FRS | 107484 | .0528 |
| Mellaril | 30mg/mL O/L | SAN | 027359 | .1130 |
| Mellaril | 2mg/mL O/L | SAN | 027375 | .0270 |
| Mellaril | 50mg Tab | SAN | 027545 | .1470 |
| | 3 | SAN | 027537 | .1070 |
| Mellaril | 25mg Tab | | | |
| Mellaril | 100mg Tab | SAN | 027553 | .2540 |
| Mellaril | 10mg Tab | SAN | 027529 | .0860 |
| Meprobamate | 400mg Tab | DTC | 092738 | .0127 |
| Mesantoin | 100mg Tab | SAN | 027421 | .0920 |
| Mestinon | 180mg LA Tab | HLR | 035890 | .2610 |
| Mestinon | 60mg Tab | HLR | 013404 | .1103 |
| Metamucil | Oral Pd 340g Pk | SEA | 242438 | 7.6000 |
| Metandren | 25mg Tab | CIB | 005630 | .7000 |
| Metandren | 10mg Tab | CIB | 005622 | .2790 |
| Methotrexate | 50mg/2mL Inj Sol-2mL Pk | LED | 321397 | 10.7500 . |

| Product Name | Strength & Dosage | Manuf'r | DIN | Price | |
|--------------------------|--|---------|--------|---------|--|
| Methotrexate | 5mg/2ml Inj Sol-2ml Pk | LED | 321400 | 6.2500 | |
| Methotrexate | 2.5mg Tab | LED | 014915 | .3750 | |
| Methotrexate Sodium | 20mg/2mL Inj Sol-2mL Pk | HOR | 614335 | 12.5000 | |
| Methyldopa | 500mg Tab | DIC | 456020 | .1065 | |
| Methyldopa | 250mg Tab | DTC | 456004 | .0479 | |
| Methyldopa | 125mg Tab | DIC | 456012 | .0283 | |
| Mexitil | 200mg Cap | 30E | 599964 | .4780 | |
| Mexitil | 100mg Cap | ROE | 599956 | .3570 | |
| Micatin | 2% Cr | MCN | 326968 | .3659 | |
| Micatin | 2% Lot | MCN | 471534 | .3890 | |
| Micro-K Extencaps | 8mEq LA Cap | ROB | 516244 | .0683 | |
| Micro-K-10 | 10mEq LA Cap | ROB | 632759 | .0818 | |
| Microlax | Micro Enema 4 Pk | PHD | 024848 | 4.5000 | |
| Micronor | 0.35mg Tab-28 Pk | ORT | 037605 | 8.2900 | |
| Midamor | 5mg Tab | MSD | 487805 | .2131 | |
| Milk of Magnesia | 80mg/nL O/L 450mL Pk | WAM | 036218 | 3.1500 | |
| Milk of Magnesia | 80mg/mL O/L 500mL Pk | DTC | 093807 | 2.9000 | |
| Milk of Magnesia | 300mg Tab 100 Pk | DTC | 093815 | 2.3000 | |
| Milontin | 500mg Cap | PDA | 022810 | .2034 | |
| Miltown | 400ng Tab | HOR | 013846 | .0613 | |
| Min-Ovral | 0.03mg & 0.15mg Tab-21 Pk | WYE | 300640 | 7.5500 | |
| Min-Ovral | 0.03mg & 0.15mg Tab-28 Pk | WYE | 342815 | 7.5500 | |
| Mineral Oil | 0/L 500mL Pk | DIC | 093947 | 3.8000 | |
| Minestrin 1/20 | 0.02mg & 1mg Tab-21 Pk | PDA | 315966 | 8.0000 | |
| Minestrin 1/20 | 0.02mg & lmg Tab-28 Pk | PDA | 343838 | 8.0000 | |
| Minipress | 5mg Tab | PFI | 560979 | .3280 | |
| Minipress | 2mg Tab | PFI | 560960 | .2387 | |
| Minipress | lng Tab | PFI | 560952 | . 1757 | |
| Mintezol | 500mg Chew Tab | MSD | 140228 | .7297 | |
| Miocarpine | 6% Oph Sol | CEV | 526738 | .2688 | |
| Miocarpine | 4Z Oph Sol | CEV | 527572 | . 1912 | |
| • | 27 Oph Sol | CEV | 527556 | . 1665 | |
| Miocarpine Miocarpine | 1Z Oph Sol | CEV | 527548 | . 1493 | |
| Mitomycin | Inj Pd-5mg Pk | BRI | 381799 | 60.6000 | |
| Mixtard | 1000U/10mL Inj Susp 10mL Pk | HOR | 552259 | 18.9000 | |
| Mixtard Human | 1000U/10mL Inj Susp 10mL Pk | HOR | 632694 | 18.9000 | |
| Mobenol | 500mg Tab | HOR | 013889 | .0748 | |
| Modane | 7.5mg/mL 0/L 114mL Pk | ADI | 323810 | 9.5500 | |
| Modane | 7.5mg/ml 0/L 114ml FK 75mg Tab 100 Pk | ADI | 323802 | 23.8000 | |
| Modecate | 3 | SOU | 349917 | 30.9500 | |
| Moditen Enanthate | 125mg/5ml Inj Susp-5ml Pk | SQU | 029173 | 30.8500 | |
| Moditen HCl | 125mg/5mL Inj Sol-5mL Pk | | 471518 | 9.0000 | |
| Moditen HCl | 25mg/10mL Inj Sol-10mL Pk | SQU | 245240 | .0254 | |
| | 0.5mg/mL 0/L | sou | | | |
| Moditen HCl | 5mg Tab | | 029408 | .2610 | |
| Moditen HCl | 2mg Tab | SQU | 029386 | . 1985 | |
| Moditen HCI | ing Tab | SQU | 029378 | . 1565 | |
| Moduret | 5mg & 50mg Tab | MSD | 487813 | .2641 | |
| Mogadon | 5mg Tab | HLR | 511528 | . 1095 | |
| Mogadon | 10mg Tab | HLR | 511536 | . 1635 | |
| Monistat | 2% Vag Cr | ORT | 980625 | .1976 | |
| Monistat | 100mg Vag Sup-15 Pk | ORT | 980617 | 14.9600 | |
| Monistat Derm | 2% Cr | ORT | 497797 | .3657 | |
| Monistat 3 | 400mg Vag Sup | ORT | 530999 | 4.0830 | |
| Monistat 5 | 100mg Tamp | ORT | 504203 | 2.4500 | |
| Monistat 7 | 2% Vag Cr-App | ORT | 321036 | .2606 | |
| Monistat 7 | 100mg Vag Sup-7 Pk | ORT | 387193 | 13.0500 | |
| Monotard MC (Pork) | 1000U/10mL Inj Susp 10mL Pk | N00 | 612359 | 19.9000 | |

| Product Name | Strength & Dosage | Manuf'r | DIN | Price |
|------------------------|------------------------|---------|--------|---------|
| Morphine | 15mg/mL Inj Sol-1mL Pk | AHA | 335371 | .4730 |
| Morphitec-1 | 1mg/mL O/L | TCH | 607762 | .0137 |
| Morphitec-5 | 5mg/mL O/L | TCH | 607770 | .0907 |
| Motilium | 10mg Tab | JAN | 642851 | .1900 |
| Motrin | 600mg Tab | UPJ | 484911 | .2335 |
| Motrin | 400mg Tab | UPJ | 364142 | . 1665 |
| Motrin | 300mg Tab | UPJ | 327794 | .1289 |
| Motrin | 200mg Tab | UPJ | 252409 | .1057 |
| Mucomyst | 20% Aero Sol-10mL Pk | BRI | 606235 | 5.8240 |
| Mucomyst | 20% Aero Sol-30mL Pk | BRI | 990833 | 14.2230 |
| Multipax | 50mg Cap | ROR | 557900 | .1139 |
| Multipax | 25mg Cap | ROR | 557919 | .0923 |
| Multipax | 10mg Cap | ROR | 557927 | .0613 |
| Muro Tears | Oph Sol | HCI | 544787 | .2554 |
| Muro-128 | 5% Oph Oint-3.5g Pk | HCI | 514675 | 3.7917 |
| Muro-128 | 5% Oph Sol | HCI | 514667 | .2949 |
| Murocel | 1% Oph Sol | HCI | 514705 | .2949 |
| Mustargen | Inj Pd-10mg Pk | MSD | 016063 | 5.5500 |
| - | 400mg Tab | LED | 127965 | .2310 |
| Myambutol | 3 | LED | 127957 | .0830 |
| Myambutol | 100mg Tab | UPJ | 030805 | .0550 |
| Mycifradin | 25mg/mL O/L | UPJ | 030996 | . 1755 |
| Mycifradin | 500mg Tab | UPJ | | .4320 |
| Mycifradin | 500mg/mL Top Sol | | 030813 | .1300 |
| Myciguent | 0.5% Oint | UPJ | 031070 | |
| Myclo | 10mg/g Cr | BOE | 516805 | .2597 |
| Myclo | 10mg/mL Top Sol | BOE | 516821 | |
| Myclo | 10mg/g Vag Cr-App | BOE | 516813 | .2033 |
| Myclo | 100mg Vag Tab | BOE | 516848 | 1.6111 |
| Mycostatin | 100,000U/g Cr | SQU | 029092 | . 1852 |
| Mycostatin | 100,000U/mL O/L | SQU | 248169 | .1092 |
| Mycostatin | 100,000U/g Oint | SQU | 029556 | .1852 |
| Mycostatin | 500,000V Tab | SQU | 029416 | . 1336 |
| Mycostatin | 25,000U/g Vag Cr | Sou | 295973 | .0582 |
| Mycostatin | 100,000U Vag Tab | squ | 029491 | . 1946 |
| Mydfrin | 2.5% Oph Sol | ALC | 465763 | .8064 |
| Mydrapred | 0.25% & 1% Oph Sol | ALC | 411124 | 1.8500 |
| Mylanta-2 Plain | 80mg & 80mg/mL O/L | PDA | 420646 | .0131 |
| Myleran | 2mg Tab | BWE | 004618 | .8800 |
| Myochrysine | 50mg/mL Inj Sol-1mL Pk | RPP | 025089 | 12.8576 |
| Myochrysine | 25mg/mL Inj Sol-1mL Pk | RPP | 025070 | 8.2805 |
| Myochrysine | 10mg/mL Inj Sol-1mL Pk | RPP | 025062 | 6.8280 |
| Mysoline | 250mg Tab | AYE | 002631 | .0561 |
| Mysoline | 125mg Tab | AYE | 002623 | .0419 |
| MOS | 1mg/mL O/L | ICN | 486582 | .0250 |
| MOS-5 | 5mg/mL O/L | ICN | 514217 | .0763 |
| MS Contin | 60mg LA Tab | PFR | 665150 | 1.4400 |
| MS Contin | 30mg LA Tab | PFR | 665142 | .8200 |
| MS Contin | 15mg LA Tab | PFR | 665134 | .5400 |
| MS Contin | 100mg LA Tab | PFR | 665169 | 2.2000 |
| Nadopen-V | 25mg/mL 0/L | NDA | 018635 | .0360 |
| Nadopen-V | 300mg Tab | NDA | 018740 | .0348 |
| Nadostine | 100,000U/g Cr | NDA | 288217 | .1493 |
| Nadostine | 100,000U/mL 0/L | NDA | 282219 | .0800 |
| Nadostine | 100,000U/g Oint | NDA | 288195 | . 1859 |
| | 500,000U Tab | NDA | 270113 | .0873 |
| Nadostine | | | | |
| Nadostine Nadostine | 25,000U/g Vag Cr | NDA | 288209 | .0416 |

| Product Name | Strength & Dosage | Manuf'r | DIN | Price | |
|-------------------------|---------------------------------|---------|--------|---------|--|
| Nalcrom | 100mg Cap | FIS | 500895 | .7043 | |
| Nalfon | 300mg Cap | LIL | 328642 | .2088 | |
| Nalfon | 600mg Tab | LIL | 345504 | .3828 | |
| Naphcon Forte | 0.1% Oph Sol 15mL Pk | ALC | 390283 | 7.5000 | |
| Naprosyn | 500mg Sup | SYN | 531022 | .9537 | |
| Naprosyn | 500mg Tab | SYN | 525537 | .6996 | |
| Naprosyn | 375mg Tab | SYN | 583367 | .3989 | |
| Naprosyn | 250mg Tab | SYN | 335193 | .3006 | |
| Naprosyn | 125mg Tab | SYN | 299413 | . 1817 | |
| Narcan | 0.4mg/mL Inj Sol-1mL Pk | DUP | 589020 | 6.7850 | |
| Nardil | 15mg Tab | PDA | 476552 | . 1949 | |
| Natulan | 50mg Cap | HLR | 012750 | .2933 | |
| Natural Source Laxative | Oral Pd 340g Pk | LEA | 599875 | 5.0000 | |
| Navane | 5mg Cap | PFI | 024449 | .2164 | |
| Navane | 2mg Cap | PFI | 024430 | .1259 | |
| Navane | 10mg Cap | PFI | 024457 | .2787 | |
| Naxen | 500mg Tab | SYP | 615331 | .3613 | |
| Naxen | 375mg Tab | SYP | 615323 | .2459 | |
| Naxen | 250mg Tab | SYP | 615315 | .1821 | |
| Naxen | 125mg Tab | SYP | 615307 | .0983 | |
| Nebcin | 60mg/1.5mL Inj Sol-1.5mL Pk | LIL | 375764 | 4.8230 | |
| Nebcin | 80mg/2mL Inj Sol-2mL Pk | LIL | 325449 | 5.2340 | |
| Nebcin | 80mg/2ml Inj Sol-2ml Pk | LIL | 381969 | 5.7980 | |
| Nebcin | 20mg/2mL Inj Sol-2mL Pk | LIL | 325457 | 2.5930 | |
| NegGram | 50mg/mL O/L | WIN | 036250 | .0556 | |
| NegGram | 500mg Tab | WIN | 033723 | .3361 | |
| Nemasol | 500mg Tab | ICN | 236691 | .1374 | |
| Nembutal | 100ng Cap | ABB | 000086 | . 1567 | |
| Neo-Synephrine | 0.25% Nas Sol 25mL Pk | STP | 561819 | 3.7000 | |
| Neo-Tears | 0.1% Oph Sol | BHI | 469033 | .2300 | |
| Neoloid | Emuls 115mL Pk | LED | 127922 | 8.3000 | |
| Neosporin | | | | | |
| 10000U & 5mg & 400U/g 0 | nh Oint-3.5g Pk | BWE | 522422 | 4.5000 | |
| Neosporin | P. 0111 0105 111 | 22 | J | 21000 | |
| 10000U & 2.5mg & 0.025m | g/ml Onh/Ot Sol | BWE | 601659 | .5250 | |
| Nerisone | 0.1% Cr | STI | 587826 | .2654 | |
| Nerisone | 0.1% Oily Cr | STI | 587818 | .2687 | |
| Nerisone | 0.1% Oint | STI | 587834 | .2689 | |
| Neuleptil | 5mg Cap | RPP | 024880 | .1100 | |
| Neuleptil | 10mg Cap | RPP | 024899 | . 1650 | |
| Newleptil | 10mg/mL O/L | RPP | 379301 | . 1952 | |
| Neutralca-S | 40mg & 40mg/mL O/L | DES | 261173 | .0086 | |
| Niacin | 50mg Tab | LIL | 015768 | .0286 | |
| Niacin | 100mg Tab | LIL | 015776 | .0338 | |
| Niacin-ICN | 50mg Tab | ICN | 268593 | .0108 | |
| Niacin-ICN | 100mg Tab | ICN | 268585 | .0186 | |
| Nilstat | 100,000U/g Cr | LED | 449792 | .0700 | |
| Nilstat | 100,000U/mL O/L | LED | 014850 | .0437 | |
| Nilstat | | LED | 449806 | .0783 | |
| Nilstat | 100,000U/g Oint 500,000U Tab | LED | 014974 | .0600 | |
| Nilstat | | LED | 278793 | .1770 | |
| Nilstat | 100,000U/g Vag Cr | LED | 015067 | .0900 | |
| Nipride | 100,000U Vag Tab | HLR | 336459 | 10.6750 | |
| | Inj Pd-50mg Pk | | | | |
| Nitro-Bid | 2% Oint-60g Pk | ROU | 442925 | 5.7000 | |
| Nitrofurantoin | 50mg Tab | DTC | 092800 | .0081 | |
| Nitrofurantoin | 100mg Tab | DTC | 092819 | .0098 | |
| Nitrogard-SR | 5mg LA Tab | SYN | 590746 | .2423 | |

| Product Name | Strength & Dosage | Manuf' | r DIN | Price | |
|-------------------|--------------------------|--------|--------|--------|--|
| Nitrogard-SR | 3mg LA Tab | SYN | 590738 | .1886 | |
| Nitrogard-SR | 2mg LA Tab | SYN | 590681 | .1616 | |
| Nitrogard-SR | 1mg LA Tab | SYN | 590673 | .1346 | |
| Nitroglycerin | 0.6mg SL Tab-100 Pk | LIL | 015962 | 2.3400 | |
| Nitroglycerin | 0.3mg SL Tab-100 Pk | LIL | 015954 | 2.3400 | |
| Nitrol | 2% Oint-30g Pk | ROR | 608785 | 4.8990 | |
| Nitrol | 2% Oint-60g PK | ROR | 990914 | 8,8500 | |
| Nitrong | 27 Oint-30g Pk | RPP | 525529 | 3,1200 | |
| Nitrong | 2% Oint-60g Pk | RPP | 990973 | 9.9300 | |
| Nitrostabilin | 0.6mg SL Tab-100 Pk | AHA | 003662 | 2.4500 | |
| Nitrostat | 0.6mg SL Tab-100 Pk | PDA | 990620 | 2.5600 | |
| Nitrostat | 0.3mg SL Tab-100 Pk | PDA | 037613 | 2.5600 | |
| Nizoral | 3 | JAN | 633836 | 1.3600 | |
| | 200mg Tab | SOU | 029041 | .0856 | |
| Noctec | 500mg Cap | SOU | 029327 | | |
| Noctec | 100mg/mL 0/L | • | | .0174 | |
| Nolvadex | 10mg Tab | ICI | 419052 | 1.2712 | |
| Nolvadex D | 20mg Tab | ICI | 638706 | 2.4167 | |
| Norfemac | 5% Cr | NRD | 441147 | .2267 | |
| Norfemac | 5% Oint | NRD | 441155 | .2218 | |
| Norflex | 60mg/2mL Inj Sol-2mL Pk | RIK | 171468 | 5.9827 | |
| Norflex | 100mg Tab | RIK | 171476 | .4928 | |
| Norinyl 1 + 50 | 0.05mg & 1mg Tab-21 Pk | SYN | 030333 | 7.5000 | |
| Norinyl 1 + 50 | 0.05mg & 1mg Tab-28 Pk | SYN | 340847 | 7.5000 | |
| Norinyl 1 + 80 | 0.08mg & 1mg Tab-21 Pk | SYN | 030341 | 8.5100 | |
| Norinyl 1 + 80 | 0.08mg & 1mg Tab-28 Pk | SYN | 340855 | 8.5100 | |
| Norinyl 2 | 0.1mg & 2mg Tab-21 Pk | SYN | 030368 | 8.5100 | |
| Norinyl 2 | 0.1mg & 2mg Tab-28 Pk | SYN | 340839 | 8.5100 | |
| Norlestrin 1/50 | 0.05mg & 1mg Tab-21 Pk | PDA | 024007 | 8.0000 | |
| Norlestrin 1/50 | 0.05mg & 1mg Tab-28 Pk | PDA | 340790 | 8.0000 | |
| Norlestrin 2.5/50 | 0.05mg & 2.5mg Tab-21 Pk | PDA | 024015 | 8.0000 | |
| Norlestrin 2.5/50 | 0.05mg & 2.5mg Tab-28 Pk | PDA | 340804 | 8,0000 | |
| Norpace | 150mg Cap | SEA | 396389 | .2724 | |
| Norpace | 100mg Cap | SEA | 396370 | .1923 | |
| Norpace CR | 150mg LA Tab | SEA | 584231 | .3825 | |
| Norpramin | 75mg Tab | MER | 425265 | .7480 | |
| • | 50mg Tab | MER | 353876 | .4965 | |
| Norpramin | 25mg Tab | MER | 353868 | .2499 | |
| Norpramin | | NOP | | . 1520 | |
| Novamoxin | 500mg Cap | | 406716 | | |
| Novamoxin | 250mg Cap | NOP | 406724 | .0780 | |
| Novamoxin | 50mg/mL O/L | NOP | 452130 | .0242 | |
| Novamoxin | 25mg/mL 0/L | NOP | 452149 | .0172 | |
| Novasen | 650mg Ent Tab | NOP | 229296 | .0189 | |
| Novasen | 325mg Ent Tab | NOP | 216666 | .0114 | |
| Novo-Ampicillin | 500mg Cap | NOP | 020885 | . 1200 | |
| Novo-Ampicillin | 250mg Cap | NOP | 020877 | .0620 | |
| Novo-Ampicillin | 50mg/mL O/L | NOP | 021148 | .0243 | |
| Novo-Ampicillin | 25mg/mL O/L | NOP | 021121 | .0150 | |
| Novo-C | 500mg Tab 100 Pk | NOP | 021997 | 3.9000 | |
| Novo-C | 250mg Tab 100 Pk | NOP | 021237 | 2.2000 | |
| Novo-C | 1000mg Tab 100 Pk | NOP | 535907 | 7.7000 | |
| Novo-C | 100mg Tab 100 Pk | NOP | 021970 | 1.5000 | |
| Novo-Clopate | 15mg Cap | NOP | 628212 | . 1880 | |
| Novo-Clopate | 7.5mg Cap | NOP | 628204 | .1100 | |
| Novo-Clopate | 3.75mg Cap | NOP | 628190 | .0500 | |
| Novo-Fibre | Tab 100 Pk | NOP | 595829 | 4.4000 | |
| Novo-Mucilax | Oral Pd 340g Pk | NOP | 551546 | 4.2000 | |
| | | NOP | 627097 | | |
| Novo-Naprox | 375mg Tab | AUP | 02/09/ | . 1700 | |

| Product Name | Strength & Dosage | Manuf' | r DIN | Price |
|--------------------------|-----------------------------|--------|--------|---------|
| Novo-Peridol | 5mg Tab | NOP | 363650 | .1521 |
| Novo-Spiroton | 25mg Tab | NOP | 613215 | .0729 |
| Novo-Spiroton | 100mg Tab | NOP | 613223 | .2250 |
| Novo-Spirozine | 25mg & 25mg Tab | NOP | 613231 | .0972 |
| Novobutamide | 500mg Tab | NOP | 021849 | .0180 |
| Novobutazone | 100mg Tab | NOP | 021660 | .0089 |
| Novochlorhydrate | 500mg Cap | NOP | 020893 | .0244 |
| Novochloroquine | 250mg Tab | NOP | 021261 | .0475 |
| Novochlorpromazine | 50mg Tab | NOP | 232807 | .0118 |
| Novochlorpromazine | 25mg Tab | NOP | 232823 | .0078 |
| Novochlorpromazine | 100mg Tab | NOP | 232831 | .0179 |
| Novochlorpromazine | 10mg Tab | NOP | 232157 | .0067 |
| Novocimetine | 600mg Tab | NOP | 603686 | .1481 |
| Novocimetine | 400ng Tab | NOP | 603678 | .1160 |
| Novocimetine | 300mg Tab | NOP | 582417 | .0750 |
| Novocimetine | 200mg Tab | NOP | 582409 | .0630 |
| Novocloxin | 500mg Cap | NOP | 337773 | .1470 |
| | 250mg Cap | NOP | 337765 | .0750 |
| Novocloxin | | NOP | 337757 | .0207 |
| Novocloxin | 25mg/mL 0/L | NOP | 021423 | |
| Novodimenate | 50mg Tab | | | .0060 |
| Novodipam | 5mg Tab | NOP | 272442 | .0021 |
| Novodipam | 2mg Tab | NOP | 272434 | .0021 |
| Novodipam | 10mg Tab | NOP | 272450 | .0031 |
| Novodoparil-15 | 250mg & 15mg Tab | NOP | 363642 | .0653 |
| Novodoparil-25 | 250mg & 25mg Tab | NOP | 363634 | .0674 |
| Novoferrogluc | 300mg Tab 100 Pk | NOP | 021458 | 1.7000 |
| Novoferrosulfa | 300mg Ent Tab 100 Pk | NOP | 232998 | 1.7000 |
| Novofibrate | 500mg Cap | NOP | 337382 | .0346 |
| Novof lupam | 30mg Cap | NOP | 496553 | .0317 |
| Novof Inpam | 15mg Cap | NOP | 496545 | .0278 |
| Novoflurazine | 5mg Tab | NOP | 021873 | .0070 |
| Novoflurazine | 2mg Tab | NOP | 021865 | .0050 |
| Novoflurazine | 10mg Tab | NOP | 021881 | .0116 |
| Novoflurazine | 1mg Tab | NOP | 021857 | .0045 |
| Novofolacid | 5mg Tab | NOP | 021466 | .0052 |
| Novofumar | 200mg Tab 100 Pk | NOP | 021431 | 1.7500 |
| Novofuran | 5mg/mL O/L | NOP | 232971 | .0150 |
| Novofuran | 50mg Tab | NOP | 021563 | .0080 |
| Novofuran | 100mg Tab | NOP | 021571 | .0098 |
| Novogesic | 325mg Tab | NOP | 389218 | .0107 |
| Novogesic Forte | 500mg Tab | NOP | 482323 | .0182 |
| Novohexidyl | 5mg Tab | NOP | 021938 | .0092 |
| Novohexidyl | 2mg Tab | NOP | 021911 | .0072 |
| Novohydrazide | 50mg Tab | NOP | 021482 | .0041 |
| Novohydrazide | 25mg Tab | NOP | 021474 | .0033 |
| | | NOP | 602876 | .0158 |
| Novolente-K Novolexin | SmEq LA Tab | NOP | 342114 | .2692 |
| | 500mg Cap | NOP | 342084 | . 1367 |
| Novolexin | 250mg Cap | | | |
| Novolexin | 50mg/mL O/L | NOP | 342092 | .0520 |
| Novolexin | 25mg/mL 0/L | NOP | 342106 | .0260 |
| Novolexin | 500mg Tab | NOP | 583421 | .2692 |
| Novolexin | 250mg Tab | NOP | 583413 | .1367 |
| Novolin 30/70 | 1000U/10mL Inj Susp 10mL Pk | | 650935 | 18.1000 |
| Novolin-Lente | 1000U/10mL Inj Susp 10mL Pk | | 612200 | 18.1000 |
| Novolin-NPH | 1000U/10mL Inj Susp 10mL Pk | | 612197 | 18.1000 |
| Novolin-Toronto | 1000U/10mL Inj Susp 10mL Pk | | 612189 | 18.1000 |
| Novolin-Ultralente | 1000U/10mL Inj Susp 10mL Pk | N00 | 644358 | 18.1000 |

| Product Name | Strength & Dosage | Manuf'r | DIN | Price |
|------------------------------|-------------------|---------|--------|-------|
| Novolorazem | 2mg Tab | NOP | 637750 | .0650 |
| Novolorazem | 1mg Tab | NOP | 637742 | .0400 |
| Novomedopa | 500mg Tab | NOP | 337498 | .1020 |
| Novomedopa | 250mg Tab | NOP | 337471 | .0533 |
| Novomedopa | 125mg Tab | NOP | 337463 | .0315 |
| Novomepro | 400mg Tab | NOP | 021547 | .0148 |
| Novomethacin | 50mg Cap | NOP | 337439 | .1410 |
| Novomethacin | 25mg Cap | | 337420 | .0814 |
| Novometoprol | 50mg Tab | | 648035 | .0970 |
| Novometoprol | 100mg Tab | | 648043 | .1780 |
| Novomaprox | 500mg Tab | | 589861 | .2580 |
| Novonaprox | 250mg Tab | | 565350 | .1300 |
| Novonaprox | 125mg Tab | | 565369 | .0640 |
| | 50mg Tab | | 274496 | .0083 |
| Novoniacin | 250mg Tab | | 021555 | .0237 |
| Novonidazol | | | 391603 | .0255 |
| Novopen-VK-500 | 60mg/mL O/L | | 021202 | .0300 |
| Novopen-VK-500 | 300mg Tab | | 151432 | .0305 |
| Novopen-500 | 500,000IU Tab | | | |
| Novopentobarb | 100mg Cap | **** | 020990 | .0289 |
| Novopheniram | 4mg Tab | | 021288 | .0065 |
| Novopoxide | 5mg Cap | | 020915 | .0087 |
| Novopoxide | 25mg Cap | | 020931 | .0138 |
| Novopoxide | 10mg Cap | | 020923 | .0104 |
| Novopramine | 50mg Tab | | 021520 | .0126 |
| Novopramine | 25mg Tab | NOP | 021512 | .0073 |
| Novopramine | 10mg Tab | NOP | 021504 | .0040 |
| Novopranol | 80mg Tab | NOP | 496502 | .0560 |
| Novopranol | 40mg Tab | NOP | 496499 | .0335 |
| Novopranol | 120mg Tab | NOP | 549657 | .1120 |
| Novopranol | 10mg Tab | NOP | 496480 | .0185 |
| Novoprednisone | 50mg Tab | NOP | 232378 | .0970 |
| Novoprednisone | 5mg Tab | NOP | 021695 | .0087 |
| Novoprofen | 600mg Tab | NOP | 629359 | .0737 |
| Novopropamide | 250mg Tab | NOP | 021350 | .0169 |
| Novopropoxyn | Cap | NOP | 151351 | .0225 |
| Novopurol | 300mg Tab | NOP | 363693 | .0335 |
| Novopurol | 200mg Tab | NOP | 565342 | .0270 |
| Novopurol | 100mg Tab | NOP | 364282 | .0137 |
| Novopyrazone | 200mg Tab | NOP | 475076 | .0507 |
| Novopyrazone | 100mg Tab | | 475068 | .0305 |
| Novoquinidine | 200mg Tab | | 021733 | .0539 |
| Novoquinine | 300mg Cap | | 021016 | .1197 |
| Novoquinine | 200mg Cap | | 021008 | .0904 |
| • | 9 - | | 021784 | .0081 |
| Novoreserpine | 0.25mg Tab | | 037486 | .0381 |
| Novoridazine Novoridazine | 50mg Tab | | 037494 | .0209 |
| | 25mg Tab | | 037478 | .0750 |
| Novoridazine | 100mg Tab | | | |
| Novoridazine | 10mg Tab | | 037508 | .0111 |
| Novorythro Estolate | 250mg Cap | | 020966 | .0816 |
| Novorythro Estolate | 50mg/mL O/L | | 262595 | .0341 |
| Novorythro Estolate | 25mg/mL O/L | NOP | 021172 | .0170 |
| Novorythro Ethyl Succin | | Non | 205050 | 0.475 |
| | 40mg/mL 0/L | | 605859 | .0475 |
| Novorythro Stearate | 250mg Tab | | 391581 | .0657 |
| Novosalmol | 4mg Tab | | 620963 | .0880 |
| Novosalmol | 2mg Tab | | 620955 | .0528 |
| Novosecobarb | 100mg Cap | NOP | 021032 | .0352 |

| Product Name | Strength & Dosage | Manuf' | r DIN | Price | |
|----------------------------|-----------------------------|--------|--------|---------|--|
| Novosemide | 40mg Tab | NOP | 337749 | .0069 | |
| Novosemide | 20mg Tab | NOP | 337730 | .0048 | |
| Novosorbide | 30mg Tab | NOP | 458694 | .0429 | |
| Novosorbide | 10mg Tab | NOP | 458686 | .0189 | |
| Novosoxazole | 500mg Tab | NOP | 021792 | .0280 | |
| Novotetra | 250mg Cap | NOP | 021059 | .0187 | |
| Novotetra | 25mg/mL 0/L | NOP | 151416 | .0130 | |
| Novothalidone | 50mg Tab | NOP | 337447 | .0187 | |
| Novothalidone | 100mg Tab | NOP | 337455 | .0310 | |
| Novotriamzide | 25mg & 50mg Tab | NOP | 532657 | .0390 | |
| Novotrimel | 400mg & 80mg Tab | NOP | 510637 | .0635 | |
| Novotrimel DS | 800mg & 160mg Tab | NOP | 510645 | .1230 | |
| Novotriphyl | 300mg Tab | NOP | 565377 | .0242 | |
| | 200mg Tab | NOP | 458716 | | |
| Novotriphyl Novotriphyl | 100mg Tab | NOP | 458708 | .0212 | |
| | | | | .0175 | |
| Novotriptyn | 50mg Tab | NOP | 037427 | .0115 | |
| Novotriptyn | 25mg Tab | NOP | 037419 | .0054 | |
| Novotriptyn | 10mg Tab | NOP | 037400 | .0040 | |
| Novoxapam | 30ng Tab | NOP | 496537 | .0099 | |
| Novoxapam | 15mg Tab | NOP | 496529 | .0075 | |
| Novoxapam | 10mg Tab | NOP | 500852 | .0071 | |
| Novozolamide | 250mg Tab | NOP | 488275 | .0204 | |
| Nozinan | 25mg/mL Inj Sol-1mL Pk | RPP | 025003 | 1.6820 | |
| Nozinan | 5mg/mL O/L | RPP | 025194 | .0398 | |
| Nozinan | 40mg/nL O/L | RPP | 025208 | .2907 | |
| Nozinan | 50mg Tab | RPP | 025607 | .2878 | |
| Nozinan | 5mg Tab | RPP | 025585 | .0739 | |
| Nozinan | 25mg Tab | RPP | 025593 | . 1900 | |
| Nozinan | 2mg Tab | RPP | 025577 | .0511 | |
| Numorphan | 1.5mg/mL Inj Sol-1mL Pk | DUP | 585688 | 2.1250 | |
| Numorphan | 5mg Sup | DUP | 585661 | 2.4417 | |
| Nupercainal | 1% Oint | CIB | 623385 | .0795 | |
| Nyaderm | 100,000U/g Cr | KLP | 382639 | .0950 | |
| Nyaderm | 100,000U/g Oint | KLP | 522864 | .1078 | |
| Nyaderm | 25,000U/g Vag Cr | KLP | 480819 | .0525 | |
| NPH Insulin | 1000U/10mL Inj Susp 10mL Pk | NOO | 612235 | 12,4000 | |
| Ocuclear | 0.025% Oph Sol | SCH | 543454 | .2860 | |
| Oestrilin . | 2.5mg Tab | DES | 252611 | .2100 | |
| Oestrilin | 1.25mg Tab | DES | 006297 | .1150 | |
| Oestrilin | 0.625mg Tab | DES | 006289 | .0700 | |
| Oestrilin | 0.3mg Tab | DES | 252603 | .0450 | |
| Ogen | 3mg Tab | ABB | 282677 | .3000 | |
| Ogen | 1.5mg Tab | ABB | 282685 | . 1896 | |
| Oncovin | ing/mL In; Sol | LIL | 611182 | 28.6200 | |
| One-Alpha | Imcg Cap | LEO | 474525 | .9000 | |
| One-Alpha | | LEO | | | |
| Opcon | 0.25mcg Cap | | 474517 | .3000 | |
| - | 0.1% Oph Sol 15mL Pk | HCI | 343978 | 6.7000 | |
| Opticrom Optimine | 2% Oph Sol | FIS | 394300 | 1.1470 | |
| | Ing Tab | SCH | 355666 | .1902 | |
| Orabase | Oral Top Oint | SQU | 990272 | .3453 | |
| Orap | 4mg Tab | MCN | 313823 | .3760 | |
| Orap | 2mg Tab | MCN | 313815 | .2080 | |
| Orap | 10mg Tab | MCN | 573817 | .8200 | |
| Orbenin | 500mg Cap | AYE | 002054 | .2823 | |
| Orbenin | 250mg Cap | AYE | 002046 | . 1487 | |
| Orbenin | Inj Pd-2000mg Pk | AYE | 002186 | 3.0000 | |
| Orbenin | Inj Pd-250mg Pk | AYE | 002151 | 1.2000 | |

O. Reg. 690/86

| Product Name | Strength & Dosage | Manuf' | r DIN | Price |
|---------------------------------------|---------------------------|--------|--------|---------|
| Orbenin | Inj Pd-500mg Pk | AYE | 002178 | 1.3500 |
| Orbenin | 25mg/mL O/L | AYE | 002445 | .0376 |
| Organidin | 6mg/mL 0/L | HOR | 354910 | .0161 |
| Organidin | 15mg Tab | HOR | 354902 | .0684 |
| Orinase | 500mg Tab | HOE | 012602 | .0762 |
| Ortho 0.5/35 | 0.035mg & 0.5mg Tab-21 Pk | ORT | 317047 | 7.1528 |
| Ortho 0.5/35 | 0.035mg & 0.5mg Tab-28 Pk | ORT | 340731 | 7.6400 |
| Ortho 1/35 | 0.035mg & 1mg Tab-21 Pk | ORT | 372846 | 7.1528 |
| Ortho 1/35 | 0.035mg & 1mg Tab-28 Pk | ORT | 372838 | 7.6400 |
| Ortho 10/11 | | | | |
| 0.035mg & 0.5mg + 0.035mg | ng & 1mg Tab-21 Pk | ORT | 538590 | 7.1528 |
| Ortho 10/11 | ng & 1mg Tab-28 Pk | ORT | 538582 | 7.6400 |
| 0.035mg & 0.5mg + 0.035mg Ortho 7/7/7 | 3 Phase Tab-21 Pk | ORT | 602957 | 7.1528 |
| Ortho 7/7/7 | 3 Phase Tab-28 Pk | ORT | 602965 | 7.1528 |
| Ortho-Novum 0.5 | 0.1mg & 0.5mg Tab-21 Pk | ORT | 022632 | 8.2833 |
| Ortho-Novum 1/50 | 0.05mg & 1mg Tab-21 Pk | ORT | 022608 | 7.1528 |
| Ortho-Novum 1/50 | 0.05mg & 1mg Tab-28 Pk | ORT | 340758 | 7.6400 |
| Ortho-Novum 1/80 | 0.08mg & 1mg Tab-21 Pk | ORT | 022659 | 8.2833 |
| Ortho-Novum 2 | 0.1mg & 2mg Tab-21 Pk | ORT | 022640 | 8.2833 |
| Ortho-Novum 5 | 0.075mg & 5mg Tab-21 Pk | ORT | 022616 | 12.7050 |
| Orudis | 50mg Cap | RPP | 336440 | .2467 |
| Orudis | 100mg Sup | RPP | 499544 | 1.1003 |
| Orudis E | 50mg Ent Tab | RPP | 566888 | .2467 |
| 0s-Cal 250 | 625mg Tab | AYE | 541915 | .0856 |
| 0s-Cal 500 | 1250mg Tab | AYE | 541907 | .1596 |
| Ostoforte | 50,000IU Cap | FRS | 009830 | .1697 |
| Otrivin | 0.1% Nas Sol 25mL Pk | CIB | 650854 | 3.9000 |
| Otrivin | 0.05% Nas Sol 25mL Pk | CIB | 623458 | 3.6000 |
| Ovral | 0.05mg & 0.25mg Tab-21 Pk | WYE | 034207 | 7.5500 |
| Ovral | 0.05mg & 0.25mg Tab-28 Pk | WYE | 340766 | 7.5500 |
| Ovulen 0.5 | 0.1mg & 0.5mg Tab-21 Pk | SEA | 028681 | 10.3100 |
| Ovulen 0.5 | 0.1mg & 0.5mg Tab-28 Pk | SEA | 341533 | 9.2180 |
| Ovulen 1 | 0.1mg & 1mg Tab-21 Pk | SEA | 028703 | 11.0450 |
| Ovulen 1 | 0.1mg & 1mg Tab-28 Pk | SEA | 340774 | 10.0540 |
| Oxazepam | 30mg Tab | DTC | 483907 | .0114 |
| Oxazepam | 15mg Tab | DTC | 483915 | .0087 |
| Oxazepam | 10mg Tab | DTC | 483893 | .0085 |
| Oxpam | 30mg Tab | ICN | 414263 | .0106 |
| Oxpam | 15mg Tab | ICN | 414255 | .0080 |
| Oxpam | 10mg Tab | ICN | 414247 | .0077 |
| Oxsoralen | 10mg Cap | ICN | 007269 | .4992 |
| Oxycocet | 5mg & 325mg Tab | TCH | 608165 | .1400 |
| Oxycodan | 5mg & 325mg Tab | TCH | 608157 | .1700 |
| Oxyderm | 5% Lot | ICN | 374326 | .0728 |
| Oxyderm | 20% Lot | ICN | 374318 | .0671 |
| Oxyderm | 10% Lot | ICN | 432938 | .0711 |
| P & S Liquid | 5% Top Sol 119mL Pk | DOR | 054232 | 11.7000 |
| P & S Plus Gel | 8% & 2% Top Sol 100mL Pk | DOR | 560448 | 17.2500 |
| P-50 | 100,000IU/mL O/L | HOR | 013633 | .0566 |
| P-50 | 500,000IU Tab | HOR | 116726 | .0874 |
| Pabafilm-15 | 7% & 3% Lot | ALC | 544809 | .0627 |
| Palafer . | 300mg Cap 30 Pk | BEE | 446483 | 8.7000 |
| Palafer | 60mg/mL O/L | BEE | 437018 | .0690 |
| Palafer Pediatric Drops | 60mg/mL O/L | BEE | 590630 | .1085 |
| Palaron | 21mg/mL 0/L | FIS | 379603 | .0346 |
| | | | , | |

| Pancrease 4,000 & 20,000 & 25,000 USP U Ent Microsph Cap Panectyl 10mg Tab RPP 025801 .1535 Panectyl 2.5mg Tab RPP 025801 .1535 Panectyl 2.5mg Tab RPP 025771 .1368 Panectyl 2.5mg Tab RPP 025771 .1368 Panectyl 2.5mg Tab RPP 025771 .1368 Panectyl 2.5mg Tab RPP 025771 .1368 Panectyl 2.5mg Tab RPP 025771 .1368 Panectyl 2.5mg Tab RPP 025771 .1368 Panectyl 207. Gel STI 263702 .0831 Panectyl 157. Gel STI 263809 .1060 Paraldebyde Iaj 50-15mL Pk GLA 012149 1.2740 Paraldebyde Iaj 50-15mL Pk GLA 012149 1.2740 Paraldebyde O/L 250mL Pk PDA 156493 6.2000 Paralded | Product Name | Strength & Dosage | Manuf' | - DIN | Price |
|---|---|-------------------|--------|--------|--------|
| Panectyl | | COUCH II F . M | | | |
| Panecty Sag Tab RPP 025798 .1622 Panexy 5% Gel STI 263702 .0831 Panexy 5% Gel STI 263702 .0831 Panexy 15% Gel STI 263702 .0831 Panexy 15% Gel STI 263702 .0831 Panexy 15% Gel STI 263899 .1080 Panexy 15% Gel STI 263899 .1080 Panexy 10% Gel STI 263899 .1080 Paraldehyde 1aj Sol-5mL Pk GLA 012149 1.2740 Paraldehyde 0/L AHA 002755 .0360 Paraldel 5mg Cap SAN 55843 1.1230 Paraldel 2.5mg Tab SAN 55843 1.1230 Paraltan 50mg Tab SKF 027111 .1886 Parastan 50mg Tab SKF 027111 .1886 Parastan 50mg Tab RPP 025550 .0376 Penbritin 50mg Cap AYE 002011 .2426 Penbritin 1mj Pd-1000mg Pk AYE 002117 .1850 Penbritin 1mj Pd-1000mg Pk AYE 002117 .1850 Penbritin 50mg/mL 0/L AYE 002419 .0496 Penbritin 50mg/mL 0/L AYE 002419 .0496 Penbritin 50mg/mL 0/L AYE 002410 .0279 Penglobe 800mg Tab AST 627135 .9424 Penglobe 800mg Tab AST 627135 .9424 Pengiollin G (Pot) 1mj Pd 1,000,001U-Pk AYE 002218 .1500 Pensicillin G (Pot) 1mj Pd 1,000,001U-Pk AYE 002218 .1500 Pensicillin G (Pot) 1mj Pd 1,000,001U-Pk AYE 002208 .1500 Pensicillin G (Pot) 1mj Pd 5,000,0001U-Pk AYE 002208 .1500 Pensicillin G (Pot) 1mj Pd 5,000,0001U-Pk AYE 002208 .1500 Pensicillin G (Pot) 1mj Pd 1,000,001U-Pk AYE 002208 .1500 Pensicillin G (Pot) 1mj Pd 1,000,001U-Pk AYE 002208 .1500 Pensicillin G (Pot) 1mj Pd 1,000,001U-Pk AYE 002208 .1500 Pensicillin | | | | | |
| Panexty 2.5mg Tab | | 3 | | | |
| Panoxy 5% Gel STI 263702 .0831 Panoxy 20% Gel STI 373036 .1380 Panoxy 15% Gel STI 403571 .1278 Panoxy 10% Gel STI 268899 .1060 Paraldehyde 0/L | | 9 | | | |
| Panoxy 207 Gel | | 3 | | | |
| Panoxy 157 Gel | • | | | | |
| Panoxyl | | | | | .1380 |
| Paraldebyde | | | | | .1278 |
| Paraldebyde | | | | | |
| Parlode | | • | | | |
| Parlode 2.5mg Tab | | | | | |
| Parlodel 2.5mg Tab SAN 371033 | | | | | 6.2000 |
| Parnate 10mg Tab SKF 027111 .1886 Parsitan 50mg Tab RPP 025550 .1383 Pediazole 40mg & 120mg/mL O/L ABB 583405 .0723 Pen-Vee 60mg/mL O/L WYE 034045 .0376 Pen-Vee 60mg/mL O/L WYE 034045 .0376 Pen-britin 500mg Cap AYE 002011 .2426 Penbritin 250mg Cap AYE 002003 .1213 Penbritin Inj Pd-1000mg Pk AYE 002127 1.8500 Penbritin Inj Pd-500mg Pk AYE 002127 1.8500 Penbritin 50mg/mL O/L AYE 002410 .0279 Penbritin 50mg/mL O/L AYE 002410 .0279 Penglobe 800mg Tab AST 627135 .9424 Penglobe 400mg Tab AST 627135 .9424 Penicillin G (Pot) Inj Pd 1,000,0001U-Pk AYE 002208 1.1500 Penicillin G (Pot) Inj Pd 5,000,0001U-Pk AYE 002208 1.1500 Penicillin V (Pot) 300mg Tab SAP 210714 .0338 Pentamycetin 0.25% Oph Sol BER 704588 .3900 Pentbaycetin 0.25% Oph Sol BER 704588 .3900 Pentobarbital 100mg Cap DTC 093572 .0265 Pentrax 4.3% Susp 100mL Pk SCJ 652326 8.7000 Peptol 800mg Tab BOR 584522 .1800 Peptol 400mg Tab BOR 584522 .1800 Peptol 400mg Tab BOR 584522 .1800 Peptol 200mg Tab BOR 584522 .1800 Peptol 400mg Tab BOR 584522 .1800 Peptol 400mg Tab BOR 584522 .1250 Peptol 200mg Tab BOR 58524 .1800 Peptol 500mg Tab BOR 58524 .1800 Peptol 200mg Tab BOR 58522 .1250 Percocet 5mg & 325mg Tab BOR 586449 .1425 Percodan 5mg & 325mg Tab BOR 58653 .3033 Periactin 0.4mg/mL O/L MSD 016314 .0328 Periactin 0.4mg/mL O/L MSD 016314 .0328 Periactin 4mg Tab MSD 01654 .1395 Peridol 2mg/mL O/L TCH 552135 .0415 Peridol 1mg Tab TCH 552135 .0415 Peridol 2mg/mL O/L TCH 552135 .0415 Peridol 2mg/mL O/L TCH 552429 .1980 Peridol 1mg Tab SCH 504422 .1238 Perimitil 5mg Tab SCH 504422 .1238 Permitil 5mg Tab SCH 504422 .1238 Permitil 5mg Tab DTC 456055 .0168 Perphenazine 4mg Tab DTC 456047 .0141 Perphenazine 4mg Tab DTC 456047 .0141 Perphenazine 4mg Tab DTC 456047 .0141 Perphenazine 4mg Tab DTC 456047 .0141 Perphenazine 4mg Tab DTC 456047 .0141 Perphenazine 16mg Tab DTC 456047 .0141 Perphenazine 16mg Tab DTC 456047 .0040 | | | | | 1.1230 |
| Parsitan | | | | | .6610 |
| Pediazole | * | | | | |
| Pen-Vee | | 0 | | | |
| Penbritin S00mg Cap | | 9 | | | |
| Penbritin | | 3 | | | |
| Penbritin | | | | | |
| Penbritin | | 3 : | | | |
| Penbritin SOmg/mL O/L ATE 002429 .0496 Penbritin 25mg/mL O/L ATE 002410 .0279 Penglobe 800mg Tab AST 627125 .9424 Penglobe 400mg Tab AST 627127 .4618 Penicillin G (Pot) Inj Pd 1,000,0001U-Pk ATE 002208 1.1500 Penicillin G (Pot) Inj Pd 5,000,0001U-Pk ATE 002208 1.1500 Penicillin V (Pot) 300mg Tab SAP 210714 .0338 Pentamycetin 0.25% Oph Sol BER 704588 .3900 Pentoabrital 100mg Cap DTC 093572 .0265 Pentrax 4.3% Susp 100mL Pk SCJ 652326 8.7000 Peptol 800mg Tab HOR 618616 .2406 Peptol 800mg Tab HOR 618616 .2406 Peptol 400mg Tab HOR 584282 .1800 Peptol 400mg Tab HOR 568449 .1425 Peptol 300mg Tab HOR 568449 .1425 Peptol 300mg Tab HOR 546232 .1250 Percocet 5mg & 325mg Tab HOR 546232 .1250 Percocet 5mg & 325mg Tab DUP 580201 .2612 Percodan 5mg & 325mg Tab DUP 580201 .2612 Percodan 5mg & 325mg Tab DUP 580236 .3033 Periactin 4mg Tab MSD 016314 .0328 Periactin 4mg Tab MSD 016454 .1395 Peridol 2mg/mL O/L TCH 552149 .1950 Peridol 2mg/mL O/L TCH 552143 .0715 Peridol 0.5mg Tab PDA 476699 .1017 Peritrate 20mg Tab PDA 476699 .1017 Peritrate 10mg Tab PDA 476699 .1017 Peritrate 10mg Tab PDA 476699 .1017 Peritrate 5mg Tab SCH 504459 .2022 Pernaitil 2mg Tab SCH 504459 .2022 Pernaitil 2mg Tab DTC 456035 .0168 Perphenazine 8mg Tab DTC 456039 .0132 Perphenazine 2mg Tab DTC 456039 .0132 Perphenazine 2mg Tab DTC 456039 .0132 Perphenazine 2mg Tab DTC 456039 .0132 Perphenazine 16mg Tab DTC 456039 .0132 .0806 Persa-Gel DTC GEl DTC | 1 2 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 | | | | |
| Penbritin 25mg/mL O/L | | | | | |
| Penglobe | | | | | |
| Penglobe | | | | | |
| Penicillin G (Pot) | | | | | |
| Penicillin G (Pot) | | | | | |
| Penicillin V (Pot) 300mg Tab SAP 210714 .0338 Pentamycetin 0.25% Oph Sol BER 704598 .3900 Pentobarbital 100mg Cap DTC 093572 .0265 Pentrax 4.3% Susp 100mL Pk SCJ 652326 8.7000 Peptol 800mg Tab HOR 618616 .2406 Peptol 600mg Tab HOR 584282 .1800 Peptol 400mg Tab HOR 568449 .1425 Peptol 300mg Tab HOR 568449 .1425 Peptol 200mg Tab HOR 546240 .0990 Peptol 200mg Tab HOR 546232 .1250 Percocet 5mg & 325mg Tab DUP 580201 .2612 Percodan 5mg & 325mg Tab DUP 580201 .2612 Percodan 5mg & 325mg Tab DUP 580236 .3033 Periactin 0.4mg/mL 0/L MSD 016314 .0328 Periactin 4mg Tab MSD 016454 .1395 Peridol 2mg/mL 0/L TCH 552429 .1950 Peridol 2mg/mL 0/L TCH 552135 .0415 Peridol 0.5mg Tab TCH 552135 .0415 Peritrate 20mg Tab PDA 476609 .1017 Peritrate 10mg Tab PDA 476579 .1908 Peritrate Forte 80mg Tab PDA 476579 .1908 Permitil 2mg Tab SCH 504432 .1238 Permitil 2mg Tab SCH 504432 .1238 Permitil 2mg Tab DTC 456055 .0168 Perphenazine 8mg Tab DTC 456035 .0163 Perphenazine 2mg Tab DTC 456035 .0163 Perphenazine 2mg Tab DTC 456035 .0163 Perphenazine 2mg Tab DTC 456035 .0132 Perphenazine 16mg Tab DTC 456035 .0132 Perphenazine 16mg Tab DTC 481920 .0338 Persa-Gel 5% Gel ORT 530190 .0806 Persa-Gel 0% TG 50204 .0851 | | | | | |
| Pentamycetin 0.25% Oph Sol BER 704598 .3900 Pentobarbital 100mg Cap DTC 093572 .0265 Pentrax 4.3% Susp 100mL Pk SCJ 652326 8.7000 Peptol 800mg Tab HOR 618616 .2406 Peptol 600mg Tab HOR 584282 .1800 Peptol 400mg Tab HOR 568449 .1425 Peptol 300mg Tab HOR 546240 .0900 Peptol 200mg Tab HOR 546240 .0900 Peptol 200mg Tab HOR 546240 .0900 Peptol 200mg Tab HOR 546232 .1250 Percocet 5mg & 325mg Tab DUP 580201 .2612 Percocet 5mg & 325mg Tab DUP 580201 .2612 Percocat 5mg & 325mg Tab DUP 580201 .2612 Percocat 5mg & 325mg Tab DUP 580201 .2612 Peridol 7mg Ta | | | | | |
| Pentobarbital 100mg Cap | | 9 | | | |
| Pentrax 4.3% Susp 100mL Pk SCJ 652326 8.7000 Peptol 800mg Tab HOR 618616 .2406 Peptol 600mg Tab HOR 584282 .1800 Peptol 400mg Tab HOR 568449 .1425 Peptol 300mg Tab HOR 546240 .0900 Peptol 200mg Tab HOR 546232 .1250 Percocet 5mg & 325mg Tab DUP 580201 .2612 Percocet 5mg & 325mg Tab DUP 580201 .2612 Percodan 5mg & 325mg Tab DUP 580236 .3033 Periactin 0.4mg/mL O/L MSD 016454 .1395 Periactin 4mg Tab MSD 016454 .1395 Peridol 2mg/mL O/L TCH 552429 .1950 Peridol 2mg/mL O/L TCH 552143 .0715 Peridol 1mg Tab TCH 552143 .0715 Peridol 0.5mg Tab TCH 552135 .0415 Peritrate 20mg Tab PDA 476595 .0740 Peritrate 20mg Tab <td></td> <td></td> <td></td> <td></td> <td></td> | | | | | |
| Peptol 800mg Tab HOR 618616 .2406 Peptol 600mg Tab HOR 584282 .1800 Peptol 400mg Tab HOR 568449 .1425 Peptol 300mg Tab HOR 568240 .0900 Peptol 200mg Tab HOR 546232 .1250 Percocet 5mg & 325mg Tab DUP 580201 .2612 Percodan 5mg & 325mg Tab DUP 580236 .3033 Periactin 0.4mg/ml O/L MSD 016314 .0328 Periactin 4mg Tab MSD 016454 .1395 Peridol <td></td> <td>3 1</td> <td></td> <td></td> <td></td> | | 3 1 | | | |
| Peptol 600mg Tab HOR 584282 .1800 Peptol 400mg Tab HOR 568449 .1425 Peptol 300mg Tab HOR 546240 .0900 Peptol 200mg Tab HOR 546232 .1250 Percocet 5mg & 325mg Tab DUP 580201 .2612 Percodan 5mg & 325mg Tab DUP 580236 .3033 Periactin 0.4mg/mL O/L MSD 016314 .0328 Periactin 4mg Tab MSD 016454 .1395 Periactin 4mg Tab MSD 016454 .1395 Peridol 2mg/mL O/L TCH 552429 .1950 Peridol 0.5mg Tab TCH 552143 .0715 Peridol 0.5mg Tab TCH <td></td> <td></td> <td></td> <td></td> <td></td> | | | | | |
| Peptol 400mg Tab HOR 568449 .1425 Peptol 300mg Tab HOR 546240 .0900 Peptol 200mg Tab HOR 546232 .1250 Percocet 5mg & 325mg Tab DUP 580236 .3033 Percocat 5mg & 325mg Tab DUP 580236 .3033 Periactin 0.4mg/mL O/L MSD 016314 .0328 Periactin 4mg Tab MSD 016454 .1395 Periactin 2mg Tab TCH 552129 .1950 Periactin 1mg Tab TCH 552135 .0415 Periactin 2mg Tab PDA | | | | | |
| Peptol 300mg Tab HOR 546240 .0900 Peptol 200mg Tab HOR 546232 .1250 Percocet 5mg & 325mg Tab DUP 580231 .2612 Percodan 5mg & 325mg Tab DUP 580236 .3033 Periactin 0.4mg/mL O/L MSD 016314 .0328 Periactin 4mg Tab MSD 016454 .1395 Peridol 2mg/mL O/L TCH 552429 .1950 Peridol 2mg/mL O/L TCH 552429 .1950 Peridol 1mg Tab TCH 552143 .0715 Peridol 0.5mg Tab TCH 552135 .0415 Peritrate 20mg Tab PDA 476509 .1017 Peritrate 10mg Tab PDA <td>•</td> <td>3</td> <td></td> <td></td> <td></td> | • | 3 | | | |
| Peptol 200mg Tab HOR 546232 .1250 Percocet 5mg & 325mg Tab DUP 580201 .2612 Percodan 5mg & 325mg Tab DUP 580201 .2612 Percodan 5mg & 325mg Tab DUP 580206 .3033 Periactin 0.4mg/mL O/L MSD 016314 .0328 Periactin 4mg Tab MSD 016454 .1395 Peridol 2mg/mL O/L TCH 552429 .1950 Peridol 1mg Tab TCH 552143 .0715 Peridol 0.5mg Tab PDA 476509 .1017 Peridol 0.5mg Tab P | - | 3 | | | |
| Percocet 5mg & 325mg Tab DUP 580201 .2612 Percodan 5mg & 325mg Tab DUP 580236 .3033 Periactin 0.4mg/mL O/L MSD 016314 .0328 Periactin 4mg Tab MSD 016454 .1395 Periactin 4mg Tab MSD 016454 .1395 Peridol 2mg/mL O/L TCH 552429 .1950 Peridol 1mg Tab TCH 552143 .0715 Peridol 0.5mg Tab TCH 552135 .0415 Peridol 0.5mg Tab PDA 476609 .1017 Peritrate 20mg Tab PDA 476609 .1017 Peritrate 10mg Tab PDA 476575 .0740 Peritrate 30mg Tab PDA 476575 .1908 Permitil 5mg Tab SCH 504459 .2022 Permitil 2mg Tab SCH 504432 .1238 Permitil 1mg Tab SCH <td></td> <td></td> <td></td> <td></td> <td></td> | | | | | |
| Percodan 5mg & 325mg Tab DUP 580236 .3033 Periactin 0.4mg/mL O/L MSD 016314 .0328 Periactin 4mg Tab MSD 016454 .1395 Periactin 4mg Tab MSD 016454 .1395 Peridol 2mg/mL O/L TCH 552429 .1950 Peridol 1mg Tab TCH 552143 .0715 Peridol 0.5mg Tab TCH 552135 .0415 Peridol 0.5mg Tab PDA 476609 .1017 Peritrate 20mg Tab PDA 476595 .0740 Peritrate 10mg Tab PDA 476595 .0740 Peritrate 8mg Tab PDA 476595 .0740 Peritrate 8mg Tab PDA 476595 .0740 Permitil 5mg Tab SCH 504459 .2022 Permitil 2mg Tab SCH 504432 .1238 Permitil 1mg Tab SCH | | 2 | | | |
| Periactin 0.4mg/mL O/L MSD 016314 0328 Periactin 4mg Tab MSD 016454 1395 Peridol 2mg/mL O/L TCH 552429 1950 Peridol 1mg Tab TCH 552143 0715 Peridol 0.5mg Tab TCH 552135 0415 Peridol 0.5mg Tab PDA 476609 1017 Peritrate 20mg Tab PDA 476595 0740 Peritrate Forte 80mg Tab PDA 476579 1908 Permitil 5mg Tab SCH 504459 2022 Permitil 2mg Tab SCH 504432 1238 Permitil 1mg Tab SCH 504424 0894 Perphenazine 8mg Tab DTC 456055 0168 Perphenazine 4mg Tab DTC 456047 0141 Perphenazine 2mg Tab DTC 456047 0141 Perphenazine 2mg Tab DTC 456039 0132 Perphenazine 2mg Tab DTC 456039 00132 Perphenazi | | 9 | | | |
| Periactin 4mg Tab MSD 016454 .1395 Peridol 2mg/mL O/L TCH 552429 .1950 Peridol 1mg Tab TCH 552143 .0715 Peridol 0.5mg Tab TCH 552135 .0415 Peridol 0.5mg Tab PDA 476609 .1017 Peritrate 10mg Tab PDA 476595 .0740 Peritrate Forte 80mg Tab PDA 476579 .1908 Permitil 5mg Tab SCH 504459 .2022 Permitil 2mg Tab SCH 504432 .1238 Permitil 1mg Tab SCH 504432 .1238 Permitil 1mg Tab SCH 504432 .1238 Permitil 1mg Tab SCH 504432 .0338 Perphenazine 8mg Tab DTC 456055 .0168 Perphenazine 4mg Tab DTC 456047 .0141 Perphenazine 16mg Tab DTC | | 9 | | | |
| Peridol 2mg/mL O/L TCH 552429 .1950 Peridol 1mg Tab TCH 552143 .0715 Peridol 0.5mg Tab TCH 552135 .0415 Peritrate 20mg Tab PDA 476699 .1017 Peritrate 10mg Tab PDA 476595 .0740 Peritrate Forte 80mg Tab PDA 476579 .1908 Pernitil 5mg Tab SCH 504459 .2022 Permitil 2mg Tab SCH 504432 .1238 Permitil 1mg Tab SCH 504424 .0894 Perphenazine 8mg Tab DTC 456055 .0163 Perphenazine 4mg Tab DTC 456047 .0141 Perphenazine 2mg Tab DTC 456039 .0132 Perphenazine 16mg Tab DTC 481920 .0338 Persa-Gel 5% Gel 0RT 530190 .0806 Persa-Gel 10% Gel 0RT 530204 .0851 | | | | | |
| Peridol lmg Tab TCH 552143 .0715 Peridol 0.5mg Tab TCH 552135 .0415 Peridol 0.5mg Tab PDA 476609 .1017 Peritrate 20mg Tab PDA 476599 .0740 Peritrate Forte 80mg Tab PDA 476579 .1908 Permitil 5mg Tab SCH 504459 .2022 Permitil 2mg Tab SCH 504432 .1238 Permitil 1mg Tab SCH 504424 .0894 Perphenazine 8mg Tab DTC 456055 .0168 Perphenazine 4mg Tab DTC 456047 .0141 Perphenazine 2mg Tab DTC 456047 .0141 Perphenazine 2mg Tab DTC 456039 .0132 Perphenazine 16mg Tab DTC 456039 .0338 Persa-Gel 5% Gel ORT 530190 .0806 Persa-Gel 10% Gel ORT <td></td> <td>3</td> <td></td> <td></td> <td></td> | | 3 | | | |
| Peridol 0.5mg Tab TCH 552135 .0415 Peritrate 20mg Tab PDA 476609 .1017 Peritrate 10mg Tab PDA 476595 .0740 Peritrate 80mg Tab PDA 476579 .1908 Permitil 5mg Tab SCH 504459 .2022 Permitil 2mg Tab SCH 504432 .1238 Permitil 1mg Tab SCH 504424 .0894 Perphenazine 8mg Tab DTC 456055 .0168 Perphenazine 4mg Tab DTC 456047 .0141 Perphenazine 2mg Tab DTC 456039 .0132 Perphenazine 2mg Tab DTC 456039 .0132 Perphenazine 16mg Tab DTC 456039 .0338 Persa-Gel 5% Gel ORT 530190 .0806 Persa-Gel 10% Gel ORT 530204 .0851 | | 3 | | | |
| Peritrate 20mg Tab PDA 476609 .1017 Peritrate 10mg Tab PDA 476595 .0740 Peritrate 80mg Tab PDA 476595 .1908 Permital 5mg Tab SCH 504459 .2022 Permitil 2mg Tab SCH 504432 .1238 Permitil 1mg Tab SCH 504424 .0894 Perphenazine 8mg Tab DTC 456055 .0168 Perphenazine 4mg Tab DTC 456047 .0141 Perphenazine 2mg Tab DTC 456039 .0132 Perphenazine 16mg Tab DTC 456039 .0132 Perphenazine 16mg Tab DTC 431920 .0338 Persa-Gel 5% Gel ORT 530190 .0806 Persa-Gel 10% Gel ORT 530204 .0851 | | 9 | | | |
| Peritrate 10mg Tab PDA 476595 .0740 Peritrate Forte 80mg Tab PDA 476579 .1908 Permitil 5mg Tab SCH 504459 .2022 Permitil 2mg Tab SCH 504432 .1238 Permitil 1mg Tab SCH 504424 .0894 Perphenazine 8mg Tab DTC 456055 .0168 Perphenazine 4mg Tab DTC 456047 .0141 Perphenazine 2mg Tab DTC 456039 .0132 Perphenazine 16mg Tab DTC 481920 .0338 Persa-Gel 5% Gel ORT 530190 .0806 Persa-Gel 10% Gel ORT 530204 .0851 | | 3 | | | |
| Peritrate Forte 80mg Tab PDA 476579 .1908 Permitil 5mg Tab 5CH 504459 .2022 Permitil 2mg Tab 5CH 504432 .1238 Permitil 1mg Tab 5CH 504424 .0894 Perphenazine 8mg Tab DTC 456055 .0168 Perphenazine 4mg Tab DTC 456047 .0141 Perphenazine 2mg Tab DTC 456039 .0132 Perphenazine 16mg Tab DTC 481920 .0338 Persa-Gel 5% Gel ORT 530190 .0806 Persa-Gel 10% Gel ORT 530204 .0851 | | 3 | | | |
| Permitil 5mg Tab SCH 504459 .2022 Permitil 2mg Tab SCH 504432 .1238 Permitil 1mg Tab SCH 504424 .0894 Perphenazine 8mg Tab DTC 456055 .0163 Perphenazine 4mg Tab DTC 456047 .0141 Perphenazine 2mg Tab DTC 456039 .0132 Perphenazine 16mg Tab DTC 481920 .0338 Persa-Gel 5% Gel ORT 530190 .0806 Persa-Gel 10% Gel ORT 530204 .0851 | Peritrate Forte | 3 | | | |
| Permitil 2mg Tab SCH 504432 .1238 Permitil 1mg Tab SCH 504424 .0894 Perphenazine 8mg Tab DTC 456055 .0168 Perphenazine 4mg Tab DTC 456047 .0141 Perphenazine 2mg Tab DTC 456039 .0132 Perphenazine 16mg Tab DTC 481920 .0338 Persa-Gel 5Z Gel ORT 530190 .0806 Persa-Gel 10Z Gel ORT 530204 .0851 | Permitil | | | | |
| Permitil lmg Tab SCH 504424 .0894 Perphenazine 8mg Tab DTC 456055 .0168 Perphenazine 4mg Tab DTC 456047 .0141 Perphenazine 2mg Tab DTC 456039 .0132 Perphenazine 16mg Tab DTC 481920 .0338 Persa-Gel 5% Gel ORT 530190 .0806 Persa-Gel 10% Gel ORT 530204 .0851 | Permitil | | SCH | 504432 | |
| Perphenazine Smg Tab DTC 456055 .0168 Perphenazine 4mg Tab DTC 456047 .0141 Perphenazine 2mg Tab DTC 456039 .0132 Perphenazine 16mg Tab DTC 481920 .0338 Persa-Gel 5% Gel ORT 530190 .0806 Persa-Gel 10% Gel ORT 530204 .0851 | Permitil | | | | |
| Perphenazine 4mg Tab DTC 456047 .0141 Perphenazine 2mg Tab DTC 456039 .0132 Perphenazine 16mg Tab DTC 481920 .0338 Persa-Gel 5% Gel ORT 530190 .0806 Persa-Gel 10% Gel ORT 530204 .0851 | Perphenazine | 9 | DTC | 456055 | .0168 |
| Perphenazine 2mg Tab DTC 456039 .0132 Perphenazine 16mg Tab DTC 481920 .0338 Persa-Gel 5% Gel ORT 530190 .0806 Persa-Gel 10% Gel ORT 530204 .0851 | Perphenazine | 9 | DTC | 456047 | .0141 |
| Perphenazine 16mg Tab DTC 481920 .0338 Persa-Gel 5% Gel 0RT 530190 .0806 Persa-Gel 10% Gel 0RT 530204 .0851 | Perphenazine | | DTC | 456039 | .0132 |
| Persa-Gel 5% Gel ORT 530190 .0806 Persa-Gel 10% Gel ORT 530204 .0851 | Perphenazine | | DTC | 481920 | .0338 |
| | Persa-Gel | | ORT | 530190 | .0806 |
| Pertofrane 25mg Tab GEI 010448 .2830 | | 10% Gel | ORT | 530204 | .0851 |
| | Pertofrane | 25mg Tab | GEI | 010448 | .2830 |

| Product Name | Strength & Dosage | Manuf'ı | - DIN | Price |
|------------------------|---------------------------------|---------|--------|---------|
| Pethidine | 50mg Tab | AHA | 003506 | .0742 |
| Phenazine | 8mg Tab | ICN | 294799 | .0185 |
| Phenazine | 4mg Tab | ICN | 296317 | .0150 |
| Phenazine | 2mg Tab | ICN | 296309 | .0133 |
| Phenazine | 16mg Tab | ICN | 294802 | .0291 |
| Phenazo | 200mg Tab | ICN | 454583 | .1048 |
| Phenazo | 100mg Tab | ICN | 271489 | .0629 |
| Phenergan | 50mg/2mL Inj Sol-2mL Pk | RPP | 025046 | 1.0483 |
| Phenergan | 2mg/mL O/L | RPP | 025429 | .0195 |
| Phenergan | 12.5mg Sup | RPP | 025380 | .6222 |
| Phenergan | 25mg Tab | RPP | 213896 | .0717 |
| Phenergan | 10mg Tab | RPP | 025712 | .0687 |
| Phenobarbital | 4mg/mL O/L | DTC | 588180 | .0107 |
| Phenobarbital | 4mg/mL O/L | SAN | 604585 | .0140 |
| Phenobarbital | 60mg Tab | PDA | 023817 | .0154 |
| Phenobarbital | 60mg Tab | DTC | 093556 | .0110 |
| Phenobarbital | 30mg Tab | PDA | 023809 | .0089 |
| Phenobarbital | 30mg Tab | DTC | 023503 | .0050 |
| Phenobarbital | 30mg Tab | SAN | 604550 | |
| Phenobarbital | | PDA | 023795 | .0080 |
| | 15mg Tab | DTC | | .0070 |
| Phenobarbital | 15mg Tab | | 093505 | .0044 |
| Phenobarbital | 15mg Tab | SAN | 604542 | .0070 |
| Phenobarbital | 100mg Tab | DTC | 093564 | .0137 |
| Phenobarbital | 100mg Tab | SAN | 604577 | .0180 |
| Phenobarbital-ICN | 60mg Tab | ICN | 320714 | .0150 |
| Phenobarbital-ICN | 30mg Tab | ICN | 293903 | .0080 |
| Phenobarbital-ICN | 15mg Tab | ICN | 271276 | .0062 |
| Phenobarbital-ICN | 100mg Tab | ICN | 344036 | .0177 |
| Phenylbutazone. | 100mg Tab | DTC | 093041 | .0077 |
| PhisoHex | 3% Top Emuls | WIN | 205389 | .0393 |
| Phospholine Iodide | 0.25% Oph Sol | AYE | 002348 | 3.2460 |
| Phospholine Iodide | 0.125% Oph Sol | AYE | 002313 | 2.8660 |
| Phospholine Iodide | 0.06% Oph Sol | AYE | 052817 | 2.4980 |
| Phyllocontin | 225mg LA Tab | PFR | 491179 | .1465 |
| Phyllocontin-350 | 350mg LA Tab | PFR | 593230 | .1865 |
| Pilopine HS | 4% Oph Gel | ALC | 575240 | 2.1280 |
| Piportil L4 | 50mg/mL Inj Sol-1mL Pk | RPP | 990507 | 14.4733 |
| Piportil L4 | 25mg/mL Inj Sol-1mL Pk | RPP | 427918 | 8.5333 |
| Piportil L4 | 100mg/2mL Inj Sol-2mL Pk | RPP | 427926 | 23.5600 |
| Plaquenil | 200mg Tab | WIN | 033669 | .2740 |
| Polaramine | 0.4mg/mL 0/L | SCH | 225533 | .0249 |
| Polaramine | 2mg Tab | SCH | 028207 | .0936 |
| Poly-Vi-Sol | Ped O/L 50mL Pk | MJO | 477583 | 13.7000 |
| Polysporin | | | | |
| 10,000U & 500U/g Oph (| Dint-3.5g Pk | BWE | 299219 | 2.9400 |
| Polysporin | 10,000U & 0.025mg/mL Oph/Ot Sol | BWE | 035343 | .3120 |
| Polytar | 1% Shampoo 150mL Pk | STI | 249866 | 5.4500 |
| Pondocillin | 32.4mg/mL O/L | LEO | 582239 | .0884 |
| Pondocillin | 500mg Tab | LEO | 582247 | .4720 |
| Ponstan | 250mg Cap | PDA | 155225 | .3395 |
| Pontocaine | 1% Cr | WIN | 205451 | .2376 |
| Potassium Chloride | 20mEq/10mL Inj Sol-10mL Pk | SOU | 511978 | .7390 |
| Potassium-Rougier | 1.33mEq/mL O/L | ROG | 026700 | .0157 |
| Potassium-Sandoz | 12mEq Eff Tab | SAN | 027596 | .1994 |
| Pred Forte | 1% Oph Sol | ALL | 301175 | 1.0200 |
| Pred Mild | 0.12% Oph Sol | ALL | 299405 | .9240 |
| Prednisone | | DTC | 093629 | .0097 |

| Product Name | Strength & Dosage | Manuf' | r DIN | Price | |
|------------------------|-----------------------------|--------|--------|---------|--|
| Prednisone | 5mg Tab | SAP | 232092 | .0099 | |
| Prednisone | 5mg Tab | KNR | 610623 | .0090 | |
| Prefrin | 0.12% Oph Sol | ALL | 395161 | .2834 | |
| Premarin | 2.5mg Tab | AYE | 002593 | .3233 | |
| Premarin | 1.25mg Tab | AYE | 002585 | .1513 | |
| Premarin | 0.625mg Tab | AYE | 002577 | .0911 | |
| Premarin | 0.3mg Tab | AYE | 002569 | .0617 | |
| Premarin | 0.625mg/g Vag Cr | AYE | 002089 | .2478 | |
| Presun 15 Creamy | 8% & 3.3% Lot | WSD | 539856 | .0372 | |
| Pro-Banthine | 15mg Tab | SEA | 028592 | .1467 | |
| Pro-Banthine | 7.5mg Tab | SEA | 028584 | . 1366 | |
| Procan SR | 750ng LA Tab | PDA | 638684 | .4501 | |
| Procan SR | 500mg LA Tab | PDA | 638676 | .3333 | |
| Procan SR | 250mg LA Tab | PDA | 638692 | .1818 | |
| Procyclid | 0.5mg/mL 0/L | ICN | 485012 | .0162 | |
| Procyclid | 5mg Tab | ICN | 306290 | .0226 | |
| Procytox | Inj Pd-1000ng Pk | HOR | 013552 | 10.8500 | |
| Procytox | Inj Pd-200mg Pk | HOR | 013544 | 4.6500 | |
| Procytox | 50mg Tab | HOR | 013749 | .3527 | |
| Procytox | 25mg Tab | HOR | 262676 | .2730 | |
| Prodiem Plain | Gran 100g Pk | ROR | 536695 | 4.6000 | |
| Proloid | 125mg Tab | PDA | 483559 | .0535 | |
| Proloid | 60mg Tab | PDA | 483540 | .0382 | |
| Proloid | 30mg Tab | PDA | 483583 | .0339 | |
| Prolopa 100-25 | 100mg & 25mg Cap | HLR | 386464 | .2995 | |
| Prolopa 200-50 | 200mg & 50mg Cap | HLR | 386472 | .5000 | |
| Prolopa 50-12.5 | 50mg & 12.5mg Cap | HLR | 522597 | .1820 | |
| Proloprim | 200mg Tab | BWE | 677590 | .4000 | |
| Proloprim | 100mg Tab | BWE | 675229 | . 1870 | |
| Promazine | 50mg Tab | DTC | 093599 | .0449 | |
| Promazine | 25mg Tab | DTC | 093580 | .0358 | |
| Pronestyl | 500mg Cap | SOU | 353523 | .3440 | |
| Pronestyl | 375mg Cap | SQU | 296031 | .2585 | |
| Pronestyl | 250mg Cap | SOU | 029076 | . 1726 | |
| Pronestyl | 100mg/10mL Inj Sol-10mL Pk | SQU | 029181 | 7.6000 | |
| Pronestyl SR | 500mg LA Tab | SQU | 639885 | .3450 | |
| Propaderm | 0.025% Cr | AHA | 002712 | . 1207 | |
| Propaderm | 0.025% Lot | AHA | 270466 | .2792 | |
| Propaderm | 0.025% Oint | AHA | 003697 | .1207 | |
| Propanthel | 15mg Tab | ICN | 294837 | .0225 | |
| Propine | 0.1% Oph Sol | ALL | 529117 | 1.3574 | |
| Propranolol | 80mg Tab | DTC | | | |
| Propranolol | 40mg Tab | DTC | 523380 | .0612 | |
| Propranolol | 10mg Tab | DTC | 523399 | .0372 | |
| Propyl-Thyracil | 50mg Tab | FRS | 523402 | .0202 | |
| Propyl-Thyracil | 100mg Tab | | 010200 | .0865 | |
| Prostaphlin | 3 | FRS | 010219 | . 1354 | |
| Prostigmin | Inj Pd-500mg Pk | BRI | 004111 | 4.0150 | |
| Prostigmin | 0.5mg/mL Inj Sol-1mL Pk | HLR | 012955 | .6496 | |
| Protamine Zinc Insulin | 15mg Tab | HLR | 013382 | .1058 | |
| Protaphane MC (Pork) | 1000U/10mL Inj Susp 10mL Pk | N00 | 612219 | 12.4000 | |
| Provera | 1000U/10mL Inj Susp 10mL Pk | N00 | 612170 | 19.9000 | |
| rovera | 5mg Tab | UPJ | 030937 | . 1975 | |
| | 100mg Tab | UPJ | 030945 | .9310 | |
| Proviodine | 10% Top Sol | ROG | 172944 | .0060 | |
| Proviodine | 10% Vag Gel | ROG | 026611 | .0564 | |
| Proviodine | 10% Vag Sol | ROG | 252824 | .0209 | |
| Purinethol | 50mg Tab | B₩E | 004723 | 1.2800 | |

| Product Name | Strength & Dosage | Manuf'ı | DIN | Price |
|---------------------|-------------------------------------|------------|------------------|---------|
| Purinol | 300mg Tab | HOR | 415766 | .0530 |
| Purinol | 200mg Tab | HOR | 415758 | .0440 |
| Purinol | 100mg Tab | HOR | 415731 | .0190 |
| Pyribenzamine | 50mg Tab | CIB | 623504 | .0800 |
| Pyridium | 200mg Tab | PDA | 476722 | .2154 |
| Pyridium | 100mg Tab | PDA | 476714 | .1291 |
| PMS-Dimenhydrinate | 50mg Tab | PMS | 586331 | ,0448 |
| PMS-Dopazide-15 | 250mg & 15mg Tab | PMS | 584967 | .0649 |
| PMS-Dopazide-25 | 250mg & 25mg Tab | PMS | 584975 | .0671 |
| PMS-Metronidazole | 250mg Tab | PMS | 584339 | .0255 |
| PMS-Promethazine | 2mg/mL O/L | PMS | 583979 | .0179 |
| PMS-Propranolol | 80mg Tab | PMS | 582271 | .0700 |
| | 40mg Tab | PMS | 582263 | .0380 |
| PMS-Propranolol | 120mg Tab | PMS | 582298 | . 1300 |
| PMS-Propranolol | 10mg Tab | PMS | 582255 | .0210 |
| PMS-Propranolol | | PMS | | |
| PMS-Sulfasalazine | 500mg Tab | PMS | 598461 | .0945 |
| PMS-Theophylline | 5.3mg/mL O/L | | 575151 | .0094 |
| PMS-Thioridazine | 50mg Tab | PMS | 575135 | .0546 |
| PMS-Thioridazine | 25mg Tab | PMS | 575127 | .0286 |
| PMS-Thioridazine | 100mg Tab | PMS | 575143 | .1016 |
| PMS-Thioridazine | 10mg Tab | PMS | 575119 | .0167 |
| PVF 500 | 60mg/mL O/L | FRS | 248835 | .0463 |
| PVF-K 500 | 300mg Tab | FRS | 248843 | .0680 |
| Questran | 440mg/g Oral Pd-378g Pk | BRI | 634093 | 22.9446 |
| Questran | 440mg/g Oral Pd 9g Pouch Pk | BRI | 464880 | .7353 |
| Quibron-T | 10mg/mL O/L | BRI | 547115 | .0294 |
| Quibron-T | 300mg Tab | BRI | 521736 | .1623 |
| Quibron-T/SR | 300mg LA Tab | BRI | 556742 | .1890 |
| Quide | 50mg Tab | MER | 279447 | .3036 |
| Quide | 10mg Tab | MER | 037370 | . 1265 |
| Quinaglute-Duratabs | 324mg LA Tab | BER | 704644 | .5765 |
| Quinate | 325mg Tab | ROG | 311731 | .2960 |
| Quinidex Extentabs | 300mg LA Tab | ROB | 346837 | .3000 |
| Quinidine | 200mg Tab | AHA | 003611 | .1550 |
| Quinidine | 200mg Tab | BWE | 004782 | . 1270 |
| Quinidine | 200mg Tab | PDA | 023868 | .1884 |
| Quinidine | 200mg Tab | ROG | 026883 | .0540 |
| Quinidine | 200mg Tab | DTC | 094412 | . 0554 |
| Quinine | 300mg Cap | DTC | 093750 | .1249 |
| Quinine Sulfate | 200mg Cap | DTC | 093742 | .0779 |
| Radiostol | 50,000IU Cap | AHA | 002690 | .2470 |
| Raudixin | 50mg Tab | SOU | 029440 | . 1830 |
| Raudixin | 100mg Tab | SOU | 029459 | .2980 |
| Reflocheck | Strip-100 Pk | BOM | 980706 | 39.6000 |
| Reglan | 10mg/2mL Inj Sol-2mL Pk | ROB | 386006 | 1.3160 |
| Reglan | 1mg/mL O/L | ROB | 386022 | .0280 |
| Reglan | 5mg Tab | ROB | 631671 | .0857 |
| Reglan | 10mg Tab | ROB | 386014 | . 1250 |
| Regulex | 100mg Cap 100 Pk | AYE | 472166 | 8.3000 |
| | | DTC | 093238 | .0176 |
| Reserpine | 0.25mg Tab | DTC | | |
| Reserpine | 0.1mg Tab | | 093211 | .0197 |
| Resphid | 500mg LA Tab | BOE | 574945 | .2453 |
| Resphid | 250mg LA Tab | BOE | 574937 | .1690 |
| Restoril | 30mg Cap | SAN | 604461 | .1500 |
| Restoril | I mad I on | SAN | 604453 | . 1300 |
| | 15mg Cap | | | |
| Revit Rhinalar | Tab 120 Pk 0.025% Nas Sp-25mL Pk | ICN SYP | 629022 421456 | 9.2000 |

| Product Name | Strength & Dosage | Manuf'r | DIN | Price |
|-----------------------|-------------------------|---------|--------|---------|
| Ridaura | 3mg Cap | SKF | 600733 | 1.1000 |
| Rifadin | 300mg Cap | MER | 249483 | .8700 |
| Rifadin | 150mg Cap | MER | 249475 | .5529 |
| Rimactane | 300mg Cap | CIB | 210463 | .9350 |
| Rimactane | 150mg Cap | CIB | 210471 | .5940 |
| Rimifon | 100mg Tab | HLR | 013323 | .0279 |
| Riopan | 480mg Chew Tab | AYE | 571229 | .0521 |
| Riopan | 96mg/mL O/L | AYE | 571202 | .0085 |
| Riopan Extra Strength | 1080mg/mL 0/L | AYE | 640476 | .0122 |
| Ritalin | 10mg Tab | CIB | 005606 | .1970 |
| Ritalin SR | 20mg LA Tab | CIB | 632775 | .3640 |
| Rivotril | 2mg Tab | HLR | 382841 | |
| Rivotril | | | | .2330 |
| | 0.5mg Tab | HLR | 382825 | . 1340 |
| Robidex | 3mg/mL O/L | ROB | 454389 | .0224 |
| Robidone | lmg/mL O/L | ROB | 316970 | .0240 |
| Robidrine | 6mg/mL O/L | ROB | 425516 | .0190 |
| Robidrine | 60mg Tab | ROB | 342726 | .0655 |
| Robigesic | 24mg/mL O/L | - ROB | 330884 | .0270 |
| Robigesic | 16mg/mL O/L | ROB | 658049 | .0269 |
| Robigesic | 325mg Tab | ROB | 330876 | .0403 |
| Robinul | 0.2mg/mL Inj Sol-1mL Pk | ROB | 026425 | 1.4336 |
| Robinul | lmg Tab | ROB | 026514 | .0806 |
| Robinul Forte | 2mg Tab | ROB | 026522 | . 1456 |
| Robitussin | 20mg/mL 0/L | ROB | 026468 | .0123 |
| Rocaltrol | 0.5mcg Cap | HLR | 481815 | 1.0075 |
| Rocaltrol | 0.25mcg Cap | HLR | 481823 | .6295 |
| Rofact | 300mg Cap | ICN | 343617 | .7233 |
| Rofact | 150mg Cap | ICN | 393444 | .4668 |
| Rounox | 325mg Tab | ROG | 277193 | |
| | | | | .0179 |
| Rouphylline | 10mg/mL O/L | ROG | 405310 | .0087 |
| Rouphylline | 200mg Tab | ROG | 346071 | .0210 |
| Rouphylline | 100mg Tab | ROG | 451282 | .0180 |
| Roychlor | 1.33mEq/mL O/L | ROY | 485284 | .0122 |
| Royonate | 1.33mEq/mL 0/L | ROY | 485357 | .0136 |
| Rubramin | ing/mL Inj Sol 10mL Pk | SQU | 029165 | 7.3000 |
| Rubramin | .lmg/mL Inj Sol 10mL Pk | SQU | 029157 | 2.7000 |
| Rynacrom | 2% Nas Sol-26mL Pk | FIS | 605255 | 16.6010 |
| Rynacrom | 10mg/Cart Pd Inh | FIS | 328944 | .2112 |
| Rythmodan | 150mg Cap | ROU | 439363 | .2500 |
| Rythmodan | 100mg Cap | ROU | 382876 | . 1770 |
| Rythmodan L.A. | 250mg LA Tab | ROU | 619760 | .5215 |
| S.A.S. Enteric 500 | 500mg Ent Tab | ICN | 445126 | .1144 |
| S.A.S. 500 | 500mg Tab | ICN | 263869 | .0790 |
| Sal-Adult | 650mg Sup | BEE | 451746 | .6375 |
| Sal-Infant | 150mg Sup | BEE | 451738 | .5003 |
| Salazopyrin | 3g/100mL Enema-100mL Pk | PHD | 544442 | 4.5400 |
| Salazopyrin | 500mg Ent Tab | PHD | 158526 | . 1699 |
| Salazopyrin | 3 | PHD | 024856 | |
| | 500mg Tab | | | .1123 |
| Sandomigran | 0.5mg Tab | SAN | 329320 | . 2470 |
| Sandomigran DS | ing Tab | SAN | 511552 | .4090 |
| Sansert | 2mg Tab | SAN | 027499 | .4580 |
| Scabanca | 25% Cr | SAN | 604437 | .0661 |
| Seconal | 50mg Cap | LIL | 015261 | .0639 |
| Seconal | 100mg Cap | LIL | 015288 | .0730 |
| Seldane | 6mg/mL Susp | MER | 614394 | .0498 |
| Seldane | 60mg Tab | MER | 590908 | .3470 |
| Selexid | 200mg Tab | LEO | 657212 | .5000 |

| Product Name | Strength & Dosage | Manuf'r | DIN | Price |
|--------------------|-------------------------------|------------|------------------|---------|
| | | | | |
| Selsun | 2.5% Lot | ABB NOO | 243000 612251 | .0377 |
| Semilente Insulin | 1000U/10mL Inj Susp 10mL Pk | | | 12.4000 |
| Senokot | 15mg/3g Gran 200g Pk | PFR | 026042 | 11.7000 |
| Senokot | 5mg/mL O/L 250mL Pk | PFR | 367729 | 11.1000 |
| Senokot | 30mg Sup 6 Pk | PFR | 026107 | 4.8000 |
| Senokot | 8.6mg Tab 100 pk | PFR | 026158 | 9.2000 |
| Septra | 40mg & 8mg/mL O/L | BWE | 270644 | .0300 |
| Septra | 400mg & 80mg Tab | BWE | 270636 | . 1740 |
| Septra DS | · 800mg & 160mg Tab | BWE | 368040 | .3120 |
| Serax | 30mg Tab | WYE | 231363 | .0610 |
| Serax | 15mg Tab | WYE | 295698 | .0421 |
| Serax | 10mg Tab | WYE | 295701 | .0337 |
| Serentil | 25mg/mL 0/L | SAN | 259489 | .2510 |
| Serentil | 50mg Tab | SAN | 027464 | .3720 |
| Serentil | 25mg Tab | SAN | 027456 | .2700 |
| Serentil | 10mg Tab | SAN | 027448 | .2200 |
| Serophene | 50mg Tab | PMS | 640158 | 2.7090 |
| Serpasil | 5mg/2mL Inj Sol-2mL Pk | CIB | 436917 | 3.2710 |
| Serpasil | 0.25mg Tab | CIB | 005665 | .0840 |
| Serpasil | 3 | CIB | 005657 | .0490 |
| Sertan | 0.1mg Tab | ICN | | |
| Siblin | 250mg Tab | | 294985 | .0550 |
| | Oral Pd 450g Pk | PDA | 990078 | 19.0000 |
| Sincomen | 100mg Tab | BER | 544477 | .2730 |
| Sinemet | 250mg & 25mg Tab | MSD | 328219 | .4286 |
| Sinemet | 100mg & 25mg Tab | MSD | 513997 | .4061 |
| Sinemet | 100mg & 10mg Tab | MSD | 355658 | .2712 |
| Sinequan | 75mg Cap | PFI | 400750 | .5310 |
| Sinequan | 50mg Cap | PFI | 024341 | .3699 |
| Sinequan | 25mg Cap | PFI | 024333 | . 1993 |
| Sinequan | 150mg Cap | PFI | 584274 | .9637 |
| Sinequan | 100mg Cap | PFI | 326925 | .6995 |
| Sinequan | 10mg Cap | PFI | 024325 | .1625 |
| Sintrom | 4mg Tab | GEI | 010391 | .2950 |
| Sintrom | 1mg Tab | GEI | 010383 | .0940 |
| Slo-Pot 600 | 8mEq LA Tab | ICN | 554308 | .0151 |
| Slow-K | 8mEq LA Tab | CIB | 074225 | .0515 |
| Slow-Trasicor | 80mg LA Tab | CIB | 534579 | .2970 |
| Slow-Trasicor | 160mg LA Tab | CIB | 534587 | .5980 |
| Sodium Bicarbonate | 600mg Tab 100 Pk | DTC | 221619 | 3.7000 |
| Sodium Bicarbonate | 300mg Tab 100 Pk | DTC | 093068 | 3.4000 |
| | | | | |
| Sodium Bicarbonate | 300mg Tab 100 Pk | CLK | 502286 | 3.9000 |
| Sodium Chloride | 0.9% Inj Sol-10mL Pk | SQU | 990167 | .9410 |
| Sofracort | 5mg & 50mcg & 0.5mg/mL Ot Sol | ROU | 228052 | .9810 |
| Soframycin | 0.5% Oph Oint-5g Pk | ROU | 026964 | 3.9000 |
| Soframycin | 0.5% Oph Sol | ROU | 026921 | .7125 |
| Solazine | 5mg Tab | HOR | 013919 | .0680 |
| Solazine | 2mg Tab | HOR | 013900 | .0491 |
| Solazine | 10mg Tab | HOR | 013927 | .0814 |
| Solazine | 1mg Tab | HOR | 013897 | .0396 |
| Solium | 5mg Cap | HOR | 013463 | .0383 |
| Solium | 25mg Cap | HOR | 013498 | .0796 |
| Solium | 10mg Cap | HOR | 013471 | .0498 |
| Solu-Cortef | Inj Pd-100mg Pk | UPJ | 030600 | 1.4400 |
| Solu-Cortef | Inj Pd-1000mg Pk | UPJ | 030635 | 5.1100 |
| Solu-Cortef | Inj Pd-250mg Pk | UPJ | 030619 | 2.2300 |
| Solu-Cortef | Inj Pd-500mg Pk | UPJ | 030627 | 3.7300 |
| | and in ocome in | UPJ | 030651 | 8.9600 |

| Product Name | Strength & Dosage | Manuf'r | DIN | Price |
|------------------|---------------------------------------|---------|------------------|---------|
| Solu-Medrol | Inj Pd-40mg Pk | UPJ | 030643 | 3.7800 |
| Solu-Medrol | Inj Pd-500mg Pk | UPJ | 030678 | 22.4600 |
| Som-Pam | 30mg Cap | ICN | 414239 | .0343 |
| Som-Pam | 15mg Cap | ICN | 414220 | .0292 |
| Sonnol | 30mg Tab | HOR | 483818 | .0675 |
| Somnol | 15mg Tab | HOR | 483826 | .0600 |
| Somophyllin-T | 200mg Cap | FIS | 442283 | . 1584 |
| Somophyllin-T | 100mg Cap | FIS | 442275 | .1711 |
| Somophyllin-12 | 50mg LA Cap | FIS | 551422 | .1296 |
| Somophyllin-12 | 300mg LA Cap | FIS | 609021 | .2011 |
| Somophyllin-12 | 250mg LA Cap | FIS | 551414 | . 1853 |
| Somophyllin-12 | 200mg LA Cap | FIS | 609013 | .1673 |
| Somophyllin-12 | 100mg LA Cap | FIS | 551430 | .1446 |
| Sotacor | 160mg Tab | BRI | 483923 | .7350 |
| Sparine | 50mg Tah | WYE | 034185 | .0970 |
| Sparine | 25mg Tab | WYE | 034177 | .0630 |
| Staphcillin | Inj Pd-1g Pk | BRI | 004081 | 3.8000 |
| Statex | 5mg/mL O/L | PMS | 591475 | .0560 |
| Statex | ing/mL O/L | PMS | 591467 | .0205 |
| Statex | 20mg/mL Oral Drops | PMS | 621935 | .3200 |
| Staticin | 1.5% Lot | WSD | | |
| Stelazine | lng/mL Inj Sol-1mL Pk | SKF | 512591 026999 | .1135 |
| Stelazine | | SKF | | |
| Stelazine | 20mg/10mL Inj Sol-10mL Pk | | 027006 | 9.8560 |
| | 10mg/mL O/L | SKF | 027022 | .2222 |
| Stelazine | 5mg Tab | SKF | 027162 | . 1514 |
| Stelazine | 2mg Tab | SKF | 027154 | .1143 |
| Stelazine | 10mg Tab | SKF | 027170 | .1818 |
| Stelazine | lng Tab | SKF | 027146 | .0872 |
| Stemetil | 10mg/2mL Inj Sol-2mL Pk | RPP | 578185 | 1.2350 |
| Stemetil | lmg/nL O/L | RPP | 025216 | .0361 |
| Stemetil | 5mg Sup | RPP | 025356 | .3817 |
| Stemetil | 10mg Sup | RPP | 025364 | .8120 |
| Stemetil | 5mg Tab | RPP | 025682 | . 1245 |
| Stemetil | 10mg Tab | RPP | 025690 | . 1521 |
| StieVAA | 0.05% Cr | STI | 518182 | .2793 |
| StieVAA | 0.025% Cr | STI | 578576 | .2831 |
| StieVAA | 0.025% Gel | STI | 587966 | .2871 |
| StieVAA | 0.01% Gel | STI | 587958 | .2799 |
| StieVAA | 0.025% Sol | STI | 578568 | .1417 |
| StieVAA | 0.05% Top Sol | STI | 518174 | .1431 |
| Stilboestrol | 5mg Tab | AHA | 003379 | . 1874 |
| Stilboestrol | 1mg Tab | AHA | 003360 | . 1402 |
| Stilboestrol | 0.5mg Tab | AHA | 003352 | .1492 |
| Stilboestrol | 0.1mg Tab | AHA | 003336 | .1148 |
| Stoxil | 0.5% Oph Oint-4g Pk | SKF | 027200 | 13.0000 |
| Stoxil | 0.1% Oph Sol | SKF | 027014 | 1.2120 |
| Sudafed | 6mg/mL O/L | BWE | 004561 | .0160 |
| Sudafed | 60mg Tab | BWE | 004766 | .0899 |
| Sulamyd | 10% Oph Oint-3.5g Pk | SCH | 028347 | 2.9058 |
| Sulamyd | 30% Oph Sol | SCH | 028061 | .2347 |
| Sulamyd | 10% Oph Sol | SCH | 028053 | . 1260 |
| Sulcrate | lg Tab | NRD | 506346 | .3248 |
| Sulfamethoxazole | & Trimethoprim | | | |
| Sulfamethoxazole | 400mg & 80mg Tab & Trimethoprim DS | DTC | 516759 | .0653 |
| | 800mg & 160mg Tab | DTC | 516767 | .1000 |
| Sulfapyridine | 500mg Tab | PDA | 155470 | .0981 |

| Product Name | Strength & Dosage | Manuf'r | DIN | Price |
|------------------|---------------------------------|---------|--------|-----------------|
| Sulfated Insulin | 1000U/10mL Inj Susp 10mL Pk | NOO | 648094 | 45.3500 |
| Sulfinpyrazone | 200mg Tab | DTC | 481947 | .0560 |
| Sulfinpyrazone | 100mg Tab | DTC | 481955 | .0323 |
| Sulfisoxazole | 500mg Tab | SAP | 210730 | .0315 |
| Sultrin | Vag Cr-App | ORT | 153605 | .1788 |
| Sunstop | 67. & 47. Lot | WAM | 607851 | .0249 |
| Supasa | 640mg Sup | NRD | 315133 | .6608 |
| Supasa | 320mg Sup | NRD | 315117 | .5622 |
| Supasa | 160mg Sup | NRD | 377961 | .4928 |
| Surfak | 50mg Cap 100 Pk | HOE | 012483 | 20.6000 |
| Surfak | 240mg Cap 30 Pk | HOE | 012491 | 8.8000 |
| Surmontil | 75mg Cap | RPP | 442437 | .5534 |
| Surmontil | 100mg Tab | RPP | 025852 | .7043 |
| Surmontil | 50mg Tab | RPP | 025844 | .3873 |
| Surmontil | 25mg Tab | RPP | 025836 | .2012 |
| Surmontil | 12.5mg Tab | RPP | 025828 | . 1587 |
| Sustaine | 0.1% Nas Sol 25mL Pk | WIN | 537411 | 2.0000 |
| | | WIN | 537381 | 1.9000 |
| Sustaine | 0.05% Nas Sol 25mL Pk | DUP | 589012 | .4860 |
| Symmetrel | 100mg Cap | | | |
| Symmetrel | 10mg/mL O/L | DUP | 589004 | .0830 |
| Synacthen Depot | 1mg/mL Inj Susp-1mL Pk | CIB | 253952 | 15.9300 |
| Synalar Bi-Otic | 10000U & 5mg & 0.25mg/mL Ot Sol | SYP | 189499 | 1.3000 |
| Synalar Mild | 0.01% Cr | SYP | 030414 | .1150 |
| Synalar Mild | 0.01% Oint | SYP | 030392 | . 1860 |
| Synalar Regular | 0.025% Cr | SYP | 030422 | . 1834 |
| Synalar Regular | 0.025% Oint | SYP | 030406 | . 1834 |
| Synalar Solution | 0.01% Top Sol | SYP | 030260 | .2826 |
| Synamol Mild | 0.01% Emol Cr | SYP | 424927 | .1150 |
| Synamol Regular | 0.025% Emol Cr | SYP | 424935 | . 1834 |
| Synkavite | 5mg/mL Inj Sol-1mL Pk | HLR | 012912 | .9408 |
| Synkavite | 10mg/mL Inj Sol-1mL Pk | HLR | 012920 | 1.1088 |
| Synkavite | 5mg Tab | HLR | 013374 | .0543 |
| Synthroid | 0.3mg Tab | FLI | 009695 | .0353 |
| Synthroid | 0.2mg Tab | FLI | 009687 | .0258 |
| Synthroid | 0.15mg Tab | FLI | 212164 | .0242 |
| Synthroid | O.lmg Tab | FLI | 009660 | .0225 |
| Synthroid | 0.05mg Tab | FLI | 009652 | .0169 |
| Synthroid | 0.025mg Tab | FLI | 009644 | .0330 |
| Syntocinon-10 | 10IU/mL Inj Sol-1mL Pk | SAN | 035998 | .6060 |
| Syntocinon-5 | 5IU/mL Inj Sol-1mL Pk | SAN | 282316 | . 4930 |
| SMP Atropine | 2% Oph Sol | CEV | 527955 | .8042 |
| SMP Atropine | 17. Oph Sol | CEV | 527947 | .5264 |
| Tace | 25mg Cap | MER | 017973 | .8216 |
| Tace | 12mg Cap | MER | 017965 | .3875 |
| Tagamet | 60mg/mL O/L | SKF | 397482 | .1289 |
| Tagamet | 600mg Tab | SKF | 563587 | .4420 |
| | | SKF | 563579 | .3626 |
| Tagamet | 400mg Tab | SKF | 397474 | .2347 |
| Tagamet | 300mg Tab | | | |
| Tagamet | 200mg Tab | SKF | 563560 | .2754 4.5000 |
| Talwin | 300mg/10mL Inj Sol-10mL Pk | WIN | 036277 | |
| Talwin | 50mg Tab | WIN | 033731 | .2217 |
| Tantum | 0.15% Oral Rinse | RIK | 574171 | .0505 |
| Tapazole | 5mg Tab | LIL | 015741 | .0831 |
| Tarasan | 50mg Tab | HLR | 013242 | . 1945 |
| Tarasan | 15mg Tab | HLR | 013234 | .0960 |
| Tavist | 1mg Tab | ANC | 349046 | . 1411 |
| Tears Naturale | Oph Sol | ALC | 390294 | .2912 |

O. Reg. 690/86

| Product Name | Strength & Dosage | Manuf' | r DIN | Price |
|---------------------------|----------------------------|------------|------------------|---------|
| Tears Plus | Oph Sol | ALL | 579408 | .2341 |
| Tebrazid | 500mg Tab | ICN | 283991 | .3692 |
| Tegison | 25mg Cap | HLR | 616419 | 2.1117 |
| Tegison | 10mg Cap | HLR | 616400 | 1.2017 |
| Tegopen | Inj Pd-2000mg Pk | BRI | 407615 | 2.9000 |
| Tegopen | Inj Pd-250mg Pk | BRI | 407593 | 1.0500 |
| Tegopen | Inj Pd-500mg Pk | BRI | 407607 | 1.6500 |
| Tegretol | 200mg Tab | GEI | 010405 | .1730 |
| Tegretol Chew Tabs | 200mg Chew Tab | GEI | 665088 | .1620 |
| Tegretol Chew Tabs | 100mg Chew Tab | GEI | 369810 | .0810 |
| Temposil | 50mg Tab | LED | 014958 | .3500 |
| Tempra | 90mg/mL O/L | MJO | 221627 | .2218 |
| Tempra | 80mg/mL O/L | MJO | 642401 | . 1994 |
| Tenormin | 50mg Tab | ICI | 520683 | .4018 |
| Tenormin | 100mg Tab | ICI | 486833 | .6554 |
| Tensilon | 100mg/10mL Inj Sol-10mL Pk | HLR | 013064 | 9.4584 |
| Terfluzine | 10mg/mL 0/L | ICN | 298212 | .1560 |
| Terfluzine | 5mg Tab | ICN | 271527 | .0098 |
| Terfluzine | 2mg Tab | ICN | 303453 | .0081 |
| Terfluzine | 10mg Tab | ICX | 280399 | .0115 |
| Terfluzine | Ing Tab | ICN | 294861 | .0067 |
| Tersa-Tar | 3% Shampoo 150mL Pk | TCD | 632309 | 4.0000 |
| Tersaseptic | 0.5% Top Sol | TCD | 632317 | .0142 |
| Tertroxin | 25mcg Tab | GLA | 012327 | .0750 |
| Tes-Tape | Strip-100Pk | LIL | 980609 | 5.9500 |
| Tetanus Immune Human Glob | Inj Sol-2500 Pk | CNG | 074942 | 2.7800 |
| Tetracycline | 250mg Cap | SAP | 210765 | .0235 |
| Tetracyn | 250mg Cap | PFI | 024422 | .0597 |
| Theo-Dur | 300mg LA Tab | AST | 461008 | .2068 |
| Theo-Dur | 200mg LA Tab | AST | 460990 | .1718 |
| Theo-Dur | 100mg LA Tab | AST | 460982 | . 1545 |
| Theochron | 300mg LA Tab | FOR | 599905 | . 1656 |
| Theochron | 200mg LA Tab | FOR | 631701 | . 1376 |
| Theochron | 100mg LA Tab | FOR | 631698 | . 1235 |
| Theolair | 250mg Tab | RIK | 461687 | .2415 |
| Theolair | 125mg Tab | RIK | 395218 | . 1645 |
| Theolair Alcohol Free Ora | | | | |
| | 5.3mg/mL O/L | RIK | 461709 | .0150 |
| Theolair-SR | 500mg LA Tab | RIK | 502014 | . 2470 |
| Theolair-SR | 300mg LA Tab | RIK | 545732 | . 1595 |
| Theolair-SR | 250mg LA Tab | RIK | 461695 | . 1520 |
| Theolixir | 5.3mg/mL 0/L | ICN | 452327 | .0092 |
| Theophylline | 5.3mg/mL 0/L | DES | 261203 | .0028 |
| Theophylline | 5.3mg/mL 0/L | TCH | 532223 | .0066 |
| Thiamine | 50mg Tab | PDA | 023922 | .0560 |
| Thio-Tepa Thioridazine | Inj Pd-15mg Pk | LED SAP | 237035 238775 | 11.0000 |
| Thioridazine | 2mg/nL 0/L | SAP | 238805 | .0141 |
| Thioridazine | 50mg Tab 50mg Tab | DTC | 456098 | .0392 |
| Thioridazine | 25mg Tab | SAP | 238791 | .0247 |
| Thioridazine | 25mg Tab | DTC | 456071 | .0216 |
| Thioridazine | 100mg Tab | DTC | 456101 | .0744 |
| Thioridazine | 10mg Tab | SAP | 238783 | .0144 |
| Thioridazine | 10mg Tab | DTC | 456063 | .0112 |
| Thyroid | 125mg Tab | PDA | 023965 | .0370 |
| Thyroid | 60mg Tab | PDA | 023957 | .0290 |
| | 55.5 | . 0.5 | 020001 | .0200 |

| Product Name | Strength & Dosage | Manuf'r | DIN | Price |
|------------------|---------------------------------|---------|--------|---------|
| Thyroid | 30mg Tab | PDA | 023949 | .0223 |
| Tiamol | 0.05% Emol Cr | TIC | 598933 | .1600 |
| Timolide | 10mg & 25mg Tab | FRS | 509353 | .3240 |
| Timortic | 0.5% Oph Sol | MSD | 451207 | 2.2960 |
| Timoptic | 0.25% Oph Sol | MSD | 451193 | 1.9400 |
| Tobrex | 0.3% Oph Oint | ALC | 614254 | 1.8000 |
| Tobrex | 0.3% Oph Sol | ALC | 513962 | 1.2900 |
| Tofranil | 50mg Tab | GEI | 010480 | .3190 |
| Tofranil | 25mg Tab | GEI | 010472 | .1720 |
| Tofranil | 10mg Tab | GEI | 010464 | .1060 |
| Tolbutamide | 500mg Tab | DTC | 093033 | .0152 |
| Tolbutamide | 500mg Tab | SAP | 209872 | .0202 |
| Tolectin | 200mg Tab | MCN | 364126 | .2640 |
| Tolectin DS | 400mg Cap | MCN | 484938 | .3885 |
| | 0.25% Emol Cr | HOE | 420271 | .3208 |
| Topicort | 0.05% Emol Cr | HOE | | |
| Topicort Mild | 0.05% Gel | | 486450 | .1908 |
| Topsyn | | SYN | 281913 | .3535 |
| Trancopal | 200mg Tab | WIN | 033626 | .2175 |
| Trandate | 200mg Tab | AHA | 603643 | .2970 |
| Trandate | 100mg Tab | AHA | 603651 | .1680 |
| Transderm-V | 1.5mg Transderm Syst | CIB | 623547 | 1.3944 |
| Tranxene | 15mg Cap | ABB | 264911 | .3209 |
| Tranxene | 7.5mg Cap | ABB | 264946 | .1787 |
| Tranxene | 3.75mg Cap | ABB | 264938 | . 1376 |
| Trasicor | 80mg Tab | CIB | 402583 | .2910 |
| Trasicor | 40mg Tab | CIB | 402575 | . 1940 |
| Trasicor | 20mg Tab | CIB | 402567 | .1090 |
| Trasylol | 100,000KIU/10mL Inj Sol-10mL Pk | MIT | 513954 | 23.0160 |
| Travamine | 50mg Tab | ICN | 272671 | .0071 |
| Travase | 82,000V/g Oint | FLI | 265381 | 1.9245 |
| Trental | 400mg LA Tab | HOE | 586625 | .4158 |
| Treosulfan | 250mg Cap | LEO | 452122 | .7040 |
| Triadapin | 75mg Cap | PWC | 629294 | . 4336 |
| Triadapin | 50mg Cap | PWC | 629286 | .2089 |
| Triadapin | 25mg Cap | PWC | 629278 | .1314 |
| Triadapin | 100mg Cap | PWC | 629308 | .5705 |
| Triadapin | 10mg Cap | PWC | 629251 | .1070 |
| Triaderm | 0.1% Cr | KLP | 385204 | .0442 |
| Triaderm | 0.025% Cr | KLP | 385182 | .0351 |
| Trianide Mild | 0.025% Cr | TCH | 535249 | .0574 |
| Trianide Regular | 0.1% Cr | TCH | 535273 | . 1379 |
| Tridesilon | 0.05% Cr | MIT | 521248 | .1978 |
| Tridesilon | 0.05% Oint | MIT | 521264 | .3163 |
| Trifluoperazine | 5mg Tab | DTC | 249084 | .0081 |
| Trifluoperazine | 2mg Tab | DTC | 249076 | .0056 |
| Trifluoperazine | 10mg Tab | DTC | 249092 | .0143 |
| Trifluoperazine | 1mg Tab | DTC | 249068 | .0062 |
| Trikacide | 500mg Vag Tab App | ICN | 283967 | .2145 |
| Trilafon | 5mg/mL Inj Sol-1mL Pk | SCH | 028002 | 1.5820 |
| Trilafon | 0.4mg/mL O/L | SCH | 028150 | .0467 |
| Trilafon | 8mg Tab | SCH | 028312 | .0579 |
| Trilafon | 4mg Tab | SCH | 028304 | .0482 |
| Trilafon | 2mg Tab | SCH | 028290 | .0386 |
| Trilafon | 16mg Tab | SCH | 028320 | .0697 |
| Trilafon Conc. | 3.2mg/mL O/L | SCH | 028169 | .1395 |
| Trilisate | Tab | PFR | 449636 | . 1475 |
| Triphasil | 3 Phase Tab-21 Pk | WYE | 579386 | 7.9000 |

| Product Name | Strength & Dosage | Manuf'r | DIN | Price |
|--------------------|-----------------------------|---------|--------|---------|
| Triphasil | 3 Phase Tab-28 Pk | WYE | 586609 | 7.9000 |
| Triptil | 5mg Tab | MSD | 322261 | . 1783 |
| Triptil | 10mg Tab | MSD | 322741 | .2587 |
| Trisyn | Emol Cr | SYP | 552283 | .2458 |
| Trobicin | Inj Pd-2g Pk | UPJ | 210196 | 11.3000 |
| Tronothane | 17. Cr | ABB | 000116 | .2313 |
| Tylenol No. 4 | 60mg Tab | MCN | 396516 | .2730 |
| Tylenol No.2 | 15mg Tab | MCN | 425370 | .0285 |
| Tylenol No.3 | 30mg Tab | MCN | 425389 | .0406 |
| Ulone | 5mg/mL 0/L | RIK | 026328 | .0291 |
| Ultralente Insulin | 1000U/10mL Inj Susp 10mL Pk | N00 | 612243 | 12.4000 |
| Ultrastop | 8% & 3.5% Cr | CDM | 626708 | .0487 |
| UltraMOP | 10mg Cap | CDM | 646237 | .3500 |
| Unicort | 1% Cr | AHA | 303895 | .0206 |
| Unicort | 0.5% Cr | AHA | 303887 | .0148 |
| Univol | 40mg & 40mg/mL O/L | HOR | 013625 | .0100 |
| Urecholine | 5mg/mL Inj Sol-1mL Pk | FRS | 349747 | 2.3650 |
| Urecholine | 25mg Tab | FRS | 349739 | .5072 |
| Urecholine | 10mg Tab | FRS | 349720 | .3375 |
| Uremol-HC | 1% & 10% Cr | TCD | 503134 | .1218 |
| Uremol-HC | 1% & 10% Lot | TCD | 560022 | .0663 |
| Uridon | 50mg Tab | ICN | 298964 | .0203 |
| Uridon | 100mg Tab | ICN | 293881 | .0325 |
| Uritol | 20mg/2mL Inj Sol-2mL Pk | HOR | 467766 | 1.2958 |
| Uritol | 40mg Tab | HOR | 344079 | .0728 |
| | 3 | ICN | 263907 | .0044 |
| Urozide | 50mg Tab | ICN | | |
| Urozide | 25mg Tab | | 263893 | .0035 |
| V-Cillin K | 25mg/mL O/L | LIL | 015563 | .0211 |
| Valisone | 0.1% Scalp Lot | SCH | 027944 | .1700 |
| Valium | 10mg/2mL Inj Sol-2mL Pk | HLR | 012874 | .9500 |
| Valium | ing/mL O/L | HLR | 013110 | .0335 |
| Valium | 5mg Tab | HLR | 013285 | .0612 |
| Valium | 2mg Tab | HLR | 013277 | .0439 |
| Valium | 10mg Tab | HLR | 013293 | .0994 |
| Vancenase | Nas Sp 200-dose Pk | SCH | 422053 | 12.0000 |
| Vanceril | Aero Pd-200 dose Pk | SCH | 374407 | 12.0000 |
| Vanquin | 10mg/mL O/L | PDA | 023477 | .0909 |
| Vanquin | 50mg Tab | PDA | 023841 | .3692 |
| Vaponefrin | 2.25% Inh Sol 30mL Pk | ROR | 480363 | 18.0660 |
| Vasocon | 0.1% Oph Sol 15mL Pk | CEV | 528005 | 5.4000 |
| Velbe | Inj Pd-10mg Pk | LIL | 015431 | 37.7600 |
| Velosef | 500mg Cap | SQU | 301639 | 1.0450 |
| Velosef | 250mg Cap | son | 301620 | .5330 |
| Velosef | Inj Pd-1000mg Pk | SQU | 348295 | 4.0000 |
| Velosef | Inj Pd-500mg Pk | SQU | 348287 | 2.7500 |
| Velosef | 50mg/mL O/L | squ | 301647 | .1180 |
| Velosulin | 1000U/10mL Inj Sol 10mL Pk | HOR | 552267 | 18.9000 |
| Velosulin Human | 1000U/10mL Inj Sol 10mL Pk | HOR | 632686 | 18.9000 |
| Ventolin | 5mg/mL Inh Sol-10mL Pk | AHA | 334227 | 6.7000 |
| Ventolin | Inh-200 dose Pk | AHA | 303569 | 9.5000 |
| Ventolin | 2.5mg/5mL Inj Sol | AHA | 602922 | .8100 |
| Ventolin | 0.25mg/5mL Inj Sol | AHA | 602914 | .7700 |
| Ventolin | 4mg Tab | AHA | 332267 | . 1395 |
| Ventolin | 2mg Tab | AHA | 361135 | .0750 |
| Ventolin Rotacaps | 400mcg/Cart Inh Pd | AHA | 622079 | .1810 |
| Ventolin Rotacaps | 200mcg/Cart Inh Pd | AHA | 622060 | .1280 |
| Vernox | 100mg Tab | JAN | 556734 | 2.0833 |

| Product Name | Strength & Dosage | Manuf'r | DIN | Price |
|----------------------|-------------------------|---------|--------|---------|
| Vimicon | 0.4mg/mL 0/L | FRS | 009989 | .0312 |
| Vimicon | 4mg Tab | FRS | 010073 | . 1584 |
| Vioform | 3% Cr | CIB | 005142 | . 1669 |
| Vioform | 3% Oint | CIB | 005797 | . 1669 |
| Viokase | Oral Pd-115g Pk | ROB | 651672 | 28,8512 |
| Viokase | 325mg Tab | ROB | 651680 | .1075 |
| Vira-A | 3% Oph Oint-3.5g Pk | PDA | 381780 | 11.4400 |
| Viroptic | 1% Oph Sol | BWE | 589055 | 2,5330 |
| Visidex II | Stick-25 Pk | AME | 990280 | 11.7500 |
| Viskazide 10/25 | 10mg & 25mg Tab | SAN | 568627 | .5200 |
| Viskazide 10/20 | 10mg & 50mg Tab | SAN | 568635 | .5200 |
| Visken | 5mg Tab | SAN | 417270 | .3070 |
| | | SAN | 417289 | .7580 |
| Visken | 15mg Tab | SAN | | |
| Visken | 10mg Tab | | 443174 | .5230 |
| Vitamin A | 50,000IU Cap | NOP | 021075 | .0613 |
| Vitamin A | 25,000IU Cap | NOP | 021067 | .0354 |
| Vitamin A Acid | 0.05% Cr | ROR | 493333 | .2780 |
| Vitamin A Acid | 0.05% Gel | ROR | 419001 | .2780 |
| Vitamin A Acid | 0.01% Gel | ROR | 590797 | .2780 |
| Vitamin B1 | 50mg Tab | LEA | 610267 | .0207 |
| Vitamin B1-ICN | 50mg Tab | ICN | 268631 | .0280 |
| Vitamin B6 | 25mg Tab | LEA | 232475 | .0196 |
| Vitamin B6 | 25mg Tab | WAM | 416185 | .0242 |
| Vitamin B6-ICN | 25mg Tab | ICN | 268607 | .0280 |
| Vitamin C | 500mg Tab 100 PK | CLK | 453951 | 4.2000 |
| Vitamin C | 250mg Tab 100 Pk | WAM | 036161 | 2.2000 |
| Vitamin C | 250mg Tab 100 Pk | CLK | 570397 | 1.7000 |
| Vitamin C | 100mg Tab 100 Pk | CLK | 492752 | 1.8000 |
| Vivol | 5mg Tab | HOR | 013765 | .0262 |
| Vivol | 2mg Tab | HOR | 013757 | .0170 |
| Vivol | 10mg Tab | HOR | 013773 | .0470 |
| Voltaren | 50mg Ent Tab | GEI | 514012 | . 4500 |
| | 9 | | | |
| Voltaren | 25mg Ent Tab | GEI | 514004 | . 2250 |
| Voltaren | 50mg Sup | GEI | 632724 | .7500 |
| Voltaren | 100mg Sup | GEI | 632732 | 1.0100 |
| Voltaren SR | 100mg LA Tab | GEI | 590827 | .9000 |
| VC-K 500 | 60mg/mL O/L | LIL | 331945 | .0360 |
| Warfilone | 5mg Tab | FRS | 010308 | . 1334 |
| Westcort | 0.2% Cr | WSD | 423165 | . 1753 |
| Westcort | 0.2% Oint | WSD | 590800 | . 1753 |
| Winpred | 5mg Tab | ICN | 271381 | .0107 |
| Winpred | 1mg Tab | ICN | 271373 | .0624 |
| Winstrol | 2mg Tab | WIN | 033812 | .2060 |
| Wycillin 5 Million | Sugar-10-1 Ph | WYE | 255615 | 3.9000 |
| 5,000,0001U/10mL Inj | | UPJ | 355615 | .1540 |
| Xanax | 0.5mg Tab | | 548367 | |
| Xanax | 0.25mg Tab | UPJ | 548359 | . 1286 |
| Xylocaine Viscous | 27. 0/L | AST | 001686 | .0650 |
| Zanosar | Inj Pd-1g Pk | UPJ | 622141 | 25.0000 |
| Zantac | 50mg/2mL Inj Sol-2mL Pk | GLA | 603791 | 1.9060 |
| Zantac | 300mg Tab | GLA | 641790 | 1.5625 |
| Zantac | 150mg Tab | GLA | 553379 | .8223 |
| Zarontin | 250mg Cap | PDA | 022799 | .1913 |
| Zarontin | 50mg/mL O/L | PDA | 023485 | .0383 |
| Zaroxolyn | 10mg Tab | PWC | 301671 | . 1765 |
| Zaroxolyn | 5mg Tab | PWC | 301698 | .1341 |
| | | | , | |

| Product Name | Strength & Dosage | Manuf'r | DIN | Price |
|--------------|---------------------|---------|--------|---------|
| Zaroxolyn | 2.5mg Tab | PWC | 301663 | .1024 |
| Zetar | 30% Emuls 125mL Pk | ROR | 426415 | 10.2000 |
| Zetar | 1% Shampoo 250mL Pk | ROR | 426423 | 10.4500 |
| Zinc Oxide | 15% Oint | DTC | 093661 | .0184 |
| Zovirax | 5% Oint 4g Pk | BWE | 569771 | 9.9000 |
| Zyloprim | 300mg Tab | BWE | 294322 | . 1974 |
| Zyloprim | 200mg Tab | BWE | 506370 | .1310 |
| Zyloprim | 100mg Tab | BWE | 004588 | .0650 |
| Zynol | 200mg Tab | HOR | 463051 | .0625 |
| Zynol | 100mg Tab | HOR | 463043 | .0425 |
| 10-Benzagel | 10% Gel | ROR | 426288 | .0958 |
| 282 | 15mg Tab | FRS | 108103 | .0641 |
| 292 | 30mg Tab | FRS | 219843 | .0753 |
| 5-Benzagel | 5% Gel | ROR | 426261 | .0823 |
| 642 | 65mg Tab | FRS | 010081 | .0830 |

O. Reg. 690/86, Sched. 2.

(9797)

50

PRESCRIPTION DRUG COST REGULATION ACT, 1986

O. Reg. 691/86. Notice to Patients. Made—November 17th, 1986. Approved—November 26th, 1986. Filed—November 27th, 1986.

REGULATION MADE UNDER THE PRESCRIPTION DRUG COST REGULATION ACT, 1986

NOTICE TO PATIENTS

1.—(1) For the purposes of subsection 4 (3) of the Act, the posting of the following notice clearly and prominently in or adjacent to the dispensary area so that it is readable by a person presenting a prescription is prescribed as the manner in which persons shall be informed of the right to request an interchangeable product:

NOTICE TO PATIENTS

(13 Millimetres bold face)

(8 Millimetre

capitals and

5 Millimetre

lower case)

When dispensing your prescription your pharmacist may select an alternate brand of the same drug where permitted by Ontario law.

You have the right to request an interchangeable product. (Bold face)

Ask your pharmacist if a lower priced drug is being used to dispense your prescription.

Please feel free to consult your pharmacist about your prescription.

(OCP Crest) ONTARIO COLLEGE OF PHARMACISTS. (4 Millimetre capital letters bold face)

- (2) A notice referred to in subsection (1) shall,
 - (a) be 27.5 centimetres in width by 38.5 centimetres in height;
 - (b) be lettered in black on a yellow background; and
 - (c) have letters of sizes indicated in subsection (1). O. Reg. 691/86, s. 1.
- 2.—(1) For the purposes of subsection 6 (4) of the Act, the posting of the following notice clearly and prominently in or adjacent to the dispensary area so

that it is readable by a person presenting a prescription is prescribed as the manner in which persons shall be informed of the usual and customary dispensing fee:

OUR USUAL AND CUSTOMARY FEE WHEN DISPENSING INTERCHANGEABLE PRODUCTS IS \$......

- (2) For the purposes of subsection 6 (4) of the Act, the following information is prescribed as being the information to be included in a notice referred to in subsection (1):
 - 1. The fact that prior to dispensing and upon request the pharmacist will provide the price of the prescription to the person presenting the prescription without obligation.
 - The fact that certain prescriptions may warrant a different fee.
 - The fact that the following list of services may be included in the fee of the pharmacist in addition to the service of dispensing of the prescription, and indicating which are included in the fee,
 - i. the establishment of patient medication profiles,
 - ii. professional consultation,
 - iii. health care services information,
 - iv. after hours emergency prescription service, and
 - v. delivery service.
 - 4. The fact that services other than those referred to in paragraph 3 may be included in the fee of the pharmacist and indicating the nature of the services.
 - 5. The fact that some of the services referred to in paragraphs 3 and 4 may be available at an extra charge.
 - (3) A notice referred to in subsection (1) shall be,
 - (a) 27.5 centimetres in width by 38.5 centimetres in height; and
 - (b) lettered in black on a yellow background. O. Reg. 691/86, s. 2.
- 3. A drug may be dispensed in less than the entire quantity prescribed,
 - (a) if the proper exercise of professional judgment by the dispenser so requires;

- (b) when a lesser quantity is being paid for under an agreement between an insurer or other person and a beneficiary or subscriber to provide payment for health care services upon the payment of an agreed amount of money; or
- (c) when a lesser quantity is being paid for under the provisions of section 8 of Ontario Regulation 689/86 (General). O. Reg. 691/86, s. 3.
- 4.—(1) A person who dispenses a drug pursuant to a prescription shall provide a receipt to the person to whom the drug is supplied at the same time that the drug is supplied that sets out the amount being charged in respect of,
 - (a) a dispensing fee;
 - (b) the cost of the drug; and
 - (c) the total price of the prescription.
- (2) Subsection (1) does not apply to an interchangeable drug that does not require a prescription. O. Reg. 691/86, s. 4.
- 5.—(1) Every operator of a pharmacy shall retain each invoice and purchase record, including any record of price reductions granted by manufacturers or wholesalers in the form of rebates, discounts, refunds or free goods, that is received by each pharmacy operated by the operator that relates to the purchase by the pharmacy of drug products to which the Act applies.
- (2) An invoice or record referred to in subsection (1) shall be retained by the operator in the pharmacy or readily available to the pharmacy to which it relates for at least two years from the receipt of the invoice or record. O. Reg. 691/86, s. 5.
- 6. This Regulation comes into force on the day that section 14 of the Act is proclaimed in force.

COUNCIL OF THE ONTARIO COLLEGE OF PHARMACISTS:

BARRY F. HOLLIDAY
President

WILLIAM R. WENSLEY
Registrar

Dated at Toronto, this 17th day of November, 1986.

PENSION BENEFITS ACT

(9798)

O. Reg. 692/86. General. Made—November 26th, 1986. Filed—November 27th, 1986. REGULATION TO AMEND REGULATION 746 OF REVISED REGULATIONS OF ONTARIO, 1980 MADE UNDER THE PENSION BENEFITS ACT

 Regulation 746 of Revised Regulations of Ontario, 1980 is amended by adding thereto the following sections:

25a.—(1) The amount or value of the bridging supplement or special allowance that a person is receiving or for which a person has satisfied all eligibility conditions under a pension plan that provides a bridging supplement or a special allowance shall not be reduced by reason of the entitlement of the person to receive a retirement benefit under the Canada Pension Plan or the Quebec Pension Plan prior to the person attaining sixty-five years of age.

- (2) Where a pension plan provides a bridging supplement or a special allowance and does not contain a specific reference to the age at which the supplement or allowance is reduced or ceases being paid to the recipient, the age shall be deemed to be attainment of sixty-five years of age.
- (3) Subsection (2) does not apply where a pension plan is amended to specify an age or date for the purpose of determining when a bridging supplement or a special allowance shall be reduced or cease to be paid. O. Reg. 692/86, s. 1, part.
- 25b.—(1) Where a pension plan provides that a pension benefit vary as a result of a retirement pension payable under the *Canada Pension Plan* or the *Quebec Pension Plan* and the pension plan does not contain a reference to a specific age of the recipient of the benefit at which the variation will occur, the variation shall not be made prior to the recipient attaining sixty-five years of age.
- (2) Subsection (1) does not apply to a pension plan that is amended to establish an age or date for variation of the benefit prior to the recipient attaining sixty-five years of age. O. Reg. 692/86, s. 1, part.
- 25c. A pension plan that provides a pension benefit that may be varied as a result of a recipient's entitlement to a retirement pension under the Canada Pension Plan or the Quebec Pension Plan prior to attaining the age of sixty-five years shall take into account the adjustment made to the retirement pension under the Canada Pension Plan or the Quebec Pension Plan. O. Reg. 692/86, s. 1, part.

50

(9799)

LIQUOR LICENCE ACT

O. Reg. 693/86. General. Made—November 26th, 1986. Filed—November 27th, 1986.

REGULATION TO AMEND REGULATION 581 OF REVISED REGULATIONS OF ONTARIO, 1980 MADE UNDER THE LIOUOR LICENCE ACT

1. Regulation 581 of Revised Regulations of Ontario, 1980 is amended by adding thereto the following sections:

59g. Notwithstanding subsection 9 (2), liquor may be sold and served at the Canadian Figure Skating Championships closing banquet in licensed premises at the Holiday Inn, Ottawa Centre, Ottawa, between the hours of 1 a.m. and 3 a.m. on the 8th day of February, 1987. O. Reg. 693/86, s. 1, *part*.

59h. Notwithstanding subsections 9 (1) and (2), liquor may be sold and served at the Pan-Icarian Convention banquet in licensed premises at the Sheraton Centre, Toronto from 11 p.m. on the 6th day of September, 1987 until 1 a.m. of the following day. O. Reg. 693/86, s. 1, part.

(9800)

MENTAL HEALTH ACT

O. Reg. 694/86. Application of Act. Made—November 26th, 1986. Filed—November 27th, 1986.

REGULATION TO AMEND REGULATION 609 OF REVISED REGULATIONS OF ONTARIO, 1980 MADE UNDER THE MENTAL HEALTH ACT

1. Schedule 1 to section 1 of Regulation 609 of Revised Regulations of Ontario, 1980 is amended by adding thereto the following item:

17a. Kenora

Lake of the Woods District Hospital

CROP INSURANCE ACT (ONTARIO)

O. Reg. 695/86. Crop Insurance Plan—Winter Wheat. Made—October 20th, 1986. Approved—November 26th, 1986. Filed—November 28th, 1986.

REGULATION TO AMEND REGULATION 229 OF REVISED REGULATIONS OF ONTARIO, 1980 MADE UNDER THE CROP INSURANCE ACT (ONTARIO)

- 1.—(1) Section 9 of the Schedule to Regulation 229 of Revised Regulations of Ontario, 1980, as amended by section 2 of Ontario Regulation 635/84, is revoked and the following substituted therefor:
- 9.—(1) Subject to subsection (2), the coverage provided under a contract of insurance shall be 70 per cent of the average farm yield in bushels of the total acreage seeded to winter wheat by the insured person in accordance with the regulations.
- (2) The coverage provided under subsection (1) shall be increased following each consecutive no claim year as follows:
 - 1. Following the first no claim year, to 73 per cent of the average farm yield.
 - 2. Following the second no claim year, to 76 per cent of the average farm yield.
 - 3. Following the third no claim year, to 78 per cent of the average farm yield.
 - Following the fourth no claim year, to a maximum of 80 per cent of the average farm yield.
- (3) The number of bushels determined under subsection (1) or (2) constitutes the total guaranteed production under a contract of insurance.
 - (2) Subsection 11 (1) of the said Schedule, as remade by section 2 of Ontario Regulation 619/85, is revoked and the following substituted therefor:
- (1) For the purposes of this plan, the established price, as selected by the grower, for winter wheat is,
 - (a) \$2.75;
 - (b) \$3.25; or

(9801)

2688

50

50

(c) \$3.75.

per bushel.

- (3) Subsection 12 (1) of the said Schedule, as remade by section 3 of Ontario Regulation 619/85, is revoked and the following substituted therefor:
- (1) The total premium is,
 - (a) \$7.30 per acre where the established price is \$2.75 per bushel;
 - (b) \$8.70 per acre where the established price is \$3.25 per bushel; and
 - (c) \$10 per acre where the established price is \$3.75 per bushel.
- (4) Section 12 of the said Schedule is amended by adding thereto the following subsection:
- (4) The premium prescribed by subsections (1) and (2) shall be discounted by 20 per cent where the insured person is,
 - (a) at the maximum coverage level prescribed in paragraph 4 of subsection 9 (2) for at least one year; and
 - (b) the total premium paid by the insured person since 1972 is greater than the total indemnities received by that person since 1972.
 - 2.—(1) Subparagraph 5 (1) of Form 1 of the said Regulation is amended by striking out "15th day of June" in the third and fourth lines and inserting in lieu thereof "1st day of July".
 - (2) Subparagraph 5 (3) of the said Form 1, as amended by subsection 6 (1) of Ontario Regulation 99/82 and section 4 of Ontario Regulation 571/83, is revoked and the following substituted therefor:
- (3) Where the damaged acreage is 3 acres or more and is reseeded in accordance with clause (2) (a), the contract of insurance shall cease to apply to such reseeded acreage, the total guaranteed production shall be reduced accordingly and the Commission shall pay to the insured person for each acre reseeded a reseeding benefit of,
 - (a) \$30 per acre where the established price is \$2.75 per bushel;
 - (b) \$35 per acre where the established price is \$3.25 per bushel; or

- (c) \$40 per acre where the established price is \$3.75 per bushel.
- (3) Subparagraph 6 (1) of the said Form 1 is amended by striking out "16th day of June" in the first and second lines and inserting in lieu thereof "2nd day of July".
- (4) Clause 7 (d) of the said Form 1 is revoked and the following substituted therefor:
 - (d) for Sample, 70 per cent of the yield harvested.

THE CROP INSURANCE COMMISSION OF ONTARIO:

HENRY EDIGER
Chairman

JACK MULDER Secretary

Dated at Toronto, this 20th day of October, 1986.

(9802)

50

COURTS OF JUSTICE ACT, 1984

O. Reg. 696/86. Provincial Judges Benefits. Made—November 26th, 1986. Filed—November 28th, 1986.

REGULATION TO AMEND ONTARIO REGULATION 332/84 MADE UNDER THE COURTS OF JUSTICE ACT, 1984

1. Section 44 of Ontario Regulation 332/84, as remade by section 15 of Ontario Regulation 803/84 and amended by section 7 of Ontario Regulation 270/85, is further amended by adding thereto the following subsections:

(11a) Where moneys have been transferred to the Fund under subsection (1) in respect of a person, the Board upon a written request signed by the person shall authorize payment to the person of an amount specified or identified in the request not exceeding the maximum amount computed in accordance with the following formula:

M = T + P + I - R

where,

- M = maximum amount of payment that may be authorized.
- T = the amount transferred to the Public Service Superannuation Fund from another pension plan attributable to contributions made by the person, but not the person's employer, to the other plan.
- P = where the person has not received a benefit under the *Public Service Superannuation Act*, \$0, or where the person has received a benefit under the *Public Service Superannuation Act*, the amount of the contributions by the person directly to the Public Service Superannuation Fund apart from amounts the person was required to contribute under the *Public Service Superannuation Act*.
- I = interest earned by the amounts represented by T and P under the Public Service Superannuation Act.
- R = the amount by which benefits received by the person under the *Public Service Superannu*-

- ation Act and this Regulation exceed the amount that the person would have received had the amounts represented by T and P not been paid or transferred to the Public Service Superannuation Fund.
- (11b) Subsection (11a) applies only in respect of written and signed requests made to the Board before the 1st day of January, 1988.
- (11c) Where the amount specified or identified in a request mentioned in subsection (11a) is less than the full amount that the person is entitled to, the Board must authorize payment of amounts related to the earliest period or periods of service before amounts related to a later period or periods of service.
- (11d) There shall be deducted from the credit for service of a person in the Plan a number of years of service equal to the number of years of service in relation to which the person has taken a refund from the Fund under subsection (11a).
- (11e) Interest shall be paid on amounts paid under subsection (11a) commencing the 1st day of July, 1984 to the date of payment. O. Reg. 696/86, s. 1.

(9803) 50

Publications Under The Regulations Act

December 20th, 1986

PARKWAY BELT PLANNING AND DEVELOPMENT ACT

O. Reg. 697/86.

Municipality of Metropolitan Toronto,
Borough of Etobicoke (now the City of
Etobicoke).

Made—November 24th, 1986.

Filed—December 1st, 1986.

REGULATION TO AMEND ONTARIO REGULATION 478/73 MADE UNDER THE PARKWAY BELT PLANNING AND DEVELOPMENT ACT

- 1. Paragraph (v) of section 2 of Ontario Regulation 478/73, as remade by section 1 of Ontario Regulation 453/78, is revoked and the following substituted therefor:
 - (v) That portion of Lot A lying north of the southerly limit of the Ontario Hydro right of way, those portions of lots B, C, D and E lying north of Rathburn Road, and Lot F, all in the Concession fronting on the River Etobicoke in a range with Concession II, north of Dundas Street in the City of Mississauga (formerly the Township of Toronto) excepting therefrom the following:
 - Those parts of lots E and F and that part of the road allowance between the said lots E and F, being those parts designated as parts 1, 2 and 3 on a reference plan deposited in the Land Registry Office for the Registry Division of Toronto Boroughs and York South (No. 64) as Number 66R-8678.
 - 2. That portion of Lot B lying north of Rathburn Road, south of Eglinton Avenue and bounded on the east by a line running from the southerly limit of Eglinton Avenue southerly along the west limit of lands designated as parts 1 and 2 on Reference Plan 66R-13577 deposited in the Land Registry Office for the Land Titles Division of Toronto (No. 66); thence along the west limit of lands designated as Block B on Plan of Subdivi-

sion M-1861 registered in the Land Registry Office for the Land Titles Division of Toronto (No. 66) south a distance of 930.86 feet to the northerly limit of Centennial Park Road and thence along the easterly limit of Centennial Park Road to its intersection with the northerly limit of Rathburn Road.

- That portion of Lot C lying north of Rathburn Road and south of Eglinton Avenue.
- 4. The whole of lots 39, 40, 41, 42, 43 and 44 according to a plan of subdivision registered in the Land Registry Office for the Registry Division of Toronto Boroughs and York South (No. 64) as Plan 3387.
- 5. Those portions of lots D and E, being that portion designated as parts 1, 2 and 3 on Ministry of Government Services Plan 886-9L, being a reference plan deposited in the Land Registry Office for the Registry Division of Toronto Boroughs and York South (No. 64) as Plan 64R-5248.
- 6. Those portions of lots D, E and F, and part of the unopened allowance for road between lots E and F, being described in instrument numbers 35332 and 56081 registered in the Land Registry Office for the Registry Division of Toronto Boroughs and York South (No. 64).
- 7. That portion of lots E and F, and part of the unopened allowance for road between lots E and F, lying north of the northerly limit of the lands described in Instrument Number 56081 registered in the Land Registry Office for the Registry Division of Toronto Boroughs and York South (No. 64), east of the centre line of Etobicoke Creek as shown on Reference Plan R-3581 deposited in the Land Registry Office for the Land Titles Division of Toronto (No. 66), south of the southerly limit of the lands shown on Registered Plan 66R-8597 deposited in the Land Registry Office for the Land Titles

Division of Toronto (No. 66) described as having a bearing of north 14° 18′ 10″ east, and south and west of the lands designated as parts 1 and 2 on Reference Plan 64R-5248 deposited in the Land Registry Office for the Registry Division of Toronto Boroughs and York South (No. 64).

- Those portions of lots E and F and part of the unopened allowance for road between lots E and F, being that portion designated as Part 2 on Reference Plan R-3581 deposited in the Land Registry Office for the Land Titles Division of Toronto (No. 66).
- That portion of Elmcrest Road (formerly Mercer Road) lying north of Rathburn Road and south of Eglinton Avenue, in the City of Etobicoke.

BERNARD GRANDMAÎTRE
Minister of Municipal Affairs

Dated at Toronto, this 24th day of November, 1986.

(9806)

HEALTH PROTECTION AND PROMOTION ACT, 1983

O. Reg. 698/86.
Designation of Communicable Diseases.
Made—November 28th, 1986.
Filed—December 1st, 1986.

REGULATION TO AMEND ONTARIO REGULATION 161/84 MADE UNDER THE HEALTH PROTECTION AND PROMOTION ACT, 1983

- 1.—(1) Item 7 of section 1 of Ontario Regulation 161/84 is revoked and the following substituted therefor:
 - 7. Campylobacter enteritis
- (2) Item 19 of the said section 1 is revoked and the following substituted therefor:
 - 19. Hemorrhagic fevers,
 - i. Ebola virus disease
 - ii. Marburg virus disease
 - iii. Other viral causes
- (3) Section 1 of the said Regulation is amended by adding thereto the following items:

22a. Invasive Haemophilus influenzae b infections

MOTO INDIA

56a. Verotoxin-producing E. coli infections

MURRAY ELSTON
Minister of Health

Dated at Toronto, this 28th day of November, 1986.

(9807)

HEALTH PROTECTION AND PROMOTION ACT, 1983

O. Reg. 699/86.
Designation of Reportable Diseases.
Made—November 28th, 1986.
Filed—December 1st, 1986.

REGULATION TO AMEND ONTARIO REGULATION 162/84 MADE UNDER THE HEALTH PROTECTION AND PROMOTION ACT, 1983

- 1.—(1) Item 7 of section 1 of Ontario Regulation 162/84 is revoked and the following substituted therefor:
 - 7. Campylobacter enteritis
- (2) Item 13 of the said section 1 is revoked and the following substituted therefor:
 - 13. Encephalitis,
 - i. Primary, viral
 - ii. Post-infectious
 - iii. Vaccine-related
 - iv. Subacute sclerosing panencephalitis
 - v. Unspecified
- (3) Item 16 of the said section 1 is revoked and the following substituted therefor:
 - 16. Fungal systemic diseases,
 - i. Blastomycosis
 - ii. Histoplasmosis
- (4) Item 19 of the said section 1 is revoked and the following substituted therefor:
 - 19. Giardiasis, except asymptomatic cases

- (5) Item 22 of the said section 1 is revoked and the following substituted therefor:
 - 22. Hemorrhagic fevers,
 - i. Ebola virus disease
 - ii. Marburg virus disease
 - iii. Other viral causes
- (6) Section 1 of the said Regulation is amended by adding thereto the following items:
 - 24a. Invasive Haemophilus influenzae b infections

36a. Neonatal herpes

53a. Taenia solium infections

61a. Verotoxin-producing E. coli infections

MURRAY ELSTON Minister of Health

Dated at Toronto, this 28th day of November, 1986.

(9808) 51

MUNICIPAL BOUNDARY NEGOTIATIONS ACT, 1981

O. Reg. 700/86.

Municipality of Neebing, City of Thunder Bay Boundary.

Made—November 26th, 1986.

Filed—December 3rd, 1986.

ORDER IN COUNCIL

R.O.C. 433/86

WHEREAS The Corporation of the City of Thunder Bay and The Corporation of the Municipality of Neebing have entered into an agreement dated the 27th day of May, 1986 for the resolution of certain boundary issues;

AND WHEREAS public notice was given by the Clerk of the Executive Council under subsection 17 (1) of the Municipal Boundary Negotiations Act, 1981 of the intention to make an order implementing the intermunicipal agreement;

AND WHEREAS no objections to the proposed issuance of the Order were filed with the Clerk of the Executive Council within the filing period;

Now Therefore on the recommendation of the undersigned, the Lieutenant Governor, by and with the advice and concurrence of the Executive Council, orders under section 14 of the Municipal Boundary Negotiations Act, 1981 that,

- 1. On the 1st day of January, 1987, the portion of the Municipality of Neebing described in the Schedule is annexed to the City of Thunder Bay.
- 2. All real property of The Corporation of the Municipality of Neebing situate in the annexed area vests in The Corporation of the City of Thunder Bay on the 1st day of January, 1987.
- 3. On the 1st day of January, 1987, the by-laws of The Corporation of the City of Thunder Bay extend to the annexed area and the by-laws of The Corporation of the Municipality of Neebing cease to apply to such area, except,
 - (a) by-laws that were passed,
 - (i) by the council of The Corporation of the Municipality of Neebing under section 34 or 41 of the *Planning Act*, 1983 or a predecessor of those sections, or
 - (ii) by the council of The Corporation of the Municipality of Neebing that are kept in force by subsection 13 (3) of The Municipal Amendment Act, 1941,

which shall remain in force until repealed by the council of The Corporation of the City of Thunder Bay; and

- (b) by-laws conferring rights, privileges, franchises, immunities or exemptions that could not have been lawfully repealed by the council of The Corporation of the Municipality of Neebing.
- 4. The clerk of The Corporation of the Municipality of Neebing shall forthwith prepare and furnish to the clerk of The Corporation of the City of Thunder Bay a special collector's roll showing all arrears of taxes or special rates assessed against the lands in the annexed area up to and including the 31st day of December, 1986 and the persons assessed therefor.
- 5.—(1) All real property taxes levied under any general or special Act and uncollected in the annexed area that are due and unpaid on the 1st day of January, 1987 shall be deemed on that date to be taxes due and payable to The Corporation of the City of Thunder Bay and may be collected by The Corporation of the City of Thunder Bay.

- (2) All business taxes levied and uncollected in the annexed area that are due and unpaid on the 1st day of January, 1987 shall continue after that date to be taxes due and payable to The Corporation of the City of Thunder Bay and may be collected by The Corporation of the City of Thunder Bay.
- 6. For the purposes of the assessment roll to be prepared for the City of Thunder Bay under subsection 13 (1) of the *Assessment Act* in 1986, the annexed area shall be deemed to be a part of the City of Thunder Bay.
- 7. The Corporation of the City of Thunder Bay shall pay to The Corporation of the Municipality of Neebing on or before the sixtieth day after the filing of this Order, the sum of \$6,200 as compensation for loss of assessment in the annexed area.
- 8. The agreement between The Corporation of the City of Thunder Bay and The Corporation of the Municipality of Neebing entered into on the 27th day of May, 1986 is hereby given effect. O. Reg. 700/86.

Recommended

Bernard Grandmaître
Minister of Municipal
Affairs

Concurred

JAMES BRADLEY
Chairman

Approved and Ordered, November 26th, 1986.

LINCOLN M. ALEXANDER
Lieutenant Governor

Schedule

AREA TO BE ANNEXED TO THE CITY OF THUNDER BAY

The portion of the Municipality of Neebing described as follows:

Beginning at the southerly angle of Part 43 as shown on a Plan registered in the Land Titles Office for the Registry Division of Thunder Bay (No. 55) as Number FWR 69, the said angle being an angle of the City of Thunder Bay on the westerly high water mark of Lake Superior lying northwesterly of Grand Point;

Thence due east to the meridian of longitude 89° 06′ 30″ west;

Thence due north along the said meridian to the boundary of the City of Thunder Bay lying due east of the mouth of the Mission River;

Thence westerly and southerly following the boundaries between the said City and the Municipality of Neebing to the place of beginning. O. Reg. 700/86, Sched.

PLANNING ACT, 1983

O. Reg. 701/86.

Restricted Areas—District of Manitoulin, Geographic townships of Campbell, Dawson, Mills and Robinson. Made—November 28th, 1986. Filed—December 4th, 1986.

REGULATION TO AMEND ONTARIO REGULATION 672/81 MADE UNDER THE PLANNING ACT, 1983

- Ontario Regulation 672/81 is amended by adding thereto the following sections:
- 80. Despite subsection 5 (3), two guest cabins may be erected and used on the land in the geographic Township of Campbell in the District of Manitoulin, being the west half of Lot 8, Concession XVII, designated as Part 1 on Plan 31R-966 deposited in the Land Registry Office for the Land Titles Division of Manitoulin (No. 31), if the combined ground floor area of both guest cabins does not exceed 32.7 square metres. O. Reg. 701/86, s. 1, part.
- 81. Despite subsection 50 (1), a seasonal dwelling and buildings and structures accessory thereto may be erected and used on the land in the geographic Township of Robinson in the District of Manitoulin, being part of Lot 6, Concession I, designated as Part 47 on Plan RR-33 deposited in the Land Registry Office for the Land Titles Division of Manitoulin (No. 31), if the ground floor area of the seasonal dwelling does not exceed 19 square metres. O. Reg. 701/86, s. 1, part.

PAULINE MORRIS Director Plans Administration Branch North and East Ministry of Municipal Affairs

51

Dated at Toronto, this 28th day of November, 1986.

(9831)

MENTAL HEALTH ACT

O. Reg. 702/86. Application of Act. Made—December 3rd, 1986. Filed—December 4th, 1986. REGULATION TO AMEND REGULATION 609 OF REVISED REGULATIONS OF ONTARIO, 1980 MADE UNDER THE MENTAL HEALTH ACT

 Schedule 1 to section 1 of Regulation 609 of Revised Regulations of Ontario, 1980 is amended by adding thereto the following item:

20a. Kingston Kingston Penitentiary, Regional Treatment Centre

2.—(1) Clause 4 (3) (c) of the said Regulation is amended by adding thereto the following item:

la. Kingston Kingston Penitentiary,
Regional Treatment Centre

(2) Clause 4 (3) (e) of the said Regulation is amended by adding thereto the following item:

1a. Kingston Kingston Penitentiary, Regional Treatment Centre

(9832)

51

HEALTH CARE ACCESSIBILITY ACT, 1986

O. Reg. 703/86. Administrative Charge. Made—December 3rd, 1986. Filed—December 4th, 1986.

REGULATION MADE UNDER THE HEALTH CARE ACCESSIBILITY ACT, 1986

ADMINISTRATIVE CHARGE

1. The administrative charge for the purpose of subsection 4 (2) of the Act is \$50. O. Reg. 703/86, s. 1.

(9833)

51

HEALTH INSURANCE ACT

O. Reg. 704/86. General. Made—December 3rd, 1986. Filed—December 4th, 1986.

REGULATION TO AMEND REGULATION 452 OF REVISED REGULATIONS OF ONTARIO, 1980 MADE UNDER THE HEALTH INSURANCE ACT

1. Schedule 16 to Regulation 452 of Revised Regulations of Ontario, 1980, as remade by section 6 of Ontario Regulation 290/84 and amended by section 1 of Ontario Regulation 827/84, section 1 of Ontario Regulation 347/85, section 5 of Ontario Regulation 32/86, section 1 of Ontario Regulation 158/86 and section 1 of Ontario Regulation 288/86, is further amended by revoking:

"L700 PATIENT DOCUMENTATION AND SPECIMEN COLLECTION FEE

7"

on page 1165 under the heading "LABORATORY MEDICINE" and substituting therefor:

"L700 PATIENT DOCUMENTATION AND SPECIMEN COLLECTION FEE 8"

- 2. This Regulation shall be deemed to have come into force on the 1st day of July, 1986.
- 3. A reference in this Regulation to any page number is a reference to that page (foot pagination) in *The Ontario Gazette* dated the 19th day of May, 1984.

(9834)

51

HEALTH DISCIPLINES ACT

O. Reg. 705/86.
Dental Hygienists.
Made—November 12th, 1986.
Approved—December 3rd, 1986.
Filed—December 4th, 1986.

REGULATION TO AMEND REGULATION 446 OF REVISED REGULATIONS OF ONTARIO, 1980 MADE UNDER THE HEALTH DISCIPLINES ACT

- 1. Section 8 of Regulation 446 of Revised Regulations of Ontario, 1980, as remade by section 1 of Ontario Regulation 681/84, is revoked and the following substituted therefor:
- 8. Every registered dental hygienist shall pay annually a renewal fee of \$110 on or before the 1st day of January in each year. O. Reg. 705/86, s. 1.

COUNCIL OF THE ROYAL COLLEGE OF DENTAL SURGEONS OF ONTARIO:

KENNETH F. POWNALL Registrar

Dated at Toronto, this 12th day of November, 1986.

(9835)

LOCAL SERVICES BOARDS ACT

O. Reg. 706/86.
Establishment of Local Services
Board—Community of Jogues.
Made—November 28th, 1986.
Filed—December 4th, 1986.

REGULATION TO AMEND ONTARIO REGULATION 459/85 MADE UNDER THE LOCAL SERVICES BOARDS ACT

1. Section 4 of Ontario Regulation 459/85 is amended by striking out "and 4" in the second line and inserting in lieu thereof "4 and 6".

DAVID PETERSON
Premier and Acting Minister of
Northern Development and Mines

Dated at Toronto, this 28th day of November, 1986,

(9836)

5

OCCUPATIONAL HEALTH AND SAFETY ACT

O. Reg. 707/86.
Control of Exposure to Biological or Chemical Agents.
Made—December 3rd, 1986.
Filed—December 4th, 1986.

REGULATION TO AMEND ONTARIO REGULATION 654/86 MADE UNDER THE OCCUPATIONAL HEALTH AND SAFETY ACT

 Part 1 of the Schedule to Ontario Regulation 654/86 is amended by striking out,

Zinc chromates

76

where it appears on page 2354 (footnote pagination) of *The Ontario Gazette* dated the 22nd day of November, 1986 and inserting in lieu thereof,

2.—(1) Part 4 of the said Schedule is amended by striking out,

Styrene * (100-42-5)

50

213

100

425

where it appears on page 2394 (footnote pagination) of *The Ontario Gazette* dated the 22nd day of November, 1986 and inserting in lieu thereof,

Styrene * (100-42-5)

50

213

200

852

(2) The said Part 4 is further amended by striking out,

Zinc chromates (as chromium) (sum of (13530-65-9), (1103-86-9), and (37300-23-5))

0.01

where it appears on page 2400 (footnote pagination) of *The Ontario Gazette* dated the 22nd day of November, 1986.

(9837)

51

PLANNING ACT, 1983

O. Reg. 708/86.

Restricted Areas—County of Leeds and Grenville, Township of Oxford (on Rideau).

Made—December 4th, 1986. Filed—December 5th, 1986.

REGULATION TO REVOKE ONTARIO REGULATION 372/77 MADE UNDER THE PLANNING ACT, 1983

1. Ontario Regulations 372/77 and 22/81 are revoked.

BERNARD GRANDMAÎTRE Minister of Municipal Affairs

Dated at Toronto, this 4th day of December, 1986.

(9838)

51

PLANNING ACT, 1983

O. Reg. 709/86.

Zoning Areas—Part of the Districts of Nipissing and Sudbury.

Made—November 28th, 1986.

Filed—December 5th, 1986.

REGULATION TO AMEND ONTARIO REGULATION 40/85 MADE UNDER THE PLANNING ACT, 1983

- Section 18 of Ontario Regulation 40/85 is amended by adding thereto the following subsection:
- (2) Notwithstanding any other provision of this Order, no person shall erect a habitable building or structure on a lot fronting on Lake Nipissing unless the openings in the building or structure are above 197.25 metres C.G.D. O. Reg. 709/86, s. 1.
 - Subsection 34 (2) of the said Regulation is revoked and the following substituted therefor:
- (2) A dwelling unit accessory to a use permitted by subsection (1) may be located and used in the principal building or structure other than a building or structure used as an automobile service station, a vehicle sales and service establishment or a workshop. O. Reg. 709/86, s. 2.
 - The Schedule to the said Regulation is amended by adding thereto the following section:

16.—(1) Notwithstanding any other provision of this Order, the land described in subsection (2) may be used for a gravel pit.

(2) Subsection (1) applies to the land situate in the geographic Township of Crerar in the Territorial District of Nipissing, being part of Lot 4, Concession IV, shown as Part 1 on a Plan deposited in the Land Registry Office for the Land Titles Division of Nipissing (No. 36) as Number 36R-6982.

O. Reg. 709/86

PAULINE MORRIS Director Plans Administration Branch North and East Ministry of Municipal Affairs

Dated at Toronto, this 28th day of November, 1986.

(9839)

PLANNING ACT, 1983

O. Reg. 710/86. Zoning Areas-Part of the Districts of Nipissing and Sudbury. Made-October 10th, 1986. Filed-December 5th, 1986.

REGULATION TO AMEND ONTARIO REGULATION 40/85 MADE UNDER THE PLANNING ACT, 1983

- 1. The Schedule to Ontario Regulation 40/85 is amended by adding thereto the following section:
- 17. Notwithstanding that the land in the geographic Township of Loudon, District of Nipissing, being that part of Lot 12, Concession II, described as Part 1 on a Plan deposited in the Land Registry Office for the Registry Division of Nipissing (No. 36) as Number 36R-7135 is in a zone designated as Rural in clause 4 (a), it shall be deemed to be in the Seasonal Residential Zone to which Part V applies.

PAULINE MORRIS Director Plans Administration Branch North and East Ministry of Municipal Affairs

2698

Dated at Toronto, this 10th day of October, 1986.

PLANNING ACT, 1983

O. Reg. 712/86

O. Reg. 711/86. Zoning Areas-Part of the Districts of Nipissing and Sudbury. Made-October 10th, 1986. Filed—December 5th, 1986.

REGULATION TO AMEND ONTARIO REGULATION 40/85 MADE UNDER THE PLANNING ACT, 1983

- 1. The Schedule to Ontario Regulation 40/85 is amended by adding thereto the following section:
- 18. Notwithstanding that the parcel of land in the geographic Township of MacPherson, being that part of Lot 1, Concession V, described as Part 1 on a Plan deposited in the Land Registry Office for the Registry Division of Nipissing (No. 36) as Number 36R-3439, is shown on a map referred to in clause 4 (b) as in a Rural Zone, it shall be deemed to be in the General Commercial Zone to which Part VI applies.

PAULINE MORRIS Director Plans Administration Branch North and East Ministry of Municipal Affair.

Dated at Toronto, this 10th day of October, 1986.

(9841)

PLANNING ACT, 1983

O. Reg. 712/86. Zoning Areas-Part of the Districts of Nipissing and Sudbury. Made-October 23rd, 1986. Filed-December 5th, 1986.

REGULATION TO AMEND **ONTARIO REGULATION 40/85** MADE UNDER THE PLANNING ACT, 1983

- 1. The Schedule to Ontario Regulation 40/85 is amended by adding thereto the following section:
- 19. Notwithstanding any other provision of this Order, no building or structure shall be erected within thirty metres of the Temagami River, measured from

(9840)

6337

51

the top of the bank, on that parcel of land in the geographic Township of Crerar in the Territorial District of Nipissing, being that part of Lot 1, Concession V, described as Part 6 on a Plan deposited in the Land Registry Office for the Registry Division of Nipissing (No. 36) as Number NRD-1872.

PAULINE MORRIS
Director
Plans Administration Branch
North and East
Ministry of Municipal Affairs

Dated at Toronto, this 23rd day of October, 1986.

(9842)

3

LIQUOR LICENCE ACT

O. Reg. 713/86. General. Made—December 3rd, 1986. Filed—December 5th, 1986. REGULATION TO AMEND REGULATION 581 OF REVISED REGULATIONS OF ONTARIO, 1980 MADE UNDER THE LIQUOR LICENCE ACT

 Regulation 581 of Revised Regulations of Ontario, 1980 is amended by adding thereto the following section:

53a.—(1) In this section, "stadium facility" means the lands and premises comprising a stadium facility located on Parcel A as shown on Map 2 in Appendix D, City of Toronto By-law 204-86.

(2) Subsection 6 (2) of the Act does not apply, in respect of the stadium facility, to Stadium Corporation of Ontario Limited or a licensee of licensed premises in the stadium facility. O. Reg. 713/86, s. 1.

(9843)



Publications Under The Regulations Act

December 27th, 1986

PLANNING ACT, 1983

O. Reg. 714/86.

Restricted Areas—District of Thunder Bay, Geographic townships of Pearson and Scoble.

Made—November 4th, 1986. Filed—December 9th, 1986.

REGULATION TO AMEND ONTARIO REGULATION 219/75 MADE UNDER THE PLANNING ACT, 1983

- 1. Ontario Regulation 219/75 is amended by adding thereto the following section:
- 20. Notwithstanding any other provision of this Order, a single-family cottage and buildings and structures accessory thereto may be erected and used on that parcel of land in the geographic Township of Pearson in the Territorial District of Thunder Bay, described as Lot 1 on a Plan registered in the Land Registry Office for the Land Titles Division of Thunder Bay (No. 55) as Number M-99. O. Reg. 714/86, s. 1.

PAULINE MORRIS
Director
Plans Administration Branch
North and East
Ministry of Municipal Affairs

Dated at Toronto, this 4th day of November, 1986.

(9845)

PLANNING ACT, 1983

O. Reg. 715/86. Rules of Procedure—Consent Applications. Made—December 3rd, 1986. Filed—December 9th, 1986.

REGULATION TO AMEND ONTARIO REGULATION 406/83 MADE UNDER THE PLANNING ACT, 1983

1. Paragraph 5 of section 5 of Ontario Regulation 406/83 is revoked and the following substituted therefor:

- 5. Where the land that is the subject of the application is within or adjoins the area covered by the Niagara Escarpment Plan, to the senior planner of the district office of the Niagara Escarpment Commission having jurisdiction in the area in which the land is situated.
- Section 5 of the said Regulation is amended by adding thereto the following paragraph:
 - 6a. Where the land that is the subject of the application is within an area that is under the jurisdiction of a conservation authority, to its chief administrative officer, unless he or she has advised the official in writing that he or she does not wish to receive copies of applications.
- 3. Sections 9 and 10 of the said Regulation are revoked.
- 4. This Regulation comes into force on the 1st day of January, 1987.

(9846)

52

NIAGARA ESCARPMENT PLANNING AND DEVELOPMENT ACT

O. Reg. 716/86.

Development Within the Development Control Area.

Made—November 26th, 1986.

Filed—December 10th, 1986.

REGULATION TO AMEND REGULATION 685 OF REVISED REGULATIONS OF ONTARIO, 1980 MADE UNDER THE NIAGARA ESCARPMENT PLANNING AND DEVELOPMENT ACT

 Schedule 1 to Regulation 685 of Revised Regulations of Ontario, 1980, as amended by section 2 of Ontario Regulation 181/82, section 1 of Ontario Regulation 694/82, section 1 of Ontario Regulation 98/86 and section 1 of Ontario Regulation 290/86, is further amended by adding thereto the following item:

8b. By-law 50-1981 Township of Artemesia

BERNARD GRANDMAÎTRE
Minister of Municipal Affairs

Dated at Toronto, this 26th day of November, 1986.

(9848)

APPRENTICESHIP AND TRADESMEN'S OUALIFICATION ACT

O. Reg. 717/86. General. Made—December 3rd, 1986. Filed—December 10th, 1986.

REGULATION TO AMEND
REGULATION 36 OF
REVISED REGULATIONS
OF ONTARIO, 1980
MADE UNDER THE
APPRENTICESHIP AND
TRADESMEN'S QUALIFICATION
ACT

- 1. Section 5 of Regulation 36 of Revised Regulations of Ontario, 1980 is amended by adding thereto the following subsection:
- (2) Sections 9 and 10 of the Act and section 10 of this Regulation do not apply to each person who is engaged in a trade for which an apprenticeship training program is established by an employer and approved by the Director. O. Reg. 717/86, s. 1.

(9849) 52

APPRENTICESHIP AND TRADESMEN'S QUALIFICATION ACT

O. Reg. 718/86. Industrial Electrician. Made—December 3rd, 1986. Filed—December 10th, 1986.

REGULATION MADE UNDER THE APPRENTICESHIP AND TRADESMEN'S QUALIFICATION ACT

INDUSTRIAL ELECTRICIAN

1. In this Regulation,

"certified trade" means the trade of industrial electrician;

"industrial electrician" means a person who, in an industrial plant, shop or premises,

- (a) lays out, assembles, installs, repairs, maintains, connects or tests electrical fixtures, apparatus, control equipment and wiring for electrical systems,
- (b) plans installations from blueprints, sketches, specifications and installs all electrical and electronic devices,
- (c) systematically diagnoses faults in electrical and electronic systems and equipment and repairs or replaces electrical and electronic components as required,
- (d) measures, cuts, threads, bends, assembles and installs conduits and other electrical conductor enclosures,
- (e) splices and terminates electrical conductors, and
- (f) tests electrical and electronic equipment for proper function. O. Reg. 718/86, s. 1.
- 2. The trade of industrial electrician is designated as a certified trade for the purposes of the Act. O. Reg. 718/86, s. 2.
- 3. An apprentice training program is established for the certified trade and shall consist of five periods of related training and work experience of 1,800 hours per period,
 - (a) at full-time educational day classes provided at a location approved by the Director or in courses that, in the opinion of the Director, are equivalent thereto in each of the subjects contained in Schedule 1; and
 - (b) in work experience training provided by the employer of an apprentice in the subjects contained in Schedule 2. O. Reg. 718/86, s. 3.
- 4. The subjects of examination for an apprentice in the certified trade are based on the subjects contained in Schedules 1 and 2. O. Reg. 718/86, s. 4.
- 5. Notwithstanding subsection 8 (2) of Regulation 36 of Revised Regulations of Ontario, 1980, every hour worked by an apprentice in excess of the regular daily hours of related training and work experience of the apprentice shall be included in computing the hours spent by the apprentice in related training and work experience. O. Reg. 718/86, s. 5.
- 6. The rate of wages for an apprentice in the certified trade, whether for the regular daily hours of work or for hours of work in excess of the regular daily hours of work of the apprentice, shall be not less than,

- (a) 40 per cent during the first period;
- (b) 50 per cent during the second period;
- (c) 60 per cent during the third period;
- (d) 70 per cent during the fourth period; and
- (e) 80 per cent during the fifth period,

of the average hourly rate of wages or its equivalent for journeymen employed by the employer in the certified trade or where the employer is the only journeyman employed, of the average hourly rate of wages for journeymen in the area. O. Reg. 718/86, s. 6.

- 7. The number of apprentices who may be employed by an employer in the certified trade shall not exceed,
 - (a) where the employer is a journeyman in the certified trade, one apprentice plus one additional apprentice for each additional two journeymen employed by the employer and with whom the apprentice is working; and
 - (b) where the employer is not a journeyman in the certified trade, one apprentice for the first journeyman employed by the employer plus one additional apprentice for each additional two journeymen employed by the employer in the certified trade and with whom the apprentice is working. O. Reg. 718/86, s. 7.

- 8. Notwithstanding section 7, on the advice of the provincial advisory committee or local apprenticeship committee appointed under the Act for the certified trade, the Director may determine the ratio of apprentices to journeymen who may be employed by an employer in the certified trade. O. Reg. 718/86, s. 8.
- 9. The Director shall issue a progress record book to an apprentice in the certified trade for the purpose of recording the progress of the apprentice in respect of related training and work experience, and the apprentice shall be responsible for keeping the progress record book up to date and for its safekeeping. O. Reg. 718/86, s. 9.
- 10. An applicant for a certificate of qualification in the certified trade who is required to satisfy the Director under clause 11 (4) (b) or (c) of the Act shall submit to the Director proof of experience within the trade that, in the opinion of the Director, is equivalent to work experience training in the subjects contained in Schedule 2. O. Reg. 718/86, s. 10.
- 11.—(1) Section 9 and subsection 11 (2) of the Act do not apply to any person who works or is employed in the certified trade.
- (2) Section 10 and subsection 11 (3) of the Act do not apply to an employer in the certified trade. O. Reg. 718/86, s. 11.
- 12. A certificate of qualification in the certified trade is not required to be renewed. O. Reg. 718/86, s. 12.

Schedule 1 IN-SCHOOL TRAINING

| ITEM | COLUMN 1 | COLUMN 2 | | | | | | | | | | |
|------|--------------------|---|--|--|--|--|--|--|--|--|--|--|
| TIEM | Unit of Study | Instruction to be given | | | | | | | | | | |
| 1 | Safety | Demonstrate a knowledge of safety rules and hazards as specified in the Occupational Health and Safety Act and Ontario Regulation 183/84 (Electrical Safety Code). Understand the care and use of hand and power tools and equipment including: ladders, scaffolding and hoisting equipment. Understand and apply safety rules and precautions pertaining to electrical equipment and installations. | | | | | | | | | | |
| 2 | Trade Calculations | Add, subtract, multiply, divide whole numbers, fractions and decimals. Compute metric conversions, weights, measures, ratios, proportions, percentages, areas, volumes, linear and angular mensuration, square roots, algebraic fundamentals, linear equations, formulae, shop calculations and trigonometric functions such as right angled and oblique triangles. | | | | | | | | | | |
| | Blueprints | Demonstrate a knowledge of the reproduction process, basic drawings and sketching, architectural symbols, plan views, elevations, electrical, electronic, and mechanical drawings specifications, branch circuit wiring, service equipment, grounding and bonding, field modifications, circuit changes, basic drafting skills. | | | | | | | | | | |

| | COLUMN 1 | COLUMN 2 |
|------|---|---|
| Ітем | Unit of Study | Instruction to be given |
| 3 | Electrical/ Electronic Theory | Determine and apply electrical/electronic theory and trade practice, circuit theory, atomic theory, Ohm's Law, laws of magnetism, wire calculations, electromotive force and terminal voltages, analysis of series and parallel circuits, chemical cells, motors, motor controls, capacitors, resistors, photo-electric devices, semi-conductors. Identify the type, characteristic of each type of circuit and/or logic systems and precautions to be taken with each. |
| 4 | Hand and Power Tools | Select and use hand and power tools such as: hammers, screwdrivers, wrenches, pliers, hacksaws, wood cutting and masonary saws, files, chisels, portable hand and power drills, conduit benders and pipe threaders, soldering and brazing equipment, grinding, levelling equipment, and wire pulling systems. |
| 5 | Wiring Methods: Power Distribution | Install, replace, test, and maintain switch gear, transformers and distribution systems. Repair breakers, bus duct, secondary transformers and feeds to electrical equipment. Select, install, and replace fuses. |
| | Construction | Select, bend, thread, install conduit and fittings. Select, install raceways, fittings, busways, trays, supports and fittings, junction boxes, pull boxes, switch boxes and electrical splitter boxes. Select, install, terminate wire. Pull wire. |
| | Canadian Electric Code | Interpret and apply regulations of the code in any given situation. |
| | Illumination | Select correct illumination equipment/fixtures. Layout, install, maintain/repair and replace fixtures. (Observing fixture hazards). |
| 6 | Rotating Equipment | Install, test, and maintain/repair rotating machinery (including alignment and vibration) for AC and DC motors, generators and controls. Install, test, maintain/repair electric braking and clutch systems. |
| 7 | Troubleshooting | Systematically diagnose faults in an electrical/electronic system or piece of equipment and correct fault. Adjust, repair, or replace faulty component, circuit or device. Check operation of circuit or device after repair for proper function. |
| 8 | Drive Systems | Install, set up, replace, test and maintain/repair and operate (for test purposes) A/C—D/C magnetic solid state drive systems to the specifications of the process. |
| 9 | Electrical- Pneumatic and Hydraulic Devices | Select, identify, and perform diagnostic procedures on electrical-pneumatic systems, pneumatic solenoids, valves, electrical-pneumatic converters, electrical-pneumatic controls and electro-pneumatic and hydraulic devices. |
| 10 | Cranes, Elevating, and Hoisting Equipment | Identify, install, test, maintain/repair electrical equipment for AC/DC cranes, hoists, and elevating devices. Install, test, maintain/repair wiring, relays, timers, solid state components, limit switches, transformers, motors, rectifiers, control devices, brakes for cranes, hoists and elevating devices. |

| Imme | COLUMN 1 | Column 2 |
|------|---|--|
| ITEM | Unit of Study | Instruction to be given |
| 11 | Welding Machines | Install, test, set up and maintain/repair various types of resistance welding and arc welding machines. Install, test, repair variable voltage/current devices, such as transformer tapping, phase shifting, pulsating and timing controls. Comprehend principles of arc, resistance and wire welding. Identify, test, install, maintain/repair wire feed, speed, pneumatic and hydraulic controls. |
| 12 | Heating | Install, test, operate and maintain/repair electrical systems for gas fired, oil fired and electric resistance furnaces. Install, test, maintain/repair electrical components such as solenoids, safety circuits, flaming circuits, igniter circuits, air/environmental controls, recording controls, thermocouples, gold fuses and temperature controls. Install, test, maintain/repair and operate for purpose of testing induction and di-electric heating equipment. Knowledge of the hazards of this type of equipment. |
| 13 | Programmable Controllers | Identify, install, replace, test, maintain/repair and program programmable controllers. Apply programming techniques using principals of electrical equipment such as: relays, latches, counters and timers. Test, replace, maintain/repair and program various elements such as: power supply, memory, microprocessor module, input/output modules and main frame. |
| 14 | Microprocessors and Microcomputer Systems | Identify, install, replace, test, maintain/repair elements within the system with respect to gating, flip flops, decoders/encoders, multiplexer and demultiplexers, buffers and tri-state devices, bus transceivers, peripherals, such as printers, C.R.T. displays, punch tapes, keyboards and telephone interface and links. Apply programming techniques for sequences, convert functions and arithmetic functions. Comprehend elementary programming techniques to communicate with computer and systems. |
| 15 | Numerical Control | Troubleshoot, test and diagnose faults in numerical control equipment. Apply binary techniques and basic logic, operate for test purposes numerical control equipment. Install, test, maintain/repair components, tape readers, roto pulsers, tachometers and servos. |
| 16 | Test Equipment | Interpret and apply principles of operation and application of testing equipment. Select and use analog/digital instrument testing equipment such as oscilloscopes, multimeters, voltmeters, ammeters, ohmmeters, wattmeters, insulation testers, tachometers, demand and power factor meters. |
| 17 | Instrumentation | Identify, install, repair and replace measuring instruments for: temperature, pressure, volume, flow, weight, linear measurement, density, specific gravity, pH and gas analysis. Calibrate, adjust and repair electric/electronic air conditioning equipment. |

O. Reg. 718/86, Sched. 1.

Schedule 2

WORK EXPERIENCE TRAINING

| Ітем | Column 1 | COLUMN 2 |
|------|--|--|
| HEM | Unit of Study | Instruction to be given |
| 1 | Trade Practice | Apply safety rules and remove hazards as specified in the <i>Occupational Health and Safety Act</i> , and Ontario Regulation 183/84 (Electrical Safety Code) and specific company safety rules and regulations. Use and maintain hand and power tools and equipment, testing instruments, including tools for layout, cutting, drilling, reaming, threading, forming and bending, fastening, welding, soldering, grinding and levelling, wire and cable pulling, rigging. |
| 2 | Electrical/ Electronic Theory | Apply A/C—D/C theory and electronic theory to industrial installations, repair and maintenance. Apply related formulae and calculations, codes, standards and regulations. |
| 3 | Blueprints | Interpret and use architectural, electrical/electronic, mechanical and structural drawings and blueprints. Understand specifications and change notices. Modify drawings. |
| 4 | Wiring Methods: Power Distribution | Install, repair, and maintain switch gear, transformers, breakers and feeds to other electrical equipment. Test protective devices. |
| | Conduits, Raceways, and Busways | Select and install rigid and flexible conduits and fittings, raceways, busways and fittings, wire, cable, switchgear and switches. |
| | Wire and Cable | Install building cable, underground cable, free air conductors, high and low voltage conductors. Tape, insulate and terminate conductors. Conduct insulation testing. Pull wire and cable. |
| | Illumination | Install, repair, and maintain lighting systems such as: fluorescent, incandescent, quartz, metal arc and vapour lighting systems. |
| 5 | Rotating Equipment | Install, repair, test and maintain rotating equipment such as: generators, A/C motors, D/C motors and alternators. Install, test, repair, and maintain electrical braking and clutch systems. |
| 6 | Drive Systems A/C—D/C | Install, repair, and maintain A/C and D/C magnetic solid state drive systems, amplifiers, rectifiers, single and dual converters. Test and maintain batteries and contactors. |
| 7 | Cranes, Elevating, and Hoisting Equipment | Install, repair, and maintain crane, hoists and elevating equipment. |
| 8 | Welding Devices | Install, repair, and maintain welding equipment. |
| 9 | Furnace Heating | Install, repair, and maintain electrical systems such as: gas fired, oil fired, electric resistance, induction and di-electric furnaces and heating devices. |
| 10 | Programmable Controllers | Install, test, replace, maintain/repair various elements such as: power supply, memory, microprocessor, input/output modules, relays, latches, counters and timers. Program for test purposes. |

| Impa | COLUMN 1 | COLUMN 2 Instruction to be given | | | | | | | | | |
|------|----------------------------------|---|--|--|--|--|--|--|--|--|--|
| ITEM | Unit of Study | | | | | | | | | | |
| 11 | Microprocessors Microcomputer | Install, repair, maintain, test elements of the system such as: card sub-assemblies gates, decoders/encoders printers, displays, punch tape equipment and keyboards. Apply programming techniques for test purposes. | | | | | | | | | |
| 12 | Numerical Control | Test, repair, and operate control equipment for test purposes. Test and repair tape readers, roto pulsers, tachometers and servos. | | | | | | | | | |
| 13 | Instrumentation | Install, repair, and replace measuring instruments for: temperature, pressure, volume flow, weight, linear measurement, density, specific gravity, pH and gas analysis. Calibrate, adjust, and repair electrical and electronic measuring instruments and air conditioning equipment. | | | | | | | | | |

O. Reg. 718/86, Sched. 2.

52

(9850)

HEALTH DISCIPLINES ACT

O. Reg. 719/86. Pharmacy. Made—November 19th, 1986. Approved—December 10th, 1986. Filed—December 11th, 1986.

REGULATION TO AMEND REGULATION 451 OF REVISED REGULATIONS OF ONTARIO, 1980 MADE UNDER THE HEALTH DISCIPLINES ACT

- 1. Section 42 of Regulation 451 of Revised Regulations of Ontario, 1980 is amended by striking out "and" at the end of sub-subclause (1) (a) (ii) (B), by adding "and" at the end of sub-subclause (C) and by adding thereto the following sub-subclause:
 - (D) are required to be posted under the Prescription Drug Cost Regulation Act, 1986;

COUNCIL OF THE ONTARIO COLLEGE OF PHARMACISTS:

BARRY HOLLIDAY
President

WILLIAM R. WENSLEY
Registrar

Dated at Toronto, this 19th day of November, 1986.

HEALTH PROTECTION AND PROMOTION ACT, 1983

O. Reg. 720/86. Rabies—Immunization. Made—December 10th, 1986. Filed—December 11th, 1986.

REGULATION TO AMEND ONTARIO REGULATION 594/85 MADE UNDER THE HEALTH PROTECTION AND PROMOTION ACT, 1983

- 1. Table 1 to Ontario Regulation 594/85, as amended by section 1 of Ontario Regulation 120/86, section 3 of Ontario Regulation 287/86, section 1 of Ontario Regulation 501/86, section 1 of Ontario Regulation 622/86 and section 1 of Ontario Regulation 660/86, is further amended by adding thereto the following item:
- 10. Oxford County

March 1, 1987

(9873)

52

HEALTH INSURANCE ACT

O. Reg. 721/86. General. Made—December 10th, 1986. Filed—December 11th, 1986.

REGULATION TO AMEND REGULATION 452 OF REVISED REGULATIONS OF ONTARIO, 1980 MADE UNDER THE HEALTH INSURANCE ACT

O. Reg. 721/86

- 1. Paragraph 1 of subsection 53 (2) of Regulation 452 of Revised Regulations of Ontario, 1980 is revoked and the following substituted therefor:
 - 1. Anaesthetic services rendered in connection with the removal of an impacted tooth by a dentist in a hospital, where the services rendered by the dentist do not meet the conditions set out in subsection 46 (4).
- 1a. Anaesthetic services rendered in connection with services rendered by a dentist outside of a hospital.

(9874)

HEALTH INSURANCE ACT

O. Reg. 722/86. General. Made-December 10th, 1986. Filed—December 11th, 1986.

REGULATION TO AMEND **REGULATION 452 OF** REVISED REGULATIONS OF ONTARIO, 1980 MADE UNDER THE HEALTH INSURANCE ACT

1.—(1) Subsection 52 (3 fa) of Regulation 452 of Revised Regulations of Ontario, 1980, exclusive of the clauses, as made by subsection 1 (2) of Ontario Regulation 290/84 and amended by subsection 1 (2) of Ontario Regulation 548/84, subsection 1 (1) of Ontario Regulation 18/86 and subsection 1 (2) of Ontario Regulation 32/86, is revoked and the following substituted therefor:

(3fa) Notwithstanding subsection (3ea), amount payable by the Plan for an insured service rendered by a laboratory on or after the 1st day of April, 1984 and before the 1st day of April, 1985 is, the amount arrived at by multiplying the applicable individual unit value for such service set out opposite the service in Schedule 16 by the amount calculated

- (2) Subsection 52 (3fb) of the said Regulation, as made by subsection 1 (2) of Ontario Regulation 32/86, is revoked and the following substituted therefor:
- (3fb) Notwithstanding subsection (3ea), the amount payable by the Plan for an insured service rendered by a laboratory on or after the 1st day of April, 1985 and before the 1st day of July, 1985 is,
 - (a) where the service is authorized by a physician who has clinically assessed the patient;
 - (b) where the physician does not hold a certificate from the Royal College of Physicians and Surgeons of Canada in a specialty; and
 - (c) where the total individual unit values for the services authorized by the physician during the period from the 1st day of April, 1985 to the 31st day of March, 1986 are greater than 150,000 but less than 200,001,

the amount arrived at by multiplying the applicable individual unit value for such service set out opposite the service in Schedule 16 by the amount calculated

- (d) multiplying the first 150,000 individual unit values by 47.7 cents;
- (e) multiplying the excess by 35.8 cents;
- (f) adding the amounts arrived at under clauses (d) and (e); and
- (g) dividing the amount arrived at under clause (f) by the total individual unit values.
- subsection (3eb), the (3fc) Notwithstanding amount payable by the Plan for an insured service rendered by a laboratory on or after the 1st day of July, 1985 is,
 - (a) where the service is authorized by a physician who has clinically assessed the patient;
 - (b) where the physician does not hold a certificate from the Royal College of Physicians and Surgeons of Canada in a specialty; and
 - (c) where the total individual unit values for the services authorized by the physician during the period from the 1st day of April, 1985 to the 31st day of March, 1986 are greater than 150,000 but less than 200,001,

the amount arrived at by multiplying the applicable individual unit value for such service set out opposite the service in Schedule 16 by the amount calculated

- (d) multiplying the first 150,000 individual unit values by 48.3 cents;
- (e) multiplying the excess by 36.2 cents;
- (f) adding the amounts arrived at under clauses (d) and (e); and
- (g) dividing the amount arrived at under clause (f) by the total individual unit values. O. Reg. 722/86, s. 1 (2).
- (3) Subsection 52 (3h) of the said Regulation, exclusive of the clauses, as made by subsection 1 (2) of Ontario Regulation 290/84 and amended by subsection 1 (3) of Ontario Regulation 548/84. subsection 1 (2) of Ontario Regulation 18/86 and subsection 1 (3) of Ontario Regulation 32/86, is revoked and the following substituted therefor:
- (3h) Notwithstanding subsection (3ea), the amount payable by the Plan for an insured service rendered by a laboratory on or after the 1st day of April, 1984 and before the 1st day of April, 1985 is,

the amount arrived at by multiplying the applicable individual unit value for such service set out opposite the service in Schedule 16 by the amount calculated

- (4) Subsection 52 (3i) of the said Regulation, as made by subsection 1 (3) of Ontario Regulation 32/86, is revoked and the following substituted therefor:
- (3i) Notwithstanding subsection (3ea), the amount payable by the Plan for an insured service rendered by a laboratory on or after the 1st day of April, 1985 and before the 1st day of July, 1985 is,
 - (a) where the service is authorized by a physician who has clinically assessed the patient:
 - (b) where the physician does not hold a certificate from the Royal College of Physicians and Surgeons of Canada in a specialty; and
 - (c) where the total individual unit values for the services authorized by the physician during the period from the 1st day of April, 1985 to the 31st day of March, 1986 are greater than 200,000,

the amount arrived at by multiplying the applicable individual unit value for such service set out opposite the service in Schedule 16 by the amount calculated

- (d) multiplying the first 150,000 individual unit values by 47.7 cents;
- (e) multiplying the next 50,000 individual unit values by 35.8 cents;
- (f) multiplying the excess by 23.9 cents;
- (g) adding the amounts arrived at under clauses (d), (e) and (f); and
- (h) dividing the amount arrived at under clause (g) by the total individual unit values.
- (3j) Notwithstanding subsection (3eb), the amount payable by the Plan for an insured service rendered by a laboratory on or after the 1st day of July, 1985 is,
 - (a) where the service is authorized by a physician who has clinically assessed the patient:
 - (b) where the physician does not hold a certificate from the Royal College of Physicians and Surgeons of Canada in a specialty; and
 - (c) where the total individual unit values for the services authorized by the physician during the period from the 1st day of April, 1985 to the 31st day of March, 1986 are greater than 200,000.

the amount arrived at by multiplying the applicable individual unit value for such service set out opposite the service in Schedule 16 by the amount calculated by,

- (d) multiplying the first 150,000 individual unit values by 48.3 cents;
- (e) multiplying the next 50,000 individual unit values by 36.2 cents;
- (f) multiplying the excess by 24.2 cents;
- (g) adding the amounts arrived at under clauses (d), (e) and (f); and
- (h) dividing the amount arrived at under clause (g) by the total individual unit values. O. Reg. 722/86, s. 1 (4).

(9875)

52

LOCAL ROADS BOARDS ACT

O. Reg. 723/86.

Establishment of Local Roads Areas-Northwestern Region.

Made-December 3rd, 1986.

Filed-December 12th, 1986.

REGULATION TO AMEND **REGULATION 599 OF** REVISED REGULATIONS OF ONTARIO, 1980 MADE UNDER THE LOCAL ROADS BOARDS ACT

1. Schedule 4 to Regulation 599 of Revised Regulations of Ontario, 1980, as remade by section 1 of Ontario Regulation 389/85, is revoked and the following substituted therefor:

Schedule 4

STRIKER LOCAL ROADS AREA

All those portions of the Township of Striker in the Territorial District of Algoma shown outlined on Ministry of Transportation and Communications Plan N-357-5, filed with the Administrative Services Office of the Ministry of Transportation and Communications at Toronto on the 10th day of November, 1986. O. Reg. 723/86, s. 1.

2. Schedule 32 to the said Regulation, as remade by section 1 of Ontario Regulation 274/84, is revoked and the following substituted therefor:

Schedule 32

REEF POINT LOCAL ROADS AREA

All those portions of the Township of Watten in the Territorial District of Rainy River shown outlined on Ministry of Transportation and Communications Plan N-1015-7, filed with the Administrative Services Office of the Ministry of Transportation and Communications at Toronto on the 10th day of November, 1986. O. Reg. 723/86, s. 2.

3. Schedule 97 to the said Regulation, as remade by section 3 of Ontario Regulation 87/83, is revoked and the following substituted therefor:

Schedule 97

PERCH LAKE LOCAL ROADS AREA

All those portions of the townships of Asmussen and Baker and unsurveyed territory lying south of the townships of Baker and Asmussen in the Territorial District of Rainy River, shown outlined on Ministry of Transportation and Communications Plan N-5000-C3, filed with the Administrative Services Office of the Ministry of Transportation and Communications at Toronto on the 10th day of November, 1986. O. Reg. 723/86, s. 3.

4. Schedule 113 to the said Regulation, as remade by section 4 of Ontario Regulation 132/84, is revoked and the following substituted therefor:

Schedule 113

PICKEREL LAKE LOCAL ROADS AREA

All those portions of the townships of Broderick, Malachi, Rudd, Gidley and Pelican in the Territorial District of Kenora, shown outlined on Ministry of Transportation and Communications Plan N-1364-3, filed with the Administrative Services Office of the Ministry of Transportation and Communications at Toronto on the 10th day of November, 1986. O. Reg. 723/86, s. 4.

> EDWARD FULTON Minister of Transportation and Communications

> > 52

52

Dated at Toronto, this 3rd day of December, 1986.

(9882)

HIGHWAY TRAFFIC ACT

O. Reg. 724/86. Demerit Point System. Made-December 3rd, 1986. Filed-December 12th, 1986.

REGULATION TO AMEND **ONTARIO REGULATION 359/81** MADE UNDER THE HIGHWAY TRAFFIC ACT

- 1. Subsection 8 (2) of Ontario Regulation 359/81, as remade by section 1 of Ontario Regulation 276/84, is amended by adding thereto the following clause:
 - (d) a person who is a resident of any province of Canada other than Ontario, country or state and who holds a valid driver's licence in accordance with the laws of that province, country or state.

(9883)

ADMINISTRATION OF JUSTICE ACT

O. Reg. 725/86.

Fees and Expenses—Justices of the Peace. Made—December 10th, 1986. Filed-December 12th, 1986.

REGULATION TO AMEND ONTARIO REGULATION 620/85 MADE UNDER THE ADMINISTRATION OF JUSTICE ACT

- 1. Section 4 of Ontario Regulation 620/85 is revoked and the following substituted therefor:
- 4.—(1) Where a justice of the peace who is not employed in the public service of Ontario is required to travel to perform duties, the justice of the peace shall be paid,
 - (a) a travel allowance as set out in Ontario Regulation 283/82, entitled "Kilometre Allowances"; and
 - (b) an allowance for meal and accommodation expenses in accordance with the provisions of the Ministry of the Attorney General Manual of Administration.
- (2) No allowance is payable under this section where the duties are performed at the location where the justice of the peace is normally assigned at times when the justice of the peace is normally scheduled to be in attendance at that location. O. Reg. 725/86, s. 1.

(9884) 52

LEGAL AID ACT

O. Reg. 726/86. General. Made—December 1st, 1986. Approved—December 10th, 1986. Filed—December 12th, 1986.

REGULATION TO AMEND ONTARIO REGULATION 59/86 MADE UNDER THE LEGAL AID ACT

- Section 1 of Ontario Regulation 59/86 is amended by adding thereto the following clause:
- (ea) "Convocation" means a regular or special meeting of the benchers of the Law Society convened for the purpose of transacting business:
- 2. The said Regulation is amended by adding thereto the following Part:

PART II-A

TARIFF REVIEW COMMITTEE

- 3a.—(1) There shall be a Committee, known as the Tariff Review Committee, composed of,
 - (a) two members appointed by the Law Society; and
 - (b) two members appointed by the Attorney General.
 - (2) The Tariff Review Committee,
 - (a) shall monitor the schedule of fees prescribed by this Regulation in light of all relevant economic circumstances and the fees generally charged by solicitors to clients of modest means;
 - (b) shall, by the 31st day of January in each year, recommend to the Legal Aid Committee,
 - (i) whether and to what extent the schedule of fees should be amended, and
 - (ii) the percentage, not exceeding 5 per cent, by which fees payable to solicitors for legal aid provided pursuant to certificates issued after the 31st day of March in that year or provided as duty counsel after that 31st day of March should be reduced under subsection 25a (2) or (3) of the Act.
- (3) The Legal Aid Committee shall submit any recommendations received under clause (2) (b), together with its recommendations, if any, to Convocation and the Law Society, after considering the recommendations, shall submit to the Attorney General,
 - (a) by the 28th day of February in each year, a draft regulation setting out the percentage, not exceeding 5 per cent, by which fees payable to solicitors for legal aid provided pursuant to certificates issued after the 31st day of March in that year or provided as duty counsel after that 31st day of March are to be reduced under subsection 25a (2) or (3) of the Act; and
 - (b) by the 31st day of March in each year, its recommendations on whether and to what extent the schedule of fees should be amended.
- (4) Subclause (2) (b) (ii) and clause (3) (a) do not apply until the 1st day of January, 1988. O. Reg. 726/86, s. 2.
 - 3. Clause 4 (1) (e) of the said Regulation is revoked.

- 4.—(1) Subsection 88 (1) of the said Regulation is amended by adding thereto the following clause:
- (fa) all assessable administrative expenses;
- (2) Subsection 88 (2) of the said Regulation is amended by adding thereto the following clause:
 - (da) the assessable administrative expenses;
 - 5. The said Regulation is further amended by adding thereto the following Part:

PART VI-A

CONTRIBUTIONS TO FUND

91a.—(1) The Law Society shall contribute to the Fund a percentage of the assessable administrative expenses as follows:

- 1. On or before the 31st day of March, 1987, an amount equal to 12.5 per cent of the estimated assessable administrative expenses for the fiscal year beginning on the 1st day of April, 1986, as estimated by the Director.
- 2. On or before the 30th day of June, 1987, the difference, if any, between 12.5 per cent of the assessable administrative expenses for the fiscal year referred to in paragraph 1 and the amount paid under that paragraph.
- 3. On or before the 31st day of March, 1988, an amount equal to 25 per cent of the estimated assessable administrative expenses for the fiscal year beginning on the 1st day of April, 1987, as estimated by the Director.
- 4. On or before the 30th day of June, 1988, the difference, if any, between 25 per cent of the assessable administrative expenses for the fiscal year referred to in paragraph 3 and the amount paid under that paragraph.
- 5. On or before the 31st day of March in each year, beginning in 1989, an amount equal to 50 per cent of the estimated assessable administrative expenses for the fiscal year that began on the preceding 1st day of April, as estimated by the Director.
- 6. On or before the 30th day of June in each year, beginning in 1989, the difference, if any, between 50 per cent of the assessable administrative expenses for the fiscal year referred to in paragraph 5 and the amount paid under that paragraph.
- (2) Where the amount paid under paragraph 1, 3 or 5 of subsection (1) exceeds 12.5, 25 or 50 per cent, as

the case may be, of the assessable administrative expenses for the relevant fiscal year, the excess shall be credited to future obligations of the Law Society under subsection 25a (1) of the Act.

- (3) All fees payable to solicitors for legal aid provided pursuant to certificates issued on or after the 1st day of April, 1988 or provided as duty counsel on or after that day shall be reduced by 5 per cent.
- (4) The total amount produced by the reduction under subsection (3) in a fiscal year shall be applied to discharge the obligation of the Law Society in that fiscal year by an amount not exceeding 50 per cent of its obligation under subsection 25a (1) of the Act in that fiscal year.
- (5) Payments required by paragraphs 5 and 6 of subection (1) shall be adjusted to reflect the reduction under subsection (4) for the relevant fiscal year as estimated by the Director and the actual reduction, respectively. O. Reg. 726/86, s. 5.
 - 6. Subsection 97 (1) of the said Regulation is revoked and the following substituted therefor:
- (1) Subject to subsection (3), the schedule of fees in Schedules 2, 3, 4, 5 and 6 constitutes the fees to be paid to solicitors for professional services provided under the Act subject to any qualifications set out in the Schedules and the reductions referred to in section 22 of the Act. O. Reg. 726/86, s. 6.
 - 7. This Regulation shall be deemed to have come into force on the 1st day of July, 1986.

THE LAW SOCIETY OF UPPER CANADA

ARTHUR SCACE Treasurer

KENNETH JARVIS Secretary

Dated at Toronto, this 1st day of December, 1986.

(9885)

PUBLIC SERVICE SUPERANNUATION

O. Reg. 727/86. Supplementary Benefits-Deputy Ministers Service. Made-December 10th, 1986. Filed-December 12th, 1986.

REGULATION TO REVOKE ONTARIO REGULATION 59/85 MADE UNDER THE PUBLIC SERVICE SUPERANNUATION ACT

1. Ontario Regulation 59/85 is revoked.

(9886)

52

PLANNING ACT, 1983

O. Reg. 728/86.
Restricted Areas—County of Renfrew,
Township of McNab.
Made—December 1st, 1986.
Filed—December 12th, 1986.

REGULATION TO REVOKE ONTARIO REGULATION 311/74 MADE UNDER THE PLANNING ACT, 1983

1. Ontario Regulations 311/74, 329/76 and 437/81 are revoked.

BERNARD GRANDMAİTRE Minister of Municipal Affairs

Dated at Toronto, this 1st day of December, 1986.

(9887)

52

PLANNING ACT, 1983

O. Reg. 729/86.
Restricted Areas—County of Renfrew—Township of Rolph, Buchanan, Wylie and McKay.
Made—December 1st, 1986.
Filed—December 12th, 1986.

REGULATION TO REVOKE ONTARIO REGULATION 312/74 MADE UNDER THE PLANNING ACT, 1983

- 1.—(1) Ontario Regulation 312/74 is revoked.
- (2) Section 38 of Ontario Regulation 334/76 is revoked.

BERNARD GRANDMAÎTRE
Minister of Municipal Affairs

Dated at Toronto, this 1st day of December, 1986.

PLANNING ACT, 1983

O. Reg. 730/86.
Restricted Areas—County of Renfrew,
Township of Alice and Fraser.
Made—December 1st, 1986.
Filed—December 12th, 1986.

REGULATION TO REVOKE ONTARIO REGULATION 314/74 MADE UNDER THE PLANNING ACT, 1983

- 1.—(1) Ontario Regulation 314/74 is revoked.
- (2) Section 40 of Ontario Regulation 334/76 is revoked.

BERNARD GRANDMAITRE Minister of Municipal Affairs

Dated at Toronto, this 1st day of December, 1986.

(9889)

52

PLANNING ACT, 1983

O. Reg. 731/86.
Restricted Areas—County of Renfrew,
Township of Admaston.
Made—December 1st, 1986.
Filed—December 12th, 1986.

REGULATION TO REVOKE ONTARIO REGULATION 316/74 MADE UNDER THE PLANNING ACT, 1983

- 1.—(1) Ontario Regulations 316/74, 77/77, and 970/78 are revoked.
- (2) Section 42 of Ontario Regulation 334/76 is revoked.

BERNARD GRANDMAİTRE Minister of Municipal Affairs

Dated at Toronto, this 1st day of December, 1986.

(9888)

52 (9890)

52

Publications Under The Regulations Act

January 3rd, 1987

PLANNING ACT, 1983

O. Reg. 732/86.

Restricted Areas—County of Ontario (now The Regional Municipality of Durham), Township of Pickering (now the Town of Pickering).

Made—December 9th, 1986. Filed—December 15th, 1986.

REGULATION TO AMEND ONTARIO REGULATION 102/72 MADE UNDER THE PLANNING ACT, 1983

- 1. Ontario Regulation 102/72 is amended by adding thereto the following section:
- 64.—(1) A barn may be erected and used as an accessory structure to the single-family dwelling existing on the land described in subsection (2) on the date this section comes into force.
- (2) Subsection (1) applies to that parcel of land in the Town of Pickering in The Regional Municipality of Durham, formerly in the Township of Pickering in the County of Ontario, being that part of Lot 10, Concession VIII, designated as Part 3 on a Plan deposited in the Land Registry Office for the Registry Division of Durham (No. 40) as Number 40R-1591. O. Reg. 732/86, s. 1.

L. J. FINCHAM
Director
Plans Administration Branch
Central and Southwest
Ministry of Municipal Affairs

Dated at Toronto, this 9th day of December, 1986.

(9891)

PLANNING ACT, 1983

O. Reg. 733/86.
Restricted Areas—County of Simcoe,
Township of Vespra.
Made—December 9th, 1986.
Filed—December 15th, 1986.

REGULATION TO AMEND ONTARIO REGULATION 62/73 MADE UNDER THE PLANNING ACT, 1983

- 1. Ontario Regulation 62/73 is amended by adding thereto the following section:
- 59.—(1) Despite any other provision of this Order, buildings and structures and accessory buildings and structures may be erected and used for the purposes of a retail store, a floral and garden nursery, garden and nursery equipment rentals and the sale of farm implements on the land described in subsection (2) if at least sixty-five parking spaces are provided.
- (2) This section applies to that part of Lot 18, Concession IV, in the City of Barrie, (formerly in the Township of Vespra) in the County of Simcoe, described as follows:

Premising that the east limit of the road allowance between concessions IV and V has a bearing of north 31° 34′ west;

Beginning at the southwest angle of the said Lot 18;

Thence north 31° 34′ west along the east limit of the road allowance between concessions IV and V, 150.11 feet to a point;

Thence north 58° 18′ 30″ east, 27.03 feet to an iron bar found in the east limit of the road allowance between concessions IV and V as widened by instrument numbers 13256 and 157757;

Thence north 31° 32′ 30″ west along said widened limits of the road allowance between concessions IV and V, 690.65 feet to the point of commencement of the herein described parcel;

Thence north 58° 27′ 30" east, 913.77 feet to an iron tube;

Thence north 31° 32′ 30″ west, 234 feet to an iron tube:

Thence south 58° 27′ 30″ west, 913.77 feet to a Department of Highways monument planted in the east limit of the road allowance between concessions IV and V, as widened by instrument numbers 13256 and 139577;

Thence south 31° 32′ 30″ east along said widened limits of the road allowance between concessions IV and V, 234 feet to the point of commencement of the herein described parcel. O. Reg. 733/86, s. 1.

L. J. FINCHAM
Director
Plans Administration Branch
Central and Southwest
Ministry of Municipal Affairs

Dated at Toronto, this 9th day of December, 1986.

(9892)

MENTAL HEALTH ACT

O. Reg. 734/86. Application of Act. Made—December 10th, 1986. Filed—December 16th, 1986.

REGULATION TO AMEND REGULATION 609 OF REVISED REGULATIONS OF ONTARIO, 1980 MADE UNDER THE MENTAL HEALTH ACT

- 1. Subsection 7 (1) of Regulation 609 of Revised Regulations of Ontario, 1980 is revoked and the following substituted therefor:
- (1) Every psychiatric facility listed in Schedules 2, 3 and 4 is exempt from the application of Part II of the Act other than the following sections: section 8a, clause 20 (3) (b), sections 29 and 29a, section 30, subsections 30a (1a), (1b) and (2), sections 33, 33a, 33b, 33c, 33d, 33e and 33f. O. Reg. 734/86, s. 1.
 - 2. Section 16 of the said Regulation, as amended by section 2 of Ontario Reg-

ulation 155/84, is further amended by adding thereto the following subsections:

- (24) An application to the review board under subsection 8a (1) of the Act shall be in Form 25.
- (25) A notice to the review board under subsection 8a (1) of the Act shall be in Form 26.
- (26) A notice by the officer in charge to an informal patient under subsections 30a (1b) and (2) of the Act shall be in Form 27.
- (27) A request to examine or to copy part or all of the clinical record under subsection 29a (2) of the Act shall be in Form 28.
- (28) An application to the review board under subsection 29a (4) of the Act shall be in Form 29.
- (29) A notice to the patient under subsections 30a (1) and (2) of the Act shall be in Form 30.
- (30) An application to the review board under subsection 29a (14) of the Act shall be in Form 31.
- (31) An application to the review board under subsection 35 (2a) of the Act shall be in Form 32.
- (32) A notice to the patient under subsection 30a (1a) of the Act shall be in Form 33.
- (33) A notice to the Area Director of Legal Aid under subsections 30a (1), (1a) and (1b) of the Act shall be in Form 34.
- (34) An application to the review board under subsection 32a (1) of the Act to extend the time period for conducting or completing a review shall be in Form 35.
- (35) An application to the review board under subsection 32a (1) of the Act to extend an involuntary certificate shall be in Form 36.
- (36) An application to court under subsections 33f (1c) and (1e) of the Act to extend time for appeal shall be in Form 37.
- (37) An application to court under subsection 33f (1e) of the Act to extend an involuntary certificate shall be in Form 38. O. Reg. 734/86, s. 2.
- 3. Form 1 of the said Regulation is revoked and the following substituted therefor:

Form 1

Mental Health Act

APPLICATION BY PHYSICIAN FOR PSYCHIATRIC ASSESSMENT

2716

| the | undersigned | physician, | state | that |
|-----|-------------|------------|-------|------|
|-----|-------------|------------|-------|------|

| 1. | On the day of |
|----|---|
| | (home address) |
| 2. | I have reasonable cause to believe that the said person (check appropriate box(es)), |
| | (a) has threatened or attempted or is threatening or attempting to cause bodily harm to himself/herself; |
| | (b) has behaved or is behaving violently towards another person or has caused or is causing another person to fear bodily harm from him/her; or |
| | $\ \ \ \ \ \ \ \ \ \ \ \ \ $ |
| 3. | The facts upon which I based my belief as to the behaviour referred to in Item 2 of the said person |
| | (\underline{a}) that were observed by me, are as follows: |
| | |
| | (\underline{b}) that were communicated to me by others, are as follows: |
| | |
| ц. | In addition, I am of the opinion that the said person is apparently suffering from mental disorder of a nature or quality that likely will result in (check appropriate box(es)), |
| | (\underline{a}) serious bodily harm to the person; |
| | (\underline{b}) serious bodily harm to another person; or |
| | (c) imminent and serious physical impairment of the person. |
| 5. | The facts upon which I formed my opinion as to the nature and quality of the said person's mental disorder, |
| | (\underline{a}) that were observed by me, are as follows: |
| | ••••• |
| | (b) that were communicated to me by others, are as follows: |
| | ••••• |
| 6. | The facts upon which I formed by opinion as to the likely behaviour referred to in Item 5 of the said person, |
| | (\underline{a}) that were observed by me, are as follows: |
| | ••••••••••••••••• |
| | 2717 |

| (\underline{b}) that were communicated to me by others, are as follows: |
|--|
| |
| 7. I made careful inquiry into all of the facts necessary for me to form my opinion as to the nature and quality of the said person's mental disorder. |
| 8. The reason(s) why no measure short of hospitalization is/are appropriate for this assessment is/are as follows: |
| |
| I therefore hereby make application for a psychiatric assessment of the said |
| To the best of my knowledge the said person routinely receives the following medication: |
| |
| To the best of my knowledge the said person has received the following medication within the last twenty-four hours: |
| |
| Signed this day of, 19 |
| (minnahuna ac mhuniaina) |
| (signature of physician) NOTES: |

- 1. Subsection 9(4) of the Act provides:
- (4) An application under subsection (1) is not effective unless it is signed by the physician within seven days after he examined the person who is the subject of the examination.
- 2. Subsection 9(5) of the Act provides:
- (5) An application under subsection (1) is sufficient authority for seven days from and including the day on which it is signed by the physician,

(a) to any person to take the person who is the subject of the application in custody to a psychiatric facility forthwith; and

to detain the person who is the subject of the application in a psychiatric facility and to restrain, observe and examine him in the facility for not more than 72 hours.

O. Reg. 734/86, s. 3.

- 4.—(1) Form 2 of the said Regulation is amended by striking out "assessment" in the thirty-sixth line and inserting in lieu thereof "examination".
- (2) Note 3 to the said Form 2 is amended by striking out "assessment" in the thirteenth line and inserting in lieu thereof "examination".
 - 5. Form 3 of the said Regulation is revoked and the following substituted therefor:

See

Form 3

Mental Health Act

CERTIFICATE OF INVOLUNTARY ADMISSION

| See Note | I, have observed and examined (print name of physician) |
|-------------|--|
| | (print full name and status of person) |
| | and am of the opinion both that such person is suffering from mental disorder of a nature or quality that likely will result in (check appropriate box(es)), |
| | (\underline{a}) serious bodily harm to the person; |
| | \Box (\underline{b}) serious bodily harm to another person; or |
| | (c) imminent and serious physical impairment of the person, |
| | unless the person is retained in the custody of a psychiatric facility and that the person is not suitable for |
| | I further state that the facts upon which I formed by opinion as to the likely behaviour of the said person referred to above, |
| | (\underline{a}) that were observed by me, are as follows: |
| | |
| | (\underline{b}) that were communicated to me by others, are as follows: |
| | |
| | I further state that the reason(s) why the person is not suitable for |
| | voluntary patient is/are as follows: |
| | *************************************** |
| igned thi | s, 19 |
| | |
| | (signature of physician) |
| | |

NOTE:

Status of the person,

The person is,

- (a) an informal or voluntary patient;
- (b) the subject of an application for assessment under section 9 of the Mental Health Act; or
- (c) the subject of an order under section 26 of the Mental Health Act.

O. Reg. 734/86, s. 5.

- 6. Form 4 of the said Regulation is amended by inserting after "informal" in the nineteenth line "or voluntary".
- 7.—(1) The heading to Form 5 of the said Regulation is amended by inserting after "INFORMAL", "OR VOLUNTARY".
- (2) The said Form 5 is further amended by inserting after "informal" in the thirteenth line "or voluntary".
 - 8. Form 6 of the said Regulation is amended by striking out "AND I AUTHORIZE you, the authorities at the said psychiatric facility, to examine him/her." in the thirty-first and thirty-second lines.
 - 9. Form 7 of the said Regulation is amended by striking out "AND I AUTHORIZE you, the authorities at the said psychiatric facility, to treat him/her." in the thirty-fourth and thirty-fifth lines.
- 10. Form 10 of the said Regulation is amended by inserting after "informal" in the seventeenth line "or voluntary".
- 11. Note 3 to Form 13 of the said Regulation is amended by striking out "120" in the sixth line and inserting in lieu thereof "72" and by inserting after "informal" in the tenth line "or voluntary".
- 12.—(1) Form 14 of the said Regulation is amended by inserting after "patient" in the nineteenth line "and date of birth, where available".
- (2) Note 1 to the said Form 14 is amended by striking out "majority" in the fifth line and inserting in lieu thereof "sixteen years".
- (3) Note 4 to the said Form 14 is revoked and the following substituted therefor:
 - 4. Nearest relative.

Clause 1 (j) of the Act provides,

- (j) "nearest relative" means,
 - (i) a person to whom the person is married, with whom the person is living and who has attained the age of sixteen

years and is mentally competent, or

- (ii) if none or if none is available, a person of the opposite sex with whom the person is living outside marriage in a conjugal relationship and who has attained the age of sixteen years and is mentally competent, if the two persons,
 - (A) have cohabited for at least one year,

- (B) are together the parents of a child, or
- (C) have together entered into a cohabitation agreement under section 53 of the Family Law Act, 1986, or
- (iii) if none or if none is available, any one of the children who has attained the age of sixteen years and is mentally competent, or
- (iv) if none or if none is available, either of the parents who is mentally competent or the guardian, or
- (v) if none or if none is available, any one of the brothers or sisters who has attained the age of sixteen years and is mentally competent, or
- (vi) if none or if none is available, any other of the next of kin who has attained the age of sixteen years and is mentally competent.
- 13.—(1) The heading to Form 16 of the said Regulation, as remade by section 3 of Ontario Regulation 155/84, is revoked and the following substituted therefor:

NOTICE TO REVIEW BOARD UNDER SUBSECTION 31 (1) OF THE ACT

- (3) The said Form 16 is further amended by striking out

(psychiatric facility)"

in the ninth line.

14.—(1) The heading to Form 17 of the said Regulation is amended by striking out "REGIONAL".

- (2) The said Form 17 is further amended by striking out "the Review Board" in the fourth line and inserting in lieu thereof "the panel of the review board having jurisdiction for
 - (name of psychiatric facility)".

in the seventh line.

- 15.—(1) The heading to Form 18 of the said Regulation is amended by striking out "REGIONAL".
- (2) The said Form 18 is further amended by striking out "the Review Board" in the fifth line and inserting in lieu thereof "the panel of the review board having jurisdiction for

(name of psychiatric facility)".

- 16.—(1) The heading to Form 19 of the said Regulation is revoked and the following substituted therefor: "APPLICATION TO REVIEW BOARD UNDER SUBSECTIONS 35 (2) AND (4) OF THE ACT".
- (2) The said Form 19 is further amended by striking out "the Review Board" in the sixth line and inserting in lieu thereof "the panel of the review board having jurisdiction for

(name of psychiatric facility)".

- (4) The said Form 19 is further amended by adding before "Notes" in the thirtyseventh line.
- NOTE: The form shall indicate the duration for the course of treatment. In no case shall the duration exceed three months.

- (5) Note 1 to the said Form 19 is amended by striking out "majority" in the fourth line and inserting in lieu thereof "sixteen years".
- (6) Note 2 to the said Form 19 is amended by striking out "clause 1 (b)" in the second line and inserting in lieu thereof "clause 1 (g)".
- (7) Note 3 to the said Form 19 is revoked and the following substituted therefor:
 - 3. Nearest relative.

Clause 1 (j) of the Act provides,

- (j) "nearest relative" means,
 - (i) a person to whom the person is married, with whom the person is living and who has attained the age of sixteen years and is mentally competent, or
 - (ii) if none or if none is available, a person of the opposite sex with whom the person is living outside marriage in a conjugal relationship and who has attained the age of sixteen years and is mentally competent, if the two persons,

- (A) have cohabited for at least one year,
- (B) are together the parents of a child, or
- (C) have together entered into a cohabitation agreement under section 53 of the Family Law Act, 1986, or
- (iii) if none or if none is available, any one of the children who has attained the age of sixteen years and is mentally competent, or
- (iv) if none or if none is available, either of the parents who is mentally competent or the guardian, or
- (v) if none or if none is available, any one of the brothers or sisters who has attained the age of sixteen years and is mentally competent, or
- (vi) if none or if none is available, any other of the next of kin who has attained the age of sixteen years and is mentally competent.

17. Form 20 of the said Regulation is revoked and the following substituted therefor:

Form 20

Mental Health Act

STATEMENT IN SUPPORT OF APPLICATION UNDER SECTION 35 OF THE ACT

| RE: | (print full name of involuntary patient) |
|------|--|
| See | I, of (print name) |
| Note | 1 |

(address)

state that:

- I examined the above-named involuntary patient on the day of, 19....
- I am of the opinion that the mental condition of the above-named involuntary patient will be or is likely to be substantially improved by the following

| psychiatric treatment or course of psychiatric treatment |
|--|
| (specify proposed treatment or course of following time period |
| treatment) (indicate proposed |
| duration of the order) |

See

3. I am of the opinion that the mental condition of the above-named involuntary patient will not or is not likely to improve without the proposed psychiatric treatment or course of psychiatric treatment.

| | | | | | | | | | | | | | | | ٠ | | | | | | | | | | ۰ | ۰ | | | | | | | | |
|-------------|--|--|--|--|--|--|--|--|--|--|--|--|--|--|---|--|--|--|--|--|--|--|--|--|---|---|--|--|--|--|--|--|--|--|
| (signature) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |

DATED the, 19...

- NOTE 1: An application under section 35 of the Act must be supported by the statements of the attending physician and a psychiatrist who is a member and a psychiatrist who is not a member of the medical staff of the psychiatric facility in which the patient is detained. See clause 35(4)(b) of the Act.
- NOTE 2: The form shall indicate the duration for the course of treatment. In no case shall that duration exceed three months.

O. Reg. 734/86, s. 17.

- 18. The heading to Form 21 of the said Regulation is amended by adding at the end thereof "TO MANAGE ONE'S ESTATE".
- 19. The heading to Form 23 of the said Regulation is amended by adding at the end thereof "TO MANAGE ONE'S ESTATE".
- 20. The heading to Form 24 of the said Regulation is amended by adding at the end thereof "OF CERTIFICATE OF INCOMPETENCE TO MANAGE ONE'S OWN ESTATE".
- 21. The said Regulation is amended by adding thereto the following Forms.

Form 25

Mental Health Act

APPLICATION TO REVIEW BOARD UNDER SECTION 8a OF THE ACT

To: The Chairman of the panel of the review board having jurisdiction for

in which the applicant is an informal patient between 12 and 15 years of age inclusive.

| | Re: |
|------|--|
| | (print full name of informal patient) |
| | |
| | |
| | (date of birth, where available) |
| | |
| | of |
| | (home address) |
| | (None datass) |
| | Ι, |
| | (print full name of informal patient) |
| | (print full name of informal pattent) |
| | |
| See | hereby apply for an inquiry into whether I need observation, |
| Note | care and treatment in |
| | (print name of psychiatric facility) |
| | |
| | |
| | |
| | (signature of witness) (signature of officer in charge) |
| | |
| | DATED the day of, 19 |
| | |
| | |
| | |

- (3) In determining whether the child needs observation, care and treatment in the psychiatric facility the review board shall consider,
 - whether the child needs observation, care and treatment of a kind that the psychiatric facility can provide;
 - (b) whether the child's needs can be adequately met if the child is not an informal patient in the psychiatric facility;
 - whether there is an available alternative to the psychiatric facility in which the child's needs could be more appropriately met:
 - the child's views and wishes, where they (d) can be reasonably ascertained; and
 - (e) any other matter that the review board considers relevant.

Form 26

Mental Health Act

NOTICE TO REVIEW BOARD UNDER SUBSECTION 8a(2) OF THE ACT

| | To: The Chairman of the panel of the review board having jurisdiction for |
|------|---|
| | (print name of psychiatric facility) |
| | |
| | Re: |
| | (print full name of informal patient) |
| | |
| | (date of birth, where available) |
| | |
| | of(home address) |
| | |
| | The above-named informal patient who is between 12 and 15 years of age inclusive has been in this facility without |
| | review for a period of 6 consecutive months commencing |
| | |
| | (date of admission) |
| | |
| See | Under section 8a(2) of the Act, the review board must conduct an inquiry as to whether this patient requires |
| Note | further observation, care and treatment |
| | in |
| | (name of psychiatric facility) |
| | |
| | |
| | (signature of witness) (signature of officer in charge) |
| | DATED the day of, 19 |
| | NOTE: Subsection 8a(3) of the Act provides, |
| | (3) In determining whether the child needs observation, care and treatment in the psychiatric facility, the review board shall consider, |

2725

(a) whether the child needs observation, care and treatment of a kind that the psychiatric facility can provide;

To:

- (b) whether the child's needs can be adequately met if the child is not an informal patient in the psychiatric facility;
- whether there is an available alternative (c) to the psychiatric facility in which the child's needs could be more appropriately met:
- the child's views and wishes, where they (d) can be reasonably ascertained; and
- any other matter that the review board (e) considers relevant.

O. Reg. 734/86, s. 21, part.

Form 27

Mental Health Act

NOTICE BY OFFICER IN CHARGE TO INFORMAL PATIENT UNDER SUBSECTIONS 30a (1b) and (2) OF THE ACT

patient identification number (used for notice to Area Director of Legal Aid)

(date of birth,

| (print name of informal patient) | (date of birth, where available) |
|--|----------------------------------|
| · · | |
| of | |
| (home address) | |
| | |
| | |
| | |
| This is to inform you that as an informal patien | t between 12 and |
| 15 years of age inclusive in (print name of psyc | histria facility |
| • | |
| you have the right to apply to the review board | |
| of the Mental Health Act. You may apply for suc | h a hearing by |
| completing Form 25 (attached) or by writing to e | ither the |
| chairman of the panel of the review board (print | name of chairman) |
| or to the officer in charge of the psychiatric f | acility |
| (print name of officer in charge) Upon such ap | oplication, an |
| (Print name or orriver in charge) | |

inquiry as to whether you need to stay in this psychiatric facility for observation, care and treatment will begin.

| (date) | (signature of officer in charge) | |
|--------|----------------------------------|--|
| | | |

After you receive this notice, a person called a "rights advisor" will be in contact with you to inform you as to your rights and help you in applying for a hearing if that is what you wish to do.

For further information or assistance with anything mentioned in this notice, please contact

(print name(s) of appropriate staff member(s)) (telephone number)

NOTES: For your information, subsection 8a(3) sets out what matters the review board will consider in deciding whether you are to remain in the psychiatric facility. Specifically, subsection 8a(3) of the Act provides,

- (3) In determining whether the child needs observation, care and treatment in the psychiatric facility, the review board shall consider,
 - (a) whether the child needs observation, care and treatment of a kind that the psychiatric facility can provide;
 - (b) whether the child's needs can be adequately met if the child is not an informal patient in the psychiatric facility;
 - (c) whether there is an available alternative to the psychiatric facility in which the child's needs could be more appropriately met;
 - (d) the child's views and wishes, where they can be reasonably ascertained; and
 - (e) any other matter that the review board considers relevant.

Form 28

Mental Health Act

REQUEST TO EXAMINE OR TO COPY CLINICAL RECORD UNDER SUBSECTION 29a(2) OF THE ACT

| | To: Officer i | n charge of | | |
|---------|---------------------|--------------------|---|-------------|
| | | . (print | name of psychiatric | c facility) |
| | 0 | | | |
| | THE PERSON NAMED IN | | 1171 17 - | |
| | Re: | | | |
| | | (print full na | ame of patient) | |
| | | | | |
| | | (date of hirth | where available) | |
| | | (date of bittin) | where available, | |
| | | | | |
| See | I, | | | |
| Note 1 | | (print full name | of applicant) | |
| | | | | |
| | request to exa | mine or to copy th | he clinical record o | compiled |
| | with regard to | , | | |
| See | | | | |
| Notes 2 | | | | |
| and 3 | | (print full name | e of patient) | |
| | | | | |
| | | | | |
| | (signature c | of witness) | (signature of a | onlicant) |
| | (Dignacare o | /L wichessy | (Signature of a) | ppricant, |
| | | | | |
| | | | | , 19 . |
| | | | | |
| | | | | |
| NO | | | tient if sixteen ye ally competent or t | |
| | | t relative where t | | 116 |

- sixteen years of age or older or mentally competent.
 - 2. Clause 29(1)(b) of the Act provides,
 - (b) "patient" includes former patient, out-patient, and former out-patient.
 - 3. Clause 1(j) of the Act provides,
 - (j) "nearest relative" means, 2728

- (i) a person to whom the person is married, with whom the person is living and who has attained the age of sixteen years and is mentally competent, or
- (ii) if none or if none is available, a person of the opposite sex with whom the person is living outside marriage in a conjugal relationship and who has attained the age of sixteen years and is mentally competent, if the two persons,
 - (A) have cohabited for at least one year,
 - (B) are together the parents of a child, or
 - (C) have together entered into a cohabitation agreement under section 53 of the <u>Family Law Act</u>, 1986,
- (iii) if none or if none is available, any one of the children who has attained the age of sixteen years and is mentally competent, or
- (iv) if none or if none is available, either of the parents who is mentally competent or the guardian, or
- (v) if none or if none is available, any one of the brothers or sisters who has attained the age of sixteen years and is mentally competent, or
- (vi) if none or if none is available, any other of the next of kin who has attained the age of sixteen years and is mentally competent.

O. Reg. 734/86, s. 21, part.

Form 29

Mental Health Act

APPLICATION TO REVIEW BOARD UNDER SUBSECTION 29a(4) OF THE ACT

| To: The Chairman of the panel of the review board having |
|--|
| jurisdiction for |
| (print name of psychiatric facility) |
| |
| I,, the officer in |
| (print name of officer in charge) |
| charge of, having |
| (print name of psychiatric facility) |
| been advised by that |
| (print name of attending physician) |

| т | THE CIVILING CHEET IS |
|------------|---|
| | disclosure of the clinical record of |
| | (print name of patient |
| | is likely to result in, |
| | |
| Check one | (a) serious harm to the treatment or recovery of the patient while in treatment at the psychiatric facility; or |
| | (b) serious physical harm or serious emotional harm t another person, |
| | hereby apply for authority to withhold |
| Strike one | |
| DELIKE OHE | of the clinical record. |
| | |
| | |
| | |
| | (signature of witness) (signature of officer in charge |
| | 10 |
| | DATED the day of, 19 |
| | |
| NC | OTE: Clause 29a(4) of the Act provides, |
| | (4) Within seven days after the patient makes a request to examine or copy the clinical record, the officer in charge, upon the advice of the attending physician, may apply to the review board for authority to withhold all or part of the clinical record. |
| | O. Reg. 734/86, s. 21, pa |
| | |
| | |
| | Form 30 |
| | Mental Health Act |
| | NOTICE TO PATIENT |
| | UNDER SUBSECTIONS 30a(1) and (2) OF THE ACT |
| | |
| | |
| | patient identification number (used for notice to Area Director of Legal Aid) |
| | |
| то: | |
| | (print name of patient) |
| of | |
| | (home address) |

This is to inform you that you are being detained under the authority of a

| or | Certificate of Involu | untary Admission (Form 3)) Under) Section) 14 |
|----------------|--|---|
| | on (date) is of the opinion that yo | |
| The | | physical impairment to you (date of expiry) |
| a he by coeith | earing before the review becompleting Form 16 (attachmer the officer in charge | detention, you have the right to oard. You may apply for a hearing ed) or by writing directly to of the psychiatric facility or the chairman of the panel rge) |
| | (date) | (signature of attending physician) (print name of attending physician) |

After you receive this notice, a person called a "rights advisor" will be in contact with you to inform you as to your rights and help you in applying for a hearing if that is what you wish to do.

For further information or assistance with anything mentioned in this notice, please contact

(print name(s) of appropriate staff member(s)) (telephone number)

(print name of psychiatric facility)

NOTE: Under subsection 30a(2) of the Act, the patient must be informed that he or she has the right to a hearing before the review board under subsection 33b(1).

Specifically, subsection 30a(2) of the Act provides,

(2) A notice under subsection (1), (1a) or (1b) shall inform the patient and the area director that the patient or any person on his behalf is entitled to a hearing by the review board if the patient or the person gives or transmits to the officer in charge or to a review board notice in writing requiring a hearing and the patient or the person may so require such a hearing.

Subsection 33b(1) of the Act provides,

(1) A review board that receives notice in writing placing a matter before it for decision shall appoint a time and place for and hold a hearing.

O. Reg. 734/86, s. 21, part.

Form 31

Mental Health Act

APPLICATION TO REVIEW BOARD UNDER SUBSECTION 29a(14) OF THE ACT

| To: | The Chairman of the panel of the review board having |
|-----|--|
| | jurisdiction for |
| | (name of psychiatric facility) |
| | |
| Re: | |
| | (print full name of patient) |
| | |
| | |
| | |

| O. Reg. | 734/86 THE ONTARIO GAZETTE | 6 |
|-------------|--|----|
| | of | |
| | (home address) | |
| 300 | | |
| See Note | (print full name of patient) | |
| | | |
| | hereby apply for an inquiry into whether or not I am mentally competent | |
| | Check Appropriate Box(es) | |
| | to examine my clinical record | |
| | to consent to the disclosure of my clinical record | |
| | | |
| | (signature of witness) (signature of patient) | |
| | DATED the day of, 19 | |
| | | |
| | NOTE: Clause 29(1)(b) of the Act provides, | |
| | (b) " patient" includes former patient, out- patient, and former out-patient. | |
| | O. Reg. 734/86, s. 21, p | ar |
| | | |
| | Form 32 | |
| | Mental Health Act | |
| | APPLICATION TO REVIEW BOARD | |
| | UNDER SUBSECTION 35(2a) OF THE ACT | |
| | | |
| To: | The Chairman of the panel of the review board having | |
| | jurisdiction for | |
| | (12 Followidelia Indilite!) | |
| Re: | | |
| | (print full name of patient) | |

| of |
|--|
| (home address) |
| |
| Ι, |
| (print full name of involuntary patient) |
| hereby apply for an inquiry into whether or not I am mentally |
| competent to consent to psychiatric treatment. |
| compacent to constant or parameter than the constant of the co |
| |
| |
| |
| (signature of witness) (signature of patient) |
| (signature of witness) (signature of patient) |
| |
| |
| DATED the day of, 19 |
| |
| |
| |
| Form 33 |
| Mental Health Act |
| NOTICE TO PATIENT |
| UNDER SUBSECTION 30a(1a) OF THE ACT |
| 1 |
| |
| patient identification number |
| (used for notice to Area Director of Legal Aid) |
| |
| To: |
| (print name of patient) |
| |
| of |
| (home address) |
| · · · · · · · · · · · · · · · · · · · |
| |
| This is to inform you that on I, |
| This is to inform you that onI, (date of determination) |
| |
| |

you are not mentally competent to

| Check the Appropriate Box(es) |
|---|
| |
| Consent to treatment (if an involuntary patient) (Form 32) |
| Examine your clinical record (Form 31) |
| Consent to the disclosure of your clinical record (Form 31) |
| Manage your estate (Form 18) |
| |
| |
| |
| If you wish to challenge this (these) determination(s), you have |
| the right to a hearing before the review board. You may apply |
| for a hearing by completing the relevant form or by writing to |
| either the officer in charge of the psychiatric facility |
| or the chairman of the |
| (print name of officer in charge) |
| of the region heard |
| of the review board (print name of chairman) |
| (print name of chairman) |
| (print name of chairman) |
| (date) (signature of attending physician) |
| (print name of chairman) |
| (print name of chairman) (date) (signature of attending physician) |
| (print name of chairman) (date) (signature of attending physician) |
| (date) (signature of attending physician) (print name of attending physician) |
| (date) (signature of attending physician) (print name of attending physician) After you receive this notice, a person called a "rights advisor" |
| (date) (signature of attending physician) (print name of attending physician) (print name of attending physician) After you receive this notice, a person called a "rights advisor" will be in contact with you to inform you as to your rights and |
| (date) (signature of attending physician) (print name of attending physician) (print name of attending physician) After you receive this notice, a person called a "rights advisor" will be in contact with you to inform you as to your rights and help you in applying for a hearing if that is what you wish to |
| (date) (signature of attending physician) (print name of attending physician) (print name of attending physician) After you receive this notice, a person called a "rights advisor" will be in contact with you to inform you as to your rights and help you in applying for a hearing if that is what you wish to |
| (date) (signature of attending physician) (print name of attending physician) (print name of attending physician) After you receive this notice, a person called a "rights advisor" will be in contact with you to inform you as to your rights and help you in applying for a hearing if that is what you wish to do. |
| (date) (signature of attending physician) (print name of attending physician) (print name of attending physician) After you receive this notice, a person called a "rights advisor" will be in contact with you to inform you as to your rights and help you in applying for a hearing if that is what you wish to do. For further information or assistance with anything mentioned in |
| (date) (signature of attending physician) (print name of attending physician) (print name of attending physician) After you receive this notice, a person called a "rights advisor" will be in contact with you to inform you as to your rights and help you in applying for a hearing if that is what you wish to do. For further information or assistance with anything mentioned in |
| (date) (signature of attending physician) (print name of attending physician) (print name of attending physician) After you receive this notice, a person called a "rights advisor" will be in contact with you to inform you as to your rights and help you in applying for a hearing if that is what you wish to do. For further information or assistance with anything mentioned in this notice, please contact |
| (date) (signature of attending physician) (print name of attending physician) (print name of attending physician) After you receive this notice, a person called a "rights advisor" will be in contact with you to inform you as to your rights and help you in applying for a hearing if that is what you wish to do. For further information or assistance with anything mentioned in |
| (date) (signature of attending physician) (print name of attending physician) After you receive this notice, a person called a "rights advisor" will be in contact with you to inform you as to your rights and help you in applying for a hearing if that is what you wish to do. For further information or assistance with anything mentioned in this notice, please contact (print name(s) of appropriate staff member(s)) (telephone number) |
| (date) (signature of attending physician) (print name of attending physician) (print name of attending physician) After you receive this notice, a person called a "rights advisor" will be in contact with you to inform you as to your rights and help you in applying for a hearing if that is what you wish to do. For further information or assistance with anything mentioned in this notice, please contact |

NOTE: Under subsection 30a(2) of the Act, the patient must be informed that he or she has the right to a hearing before the review board under subsection 33b(1).

Subsection 30a(2) of the Act provides,

(2) A notice under subsection (1), (1a) or (1b) shall inform the patient and the area director that the patient or any person on his behalf is entitled to a hearing by the review board if the patient or the person gives or transmits to the officer in charge or to the review board notice in writing requiring a hearing and the patient or the person may so require such a hearing.

Subsection 33b(1) of the Act provides,

(1) A review board that receives notice in writing placing a matter before it for decision shall appoint a time and place for and hold a hearing.

O. Reg. 734/86, s. 21, part.

Form 34

Mental Health Act

NOTICE TO AREA DIRECTOR OF LEGAL AID UNDER SUBSECTIONS 30a(1), (1a) and (1b) OF THE ACT

| | PART A (COMPLETE ONLY IF APPROPRIATE) |
|------|--|
| | |
| | This is to inform you that |
| | (patient identification number) |
| | is being detained in(print name of psychiatric facility) |
| | |
| | under the authority of a |
| | |
| | Check Appropriate Box |
| | |
| | Certificate of Involuntary Admission |
| See | (Form 3) Under |
| Note | or) Section) 14 |
| | Certificate of Renewal |
| | (Form 4) |
| | |
| | This certificate was completed by |
| | (print name of physician) |
| | and expires on |
| | (date of expiry) |
| | |

| | (date) | (signature of attending physician) |
|-----------|--------------------|--|
| | | |
| | | (print name of attending physician) |
| | | 1 |
| | | |
| NOTE: | be informed of his | Oa(2) of the Act the patient must or her right to a hearing before nder subsection 33b(1). |
| | (See appended note | es) |
| | | |
| PART B | (COMPLETE ONLY IF | APPROPRIATE) |
| | | |
| This is | to inform you tha | (patient identification number) |
| | | (patient identification number) |
| is an i | nformal patient be | tween 12 and 15 years of age |
| | _ , | |
| inclusi | - | (print name of psychiatric |
| | where availab | |
| | | |
| ent to to | | |
| | | the right to apply to the review (1) of the Act to inquire into |
| | | bservation, care and treatment in |
| the psy | chiatric facility. | |
| | | |
| | | |
| | | |
| | | |
| | (date) | (signature of officer in charge) |
| | | |
| | | |
| | | (print name of officer in charge) |

NOTE: See appended notes

PART C (COMPLETE ONLY IF APPROPRIATE)

| This is to inform you that(print name of physician) |
|---|
| has made a determination that the patient, |
| is not mentally competent to (patient identification number) |
| Check Appropriate Box(es) |
| Consent to treatment, if an involuntary patient (section 35(2a)) |
| Examine his or her clinical record (section 29a(14)) |
| Consent to the disclosure of his or her clinical record (section 29(14)) |
| Manage his or her estate (section 36(1)) |
| (date) (signature of attending physician) |
| (print name of attending physician) |
| NOTE: Under subsection 30a(2) of the Act the patient must be informed of his or her right to a hearing before the review board under subsection 33b(1). (See appended notes) |
| For further information or assistance with anything |
| mentioned in this notice, please contact |
| |
| (non-(n) - C non-non-(n) - (n) - (n) |
| (name(s) of appropriate staff member(s)) |
| |
| (print name of psychiatric facility) |

NOTES: Subsection 14(5) of the Act provides,

- (5) The attending physician shall not complete a certificate of involuntary admission or a certificate of renewal unless, after he has examined the patient, he is of the opinion both,
 - (a) that the patient is suffering from mental disorder of a nature or quality that likely will result in,
 - (i) serious bodily harm to the patient,
 - (ii) serious bodily harm to another person, or
 - (iii) imminent and serious physical impairment of the patient,

unless the patient remains in the custody of a psychiatric facility; and

(b) that the patient is not suitable for admission or continuation as an informal or voluntary patient.

Subsections 8a(1), (2), (3), (4) and (5) of the Act provide,

- (1) A child who is twelve years of age or older but less than sixteen years of age, who is an informal patient in a psychiatric facility and who has not so applied within the preceding three months may apply in the prescribed form to the review board to inquire into whether the child needs observation, care and treatment in the psychiatric facility.
- (2) Upon the completion of six months after the later of the child's admission to the psychiatric facility as an informal patient or the child's last application under subsection (1), the child shall be deemed to have applied to the review board in the prescribed form pursuant to subsection (1).
- (3) In determining whether the child needs observation, care and treatment in the psychiatric facility, the review board shall consider,
 - (a) whether the child needs observation, care and treatment of a kind that the psychiatric facility can provide;
 - (b) whether the child's needs can be adequately met if the child is not an informal patient in the psychiatric facility;
 - (c) whether there is an available alternative to the psychiatric facility in which the child's needs could be more appropriately met;

- (d) the child's views and wishes, where they can be reasonably ascertained; and
- (e) any other matter that the review board considers relevant.
- (4) The review board by an order in writing may,
 - (a) direct that the child be discharged from the psychiatric facility; or
 - (b) confirm that the child may be continued as an informal patient in the psychiatric facility.
- (5) Nothing in this section prevents a physician from completing a certificate of involuntary admission in respect of the child.

Section 30a of the Act provides,

- (1) An attending physician who completes a certificate of involuntary admission or a certificate of renewal shall give or transmit a notice in writing of completion and filing of the certificate to the patient who is subject of the certificate and to the area director for the area, in accordance with the Legal Aid Act, in which the psychiatric facility is located.
- (1a) A physician who determines that a patient is not mentally competent to consent to treatment, to examine a clinical record or to manage his estate shall give or transmit a notice in writing of that determination to the patient and to the area director, in accordance with the Legal Aid Act in which the psychiatric facility is located.
- (1b) The officer in charge shall give or transmit a notice in writing of the child's right to apply to the review board under section 8a of the Act to the child and to the area director for the area, in accordance with the Legal Aid Act, in which the psychiatric facility is located.
- (2) A notice under subsection (1), (1a) or (1b) shall inform the patient and the area director that the patient or any person on his behalf is entitled to a hearing by the review board if the patient or the person gives or transmits to the officer in charge or to the review board notice in writing requiring a hearing and the patient or the person may require such a hearing."

Subsection 33b(1) of the Act provides,

(1) A review board that receives notice in writing placing a matter before it for decision shall appoint a time and place for and hold a hearing. See

Form 35

Mental Health Act

APPLICATION TO REVIEW BOARD

UNDER SUBSECTION 32a(1) OF THE ACT

TO EXTEND TIME PERIOD FOR CONDUCTING OR COMPLETING A REVIEW

To: The Chairman of the panel of the review board having

| jurisdiction for |
|---|
| (print name of psychiatric facility) |
| Re: |
| (print name of involuntary patient) |
| I,, request |
| (print name of applicant) |
| that the time for conducting or completing the review regarding the status of |
| be extended. (print name of involuntary patient) |
| The date on which the certificate of involuntary admission or renewal is due to expire is |
| |
| |
| |
| (signature of witness) (signature of applicant) |
| |
| DATED the day of, 19 |
| NOTE: Clause 32a(1) of the Act provides, |
| (1) Where, before a certificate of involuntary admission, a certificate of renewal or an extension of a certificate expires, the patient or the person acting on the patient's behalf files a notice with the review board requesting |

that the time for conducting or completing a review be extended beyond the time period for the certificate under subsection 14(4), the review board shall extend the certificate.

Form 36

Mental Health Act

APPLICATION TO REVIEW BOARD UNDER SUBSECTION 32a(1) OF THE ACT TO EXTEND INVOLUNTARY CERTIFICATE

| To: | jurisdiction for |
|--------|---|
| | (print name of psychiatric facility) |
| Re: | |
| | (print name of involuntary patient) |
| ı, _ | (print name of applicant), request that |
| the | review board extend the |
| Ch | eck Appropriate Box |
| | Certificate of involuntary admission |
| | Certificate of renewal |
| | Extension of certificate |
| of _ | (print name of involuntary patient) completed |
| on (| and that is due to expire on |
| | . I request that the extension be |
| for | a period of(requested duration of order) |
| | |
| | |
| (8 | ignature of witness) (signature of applicant) |
| D A ME | day of |

NOTE: Clause 32a(1) of the Act provides,

(1) Where, before a certificate of involuntary admission, a certificate of renewal or an extension of a certificate expires, the patient or the person acting on the patient's behalf files a notice with the review board requesting that the time for conducting or completing a review be extended beyond the time period for the certificate under subsection 14(4), the review board shall extend the certificate.

Clause 32a(2) of the Act provides,

- An extension of a certificate under subsection
 is effective,
 - (a) for the next period of time provided for renewal of the certificate under subsection 14(4) or any shorter period set by the board;
 - (b) until the certificate is rescinded; or
 - (c) until the patient or the person withdraws the request for review,

whichever first occurs,

O. Reg. 734/86, s. 21, part.

Form 37

Mental Health Act

APPLICATION TO COURT

UNDER SUBSECTIONS 33f(1c) and (1e) OF THE ACT
TO EXTEND TIME FOR APPEAL

To: Court having jurisdiction to order the extension of the time to conduct or complete an appeal from a decision of the review board.

| Re: | | | |
|-----|----|---|--|
| | | (print full name of involuntary patient) | |
| | of | | |
| | | (print full name of psychiatric facility) | |
| I, | | | |
| | | (print full name of applicant) | |

| request that the court order the extension of the time for an | | | | | |
|---|--|--|--|--|--|
| appeal/an answer regarding the status | | | | | |
| (print name of patient) | | | | | |
| | | | | | |
| | | | | | |
| (signature of witness) (signature of applicant) | | | | | |
| DATED the day of, 19 | | | | | |
| NOTE: Subsections 33f(l), (la), (lb), (lc), and (le) of the Act provide, | | | | | |
| (1) A party to proceedings before a review board may appeal from its decision in accordance with the rules of court to the county or district court of the county or district in which is located the psychiatric facility where the patient is detained. | | | | | |
| (la) The appellant shall file a notice of appeal under subsection (l) with proof of service within ten days after the day the written reasons for decision of the review board are given and shall perfect the appeal within fourteen days after receiving a copy of the record and transcript. | | | | | |
| (lb) The respondent shall file an answer with proof of service within seven days after the appeal | | | | | |

- is perfected.
- (1c) The court may by order extend the time for an appeal or an answer under subsection (la) or (lb).
- (le) Where, before a certificate of involuntary admission, a certificate of renewal or an extension of a certificate expires, a party to an appeal applies to the court for an extension of the time for conducting or completing the appeal beyond the time period for the certificate under subsection 14(4), the court may by order extend the effectiveness of the certificate.

O. Reg. 734/86, s. 21, part.

Form 38

Mental Health Act

APPLICATION TO COURT UNDER SUBSECTIONS 33f(le) OF THE ACT TO EXTEND INVOLUNTARY CERTIFICATE

| See | |
|-------|--|
| Notes | |

Re:

To: Court having jurisdiction to order the extension of the effectiveness of a certificate of involuntary admission, certificate of renewal or an extension of a certificate.

| (print full name of involuntary patient) |
|---|
| of(print full name of psychiatric facility) |
| I, |
| (print full name of applicant) request that the court extend the effectiveness of |
| Check Appropriate Box |
| Certificate of involuntary admission |
| Certificate of renewal |
| Extension of certificate |
| completed on and that is due to (date of completion) expire on (date of expiry) |
| |
| (signature of witness) (signature of applicant) |
| DATED the day of, 19 |

- NOTES: 1. Subsection 33f(le) of the Act provides,
 - (le) Where, before a certificate of involuntary admission, a certificate of renewal or an extension of a certificate expires, a party to an appeal applies to the court for an extension of the time for conducting or completing the appeal beyond the time period for the certificate under subsection 14(4), the court may by order extend the effectiveness of the certificate.
 - Subsection 33f(lf) of the Act provides,
 - An extension of a certificate under subsection (le) is effective,
 - for the next period of time provided for renewal of the certificate under subsection 14(4) or any shorter period set by the court;
 - (b) until the certificate is rescinded;
 - until the party appealing withdraws (c) the appeal,

whichever first occurs.

O. Reg. 734/86, s. 21, part.

O. Reg. 736/86

22. This Regulation comes into force on the day that section 33 of the Equality Rights Statute Law Amendment Act, 1986 comes into force.

(9893)

FARM PRODUCTS MARKETING ACT

O. Reg. 735/86. Apples—Plan. Made—December 10th, 1986. Filed-December 17th, 1986.

REGULATION TO AMEND **REGULATION 340 OF** REVISED REGULATIONS OF ONTARIO, 1980 MADE UNDER THE FARM PRODUCTS MARKETING **ACT**

- 1. Section 1 of Regulation 340 of Revised Regulations of Ontario, 1980 is revoked and the following substituted therefor:
- 1. The plan in the Schedule is continued for the control and regulation of the producing and marketing within Ontario of apples. O. Reg. 735/86, s. 1.

- 2. Clause 2 (e) of the Schedule to the said Regulation is revoked and the following substituted therefor:
 - (e) "processing" means,
 - (i) baking, canning, dehydrating, drying, freezing, slicing or pressing and includes making juice or cider from apples, or
 - (ii) processing with sugar or another substance including, but not limited to, sulphur dioxide;

(9894)

FARM PRODUCTS MARKETING ACT

O. Reg. 736/86. Apples—Marketing. Made-November 13th, 1986. Filed-December 17th, 1986.

REGULATION TO AMEND REGULATION 341 OF REVISED REGULATIONS OF ONTARIO, 1980 MADE UNDER THE FARM PRODUCTS MARKETING ACT

- 1. Clause 1 (e) of Regulation 341 of Revised Regulations of Ontario, 1980 is revoked and the following substituted therefor:
 - (e) "processing" means,
 - baking, canning, dehydrating, drying, freezing, slicing or pressing and includes making juice or cider from apples, or
 - (ii) processing with sugar or another substance including, but not limited to, sulphur dioxide;
- 2.—(1) Clause 3 (1) (b) of the said Regulation is amended by striking out "Provisional".
- (2) Section 3 of the said Regulation, as amended by section 1 of Ontario Regulation 260/85, is further amended by adding thereto the following subsection:
- (3) The Board exempts from subsection 6 (1) a producer who makes less than 7,500 gallons of cider per year from apples produced by him or her in so far as the making of cider from such apples is concerned. O. Reg. 736/86, s. 2 (2).

THE FARM PRODUCTS MARKETING BOARD:

KENNETH W. KNOX Chairman

GLORIA MARCO BORYS
Secretary

Dated at Toronto, this 13th day of November, 1986.

(9895)

PLANNING ACT, 1983

O. Reg. 737/86.

Delegation of Authority of Minister under Section 4 of the Planning Act, 1983—Condominium Plans.

Made—December 17th, 1986.

Filed—December 18th, 1986.

REGULATION TO AMEND ONTARIO REGULATION 475/83 MADE UNDER THE PLANNING ACT, 1983

- 1. Section 2 of Ontario Regulation 475/83, as amended by section 1 of Ontario Regulation 250/86 and section 1 of Ontario Regulation 282/86, is further amended by adding thereto the following subsection:
- (2) Clause (1) (c) does not apply to an application for approval or exemption of a condominium description in The Regional Municipality of Waterloo if the property is exempt from the Rental Housing Protection Act, 1986. O. Reg. 737/86, s. 1.

BERNARD GRANDMAÎTRE Minister of Municipal Affairs

Dated at Toronto, this 17th day of December, 1986.

(9920)

ONTARIO DRUG BENEFIT ACT, 1986

O. Reg. 738/86. General. Made—December 10th, 1986. Filed—December 18th, 1986.

REGULATION TO AMEND ONTARIO REGULATION 689/86 MADE UNDER THE ONTARIO DRUG BENEFIT ACT, 1986

- 1. Clause 5 (2) (c) of Ontario Regulation 689/86 is revoked and the following substituted therefor:
 - (c) an amount that shall not exceed 55 cents per minute for compounding the extemporaneous preparation.
- This Regulation shall be deemed to have come into force on the 1st day of December, 1986.

(9921)

LOCAL SERVICES BOARDS ACT

O. Reg. 739/86.

Establishment of Local Services Board—Community of Goulais River.

Made—December 12th, 1986. Filed—December 18th, 1986.

REGULATION TO AMEND ONTARIO REGULATION 642/85 MADE UNDER THE LOCAL SERVICES BOARDS ACT

1. The Schedule to Ontario Regulation 642/85 is revoked and the following substituted therefor:

Schedule

All that parcel or tract of land in the townships of Dennis, Fenwick, Haviland, Kars, Tupper and Van Koughnet in the Territorial District of Algoma and Province of Ontario described as follows:

Beginning at the southeast corner of the Township of Van Koughnet;

Thence northerly along the east boundary of the said township to the northeast corner thereof;

Thence westerly along the north boundary of the said township to the southeast corner of the Township of Tupper;

Thence northerly along the east boundary of the said township to the northeast corner thereof;

Thence westerly along the north boundary of the townships of Tupper and Haviland to the highwater mark on the easterly shore of Batchawana Bay of Lake Superior;

Thence in a general southerly and westerly direction following the said high-water mark to its intersection with the west boundary of the Township of Haviland;

Thence southerly along the said west boundary to the southwest corner of the said township;

Thence westerly along the north boundary of the Township of Kars to the high-water mark on the easterly shore of Whitefish Bay of Lake Superior;

Thence in a general southerly, easterly and southerly direction following the said high-water mark to the north limit of section 3 in the Township of Dennis;

Thence westerly along the said north limit to the southeast corner of section 33 in the said township;

Thence northerly along the east limit of the said section to the northeast corner of the southeast quarter thereof;

Thence westerly along the north limit of the said southeast quarter to the northwest corner thereof;

Thence northerly along the east limit of the northwest quarter of the said section to the northeast corner thereof; Thence easterly along the north limit of the said section to the southeast corner of section 28 in the said township;

Thence northerly along the east limit of the said section to the northeast corner thereof;

Thence easterly along the south limit of section 22 in the said township to the southeast corner of the southwest quarter thereof;

Thence northerly along the west limit of the southwest and northwest quarters of the said section to the northeast corner of the last-mentioned quarter;

Thence easterly along the south limit of sections 15 and 14 in the said township to the high-water mark of Goulais Bay of Lake Superior;

Thence in a general northeasterly and southeasterly direction along the said high-water mark to the south boundary of the Township of Fenwick;

Thence easterly along the south boundary of the townships of Fenwick and Van Koughnet to the place of beginning. O. Reg. 739/86, s. 1.

DAVID PETERSON
Premier and Acting Minister of
Northern Development and Mines

Dated at Toronto, this 12th day of December, 1986.

(9922)

FAMILY BENEFITS ACT

O. Reg. 740/86. General. Made—December 18th, 1986. Filed—December 19th, 1986.

REGULATION TO AMEND REGULATION 318 OF REVISED REGULATIONS OF ONTARIO, 1980 MADE UNDER THE FAMILY BENEFITS ACT

- 1.—(1) Paragraph 5 of subsection 12 (3) of Regulation 318 of Revised Regulations of Ontario, 1980, as remade by subsection 1 (1) of Ontario Regulation 676/85, is revoked and the following substituted therefor:
 - 5. Where a legally qualified medical practitioner certifies that a beneficiary is pregnant or where a beneficiary has given birth to a child or has care, custody and control of a newborn child, for additional needs of the

beneficiary due to the pregnancy or birth, an amount not exceeding \$26 for a period not exceeding six months, commencing in any month after the third month of the pregnancy and ending not later than the sixth month after the birth of the child. O. Reg. 740/86, s. 1 (1).

(2) The Table to paragraph 7 of the said subsection 12 (3), as remade by subsection 1 (3) of Ontario Regulation 504/86, is revoked and the following substituted therefor:

TABLE

MONTHLY AMOUNT FOR SHELTER SUBSIDY

| Number of Beneficiaries | Column A | Column B |
|----------------------------|----------|----------|
| 1 | \$119 | \$147 |
| 2 | 208 | 216 |
| 3 | 218 | 226 |
| 4 | 228 | 237 |
| 5 | 238 | 247 |
| 6 or more | 248 | 258 |

- (3) Subparagraph ii of paragraph 12 of the said subsection 12 (3), as remade by subsection 1 (3) of Ontario Regulation 676/85, is revoked and the following substituted therefor:
 - ii. "special needs minimum" means,
 - A. \$99, where the applicant or recipient is a single person or a married person and only one spouse is a blind person, a disabled person or a person referred to in subsection 2 (5) or (6), or
 - B. \$198, where the applicant or recipient is a married person and both spouses are blind persons, disabled persons or persons referred to in subsection 2 (5) or (6).
- (4) Subsection 12 (4) of the said Regulation, as remade by subsection 1 (4) of Ontario Regulation 676/85, is revoked and the following substituted therefor:
- (4) For the purpose of computing the amount of allowance of an applicant or recipient who is eligible under clause 7 (1) (f) of the Act, the monthly budgetary requirements shall be equal to \$163 for the first foster

child, \$134 for the second foster child and \$110 for each additional foster child. O. Reg. 740/86, s. 1 (4).

- 2. Clauses 27 (2) (a) and (b) of the said Regulation, as remade by section 2 of Ontario Regulation 676/85, are revoked and the following substituted therefor:
 - (a) \$51 for each of his or her dependants who attains the age of four years or more but who has not attained the age of thirteen years in the calendar year in which the amount is paid; and
 - (b) \$97 for each of his or her dependants who attains the age of thirteen years or more in the calendar year in which the amount is paid.
- 3.—(1) Subsection 30 (3) of the said Regulation, as remade by subsection 3 (1) of Ontario Regulation 676/85, is revoked and the following substituted therefor:
- (3) For the purposes of clause (2) (a), the amount shall be,
 - (a) \$419, where the applicant or recipient is a single person;
 - (b) \$666, where the applicant or recipient is a married person and only one spouse is a blind person, a disabled person or a person referred to in subsection 2 (5) or (6); or
 - (c) \$838, where the applicant or recipient is a married person and both spouses are,
 - (i) blind or disabled persons, or
 - (ii) persons referred to in subsection 2 (5) or (6),

and, where the applicant or recipient has one or more dependent children, in addition an amount determined in accordance with Schedule D. O. Reg. 740/86, s. 3 (1).

- (2) Subsection 30 (5) of the said Regulation, as remade by subsection 3 (2) of Ontario Regulation 676/85, is revoked and the following substituted therefor:
- (5) For the purposes of clause (4) (a), the amount shall be,
 - (a) \$458, where the applicant or recipient is a single person;
 - (b) \$729, where the applicant or recipient is a married person and only one spouse is a blind person, a disabled person or a person referred to in subsection 2 (5) or (6); or

- (c) \$916, where the applicant or recipient is a married person and both spouses are,
 - (i) blind or disabled persons, or
 - (ii) persons referred to in subsection 2 (5) or (6),

and, where the applicant or recipient has one or more dependent children, in addition an amount determined in accordance with Schedule E. O. Reg. 740/86, s. 3 (2).

- 4. Subsection 34 (1) of the said Regulation, as remade by section 7 of Ontario Regulation 216/84 and amended by section 11 of Ontario Regulation 825/84 and section 5 of Ontario Regulation 676/85, is further amended by striking out "\$334" in the ninth line and inserting in lieu thereof "\$351".
- 5. Subsection 35 (1) of the said Regulation, as remade by section 6 of Ontario Regulation 676/85, is revoked and the following substituted therefor:
- (1) Where a recipient who has been a resident in an institution approved by the Director is discharged or is about to be discharged from the institution in order to establish a permanent residence in the community and in the opinion of the Director needs financial assistance in establishing the residence, there may be paid to the recipient, in addition to an allowance, a benefit up to a maximum amount of \$600. O. Reg. 740/86, s. 5.
 - 6. Schedules A, B, C, E and F of the said Regulation, as remade by section 8 of Ontario Regulation 676/85, are revoked and the following substituted therefor:

Schedule A

AMOUNTS FOR BASIC NEEDS

(Board and Lodging-Profit*)

| Number of | One Adult Person | | Two Adult Persons | | |
|-----------|------------------|---------|-------------------|---------|--|
| Children | Minimum | Maximum | Minimum | Maximum | |
| 0 | \$298 | \$351 | \$464 | . \$578 | |
| 1 | 469 | 586 | 575 | 668 | |
| 2 | 579 | 676 | 665 | 753 | |
| 3 | 669 | 761 | 742 | 838 | |

The above Table indicates the amounts for one or two adults and the three oldest children in a family. For each child in excess of three children, add an amount up to \$86.

*Refer to paragraph 1 of subsection 12 (3)

O. Reg. 740/86, s. 6, part.

Schedule B

AMOUNTS FOR BASIC NEEDS

(Board and Lodging-Non-Profit*)

| Number of | One Adult Person | | Two Adult Persons | |
|-----------|----------------------------|----------------------------|----------------------------|----------------------------|
| Children | Minimum | Maximum | Minimum | Maximum |
| 0 1 2 | \$298 469 579 669 | \$320 535 616 693 | \$464 575 665 742 | \$526 607 685 762 |

The above Table indicates the amounts for one or two adults and the three oldest children in a family. For each child in excess of three children, add an amount up to \$78.

*Refer to paragraph 2 of subsection 12 (3)

Schedule C

AMOUNTS FOR BASIC NEEDS

| Number of Children | 16 Years and Over | 10-15 Years | 0-9 Years | One Adult Person | Two Adult Persons |
|-----------------------|----------------------------|----------------------------|----------------------------|---|--|
| 0 | 0 | 0 | 0 | \$351 | \$622 |
| 1 | 0 0 1 | 0 1 0 | 1 0 0 | 587 607 647 | 713 727 764 |
| 2 | 0 0 0 1 1 2 | 0 1 2 0 1 | 2 1 0 1 0 0 | 678 698 712 738 752 789 | 799 813 822 850 859 888 |
| 3 | 0 0 0 | 0 1 2 | 3 2 1 | 764 784 798 | 885 899 908 |
| | 0 1 1 1 2 2 2 3 | 3 0 1 2 0 1 | 0 2 1 0 1 0 | 807 824 838 847 875 884 913 | 917 936 945 954 974 983 1012 |

The above Table indicates the amounts for one or two adults and the three oldest children in a family. For each additional child in the family in excess of three children, add to the appropriate amount set out in the Schedule for a family with three as follows:

| (a) | 16 years and over | \$124 |
|-----|-------------------|-------|
| (b) | 10-15 years | 95 |
| (c) | 0-9 years | 86 |

O. Reg. 740/86, s. 6, part.

Schedule D

AMOUNTS FOR BASIC NEEDS

(Board and Lodging-Non-Profit*)

| | Age of | Dependent C | hildren |
|---|----------------------|----------------|--------------|
| | 16 Years and over | 10-15 Years | 0-9 Years |
| A. Family with One Adult Beneficiary | | | |
| 1. First Dependent Child | \$273 | \$233 | \$216 |
| 2. Second Dependent Child, add to the amount in item 1 | . 131 | 97 | 81 |
| 3. For each additional Dependent Child, add to the aggregate of items 1 and 2 | 115 | 86 | 78 |
| B. Family with Two Adult Beneficiaries | | | |
| 1. First Dependent Child | \$131 | \$ 97 | \$ 81 |
| 2. For each additional Dependent Child, add to the amount in item 1 | 115 | 86 | 78 |

O. Reg. 740/86, s. 6, part.

Schedule E

AMOUNTS FOR BASIC NEEDS

(For Renters, Owners and Profit Boarders*)

| | Age of | Dependent C | hildren |
|---|----------------------|----------------|--------------|
| | 16 Years and over | 10-15 Years | 0-9 Years |
| A. Family with One Adult Beneficiary | | | |
| 1. First Dependent Child | \$296 | \$256 | \$236 |
| 2. Second Dependent Child, add to the amount in item 1 | 142 | 105 | 91 |
| 3. For each additional Dependent Child, add to the aggregate of items 1 and 2 | 124 | 95 | 86 |
| B. Family with Two Adult Beneficiaries | | | |
| 1. First Dependent Child | \$142 | \$105 | \$ 91 |
| 2. For each additional Dependent Child, add to the amount in item 1 | 124 | 95 | 86 |
| *Refer to subsection 30 (5) | | | |

O. Reg. 740/86, s. 6, part.

7. This Regulation comes into force on the 1st day of January, 1987.

(9923)

GENERAL WELFARE ASSISTANCE ACT

O. Reg. 741/86. General. Made—December 18th, 1986. Filed—December 19th, 1986.

REGULATION TO AMEND REGULATION 441 OF REVISED REGULATIONS OF ONTARIO, 1980 MADE UNDER THE GENERAL WELFARE ASSISTANCE ACT

- 1.—(1) Paragraph 7 of subsection 12 (2) of Regulation 441 of Revised Regulations of Ontario, 1980, as remade by subsection 1 (1) of Ontario Regulation 677/85, is revoked and the following substituted therefor:
 - 7. Where a physician certifies that an applicant or recipient or a dependant of an applicant or recipient is pregnant or where the applicant or recipient or a dependant of an applicant or recipient has given birth to a child or has care, custody and control of a new born child for additional needs due to the pregnancy or birth, an amount not exceeding \$6 weekly or \$26 monthly for a period not exceeding six months, commencing in any month after the third month of pregnancy and ending not later than the sixth month after the birth of the child.
- (2) The Table to paragraph 9 of the said subsection 12 (2), as remade by subsection 1 (3) of Ontario Regulation 503/86, is revoked and the following substituted therefor:

TABLE

MONTHLY AMOUNT FOR SHELTER SUBSIDY

| Number of Beneficiaries | COLUMN A | COLUMN B |
|----------------------------|----------|----------|
| 1 | \$119 | \$147 |
| 2 | 208 | 216 |
| 3 | 218 | 226 |
| 4 | 228 | 237 |
| 5 | 238 | 247 |
| 6 or more | 248 | 258 |

- (3) Clause 12 (3) (c) of the said Regulation, as remade by subsection 1 (3) of Ontario Regulation 677/85, is revoked and the following substituted therefor:
 - (c) who is a foster parent with a foster child other than a child in the care of a children's aid society within the meaning of the Child and Family Services Act, 1984, is a monthly amount equal to \$163 for the first foster child, \$134 for the second foster child and \$110 for each additional foster child.
- 2. Subsection 13a (1) of the said Regulation, as remade by section 2 of Ontario Regulation 677/85, is revoked and the following substituted therefor:
- (1) Where a recipient who has been resident in an institution approved by the Director is discharged or about to be discharged from the institution in order to establish a permanent residence in the community and, in the opinion of the welfare administrator, needs financial assistance in establishing the residence, there shall be paid to the recipient, in addition to the amount of general assistance computed in accordance with subsection 11 (1), an amount determined by the welfare administrator up to a maximum of \$450. O. Reg. 741/86, s. 2.
 - 3. Schedules A and B, as remade by section 3 of Ontario Regulation 677/85, and Schedule C, as remade by section 4 of Ontario Regulation 677/85 and amended by section 2 of Ontario Regulation 503/86, to the said Regulation, are revoked and the following substituted therefor:

Schedule A

AMOUNTS FOR BASIC NEEDS

(Board and Lodging-Profit*)

| No. of Dependants | | One Adu | lt Person | | | | | |
|----------------------|-------------------|---------------|--------------|---------------|--------------|---------------|--------------|---------------|
| Other than a Spouse | Minimum | | Maximum | | Minimum | | Maximum | |
| a Spouse | weekly \$ | monthly \$ | weekly \$ | monthly \$ | weekly \$ | monthly \$ | weekly \$ | monthly \$ |
| 0 | Employal 43.30 | ble: 188 | 78.90 | 343 | 76.20 | 331 | 124.30 | 540 |
| | Unemplo 46.70 | yable: 203 | 80.80 | 351 | 70.20 | 331 | 124.50 | 340 |
| 1 | 77.10 | 335 | 114.20 | 496 | 96.90 | 421 | 142.70 | 620 |
| 2 | 98.00 | 426 | 132.60 | 576 | 115.10 | 500 | 159.70 | 694 |
| 3 | 116.00 | 504 | 149.60 | 650 | 130.50 | 567 | 177.00 | 769 |

For each additional child or dependant in the family in excess of three, add an amount up to \$17.30 weekly or up to \$75 monthly, as the case may be.

*Refer to paragraph 1 of subsection 12 (2)

O. Reg. 741/86, s. 3, part.

Schedule B

AMOUNTS FOR BASIC NEEDS

(Board and Lodging—Non-Profit*)

| No. of Dependants | | One Adu | lt Person | - | Two Adult Persons | | | |
|------------------------|-------------------|---------------|--------------|---------------|-------------------|---------------|--------------|---------------|
| Other than a Spouse | Minimum | | Maximum | | Minimum | | Maximum | |
| a Spouse | weekly \$ | monthly \$ | weekly \$ | monthly \$ | weekly \$ | monthly \$ | weekly \$ | monthly \$ |
| 0 | Employal 43.30 | ble: 188 | 61.20 | 266 | 76,20 | 331 | 114.20 | 496 |
| U | Unemploy 46.70 | yable: 203 | 62.80 | 273 | 70.20 | 331 | 114.20 | 470 |
| 1 | 77.10 | 335 | 104.00 | 452 | 96.90 | 421 | 131.00 | 569 |
| 2 | 98.00 | 426 | 120.80 | 525 | 115.10 | 500 | 147.10 | 639 |
| 3 | 116.00 | 504 | 136.90 | 595 | 130.50 | 567 | 162.90 | 708 |

For each additional child or dependant in the family in excess of three, add an amount up to \$16.10 weekly or up to \$70 monthly, as the case may be.

*Refer to paragraph 2 of subsection 12 (2)

Schedule C

AMOUNTS FOR BASIC NEEDS

| No. | No. Dependants Children Cl | | Children 0-9 | One Adu | lt Person | Two Adult Persons | | |
|------------|----------------------------|-------|-----------------|----------------------------|---------------|-------------------|---------------|--|
| Dependants | and over | years | years | weekly \$ | monthly \$ | weekly \$ | monthly \$ | |
| 0 | 0 | 0 | 0 | Employable 67.40 | 293 | 131.60 | 572 | |
| | | | | Unemployable: 69.30 301 | | | | |
| 1 | 0 | 0 | 1 | 114.40 | 497 | 150.10 | 652 | |
| | 0 | 1 | 0 | 118.50 | 515 | 153.30 | 666 | |
| | 1 | 0 | 0 | 125.40 | 545 | 160.20 | 696 | |
| 2 | 0 | 0 | 2 | 132.80 | 577 | 167.30 | 727 | |
| | 0 | 1 | 1 | 136.90 | 595 | 170.50 | 741 | |
| | 0 | 2 | 0 | 140.20 | 609 | 172.20 | 748 | |
| | 1 | 0 | 1 | 143.80 | 625 | 177.40 | 771 | |
| | 1 | 1 | 0 | 147.10 | 639 | 179.10 | 778 | |
| | 2 | 0 | 0 | 154.00 | 669 | 185.50 | 806 | |
| 3 | 0 | 0 | 3 | 150.10 | 652 | 184.60 | 802 | |
| | 0 | 1 | 2 | 154.20 | 670 | 187.80 | 816 | |
| | 0 | 2 | 1 | 157.40 | 684 | 189.40 | 823 | |
| | 0 | 3 | 0 | 159.00 | 691 | 191.00 | 830 | |
| | 1 | 0 | 2 | 161.10 | 700 | 194.70 | 846 | |
| | 1 | 1 | 1 | 164.30 | 714 | 196.30 | 853 | |
| | 1 | 2 | 0 | 165.90 | 721 | 197.90 | 860 | |
| | 2 | 0 | 1 | 171.20 | 744 | 202.80 | 881 | |
| | 2 | 1 | 0 | 172.80 | 751 | 204.40 | 888 | |
| | 3 | 0 | 0 | 179.30 | 779 | 210.80 | 916 | |

For each additional child or dependant in the family in excess of three, add to the appropriate amount set out in the Schedule for a family of three dependants as follows:

| | Weekly | Monthly |
|-----------------------------|---------|---------|
| Dependant 16 years and over | \$25.30 | \$110 |
| Child 10-15 years | 18.90 | 82 |
| Child 0-9 years | 17.30 | 75 |

O. Reg. 741/86, s. 3, part.

4. This Regulation comes into force on the 1st day of January, 1987.

(9924)

O. Reg. 742/86

FAMILY BENEFITS ACT

O. Reg. 742/86. General. Made—December 18th, 1986. Filed—December 19th, 1986.

REGULATION TO AMEND REGULATION 318 OF REVISED REGULATIONS OF ONTARIO, 1980 MADE UNDER THE FAMILY BENEFITS ACT

 Regulation 318 of Revised Regulations of Ontario, 1980 is amended by adding thereto the following section:

8a. For the purposes of section 8, a retirement pension that is available to a person prior to the month in which the person attains sixty-five years of age under the Canada Pension Plan or the Quebec Pension Plan (Quebec) shall not be considered to be compensation or a financial resource to which that person is entitled. O. Reg. 742/86, s. 1.

- 2. Subsection 15 (4) of the said Regulation, as made by section 1 of Ontario Regulation 484/85, exclusive of the clauses, is revoked and the following substituted therefor:
- (4) Notwithstanding section 11, where the amount of the allowance payable to a recipient who is,

would be reduced to zero under section 13 by reason of income that includes income from a spouse's allowance payable to a widow or widower under the *Old Age Security Act* (Canada), the amount of the allowance shall be continued at \$2.50 per month so long as the recipient remains otherwise eligible for an allowance until the recipient attains sixty-five years of age.

- (5) Notwithstanding section 11, where the amount of the allowance payable in the month of January, 1987 to a recipient would be reduced to zero under section 13 by reason of income that includes income from a disability benefit under the Canada Pension Plan or the Quebec Pension Plan (Quebec), the amount of the allowance shall be continued at \$2.50 per month so long as the recipient remains otherwise eligible for an allowance. O. Reg. 742/86, s. 2, part.
 - 3. This Regulation comes into force on the 1st day of January, 1987.

GENERAL WELFARE ASSISTANCE ACT

O. Reg. 743/86. General. Made—December 18th, 1986. Filed—December 19th, 1986.

REGULATION TO AMEND
REGULATION 441 OF
REVISED REGULATIONS OF
ONTARIO, 1980
MADE UNDER THE
GENERAL WELFARE ASSISTANCE
ACT

- 1. Section 2 of Regulation 441 of Revised Regulations of Ontario, 1980 is amended by striking out "and" at the end of clause (a), by adding "and" at the end of clause (b) and by adding thereto the following clause:
 - (c) recipients of a benefit under the Canada Pension Plan or the Quebec Pension Plan (Quebec).
- Section 3 of the said Regulation, as amended by section 2 of Ontario Regulation 691/83 and section 2 of Ontario Regulation 402/84, is further amended by adding thereto the following subsection:
- (2) For the purposes of clause (3) (b), a retirement pension that is available to a person prior to the month in which the person attains sixty-five years of age under the Canada Pension Plan or the Quebec Pension Plan (Quebec) shall not be considered to be compensation or a financial resource to which that person is entitled. O. Reg. 743/86, s. 2.
 - 3. This Regulation comes into force on the 1st day of January, 1987.

(9926)

HEALTH INSURANCE ACT

O. Reg. 744/86. General. Made—December 18th, 1986. Filed—December 19th, 1986.

REGULATION TO AMEND REGULATION 452 OF REVISED REGULATIONS OF ONTARIO, 1980 MADE UNDER THE HEALTH INSURANCE ACT

- 1. Items 12 and 51 of Part I of Schedule 9 to Regulation 452 of Revised Regulations of Ontario, 1980 are revoked and the following substituted therefor:
- 12. Etobicoke

Four Seasons Physiotherapy

51. Ottawa

The Ottawa and District Physiotherapy Clinic

(9927)

0.00

HEALTH INSURANCE ACT

O. Reg. 745/86. General. Made—December 18th, 1986. Filed—December 19th, 1986.

REGULATION TO AMEND REGULATION 452 OF REVISED REGULATIONS OF ONTARIO, 1980 MADE UNDER THE HEALTH INSURANCE ACT

- Subsection 59 (1k) of Regulation 452
 of Revised Regulations of Ontario,
 1980, as made by section I of Ontario
 Regulation 215/86, is revoked and
 the following substituted therefor:
- (1k) The amount payable by the Plan for an insured service rendered by a physician outside Ontario to an insured person on or after the 1st day of April, 1986 and before the 1st day of January, 1987 is the lesser of,
 - (a) the amount actually billed by the physician;or

- (b) the amount set out opposite the service in Schedule 15 as it existed on the 18th day of December, 1986 or 48.3 cents multiplied by the applicable individual unit value for such service set out opposite the service in Schedule 16, as the case may be.
- (11) The amount payable by the Plan for an insured service rendered by a physician outside Ontario to an insured person on or after the 1st day of January, 1987 is the lesser of,
 - (a) the amount actually billed by the physician; or
 - (b) the amount set out opposite the service in Schedule 15 or 48.3 cents multiplied by the applicable individual unit value for such service set out opposite the service in Schedule 16, as the case may be. O. Reg. 745/86, s. 1.
 - Subsection 67 (2l) of the said Regulation, as made by section 2 of Ontario Regulation 215/86, is revoked and the following substituted therefor:
- (21) The amount payable by the Plan for an insured service rendered by a physician in Ontario to an insured person on or after the 1st day of April, 1986 and before the 1st day of January, 1987 is the amount set out opposite the service in Schedule 15 as it existed on the 18th day of December, 1986 or 48.3 cents multiplied by the individual applicable unit value for such service set out opposite the service in Schedule 16, as the case may be.
- (2m) The amount payable by the Plan for an insured service rendered by a physician in Ontario to an insured person on or after the 1st day of January, 1987 is the amount set out opposite the service in Schedule 15 or 48.3 cents multiplied by the individual applicable unit value for such service set out opposite the service in Schedule 16, as the case may be. O. Reg. 745/86, s. 2.
 - 3. Schedule 15 to the said Regulation, as remade by section 3 of Ontario Regulation 215/86 and amended by section 1 of Ontario Regulation 342/86 and section 1 of Ontario Regulation 610/86, is revoked and the following substituted therefor:

Schedule 15

Schedule of Benefits

PREAMBLE

A. General

- 1. The rates listed in this Schedule of Benefits are the maximum payments which can be made by the Ontario Health Insurance Plan.
- 2. Insured medical services are limited to the services which are medically necessary, which are listed in this Schedule of Benefits and which are not specifically excluded by legislation or regulation. (See Appendix for list of specific exclusions).
- 3. Additions, deletions or other modifications of the Schedule of Benefits require recommendation by the Ontario Health Insurance Plan. Such recommendations are made in consultation with the Ontario Medical Association.

4. This Schedule is a public document and frank discussion with patients regarding the listed rates is

recommended.

5. Claims for services which are not listed in the Schedule or which are listed as N.A.B. (not a benefit) or which are excluded as benefits by legislation or regulation should not be submitted to the Plan. Such services may be charged directly to patients or others requesting them.

6. The principles governing proper professional charges are incorporated in the Regulations (Medicine) of the Health Disciplines Act.

7. Each physician who participates in the care of a patient is entitled to compensation commensurate with the

services he/she renders.

8. Whenever possible, the physician should acquaint the patient or person financially responsible with his obligations to those concerned with his care. This is particularly important where supportive or concurrent care is rendered or when a consultation and/or procedure are being arranged.

9. Each physician participating in the care of a patient should render to the patient, or to the financially

responsible party, an itemized statement of charges for professional services.

10. Each physician participating in the care of a patient should, on request, send a receipt to the patient for all payments made by him/her.

II. If fees are collected by an organized group, the name of the physician rendering the service should be clearly shown on the bill or claim card.

12.Claims may be submitted for services which a patient receives from the team of staff physician, resident, intern and clerk in a teaching unit, provided that the conditions as set out hereunder apply.

On October 10, 1972, the Minister of Health confirmed that the joint recommendations of the College and the 0.M.A. governing the charging of fees for services provided by interns and residents in clinical teaching units are acceptable to the Ministry of Health. In his letter the Minister made it very clear that he is looking to the College and the Medical Schools to ensure that the ethical rules governing these billing procedures are followed meticulously in all cases.

It has been carefully explained that the responsible staff physician must be present in the clinical teaching unit at the time the services are rendered and must be identified to the patient at the earliest possible moment. No fees are to be charged for services given by the intern or resident prior to this identification taking place.

The following rules are now in effect:-

When patient care is rendered in a clinical teaching unit or other setting for clinical teaching by a health care team, the physician responsible shall be personally identified to the patient. His/her relationship to the team shall be defined by the clinical teaching unit Director and his/her role must be known to the patient and other members of the team. He/she shall assume full responsibility for the appropriateness and the quality of the services rendered.

Specific regulations must vary with the service and form of care being delivered:-

(a) In order to claim for physical procedures being carried out by an interm or resident, the responsible

staff man must be in the clinical teaching unit and immediately available to intervene.

- (b) In psychotherapy where the presence of the staff physician would distort the psychotherapy milieu, it is appropriate for the staff physician to claim for psychotherapy when a record of the interview is carefully reviewed with the resident and the procedure thus supervised. However, the time charged by the staff physician may not exceed the total time spent by him/her in both such interview and in direct supervision.
- (c) In other departments or services, the staff physician should only claim for visits on the days when actual supervision of that patient's care takes place through the presence of that staff physician in the clinical teaching unit on that day. This, of course, involves a physical visit to the patient and/or a chart review with detailed discussion with the other member(s) of the health team.
- (d) In those situations where on a regular basis a staff member might supervise concurrently multiple procedures or services through the use of other members of the team, the total claims made by the staff physician shall not exceed the amount that the staff physician might make in the absence of the other members of the team.

Any claim rendered should be in the name of the responsible staff physician.

13. Charges for missed appointments are not benefits of OHIP.

PREAMRI F

B. Terms and Definitions:

Call or Visit: is the service by a physician to a patient for assessment and/or treatment.

1. Consultations:

(a) Consultation refers to the situation where a physician, in light of his/her professional knowledge of the patient, requests the opinion of another physician competent to give advice in this field, because of the complexity, obscurity or seriousness of the case or because another opinion is requested by the patient or an authorized person acting on his/her behalf. The consultant is obliged to perform a general or specific assessment, review the laboratory or other data and submit his/her findings, opinions and recommendations in writing to the referring physician.

(b) If a consultant is requested by a physician on duty in the emergency department to see a patient in consultation, the former may charge a consultation fee for this service. If the consultant is requested to perform this same service by a resident or interm, the former may charge a general or specific

assessment according to his/her specialty.

(c) Consultations required by hospital by-law and/or statute are not insured service except where contrary indications are noted in this Schedule.

(d) For laboratory and procedural benefits connected with consultations, see listings of Diagnostic and Therapeutic Procedures and Laboratory Medicine.

A consultation is not to be claimed as such when:

(i) The patient presents him/herself to a consultant's office without prior knowledge of the primary physician.

The sending of a report to the primary physician under these circumstances does not justify a consultation.

(ii) The primary physician is not asked for professional advice but is simply asked by the patient for the name a specialist in a particular field and the patient seeks out the specialist him/herself.

(f) A repeat consultation requires all of the criteria of a full consultation and implies interval care by the primary physician. The situation in which the consultant requests the patient to return for a later examination is not a repeat consultation.

(g) A limited consultation may involve all the components of a full consultation but is less demanding, and in terms of time, normally requires substantially less of the physician's time than the full

consultation.

- (h) A diagnostic radiology consultation applies when radiographs made elsewhere are referred to a radiologist for his/her written opinion or when a radiologist is required to make a special visit at Night (5:00 p.m. to 7:00 a.m.) or Saturdays, Sundays and Holidays to consult on the advisability of performing a diagnostic radiological procedure which eventually is not done. A consultation does not apply when the radiographs referred to above are used for comparison purposes with radiographs made in the consultant's facilities.
- (i) A diagnostic laboratory medicine consultation applies when tissue, slides, and/or specimens are referred to a second pathologist not in the same institution for a written opinion. It includes secretarial or other assistance but does not apply when the above are used for comparison with tissue, slides, materials or tests done in the consultant's facilities. When a diagnostic laboratory medicine consultation fee is claimed, surgical pathology fees may not also be claimed.

(j) A laboratory medicine consultation or repeat consultation applies when a laboratory medicine physician is

requested to examine a patient and provide a written opinion.

(k) A diagnostic nuclear medicine consultation applies when nuclear medicine studies are referred to a nuclear medicine specialist for a written opinion, or when the nuclear medicine physician is required to make a special visit at Night (5:00 p.m. to 7:00 a.m.) or Saturdays, Sundays and Holidays to consult on the advisability of performing a nuclear-medicine procedure which eventually is not done. A consultation does not apply when procedures done elsewhere are used for comparison purposes with nuclear medicine studies made in the consultant's facilities.

 A nuclear medicine consultation or repeat consultation applies when a nuclear medicine specialist is
requested to examine a patient and provide a written opinion, all of which takes a greater amount of time and effort than a nuclear medicine study would normally require. It may be done in conjunction with a nuclear medicine study but if so, the lesser professional fee (P_2) rather than the greater fee (P_1) should be claimed in addition to the technical fee (T).

(m) Some nuclear medicine specialists have other specialist qualifications which allow them to claim another consultation (e.g. internal medicine). A nuclear medicine consultation or repeat consultation may be claimed in lieu of another consultation (e.g. internal medicine) but would not be combined with such a

consultation by the same consultant.

(n) A prenatal consultation by a paediatrician applies when a physician considers a foetus of greater than 20 weeks gestation to be at risk or in jeopardy by reason of continuation of pregnancy in the presence of maternal and/or foetal distress, and requests the opinion of a paediatrician competent to give advice in this field. The paediatrician shall perform a general or specific assessment, review laboratory and other data and submit his/her findings and recommendations in writing to the referring physician. Such a consultation does not preclude the paediatrician from a post-natal consultation on the infant.

(o) A special surgical consultation may apply when a surgeon provides all the components of a regular consultation but is required to spend at least fifty minutes with the patient (exclusive of any tests) in consultation because of the very complex, obscure or serious nature of the problem. The surgeon should claim \$96.25 for special consultations on an I.C. basis (A935). See para 32 section B.

(p) An emergency physician consultation applies when a patient is referred by another physician (other than an E.R. physician) who has seen and examined the patient and requested the opinion of an emergency room physician because of the complexity, obscurity or seriousness of the case. The consultant shall perform the necessary assessment, review the laboratory, x-ray or other data and submit his/her findings, opinions and recommendations in writing to the referring physician. A copy of the E.R. chart does not constitute a consultation report. This consultation is not chargeable for the routine transfer of care to the E.R. nor for the provision of treatment for a previously diagnosed condition. It does not apply to patients who present themselves to the E.R. or are brought by people acting on their behalf. It is anticipated that these consultations will replace some of the consultations that would otherwise be provided by consultants in other branches of medicine. If the consultation leads to admission to hospital, no separate fee is chargeable for the admission assessment by the same physician. The consultation fee for a specialist in emergency medicine (F.R.C.P.) is \$53.20 (HO55); for all others, \$34.00 (HO65)

Note: OHIP benefits for consultations normally are limited to one consultation per year, per patient, by any one physician. However, if the same patient is referred to the same consultant a second time within the year with a clearly defined unrelated diagnosis, one additional consultation may be claimed per year.

General Assessment: shall comprise a full history, an enquiry into, and an examination of all parts or systems (and may include a detailed examination of one or more parts or systems), an appropriate record, and advice to the patient.*

OHIP benefits for general assessments normally are limited to one per year per patient by any one physician. However, if the same patient presents again within the year to the same physician with a clearly defined new diagnosis, one additional general assessment may be claimed per year. In the case of a patient who proceeds normally to hospital, the admitting physician may claim one additional general assessment per year provided 90 days have elapsed since the last general assessment rendered (anywhere) to that patient by the admitting physician. If the patient doesn't qualify for a general assessment by the admitting physician, he/she may claim a general re-assessment.

General Re-Assessment; shall comprise the same services as a general assessment except that the history need not include all the detail already obtained in the original general assessment.*

OHIP benefits for general re-assessments, except for hospital admission re-assessments, are limited to two per year, per patient, by any one physician.

4. Specific Assessment: shall comprise a full history of the presenting complaint, enquiry concerning, and detailed examination of the affected part, region or system, as needed to make a diagnosis, and/or exclude disease and/or assess function, an appropriate record, and advice to the patient.* (This may vary among sections.)

Physicians qualified in two specialties (EENT for example) may only claim for one visit, e.g.: a consultation (if referred) or a specific assessment (if non-referred), if both systems are examined during the same visit. However, two consultations or two specific assessments, etc. may be claimed if both systems are examined, each on a separate visit.

OHIP benefits for specific assessments normally are limited to one per year, per patient, by any one physician. However, if the same patient presents again within the year to the same physician with a clearly defined new diagnosis, one additional specific assessment may be claimed per year.

- 5. Specific Re-Assessment: shall comprise a full relevant history and a comprehensive physical examination of one or more systems but not requiring an evaluation of the patient as a whole.* This service is the admission assessment when the patient has been seen prior to admission in the same illness. It is included in the surgical fee except for those procedures marked I.O.P.
- 6. Partial Assessment: shall comprise a history of the presenting complaint, the necessary physical examination, an appropriate record and advice to the patient. It also applies to subsequent visits for assessing the response to treatment and/or advice provided in a previous service.
- 7. Intermediate Assessment: is a primary care service for physicians providing general practice or paediatric services and is a more extensive assessment than a minor assessment. It shall comprise a history of the presenting complaint(s), enquiry concerning and examination of the affected part(s), region(s), or system(s) or mental or emotional disorder as needed to make a diagnosis, exclude disease and/or assess function, an appropriate record, and advice to the patient.*
- Multiple Systems Assessment: shall comprise a detailed history and examination of more than one system, part or region, an appropriate record and advice to the patient.
- Minor Assessment: is a visit which involves a direct doctor-patient interaction at which either or both of the following are provided and an appropriate record made of the visit:
 - (a) a brief assessment which includes the necessary history and examination of the affected part or region or mental or emotional disorder;
 - (b) brief advice or information regarding health maintenance, diagnosis, treatment and/or prognosis.
- 10. Mini Assessment: applies when a physician examines and/or treats a patient for a completely unrelated problem in addition to the examination/treatment of a W.C.B. related problem (for which the W.C.B. will only pay a minor assessment) during the same office visit. The fee for the mini assessment is \$6.90 (A008).

^{*}For laboratory and other investigation performed in conjunction with a consultation or visit, see Diagnostic and Therapeutic Procedures and Laboratory Medicine.

- 11. Re-Assessments (by physician on duty in the Emergency Department): one re-assessment may be charged when, at least two hours after the original assessment is completed (including appropriate investigation and necessary treatment), a subsequent assessment indicates that further provision of care and/or investigation is required and performed. Re-assessments are not to be claimed for discharge assessments nor when the patient is admitted by the physician on duty in the Emergency Department, nor when this assessment leads directly to referral for consultation.
- 12. Well Baby Care: the periodic visits of a well baby during the first two years of life involving complete examination with necessary weight and measurements and instructions to the parent(s) regarding health care,
- 13. Annual Health or Annual Physical Examinations (Including Primary and Secondary School Examinations): shall comprise all the elements of a general assessment as it pertains to an individual after the second birthday who presents and reveals no apparent physical or mental illness.
 OHIP benefits for any one physician are limited to one Annual Health Examination per patient per year after the second birthdate. To qualify, an Annual Health Examination normally must be requested by the patient rather than a third party. Regulation 452 of Revised Regulations of Ontario, 1980 under the Health Insurance Act, examinations for the purpose of "legal requirements or proceedings" are excluded from coverage. However, it is recognized that an annual Health Examination will satisfy some or all of the requirements for examinations required by statute but excluded by the above mentiond Regulation. In such instances and where a prior claim for an Annual Health Examination has not been submitted to the Plan in the previous twelve months for that patient, it would be appropriate to submit a claim to OHIP for this service. The OHIP benefit in these cases covers the Annual Health Examination only and not any charges peculiar to the legal requirements, such as charges for the completion of forms.
- 14. Long Term Institutional Care: includes the listings for consultations, assessments and other visits to patients in chronic care hospitals, convalescent hospitals, nursing homes and other institutions in which such patients are covered by extended care legislation.
 Admission Assessments to Long Term Care Institutions:

Type 1 - applies when the admitting physician has not performed a consultation, general assessment or general re-assessment prior to admission and when he carries out a general assessment (on admission) and provides a report for the medical record.

Type 2 - applies when the admitting physician has performed and claimed for a consultation, general assessment or general re-assessment prior to admission, makes an initial visit and records an admission note describing the condition of the patient following admission.

Type 3 - applies when the admitting physician readmits a patient after a 7 day stay in another institution; the admitting physician shall carry out a general re-assessment and provide a report for the medical record.

- Note: When a physician already is in the institution and is asked to assess one of his own in-patients on a non-emergent or an emergent basis, the subsequent visit listings apply. However, if he is asked to assess another physician's patient on an emergency basis, the General Listings should be used.
- 15. Subsequent Visits to Long Term Care Institutions: include the supervisory care as well as the active treatment of acute intercurrent illness when the physician is already in the long term care institution. The supervisory care component includes discussion with the patient and/or family and/or examination of the patient and also includes as required, discussion with the nurse, chart review and annotation of the chart. When acute intercurrent illness requires a special visit, the appropriate fees under General Listings and Premiums apply. For acute intercurrent illnesses requiring visits after the monthly maximums have been claimed, extra visits should be made on an I.C.-basis (W121 \$12.70).
- 16. Pre-dental General Assessment: is the history and examination of a patient required prior to dental surgery under anaesthesia in hospital. A diagnosis is not required by OHIP for this service.
- 17. Newborn Care: is the routine care of a well baby up to ten days of age and should include a complete physical examination of the baby and necessary instructions to the mother. The service shall involve at least two visits and normally may not be claimed for the same patient by more than one physician. When a well baby is transferred to another hospital (because of the mother's state of health, for example) claims for newborn care by a physician at each hospital may be appropriate.
- 18. Low Birth Weight Baby Care: is the care of a baby weighing less that 2.5 kilograms at birth.
- 19. Psychotherapy: is any form of treatment for mental illness, behavioural maladaptations, and/or other problems that are assumed to be of an emotional nature, in which a physician deliberately establishes a professional relationship with a patient for the purposes of removing, modifying, or retarding existing symptoms, or attenuating or reversing disturbed patterns of behaviour, and of promoting positive personality growth and development. Accordingly, therefore, a psychotherapeutic procedure may be claimed if a half hour or major part thereof has been spent by a physician in such treatment of the patient. The minimum time period for psychotherapy (to be charged as such) is twenty minutes. In order to claim for a major portion of a second or subsequent time interval of psychotherapy for the same patient during the same visit, the preceding time interval must be a full 30 minutes of psychotherapy. When psychotherapy extends beyond thirty minutes, the major part (16 minutes) of the next half hour must be spent with the patient to qualify for an additional half hour fee. Similarly, after one hour of psychotherapy, the major part (16 minutes) of the next half hour, and so on.

- 20. Counselling: as distinct from psychotherapy, is that form of activity in which the physician engages in an educational dialogue with the patient(s), on an individual or group basis wherein the goal of the physician and patient(s) is to become aware of the patients' problems or situation and of modalities for prevention and/or treatment. Counselling is not to be claimed for the advice that is a normal part of any consultation or assessment, for ongoing treatment or as a substitute for patient assessment fees. Counselling must be rendered personally, by the attending physician.
- 21. Genetic Counselling: includes interviewing the appropriate family members, the collection and assessment of adequate clinical and genetic data to make a diagnosis, construct a pedigree and assess the risks to persons seeking advice. It includes imparting this information and the various alternatives to the appropriate family members for dealing with the problem in such a way that they can make informed decisions about the genetic problem.
- Documentation: when a physician examines or treats a patient, an appropriate record of such service should be made. (See Appendix B).
- 23. Visit for Procedure: when the sole reason for an office visit is the performance of a certain procedure, the listed benefit for the procedure will apply. (See Diagnostic and Therapeutic Procedures Preamble for exceptions). When procedures are carried out in the office, mergency or outpatient department on an elective basis, special visit fees should not be claimed in addition to the procedural fee. When procedure(s) are carried out by a physician's employee(s) under the direct supervision of the physician in his office, the usual claims may be made for procedure(s) which are generally and historically accepted as those which may be carried out by the nurse or other medical assistant in the employ of the physician. "Procedures" in this context do not include such services as assessments, consultations, psychotherapy, counselling, etc. Direct supervision requires that during the procedure the physician be physicially present in the office or clinic at which the service is rendered.** While this does not preclude the physician from being otherwise occupied he must be in personal attendance to ensure that procedures are being performed competently and he must at all times be available immediately to approve, modify or otherwise intervene in a procedure as required in the best interests of the patient.

For physiotherapy procedures performed under direct physician's supervision as detailed above, see Code 6467 listed in Diagnostic & Therpeutic Procedures - Physical Medicine.

**Some procedures may not require the physical presence of a physician for adequate supervision. Exceptions to this requirement of direct supervision may be made upon recommendation of the Ontario Medical Association and the College of Physicians and Surgeons of Ontario.

- 24. Health Examination: this may vary in extent according to the purpose for which required (e.g. pre-employment, insurance, free from infection, etc.). This is not a benefit of OHIP and the fee should be according to the type of assessment necessary for this purpose and billed to the patient or party requesting the service.
- 25. Age: (unless otherwise specified) Newborn - up to 10 days of age. Infant - up to 2 years. Child - up to and including 15 years. Adolescent - up to and including 17 years. Adult - 18 years or over.
- 26. Most Responsible Physician: is the attending physician who is primarily responsible for the day to day care of the patient in hospital. In cases of unusual severity where the consultant assumes the role of the most responsible physician, the consultant may claim on a per visit basis and the family physician may claim supportive care. Where the family physician remains the most responsible physician and requests only a consultation, the family physician may claim on a per visit basis and the consultant may claim a consultation only.
- 27. Transferral and Referral:
 - (a) A referral takes place when one physician requests for his patient the services of another. The services of the latter may consist of:
 - (i) an opinion (i.e. a consultation).
 - (ii) diagnostic tests or procedures (e.g. skin test, biopsy, etc.).

Note: In such cases the referring physician continues to treat the case himself.

(iii)treatment (surgical or medical).

The referring physician's OHIP registration number must be included on the claim submission.

(b) A transferral, as distinguished from a referral, takes place where the responsibility for the care of the patient is completely transferred permanently or temporarily, from one physician to another (e.g. where the first physician is leaving temporarily on holidays and unable to continue to treat the case). Physicians who are substituting for other physicians should consider that patients of the latter have been temporarily transferred (not referred) to their care. The physician to whom the patient is transferred should be regarded as substituting for the other physician. Where the care of the patient

involves a benefit containing several components such as surgery, the physicians may consider the surgical benefit a team benefit and decide among themselves how each is to be compensated; traditionally physicians in these circumstances have reciprocated by exchanges of coverage for each other. When physicians routinely or frequently substitute for each other in providing hospital visits to registered bed patients in active treatment hospitals, e.g. weekend coverage or daily rounds by various members of a group, the most responsible physician may claim for all the visits.

- 28. Concurrent Care: applies when the family physician remains the most responsible physician but because of the seriousness or complexity of the condition, requests continued directive care by a consultant. The family physician may claim on a per visit basis and the consultant may also claim on a per visit basis not to exceed four such claims during the first week of concurrent care and not to exceed two such claims each week thereafter while the patient's condition remains serious this arrangement being agreeable to both physicians.
- 29. Multidisciplinary Care: applies when the complexity of the medical condition requires the services of several physicians in different disciplines. In such cases, each physician should render a separate account on a per visit basis. This does not refer to a situation where a single benefit for a team of physicians is listed in this Schedule.
- 30. Supportive Care: is the care rendered in hospital by the referring physician, who is not actively treating the case (e.g. writing orders), to a patient under the care of another physician, at the desire of the patient or family, for purposes of liaison or reassurance. The physician may claim for this care on a per visit basis not to exceed four such claims during the first week of supportive care (determined by the date of the first supportive care visit) and not to exceed two such claims each week thereafter. If medical complications develop or are present in the post-operative period which require active management by the referring physician, hospital medical care fees should be applied not supportive post-operative fees.
- 31. Terminal Care (In Hospital): applies to one designated physician responsible for the care of a terminally ill patient suffering from malignant disease. Terminal care will be deemed to start when there is no aggressive treatment of the underlying disease process and care is directed to maintaining the comfort of the patient until death occurs. Terminal care should be claimed retroactively after death on the basis of visits actually rendered for a period not to exceed four weeks prior to death. Terminal care visit fees as described above do not apply when unexpected death occurs after prolonged hospitalization for another diagnosis unrelated to the cause of death. Visits to patients in hospital may be claimed at \$14.30 (C382) by general and family practitioners and at \$15.60 (C982) by specialists. For patients receiving terminal care in chronic hospitals, the above fees should be claimed with codes W882 and W882 respectively.
- 32. Independent Consideration "I.C.": Independent consideration may be given where a set fee is not listed in the Fee Schedule. Claims rendered under this heading should contain an explanation of the fee claimed. It is helpful to the Medical Consultant if claims for I.C. include an operative or consultation report and a comparison of the scope and difficulty of the procedure with other procedures in the Schedule.
- 33. Specialist: A specialist shall be defined (for purposes of application in the case of any given service within this Schedule) as one who holds a certificate from The Royal College of Physicians and Surgeons of Canada in the specialty which normally is considered to-encompass the service in question.

A specialist rendering services outside of his specialty should use the codes and tariffs listed in the General Practice section of the Schedule.

34. Differential Benefits:

(a) Procedural fees apply to any physician rendering the services regardless of specialty.

- (b) Specialists providing primary care in a general practice setting shall claim the appropriate visit fees (as defined in the Preamble) listed under the heading Family Practice and Practice in General. Certain other non specialist services such as counselling and interviews are under the same heading for the use of any physician providing such services.
- (c) Specialists in paediatrics who practice allergy may claim specialist fees for their allergy services regardless of the age of their patients.

35. Referring Physician's Services:

(a) For the services rendered prior to the operation, the referring physician should claim on a

fee-for-service basis, for example:

- (i) Visits as rendered.
- (ii) In addition to (i) above, in acute cases if detained, he may claim detention fees if appropriate. See Preamble, paragraph 8.45.
- (b) (i) For services rendered as an assistant during the operation, the referring physician should claim an assistant's fee.

- (ii) In cases in which the referring physician is required to be present in the interest of the patient but does not actually assist at the surgical procedure, he should claim on a hospital visit basis for this service.
- (c) For the services rendered after the operation, the referring physician may claim on the basis of supportive care fees as outlined in the schedule.

36. Assistants' Services:

- (a) The assistants' fees are determined by adding the listed basic units and time units and multiplying the total number of units by \$8.81. For all cases commencing after 5:00 p.m. and before midnight or on Saturdays, Sundays and Holidays, increase the total assistant's fee by 40% (E4008). For all cases commencing after midnight and before 7:00 a.m. any night of the week, increase the total assistant's fee by 50% (E4018).
- (b) When a physician is required to make a special visit to the hospital to assist at surgery, he may charge a special visit premium of \$29.65 (09988) for a case commencing after 5:00 p.m. and before midnight or on Saturdays, Sundays and Holidays or \$44.50 (0998) for a case commencing after midnight and before 7:00 a.m. any night of the week. These premiums are in addition to the E400 and E401 premiums but apply only to the first patient treated on each special visit.
- (c) The time units are computed by allowing one unit (\$8.81) for each 15 minutes or part thereof of time (up to two hours) spent by the assistant. When assisting for more than two hours per case, time units for periods in excess of two hours are computed by allowing two units for each 15 minutes or part thereof. Time for purposes of these calculations includes scrub time and time spent in the operating room. If claims are being made in coded form (see explanatory comments at front of Fee Schedule), the suffix B should be added to the fee code for the procedure. The basic units should be listed separately from the time units on the claim card.
- (d) When multiple or bilateral surgical procedures are done during the same anaesthetic, the assistant's benefit shall be based on the basic units for the major procedure plus time. When bilateral procedures or surgical revisions are carried out at separate times with separate anaesthetics, the assistant shall be entitled to receive a full assistant's benefit for each procedure.
- (e) In surgical procedures requiring more than one assistant, the second assistant shall compute his fee on the same basis as the first assistant. Each claim for second assistant should be accompanied by a statement from the operating surgeon confirming the necessity for his/her services.
- (f) When a surgeon requires an assistant at a procedure for which no assistant's fee is listed, the assistant may calculate his fee by taking the number of basic units used by the anaesthetist, adding his time units and multiplying the total number of units by \$8.81.
- (g) When assistants at surgery claim for procedures for which no assistants' fees have actually been listed in the schedule, the assistants should support their claims with a statement of explanation from the surgeon, confirming the medical necessity for their attendance.
- Note: Code M400B to be used by OHIP for services performed by an assistant where no assistant units are listed. All such services must be assessed for appropriateness by the OHIP Medical Consultant.
- (h) Where the attendance of a physician is requested by the patient's other medical attendants for the sole purpose of monitoring or special supportive care, and when the physician is in constant attendance, the fee shall be 3 units plus time (E0038).
- (i) When an anaesthetic has begun and the operation is cancelled prior to commencement of surgery, the assistant who has scrubbed but is not required to do more, should claim 3 basic units plus time units (E006B). If the operation is cancelled after surgery has commenced, the procedural basic units plus time units will apply. If the procedure is cancelled prior to the induction of anaesthesia and the assistant is scrubbed, a subsequent hospital visit only may be claimed.

37. Anaesthetists' Services

- (a) The tariff is for all types of anaesthesia. The fee is for professional services, including pre-anaesthetic evaluation and post-anaesthetic follow-up and all immediate supportive measures, and does not include the cost of materials used.
- (b) If an anaesthetist is requested by another physician to see a patient in consultation (see para. 1(a)) because of the complexity, obscurity or seriousness of the case prior to the administration of an anaesthetic, he may claim a consultation fee as well as the anaesthetic fee. If this consultation is provided less than 36 hours prior to the administration of an anaesthetic, this consultation should be claimed at \$59.00 under fee code E015. The routine pre-anaesthetic evaluation of the patient required by the Public Hospitals Act does not qualify as a consultation, regardless of where and when this evaluation is performed. Anaesthetic consultations do not apply when hospital, departmental by-laws, statutes or policies require automatic consultations on any patient requiring anaesthesia.
- (c) If an anaesthetist examines a patient prior to surgery and the surgery is cancelled prior to the induction of anaesthesia, he or she may claim a hospital visit fee for this service. When an anaesthetic has begun and the operation is cancelled due to a complication prior to the commencement of surgery, the anaesthetist should claim 4 basic units plus time (EOOGC). If the operation is cancelled after surgery has commenced, the procedural basic fee plus time units will apply.
 - *For laboratory and other investigation performed in conjunction with a consultation or visit, see Diagnostic and Therapeutic Procedures and Laboratory Medicine.

- (d) The anaesthetist's fees are determined by adding the basic and time units together and multiplying the sum by \$10.16. For cases commencing after 5:00 p.m. and before midnight or on Saturdays, Sundays and Holidays, increase the total anaesthetic fee by 40% (E400C). For cases commencing after midnight and before 7:00 a.m., any night of the week, increase the total anaesthetic fee by 50% (E401C).
- (e) When an anaesthetist is required to make a special visit to the hospital to administer an anaesthetic, he may claim a special visit premium of \$29,65 (C990C) for a case commencing after 5:00 p.m. and before midnight or on Saturdays, Sundays and Holidays or \$44,50 (C999C) for a case commencing after midnight and before 7:00 a.m. any night of the week. These premiums are in addition to the E400 and E401 premiums but only apply to the first patient treated on each special visit.
- (f) When an anaesthetist administers an anaesthetic to a patient under the age of one (E009) or over the age of seventy (E007), add one unit to the total fee. When an anaesthetist administers an anaesthetic to a patient of any age with an incapaciting systemic disease that is a constant threat to life or to a moribund patient who is not expected to survive for 24 hours with or without the operation, add one unit to the total fee (E008).
- (g) Basic units are listed for most procedures and include the value of all anaesthetic services except the actual time spent administering the anaesthesia, any modifying factors, or unusual detention with the patient (see paragraph n).
- (h) Except during maintenance of continuous conduction anaesthesia time units are computed by allowing one unit for each 15 minutes or part thereof of anaesthesia time (up to two hours); following the first two hours of anaesthesia, time units for periods in excess of two hours shall be computed on the basis of two units for each 15 minutes or part thereof; time units for periods in excess of eight hours shall be computed on the basis of three units for each 15 minutes or part thereof. Anaesthesia time begins when the anaesthetist is first in attendance with the patient for the purposes of creating the anaesthetic state and ends when he is no longer in personal attendance (when the patient may be safely placed under customary post-operative supervision).
- If claims are being made in coded form (see explanatory comments at front of Fee Schedule), the suffix C should be added to the fee code for the procedure.
- (j) In special cases when the anaesthetic services of more than one anaesthetist are deemed necessary in the interest of the patient, the second anaesthetist shall charge 4 basic units (E001) plus time units for the time spent assisting the first anaesthetist.
- (k) When multiple or bilateral surgical procedures are done during the same anaesthetic, the anaesthetic benefit shall be based upon the basic units for the major procedure plus time. When bilateral procedures or surgical revisions are carried out at separate times with separate anaesthetics, the anaesthetist shall be entitled to receive a full anaesthetic fee for each procedure.
- In procedures where no value is listed, or with I.C., the basic portion of the calculated value will be the same as listed for a comparable procedure considering the region and modifying conditions or techniques.
- (m) when a pump with or without an oxygenator and with or without hypothermia is employed in conjunction with an anaesthetic, the anaesthetic "Basic Units" will be 28 units; this replaces the listed basic units for the procedure.
- (n) Controlled hypotention may be billed for (10 units) when it is carried out in association with anaesthesia using any technique to deliberately lower and maintain the mean blood pressure by at least 25%. Incidental hypotension from the use of any anaesthetic agent does not constitute controlled hypotension. The additional 10 units may be claimed under EOO4C.
- (o) When unusual detention with the patient before or after anaesthesia is essential for the safety and welfare of such patient, the necessary time will be valued on the same basis as indicated for the anaesthetic time.
- (p) For detention not associated with anaesthesia detention rates and criteria (see paragraph B.45).
- (q) When the attendance of the anaesthetist is requested by the patient's other medical attendants for the purpose of monitoring or special supportive care, and when the anaesthetist is in constant attendance, the benefit shall be 3 units plus time. The code is EOO3C.
- (r) Introduction of a catheter for continuous conduction analgesia and anaesthesia in obsetrics has a basic value of 6 units. Maintenance and/or supervision may be claimed at one unit for each half hour of maintenance to a maximum of 5 units. No fee is chargeable for the first hour following introduction of the catheter and first dose. Time units for delivery may be claimed at one unit per quarter hour.
- (s) When a physician administers an anaesthetic and/or other medication prior to, or during a procedure(s) or immediately after a procedure which he/she performs on the same patient, he/she should claim for the procedure(s) only. However, when a physician administers a pudendal, femoral, intercostal, sciatic, ilioinguinal, iliohypogastric, ulnar, median, or radial block in addition to performing a procedure, he may claim \$13.10 (6224) in addition to the procedure.
- (t) When hypothermia is used by the anaesthetist in procedures not specifically identified as requiring hypothermia, the basic value is 25 units. This basic value replaces the basic value listed in the Schedule for the procedure. When the basic value claimed is 25 units, the anaesthetic service may be claimed under code ECO2C.

- (u) When a patient is known to have malignant hyperthermia or there is a strong suspicion of susceptibility, and the anaesthetic requires full malignant hyperthermia set up and management, add 5 units to the anaesthetic claim (E012). This add-on does not apply to Z245 on page 75.
- (v) Anaesthetic management for the emergency relief of acute upper airway (above the carina) obstruction (excluding choanal atresia) - basic 10 units (E013).
- (w) When one anaesthetist starts a procedure and is replaced by another part way through a surgical procedure or delivery, the first anaesthetist should charge the appropriate basic fee plus time units and the second anaesthetist should charge for time units only. The second anaesthetist should use code EOOSC for such time units except in the case of continuous conduction anaesthesia; for which POIS (plus E1OOC) applies (see para, 37(r)). EOO2C, EOO3C, EOO4C, EOOSC qualify for the premiums E4OOC or E4O1C only if the case originally started within the time stated under para, 37(d) above.
 - Each anaesthetist should state on his/her claim card which part of the anaesthetic is being claimed and the time begun and completed.
- (x) General anaesthesia for the purposes of this Fee Schedule includes all forms of anaesthesia except local infiltration.
- (y) Maintenance/Supervision of epidural catheter for relief of pain (G247) see p.63. For visits rendered after 5 p.m. and before midnight or on Saturdays, Sundays and Holidays add 30% (E402). For visits after midnight but before 7 a.m. add 50% (E403).
- 38. General Listings: include the basic listings for consultations, assessments and other visits wherever they are rendered, except for non-emergency services to hospital or long-term care institution in-patients and for care rendered by a physician on duty in the emergency department. These latter services are listed separately in the Schedule.
- Non-Emergency Hospital in-Patient Services: include the fee listings for consultations and other visits rendered to registered bed patients on a non-emergency basis.
 - (a) When a patient has not been seen previously by the physician in charge, the first visit after admission may be claimed as a consultation or general or specific assessment. When the patient has been previously attended before admission, the first visit after admission may be claimed as a general re-assessment or specific re-assessment (depending on the specialty) if the patient has been seen before in the same illness. However when a patient is admitted to hospital by one physician and is subsequently transferred to another physician, only one general or specific assessment or re-assessment may be claimed per patient admission.
 - (b) Subsequent routine visits should be claimed as subsequent visits (minor assessments). Payments for hospital visits are usually limited to one per patient per day prior to the weekly and monthly limitations that apply after the patient has been hospitalized for 5 weeks, (6 weeks for paediatricians). However, it is not the intent of the Fee Schedule that visit fees be claimed for every day a patient is in hospital unless a physician actually visits the patient each day. For acute illnesses or exacerbation of original illness requiring hospital visits after 5 weeks of hospitalization, claims for extra visits should be made on an independent consideration basis (C121).
 - (c) When a patient in hospital is referred by one physician to another, the second physician should not be limited by the "Subsequent Hospital Visit" formula for the number of hospital visits already rendered by the first physician. In other words, the second physician is entitled to claim for his visits up to 5 weeks just as if the patient was being attended to in hospital for the first time. If the patient is transferred to the care of another physician, the "Subsequent Hospital Visit" formula would apply just as it would if only one physician was involved in the care.
 - (d) When a physician is already in the hospital and is asked to assess one of his own in-patients on a non emergency or emergency basis, the subsequent hospital visit listings apply. However if he is asked to assess another physician's patient on an emergency basis, the General Listings apply.
- 40. Emergency Department Physician on Duty Services: include the fee listings for minor and multiple systems assessments and re-assessments during regular and premium hours rendered by the physician on duty. Any physician on duty in the emergency department should claim these fees regardless of his/her specialty.

The listings under the heading "Emergency Department - Physician on Duty" are meant to apply to those circumstances wherein either emergency or other physicians have elected or are required to be physically and continously present in the Emergency Department or environs for an arranged designated period of time. In addition to applying to full or part time emergency room physicians who work pre-arranged shifts, these listings also apply to the services rendered by physicians who provide on-call emergency room coverage for designated periods of time and limit the services they provide, in the community served by the hospital, predominantly to emergency room coverage. When special visits are rendered by such physicians, A and K codes may be charged for the first patient seen:

- (a) for up to a maximum of two special visits after 8:00 a.m. and up to 5:00 p.m.;
- (b) for up to a maximum of three special visits after 5:00 p.m. and up to midnight;

treated (and charged for under the A and K codes).

(c) for the number of special visits rendered after midnight and up to 8:00 a.m.. When an on call physician practising in the area elects to be continuously present in the Emergency Department or environs for an arranged designated period of time because the volume of patients requires it, e.g. during a busy holiday period, the fees under Emergency Department - Physician on Duty (H101, H103, H104, etc.) should be charged after the patients responsible for the initial special visit have been examined and/or

When an emergency physician is required to make a special visit to the Emergency Department prior to or after his regular arranged designated period of time on duty, he may charge the appropriate fee under the General Listings plus the applicable special visit premium for the first patient assessed; all subsequent patients assessed during this visit to the hospital should be billed under the Emergency Department - Physician on Duty listings.

When a physician is on duty in the Emergency Department, sees a patient and admits the patient to hospital, this physician may claim a minor or multiple systems assessment depending on the service initially provided. Either the patient's attending physician or the emergency department physician (but not both) may render and claim the hospital admission assessment. If the emergency department physician (instead of the attending physician) provides the admission general assessment, he may claim a general re-assessment (COO4) as well as the initial assessment provided both services are actually rendered separately.

SPECIAL VISIT TO EMERGENCY OR O.P.D.

Consultation:

- Consultation, patient not admitted:
 The benefit for the consultation (or repeat consultation) plus the appropriate special visit surcharge (K99-) may be claimed.
- 2. Consultation, patient admitted:
 (a) The benefit for the consultation (or repeat consultation) plus the appropriate special visit surcharge (K99-) followed by hospital visits (if rendered) may be claimed. However, if the consultant also is the "most responsible physician", he may not also claim a hospital in-patient consultation, repeat consultation, general or specific assessment, general or specific re-assessment since the initial consultation rendered in the emergency department serves as the admission
 - assessment.

 (b) If the consultant is not also the most responsible physician, the latter may claim the appropriate admission assessment.

Assessment:

- Assessment, patient not admitted The benefit for the assessment (or re-assessment) plus the appropriate special visit surcharge (K99-) may
 be claimed.
- General/specific assessment plus patient admission The benefit for the general or specific assessment plus the appropriate special visit surcharge (K99-)
 followed by hospital visits may be claimed. However, the admitting physician may not also claim a
 hospital in-patient general/specific assessment or reassessment since the initial general/specific
 assessment rendered in the emergency department serves as the admission.
- Minor/intermediate assessment plus patient admission The benefit for the minor or intermediate assessment plus the appropriate special visit surcharge (K99-) may be claimed. In addition, the admitting physician may claim for a hospital in-patient general or specific reassessment if rendered.

Procedure:

Except for procedures for which the listed benefits specifically include the associated consultation or other assessment, claims may be made for both the procedure and the assessment.

Note:

If a physician has an office in the hospital and is called to assess a patient in the Emergency Department or 0.P.D., the special visit premiums do not apply.

41. Emergency Department Equivalent:

An Emergency Department Equivalent is an office or other place (other than a hospital emergency department) in which a physician renders services as part of an emergency service being made available to the community.

"Emergency Department Equivalent" includes a place used by a physician to render services exclusively to the office practice patients of one or more physicians outside the office hours of those physicians if the place is open for patients to attend.

- A place is an Emergency Department Equivalent only during the period of time that the emergency service is being made available.
- A place may be an Emergency Department Equivalent notwithstanding that the physicians rendering services therein are not continuously present and only attend on call.
- A physician may add a premium of 30% (E030) to the appropriate General Listings for services provided in an Emergency Department Equivalent if

PREAMPLE

- 1) the services were rendered on a Saturday, Sunday or holiday ("holiday" is defined in paragraph 8.43(c) below);
- the services were rendered on the day they were first requested; and,
- 3) the services were rendered for the purpose of dealing with an emergency.
- 42. Long-Term Institutional Care: See paragraph B.14.

Premiums:

 Special Visit Fees Applicable in Addition to Fees for Services Listed Under Consultations and Visits, Critical Care and Injections or Infusions (pages 1-18, 54, 58).

(a) A special visit is one initiated by a patient or his representative where the physician is required to

travel from one location to another to see the patient.

Subject to paragraphs (b) to (r), the appropriate special visit fee applies when a physician makes a special visit to his office even if the office is in the physician's home, or to the patient's home or other location (hotel, motel, roadside, ski slope, etc.), or to the Emergency Department, 0.P.D., hospital or long-term care institution from a location outside any premises of, or operated by or on behalf of, the hospital or institution.

(b) A special visit may also involve an emergency call with sacrifice of office hours. The benefits for this type of special visit apply in a situation where the demands of the patient and/or the physician's interpretation of the patient's condition is such that the physician responds immediately and makes a special

visit at the sacrifice of regular office hours.

(c) A special visit at night or on a Saturday, Sunday or holiday may be claimed when non-elective or emergent calls are made by the physician between 5:00 p.m. and 7:00 a.m. or are received and made on Saturdays, Sundays and Holidays. Holidays are defined for the purpose of this Schedule as New Year's Day, Good Friday, Easter Monday, Victoria Day, Canada Day, Civic Holiday, Labour Day, Thanksgiving, Remembrance Day, Christmas Day and Boxing Day. If any of these holidays fall on a Saturday or Sunday, the Friday before or Monday following will be recognized as the holiday.

(d) Only one special visit (daytime; emergency call with sacrifice of office hours; or nights, Saturdays, Sundays and Holidays) may be claimed for the same patient, same visit. Special visits only apply to non-elective or emergent calls and do not apply to non-eferred or transferred obstetrics. Special visits do not apply to visits on regular rounds to registered bed patients nor do they apply to admission assessments of

patients who have been admitted to hospital on an elective basis, regardless of the time performed.

(e) An elective home visit is a visit to a patient's "home" deemed medically necessary by the physician,

(e) An elective home visit is a visit to a patient's "home" deemed medically necessary by the physician, initiated by the physician or the patient and carried out at any time convenient to the physician. Physicians providing such services should charge in addition to the appropriate fee under the heading General Listings, the premiums under paragraph 43(j) only, even if the elective visits are rendered at Night, on Saturdays, Sundays and Holidays.

If an institution has arranged to have quarters in the same or in a proximal building in order that a physician will be available to make visits to the institution, particularly at night, these are not considered

to be "special visits" to the institution.

If a physician is called to pronounce a patient dead, a minor assessment may be claimed along with the

appropriate surcharge for the special visit.

(f) When additional patients are assessed during special visits, the "additional patient" premiums are not normally applicable unless the additional patient himself qualifies for a special visit. However, extra patients seen during a home visit while the physician is there rendering a special visit to another patient also qualify for the "additional patient" premiums if an assessment is rendered. The maximum number of special visit premiums per special visit (to any location) is ten. Patients who drop in to the office while the physician is there for reasons other than rendering a special visit do not qualify for any of the special visit premiums. Extra in-patients seen during a special visit to a hospital or other institution do not qualify for the "additional patient" premiums unless the physician has been asked specifically to see these extra patients as well.

Note: Patients seen during "office hours" held at night or on Saturday, Sunday or Holidays do not qualify for

any of the special visit premiums.

(g) No special visit fee is chargeable in respect of services rendered in a place, other than a hospital,

long term care facility that is open for patients to attend.

No special visit fee is chargeable for services rendered at any time in an Emergency Department Equivalent (see paragraph B.41 above), whether or not the services qualified for the Emergency Department Equivalent premium.

(h) When no consultation or visits may be claimed e.g. for post-op hospital visits by operating surgeon, the minimum premiums for special visits apply for additional patients seen during a special visit. Minimum premiums also apply to additional patients seen requiring Critical Care (excluding services to a critically

ill patient where team fees apply), Injections or Infusions.
(i) K992, C992, K993, C993 are also applicable to assistant and/or anaesthetist at non-elective surgery.

(j) Daytime Special Visits (Monday to Friday) to Emergency Department or O.P.D.: for other locations see

K990 First patient seenadd ' \$14.80
For each additional patient requiring a special visit and seen during same
K991 special visit, add 30% to consultation or visit - minimumadd \$8.50

PREAMBLE

| (k) Emergency Call with Sacrifice of Office hours: | |
|---|-------------------|
| K992 First patient seenadd | \$29,65 |
| For each additional patient requiring a special visit and seen during same | |
| K993 special visit, add 30% to consultation or visit fee - minimumadd | \$12,70 |
| (1) Evenings (5:00 p.m. to midnight) and Saturdays, Sundays, Holidays: | 312.70 |
| | enn cr |
| K994 First patient seenadd | \$29.65 |
| For each additional patient requiring a special visit and seen during same | |
| K995 special visit, add 30% to consultation or visit - minimumadd | \$12.70 |
| (m) Nights (midnight to 7:00 a.m.): | |
| K996 First patient seenadd | \$44.50 |
| For each additional patient requiring a special visit and seen during same | |
| K997 special visit, add 50% to consultation or visit - minimumadd | \$19.50 |
| (n) Special Visit to the Patient's Home or Equivalent: use the appropriate | listing above |
| (i, j, k, l,m) but substitute the prefix "B" for "K" (e.g. B990 instead of K990). | |
| (o) Special Visit to Hospital In-Patient: use the appropriate listing above (i, j, k, l, | |
| m) but substitute the prefix "C" for "K" (e.g. C990 instead of K990). | |
| (p) Special Visit to Long-Term Care Institution: use the appropriate listing above (i, j, | |
| k, 1, m) but substitute the prefix "k" for "K" (e.g. k990 instead of 1990). | |
| | |
| (q) Special Visit to Office or Other Similar Facility: use the appropriate listing above | |
| (i, j, k, l, m) but substitute the prefix "A" for "K" (e.g. A990 instead of K990). | |
| (r) Special Visit to Any non-professional setting not listed above: use the appropriate | |
| listing above (i, j, k, l, m) but substitute the prefix "O" for "K" (e.g. Q990 | |
| instead of 1990). | |
| 44. Special Care Unit (e.g. I.C.U. or C.C.U.): | |
| For each patient seen on visit to I.C.U. or C.C.U. (excluding supportive care, critical, | |
| ventilatory, comprehensive and neonatal intensive care claimed on a per diem basis) | |
| C101, add to all such hospital visits | \$7.20 |
| Note: Where visit is not chargeable, e.g. post operative care by surgeon, claim only ClO1 | 37 123 |
| (excluding Supportive Care, Critical, Comprehensive, Ventilatory Care and Neonatal Intensive C | lme |
| 45. Detention: may be charged when a physician is required to spend considerable extra time in act | |
| | |
| the patient (and to the exclusion of all other work). Claims for detention must be subs | |
| explanation on the claim card or in an accompanying letter, and should be made on an "I.C." ba | sis according to |
| the following guidelines: | |
| After 20 minutes if the physician spends more than this amount of time providing a m | minor, partial or |
| intermediate assessment or subsequent hospital visit; | |
| After 40 minutes if the physician spends more than this amount of time providin | g a specific or |
| general re-assessment or multiple systems assessment; | |
| After 1 hour if the physician spends more than this amount of time providing a cons | ultation, repeat |
| consultation, specific or general assessment, multi systems assessment. | |
| Detention is not meant to apply to procedural items or obstetrics and does not include t | ime waiting for |
| x-rays, lab reports or for the operating room. | |
| K001 - Per guarter hour or part thereof | . \$17.80 |
| 46. Detention: While in Attendance With Patient(s) in Ambulance: | 11,100 |
| VIII - Doe quartee hove on part thereof | \$35,60 |

47. Non Elective Surgical Procedures, Obstetrics or Clinical Procedures Associated with Diagnostic Radiological Examination or Detention While in Attendance With Patient(s) in Ambulance: - when such procedures including fractures or dislocations or major invasive procedures contained in the list of Diagnostic and Therapeutic Procedures or elective procedures which because of intervening emergency procedure(s) commence after 5:00 p.m. and before midnight or on Saturdays, Sundays and Holidays, increase the procedural fee(s) by 30% (E409). When the foregoing procedures commence after midnight and before 7:00 a.m. any night during the week, increase the procedural fee(s) by 50% (E410).

K101 is not applicable to attendance in a vehicle other than an Ambulance.

These premiums are not chargeable in addition to the obstetrical fee(s) if labour is induced by medical and/or surgical means by the same physician unless the reason for the induction is fetal distress, diabetes, premature rupture of membrane, severe pre-eclampsia - hypertension or abruption. However a forewater A.R.M. or oxytocin augmentation of labour carried out on a patient in desultory labour does not constitute induction. Major Invasive Procedures are considered to be the following:

| G211 | G266 | G275 | G288 | G294 | G323 | G330 | G349 | G411 | R841 | R852 |
|------|------|------|------|------|------|------|------|------|------|------|
| G246 | G267 | G277 | G290 | 6295 | G324 | G331 | G360 | G412 | R843 | R853 |
| G254 | G268 | G280 | G291 | G302 | G327 | G332 | G380 | G418 | R849 | R854 |
| G264 | G269 | G285 | G292 | G303 | G328 | G347 | G390 | R833 | R850 | Z804 |
| G265 | G270 | G287 | G293 | 6304 | G329 | G348 | G399 | R840 | R851 | Z805 |

K101 - Per quarter hour or part thereof

These premiums are not chargeable (during or after a "shift") by emergency or other physicians who have elected or are required to be physically and continuously present in the Emergency Department or environs for an arranged designated period of time.

E409 or E410 may not be claimed for procedures which mainly involve the interpretation of test results and are not applicable to assessments or consultations. Neither are they applicable to procedures listed in the Diagnostic Radiology, Nuclear Medicine or Diagnostic Ultrasound sections of the Schedule.

- 48. Non Elective Diagnostic Radiology, Laboratory Medicine, Nuclear Medicine or Diagnostic Ultrasound Examinations: when a physician providing the foregoing services makes a special visit to see a patient in consultation, perform a procedure or conclude that a procedure is not medically indicated, between 5:00 p.m. to midnight or on Saturdays, Sundays and Holidays, a \$29.65 premium (C109) should be claimed in addition to the appropriate consultation fee or procedural fee or by itself if the decision is made not to perform the procedure. For such services rendered between midnight and 7:00 a.m., the premium is \$44.50 (C110).
- 49. Anaesthetists' Services: for all cases commencing after 5:00 p.m. and before midnight or on Saturdays, Sundays and Holidays, increase the total anaesthetic fee by 40% (E400C). For all cases commencing after midnight and bfore 7:00 a.m., any night during the week, increase the total anaesthetic fee by 50% (E401C). For cases requiring a special visit to the hospital, an additional premium of \$29.65 (C998C) during the 40% premium period and \$44.50 (C999C) during the 50% premium period may be charged to the first patient treated on each special visit.
- 50. Assistants' Services: for all cases commencing after 5:00 p.m. and before midnight or on Saturdays, Sundays and Holidays, increase the total assistant's fee by 40% (E4008). For all cases commencing after midnight and before 7:00 a.m., any night during the week, increase the total assistant's fee by 50% (E4018). For cases requiring a special visit to the hospital, an additional premium of \$29.65 (C9988) during the 40% premium period and \$44.50 (C9998) during the 50% premium period may be charged to the first patient treated on each special visit.
- 51. Travelling Time: may be charged directly to patients (since it is a non-insured service) when special visits are made by physicians to see patients outside their normal area of practice. Travelling time may be charged at the same rate as detention.
- 52. A Locum Tenens
 - (a) Must replace the employing physician, who must be absent from the practice.
 - (b) Must replace the employing physician for a continuous period up to a maximum of 12 weeks, with an extension on request for a further 6 weeks.
 - (c) Must be the same specialty as the employing physician.
 - (d) Must be licensed by the College of Physicians and Surgeons of Ontario in a category of licence that
 - allows him or her to practice independently without supervision.

 Prior notification must be given OHIP of the name and OHIP physician number and/or licence number of the locum tenens and the exact dates of employment, together with an authorization from the locum tenens to make payment for his or her services to the employer.
 - If these conditions are met, the locum tenens may sign the employing physician's claim cards.
 - If any of the above conditions are not met, the physician involved must submit claims to CHIP on his or her own claim cards.

APPENDIX C

BENEFITS OUTSIDE ONTARIO

Under Code R091 payment will be made at the usual and customary fee paid by insurers in the place where the service was rendered, provided that all of the following conditions are met:

- 1) the insured service is a surgical or other complex medical procedure.
- the procedure is generally accepted within Ontario as medical treatment for the insured person's condition;
- 3) the procedure is not performed in Ontario;
- the insured person is referred by a physician in Ontario to the physician outside Ontario who will perform the procedure;
- 5) the insured person departs from Ontario for the express purpose of having the procedure performed;
- 6) prior written approval has been obtained from the Plan.

APPENDIX D

1. Surgery to alleviate significant physical symptoms that are refractory to medical treatment that has been actively undertaken for at least a six month period, or to restore or improve function to any area altered by disease, trauma or congenital deformity normally is a benefit under the Ontario Health Insurance Plan. Surgery solely to alter or restore appearance is not a benefit of OHIP except under the circumstances as listed in the following policy.

2. Emotional, psychological or psychiatric grounds are not considered sufficient reason for OHIP coverage of

surgery for alteration of appearance except under exceptional circumstances.

3. On request of the attending physician, exceptions may be made on an independent consideration basis if the proposed surgery is to alter a significant defect in appearance caused by disease, trauma or congenital deformity, and if the surgery is

recommended by a Mental Health Facility (as designated by The Mental Hospitals Act) or equivalent,

performed on a patient who is less than 18 years of age and the defect is in the area of the body which normally and usually would not be clothed, or

recommended by a Correctional Institution (tattoo removal only), or

essential in order to obtain employment as documented by the attending physician and either by a Canada Manpower Employment Centre or by an employer with regard to a specific job, (tattoo removal

In establishing this policy, it has been recognized that

- peer acceptance in our society often is influenced disproportionately by the facies. children are especially susceptible to emotional trauma caused by physical appearances.
- Surgery to revise or remove features of physical appearance which are familial in nature is not a benefit of
- Within the context of this policy, the word "disease" does not include the normal sequelae of aging. Surgery
- to alter changes in appearances caused by aging is not a benefit of OMIP.
 Within the context of this policy, the word "trauma" includes trauma due to treatment such as surgery, radiation, etc.
- The phrase "reasonable period of convalescence" should be considered as two years. Independent consideration will be given to the questionable cases.
- Authorization from OHIP is not required for all surgery to alter appearance. It is required only for those categories of procedures for which some cases may not be a benefit under OHIP policy.

Suitable documentation may be requested by OHIP in some cases before authorization can be considered.

- The treatment of acute medical or surgical complications resulting from surgery for alteration of appearance and/or function is a benefit of the Plan whether or not the original surgery was covered by OHIP. No authorization is required.
- 12. Revision of surgery for alteration of appearance, because of undesirable results, is a benefit of the Plan if the original surgery was a benefit and if the revision either is part of a pre-planned staged process or occurs within a reasonable period of convalescence. OHIP authorization is required only if the original surgical procedure, if it had been carried out at the time of the proposed revision, would have required such authorization.

Surface Pathology Trauma Scars

- (a) Neck or Face
 - Includes ears and non-hair bearing areas of the scalp.
 - Repair of all such scars is a benefit of OHIP, except for scars resulting from previous surgery to alter appearance that was not originally a benefit of OHIP.
 - Repair procedures will depend upon the lesion but may include excision, revision, dermabrasion, etc. Rhytidectomy procedures for cosmetic reasons, however, are not a benefit of OHIP.
 - OHIP authorization for repair of such scars is not required but manual assessment of the claims will be necessary to ensure that the most appropriate procedure codes are used.

(b) Scars in other Anatomical Areas

Repair of scars which interfere with function or which are significantly symptomatic (pain, ulceration, etc.) is a benefit of OHIP.

Scars with no significant symptoms or functional interference

 Repair is a benefit if such a repair is part of a pre-planned post-traumatic (including post-surgical) staged process. OHIP notification must be included as part of the planning process.

(ii) Other post-traumatic scar revision is not a benefit of OHIP.

- OHIP authorization is required for all scar repair procedures in areas other than the face or neck. Scar revision codes should be used (RO26-RO29).
- Keloids
 - (a) Head or Neck
 - The repair of all such keloids is a benefit of OHIP.

APPENDIX D

- Repair procedures may include excision, injection, dermabrasion or planing.
- No OHIP authorization is required.
- (b) Excision of keloids in other areas
 - Not a benefit of OHIP unless significantly symptomatic (pain, ulceration, etc.) or there is functional impairment.
 - OHIP authorization is required.

Tattoos

- (a) Face or Neck
 - Excision or destruction of all such tattoos is a benefit of OHIP.
 - Authorization is not required but adjudication of repair procedures will be identical to that for scars in these areas.
- (b) Other Anatomical Areas
 - Excision or destruction of concentration camp or P.O.W. tattoos is a benefit of OHIP. Otherwise, not a benefit of OHIP except as described in Para D-3 (Page xxii).
- Benign lesions such as naevi, keratoses, spider naevi, papillomata, neurofibromata

(a) Face or Neck

- Excision or destruction of these lesions is a benefit of OHIP.
- Authorization is not required.
- (b) Other Anatomical Areas
 - Normally not a benefit of OHIP if removed for alteration of appearance only, rather than for medical necessity or because of clinical suspicion or evidence of malignancy.
 - Removal of very large lesions that would be considered disfiguring in patients of any age may be a benefit of OHIP.
 - Authorization is required.

Hair Loss

- - (i) Patients less than 18 years of age
 - Repair is a benefit for non-hereditary etiologies.
 - Authorization is not required. However, if it is possible that a planned staged procedure will extend beyond the age limit, pre-authorization should be obtained, since it will be necessary after the 18th birthday.
 - (ii) Post-traumatic
 - Repair to the area of traumatic hair loss is a benefit of OHIP only if carried out within a reasonable period of convalescence. (See Para. 7, page xxiii).
 - OHIP authorization is required.
 - Usual repair procedures may include skin shifts of flaps, skin grafts, or hair plugs.
- (iii) Other Etiology
 - Not a benefit of OHIP.
 - (b) Other Anatomical Areas
- Not a benefit of OHIP. Epilation of Hair
 - (a) Face
 - This procedure is a benefit of OHIP only for those patients with documented endocrine abnormality or drug-induced hirsutism.
 - (b) OHIP authorization is required.
 - (c) Other Anatomical Areas Not a benefit of OHIP.

Redundant Skin

- (a) Excision of redundant skin for elimination of wrinkles, etc. is not a benefit of OHIP.(b) Blepharoplasty is not a benefit of OHIP unless there is documented evidence of medical necessity from the appropriate physician such as visual field defect caused by the redundant eyelid skin. OHIP authorization is required. (Include documentation of visual fields).

Sub-surface Pathology

Congenital deformities

- (a) Head or Neck
 - Repair is a benefit of OHIP except for:
 - surgery to revise or remove features which are familial in nature or do not interfere with function surgery to correct "outstanding ears" in patients who are eighteen years of age or over.

 - OHIP authorization is required.
- (b) Other Anatomical Areas
 - Normally not a benefit of OHIP if surgery is for alteration of appearance only.
- Post-Traumatic Deformities
 - Reconstructive procedures are a benefit at the acute stage; within two years, or if part of a pre-planned staged process of repair.
 - Repair of procedures may include bone revision, tissue shifts and grafts, prosthesis implantation, etc.
 - OHIP authorization is required for repairs beyond the acute stage.

APPENDIX D

Deformities resulting from local disease (such as loss or distortion of bone, muscle, connective tissue, adipose tissue, etc.)

(a) Head or Neck

Reconstructive procedure for significant abnormalities are a benefit at the acute stage; during a chronic disease process; within a reasonable period of convalescence (see Para. 7, Page xxiii) or if part of a planned staged process of repair initiated during one of these periods. Repair procedures normally could include tissue grafts, flaps or shifts, bone revision, prosthesis

insertion, etc.

Face lifts, modified face lifts, brow lifts, etc., are not a benefit of the Plan if skin only is involved in the procedure. However, a repair such as ptosis repair or face lift with underlying slings is a benefit of OHIP if the procedure is to correct significant deformity following stroke, cancer, VIIth nerve palsy, etc.

OHIP authorization is required for repair of deformities resulting from local disease.

(b) Other Anatomical Areas

Not a benefit of OHIP if the correction is for appearance only.

Correction of severe deformity resulting from polio or neurological disease will be considered for payment - OHIP authorization is required.

Breast Surgery

(a) Augmentation Mammoplasty

This procedure is a benefit of OHIP unilaterally or bilaterally for a female patient with breast aplasia.

It may be an OHIP benefit unilaterally for a female patient with a severely hypoplastic breast.

Additional documentation may be required.

Unilateral augmentation mammoplasty may be a benefit of the Plan if there is gross disproportion present or in association with an approved unilateral reduction mammoplasty or postmastectomy reconstruction of the contralateral breast.

The correct code for the repair procedure is R112

OHIP authorization is required.

(b) Post-Mastectomy Reconstruction

Unilateral or bilateral breast reconstruction is a benefit of OHIP when the procedure is subsequent to total or partial mastectomy (including wedge resection) or prophylactic mastectomy as listed in the Schedule of Benefits.

Authorization is not required.

(c) Reduction Mammoplasty

- Reduction Mammoplasty may be approved where there is significant associated symptomatology. Ptosis and/or size are not sufficient grounds for OHIP coverage of reduction mammoplasty.
- Unilateral Reduction Mammoplasty may be a benefit of the Plan if there is gross disproportion present or in association with approved unilateral augmentation mammoplasty, or post mastectomy reconstruction of the contralateral breast. Additional documentation may be required.

OHIP authorization is required.

(d) Mastectony

This procedure is a benefit of the Plan.

Authorization is not required.

(e) Accessory Breasts or accessory nipples

- Excision of such accessory tissue is a benefit of the Plan.
- The appropriate code should be used from the Schedule listings under Skin and Subcutaneous tissue.

Authorization is not required.

(f) Inverted Nipple(s)

Not a benefit of OHIP

Septorhinoplasty

- This is a benefit of OHIP when the rhinoplasty component is necessary to obtain an adequate airway or following trauma within 2 years or part of a pre-planned staged plastic repair. (See Para 7, Page xxiii).
- In cases where a septoplasty is necessary to improve function and a rhinoplasty is done to improve the cosmetic effect. OHIP will pay the part of the operation that was medically necessary (e.g. if a septorhinoplasty is performed and a septoplasty was necessary to improve the airway, OHIP will pay MO12 and the surgeon is entitled to claim the difference from the patient).

OHIP authorization is required. A description of the external deformity should be provided. Excision of excess fatty tissue and/or skin is not a benefit of the Plan except for panniculectomy where there

is significant symptomatology. OHIP authorization is required.

Sex-Reassignment Surgery

(1) Sex-reassignment surgical procedures are a benefit of OHIP only if they are performed on patients who have completed the Gender Identity Clinic program operated by the Clarke Institute of Psychiatry in Toronto. Moreover, claims are accepted for payment only for those patients for whom the Clinic has recommended that surgery take place. This surgery need not take place in Toronto or even in Ontario. Surgery recommended by the Clinic which takes place outide the Province of Ontario may be approved for payment at rates in accordance with the current OHIP Schedule of Benefits.

(2) Within the foregoing guidelines, reconstruction of genitalia and mastectomy are benefits of the Plan. However, since the hormonal treatments associated with sex-reassignment themselves give rise to breast enlargement, augmentation mammoplasty or breast reconstruction in a male to female conversion is not a benefit of OHIP, in keeping with the previously outlined policy regarding breast surgery in females.

OHIP authorization is required.

Code FAMILY PRACTICE AND PRACTICE IN GENERAL(00)

| | General Listings: | |
|-------|--|--------|
| A005 | Consultation | 46.30 |
| A006 | Repeat consultation | 35,60 |
| A003 | General assessment | 43.00 |
| A004 | | 25.40 |
| A903 | Pre-dental general assessment | 38.10 |
| A007 | Intermediate assessment/Well baby care | 21.20 |
| A001 | Minor assessment | 14.30 |
| K017 | Annual health examination - child after second birthday | |
| | | 26.20 |
| K009 | - adolescent, adult | 38.10 |
| | Oculo-visual assessment(i.e.major eye examination to include refraction and tonometry) | 34.80 |
| N.C. | Telephone advice including renewal of prescriptions | N.A.B. |
| N.C. | Dispensing service fee | N.A.B. |
| | | |
| | Non-Emergency Hospital In-Patient Services: (see para, B39 of Preamble - for emergency | |
| | calls and other special visits to in-patients, use General Listings and Premiums | |
| | [para. B43 of Preamble] when applicable). | |
| 0005 | Consultation | 46.30 |
| 0006 | Repeat consultation | 35.60 |
| 0003 | General assessment | 43.00 |
| 0004 | General re-assessment | 25.40 |
| 0903 | Pre-dental general assessment | 38.10 |
| | Subsequent visits:(minor assessments) | |
| CO02 | up to five weeksper visit | 14.30 |
| | from sixth to thirteenth week inclusive (not to exceed \$42.90 per week)per visit | 14.30 |
| 0009 | after thirteenth week (not to exceed \$85.80 per month)per visit | 14.30 |
| | Concurrent care (minor assessment)per visit | 14.30 |
| 0000 | Supportive care (minor assessments) | 12.70 |
| WIU | | 12.70 |
| 1007 | Attendance at maternal delivery for care of high risk baby(s) | E4 10 |
| | - (if only service rendered at time of delivery) | 54.10 |
| note: | Consultation should not be claimed with attendance at maternal delivery | |
| | other fees may apply. | 46.70 |
| | Newborn care in hospital and/or home | 46.70 |
| | Low birth weight baby care (uncomplicated) initial visit (per baby) | 29.30 |
| H003 | thereafterper visit | 14.30 |
| | | |
| | Emergency Department - Physician on Duty: (see para. 840 of Preamble) | |
| | Assessments may include interpretation of x-ray, E.C.G. and other laboratory data as | |
| | required. | |
| H103 | Multiple Systems Assessment | 23.30 |
| | Minor assessment | 12.30 |
| | Re-assessment (see Preamble - para, 811) | 11.90 |
| | When above visits are rendered by the physician on duty in premium hours, apply the | |
| | following fees. | |
| | 12 Midnight to 8:00 a m | |
| H133 | Multiple Systems assessment | 35.00 |
| U121 | Minor assessment | 18.40 |
| LITCI | Re-assessment | 17.80 |
| n124 | | 17.00 |
| | Saturdays, Sundays and Hol idays | 30,30 |
| H153 | Multiple systems assessment | 16.00 |
| | Minor assessment | |
| H154 | Re-assessment | 15.40 |
| | | |
| | When any other service is rendered by the physician on duty in premium hours (and | |
| | assessments are not chargeable), apply one of the following premiums per patient | |
| | visit. | |
| | - 12 midnight to 8:00 a.m | 11.70 |
| H113 | - Saturdays, Sundays or Holidays | 7.00 |
| | Emergency or O.P.D Physician in Hospital But Not on Duty in the Emergency Depart- | |
| | ment When seeing Patient(s) in Emergency or O.P.D.: use General Listings | |
| | Long Term Institutional Care: (for emergency calls and other special visits to | |
| | institutional patients, use General Listings and Premiums [para. 843 of Preamble] | |
| | when applicable). | |
| | | |

Code FAMILY PRACTICE AND PRACTICE IN GENERAL - Cont'd.

| | Chronic Care Hospitals, Convalescent Hospitals, Nursing Homes, or Other Institutions in Wh Patients are covered by Extended Care Legislation: | ich |
|-------|--|-----------|
| W105 | | 46.30 |
| | Consultation | 35.60 |
| W106 | Repeat Consultation | 43.00 |
| W102 | Admission assessment (see Preamble) Type 1 | 14.30 |
| W104 | Type 2 | |
| W107 | Type 3 | 25.40 |
| W109 | Annual physical examination | 39.30 |
| W004 | General re-assessment of patient in nursing home and covered by extended care legislation | |
| | (as per the Nursing Homes Act) | 14.30 |
| W903 | Pre-dental and pre-surgery general assessment | 38.10 |
| | Subsequent visits (minor assessments see para, B15): | |
| | - chronic care or convalescent hospital (maximum of 10 per patient, per month) | |
| W002 | first two visits per month (chargeable by most responsible physician)per visit | 14.30 |
| W001 | - subsequent visits per monthper visit | 10.60 |
| | - nursing home or other institution covered by extended care legislation (maximum of 5 | |
| | per patient, per month) | |
| W003 | - first visit per month (chargeable by most responsible physician)per visit | 14.30 |
| W008 | - subsequent visits per monthper visit | 10.60 |
| 1000 | Subsequent visites per month. | |
| | Homes for the Aged and Other Institutions in Which Patients are Not Covered by Extend- | |
| | ed Care Legislation: (use General Listings and Premiums [para. B43 of Preamble] | |
| | when applicable.) General Listings under these circumstances also apply to patients | |
| | seen in bed rather than in an office supplied by the institution. | |
| | Psychotherapy: (includes narcoanalysis or psychoanalysis or treatment of sexual | |
| | | |
| 11007 | dysfunction) | 41.00 |
| K007 | Individual - per 1/2 hour or major part thereof (see Preamble) | 41.00 |
| | Group - (four to eight people) per 1/2 hour or major part thereof | 7 60 |
| K012 | - per member (up to six hours per day) | 7.60 |
| N.C. | - per member (seventh to ninth hour per day) | N.A.B |
| | Family - (two or more family members in attendance at the same time) per 1/2 hour | |
| K004 | or major part thereof | 46.30 |
| Note: | | |
| | 1.) Psychotherapy or hypnotherapy or counselling is not to be claimed in conjunction | |
| | with other consultations or assessments rendered by the same physician during the | |
| | same patient visit unless there are clearly defined unrelated diagnoses for the | |
| | two services. | |
| | The minumum time period for psychotherapy (to be claimed as such) is 20 minutes. | |
| | (See Preamble, part B, paragraph 19.) | |
| | Hypnotherapy: | |
| | Individual - per 1/2 hour or major part thereof | 41.00 |
| Note: | | |
| | conjunction with delivery. | |
| | Group, for induction and training for hypnosis (up to eight people) per 1/2 hour or | |
| K011 | major part thereof, per member | 7.60 |
| VOII | Counselling - intended as an educational experience - not intended for ongoing therapy | , , , , , |
| | or as a substitute for a minor assessment - one or more people - per 1/2 hour or | |
| V010 | | 38.90 |
| K013 | major part thereof, | 30.90 |
| Note: | (1) Psychotherapy or hypnotherapy or counselling are not to be claimed in conjunct- | |
| | ion with other consultations or visits rendered by a physician during the same | |
| | patient visit unless there are clearly defined different diagnoses for the two | |
| | services. | |
| | (2) The minimum time period for psychotherapy (to be claimed as such) is 20 minutes. | |
| | (See Preamble, part B, paragraph 19). | |
| | Certification of Mental Illness— | |
| | Application for psychiatric assessment, (as mandated by the Mental Health Act) - | |
| | including necessary history, examination, notification of the patient, family and | |
| K623 | relevant authorities and completion of Form 1 | 74.10 |
| | Certification of involuntary admission (as required by the Mental Health Act) - including | |
| | history, examination, notification of the patient, family and relevant authorities and | |
| K624 | completion of Form 3 | 87.65 |
| K629 | All other re-certification(s) of involuntary admission | 26.20 |
| Note: | | |
| HUUC. | Constitution of assessment formatty may not be cramed in decreasing | |

| Code | FAMILY PRACTICE AND PRACTICE IN GENERAL - Cont'd. Certification of incompetence (financial) including assessment to determine | |
|---------------|---|----------------|
| N.C. | incompetence | N.A.B. |
| | Interviews | |
| K002 | Interviews with relatives on behalf of a patient, per 1/2 hour or major part thereof Interviews with C.A.S. or legal guardian on behalf of a patient, per 1/2 hour or major | 38.90 |
| K003 Note: | part thereof KOO2, KOO3 - Should be claimed on the patient's claim card with diagnosis. These listings apply to situations where medically necessary information cannot be obtained from or given to the patient (e.g. because of illness, incompetence, etc). | 38.90 |
| | Diagnostic interview and/or counselling with child and/or parent: | |
| Note: | | 41.00 |
| N.C. | for testing per 1/2 hour | N.A.B. |
| N.C. | 1/2 hour or major part thereof | N.A.B. |
| N.C. | per 1/2 hour or major part thereof | N.A.B. |
| | Genetic Counselling: | |
| K019 K020 | Individual or family - per 1/2 hour (maximum 2 hours) Interview with relatives - per 1/2 hour (maximum 2 hours) Note: The minimum time period required for any of the time based services listed on this page is twenty minutes - see para. B19 of Preamble for elaboration of the principles of the billing procedure. | 46.30 46.30 |
| | Sexual Assault Examination for Investigation and/or Confirmation of Alleged Sexual | |
| K018 | Assault and Documentation | 205.00* |
| K021 | - female - male Note: NOI8 and NO21 may only be claimed when the kit, provided by the Ministries of the Attorney General and Solicitor General, has been used. | 160.00* |
| -A po | rtion of the listed benefits for KD18 and KD21 is recovered by OHIP from the Ministries of the Attorney General and the Solicitor General. | |
| | Certification and Reports: | |
| | With or Without Examination: | |
| N.C. N.C. | Certification of health (ordinary) or competency Free from infection (barbers, waiters, etc.) Certification of disability or previous immunization, Insurance report based on | N.A.B. |
| N.C. | previous examination or on illness or death | N.A.B. |
| | abortion committee) - the fee should reflect fairly the difficulty of the matter and the experience and expertise of the physician, the nature and omplexity of the | |
| N.C. | report and the time required to prepare it | N.A.B. |
| | ALLERGY | |
| | Since the Royal College of Physicians and Surgeons of Canada has not set a standard for "Allergy Specialist", fees for consultations and visits shall be applicable to a specific allergist as they refer to him in his own General or Specialty Tariff except for the following: | |
| vana | Clinical interpretation by immunologists where a report of a survey is submitted in writing to the patient's physician (not to apply when the immunologist receives a | 24.00 |
| K399 | consultation fee) | 24.20 |
| | AWESTHESIA (01) | |
| | General Listings: | |
| | Consultation | 67.60 |
| | Repeat consultation | 43.00 38.90 |
| | Partial assessment | 17.20 |

Premiums for Special Visits by Physicians, Detention Visits to I.C.U. or C.C.U. Chargeable in Addition to Above Fees - see Para. B43-46 of Preamble.

49.60

38.10 34.00

21.30

CONSULTATIONS AND VISITS

| | CONSULTATIONS AND VISITS | |
|------------------------------|--|---|
| Code | ANAESTHESIA (01) - Cont'd. | |
| | Emergency or O.P.D Physician in Hospital But Not on Duty in the Emergency Department When Seeing Patient(s) in the Emergency or O.P.D.:- use General Listings. | |
| | Non-Emergency Hospital In-Patient Services: (see para. B39 of Preamble - for emergency calls and other special visits to in-patients, use General Listings and Premiums [para. B43 of Preamble] when applicable). | |
| C012 C017 C019 | | 67.60 43.00 38.90 22.90 15.60 15.60 15.60 |
| | CARDIOLOGY (60) For Services not listed, refer to Internal Medicine Section. | |
| A603 A604 | Limited consultation | 96.25 63.50 63.50 49.15 35.60 21.10 |
| | Emergency or O.P.D.: - Physician in Hospital But not on Duty in the Emergency Department When Seeing Patients(s) in the Emergency or O.P.D.: - use General Listings. | |
| C605 | Non-Emergency Hospital In-Patients Services: (see para. B39 of Preamble - for emergency calls and other special visits to in-patients, use General Listings and Premiums [para. B43 of Preamble] when applicable). Consultation | 96,25 |
| C675 C606 C603 C604 | Repeat consultation | 63.50 63.50 49.15 35.60 |
| C602 C607 C609 C608 | up to five weeksper visit from sixth to thirteenth week inclusive (not to exceed \$46.80 per week)per visit after thirteenth week (not to exceed \$93.60 per month)per visit | 15.60 15.60 15.60 15.60 |
| A095 A096 A093 A094 | Repeat consultation | 49.60 38.10 34.00 17.20 |
| | Emergency or O.P.D Physician in Hospital but not on Duty in the Emergency Department when Seeing Patient(s) or O.P.D.: - use General Listings | |
| | Non-Emergency Hospital In-Patient Services: (see para. B39 of Preamble - for emergency cother special visits to in-patients, use General Listings and Premiums [para. B43 of Pumber applicable). | alls and reamble] |

Premiums for Special Visits by Physicians, Detention Visits to I.C.U. or C.C.U. Chargeable in Addition to Above Fees - see Para. B43-46 of Preamble.

CO93 Specific assessment CO94 Specific re-assessment

| Code | CARDIOVASCULAR AND THORACIC SURCERY (09) - Cont'd. | |
|--------------|---|----------------|
| 0092 | Subsequent visits: (minor assessments) up to five weeks | 15.60 |
| C097 C099 | from sixth to thirteenth weeks inclusive (not to exceed \$46.80 per week) .per visit after thirteenth week (not to exceed \$93.60 per month)per visit | 15.60 15.60 |
| 0098 | Concurrent care (minor assessment) | 15.60 |
| | Consultation | 49.60 38.10 |
| | CLINICAL DHUNDLOGY (62) For Services not listed, refer to Internal Medicine Section. | |
| | aGeneral Listings: (Use these listings when performed at locations other than those designated in the following sections). | |
| A625 A525 | Consultation | 96.25 63.50 |
| A626 A623 | Repeat consultation General assessment | 63.50 49.15 |
| A624 | General re-assessment | 35.60 |
| A628 | Partial assessment | 21.10 |
| | Emergency or 0.P.D.: - Physician in Hospital But not on Duty in the Emergency Department When Seeing Patient(s) in the Emergency or 0.P.D.: - use General Listings | |
| | Non-Emergency Hospital In-Patients Services: (see para B39 of Preamble – for emergency calls and other special visits to in-patients, use General Listings and Premiums [para, B43 of Preamble] when applicable). | |
| C625 | Consultation | 96.25 |
| C525 C626 | Limited consultation | 63.50 63.50 |
| C623 C624 | General assessment General ne-assessment | 49.15 35.60 |
| cen | Subsequent visits (minor assessments): up to five weeks | 15,60 |
| C622 C527 | from sixth to thirteenth week inclusive (not to exceed \$46.80 per week)per visit | 15.60 |
| C629 C528 | after thirteenth week (not to exceed \$93.60 per month)per visit Concurrent care (minor assessments)per visit | 15.60 15.60 |
| | DERMATOLOGY (02) | |
| A025 | General Listings: Consultation | 46.30 |
| A026 | Repeat consultation | 38.10 |
| A023 A024 | Specific assessment | 32.80 16.90 |
| | Emergency or O.P.D Physician in Hospital But Not on Duty in the Emergency Department When Seeing Patient(s) in the Emergency or O.P.D.: - use General Listings | |
| | Non-Emergency Hospital In-Patient Services: (See para. 839 of Preamble – for emergency calls and other special visits to in-patients, use General Listings and Premiums | |
| conse | [para. B43 of Preamble] when applicable). | 46.30 |
| 0025 | Consultation | 38.10 |
| 0023 | Specific assessment | 32.80 21.30 |
| 0024 | Specific re-assessment | 21.30 |

Premiums for Special Visits by Physicians, Detention Visits to I.C.U. or C.C.U.

Chargeable in Addition to Above Fees - see Para. B43-46 of Preamble.

| Code | DERMATOLOGY (02) - Cont'd. | |
|------------------------------|---|--|
| C022 C027 C029 C028 | Subsequent visits: (minor assessments) up to five weeks | 15.60 15.60 15.60 15.60 |
| | Long Term Institutional Care - Chronic and Convalescent Hospitals, Homes for the Aged - Patients Covered by Extended Care Legislation and Nursing Homes. | |
| | Consultation | 46.30 38.10 |
| | GASTROENTEROLOGY (41) For Services not listed, refer to Internal Medicine Section. | |
| A545 A416 A413 | General Listings: (Use these listings when performed at locations other than those designated in the following sections). Consultation Limited consultation Repeat consultation General assessment General assessment Partial assessment | 96.25 63.50 63.50 49.15 35.60 21.10 |
| | Emergency or O.P.D.: - Physician in Hospital But not on Duty in the Emergency Department When Seeing Patient(s) in the Emergency or O.P.D.: - use General Listings. | |
| | Non-Emergency Hospital In-Patients Services: (see para. B39 of Preamble - for emergency calls and other special visits to in-patients, use General Listing and Premiums [para. B43 of Preamble] when applicable). | |
| C545 | Repeat consultation General assessment General re-assessment | 96.25 63.50 63.50 49.15 35.60 |
| C412 C417 C419 C418 | Subsequent visits (minor assessments): up to five weeks | 15.60 15.60 15.60 15.60 |
| | GENERAL SURGERY (03) General Listings: Consultation Repeat consultation Specific assessment Partial assessment | 49.60 38.10 34.00 17.20 |
| | Emergency or O.P.D Physician in Hospital But Not on Duty in the Emergency Depart- ment When Seeing Patient(s) in the Emergency or O.P.D.: use General Listings | |
| | Non-Emergency Hospital In-Patient Services: (see para. 839 of Preamble – for emergency calls and other special visits to in-patients, use General Listings and Premiums [para. 843 of Preamble] when applicable). | |
| | Consultation Repeat consultation Specific assessment Specific assessment | 49.60 38.10 34.00 21.30 |

Premiums for Special Visits by Physicians, Detention Visits to I.C.U. or C.C.U. Chargeable in Addition to Above Fees - see Para. B43—46 of Preamble.

| | GENERAL SURGERY (03) - Cont'd. Subsequent visits: (minor asessments) | |
|------------------------------|---|----------------------------------|
| C032 C037 C039 C038 | up to five weeks | 15.60 15.60 15.60 15.60 |
| | Long Term Institutional Care - Chronic and Convalescent Hospitals, Homes for the Aged - Patients Covered by Extended Care Legislation and Nursing Homes | |
| W035 W036 | Consultation | 49.60 38.10 |
| W032 W031 | First 2 visits per month (chargeable by the most responsible physician)per visit Subsequent visits per month Nursing home or other institution, covered by extended care legislation (maximum of 5 per patient, per month) | 14.30 11.50 |
| W033 W038 | First visit per month (chargeable by the most responsible physician)per visit Subsequent visits per monthper visit | 14.30 11.50 |
| | GENERAL THORACIC SURGERY (64) | |
| A845 A646 A643 A644 | General Listings: Consultation Repeat consultation Specific assessment Partial assessment | 49.60 38.10 34.00 17.20 |
| | Emergency or O.P.D Physician in Hospital But Not on Duty in the Emergency Department When Seeing Patient(s) in the Emergency or O.P.D.: (Use General Listings) | |
| | Non-emergency Hospital In-Patient Services: (see para, 839 of Preamble) - For emergency calls and other special visits to in-patients, use General Listings and premiums [para, B43 of Preamble] when applicable). | |
| C845 C646 C643 C644 | Consultation | 49.60 38.10 34.00 21.30 |
| C642 C647 C649 C648 | Subsequent visits: (minor assessments) up to five weeks from sixth to thirteenth week inclusive (not to exceed \$46.80 per week)per visit after thirteenth week (not to exceed \$93.60 per month) | 15.60 15.60 15.60 15.60 |
| | Long Term Institutional Care - Chronic and Convalescent Hospitals, Homes for the Aged - Patients Covered by Extended Care Engislation and Nursing Homes: | |
| W645 W646 | Consultation | 49.60 38.10 |
| | HACHATOLOGY (61) For Services not listed, refer to Internal Medicine Section. | |
| | <pre>General Listings: (Use these listings when performed at locations other than those designated in the following sections).</pre> | |
| | Consultation Limited consultation Repeat consultation General assessment | 96.25 63.50 63.50 49.15 |
| A614 A618 | General re-assessment Partial assessment | 35.60 21.10 |

Prewiums for Special Visits by Physicians, Detention Visits to I.C.U. or C.C.U. Chargeable in Addition to Above Fees - see Para. 843—46 of Preamble.

| Code | HASHATOLOGY (61) - Cont'd. | |
|--|--|--|
| | Emergency or O.P.D.: - Physician in Hospital But not on Duty in the Emergency Department When Seeing Patient(s) in the Emergency or O.P.D.: - use General Listings | |
| | Non-Emergency Hospital In-Patients Services: (see para. B39 of Preamble - for emergency calls and other special visits to in-patients, use General Listings and Premiums [para. B43 of Preamble] when applicable). | |
| C655 C616 C613 | Consultation Limited consultation Repeat consultation General assessment General re-assessment Subsequent visits (minor assessments): up to five weeks from sixth to thirteenth week inclusive (not to exceed \$46.80 per week) per visit after thirteenth week (not to exceed \$93.60 per month) per visit Concurrent care (minor assessments) per visit | 96.25 63.50 63.50 49.15 35.60 15.60 15.60 |
| | INTERNAL MEDICINE (13) | |
| A136 A133 A134 | | 96.25 63.50 63.50 49.15 35.60 21.10 |
| C136 C133 C134 C132 C137 C139 | Non-Emergency In-Patient Services: (see para. 839 of Preamble - for emergency calls and other special visits to in-patients, use General Listings and Premiums [para. 843 of Preamble] when applicable). Consultation Limited consultation Repeat consultation General assessment Subsequent visits: (minor assessments) up to five weeks per visit from sixth to thirteenth week inclusive (not to exceed \$46.80 per week) per visit after thirteenth week (not to exceed \$93.60 per month) per visit Concurrent care (minor assessments) per visit | 96.25 63.50 63.50 49.15 35.60 15.60 15.60 15.60 |
| W235 W435 W236 W232 W234 W237 | Long Term Institutional Care: (for emergency calls and other special visits to institutional patients, use General Listings and Premiums [para. B43 of Preamble] when applicable). Chronic Care Hospitals, Convalescent Hospital, Nursing Homes or other Institutions in which patients are Covered by Extended Care Legislation: Consultation Repeat consultation Admission assessment (see Preamble) Type 1 Type 2 Type 3 | 96.25 63.50 63.50 43.00 14.30 25.40 |
| | Annual physical examination General re-assessment of patient in nursing home or covered by extended care legislation May only be claimed 6 months after Annual Health Examination (as per the Nursing Homes Act). Subsequent visits(minor assessments): | 39.30 14.30 |
| W132 | - chronic care or convalescent hospital (maximum of 10 per patient, per month) - first two visits per month (chargeable by most responsible physician)per visit | 15.60 |

Premiums for Special Visits by Physicians, Detention Visits to I.C.U. or C.C.U. Chargeable in Addition to Above Fees - see Para. B43—46 of Preamble.

| Loose | INTERMAL MEDICINE (13) - Cont'd. | |
|----------------------|---|-------------------------|
| | nursing home or other institution, covered by extended care legislation (maximum of 5 per patient, per month) | |
| W133 W138 | - first visit per month (chargeable by most responsible physician)per visit - subsequent visits per monthper visit | 15.60 11.50 |
| | Homes for the Aged and Other Institutions in which Patients are Not Covered by Extended Care Legislation: use General Listings and Premiums (para. 843 of Premible) when applicable. General Listings under these circumstances also apply to patients seen in bed rather than an office supplied by the Institution. | |
| | LABORATORY MEDICINE (28) - The following fees are applicable to specialists in Medical Biochemistry, Medical Microbiology, Anatomic and General Pathology General Listings: | |
| A236 | Consultation Repeat or limited consultation Diagnostic consultation - see definition in Preamble | 63.50 43.00 41.80 |
| | Non-Emergency Hospital In-Patient Services: (see para, 839 of Preamble - for emergency calls and other special visits to in-patients, use General Listings and Premiums [para, 843 of Preamble] when applicable). | |
| C285 | Consultation | 63.50 |
| | Repeat or limited consultation | 43.00 |
| | Diagnostic consultation | 41.30 |
| | | 13.00 |
| | NEUROLOGY (18) | |
| | General Listing: | |
| A185 | Consultation | 96.25 |
| A385 | Limited consultation | 63.50 |
| | Repeat consultation | 63.50 |
| | General assessment | 49.15 |
| | Partial assessment | 21.10 |
| | | |
| | Emergency or O.P.D Physician in Hospital But not on Duty in the Emergency Depart- ment When Seeing Patient(s) in the Emergency or O.P.D.: - use General Listings | |
| | Non-Emergency Hospital In-Patient Services: (see para, 839 of Preamble - for emergency calls and other special visits to in-patients, use General Listings and Premiums [para, 843 of Preamble] when applicable). | |
| | Consultation | 96.25 |
| | Limited consultation | 63.50 63.50 |
| | General assessment | 49.15 |
| | General re-assessment | 35.60 |
| | Subsequent visits: (minor assessments) up to five weeksper visit | |
| C182 C187 C189 | up to five weeks per visit from sixth to thirteenth week inclusive (not to exceed \$46.80 per week)per visit after thirteenth week (not to exceed \$93.60 per month) | 15.60 15.60 15.60 |
| C188 | Concurrent care (minor assessments)per visit | 15.60 |
| | Long Term Institutional Care - Chronic and Convalescent Hospitals, Homes for the Aged - Patients Covered by Extended Care Legislation and Mursing Homes: | |
| W185 | Consultation | 96,25 |
| | Limited consultation | 63.50 |
| | Reneat consultation | 63,50 |

Premiums for Special Visits by Physicians, Detention Visits to I.C.U. or C.C.U. Chargeable in Addition to Mbowe Fees - see Para. B43-46 of Preamble.

| Code | NEURUSURGERY (04) | |
|------------------------------|---|----------------------------------|
| | General Listings: | |
| A045 A046 A043 A044 | Consultation | 72.90 41.40 41.40 21.30 |
| | Emergency or O.P.D Physician in Hospital But Not on Duty in the Emergency Department When Seeing Patient(s) in the Emergency or O.P.D.: - use General Listings | |
| | Non-Emergency Hospital In-Patient Services: (see para. B39 of Preamble - for emergency calls and other special visits to in-patients, use General Listings and Premiums [para. B43 of Preamble] when applicable). | |
| | | 72.90 |
| CO43 | Repeat consultation Specific assessment Specific re-assessment | 41.40 41.40 21.30 |
| | Subsequent visits: (minor assessments) | |
| CO42 CO47 CO49 | up to five weeksper visit from sixth to thirteenth week inclusive (not to exceed \$46.80 per week)per visit after thirteenth week (not to exceed \$93.60 per month)per visit | 15.60 15.60 15.60 |
| | Concurrent care (minor assessments)per visit | 15.60 |
| | Long Tenm Institutional Care - Chronic and Convalescent Hospital, Homes for the Aged - Patients Covered by Extended Care Legislation and Mursing Homes: | |
| W045 W046 | Consultation | 72.90 41.40 |
| | NUCLEAR MEDICINE (63) | |
| | Repeat consultation | 54.50 37.70 |
| G935 G632 | Diagnostic consultation - see definition in Preamble | 24.20 21.10 |
| | Obstetrics and Gynnecology (20) | |
| ***** | General Listings | 49.15 |
| A206 A203 | Specific assessment* | 38.10 34.00 |
| A2U4 | Partial assessment* | 16.80 |
| | Emergency or O.P.D Physician in Hospital But Not on Duty in the Emergency Depart- ment When Seeing Patient(s) in the Emergency or O.P.D.: - use General Listings. | |
| | Non-Emergency Hospital In-Patient Services: (see para. B39 of Preamble - for emergency calls and other special visits to in-patients, use General Listings and Premiums [para. B43 of Preamble] when applicable). | |
| C205 | Consultation* | 49.15 |
| C206 | Repeat consultation* Specific assessment* | 38.10 |
| C203 C204 | Specific re-assessment* | 34.00 21.30 |
| C202 | Subsequent visits: (minor assessments) up to five weeks | 15.60 |
| C207 C209 | from sixth to thirteenth week inclusive (not to exceed \$46.80 per week)per visit after thirteenth week (not to exceed \$93.60 per month)per visit | 15.60 15.60 |
| C208 Note: | Concurrent care (minor assessments)per visit | 15.60 |
| | Long Term Institutional Care - Chronic and Convalescent Hospitals, Homes for the Aged - Patients Covered by Extended Care Legislation and Nursing Homes: | |
| | Consultation* | 49.15 38.10 |
| HOU | impun minut mit mit accessores essesses essesses essesses essesses essess | |

*May include biopsy of cervix, (except when done in conjunction with A204), Papanicolaou smear, examinations of trichomonas suspension. Chargeable in Addition to Above Fees - see Para. B43-46 of Preamble.

THE ONTARIO GAZETTE

CONSULTATIONS AND VISITS

| code | Uminipulli (23) | |
|------|--|-------|
| | General Listings: | |
| A235 | Consultation | |
| A236 | Repeat consultation | 47.50 |
| | Specific assessment | 38.10 |
| A234 | Partial assessment | 34.80 |
| | | 17.20 |
| | Emergency or O.P.D Physician in Hospital But Not on Duty in the Emergency Depart- | |
| | ment When Seeing Patient(s) in the Emergency or O.P.D.: - use General Listings | |
| | the state of the s | |
| | Non-Emergency Hospital In-Patient Services: (see para, 839 of the Preamble - for | |
| | emergency calls and other special visits to in-patients, use General Listings and | |
| | Premiums [para. 843 of Preamble] whe applicable). | |
| | | |
| C235 | Consultation | 47.50 |
| C236 | Repeat consultation | 38.10 |
| C233 | Specific assessment | 34.80 |
| C234 | Specific re-assessment | 21.30 |
| | Subsequent visits: (minor assessments) | |
| C232 | up to five weeksper visit | 15.60 |
| C237 | from sixth to thirteenth week inclusive (not to exceed \$46.80 per week)per visit | 15.60 |
| C239 | after thirteenth week (not to exceed \$93.60 per month)per visit | 15.50 |
| CZ38 | Concurrent care (minor assessments)per visit | 15.60 |
| | | |
| | Long Term Institutional Care - Chronic and Convalescent Hospitals, Homes for the Aged | |
| 1606 | - Patients Covered by Extended Care Legislation and Mursing Homes: | 47.50 |
| W535 | Consultation | 47.50 |
| W536 | Repeat consultation | 38.10 |
| | ORTHOPAEDIC SURGERY (06) | |
| | and reple south (60) | |
| | General Listings: | |
| A065 | Consultation | 46.30 |
| A066 | Repeat consultation | 38.10 |
| A063 | Specific assessment | 32.80 |
| A064 | Partial assessment | 16.80 |
| | | |
| | Emergency or O.P.D Physician in Hospital But Not on Duty in the Emergency Depart- | |
| | ment When Seeing Patient(s) in the Emergency or O.P.D.: - use General Listings | |
| | the state of the s | |
| | Non-Emergency Hospital In-Patient Services: (see para. 839 of Preamble - for emergency | |
| | calls and other special visits to in-patients, use General Listings and Premiums | |
| | [para. 843 of Preamble] when applicable). | |
| | | 46.00 |
| | Consultation | 46.30 |
| 0066 | Repeat consultation | 38.10 |
| 0063 | Specific assessment | 32.80 |
| CO64 | Specific re-assessment | 21.30 |
| 0000 | Subsequent visits: (minor assessments) | 15 60 |
| 0062 | up to five weeksper visit | 15.60 |
| | from sixth to thirteenth week inclusive (not to exceed \$46.80 per week)per visit | 15.60 |
| 0069 | after thirteenth week (not to exceed \$93.60 per month)per visit | 15.60 |
| LUbb | Concurrent care (minor assessment)per visit | 15.60 |

| Code | ORTHOPAEDIC SURGERY (06) - Cont'd. | |
|--|---|--|
| 15 | Long Term Institutional Care - Chronic and Convalescent Hospitals, Homes for the Aged - Patients Covered by Extended Care Legislation and Nursing Homes: | |
| WD65 WD66 | Repeat consultation | 46.30 38.10 |
| W062 W061 | - chronic care or convalescent hospital (maximum of 10 per patient, per month) - first two visits per month (chargeable by most responsible physician)per visit - subsequent visits per month | 14.30 11.50 |
| W063 W068 | - first visit per month (chargeable by most responsible physician per visit subsequent visits per month per visit | 14.30 11.50 |
| | OTOLARYNGOLOGY (24) | |
| A246 | Specific assessment | 47.50 38.10 34.00 17.20 |
| | Emergency or O.P.D Physician in Hospital But Not on Duty in the Emergency Depart- ment When Seeing Patient(s) in the Emergency or O.P.D.: - use General Listings | |
| | Non-Emergency Hospital In-Patient Services: (see para. 839 of Preamble - for emergency calls and other special visits to in-patients, use General Listings and Premiums | |
| C245 C246 C243 C244 | [para. B43 of Preamble] when applicable). Consultation | 47.50 38.10 34.00 21.30 |
| C242 C247 C249 C248 | up to five weeks | 15.60 15.60 15.60 15.60 |
| | Long Term Institutional Care - Chronic and Convalescent Hospitals, Homes for the Aged - Patients Covered by Extended Care Legislation and Mursing Homes: | |
| W345 W346 | Consultation | 47.50 38.10 |
| | PAEDIATRICS (26) | |
| A265 A665 A565 A266 A263 A264 A007 A261 K267 K269 | Repeat consultation General assessment General re-assessment Intermediate assessment Intermediate assessment/Well baby care Minor assessment Annual health examination - child after second birthday - adolescent Diagnostic interview and/or counselling with child and/or parent - see Practice in General Listings (n.3) | 96.25 58.20 63.50 63.50 45.30 29.90 21.20 14.30 26.20 38.10 |
| | mergency or O.P.D Physician in Hospital But Not on Duty in the Emergency Depart- ment When Seeing Patient(s) in the Emergency or O.P.D.: - use General Listings | |

Premiums for Special Visits by Physicians, Detention Visits to 1.C.U. or C.C.U. Chargeable in Addition to Above Fees - see Para. B43-46 of Preamble.

96.25 63.50

CONSULTATIONS AND VISITS

| Code | PAEDLATRICS (26) - Cont'd. | |
|-------|---|-------------------------|
| | Non-Emergency Hospital In-Patient Services: (see para. B39 of Preamble - for emergency calls and other special visits to in-patients, use General Listings and Premiums [para. B43 of Preamble] when applicable). | |
| 00.00 | | |
| C565 | Consultation | 96.25 58.20 63.50 |
| | Repeat consultation | 63.50 |
| | General assessment | 45.30 |
| C264 | General re-assessment | 29.90 |
| C262 | up to six weeksper visit | 15.60 |
| C267 | from seventh to thirteenth week inclusive (not to exceed \$46.80 per week) .per visit | 15.60 |
| C269 | after thirteenth week (not to exceed \$93.60 per month)per visit | 15,60 |
| | Concurrent care (minor assessments)per visit | 15,60 |
| H267 | Attendance at maternal delivery | 54.10 |
| Note: | | 57.10 |
| H261 | Newborn care in hospital and/or home | 49.15 |
| 16201 | Low birthweight baby care (uncomplicated) | .5000 |
| H262 | - initial visit (per baby) | 43,00 |
| | - thereafter | 14.30 |
| | Pre-adoption examination and evaluation for C.A.S. | N.A.B |
| N.C. | Pre-dooption examination did evaluation for GAS. | N.A.D |
| | Character and Complement throughout | |
| | Chronic and Convalescent Hospital: | 96,25 |
| | Consultation | |
| | Limited consultation | 63.50 |
| | Repeat consultation | 63.50 |
| W562 | Admission assessment (see Preamble) Type 1 | 43.00 |
| W564 | Type 2 | 14.30 |
| W567 | Type 3 | 25.40 |
| | Subsequent visits (maximum of 10 per patient, per month) | |
| W262 | - first two visits per month (chargeable by most responsible physician)per visit | 15.60 |
| W261 | - subsequent visits per monthper visit | 10.60 |
| W269 | Annual physical examination | 26,20 |
| | | |
| Note: | In surgical cases requiring medical direction, standard in-hospital medical fees are to be charged in addition to the surgical fee. This includes all operations on | |
| | babies under one year of age, and all other older children who require medical | |
| | supervision. | |
| | 30pc1 +13+0114 | |
| | | |
| | PHYSICAL MEDICINE AND REHABILITATION (31) | |
| | General Listinos: | |
| A315 | Consultation | 96,25 |
| AS15 | Limited consultation | 63.50 |
| | Repeat consultation | 63.50 |
| | General assessment | 47.50 |
| | beneral discostrett | 34.40 |
| A310 | | 21.30 |
| A314 | Partial assessment | 21.3 |
| | O D D Charles in Hamilton Data Not on Data in the Common Depart | |
| | Emergency or O.P.D Physician in Hospital But Not on Duty in the Emergency Depart- ment When Seeing Patient(s) in the Emergency or O.P.D.:- use General Listings | |
| | ment men beeing racient(s) in the one-yearty or our unit - use benefit distings | |
| | Non-Emergency Hospital In-Patient Services: (see para. B39 of Preamble - for emergency | |
| | calls and other special visits to in-patients, use General Listings and Premiums | |
| | [para, B43 of Preamble] when applicable). | |
| | Lhara en on Lieumpiel wier abhitemiele | |

Premiums for Special Visits by Physicians, Detention Visits to I.C.U. or C.C.U. Chargeable in Addition to Above Fees - see Para. B43-46 of Preamble.

| Code | PHYSICAL MEDICINE AND REMABILITATION (31) - Cont'd. | |
|--------------|--|----------------|
| C316 | Repeat consultation | 63.50 |
| C313 | General assessment | 47.50 |
| C314 | General re-assessment | 34.40 |
| | Subsequent visits: (minor assessments) | |
| C312 | up to five weeksper visit | 15.60 |
| C317 C319 | from sixth to thirteenth week inclusive (not to exceed 46.80 per week)per visit after thirteenth week (not to exceed \$93.60 per month)per visit | 15.60 15.60 |
| | Concurrent care (minor assessments)per visit | 15.60 |
| W10 | concerned care (minor assessments) | 13.00 |
| | Long Term Institutional Care: | |
| | Chronic Care Hospitals, Convalescent Hospitals, Nursing Homes or Other Institutions in | |
| W515 | which Patients are Covered by Extended Care Legislation: Consultation | 96.25 |
| W310 | Limited consultation | 63.50 |
| | Repeat consultation | 63.50 |
| W512 | Admission assessment (see Preamble) Type 1 | 43.00 |
| W514 | Type 2 | 14.30 25.40 |
| W517 | Annual physical examination | 39.30 |
| W314 | General re-assessment of patient in nursing home or covered by extended care legislation May only be claimed 6 months after Annual Health Examination (as per the Nursing Homes | 14.30 |
| | Act). | |
| | Subsequent visits (minor assessments): - chronic care or convalescent hospital (maximum of 10 per patient, per month) | |
| W312 | - first two visits per month (chargeable by most responsible physician)per visit | 15.60 |
| W311 | - subsequent visits per monthper visit | 11.50 |
| | - nursing home or other institution covered by extended care legislation (maximum of 5 | |
| 1010 | per patient, per month) | 15.60 |
| W313 W318 | - first visit per month (chargeable by most responsible physician)per visit - subsequent visits per monthper visit | 11.50 |
| MOTO | Homes for the Aged and Other Institutions in which Patients are Not Covered by Extend- | 11,000 |
| | ed Care Legislation: - use General Listings and Premiums (para. 843 of Preamble when | |
| | applicable). General Listings under these circumstances also apply to patients seen | |
| | in bed rather than an office supplied by the institution. | |
| | Team Management in a Rehabilitation Unit (active in-patient rehabilitation management | |
| | from the initiation of rehabilitation care). | |
| | | |
| | Active in-patient rehabilitation management from the initiation of rehabilitation care | |
| | as it applies to fee codes H312, H317 and H319 means when this service is rendered by one physiatrist even if part of the service is rendered in an active treatment | |
| | hospital and part is rendered in a rehabilitation unit, the weekly and monthly | |
| | limitations under the following fee codes apply to the total rehabilitation care | |
| | rendered. In other words, it is not possible to charge the maximum fees allowed | |
| | under C312, C317 and C319 and then start billing de novo under H312, H317 and H319 | |
| | under the above circumstances. | |
| H312 | up to twelve weeksper visit | 15.60 |
| H317 | from thirteenth to twenty-sixth week (not to exceed \$46.80 per week)per visit | 15.60 |
| H319 | twenty-seventh week onwards (not to exceed \$93.60 per month)per visit | 15.60 |
| | and the second s | |
| 1122 | Rehabilitation Procedures: Interviewing and counselling of patients and/or relatives | 38.90 |
| H313 | per half hour or major part thereof (includes report) | 30.30 |
| | Physiatric Management: applies to physiatrists regulating the day to day management | |
| | of patients when medical necessity requires prescription development, advice and | |
| | supervision. It may be billed on the days when rehabilitation services are provided | |
| | to patients seen previously by the physiatrist for consultation or assessment. The fee is not meant as an administrative fee for supervising a department of rehabili- | |
| | tation nor is it to be charged on the same day as claims are made for any other | |
| | services which are provided by the physiatrist to the same patient(s). This fee | |
| | applies only to those patients who require and receive frequent attention by the | |
| | physician during the course of rehabilitation with regard to rehabilitative services | 0.50 |
| K313 | of physical or occupational therapy, speech therapy and discharge planning | 2.50 |

Premiums for Special Visits by Physicians, Detention Visits to I.C.U. or C.C.U. Chargeable in Addition to Above Fees - see Para, B43-46 of Preamble.

| CALLE | PLASTIC SURGERY (08) | |
|--|---|---|
| | General Listings: | |
| A085 | Consultation | 45.00 |
| A086 | Repeat consultation | 46.30 38.10 |
| A083 | Specific assessment | 33,60 |
| A084 | Partial assessment | 16.80 |
| | | 20,00 |
| | Emergency or O.P.D Physician in Hospital But Not on Duty in the Emergency Department When Seeing Patient(s) in the Emergency or O.P.D.: use General Listings | |
| | Non-Emergency Hospital In-Patient Services: (see para. 839 of Preamble - for emergency calls and other special visits to in-patients, use General Listings and Premiums [para. 843 of Preamble] when applicable). | |
| 0085 | Consultation | 46.30 |
| 0086 | Repeat consultation | 38.10 |
| 0083 | Specific assessment | 33,60 |
| | Specific re-assessment | 21.30 |
| | Subsequent visits:(minor assessments) | |
| 0082 | up to five weeksper visit | 15.60 |
| 0087 | from sixth to thirteenth week inclusive (not to exceed \$46.80 per week)per visit | 15.60 |
| 0089 | after thirteenth week(not to exceed \$93.60 per month)per visit | 15.60 |
| C088 | Concurrent care (minor assessments)per visit | 15.60 |
| | Long Term Institutional Care - Chronic and Convalescent Hospitals, Homes for the Aged | |
| | - Patients Covered by Extended Care Legislation and Nursing Homes: | |
| | Tuesday and an an an an an an an an an an an an an | |
| W085 | Consultation | 46.30 |
| W086 | Repeat consultation | 38.10 |
| | | |
| | PSYCHIATRY (19) | |
| | Canani Linkings | |
| | General Listings: | 105 70 |
| | Consultation | 105.70 |
| A395 | Consultation | 63.50 |
| A395 A196 | Consultation | 63.50 63.50 |
| A395 A196 A193 | Consultation Limited consultation Repeat consultation Specific assessment | 63.50 |
| A395 A196 | Consultation | 63.50 63.50 49.15 |
| A395 A196 A193 | Consultation Limited consultation Repeat consultation Specific assessment | 63.50 63.50 49.15 |
| A395 A196 A193 | Consultation | 63.50 63.50 49.15 |
| A395 A196 A193 | Consultation | 63.50 63.50 49.15 |
| A395 A196 A193 A194 | Consultation Limited consultation Repeat consultation Specific assessment Partial assessment Emergency or O.P.DPhysician in Hospital But Not on Duty in the Emergency Department When Seeing Patient(s) in the Emergency or O.P.D.: use General Listing Non-Emergency Hospital Services: (in-patient, day care, night care, residential care - see Para, 839 of Preamble - for emergency calls or other special visits to patients use General Listings and Premiums [para, 843 of Preamble] when applicable). | 63.50 63.50 49.15 21.10 |
| A395 A196 A193 A194 | Consultation | 63.50 63.50 49.15 21.10 |
| A395 A196 A193 A194 C195 C395 | Consultation Limited consultation Repeat consultation Specific assessment Partial assessment Emergency or O.P.DPhysician in Hospital But Not on Duty in the Emergency Department When Seeing Patient(s) in the Emergency or O.P.D.: use General Listing Non-Emergency Hospital Services: (in-patient, day care, night care, residential care see Para, 839 of Preamble - for emergency calls or other special visits to patients use General Listings and Premiums [para, 843 of Preamble] when applicable). Consultation Limited consultation | 63.50 63.50 49.15 21.10 |
| A395 A196 A193 A194 | Consultation Limited consultation Repeat consultation Specific assessment Partial assessment Emergency or O.P.DPhysician in Hospital But Not on Duty in the Emergency Department When Seeing Patient(s) in the Emergency or O.P.D.: use General Listing Non-Emergency Hospital Services: (in-patient, day care, night care, residential care - see Para, 839 of Preamble - for emergency calls or other special visits to patients use General Listings and Premiums [para, 843 of Preamble] when applicable). Consultation Limited consultation Repeat consultation | 63.50 63.50 49.15 21.10 |
| A395 A196 A193 A194 C195 C395 C196 | Consultation Limited consultation Specific assessment Partial assessment Emergency or O.P.DPhysician in Hospital But Not on Duty in the Emergency Department When Seeing Patient(s) in the Emergency or O.P.D.: use General Listing Non-Emergency Hospital Services: (in-patient, day care, night care, residential care - see Para, 839 of Preamble - for emergency calls or other special visits to patients use General Listings and Premiums [para, 843 of Preamble] when applicable). Consultation Limited consultation Specific assessment Specific re-assessment Specific re-assessment Subsequent visits: (minor assessments) | 63,50 63,50 49,15 21,10 105,70 63,50 63,50 49,15 35,60 |
| A395 A196 A193 A194 C195 C395 C196 C193 | Consultation Limited consultation Repeat consultation Specific assessment Partial assessment Emergency or O.P.DPhysician in Hospital But Not on Duty in the Emergency Department When Seeing Patient(s) in the Emergency or O.P.D.: use General Listing Non-Emergency Hospital Services: (in-patient, day care, night care, residential care- see Para. 839 of Preamble - for emergency calls or other special visits to patients use General Listings and Premiums [para. 843 of Preamble] when applicable). Consultation Limited consultation Repeat consultation Specific assessment Specific re-assessment Subsequent visits: (minor assessments) up to five weeks | 63,50 63,50 49,15 21,10 105,70 63,50 63,50 63,50 63,50 15,60 |
| A395 A196 A193 A194 C195 C395 C196 C193 C194 C192 C197 | Consultation | 63,50 63,50 49,15 21,10 105,70 63,50 63,50 49,15 35,60 15,60 |
| A395 A196 A193 A194 C195 C395 C196 C199 C197 C199 | Consultation Emergency or O.P.DPhysician in Hospital But Not on Duty in the Emergency Department When Seeing Patient(s) in the Emergency or O.P.D.: use General Listing Non-Emergency Hospital Services: (in-patient, day care, night care, residential care see Para, B39 of Preamble – for emergency calls or other special visits to patients use General Listings and Premiums [para, 843 of Preamble] when applicable). Consultation Limited consultation Repeat consultation Specific assessment Subsequent visits:(minor assessments) up to five weeks from sixth to thirteenth week inclusive(not to exceed \$46,80 per week)per visit after thirteenth week(not to exceed \$93,60 per month) per visit | 105.70 63.50 49.15 21.10 105.70 63.50 63.50 49.15 35.60 15.60 15.60 |
| A395 A196 A193 A194 C195 C395 C196 C199 C197 C199 | Consultation | 63,50 63,50 49,15 21,10 105,70 63,50 63,50 49,15 35,60 15,60 |
| A395 A196 A193 A194 C195 C395 C196 C199 C197 C199 | Consultation | 105.70 63.50 49.15 21.10 105.70 63.50 63.50 49.15 35.60 15.60 15.60 |
| A395 A196 A193 A194 C195 C395 C196 C193 C194 C192 C197 C199 C198 | Consultation | 63,50 63,50 49,15 21,10 105,70 63,50 63,50 63,50 49,15 35,60 15,60 15,60 |
| A395 A196 A193 A194 C195 C395 C196 C193 C194 C192 C197 C198 W195 W395 | Consultation Limited consultation Repeat consultation Specific assessment Partial assessment Emergency or O.P.DPhysician in Hospital But Not on Duty in the Emergency Department When Seeing Patient(s) in the Emergency or O.P.D.: use General Listing Non-Emergency Hospital Services: (in-patient, day care, night care, residential care - see Para, 839 of Preamble - for emergency calls or other special visits to patients use General Listings and Premiums [para, 843 of Preamble] when applicable). Consultation Limited consultation Repeat consultation Specific assessment Specific re-assessment Subsequent visits: (minor assessments) up to five weeks up to five weeks from sixth to thirteenth week (not used \$46,80 per week) per visit after thirteenth week(not to exceed \$93,60 per month) Concurrent care (minor assessments) uper visit Concurrent care (minor assessments) uper visit Concurrent care (minor assessments) uper visit Long Term Institutional Care - Chronic and Convalescent Hospitals, Homes for the Aged - Patients Covered by Extended Care Legislation and Nursing Homes: | 63,50 63,50 49,15 21,10 105,70 63,50 63,50 49,15 35,60 15,60 15,60 15,60 |

Premiums for Special Visits by Physicians, Detention Visits to I.C.U. or C.C.U. Chargeable in Addition to Above Fees - see Para. 843-46 of Preamble.

| Code | PSYCHIATRY (19) - Cont'd, | |
|-------|--|-------------------|
| | Other Services: | |
| N.C. | Specific assessment with report to referring approx | |
| | consultation on bendit of disturbed child (including report). | N.A.B. |
| A197 | CONSULTATIVE interview with parents | 02.00 |
| A198 | consultative interview with child | 93.00 93.00 |
| Note: | (ASSESSIBLE CONTENENCE WITH Darrents should be claimed on the basic of family | 93.00 |
| | therapy). Inis use of family therapy is the exception to the note that | |
| | psychotherapy may not be claimed with a visit fee. | |
| | A197, A198 - are to be considered as consultations. | |
| | | |
| | Therapeutic supervision with any para-medical organization | |
| N.C. | (health education, correction and other community resources) | N.A.B. |
| N.C | Appearance before Advisory Review Board or Review Board - per 1/2 hour or major part | N.A.B. |
| N.C. | thereof | IV.A.D. |
| K620 | the Mental Health Act) - per 1/2 hour or major part thereof | 45.90 |
| | Interviews with relatives on behalf of a patient, C.A.S. or legal guardian, etc see | 43.50 |
| NOCE. | Practice in General Listings (p.3) | |
| | Certification of Mental Illness | |
| | Application for psychiatric assessment, (as mandated by the Mental Health Act) - | |
| | including necessary history, examination, notification of the patient, family and | |
| K623 | relevant authorities and completion of Form 1 | 74.10 |
| | Certification of involuntary admission (as required by the Mental Health Act including | |
| | history examination, notification of the patient, family and relevant authorities | |
| K624 | and completion of Form 3 | 87.65 |
| N.C. | Certification of incompetence(financial) including assessment to determine incom- | |
| | petence | N.A.B. |
| K629 | All other re-certification(s) of involuntary admission | 26.20 |
| Note: | Consultation or assessment normally may not be claimed in addition to certification | |
| | or re-certification (same visit). | |
| | 0 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 | |
| | Psychotherapy: (see Preamble, paragraph 8.19) | |
| noces | (1) For electrotherapy fees see Diagnostic and Therapeutic Procedures. (2) Individual psychotherapy or Hypnotherapy or Counselling, rendered in the office, | |
| | are not to be charged in conjunction with other consultations or visits rendered | |
| | by a physician on the same day unless there are clearly defined different | |
| | diagnoses for the two services. | |
| | (3) When charging group therapy, the smaller (4 or 5 people) or larger group (6 to | |
| | 12 people) is to be charged for but not more than one for the same group. | |
| | Individual outpatient psychotherapy (including aversive conditioning, narcoanalysis, | |
| K197 | psychoanalysis) per 1/2 hour or major part thereof | 45.05 |
| | Page 1 | |
| | Individual inpatient psychotherapy (including aversive conditioning, narcoanalysis, | |
| K190 | psychoanalysis) per 1/2 hour or major part thereof | 45.05 |
| | Group psychotherapy - out-patients | |
| K203 | per member, per 1/2 hour or major part thereof (up to six hours per day)-4 people | 11.30 |
| K204 | -5 people | 9.25 |
| K205 | -6-12 people | 8.00 |
| N.C. | per member, per 1/2 hour (seventh to ninth hour per day) | N.A.B. |
| | Group psychotherapy - in-patients | 11 20 |
| K200 | per member, per 1/2 hour or major part thereof (up to six hours per day)-4 people | 11.30 |
| K201 | -5 people | 9.25 |
| K202 | -6-12 people | 8.00. N. A. D. |

Premiums for Special Visits by Physicians, Detention Visits to I.C.U. or C.C.U. Chargeable in Addition to Above Fees - see Para. 843-46 of Preamble.

| K195 | per 1/2 hour or major part thereof | 51.60 |
|------------------------------|---|---|
| K193 | Family therapy - in-patients (two or more family members) per 1/2 hour or major part thereof | 51.60 |
| Note: | Family therapy should be claimed on the patient's claim card with diagnosis. | |
| K192 K194 | Hypnotherapy: Individual - per 1/2 hour or major part thereof Group - for induction and training for hypnosis (up to eight people) per 1/2 hour or major part thereof - per member | 45.05 9.25 |
| | Note: Hypnotherapy may not be claimed with diagnosis of acne, psoriasis, smoking, obesity nor in conjunction with delivery. | |
| | RADIOLOGY-DIAGNOSTIC (33) | |
| A335 | General Listings: Consultation | 25.40 |
| C335 | Non-Emergency Hospital Service: Consultation | 25.40 |
| | RADIATION ONCOLOGY - (THERAPEUTIC RADIOLOGY) (34) | |
| A745 | General Listings: Consultation Limited consultation Repeat consultation Specific assessment Partial assessment | 96.25 63.50 63.50 37.30 21.10 |
| C345 | Non-Emergency Hospital In-Patient Services: | 25.05 |
| | Consultation Limited consultation Repeat consultation Specific assessment Specific re-assessment | 96.25 63.50 63.50 37.30 21.10 |
| C342 C347 C349 C348 | Subsequent visits: (minor assessment) up to five weeks from sixth to thirteenth week inclusive (not to exceed \$46.80 per week)per visit after thirteenth week(not to exceed \$93.50 per month)per visit Concurrent Care (minor assessments)per visit | 15.60 15.60 15.60 15.60 |
| | RESPIRATORY DISEASE (47) For Services not listed, refer to Internal Medicine Section. | |
| | General Listings: (Use these listings when performed at locations other than those designated in the following sections). | |
| A475 A575 A476 | Consultation Limited consultation Repeat consultation | 96.25 63.50 63.50 |

Premiums for Special Visits by Physicians, Detention Visits to I.C.U. or C.C.U. Chargeable in Addition to Above Fees – see Para. B43—46 of Preamble.

| RESPI | RATORY DISEASE (47)- Cont'd. | |
|--|--|---|
| A473 A474 A478 | General assessment General re-assessment Partial assessment | 49.15 35.60 21.10 |
| | Emergency or O.P.D.: -Physician in Hospital But not on Duty in the Emergency Depart- ment When Seeing Patient(s) in the Emergency or O.P.D.:-Use General Listings | |
| C475 C575 C476 C473 C474 C472 C477 C479 | Non-Emergency Hospital In-Patient Services: (para. B39 of Preamble - for emergency calls and other special visits to in-patients, use General Listings and Premiums [para. B43 of Preamble] when applicable). Consultation Limited consultation Repeat consultation General assessment General re-assessment Subsequent visits (minor assessments): up to five weeks from sixth to thirteenth week inclusive(not to exceed \$46.80 per week)per visit after thirteenth week(not to exceed \$93.60 per month)per visit | 96,25 63,50 63,50 49,15 35,60 15,60 15,60 |
| C478 | Concurrent care (minor assessments)per visit | 15.60 |
| | General Listings: (Use these listings when performed at locations other than those designated in the following sections.) | |
| A485 A595 A486 A483 A484 A488 | Consultation Limited consultation Repeat consultation General assessment General re-assessment Partial assessment | 96.25 63.50 63.50 49.15 35.60 21.10 |
| | Emergency or O.P.D.:- Physician in Hospital But not on Duty in the Emergency Depart- ment When Seeing Patient(s) in the Emergency or O.P.D.: - use General Listings | |
| | Non-emergency Hospital In-Patient Services: (see para, B39 of Preamble - for emergency calls and other special visits to in-patients, use General Listings and Premiums [para, B43 of Preamble] when applicable). | |
| C485 C595 C486 C483 C484 | Consultation Limited consultation Repeat consultation General assessment General re-assessment Subsequent visits(minor assessments): | 96.25 63.50 63.50 49.15 35.60 |
| C482 C487 C489 C488 | from sixth to thirteenth week inclusive(not to exceed \$46.80 per week)per visit after thirteenth week(not to exceed \$93.60 per month)per visit Concurrent care(minor assessments)per visit | 15.60 15.60 15.60 15.60 |
| | UROLOGY (35) | |
| A355 A356 A353 A354 | General Listings: Consultation* Repeat consultation* Specific assessment* Partial assessment | 46.30 38.10 34.00 16.80 |

Premiums for Special Visits by Physicians, Detention Visits to I.C.U. or C.C.U. Chargeable in Addition to Above Fees - see Para. 843-46 of Preamble.

| UROLOGY | (35) | - | Cont'd | | | |
|-----------|------|---|--------|---|--|--|
| Consessed | | 0 | 0.0 | - | | |

y or O.P.D. - Physician in Hospital But Not on Duty in the Emergency Department When Seeing Patient(s) in the Emergency or O.P.D.: use General Listings

Non-Emergency Hospital In-Patients Services: (see para, B39 of Preamble - for emergency calls and other special visits to in-patients, use General Listings and Premiums [para. B43 of Preamble] when applicable).

| C355 | Consultation* |
|------|---|
| C356 | Repeat consultation* |
| C353 | Specific assessment* |
| C354 | Specific re-assessment |
| | Subsequent visits:(minor assessments) |
| C352 | up to five weeksper visit |
| C357 | |
| C359 | after thirteenth week (not to exceed \$93.60 per month)per visit |
| C358 | Concurrent care (minor assessments)per visit |
| | Long Term Institutional Care - Chronic and Convalescent Hospitals, Homes for the Aged |
| | - Patients Covered by Extended Care Legislation and Mursing Homes: |
| W355 | Consultation* |
| | Receat consultation* |

*May include physical examination pertaining to the genito-urinary tract and when necessary such procedures as urethral calibration, catheterization and prostatic

fluid examination, but not to include endoscopic examination.

Premiums for Special Visits by Physician, Detention Visits to I.C.U. or C.C.U. Chargeable in Addition to Above fees - see para. 843-46 of Preamble.

12,65

LABORATORY MEDICINE

Code

1.806

ANATOMICAL PATHOLOGY, HISTOLOGY AND CYTOLOGY (Fees for Diagnostic Interpretation of Laboratory Procedures)

Preamble

 The following fees involve responsibilities for accessioning specimens and interpreting the diagnostic descriptions.

2. On occasion the services provided by the laboratory physician may involve substantially greater professional responsibility and expertise than is provided for in these fees. In such cases, the physician may bill for these on an independent consideration basis provided that the nature of the services and their distinguishing features are adequately described.

3. The surgical pathology fees are organized according to services requiring increasing expertise and time and are defined as follows: Simple specimen - includes gross and, where necessary, microscopic examination and interpretation of small tissues requiring less time, effort and risk than the next category. A simple specimen will ordinarily include tissue considered by the physician to be "normal" (e.g. uterine tubes, vas deferens, hernial sac, etc.). Small or uncomplicated specimen - includes small tissues thought to be abnormal which carry more professional risk and effort than those described in the previous category, and in which the number of slides is small. As a rule, this category would apply to a single small specimen or to two specimens if two tissues are combined on a slide (e.g. skin biopsy, endometrial biopsy). Multiple small specimens or curettings requiring multiple slides - includes specimens requiring several slides e.g. prostate curettings, uterine curettings, multiple endoscopic gastrointestinal tract biopsies from the same segment of the G.I. tract (multiple specimens or slides).

4. The physician assumes responsibility for all cytology smears and the listed professional benefits (L804 to L814 inclusive) are weighted averages of the professional component, these benefits, therefore are applicable in each case whether or not all slides are examined by the physician.

5. The benefit for seminal fluid examination (complete) is to include sperm count, volume estimation, motility and morphology and viscosity. The benefit for seminal fluid examination (L820) carried out post vasectomy is not to be claimed by the operating surgeon unless the patient requires more than one office visit post-operatively.

6. This Preamble is intended to apply to everyone using codes L800 to L846.

 The fees for diagnostic interpretation of laboratory procedures (L800 codes) are net fees and do not usually include overhead costs e.g., secretarial, handling and transport of specimen etc.,

Anatomic Fathology - Surgical Pathology Diagnostic examinations - see definitions

or other brushings and washings

| L839 | - simple specimen | 16.90 |
|------|---|--------|
| L821 | - small or uncomplicated specimen | 22.50 |
| L840 | - multiple small specimens or curettings requiring multiple slides | 42.20 |
| L822 | Operative consultation, with or without frozen section | 63.30 |
| | - each additional frozen section or direct smear and/or selection of tissue for | |
| L823 | biochemical assay (e.g. estrogen receptors), add | 31,-60 |
| L801 | Metabolic bone studies | 69.75 |
| L833 | Nerve teasing | 42.20 |
| 2000 | | |
| | Anatomic Pathology - Cytopathology | |
| | Cervical vaginal specimens (including all types of cellular | |
| L812 | abnormality, assessment of flora, and/or cytohormonal evaluation) | 3,80 |
| | Aspiration biopsy (lung, breast, thyroid, prostate, etc.) | 38.20 |
| 2003 | Bronchial, oesophageal, gastric, endometrial | 30.00 |
| | brondital, desoprageal, gastric, enduletrial | 10.00 |

LABORATORY MEDICINE

| auc | | |
|--|---|---|
| L808 | Imprint, touch preparation and/or direct smear | 10.60 |
| L815 | (e.g. cellular abnormalities, asbestos bodies, lipids, hemosiderin, etc.) | 7.80 |
| L804 | maturation, etc. Fluids (pleural, ascitic cyst, pericardial, C.S.F., urine | 3.80 |
| L810 | and joint, etc.) Synovial fluid analysis, description, viscosity, mucin | 10.60 |
| L824 | clot, cell count, and compensated PL for crystals Compensated polarized light microscopy for synovial | 21.10 |
| L825 L819 L820 | fluid crystals Seminal fluid analysis for infertility Smear for spermatozoa (post vasectomy) | 11.00 10.60 5.30 |
| L807 L811 L803 | Cytogenetics Smear for sex chromatin (Barr Body) or Neutorphil drumsticks | 4.20 5.10 63.30 |
| L834 L835 L841 L937 L817 L842 | Special Procedures and Interpretation - Histology or Cytology Histochemistry of muscle - 1 to 3 erzymes - each additional enzyme Enzyme histochemistry and interpretation (per enzyme) Immunohistochemistry and interpretation - per marker Anti-tissue antibodies and interpretation Anti-tissue antibodies, screening dilution, titration and interpretation, add | 21.10 6.75 10.60 10.60 5.10 5.40 |
| L843 | Special microscopy of tissues (polarization, interference, phase contrast, dark field, autofluorescence or other) and interpretation | 16.90 |
| L844 L845 L832 L816 | autofluorescence or other) and interpretation Specimen radiography or microradiography and interpretation X-ray diffraction analysis and interpretation Electron microscopy: TBM, STBM or SBM technique | 11.00 12.65 20.30 105.50 |
| L831 L836 | Analytical electron microscopy, elemental detection, mapping, or electron diffraction, add per case Morphometry, per parameter | 42.20 |
| L846 | Flow cell cytometry and interpretation, per parameter | 21.10 |
| L827 | Biochemistry and Immunology Interpretation of carcino embryonic antigen (CEA) Interpretation of homone receptors for carcinoma to include | 4.60 |
| L828 | estrogen and/or progesterone assays | 5.80 |
| L800 L826 L802 Z403 L830 | Hematopathology Blood film interpretation (Romanowsky stain) Blood film interpretation (special stain) Bone marrow interpretation (Romanowsky stain) Bone marrow aspiration Terminal transferase by immunofluorescence | 11.30 10.60 38.20 28.70 10.60 |
| 1838 | Laukocuta phonotuning by monoclonal antibody technique | 16 90 |

NUCLEAR MEDICINE - IN VIVO

Column T - is the technical benefit for the production of records, radiopharmaceutical agents, apparatus, premises, technical services, administration and secretarial services.

Column P1 - is the professional benefit for supervision of the procedure, appropriate patient interview and/or examination, correlation of related data, interpretation of results, and provision of a written report. The physician need not be continuously present in the nuclear medicine department or private facility while the procedures are being carried out but must be physically present frequently enough to carry out the appropriate patient interview and/or examination and approve, modify or intervene in the procedures as required.

Column P_2 - is the professional benefit for interpretation of results and provision of a written report. If the physician does not meet the criteria for P_1 or has claimed any visit in conjunction with that Nuclear Medicine procedure, the lesser professional fee (P_2) will be claimed. Notes: 1. The total benefit is arrived at by adding T plus P_1 (first code listed, e.g.,J802 or by adding T plus P_1 (cerond code listed e.g.,J602).

adding T plus P_2 (second code listed, e.g. J602). ¹
2. When coding the total benefit use suffix A; when coding technical portion only use suffix B; when coding professional portion only use suffix C.

3. If quantification or data manipulation is carried out in addition to visual inspection of imaging studies, add 30% to the appropriate professional benefit except when SPECT is claimed. For claim purposes, use prefix "Y". Such activity must add significant diagnostic information not available by inspection alone and does not include simple image enhancement techniques such as smoothing, background subtraction, etc. Recording of images on videotape for replay and production of images on the video display of a computer do not in themselves justify the additional benefit.

The claims for cardiac wall motion studies and calculation of ventricular ejection fract ion (J811 and J813) already include an allowance for data manipulation as a general rule and no additional benefit may be claimed. The additional computer benefit may be claimed only when additional cardiac quantifications are performed i.e. stroke volume ratio and volume response curves and/or phase analysis.

4. The total benefit is arrived at by adding T plus P₁ (first code listed e.g., J801) or by adding T plus P₂ (second code listed e.g., J601).

5. If examination of Brain, Lung, Liver or Spleen is limited to one view, the benefit (T and

P₁ or P₂) is to be reduced by 50%. 6. Repeat Studies on the same day may be claimed only after exercise or drug intervention. 7. The phrase "nuclear medicine specialist" should be interpreted as "nuclear medicine physician" since not all physicians practising nuclear medicine are certified as specialists in

this discipline by the Royal College of Physicians and Surgeons.

8. When tomographic examination (SPECT) is billed, the 30% add on referred to in para. 1 may not be charged.

| Code | | T | P ₁ | P ₂ |
|-------------|---|----------|----------------|----------------|
| | Cardiovascular System | | | |
| J802/J602 | Venography - peripheral and superior vena cava | | 31.25 | 15.10 |
| J804/J604 | First transit without blood pool images | | 15.10 | 8.10 |
| J867/J667 | First transit with blood pool images | 50.40 | 22.20 | 11.10 |
| J806/J606 | Cardioangiography - first pass for shunt detection, cardiac | | | |
| | output and transit studies | 83.70 | 44.35 | 22.20 |
| J807/J607 | Myocardial perfusion scintigraphy - immediate post stress, | | | |
| 000770007 | resting | 191.60 | 37.30 | 19.20 |
| J808/J608 | - delayed | 70,60 | 20.15 | 10.10 |
| J810/J610 | Myocardial scintigraphy - acute infarction, injury | 77.70 | 31,25 | 15.10 |
| J811/J611 | Myocardial wall motion studies | 83.70 | 44.35 | 22,20 |
| | - repeat same day (maximum of three repeats) | 42.35 | 22.20 | 11.10 |
| J812/J612 | | 119.00 | 65.50 | 33.25 |
| J813/J613 | Myocardial wall motion studies with ejection fraction | 42.35 | 33.25 | 17.20 |
| J814/J614 | - repeat same day (maximum of three repeats) | 42.33 | 33.23 | 17.20 |
| J815/J615 | Detection of venous thrombosis using radioiodinated | 110.00 | 22.25 | 17.00 |
| | fibrinogen up to ten days | 115.95 | 33.25 | 17.20 |
| | | | | |
| | Endocrine System | | | |
| J816/J616 | Adrenal scintigraphy with idocholesterol | 339.80 | 33.25 | 16.10 |
| J868/J668 | with idocholesterol and dexamethasone suppression | 398.30 | 44.35 | 22.20 |
| J869/J669 | - with MIBG | 489.10 | 39.30 | 19.20 |
| J817/J617 | Thyroid uptake | 25.20 | 16.10 | 8.10 |
| J870/J670 | - repeat | 13.10 | 8.10 | 8.10 |
| J818/J618 | Thyroid scintigraphy with Tc99m or I-131 | 56.50 | 29.20 | 14.10 |
| J871/J671 | - with I-123 | 90.80 | 29.20 | 14.10 |
| J820/J620 | Parathyroid scintigraphy - dual isotope technique with T1201 | | | |
| 0020/0020 | and Tc99m Iodine | 207 - 70 | 55.45 | 28,20 |
| J872/J672 | Metastatic survey with I-131 | 211.80 | 41.30 | 20.15 |
| 00/2/00/2 | recascacie survey with 1-151 | 211100 | 1200 | |
| | Cartesiatestinal Curtem | | | |
| 1001 / 1601 | Gastrointestinal System | 39,30 | 8.10 | 8,10 |
| J821/J621 | Schilling test - single isotope | 42.35 | 8.10 | 8.10 |
| J823/J623 | - dual isotope | | 8.10 | 8.10 |
| J824/J624 | Malabsorption test with C14 substrate | | 15.10 | 8.10 |
| J873/J673 | - with whole body counting | 121.00 | | 8.10 |
| J825/J625 | Gastrointestinal protein loss | 72.60 | 8.10 | 9.10 |
| | | | | |

NUCLEAR MEDICINE - IN VIVO

| Code | | T | P1 | P ₂ |
|------------|---|--------|-------|----------------|
| | Gastrointestinal System - Cont'd. | | . 1 | . 2 |
| | | | | |
| J874/J674 | Gastrointestinal blood loss - Cr51 | 54,50 | 8.10 | 8.10 |
| J826/J626 | Calcium absorption - Ca45 | 54.50 | 8.10 | 8.10 |
| J875/J675 | Calcium 47 absorption/excretion | 222.90 | 33.25 | |
| J827/J627 | Esophageal motility studies - one or more | | | 16.10 |
| J829/J629 | Cachemistration toronist | 105.90 | 82.70 | 41.30 |
| | Gastrointestinal transit | 90.80 | 34.30 | 16.10 |
| J876/J676 | Gastrointestinal reflux | 50.40 | 33.25 | 16.10 |
| J877/J677 | Gastroesophageal aspiration | 35.30 | 22.20 | 11.10 |
| J830/J630 | Abdominal scintigraphy for gatrointestinal bleed - Tc99m | | | |
| | sulphur colloid or TcO4 | 75,60 | 30.30 | 15.10 |
| J878/J678 | - labelled RBCs | 126.10 | 37.30 | 18.10 |
| J879/J679 | - LeVeen shunt patency | 58.50 | 33.25 | 16.10 |
| J831/J631 | Biliary scintigraphy | 100.80 | 37.30 | 18.10 |
| J832/J632 | | | | |
| J833/J633 | Liver/spleen scintigraphy | 70.60 | 30.30 | 15.10 |
| 1633/1633 | Salivary gland scintigraphy | 84.70 | 29.20 | 14.10 |
| | | | | |
| | Genitourinary System | | | |
| J834/J634 | Dynamic renal imaging | 84.70 | 30.30 | 15.10 |
| J835/J635 | Computer assessed renal function (includes first transit) | 115.95 | 55.45 | 25.20 |
| J880/J680 | - repeat | | 28,20 | 13.10 |
| J836/J636 | Static renal scintigraphy | | | |
| J837/J637 | | 28.20 | 10.10 | 8.10 |
| | ERPF | 35.30 | 8.10 | 8.10 |
| J838/J638 | GFR by blood sample method | 35.30 | 8.10 | 8.10 |
| J839/J639 | Cystography for vesicoureteric reflux | 105.90 | 20.15 | 12.10 |
| J840/J640 | Testicular and scrotal scintigraphy (includes first | | | |
| | transit) | 72.60 | 38.30 | 19.20 |
| | | . 2000 | 00000 | 13020 |
| | Hematopoietic System | | | |
| J841/J641 | | 20, 20 | 0.10 | 0.10 |
| | Plasma volume | 38.30 | 8.10 | 8.10 |
| J843/J643 | Red cell volume | 42.35 | 8.10 | 8.10 |
| J847/J647 | Ferrokinetics - clearance, turnover, and utilization | 352.95 | 28.20 | 14.10 |
| J848/J648 | Red cell, white cell or platelet survival | 90,80 | 22.20 | 11.10 |
| J849/J649 | Red cell survival with serial surface counts | 131.10 | 28.20 | 14.10 |
| J881/J681 | Bone marrow scintigraphy - whole body | 100.80 | 43.40 | 21.20 |
| J882/J682 | | | | |
| | - single site | 74.60 | 36.30 | 18.10 |
| J883/J683 | In-111 leukocyte scintigraphy - whole body | 320.70 | 46.40 | 23.20 |
| J884/J684 | - single site | 282.40 | 36.30 | 18.10 |
| | | | | |
| | Musculoskeletal System | | | |
| J850/J650 | Bone scintigraphy - general survey | 92.80 | 43.40 | 21,20 |
| J851/J651 | - single site | 74.60 | 36.30 | 18.10 |
| J852/J652 | Gallium scintigraphy - general survey | 156.30 | 46.40 | 23.20 |
| J853/J653 | - single site | 108.90 | 36.30 | 18.10 |
| | | | | |
| J854/J654 | Bone mineral density | 27.20 | 8.10 | 8.10 |
| J855/J655 | Total body calcium - neutron activation | 171.45 | 50.40 | 25.20 |
| J356/J656 | Bone mineral content by dual photon absorpiometry | | 50.40 | 25.20 |
| Note: | J850/J650 and J851/J651 are not to be billed together. J804 | | | |
| | may be claimed in addition to J850/J650 or J851/J651 for | blood | | |
| | pool study. | | | |
| | | | | |
| | Nervous System | | | |
| J857/J657 | CSF circulation - with Tc99m or I-131 HSA | 105.90 | 37.30 | 18.10 |
| | | | | |
| J885/J685 | - with In-lll | 272.30 | 43.40 | 21.20 |
| J886/J686 | - via shunt puncture | 78.60 | 41.30 | 20.15 |
| J858/J658 | Brain scintigraphy | 79.70 | 29.20 | 14.10 |
| | | | | |
| | Respiratory System | | | |
| J859/J659 | Perfusion lung scintigraphy | 75.65 | 35.30 | 18.10 |
| J887/J687 | Ventilation lung scintigraphy | 94.80 | 35.30 | 18.10 |
| J860/J660 | Perfusion and ventilation scintigraphy - same day | 151.30 | 45.40 | 22.20 |
| 0.0070000 | retrustor and reserration series graphy - same day | 434.50 | 73.70 | EE . EU |
| | Missallaness | | | |
| 3001 /3001 | Miscellaneous . | 00.00 | F2 40 | 20.00 |
| J861/J661 | Radionuclide lymphangiogram | 98.80 | 52.40 | 26.20 |
| J862/J662 | Ocular tumour localization | 66.60 | 58.50 | 29.20 |
| J864/J664 | Tear Duct scintigraphy | 85.70 | 42.35 | 21.20 |
| J865/J665 | Total body counting | 165.40 | 47.40 | 24.20 |
| J866/J666 | Tomography (SPECT) | 38.30 | 22,20 | 11.10 |
| - 300,0000 | -3-4-0 (- co.) | | | |

NUCLEAR MEDICINE - IN VIVO

Code

CLINICAL PROCEDURES ASSOCIATED WITH DIAGNOSTIC NUCLEAR MEDICINE PROCEDURES

Such procedural benefits are intended for the professional service of placing an instrument or introducing diagnostic radiopharmaceuticals. They are not intended to be used for simple subcutaneous, intranuscular or intravenous injection nor for oral administration. Rather than double listing the procedures and benefits in this part of the fee schedule, physicians are directed to the following reference points in the schedule.

- a) Intravenous injection for peripheral venography G376 or G379 on page 59 b) Intra-articular injections G370 on page 58 c) Injection into CSF spaces or shunt apparatus Z801 or Z821 on page 145
- d) Arterial puncture G479 on pages 49 & 51
- e) Paracentesis in conjunction with shunt patency study Z590 on page 124

NUCLEAR MEDICINE - IN VITRO (see Radioassays under Laboratory Medicine.)

RADIATION ONCOLOGY (THERAPEUTIC RADIOLOGY)

| | · · · · · · · · · · · · · · · · · · · | |
|-------|--|-------------|
| Code | RADIOTHERAPY (Including Therapeutic Isotopes) | |
| 0000 | The listed benefits are for the professional services of a certified therapeutic radio | |
| | services of a certified the professional services of a certified therapeutic radio | logist, the |
| | services of a specialist for the intracavitary or interstitial application of radius | n or sealed |
| | sources and the services of a specialist using non-sealed sources of radioisotopes | in a labor- |
| | atory authorized by the Atomic Energy Control Board of Canada. Other medical servi | ices to the |
| | patient are not included in these figures. The cost of material is additional house | oune whom |
| | the service is rendered in a public hospital, the cost of material is contained | within the |
| | hospital's global budget. | within as |
| Note: | | |
| nocc. | OCI/PMH. | itres or |
| | UNI/ ITTIS | |
| | (2)X305, X306, X323, X324, X334 - May only be performed on an inpatient and when done in | 1 |
| | hospital, this service is a hospital charge and cannot be claimed from OHIP | |
| | (see Bulletin #4070). When done in an OCTRF Cancer Centre, may be claimed from OHIP | by all |
| | physicians, including certified therapeutic radiologists. | |
| | | |
| | TELERADIOTHERAPY | |
| | | |
| | Major treatment planning (150 KVP or higher), dosage calculation and preparation of | |
| X301 | the control prainting (150 ker of higher), cosage calculation and preparation of | |
| V201 | any special treatment device | 53.10 |
| ugon | Teleradiotherapy - x-ray, 151 KVP or higher, radium, cobalt, cesium betatron linear | |
| X302 | accelerator - benefit per treatment visit | 13.60 |
| X304 | Minor teleradiotherapy - x-ray, 150 KVP or less - benefit per treatment visit | 8.90 |
| | Intracavitory contact x-ray therapy including signoidoscopy or proctoscopy - first | |
| X305 | application | 127,00 |
| X306 | repeat application | 63,60 |
| | - space appril control of a con | 03,00 |
| | Note: For minor teleradiotherapy administered by other than certified therapeutic | |
| | | |
| | radiologists, use the listing under Diagnostic and Therapeutic Procedures. | |
| | NAME OF TAXABLE PARTY O | |
| | RADIUM AND RADIOISOTOPES (sealed sources) | |
| | | |
| | Treatment planning, dosage calculation and preparation of any special treatment | |
| X322 | device | 53.10 |
| | Intracavitary application of radium or sealed sources including dilatation and curet- | |
| | tage carried out at the same time as application | |
| X323 | - first application | 157.30 |
| X334 | - repeat application | 78.60 |
| X324 | Interstitial application of radium or sealed radioisotope | 156.05 |
| X325 | Application of radium or radioisotope plaque or mould | 48.25 |
| AGES | Note: X325 may be claimed as an in or outpatient service. | 40.23 |
| | | |
| | If claimed as inpatient service, follow directions in Note (2) above. | |
| | If claimed as outpatient service, allow to all listed physicians. | |
| | Payment for outpatient services must be made to the registered Department of | |
| | Radiology, in the case of a hospital, even though there is no technical component | |
| | listed. | |
| | | |
| | RADIOISOTOPES (non-sealed sources) | |
| | The following benefits include treatment planning, dosage calculation and preparation | |
| | of materials. Appropriate visit and procedural benefits (e.g. paracentesis) may be | |
| | claimed in addition. Thyroid benefits (X326, X327, X335) include administration(s) | |
| | within any three month period. | |
| vanc | | 70.10 |
| X326 | Thyroid malignancy | 70.10 |
| X327 | Hyperthyroidism | 63.80 |
| X335 | Induction of hypothyroidism | 63.80 |
| X336 | Prostate malignancy | 63.80 |
| X328 | Polycythaemia | 37.30 |
| X329 | Metastatic disease of bone | 58.00 |
| X330 | Ascites and/or pleural effusion(s) due to malignancy | 45.50 |
| X332 | Arthritis - single or multiple site | 30.00 |
| X333 | Metastatic disease with radioactive lymphogram | 45.50 |
| - | reconstante discuse with individuelies lymphogram accessors accessors accessors accessors | 43.50 |
| | | |

Column T - The benefit for radiological examination including the production of radiographs, supplying of contrast media, apparatus, premises, technical services, administration and collection costs.

Column P - The benefit for consultation between radiologist and referring physician, fluoroscopy, in

Column P - The benefit for consultation between radiologist and referring physician, fluoroscopy, interpretation of radiographs and fluoroscopic findings and supervision of x-ray services by a radiologist. Hospital out-patient technical fees will be paid at 90.51% of the technical fee listed in this Schedule of Benefits.

Private offices and hospital out-patient departments will bill Column T plus P.

When coding the total benefit use suffix A; when coding the technical portion only use suffix B; when coding the professional portion only use suffix C.

Radiologists should use Column P as a guideline for negotiating remuneration with hospitals.

Benefits for clinical procedures related to x-ray examinations are listed in the following section, or under Diagnostic and Therapeutic or Surgical Procedures. "Clinical Procedures", in this context, are those by which contrast media are introduced, except oral or rectal administration for study of the alimentary tract, and intravenous injections, which are an integral part of the study, performed by the physician collecting the benefit for the procedure.

If less than minimum number of views are performed, reduce listed fees by 25%.

If the examinations which are requested by the referring physician yield abnormal findings or if they would yield information which in the opinion of the radiologist would be insufficient, governed by the needs of the patient and the requirements of the referring physician, the radiologist may add further views and charge for them (if listed).

Fee Schedule Interpretations

- When a radiologist is asked to x-ray one extremity only, no additional charge should be made for comparison x-rays initiated by the radiologist.
 - 2. Nephrotomography is covered by the listings for intravenous pyelogram and planigram.

3. A stereo pair is to be counted as two views.

4. No extra claim should be charged for rapid sequence I.V.P.

- 5. No additional claim is warranted for the use of the image intensifier in diagnostic radiology.
 6. Fluoroscopy claims should not be submitted for any examination performed by the radiologist where fluoroscopy is generally regarded as an integral part of the examinations e.g. examinations of the G.I. tract, urinary tract, special procedures.
- 7. "Colon-air contrast" may be claimed when performed according to generally accepted criteria. The colon should be scrupulously prepared. Five to eight full size views of the abdomen should be obtained after fluoroscopically controlled introduction of air and barium.
- 8. "Oesophagus, stomach and duodenum, double contrast" presupposes the introduction of gas, the use of antifoam agent and a suitable barium mixture.
- 9. Abdomen and chest studies should not be routinely done and claimed in gastrointestinal examina-
- 10. Three or more views of the chest should not be done routinely and claimed when a chest examination is requested.

11. Chest studies should not be routinely done and claimed in mammography cases.

- 12. Nasal bones or accessory nasal sinuses should not be routinely claimed in skull examination
- 13. Abdomen and/or pelvis should not be routinely claimed in lumbar spine examination requests.
- 14. A survey film of the abdomen is a single view. The ordering of additional films should be left to the discretion of the radiologist who should have the power to determine what examination is adequate for a specific patient. Obviously, if progress of a long tube is being followed, a survey film is sufficient. If, however, an intestinal obstruction is being followed, a single film is usually inadequate.
- 15. Conventional films of the spine should not be routinely done and claimed for before myelographty. The necessity of having plain film studies of the spine prior to interpreting the myelographic studies is obvious. It is not essential, however, that these be done at the institution where the myelogram was done. If they have ben done at an outside office, then it is a matter for the radiologist and the referring physician to have the films available. If they cannot be made available to the radiologist, it is an acceptable practice for him to do the required examination of these areas and to claim for them so that they may be available for interpretation along with the myelographic study.

16. Pharynx and oesophagus (cine or videotape) - X106 should not be claimed routinely with X108 and

X109 but only when specifically indicated.

- 17. Lumbar or lumbosacral spine (XO28) does not include the entire sacrum. An examination of the sacrum may be carried out and claimed for only when specifically indicated.
- 18. X006 and X007 are not both to be routinely claimed on the same patient but only when specifically ordered.

19. A maximum of two computed tomography examinations per patient per day may be claimed.

20. Complex head CT Scans are meant to be multi planer (multi directional) head CT Scans - to include one or more of the following areas: pituitary fossa, posterior fossa, internal auditory meati, orbits and related structures, the temporal bone and its contents and the temporamandibular joints. X400, X401 and X188 are not to be billed in addition to those fees for complex head studies.

21. All benefits listed apply to unilateral examinations unless otherwise specified.

22. Claims for X-ray services, when referred by an Osteopath, Chiropodist or Chiropractor to a private X-ray facility are not benefits of OHIP.

23. Claims for X-ray services, when referred by and Osteopath or Chiropractor to a hospital outpatient department are benefits.

| Code | | T | Р |
|-------|--|--------|--------|
| | Head and Neck | | |
| X001 | Skull - four views | 29.90 | 10.00 |
| X009 | - five or more views | | |
| X003 | | 37.30 | 12.40 |
| | Sella turcica (when skull not examined) | 14.90 | 4.80 |
| X004 | Facial bones - minimum of three views | 21.70 | 7.80 |
| X005 | Nose - minimum of two views | 14.90 | 4.80 |
| X006 | Mandible - minimum of three views (uni or bilateral) | 21.70 | 7.30 |
| X012 | four or more views | 29.90 | 10.00 |
| | Temporomandibular joints - minimum of four views including open and closed | | |
| X007 | mouth views | 21.70 | 7.80 |
| X008 | Sinuses - minimum of three views | 21.70 | 7.80 |
| X010 | Mastoids - bilateral - minimum of six views | 28.70 | 10.35 |
| | | | |
| X011 | Internal auditory meati (when skull not examined) | 21.70 | 7.80 |
| N.C. | Teeth, up to 1/4 set | N.A.B. | N.A.B. |
| N.C. | Teeth, up to 1/2 | N.A.B. | N.A.8. |
| N.C. | Teeth, full set | N.A.B. | N.A.8. |
| N.C. | Teeth, bite wing | N.A.B. | N.A.B. |
| X016 | Eye, for foreign body | 14.80 | 6.90 |
| X017 | Eye, for localization, additional | 15.30 | 17.80 |
| | | | |
| X018 | Optic foramina | 16.80 | 6.90 |
| X019 | Salivary gland region | 13.80 | 6.00 |
| X020 | Neck for soft tissues - minimum of two views | 13.80 | 6.00 |
| | | | |
| | Spine and Pelvis | | |
| X025 | Cervical spine - two or three views | 25.90 | 6.00 |
| X202 | - four or five views | 33.30 | 8.00 |
| X203 | - six or more views | 40.40 | 9.90 |
| | | 23.70 | |
| X027 | Thoracic spine - two views | | 6.00 |
| X204 | - three or more views | 31.10 | 7.90 |
| X028 | Lumbar or lumbosacral spine – two or three views | 25.90 | 6.00 |
| X205 | - four or five views | 33.30 | 8.00 |
| X206 | - six or more views | 40.50 | 10.00 |
| X032 | Entire spine - (scoliosis series) minimum of four views | 53,60 | 15.70 |
| NUVE | - Orthoroentgenogram (3 foot film) | 00000 | 201.0 |
| X033 | | 21.70 | 7.30 |
| | - single view | 29.80 | 9.90 |
| X031 | - two or more views | | |
| X034 | Sacrum and/or coccyx - two views | 24.90 | 4.80 |
| X207 | - three or more views | 31.10 | 7.90 |
| X035 | Sacro-iliac joints - two or three views | 21.70 | 7.80 |
| X208 | - four or more views | 29.00 | 9.90 |
| X036 | Pelvis and/or hip(s) - one view | 14.90 | 4.80 |
| 74000 | - two views (e.g. A.P. and frog view, | | |
| | both hips; | | |
| W027 | | 27 00 | 6 00 |
| X037 | or A.P. both hips plus lateral one hip, | 27.80 | 6.90 |
| | - three or more views (e.g. pelvis and sa | | |
| | iliac joints, or A.P. both hips plus late | eral | |
| X038 | each hip) | 31.90 | 7.80 |
| | | | |
| | Upper Extremities | | |
| X045 | Clavicle - two views | 14.90 | 4.80 |
| X209 | - three or more views | 22.90 | 6.80 |
| AZUS | # UNITED OF HILLS AND AND AND AND AND AND AND AND AND AND | 22.00 | 0,000 |
| | Acromioclavicular joints (bilateral) with or without weighted distraction | 21.70 | 7.00 |
| X046 | - two views | | 7.80 |
| X210 | - three or more views | 29.65 | 9.90 |
| X047 | Sternoclavicular joints - (bilateral) - two or three views | 17.85 | 6.00 |
| X211 | - four or more views | 25.80 | 7.90 |
| X048 | Shoulder - two views | 17.85 | 6.00 |
| X212 | - three or more views | 25.80 | 7.90 |
| X049 | | 17,85 | 6.00 |
| | | 25.80 | 7.90 |
| X213 | - three or more views | 14.90 | 4.80 |
| X050 | Humerus - including one joint - two views | | |
| X214 | - three or more views | 22.90 | 6.80 |
| X051 | Elbow - two views | 14.90 | 4.80 |
| X215 | - three or four views | 22.90 | 6.80 |
| X216 | - five or more views | 30.90 | 8.80 |
| X052 | Forearm - including one joint - two views | 14,90 | 4.80 |
| | - three or more views | 22.90 | 6.80 |
| X217 | | 14.90 | 4.80 |
| X053 | Wrist - two or three views | 17.70 | 7,00 |
| | | | |

| Code | DIAGNOSTIC RADIOLOGY | - | |
|------|---|--------|--------|
| Code | | T | P |
| | | | |
| | Upper Extremities - Cont'd. | | |
| | | | |
| X218 | - four or more views | 22,90 | 6.80 |
| X054 | Hand - two or three views | 14.90 | 4.80 |
| X219 | - four or more views | 22,90 | 6.80 |
| X055 | Wrist and hand - two or three views | 21.70 | 9.90 |
| X220 | - four or more views | 27.60 | 11.80 |
| X056 | Finger or thumb - two views | 11.50 | 3.50 |
| | | | |
| X221 | - three or more views | 14.90 | 4.80 |
| | | | |
| | Lower Extremities | | |
| X060 | Hip - (unilateral) - two or more views | 23.70 | 6.00 |
| X063 | Femur, including one joint - two views | 14.90 | 4.80 |
| X223 | - three or more views | 22.90 | 6.80 |
| X065 | Knee (including patella) - two views | 14.90 | 4.80 |
| X224 | - three or four views | 22.90 | 6.80 |
| X225 | | 30.90 | 8.80 |
| | - five or more views | | |
| X066 | Tibia and fibula (including one joint) - two views | 14.90 | 4.80 |
| X226 | - three or more views | 22.90 | 6.80 |
| X067 | Ankle - two or three views | 14.90 | 4.80 |
| X227 | - four or more views | 22.90 | 6.80 |
| X068 | Calcaneus - two views | 14.90 | 4.80 |
| X228 | - three or more views | 22.90 | 6.80 |
| X069 | Foot - two or three views | 14.90 | 4.80 |
| X229 | - four or more views | 22.90 | 6.80 |
| | | 11.50 | 3.50 |
| X072 | Toe - two views | | |
| X230 | - three or more views | 14.90 | 4.80 |
| X064 | Leg length studies (Orthoroentgenogram) | 21.70 | 7.80 |
| | | | |
| | Skeletal Surveys | | |
| | Skeletal survey for bone age, | | |
| X057 | - single film | 14.90 | 4.80 |
| X058 | - two or more films or views | 21.90 | 7.90 |
| AU30 | Other author of the company and mother in order the | 21.50 | 7.50 |
| v000 | Other survey studies - e.g., rheumatoid, metabolic or metastatic | 7,40 | 2,50 |
| X080 | - basic | | |
| X081 | - plus per film or view | 7.40 | 2.50 |
| | | | |
| | Chest · | | |
| N.C. | Miniature chest film - for survey purposes only | N.A.B. | N.A.B. |
| X090 | Single film | 14.90 | 4.80 |
| X091 | Two views | 21.95 | 7.90 |
| X092 | Three or more views | 28.10 | 9.40 |
| | Ribs - two or more views | 17.85 | 6.00 |
| X039 | | 17.85 | |
| X040 | Sternum - two or more views | | 6.00 |
| X096 | Thoracic inlet - two or more views | 14.90 | 4.80 |
| | | | |
| | Abdomen | | |
| X100 | Single view | 14.90 | 4.80 |
| X101 | Two or more views | 22.80 | 6.90 |
| | | | |
| | G.I. Tract | | |
| V105 | Palatopharyngeal analysis (cine or videotape) | 29.50 | 19.70 |
| X105 | Palatopharyngeal analysis (time or videocape) | | 19.70 |
| X106 | Pharynx and oesophagus (cine or videotape) | 29.50 | |
| X107 | Oesophagus - when X103, X104, X108 or X109 not billed | 26.70 | 12.70 |
| X108 | Oesophagus, stomach and duodenum - including survey film if taken | 46.30 | 22.80 |
| | Oesophagus, stomach and duodenum - double contrast, including survey film, if | | -01 |
| X104 | taken | 48.20 | 25.00 |
| | Oesophagus, stomach and duodenum - double contrast, including survey film, if | | |
| X103 | taken, and small bowel | 61.00 | 31.70 |
| X103 | Oesophagus, stomach and small bowel | 59.10 | 29.60 |
| | Ucaoparia diadagagam | 39.40 | 19.70 |
| X110 | Hypotonic duodenogram | | |
| X111 | Small bowel only- when only examination performed during patient's visit | 26.70 | 12.70 |
| X112 | Colon - barium enema (including survey film, if taken) | 48.30 | 20.70 |
| X113 | Colon - air contrast, primary or secondary, including survey films | | |
| | if taken | 61.10 | 26.90 |
| X114 | Gallbladder (one or multiple day examinations) | 29.90 | 10.00 |
| X120 | Gallbladder (one or multiple day examinations with preliminary plain film) | 39.80 | 10.00 |
| | /ara ar marrier A marrier Marrier Marrier Marrier Marrier Marrier Marrier Marrier - | | |
| | | | |

| | DIAGNOSTIC RADIOLOGY | | |
|------|--|--------|-------|
| Code | | Т | Р |
| | | | 1 |
| | G.I. Tract - Cont'd. | | |
| | usis made - dure de | | |
| | | | |
| X116 | T-Tube cholangiogram | 21.70 | 7.80 |
| X117 | Operative cholangiogram | 21.70 | 7.80 |
| X118 | Intravenous cholangiogram | 49.50 | 17.70 |
| X123 | Approximation of the contract | | |
| VIZO | Operative pancreatogram or E.R.C.P. | 21.70 | 7.80 |
| | | | |
| | G. U. Tract | | |
| X129 | Retrograde pyelogram, unilateral or bilateral | 21.70 | 7,80 |
| X130 | Intervenie enlane inlatin enlation of its enterest of the ente | | |
| | Intravenous pyelogram including preliminary film | 49.50 | 19.70 |
| X137 | Cystogram (catheter) | 23.80 | 6.00 |
| X135 | Cystourethrogram, stress or voiding (catheter) | 27.60 | 11.30 |
| X131 | Cystourethrogram (non-catheter) | 5.80 | |
| X191 | System of all (nor-carreter) | | 4.00 |
| | Intestinal conduit examination or nephrostogram | 21.70 | 7.80 |
| X138 | Percutaneous artegrade pyelogram | 21.70 | 7.80 |
| X139 | Percutaneous nephrostomy | 21.70 | 7.80 |
| X134 | Heatherman / not mounted | | |
| | Urethrogram (retrograde) | 17.85 | 6.00 |
| X136 | Vasogram | 17.85 | 6.00 |
| | | | |
| | Obstetrics and Gynaecology | | |
| X143 | | 24.00 | 4 00 |
| | Survey film | 14.90 | 4.80 |
| X144 | Pelvimetry | 21.70 | 7.80 |
| X146 | Any combination of above | 37.60 | 11.80 |
| X147 | Hysterosalpingogram | 29.80 | 9.90 |
| X148 | Tables schedules feeded Americal and Allender 1 | | |
| A140 | Intra-uterine foetal transfusion - radiological control | 39.40 | 19.70 |
| | | | |
| | Fiuoroscopy - by physician with or without spot films | | |
| X195 | Chest | 9.30 | 9.90 |
| | C 1 - 1 | | |
| X196 | Skeleton | 9.30 | 9.90 |
| X197 | Abdomen | 9.30 | 9.90 |
| | Fluoroscopic control of clinical procedures done by another physician per | | |
| X189 | 1/A hours | 7 20 | 16.50 |
| V103 | 1/4 hour | 7.30 | 16.50 |
| | | | |
| | Special Examinations | | |
| X155 | Abdominal or pelvic pneumogram | 40.00 | 9.90 |
| | Angiography | 40.00 | 3.50 |
| | | | |
| | - by catheterization | | |
| | - abdominal, thoracic, cervical or cranial | | |
| | - using single films | | |
| X179 | non-selective | 20, 20 | 0.00 |
| | | 29.30 | 9.90 |
| X180 | selective (per vessel to max. of 4) | 39.40 | 19.70 |
| X181 | - using film changer, Cine or multiformat camera non-selective | 59.60 | 19.70 |
| X182 | selective (per vessel to a max. of 4) | 79.40 | 29,60 |
| X140 | | | |
| | selective (6 or more vessels) | I.C. | I.C. |
| X178 | Intravenous angiocardiography - with quantification | - | 29.80 |
| X172 | - without quantification | - | 22.40 |
| | Carotid angiogram - direct puncture | | |
| X160 | - unilateral | 48,90 | 29,60 |
| X161 | hilatoral | | |
| YTOT | - bilateral | 78.60 | 44.40 |
| | Peripheral angiogram | | |
| X174 | - unilateral | 29.80 | 9.90 |
| X175 | - bilateral | 39.40 | 19.70 |
| X198 | | | |
| | Splenoportogram | 59.10 | 19.70 |
| X199 | Translumbar aortogram | 59.10 | 19.70 |
| | Vertebral angiogram - direct puncture | | |
| | or retrograde brachial injection | | |
| X132 | unilatoral | 40.00 | 20.00 |
| | - unilateral | 48.90 | 29.60 |
| X133 | - bilateral | 79.95 | 44.40 |
| X156 | Arthrogram,tenogram or bursogram | 26.20 | 21.70 |
| | - with fluoroscopy and complete | | |
| vano | | 26.70 | 21 60 |
| X200 | positioning throughout by physician | 36.70 | 31.60 |
| X157 | Bone density (mineral content) measurement | 33.50 | 15.70 |
| X158 | Bronchogram - unilateral | 29.30 | 19.70 |
| X159 | - bilateral | 38.90 | 29.60 |
| X162 | | | |
| | Cerebral stereotaxis | 59.60 | 19.70 |
| X122 | Cholangiogram, percutaneous trans-hepatic | 29.60 | 14.80 |
| | | | |

| | DIAGNOSTIC RADIOLOGY | | |
|--------------|--|-------|-------|
| Code | | T | P |
| | | | |
| | Computed tomography | | |
| X400 | -head - without I.V. contrast | - | 37.70 |
| X401 | -with I.V. contrast | - | 56.50 |
| X188 | -with and without I.V. contrast | - | 66.00 |
| X402 | -complex head (See Radiology Preamble Para 20) - without I.V. contrast | - | 56.50 |
| X405 | - with I.V. contrast | - | 66.00 |
| X408 | - with and without I.V. contrast | - | 75.40 |
| X403 | -neck - without I.V. contrast | - | 37.70 |
| X404 | -with I.V. contrast | - | 56.50 |
| X124 | -with and without I.V. contrast | | 66.00 |
| X406 | -thorax - without I.V. contrast | - | 56.50 |
| X407 | -with I.V. contrast | - | 66.00 |
| X125 | -with and without I.V. contrast | - | 75.40 |
| X409 | -abdomen - without I.V. contrast | - | 75.40 |
| X410 | -with I.V. contrast | | 84.80 |
| X126 | -with and without I.V. contrast | | 94.20 |
| X412 | -extremities (one or more) - without I.V. contrast | - | 37.70 |
| X413 | with I.V. contrast | | 56.50 |
| X127 | | - | 66.00 |
| | -with and without I.V. contrast | - | |
| X415 | -spine -without I.V. contrast | - | 75.40 |
| X416 | -with I.V. contrast | - | 84.80 |
| X128 | -with and without I.V. contrast | 40.00 | 94.20 |
| X151 | Cordotomy, percutaneous | 48.90 | 29.60 |
| X163 | Dacrocystogram | 29.80 | 9.90 |
| X164 | Discogram(s) - one or more levels | 29.30 | 19.70 |
| X167 | Fistula or sinus injection | 21.70 | 7.80 |
| X169 | Laminogram, planigram, tomogram | 40.00 | 9.90 |
| X170 | Laryngogram | 29.30 | 19.70 |
| X171 | Lymphangiogram | 49.50 | 19.70 |
| X192 | Marimary ductography | 21.70 | 7.80 |
| X184 | Marmogram - unilateral | 24.80 | 10.85 |
| X185 | - bilateral | 36.90 | 16.30 |
| X186 | - using xeroradiography - unilateral | 30.70 | 10.85 |
| X187 | - bilateral | 47.10 | 16.30 |
| X150 | Mechanical evaluation of knee | 25.50 | 13.80 |
| X193 | Microradioscopy of the hands | 14,70 | 9.90 |
| X173 | Myelogram (spine and/or posterior fossa) | 35.00 | 23.70 |
| X190 | Pantomography | 17.85 | 6.00 |
| X154 | Penis | 16.00 | 4.00 |
| X165 | Photographic subtraction | - | 9.90 |
| X176 | Sia logram | 29.80 | 9.90 |
| X177 | Skin thickness measurement | 15.70 | 7.80 |
| X183 | Ventriculogram | 48.90 | 29.60 |
| X166 | Examination using portable machine in home, add to first examination only | 63.20 | 23.00 |
| YIOO | Note: This code does not apply to the use of a portable machine in a | 00120 | |
| | hospital. Can only be claimed once per day regardless of the number | | |
| | of people x-rayed in the same home. | | |
| | or people x-rayed in the same names | | |
| | Magnetic Resonance Imaging | | |
| | ragilet to resolution illustria | | |
| | The following professional fees should be interpreted in the spirit of the | | |
| | definition of column P as set out in the Diagnostic Radiology Preamble. | | |
| | definition of column r as sec out in the biagnostic hadrology frembres | | |
| X421 | -head - multislice S.E. (1 or 2 echos) | - | 54.70 |
| | - multislice I.R. | | 35.60 |
| X422 X425 | - repeat (another plane, different pulse sequence - max. 2) | | 27.30 |
| | -neck - multislice S.E. (1 or 2 echos) | | 54.70 |
| X431 | -neck - multistice S.E. (1 or 2 euros) | - | 35.60 |
| X432 | - multislice I.R. | - | 27.30 |
| X435 | - repeat (another plane, different pulse sequence - max. 2) | - | |
| X441 | -thorax - multislice S.E. (1 or 2 echos) | - | 63.70 |
| X442 | - multislice I.R. | - | 54.70 |
| X445 | - repeat (another plane, different pulse sequence - max. 2) | - | 31.90 |
| X451 | -abdomen - multislice S.E. (1 or 2 echos) | - | 63.70 |
| X452 | - multislice I.R | - | 54.70 |
| X455 | - repeat (another plane, different pulse sequence - max. 2) | ′ - | 31.90 |
| X461 | -pelvis - multislice S.E. (1 or 2 echos) | - | 63.70 |
| X462 | - multislice I.R. | - | 54.70 |
| X465 | - repeat (another plane, different pulse sequence - max. 2) | - | 31.90 |
| X471 | -extremities - multislice S.E. (1 or 2 echos) | - | 54.70 |
| X472 | - multislice I.R. | - | 35.60 |
| X475 | - repeat (another plane, different pulse sequence - max. 2) | - | 27.30 |
| X481 | -spine - multislice S.E. (1 or 2 echos) | - | 63.70 |
| X482 | - multislice I.R | - | 54.70 |
| X485 | - reneat (another plane, different pulse sequence - max. 2) | - | 31.90 |
| X486 | When gating is performed, to listed fee | | |
| | | | |

CLINICAL PROCEDURES, ASSOCIATED WITH DIAGNOSTIC RADIOLOGICAL EXAMINATIONS

- Note: 1. These procedural fees are intended to cover compensation for the professional service of placing an instrument and introducing contrast media if done (except oral or rectal administration for study of the alimentary tract). Injection of materials to enhance the effect of contrast media is included in the procedure benefits.
 - 2. Radiological charges are additional: see similar entries under DIAGNOSTIC RADIOLOGY.
 - Where similar procedures are done for diagnostic physiological studies of non-radiological nature, e.g. cardiac catheterization or intra-arterial infusion, they are listed separately under Surgery or Diagnostic and Therapeutic Procedures. See Index.

| Code | | Sans | Anaes | |
|---------------|---|-------|-----------------|---|
| 0000 | Angiography | Spec. | Prides | |
| | - by catheterization | | | |
| | - abdominal, thoracic, cervical or cranial | | | |
| | Insertion of catheter (including cut down, if necessary) and injection, if | | | |
| 1001 | | | | |
| J021 | given | | 92.60 | 5 |
| J022 | maximum of four), each | | 46.40 | |
| OULL | Selective catheterization (spinal and parathyroid angiography) - add to | • | 40.40 | |
| J014 | catheter insertion fee - per vessel each | | 23.10 | |
| | ("Selective" means manipulation of the catheter from the vessel of intro- | • | 23.10 | |
| | duction into a branch, tributary, or cardiac chamber with angiogram(s)). | | | |
| J031 | Carotid angiogram - direct puncture | | 73.85 | 5 |
| J019 | Non-selective intravenous angiocardiography, including quantification | | 92.60 | 5 |
| 1000 | Transluminal angioplasty including angiography with or without pressure | | | |
| J025 | measurements - one or more sites or vessels | | 241.40 | 5 |
| Note: J048 | J021 & J022 may not be claimed with J025 Percutaneous trans-hepatic catheter portal venography | | 188.30 | 5 |
| J027 | Peripheral arteriogram - direct puncture | | 46.40 | 4 |
| J026 | Peripheral venogram - direct puncture | • • • | 37.20 | 4 |
| 0000 | Selective coronary catheterization including angiogram, see G293 and | •• | 37 020 | _ |
| | (297, page 52 | | | |
| J033 | Splenoportogram | | 73.85 | 4 |
| J034 | Trans-lumbar aortogram | | 73.85 | 5 |
| J032 | Vertebral angiogram - direct puncture or by retrograde brachial injection | | 73.85 | 5 |
| | Embolization e.g. for treatment of hemangiama or renal carcinoma | | | |
| J040 | first vessel, charge appropriate angiographic procedural and radiological fees plus | | 63.70 | |
| J047 | - each addition vessel catheterized and occluded, per vessel | ** | 29.90 | |
| 0047 | Intra-arterial infusion of drugs e.g. for control of gastrointestinal | • • | 27.30 | |
| | haemorrhage - charge appropriate angiographic procedural and radio- | | | |
| J023 | logical fees plus a per diem supervision fee of | | 17.90 | |
| J035 | Pressure measurements during angiography | | 17.90 | |
| J001 | Arthrogram, tenogram or bursogram | | 17.90 | 4 |
| 2004 | Biliary duct calculus manipulation etc see Z562 on page 132. | | 70.00 | _ |
| J024 J044 | Bronchial brushing - unilateral | | 73.85 | 6 |
| J002 | - bilateral Bronchogram - unilateral | | 110.30 22.10 | 6 |
| J043 | - bilateral | | 33.40 | 6 |
| J003 | Bronchogram with intra-tracheal catheter - unilateral | | 45.20 | 6 |
| J042 | - bilateral | | 67.60 | 6 |
| J050 | Carotid or vertebral artery occlusion by detachable balloon - percutaneous | | 202.80 | |
| J005 | Dacrocystogram | | 27.50 | 4 |
| J006 | Discogram - one disc | | 63.70 | 4 |
| J030 | - each additional disc | | 32.80 | _ |
| J049 J036 | Embolization of spinal arteriovenous malformation – percutaneous | | 289.75 17.85 | 5 |
| J008 | Fistula or sinus injection | | 37.20 | 4 |
| J004 | Intramammary needling for localization under mammographic control | | 27.50 | * |
| 300. | Intubation of small intestine - see Z540 on page 129. | | 27.000 | |
| J009 | Laryngogram | | 22.10 | |
| J010 | Lymphangiogram - per side | | 63.70 | |
| J037 | Mammary ductography | • • | 27.50 | |
| J011 | Myelogram | | 63.70 | 4 |
| 1000 | - with supine views requiring removal and re-inroduction of spinal | | 12.00 | |
| J038 J020 | needle, add | | 17.85 17.85 | |
| 0020 | - with horse in increase and | • • | 17.00 | |

THE ONTARIO GAZETTE

CLINICAL PROCEDURES, ASSOCIATED WITH

| | DIAGNOSTIC RADIOLOGICAL EXAMINATIONS | | |
|------|--|--------|-------|
| Code | | Spec. | Anaes |
| | | | |
| J012 | Nephrotomogram | - | 4 |
| J045 | Percutaneous antegrade pyelogram | 73.85 | 4 |
| J055 | Percutaneous Gastrostomy | 135.60 | - |
| J046 | Percutaneous nephrostomy | 135.60 | 4 |
| J041 | Percutaneous removal of intravascular foreign bodies | 178.80 | I.C. |
| J051 | Percutaneous spinal cord puncture for syringogram | 62.75 | 4 |
| J013 | Percutaneous trans-hepatic cholangiogram | 63.70 | 4 |
| J015 | Peritoneal pneumogram | 27.50 | 4 |
| J052 | Positive contrast cisternogram | 82.10 | 4 |
| J017 | Presacral insufflation | 46.40 | 4 |
| J039 | Renal cyst puncture | 73.85 | 4 |
| J018 | Sialogram | 27.50 | 4 |
| J007 | Tomogram | - | 4 |
| | Urethrogram, urethrocystogram, or intestinal conduit examination, nephros- | | |
| J028 | togram, cystogram | 17.85 | |
| J029 | Vasogram | 49.30 | 4 |

DIAGNOSTIC ULTRASOUND

T and P Columns should be interpreted in the spirit of the first two paragraphs on page 39, but without limiting the performance of these tests to suitably trained physicians of any one specialty. Furthermore, the physician must be physically available to approve, modify or intervene in the examination as required or the examination must be completely recorded by video/computer methods and reviewed in its entirety by the physician. No fee (either professional or technical) may be charged if the physician's only involvement is the interpretation of hard copy (films).

Notes: A-Mode-implies a one-dimensional ultrasonic measurement procedure.

A-Mode-implies a one-dimensional ultrasonic measurement procedure.

M-Mode-implies a one-dimensional ultrasonic measurement procedure with movement of the trace to record amplitude and velocity of moving echo-producing structures.

Scan B-Mode-implies a two-dimensional ultrasonic scanning procedure with a two-dimensional display. All ultrasound examinations include a permanent record

and interpretative report.

The total benefit is arrived at by adding T plus P. When coding the total benefit use suffix A; when coding the technical portion only use suffix B; when coding the

professional portion only use suffix C.

| Code | Head and Neck | T | Р |
|----------------------|--|-------------------------|-------------------------|
| J100 J122 | Echoencephalography - midline, A-mode | \$ 43.30 | 4.25 25.80 |
| J102 J103 J107 | Quantitative, A-mode B-scan immersion B-scan contact | 21.90 42.90 21.70 | 33.10 44.00 21.80 |
| J108 J105 | Biometry (Axial length - A-mode) Face and/or neck (excluding vascular study) | 28.50 43.30 | 22.20 25.80 |
| J106 | Paranasal sinuses, A-mode | 5.90 | 2.50 |
| | Heart - echocardiography (see listings on page 54) | | |
| J125 | Thorax chest masses, pleural effusion - A & B-mode | 44.60 | 26.60 |
| J135 | Abdomen and Retroperitoneum Abdominal scan, complete | 44.60 | 26.60 |
| J128 | Abdominal scan, limited study (e.g. gailbladder only, aorta only or follow-up study) | 29.40 | 17.60 |
| | Pelvis | | |
| J159 J162 | Pregnancy, complete Pelvis, complete Pelvis or pregnancy, limited study (e.g. fetal age determination, placen- | 44.60 44.60 | 26.60 26.60 |
| J163 | tal localization, I.U.C.D. localization) | 29.40 | 17.60 |
| 200 | Vascular System Extra-cranial vessel assessment (bilateral carotid and/or subclavian and/or | | |
| J190 J191 J192 | vetebral arteries) - Doppler scan or B scan | 9.10 | 18.60 18.60 25.40 |
| J201 | - Duplex scan i.e. simultaneous real time, B mode imaging and spectral analysis | | 36.00 |
| J193 J194 | Peripheral artery evaluation (not to be billed routinely with J190, J191 or J192) - Doppler scan or 8 scan, unilateral | | 15.40 |
| J194 J195 | - frequency analysis, unilateral 1 - frequency analysis with Doppler scan, unilateral 2 - Duplex scan i.e. simultaneous real time, B-mode imaging and spectral | 3.50 5.40 | 12.70 21.20 |
| J202 | analysis, unilateral | 0.30 | 18.00 |
| J198 | permanent record) not chargeable during surgery or during patient's post operative stay in hospital | 6.75 | 10.30 |
| | | | |

DIAGNOSTIC ULTRASOUND

| Code | | T | Р |
|------|--|-------|-------|
| | | | |
| | Vascular laboratory fees | | |
| | Ankle pressure determination - not chargeable during surgery or during the | | |
| J199 | patients' post operative stay in hospital | | 8.40 |
| | Ankle pressure measurements with segmental pressure recordings and/or | | |
| J200 | pulse volume recordings and/or Doppler recordings | 18.70 | 23.75 |
| | Ankle pressure measurements with exercise and/or quantitative measure- | | |
| J196 | ments added to the above | 7.30 | 11.20 |
| J197 | Penile pressure recordings - two or more pressures | 6.30 | 8.40 |
| | | | |
| | Miscellaneous | | |
| J180 | Echography for placement of radiation therapy fields, scan B-mode | 32.20 | 20.50 |
| J182 | Extremities - per limb (excluding vascular study) | 21.60 | 12.90 |
| J127 | | 21,60 | 12.90 |
| J183 | Testicular scan - per testis | 21.60 | 12.90 |
| 0100 | Ultrasonic guidance of biopsy, aspiration, amniocentesis or drainage | 22400 | 12,50 |
| J149 | | 43.30 | 25,80 |
| 0149 | procedures (one physician only) | 43.30 | 23.00 |

PULMONARY FUNCTION STUDIES

Column T - The benefit for testing including supplying of equipment, premises and technical services.

Column P - the benefit for professional services including responsibility for quality control and technician training, interpretation of the results of the tests, and consultation between the physician responsible for the tests and the referring physician concerning the results of the test.

Notes: 1. The total benefit is obtained by adding columns T and P together. When coding the total benefit use suffix A; when coding the technical portion use only suffix B; when coding the professional portion only use suffix C.

The benefits for J301, J324, J304 and J327 must be performed with a permanent record and represent the best of three recorded test results with or without bronchodilator.

Vital capacity, J301, and flow volume loop, J304, cannot be claimed at the same time.
 Each of the following tests designated by an individual code number is considered to be specific and requires individual ordering.

 Exercise assessment (J315, E450, E451, J316, J317) requires a physician to be in attendance at all times.

| | 6. J309 and J310 cannot be claimed at the same time. | | |
|-------|---|--------|--------|
| Code | | T | Р |
| | | | |
| | Vital capacity, FEV, FEV, FVC with or without MMEFR(FEF 25-75) calcula- | | |
| J301 | tion | 8,60 | 6.50 |
| J324 | Repeat J301 after homochodilator | 2.60 | 2.60 |
| J304 | Flow volume loop (FVC, FEV ₁ , FEV ₁ /FVC, V ₅₀ , V ₂₅) Repeat J304 after bronchodilator | 17.30 | 12.30 |
| J327 | Repeat J304 after bronchod lator 50° 25° | 2.60 | 2.60 |
| J311 | Functional residual capacity by gas dilution method | 15.10 | 13.30 |
| J307 | Functional residual capacity by body plethysmography | 16.20 | |
| J305 | Lung compliance (pressure volume curve of the lung from TLC to FRC) | | 13.50 |
| 0.500 | | 48.20 | 41.00 |
| J306 | Airways resistance by plethysmography or estimated using esophageal catheter | 34.05 | 10.00 |
| J340 | | 14.95 | 12.20 |
| | Maximum inspiratory and expiratory pressures | 2,50 | 1.70 |
| J309 | Carbon monoxide diffusing capacity by steady state at rest | 10.00 | 7.60 |
| J310 | Carbon monoxide diffusing capacity by single breath method | 19.90 | 13.70 |
| J308 | Carbon dioxide ventilatory response | 18.50 | 12.40 |
| J328 | Oxygen ventilatory response (physician must be present) | 18.50 | 18.50 |
| | Stage I: Graded exercise to maximum tolerance exercise (must include | | |
| | continuous heart rate and ventilation at rest and at each work- | | |
| J315 | load) | 46.00 | 30.70 |
| E450 | J315 plus J301 or J304 before and/or after exercise, add | 12.30 | 6.20 |
| | J315 plus 12 lead E.C.G. done at rest, used for monitoring during the | | |
| E451 | exercise and followed for at least 5 minutes post exercise, add | 16.75 | 19.40 |
| | Stage II: Repeated steady state graded exercise (must include heart rate, | | |
| | ventilation, VO2, VCO2, BP, ECG, end tidal and mixed venous | | |
| | 2. 2. | | |
| J316 | OD, at rest, 3 levels of exercise and recovery) | 121.40 | 56.90 |
| J317 | Stage III: J316 plus arterial blood gases, pH and bicarbonate or lactate | 160.90 | 96.70 |
| | Assessment of exercise induced asthma (workload sufficient to achieve | | |
| | * heart rate 85% of predicted maximum; performance of J301 or J304 | | |
| J330 | before exercise and 5-10 minutes post exercise) | 30.80 | 18.60 |
| G479 | Arterial puncture for blood gas analysis | 50.00 | 7.80 |
| J319 | Blood gas analysis: pH, PO ₂ , PCO ₂ , bicarbonate and base excess | 10.40 | 7.00 |
| J318 | Arterialized venous blood sample collection (e.g. ear lobe) | 3.50 | - |
| 0010 | A-a oxygen gradient requiring measurement of RO by sampling mixed expired | 5.50 | |
| J320 | | 25.50 | 9.80 |
| J331 | gas and using alveolar air equation | | |
| J313 | Estimate of shunt (Qs/Qt) breathing pure oxygen | 25.50 | 12.80 |
| | Mixed venous PCO2, by the rebreathing method | 10.40 | 3.50 |
| J323 | 0, saturation by eximeter at rest, with or without 0, | 9.70 | 4.90 |
| J332 | Okygen saturation by oximeter at rest, at exercise of during sleep | 14.70 | 7.45 |
| J334 | J332 with supplemental O ₂ | 22.40 | 11.40 |
| J322 | Standard 0, consumption and CO, production | 24.70 | 6.40 |
| 1000 | Non-specific bronchial provocative test (histamine, methylcholine, thermal | | |
| J333 | challenge) | 35.75 | 26.30 |
| J335 | Antigen challenge test | 48.00 | 26.30 |
| | Sleep apnea (overnight) study with continuous monitoring of oxygen | | |
| | saturation and ventilation by plethysmography and with technician | | |
| | attendance during study period; to include physician attendance at set | | |
| | up, monitoring and interpretation (special visit premiums | | |
| J339 | not chargeable) | 212.00 | 112.80 |
| J336 | Interpretation of J339 only | 212.00 | 41.90 |
| | Same as J339 plus additional monitoring to stage sleep | | |
| | (e.g., E.E.G., E.O.G.) and continuous monitoring of E.C.G., | | |
| J337 | add to J339 when both performed | 127.20 | 41.90 |
| J338 | Interpretation of J337 only, add to J336 when both performed | 127.20 | 17.40 |
| | , | | |

Code With a few exceptions specifically indicated below, the listed procedural benefits are for the procedure(s) alone. Consultations or visit benefits when such services are rendered, may be claimed in addition to the procedural benefits.

When a procedure(s) is the sole reason for a visit, add \$4.30 basic fee per visit for those procedures marked (+) regardless of the number of procedures carried out during that visit. However, if the patient visit is to a physician's office or a diagnostic facility controlled directly or indirectly by a physician who has examined (or is about to examine the patient) and referred the patient to such a diagnostic facility, no basic fee should be claimed under these circumstances.

Note: G700 is not payable to a hospital department. Fee Schedule Interpretations $% \left(1\right) =\left(1\right) \left(1\right)$

- 1. Urinalysis and other laboratory tests listed on page 64, apply when these services are performed by a physician in his office with or without an associated consultation or visit. The same tests listed in the Laboratory Medicine Section of the Schedule apply to licensed laboratories.
- 2. Some fees for Diagnostic and Therapeutic Procedures have the technical and professional components listed separately. The technical component includes the salaries of support staff, equipment depreciation or lease costs, supplies and costs associated with the preparation of a written report. The professional component includes the clinical supervision of the diagnostic facility, interpretation of the test results and a written report. When only one fee is listed for a service, it represents the professional component only.
- 3. The Preamble applicable to Surgical Procedures also applies, where appropriate, to Diagnostic and Therapeutic Procedures.

ALL FRGY

Note: If a patient presents for an allergy injection and has an acute infectious condition, albeit of the respiratory system, or some other unnelated condition which would have otherwise required a separate office visit, the physician is entitled to charge the appropriate assessment fee as well as the injection fee. If a patient requires a brief assessment of his allergic condition as well as the allergy injection, the physician should bill the injection and basic fees.

| Acute desensitization; e.g., ATS, penicillin 7.45 G201 Direct nasal tests, \$1.31 each, maximum 3.93 Hyposensitization, including assessment and supervision (one or more injections) 7.60 G202 - when sole reason for visit (G700 plus G202) 7.60 Insect venom desensitization (immunotherapy) - pen injection (to a maximum of 5 per patient per diem. In addition to G205, after the initial major assessment, a minor or partial assessment may be claimed once per day if rendered 1.00 G203 (Ophthalmic tests - direct, \$1.31 each, maximum 3.93 - quantitative 10.50 G206 Patch test, \$1.31 each, maximum of 35 per year 10.50 G207 Bronchial provocative testing - per session (limit of 6 sessions per patient) Skin tests provided in physician's office or hospital including physician interpretation \$0.65 cents each - technical component, maximum 7.50 Insect venom skin testing provided in physician's office or hospital including physician interpretation \$0.15 cents each - professional component, maximum 7.50 Insect venom skin testing provided in physician's office or hospital including physician interpretation, \$1.06 each, maximum 1.50 G209 Penicillin hypersensitivity skin test, \$0.90 each, maximum 1.50 ANAESTHESIA Examination Under Anaesthesia - when sole procedure performed not otherwise listed in the Schedule. With or without intubation (diagnosis required) 7.80 CARDIOVASQULAR Vascular Cannulation G479 Arterial princture 7.80 CARDIOVASQULAR Vascular Cannulation Garpon central vein; e.g., for pressure measurements or for feeding line, including cut down as necessary 7.90 G268 Or feeding line, including cut down as necessary 7.90 | | | Proced. | |
|---|-------|---|---------|--------|
| Direct nasal tests, \$1.31 each, maximum | | | | Anaes. |
| Hyposensitization, including assessment and supervision (one or more injections) - when sole reason for visit (G700 plus G202) | +G200 | | | |
| ### 16202 injections) G212 - when sole reason for visit (G700 plus G202) Insect verom desensitization (immunotherapy) - per injection (to a maximum of 5 per patient per diem. In addition to G205, after the initial major assessment, a minor or partial assessment may be claimed once per day if rendered | +G201 | | 3.93 | |
| Table Tabl | | Hyposensitization, including assessment and supervision (one or more | | |
| Table Tabl | +G202 | injections) | 3.30 | |
| Insect venom desensitization (immunotherapy) - per injection (to a maximum of 5 per patient per diem. In addition to 6205, after the initial major assessment, a minor or partial assessment may be claimed once per day if rendered 11.00 6203 Ophthalmic tests - direct, \$1.31 each, maximum 3.93 45204 - quantitative 10.50 6206 Patch test, \$1.31 each, maximum of 35 per year 10.50 6207 Patch test, \$1.31 each, maximum of 50 per year for industrial or occupational dermatoses 72.00 6208 Fonnchial provocative testing - per session (limit of 6 sessions per patient) Skin tests provided in physician's office or hospital including physician interpretation \$0.65 cents each - technical component, maximum 7.50 Insect verom skin testing provided in physician's office or hospital including physician interpretation, \$1.06 each, maximum 7.50 Insect verom skin testing provided in physician's office or hospital including physician interpretation, \$1.06 each, maximum 7.50 Insect verom skin testing provided in physician's office or hospital including physician interpretation, \$1.06 each, maximum 7.50 Insect verom skin testing provided in physician's office or hospital including physician interpretation, \$1.06 each, maximum 7.50 Insect verom skin testing provided in physician's office or hospital including physician interpretation, \$1.06 each, maximum 7.50 Insect verom skin testing provided in physician's office or hospital including or all anaesthetic hypersensitivity skin test, \$0.90 each, maximum 7.50 ANAESTHESIA Examination Under Anaesthesia – when sole procedure performed not otherwise listed in the Schedule, with or without intubation (diagnosis required) | G212 | - when sole reason for visit (G700 plus G202) | 7,60 | |
| of 5 per patient per diem. In addition to G205, after the initial major assessment, a minor or partial assessment may be claimed once per day if rendered | | | | |
| assessment, a minor or partial assessment may be claimed once per day if rendered Ophthalmic tests - direct, \$1.31 each, maximum | | | | |
| G205 if rendered G206 Ophthalmic tests - direct, \$1.31 each, maximum G206 Patch test, \$1.31 each, maximum of 35 per year G206 Patch test, \$1.31 each, maximum of 35 per year G207 Patch test, \$1.31 each, maximum of 50 per year for industrial or occupational dermatoses G208 Bronchial provocative testing - per session (limit of 6 sessions per patient) Skin tests provided in physician's office or hospital including physician G209 interpretation \$0.65 cents each - technical component, maximum G209 S0.15 cents each - professional component, maximum G209 Insect verom skin testing provided in physician's office or hospital including physician interpretation, \$1.06 each, maximum G209 Local anaesthetic hypersensitivity skin test, \$0.90 each, maximum of 25 per year G209 Penicillin hypersensitivity skin test, \$0.90 each, maximum of 25 per year G209 Penicillin hypersensitivity skin test, \$0.90 each, maximum of 15 per year G200 Penicillin hypersensitivity skin test, \$0.90 each, maximum of 15 per year G200 WAMESTHESIA Examination Under Anaesthesia - when sole procedure performed not otherwise listed in the Schedule, With or without intubation (diagnosis required) G200 Arterial puncture G201 Arterial puncture G202 Arterial puncture G203 Unbilical artery or central vein; e.g., for pressure measurements or G203 Unbilical artery catheterization (including obtaining of blood sample) G200 S200 Unbilical artery catheterization (including obtaining of blood sample) G201 S200 S200 S200 S200 S200 S200 S200 S | | | | |
| Ophthalmic tests - direct, \$1.31 each, maximum | 6205 | | 11.00 | |
| - quantitative — quantitative — 10.50 Record Patch test, \$1.31 each, maximum of 35 per year — 45.85 \$1.44 each, maximum of 50 per year for industrial or occupational dermatoses — 72.00 Record Bronchial provocative testing – per session (limit of 6 sessions per patient) 12.00 Skin tests provided in physician's office or hospital including physician interpretation \$0.65 cents each – technical component, maximum — 32.50 Group — 30.15 cents each – professional component, maximum — 7.50 Insect verom skin testing provided in physician's office or hospital including physician interpretation, \$1.06 each, maximum — 31.80 Local anaesthetic hypersensitivity skin test, \$0.90 each, maximum of 25 per year — 22.50 Group — 22.50 ANAESTHESIA Examination Under Anaesthesia – when sole procedure performed not otherwise listed in the Schedule. With or without intubation (diagnosis required) — 45.50 CARDIOVASQULAR Vascular Cannulation Group Arterial puncture — 7.80 Cannulation of artery or central vein; e.g., for pressure measurements or 26.70 Group Horizon — 26.70 Group — 26. | | | | |
| As 2.50 Patch test, \$1.31 each, maximum of 35 per year \$1.44 each, maximum of 50 per year for industrial or occupational dematoses tional dematoses Roccord Bronchial provocative testing – per session (limit of 6 sessions per patient) Skin tests provided in physician's office or hospital including physician \$2.00 \$3.15 cents each – technical component, maximum \$3.50 \$3.15 cents each – professional component, maximum \$3.50 Insect verom skin testing provided in physician's office or hospital including physician interpretation, \$1.06 each, maximum \$3.80 Local anaesthetic hypersensitivity skin test, \$0.90 each, maximum of 25 per year \$3.80 ANAESTHESIA Examination Under Anaesthesia – when sole procedure performed not otherwise listed in the Schedule. with or without intubation (diagnosis required) ASSOULAR Vascular Cannulation \$4.80 CARDIOVASQULAR Vascular Cannulation G479 Arterial princture Cannulation of artery or central vein; e.g., for pressure measurements or Cannulation of artery or central vein; e.g., for pressure measurements or Gannulation artery catheterization (including obtaining of blood sample) 38.80 | | | | |
| \$1.44 each, maximum of 50 per year for industrial or occupational dermatoses. Ronchial provocative testing - per session (limit of 6 sessions per patient) 12.00 Skin tests provided in physician's office or hospital including physician interpretation \$0.65 cents each - technical component, maximum 32.50 G197 Insect verom skin testing provided in physician's office or hospital including physician interpretation, \$1.06 each, maximum 7.50 Insect verom skin testing provided in physician's office or hospital including physician interpretation, \$1.06 each, maximum 31.80 Local anaesthetic hypersensitivity skin test, \$0.90 each, maximum of 25 per year 22.50 G195 Penicillin hypersensitivity skin test, \$0.90 each, maximum of 15 per year 13.50 ANAESTHESIA Examination Under Anaesthesia - when sole procedure performed not otherwise listed in the Schedule. G260 With or without intubation (diagnosis required) | | | | |
| fige tional demmatoses 72.00 ### ### ### ### ### ### ### ### ### | 6206 | | 45.85 | |
| #6207 Bronchial provocative testing - per session (limit of 6 sessions per patient) Skin tests provided in physician's office or hospital including physician interpretation \$0.65 cents each - technical component, maximum. \$0.15 cents each - professional component, maximum. 7.50 Insect verom skin testing provided in physician's office or hospital including physician interpretation, \$1.06 each, maximum. 31.80 Local anaesthetic hypersensitivity skin test, \$0.90 each, maximum of 25 per year Penicillin hypersensitivity skin test, \$0.90 each, maximum of 15 per year. ANAESTHESIA Examination Under Anaesthesia - when sole procedure performed not otherwise listed in the Schedule. with or without intubation (diagnosis required). 45.50 CARDIOVASQULAR Vascular Cannulation G479 Arterial puncture. Cannulation of artery or central vein; e.g., for pressure measurements or Cansulation of artery or central vein; e.g., for pressure measurements or G58 for feeding line, including cut down as necessary. 26.70 G309 Unbilical artery catheterization (including obtaining of blood sample). 32.50 32.50 32.50 32.50 34.80 | | | 70.00 | |
| Skin tests provided in physician's office or hospital including physician interpretation \$0.65 cents each - technical component, maximum | | | | |
| interpretation \$0.65 cents each - technical component, maximum | +G207 | | 12.00 | |
| G197 \$0.15 cents each - professional component, maximum | | | | |
| Insect verom skin testing provided in physician's office or hospital including physician interpretation, \$1.06 each, maximum | G209 | | 32.50 | |
| ding physician interpretation, \$1.06 each, maximum | G197 | \$0.15 cents each - professional component, maximum | 7.50 | |
| Local anaesthetic hypersensitivity skin test, \$0.90 each, maximum of 25 per year | | Insect verom skin testing provided in physician's office or hospital inclu- | | |
| Local anaesthetic hypersensitivity skin test, \$0.90 each, maximum of 25 per year | G199 | ding physician interpretation, \$1.06 each, maximum | 31.80 | |
| G195 year 22.50 G196 Penicillin hypersensitivity skin test, \$0.90 each, maximum of 15 per year 13.50 ANAESTHESIA Examination Under Anaesthesia - when sole procedure performed not otherwise listed in the Schedule. G260 with or without intubation (diagnosis required) | | | | |
| ANAESTHESIA Examination Under Anaesthesia - when sole procedure performed not otherwise listed in the Schedule. G260 with or without intubation (diagnosis required) | G195 | | 22,50 | |
| ANAESTHESIA Examination Under Anaesthesia - when sole procedure performed not otherwise listed in the Schedule. G260 with or without intubation (diagnosis required) | | Ponicillin hyperconsitivity skin test \$0.00 each maximum of 15 per war | | |
| Examination Under Anaesthesia - when sole procedure performed not otherwise listed in the Schedule. G260 with or without intubation (diagnosis required) | 0130 | remembers and the sense of the | 10.00 | |
| Examination Under Anaesthesia - when sole procedure performed not otherwise listed in the Schedule. G260 with or without intubation (diagnosis required) | | ANACCTICCIA | | |
| otherwise listed in the Schedule. G260 with or without intubation (diagnosis required) | | | | |
| CARDIOVASCULAR Vascular Cannulation Cannulation of artery or central vein; e.g., for pressure measurements or Cansulation of artery or central vein; e.g., for pressure measurements or Cansulation of artery or central vein; e.g., for pressure measurements or Cansulation of artery or central vein; e.g., for pressure measurements or Cansulation of artery or central vein; e.g., for pressure measurements or Cansulation of artery or central vein; e.g., for pressure measurements or Cansulation of artery or central vein; e.g., for pressure measurements or Cansulation of artery or central vein; e.g., for pressure measurements or Cansulation of artery or central vein; e.g., for pressure measurements or Cansulation of artery or central vein; e.g., for pressure measurements or Cansulation of artery or central vein; e.g., for pressure measurements or Cansulation of artery or central vein; e.g., for pressure measurements or Cansulation of artery or central vein; e.g., for pressure measurements or Cansulation of artery or central vein; e.g., for pressure measurements or Cansulation of artery or central vein; e.g., for pressure measurements or Cansulation of artery or central vein; e.g., for pressure measurements or Cansulation of artery or central vein; e.g., for pressure measurements or Cansulation of artery or central vein; e.g., for pressure measurements or Cansulation of artery or central vein; e.g., for pressure measurements or Cansulation of artery or central vein; e.g., for pressure measurements or Cansulation of artery or central vein; e.g., for pressure measurements or Cansulation of artery or central vein; e.g., for pressure measurements or Cansulation of artery or central vein; e.g., for pressure measurements or Cansulation of artery or central vein; e.g., for pressure measurements or Cansulation or central vein; e.g., for pressure measurements or central vein; e.g., for pressure measurements or central vein; e.g., for pressure measurements or central vein; e.g., for pressure measurements or central vein; e.g., for | | | | |
| CARDIOVASCULAR Vascular Cannulation G479 Arterial puncture 7.80 Cannulation of artery or central vein; e.g., for pressure measurements or C268 for feeding line, including cut down as necessary 26.70 G309 Unbilical artery catheterization (including obtaining of blood sample) 38.80 | 0000 | | 45 50 | 4 |
| Vascular Cannulation G479 Arterial puncture Cannulation of artery or central vein; e.g., for pressure measurements or G268 for feeding line, including cut down as necessary G309 Umbilical artery catheterization (including obtaining of blood sample) 38.80 | 6260 | with or without intubation (diagnosis required) | ,45.50 | 4 |
| Vascular Cannulation G479 Arterial puncture Cannulation of artery or central vein; e.g., for pressure measurements or G268 for feeding line, including cut down as necessary G309 Umbilical artery catheterization (including obtaining of blood sample) 38.80 | | | | |
| G479 Arterial puncture 7.80 Cannulation of artery or central vein; e.g., for pressure measurements or 26.70 G309 Unbilical artery catheterization (including obtaining of blood sample) 38.80 | | | | |
| Cannulation of artery or central vein; e.g., for pressure measurements or G268 for feeding line, including cut down as necessary | | Vascular Cannulation | | |
| G268 for feeding line, including cut down as necessary | G479 | | 7.80 | |
| G309 Umbilical artery catheterization (including obtaining of blood sample) 38.80 | | Cannulation of artery or central vein; e.g., for pressure measurements or | | |
| | G268 | | 26.70 | |
| | G309 | Umbilical artery catheterization (including obtaining of blood sample) | 38.80 | |
| | | | 7.90 | |

| | | Desced | |
|---------------|---|-----------------------|----|
| Code | | Proced. Fee Anaes. | |
| | CARDIOVASCULAR - Cont'd. | | |
| +G482 | - child | 5 40 | |
| +G489 | - adolescent or adult | 5.40 1.90 | |
| +G483 | Therapeutic venisection | 8.20 | |
| G232 | Unbilical vein catheterization (including obtaining of blood sample) | 16.95 | |
| | Insertion of Swan-Ganz catheter (not included in anaesthetic, respiratory | | |
| G287 Note: | or critical care benefits) | 139.30 | 4 |
| NOCE. | - when dye dilution densitometry done in addition, add to a max, of 3 | | |
| G304 | times per Swan-Ganz insertion | 42.40 | |
| | Thermal Dilution studies (- when thermal dilution studies are done in add | | |
| G360 | ition add to a maximum of 3 times per Swan Ganz insertion) | 42.40 | |
| G398 G399 | Insertion of permanent feeding line; e.g., Hickman or Broviac catheter | 115.50 | 4 |
| G312 | Surgical removal of Hickman or Broviac catheter Insertion of subcutaneous venous access reservoir (chemoshunt) | 33.60 115.50 | 4 |
| G317 | - revision same site | 50.80 | 4 |
| G271 | Anticoagulant supervision - long term, telephone advice - per month | 9.00 | |
| | | | |
| | Blood Transfusions: | | |
| G279 | Indirect transfusion | 16.00 | |
| 62/5 | Exchange transfusion (procedure only) | 174.50 | |
| G280 | Assistant at exchange transfusion (see Preamble - page xi, item 36(g)) Intra-uterine foetal transfusion - initial or subsequent | 158.90 | |
| | Donor cell pheresis (platelets or leukocytes) | 13.10 | |
| | Therapeutic plasma exchange | 2002 | |
| G277 | Initial and repeat, to a maximum of 5 per year, each | 63.50 | |
| G278 | - more than 5 per year, each | 32.35 | |
| G2/2 | Manual plasmapheresis | I.C. | |
| | Cardioversion: | | |
| G285 | Cardioversion (electrical) - limit of three sessions per patient, per day | 56.10 | 5 |
| | , , , , , , , , , , , , , , , , , , , | | |
| | Cardiac Catheterization | | |
| | When more than one procedure is carried out at one sitting, the additional | | |
| | procedures are to be charged at 50% of the listed benefits. | | |
| | Hemodynamic/Flow/Metabolic Studies | | |
| G290 | Right heart - pressures only | 131.10 | 5 |
| | Left heart - retrograde aortic | 165.50 | 5 |
| G292 | - transeptal | 233.50 | 5 |
| G296 | Dye dilution densitometry and/or thermal dilution studies - benefit covers all studies on same day in cath lab | 87.20 | |
| | When G296 is done in addition to G287 use Code G304 instead | 137 220 | |
| G299 | Oxymetry | 87.20 | |
| G289 | Fick determination | 87.20 | |
| G300 | Metabolic studies; e.g., coronary sinus lactate and pyruvate determinations | 87.20 | |
| G301 | | 96.25 | |
| 6305 | Isotope studies during cardiac catheterization | 87.20 96.25 | |
| 3303 | Intracardiac phonocardiography | 70.23 | |
| | Angiography | | |
| G297 | Angiograms (any number of injections) | 96.25 | |
| | Bypass graft angiogram (including internal mammary artery implant) | co co | |
| G509 G293 | - per graft injection | 63.50 228.55 | |
| 6263 | Selective coronary catheterization - both arteries | 77.00 | |
| Œ | Transluminal coronary angioplasty, including angiography with or without | 77.00 | |
| G265 | pressure measurements, one or more sites or (on a single vessel) | 339.10 | 5 |
| 6262 | - each additional vessel, add | 169.60 | |
| 0201 | Percutaneous angioplasty including angiography with or without pressure | 100 00 | 00 |
| G321 G322 | measurements on aortic valve, pulmonic valve, pulmonary branch stenosis - for coarctation of aorta | 409.60 327.70 | 20 |
| الكاكلا | - IUI CUDICUDUIUI UI DUICD | 367.70 | 20 |
| | Electrophysiology/Pacing | | |
| | Endocardial mapping studies (does not include G267 or G294) | 218.30 | 5 |
| | Intracardiac electrocardiography and/or atrial pacing | 87.20 | |
| 626/ | HIS bundle ECG | 145.40 | |
| G266 | with or without HIS bundle ECG | 196,60 | |
| | Insertion of temporary endocardial electrode | 131.10 | 5 |
| | Repositioning of temporary endocardial electrode | 54.70 | 5 |
| | | | |
| 0000 | Endomyocardial Biopsy | 145 40 | |
| U2005 | Endomyocardial biopsy - transvascular, right or left | 145.40 | |

| | D11 00 00 11 00 11 00 00 00 00 00 00 00 0 | Pro | ced. |
|-------|--|----------------|-------|
| Code | | Fee | Anaes |
| | CARDIOVASCULAR - Cont'd. | | |
| | Electrocardiography - professional component must include pertinent | | |
| | written interpretation | | |
| G313 | E.C.G professional component | 8.30 | |
| +G310 | - technical component | 6.10 | |
| | Maximal stress E.C.G. (exhaustion, symptoms or E.C.G. changes) or submaximal | | |
| | stress E.C.G. (to target heart rate for patient) by a standard technique - | | |
| | with treadmill or ergometer and oscilloscopic continuous monitoring includ- | | |
| | ing E.C.G's taken during the procedure and resting E.C.G's before and after | | |
| | the procedure - physician must be in attendance at all times. The profes- | | |
| | sional component includes the necessary clinical assessment immediately | | |
| G315 | prior to testing. | 20.50 | |
| G319 | - technical component | 30.50 48.30 | |
| G316 | Vector - technical component | 15.70 | |
| G335 | - professional component | 8.80 | |
| 0000 | - professional carporate | 0.00 | |
| | Continuous ECG Monitoring; e.g., Holter | | |
| | Level 1 - Requires a recorder capable of recording or analyzing all beats and | | |
| | transmitting this information to a scanner which is capable of analyzing or | | |
| | printing every beat and also performing a trend analysis on the 12 or 24 | | |
| | hour tape period. | | |
| | Level 2 - Requires a recorder capable of recording only a portion of each | | |
| | minute or a predetermined time period after an abnormal complex is sensed. | | |
| | The scanner of this recorder is capable of analyzing this tape and printing | | |
| | out all beats in the predetermined time period analyzing - the ST segment, | | |
| | heart rate and ventricular premature beat frequency. | | |
| | Level 3 - Requires a recorder capable of recording beats for only a portion of | | |
| | a minute and feeding this information into a scanner through an adapter | | |
| | that feeds the information through the standard E.C.G. machine. | | |
| G650 | Level 1 - professional component | 41.00 | |
| G651 | - technical component - recording | 22.20 | |
| G652 | - scanning | 30.50 | |
| G653 | Level 2 - professional component | 29.70 | |
| G654 | - technical component - recording | 21.60 | |
| G655 | - scanning | 14.80 | |
| G656 | Level 3 - professional component | 19.70 | |
| G657 | - technical component - recording | 14.80 | |
| G658 | - scanning | 9.90 | |
| | Interpretation of telephone transmitted E.C.G. rhythm strip | | |
| G320 | - professional component (must include pertinent writen interpretation). | 3.60 | |
| G311 | - technical component | 1.80 | |
| 0000 | Single chamber reprogramming including electrocardiography | 0.10 | |
| G283 | - professional component | 8.10 | |
| G284 | - technical component | 8.10 | |
| 0100 | Dual chamber reprogramming including electrcardiography | 12,10 | |
| G180 | - professional component | | |
| G181 | - technical component | 10.80 | |
| G307 | - professional component | 8.10 | |
| G308 | - technical component | 8.10 | |
| 3300 | - GOURTIOUT COMPAREIU seesseesseesseesseesseesseesseesseesse | 0.10 | |
| | Non Invasive Cardiography: | | |
| Note: | When more than one procedure of items marked (*) are performed at one sitting, | | |
| | the major procedure is to be claimed at full benefit and the remainder at | | |
| | 50% of the listed benefit(s). | | |
| | *Phonocardiogram - multiple channel (not less than 3 channels) | | |
| G504 | - professional component | 14.80 | |
| G505 | - technical component | 36.00 | |
| G506 | (with pharmacologic intervention), add | 7.40 | |
| G507 | *Apex cardiogram - professional component | 9.00 | |
| G508 | - technical component | 9.00 | |
| Note: | Fees for apex cardiography and E.C.G. may be charged when both | | |
| | services are rendered. | | |
| | | | |

| | DIAGNOSTIC AND THERAPEUTIC PROCEDURES | | |
|-------|--|--------|-------|
| Code | | _ | Anne |
| | | Fee | Anaes |
| | CARDIOVASCULAR - Cont'd. | | |
| | | | |
| | Blood Flow Study (Doppler or other) - uni or bilateral | | |
| | *Phlebography and/or carotid pulse tracing (with systolic time intervals) | | |
| G518 | - professional component | 9.60 | |
| C519 | - technical component | 9.60 | |
| G502 | Carotid phonoangiography - professional component | 9.00 | |
| G503 | Oculoplethysmography - professional component | 9.00 | |
| G120 | Impedance plethysmography - professional component | 5,85 | |
| G121 | - technical component | 11.60 | |
| | Echacadianeach. | | |
| | Echocardiography Professional components: P ₁ is the professional fee for the performance | | |
| | of some or all of the procedure by a suitably trained physician or | | |
| | alternatively, the same physician being physically present in the echo- | | |
| | cardiography laboratory to supervise the procedure, interpret the | | |
| | | | |
| | results and provide a written report. P ₂ is the professional fee for interpretation of the results (the video tape must be reviewed in its | | |
| | entirety by the physician) and provision of a written report by a | | |
| | suitably trained physician. | | |
| | Complete study - 1 dim technical component | 32.60 | |
| G561 | - professional component (P ₁) | 31.50 | |
| G562 | - professional component (P2) | 23.30 | |
| G566 | = / (I)ML = TeChn1(A) COMMONENT | 55.95 | |
| 0567 | - professional component (P ₁) - professional component (P ₂) - 1 and 2 dim - technical component | 49.60 | |
| G568 | - professional component (P2) | 37.30 | |
| G570 | a did a dillie decentari componente essessioni essessioni | 71.80 | |
| G571 | - professional component (P ₁) - professional component (P ₂) | 65.70 | |
| 0572 | Limited study - 1 or 2 dim. for follow up studies - not to be charged in | 49.15 | |
| G574 | conjunction with pregnancy study - technical component | 15.50 | |
| G575 | - professional component (P ₁ or P ₂) | 15.50 | |
| ۵, ۵ | Cardiac Doppler study in conjunction with complete 12 and 2 dim. echocardio- | 13.30 | |
| G577 | graphy studies - technical component | 42,40 | |
| G578 | - professional component (P ₁) | 32.80 | |
| G579 | Saline study (including venipuncture) - professional component (P ₁) | 10.15 | |
| | | | |
| | Peripheral Arterial and Venous Systems - see listings under Diagnostic | | |
| | Ultrasound. | | |
| | | | |
| | CRITICAL CARE | | |
| | Life Threatening Emergency Situation - Resuscitation in emergency situation | | |
| | (cardiac arrest, massive injury, cardio-respiratory failure, resuscita- | | |
| | tion of newborn (see Preamble relating to Obstetrics), severe shock, coma) includes immediate crisis related examination and usual | | |
| | resuscitative measures and to include as required, defibrillation, | | |
| | cardioversion, cut downs, intravenous-lines, arterial and/or venous | | |
| | catheters, pressure infusion sets and pharmacological agents, urinary | | |
| | catheters, C.V.P. lines, blood gases, nasogastric tubes with or without | | |
| | lavage, endotracheal intubation and tracheal toilet. | | |
| G521 | benefit per physician - first 1/4 hour | 70.00 | |
| 0523 | - second I/4 hour | 35.00 | |
| | - after first 1/2 hour (per 1/4 hour or major part | | |
| 6522 | thereof) | 23.10 | |
| | | | |
| | Other Resuscitation - includes cutdowns, intravenous lines, arterial and/or | | |
| | venous catheters pressure infusion sets and pharmacological agents, | | |
| | urinary catheters, C.V.P. lines, blood gases, nasogastric tubes, with or | | |
| 6395 | without lavage, endotracheal intubation and tracheal toilet. benefit per physician - first 1/4 hour | 36.00 | |
| (333) | - after first 1/4 hour (per 1/4 hour or major part | 30.00 | |
| 6391 | thereof) | 18,00 | |
| | | | |
| | Consultation or assessments rendered before or after provision of resuscitative | | |
| | care may be claimed on a fee for service basis but not when claiming Critical, | | |
| | Ventilatory or Comprehensive care fees. | | |
| | When claiming Critical, Ventilatory or Comprehensive Care fees no other Critical | | |
| | Care codes may be claimed by the same physician(s). | 40.55 | |
| G303 | Transthoracic pacemaker - insertion | 43.70 | |
| | Endotracheal intubation for resuscitation (not to be claimed when followed | 20. 50 | |
| 6211 | by a surgical procedure) | 30.50 | |
| | | | |

Code

G405

G406

G407

Proced. Fee Anaes

157.30

78.60

52.40

CRITICAL CARE - Cont'd.

Critical Care - (Intensive Care Unit) - includes provision in an Intensive Care Area of all aspects of care of a critically ill patient excluding ventilatory support and includes initial consultation and assessment, emergency resuscitation, intravenous lines, cut downs, pressure infusion set and pharmacological agents, insertion of arterial, C.V.P. or urinary catheters and nasogastric tubes, securing and interpretation of laboratory tests, oximetry, transcutaneous blood gases and intracranial pressure monitoring interpretation and assessment when indicated (excluding insertion of ICP measuring device). These fees are not chargeable for services rendered to stablized patients in I.C.U.'s, or patients admitted for ECG monitoring or observation alone.

| | Physician-in-charge is the physician(s) daily providing the above. | |
|------|--|--------|
| G400 | 1st day | 179.80 |
| G401 | 2nd to 10th days (inclusive) per diem | 89.90 |
| G402 | 11th day onwards per diem | 44.90 |
| | | |

Ventilatory Support (Intensive Care Unit) - includes provision of ventilatory care including initial consultation and assessment of the patient, endotracheal intubation with positive pressure ventilation including intravenous lines, cutdown, pressure infusion, insertion arterial C.V.P. lines, tracheal toilet, use of artificial ventilator and all necessary measures for its supervision, obtaining and interpretation of blood gases, oximetry, transcutaneous blood gas application and assessment.

| Physician-in-charge is the physician(s) daily providing the above. |
|--|
| 1st day |
| 2nd to 10th day (inclusive) per diem |
| 11th day onwards per diem |
| Comprehensive Care (Intensive Care Unit) - these fees apply to Intensive |
| Care physicians who provide complete care (both Critical Care and |
| Ventilatory Support as defined above) to Intensive Care Area patients. |
| These fees include the initial consultation and assessment and |
| subsequent examinations of the patient, endotracheal intubation, |
| tracheal toilet, artificial ventilation and all necessary measures for |
| respiratory support, emergency resuscitation, insertion of intravenous |
| lines, cut downs, arterial and/or venous catheters, pressure infusion |
| sets and pharmacological agents, insertion of CVP lines, defibrillation, |
| cardioversion and usual resuscitative measures, insertion of urinary |
| catheters and nasogastric tubes, securing and interpretation of blood |
| gases and laboratory tests, oximetry, transcutaneous blood gases, |
| intracranial pressure monitoring interpretation and assessment when |
| indicated (excluding insertion of ICP measuring device). These fees are |
| not chargeable for services rendered to stabilized patients in I.C.U.'s, |

| | Physician-in-charge is the physician(s) daily providing the above. | |
|------|--|--------|
| G557 | 1st day | 262.10 |
| G558 | 2nd to 10th days (inclusive) per diem | 131.10 |
| G550 | 11th day owned par diem | 65.50 |

If Ventilatory Support only is provided, for example, by the anaesthetist(s), claims should then be made under Ventilatory Support. Comprehensive Care fees do not apply. Other physicians should then charge Critical Care fees or the appropriate consultation, visit or procedures.

or patients admitted for ECG monitoring or observation alone.

The fees under Physician-in-Charge apply per patient treated, i.e., while the physician-in-charge may change during the course of treatment, the daily fee formula as set out should be charged by the physicians involved as if there was only one physician-in-charge during the treatment program; in this sense, the daily fees are team fees.

If patient has been discharged from Unit more than 48 hours and is re-admitted to Unit, 1st day rate applies again on day of re-admission. The appropriate consultation, procedure and visit fees shall apply after stopping Critical Care, Ventilatory Support or Comprehensive Care. Other physicians apart from those providing Critical Care or Comprehensive Care may charge the appropriate consultation, visit and

procedure fees not listed in the fee schedule for Critical Care. These claims will be adjudicated by the Plan on an Independent Consideration basis.

| Code | 33.33.10.10.11.20.13.1100.20.13 | Pro Fee | ced. Anaes |
|----------------|--|------------------|---------------|
| | CRITICAL CARE - Cont'd. | | |
| | | | |
| Hypert G800 | Physician in chamber with patient - per dive, first 1/4 hour | £ 40.30 | |
| | - after first 1/4 hour (per 1/4 hour or | \$ 48.10 | |
| G801 | major part thereof) - after 2 hours in chamber (per 1/4 hour | 24.20 | |
| G802 | or major part thereof) | 48.10 | |
| G803 | increase the above fee(s) by 20% | | |
| G804 | Physician not in chamber with patient(s) - per dive, first 1/4 hour | 36.00 | |
| G805 | after first 1/4 hour (per 1/4 hour or major part thereof) Consultation(s) or assessment(s) and special visit premium(s) may be claim- | 18.00 | |
| | ed on a per patient basis when these services are rendered. | | |
| Note: | Hyperbaric therapy is not a benefit of OHIP for treatment of some conditions. Please refer to OHIP District Medical Consultant for qualifying diagnosis. | | |
| | 17119 0149 0313. | | |
| G210 H | typothermia (therapeutic) induction and management | 163.80 | |
| 1 | Meonatal Intensive Care | | |
| l | Level A: Full life support including invasive monitoring, ventilatory support and parenteral alimentation (all modalities) | | |
| G600 | - lst day | 262.10 | |
| G601 | - 2nd to 10th days (inclusive) per diem | 131.10 | |
| G602 | - 11th day onwards, per diem | 65.50 | |
| | Level B: Intensive care including full monitoring both invasive and non-in- | | |
| | vasive, oxygen administration and intravenous therapy, but without ven- tilatory support | | |
| G610 | - 1st day | 169.60 | |
| 6611 | 2nd day onwerds, per diem Level C: Intermediate care including oxygen administration, non-invasive monitoring and gavage feeding. | 47.90 | |
| G620 | - 1st day | 113.70 | |
| G621 | - 2nd day onwards, per diem | 23.75 | |
| | The above benefits include the initial consultation or assessment and subsequent examination of the patient and, as required, insertion of arter- | | |
| | ial, venous, C.V.P. or urinary catheters, intravenous lines, interpreting | | |
| | of blood gases, nasogastric tubes, pressure infusion sets and pharmaceutical agents, endotracheal intubation, tracheal toilet, artificial venti- | | |
| | lation and all necessary measures for respiratory support. | | |
| | These are team fees which apply to neonatologists/paediatricians/anaest- | | |
| | hetists providing complete care. If ventilator care only is provided by anaesthetists, the above listings do not apply. Claims should then be made | | |
| | under Ventilatory Support (G405, etc.) with Neonatology Paediatric | | |
| | components billed on a fee for service basis. If infant has been transferred from one level to another in either direc- | | |
| | tion, up or down, second day benefits apply. | | |
| | Regular visit and procedure benefits will apply the day following term- ination of Neonatal Intensive Care. | | |
| | If patient has been discharged from Unit more than 48 hours and is re- | | |
| | admitted to Unit, 1st day rate applies again on day of re-admission. | | |
| | The appropriate consultation, procedure and visit benefits shall apply after stopping artificial respiration or special care. | | |
| | When claiming Critcal, Ventilatory or Comprehensive Care Fees no other Critical Care Codes may be claimed by the same physician(s). | | |
| | Tabania Can Maribanian | | |
| | Intensive Care Monitoring This category excludes Cardio-Pulmonary Resuscitation and Ventilatory | | |
| | Support and should be claimed on the basis of the appropriate consultation, procedure and visits benefit. | | |
| | DIALYSIS: team benefits to include listed items. (This does not include preliminary investigation of the case). | | |
| | Haemodialysis (to include haemofiltration, haemoperfusion) | | |
| R849 | Initial and acute (to include surgical components) | 741.40 | 6 |
| R850 G325 | Insertion of Scribner shunt (to be included in the \$741.40 initial) Medical component (to be included in the \$741.40 initial) | 266.20 475.10 | 6 |
| G323 | Acute, repeat (maximum of 3) | 241.70 | |

| | DIAGNOSTIC AND THERAPEUTIC PROCEDURES | | Descri | |
|-------|---|---|-------------|--------|
| Code | | | Prox Fee | Anaes |
| code | | | 1 66 | Airacs |
| | DIALYSIS - Cont'd. | | | |
| | | | | |
| G326 | Chroniceach | | 55.50 | |
| G327 | Revision of Scribner shunt - single | | 87.20 | 4 |
| G328 | - both | | 129.40 | 4 |
| G329 | De-clotting of Scribner shunt | | 79.50 | |
| R843 | Removal of cannula or A.V. shunt | | 69.10 | 4 |
| R827 | Creation of A.V. fistula - see listing on page 122 | 4 | 305.15 | 6 |
| R841 | Obliteration of A.V. fistula | - | 69.90 | 4 |
| R851 | By-pass graft for haemodialysis - synthetic | - | 339.10 | 7 |
| R840 | - autogenous vein | | 360.40 | 7 |
| R833 | Ligation or removal of by-pass graft | | 69.90 | 4 |
| G324 | Insertion of subclavian or external jugular catheter for haemodialysis | | 79.50 | |
| G336 | - Revision | | 13.10 | |
| | | | | |
| | Peritoneal dialysis | | | |
| G330 | Acute (up to 48 hours) includes stylette cannula insertion (temporary) | | 169.60 | |
| G331 | Repeat acute (up to 48 hours) - maximum of 3 | | 152.80 | |
| G332 | Chronic (up to 48 hours) - maximum of \$158.20 per week | | 79.10 | |
| R852 | Insertion of peritoneal cannula by laparotomy | | 158.90 | 6 |
| R853 | Insertion of Tenchkov type peritonal catheter - chronic - by trocar | | 79.50 | 4 |
| R854 | Removal of Tenchkov type peritoneal catheter | | 43.20 | |
| | | | | |
| | Home/self-care dialysis - services rendered by physician | | | |
| | Hemodialysis and peritoneal dialysis (intermittent peritoneal dialysis and | | | |
| | continuous ambulatory peritoneal dialysis) - includes routine clinic | | | |
| | visits (system/drug/dialysis technique/blood work review and physical | | | |
| | examination), counselling/psychotherapy of patients and relatives and | | | |
| G333 | supervised dialysis when required, per patient, per week | | 25.40 | |
| | When physicians are required to make emergency visits to see patients on | | | |
| | any form of home/self-care dialysis the appropriate visits and premiums | | | |
| | are benefits. When the patient requires hospitalization, the appropriate | | | |
| | fees for daily care and in-hospital dialysis are benefits instead of | | | |
| | G333. | | | |
| | | | | |
| | ENDOCRINOLOGY AND METABOLISM | | | |
| | | | 5 40 | |
| +G493 | ACTH test - single or multiple, per injection | | 5.40 | |
| | Antidiuretic hormone response test including the 8 hour water | | 14.40 | |
| +G337 | deprivation test | | 14.40 | |
| | Clonidine suppression test (for the investigation of pheochromocytoma) - | | 01 00 | |
| +G338 | with physician present - includes venipunctures | | 21.20 | |
| | Glucagon test | | 0.70 | |
| +G494 | (Type A) for carbohydrate response | | 8.70 | |
| | (Type B) for hypertension, pheochromocytoma and insulinoma | | 26.00 | |
| +G495 | provocative test (including cold pressor test) | | 36.00 | |
| | Growth hormone exercise stimulation test with physician present (includes | | 21 20 | |
| G358 | venipunctures) | | 21.20 | |
| +G340 | Histamine test to include a control cold pressor test | | 38.60 | |
| +G341 | Hypertonic saline infusion test | | 14.40 26.50 | |
| +G342 | Implantation of hormone pellets | | 20.50 | |
| 10407 | Insulin hypoglycemia pituitary function test with or without TRH and | | 42,40 | |
| +G497 | LHRH alone or in combination | | 8.70 | |
| +G498 | Intravenous glucose tolerance test | | 42.40 | |
| +G499 | Intravenous tolbutamide test | | 36.00 | |
| +G513 | Pentagastrin stimulation for calcitonin | | 36.00 | |
| +G344 | Phentolamine test | | 5.40 | |
| +G501 | TRH or LHRH test, per injection | | 36.00 | |
| +G490 | Saralasin test | | 30,00 | |
| | CACTDOCIVÍTEDO OCV | | | |
| | GASTROENTEROLOGY | | | |
| 0240 | Oesophageal tamponade (Blakemore bag) - insertion | | 38.60 | |
| G349 | Oesophageal motility study(ies) with manametry | | , | |
| G350 | - standard, with physician in continuous attendance | | 76.20 | |
| | | | 16.95 | |
| G343 | - interpretation only Oesophageal acid perfusion test and/or provocative drug testing with | | 20420 | |
| cara | physician in continuous attendance | | 28.80 | |
| 6353 | hilibarcian in continuous accentiance | | | |

| | | | Pro | ced. |
|-------|--|----|------|-------|
| Code | | F | ee | Anaes |
| | GASTROENTEROLOGY - Cont'd. | | | |
| G252 | internativism and. | | | |
| 6232 | - interpretation only | 9 | .20 | |
| G251 | Oesophageal pH study for reflux, with installation of acid | ~ | - 00 | |
| G351 | - standard, with physician in continuous attendance | | .80 | |
| G346 | - with 24 hour monitoring | | .90 | |
| 0.540 | - tracing interpretation only | 19 | .95 | |
| +G355 | (a) diagnostic | 0 | .20 | |
| G356 | (b) therapeutic - with or without ice water lavage | | .80 | |
| | Gastric secretion studies (Augmented Histamine or Histalog, or Pentagastrin) | 20 | •00 | |
| +G357 | - procedure and supervision | 15 | .90 | |
| G352 | Biliary tract provocative test with cholecystokinin | | .20 | |
| G354 | Anal-rectal manametry with physician in continuous attendance | | .60 | |
| G253 | - interpretation only | | .10 | |
| | | | 020 | |
| | GYNAECOLOGY | | | |
| | | | | |
| | Artificial insemination | 21 | .60 | |
| G363 | Cervical mucous penetration test | 14 | .80 | |
| G361 | Endometrial flushing | 14 | .80 | |
| +G364 | Huhner's test | 14 | .80 | |
| G374 | Tests of tubal patency e.g. Rubin's | 16 | .95 | 4 |
| G378 | Insertion of intra-uterine contraceptive device | 18 | .00 | |
| +G365 | Papanicolaou smear | 3 | .80 | |
| | (The Papanicolaou smear is included in the consultation, repeat consul- | | | |
| | tation, general or specific assessment (or re-assessment), partial | | | |
| | assessment, annual health or routine post-natal visit when a pelvic | | | |
| | examination is a normal part of the foregoing services.) | | | |
| | Cost of I.U.C.D. and laminaria tent may be charged directly to the patient. | | | |
| | TALLECTTONE OF TARRICTONE | | | |
| | INJECTIONS OR INFUSIONS | | | |
| +C360 | B.C.G. innoculation, following tuberculin tests | | EO | |
| | Multiple B.C.G. innoculations used for treatment of carcinoma are to be | 4 | .50 | |
| nouc. | considered experimental and no claims should be made for this service. | | | |
| +6370 | Bursa, joint, ganglion or tendon sheath and/or aspiration | 17 | .00 | |
| G371 | -each additional site or area, (to maximum \$42.50 per visit) | | .50 | |
| | G370, G371 - not allowed in addition to surgical benefits when performed at | 0 | .30 | |
| | time of surgery. | | | |
| | | | | |
| | Chemonucleolysis | | | |
| | Lateral discography | | | |
| G390 | - first disc | 53 | .20 | 4 |
| G368 | - if lumbosacral disc included, add | 47 | .30 | |
| G386 | - second and subsequent discseach | 26 | .60 | |
| | Injection for chemonucleolysis | | | |
| G392 | - initial injection | | .20 | |
| G393 | - any subsequent injection at other levels, each | | .10 | |
| G396 | Injections of extensive keloids | | .30 | |
| G397 | - under general anaesthesia | 38 | .50 | 4 |
| 0270 | Intramuscular, subcutaneous, or intradernal including interpretation | | | |
| G372 | - with visit - each injection | 1 | .90 | |
| Note: | Use G372 for rabies injection(s). | | | |
| | Intramuscular, subcutaneous or intradermal, including interpretation | | | |
| G373 | - sole reason - first injection | | .50 | |
| G372 | - sole reason - Trist Injection | | .90 | |
| 3572 | Intralesional infiltration | 1 | .50 | |
| +G375 | - one or two lesions | 7 | .65 | |
| +6377 | - 3 or more lesions | | .30 | |
| G383 | - extensive | | .C. | |
| G462 | Administration of oral polio vaccine - if only service rendered | | 40 | |
| G384 | Infiltration of tissues for trigger point | | .65 | |
| G385 | - for each additional site, add (to a max. of 2) | | .90 | |

| Cada | | Proced | |
|-------|---|---------|-----|
| Code | | Fee Ana | les |
| | THURCTIONS OF INCUSIONS Contid | | |
| | INJECTIONS OR INFUSIONS - Cont'd. | | |
| | T-A | | |
| .0276 | Intravenous | 0.70 | |
| +G376 | Infant | 8.70 | |
| +G379 | Child or adult | 5.30 | |
| | Notes: (1) G376 or G379 apply to cryoprecipitate infusion. | | |
| | (2) G376, G379 may not be claimed with G279 nor with x-rays. | | |
| | (3) Except for G381, G281, injections into established I.V. appara- | | |
| | tus may not be claimed. | | |
| +G380 | Cut down including cannulation as necessary | 23.10 | |
| | Chemotherapy (marrow suppressant) - with each injection initiated by a | | |
| | physician by intravenous infusion for treatment of malignant or auto- | | |
| | immune disease | | |
| | - single injection (for agents other than adrianycin, cisplatin, bleo- | | |
| +G381 | mycin or high dose methotrexate) | 11.90 | |
| G281 | - each additional injection (other than above drugs) | 5.90 | |
| | Chemotherapy and patient assessment provided by physician in hospital based | | |
| | clinics or to in-patients (the following benefits include patient asses- | | |
| | sment for a 24 hour period, drug administration and establishment of | | |
| | intravenous to a maximum of one fee claimed, every three weeks) | | |
| | - single agent intravenous chemotherapy i.e. | | |
| 0220 | | 40.10 | |
| G339 | adrianycin, cisplatin or bleomycin | 40.10 | |
| 0045 | -multiple agent intravenous chemotherapy including at least one of | ra cr | |
| G345 | either adriamycin, cisplatin or bleomycin | 53.65 | |
| | -special single agent chemotherapy utilizing either high-dose metho- | | |
| | trexate with folinic acid rescue - methotrexate given in a dose of | | |
| | greater than 1 g/m² or high dose cisplatin greater than 75 mg/m² given | | |
| G359 | concurrently with hydration and osmotic diuresis | 76.20 | |
| | Supervision of chemotherapy (marrow suppressant) for malignant or | | |
| G382 | auto-immune disease by telephone - monthly | 9.70 | |
| | Varicose veins (maximum per visit - \$17.30) | | |
| +G387 | - single injection | 8.70 | |
| G388 | - multiple (unilateral or bilateral) each additional | 4.30 | |
| | Compression sclerotherapy (includes multiple injections, compression ban- | | |
| G536 | daging and one post injection visit) | 65.50 | |
| G537 | Repeat compression sclerotherapy | 21.90 | |
| 0007 | Management of parenteral alimentation - physician in charge - not to be | | |
| 6510 | charged in addition to hospital visitsper visit | 17.80 | |
| 0010 | Charges in addition to hospital visits | 27 400 | |
| | LABORATORY MEDICINE IN PRIVATE OFFICE | | |
| | The following benefits apply to physicians who perform these particular | | |
| | | | |
| | tests in their own offices. The L.M.S. schedule for Laboratory Medicine | | |
| | on pages 21–32 for these particular tests applies to licensed | | |
| | laboratories. | 1/23 | |
| G013 | Aminophylline (theophylline) | Nil | |
| G001 | Cholesterol, total | 4.80 | |
| | Glucose, quantitative or semi-quantitative - see Laboratory Medicine | | |
| G002 | Preamble, page 19, para. 4 | 1.80 | |
| G481 | Hemoglobin screen and/or haematrocrit (any method or instrument) | 1.20 | |
| G003 | Lactic dehydrogenase (L.D.H.) total | 3.50 | |
| G004 | Occult blood | 1.35 | |
| G005 | | 3.40 | |
| G006 | SGOT | 3.50 | |
| G007 | Urea nitrogen (B.U.N.) | 2.10 | |
| G008 | | 2.10 | |
| 4000 | Urinalysis, routine (includes microscopic examination of centrifuged speci- | - | |
| | men plus any of S.G., pH, protein, sugar, haemoglobin, ketones, urobi- | | |
| G009 | linogen, bilirubin) | 3,90 | |
| G010 | - one or more parts of above without microscopy | 1.80 | |
| | Fungus culture including KOH preparation and smear | 11.20 | |
| G011 | Wet preparation (for fungus, trichomonas, parasites) | 1.70 | |
| G012 | wer preparation (for fungus, or foliationas, parasities) | 10,0 | |
| | | | |

| | DIRECTION AND THE PROCEDURES | Desc | cod |
|-------|---|------------|-------|
| Code | | _ | ced. |
| | | Fee | Anaes |
| | NEPHROLOGY | | |
| | | | |
| | Nephrological management of donor procurement - includes management of the | | |
| | neurologically "dead" donor on life support systems, assesment of renal | | |
| | functions pre-nephrectomy, pre-nephrectomy immunotherapy, assessment as | | |
| G411 | to potential recipients to be called in, etc. | 163.80 | |
| G347 | Renal perfusion with hypothermia for organ transplantation | 81.90 | |
| G348 | Renal preservation with continuous machine perfusion | 31.90 | |
| - | Nephrological component of transplantation, including complete patient care | 01.50 | |
| G412 | for first 48 hours following transplantation | 573.40 | |
| 0112 | to the total strong character | 3/3.40 | |
| | NERVE BLOCKS - not to be charged when used as local anaesthetic for | | |
| | surgical procedures | | |
| | Note: Time units are not applicable to nerve blocks. If one physician | | |
| | | | |
| | gives the anaesthetic and another does the nerve block, claim the anaes- | | |
| | thetic under G260, page 55. | | |
| cm a | Desable 1 -1 | 47.00 | |
| G214 | | 46.30 | |
| 0215 | Coeliac ganglion | 71.30 | |
| G239 | | 108.10 | |
| G216 | Epidural block | 63.70 | |
| G245 | Epidural or intrathecal injection of sclerosing solution | 140.10 | |
| G243 | Femoral nerve - unilateral | 46.30 | |
| G244 | - bilateral | 69.40 | |
| G246 | Introduction of epidural catheter for relief of pain: institution | 65.50 | |
| G255 | - with insertion of subcutaneous port | 163.80 | |
| | - plus hospital visits for each additional visit rendered (to a maximum | | |
| G247 | of 4 visits per day). See also Preamble para B37(y) | visit fees | |
| G218 | Ilioninguinal and iliohypogastric nerves | 46,30 | |
| G219 | Infraorbital | 28.90 | |
| G220 | Intercostal nerve | | |
| G221 | | 28.90 | |
| G222 | - for each additional one, add | 14.40 | |
| - | Intrathecal spinal | 63.70 | |
| G225 | Mental branch of mandibular nerve | 28.90 | |
| G250 | Maxillary or mandibular division of trigeminal nerve | 63.70 | |
| G241 | Obturator nerve - unilateral | 46.30 | |
| G242 | - bilateral | 69.40 | |
| G227 | Other cranial nerve block | 71.30 | |
| | Paravertebral nerve block of cervical, thoracic or lumbar or sacral or | | |
| 6228 | cocygeal nerves | 46.30 | |
| G123 | - for each additional one, add (to a maximum total of \$138.50) | 23.10 | |
| G229 | Pudendal - unilateral | 46.30 | |
| G240 | - bilateral | 69.40 | |
| Note: | - for obstetrical continuous conduction anaesthesia, see PO14, PO15 on | | |
| | page 72. | | |
| G422 | Retrobulbar injection (not to be claimed when used as a local anaesthesia). | 28,90 | |
| 6230 | Sciatic nerve | 46.30 | |
| G226 | - bilateral | 69.40 | |
| G248 | Single shot caudal block done in conjunction with anaesthesia | 13.10 | |
| - | Somatic or peripheral nerves not specifically listed | 20.20 | |
| G231 | - one nerve or site | 28.90 | |
| G223 | - additional nerve(s) or site(s), add | 14.40 | |
| G232 | | 46.30 | |
| - | Spleno-palatine ganglion | | |
| G233 | Splanchnic | 46.30 | |
| G234 | Stellate ganglion | 46.30 | |
| G256 | Superior laryngeal nerve | 28.90 | |
| G235 | Supraorbital | 28.90 | |
| G236 | Sympathetic block(s) (lumbar or thoracic) | 46.30 | |
| G237 | - bilateral | 69.40 | |
| G238 | Transverse scapular nerve | 46.30 | |
| G217 | Trigeminal ganglion | 71.30 | |
| | When alcohol or other sclerosing solutions are used, add 50% to the appro- | | |
| | priate nerve block fees as listed above with the exception of fee codes | | |
| E958 | G245 and G246. | | |
| | | | |
| | NEUROLOGY | | |
| | | | |
| G273 | Epidural injection of adrenal steroid or autologous blood | 62.70 | |
| G274 | - post laminectomy into operative site | 76.60 | |
| Z804 | Lumbar puncture | 34.60 | |
| Z805 | - with instillation of medication | 46.30 | |
| G410 | Amytal test (Wada) - bilateral-supervision and coordination of tests | 57.75 | |
| G413 | Electrocorticogram - supervision and interpretation | 144.20 | |
| 0413 | Erecti occi erecgi un - supei vistori uno interprecation ssssssssssssssssssss | | |

| C | | | ced. |
|-------|---|--------|-------|
| Code | | Fee | Anaes |
| | NEUROLOGY - Cont'd. | | |
| G419 | Tensilon test | 16.95 | |
| G551 | Katzman test (subarachnoid infusion test) including lumbar punctures | 144.20 | |
| | | | |
| | Electroencephalography | | |
| | An EEG consists of at least a twenty minute recording with referential and bipolar montages and at least eight channels (except in neonates). | | |
| | Hyperventilation and photic stimulation should be done in all cases | | |
| | where clinically possible. | | |
| +G414 | Technical component | 22.00 | |
| G415 | Professional component | 18.75 | |
| G416 | With activating or sleep inducing drugs and/or sleep deprivation, add | 13.50 | |
| Note: | Use code G416 if claim states sleep recording but is not for overnight | | |
| G417 | recording. Use G550 for overnight sleep recording. Inserting subtemporal needle electrodes, add | 13.50 | |
| GHZI | Videotape recording of clinical signs in association with spontaneous EEG, | 10000 | |
| G545 | add to routine fees, per 1/4 hour (maximum of 1 hour) | 12.50 | |
| | Radiotelemetry or portable recordings to monitor spontaneous EEG from a | | |
| G546 | freely moving patient, add to routine fees | 26.00 | |
| | | | |
| | Evoked Responses | | |
| G547 | Simple average evoked potential studies with one sensory modality of stimulation | 20.30 | |
| 4547 | Complex evoked potential studies involving several sensory modalities, | 20.50 | |
| | multiple threshold determinations, of more than four simultaneous channels | | |
| G548 | of recording, not completely under supervision | 52.90 | |
| | Complex evoked potential studies performed completely under direct | | |
| G549 | 'professional supervision | 106.10 | |
| | Class Laboratorias | | |
| CSSO | Sleep Laboratories Overnight sleep recording - complete interpretation with sleep staging | 77.20 | |
| | G550 - if not overnight sleep recording, use code G416. | 77.20 | |
| | Polygraphic recording of three parameters in addition to EEG (such as | | |
| | respiration, eye movement, EKG, muscle movements, etc.) add | | |
| G544 | per item (to a maximum of \$22.95) | 7.65 | |
| | ON ITI IAI MOLOCY | | |
| | OPHTHALMOLOGY | | |
| Note: | G424, G423 - Contact Lens fitting is not a benefit except under certain | | |
| | specific conditions. See Preamble, Appendix A. | | |
| G424 | Contact lens fitting (with follow-up for 3 months) | 155.60 | |
| | One eye only, when the other eye has been previously fitted by the same | 00.10 | |
| G423 | physician (with follow-up for 3 months) | 80.10 | |
| G463 | Hydrophilic "Bandage" lens fitting | 80.10 | |
| G438 | Colour vision detailed assessment (not to be claimed for screening tests such as Ishihara, HRR and University, etc.) | 21.60 | |
| G437 | Dark adaptation curve (Goldmann adaptometer or equivalent) | 30.50 | |
| G453 | Electro-oculogram - interpretation fee | 17.40 | |
| +G439 | Electro-retinography with report | 42.40 | |
| +G425 | Fluorescein angiography | 42.40 | |
| +G444 | Fluorescein angioscopy | 12.30 | |
| G426 | G425, G444 - for bilateral procedures, add 50% of the listed Benefit. Glaucoma provocative tests, including water drinking tests | 25.60 | |
| G428 | | 8.60 | |
| G427 | Ophthalmodynamometry | 8.60 | |
| | Radioactive phosphorus examination | | |
| G429 | - anterior approach | 37.70 | |
| G430 | - posterior approach | 76.20 | |
| G421 | Subconjunctival or sub-Tenons capsule injection | 14.20 | |
| +G435 | G429, G430, G421 - for bilateral procedures, add 50% of the listed Benefit. Tonometry | 4.50 | |
| 10H33 | (Not to be claimed if done in conjunction with an ophthalmological consult- | 7650 | |
| | ation or specific assessment). | | |
| G433 | Tonography (to include tonometry) with or without water | 17.40 | |
| G436 | Visual fields - kinetic (with permanent record) | 8.60 | |
| G432 | Visual fields - static perimetry | 25.60 | |
| G464 | Visual evoked response | 21.60 | |
| 6468 | Botulinum toxin injection of extraocular muscle with electromyographic | 73 70 | |

| C. I. | | Pro | ced. |
|-------|--|---------|-------|
| Code | 0775 to 1010 to 0.00 | Fee | Anaes |
| | OTOLARYNGOLOGY | | |
| +G420 | Ear syringing or curetting (not claimed with Z907) - uni or bilateral Diagnostic Hearing Tests (not applicable to fixed level screening audio- | 4.30 | |
| | metry) | | |
| | Pure tone threshold audiometry with or without bone conduction | | |
| G440 | - technical component | 7.90 | |
| G525 | - professional component | 4.95 | |
| | Pure tone threshold audiometry (with or without bone conduction) and speech reception threshold and/or speech discrimination scores | | |
| G441 | - technical component | 11.20 | |
| G526 | - professional component | 10.90 | |
| | Automatic impedance audiometry - with or without stapedial reflexes and/or | | |
| G442 | compliance - technical component | 2.50 | |
| +0529 | - professional component | 1.70 | |
| G448 | Sound field audiometry (infants and children) - technical component | 16.90 | |
| G450 | - professional component | - 15.20 | |
| | Advanced testing e.g. recruitment, tests of malingering, central tests and | | |
| | stapedial reflex decay tests; manual impedance testing (not to be billed | | |
| | with G442 and G529) - per test (maximum 3 tests). | | |
| G443 | - technical component | 7.20 | |
| G530 | - professional component | 5.10 | |
| 0000 | Hearing aid evaluation and/or fitting of tinnitus masker (does not include | 3.10 | |
| | C526 and G441) | | |
| G447 | | 27.00 | |
| +G531 | - technical component | | |
| 70001 | - professional component | 11.00 | |
| | Hearing aid re-evaluation and/or re-fitting of tinnitus masker (does not include G526 and G441) | | |
| G445 | - technical component | 13.50 | |
| +G446 | - professional component | 5.40 | |
| G811 | Cortical evoked audiometry - technical component | 27.85 | |
| G812 | - professional component | 9.30 | |
| | Cortical evoked audiometry, multiple frequency, (minimum of 4 frequencies | | |
| | in each ear) - as required by W.C.B. | | |
| N.C. | - technical component | N.A.B. | |
| N.C. | - professional component | N.A.B. | |
| G813 | Brainstem evoked audiometry - technical component | 27.85 | |
| G814 | - professional component | 13.50 | |
| 004 | Flectrocochleography (per ear) - to include myringotomy if performed | 1000 | |
| G315 | Electrocochleography (per ear) - to include myringotomy if performed - technical component | 27.85 | |
| G316 | - professional component | 89.30 | |
| 0010 | provide the provid | | |
| | Diagnostic Balance Tests | | |
| +G449 | Caloric testing without ENG - professional component | 6.10 | |
| G104 | Positional testing with ENG - technical component | 17.30 | |
| G105 | - professional component | 15,60 | |
| G451 | Caloric testing with ENG - technical component | 17.30 | |
| +G533 | - professional component | 15.60 | |
| G454 | Stroboscopy - professional component | 14.30 | |
| G191 | Optokinetic tests - professional component | 10.60 | |
| | Computerized rotation tests - professional component | 17.30 | |
| 4200 | processing and the processing and processing and and and and and and and and and and | | |
| | Diagnostic Taste Tests | | |
| | Electrogustometry or conventional taste tests | | |
| +G452 | - professional component | 12.20 | |
| .015 | professional component territorial | | |
| | PHYSICAL MEDICINE | | |
| | | | |
| | Electromyography and nerve conduction studies | | |
| | When patients are referred directly to EMG facilities solely for testing, | | |
| | consultation and visit fees are not benefits in addition to the | | |
| | following fees: | | |
| | Schedule A - Complete procedure i.e. conduction studies on two or more | | |
| | nerves presumed to be involved in the disease process along | | |
| | with EMG studies of multiple muscles and/or detailed studies | | |
| | of neuromuscular transmission. It also includes as necessary | | |
| | study of normal nerves and/or opposite side for comparison. | | |
| | - professional component - when physician performs EMG, performs and/or | | |
| G456 | supervises nerve conduction studies and interprets results | 84.80 | |
| G459 | - interpretation only | 18.60 | |
| G455 | - technical component | 25.40 | |

| | DIAGNOSTIC AND THERAPEUTIC PROCEDURES | 0 | |
|---------------|---|----------------|-------|
| Code | | _ | ced. |
| ······· | PHYSICAL MEDICINE - cont'd. | Fee | Anaes |
| | | | |
| | Schedule B - Limited procedure i.e. conduction studies on a single nerve (motor and/or sensory conduction) and/or limited EMG studies of the involved muscle(s) and/or limited neuromuscular transmission study | | |
| | - professional component - when physician performs EMG, performs and/or | | |
| G457 | supervises nerve conduction studies and interprets results | 60.20 | |
| G469 | - interpretation only | 18.60 | |
| G466 | - technical component | 16.95 | |
| +G460 | | 7.20 | |
| +G461 | - minor | 4.05 | |
| | Therapeutic Procedures | | |
| +G465 | Manipulation (by physician) - major joint(s) or spine - one or more joints. (under general anaesthesia, see Surgical Procedures) | \$11.80 | |
| | Miscellaneous therapeutic procedures | | |
| +G467 | - as listed below (physician's own patients) | 6.75 | |
| Notes: | | | |
| | performed by an appropriately trained paramedic under that | | |
| | physician's direct supervision. | | |
| | (2) Only one G467 may be claimed per patient visit. | | |
| | (3) Not allowed to hospital inpatient, outpatient or approved | | |
| | physiotherapy facility. Superficial thermal therapy - radiant, hot pack, whirlpool, paraffin bath, or ice. | | |
| | Deep heat - short wave diathermy, microwave diathermy or ultrasound. Light (Ultraviolet) - general or local application. | | |
| | P.U.V.A. Electrotherapy - Galvanic, Faradic and sinusoidal currents, iontophonesis, transcutaneous nerve stimulation for relief of pain. | | |
| | Hydrotherapy - local (arm or leg) and general (Hubbard) for body immersion; therapeutic pool for under water exercise. | | |
| | Mechanotherapy - massage, mechanical device - traction, pulleys and weights, treadles, stationary bicycles, shoulder wheels. | | |
| | Therapeutic exercise (physiotherapy). | | |
| 0405 | Location and injection of peripheral motor nerves for reduction of spa sticity including electrodiagnosis of motor point: | 20.00 | |
| G485 | | 38.60 24.20 | |
| G486 | | 24.20 | |
| G487 | Repeat procedure within one month | 24.20 | |
| G488 | - major nerve | 15.90 | |
| N.C. | | 13.50 | |
| | tion of the needle(s) for the management of pain, physician | N.A.B. | |
| | | | |
| | PSYCHIATRY | | |
| G471 Note: | | 26.60 | 2 |
| | TELERADIOTHERAPY | | |
| | Minor teleradiotherapy - X-ray, 150 K.V.P. or less - charge per treatment | | |
| +G472 | | 8.90 | |
| Note: | | | |
| | physician may charge the appropriate consultation or assessment fee in | | |
| | addition to the procedural fee(s). On subsequent visits, only the minor | | |
| | teleradiotherapy fee plus G700 should be claimed unless additional | | |
| | procedures have been performed or unless there has been a complication | | |
| | or change to a totally unrelated diagnosis. In the first exception, the | | |
| | minor teleradiotherapy plus the benefits for additional procedures may | | |
| | be claimed. In the second exception, the appropriate assessment and | | |
| | minor teleradiotherapy benefits may be claimed. | | |
| | THETHOCOLOUN (infers and mammagasahu) ass on more areas | | |
| CAOS | THERMOGRAPHY (infra-red mammography) - one or more areas | 13.50 | |
| | Technical component | 6.75 | |
| 0492 | FIVICASIUNAI CUIPUIRILE | 0.75 | |
| | | | |

DIMONDELL WE INCOVED TO PROTECTIVE

| | DIMINOSTIC WID HEAVED TO PROTECTIONS | | |
|--------------|--|---------|--------|
| Code | | Fee | Anaes |
| | DISPOSAL APPROPRIATE AND ADDRESS OF THE PARTY OF THE PART | 100 | relacs |
| | PHYSICAL MEDICINE AND REMABILITATION - Cont'd. | | |
| | Therapeutic Procedures | | |
| +G465 | Manipulation (by physician) - major joint(s) or spine - one or more joints. | \$11.80 | |
| | (under general anaesthesia, see Surgical Procedures) | 311°On | |
| | | | |
| | Miscellaneous therapeutic procedures | | |
| +G46/ | - as listed below (physician's own patients) | 6.75 | |
| Notes: | (1) May be claimed by a physician for physiotherapy procedures | | |
| | performed by an appropriately trained paramedic under that physician's direct supervision. | | |
| | (2) Only one G467 may be claimed per patient visit. | | |
| | (3) Not allowed to hospital inpatient, outpatient or approved | | |
| | physiotherapy facility. | | |
| | Superficial thermal therapy - radiant, hot pack, whirlpool, paraffin bath, or ice. | | |
| | Deep heat - short wave diathermy, microweve diathermy or ultrasound. | | |
| | Light (Ultraviolet) - general or local application. | | |
| | P.U.V.A. | | |
| | Electrotherapy - Galvanic, Faradic and sinusoidal currents, iontophoresis, | | |
| | transcutaneous nerve stimulation for relief of pain. | | |
| | Hydrotherapy - local (arm or leg) and general (Hubbard) for body immersion; | | |
| | therapeutic pool for under water exercise. Mechanotherapy - massage, mechanical device - traction, pulleys and | | |
| | weights, treadles, stationary bicycles, shoulder wheels. | | |
| | Therapeutic exercise (physiotherapy). | | |
| | | | |
| | Location and injection of peripheral motor nerves for reduction of spa | | |
| CADE | sticity including electrodiagnosis of motor point: | 00.00 | |
| G485 G486 | Major nerve and/or branches | 38.60 | |
| UHCU | Repeat procedure within one month | 24.20 | |
| G487 | - major nerve | 24.20 | |
| G488 | - additional major nerve | 15.90 | |
| N.C. | Acupuncture: 1.e. including insertion of needle(s) into specifically | | |
| | selected point(s) combined with manual, electrical or thermal stimula- | | |
| | tion of the needle(s) for the management of pain, physician | N.A.B. | |
| | PSYCHIATRY | | |
| G47I | Electroconvulsive therapy (E.C.T.) cerebral-single or multiple | 26.60 | 2 |
| Note: | - Electrosleep therapy or Sedac therapy are not benefits of OHIP. | | |
| | THE COMMITTEE OF THE CO | | |
| | TELERADIOTHERAPY Minor teleradiotherapy - X-ray, 150 K.V.P. or less - charge per treatment | | |
| +G472 | visit | 8.90 | |
| | For the first minor teleradiotherapy procedure rendered to a patient, the | 0.50 | |
| | physician may charge the appropriate consultation or assessment fee in | | |
| | addition to the procedural fee(s). On subsequent visits, only the minor | | |
| | teleradiotherapy fee plus G700 should be claimed unless additional | | |
| | procedures have been performed or unless there has been a complication or change to a totally unrelated diagnosis. In the first exception, the | | |
| | minor teleradiotherapy plus the benefits for additional procedures may | | |
| | be claimed. In the second exception, the appropriate assessment and | | |
| | minor teleradiotherapy benefits may be claimed. | | |
| | THE DUCCHARILY (in face and assumptions to the control of the cont | | |
| G491 | THERMOGRAPHY (infra-red mammography) - one or more areas Technical component | 13.50 | |
| | Professional component | 6.75 | |
| | | | |
| | UROLOGY | 46.77 | |
| G484 | Cystometrogram with selective sacral nerve block studies | 48.10 | |
| | Cystometrogram and/or voiding pressure studies and/or flow rate with or without postural studies and/or urethral pressure profile including | | |
| +G475 | interpretation with or without use of EMG including interpretation | 20.50 | |
| | Complete multichannel urodynamic assessment - pressure-flow studies, | 20,000 | |
| | urethral pressure monitoring, with or without fluoroscopic cysto- | | |
| G193 | urethrography | 28.70 | |
| | - with EMG, add to G193 | 7.20 | |
| +G474 | - unethral pressure profile alone including interpretation - interpretation of comprehensive urodynamic studies (when the procedure is | 7.60 | |
| G477 | done by paramedical personnel) | 4.70 | |
| | Prostatic massage | 4.70 | |
| | | | |

THE ONTARIO GAZETTE

| Code | | Proced. |
|-------|---|-----------|
| code | | Fee Anaes |
| | UROLOGY | |
| G484 | Cystometrogram with selective sacral nerve block studies | 48,10 |
| | Cystometrogram and/or voiding pressure studies and/or flow rate with or | |
| | without postural studies and/or urethral pressure profile including | |
| +G475 | interpretation with or without use of EMG including interpretation | 20,50 |
| | Complete multichannel urodynamic assessment - pressure-flow studies, | 2000 |
| | urethral pressure monitoring, with or without fluoroscopic cysto- | |
| G193 | urethrography | 28,70 |
| G194 | - with EMG, add to G193 | 7.20 |
| +G474 | - urethral pressure profile alone including interpretation | |
| TG4/4 | | 7.60 |
| | - interpretation of comprehensive urodynamic studies (when the procedure is | |
| G477 | done by paramedical personnel) | 4.70 |
| +G476 | Prostatic massage | 4.70 |

OBSTETRICS

I. Obstetrical care is divided into its components. A prenatal major assessment when performed may be claimed; it shall comprise a full history, an inquiry into, and an examination of all parts or systems (and may include a detailed examination of one or more parts or systems), an appropriate record and advice to the patient. All other prenatal visits shall comprise the necessary history and inquiry, examination, appropriate record, pregnancy related courselling and advice to the patient. Normal (uncomplicated) prenatal care includes a prenatal general assessment visit, then monthly visits to 32 weeks, followed by visits every 2nd week to 36 weeks, then weekly visits until delivery. However, complicated pregnancies may require additional visits. Labour - delivery and postpartum care are listed separately.

2. If an uncomplicated obstetrical patient is transferred from one physician to another physician for obstetrical care, the appropriate assessment benefit may be changed by the second physician, followed by prenatal visits. This statement does not apply to physicians substituting for each other or when the second physician sees the patient for the first time in labour. If the obstetrical patient is referred to a consultant for obstetrical care because of the complexity, obscurity or seriousness of the case, the

consultant may claim a consultation in addition to the prenatal visits.

3. Illnesses resulting from or associated with pregnancy or false labour requiring added home or

hospital visits, shall be claimed on a per visit basis.

4. When a pregnant patient visits her physician for a condition unrelated to her pregnancy and apart from her routine scheduled prenatal visits, the physician may charge the appropriate visit benefit.

5. The listings under the heading Referred Services may be claimed by the consultant physician in addition to the appropriate consultation or visit benefit. They may not be claimed by physicians providing obstetrical care to their own patients.

6. If a consultant is requested by another physician to perform a surgical induction of labour, or emergency removal of a Shirodkar suture (except at delivery) assuming someone else has inserted the

suture, the consultant should claim consultation benefit for this (these) service(s).

7. Medical induction or stimulation of labour may be claimed once per pregnancy by any one physician and only when carried out for a recognized obstetrical complication(s) and does not qualify for detention benefits.

8. The listings for "Attendance at labour and attendance at delivery" and for "Attendance at delivery" may not be claimed by any physician when a patient is transferred to a second physician for

normal obstetrical care.

9. Ordinary immediate care of the newborn is included in the labour-delivery fee and when the service is rendered by the anaesthetist, it is included in the anaesthetic benefit. A life threatening emergency situation requiring active resuscitation of the newborn provided by any physician may be claimed under codes GS21, GS23. When indicated, endotracheal intubation and tracheo-bronchial toilet should be billed under G211, and not at GS21, GS22, GS23.

10. When a physician provides newborn care and also performs a circumcision on the same newborn or

infant, both services may be claimed.

11. When an obstetrician routinely transfers all newborns to another physician, the latter should not claim consultation benefit for these "transferrals". If the baby is well, the physician should charge the newborn care in hospital benefit plus for attendance at maternal delivery if this service is given. If the baby is sick, the physician may claim a general assessment and for attendance at maternal delivery (if this service is given) plus daily visits for as long as his services are required. If an obstetrician normally cares for newborns himself or transfers the care of newborns to a family physician but refers a newborn to a paediatrician because of the complexity, obscurity or seriousness of the case, the latter may claim for this service according to the following guidelines:

a) If attendance at maternal delivery is provided, code H267 may be claimed and if a general assessment of the baby is carried out, code C263 may be claimed as well. However, a postnatal consul-

tation of the baby, code C265 may not be claimed in addition to code H267.

b) If a paediatrician has not attended delivery, a postnatal consultation may be claimed (if this

service is rendered) even though a prenatal consultation may already have been claimed.

12. When a physician provides prenatal visits, attends labour, assists or administers the anaesthetic at Caesarean section and visits the patient post-operatively, he is entitled to claim for prenatal visits, attendance at labour, assistant's or anaesthetist's benefits for Caesarean section and post-operative supportive care while the patient is in hospital.

13. Physicians may claim for assisted breech delivery (PO20) when the service includes spontaneous

delivery to the umbilicus, with extraction of the shoulders, arms and aftercoming head.

14. The Preamble applicable to Surgical Procedures (pages 75-77) also applies to obstetrics where

appropriate.

15. The premiums applicable to Obstetrics are as follows: When deliveries and other obstetrical procedures done in continuity with the delivery occur after 5:00 p.m. and before midnight or on Saturdays, Sundays and Holidays, increase the procedural fee(s) by 30% (E409). When time of delivery occurs after midnight and before 7:00 a.m. any night during the week, increase the procedural fee(s) by 50% (E410). These premiums are not chargeable in addition to the obstetrical procedural fee(s) if labour is induced by medical and/or surgical means by the same physician unless the reason for the induction is fetal distress, diabetes, premature rupture of membrane, severe pre-eclampsia-hypertension or abruption. However a forewater A.R.M. or oxytocin augmentation of labour carried out on a patient in desultory labour does not constitute induction.

OBSTETRICS

| - | Code | OBSTETRICAL CARE | Asst | Obst*n | Anaes |
|-----|---------------|---|------|-----------------|-------|
| | | Prenatal Care: | | | |
| | P003 | - General assessment (major prenatal visit) | \$ | 43.00 | |
| - 1 | P004 | - Minor prenatal assessment (all other prenatal visits) | | 17.20 | |
| | | | | | |
| | | Labour - Delivery: | | | |
| - 1 | P006 | - Vaginal | | 225.30 | |
| | | - Operative delivery i.e. mid-cavity rotation | | 045 00 | - |
| | P020 | or assisted breech delivery | | 245.80 | 5 |
| | E502 | - Following a caesarian section VBACadd | _ | 16.40 | - |
| | P018 P041 | - Caesarean section | 6 | 250.30 | 6 |
| | P041 | - Caesarean section including hysterectomy | | 537.80 | 8 |
| | E500 | Multiple births, any method of delivery - each child, extra | 0 | 81.90 | O |
| | 2000 | (If one child is born vaginally and the other(s) by Caesarean section, | | 01.50 | |
| | | claim P018, P041 or P042 plus one at 85% of P006 or P020, then E500 for | | | |
| | | third and subsequent births.) | | | |
| | | Attendance at labour only (when patient is transferred to another centre | | | |
| | P038 | for delivery) | | 94.20 | |
| - | P009 | Attendance at labour with physician in attendance at delivery | | 225.30 | |
| | | Attendance at labour (when same physician assists or gives anaesthetic at | | | |
| | 0011 | Caesarean section or gives anaesthetic at operative delivery and claims | | 125 20 | |
| | P011 | separately for these services as assistant or anaesthetist) | | 135.20 94.20 | |
| | P010 | Repair of third degree laceration i.e. repair of at least 2 cm of rectal | | 54.20 | |
| | P028 | mucosa, anal sphincter and perineum | | 73.70 | 4 |
| | OLO | Postpartum haemorrhage - exploration of vagina and cervix, uterine | | | |
| | Z774 | curettage | | 74.50 | 5 |
| | P007 | Post natal care in hospital and/or home | | 46.70 | |
| | P008 | Post natal care in office | | 21.30 | |
| | | | | | |
| | 2000 | Referred Services (1.0.P.) - when only service(s) rendered | | 49.15 | 4 |
| | P036 P039 | Repair of vaginal laceration | | 49.15 | 4 |
| | P029 | Manual removal of retained placenta | | 49.15 | 4 |
| | P013 | Obstetrical anaesthesia | | | 5 |
| | . 010 | Continuous conduction anaesthesia | | | |
| | P014 | (a) introduction of catheter for analgesia including first dose | | | 6 |
| | | (b) maintenance and/or supervision (one unit for each 1/2 hour to a maximum | | | |
| | | of 5 units - not to be claimed for first hour following introduction | | | |
| | P015 | of catheter and first dose) | | | |
| | E100C | (c) attendance at delivery - per 1/4 hour - time units | | 13.10 | |
| | G224 | Pudendal block (bilateral) - see para. 3/(s) on page xill | | 13.10 | |
| | | High Risk Pregnancies | | | |
| | Z776 | Fetal blood sampling (I.O.P.) | | 28.90 | |
| | | Fetoscopy (may include fetal blood sample, cell harvest or amniocentesis) | | | |
| | Z773 | (I.O.P.) | | 140.70 | |
| | Z739 | Oxytocin challenge test (1.0.P.) | | 41.40 | |
| | | Double set up examination to rule out placenta praevia, or trial of forceps | | 49,60 | |
| | Z734 | - failed leading to Caesarian section (same physician) | • | 57.95 | |
| | P022 P023 | Oxytocin infusion for stimulation of desultory labour | | 57.95 | |
| | 1023 | Pharmacological suppression of premature labour by 1.V. therapy - to be | | 57.55 | |
| | | claimed once per pregnancy by most responsible physician after 3 hours | | | |
| | Z721 | of supervision in same institution (1.0.P.) | | 57.95 | |
| | Z778 | Amniocentesis - diagnostic or genetic (I.O.P.) | | 41.40 | |
| | Z779 | Chorionic villus sampling (1.0.P.) | | 78.60 | |
| | 0001 | Suture of incompetent cervix in pregnancy (1.0.P) | 2 | 122,90 | 4 |
| | P031 | cervical cerclage - any technique | | risit fee | 4 |
| | U.V.C P034 | Uterine inversion, manual replacements | , | 107.50 | 4 |
| | 1054 | out the interston, indiad reproduction | | | |

(Listings for ectopic pregnancy, hysterotomy, abortion and postpartum tubal interruption are on pages 149,150)

- Preamble FOR DEFINITION OF THE ROLE OF THE REFERRING PHYSICIAN, SEE REFERRING PHYSICIAN SERVICES ON PAGE ix.
 - FOR DEFINITION OF THE ROLES OF THE ANAESTHETIST, SEE ANAESTHETIST SERVICES ON PAGES x and xi. (1) The surgical benefit (except for those procedures marked I.O.P., Complete Care and Fractures and Dislocations requiring no reduction) includes hospital visits rendered by the surgeon two days prior to surgery, the operative procedure, the post-operative care usually associated with the procedure(s) rendered by the surgeon while the patient is in hospital, and one office visit for follow up examination if necessary. If the surgeon is required to perform a procedure(s) not usually associated with the original surgical procedure, he may claim for these on a fee for service basis. If special visits to hospital are required at any time post-operatively, the surgeon may claim the special visit premiums even if the basic hospital visit fees are not chargeable (under these circumstances the hospital visits should be claimed on an N/C (no charge) basis.) The surgical benefit as noted above does not include the major pre-operative visit i.e. the consultation or assessment fee chargeable when the decision to operate is made and the operation is scheduled, regardless of the time interval between the major pre-operative visit and surgery. The hospital or day-care admission assessment (consultation, repeat consultation, general or specific assessment or re-assessment) is not a benefit to the surgeon unless it happens to be the major pre-operative visit as defined above. Hospital visits (minor assessments) may be claimed for visits rendered more than two days prior to surgery. Other visits (excluding admission assessments) prior to admission may be claimed for in addition to the surgical fee. For patients remaining in hospital because of complications, hospital visit fees may be claimed in addition to the surgical or procedural fee after six weeks of hospitalization in the case of fractures and dislocations and after two weeks post operatively for other procedures. Because the number of hospital visits is limited to three per week after the fifth week of hospitalization and six per month after the thirteenth week of hospitalization, the starting point for calculating the number of hospital visits is based on the date of agmission if the operating surgeon has admitted the patient or the date of referral (first day of service) if the patient has been referred to the operating surgeon while in hospital. The surgical benefit includes the generally accepted surgical components of the procedure. The listed benefit of a procedure normally includes repair of any introgenic complications occurring during the course of the surgery.
 - (2) When a physician makes a special trip to perform a non-elective surgical procedure during the daytime (Monday to Friday), he should claim the appropriate special visit, a consultation if the case is referred or the appropriate assessment if the case is not referred plus the procedural benefit(s). If the non-elective procedure is carried out at night (after 5:00 p.m. and before 7:00 a.m.), or Saturdays, Sundays and Holidays, the physician may claim the special visit applicable to the consultation or assessment, and the surgical premium (E409 or E410 see paragraph 47 of the Preamble).
 - (3) When more than one procedure is carried out by a surgeon under the same anaesthesia or within 14 days during the same hospitalization for the same condition, the full benefit applies to the major procedure and 85% of the listed benefit(s) applies to the otner procedure(s) performed unless otherwise stated in the Preamble(s) or Schedule. The above statement applies to staged or bilateral procedures but does not apply when a normal appendix or simple ovarian or para-ovarian cyst is removed incidentally during an operation, for which no claim should be made.
 - (4) When a subsequent operation becomes necessary for the same condition because of a complication or for a new condition, the full benefit should apply for each procedure.
 - (5) When a subsequent non-elective procedure is done for a new condition by the same surgeon, the full benefit will apply to each procedure. When a subsequent elective procedure is done for a different condition within 14 days during the same hospitalization by the same surgeon, the benefit for the lesser procedure shall be reduced by 15%.
 - (6) When different operative procedures are done by two different surgeons under the same anaesthesia for different conditions, the benefit will be 100% of the listed benefit for each condition. Under these circumstances, the basic assistants' benefit should not be charged by either operating surgeon; however time units may be claimed.
 - (7) As a general rule, when elective bilateral procedures are performed by two surgeons at the same time, one surgeon should charge for the surgical procedures and the other surgeon should claim the assistant's benefit.
 - (8) Where two surgeons are working together in surgery in which neither a team fee or other method of billing is set out in the benefit schedule, the surgeon should identify himself as the operating surgeon and claim accordingly; the surgeon who is assisting him should identify himself as such and claim the assistant's benefit. Where the second or assistant surgeon is brought into the case on a consultation basis, he may, when indicated, claim a consultation as well but should be prepared to justify it on an I.C. basis. If the nature or complexity of a procedure requires more than one operating surgeon each providing a separate service in

his own specialized field e.g. one surgeon carries out the ablative part and another surgeon the reconstructive part of the procedure, then each surgeon should claim the listed benefit for his services. This statement applies when the additional procedure(s) are not the usual components of the main procedure. If one surgeon in addition to performing a specialized portion of a procedure, acts as an assistant during the remainder of the procedure, he may also claim time units for assisting.

- (9) Unless otherwise stated, the listed benefits are for unilateral procedures only.
- (10) When a procedure is performed, a procedural benefit, if listed, should be claimed. Substitution of consultation and/or visit benefits for procedural benefits (except as in paragraph 11), is not in keeping with the intent of the benefit schedule.
- (11) When a surgical benefit (non I.O.P., Complete Care, Fracture or Dislocation) is less than the consultation benefit and the case is referred, the physician may claim the consultation benefit instead of the surgical benefit. However, to avoid the consultation being counted as such under the OHIP limitation rules on the number of consultations allowed per year, the physician should claim the consultation fee under the surgical procedure nomenclature or code. Since the consultation is replacing a procedural benefit which includes the pre- and post-operative and surgical care, no additional claims beyond the consultation should be made.
- (12) If a physician performs a minor surgical procedure and during the same visit assesses and treats the patient for another completely unrelated and significant problem involving another body system, the physician should claim for the procedure as well as the appropriate assessment
- (13) Where a procedure is specified as "Independent Operative Procedure (I.D.P.)", the procedural benefit should be claimed in full along with the appropriate consultation or visit when both services are actually rendered. However, when an I.D.P. procedure is done in conjunction with a non-I.O.P. procedure, there should be no claim for the consultation, pre- and post-operative care related to the I.O.P. procedure. The listed I.O.P. benefit should be claimed in these circumstances along with the non-I.O.P., benefits plus the related major pre-operative visit (see paragraph (1) of Surgical Preamble). When multiple or bilateral I.O.P. procedures are performed at the same time by the same physician, the listed procedural benefits should be claimed as if only one procedure had been performed. When a patient is examined in a physician's office and this leads to an elective Independent Operative Procedure (I.O.P.) being performed for the same problem or diagnosis by the same physician in the Emergency or Outpatient Department on a non-admission basis, the physician should claim a consultation or visit for the examination in the office and the fee for the I.O.P. carried out in the Emergency Outpatient Department. An additional assessment benefit at the time of the elective I.O.P. should only be claimed when an additional assessment is performed.
- (14) When procedures are specifically listed under Surgical Procedures, surgeons should use these listings rather than applying one of the plastic surgery listed fees under Operations on Skin and Subcutaneous Tissue.
- (15) For excision of tumours not specifically listed in this Schedule, claims should be made on an I.C. basis (code R993). Independent consideration also will be given (under code R990) to claims for other unusual but generally accepted surgical procedures which are not listed specifically in the Schedule (excluding non-major variations of listed procedures). In submitting claims, physicians should relate the service rendered to comparable listed procedures in terms of scope and difficulty (see Preamble, Part B, paragraph 32).
- (16) Cosmetic or Aesthetic Surgery: means a service to enhance appearance without being medically necessary such as (a) surgery for correction of facial wrinkles; (b) surgery for eyelid wrinkles (symmetrical and without a functional problem); (c) rhinoplasty for appearances only; and (d) augmentation mammoplasty for symmetrical deficiency without physiological abnormality. These services are not benefits of OHIP. (See Preamble, Appendix D).
- (17) Reconstructive Surgery: is surgery to improve appearance and/or function to any area altered by disease, trauma or congenital deformity. Although surgery solely to restore appearance may be included in this definition under certain limited conditions, emotional, psychological or psychiatric grounds normally are not considered sufficient additional reason for OHIP coverage of such surgery. Appendix D of the Preamble to this Schedule describes the conditions under which surgery for alteration of appearance, only, may be a benefit of the Plan.
 - Physicians should submit requests to their District OHIP office for authorization of any proposed surgery which may fall outside of OHIP coverage. (See Appendix D).
- (18) Procedural benefits (non I.O.P.) include the removal of sutures when both services are rendered by the same physician unless the removal of sutures is done on the second or subsequent office visit for follow up examination. When a physician is entitled to claim for removal of sutures i.e. as outlined in the previous sentence or is a physician other than the operating surgeon or following an I.O.P. procedure, an office visit may be claimed.

- (19) Additional claims for biopsies performed when a surgeon is operating in the abdominal or thoracic cavity should be given independent consideration.
- (20) When a listed procedure is performed and no anaesthetic is required, the procedure should be claimed under the "local anaesthetic" listing.
- (21) When a physician administers an anaesthetic and/or other medication prior to, during a procedure(s) or immediately after a procedure(s) which he/she performs on the same patient, he/she should claim for the procedure(s) only. However, when a physician administers a pudendal, femoral, intercostal, sciatic, ilioguinal, iliohypogastric, ulnar, median or radial block in addition to performing a procedure, he may claim \$13.10 (G224) in addition to the procedure.
- (22) If claims are being submitted in coded form, the surgeon should add the suffix A to the listed procedural code, the surgical assistant should add the suffix B to the listed procedural code and the anaesthetist should add the suffix C to the listed procedural code.

OPERATIONS ON THE INTEGLMENTARY SYSTEM

| Code | | Asst | Surg. | Anaes |
|--------------|---|------|---------------|-------|
| | SKIN AND SUBCUTANEOUS TISSUE | | | |
| | Incision (I.O.P.) | | | |
| | | | | |
| | Abscess or Haematoma | | | |
| Z101 | local anaesthetic - subcutaneous - one | | 17.20 | |
| Z173 | - two | | 25.90 | |
| Z174 | - three or more | | 34.80 | |
| Z104 | - perianal | | 17.20 | |
| Z106 | - ischiorectal or pilonidal | | 37.90 | |
| Z103 | - palmar or plantar spaces | | 37.90 | |
| Z102 | general anaesthetic - subcutaneous - one | | 37.90 | 4 |
| Z172 | - two or more | | 56.90 | 4 |
| Z105 | - perianal | | 37.90 | 4 |
| Z107 | - ischiorectal or pilonidal | | 61.60 | 4 |
| Z108 | - palmar or plantar spaces | | 61.60 | 4 |
| Z119 | Comedones, acne pustules, milia - ten or less | | 3.30 11.60 | |
| Z120 | - eleven or more | | 16.10 | |
| Z114 | Foreign body removal - local anaesthetic | | 75.90 | 4 |
| Z115 | - general anaesthetic | | I.C. | 4 |
| Z100 Z227 | - complicated (see Predible para 8.32) | 4 | 96.80 | 4 |
| Z118 | Aspiration of superficial lump for cytology | | 24.20 | - |
| Z116 | Biopsy(s) - any method - when sole procedure | | 12.60 | |
| Note: | Z116 may be allowed more than once on an I.C. basis if medically necessary | | 12.00 | |
| noce: | (in order to make a diagnosis or to plan treatment) to biopsy more than one | | | |
| | lesion or to obtain a second biopsy from an extensive lesion. If claimed, | | | |
| | may be allowed with chemical treatment of lesion (code ZI17). | | | |
| | may be arrowed with themical treatment or restor (osce 237): | | | |
| | - extensive, complicated or requiring general anaesthetic when | | | |
| Z155 | sole procedure (see Preamble para B.32) | | I.C. | I.C. |
| 7245 | Biopsy for malignant hyperthermia, three or more | | 130.70 | 10 |
| 22.13 | bropsy for marry and a first or marry and a second or marry and a | | | |
| | Excision (with or without biopsy) | | | |
| | Lesions - single or multiple sites (I.O.P.) | | | |
| | Group 1 - e.g. verruca, papilloma, keratosis, pyogenic | | | |
| | granuloma, spider naevus | | | |
| Z156 | Removal by excision and suture - single lesion | | 12.60 | 4 |
| Z157 | - two lesions | | 19.00 | 4 |
| Z158 | - three or more lesions | | 31.60 | 4 |
| | Removal by electrocoagulation and/or curreting | | | |
| Z159 | - single lesion | | 9.00 | 4 |
| Z160 | - two lesions | | 13.55 | 4 |
| Z161 | - three or more lesions | | 22.40 | 4 |
| | Group 2 - naevus | | | |
| Z162 | Removal by excision and suture - single lesion | | 12.60 | 4 |
| Z163 | - two lesions | | 19.00 | 4 |
| Z164 | - three or more lesions | | 31.60 | 4 |
| Z165 | Congenital (extensive) (see Preamble para B.32) | | I.C. | |
| Note: | Naevi removed for cosmetic purposes and not for any clinical suspicion of | | | |
| | disease or malignancy may be billed to the patient. | | | |
| | | | | |

| | SURGICAL PROCEDURES | | | |
|-------|--|------|---------|-------|
| | OPERATIONS ON THE INTEGLMENTARY SYSTEM - Cont'd. | | | |
| Code | | Asst | Surg | Anaes |
| 0000 | SKIN AND SUBCUTANEOUS TISSUE - Cont'd. | 7030 | Jurg | Aides |
| | Group 3 - plantar verruca | | | |
| Z166 | Removal by excision and suture - single lesion | | 24.90 | 4 |
| Z167 | - two lesions | | 37.10 | 4 |
| Z168 | - three or more lesions | | 61,60 | 4 |
| | Removal by electrocoagulation and/or curetting | | | |
| Z169 | - single lesion | | 17,20 | 4 |
| Z170 | - two lesions | | 25.90 | 4 |
| Z171 | - three or more lesions | | 51.30 | 4 |
| | Group 4 - cyst, haemangioma, lipoma | | | |
| | Face or neck | | | |
| Z122 | local anaesthetic - single lesion | | 27.60 | |
| Z123 | - two lesions | | 40.70 | |
| Z124 | - three or more lesions | | 55,95 | |
| Z145 | general anaesthetic - single lesion | 3 | 56.15 | 4 |
| Z146 | - two lesions | 3 | 84.40 | 4 |
| Z147 | - three or more lesions | 3 | 112.20 | 4 |
| Z148 | - extensive or massive (see Preamble para 8.32) | | I.C. | 5 |
| 2270 | - CACCIDITE OF MESSIVE (SCENT CONTROL PORT OF ORDER) | | | |
| | Other areas | | | |
| Z125 | local anaesthetic - single lesion | | 21.20 | |
| Z126 | - two lesions | | 32.60 | |
| Z127 | - three or more lesions | | 42.80 | |
| Z149 | general anaesthetic - single lesion | 3 | 42.80 | 4 |
| | general andestrects - Single resion | 3 | 56.15 | 4 |
| Z150 | - two lesions | | | 4 |
| Z151 | - three or more lesions | | 84.40 | |
| Z152 | - extensive or massive (see Preamble para B.32) | 3 | I.C. | 5 |
| R034 | Congenital dermoid cyst - adult | 3 | 106.50 | 4 |
| R043 | - infant or child | | 172.00 | 4 |
| R042 | - midline, e.g. nasal | 3 | 233.50 | 4 |
| R037 | Giant cell tumour | 3 | 106.50 | 4 |
| R035 | Pilonidal cyst - simple excision or marsupialization | 3 | 156.90 | 4 |
| R036 | - excision and skin shift | 3 | 213.00 | 4 |
| | | | | |
| | Inguinal, perineal or axillary skin and sweat glands for hyperhydrosis and/ | | | |
| | or hydradenitis | | | |
| R059 | - unilateral | 3 | 213.00 | 5 |
| R060 | - with skin graft(s) or rotation flap(s) | | 323.60 | 6 |
| NOOO | Malignant Lesions including biopsy of each lesion | | 020.00 | · |
| | | | | |
| | - single or multiple sites | | | |
| 0040 | Simple excision - face or neck | 3 | 62.25 | 4 |
| R048 | - single lesion | | 102.40 | 4 |
| R049 | - two lesions | | 204.80 | 4 |
| R050 | - three or more lesions | 3 | 204.00 | 4 |
| 2004 | Simple excision - other areas | 2 | 40.00 | 4 |
| R094 | - single lesion | | 49.80 | |
| R040 | - two lesions | | 81.90 | 4 |
| RO41 | - three or more lesions | | 163.80 | 4 |
| E540 | if excision is performed in hospital for tumour free margin with froze | n | | |
| | section, add 25% to excision or repair fees (see Note below) | | | |
| | Curettage, electrodesiccation or cryosurgery - face or neck | | | |
| R018 | - single lesion | 3 | 58.70 | 4 |
| R019 | - two lesions | 3 | 96.70 | 4 |
| R020 | - three or more lesions | 3 | 193.30 | 4 |
| | Curettage, electrodesiccation or cryosurgery - other areas | | | |
| R031 | - single lesion | 3 | 47.10 | 4 |
| R032 | - two lesions | 3 | 77.60 | 4 |
| R033 | - three or more lesions | | 155.20 | 4 |
| R081 | Chemosurgery (Mohs technique) (see Preamble para B.32) | | I.C. | I.C. |
| R051 | Laser surgery on Group 1-4 and malignant lesions | | I.C. | I.C. |
| 11001 | Lasti sargery on aroup a rana marrismano ractions overter | | | |
| Note: | When excision of benign or malignant lesions are corrected by advancement, | | | |
| HOUE. | rotation, transposition, "Z" plasty, flap or graft, claim appropriate | | | |
| | benefit listed under Repair Section instead of foregoing excision | | , | |
| | benefits. | | | |
| | Dana (C3) | | | |
| | Desais | | | |
| | Repair | | | |
| | Debridement and Dressing (I.O.P.) - not chargeable in addition to any | | | |
| | surgical procedure unless complications require such care in excess of | | | |
| | the usual post-operative care | | wic44 4 | 000 |
| U.V.C | | | visit f | ee |
| Z153 | - major (not chargeable in addition to Z176) | | 11.90 | |
| Z144 | - requiring general anaesthetic | 4 | 48.10 | 4 |
| R082 | - extensive (see Preamble para B.32) | 4 | I.C. | 5 |
| | | | | |

| | OPERATIONS ON THE INTEGLMENTARY SYSTEM - Cont.'d. | | | |
|---------------|--|------|------------------|----------|
| Code | | Asst | Surg | Anaes |
| | SKIN AND SUBCUTANEOUS TISSUE - Cont'd. | | | |
| | Quant. | | | |
| | Burns For Burn care requiring anaesthetists' and assistants' services the following | 201 | | |
| | fees apply: | 73 | | |
| R030 | Minor burns - up to 15% | 4 | | 5 |
| R039 | Moderate burns - 16% to 30% Major burns - more than 30% | 6 | | 10 15 |
| | | ., | | 13 |
| Z130 Z181 | Resuscitation - major burn, initial care, 1st 24 hours | | 90.90 | |
| 2181 | - continuing care (up to 3 days), per day Debridement and excision, per % of total body treated other | | 45.50 | |
| R637 | than hand, head or neck | | 25.40 | |
| ncco | Debridament and excision | | | |
| R660 R661 | - hand, each digit - dorsum palm - each | | 25.40 | |
| R662 | - nose, cheek, lip, ear, forehead, scalp, neck, eyelid - each | | 25.40 | |
| 0.000 | Grafting of burn, per % of total body treated | | | |
| R638 | other than hand, head or neck | | 42.20 | |
| R663 | - hand, each digit | | 50,60 | |
| R664 | - palm, dorsum - each | | 101.20 | |
| R665 R666 | - nose, lip(s) - each | | 168.75 | |
| R667 | - cheek(s), forehead - each | | 168.75 168.75 | |
| R668 | - eyelid | | 158.75 | |
| R569 R670 | - scalp, less than 10% | | 84.40 | |
| R671 | up to 50% | | 210.90 1.C. | |
| R572 | - neck, less than 10% | | 84.40 | |
| R673 | up to 50% | | 185.50 | |
| R674 | over 50% | | I.C. | |
| | Suture of Lacerations (1.0.P.) | | | |
| Z176 | - up to 5 cm | | 12.70 | 4 |
| Z154 | - up to 5 cm if on face and/or requires tying of bleeders and/or closure in layers | | 30,50 | 4 |
| Z175 | - 5.1 to 10 cm | | 30.50 | 4 |
| | - 5.1 to 10 cm. if on face and/or requires tying of bleeders and/or closure | | | |
| Z177 Z179 | in layers | | 61.00 | 4 |
| 21/7 | - 10.1 to 15 cm 10.1 to 15 cm if on face and/or requires tying of bleeders and/or closure | | 43.20 | ~ |
| Z190 | in layers | | 86.80 | 4 |
| Z191 | - more than 15.1 cm. (see Preamble para B.32) | | I.C. | 4 |
| E530 | - if inhalation general anaesthesia (other than 50% N ₂ 0/0 ₂ mixture) is used add, | | 43.20 | |
| E531 | - If extensive debridement is required, add (see Preamble para 8.32) | | I.C. | |
| E542 U.V.C | - when sutures are inserted in private office, add | | 4.90 risit fee | |
| | - removal of sutures only | , | visit iee | |
| | toxoid and routine observation until the sutures have been removed. | | | |
| R525 | Muscle Repair Similar music and an include annie of implied this | 2 | 75,80 | 4 |
| R528 | Simple muscle repair(s) to include repair of involved skin | | I.C. | 6 |
| | | | | |
| | Skin Flaps and Grafts - The benefit will depend on the size and location of the area grafted and the type of graft. Additional procedures other than | | | |
| | the skin grafting are extra, e.g. tendon grafts, inlay grafts, etc. Skin | | | |
| | flaps or grafts done during a procedure should be claimed on their own | | | |
| | merit (unless specifically listed as being inclusive for that procedure). | | | |
| | Skin Flaps A. Advancement Flaps (to include undermining of more than 2.5 cm. per side) | | | |
| | is intended to include excision of a lesion if this is technique of | | | |
| 0011 | closure. | 3 | 74,95 | 4 |
| R011 R002 | If defect is 2.1 to 5 cm - face or neck | 3 | 50.20 | 4 |
| R012 | If defect is 5.1 to 10 cm - face or neck | 3 | 113.45 | 5 |
| R003 R004 | - other areas | 3 | 75.30 1.C. | 5 |
| 1004 | 11 Degrand 10 cui suuri as chorache abdumman map (see meanbre para 6-32) | 7 | 1.0. | Ů, |
| | | | | |

| | OPERATIONS ON THE INTEGUMENTARY SYSTEM - Cont'd. | | | |
|--------------|---|------|------------------|-------|
| Code | or avitors of the intermediation of the control of | Asst | Surg | Anaes |
| | SKIN AND SUBCUTANEOUS TISSUE - Cont'd. | | | |
| | B. Rotations, Transpositions, "Z" plasties (includes undermining) but will | | | |
| 2045 | depend on the site and size. | 2 | 175 20 | |
| R045 R072 | Defect less than 2 cm average diameter - face or neck | 3 | 175.30 117.10 | 4 |
| R046 | - other areas Defect 2.1 to 5 cm average diameter - face or neck | 3 | 294.50 | 4 |
| R075 | - other areas | 3 | 196.20 | 4 |
| RO47 | Defect 5.1 to 10 cm average diameter - face or neck | 4 | 419.40 | 4 |
| R073 | - other areas | 4 | 279.75 | 4 |
| R074 | Defect more than 10 cm average diameter (See Preamble para B.32) | 4 | I.C. | 5 |
| | | | | |
| | C. Pedicle Flaps | | 117.10 | |
| R079 R077 | Small e.g. cross finger | 4 | 117.10 87.65 | 4 |
| R070 | - each subsequent stage | 4 | 258.00 | 5 |
| R071 | - each subsequent stage | 4 | 196.20 | 5 |
| R080 | Large e.g. cross leg, deltopectoral, forehead | 4 | 365.80 | 6 |
| R078 | - each subsequent stage | 4 | 273,60 | 6 |
| R103 | Delay of tube or pedicle | | 55.50 | 4 |
| R101 | Delay, intermediate flap | 3 | 116.30 | 4 |
| R100 | Delay, major flap | 4 | 256.40 | 5 |
| | | | | |
| | D. Myo-Cutaneous Flaps (to include closure by any means) | | | |
| | Sterno-mastoid, tensor fascia lata, gluteus maximus, gracilis, sartorius, rectus femoris, gastrocnemius (medial and lateral), | | | |
| R005 | trapezius | 3 | 413.70 | 5 |
| R006 | Pectoralis major, latissimus dorsi, unilateral rectus abdominus | 4 | 645.50 | 6 |
| R008 | Lower transverse rectus abdominus flap | 6 | 559.50 | 8 |
| Z195 | - repair of abdominal defect - same surgeon | | 172.00 | |
| Z196 | - different surgeon | | 331.80 | |
| | Myocutaneous - osseous flaps e.g. pectoralis major myocutaneous flap with | | | |
| R009 | rib graft, trapezius flap with scapula spine | 5 | 688.10 | 8 |
| R007 | Other (See Preamble para, B.32) | 1.6 | . I.C. | I.C. |
| | Skin Grafts | | | |
| | Skill Gratus | | | |
| | A. Split Thickness Grafts (for burn grafts see p.79) | | | |
| R084 | Very minor, very small areas, e.g. trauma | | 81.10 | 4 |
| R085 | Minor, medium sized areas, e.g. small or skin ulcer, breast, etc | | 123.30 | 4 |
| R086 | Intermediate, large areas, e.g. trunk, arms, legs | 4 | 227.70 340.80 | 5 |
| R087 R088 | Major, complex areas, e.g. face, neck, hands | 4 | 498.90 | 6 |
| KUOO | Extensive major, very large areas(s) | , | 430450 | Ů |
| | B. Full Thickness Grafts | | | |
| R092 | Minor - less than 1 cm. average diameter | | 81.90 | 4 |
| R093 | Intermediate = 1 cm. to 5 cm. average diameter | 3 | 125.70 | 4 |
| R083 | Major - over 5 cm. (See Preamble para. B.32) | 5 | 1.0. | 5 |
| R091 | Complex - eyelid, nose, lip, face | 4 | 184.70 | 5 |
| Note: | Descriptive details of procedure(s) (e.g. operative report) should be submitted with claims for professional assessment for RO91, RO83. | | | |
| | Appendage or tissue re-vascularization involving microanastomosis with or | | | |
| R057 | without micro neuroanastomosis (See Preamble para, 8.32) | I.C | . I.C. | I.C. |
| R058 | Revision of above (See Preamble para, B.32) | I.C | . I.C. | I.C. |
| | | | | |
| | Stasis Ulcer | 2 | 172 00 | 5 |
| R847 | - with skin graft - per leg | 5 | 172.00 292.45 | 5 |
| R845 | - multiple ligation and skin graft - per leg | J | 232.43 | 3 |
| | Neurovascular Island Transfer | | | |
| R061 | Minor e.g. finger tip | 3 | , 123.30 | 4 |
| R062 | Intermediate e.g. finger to thumb transfer | . 4 | 227.70 | 5 |
| R063 | Major e.g. foot to heel | . 4 | 378.50 | 6 |
| | | | | |
| | Free Island Flaps | | | |
| 20004 | Elevation of free island skin and subcutaneous flap and closure of | 10 | 731.50 | 10 |
| R064 | defect | 10 | /31.30 | 10 |
| | | | | |

| | SURGICAL PROJEDURES | | | |
|--------------|---|------|---------|-------|
| | OPERATIONS ON THE INTEGLMENTARY SYSTEM - Cont'd. | | | |
| Code | O BOOTONS OF THE INTEGORENIART STSTEM - CORE O. | | | |
| COUC | | Asst | Surg | Anaes |
| | SKIN AND SUBCUTANEOUS TISSUE - Cont'd. | | | |
| | SKIN AND SUBCUMMENTS 11550E - CONT. O. | | | |
| | Decoration of mineral and administrative for face 1.1. 1.1. 1.1. | | | |
| nnce | Preparation of microvascular recipient site for free island skin subcutan- | | | |
| R065 | eous flap | | 774.10 | |
| pocc | Transplantation of free island skin and subcutaneous flap with microvas- | | | |
| R066 | cular anastomosis | | 774.10 | |
| | Elevation of innervated free island skin and subcutaneous flap and closure | | | |
| R067 | of defect | 10 | 860.20 | 10 |
| | Preparation of microvascular recipient site for innervated free island skin | | | |
| R068 | and subcutaneous flap | | 860.20 | |
| | Transplantation of innervated free island skin and subcutaneous flap with | | | |
| R069 | microvascular anastomosis and nerve repair | | 804,45 | |
| R125 | Elevation of free island skin and muscle flap and closure of defect | 10 | 731.50 | 10 |
| | Preparation of microvascular recipient site for free island skin and muscle | | | |
| R126 | flap | | 774.10 | |
| | Transplantation of free island skin and muscle flap with microvascular | | | |
| R127 | anastomosis | | 731.50 | |
| 11067 | Elevation of free island muscle flap with tendon and nerve, and closure | | 31.000 | |
| R128 | of defect | 10 | 090 50 | 10 |
| 1120 | | 10 | 989.60 | 10 |
| R129 | Preparation of microvascular recipient site for muscle, tendon and nerve | | 000 60 | |
| RIZS | anastomosis | | 989.60 | |
| 2120 | Transplantation of free island muscle flap with tendon, nerve and micro- | | 000 50 | |
| R130 | vascular anastomosis | 10 | 989.60 | 10 |
| R131 | Elevation of free island bone flap and closure of defect | 10 | 731.50 | 10 |
| R132 | Preparation of microvascular recipient site for free island bone flap | | 774.10 | |
| | Transplantation of free island bone flap wih microvascular anastomosis | | | |
| R133 | and bone fixation | | 860.20 | |
| R134 | Elevation of free island skin and bone flap and closure of defect | 10 | 877.40 | 10 |
| | Preparation of microvascular recipient site for free island skin and bone | | | |
| R135 | flap | | 877.40 | |
| | Transplantation of free island skin and bone flap with microvascular | | | |
| R136 | anastomosis and bone fixation | | 877.40 | |
| R137 | Elevation of free toe or finger and closure of defect | 10 | 877.40 | 10 |
| | Preparation of microvascular recipient site for free toe or finger trans- | | | |
| R138 | plant | | 877.40 | |
| | Transplantation of free island toe or finger with microvascular anastomosis | | | |
| R139 | and tendon nerve and bone repair | | 1032.20 | |
| R025 | Revision of free island flaps (see Preamble para 8.32) | | I.C. | 10 |
| R106 | Skin Flaps and Grafts - other than listed above (see Preamble para 8.32) | | I.C. | I.C. |
| | | | | |
| | Destruction | | | |
| Z121 | Epilation of facial hairs (I.O.P.) - per quarter hour | | 14.40 | |
| Note: | Claims for the above procedure require OHIP authorization (see Surgical | | 2.00 | |
| 1000. | Preamble, paragraph (17)). | | | |
| | Finger or toe-nail (I.O.P.) | | | |
| 7120 | | | 20.35 | 4 |
| Z128 Z129 | Simple, partial or complete - one | | | 4 |
| 2129 | - multiple | | 30.50 | 4 |
| 7120 | Radical, including destruction of nail bed | | 50.80 | 4 |
| Z130 Z131 | - 00e | | | 4 |
| Z131 | - multiple | | 70.90 | 4 |
| 71.2.7 | Chemical and/or cryotherapy treatment of minor skin lesions (I.O.P.) | | 0.50 | |
| Z117 | - one or more lesions, per treatment | | 9.50 | |
| Maria | Plastic Planing (Dermabrasion) - face or acne | | | |
| Notes: | (1)R096, R104, R097 - not a benefit of OHIP for areas other than the face. | | | |
| | (2)RO98 - Claims for this procedure require OHIP authorization (see | | | |
| | Surgical Preamble, paragraph (17)). | | | |
| | (3)Plastic Planing/Dermabrasion by areas, as an insured service, may | | | |
| | not exceed the fee for RO97. | | 05 | |
| R096 | - each area | | 86.00 | 4 |
| R104 | - both cheeks | | 180.60 | 4 |
| R097 | - whole face | | 275.25 | 4 |
| R098 | - single area, e.g. trauma scar | | 49.35 | 4 |
| R099 | Rhinophyma, removal by shaving | | 221.20 | 4 |
| R089 | Webbed Fingers - one web space | 4 | 236.70 | 5 |
| R090 | Webbed Toes - one web space | 4 | 108.70 | 4 |
| | | | | |
| | Scar Revision - any method of closure | | | |
| Note: | OHIP authorization is required for all scar revision in areas other than | | | |
| | the face or neck (see Preamble, Appendix 0). | | | |
| R021 | up to 2.5 cm - face or neck | 3 | 101.60 | 4 |
| R026 | - other areas | 3 | 68.00 | 4 |
| TULU | - VMM: M: VM. 00000400111110001001111111111111111111 | | | |
| | | | | |

| | OPERATIONS ON THE INTEGUMENTARY SYSTEM - Cont'd. | | | |
|---------------|--|------|------------------|-------|
| Code | SKIN AND SUBCUTANEOUS TISSUE - Cont'd. | Asst | Surg | Anaes |
| R022 | 2.6 to 5 cm - face or neck | 3 | 171.20 | 4 |
| R027 | - other areas | | 114.30 | 4 |
| R023 | 5.1 cm to 10 cm - face or neck | | 244.10 | 5 |
| R028 | - other areas | 3 | 163.00 | 5 |
| R029 | - Greater than 10 cm. (see Preamble, Part B, paragraph 32). | 4 | I.C. | 6 |
| Note: | OHIP authorization is required for all scar revisions in areas other than the face or neck (see Preamble, Appendix D). | | | |
| | than the face of fleck (see Fleahble, Appendix b). | | | |
| | Plastic Surgery Procedures: | | | |
| | The setting of benefits covering the various procedures of plastic | | | |
| | surgery is a very difficult problem. Since many procedures are divided | | | |
| | into stages which have to be considered in assessing a fee, it is felt | | | |
| | that all such plastic surgical procedures should be classed by the | | | |
| | responsible specialist as very minor, major, intermediate, major, or extensive major. Benefits should be claimed according to procedures set | | | |
| | forth in the tariff, except in cases which are difficult to define, in | | | |
| | which case "I.C." should be the basis of the claim. The minimum benefit | | | |
| | for each would be as follows: | | | |
| R150 | Very Minor | | 81.10 | 4 |
| R151 | Minor | | 122.90 | 4 |
| R152 | Intermediate | | 227.70 | 5 |
| R153 R154 | Major | | 340.80 499.70 | 6 |
| Notes: | | 4 | 433.70 | 0 |
| 110663 | submitted with claims for codes R150-R154 for professional assessment. | | | |
| | (2) Taking of skin by a surgeon for grafting by an Oral Surgeon claim as | | | |
| | R150. | | | |
| ~ | 4.003 | 2 | 170.05 | - |
| Z132 | Insertion of tissue expander (I.O.P.) | 3 | 172.85 | 5 |
| Note: Z137 | Authorization may be required from OHIP (e.g. for scars of legs etc.) Percutaneous inflation of tissue expander(s) per visit (1.0.P.) | | 20.30 | |
| E541 | Each additional expander - to a maximum of 3 per visit add 50% | | -0.00 | |
| Z138 | Replacement of tissue expander by permanent prosthesis (1.0.P.) | | 172.00 | 4 |
| | | | | |
| | OPERATIONS ON THE BREAST | | | |
| | Incision | | | |
| Z141 | Needle biopsy - one or more (I.O.P.) | | 21.30 | |
| Z139 | Aspiration of cyst - one or more (I.O.P.) | | 21.30 | |
| | Drainage of intramammary abscess or hematoma - single ore multi loculated | | | |
| | (I.O.P.) | | | |
| Z140 | - local anaesthetic | | 21.30 | |
| Z740 | - general anaesthetic | | 53.65 | 4 |
| | Excision | | | |
| | Tumour or tissue for diagnostic biopsy and/or treatment e.g. carcinoma, | | | |
| | fibroadenoma or fibrocystic disease (single or multiple - same | | | |
| R107 | breast) | 3 | 116.30 | 4 |
| | Partial mastectomy or wedge resection for treatment of breast disease | 2 | 176 10 | |
| R111 | with or without biopsy e.g. carcinoma or extensive fibrocystic disease | 3 | 176.10 206.40 | 4 |
| E546 | - with radical axillary node dissection, add | | 200.40 | 2 |
| R115 | - simple | 3 | 150.70 | 4 |
| R116 | - subcutaneous with nipple preservation | 4 | 232.65 | 5 |
| Note: | R116, R117 - include skin grafts if required. | | | |
| | R109 - allowed skin graft in addition if claimed. | | | |
| 0100 | Mastectamy - female (with or without biopsy) - simple | Λ | 232.65 | 5 |
| R108 R117 | - simple subcutaneous with nipple preservation | | 232.65 | 5 |
| R109 | Mastectomy, radical or modified radical (with or without biopsy) | 5 | 430.10 | 6 |
| | , | | | |

| | OPERATIONS ON THE INTEGLMENTARY SYSTEM - Cont'd. | | | |
|---------------|---|------|--------|-------|
| Code | | Asst | Surg | Anaes |
| | OPERATIONS ON THE BREAST - Cont'd. | | | |
| | Repair | | | |
| Notes: | R118 - R112 - Claims for these procedures may require OHIP authorization (see Surgical Preamble, paragraphs (16), (17) and Preamble, Appendix D). Post-mastectomy breast reconstruction | | | |
| R119 | - breast mound creation by prosthesis and/or soft tissue | 4 | 266,20 | 5 |
| R118 | - breast skin reconstruction by local flaps or grafts | | 356.35 | 5 |
| E529 Note: | - with breast mound creation by prosthesis and/or soft tissue, .add - by myocutaneous flaps - see codes ROO5 - ROO9 | | 90.10 | |
| R114 | - revision of breast mound | 3 | 202.30 | Δ |
| R113 | Nipple-areola preservation and tissue-banking | 3 | 103.20 | 4 |
| R121 | Reimplantation of tissue-banked nipple-areola | | 120.40 | 4 |
| R120 | Nipple-areola reconstruction by grafts | | 202.30 | 4 |
| | Reduction mammoplasty (female, to include nipple transplantation or | | | |
| R110 | grafting) - unilateral | 5 | 417.00 | 7 |
| R112 | Augmentation mammoplasty - unilateral | | 175.10 | 4 |
| Z142 | Removal of breast prosthesis (1.0.P.) | | 69.50 | 4 |
| Z133 | Breast capsulotomy closed (1.0.P.) - no anaesthetic | | 10.85 | |
| Z134 | - general anaesthetic | 3 | 69.60 | 4 |
| 7135 | Open capsulotomy with or without replacement of breast prosthesis (1 0 P) | 3 | 172 M | Δ |

OPERATIONS ON THE MUSCULOSKELETAL SYSTEM

Preamble:

(1) Corrective splints must be "corrective" to qualify for a benefit as such. The corrective splint listings are not applicable to simple immobilization such as with a Jones bandage or metal finger

splint following soft tissue injury.

The removal of a wire or pin or other device when used for traction or external fixation (except for rigid external fixators) in the treatment of a fracture or other orthopaedic procedure is to be included in the procedural fee unless a general anaesthetic is required in which case a fee may be claimed. Removal of devices used for internal fixation more than 30 days after insertion may be charged for in addition to the procedural benefit.

(3) The benefit for total hip replacement also includes denervation of the hip joint and adductor

tenotamy.

The benefit for obtaining a bone graft is not to be claimed in cases of pseudarthrosis repair, fusions or for listings in which bone grafting is included.

(5) For the supervision of limb fitting and 6 months post-operative care following amputation, claim visit fees. Amoutation with immediate fitting to include supervision of final limb fitting - add 40% (E586).

(6) Arthroscopic surgery shall constitute an arthrotomy for the purposes of this schedule and procedures shall command the same benefits.

Fractures and Dislocations:

- (a) For fractures or dislocations requiring open or closed reduction or no reduction, the major pre-operative visit i.e. consultation or appropriate assessment may be claimed in addition to the listed benefits.
- (b) OPEN REDUCTION shall mean the treatment of a fracture and/or dislocation by either closed intramedullary fixation or by an operative procedure to expose the fracture. The benefits include fixation by internal or external devices.

(c) CLOSED REDUCTION shall mean the reduction of a fracture or dislocation by non-operative methods (including traction).

(d) NO REDUCTION shall mean the treatment of a fracture or dislocation by any other method and includes

the use of the initial external support. (e) The stated benefit covers full or after treatment up to 6 weeks except if additional reductions are

necessary or if patient is transferred to another surgeon or if the patient is paraplegic. (f) In multiple fractures or dislocations, the benefit for the major fracture or dislocation shall be 100% and the benefit for the other fractures or dislocations 85%. When no procedural benefit is applicable, but when that fracture or dislocation necessitates hospitalization or concurrent care

over that demanded by the major injury, a visit benefit may be claimed in addition to other procedural benefits. For repeat reductions (closed or open) for the same fracture or dislocation, the full benefit should

- be claimed for the final reduction and after care previous reductions by the same surgeon should be claimed at 85%. (h) Emergency splinting of fractures in the emergency department should be on the basis of appropriate
- visit benefit, plus application of cast if appropriate.

(i) Transferred cases -

- (1) When patients are transferred to a chronic or convalescent facility, additional visit benefits on a chronic care basis shall be allowed to other than the operating surgeon (and also to the surgeon after 6 weeks).
- (2) When patients are transferred to another physician for after care of fractures and dislocations treated by closed or no reduction, the physician rendering the initial care should claim 75% of the listed fee and the surgeon rendering subsequent care visit fees except where otherwise specified. In cases involving open reduction, the percentage should be 80% for the surgeon providing the initial care.

(3) In cases where the original physician attempts to reduce a fracture or dislocation under general anaesthesia, is unsuccessful and refers the patient to another physician for definitive

care, the original physician should claim 75% of the listed fee.

(j) Paraplegia associated with fractures and dislocations may be claimed by charging visit fees after the first 2 weeks of post-operative care in addition to the appropriate procedural fees. Pseudarthrosis may be allowed as the appropriate benefit after the fracture is 4 months old.

For fractures and dislocations not requiring reduction, visit fees apply unless a specific fee is listed. If the listed fee is less than the consultation, the consultation should be claimed under the fracture/dislocation code number.

| Code | GENERAL FEES Bone/Fascial/Denmis Grafts | Asst | Surg | Anaes |
|----------------------|---|------|--------------------------|-------|
| E551 E552 Z242 | Autogenous - separate incision - same incision - different surgeon (1.0.P.) | | 76.50 51.60 170.40 | 4 |

| | COPPATIONS ON THE MARCH OCUPPATION CONTRACTOR CONTRACTO | | | |
|------|--|------|--------|-------|
| Codo | OPERATIONS ON THE MUSCULOSKELETAL SYSTEM - Cont'd. | | | |
| Code | GENERAL FEES - Cont'd. | Asst | Surg | Anaes |
| E553 | Homogenous - bank | | 22.00 | |
| 2000 | Allograft - donor - 85% of excision fee | | 22.00 | |
| R200 | - cadaver - per long bone, each | | 127.80 | |
| | por rong court essessessessessessessessessessessessess | | 127.00 | |
| | Fixation | | | |
| E547 | Methyl methacrylate (not arthroplasty) | | 52,40 | |
| £555 | Rigid external fixation (excluding casts) for closed reduction, add 40% | | 32.70 | |
| | to closed reduction fee | | | |
| E544 | Cast - bracing with closed reduction, add 40% to reduction fee | | | |
| E569 | Percutaneous pinning, add 30% to closed reduction | | | |
| E590 | Rigid external fixation - pseudarthosis | | 67.20 | |
| R267 | Removal fixation device - general anaesthetic | 3 | 140.10 | 4 |
| R258 | - local anaesthetic | 3 | 48.10 | 4 |
| R598 | Removal of extensive external fixation device under general anaesthesia | | 42,90 | 4 |
| 7210 | Insertion traction pin - excludes fractures and dislocations (I.O.P.) | | 29.30 | |
| | , | | | |
| | Wound Care | | | |
| Z783 | Secondary closure | | 85.80 | |
| E550 | Closed irrigation during a surgical procedure | | 55.70 | |
| | Extensive debridement of compound fractures or dislocations - | | | |
| E556 | add 40% to reduction fee | | | 2 |
| R517 | Excision of foreign body | | 95.00 | 4 |
| | | | | |
| | Electrical Stimulation | | | |
| Z250 | External or internal (I.O.P.) | | 170.40 | 4 |
| | | | | |
| | Casts (I.O.P.) | | | |
| | Application of plaster casts or corrective splints are not chargeable if | | | |
| | applied at the time of surgery (except for the application of a cast brace) | | | |
| | or applied during the first 6 weeks for a fracture or dislocation when a | | | |
| | procedural fee is applicable. The subsequent application of plaster casts | | | |
| | is chargeable according to the following schedule. Cost of material is | | | |
| | extra. | | | |
| Z201 | Finger | | 8.80 | |
| Z202 | Hand | | 13.20 | 4 |
| Z203 | Arm, forearm or wrist | | 21.10 | 4 |
| Z199 | Foot | | 13.20 | 4 |
| 7213 | Below knee, knee splints (Stove pipe, etc.) | | 21.10 | 4 |
| 7211 | Whole leg (mid thigh to toes) | | 25.55 | 4 |
| Z198 | Toes | | 8.80 | 4 |
| Z205 | Head and Torso | | 85.80 | 4 |
| Z208 | Shoulder spica | | 85.80 | 4 |
| Z206 | Body cast | | 50.80 | 4 |
| Z207 | Hip spica = unilateral | | 85.80 | 4 |
| 7209 | - bilateral | 3 | 107.30 | 4 |
| 7216 | Wedging of casts in other than fracture treatment | | 8.80 | |
| Z200 | Application of Unna's paste | | 13.20 | |
| 2873 | Application of cast brace (must include hinge) | | 59.60 | |
| 7204 | Removal of plaster (not associated with fractures or dislocation within 6 | | 0.00 | |
| Z204 | weeks of initial treatment) | | 8.80 | |
| | HAND and WRIST | | | |
| | LMA GIN M/T21 | | | |
| | Amoutation | | | |
| R606 | Phalanx | | 142.50 | 4 |
| E582 | - each additional | | 41.50 | 7 |
| R608 | Metacarpal or metaphalangeal joint | | 167.90 | 4 |
| F583 | - each additional | | 41.50 | 7 |
| R610 | Trans. metacarpal 2nd or 5th ray | | 246.20 | 4 |
| R611 | Hand - all metacarpals | 3 | 255_60 | 4 |
| R612 | Wrist | | 255.60 | 5 |
| | | | | |

| | OPERATIONS ON THE MUSCULOSKELETAL SYSTEM - Cont'd. | | | |
|--------------|--|------|------------------------------------|-------|
| Code | STATE OF THE TOSOCOSTOLLINE STATES - ONLY U. | Asst | Surg | Anaes |
| | HAND and WRIST - Cont'd. | | | |
| | Arthrodesis | | | |
| R465 | Finger-thumb | 3 | 226,50 | 4 |
| R466 | Wrist | | 344.10 | 4 |
| | | | | |
| 0.407 | Arthroplasty | | | - |
| R437 R485 | Wrist - interposition | 3 | 330.10 | 5 |
| R479 | - total | 6 | 376.40 | 6 |
| R435 | Hand - interposition - single | 3 | 224.05 | 5 |
| R436 | - multiple | 3 | 405.50 | 6 |
| R489 | Single joint - total | 3 | 256.40 | 5 |
| R449 | Multiple joints - total max | 3. | 683.60 | 6 |
| R500 | Removal only | | 127.80 | 4 |
| R236 E564 | Carpal replacement | 3 | 283.85 | 5 |
| E304 | Revision of arthroplasty - add 35% | | | |
| A | rthroscopy | | | |
| R209 | Diagnostic arthroscopy | 3 | 85.80 | 4 |
| R211 | - with Synovial biopsy | | 94.60 | 4 |
| R212 | - with Removal of loose body, screw | . 3 | 226.10 | 4 |
| R213 | - with Drilling of defect (includes removal of loose body) | . 3 | 278.50 | 4 |
| R221 R224 | - with Debridement - local | 3 | 278.50 | 4 |
| R230 | - total | 3 | 340.00 | 4 |
| R232 | - total | 3 | 481.70 | 4 |
| R233 | - with Pinning of osteochondral fragment | 3 | 278.50 | 4 |
| | | | | |
| | Arthrotomy | | | |
| R409 | Finger | 2 | 147.90 | 4 |
| R410 | Wrist | 3 | 188.00 | 4 |
| | Aspiration/Injection - see page 63. | | | |
| | Tapitation algebraich ace page our | | | |
| | Biopsy | | | |
| Z230 | Bones - punch, x-ray control (I.O.P.) | | 63.90 | 4 |
| 2014 | - open biopsy or taking of bone graft by other than operating surgeon | | 107.00 | |
| Z214 E563 | (I.O.P.) | 4 | 127.80 | 4 |
| Z221 | Joint - via arthroscope | | 9.60 | |
| R409 | - open finger | | 147.90 | 4 |
| R410 | - open wrist | 3 | 188.00 | 4 |
| 7228 | Muscle (1.0.P.) | | 85.80 | 4 |
| | | | | |
| NOOO | Decompression - Denervation | 2 | 125 00 | 4 |
| N290 | Decompression median nerve at wrist (carpal tunnel syndrome) Exploration and/or decompression and/or transposition and/or neurolysis of | 3 | 135.00 | 4 |
| N285 | major nerve (excluding carpal tunnel nerve) | 4 | 221.20 | 4 |
| , 200 | mayor harte (and dailing output dailine) harter sections | | | |
| | Incision and Drainage (Osteomyelitis) | | | |
| R219 | Incision and drainage - phalanx/metacarpal/carpus | 3 | 161.20 | 4 |
| R218 | Sequestrectomy - phalanx/metacarpal/carpus | 3 | 127.80 | 4 |
| R217 R409 | Saucerization and bone graft phalanx/metacarpal/carpus | 4 | 213.80 | 4 |
| R410 | Incision and drainage - joint (finger) - joint (wrist) | 3 | 188.00 | 4 |
| R534 | Tendon sheath | | 130.25 | 4 |
| | | | | - |
| | Examination/Manipulation | | | |
| 7000 | Manipulation - hand/wrist | | 20.00 | 4 |
| 7222 | - under general anaesthetic (I.O.P.) | | 20.90 | 4 |
| | - without general amestratic, see page 05. | | | |
| | Excision - Bone | | , | |
| R316 | Proximal row carpectomy | 3 | 299.00 | 5 |
| R285 | Carpal - bone (one) | 3 | 189.20 | 4 |
| R317 | Dorsal exostosis (triquetrum) | 3 | 166.70 | 4 |
| R286 | Radial styloid | 3 | 206 . 80 170 . 40 | 4 |
| R283 R272 | Phalanx/metacarpal Bone tumour (See Preamble Para B.32) | I.C. | I.C. | I.C. |
| NE/C | CONTROL VALUE (CONTROL ON DESCRIPTION OF THE PROPERTY OF THE P | **** | 1006 | 2.00 |

| | OPERATIONS ON THE MUSCULOSKELETAL SYSTEM - Cont'd. | | | |
|--------|--|-------|----------|---------|
| Code | | Asst | Surg | Anaes |
| | HAND and WRIST - Cont'd. | 7036 | 341 9 | MILICO |
| | | | | |
| | Excision - Joint | | | |
| 0.400 | | _ | | |
| R425 | Synovectomy/capsulectomy/debridement - finger joint | 3 | 199.50 | 4 |
| R414 | - two or more joints | 3 | 299.40 | 4 |
| R407 | Synovectomy of extensor tendons | | 196.20 | 4 |
| R418 | Synovectamy/debridement - wrist | 3 | 299.40 | 4 |
| R492 | Radio-ulnar meniscectomy | 3 | 204.60 | 4 |
| 11.130 | The state of the s | 3 | 207,00 | 4 |
| | Fundadas Manala and Finday | | | |
| | Excision - Muscle and Tendon | | | |
| R522 | Muscle - simple (See Preamble Para 8.32) | 3 | 170.40 | I.C. |
| R523 | - complex (See Preamble Para B.32) | 4 | 427.60 | I.C. |
| R550 | Tendon sheath - single | 3 | 209.70 | 4 |
| E572 | - each additional, add | | 74,50 | 1(max.) |
| R551 | Fascia for Dupuytrens - simple or complex | 3 | 286.70 | 4 |
| MOST | rascia for bapayards - simple or complex | 3 | 200.70 | 4 |
| | | | | |
| | Excision - Ganglion | | | |
| R549 | Simple or complex | 3 | 104.00 | 4 |
| | | | | |
| | Reconstruction - Bone | | | |
| 0007 | | | 140 10 | |
| R257 | Osteotomy - phalanx - terminal | | 142.10 | 4 |
| R258 | - phalanx - middle proximal or metacarpal | 3 | 168.75 | 4 |
| E591 | - each additional | | 36,90 | |
| R321 | Pseudoarthrosis - phalanx, metacarpal | 3 | 229,80 | 4 |
| R322 | - scaphoid | 3 | 263.00 | 4 |
| NUCL | - Jugaturu | 3 | 200,00 | - |
| | | | | |
| | Reconstruction - Ligaments | | | |
| R597 | Simple/single repair - wrist | 3 | 204.80 | 4 |
| R548 | Extensive/multiple repair - wrist | 3 | 346.90 | 4 |
| R601 | Metacarpal phalangeal repair | 3 | 213,00 | 4 |
| 1001 | recocarpar pratargear repair | - | -1500 | |
| | 200 | | | |
| | Reconstruction - Nerve - see page 146. | | | |
| | | | | |
| | Reconstruction - Tendon | | | |
| R557 | Tenoplasty - one | 3 | 197.50 | 4 |
| E050 | - each additional, add | | 67.70 | |
| | | 3 | 270.30 | 4 |
| R559 | Tendon graft - one | 3 | | |
| E052 | - each additional, add | | 106.90 | 1(max.) |
| R536 | Reconstruction of flexor tendon pulley, per finger | | 85.80 | 4 |
| R554 | Silicone rod insertion - one | 3 | 255.20 | 4 |
| E051 | - each additional, add | | 116.70 | |
| R563 | Transplant/transfer - single | 3 | 249.00 | 4 |
| | | 9 | | |
| E054 | - each additional, add | 2 | 80.70 | 1(max.) |
| R578 | Tendon repair - extensor - single | 3 | 111.40 | 4 |
| E580 | - each additional, add | | 41.60 | |
| R585 | Tendon repair - flexor - single | 3 | 208.90 | 4 |
| E581 | - each additional, add | | 77.80 | |
| | Mallet finger - closed | | visit fe | 20 |
| | mariet ringer - crosed | | | |
| R574 | - K-wire | 2 | 116.10 | 4 |
| R573 | - open | 3 | 127.50 | 4 |
| U.V.C. | Boutonniere - closed | | visit fe | |
| R577 | - 0061 | 3 | 127,80 | 4 |
| R582 | - late | 3 | 213.80 | 4 |
| NUCL | - INV *********************************** | | | |
| | B | | | |
| | Reconstruction - Extremities | | F10 ~ | - |
| R602 | Pollicization | 5 | 512.80 | 6 |
| R603 | Digital reimplantation involving microvascular and neuro anastomosis | 8 | 1376.25 | 8 |
| R604 | Revision of R602, R603 (See Preamble Para B.32) | I.C. | I.C. | 1.C. |
| R605 | Reconstruction and plastic repair of traumatically amputated extremities | | | |
| NOUS | | TC | I.C. | I.C. |
| | (See Preamble Para B.32) | 1.000 | 1.00 | 1.00 |
| | | | | |

| | OPERATIONS ON THE MUSCULOSKELETAL SYSTEM - Cont'd. | | | |
|--------------|--|------|-----------------|-------|
| Code | | Asst | Surg | Anaes |
| | | | | |
| | HAND and WRIST - Cont'd. | | | |
| | | | | |
| | Release - Tendon | | | |
| R575 | Tenolysis - flexor and/or extensor tendon of one digit | 3 | 170.40 | 4 |
| E537 | - each additional digit (max. 2), add | 2 | 77.00 | |
| R541 | Flexor tenolysis with pulley preservation | 3 | 245.80 | 4 |
| | Tenotomy or fasciotomy (closed) (I.O.P.) | | 40.00 | |
| Z247 | - finger - one | | 43.00 | 4 |
| Z248 | - two | | 63.90 | 4 |
| Z249 | - three or more | | 86.00 | 4 |
| Z231 | - palmar or plantar | | 63.90 | 4 |
| R536 | - palmar or plantar | 2 | 93.40 | 4 |
| R537 | - Wrist | 3 | 120.40 | 4 |
| E571 | - more than one, add | | 77.00 | |
| | | | | |
| F004 | Reduction - Fractures | | 42.00 | |
| F004 | Phalanx - no reduction, rigid immobilization | | 43.00 | 4 |
| F005 | - closed | | 87.65 | 4 |
| E558 | - each additional | 4 | 19.25 154.00 | 4 |
| F007 | - open | 4 | 43.00 | 4 |
| F008 | Metacarpal - no reduction, one or more, rigid immobilization | | | 4 |
| F009 | - closed, one or more | 4 | 87.65 | 4 |
| F011 | - open | 4 | 146.60 42.20 | |
| E559 | - each additional add, (open) | | 68.40 | |
| F006 | Intra-articular - closed | 2 | | 4 |
| F010 | - open | 3 | 146.60 43.00 | 4 |
| F012 | Bennett's - no reduction, rigid immobilization | 3 | 106.10 | 4 |
| F013 | - closed | 4 | 190.05 | 4 |
| F015 | - open | 4 | 43.00 | * |
| F102 | Carpus - no reduction, rigid immobilization | | 101.60 | 4 |
| F016 | - closed, one or more | A | 195.80 | 4 |
| F017 | - open, one or more | * | 43.00 | 4 |
| F018 | Scaphoid - no reduction, rigid immobilization | 4 | 213.80 | 4 |
| F019 | - open | | 170.40 | 4 |
| F020 | - excision | 7 | 170.40 | 7 |
| | Reduction - Dislocations | | | |
| 0001 | Finger - closed - one | | 50,40 | 4 |
| D001 E576 | - each additional, add | | 8.80 | |
| 0003 | - each dulitional, and | 3 | 171,20 | 4 |
| 0003 | Metacarpal/phalangeal - closed - one | , | 50.40 | 4 |
| | - each additional, add | | 8.80 | |
| E577 D006 | - open | 3 | 160.60 | 4 |
| DO07 | Carpal - closed | | 113.00 | 4 |
| D007 | - Open | 3 | 213.00 | 4 |
| 1000 | - upar | | | |
| | ELBOW and FOREARM | | | |
| | LLOW WAS WELLT | | | |
| | Amoutation | | | |
| R613 | Amputation Through radius and ulna | 4 | 270.30 | 5 |
| R614 | Elbow disarticulation | 4 | 255.60 | 5 |
| 1.017 | | | | |
| | Arthrodesis | | | |
| R466 | Elbow | . 3 | 344.10 | 4 |
| | | | | |
| | Arthroplasty | | | |
| R281 | Ulna replacement (lower end) | . 3 | 262.10 | 4 |
| R288 | Implant radial head | , , | 222.00 | 4 |
| R499 | Removal of total replacement | . 3 | 355.50 | 7 |
| R486 | Complete arthroplasty replacement | . 6 | 432.10 | 8 |
| R510 | Interposition arthroplasty | . 6 | 384.80 | 7 |
| E564 | Revision of elbow arthroplasty, add 35% | | | |
| | | | | |

| | OPERATIONS ON THE MICCH OCCUPIETAL CONTRA | | | |
|--------------|--|------|------------------|-------|
| Code | OPERATIONS ON THE MUSCLLOSKELETAL SYSTEM - Cont'd. | 0 | | |
| | | Asst | Surg | Anaes |
| | ELBOW and FOREARM - Cont'd. | | | |
| | Ambhannan | | | |
| R209 | Arthroscopy Diagnostic arthroscopy | | | |
| R211 | Diagnostic arthroscopy - with Synovial biopsy | 3 | 85.80 | 4 |
| R212 | - with Removal of loose body, screw | 3 | 94.60 | 4 |
| 9213 | - with Drilling of defect (includes removal of loose body) | 3 | 226.10 | 4 |
| R221 | - with Debridement - local | 3 | 278.50 278.50 | 4 |
| R224 | - total | 3 | 340.00 | 4 |
| R230 | - with Synovectomy - partial | 3 | 229.40 | 4 |
| R232 | - total | 3 | 481.70 | 4 |
| R233 | - with Pinning of osteochondral fragment | 3 | 278.50 | 4 |
| | | | 2,000 | |
| | Arthrotomy | | | |
| R445 | Elbow, loose body, etc. | 3 | 176.10 | 4 |
| | | | | |
| | Aspiration/Injection - see page 58. | | | |
| | Diame. | | | |
| 7225 | Biopsy | | | |
| 7214 | Bone - needle (I.O.P.) - open (I.O.P.) | | 63.90 | 4 |
| E563 | Joint - via arthroscope | | 127,80 | 4 |
| R432 | - open | 2 | 9.60 149.90 | 4 |
| 7228 | Muscle/soft tissue (I.O.P.) | 3 | 85.80 | 4 |
| | | | 00.00 | 4 |
| | Decompression/Denervation | | | |
| | Fasciotomy for compartments syndrome (not including secondary closure | | | |
| R495 | wound) | 3 | 282,50 | 4 |
| Z783 | Secondary closure | - | 85.80 | |
| Z251 | Catheter - insertion (I.O.P.) | | 43.00 | |
| | - monitoring | 1 | risit fees | |
| | Exploration and/or decompression and/or transposition and/or neurolysis of | | | |
| N190 | ulnar nerve (elbow) | 4 | 185.95 | 4 |
| R426 | Denervation - elbow | 3 | 227.30 | 4 |
| | * | | | |
| 0220 | Incision and Drainage (Osteomyelitis) | | | |
| R228 R231 | Acute, incision and drainage | 3 | 267.05 | 4 |
| R229 | Sequestrectomy | 3 | 313.75 | 4 |
| 7226 | Soft tissue or bursa, incision and drainage | 3 | 399.40 85.30 | 4 |
| R445 | Elbow, incision and drainage | 3 | 176.10 | 4 |
| | Libon, Incidial and distinge second consecution control and distinger | , | 170.10 | 4 |
| | Examination/Manipulation | | | |
| 7222 | Manipulation under general anaesthetic (I.O.P.) | | 20,90 | 4 |
| | - without general anaesthetic, see page 63. | | | |
| | | | | |
| | Excision - Bone | | | |
| R287 | Radial head | 3 | 192.10 | 4 |
| R296 | Radial styloid | 3 | 206.80 | 4 |
| R643 | Ulna lower end | 3 | 170.40 | 4 |
| R290 | Olecranon with facial major | 3 | 183.50 | 4 |
| R291 | Olecranon with fascial repair | 3 | 272.80 | 4 |
| | Excision - Bursae | | | |
| R595 | Olecranon | 2 | 89.30 | A |
| 1737 | VICUARUI | 3 | 03.30 | 4 |
| | Excision - Joint Contents | | | |
| R421 | Synovectomy/capsulectomy/debridement, etc | 3 | 275.25 | 4 |
| | discountry, and the same of th | | | |
| | Excision - Muscles | | | |
| R524 | Myositis ossificans | 4 | 255.60 | 5 |
| R517 | Foreign body removal | | 95.00 | 4 |
| | William Control of the Control of th | | | |
| | Excision - Turours | | 170 10 | |
| R591 | Soft tissues - superficial (See Preamble Para B.32) | | 170.40 | I.C. |
| R592 | - deep (See Preamble Para B.32) | | 427.60 | I.C. |
| | Excision - Bone Tumours | | | |
| R294 | Existoris - Bone lumours | 4 | 145.40 | 4 |
| R295 | Simple excision | | 255.20 | 4 |
| R293 | Extensive with replacement | | 598.00 | 6 |
| | The second secon | | | |

| Code | OPERATIONS ON THE MUSCULOSKELETAL SYSTEM - Cont'd. | Annh | C | |
|--------------|--|------|------------------|---------|
| code | | Asst | Surg | Anaes |
| | ELBOW and FOREARM - Cont'd. | | | |
| | | | | |
| R323 | Reconstruction - Bone - Pseudarthrosis Radius or ulna | 3 | 268.50 | 4 |
| R473 | Radius and ulna | 3 | 362.90 | 4 |
| 1475 | That is all all all all all all all all all al | , | 502.50 | 7 |
| | Reconstruction - Bone - Osteotomy | | | |
| R259 | Radius or ulna | 3 | 262.55 | 4 |
| R324 | Radius and/or ulna reconstruction congenital abnormality, synostosis,etc | 3 | 351.00 | 4 |
| | Reconstruction - Fascia | | | |
| R476 | Repair fascial defects - small | 3 | 127.80 | 4 |
| | large with or without synthetic graft or rotation | | | |
| R478 | flap | 4 | 256.00 | 5 |
| | December of the Lieuwebe | | | |
| R597 | Reconstruction - Ligaments Simple/single repair | 3 | 204,80 | 4 |
| R548 | Extensive/multiple repair | - | 346.90 | 4 |
| | | | | |
| | Reconstruction - Tendons | | | |
| R578 | Suture extensor tendon - single | 3 | 111.40 | 3 |
| E580 R585 | - each additional, add | 3 | 41.60 | Δ |
| E581 | - each additional, add | , | 77.80 | , |
| R557 | Tenoplasty - single | 3 | 197.60 | 4 |
| E050 | - each additional, add | | 67.70 | |
| R556 | Tenolysis - single | 3 | 178.60 | 4 |
| E599 R563 | - each additional, (max. 2) add | 3 | 77.00 249.00 | 4 |
| E054 | - each additional, add | , | 80.70 | 1(max.) |
| R583 | Steindler flexoplasty | 3 | 299.00 | 5 |
| | | | | |
| 0510 | Release | 4 | 120,40 | 4 |
| R519 R521 | Muscles and tendons - simple, e.g. tennis elbow radical, e.g. muscle slide | 5 | 268.30 | 5 |
| NJE1 | - radical, e.g. muscle since | - | 200,00 | |
| | Reduction - Dislocations | | | |
| D009 | Elbow joint - closed reduction | | 73.90 | 4 |
| 0010 | - open reduction - acute | 3 | 222.60 | 4 |
| R400 D012 | - repair chronic, recurrent | 3 | 34.20 | 4 |
| 0012 | - open reduction - acute | 3 | 170.40 | 4 |
| R540 | - recurrent | 3 | 200.70 | 6 |
| R558 | - late | 4 | 315.40 | 6 |
| | Deduction Francisco | | | |
| F029 | Reduction - Fractures Epicondyle - no reduction | | 59.60 | |
| F037 | - closed reduction | 3 | 111.00 | 4 |
| F038 | - open reduction | 4 | 188.80 | 4 |
| F039 | Transcondylar/condylar - no reduction | | 59.60 | 4 |
| F040 | - closed reduction | 3 | 182.30 276.10 | 4 |
| F045 F041 | - crosed reduction with traction | 4 | 331.80 | 4 |
| F034 | Olecranon - no reduction, rigid immobilization | | 111.00 | 4 |
| F035 | - closed reduction | 3 | 113.90 | 4 |
| F036 | - open reduction | 4 | 198.20 | 4 |
| F024 | Radius and ulnar shaft - no reduction, rigid immobilization | 3 | 59.60 131.10 | 4 |
| F025 F026 | - closed reduction | | 325.20 | 4 |
| F014 | Radius and ulna - Monteggia - no reduction, rigid immobilization | " | 59.60 | |
| F022 | ~ closed reduction | | 127.80 | 4 |
| | - open reduction of ulna plus closed reduction | 2 | 412 00 | 4 |
| F023 | radial head | 3 | 213.80 | 4 |
| | | | | |

| | OPERATIONS ON THE MUSCULOSKELETAL SYSTEM - Cont'd. | | | |
|--------------|---|------|------------------------------------|--------|
| Code | | Asst | Surg | Anaes |
| | ELBOW and FOREARM - Cont'd. | | | |
| F031 | Radius or ulna - no reduction, rigid immobilization | | 59.60 | |
| F032 | - closed reduction | 3 | 103.80 | 4 |
| F033 | - open reduction | 4 | 201.50 | 4 |
| F027 | - no reduction, rigid immobilization | | 59,60 | |
| F028 | - Closed reduction | 3 | 96.90 | 4 |
| F030 F021 | - open reduction | 4 | 190.50 | 4 |
| , 021 | | 4 | 221.80 | 5 |
| | SHOULDER/ARM/CHEST | | | |
| | Amputation | | | |
| R617 | Forequarter | 10 | 433.35 | 15 |
| R616 R615 | Shoulder disarticulation | | 328.90 | 9 |
| MOID | High humerus | 4 | 326.00 | 5 |
| | Arthrodesis | | | |
| R467 | Shoulder | 4 | 413.70 | 6 |
| | Arthroplasty | | | |
| R438 | Humeral prosthesis | 4 | 396.30 | 6 |
| R487 R240 | Total prosthesis | | 613.20 | 10 |
| R498 | Revision total arthroplasty shoulder | 6 | 832.30 | 10 |
| E564 | Revision of prosthesis, add 35% | 3 | 350,00 | 0 |
| | Authorosom | | | |
| R209 | Arthroscopy Diagnostic arthroscopy | 3 | 85.80 | 4 |
| R211 | - with Synovial biopsy | 3 | 94.60 | 4 |
| R212 | - with Removal of loose body, screw | | 226.10 | 4 |
| R213 R221 | - with Drilling of defect (includes removal of loose body) - with Debridement - local | 3 | 278.50 | 4 |
| R224 | - total | 3 | 278 . 50 340 . 00 | 4 |
| R230 | - with Synovectomy - partial | 3 | 229.40 | 4 |
| R232 | - total | 3 | 481.70 | 4 |
| R233 | - with Pinning of osteochondral fragment | 3 | 278.50 | 4 |
| | Arthrotony | | | |
| R411 | Shoulder | 4 | 197.20 | 4 |
| | Aspiration/Injection - see page 58. | | | |
| | Diago. | | | |
| 7220 | Biopsy Bones - needle/punch, x-ray control (I.O.P.) | | 63.90 | 4 |
| 7214 | - open (I.O.P.) | 4 | 127.80 | 4 |
| E563 | Joint - via arthroscope | | 9.60 | |
| R411 Z228 | - open | 4 | 197.20 85.80 | 4 |
| | out trade - open (1000 of 00000000000000000000000000000000 | | 03.00 | 4 |
| | Incision and Drainage | | | |
| R222 R225 | Humerus/clavicle/scapula - incision and drainage | 4 | 231.80 256.00 | 4 |
| R223 | Saucerization with bone graft | | 342.40 | 4 |
| 7226 | Bursae/soft tissue | | 85.80 | 4 |
| R411 | Joint | 4 | 197.20 | 4 |
| | Examination and Manipulation | | | |
| 7223 | Manipulation under general anaesthetic (I.O.P.) | | 43.00 | 4 |
| | - without general anaesthetic, see page 63. | | | |
| | Excision - Clavicle or Acromion | | | |
| R298 | Simple (includes ligament) | 4 | 186.60 | 4 |
| R641 R214 | Major Tumour (see Preamble para B.32) | 1.0. | 427,60 | Region |
| 14.17 | | 1.0. | .27 600 | negron |
| 200 | Excision - Humerus | | 004 | |
| R292 R294 | Head | | 264.60 145.40 | 5 |
| R295 | Benign tumour | | 255.20 | 4 |
| R297 | Malignant tumour with reconstruction | | 601.30 | 6 |

| | OPERATIONS ON THE MUSCULOSKELETAL SYSTEM - Cont'd. | | | |
|--------------|---|------|------------------|---------|
| Code | | Asst | Surg | Anaes |
| | SHOULDER/ARM/CHEST - Cont'd. | | | |
| | Excision - Joint | | | |
| R422 | Synovectamy and debridement | 4 | 374.80 | 5 |
| R512 | Excision of subacromial bursae | 3 | 186.40 | 4 |
| R522 | Muscle/fascia - simple | 3 | 170.40 | I.C. |
| R523 | - complex | 4 | 427.60 | I.C. |
| R416 | acromial ligament) | 4 | 182.70 | 4 |
| R490 | Acramio/sterno-clavicular meniscectany | 3 | 185.10 | 4 |
| | Reconstruction - Pseudarthrosis and Osteotomy | | | |
| R329 | Pseudarthrosis - clavicle | 4 | 237.15 | 4 |
| R325 | - humerus | 4 | 305.60 | 4 |
| R260 R298 | Osteotany – humerus | | 257.80 | 4 |
| R235 | - clavicle - glenoid | 4 | 186.60 246.20 | 4 |
| NZJJ | | 4 | 240,20 | 4 |
| | Reconstruction - Nerves - see page 146. | | | |
| | Reconstruction - Muscles/Soft Tissues | | | |
| R527 | Muscle transplant - pectoralis major | 6 | 383.00 | 6 |
| R521 | Muscle/tendon release | 5 | 268.30 | 5 |
| R526 | Release - sternanastoid | 5 | 260.90 | 5 |
| R353 | Scapulopexy - congenital elevation | 6 | 340.00 | 6 4 |
| R568 R589 | Trapezius/sternomastoid/transplant | 4 | 299.00 200.90 | 4 |
| | Rotator cuff repair - simple, end-to-end or side-to-side (includes acromio- | | | |
| R593 | plasty, excision of coraco-acromial ligament) | 4 | 279.30 | 5 |
| R594 | required, acromioplasty, excision of coraco-acromial ligament, excision of distal clavicle) | 4 | 411.60 | 5 |
| | Reduction - Fractures | | | |
| F047 | Tuberosity - no reduction | | 59.60 | |
| F048 | - closed reduction | 3 | 104.00 | 4 |
| F049 | - open reduction (without cuff tear) | 4 | 256.00 | 4 |
| F053 | Neck without dislocation of head - no reduction | | 59.60 | |
| F054 | - closed reduction | 5 | 117.55 289.20 | 4 |
| F055 F050 | - open reduction | 2 | 59.60 | 6 |
| F050 | - closed reduction | 3 | 162.20 | 4 |
| F052 | - open reduction | 5 | 340.00 | 6 |
| F042 | Shaft - no reduction | | 59.60 | |
| F043 | - closed reduction | 3 | 130.25 | 4 |
| F044 | - open reduction | 4 | 285.30 | 4 |
| | Clavicle - no reduction | | visit fees | |
| F110 | - closed reduction with anaesthetic | 3 | 55.20 204.00 | 4 |
| F118 F119 | - open reduction | 4 | 59.60 | 4 |
| F119 F120 | Scapula - no reduction closed reduction with anaesthetic | 3 | 102.40 | 4 |
| F121 | - open reduction | 4 | 213.80 | 5 |
| F122 | Sternum - no reduction | | 59.60 | |
| F123 | - closed reduction | | 102.40 | |
| F124 | - open reduction - pleura open (see Preamble para B.32) | 9 | I.C. | 13 |
| F125 | - pleura closed (see Preamble para B.32) | 4 | I.C. | 4 |
| | . Ribs = no reduction | | visit fees | 12 |
| F130 | - complicated - pleura open (see Preamble para B.32) | 9 | I.C. I.C. | 13 4 |
| F131 | - pleura closed (see Preamble para 8.32) | 4 | 1.0. | 4 |
| | Reduction - Dislocations | | 50.00 | |
| 0014 | Acramio-clav./sterno-clav no reduction | 4 | 59.60 118.60 | 4 |
| D025 | - closed with anaesthetic | | 204.00 | 4 |
| D023 | - open reduction | 7 | 207.00 | * |

| | OPERATIONS ON THE MUSCULOSKELETAL SYSTEM - Cont'd. | | | |
|--------------|--|------|-----------------|-------|
| Code | The state of the s | Asst | Surg | Anaes |
| | SHOULDER/ARM/CHEST - Cont'd. | | | |
| | SAME OF THE OF | | | |
| R596 | - open reduction - late | 4 | 253,10 | 4 |
| D015 | Glenohumeral joint - closed reduction - without anaesthetic | | 43.00 | |
| 0016 | - with anaesthetic | | 98.10 | 4 |
| 0017 | - open reduction - early | 4 | 285.50 | 6 |
| R472 | - late | 4 | 512.80 | 7 |
| R401 | - recurrent | 5 | 335.05 | 5 |
| | SOULL and HANDIBLE | | | |
| | SKULL GIRL PRIVUIDLE | | | |
| | Arthroplasty | | | |
| R433 | Temporo-mandibular joint - unilateral | 5 | 299.00 | 5 |
| | The second secon | , | 23.00 | , |
| | Biopsy (1.0.P.) | | | |
| 2369 | Bones - punch, simple | | 34.20 | 4 |
| Z870 | - punch, x-ray control | | 85.30 | 4 |
| 7242 | - open | 4 | 170.40 | 4 |
| | | | | |
| 7924 | Incision and Drainage | 7 | 040.00 | - |
| 7234 | Mandibular sequestrectomy (I.O.P.) | 7 | 240.30 | 7. |
| | Excision | | | |
| R272 | Bone - Tumour (see Preamble para 8.32) | 1.C. | I.C. | 1.C. |
| R278 | Maxilla, with exenteration of orbit and skin graft | | 455.90 | 7 |
| R279 | Maxilla advancement | 4 | 376.80 | 8 |
| R290 | Mandible | 4 | 302,30 | 7 |
| R284 | Mandibular condyle | 4 | 236,70 | 5 |
| R428 | Temporo-mandibular meniscectomy | 3 | 213.80 | 5 |
| | | | | |
| | Reconstruction | | | |
| R531 | Facial paralysis - static slings | 4 | 263,00 | 5 |
| R532 | - dynamic slings | 4 | 341.60 | 6 |
| R533 | Composite repair for facial paralysis, plication of paralyzed muscles, and | | 420.20 | 7 |
| E597 | resection for paralysis of over active muscles | 4 | 438.30 74.50 | 7 |
| 2357 | - with meloplasty, add | | 74.30 | |
| | Orthognathic Surgery | | | |
| | Anterior dento-alveolar osteotomy, maxilla or mandible | | | |
| R382 | | 6 | 688.10 | 10 |
| R383 | - two segments | 6 | 797.90 | 10 |
| | Posterior dento-alveolar osteotomy, maxilla | | | |
| R349 | - one side | 6 | 688.10 | 10 |
| R351 | - both sides, single segment | 5 | 797.90 | 10 |
| R385 | - both sides, separate segments | 6 | 1016.60 | 10 |
| R462 | Posterior dento-alveolar osteotomy, mandible - one side | 6 | 688.10 | 10 |
| R463 | - both sides | - | 1016.60 | 10 |
| R502 | Total U dento-alveolar osteotomy, mandible | 6 | 1051.85 | 10 |
| R507 | Total U dento-alveolar osteotomy, maxilla | | 1126.40 | 10 |
| R511 | Mandibular or maxillary visor osteotomy for alveolar hypoplasia | | 981.40 | 10 |
| R386 | Genioplasty - one segment | | 219.10 | 10 |
| R387 | - two segments, or for laterognathia | 6 | 328,50 | 10 |
| R388 | - three segments | 6 | 438.30 | 10 |
| R480 | Mandibular osteotomies for prognathism - subcondylar | 3 | 359.50 | 6 |
| R384 | - vertical ramus | 6 | 797.90 | 10 |
| R518 | - sagittal split | 6 | 797.90 | 10 |
| 2500 | Mandibular osteotomies for retrognathia, any technique | | 707.00 | 10 |
| R520 | - advancement up to 10 mm | 6 | 797.90 | 10 |
| R529 | - advancement 10 - 20 mm | 6 | 906,85 | 10 |
| R535 E588 | - advancement greater than 20 mm | 0 | 219.10 | 10 |
| LJ00 | - rui aper myracina vi raver ogracina, am | | 227,10 | |

| | CONTRATIONS ON THE NAMED A COURT STAN COURTS | | | |
|--------------|---|------|------------------|----------|
| Code | OPERATIONS ON THE MUSCULOSKELETAL SYSTEM - Cont'd. | Acct | Cuma | Anne |
| code | SKULL and MANDIBLE - Cont'd. | Asst | Surg | Anaes |
| | | | | |
| R379 | LeFort I advancement - in one segment | 10 | 688.10 | 20 |
| E961 | - in two segments, add | | 253.95 | |
| E962 R538 | - in three segments, add | 10 | 508.70 906.85 | 200 |
| E963 | LeFort I intrusion – in one segment | 10 | 253.95 | 20 |
| E964 | - in three segments, add | | 508.70 | |
| R567 | LeFort I extrusion - in one segment* | 10 | 1126.40 | 20 |
| E965 | - in two segments,add | | 253.95 | |
| E966 | - in three segments, add | | 508.70 | |
| R580 | LeFort I in cleft patient - in one segment* | 10 | 1305.80 | 20 |
| E967 | - in two segments, add | | 219.10 | |
| E968 E969 | - in three segments, add | | 438.30 175.30 | |
| E970 | - with SMR, add | | 263.00 | |
| E971 | - with closure alveolar fistula with or without bone graft, add | | 328.50 | |
| E972 | - with closure hard palate fistula with or without bone graft, add | | 438.30 | |
| R588 | Naso-maxillary osteotomy without LeFort 1* | 6 | 688.10 | 10 |
| R389 | LeFort II maxillary osteotomy and advancement* | 10 | 1236.20 | 20 |
| | Construction glenoid fossa and zygomatic arch* | | | |
| R395 | (Obwegeser technique) | 10 | 1200.90 | 20 |
| R396 | Construction absent condyle and ascending ramus* | 0 | 688.10 | 10 |
| R609 | Combined LeFort I and LeFort III osteotomy in hemifacial microsomia | 10 | 1305.80 | 20 |
| R145 | Mandibular condylotomy | | 175.30 | 5 |
| R618 | Caronoidotamy | | 175.30 | 5 |
| R644 | Corpnoidectany | | 263.00 | 5 |
| | Reconstruction unilateral mandible with bone grafts* | | | |
| R334 | - partial | 4 | 350.60 | 10 |
| R335 | - camplete | 4 | 701.20 | 10 |
| 0.545 | Reconstruction bilateral mandible with bone grafts* | | 701 20 | 10 |
| R645 R646 | - partial complete | 4 | 701.20 876.50 | 10 10 |
| R647 | Oral vestibuloplasty - with secondary epithelization | | 175.30 | 5 |
| R648 | - with skin graft | | 263.00 | 5 |
| | Temporomandibular ankylosis | | | |
| R649 | - excision bone or fibrous block | 3 | 394.85 | 6 |
| R650 | - with insertion of prosthetic device or muscle flap | | 438.30 | 8 |
| R651 | - with construction of condyle and ascending ramus* | 4 | 570.20 | 10 |
| | Onlay bone grafts to face when not part of standard osteotomy for reconstruction* | | | |
| Z253 | - mandible - unilateral | | 307.20 | |
| 7254 | - bilateral | | 394.85 | |
| 7255 | - maxilla - unilateral | | 307.20 | |
| Z256 | - bilateral | | 394.85 | |
| Z257 | - zygoma - unilateral | | 263.00 | |
| Z258 | - bilateral | | 350.60 | |
| Z259 | - temporal - unilateral | | 350.60 438.30 | |
| Z260 Z261 | - bilateral | | 350.60 | |
| Z262 | - frontal - unitateral | | 438.30 | |
| 22.02 | Application of dental arch bars, or splint, for facial osteotomy (I.O.P.) | | | |
| Z239 | - one arch bar | 4 | 113.90 | 4 |
| Z240 | - two arch bars | 4 | 175.30 | 4 |
| R354 | Interdental wiring for temporomandibular joint disorder | 3 | 131.50 | 5 |
| | Removal intermaxillary fixation devices under general anaesthesia | | 07 20 | 4 |
| R652 | - as sole procedure | | 87.20 | 4 |

^{*}Includes harvesting of bone or cartilage grafts.

| | OPERATIONS ON THE MUSCULOSKELETAL SYSTEM - Cont'd. | | | |
|--------------|--|------|--------------------|----------|
| Code | OFENTIONS OF THE MUSCOLUSKELETAL STSTEM - COME O. | Asst | Cuiron | Ananc |
| oout | SKULL and MANDIBLE - Cont'd. | M33C | Surg | Anaes |
| | | | | |
| | Orbito-cranial Surgery | | | |
| | Bilateral periorbital correction Treacher-Collins Syndrome with or | | | |
| R390 | without bone grafts* (extra-cranial) | 10 | 1454.90 | 20 |
| | Bilateral periobital correction Treacher-Collins Syndrome with skull and | | | |
| R653 | muscle transpositions* (includes skull reconstruction)(intracranial) | 10 | 1853.80 | 25 |
| R654 | Pericranial flap to orbit or face - unilateral | | 263.00 | 4 |
| R655 | - bilateral | | 350.60 | 4 |
| 5070 | - when in conjunction with coronal approach for main operation | | | |
| E973 | - unilateral | | 153.20 | |
| E974 | - bilateral | 10 | 253.95 | 05 |
| R378 R656 | LeFort III total maxillary advancement* | | 1744.10 2217.60 | 25 25 |
| R657 | LeFort III and subcranial hypertelorism correction* | | | 23 |
| NOS/ | LeFort III and LeFort I maxillary advancement* | 12 | 1998.80 | |
| R658 | | 12 | 2506.75 | 25 |
| 1000 | advancement* Upper LeFort III advancement without occlusal change* | 15 | 2300-73 | 23 |
| R659 | - unilateral | 6 | 797.90 | 10 |
| R675 | - bilateral | | 1236.20 | 25 |
| R676 | Forehead advancement (bone grafts not included) - unilateral | | 1016.60 | 25 |
| R393 | - bilateral | | 1236.20 | 25 |
| R394 | Cranial vault reshaping* - anterior or posterior half | | 1305.80 | 20 |
| R677 | Total cranial vault reshaping* | 12 | 1779.30 | 25 |
| R398 | Medial transnasal canthopexy - unilateral | 3 | 354.30 | 6 |
| £557 | - when done in conjunction with another procedure | | 131.50 | |
| R399 | Lateral canthoplasty - unilateral | 3 | 175.30 | 6 |
| E930 | - when done in conjunction with another procedure | | 87.20 | |
| R376 | Hypertelorism correction, intracranial approach* | | 1998.80 | 25 |
| R377 | Hypertelorism correction, subcranial U osteotomies* | | 1669.50 | 25 |
| R678 | Hypertelorism correction, medial orbital wall osteotomies* | | 1051,85 | 20 |
| R679 | Hypertelorism correction, medial and lateral orbital wall osteotomies* | | 1380.35 | 20 |
| R391 | Orbital dystopia* - intracranial approach | | 1669.50 1271.40 | 25 20 |
| R392 | - extracranial approach | 10 | 12/1.40 | 20 |
| | periorbital stripping and bone grafts) | | | |
| R680 | - intracranial | 12 | 1709.70 | 25 |
| R681 | - extracranial | | 1236.20 | 20 |
| 11002 | Harvesting of bone graft when not included | | | |
| Z263 | - iliac bone graft | | 87.20 | |
| Z264 | - rib graft - one rib | | 131.50 | |
| E975 | - each subsequent rib | | 65.70 | |
| Z265 | - costochondral or chondral graft - one rib | | 197.20 | |
| E976, | - each subsequent rib | | 131.50 | |
| Z266 | - split cranial graft | | 175.30 | |
| | | | | |
| | Surgery for Correction of Down's Syndrome Facial Stigmata | | | |
| 7267 | Augmentation of zygona (bilateral) | | 157.70 | |
| 7267 7268 | - with prosthetic implant | | 197.20 | |
| 2200 | Augmentation of chin | | 131.60 | |
| 7269 | - with prosthetic implant | | 131.50 | |
| 7270 | - with autogenous bone or cartilage* | | 162,20 | |
| 7271 | Horizontal resection, red lower lip | | 157.70 | |
| Note: | *Includes harvesting of bone or cartilage grafts | | | |
| | | | | |
| | Reduction - Fractures | | | |
| | 0rbit | | | |
| | Open reduction rim/wall fracture | | | |
| E173 | - zygomatic fracture dislocation | 4 | 236.70 | 6 |
| E174 | - blowout fracture of floor | 4 | 276.10 | 6 |
| | · · | | | |

| | OPERATIONS ON THE MUSCULOSKELETAL SYSTEM - Cont'd. | | | |
|--------------|--|-----|-------------------|-------|
| Code | | Ass | t Surg | Anaes |
| | SKULL and MANDIBLE - Cont'd. | | | |
| E175 | - secondary repair by combined or orbital approach | 4 | 408.00 | 6 |
| F143 | Middle 1/3 facial | 5 | 367.80 | 8. |
| F144 | Cranial-facial separation | 5 | 464.50 | 10 |
| | Nasal bones (including septum) | | | |
| U.V.C. | - no reduction | | visit fees | |
| F136 | - closed reduction | | 87.20 | 4 |
| F137 | - open reduction - if within 2 weeks of injury | | 219.10 | 5 |
| F129 | - delayed, not including septum | | 219.10 | 5 |
| U.V.C. | Mandible - no reduction - no wiring of teeth | | visit fees | |
| F138 | - closed reduction - including wiring or teeth | | 219.10 | 5 |
| 1130 | - open reduction (may include wiring of teeth) | | 217.10 | , |
| F139 | - one side | 4 | 293.30 | 5 |
| F146 | - complicated (See Preamble Para 8.32) | I.C | . I.C. | I.C. |
| F140 | - removal of interdental wire | | | 4 |
| | Maxilla | | | |
| U.V.C. | - no reduction | | visit fees | |
| F150 | - closed reduction and dental wiring | | 219.10 | 5 |
| F141 | - open reduction - simple | 4 | 127.00 | 5 |
| F142 | - with wiring and local fixation | 5 | 337.50 | 6 |
| | Doduction Dielocations | | | |
| 0062 | Reduction - Dislocations Temporo-mandibular joint - closed reduction | | 43.80 | 4 |
| D063 | - open reduction | | 219.10 | 5 |
| 0003 | - open reduction | , | 243.10 | |
| | SPINE | | | |
| | 4 | | | |
| | Arthrodesis | | | |
| R459 | Anterior or posterior fusion of one level | 7 | 347.30 | 10 |
| R419 | Fusion of C1-2 | 8 | 484.10 | 10 |
| E573 | Each additional level (to a max. of 2 additional) | | 75.40 | |
| | Fusion with other procedure(s) | | 214 60 | |
| E567 | By same surgeon - one level, add | | 214.60 273.20 | |
| E568 E929 | multiple levels, add anterior cervical interbody fusion, per level, add | | 70.90 | |
| 6929 | Fusion by different surgeon, | | 70.50 | |
| R493 | - one level | | 274.40 | |
| R494 | - multiple levels | | 322.80 | |
| E924 | - anterior cervical interbody fusion, per level, add | | 106.10 | |
| E574 | Repeat fusion, to any fusion, not to apply to N337, add | | 180.20 | |
| E548 | With instrumentation, add | | 121.85 | |
| | 45 140 | | | |
| | Aspiration/Injection - see pages 45 and 58. | | | |
| | Dianeu | | | |
| Z868 | Biopsy Bone - needle (I.O.P.) | 4 | 127.80 | 4 |
| R274 | open - posterior approach | 4 | 213.80 | 7 |
| R275 | - anterior approach | 6 | 273.60 | 8 |
| 7228 | Soft tissue - open (I.O.P.) | | 85.80 | 4 |
| | | | | |
| | Decompression - Anterior, Anterolateral or Posterolateral | | | |
| R447 | Simple anterior cervical discectomy | 8 | 351.40 | 10 |
| R452 | Simple anterior lumbar discectomy | 6 | 432.50 | 10 |
| | Anterior cervical spinal cord or nerve root decompression, including | 0 | E22 20 | 10 |
| N182 | removal of disc or vertebral body, single disc level | 8 | 533.30 1277.10 | 13 |
| R397 | Anterior decompression with instrumentation | 7 | 12//.10 | 13 |
| N186 | single disc level | 9 | 955,20 | 13 |
| 14100 | For thoracotomy or laparotomy by separate surgeon use M137 (page 104), S312 | | 2000 | |
| | (page 124) | | | |
| | Each additional disc level decompressed - to R447, R452, N182, | | | |
| E928 | N186, add | | 230,20 | |
| | | | | |

| | OPERATIONS ON THE MISCHI OSKELETIN COMPANY | | | |
|--------------|---|------|-------------------|-------|
| Code | OPERATIONS ON THE MUSCULOSKELETAL SYSTEM - Cont'd. | | | |
| COOL | | Asst | Surg | Anaes |
| | SPINE - Cont. d. | | | |
| | of Italian Country of | | | |
| | Decompression - Posterior | | | |
| R451 | Cervical hemilaminectomy for disc disease, with or without foraminotomy | _ | 504 60 | |
| | Lumbar hemilaminectomy for disc disease including removal of soft disc or | 0 | 504.60 | 10 |
| R457 | OSTRODIVTR | c | 368,60 | 8 |
| E565 | nuicipie levels, to k451, k457, only her additional level add | 0 | 63,50 | 8 |
| E566 | Bilateral, to R451, R457 add | | 68,40 | |
| N185 | Posterior laminectomy one or two levels, cervical, thoracic, lumbar | 6 | 533.30 | 9 |
| | Repeat posterior exploration or reopening of posterior exploration more | • | 300,30 | , |
| | than six months after original procedure, includes foraminatony | | | |
| N337 | discectany or neurolysis | 8 | 575,10 | 10 |
| E914 | Laminectomy extending over 3 or more laminae, to N185, N337 add | | 138.00 | |
| E915 | Foraminotomy, to R457, N185 and N337 per foramen decompressed add | | 70.90 | |
| E907 | Opening of dura (associated with any decompressive procedure), add | | 137,20 | |
| E926 | Spinal duroplasty (applies to any spinal procedure), add | | 208.90 | |
| | | | | |
| 0.051 | Incision and Drainage (Osteomyelitis) | | | |
| R251 | Bone - incision and drainage only | | 266.20 | 4 |
| R234 | Sequestrectomy - anterior | | 555.40 | 10 |
| R254 | - posterior | 4 | 317.00 | 4 |
| R270 R252 | Saucerization with bone grafting - anterior | 6 | 684.00 | 10 |
| 7226 | - posterior | 4 | 386.70 | 5 |
| 2220 | Soft tissue | | 85.80 | 4 |
| | Examination/Manipulation | | | |
| 7215 | Manipulation under general anaesthetic (I.O.P.) | | 24 20 | 4 |
| | - without general anaesthetic, see page 63. | | 34.20 | 4 |
| | with out galeral albestreets, see page 00. | | | |
| | Excision - Bone | | | |
| R373 | Spinous process | 4 | 213.80 | 4 |
| R374 | Lamina or transverse process | | 341.60 | 8 |
| R450 | Part of body or pedicle | | 512.80 | 8 |
| R455 | Total body (includes replacement) | | 854.40 | 13 |
| | | | | |
| | Excision - Muscle/Soft Tissue | | | |
| R634 | Tumours - simple | | 170.40 | I.C. |
| R635 | - radical resection | | 427.60 | I.C. |
| | | | | |
| | Reconstruction - Osteotomy (includes fixation /fusion) | | | |
| R303 | Anterior - via chest | | 639.80 | 13 |
| R636 | - via abdomen | | 684.00 | 9 |
| R271 | - via chest and abdomen | | 770.00 | 13 |
| R296 E549 | Posterior | 9 | 605.40 | 9 |
| R310 | - with rib or transverse release, and | 0 1 | 108.70 | 9 |
| R264 | Cervical | | 1025.60 898.70 | - |
| R204 | vervical | IU | 090./0 | 12 |
| | Instrumentation - Deformities | | | |
| | Anterior (Dwyer etc. includes fusion/discectomy) | | | |
| R350 | - via chest or abdomen | 9 1 | 122.30 | 17 |
| R359 | - via chest and abdomen | | 235.35 | 17 |
| R362 | Posterior (Harrington) - with or without fusion | | 680.75 | 12 |
| R369 | Readjustment of instrumentation | | 127.80 | 4 |
| E533 | Harrington instrumentation to sacrum or pelvis, add | | 68.40 | |
| E534 | Harrington instrumentation, for each level over 6, add | | 16.60 | |
| E554 | - with posterior osteotomy, add | | 129.80 | |
| R371 | Segmental procedure - with fusion | | 1031.40 | 12 |
| E535 | Segmental instrumentation to pelvis, add to R371 | | 136.00 | |
| E536 | Segmental instrumentation, for each level over 6, add | | 27.00 | - |
| R461 | Removal of - anterior instrumentation | | 255.60 | 8 |
| R348 | - posterior instrumentation | 5 | 231.00 | 8 |
| | | | | |

| | OPERATIONS ON THE MUSCULOSKELETAL SYSTEM - Cont'd. | | | |
|--------|---|------|------------|-------|
| Code | | Asst | Surg | Anaes |
| | SPINE - Cont'd. | | | |
| | Revision of entire instrumentation | | | |
| R346 | - with fusion | 0 | 1000 00 | |
| R336 | - without fusion | | 1068.20 | 12 |
| R365 | | | 854.40 | 12 |
| R366 | Electrical stimulation | 8 | 448.90 | 10 |
| | - with muscle stripping of spine | 8 | 640.60 | 12 |
| R367 | Repair or replacement of electrodes | | 211.35 | 10 |
| R368 | Removal of electrodes | 8 | 244.90 | 8 |
| R464 | Muscle stripping spine prior to surgery | b | 170.40 | 8 |
| R361 | Halo traction prior to surgery (complete care) | 3 | 256.80 | 4 |
| Note: | R361 and R464 allow full benefit if followed by surgery for correction of | | | |
| | scoliosis in same hospitalization. | | | |
| | Anterior release including Halo traction | | | |
| R358 | - via chest or abdomen | 9 | 481.70 | 13 |
| R357 | - via chest and abdomen | 9 | 598.00 | 13 |
| R356 | Localizer cast | | 117.10 | 4 |
| | | | | |
| | Reduction - Fractures or Fracture Dislocations | | | |
| U.V.C. | | ٧ | risit fees | |
| Z236 | Skull calipers (I.O.P.) | | 44.20 | |
| Z241 | Halo traction (I.O.P.) | | 70.90 | |
| Z246 | Reapplication of Halo traction (I.O.P.) | | 44.20 | |
| E562 | Counter traction pins or vest - add | | 94.60 | |
| F103 | Closed reduction | 5 | 178.60 | 5 |
| F105 | Open reduction - posterior approach | 5 | 274.40 | 10 |
| F107 | - anterior approach | 7 | 322.80 | 10 |
| E913 | With spinal cord injury, add (when total care by operating surgeon) | • | 137.20 | |
| L313 | With irrigation, including opening of dura, to fractures when combined | | 10/ 100 | |
| E927 | with decompressive procedures, add | | 274.40 | |
| E567 | Fusion by same surgeon - one level, add | | 214.60 | |
| | - two or more levels, add | | 273.20 | |
| E568 | | | 2/3.20 | |
| 0403 | Fusion by different surgeon | | 274.40 | |
| R493 | - one level, add | | | |
| R494 | - two or more levels, add | | 322,80 | |
| E548 | With instrumentation, add | | 121.85 | |
| | | | | |
| | PELVIS and HIP | | | |
| | | | | |
| | Amputation | | 700.00 | 15 |
| R631 | Hemipelvectomy - hindquarter | 10 | 702.90 | 15 |
| R630 | Hip disarticulation | 10 | 396.50 | 10 |
| | | | | |
| | Arthrodesis | | | |
| R469 | Sacro-iliac joint | | 349.00 | 5 |
| R514 | Symphysis pubis | 5 | 341.60 | 6 |
| R470 | Hip | 5 | 620.95 | 8 |
| | | | | |
| | Arthroplasty | | | |
| R439 | Unipolar | 6 | 433.35 | 8 |
| R440 | Bipplar | 8 | 616.00 | 8 |
| R241 | Revision total arthroplasty hip (includes acetabular reconstruction) | 8 | 861.00 | 10 |
| R442 | Surface replacement | 8 | 748.70 | 8 |
| E589 | Bone graft to acetabulum, add | | 89.10 | |
| E593 | Acetabular reconstruction (extensive, including bone grafts), add | | 171.40 | |
| R481 | Peattachment of greater trychanter (late) | 6 | 256.00 | 8 |
| R443 | Removal only - non cemented | 3 | 394.85 | 8 |
| R488 | - cemented | 3 | 492.30 | 8 |
| 11.00 | VQ.0 | | | |
| | Arthroscopy | | | |
| 7218 | Hip joint (I.O.P.) | | 85,80 | 4 |
| E595 | Preceding surgery (same surgeon) | | 54.70 | |
| 2333 | Treceding adigery (adire adigeon) sessessessessessessessessessessessesses | | , | |
| | Arthrotony | | | |
| R547 | Sacro-iliac joint | 5 | 256.00 | 6 |
| R415 | Hip - with removal of loose body | 5 | 266.20 | 6 |
| K413 | TITLE MICH LGIDAGI OL 1003C DOCA ************************************ | • | 200 020 | |

| | OPERATIONS ON THE MUSCULOSKELETAL SYSTEM - Cont'd. | | | |
|--------------|---|------|------------------|-------|
| Code | PELVIS AND HIP - Cont'd | Asst | Surg | Anaes |
| | Agnination (Valuation and Agnin 40 and 55 | | | |
| Z290 | Aspiration/Injection - see pages 48 and 55 Hip - infant or child, under general anaesthesia | 2 | 56,10 | 4 |
| 22.30 | The same of carries general allocautesta | 3 | 20.10 | 4 |
| | Biopsy | | | |
| Z212 | Bone - punch needle (I.O.P.) | | 63.90 | |
| 7217 | - under general anaesthetic (I.O.P.) | | 63.90 | 5 |
| Z214 E563 | - open (1.0.P.) | 4 | 127.80 | 4 |
| R415 | Joint - via arthroscope - open | - | 9.60 | _ |
| 7228 | Soft tissue - open | 5 | 266,20 85,80 | 6 |
| | | | 85.80 | 4 |
| | Denervation/Decompression | | | |
| N188 | Decompression of lateral femoral cutaneous nerve | 4 | 132.70 | 4 |
| N177 | Exploration and/or decompression of sciatic nerve | 6 | 371.90 | 6 |
| | Exploration and/or decompression and/or transposition and/or neurolysis of | | | |
| N285 | major nerve | 4 | 221.20 | 4 |
| R427 | Denervation of hip | 4 | 341.60 | 5 |
| | Incinion and Designan | | | |
| R269 | Incision and Drainage Bone, incision and drainage | 2 | 255 00 | 4 |
| R249 | Sequestrectory | | 256.00 334.60 | 4 |
| R250 | Saucerization and bone graft | 4 | 553.80 | 5 |
| 7226 | Bursae/soft tissue (1.0.P.) | | 85.80 | 4 |
| R415 | Joint | | 266.20 | 6 |
| | | | | |
| | Examination/Manipulation | | | |
| 7252 | Manipulation - under general anaesthetic (I.O.P.) | | 34.20 | 4 |
| | - without general anaesthetic, see page 63 | | | |
| | Fundada - Dana | | | |
| R639 | Excision - Bone Simple cyst, etc. | | 200 00 | |
| R330 | Major resection tumour | | 299,00 427,60 | 6 |
| R216 | Radical resection tumour | | 684.00 | 8 |
| F115 | COCCYX | | 184.10 | 4 |
| R315 | Head and neck, femur | | 399.40 | 6 |
| | | | | |
| | Excision - Muscle | | | |
| R522 | Simple | | 170.40 | I.C. |
| R523 | Complex | | 427.60 | I.C. |
| R524 | Myositis | 4 | 255,60 | 5 |
| | Excision - Joint | | | |
| R423 | Synovectomy/debridement | 5 | 415,30 | 5 |
| MACO | Symprecturity/ usus Tudates to | 3 | 413.30 | 5 |
| | Excision - Bursae | | | |
| R590 | GT trochanteric/ischial | 3 | 177.35 | 4 |
| | | | | |
| | Reconstruction - Pseudarthosis | | | |
| R364 | Pelvis | | 512.80 | I.C. |
| R328 | Hip | 6 | 421.50 | 6 |
| | Reconstruction - Osteotomy | | | |
| R265 | Pelvis - infant | 8 | 352.25 | 8 |
| R273 | - other | | 512.80 | 8 |
| R263 | Hip | | 475.95 | 7 |
| | | | | |
| | Reconstruction - Muscle/Tendon | | | |
| R521 | Muscle release | 5 | 268.30 | 5 |
| 7232 | Closed adductors - tenotomy (1.0.P.) | | 43.00 | 4 |
| Z233 R545 | Open adductors - tenotomy (I.O.P.) | 5 | 85.80 | 5 |
| K242 | Iliopsoas - tenotomy | 3 | 235.10 | 2 |

| | OPERATIONS ON THE MUSCULOSKELETAL SYSTEM - Cont'd. | | | |
|----------------|---|------|----------------------|---------|
| Code | STATE OF THE PROCESSALE STATE STATE - CORE C. | Asst | Surg | Anaes |
| | | 7030 | July | Nides |
| | PELVIS and HIP - Cont'd. | | | |
| | Reconstruction - Tendon Transfer | | | |
| R570 | Iliopsoas | 5 | 459,20 | 6 |
| R569 | Abductor | 5 | 299.40 | 6 |
| | | • | 233.40 | 0 |
| | Reduction - Fractures | | | |
| U.V.C. | Coccyx - no reduction | | visit fees | |
| F115 | - excision | | 184.10 | 4 |
| F134 | - closed reduction | 2 | visit fees 391.60 | 4 |
| F135 | - open reduction | | 600.50 | 8 |
| U.V.C. | Sacrum - no reduction | - | isit fees | U |
| U.V.C. | Femoral neck trochanteric, subtrochanteric - no reduction | 1 | risit fees | |
| F098 | - closed reduction/traction | | 376.80 | 4 |
| F099 | - open reduction - pin only | | 360.00 | 8 |
| F100 F101 | - pin and plate | | 441.50 | 8 |
| R600 | - primary prosthesis | | 387.50 | 0 |
| 1,000 | Slipped epiphysis | 0 | 255.60 | 8 |
| R607 | - closed reduction/traction | 6 | 341.60 | 8 |
| R642 | - closed reduction/internal fixation | | 341.60 | 8 |
| R627 | - open reduction/fixation | | 512.80 | 8 |
| | | | | |
| | Reduction - Dislocations | | | |
| U.V.C. D052 | Acetabulum - no reduction | | risit fees | |
| 0046 | - open reduction - lips | | 540.70 854.40 | 8 10 |
| D047 | - one pillar | | 1281.20 | 12 |
| 0042 | Hip - closed | 0 | 236.30 | 4 |
| D043 | - open | 7 | 358.40 | 7 |
| R628 | - late | 7 | 684.00 | 10 |
| 0059 | Sacro-iliac - closed, traction, spica, etc | | 378.90 | 5 |
| D060 | - open | | 523.50 | 5 |
| U.V.C. DO61 | Sacro-coccygeal - closed | | risit fees 170.40 | 5 |
| R404 | Congenital hip - closed (includes tenotomy and cast) | 3 | 168.10 | 4 |
| R405 | - repeat (includes cast) | | 116.50 | 4 |
| R406 | - open (includes tenotomy and arthrotomy) | 7 | 416.80 | 7 |
| | | | | |
| | FEMUR | | | |
| | Annu Anhilan | | | |
| R625 | Amputation Gritti-Stokes or Callander | 5 | 269.10 | 5 |
| R626 | Through femur | | 270.10 | 5 |
| | | | 2. 0 220 | |
| | Biopsy (I.O.P.) | | | |
| Z869 | Bone - core, punch | | 34.20 | 4 |
| Z870 | - x-ray control/general anaesthetic | | 85.80 | 4 |
| Z242 Z228 | - open | 4 | 170.40 85.80 | 4 |
| R256 | Injection into bone cysts | | 103.20 | 4 |
| . 4200 | ageston mos conce glass assessment and a second a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second and a second | | 200020 | |
| | Incision and Drainage (Osteomyelitis) | | | |
| R242 | Incision and drainage, bone | | 287.50 | 4 |
| R245 | Sequestrectomy | | 348.60 | 4 |
| R243 | Saucerization and graft | 5 | 547.20 | 6 |
| 7226 | Soft tissue | | 85.80 | 4 |
| | Excision - Bone | | | |
| R314 | Simple cyst/exostosis | 4 | 199.10 | 4 |
| R330 | Bone tumour - simple | 4 | 427.60 | 6 |
| R216 | - with reconstruction/graft | 8 | 684.00 | 8 |
| | | | | |

| | OPERATIONS ON THE MUSCULOSKELETAL SYSTEM - Cont'd. | | | |
|--------------|--|------|------------------|---------|
| Code | | Asst | Surg | Anaes |
| | FEMUR - Cont'd. | | | 74003 |
| | To an - cong d. | | | |
| | Excision - Muscle | | | |
| R522 | Simple | | 170.40 | I.C. |
| R523 | Complex | | 427.60 | I.C. |
| R328 | Reconstruction - Pseudarthrosis | 6 | 421,50 | 6 |
| | December of the Control | | | |
| R632 | Reconstruction - Fascial | | | |
| R633 | Simple | | 170.40 | 4 |
| | supplies with or with our synthetic graft or rotation riap | 4 | 355.50 | 5 |
| | Reconstruction - Osteotomy | | | |
| R262 | Femoral shaft | 4 | 470,20 | 5 |
| R215 | Supracondylar | 4 | 341.60 | 6 |
| | | | | |
| R333 | Reconstruction - Leg Length Operations | | | |
| R332 | Femoral langthoning - all types | 4 | 424.30 | 4 |
| R340 | Femoral lengthening - all types Femoral epiphysiodesis | 4 | 478.40 265.80 | 5 |
| R341 | Tibial and femoral epiphysiodesis | 4 | 376.80 | 5 |
| R343 | Femoral stapling | 4 | 276.50 | 4 |
| R344 | Tibial and femoral stapling | 4 | 341.60 | 5 |
| | | | | |
| DC 00 | Reconstruction - Muscles/Tendons | | | |
| R589 R587 | Quadriceps repair - simple | 3 | 200.90 | 4 |
| R530 | - reconstructive | 3 | 341.60 | 4 |
| R561 | Quadricepsplasty - all types | 3 | 336.70 166.70 | 5 |
| 2197 | Closed release of ilio-tibial band (I.O.P.) | 3 | 43.00 | 4 |
| R543 | Tenotomy of hamstrings - single | 3 | 148.70 | 4 |
| R562 | - multiple | 3 | 170.60 | 4 |
| R557 | Lengthening of hamstrings - single | 3 | 197.60 | 4 |
| E050 | - each additional, add | | 67.70 | |
| R571 | Tendon or muscle transfer | 3 | 270.95 | 5 |
| E049 R524 | - each additional, add | | 77.00 | 1(max.) |
| H324 | Excision of myositis | 4 | 255,60 | 5 |
| | Reduction - Fractures | | | |
| | Femoral shaft/supracondylar | | | |
| U.V.C. | - no reduction - cast - bed rest | V. | isit fees | |
| F094 | - closed reduction - traction - infant or child | 3 | 227.70 | 4 |
| F095 | - adult or adolescent | 3 | 359.60 | 4 |
| F097 | - closed reduction - cast | 3 | 228.55 | 4 |
| F096 | - open reduction | 6 | 435.80 | 8 |
| | KNEE | | | |
| | 10 Suda | | | |
| | Amputation | | | |
| R625 | Through knee - disarticulation | 5 | 269.10 | 5 |
| | | | | |
| DACO | Arthrodesis | 2 | 200 10 | - |
| R468 | Knee | 3 | 355.10 | 5 |
| | Arthroplasty | | | |
| R509 | Patellar arthroplasty | 3 | 213.80 | 5 |
| | Hemi-arthroplasty | | | |
| R482 | - single component (e.g. MacIntosh) | 6 | 310.50 | 6 |
| R483 | - double component (e.g. Marmar) | 6 | 394.85 | 6 |
| R441 | Total replacement/both compartments | 8 | 547.20 | 8 |
| R244 E598 | Revision total arthroplasty knee | 8 | 739.70 83.10 | 8 |
| 5390 | Removal of hemi-arthroplasty | | 73.10 | |
| R496 | - without replacement | 4 | 213.80 | 5 |
| | Removal of total arthroplasty | | | |
| R497 | - without replacement | 4 | 325,20 | 5 |
| E564 | Revision of arthroplasty, add 35% | | | |
| | | | | |

| | OPERATIONS ON THE MUSCULOSKELETAL SYSTEM - Cont'd. | | | |
|--------------|--|------|-----------------|---------|
| Code | | Asst | Surg | Anaes |
| | KNEE - Cont'd. | | | |
| | A | | | |
| | Arthroscopy | | | |
| R190 | Diagnostic arthroscopy | 3 | 85.80 | 4 |
| R191 | - with synovial biopsy | 3 | 94.60 | 4 |
| R192 R193 | - with trimming of plica, tissue, meniscus | | 112.20 | 4 |
| R194 | - with removal of loose body, screw | | 226.10 | 4 |
| R195 | - with lateral release | | 183.10 | 4 |
| R196 | - with synovectomy - anterior, 1 compartment | 3 | 171.80 | 4 |
| R197 | - with synovectomy - anterior, more than 1 compartment | 3 | 288.35 | 4 |
| R198 | - with synovectomy - total, anterior and posterior | 3 | 481.70 | 4 |
| R199 R203 | with drilling of defect (includes removal of loose body) with pinning of osteochondral fragment | 3 | 278.50 | 4 |
| R204 | - with printing of osceothorizal tragment | | 278 . 50 | 4 |
| R205 | - with debridement - more than 1 compartment | | 340.00 | 4 |
| R206 | - with abrasion arthroplasty | | 311.30 | 4 |
| R207 | - with menisectomy | 3 | 268.70 | 4 |
| R208 | - with repair medial or lateral meniscus | 3 | 268.70 | 4 |
| | Authoriton. | | | |
| R412 | Arthrotomy Knee- with or without removal of loose body | 3 | 183,50 | 4 |
| R413 | Osteochondritis dissecans with drilling and/or internal fixation | | 235.90 | 4 |
| | | | 200,500 | |
| | Aspiration - see listing on page 58. | | | |
| | A1 | | | |
| 2870 | Biopsy Bone/joint - needle (I.O.P.) | | 05.00 | 4 |
| Z242 | open (I.O.P.) | 1 | 85.80 170.40 | 4 |
| E563 | - via arthroscope | 7 | 9.60 | 7 |
| 7228 | Soft tissue - open (I.O.P.) | | 85.80 | 4 |
| | | | | |
| 2100 | Denervation/Decompression | | | |
| R426 N285 | Denervation of knee | 3 | 227.30 | 4 |
| NZOO | Denervation of gastrocnemius | 4 | 221.20 | 4 |
| | Incision and Drainage | | | |
| Z226 | Soft Tissue (I.O.P.) | | 85.80 | 4 |
| R444 | Joint | . 3 | 170.40 | 4 |
| | Eventerbles Manipulation | | | |
| 7222 | Examination/Manipulation Manipulation - under general anaesthetic (I.O.P.) | | 20.90 | 4 |
| | - without general anaesthetic, see page 63. | | 20.50 | 7 |
| | , | | | |
| | Excision | | | |
| R431 | Baker's cyst - simple | 3 | 131.10 | 4 |
| R434 | - extensive | 4 | 233.10 | 6 |
| R501 R429 | Meniscectomy | | 212.60 | 4 |
| R417 | Debridement of joint without synovectomy | 3 | 256.40 | 4 |
| R424 | Synovectomy | 3 | 379.70 | 5 |
| R506 | Prepatellar bursae | 3 | 131.70 | 4 |
| R312 | Patella - to include fascial repair | 3 | 244.10 | 4 |
| R318 | Excision exostosis/cyst patella | 3 | 111.40 | 4 |
| | Reconstruction - Meniscus | | | |
| R508 | Suturing of medial or lateral meniscus | 3 | 213.80 | 5 |
| | | | | |
| DECA | Reconstruction - Muscles/Tendons | 2 | 107.00 | |
| R584 | Tenoplasty - one | 3 | 127.80 | 4 |
| E050 R589 | - each additional, add | 3 | 67.70 200.90 | 4 |
| R587 | - late | 3 | 341.60 | 4 |
| R571 | Transplant of tendon - single | | 270.95 | 5 |
| E049 | - each additional, add | | 77.00 | 1(max.) |
| Z237 | Tenotomy - closed - one | | 43.00 | 4 |
| Z238 | - multiple | 3 | 63.90 | 4 |
| R564 R566 | - open - one | 3 | 204.60 | 4 |
| R516 | Release patellar retinaculum | | 142.50 | 5 |
| | Parallan inclination and incli | | | |

| 0-4- | OPERATIONS ON THE MUSCULOSKELETAL SYSTEM - Cont'd. | | | |
|--------|---|------|-----------|-------|
| Code | INEE - Cont'd. | Asst | Surg | Anaes |
| | December of the Lieuwete | | | |
| R599 | Reconstruction - Ligaments | | | |
| | Ligaments - simple/one | 3 | 319.10 | 4 |
| R542 | - extensive/multiple (including synthetics) | 4 | 457.10 | 6 |
| R484 | - synthetic anterior/posterior cruciate | | 435.40 | 6 |
| R539 | - removal of synthetics | 4 | 188.40 | 4 |
| | Autority B. A. | | | |
| | Reduction - Fractures | | | |
| F085 | Patella - no reduction | | 59.60 | |
| F087 | - open reduction or excision with or without repair | 4 | 242.90 | 4 |
| F021 | Osteochondral fracture - open reduction | 4 | 221.80 | 5 |
| | | | | |
| | Reduction - Dislocations | | | |
| D038 | Knee - closed reduction | | 183.30 | 4 |
| D039 | - open reduction | 5 | 272.40 | 5 |
| D040 | Patella - closed reduction - without anaesthetic | | 54.90 | |
| D031 | - with anaesthetic | | 85.80 | 4 |
| D041 | open reduction - early | | 256.00 | 5 |
| R255 | - late | A | 427.60 | 6 |
| R403 | - recurrent | 4 | 329.90 | 5 |
| R515 | Congenital dislocation - knee (open) | A | 427.60 | 6 |
| 1020 | organisal distocación - Nice (open) | 4 | 427.00 | 0 |
| | FIBULA and TIBIA | | | |
| | TIDOS GIO TIDIA | | | |
| | Amoutation | | | |
| R624 | Tibia/fibula | | 220 10 | _ |
| NUET | TIDIQ/TIDUIG | 5 | 270.10 | 5 |
| | Biopsy | | | |
| Z870 | | | 05 00 | |
| | Bone - simple - punch | | 85.80 | 4 |
| 7242 | - open | 4 | 170.40 | 4 |
| 7228 | Soft tissue - open | | 85.80 | 4 |
| R256 | Injection into bone cysts | | 103.20 | |
| | | | | |
| | Decompression/Denervation | | | |
| R495 | Decompression of fascial compartments | 3 | 282.60 | 4 |
| Z783 | Secondary closure | | 85.80 | |
| 7251 | Catheter insertion (I.O.P.) | | 43.00 | |
| U.V.C. | . Monitoring of pressure monitoring device | | visit fee | is . |
| N184 | Decompression of posterior tibial or common perineal nerve | 4 | 145.40 | 4 |
| | | | | |
| | Incision and Drainage (Osteomyelitis) | | | |
| R237 | Incision and drainage, bone | 3 | 272,00 | 4 |
| R239 | Sequestrectomy | 3 | 290,80 | 4 |
| R238 | Saucerization and bone grafting | 3 | 362.70 | 4 |
| 7226 | Soft tissue | - | 85.80 | 4 |
| LLLO | 5015 C1330C | | 00.00 | - |
| | Excision | | | |
| R311 | Exostosis/cyst | 3 | 177.35 | 4 |
| R210 | Fibular head | 3 | 170.40 | 4 |
| R295 | Tumour - simple | | 255.20 | 4 |
| R253 | | | | |
| | - extensive with repair | | | I.C. |
| R246 | Excision bony ridge to include interpositional materials | I.C | | I.C |
| R522 | Muscle/soft tissue - simple | 3 | 170.40 | I.C. |
| R523 | - complex | 4 | 427.60 | I.C. |
| | | | | |
| | Reconstruction - Pseudoarthrosis | | 207 20 | - |
| R326 | Tibia/fibula | 4 | 307.20 | 5 |
| R327 | By-pass fibular graft | 4 | 301.05 | 6 |
| R372 | Congenital pseudarthrosis | 4 | 427.60 | 6 |
| | | | | |
| | Reconstructive - Osteotomy | | | |
| R289 | Tibia and fibula - adult or child | 3 | 332.20 | 4 |
| R403 | Tuberosity (Macquet) | 4 | 329.90 | 5 |
| | , | | | |
| | Reconstruction - Leg Length Operations | | | |
| R331 | Tibial lengthening | 4 | 415.30 | 4 |
| R458 | Tibial shortening | 4 | 341.60 | 4 |
| R341 | Tibial and femoral epiphysiodesis | 4 | 376.80 | 5 |
| R339 | Tibial epiphysiodesis | | 284.30 | 5 |
| R342 | Tibial stapling - one side | | 170.40 | 4 |
| R460 | - both sides | 4 | 213.80 | 4 |
| R344 | Tibial and femoral stapling | | 341.60 | 5 |
| LOTH! | inner and rainer reduing ************************************ | | 2.2800 | |

| | OPERATIONS ON THE MUSCULOSKELETAL SYSTEM - Cont'd. | | | |
|--------------|---|------|------------------|-------|
| Code | | Asst | Surg | Anaes |
| | FIBULA AND TIBIA - Cont'd. | | | |
| | Reduction - Fractures | | | |
| F078 | Tibia with or without fibula - no reduction, rigid immobilization | | 102.60 | |
| F079 | - no reduction, rigid inhoritization | 3 | 158.90 | 4 |
| F080 | - open reduction - shaft | 4 | 314.60 | 5 |
| F081 | - medial or latral tibial plateau | 4 | 348.20 | 5 |
| E532 | - both tibial plateaus, same knee, add 50% | | | |
| F082 | Fibula - no reduction, rigid immobilization | | 59.60 | 4 |
| F083 F084 | - closed reduction | 4 | 88.90 202.95 | 4 |
| 1004 | - open reduction | 7 | 202.55 | |
| | FOOT and ANKLE | | | |
| | | | | |
| 0000 | Amputation Metatarsal/phalanx disarticulation | 4 | 137.60 | 4 |
| R620 E585 | - each additional | 4 | 41.60 | 4 |
| R621 | Ray (single) | 4 | 191.70 | 4 |
| R623 | Symes | 5 | 251.90 | 5 |
| R622 | Transmetatarsal/transtarsal | 4 | 207.70 | 4 |
| R619 | Terminal Symes | 4 | 127.80 | 4 |
| | Arthrodesis | | | |
| R466 | Ankle | 3 | 344.10 | 4 |
| R471 | Interphalangeal | 3 | 139.70 | 4 |
| E575 | - each additional | | 36.90 | |
| R477 | Metatarsophalyngeal | 3 | 237.60 | 4 |
| R474 R513 | Midtarsal/subtalar | 3 | 310.90 341.60 | 4 5 |
| R475 | Pan-talar, one stage | 3 | 553.00 | 6 |
| | • | | | |
| | Arthroplasty | | 070 40 | - |
| R485 | Ankle-total replacement | 6 | 376.40 | 6 |
| R247 R479 | Revision total arthroplasty ankle | 6 | 498.10 | 6 |
| 1473 | Metatarsophalyngeal interposition | - | 2,00,10 | |
| R456 | - single | 3 | 127.80 | 5 |
| E538 | - each additional, add | | 33.90 | _ |
| R453 | Metatarsopohalyngeal (Swansons, etc.) | 3 | 255.60 | 5 |
| R454 R500 | - multiple | 3 | 341.60 127.80 | 4 |
| E564 | Revision of arthroplasty, add 35% | , | 127 000 | |
| | , | | | |
| | Arthoscopy | 2 | 05.00 | 4 |
| R209 | - Diagnostic arthroscopy - with Synovial biopsy | 3 | 85.80 94.60 | 4 |
| R211 R212 | - with Removal of loose body, screw | 3 | 226.10 | 4 |
| R213 | - with Drilling of defect (includes removal of loose body) | | 278.50 | 4 |
| R221 | - with Debridement - local | 3 | 278.50 | 4 |
| R224 | - total | 3 | 340.00 | 4 |
| R230 | - with Synovectomy - partial total | 3 | 229.40 481.70 | 4 |
| R232 R233 | - with Pinning of osteochondral fragment | | 278.50 | 4 |
| NE35 | - With I having of observation in agreement the second control of | 1 | | |
| | Arthrotomy | | | |
| R503 | Ankle - removal of loose body, etc. | 3 | 147.00 | 4 |
| E539 | - with osteotomy of malleolus, add | 3 | 103.80 | 4 |
| R504 R505 | Metatarsal/phalangeal | | 127.80 | 4 |
| 11303 | | | | |
| | Aspiration - see listings on page 58. | | | |
| | Pinney | | , | |
| Z869 | Biopsy Bone ~ needle ~ punch (I.O.P.) | | 34.20 | 4 |
| Z870 | - punch - under general anaesthetic | | 85.80 | |
| Z242 | - open | 4 | 170.40 | 4 |
| E563 | Joint - via arthroscope | | 9.60 | 4 |
| R409 | - open | | 147.90 85.80 | 4 |
| Z228 | SUIT LISSUE - Upen (1.00,F.) | | W.W | |
| | Incision and Drainage | | | 1. |
| R220 | Incision and drainage - bone | 3 | 200.50 | 4 |
| R201 | Sequestrectory | 4 | 170.40 | 4 |
| | | | | |

SUMBILIAL PROJECUISES

| | OPERATIONS ON THE MUSCULOSKELETAL SYSTEM - Cont'd. | | | |
|------|--|------|--------|-------|
| Code | GENTLES OF THE POSSELENKEETE STSTEP - CORE C. | 0 4 | | A |
| code | | Asst | Surg | Anaes |
| | | | | |
| | FOOT AND ANKLE - Cont'd. | | | |
| | | | | |
| R202 | Saucerization and bone graft | 4 | 341,60 | 4 |
| 7226 | Bursae (1.0.P.) | | 85.80 | 4 |
| R503 | Joints | 3 | 147.00 | 4 |
| | | 3 | | |
| 7228 | Soft tissue (I.O.P.) | | 85.80 | 4 |
| | | | | |
| | Examination/Manipulation | | | |
| 7222 | - under general anaesthetic | | 20,90 | 4 |
| | - without general anaesthetic, see page 68. | | | |
| | Club foot, etc manipulation and cast/strapping | | | |
| 7235 | - without anaesthetic | | 17.50 | |
| | - without didestrictic | | 17.50 | |
| 7224 | - with anaesthetic | | 34.20 | 4 |
| | | | | |
| | Excision - Bone | | | |
| R299 | Phalanx | 3 | 112,40 | 4 |
| R309 | Metatarsal head | 3 | 154.40 | 4 |
| F587 | _ nach additional | 2 | | 4 |
| | - each additional | - | 36.90 | |
| R305 | Accessory navicular (scaphoid) | 3 | 137.40 | 4 |
| R302 | Bunion/bunionette | 3 | 132.90 | 4 |
| R307 | Calcaneal spur | 3 | 122,90 | 4 |
| R282 | Exostosis (dorsal, subungual) | 3 | 88,70 | 4 |
| R308 | Os calcis, talus | 3 | 250.70 | 4 |
| R301 | Sesamoid, one or both | 3 | 124.90 | 4 |
| | | | | |
| R306 | Tarsal bar | 3 | 203.20 | 4 |
| R266 | Tumour (foot) (see Preamble para B.32) | 3 | 213.00 | 4 |
| | | | | |
| | Excision - Joint | | | |
| R420 | Ankle synovectomy | 3 | 241.45 | 4 |
| R425 | Metatansophalangeal synovectomy - one | 3 | 199.50 | 4 |
| | | | | |
| R414 | - two or more | 3 | 299.40 | 4 |
| | | | | |
| | Excision - Soft Tissue | | | |
| R549 | Ganglion - simple or complex | 3 | 104.00 | 4 |
| R506 | Bursa | 3 | 131.70 | 4 |
| R551 | Fascia (Dupytrens) - partial or complete | 3 | 286.70 | 4 |
| | | | | |
| R522 | Muscle - simple | 3 | 170.40 | I.C. |
| R523 | - complex | 4 | 427.60 | I.C. |
| | | | | |
| | Reconstruction - Pseudarthrosis | | | |
| R363 | Malleoli | 3 | 261,10 | 4 |
| R321 | Tarsals/metatarsals/phalanx | | 229.30 | 4 |
| 1000 | The surface surface surface of the s | - | | - |
| | | | | |
| | Reconstruction - Osteotomy | | 000 55 | |
| R259 | Os calcis | 3 | 262.55 | 4 |
| R276 | Metatarsals and phalanx | 3 | 127.80 | 4 |
| E596 | - each additional | | 36.90 | |
| R277 | Midtarsal/tarsal | 3 | 213.80 | 4 |
| R337 | Shortening metatarsal - one | 4 | 199.10 | 4 |
| | to an man | 4 | 240.80 | 4 |
| R338 | - two or more | 4 | 240.00 | 4 |
| | | | | |
| | Reconstruction - Forefoot | | | |
| R430 | Claw and harmer toe | 3 | 133.50 | 4 |
| E594 | - each additional hammer toe, add | | 36.90 | |
| R304 | Hallux Valgus - e.g. Mayo, Keller | 3 | 191.70 | 4 |
| R355 | - e.g. Joplin, McBride | 3 | 235,50 | 4 |
| R360 | Major forefoot reconstruction - max. | 3 | 325.60 | 5 |
| | | - | | 4 |
| R446 | Overlapping 5th toe | 3 | 120.40 | 4 |
| | | | | |
| | | | | |

| | OPERATIONS ON THE MUSCULOSKELETAL SYSTEM - Cont'd. | | | |
|--------------|--|------|-----------------|---------|
| Code | | Asst | Surg | Anaes |
| | FOOT HE AND F. A. A. | | | |
| | FOOT AND ANKLE - Cont'd. | | | |
| | Reconstruction - Club Foot | | | |
| R408 | Posterior or medial release | 4 | 276.10 | 4 |
| R448 | Posteromedial release, lateral shortening, tendon transfers and fusion | | 327.30 | 4_ |
| R546 | Plantar fascia release (Steindler) | 3 | 146.00 | 4 |
| | , | | | |
| | Reconstruction - Ligaments | | | |
| R597 | Ankle - one | | 204.80 | 4 |
| R548 | - extensive/multiple | 3 | 346.90 | 4 |
| | Ot-uties Tendens | | | |
| R640 | Reconstruction - Tendons Exploration - tendon sheath | 3 | 111.40 | 4 |
| K040 | Tenolysis - extensive release | | 221010 | , |
| R556 | - one | 3 | 178,60 | 4 |
| E599 | - each additional digit (max. 2), add | | 77.00 | |
| | Tendon transfer foot and ankle | | | |
| R565 | - single | 3 | 223,60 | 4 |
| E055 | - each additional, add | | 83.80 | 1(max.) |
| R572 | Tenodesis | 3 | 228.55 | 4 |
| R560 | Graft | 4 | 223.60 | 4 |
| E053 | - each additional, add | 3 | 197.60 | 4 |
| R557 E050 | Lengthening or shortening - one | 3 | 67.70 | 7 |
| R578 | Suture extensor tendon - one | 3 | 111,40 | 4 |
| £580 | - each additional | | 41.60 | |
| R585 | Suture flexor tendon - one | 3 | 208.90 | 4 |
| E581 | - each additional, add | | 77.80 | |
| R589 | Achilles tendon repair - early | 3 | 200.90 | 4 |
| R587 | - late | 3 | 341.60 | 4 |
| R579 | Tenotomy (open) - one toe | | 77.00 | 4 |
| R581 | - more than one toe | | 170.40 43.00 | 4 |
| Z229 Z243 | (closed) - one toe (I.O.P.) | | 85.80 | 4 |
| 2243 | Achilles or tibialis anterior/posterior | | ,50,600 | , |
| R544 | tenotomy - open | 3 | 151.10 | 4 |
| R555 | - closed | | 116.70 | 4 |
| | | | | |
| | Reduction - Fractures | | 50.60 | |
| F074 | Ankle - no reduction, rigid immobilization | 3 | 59.60 127.80 | 4 |
| F075 | - closed reduction open - one malleolus | | 209.70 | 4 |
| F076 F077 | - multiple malleoli or ligaments | 4 | 275.25 | 5 |
| 10// | Ankle fracture with tibial Plafond burst | | 2. 3423 | |
| F104 | - closed | 3 | 213.80 | 4 |
| F108 | - open | 4 | 320.70 | 6 |
| | Metatarsus - no reduction | | | |
| F061 | - one or more | | 43.00 | |
| F062 | - with rigid immobilization | 3 | 59.60 86.40 | 4 |
| F063 | - closed reduction - one or more | 4 | 156.90 | 4 |
| F064 F065 | - open reduction - one | 4 | 219.95 | 4 |
| F070 | Os calcis - no reduction - rigid immobilization | | 86.00 | |
| F071 | - closed reduction | | 142.50 | 4 |
| F072 | - open reduction | 4 | 248.60 | 4 |
| | Phalany - no reduction | | 40.0 | |
| F056 | - rigid immobilization - one | | 43.00 | |
| E560 | - each additional | , | 10.40 | 4 |
| F058 | - closed reduction - one | | 13.10 | 4 |
| E561 F060 | - each additional | | 151.55 | 4 |
| | - Open 1 addresses assesses assesses assesses and a contract of the contract o | | | |

| Code | OPERATIONS ON THE MUSCULOSKELETAL SYSTEM - Cont'd. | Asst | Surg | Anaes |
|--------------|--|------|------------------|-------|
| 0000 | FOOT AND ANKLE - Cont'd. | ASSE | Sury | Mides |
| | Tarsus excluding os calcis | | | |
| F066 | - no reduction - rigid immobilization | | 85.80 | |
| F067 F068 | - closed reduction | 3 | 145.40 209.30 | 4 |
| 1000 | Intra-articular fracture - I.P. joint | 4 | 209.30 | 4 |
| F057 | - closed reduction | | 68.40 | |
| F059 | - open reduction | 3 | 127,80 | 4 |
| | Reduction - Dislocations | | | |
| D035 | Ankle - closed reduction | 4 | 97.70 | 4 |
| D036 | - open reduction | 4 | 222.40 | 4 |
| R402 D027 | - recurrent dislocation and/or subluxation | | 324.00 50.40 | 5 |
| E578 | Interphalangeal - closed | | 8,60 | 4 |
| 0029 | - open | | 133.50 | 4 |
| D030 | Metatarsophalangeal - closed | | 50.40 | 4 |
| E579 D032 | - each additional | | 8.60 144.20 | 4 |
| 0032 | - open | 4 | 129.80 | 4 |
| D034 | - open | 4 | 223.00 | 4 |

OPERATIONS ON THE RESPIRATORY SYSTEM

| | OPERATIONS ON THE RESPIRATORY SYSTEM | | | |
|--------------|--|------|------------------|--------|
| Code | | Asst | Surg | Anaes |
| | NOSE | 7050 | July | rides |
| | NUOC. | | | |
| | Nasopharynx | | | |
| | E.U.G.A. of nasopharynx for malignant disease including biopsies (not | | | |
| | to be charged if done in conjunction with T & A adenoidectory or | | | |
| Z298 | quadroscony) ([() P] | | 34.80 | |
| R181 | EXCISION OF nasopharyngeal lesion with palatal split | 4 | 434.20 | 7 |
| R182 | excision of hasopharyngeal lesion with mandibulotomy, glossotomy and/or | | | |
| KIOZ | palatal split Fiberoptic endoscopy of upper ainway (nose, hypopharynx or larynx)(1.0.P.) - if only operative procedure performed | 7 | 843.80 | 10 |
| Z296 | - if only operative procedure performed | | 15.15 | |
| Z297 | Insertion of prosthesis for nasal septal perforation (I.O.P.) | | 15.15 | |
| | | | | |
| | Incision (I.O.P.) | | | |
| Z301 | Drainage of abscess or haematoma | | 47.50 | 4 |
| Z302 | Turbinate reduction - uni or bilateral (to include cautery, cryosurgery, | | 47,50 | 4 |
| 2302 | turbinectamy) | | 47.50 | 4 |
| | Excision | | | |
| Z304 | Nasal polyp (I.O.P.) - single | | 17.80 | |
| | - multiple or involving general anaesthetic | | | |
| Z305 | (unilateral) | | 47.50 | 4 |
| Z308 | Choanal polypectomy (I.O.P.) - unilateral | | 47.50 | 4 |
| Z309 Z310 | Biopsy (I.O.P.) - single multiple or involving general anaesthetic | | 15.15 43.40 | 4 |
| Z311 | Removal of foreign body (I.O.P.) - simple | | 8.80 | 4 |
| 2311 | - complicated, or involving general | | 0.00 | |
| Z312 | anaesthetic | | 43.40 | 4 |
| M010 | Excision of intranasal lesions by lateral rhinotomy approach | | 421.90 | 7 |
| MO11 | Excision of other intranasal lesions (See Preamble Para. B.32) | I.C. | I.C. | I.C. |
| | D | | | |
| | Reconstruction Septoplasty (when antrum lavage, polypectomy, turbinate reduction, | | | |
| | intranasal ethnoidectomies or antrostomies are done in addition, add | | | |
| M012 | 50% of the appropriate fees to MO12 MO13, MO14, MO15, MO16, MO19, MO24). | | 215.00 | 4 |
| M013 | Partial septorhinoplasty (excluding osteotomies) | | 308.00 | 7 |
| MO14 | Septorhinoplasty | | 413.70 | 7 |
| MO19 | - with autologous bone or cartilage graft from site other than | _ | 500 00 | - |
| MO24 | nose | | 589.80 463.70 | 7 7 |
| R319 | - with non-autologous graft or implant | | 308.00 | 4 |
| R320 | - non-autologous or prosthetic implant (without septorhinoplasty) | | 198.20 | 4 |
| Note: | MO13, MO14, MO19, MO24, R319, R320 - claims for these procedures require | | | |
| | OHIP authorization. (See Surgical Preamble, paragraph (17)). | | | |
| | | | 000.10 | |
| M015 | Septodermoplasty (to include fascial and other grafts) | | 262.10 | 4 |
| M016 M017 | Repair of septal perforation | | 33.80 | 4 |
| E603 | - with fluorescein injection, add | | 43.40 | , |
| 2000 | Endonasal augmentation for atrophic rhinitis - unilateral (including | | | |
| M018 | obtaining graft or preparing implant) | | 262.10 | 4 |
| M020 | Repair of choanal atresia - uni or bilateral | 4 | 308.00 | 4 |
| M021 | Puncture and insertion of tube for choanal atresia - uni or bilateral | | 105.50 | 4 |
| M028 | Dilation of choanal atresia - uni or bilateral | | 63.30 | 4 |
| | billed with repair of cleft lip) | | | |
| M030 | - complex, to include necessary grafts and septoplasty | 4 | 528.40 | 7 |
| M031 | - tip and septum reconstruction only | | 217.10 | 4 |
| | | | | |
| 7011 | Treatment of Epistaxis (Nasal Haemorrhage) | | 0.70 | A |
| Z314 | Cauterization (I.O.P.) - unilateral | | 9.70 13.10 | 4 |
| Z315 Z316 | Anterior packing (I.O.P.) - unilateral Posterior packing (I.O.P.) - uni or bilateral | | 30.30 | 4 |
| MO27 | Ligation of external carotid artery - unilateral | 6 | 253.95 | 6 |
| R788 | Ligation of internal maxillary artery - unilateral | 7 | 345.70 | 10 |
| R789 | Ligation of anterior artery ethnoidal - unilateral | 6 | 253.95 | 6 |
| | | | | |

| | OPERATIONS ON THE RESPIRATORY SYSTEM - Cont'd. | | | |
|-------|--|------|------------------|-------|
| Code | NOSE - Cont'd. | Asst | Surg | Anaes |
| | | | | |
| | ACCESSORY NASAL SINUSES | | | |
| | Antrum or sinus lavage (I.O.P.) | | | |
| Z319 | Antral puncture and/or lavage - uni or bilateral | | 36.45 | 4 |
| M054 | Maxillary, intranasal antrostomy - unilateral | 4 | 105.50 | 4 |
| | Maxillary, Caldwell-Luc (intranasa) antrostomy included) | | | |
| M055 | - unilateral | 4 | 210.90 | 4 |
| M056 | Maxillectomy - partial or complete | 7 | 663.55 | 10 |
| E947 | - with orbital exenteration, add | | 262.10 | |
| Z318 | Frontal trephine or sinusotomy (I.O.P.) | | 113.90 | 4 |
| M058 | Radical frontal sinusectomy | | 393.20 | 5 |
| 11000 | Coronal and/or osteoplastic procedure for frontal sinusectomy, recon- | | | |
| M063 | struction or obliteration - unilateral or bilateral | 7 | 611.90 | 10 |
| M059 | External frontal-ethnoidal sinusectomy and/or reconstruction | | 202 00 | - |
| M060 | - unilateral | 4 | 393.20 | 6 |
| MUOU | Intranasal ethnoidectomy - unilateral | | 135.20 | 4 |
| M023 | External or transantral ethnoidectomy - unilateral (to include Caldwell- | | 200 00 | 4 |
| MO61 | Luc with transantral approach) | 4 | 308.00 | 4 |
| M064 | Trans-septal sphenoidotomy or sphenoid sinusectomy | 7 | 303.90 523.50 | 10 |
| M062 | Vidian neurectomy - unilateral | | 217.90 | 4 |
| M066 | Closure of antral fistula - minor | 4 | 84,40 | 4 |
| 11000 | - complex or involving general anaesthetic (to | | 0+0+0 | 4 |
| M067 | include Caldwell-Luc if necessary) | | 294.90 | 5 |
| 11007 | include calowers—cuc is necessary/ | | 254.50 | 5 |
| | LARYNX | | | |
| | Endoscopies (I.O.P.) | | | |
| | Laryngoscopy: | | | |
| Z321 | Direct - with or without biopsy | | 52.40 | 6 |
| Z322 | - with removal of foreign body | | 90.90 | 6 |
| 7323 | - with removal of lesion(s) | | 126.60 | 6 |
| Z343 | - with dilatation of larynx, to include bronchoscopy if necessary | | 172,85 | 6 |
| Z324 | Indirect - with biopsy or removal of foreign body | | 30.30 | 6 |
| E600 | Using operating microscope - add to charges for laryngoscopy (i.e. to Z321 | | | |
| | Z3Z3, Z3Z7, Z3Z8, Z330, Z342, Z343, Z348) | | 28.70 | |
| | | | | |
| | Introduction | | | |
| M080 | Teflon augmentation larynx | | 155.60 | 6 |
| | | | | |
| | Excision (to include laryngoscopy) | - | 71.0 | 10 |
| M081 | Laryngectomy - total | 6 | 716.80 | 13 |
| E882 | - with hemi thyroidectomy, add | | 151.55 | |
| E883 | - with subtotal thyroidectomy, add | | 227.70 | |
| E884 | - with total throidectomy, add | | 319.50 380.10 | 8 |
| M082 | Laryngofissure | 6 | 759.40 | 9 |
| M084 | Laryngectomy + segmental, including reconstruction | | 337.50 | 8 |
| M085 | Arytenoidectomy or arytenoidopexy or lateralization procedure | 9 | 337.30 | 0 |
| | Bonsin (to include languagemy) | | | |
| | Repair (to include laryngoscopy) Laryngoplasty - e.g. repair of stenosis and fractures, transections - not | | | |
| M090 | to be billed with MO84 | | 548.90 | 6 |
| M089 | Creation of tracheo-oesophageal fistula | 3 | 168.75 | 4 |
| Z320 | Insertion of voice prosthesis (1.0.P.) | | 21.90 | |
| 7303 | Removal of laryngeal stent or keel | | 88.50 | 4 |
| | The second of th | | | |

| | OPERATIONS ON THE RESPIRATORY SYSTEM - Cont'd. | | | |
|--------------|--|------|---------|--------|
| Code | | Asst | Surg | Anaes |
| | | 030 | July | /vides |
| | TRACHEA AND BRONCHI | | | |
| | Preamble: | | | |
| | (1) When laryngoscopy and bronchoscopy or oesophago-bronchoscopy are carried | | | |
| | out as combined procedures, the physician should claim for one or the | | | |
| | other but not both. | | | |
| | (2)No claim should be made for bronchoscopy carried out immediately | | | |
| | following thoracic surgery under the same anaesthetic by the same | | | |
| | surgeon. | | | |
| | F-t /1 0 0) | | | |
| | Endoscopy (I.O.P.) Bronchoscopy | | | |
| | - with or without bronchial biopsy, suction or injection of contrast | | | |
| Z327 | material | | 95.80 | 6 |
| E632 | - with removal of foreign body, add | | 54.90 | 0 |
| E633 | - with dilatation of stricture, add | | 37.90 | |
| E634 | - with selective endobronchial blocker or catheter insertion, add | | 37.90 | |
| | - with palliative endobronchial tumour resection including laser or | | 07 830 | |
| E635 | cryotherapy, add | | 54,90 | |
| | - with broncho alveolar lavage for obtaining specimens suitable for | | 3.655 | |
| | differential cellular analysis (for assessment of interstitial lung | | | |
| E636 | disease), add | | 21.10 | |
| | - with selective brushings of all 18 segmental bronchi for occult carcinoma | | | |
| E637 | in situ; specimens labelled as to site, add | | 59.00 | |
| E638 | - with transbronchial lung biopsy under image intensification only, add | | 63.30 | |
| E622 | - any bronchoscopic procedure for patients under 3 years of age, add | | 67.60 | |
| | Repeat bronchoscopy for tracheobronchial toilet when performed within one | | | |
| Z359 | week of another bronchoscopic procedure | | 43.40 | 6 |
| | Quadroscopy or panendoscopy - with or without biopsy (nasopharyngoscopy, | | | |
| | laryngoscopy, bronchoscopy, oesophagoscopy with or without gastroduo- | | | |
| Z355 | denoscopy), using separate instruments in search of malignant disease | | 154.80 | 6 |
| | Tools 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 | | | |
| 7244 | Tracheo-bronchial aspiration (I.O.P.) | | 23 50 | |
| Z344 Z345 | First procedure | | 31.50 | |
| 2343 | Subsequent procedures performed by same physician | | 15.80 | |
| | apply or (3) within the first two hours post-operatively.) | | | |
| 7326 | Change of tracheostomy tube | | 9.60 | |
| Z346 | Transtracheal aspiration | | 19.00 | |
| Z356 | Closure of persistent tracheostoma | | 113.90 | |
| 2000 | Stock Comparison of Additional Comparison of | | 240.50 | |
| | Incision (I.O.P.) | | | |
| Z741 | Tracheotomy | 3 | 133,50 | 6 |
| E639 | - with anterior cricoid split, add | | 66.80 | |
| Z738 | Insertion of Montgomery "T" Tube or similar laryngeol or tracheal stent | 4 | 176.10 | 8 |
| | | | | |
| | Excision | | | |
| M099 | Segmental resection of cervical trachea | 9 | 688.10 | 10 |
| E631 | - with resection of cricoid, add | | 266.20 | |
| M103 | Segmental resection of trachea with either sternotomy or thoracotomy | | .097.70 | 13 |
| M104 | Carinal resection (without pulmonary resection) | | 700.40 | 15 |
| E623 | Re-operation after 30 days, add | | 352.25 | |
| | David | | | |
| W100 | Repair | 2 | CAA CO | 10 |
| M100 | Tracheal rupture, transcervical | | 544.60 | 10 |
| M101 | Tracheal-bronchial rupture, transthoracic | 7 | 735.60 | 13 |
| | CHEST WALL AND MEDIASTINUM | | | |
| | Excision | | | |
| M105 | Chest wall tumour, resection of 2 or 3 ribs or cartilages | 9 | 438.30 | 13 |
| 11100 | - for each additional rib (more than 3) to a maximum of 3 additional, | | | 13 |
| E601 | add | | 48.70 | |
| | | | | |

| Code Asst Surg Anaes | | OPERATIONS ON THE RESPIRATORY SYSTEM - Cont.'d. | | | |
|--|-------|---|------|--------|-------|
| February | Code | | Asst | Surg | Anaes |
| Total stermectory Sexision of first rib and/or cervical rib to include scalenotomy when required require | | CHEST WALL AND MEDIASTINUM - Cont'd. | | | |
| Total stermectory Sexision of first rib and/or cervical rib to include scalenotomy when required require | | | | | |
| Excision of first rib and/or cervical rib to include scalenotomy when required required required 1.0 August 1. | | | | | |
| Mode | M107 | Total sternectomy | 9 | 688.10 | 13 |
| Repair Chest well Chest w | | | | 345.70 | 6 |
| Repair Chest wall pleura - closed 1.0. 5 | | | | | 13 |
| Chest wall | M108 | Ligation of thoracic duct - as sole procedure | 6 | 348.20 | 6 |
| Chest wall | | | | | |
| M10 | | | | | |
| M110 | MILOS | | | T.C | 6 |
| ### ### ### ### ### ### ### ### ### ## | | | | | |
| ### 1872 For fixation of each additional rib exceeding four ribs, add 47,10 2 ### 213.00 6 ### 213.00 10 ### 213.00 10 ### 213.00 10 ### 213.00 7 ## | | | 4 | | |
| M117 Sternal fixation for trauma | | - for fixation of each additional rib exceeding four ribs, add | | | |
| Surgical Collapse Thoracoplasty - one stage Pectus excavatum or carinatum repair (by reconstruction, not implant) 6 584.90 11 | M117 | | 4 | 213.00 | 6 |
| ### Processor Page | R352 | | | 584.90 | 11 |
| ### Processor Page | | | | | |
| - for each additional rib (more than 3) to a maximum of 3 additional, add | | Surgical Collapse | | | |
| ### Add ### April ### Apri | MIII | | 9 | 258.00 | 10 |
| Incision | | | | 47.40 | |
| Incision Z353 Incisional biopsy of chest wall tumour (I.O.P.) 3 75.80 4 Z354 Excisional biopsy of rib for tumour (I.O.P.) 4 120.40 6 Z357 Thoracic window creation (I.O.P.) 5 193.30 7 Z358 Thoracic window closure (I.O.P.) 5 193.30 7 Z358 Thoracic window closure (I.O.P.) 4 94.20 6 Endoscopies (I.O.P.) Z329 Mediastinoscopy 158.90 6 Z330 - with bronchoscopy 210.50 6 - with transbronchial biopsy under image intensification (including bronchoscopy) 233.50 6 Z348 - with bronchoscopy and mediastinotomy 3 296.55 6 Z347 Anterior mediastinotomy - when sole procedure performed 3 167.90 6 LUNGS AND PLEURA Introduction - Thoracentesis (I.O.P.) Z331 Aspiration for diagnostic sample 21.30 Z332 Aspiration for diagnostic sample 39.10 4 Z401 Administration of chemotherapy or sclerosing agent, add 9.40 Total unilateral lung lavage with or without biognostic sample 39.10 4 Endoscopy (I.O.P.) Z335 Thoracoscopy (pleuroscopy) with or without pleural biopsy, suction, etc. 94.20 5 Incision Z340 Biopsy of lung, needle (I.O.P.) including diagnostic aspiration 39.10 4 Z356 Biopsy of lung, needle (I.O.P.) including diagnostic aspiration 39.10 4 Z360 Biopsy of lung, needle (I.O.P.) including diagnostic aspiration 39.10 4 Z361 Closed drainage effusion or pneumothorax, (I.O.P.) 53.20 4 Endoscopy (I.O.P.) 53.20 4 Endoscopy for removal of foreign body 9 300.95 13 M137 Thoracotomy for nemoval of foreign body 9 300.95 13 M138 Thoracotomy or post-operative haemorrhage or empyena 9 300.95 13 | | | 2 | | - |
| 2353 Incisional biopsy of chest wall tumour (I.O.P.) 3 75.80 4 | 2/42 | Prinent cotomy (1.0.P.) | 3 | 90.10 | 5 |
| 2353 Incisional biopsy of chest wall tumour (I.O.P.) 3 75.80 4 | | Incipion | | | |
| Endoscopies (I.O.P.) Thoracic window creation (I.O.P.) Endoscopies (I.O.P.) Endoscopies (I.O.P.) Mediastinoscopy - with bronchoscopy 353 | | 3 | 75.80 | 4 |
| Thoracic window creation (I.O.P.) 5 193.30 7 Thoracic window closure (I.O.P.) 4 94.20 6 Endoscopies (I.O.P.) 4 94.20 6 Endoscopies (I.O.P.) 8 Mediastinoscopy 1 158.90 6 Taylor - with bronchoscopy 2 10.50 6 - with transbronchial biopsy under image intensification (including bronchoscopy) 2 23.50 6 Taylor - with bronchoscopy 3 23.50 6 Taylor - with bronchoscopy and mediastinotomy 3 265.55 6 Taylor - with bronchoscopy and mediastinotomy 3 266.55 6 Taylor - with bronchoscopy and mediastinotomy 3 266.55 6 Therefore mediastinotomy - when sole procedure performed 3 167.90 6 LUNGS AND PLEURA Introduction - Thoracentesis (I.O.P.) 2 21.30 Taylor - Administration of chemotherapy or sclerosing agent, add 9.40 Total unilateral lung lawage with or without diagnostic sample 39.10 4 Total unilateral lung lawage with or without bronchoscopy using double 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 | | | | | |
| Endoscopies (1.0.P.) Endoscopies (1.0.P.) Mediastinoscopy - with bronchoscopy - with bron | | | | | 7 |
| Mediastinoscopy | | | | 94.20 | 6 |
| Mediastinoscopy | | | | | |
| - with bronchoscopy - with transbronchial biopsy under image intensification (including bronchoscopy) - with transbronchial biopsy under image intensification (including bronchoscopy) - with bronchoscopy and mediastinotomy - when sole procedure performed - with bronchoscopy and mediastinotomy - when sole procedure performed - with bronchoscopy and mediastinotomy - when sole procedure performed - with bronchoscopy - when sole procedure performed - with procedure performed - wi | | | | 150.00 | - |
| - with transbronchial biopsy under image intensification (including bronchoscopy) 233,50 6 2348 - with bronchoscopy and mediastinotomy 3 296,55 6 2347 Anterior mediastinotomy - when sole procedure performed 3 167,90 6 LUNGS AND PLEURA Introduction - Thoracentesis (I.O.P.) 2331 Aspiration for diagnostic sample 21,30 2332 Aspiration with therapeutic drainage with or without diagnostic sample 39,10 4 2606 Administration of chemotherapy or sclerosing agent, add 9,40 2334 Total unilateral lung lawage with or without bronchoscopy using double 258,00 13 Endoscopy (I.O.P.) 2335 Thoracoscopy (pleuroscopy) with or without pleural biopsy, suction, etc. 94,20 5 Incision 2540 Biopsy of pleura, needle (I.O.P.) including diagnostic aspiration 39,10 4 2336 Biopsy of pleura, needle (I.O.P.) including diagnostic aspiration 39,10 4 2337 Riboracotomy for removal of foreign body 9,30,95 13 2337 Thoracotomy for post-operative haemorrhage or empyena 9,30,95 13 2313 Thoracotomy with or without biposy 9,300,95 13 23140 Thoracotomy or post-operative haemorrhage or empyena 9,30,95 13 | | | | | _ |
| bronchoscopy) 233,50 6 2348 - with bronchoscopy and mediastinotomy 3 296,55 6 2347 Anterior mediastinotomy - when sole procedure performed 3 167,90 6 LUNGS AND PLEURA Introduction - Thoracentesis (I.O.P.) 2331 Aspiration for diagnostic sample 21,30 2332 Aspiration with therapeutic drainage with or without diagnostic sample 39,10 4 2606 Administration of chemotherapy or sclerosing agent, add 9,40 Total unilateral lung lavage with or without bronchoscopy using double 2334 lumen tube and single lung anaesthesia 258,00 13 Endoscopy (I.O.P.) 2336 Biopsy of lung, needle (I.O.P.) without pleural biopsy, suction, etc. 94,20 5 Incision 2340 Biopsy of pleura, needle (I.O.P.) - including diagnostic aspiration 39,10 4 2336 Biopsy of pleura, needle (I.O.P.) - including diagnostic aspiration 39,10 4 2337 Rib resection for drainage (I.O.P.) - solerosing agent 9,40 2337 Rib resection for drainage (I.O.P.) 6 107,30 6 2338 Thoracotomy for nemoval of foreign body 9 300,95 13 2349 Thoracotomy for post-operative haemorrhage or empyena 9 330,95 13 | 2330 | | | 210.30 | 0 |
| - with bronchoscopy and mediastinotomy | 7333 | | | 233.50 | 6 |
| LUNGS AND PLEURA Introduction - Thoracentesis (I.O.P.) Z331 Aspiration for diagnostic sample | | | 3 | | |
| LUNGS AND PLEURA Introduction - Thoracentesis (I.O.P.) 2331 Aspiration for diagnostic sample | | Anterior mediastinotomy - when sole procedure performed | 3 | 167.90 | 6 |
| Introduction - Thoracentsis (I.O.P.) 2331 Aspiration for diagnostic sample | | | | | |
| Aspiration for diagnostic sample | | | | | |
| Aspiration with therapeutic drainage with or without diagnostic sample 39.10 4 Administration of chemotherapy or sclerosing agent, add 9,40 Total unilateral lung lavage with or without bronchoscopy using double lumen tube and single lung anaesthesia 258.00 13 Endoscopy (I.O.P.) Thoracoscopy (pleuroscopy) with or without pleural biopsy, suction, etc 94.20 5 Incision 77.80 4 Biopsy of lung, needle (I.O.P.) 77.80 4 Biopsy of pleura, needle (I.O.P.) - including diagnostic aspiration 39.10 4 Closed drainage effusion or pneumothorax, (I.O.P.) 53.20 4 E606 with administration of chemotherapy or sclerosing agent 9.40 Z337 Rib resection for drainage (I.O.P.) 6 107.30 6 M133 Thoracotomy for nemoval of foreign body 9 300.95 13 M137 Thoracotomy for post-operative haemornhage or empyema 9 300.95 13 | | | | 21 20 | |
| E606 Administration of chemotherapy or sclerosing agent, add 9,40 Total unilateral lung lavage with or without bronchoscopy using double lunen tube and single lung anaesthesia 258,00 13 Endoscopy (I.O.P.) Thoracoscopy (pleuroscopy) with or without pleural biopsy, suction, etc. 94,20 5 Incision Z340 Biopsy of lung, needle (I.O.P.) 77,80 4 Z336 Biopsy of pleura, needle (I.O.P.) – including diagnostic aspiration 39,10 4 Z341 Closed drainage effusion or pneumothorax, (I.O.P.) 53,20 4 E606 – with administration of chemotherapy or sclerosing agent 9,40 Z337 Rib resection for drainage (I.O.P.) 6 107,30 6 M133 Thoracotomy for nemoval of foreign body 9 300,95 13 M137 Thoracotomy with or without biopsy 9 330,95 13 M137 Thoracotomy for post-operative haemorrhage or empyema 9 330,95 13 | | Aspiration for diagnostic sample | | | Λ |
| Total unilateral lung lavage with or without bronchoscopy using double lumen tube and single lung anaesthesia | | | | | 7 |
| Endoscopy (I.O.P.) Z335 Thoracoscopy (pleuroscopy) with or without pleural biopsy, suction, etc | 2000 | Total unilateral lung layage with or without bronchoscopy using double | | 3.10 | |
| Endoscopy (I.O.P.) Thoracoscopy (pleuroscopy) with or without pleural biopsy, suction, etc | Z334 | lumen tube and single lung anaesthesia | | 258.00 | 13 |
| Incision Z340 Biopsy of lung, needle (I.O.P.) | | | | | |
| Incision Z340 Biopsy of lung, needle (I.O.P.) | | Endoscopy (I.O.P.) | | 04.00 | |
| 2340 Biopsy of lung, needle (I.0.P.) 77.80 4 2336 Biopsy of pleura, needle (I.0.P.) - including diagnostic aspiration 39.10 4 2341 Closed drainage effusion or pneumothorax, (I.0.P.) 53.20 4 6 6 6 7 7 7 7 7 7 7 | Z335 | Thoracoscopy (pleuroscopy) with or without pleural biopsy, suction, etc | | 94.20 | 5 |
| 2340 Biopsy of lung, needle (I.0.P.) 77.80 4 2336 Biopsy of pleura, needle (I.0.P.) - including diagnostic aspiration 39.10 4 2341 Closed drainage effusion or pneumothorax, (I.0.P.) 53.20 4 6 6 6 7 7 7 7 7 7 7 | | Indiaina | | | |
| 2336 Biopsy of pleura, needle (I.O.P.) – including diagnostic aspiration 39.10 4 2341 Closed drainage effusion or pneumothorax, (I.O.P.) 53.20 4 E606 – with administration of chemotherapy or sclerosing agent 9,40 2337 Rib resection for drainage (I.O.P.) 6 107.30 6 M133 Thoracotomy for nemoval of foreign body 9 330.95 13 M137 Thoracotomy with or without biopsy 9 330.95 13 M134 Thoracotomy for post-operative haemorrhage or empyema 9 330.95 13 | 73/0 | | | 77.80 | 4 |
| 2341 Closed drainage effusion or pneumothorax, (I.O.P.) 53.20 4 | | Rinnsy of pleura needle (I.O.P.) - including diagnostic aspiration | | | |
| E606 - with administration of chemotherapy or sclerosing agent 9,40 | | Closed drainage effusion or pneumothorax, (I.O.P.) | | | 4 |
| Z337 Rib resection for drainage (I.O.P.) 6 107.30 6 M33 Thoracotomy for nemoval of foreign body 9 330.95 13 M137 Thoracotomy with or without biopsy 9 330.95 13 M134 Thoracotomy for post-operative haemorrhage or empyema 9 330.95 13 | | - with administration of chemotherapy or sclerosing agent | | | |
| M137 Thoracotomy for nenoval of foreign body 9 330,95 13 M137 Thoracotomy with or without biopsy 9 330,95 13 M134 Thoracotomy for post-operative haemorrhage or empyena 9 330,95 13 | | Rib resection for drainage (L.O.P.) | 6 | | _ |
| MI37 Thoracotomy with or without biopsy | M133 | Thoracotomy for removal of foreign body | 9 | | |
| | | Thoracotomy with or without biopsy | 9 | | |
| MISE Thoracocomy with repair of ruptured diaphragm | | Thoracotomy for post-operative haemorrhage or empyema | 9 | | |
| | M132 | Inoracotomy with repair of ruptured diaphragm | 7 | 430.10 | 13 |

OPERATIONS ON THE DESCRIPATION SYSTEM - Cont. d

| | OPERATIONS ON THE RESPIRATORY SYSTEM - Cont'd. | | | |
|--------|--|------|--------|-------|
| Code | | Asst | Surg | Anaes |
| | | | | |
| | LUNG AND PLEURA - Cont'd. | | | |
| M130 | Closum of homeho played fictula (teacethomeic on teams atomal) | 0 | 400 00 | 12 |
| E609 | Closure of broncho-pleural fistula (transthoracic or trans-sternal) | 9 | 495.60 | 13 |
| E009 | - with intercostal muscle bundle, add | | 103.20 | |
| E610 | - with myovascular flap (pectoralis major, latissimus dorsi, rectus | | 000 00 | |
| | abdominus), add | 11 | 223.60 | 15 |
| M135 | Major decortication of lung for empyema or tumour | 11 | 503.00 | 15 |
| 7220 | Intercostal drainage with insufflation of sclerosing agent under general | | 154.00 | _ |
| Z339 | anaesthesia (I.O.P.) | 4 | 154.80 | 6 |
| 7220 | Excision (1.0 P.) | ^ | 170.00 | 10 |
| Z338 | Biopsy of pleura or lung - with limited thoracotomy (I.O.P.) | | 172.00 | 13 |
| M138 | Hilar lymphnode or lung biopsy with full thoracotomy | 9 | 348.20 | 13 |
| 142.40 | Pneumonectomy with or without radical mediastinal node dissection or | | 011 00 | |
| M142 | pericardial resection requiring repair | 10 | 811.00 | 14 |
| E612 | - total extra-pleural pneumonectomy, add | | 286.70 | |
| E613 | - sleeve pneumonectomy, add | | 210.50 | |
| E614 | - omental graft, add | | 137.60 | |
| E615 | - intra-pericardial dissection, add | | 102.40 | |
| E611 | - with resection of diaphragm including reconstruction | | 122.90 | |
| M143 | Lobectomy with or without radical mediastinal node dissection | 10 | 811.00 | 13 |
| E616 | - bi-lobectomy on right side, add | | 120.40 | |
| E617 | - with pleural tent, add | | 66.80 | |
| E618 | - with decortication of remaining lobe(s) | | 103.20 | 2 |
| E619 | - sleeve lobectomy, add | | 137.60 | |
| E620 | - with wedge bronchoplasty, add | | 66.80 | |
| E611 | with resection of diaphragm including reconstruction | | 122.90 | |
| E621 | - with diagnostic wedge resection | | 38.90 | |
| E624 | - with completion pneumonectomy for positive resection margin, add | | 94.20 | |
| E625 | - with sleeve resection of pulmonary artery, add | | 120.40 | |
| M144 | Segmental resection, including segmental bronchus and artery | | 811.00 | 13 |
| M145 | Wedge resection of lung | 10 | 364.50 | 13 |
| E608 | - each additional (to a maximum of three) | | 53.20 | |
| E611 | - with resection of diaphragm including reconstruction | | 122.90 | |
| M151 | Bullectomy for major bullous disease | | 540.70 | 13 |
| M149 | Pleurectomy, and/or apical bullectomy for pneumothorax | 10 | 364.50 | 13 |
| | Re-operation more than 30 days subsequent to previous excision, add to | | | |
| E607 | appropriate excision fee | | 129.00 | |
| | | | | |

OPERATIONS ON THE CARDIOVASCULAR SYSTEM

| Code | | Asst | Cumm | Anna |
|---------------|--|------|------------------|----------|
| | (a)with hypothermia and without bypass - basic fee for cardiovascular | MOSE | Surg | Anaes |
| R700 Note: | procedures | | | 25 |
| E650 | less than 25 units. (b)pump bypass - (anaesthetist - see Preamble,paragraph B.37[m]) | | 307,20 | 28 |
| | (bypass includes cannulating and decannulating heart or major vein, major artery, supervision of pump and pump run.) (c)circulatory assist device e.g. intra-aortic balloon (includes cannulation, repair of artery, daily care and supervision)(I.O.P.) | | | |
| Z743 | | | 258.00 | 5 |
| 2780 | | | 184.30 | 5 |
| Z744 Note: | (I.O.P.)open R815 not to be claimed in addition to Z744. | | 103.20 | 5 |
| Z781 | | | 32.80 | |
| ***** | (e)repositioning of intra-aortic balloon pump (no charge to be made for | | | |
| Z751 Z782 | repositioning within 24 hours of original insertion)(I.O.P.)open | | 107.30 | 5 |
| 2102 | -percutaneous -percu | | 69.20 | |
| E655 | to appropriate fee | | 146.20 | |
| | (g)removal of failed vascular graft without arterial reconstruction | | | |
| 2759 | (1.0.P.) - when sole procedure | | 158.90 | 6 |
| E670 | month after original operation), add to appropriate fee - following previous thoracotomy | | 188,40 | |
| E671 | - following previous sternotomy | | 282.60 | |
| | (i)preliminary diagnostic catheterization - extra to operative fees (see Diagnostic and Therapeutic Procedures). | | | |
| | (j) The basic anaesthetic fee of 28 units for major cardiovascular surgery includes such procedures as insertion of C.V.P. line (G268), arterial | | | |
| | line, blood sampling, blood analysis and interpretations. | | | |
| | HEART AND PERICAPOIUM | | | |
| | Cardiac massage | | | |
| | - closed (see Resuscitation on page 54) | | | |
| R765 | - open | 13 | 196.60 | 13 |
| G295 | includes insertion of temporary transvenous lead at same surgical procedure by same surgeon | 3 | 275.25 | 5 |
| G302 | Repositioning of permanent endocardial electrode (as separate procedure) | , | 275.25 | 5 |
| G269 | Insertion of permanent endocardial electrode(s) | | 125.30 | |
| G270 | Exposure of vein and implantation of pack | | 141.70 | 5 |
| G264 | Replacement of pack Atrio-ventricular sequential pacemaker-with permanent atrial and ventri- | | 124.50 | 5 |
| R752 | cular endocardial electrodes | 4 | 386.70 | 5 |
| R751 | Implantation of epicardial electrode(s) plus implantation of pack | | 395.70 | 20 |
| Z411 | Replacement of pack (I.O.P.) | 3 | 129.00 | 5 |
| 7412 | Replacement or repair of pacemaker lead (I.O.P.) | | 94.20 | 5 |
| M137 M134 | Thoracotomy - with or without biopsy | | 330.95 330.95 | 13 13 |
| 7401 | Aspiration of pericardium (I.O.P.) | | 111.80 | 13 |
| R750 | Open biggsy of pericardium and drainage (transthoracic or epigastric) | 13 | 270.30 | 13 |
| R748 | Pericandiectomy - one side open | 13 | 540.70 | 20 |
| R749 | - both sides open or sternal split | 13 | 852.00 | 20 |
| R712 R713 | Cardiotomy with exploration | 18 | 447.30 540.70 | 20 |
| R/13 | - with removal of foreign body | 18 | 447.30 | 20 |
| 10.74 | | - | , | - |

| | OPERATIONS ON THE CARDIOVASCULAR SYSTEM - Cont. d. | | | |
|--------------|---|------|------------------|----------|
| Code | OPERATIONS ON THE CARDIOVASCULAR SYSTEM - CONT. G. | Asst | Surg | Anaes |
| COOLE | HEART AND PERICARDIUM - Cont'd. | 7031 | July | Aides |
| | TEACH THE TELEVISION OF COMMENTS | | | |
| E660 | - electrophysiologic mapping of heart - epicardial | | 111.80 | |
| E661 | - endocardial and/or HIS Bundle | | 223.60 | |
| E662 | - division of accessory conduction pathways | | 55.70 | |
| R920 | Excision - ventricular tumour | 18 | 571.80 | 28 |
| R746 | - ventricular aneurysm | | 735.60 | 28 |
| R747 | - aneurysm of sinus of Valsalva | 18 | 666.80 | 28 |
| R741 | Coronary - endarterectomy | 18 | 622.60 | 20 |
| E651 | - when done in conjunction with coronary artery repair, add | | 172.00 | |
| | Excision of extensive endocardial scar, add to ventriculotomy or aneurysm | | | |
| E648 | repair | | 111.80 | |
| R742 | Coronary artery repair - one | | 761.85 | 20 |
| R743 | - two | 18 | 1024.00 | 20 |
| E654 | - each additional | | 159.70 | |
| | Use of internal mammary | | 155 00 | |
| E652 | - for construction of bypass graft, add | 12 | 155.60 | 20 |
| R754 | Ligation or division patent ductus - infant or child | | 447.30 | 20 |
| R755 | - adolescent or adult | 13 | 622.60 | 20 |
| 0067 | Interruption of bronchial collateral arteries (one or more arteries) - sole | 12 | 622 60 | 20 |
| R857 E663 | procedure - done in conjunction with other cardiac surgery | 13 | 622.60 155.60 | 20 |
| R757 | Resection coarctation - infant | 12 | 447.30 | 20 |
| R756 | - child | | 537.40 | 20 |
| R758 | - adolescent or adult | | 688.10 | 20 |
| K/ 30 | Congenital heart procedures - e.g. Blalock, Glenn, Potts, Waterston or | 13 | 000.10 | 20 |
| R759 | Central | 13 | 537.40 | 20 |
| R763 | Creation of ASD - by balloon septostomy | | 270.30 | 9 |
| R762 | - by thoracotomy or Sterling Edwards | | 537.40 | 20 |
| R715 | Closure atrial septal defect: secundum | | 537.40 | 20 |
| R716 | -endocardial cushion and valve defect | | 799.50 | 20 |
| R717 | - with anamalous pulmonary venous drainage | | 675.00 | 28 |
| R718 | Closure of ventricular septal defect | | 675.00 | 28 |
| R870 | Orthotopic cardiac transplantation | 18 | 1228.80 | 28 |
| R872 | Donor cardiectomy | | 409.60 | 8 |
| R874 | Cardiopulmonary transplantation | 18 | 1638.40 | 28 |
| | | | | |
| | Repair | | | |
| | Total repair Tetralogy of Fallot | | | |
| R720 | - with or without previous arterial shunt | 18 | 898.70 | 28 |
| R722 | Total anomalous pulmonary venous drainage | 18 | 799.50 | 28 |
| R723 | Total correction transposition of great vessels | 18 | 799.50 | 28 28 |
| R721 | Arterial repair of transposition | | 1200.10 | 28 |
| R921 | Complete A-V canal | 10 | 1053.50 | 28 |
| R922 | Single ventricle | 10 | 1053.50 | 28 |
| R923 | Double outlet - right/left ventricle | | 1200.10 | 28 |
| R924 R925 | Double outlet ventricle with transposition | | 1200.10 | 28 |
| R925 | Interrupted aortic arch | 18 | 1053.50 | 28 |
| R927 | Aorto-pulmonary window | 18 | 675.00 | 28 |
| R928 | R-V outflow tract with valve and tubular graft | 18 | 756.90 | 28 |
| R929 | Debanding arterioplasty of pulmonary artery | 18 | 670.90 | 28 |
| R768 | Pulmonary artery banding | | 447.30 | 20 |
| R769 | - with pressure studies by anaesthetist, extra/hour | | | 5 |
| R770 | Correction of cor triatriatum | 18 | 614.40 | 20 |
| R771 | Vascular ring | 18 | 537.40 | 20 |
| | | | | |
| | VALVES | | | |
| R724 | Pulmonary valvotomy | 18 | 563.60 | 28 |
| R725 | Pulmonary valvotomy and infundibular resection | 18 | 645.50 | 28 |
| R772 | Pulmonary valve replacement | 18 | 645.50 | 28 |
| | | | | |

| | OPERATIONS ON THE CARDIOVASCULAR SYSTEM - Cont'd. | | | |
|-------|---|------|---------|-------|
| Code | | Asst | Surg | Anaes |
| | | | | |
| | VALVES - Cont ^a d. | | | |
| R726 | Tricuspid valvotomy | 18 | 691.90 | 20 |
| R727 | Tricuspid annuloplasty | 18 | 563,60 | 20 |
| R728 | Tricuspid valve replacement | 18 | 645.50 | 28 |
| R729 | Mitral valvotomy | | 610.30 | 20 |
| R730 | Mitral valvotomy - restenosis | 18 | 679.90 | 20 |
| R734 | Mitral annuloplasty | | 655,40 | 20 |
| R735 | Mitral replacement | 18 | 794,60 | 28 |
| R733 | Mitral valvoplasty | | 819,20 | 28 |
| R930 | Aortic valvoloplasty | 18 | 712.70 | 28 |
| R736 | Aortic valvotomy | 18 | 602.10 | 20 |
| R737 | Aortic infundibular resection (ventriculamyotamy) | 18 | 739.70 | 28 |
| R738 | Aortic valve replacement | 18 | 860.20 | 28 |
| | Patch aortoplasty with pericardium or graft, add to R738 and/or aortic | | | |
| E647 | annuloplasty | | 225,30 | |
| | Aortic annuloplasty (reconstruction and enlargement of aortic annulus add | | | |
| E656 | to R738 and/or patch aortoplasty | | 245,80 | |
| | Replacement of aortic valve, replacement of ascending aorta, and | | 2.000 | |
| R863 | reimplantation of coronary arteries (Modified Bentall Procedure) | 18 | 1720.30 | 28 |
| | Multivalvular replacement - the fee will be that for the major valve | 20 | 1720900 | 20 |
| | replaced plus 85% of the fee for the additional valve or valves. | | | |
| | reproced pres cost of the ree for the additional valve of valves. | | | |
| | ARTERIES | | | |
| | Cannulation for infusion chemotherapy | | | |
| R775 | - superficial temporal artery | 3 | 80,30 | 4 |
| R776 | - hepatic artery | 6 | 177,30 | 6 |
| R778 | - carotid | | 124.50 | 5 |
| R760 | Dorinal indiation confusion on ilian | 10 | 344.10 | 10 |
| | Regional isolation perfusion e.g. iliac | C | | |
| R764 | Exploration of major artery | 0 | 227.70 | I.C. |
| | Incision | | | |
| 7400 | | | 00.20 | |
| Z402 | Arteriotomy (I.O.P.) | | 98.30 | 4 |
| note: | Z402 not allowed in addition to other major cardiovascular surgery when | | | |
| | performed at same time. | | | |
| | A | | | |
| | Repair - traumatic | | 000 00 | 7.0 |
| R790 | Suture of lacerated major artery | | 266.20 | I.C. |
| R795 | Repair of lacerated major artery (including patch angioplasty) | | 417.80 | 10 |
| R862 | - by bypass or interposition graft | 10 | 554.60 | 10 |
| | | | | |
| | Ligation | 2 | 00.00 | 7.0.4 |
| R781 | Ligation of artery (as sole procedure) - by region etc.* | | 86.00 | I.C.* |
| R788 | - internal maxillary artery (Caldwell-Luc approach) | | 345.70 | 10 |
| R789 | - anterior ethnoid artery | | 253.95 | 6 |
| R708 | - internal iliac artery (uni or bilateral) | 7 | 344.10 | 10 |
| | | | | |
| | Excision and/or Repair: | | | |
| | Preamble: | | | |
| | (1) Repair of arteries implies either endarterectomy and/or bypass graft. | | | |
| | (2) Fee for gas endarterectomy of coronary artery should be the same fee as | | | |
| | for coronary endarterectomy. | | | |
| | (3) The fees listed for by-pass grafts include endarterectomy and/or | | | |
| | thrombectomy of the artery being repaired. | | | |
| | (4)Common femoral artery repair (e.g. R784,R785) includes repair to the | | | |
| | profunda femoris artery as far as the first major branch. | | | |
| | (5) If the repair extends beyond the first major branch of the profunda | | | |
| | femoris artery, R815 may be claimed in addition. | | | |
| | (6) If the repair extends beyond the second major branch of the profunda | | | |
| | femoris artery, R856 instead of R815 may be claimed in addition. | | | |
| | Arterioplasty with or without patch graft including microvascular anas- | | | |
| R815 | tomosis, arterial and/or venous, (other than listed below) | 10 | 442.40 | 10 |
| R792 | Carotid - endarterectomy | 10 | 647.20 | 10 |
| R796 | - carotid body tumour | 10 | 645.50 | 10 |
| R798 | - aneurysm - reconstruction or excision with graft | 10 | 688.10 | 10 |
| | Aortic arch reconstruction | | | |
| R830 | Innominate | 10 | 726.60 | 10 |
| R831 | Subclavian | 10 | 726.60 | 10 |
| R832 | Vertebral | 10 | 726.60 | 10 |
| E659 | - with thoracotomy, add | 3 | 141.70 | 7 |
| E667 | - ruptured, add | | 223,60 | 3 |
| L00/ | Thoracic aorta aneurysm - repair or excision with graft | | | |
| R799 | - ascending | 10 | 1220,60 | 20 |
| R800 | - arch | 10 | 1515.50 | 20 |
| ROW | = Q[U] | - | | |

| | OPERATIONS ON THE CARDIOVASCULAR SYSTEM - Cont'd. | | | |
|--------------|--|------|------------------|----------|
| Code | | Asst | Surg | Anaes |
| | | | | |
| | ARTERIES - Cont'd. | | | |
| R801 | - descending with or without temporary shunt | 10 | 1056.80 | 20 |
| E667 | - ruptured, add | 10 | 223.60 | 3 |
| R803 | Thoraco – abdominal aneurysm | 18 | 2048.00 | 30 |
| R802 | Abdominal aorta - aneurysm | | 1003.50 | 17 |
| R816 | - plus unilateral common femoral repair | 10 | 1093.60 | 17 |
| R817 | - plus bilateral common femoral repair | 10 | 1179.60 | 17 |
| E626 | - plus implantation of inferior mesenteric artery, add | | 146.20 | ., |
| E627 | - ruptured, add | | 266.20 | 3 |
| | Mesenteric or celiac artery repair | | | |
| R811 | - aneurysm | 10 | 344.10 | 10 |
| R935 | - removal of band only | 10 | 344.10 | 10 |
| Note: | Use R935 for excision of coeliac ganglion. | | | |
| R936 | - endarterectomy or graft | 10 | 726.60 | 10 |
| | Aorto-Iliac repair | | | |
| R783 | - including common iliac repair (uni- or bilateral) | | 847.90 | 17 |
| R784 | - plus unilateral common femoral repair | 10 | 995.30 | 17 |
| R785 | - plus bilateral common femoral repair | 10 | 1101.80 | 17 |
| E626 | - plus implantation of inferior mesenteric artery, add | | 146.20 | |
| R814 | - embolectomy or thrombectomy of bifurcation (aorta or graft) | 10 | 386.70 | 10 |
| | Total removal of infected aortic graft (stem and limbs) (arterial recon- | | | |
| R858 | struction extra) | 10 | 770.00 | 17 |
| E664 | Closure of duodenum, add | | 106.50 | |
| 2050 | Partial removal of infected aortic graft (one limb only)(arterial recon- | 10 | 200 20 | 10 |
| R859 | struction extra) | | 288.35 | 10 |
| R805 | Renal artery - aneurysm - reconstruction or excision with graft | | 726.60 | 10 10 |
| R806 | Renal artery repair | | 726.60 | 10 |
| R807 R786 | Splenic artery aneurysm - reconstruction or excision with graft | | 344.10 675.00 | 10 |
| | Iliac repair to include internal iliac aneurysm | | 675.00 | 10 |
| R937 R860 | Ilio-femoral bypass graft Per-obturator ilio-femoral graft - with saphenous vein | 10 | 753.70 | 10 |
| R861 | - with prosthetic graft | | 735.60 | 10 |
| NOOT | Common femoral/profunda femoris repair (profundoplasty) - when sole | 10 | 755.00 | 10 |
| R855 | procedure performed | 10 | 468.60 | 10 |
| R856 | Extended profundoplasty | 10 | 653,70 | 10 |
| R933 | Axillo-femoral, femoro-femoral or axillo-axillary graft | | 550.50 | 10 |
| R934 | Aorto-femoral unilateral graft (for bilateral see R785) | 10 | 726.60 | 17 |
| R808 | Femoral aneurysm - reconstruction or excision with graft | | 503.00 | 10 |
| R864 | Repair of false aneurysm at groin anastomosis | | 748.70 | 10 |
| R809 | Femoral-popliteal endarterectomy | 10 | 636.50 | 10 |
| | Femoro-popliteal (with or without endarterectomy) | | | |
| R791 | - with saphenous vein | 10 | 718.40 | 10 |
| R794 | - with prosthetic graft | 10 | 614.40 | 10 |
| | Femoro-ant./post. tibial/peroneal bypass graft (with or without endar- | | | |
| R787 | terectomy) - with saphenous vein | 10 | 843.80 | 10 |
| R780 | - with prosthetic graft | 10 | 735.60 | 10 |
| R810 | Popliteal aneurysm | / | 675.00 | 10 |
| 2010 | Peripheral arteries other than listed | 7 | 244 10 | 10 |
| R812 | - aneurysm | 7 | 344.10 | 10 |
| R813 | Embolectomy - artery or graft (as sole procedure) | 7 | 270.30 253.95 | 10 10 |
| R867 | Thrombectomy - artery or graft (as sole procedure) | , | 255.95 | 10 |
| E649 | Embolectomy and/or thrombectomy when done in conjunction with other vascula procedures add | | 94.20 | |
| R866 | Gastric devascularization - when sole procedure | 10 | 460.40 | 10 |
| ROUG | In-situ saphenous vein arterial bypass | 10 | 100.40 | 10 |
| R797 | - popliteal | 10 | 1077.20 | 17 |
| R804 | - tibial | 10 | 1249.30 | 17 |
| 1004 | | | | |
| | VEINS | | | |
| | Excision | | | |
| | Resection of AV aneurysm or fistula with or without major graft | | | |
| R825 | - major aneurysm by region* | 10 | 817.60 | I.C.* |
| R826 | | 10 | 417.00 | I.C.* |
| | | | | |

| | OPERATIONS ON THE CARDIOVASCULAR SYSTEM - Cont'd. | | | |
|------|--|------|---------|-------|
| Code | | Asst | Surg | Anaes |
| | | | | |
| | VEINS - Cont'd. | | | |
| | | | | |
| | Ligation | | | |
| Z745 | Saphenous (I.O.P.) | | 44.50 | 4 |
| 2746 | Femoral (1.0.P.) | 3 | 62.25 | 4 |
| Z747 | Popliteal (I.O.P.) | 3 | 62.25 | 4 |
| Z748 | Internal jugular (I.O.P.) | 5 | 124.50 | 5 |
| R839 | Internal iliac | 6 | 330.95 | 10 |
| R834 | I.V.C transabdominal | 6 | 374.40 | 10 |
| R838 | - transvenous | | 253.95 | 10 |
| R868 | High ligation and stripping of long saphenous vein with groin dissection | | 124.50 | 4 |
| R869 | Stripping of short saphenous vein with popliteal dissection | | 90.10 | 4 |
| R837 | Multiple ligation and avulsion | | 124.50 | 4 |
| R844 | Recurrent varicose veins - multiple ligation and/or stripping | 5 | 296.55 | 5 |
| | Extra fascial and sub-fascial incompetent perforators by full fascial | | | |
| R842 | technique | 5 | 322.80 | 6 |
| E653 | - plus stripping, add | | 107.30 | |
| | | | | |
| | Repair | | | |
| | Lacerated major vein e.g. femoral, popliteal, vena cava, axillary, sub- | | | |
| R820 | clavian, brachial | 4 | 266.20 | 4 |
| R818 | - including patch | | 417.00 | 10 |
| R819 | - by vein graft | | 554.60 | 10 |
| R835 | S.V.C. bypass graft | | 636.50 | 17 |
| R836 | Pulmonary embolectomy | 18 | 718.40 | 20 |
| R828 | Ilio-femoral thrombectomy with or without femoral vein ligation | | 374.40 | 10 |
| E657 | - plus I.V.C. ligation, add | | 374.40 | |
| R829 | Thrombectomy, other than above - see Preamble para 8,32 | 1.C. | 1.C. | I.C. |
| R865 | Distal spleno-renal shunt | 10 | 1056.30 | 10 |
| | | | | |
| | Anastomosis | | 770 00 | 10 |
| R822 | Porto-caval | | 770,00 | 10 |
| R823 | Spleno-renal-abdominal approach | 10 | 938.00 | 10 |
| R821 | -transthoracic approach | | 938.00 | 13 |
| R824 | Meso-caval | | 726.60 | 10 |
| R827 | Creation of A.V. fistula | | 305.15 | 6 |
| R841 | Obliteration of A.V. fistula | | 69.90 | 4 |
| R833 | Ligation or removal of by-pass graft | | 69.90 | 4 |
| | | | | |

| | OPERATIONS ON THE HAEMIC AND LYMPHATIC SYSTEMS | | C | |
|-----------------------|---|------|------------------|--------|
| Code | SPLEEN AND MARROW | Asst | Surg | Anaes |
| | | | | |
| Z404 Z403 Note: | Incision (I.O.P.) Splenic puncture and aspiration Bone marrow aspiration (1) Z408 may not be allowed with Z403 (not the same as Z403). | | 69.20 28.70 | 4 |
| Z408 | (2) Bone marrow interpretation (see Laboratory medicine). Bone marrow core biopsy (with biopsy needle) | | 53.65 | 4 |
| Z430 Note: | recipient) - team fee (I.O.P.). 2430 - bone marrow transplantation is not a benefit of OHIP for treatment of some conditions. Please refer to OHIP District Medical Consultant for qualifying diagnoses. | 7 | 481.70 | 8 |
| R905 | Excision Splenectomy - partial or complete | 7 | 417.80 | 7 |
| | LYMPH CHANNELS | | | |
| R907 | Excision Cystic hygrama – unilateral | 4 | 345.70 | 6 |
| R846 | Anastomosis Micro lympho-lympho or lymphovenous | 7 | 584.90 | 7 |
| | LYMPH NODES | | | |
| Z410 Z413 | Incision (I.O.P.) Drainage of sub-fascial abscess | | 63.10 24.20 | 4 |
| | Excision | | | |
| R910 R911 | Neck - limited e.g. sub mandibular supra omohyoid | | 229.40 548.90 | 6 8 |
| R915 | accessory nerve | 6 | 589.80 | 8 |
| R912 | Ileoinquinal, radical resection | 6 | 413.70 | 8 |
| R913 | Axillary or inguinal nodes - radical resection | | 311.30 | 6 |
| R914 | - limited resection | | 172.00 | 4 |
| Z405 | Siopsy (I.O.P.) - anterior cervical, axillary, inguinal | 4 | 53.20 | 4 |
| Z406 | - scalene, posterior cervical | | 106.50 | 4 |
| Z578 | - multiple para-aortic lymph nodes | | 63.50 | 6 |
| Z407 | - percutaneous retro peritoneal - one group | . 4 | 73.70 | 4 |
| Z409 | - two or more groups | | 110.60 | 4 |
| R916 | Re-exploration of vascular graft and closure of lymph fistula in groin | . 4 | 172.00 | 6 |

OPERATIONS ON THE DIGESTIVE SYSTEM

ORAL CAVITY AND PHARYNX - to include nasopharynx, oropharynx, hypopharynx except where otherwise specified.

| Code | except where otherwise specified. | | | |
|-------|---|------|--------|-------|
| code | Incision | Asst | Surg | Anaes |
| | THC1210H | | | |
| Z506 | Designed of anal shares buston (x 0 n) | | | |
| Z510 | Drainage of oral abscess or hematoma (I.O.P.) | | 43.40 | 4 |
| 7524 | Drainage of pharyngeal abscess or hematoma (I.O.P.) | | 77.80 | 5 |
| Z501 | Drainage of hematoma or deep neck abscess (external approach) (I.O.P.) | 3 | 201070 | 4 |
| 2537 | Biopsy (I.O.P.) | | 30.30 | |
| 2337 | - involving general anaesthetic | | 65.50 | 4 |
| 7111 | Tongue tie, release of (I.O.P.) | | | |
| Z111 | - simple | | 13.10 | |
| Z112 | - complex or requiring general anaesthetic | | 43.40 | 4 |
| 5031 | Palatal fenestration | | 168.75 | 4 |
| | | | | |
| 3500 | Excision | | | |
| Z502 | Excision of lesion (I.O.P.) - less than 2 ams | 3 | 60.60 | 4 |
| 2003 | - 2 to 4 ons | 4 | 181.45 | 6 |
| S006 | - over 4 cms | 4 | 292.00 | 6 |
| \$004 | Excision of ranula | . 3 | 141.70 | 4 |
| | Composite resection of lesion of oral cavity and/or oropharynx with | | | |
| 5005 | partial resection of mandible | 10 | 589,80 | 12 |
| | Extended composite resection of lesion of oral cavity and oropharynx | | | |
| S007 | with partial resection of mandible and resection of maxilla | 10 | 696.30 | 12 |
| | Cryotherapy for treatment of pre-malignant or malignant lesions of | | | |
| 9050 | oral cavity or sinuses | | 127.00 | 4 |
| \$018 | Glossectomy - partial | 6 | 168.75 | 8 |
| 5019 | - complete | 6 | 240.40 | 8 |
| Z109 | Wedge excision of lesion (I.O.P.) | | 52.40 | 4 |
| 9020 | Glossoplasty | 4 | 168.75 | 4 |
| S023 | Extraction of tooth (complete care) - single | | 21.10 | 4 |
| E700 | - each additional tooth | | 11.05 | |
| S028 | Dentigerous cyst | 4 | 84,40 | 4 |
| | Basic units for anaesthesia with any unlisted dental surgical procedure | | | |
| S900 | performed by a dental or oral surgeon (see 37(1) on page xi, also OHIP | | | |
| | Bulletin #4069) | | | I.C. |
| S021 | Repair of extensive laceration | 4 | I.C. | I.C. |
| | - for minor lacerations, see Skin | | | |
| Z509 | Uvulectomy - partial or complete | | 21.10 | 4 |
| 5034 | Cleft palate repair | 6 | 315.40 | 8 |
| 5035 | Removal of sutures under general anaesthesia | | 33.80 | 4 |
| S032 | Bone graft to palate | 6 | 286.70 | 8 |
| 5030 | Closure of fistula - anterior alveolar | 4 | 168.75 | 4 |
| S033 | - palate | 6 | 240.40 | 6 |
| 5036 | - uvulopalatopharyngoplasty | | 204,80 | |
| S069 | Pharyngoplasty | 8 | 308,80 | 8 |
| | Excision of parapharyngeal space lesions (with mobilization of parotid | | | |
| S002 | gland) | 4 | 523.05 | 8 |
| S067 | Partial pharyngectomy - trans-hyoid or lateral | 8 | 675.80 | 11 |
| 5068 | Pharyngo-laryngectomy | 8 | 759,40 | 14 |
| E882 | - with hemithyroidectomy, add | | 151.55 | |
| E883 | - with subtotal thyroidectomy, add | | 227.70 | |
| E884 | - with total thyroidectomy, add | | 319,50 | |
| \$058 | Branchial - cleft lesion | 4 | 262,10 | 4 |
| 5059 | Branchial - cleft lesion - repeat procedure | 4 | 371.90 | 4 |
| 5061 | Thyroglossal duct remnant | 4 | 262.10 | 4 |
| 5062 | - repeat procedure | 4 | 350,20 | 4 |
| | | | | |
| | | | | |

| | OPERATIONS ON THE DIGESTIVE SYSTEM - Cont'd. | | | |
|--------------|--|------|--------|-------|
| Code | ORAL CAVITY AND PHARYNX - Cont'd. | Asst | Surg | Anaes |
| S063 | Tonsillectomy | | 126.60 | 4 |
| S065 | Tonsillectomy and Adenoidectomy - same as Tonsillectomy Adenoidectomy | | 71.70 | 4 |
| | Secondary suture or cauterization 24 hours following T & A or by a surgeon other than the operation surgeon anytime post-operatively - | | | |
| S066 | when haemorrhage occurs after initial procedure and is treated surgically | | 50.80 | 5 |
| S024 | Excision of torus palatinus | 4 | 168.75 | 4 |
| | SALIVARY GLANDS AND DUCTS Incision | | | |
| Z500 | Sialolithotomy (I.O.P.) | | 26.20 | |
| Z521 | - involving general anaesthesia | 3 | 88.50 | 4 |
| | Excision | | | |
| S042 | Submandibular gland or sublingual gland | 4 | 245.80 | 4 |
| S043 | Parotid gland - total (with preservation of facial nerve) | 6 | 589.80 | 8 |
| S044 | - total (without preservation of facial nerve) | 6 | 506.30 | 8 |
| S045 | - subtotal (with preservation of facial nerve) | 6 | 548.90 | 7 |
| S047 | - repeat subtotal (with preservation of facial nerve) | 6 | 589.80 | 7 |
| S045 | - subtotal (without preservation of facial nerve) | 6 | 337.50 | 6 |
| Z522 | Excision small tumour (I.O.P.) | 3 | 43.40 | 4 |
| | | | | |
| 20.10 | Reconstruction Plastic repair of duct | 4 | 172.00 | 4 |
| S049 | Plastic repair of duct | 4 | 172.85 | 4 |
| Z511 | Dilation and/or probing of duct (I.O.P.) | - | 26.20 | |
| S057 | Submandibular duct relocation | 6 | 308.00 | 6 |
| | LTPS | | | |
| | | | | |
| Z503 | Incision Biopsy (I.O.P.) | | 30.30 | 4 |
| 2303 | propay (1.00-r.) | | 30,00 | |
| | Excision | | | |
| S011 | Wedge resection of lip - vermillion | 3 | 84.40 | 4 |
| S010 | Wedge resection of lip with plastic repair | 3 | 204.80 | 4 |
| Z504 | Excision of lesion (I.O.P.) | 3 | 52.40 | 4 |
| 5012 | Lip shave - vermillionectomy | 3 | 172.85 | 4 |
| | | | | |
| 0010 | Reconstruction | c | 311.30 | 8 |
| S013 | Cleft lip - unilateral | | 380.90 | 8 |
| S014 S015 | Reconstruction with lip switch flap Complex reconstruction or revision of previous repair and excision | 0 | 1.0. | I.C. |
| | OESOPHAGUS | | | |
| | For procedures on the Oesophagus, the following basic units for assistants | | | |
| | and anaesthetists will apply except if a basic fee is listed: | | | |
| S073 | Cervical approach | 6 | | 7 |
| S074 | Thoracic approach | | | 13 |
| S075 | Abdominal approach | 7 | | 8 |
| | Endoscopies (I.O.P.) | | | |
| Z515 | Oesophagoscopy, with or without biopsy | | 58.60 | 4 |
| E702 | with multiple (3 or more) biopsies of a specific lesion add | | 12.90 | |
| Z516 | with removal of foreign body | | 96.25 | 4 |
| Z517 | Oesophagoscopy with injection of varices - initial | | 110.60 | 4 |
| Z518 | - subsequent | | 81.90 | 4 |
| Z519 | Oesophagoscopy with dilation with or without biopsy | | 113.00 | 4 |
| Z520 | Oesophago-bronchoscopy with or without biopsy | | 108.50 | 6 |
| Z567 | Subsequent procedure (within three months following previous endoscopic procedure) | | 71.10 | 6 |
| 2307 | Oesophagoscopy-gastroscopy with or without duodenoscopy | | | |
| Z399 | - elective | | 88.10 | 4 |
| | | | | |

| | OCEDATIONS ON THE DESCRIPTION CONTROL | | | |
|--------------|---|------|---------|-------|
| Code | OPERATIONS ON THE DIGESTIVE SYSTEM - Cont'd. | | | |
| | | ASST | Surg | Anaes |
| | OESOPHAGUS - Cont'd. | | | |
| 2400 | | | | |
| Z400 | - for active bleeding | | 106.50 | 4 |
| E701 E698 | - with laser coagulation, or diathermy, and | | 27.35 | |
| E090 | - with pneumatic dilation, add | | 84.00 | |
| Z568 | Subsequent procedure by same physician (within three months following previous endoscopic procedure) | | | |
| E702 | - with multiple (3 or more) biopsies of specific lesion, add | | 71.10 | 4 |
| E703 | - with snare polypectomy, add | | 12.90 | |
| E799 | - each additional polyp, add - (to a maximum of 2 additional polyps) | | 43.00 | |
| Note: | E799, E702, E703, E701, E698 apply only to Z399, Z400, Z515 or Z568. | | 21.00 | |
| | , | | | |
| | Incision | | | |
| | Oesophagostomy | | | |
| S084 | Cervical - other than neonatal | | 190.20 | |
| S085 | - neonatal | | 258.00 | |
| coos | Intrathoracic oesophagus tube | | | |
| S082 S083 | - via laparotony | | 348.20 | 6 |
| 5081 | - via oesophagoscope (includes Z515) | | 258.00 | 6 |
| 2001 | Transoesophageal division of oesophageal varices | | 473.50 | |
| S080 | opsophageal division/anastomesis) | | 761 06 | |
| 3000 | oesophageal division/anastomosis) | | 761.85 | |
| | Excision | | | |
| S087 | Intrathoracic diverticulum | | 430.10 | |
| \$088 | Crico pharyngeal myotomy | | 330.95 | |
| E699 | - with diverticulum excision, add | | 31.50 | |
| | Partial oesophageal resection and reconstruction(including intestinal | | | |
| \$089 | transposition) | | 917.50 | 17 |
| \$090 | Total thoracic oesophageal resection | | 761.35 | 13 |
| E730 | - with reconstruction, add | | 458.75 | 4 |
| S093 | Enucleation of benign oesphageal tumour | | 495.60 | |
| | Di- | | | |
| S161 | Repair Occophogoal matery partial (hole a partia anch) | | 495,60 | |
| E758 | Oesophageal myotomy, partial (below aortic arch) | | 184.30 | |
| E699 | - with diverticulum excision, add | | 31.50 | |
| S100 | Total thoracic oesophageal myotomy when sole procedure performed | | 625.70 | |
| E758 | - with oesophageal hiatus hernia repair, add | | 184.30 | |
| | Oesophageal hiatus hermia - abdominal or transthoracic approach | | | |
| S091 | with fundal plication | | 466.90 | |
| 5092 | Recurrent oesophageal hiatus hernia | | 602.10 | |
| E744 | - with gastroplasty, add to either SO91 or SO92 | | 98.30 | |
| | When SO91 or SO92 with or without gastroplasty is done in conjunction with | | | |
| | cholecystectomy, and/or vagotomy with-or without drainage procedures, | | | |
| | add E742 (to S091 or S092 with or without E744) for each additional | | | |
| | procedure performed. For any other combination of surgical procedures with oesophageal hiatus hernia repair (with the exception of S161 and | | | |
| E742 | S100), see surg preamble (para 3) | | 184.30 | |
| C1 1/C | Oesophageal stricture (Thal) - may include oesophageal hiatus hernia | | 201000 | |
| 5095 | repair with or without gastroplasty | | 573,40 | |
| S096 | Ruptured oesophagus, suture and drainage | | 430.10 | |
| 5097 | Oesophago-gastrostomy for by-pass (when sole procedure performed) | | 516.10 | |
| 5098 | Oesophageal bypass, abdomen to neck - with stomach | | 774.10 | |
| S099 | - with colon or jejunum | | 1073.15 | |
| | | | | |
| | Suture | | | |
| cica | Closure of oesophago-tracheal fistula (includes oesophageal reconstruction | | SET OF | |
| S102 | and lengthening if necessary) | | 557.05 | |
| | Dilation of Oesophagus (I.O.P.) - when sole procedure performed | | | |
| 7529 | Passive (bougle) - initial session | | 34,40 | |
| | ,, | | | |

| Code | OPERATIONS ON THE DIGESTIVE SYSTEM - Cont'd. | Asst | Surg | Anaes |
|--------------|---|------|------------------|-------|
| | OESOPHAGUS - Cont'd. | | | |
| | | | | |
| Z530 Z525 | - repeat session (within three months following previous dilation) Pneumatic | | 23.30 | |
| Z523 Z531 | With rigid dilators guided over a string or wire | | 45.05 22.50 | |
| | STOMACH | | | |
| Z527 | Endoscopies (I.O.P.) Gastroscopy (with or without biopsy or photography) | | 77.80 | 4 |
| Z547 | Gastroscopy with removal of foreign body | | 84.40 | 4 |
| Z528 | Subsequent (within three months following previous gastroscopy) | | 57.30 | 4 |
| | Incision | | | |
| S116 | Gastrotomy - with removal of tumour or foreign body | 6 | 344.10 | 7 |
| E731 S117 | - with suture of bleeding peptic ulcer, add | 5 | 69.60 266.20 | 2 |
| \$118 | Gastrostony | 6 | 292.45 | 7 |
| E697 | - with repair of Mallory Weis laceration, add | | 120.40 | |
| E707 | - when done with another intra-abdominal procedure | | 60.20 | |
| | Excision | | | |
| Z526 Z533 | Biopsy - (Incisional) by gastrotomy (I.O.P.) | | 62.70 31.50 | |
| S122 | Gastrectomy Wedge resection for ulcer | 7 | 344.10 | 7 |
| E708 | - with vagotomy, add | | 103.20 | |
| E713 | - after previous partial gastrectomy, add | 7 | 116.30 | 0 |
| S123 S125 | Partial or subtotal - distal proximal | 7 | 537.40 584.90 | 8 |
| E731 | - with suture of bleeding peptic ulcer, add | | 69.60 | 2 |
| E708 | - with vagotomy, add | | 103.20 | |
| E709 E711 | - with cholecystectomy, add | | 90.10 | |
| E706 | - with choledochotomy, add | | 103.20 | |
| E712 | - after previous vagotomy and pyloroplasty, add | | 90.10 | |
| E713 S128 | - after previous partial gastrectomy, add | 7 | 804.45 | 9 |
| E709 | - with cholecystectomy, add | | 103.20 | |
| E706 | - with choledochotany, add | | 103.20 116.30 | |
| E713 S129 | - after previous partial gastrectomy, add | 7 | 593.90 | 9 |
| \$131 | Vacotomy - truncal or selective | 7 | 317.80 | 7 |
| S124 | - highly selective (as sole procedure without pyloroplasty or | 7 | 430.10 | 7 |
| S124 S121 | gastroenterostomy) | 7 | 352.25 | 8 |
| S120 | Gastric bypass or partition, for morbid obesity | 7 | 524.30 | 10 |
| | Repair | | | |
| S132 | Pyloroplasty | 7 | 344.10 | 7 |
| S133 | Pyloroplasty and vagotomy | 7 | 447.30 | 7 2 |
| E731 S137 | - with suture of bleeding peptic ulcer, add | 7 | 69.60 622.60 | 8 |
| E731 | - with suture of bleeding peptic ulcer | | 69.60 | 2 |
| E721 | - with choledochotomy, add | 7 | 103.20 344.10 | 1 7 |
| S134 E716 | Gastroduodenostomy or gastrojejunostomy - either of above plus vagotomy, add | 7 | 135.20 | , |
| E711 - | - after previous gastroenterostomy, add | | 90.10 | |
| E721 | - with choledochotomy, add | | 103.20 | 1 |

| Code | OPERATIONS ON THE DIGESTIVE SYSTEM - Cont'd. | Asst | Surg | Anaes |
|---------------|--|------|------------------|--------|
| | STOMACH - Cont'd. | 7036 | July | HIQES |
| | | | | |
| C120 | Suture | | | |
| S138 S139 | closure of gastrostomy or other external fistula of stomach | 5 | 292.45 | 6 |
| S140 | Gastrorrhaphy (for perforated ulcer or wound) Closure of gastrocolic fistula | 6 | 303.90 485.80 | 7 |
| | | | | • |
| Z534 | Introduction Gastric Cooling (I.O.P.) - ice water lavage of stomach | | 24 62 | |
| 2301 | Gastric Cooling (I.O.P.) - oesophagogastric balloon, with alcohol coolant | | 24.60 | |
| Z532 | continuously recirculated | | 81.90 | 4 |
| | INTESTINES (EXCEPT RECTUM) | | | |
| | Endoscopy (I.O.P.) | | | |
| | Duodenoscopy (not chargeable if Z399 and/or Z400 performed on same | | | |
| Z560 | patient within 3 months) | | 77,80 | 4 |
| Z749 | procedure) three months following previous enabscoptic | | 61.40 | 4 |
| Z561 | - with cannulation of pancreatic and/or common bile duct | | 180.20 | 4 |
| E666 | - with biliary tract manometry, add | | 44.60 | |
| 2579 | with re-cannulation of pancreatic and/or common bile duct (within three months of previous cannulation) | | 151 55 | |
| 2313 | Endoscopy of ileostamy or colostamy, or reduction of obstructed Koch | | 151.55 | 4 |
| 2512 | ileostomy | | 31.10 | 4 |
| E747 Z514 | - to caecum, add | | 29.50 | |
| Z580 | - with biopsy | | 37.70 46.70 | 4 |
| E665 | - when Z530 or Z512 is rendered in private office, add | | 14.70 | - |
| Z555 | Endoscopy - of signoid to descending colon | | 46.70 | 4 |
| E740 E741 | - to splenic flexure, add | | 50.40 | |
| E741 | - to hepatic Flexure, add | | 29,50 29,50 | |
| | if biopsy and/or coagulation of angiodysplastic lesion(s) | | 2,500 | |
| E717 | (one or more), add to Z555 or Z580 | | 22.90 | |
| E749 Note: | - when Z555 rendered in private office, add | | 14.70 | |
| Z570 | Fulguration of polyp through colonoscope | | 40.10 | 4 |
| E719 | each additional polyp, add - (maximum of 4 additional polyps) | | 20.50 | |
| Z571 E720 | Excision of polyp through colonoscope | | 127.00 | 4 |
| L/20 | - each additional polyp, add - (maximum of 2 additional polyps) | | 65.50 | |
| | Incision | | | |
| S149 | Enterotany | - | 244 10 | 7 |
| S150 | Small intestine – including excision of polypi or biopsy | 6 | 344.10 344.10 | 7 |
| S151 | Insertion of feeding enterostany | 6 | 301.50 | 7 |
| E737 | - when done with another intra-abdominal procedure, add | _ | 69.60 | - |
| S154 S155 | Large intestine - including excision of pulypi | 6 | 344.10 327.70 | 7 |
| S156 | Exteriorization of intestine (Mickulicz) | 6 | 344.10 | 6 |
| S157 | Colostomy | 6 | 344.10 | 6 |
| S158 S160 | Caecostomy | 6 | 327.70 344.10 | 6 |
| 3100 | und value va | 0 | J+++ -10 | , |
| 01.55 | Excision | _ | 244 22 | |
| S162 2750 | Local excision of lesion of intestine Resection of exteriorized intestine (1.0.P.) | 6 | 344.10 69.60 | 7 6 |
| 2130 | Resection with anastomosis | U | 03,00 | 0 |
| | Small intestine | | | _ |
| S164 S165 | duodenumother | 6 | 481.70 | 7 |
| 2107 | Will 00000000000000000000000000000000000 | U | 777 000 | / |

| | OPERATIONS ON THE DIGESTIVE SYSTEM - Cont'd. | | | |
|----------------|--|------|------------------|----------|
| Code | | Asst | Surg | Anaes |
| | INTESTINES (EXCEPT RECTUM) - Cont'd. | | | |
| | | | | |
| 5166 | Small and large intestine | 7 | F20, 20 | . 7 |
| S166 S167 | terminal ileum, caecum and ascending colon | 7 | 520.20 520.20 | 7 |
| 3107 | Repair of entero-cutaneous fistula in conjunction with bowel resection. | , | 320.20 | , |
| E714 | add | | 69.60 | |
| S168 | Ileostomy, subtotal colectomy | 7 | 688.10 | 7 |
| S169 | Total colectomy with ileo-rectal anastomosis | 9 | 808,55 | 9 |
| S171 | below peritoneal reflection and mobilization of splenic flexure) | 7 | 704.50 | 8 |
| | Total colectomy with mucosal proctectomy with ileal pouch, ileoanal | | | |
| S172 | anastomosis and loop ileostomy | 9 | 1462.30 | 10 |
| S170 S173 | Ileostamy plus total colectomy plus abdomino-perineal resection | 9 | 970.75 817.60 | 10 10 |
| S174 | - perineal | , | 240.80 | 10 |
| E738 | - with continent ileostomy, add to either S168, S169, S170, S173 or S174 | | 327.70 | |
| | Bowel resection following previous resection with anastomosis, or following | | | |
| E718 | \$217, \$213, \$214 or \$215, add | | 120.40 | |
| Note: S188 | E718 is not to be added to S218, S181, S182, S185, S191, S192 or S193 Bowel resection without anastomosis (colostomy and mucous fistula) | 6 | 460,40 | 6 |
| S189 | Intestinal bypass for morbid obesity | 7 | 507.90 | 10 |
| 3103 | incesting bypass for morbid accords | | | - |
| | Intestinal Obstruction (mechanical) - one stage (if staged procedure, refer | | | |
| es 75 \ | to preamble on page 67 (para. 3)). | _ | 382,60 | 6 |
| S175 ` S176 | - without resection - with entero-enterostomy | 6 | 485.80 | 7 |
| S177 | - with resection | 6 | 558.70 | 7 |
| \$180 | - with enterotomy | 6 | 438.30 | 7 |
| S178 | Intestinal atresia (newborn) | 6 | 577.50 | 7 |
| S179 | Meconium ileus | 6 | 577.50 | 7 |
| | Repair | | | |
| S181 | Revision of ileostamy or colostamy - skin level | 5 | 111.80 | 5 |
| S182 | - full thickness | 6 | 296.55 | 6 |
| S192 | Simple revision of continent ileostamy pouch | 6 | 327.70 | 6 |
| S191 | Complete reconstruction of continent ileostomy to include valve repair | 6 | 804.45 671.70 | 7 |
| S193 S183 | Revision of standard ileostomy into continent ileostomy pouch | | 266.20 | 6 |
| 3100 | accopery of Signorapery men sore proceeds a per commen | | | |
| | Suture | , | occ oo | |
| S184 | Suture of intestine | 6 | 266.20 103.20 | 6 |
| E721 | with choledochotamy, add | | 103.20 | 1 |
| S185 | - with or without resection and/or anastomosis | 6 | 344.10 | 7 |
| S187 | Plication of small intestine for adhesions | 6 | 447.30 | 7 |
| Note: | For division or removal of adhesions only, use S312. | | | |
| | Manipulation (I.O.P.) | | | |
| Z538 | Reduction of prolapse | | 21.30 | 4 |
| Z539 | Dilation of gastrostomy, enterostomy, colostomy, etc | | 21.30 | 4 |
| | Intubation of small intestine (therapeutic or diagnostic) | | E4 10 | |
| Z540 | - with or without fluoroscopy | | 54.10 25.00 | |
| E732 | - WILLI DIOUSY, doll | | 20,00 | |
| | MECKEL'S DIVERTICULUM | | | |
| | Excision | - | 201 50 | - |
| S194 | Meckel's diverticulum | 5 | 301.50 | 6 |

| | OPERATIONS ON THE DIGESTIVE SYSTEM - Cont'd. | | | |
|--------------|---|------|------------------|--------|
| Code | | Asst | Surg | Anaes |
| | MECKEL'S DIVERTICULUM - Cont'd. | .030 | 341 9 | 711003 |
| S159 | . 446 m-22 h2 | | | |
| 2123 | - with small bowel resection | 6 | 344.10 | 7 |
| | MESENTERY | | | |
| | Excision | | | |
| S195 | Local excision of lesion | 5 | 258,00 | 6 |
| S199 | Resection of mesentery | 5 | 275.25 | 6 |
| | | | 2,0420 | |
| | APPENDIX | | | |
| | Incision | | | |
| S204 | Drainage of abscess | 5 | 202.30 | 6 |
| | Excision | | | |
| \$205 | Appendectory | - | 011 60 | _ |
| \$206 | - with gross perforation and peritonitis | 5 | 214,60 | 6 |
| 5250 | and gross per for defait and per fouriers | 3 | 301,30 | 0 |
| | RECTUM | | | |
| | Endoscopy | | | |
| | Signoidoscopy (with rigid scope) with or without anoscopy (I.O.P.) - | | | |
| Z535 | not to be billed with Z555 or Z580 | | 30,90 | 4 |
| Z536 | - with biopsy | | 37.70 | 4 |
| 2592 | - with decompression of volvulus | | 42.20 | 4 |
| E746 | - when Z535, Z536 or Z592 rendered in private office, add | | 4.90 | |
| | Excision | | | |
| | Proctectory | | | |
| | Anterior resection or proctosignoidectomy (anastomosis below peritoneal | | | |
| \$213 | reflection) | 8 | 657, 80 | 8 |
| \$214 | Abdomino-perineal resection or pull through | 8 | 791.30 | 10 |
| | Two surgeon team | | | |
| S215 | abdominal surgeon | 8 | 657.30 | 10 |
| \$216 | perineal surgeon | | 240.80 | |
| \$217 | Hartmann procedure | 8 | 550.50 | 9 |
| S218 7752 | Colon reconstruction following Hartmann procedure | 8 | 645.50 69.60 | 8 |
| E710 | Biopsy of rectosignoid or above for Hirschsprung's disease (I.O.P.) | 3 | 38,90 | 4 |
| \$222 | - each additional biopsy Presacral or trans-sacral proctotomy and excision of lesion | 4 | 296.55 | 6 |
| 322 | Electrocoagulation and/or excision of rectal carcinoma (I.O.P.) | 7 | 20000 | 0 |
| 7572 | - initial | 3 | 120,40 | 4 |
| Z573 | - repeat | 3 | 69,60 | 4 |
| | Polyps or tumours of rectum or sigmoid (max 2 polyps any size or | | | |
| | technique) (I.O.P.) | | | |
| Z753 | - electrocoagulation - base under 2 cm | 3 | 20.50 | 4 |
| 2754 2755 | - excision - base under 2 cm electrocoagulation or excision - base over 2 cm | 3 | 69,60 120,40 | 4 |
| Note: | For fulguration or excision of tumours through the colonoscope use codes | 3 | 120.40 | 4 |
| Noce. | 7570, 7571. | | | |
| | | | | |
| | Repair | | | |
| 5223 | Anastomosis of rectum | 4 | 412.90 | 6 |
| | Rectal prolapse | | | |
| S225 | Excision of mucous membrane | . 3 | 202.30 | 4 |
| \$226 | Perineal repair, major | | 301.50 468.60 | 4 |
| S227 S228 | Abdominal approach | 6 | 161,40 | 8 |
| 3225 | TIDELLING OF HIRE 20 MILE ************************************ | 2 | 101.40 | 4 |
| | Suture | | | |
| S229 | Suture of rectum, trauma-external approach | 4 | 202.30 | 4 |
| | | | | |

| Code | OPERATIONS ON THE DIGESTIVE SYSTEM - Cont'd. | Asst | Surg | Anaes |
|----------------------|--|------|--------------------------|--------|
| | RECTUM - Cont'd. | | | |
| S231 S525 | Closure of fistula Recto vaginal (any repair) Recto vesical | 4 5 | 289.20 381.70 | 6 6 |
| Z541 Z756 | Manipulation (I.O.P.) Dilation, and/or disimpaction or removal of foreign body under general anaesthetic (when sole procedure performed) Fecal disimpaction - no anaesthetic | | 49.15 31.50 | 4 |
| | OPERATIONS ON THE ANUS Preamble: (1)The fees for excision, ligation, injection of haemorrhoids and treatment of intra or perianal condylomata acuminata include anoscopy. | | | |
| Z543 | Endoscopy Anoscopy (proctoscopy)(I.O.P.) | | 5.30 | |
| Z544 Z545 | Incision Biopsy (I.O.P.) Thrombosed haemorrhoid(s)(I.O.P.) | | 29.30 21.30 | 4 4 |
| S241 | Sphincterotomy(ies) | 3 | 74.95 | 4 |
| S242 | - with excision of fissure(s) | 3 | 137.60 | 4 |
| S246 | Excision Excision of fissure(s) Haemorrhoidectomy, with or without sigmoidoscopy or repair of fissure(s) | 3 | 103.20 | 4 |
| S247 | and/or sphincterotomy and/or anal dilation | 3 | 188.40 | 4 |
| Z565 Z546 | including rectal dilation (I.O.P.) | | 80.30 23.30 | 4 |
| Z566 S249 Z757 | year) Local excision for malignancy | 3 | 29.30 129.00 34.40 | 4 |
| S251 | Fistula-in-ano | 3 | 180.20 | 4 |
| Z575 Z576 | Hademorrhoid injections (I.O.P.) (Maximum 6 in any one year) | | 23.30 30.10 | 4 |
| | Repair | | | |
| S253 S260 | Low imperforate anus repair | 7 | 348.20 761.85 | 7 |
| S256 S257 | Excision of scar, for stenosis | 3 | 120.40 232.65 | 4 |
| S258 S259 | Repair of anal sphincter Repair of anal sphincter and ano-rectal ring | 4 | 232.65 | 4 |
| Z548 Z549 | Destruction (I.O.P.) Cauterization of fissure Fulguration of condylomata - local anaesthetic | | 29.30 | 4 |
| Z758 | - general anaesthetic | 3 | 71.00 | 4 |
| Z550 S248 | Manipulation Dilation of anal sphincter (I.O.P.) Peter Lord procedure | | 10.20 36.90 | 4 4 |
| | LIVER Incision | | | |
| Z554 Z551 | Biopsy, incisional (I.O.P.) Biopsy, needle (I.O.P.) | | 69.60 60.20 | 4 |

| | OPERATIONS ON THE DIGESTIVE SYSTEM - Cont'd. | | | |
|--------------|--|------|------------------|-------|
| Code | | Asst | Surg | Anaes |
| | | | | |
| | LIVER - Cont'd. | | | |
| ~~~ | | | | |
| \$268 | Insertion of implantable pump for continuous liver perfusion | 7 | 512.00 | 7 |
| | Excision | | | |
| | Hepatectony | | | |
| \$269 | Local excision of lesion | 7 | 296,55 | 7 |
| \$275 | Partial lobectory | 8 | 494,80 | 8 |
| \$270 | Left lateral segmental excision (through falciform ligament) | 12 | 770.00 | 12 |
| S267 | Complete left or right lobectomy | 12 | 1074.80 | 12 |
| S271 | Extended right lobectomy, through falciform ligament | 12 | 1074.80 | 12 |
| S272 | Laparotomy, cholangiogram and biopsy (neonatal jaundice) | 6 | 327.70 | 6 |
| \$274 | Liver transplant - donor | 6 | 627.50 | 8 |
| S294 | - recipient | 20 | 1789.10 | 30 |
| S295 | Repeat Liver transplant | I.C. | 2457.60 | I.C. |
| Note: | For claims purposes, liver lobectomy includes cholecystectomy. | | | |
| | Donnie | | | |
| \$273 | Repair Maximilization and/or documentation of out/s) on absence(os) | 7 | 206 55 | 7 |
| E715 | Marsupilization and/or decompression of cyst(s) or abscess(es) | | 296,55 62,70 | 7 |
| L/13 | - more usun unice cysts or austesses, add | | 02.70 | |
| | BILIARY TRACT - no extra fee for cholangiogram during abdominal surgery | | | |
| | Endoscopy (I.O.P.) - to include examination of stomach and duodenum | | | |
| | i.e. not to be claimed with Z561 | | | |
| | Manipulation and/or removal of common bile duct stones with or without | | | |
| Z558 | sphincterotony | | 253.95 | 5 |
| | Subsequent procedure (within three months following previous endoscopic | | | |
| Z559 | procedure) | | 116.30 | 5 |
| | Insertion of endobiliary prosthesis | | | |
| Z556 | - first one | | 69.60 | |
| Z557 | - each additional (max. of 3) | | 36.90 | |
| Z593 | Nasobiliary catheter insertion | | 46.50 | |
| | Incision | | | |
| | Percutaneous transhepatic catheter drainage of obstructed bile ducts | | | |
| | including daily supervision and including percutaneous cholangingram | | | |
| S233 | and catheterization to duodenum if achieved | | 223,60 | |
| S234 | - replacement of catheter in above | | 44.20 | |
| | Biliary duct calculus manipulation and/or removal via T-tube tract (I.O.P.) | | | |
| Z562 | - when sole procedure performed | | 98.30 | 7 |
| Z542 | Intubation of bile duct for obstruction (1.0.P.) | | 58.60 | |
| S278 | Cholecystostomy | 7 | 313.75 | 7 |
| \$276 | Choledochotamy (previous cholecystectomy) | 7 | 516.10 | 8 |
| E704 S280 | with choledochoscopy, add to S276, S280 or S281 Transduodenal sphincterotomy and choledochotomy (previous cholecystectomy). | . 7 | 24.20 714.30 | 9 |
| 3200 | Choledochoduodenostamy or choledochoenterostamy or choledochochole- | • / | /14000 | , |
| S281 | dochostomy cannot be claimed with S276 | 7 | 510.30 | 9 |
| 5282 | Cholecystogastrostomy | 7 | 378,50 | 7 |
| 5283 | Cholecystoenterostany | 7 | 378,50 | 7 |
| E743 | - with entero-enterostomy, add (to \$281, \$283) | | 129.00 | |
| | Intrahepatic choledochoenterostomy (anastomosis above the common hepatic | | | |
| S285 | duct bifurcation) | 9 | 774.10 | 12 |
| | | | | |
| | Excision | 7 | 205 00 | 7 |
| S287 | Cholecystectory | 7 | 385.00 103.20 | 7 |
| E721 | - with choledochotomy, add | | 137.60 | 1 |
| E722 E728 | - with transduodenal sphincterotomy, add | | 141.70 | 1 |
| E729 | - with highly selective vagotomy, add | | 240.80 | |
| S291 | Choledochectomy for tumour (for reconstruction, refer to S281) | 8 | 344.10 | 8 |
| JEJI | orange of color (in tours and in the second | | | |
| | Repair | | | |
| S292 | Common duct stricture, dissection and/or resection | 7 | 172.00 | 10 |
| | (for reconstruction, refer to S281) | | | |
| | | | | |

| | OPERATIONS ON THE DIGESTIVE SYSTEM - Cont'd. | | | |
|--------------|---|------|------------------|---------|
| Code | GENTION OF THE DIGESTIFE STREET - COIL G. | Asst | Surg | Anaes |
| | BILIARY TRACT - Cont'd. | | | |
| S293 | Biliary duct atresia, infant | 8 | I.C. | 12 |
| Z762 | PANCREAS Biopsy, needle (I.O.P.) | | 69.60 | |
| Z577 S297 | Incision Biopsy, incisional (I.O.P.) Drainage of acute pancreatitis or abscess or marsupialization of cyst | 7 | 103.20 344.10 | 7 |
| | Excision | | | |
| S298 | Pancreatectomy Complete with splenectomy | 9 | 1074.80 | 13 |
| \$300 | "Whipple type" procedure | 9 | 1161.60 | 13 |
| S301 S309 | Local complete excision of tumour or lesion | 8 | 430.10 833.90 | 8 11 |
| E709 | - with cholecystectamy, add to S300 or S309 | , | 103.20 | 11 |
| | Repair | | 400.00 | |
| \$305 | Pancreatic cyst-gastrostomy | 7 | 498.90 498.90 | 8 8 |
| S306 S307 | - duodenostamy | 8 | 498.90 | 8 |
| 0007 | Lateral pancreatoduodenostomy or anastomosis of filleted pancreatic duct | | | |
| S304 | to intestine (Puestow) | 9 | 688.10 | 10 |
| | ABDOMEN, PERITONEUM AND OMENTUM | | | |
| | Preamble: (1) When the laparoscope is used as a means of entrance to perform an intra abdominal procedure, no extra fee for laparoscopy may be claimed. (2) When an exploratory laparotomy is performed followed by a colostomy through another incision in the abdomen, the colostomy fee should be claimed at 100% and the laparotomy at 85% of the listed fee. | | | |
| | Paracentesis(I.O.P.) | | | |
| Z590 | Aspiration for diagnostic sample | | 21.30 | |
| Z591 | Aspiration with therapeutic drainage with or without diagnostic sample | | 39.10 | 4 |
| E724 Z763 | Administration of chemotherapy or sclerosing agent, add | | 9.40 | 4 |
| 2,00 | | | | |
| Z563 | Incision Needle biopsy of peritoneum (I.O.P.) Open lavage of peritoneal cavity for diagnosis without manual exploration | | 32.80 | |
| Z564 | of peritoneal cavity (I.O.P.) | | 62.70 | 4 |
| S312 | biopsies of stomach, liver, pancreas and multiple para-aortic lymph nodes) | 6 | 258,00 | 6 |
| Note: | S312 - Use for division or removal of adhesions, if no other abdominal surgery performed. | | 200,00 | |
| | may not be claimed with other intra-abdominal procedures (except for I.O.P.) | | | |
| CZAC | Insertion of tubes and post-operative continuous peritoneal lavage - when | | 80.30 | |
| E745 S321 | combined with any other abdominal procedure, add | 6 | 335.90 | 6 |
| E733 | - with repair of intestine, single, add | | 120.40 | 3 |
| E734 | multiple and/or with resection, add | | 178.60 | 3 |
| E735 | - with splenectomy, (partial or complete) add | 2 | 240.80 158.90 | |
| E736 E739 | - with repair of lacerated liver, add | 2 | 103.20 | |
| E723 | with repair of lacerated spleen, add | 2 | 158.90 | |
| 5313 | Peritoneal abscess Subphrenic | 7 | 313.75 | 7 |
| S314 | Abdominal | | 223.60 | 6 |

| | OPERATIONS ON THE DIGESTIVE SYSTEM - Cont'd. | | | |
|---------------|--|------|------------------|-------|
| Code | The state of the s | Asst | Surg | Anaes |
| | ABDOMEN, PERITONEUM AND OMENTUM - Cont'd. | | | |
| | AND UNEIGH AND UNEIGHT - CONE d. | | | |
| 7550 | Pelvic abscess, incision and drainage - rectal or vaginal approach | | | |
| Z569 | (1.0.P.) | | 103.20 | 4 |
| Z594 Z595 | Percutaneous abdominal abscess drainage including daily supervision | | 196.60 | |
| 2353 | Removal of infected sutures from abdominal wall or re-exploration of wound | | 36.90 | |
| Z574 | for bleeding - general anaesthetic (I.O.P.) | 4 | 80.30 | 4 |
| 5311 | umbilical vein intra-abdominal dissection and catheterization (for newhorn | 7 | 00,50 | -4 |
| | see page 51,52) | 6 | 196.60 | 6 |
| 5320 | trisertion of antabuse into abdominal wall | | 49.15 | |
| S203 | Insertion of peritoneo-jugular shunt for ascites | | | _ |
| \$209 | - primary | 7 | 240.80 | 7 |
| 3203 | - revision | 7 | 172.00 | 7 |
| | Excision | | | |
| S316 | Excision of full thickness abdominal wall tumour and primary closure | | 1.0. | 6 |
| \$317 | Umbi lectomy - plastic | 4 | 94.20 | 4 |
| \$318 | Panniculectomy (includes any necessary diastasis repair) | 6 | 368,60 | 6 |
| E748 | - with repair of umbilical hernia, add | | 103.20 | |
| S319 Note: | Mesenteric cyst | 6 | 283.40 | 6 |
| noce: | S318 Panniculectomy requires OHIP authorization (see Surgical Preamble, paragraph 17) | | | |
| | paragraph 17) | | | |
| | Endoscopy | | | |
| | Peritoneoscopy, culdoscopy or laparoscopy (I.O.P.) | | | |
| Z552 | - without biopsy | 4 | 105.30 | 6 |
| 7550 | - with biopsy and/or lysis of adhesions and/or removal of foreign body | | | |
| Z553 | and/or cautery of endometrial implants | 4 | 121.65 | 6 |
| | Repair | | | |
| S325 | Omentopexy, sole operative procedure | 6 | 258.00 | 6 |
| | Herniotomy | 0 | 230.00 | U |
| 5322 | Inguinal and/or femoral - infants | 4 | 240.80 | 4 |
| S326 | - children | 4 | 214.60 | 4 |
| 5323 | - adolescents and adults | 4 | 240.80 | 4 |
| \$328 | Unilateral with exploration of other side, infants and children | 4 | 278.50 | 4 |
| 5329 | Strangulated or incarcerated | 4 | 200 65 | - |
| 5330 | - without resection of bowel | 6 | 309.65 | 5 |
| 5332 | Umbilical - Adolescent or adult | 4 | 558.70 240.80 | 4 |
| 5333 | - Child (operative) | 4 | 188,40 | 4 |
| E756 | - with resection of strangulated contents, add | | 94.20 | 2 |
| E757 | - without resection of strangulated contents, add | | 47.10 | 1 |
| E764 | When done in conjunction with other abdominal surgery add | | 81.90 | |
| S334 | Omphalocoele and gastrochisis - one stage - repair | 7 | 317.80 | 7 |
| S335 | Multiple staged - repair | 7 | 212 75 | 7 |
| 5336 | (a) Gross method or Silon mesh | 7 | 313.75 313.75 | 7 |
| 5000 | Diaphragmatic, other than oesophageal hernia | ' | 213.73 | / |
| 5337 | One stage procedure - trans-abdominal | 7 | 430.10 | 9 |
| \$338 | - trans-thoracic | 9 | 430.10 | 13 |
| \$339 | Second stage and abdominal closure | 4 | 249.85 | 9 |
| S340 | Ventral - post-operative | | 313.75 | 6 |
| S344 | Massive incisional hernia | 6 | 352.25 | 6 |
| S345 | Massive sliding inguinal hernia | 6 | 296.55 | 6 |
| E725 | Recurrent - all types, excepting oesophageal add | 5 | 73.70 | 2 |
| E726 | \$326, \$329, \$330 or \$331) | 2 | 129.00 | 2 |
| \$342 | Epigastric | | 202.30 | 4 |
| E727 | Hydrocoele - extra - applicable to adults only | 1 | 55.70 | |
| | | | | |
| | Suture | | | |
| C742 | Secondary closure for evisceration - sole operative procedure in | - | 200 CE | - |
| \$343 | abdomen | 6 | 232.65 | 6 |
| | | | | |

OPERATIONS ON THE UROGENITAL SYSTEM OPERATIONS ON THE URINARY SYSTEM

| Code | | Asst | Surg | Anaes |
|----------------|--|------|------------------|-------|
| | NIDAEN AND DEDINEDIDIA | | | |
| | KIDNEY AND PERINEPHRIUM Preamble: | | | |
| | (1)No additional claim should be made for nephroscopy when done at the time of pyelolithotomy or nephrolithotomy. | | | |
| | (2) In a routine surgical approach to the kidney and related procedures, no additional claim should be made for rib resection carried out for | | | |
| | access purposes. | | | |
| | (3)When the kidney has been operated on more than one month previously, the fee for the secondary surgery may be increased by \$71.30 (E752). | | | |
| | (4) When an adrenal ectory is performed in conjunction with a nephrectory, and is incidental to the removal of the kidney, there should be no | | | |
| | additional claim for the adrenalectomy. | | | |
| | l-stata- | | | |
| 7601 | Incision Renal biopsy, needle (I.O.P.) | | 86.00 | 4 |
| S401 | Drainage of kidney abscess | 7 | 283,40 | 7 |
| S402 | Orainage of perinephric abscess | 7 | 184.30 | 7 |
| | Exploration of renal and peri-renal tissues (with or without biopsy or | | | |
| \$403 | unroofing of cyst) Nephrotomy | 7 | 304.70 | 7 |
| \$404 | - with drainage - nephrostomy -when sole operative procedure on kidney | 7 | 304.70 | 7 |
| E763 | - when done in conjunction with other non renal procedure(s) | | 128.60 | |
| S405 | - with removal of calculus | 7 | 412.05 | 7 |
| Z600 | - change of nephrostomy tube (I.O.P.) | | 30.30 | |
| S406 | Transection of aberrant renal vessels - sole operative procedure | 7 | 326.00 | 7 |
| S407 | Pyelotomy - with drainage | 7 | 326.00 | 7 |
| \$408 \$409 | with removal of calculus - with diversion of urine | | 373.55 398.95 | 7 |
| 3409 | | , | 390.93 | , |
| 0410 | Excision | - | 407.45 | 7 |
| S410 | Calycectomy with diversion of urine | 7 | 437.45 | 7 |
| \$411 | Partial or hemi-nephrectomy | 7 | 498.10 | 7 |
| \$423 | Nephrectony | | | |
| \$412 | - ectopic kidney | 7 | 398.95 398.95 | 7 |
| S413 S415 | - lumbar transperitoneal | 7 | 446.50 | 7 |
| S416 | - thoraco-abdominal or radical nephrectomy | 9 | 575.10 | 13 |
| S417 | - thoraco-abdominal or radical nephrectomy with gland dissection | | 600.50 | 13 |
| 3417 | - thoraco-abdominal or radical nephrectomy with incision and repair of | | 000.00 | 10 |
| | inferior vena cava for removal of tumour thrombus (See Preamble, Para | | | |
| \$418 | B32) | I.C. | I.C. | I.C. |
| | Extrophy - plastic closure of bladder with closure of abdominal wall and | | | |
| | urethral lengthening with closure of pelvic floor with or without | | | |
| S424 | re-implantation of ureters | 7 | 802.80 | 10 |
| S420 | Nephro-ureterectomy, total, with resection of uretero-vesical junction | 7 | 506.30 | 10 |
| S421 | Excision of stenosed renal artery with reimplantation or homograft | 7 | 673.40 | 15 |
| S422 | Repair Pyeloplasty (with or without nephropexy) | 7 | 446.50 | 7 |
| E754 | - with removal of calculus, add | | 49.80 | , |
| S426 | Nephropexy - when sole operative procedure | 7 | 326.00 | 7 |
| S428 | Symphysiatomy, for horseshoe kidney with or without nephropexy and associated procedures | 7 | 373.55 | 7 |
| | | | | |
| C420 | Suture | 7 | 373.55 | 7 |
| S429 | Ruptured or lacerated kidney - repair or removal | , | 3/3,33 | , |
| S430 | x-ray control | 7 | 562.00 | 9 |
| | • | | | |

OPERATIONS ON THE UROGENITAL SYSTEM

| | OPERATIONS ON THE URINARY SYSTEM - Cont'd. | | | |
|--------------|--|------|------------------|--------|
| Code | | Asst | Surg | Anaes |
| | WINES AND DESCRIPTION OF THE PROPERTY OF THE P | | 501 9 | 741003 |
| | KIDNEY AND PERINEPHRIUM - Cont'd. | | | |
| | Euchan Danal Danas Laure | | | |
| S431 | Extra Renal Procedures | _ | | |
| S432 | Excision of retroperitoneal tumour Exploration of retroperitoneal tumour | / | 326.00 | 7 |
| 5433 | Sacro-coccygeal teratoma | 7 | 222.80 | 7 |
| Z630 | Extracorporeal shock wave lithotripsy (I.O.P.) | ני | 373.55 266.20 | 6 |
| | The state of the s | | 200,20 | 0 |
| | Percutaneous - Procedures (I.O.P.) | | | |
| Z629 | Percutaneous nephrostomy | | 131.10 | |
| Z623 | Insertion of stent | | 65.50 | |
| Z624 | Dilation of tract | | 81.90 | |
| Z625 | Selective catheterization of calyces | | 45.05 | |
| Z626 Z627 | Nephroscopy | | 81.90 | |
| F759 | Removal of renal calculi | 5 | 143.40 | 6 |
| 6/39 | - if disintegrated by ultrasound, add | | 81.90 | |
| | Renal Transplantation Procedures: (submit on recipient's claim) These fees | | | |
| | do not include immunosuppressive therapy which is on a fee for service | | | |
| | basis. | | | |
| \$435 | Kidney transplant (surgical team fee) | | 1020.70 | 13 |
| S434 | Kidney re-transplant (surgical team fee) | | 1222.20 | 13 |
| | Donor neohrectomy - surgical team fee, unilateral or hilateral (to include | | | |
| \$436 | renal perfusion with hypothermia when rendered by surgeon) | | 429.30 | 8 |
| E753 | - live donor, add | | 111.40 | |
| 0127 | For nephrological components, see Diagnostic and Therapeutic Procedures. | | | |
| S437 E762 | Renal autotransplantation | 7 | 763.50 | 10 |
| E/02 | Reconstruction or repair of renal artery done in addition to renal | | 007.00 | |
| | transplantation procedures, add | | 257.20 | |
| | URETER | | | |
| | Endoscopic Procedures | | | |
| | Cystoscopy with manipulation and/or removal of calculus and retrograde | | | |
| S470 | pyelogram if required | | 206.00 | 4 |
| Z628 | Cystoscopy and diagnostic ureteroscopy - above intramural ureter | | 107.30 | 4 |
| E760 | - with removal of calculus, add | | 143.40 | |
| E761 | - if disintegrated by ultrasound, add | | 81.90 | |
| | | | | |
| C440 | Incision | | | |
| S442 | Peri-ureteral abscess | 6 | 184.30 | 6 |
| S443 | Ureterotomy, abdominal or vaginal exploratory or for drainage - upper 2/3 | | 222 00 | _ |
| S444 | - lower 1/3 | 6 | 222.80 | 6 |
| 3111 | - with removal of calculus | 0 | 326.00 | 6 |
| S445 | - upper 2/3 | 6 | 321.90 | 6 |
| S446 | - lower 1/3 | 6 | 412.05 | 6 |
| | - where uneter has been previously opened | | | |
| S447 | - upper 2/3 | 6 | 373.55 | 6 |
| 5448 | - lower 1/3 | 6 | 446.50 | 6 |
| | | | | |
| | Excision | | | |
| S449 | Ureterectomy - including uretero-vesical junction | 6 | 373.55 | 7 |
| S450 | - other e.g. partial | 6 | 283.40 | 7 |
| | Repair | | | |
| S451 | Unetero-vesical anastomosis or re-implantation unilateral | 6 | 373.55 | 8 |
| 3431 | Re-implantation of ureter with extensive tapering with or without ureter- | ., | 3/3,33 | 0 |
| S561 | Olysis | 6 | 562,00 | 8 |
| S562 | Biffid ureter | 6 | 412.05 | 8 |
| \$452 | Uretero-ileal conduit | 6 | 673.40 | 9 |
| \$453 | Uretero-ileal conduit with total cystectomy | 9 | 1068.20 | 15 |
| S454 | Uretero-ileal conduit with ureterectomy and ileal replacement | 6 | 763.50 | 9 |
| | Uretero-intestinal anastomosis or transplant | | 000 | |
| \$455 | - unilateral | 6 | 283.40 | 6 |
| S462 | - bilateral | 6 | 373.55 | 6 |
| S456 | - bilateral with cystectomy, one stage | 9 | 841.30 471.85 | 13 |
| S457 S458 | Uretero-ureterostomy | 6 | 222.80 | 8 6 |
| S463 | - with lower third ureterotomy | 6 | 326.00 | 6 |
| S459 | Uretero-vaginal fistula | 6 | 479.20 | 6 |
| \$460 | Ureterolysis for peri-ureteral fibrosis - unilateral | 6 | 373.55 | 6 |
| S461 | Ureteroplasty (Hutch) - unilateral | 6 | 283.40 | 6 |
| S427 | Bladder flap (Baori) - to include re-implantation of ureter | 6 | 429.30 | 6 |
| | | | | |

OPERATIONS ON THE UROGENITAL SYSTEM
OPERATIONS ON THE URINARY SYSTEM - Cont'd,

| | OPERATIONS ON THE URINARY SYSTEM - Cont'd. | | | |
|----------------|---|------|------------------|-------|
| Code | | Asst | Surg | Anaes |
| | IDETED Cont. I d | | | |
| | URETER - Cont'd. | | | |
| | Suture | | | |
| | Spontaneous or traumatic rupture or transection | | | |
| S465 | - immediate - upper 2/3 | 6 | 326.00 | 6 |
| S466 | - lower 1/3 | 6 | 373.55 | 6 |
| S467 | - late repair - upper 2/3 | 6 | 373.55 | 6 |
| S468 | - lower 1/3 | 6 | 412.05 | 7 |
| | | | | |
| | BLADDER | | | |
| | Preamble: (1)No extra claim should be made for EUA when done at the time of | | | |
| | cystoscopy. | | | |
| | (2) Visit fees, as applicable, to be claimed for changing suprapubic tube. | | | |
| | (3)No extra claim should be made for suprapubic cystotomy when performed in | | | |
| | the routine course of gynaecological surgery. | | | |
| | | | | |
| | Endoscopy - Cystoscopy | | | |
| | Diagnostic Procedures (I.O.P.) | | co co | 4 |
| Z606 | Diagnostic with or without urethroscopy | | 60.60 | 4 |
| Z607 | Repeat within 30 days | | 30.30 | 4 |
| | bladder, brush biopsy of bladder, collection of ureteral specimens, | | | |
| | intravenous function test and retrograde injection of opaque media and | | | |
| Z608` | calibration and/or dilatation of the ureter - one or both sides | | 73.70 | 4 |
| 2000 | With transurethral biopsy, brush biopsy of renal pelvis and/or ureter | | | |
| Z610 | and/or insertion of ureteral stent | | 82.30 | 4 |
| Z612 | With manametry (to include urethral pressure profile if required) | | 70.45 | 4 |
| Z613 | With meatotomy or internal urethrotomy (female) | | 67.80 | 4 |
| Z614 | With meatotomy and retrograde pyelogram | | 82.30 | 4 |
| Z615 | With needle biopsy of prostate | | 88.50 | 4 |
| | Thereas his December | | | |
| S492 | Therapeutic Procedures With electrocoagulation - tumour(s) | | 103.20 | 4 |
| S493 | - Humer ulcer | | 103.20 | 4 |
| 3433 | With excision of tumour or tumours including base and adjacent muscles | | | |
| | and electrocoagulation if necessary | | | |
| S494 | Single tumour 1 to 2 cm. diameter | | 231.80 | 4 |
| S495 | Single tumour over 2 cm. diameter | | 373.55 | 4 |
| S496 | Multiple tumours | | 373.55 | 4 |
| S497 | With resection bladder neck, female | | 145.80 283.40 | 5 |
| \$498 | With resection bladder neck, male | | 145.80 | 4 |
| \$499 \$500 | With electro surgical ureteral meatotomy | | 145.80 | 4 |
| S501 | With removal of ureteric catheter | | 64.30 | 4 |
| 3001 | With insertion of radioactive substance, in addition to associated | | | |
| E751 | procedures | | 47.10 | |
| | With secondary surgical evacuation of bladder clots and control of | | | |
| S502 | haemorrhage | | 72.90 | 4 |
| Note: | Z608 to S502 - "with" means the listed benefit includes the cystoscopy. | | | |
| | * | | | |
| | Introduction (I.O.P.) Catheterization; acute retention, change of retention catheter or | | | |
| | instillation of medication | | | |
| Z602 | - office | | 7.40 | |
| Z603 | - home | | 13.70 | |
| Z611 | - hospital | | 7.40 | |
| | | | | |
| | Incision | | 10.00 | |
| Z605 | Aspiration (I.O.P.) | | 10.60 | 5 |
| S478 | Cystotany or cystostany | 5 | 184.30 | 2 |
| | | | | |

OPERATIONS ON THE UROGENITAL SYSTEM

| | OPERATIONS ON THE URINARY SYSTEM - Cont'd. | | | |
|-------|--|------|------------------|-------|
| Code | | Asst | Surg | Anaes |
| | 0.1000 | | | |
| | BLADDER - Cont'd. | | | |
| \$479 | Cystotomy or cystostomy and electrocoagulation of tumour | - | 202 40 | - |
| \$480 | Cystotomy with trochar and cannula and insertion of tube | 5 | 283.40 | 5 |
| E750 | - when done in conjunction with another procedure, add | | 72.90 22.30 | 5 |
| \$481 | Cystolithotomy - when sole operative procedure | 5 | 222,30 | 5 |
| S476 | Cutaneous vesicostomy | 5 | 373.55 | 5 |
| S477 | Reduction cystoplasty (bladder plication) | 5 | 304,70 | 5 |
| 3.,, | Account of suprasty (Staucer prication) | 2 | 304.70 | 2 |
| | Excision | | | |
| | Cystectamy | | | |
| S482 | Partial for tumour or diverticulum (single or multiple) | 6 | 326,00 | 6 |
| S483 | - with re-implantation of ureter | 6 | 471.85 | 7 |
| \$490 | - with re-implantation of ureters | 6 | 626.70 | 7 |
| \$484 | Complete cystectomy, without transplant | 6 | 562,00 | 10 |
| \$485 | - with unetero-intestinal transplant | 8 | 841.30 | 13 |
| \$453 | - with uretero-ileal conduit | 9 | 1068.20 | 15 |
| | Excision of urachal cyst or sinus with or without umbilical hernia | | 2000 | 10 |
| S471 | repair | 6 | 253.10 | 6 |
| S487 | Excision of urachus, repair of bladder and diversion of urine | 6 | 253.10 | 6 |
| 3101 | Extrophy-excision of bladder and repair of abdominal wall, inclusive of | | 200820 | |
| \$488 | graft | 6 | 184.30 | 6 |
| 5489 | - above including bilateral ureterosignoidostomy | 6 | 562.00 | 6 |
| S491 | Plastic repair of extrophy using bladder and including skin flaps | 6 | 562,00 | 6 |
| 0.52 | Trade of the or one open and or one of the order of the o | | | |
| | Repair | | | |
| S512 | Repair of ruptured bladder | 5 | 283,40 | 6 |
| \$513 | Cystoplasty, using intestine | 8 | 562.00 | 9 |
| \$518 | Plastic repair of bladder neck - child | 5 | 283,40 | 5 |
| \$519 | - adolescent or adult | 5 | 373.55 | 5 |
| S520 | With diverticulectomy | 5 | 471.85 | 7 |
| 3020 | The contraction of the contracti | | | |
| | Destruction | | | |
| S521 | Litholapaxy and removal of fragments | | 184.30 | 4 |
| | | | | |
| | Suture | | | |
| | Closure of fistula | | | |
| S522 | External, suprapubic | 4 | 222,30 | 4 |
| S523 | Vesico-vaginal - vaginal approach | 4 | 372.70 | 6 |
| S524 | - transvesical approach (with or without omental flap) | 5 | 398.95 | 6 |
| S525 | Vesico-rectal or vesico-signoid | 5 | 381.70 | 6 |
| Note: | Closure of fistula see also S734, S711 on page 146. | | | |
| | | | | |
| | URETHRA | | | |
| | Preamble: | | | |
| | (1) No claim should be made for pre-cystoscopy dilatation of the male | | | |
| | urethra unless urethral stricture is the primary diagnosis. No claim | | | |
| | should be made for dilatation of the female unethra when done at the | | | |
| | same time as cystoscopy | | | |
| | Endoscopy | | 20. 20 | |
| Z617 | Unethroscopy - diagnostic (I.O.P.) | | 30.30 | 4 |
| Z618 | - with biopsy (1.0.P.) | | 66,80 | 4 |
| S547 | Removal of foreign body or calculus | | 145.80 | 4 |
| | | | | |
| | Incision | | 20.10 | 4 |
| Z616 | Biopsy of urethra (without endoscopy)(1.0.P.) | 2 | 20.10 | 4 |
| \$530 | Urethrotomy - external | 3 | 184.30 | 4 |
| \$532 | - transurethral (visual) | 3 | 283.40 | 4 |
| \$538 | - repeat procedure within 6 months by same surgeon | | 163,00 184,30 | 4 |
| S531 | Urethrostany | 3 | 27.20 | 4 |
| Z604 | Meatotomy and plastic repair (1.0.P.) | 3 | 184.30 | 4 |
| \$533 | For extravasation of urine with multiple drainage | 3 | 104.30 | 4 |
| | | | | |

SUNDILIAL PROLEDUKES

| | OPERATIONS ON THE UROGENITAL SYSTEM OPERATIONS ON THE URINARY SYSTEM - Cont'd. | | | |
|--------------|--|------|------------------|-------|
| Code | | Asst | Surg | Anaes |
| | URETHRA - Cont'd. | | | |
| | uncinion - cont d. | | | |
| S534 | - above with external urethrotomy or cystotomy | 3 | 283.40 | 4 |
| Z609 | Peri-urethral abscess (I.O.P.) | | 27.20 | 4 |
| | | | | |
| ccac | Excision | 2 | 70.00 | |
| S536 S537 | Caruncle | 3 | 72 . 90 | 4 |
| S541 | Diverticulectomy - male or female | 3 | 222.80 | 4 |
| S542 | Posterior urethral valve | 4 | 283,40 | 4 |
| S543 | Prolapse urethra, excision | 3 | 72.90 | 4 |
| S544 | Urethrectomy - radical | 4 | 183.40 | 4 |
| | All the second s | | | |
| CE 40 | Repair | 4 | 226 00 | 6 |
| S548 | Urethral sling | 4 | 326.00 | 0 |
| S549 | - primary procedure | 4 | 258,90 | 6 |
| S546 | - repeat procedure for failed retropubic or vaginal surgery for stress | | 300,000 | |
| | incontinence | 4 | 303.10 | 6 |
| Note: | See also S731-S733, page 146 for stress incontinence. | | | |
| | Prosthetic procedure for urinary incontinence (e.g. Kauffman, Rosen | 2 | 200 00 | - |
| S559 | type etc.) | 3 | 326.00 373.55 | 5 |
| S560 S563 | - where perineum has been previously operated on for incontinence Removal of perineal incontinence prosthesis | 3 | 122.90 | 4 |
| 2002 | Insertion of inflatable prosthesis at bladder neck with or without uro- | 3 | 122.30 | 7 |
| S539 | dynamic control | 4 | 663.55 | 6 |
| S540 | Revision or removal of inflatable prosthesis at bladder neck | 3 | 204.80 | 4 |
| | Urethroplasty | | | |
| S545 | 1st stage - posterior | 4 | 326.00 | 6 |
| S550 | - anterior | 4 | 244.90 201.50 | 4 |
| S558 S535 | One stage repair (to include skin graft if necessary) | 4 | 326.00 | 6 |
| 3333 | the stage repair (to include skill grate it recessary) | | 020 800 | |
| | Suture | | | |
| S551 | Rupture, anterior urethra (diversion of urine extra) | 4 | 145.80 | 4 |
| S552 | Posterior urethra - immediate repair | 4 | 373.55 | 4 |
| \$553 | - late repair | 4 | 471.85 | 5 |
| S554 | Fistula Penile urethra (diversion of urine extra) | | 78.40 | 4 |
| S555 | Perineal urethra | 4 | 278.50 | 4 |
| S556 | Recto-urethral with diversion, colostomy and closure of colostomy | 6 | 471.85 | 7 |
| | | | | |
| | Destruction | 2 | 102 40 | 4 |
| S557 | Urethro-vesicolysis - when sole operative procedure | 3 | 183.40 | 4 |
| S564 | operative procedure) | | 278.50 | 4 |
| 3304 | operative procedure/ | | | |
| | Manipulation (I.O.P.) | | | |
| | Dilation of stricture male | | 0.10 | |
| Z621 | - local anaesthetic | | 9.40 45.05 | 4 |
| Z619 | - general anaesthetic Dilation of urethra, female | | 45.05 | 4 |
| Z622 Z620 | under general anaesthetic | | 35.60 | 4 |
| LULU | - under general andesoneere sessions se | | | |

OPERATIONS ON THE MALE GENITAL SYSTEM

| 0.1 | | | | |
|----------------|--|------|------------------|--------|
| Code | | Asst | Surg | Anaes |
| | PENIS | | | |
| | | | | |
| | Incision | | | |
| | Slit of prepuce (complete care) | | | |
| 25.53 | | | | |
| \$567 \$568 | - newborn | | 12.30 | |
| S569 | - infant | | 18.40 | 4 |
| 3009 | - adult or child | | 25.80 | 4 |
| | Excision | | | |
| S570 | Circumcision - newborn (Complete care) | | 29,50 | |
| S573 | - infant, adult or child | 3 | 77.00 | 4 |
| Z702 | Biopsy (I,O,P.) | | 20.10 | 4 |
| S574 | Amputation Partial | | 448.00 | |
| S575 | Partial | 4 | 145.80 | 4 |
| S576 | Radical with inguinal and femoral glands 1 or 2 stages | 6 | 373.55 471.85 | 5 7 |
| Z701 | Condylomata (I.O.P.) - local anaesthetic | ٠, | 28.05 | , |
| 2767 | - general anaesthetic | | 57,00 | 4 |
| \$599 | Excision plaque for Peyronies disease | 4 | 180.20 | 4 |
| | where grafting is necessary, add appropriate skin graft fee | | | |
| | Dennie | | | |
| \$577 | Repair Epispadias | 2 | 202 40 | 4 |
| 30// | Hypospadias | 3 | 283.40 | 4 |
| \$578 | One stage repair - with meatus to but not into glans | 4 | 245.80 | 4 |
| S571 | - with advancement of meatus into glans | 4 | 327.70 | 4 |
| S572 | into glans using free Island flap pedicle (penoscrotal) | 4 | 491.50 | 6 |
| S579 | Chordee repair | | 184.30 | 4 |
| S580 S581 | Plastic reconstruction, urethra | | 283.40 | 4 |
| S597 | Closure urethro-cutaneous fistula | Δ | 78.60 262.10 | 4 |
| E755 | - with inflatable prosthesis, add | | 47.10 | 4 |
| \$588 | Surgical removal of prosthesis | | 94.20 | 4 |
| S566 | Revision including removal of prosthesis | 4 | 204,30 | 4 |
| | | | | |
| | TESTIS | | | |
| Z703 | Incision Abscess (1.0.P.) | | 47.10 | 4 |
| Z704 | Biopsy (I.O.P.) - single | | 47.10 | 4 |
| Z705 | - bilateral | | 71.30 | 4 |
| Z706 | - with vasography (see also page 46) | | 103.20 | 4 |
| \$589 | Orchidectomy - unilateral | | 145.80 | 4 |
| S590 | Radical nemoval lymph nodes for testicular tumour | | 712.70 | 8 |
| \$598 | Radical orchidectomy for malignancy - unilateral | 3 | 201.50 | 4 |
| | Repair | | | |
| | Orchidopexy for undescended testis, any type, one or two stages to include | | | |
| \$591 | hernia repair where required | 4 | 283.40 | 4 |
| \$592 | - second stage (Torek) repair | | 47.10 | 4 |
| S593 | Exploration for undescended testicle, without orchidopexy | 4 | 222.80 | 4 |
| \$600 | Reduction of torsion of testis or appendix testis and orchidopexy (one or both sides), if required | 3 | 201.50 | 4 |
| \$595 | Ruptured testicle | | 145.80 | 4 |
| \$596 | Insertion of testicular prosthesis | | 145.80 | 4 |
| | | | | |
| | EPIDIDYMIS | | | |
| 7707 | Incision | | 47.10 | A |
| Z707 | Abscess (1.0.P.) | | 47.10 | 4 |
| | Excision | | | |
| S601 | Spermatocoele or spermatic granuloma | 3 | 145.80 | 4 |
| \$602 | Epididymectomy - unilateral | 3 | 145.80 | 4 |
| | | | | |
| 0606 | Repair | 2 | 145.00 | 4 |
| \$606 | Anastomosis Epididymovasostomy - unilateral | 3 | 145.80 | 4 |
| | | | | |

| Code | OPERATIONS ON THE MALE GENITAL SYSTEM - Cont'd. | Asst | Surg | Anaes |
|-----------------------|---|------|--------------------------|-------|
| | TUNICA VAGINALIS | | | |
| Z708 | Incision Hydrocoele aspiration (I.O.P.) | | 13.90 | |
| S611 Note: | Excision Hydrocoele - unilateral S611 when done with hermia repair use E727. | 4 | 145.80 | 4 |
| Z709 Z768 S616 | SCROTUM Incision Abscess or haematocoele (I.O.P.) - local anaesthetic general anaesthetic | | 17.00 47.10 72.90 | 4 4 |
| \$618 | Excision Resection of scrotum | 3 | 184.30 | 4 |
| S619 | Suture Trauma - laceration - depending on extent and complications (See Preamble para 8.32) | | 1.0. | I.C. |
| Z710 | VAS DEFERENS Incision Vasography (I.O.P.) | | 47.10 | 4 |
| \$623 \$625 | Repair Vasostomy and/or vasoepididymostomy (to include microscopic control if required) - including biopsy and vasography | | 184.30 222.80 | 4 4 |
| \$626 | Suture Ligation - uni or bilateral | 3 | 91.75 | 4 |
| S630 S631 Note: | SPERMATIC CORD Excision Hydrocoele - single | 3 3 | 145.80 145.80 | 4 4 |
| Z711 | SEMINAL VESICLES Incision Abscess (I.O.P.) | | 103.20 | 4 |
| \$636 | Excision Vesiculectary | 3 | 471.85 | 4 |
| | PROSTATE Preamble: (1)A T.U.R. followed within 10 days by a bilateral orchidectomy because of carcinoma of the prostate should be claimed in accordance with paragraph (3) of the Surgical Preamble. Incision | | | |
| Z712 Z713 S644 | Biopsy, needle (I.O.P.) - with drainage abscess (I.O.P.) Biopsy, perineal, open operation Removal of calculus (with or without biopsy) | 3 | 66.80 78.60 184.30 | 4 4 |
| S642 S643 | - perineal | | 373.55 373.55 | 4 |

| | OPERATIONS ON THE MALE GENITAL SYSTEM - Cont'd. | | | |
|-------|--|------|--------|-------|
| Code | | Asst | Surg | Anaes |
| | PROSTATE - Cont'd. | | | |
| | Excision Prostatectomy (not to include investigative cystoscopy) but to include vasectomy when indicated. | | | |
| S645 | Perineal | . 6 | 377.65 | 6 |
| S646 | Perineal with vesiculectomy | . 8 | 575.10 | 11 |
| S647 | - one stage | . 5 | 394.85 | 6 |
| S648 | - two stages - 1st stage | | 184.30 | 6 |
| S649 | - 2nd stage | . 5 | 222,80 | 6 |
| \$650 | - simple | . 5 | 394,85 | 6 |
| \$651 | - radical | | 663.55 | 6 |
| S641 | dissection | . 8 | 811.00 | 11 |
| S652 | Staging pelvic lymphadenectomy for prostatic cancer | . 7 | 283.40 | 7 |
| | Endoscopy Transurethral resection of prostate (no additional fee for cystoscopy, meatotomy, dilatation of stricture, internal unethrotomy or vasectomy | | | |
| \$655 | when done at the same time) | | 385.00 | 6 |
| \$654 | within one year of previous prostatectomy by same surgeon | | 270.30 | 6 |
| \$656 | Transurethral drainage of abscess | | 72.90 | 5 |
| | | | | |

OPERATIONS ON THE FEMALE GENITAL SYSTEM Preamble:

(1) In composite operations such as anterior and posterior repair and D&C or anterior and posterior repair and cauterization of cervix and biopsy, the fee shall be that of the major procedure(s).

anterior and posterior repair on a data data.

(2) No fee may be claimed for a D&C if (a) it is carried out prior to hysterectomy or ectopic pregnancy, or (b) it is carried out routinely prior to tubal occlusion.

(3)A D&C may be claimed at 85% when pregnancy termination (\$752,\$756,\$785) is carried out with tubal occlusion/interruption (\$741), or (b) if carried out for abnormal uterine bleeding (\$754) - if the D&C would have been indicated independent of the tubal occlusion procedure.

(4)When operative procedures are carried out for infertility, the fee shall be that of the major procedure. When additional procedure(s) are required e.g. uterine suspension, oophorocystectomy or myomectomy, E858 at \$41.00 may be claimed as well.

| 43.80 14.70 43.80 61.40 14.70 | 4 4 |
|---|--|
| 14.70 43.80 61.40 14.70 | 4 4 |
| 43.80 61.40 14.70 | 4 4 |
| 61.40 14.70 | 4 |
| | |
| | |
| 43.80 | |
| 61.40 102.40 | |
| 9.40 | |
| 23.30 98.30 | |
| 219.50 368.60 | |
| 155.60 | |
| 219.50 | 2 |
| I.C. 61.40 | |
| | |
| 43.80 | 4 |
| 61 40 | 4 |
| 102.40 | 4 |
| | |
| 15.15 43.80 105.70 | 4 |
| | 102,40 9,40 23,30 98,30 219,50 368,60 219,50 1,C, 61,40 43,80 15,15 43,80 |

| Code | OPERATIONS ON THE FEMALE GENETAL SYSTEM - Cont'd. | | | |
|----------------|---|------|-----------|--------|
| Code | VAGINA - Cont'd. | Asst | Surg | Anaes |
| S742 | Coloretem, a a fee continue | | | |
| S702 | Colpectomy - e.g. for carcinoma | 4 | 298,20 | 6 |
| 5,02 | Septem | 3 | 105.70 | 4 |
| | Repair | | | |
| S716 | Anterior or posterior repair (sole procedure) | 4 | 143,40 | 5 |
| S717 | Anterior and posterior repair (sole procedure) | 4 | 225,30 | 5 |
| S718 | Anterior and posterior repair and repair of enterocoele and/or vault | | | |
| S719 | prolapse | 4 | 298.20 | 5 |
| S723 | Posterior repair and repair of enterocoele and/or vault prolapse Posterior repair and repair of anal sphincter | 4 | 263.00 | 5 5 |
| 3, 23 | Anterior repair (with or without posterior repair) and repair of uterine | * | 210.30 | 3 |
| S720 | prolapse (Fothergill or Watkin's interposition) | 4 | 298,20 | 5 |
| S721 | Anterior, posterior repair with excision of cervical stump | 4 | 298.20 | 6 |
| | Post hysterectomy vault prolapse with or without enterocoele and with or | | | |
| czaa | without anterior and posterior repair - vaginal and/or abdominal | | 200 20 | _ |
| \$722 | approach | 4 | 298.20 | 6 |
| S724 | procedures) | 3 | 104,85 | 4 |
| S725 | Colpocleisis (LeFort or modification) | 5 | 219.50 | 5 |
| S726 | Construction of artificial vagina (see Preamble para B32) | | I.C. | 6 |
| | Closure of fistula | | | |
| 5523 | Vesico-vaginal - single surgeon | 4 | 372.70 | 6 |
| S734 | - two surgeons - vaginal surgeon | | 253.95 | 6 |
| S711 | - abdominal surgeon | | 253,95 | |
| Note: S231 | S711 - See also S524, page 139. Recto-vaginal (any repair) | 4 | 289,20 | 6 |
| S729 | Uretero-vaginal | | 479,20 | 6 |
| S709 | Urethro-vaginal | | 320.30 | 4 |
| | Retropubic urethropexy (e.g. Marshall Marchetti) | | | |
| S549 | for stress incontinence - primary procedure | . 4 | 258,90 | 6 |
| | - repeat procedure for failed retropubic or vaginal surgery for | | 303,10 | 6 |
| S546 | Stress incontinence | 4 | 303,10 | 0 |
| | Retropublic urethropexy - combined abdominal-vaginal procedure for stress incontinence (sling procedure) | | | |
| | - following previous failed procedures | | | |
| 5731 | - one surgeon | . 7 | 368.60 | 7 |
| S732 | - two surgeons - vaginal surgeon | . 7 | 219.50 | 7 |
| \$733 | - abdominal surgeon | | 298,20 | |
| 6740 | - following two or more failed procedures | 7 | 526,70 | 7 |
| \$748 \$749 | - one surgeon | 7 | 298.20 | 7 |
| S751 | - abdominal surgeon | | 358,60 | |
| 3/31 | - accommon surgeon sessessessessessessessessessessessesses | | | |
| | Manipulation | | | |
| | Examination and/or dilatation (may include insertion and/or removal of | | | |
| | I.U.C.D.) - when sole procedure | | 43,80 | 4 |
| Z735 | General anaesthetic (I.O.P.) | | 43,00 | -4 |
| U.V.C. | Removal of I.U.D. without G.A. | | | |
| | CERVIX UTERI | | | |
| | · | | | |
| | Endoscopy (I.O.P.) | | | |
| | Initial investigation of abnormal cytology of vulva and/or vagina or | | | |
| 2201 | cervix under colposcopic technique (to include biopsies and | | 42 00 | |
| 2731 | curetting) | | 43.80 | |
| Z730 | Follow up colposcopy | • | 7.40 | |
| | Cauterization (I.O.P.) | | | |
| U.V.C | Chemical | | visit fee | is |
| Z732 | Cryotherapy | , | 14.70 | |
| Z724 | Electrocautery | , | 7.40 | |
| 7725 | Dilatation and cauterization under general anaesthesia | | 43,80 | 4 |

| Code | OPERATIONS ON THE FEMALE GENITAL SYSTEM - Cont'd. | | Suga | Anna |
|--------------|---|-----|------------------|--------|
| COUC | <u> </u> | st | Surg | Anaes |
| | CERVIX UTERI - Cont'd. | | | |
| 0744 | Conization | | | |
| \$744 | Cervix - cone biopsy - any technique, with or without D&C | 3 | 149.10 | 4 |
| Z729 | dysplasia or carcinoma in situ) - out patient procedure | | 32,80 | |
| | Excision | | | |
| Z720 | Biopsy - with or without fulgurization (I.O.P.) | | 14,70 | 4 |
| S765 | Amputation of cervix | 4 | 148.30 | 4 |
| \$766 | Cervical stump - abdominal | 6 | 219.50 | 6 |
| 5767 | | 4 | 219.50 | 4 |
| Note: | Excision of cervical polyp(s) under general anaesthesia, use Z720 | | | |
| | Repair | | | |
| S774 | Repair of incompetent cervix - not associated with pregnancy | . 3 | 122.90 | 4 |
| | CORPUS UTERI | | | |
| | Endocony (T.O.B.) | | | |
| Z583 | Endoscopy (I.O.P.) Hysteroscopy with or without biopsy or D&C | | 78.60 | 1 |
| Z585 | - with cannuitzation of tube(s), lysis of intrauterine adhesions or | | 75.00 | 4 |
| | embryo transfer | | 104.85 | 4 |
| | Incision and Excision | | | |
| | Endometrial biopsy, cytology | | | |
| Z719 | - wash or brush (I.O.P.) | | 17.00 | |
| Z581 | Office endometrial curettage (I.O.P.) | | 30.70 | |
| Note: | The presentation of a case for abortion before a Hospital Committee is not | | | |
| | a benefit of OHIP. A pre-operative consultation by a second gynaecologist, when required by | | | |
| | the hospital is not a benefit of OHIP. | | | |
| U.V.C | Abortion - complete - under 20 weeks | | visit fe | es |
| S768 | - incomplete - including D&C | | 78.60 | 4 |
| \$752 | therapeutic - curettage, intra-amniotic injection (complete) therapeutic - intra-amniotic injection (incomplete) followed by | | 96.70 | 4 |
| S785 | curettage | | 162.20 | 4 |
| S756 | missed abortion, or evacuation of molar pregnancy | | 96.70 | 4 |
| \$770 | - hysterotany | | 209.70 | 6 |
| 5783 | - hysterotomy with tubal interruption | 6 | 221.20 | 6 |
| 5754 | removal of polyps, Rubin's test or hysterosalpingography) | | 78,60 | 4 |
| Note: | For D & C with laparascopy (Z552) use code E857 | | | |
| | Intracavitary application of radium or sealed sources including D&C carried out at same time as application (to include consultation fee) | | | |
| S753 | - first application | | 157.30 | 4 |
| \$755 | - repeat application | | 78.60 | 4 |
| S764 | Myanectorry | 6 | 298.20 | 6 |
| S757 | Hysterectomy (with or without adnexa) Total or subtotal - abdominal or vaginal | 6 | 368.60 | 5 |
| 3/3/ | - with anterior and posterior vaginal repair to | 0 | 300,00 | י |
| S758 | include enterocoele and/or vault prolapse | | | |
| | as required | 6 | 526.70 | 6 |
| 0750 | with anterior or posterior vaginal repair including | _ | 447.00 | _ |
| S759 S710 | enterocoele and/or vault prolapse | 6 | 447.30 447.30 | 6 6 |
| S769 | - with omentectomy for malignancy | 8 | 526.70 | 8 |
| 5763 | Radical (Wertheim's) | 8 | 587.40 | 8 |
| Note: | S757-5763, S710, S769 are total fees, the following codes are not allowed | | | |
| | in addition: S722, S738, S741, S745–S747, S780–S782. | | | |
| | Repair | | , | |
| S771 | Uterine suspension - any technique - sole procedure | 6 | 212.20 | 6 |
| E859 | Uterine suspension in conjunction with major procedure add | | 41.00 | |
| S779 | Hysteroplasty Excision of contra | 6 | 298,20 | 6 |
| 3/19 | Excision of septum | U | 430.20 | U |

| Code | OPERATIONS ON THE FEMALE GENITAL SYSTEM - Cont'd. | Asst | Surg | Anaes |
|----------------|--|---------|-----------------|-------|
| | | | | |
| | CORPUS UTERI - Cont'd. | | | |
| \$775 | Unification of double uterus (Strassman) | 4 | 368.60 | 4 |
| \$777 \$778 | Uterine inversion, operative | 4 | 298,20 | 6 |
| | FALLOPIAN TUBE Excision, Suture or Repair | | | |
| S784 | Excision of ectopic pregnancy | 6 | 263,00 | 6 |
| £852 | - with tuboplasty, add | | 41.00 | |
| E860 | Diagnostic laparoscopy prior to laparotomy for ectopic pregnancy add | | 61.40 | |
| \$738 | Salpingectomy and salpingo-cophorectomy (uni or bilateral) | 6 | 263.00 | 6 |
| S741 | purpose of sterilization | 6 al | 149.10 | 6 |
| \$735 | Fimbriolysis | 6 | 263.00 | 6 |
| \$736 | Salpingostomy | 6 | 307.20 | 6 |
| \$739 \$737 | Fimbriolysis and salpingostomy | 6 s | 348.20 | 6 |
| | tubal occlusion procedure | 6 | 482.50 | 5 |
| | inflamatory disease or endometriosis using operating microscope - not to charged for reconstruction following previous sterilization procedur | be e | | |
| 5743 | - unilateral or bilateral | 8 | 530.00 | 8 |
| | Infertility Procedures | | | |
| Z552 | Diagnostic laproscopy (I.O.P.) | 4 | 105.30 | 6 |
| E855 | - with dye injection, add | | 17.00 | |
| E856 | - with endometrial biopsy, add | | 17.00 | |
| E857 | - with D&C, add to Z552 | | 39.30 131.50 | 6 |
| \$727 | Laparoscopy for oocyte retrieval | 4 | 131.30 | G |
| | OVARY | | | |
| | Excision (unilateral or bilateral) | | | |
| \$780 | Biopsy of ovaries by laparotomy | | 219.50 | 6 |
| S745 | Oophorectomy and/or oophorocystectomy | | 263.00 | 6 |
| 5782 | Oophorectomy with total omentectomy | | 350.60 | 6 |
| S747 | Para ovarian cystectomy | 6 | 263.00 | 6 |
| | of chemotherapy protocol for ovarian carcinoma with or without total | - | 200 00 | - |
| \$714 | amentectarry | 6 | 368,60 | 6 |

OPERATIONS ON THE ENDOCRINE SYSTEM

| Code | | Asst | Surg | Anaes |
|-------|---|------|--------|-------|
| | THYROID GLAND | | | |
| | | | | |
| | Incision | | | |
| Z726 | Aspiration, thyroid cyst (I.O.P.) | | 24.20 | |
| Z727 | Percutaneous silicone core needle biopsy, (I.O.P.) | | 48.30 | 6 |
| Z771 | Aspiration biopsy, thyroid gland or nodule fine needle method (I.O.P.) | | 24.20 | |
| S786 | Abscess | | 69.60 | 4 |
| | | | | |
| | Excision | | | |
| | Biopsy | | | |
| S787 | Surgical | . 4 | 180.20 | 6 |
| | Thyroidectany | | | |
| \$788 | Total | | 512.00 | 8 |
| \$789 | Subtotal | | 401.40 | 7 |
| S790 | Hemi | | 307.20 | 7 |
| E880 | parathyroid(s) identification and re-implantation, add | | 155.60 | |
| E881 | - if requiring splitting of sternum, add | | 69.60 | |
| S791 | Excision of solitary nodule | . 6 | 253.95 | 6 |
| | DADATIANDOTD TIMABLE AND ADDENIAL CLANDS | | | |
| | PARATHYROID, THYMUS AND ADRENAL GLANDS | | | |
| | Excision | | | |
| S795 | Exploration and/or removal, parathyroids or parathyroid tumour | . 6 | 512,00 | 8 |
| S796 | - if requiring splitting of sternum | | 581.60 | 13 |
| E880 | - parathyroid(s) identification and re-implantation, add | | 155.60 | 13 |
| S797 | Thymectony | | 520.20 | 13 |
| S798 | Adrenalectomy or exploration - unilateral | | 364.50 | 10 |
| S799 | - bilateeral, with or without cophorectomy | | 565.20 | 11 |
| \$800 | Adrenalectomy - unilateral for pheochromocytoma | | 491.50 | 13 |
| Note: | When an adrenalectomy is performed in conjunction with a nephrectomy, and | . 10 | 751.30 | 13 |
| | is incidental to the removal of the kidney, there should be no additional | | | |
| | claim for the adrenalectomy. | | | |
| Z772 | Thymus transplant (I.O.P.) | | 69,60 | 4 |
| 2,72 | The ampliant fraction assessment assessment and a second assessment and a second assessment assessment assessment assessment as a second assessment as a second assessment as a second assessment as a second assessment as a second as a | | 07,00 | - |

OPERATIONS ON THE NERVOUS SYSTEM

| Code | | Asst | Surg | Anaes |
|--------------|---|------|------------------|----------|
| 1700 | Hypothermia - when employed, basic units for any procedure on nervous | | | |
| N100 | system | | | 25 |
| | BRAIN | | | |
| | Astrocytoma, oligodendroglioma, glioblastoma or metastatic tumour craniotomy plus excision | | | |
| N103 | - supratentorial | . 11 | 920.00 | 15 |
| N151 | - infratentorial | . 11 | 1061.70 | 15 |
| N152 | Craniotomy plus lobectomy | . 11 | 964.20 | 15 |
| E901 | With operating microscope, add | | 185.95 | |
| | Meningiama and other tumourous lesions, including pituitary tumours Craniotomy plus excision | | | |
| N102 | - supratentorial | - 11 | 1001 70 | 16 |
| N153 | - infratentorial or basal | 11 | 1061.70 | 15 15 |
| E901 | With operating microscope, add | . 11 | 185.95 | 13 |
| E902 | Lesion greater than 4 cm diameter, add to N102, N153 | | 322.80 | |
| E903 | Team fee for acoustic neuroma, same approach | 1 | 530,80 | |
| | Transphenoidal microscopic approach to the pituitary fossa for hypophysect | MIN | | |
| N111 | removal of adenoma or other tumours | . 11 | 1061.70 | 15 |
| 1/10E | Intracranial aneurysm repair | | | |
| N105 N154 | Carotid circulation - per vessel | . 11 | 1132.10 | 15 |
| E901 | Vertebrobasilar circulation (including aneurysm of vein of Galen) | . 11 | 1176.40 | 15 |
| 201 | Cerebral arteriovenous malformation | • | 185.95 | |
| | Craniotomy for obliteration and/or excision | | | |
| N106 | - supratentorial | . 11 | 1132.10 | 15 |
| N155 | - infratentorial | . 11 | 1176.40 | 15 |
| E901 | With operating microscope, add | | 185.95 | |
| | Removal of intracerebral and/or subdural hematoma in conjunction with a | | | |
| 5000 | ruptured intracranial aneurysm or arteriovenous malformation, add to | | | |
| E908 | NIOS, NIO6, NI54, NI55 | • | 199.10 | |
| N107 | Extracranial approach to include balloon catheter or embolization | - 11 | 720 00 | 15 |
| 14107 | techniques | . 11 | 738.90 | 15 |
| N218 | Superficial temporal artery | . 11 | 1017,40 | 15 |
| N156 | Occipital artery | | 1061.70 | 15 |
| E904 | Posterior fossaad | 1 | 208.10 | |
| E905 | Use of graft (autogenous vessel or synthetic)ad | 1 | 185.95 | |
| | Extracranial-intracranial long venous bypass (from internal carotid in the | | | |
| 1/1/22 | neck or any of the trunk vessels in the neck or chest to a major intra- | | 2.477.00 | 25 |
| N121 | cerebral vessel, i.e. vertebral, internal carotid, middle cerebral) Carotid-cavernous fistula | . 11 | 1477.80 | 15 |
| | Intracranial obliteration (to include combined cervical and intra- | | | |
| N108 | cranial procedure) | . 11 | 1061.70 | 15 |
| | Extracranial approach to include balloon catheter or embolization | | 2002 \$10 | 10 |
| N118 | techniques | . 11 | 645.50 | 15 |
| | Spontaneous intracerebral haemorrhage | | | |
| | Craniotomy plus removal | | | |
| N104 | - supratentorial | | 761.00 | 15 |
| N157 N120 | - infratentorial | | 853.60 416.15 | 15 15 |
| NIZU | Burr hole plus drainage | . 11 | 410.13 | 15 |
| | Craniotomy plus evacuation (to include interventriculostomy) | | | |
| N158 | - supratentorial | . 11 | 761.00 | 15 |
| N159 | - infratentorial | | 875.70 | 15 |
| N160 | Burr hole plus aspiration | | 344.90 | 15 |
| | Brain abscess: | | | |
| N117 | Craniotomy | . 11 | 920.00 | 15 |
| N115 | Burr hole aspiration | . / | 460.40 | 7 |
| Z818 | Subsequent aspiration through existing burn hole within 30 days | | 185.95 | |
| NI 13 | (1.0.P.) | . 11 | 530.80 | 11 |
| N109 | Hemispherectory | . 11 | 1247.60 | 15 |
| NI 10 | Lobectomy and/or excision of cortical scar for epilepsy | . 11 | 1450.80 | 15 |
| | | | | |

| | or and the nervous sister - cont d. | | | |
|--------------|--|-----|-------------------|--------|
| Code | · · | sst | Surg | Anaes |
| | BRAIN - Cont'd. | | | 741003 |
| 11: 00 | | | | |
| N130 N128 | Craniotomy plus midline commissurotomy | 11 | 875.70 | 15 |
| N129 | Repair of encephalocoele | 11 | 689.80 | 15 |
| N123 | Posterior fossa decompression for Arnold Chiari malformation | 11 | 831.50 | 15 |
| N119 | Stereotaxis - intracranial (to include ventriculography) | 11 | 1078.90 778.20 | 11 |
| ,,,,,, | Implantation or revision of stimulation pack or leads (peripheral nerve, | 11 | 110.20 | 11 |
| Z823 | brain, spinal cord) (I_O_P_) | | 265,40 | |
| Z824 | Removal of chronic surface or depth electrodes (I.O.P.) | | 230.20 | |
| Z813 | Burr hole plus needling of brain for biopsy (I.O.P.) | 7 | 256.40 | 7 |
| | Ventriculogram, (including burr holes, air or positive contrast) | | | |
| Z806 | (I.O.P.) | | 115.10 | |
| | Ventricular puncture through previous burr hole or fontanelle or puncture | | | |
| Z802 | and/or aspiration of cisterna magna (I.O.P.) | | 70.90 | 7 |
| Z825 | Ventriculoscopy (to include burr hole) (I.O.P.) | | 274.40 | 7 |
| E916 | - with biopsyadd | | 115.10 | |
| E917 E918 | - with interventriculostomyadd | | 115.10 | |
| Z819 | - with removal of foreign body | c | 115.10 | - |
| 4019 | External ventricular drainage (1.0.P.) | 5 | 185.95 | 5 |
| Z820 | Insertion of intracranial catheter or transducer for purposes of monitoring (I.O.P.) | 5 | 274.40 | 5 |
| Z812 | Subsequent revisions or replacements within 30 days (I.O.P.) each | 5 | 185.95 | 5 |
| | Re-opening of craniotomy for post-operative haematoma or infection, or for | , | 103.55 | 3 |
| N127 | removal of bone flap | 11 | 389.10 | 11 |
| | Intracranial duraplasty (greater than 2 cm. diameter)add to any | | 003120 | |
| E919 | intracranial procedure | | 208,10 | |
| | Intraoperative diagnostic or physiological monitoring for intracranial, | | | |
| | spinal or peripheral nerve procedures, (e.g. stimulation with recording, | | | |
| E920 | evoked potentials, ultrasound or impedance monitoring) | | 154.80 | |
| C001 | Repeat cranial procedure, applies to any intercranial procedure | | | |
| E921 | excluding those covered by N127 | | 185.95 | |
| | Cranio-Cerebral Injuries | | | |
| U.V.C | Non-operative care: | | | |
| 0.4.0 | Toperative ours. | | | |
| | Reduction of skull fracture: | | | |
| N139 | Simple, depressed | 7 | 322.80 | 7 |
| N140 | Compound | 11 | 438.30 | 11 |
| E912 | - with repair of dural lacerationadd | | 115.10 | 4 |
| | Extracerebral haematoma and/or hygroma: | | | |
| N143 | Drainage by burr hole(s) - unilateral | | 438.30 | 7 |
| N144 | Drainage and/or removal by craniotomy | 11 | 689.80 | 11 |
| | Cerebral injury | | | |
| N148 | Removal of intracerebral haematoma and/or debridement of traumatized brain (includes management of any skull fracture) | 11 | 761.00 | 15 |
| N149 | Removal of foreign body from brain | 11 | 761.00 | 15 |
| N150 | C.S.F. leak - intracranial repair (to include transsphenoidal approach) | 11 | 920.00 | 15 |
| N200 | Decompressive craniectomy (frontal, sub-temporal) | 11 | 530.80 | 11 |
| Z803 | Subdural tap(s) (I.O.P.) - unilateral | | 45.90 | |
| Z814 | Diagnostic burr hole(s) (I.O.P.) - uni or bilateral | 7 | 230.20 | 7 |
| | | | | |
| | SKULL | | | |
| | Repair of skull defect: | | | |
| N161 | Acrylic or metal cranioplasty | 11 | 486.60 | 11 |
| N201 | Rib graft cranioplasty (defect less than 7.5 cm) | 11 | 738.90 | 15 |
| N202 | Replacement of bone flap | 11 | 416.15 | 11 |
| N203 | Skull tumour, excision | 11 | 322.80 | 11 |
| N206 | - one suture | 11 | 371.90 | 11 |
| N207 | - multiple sutures | 11 | 486.60 | 15 |
| 1201 | Morcellation procedure | ** | 100.00 | 10 |
| N162 | | 11 | 371.90 | 11 |
| | | | - | |
| | | | | |

| Code | | Asst | Surg | Anaes |
|-------|--|------|--------|-------|
| | SKULL - Cont'd. | | | |
| N163 | - multiple sutures Lateral canthal advancement Unilateral | . 11 | 530.80 | 15 |
| N164 | - one surgeon | 11 | 601.30 | 15 |
| N165 | - two surgeons - major portion | | 371.90 | 15 |
| N166 | - lesser portion | - 11 | 300,60 | 13 |
| | Bilateral | | 300.50 | |
| N167 | - one surgeon | 11 | 822,50 | 15 |
| N168 | - two surgeons - major portion | 11 | 530,80 | 15 |
| N169 | - lesser portion | | 398,10 | 10 |
| N208 | Craniotomy for craniofacial repair | 11 | 920,00 | 15 |
| E922 | - with repair of frontonasal encephaloceleadd | | 185,95 | |
| | | | | |
| | ORBIT | | | |
| N211 | Craniotomy plus removal of orbital tumour | 11 | 964.20 | 15 |
| | Craniotomy plus orbital decompression (roof of orbit with or without | | | |
| N212 | lateral wall) | 11 | 902.75 | 15 |
| N213 | Craniotomy for decompression of optic nerve(s) | 11 | 964.20 | 15 |
| E901 | With operating microscope, add to N211, N213 | | 185.95 | |
| | | | | |
| | CAROTIO AND VERTEBRAL ARTERIES | | | |
| N220 | Carotid endarterectomy (with or without bypass and/or patch graft) | 10 | 647.20 | 10 |
| N223 | Vertebral endarterectomy | 10 | 689.80 | 10 |
| | Intraoperative cerebral blood flow determinations (with carotid en- | | | |
| E923 | darterectomy, etc.), add to N220, Z808 | | 115.10 | |
| Z815 | Temporal artery; biopsy, ligation or cryosurgery (I.O.P.) | | 93.00 | 4 |
| Z808 | Progressive carotid occlusion by Selverstone clamp (1.0.P.) | | 274.40 | 10 |
| Z307 | Removal of Selverstone clamp (I.O.P.) | 10 | 230.20 | 10 |
| | OPE CLASSIFIAN PROCEDURE | | | |
| N230 | CSF SHUNTING PROCEDURES | | 200 00 | |
| N209 | Shunting procedures, all types except those otherwise specified below | | 362.90 | 11 |
| N210 | Ventriculo-atrial shunt | | 407.10 | 11 |
| NZIU | Revision of CSF shunt - operative | 11 | 302,90 | 11 |
| N245 | Proximal end | 7 | 243,30 | 7 |
| N175 | Distal end (all shunts except ventriculo-atrial) | | 243.30 | 7 |
| N176 | Distal end - ventriculoatrial | | 287.50 | 7 |
| Z801 | Revision - non-operative | | 35.20 | , |
| 2001 | Conversion of shunt (e.g. ventriculoperitoneal to ventriculoatrial) - | | 33.20 | |
| N174 | includes removal of existing shunt | 7 | 362.90 | 7 |
| N246 | Removal of shunt - any type | | 158.90 | 7 |
| N247 | Ventriculo-cistemostany (Torkildsen) | | 460.40 | 11 |
| Z309 | Insertion of CSF reservoir (Ommaya) including burn holes (I.O.P.) | 11 | 208.10 | 11 |
| N249 | Third ventriculostomy | 11 | 566.10 | 11 |
| 12.15 | Injection of diagnostic or therapeutic agent into shunt apparatus | ** | 200.50 | ** |
| Z821 | (1.0.P.) | | 45.90 | |
| | , | | | |
| | CRANIAL NERVES | | | |
| | Percutaneous coagulation or glyceral injection of gasserian (trigeminal) | | | |
| N258 | ganglion or root-unilateral | 11 | 353.90 | 11 |
| | | | | |

| Code | | Asst | Surg | Anaes |
|--------------|---|------|--------|-------|
| | CRANIAL NERVES - Cont'd. | | | |
| N259 | V-Decompression or rhizotomy (partial or complete) trigeminal nerve VII-Differential section facial nerve for hemi-facial spasm (extra- | . 11 | 416.15 | 11 |
| N265 | cranial approach) | 6 | 300,60 | 6 |
| N266 | Anastomosis hypoglossal or accessory to facial nerve | 6 | 486.60 | 6 |
| E901 | With operating microscopeadd to N266, N267 Occipital and/or suboccipital craniectomy for compression, decompression | | 185.95 | |
| N267 | or section of cranial nerves | . 11 | 831.50 | 11 |
| N269 | XI-Division of nerves to sternomastoid in neck | | 252.30 | 6 |
| Z826 | Inferior dental neurectomy (I.O.P.) | . 3 | 158.90 | 4 |
| Z827 | Infraorbital or supraorbital neurectomy (I.O.P.) | . 3 | 136.80 | 4 |
| | PERIPHERAL NERVES | | | |
| | Exploration, decompression, division, excision, biopsy, neurolysis, | | | |
| M200 | transposition (including tumour and neuroma) | | 70 | |
| N188 | Minor nerve e.g. digital or cutaneous | . 4 | 132.70 | 4 |
| N285 | Major nerve (except carpal tunnel or ulnar at elbow) | . 4 | 221.20 | 4 |
| N282 | Brachial plexus (excluding thoracic outlet syndrome or cervical rib) | | 512.80 | 6 |
| N177 | Sciatic nerve in buttock | . 6 | 371.90 | 6 |
| N286 | Tumour or neuroma - major nerve | . 5 | 274.40 | 4 |
| N289 | Nerve suture - minor | | 158.90 | 4 |
| N287 | - major | . 4 | 371.90 | 4 |
| N183 | Nerve graft - minor | . 4 | 265.40 | 4 |
| N288 | - major | 4 | 530.80 | 4 |
| E899 | - for each additional cable, add to N288 | | 88,50 | |
| Z816 Z823 | Implantation of electrode for peripheral nerve stimulation | . 3 | 208.10 | 4 |
| | brain, spinal cord) I.O.P. | 6 | 265,40 | 8 |
| FOOC | Add 40% of basic fee for neurolysis, tumour excision, nerve suture or | | | |
| E906 E925 | graft when using operating microscope | | | |
| £925 | Add 30% to basic fee when repair delayed more than four weeks | | | |
| F000 | Intraoperative electrophysiological studies or functional nerve mapping, | | | |
| E900 | add | | 154.80 | |
| N290 | Carpal tunnel release | | 135.00 | 4 |
| N190 | Ulnar nerve decompression, transposition at elbow | . 4 | 185.95 | 4 |
| N283 | excision of cervical and/or first rib and to include scalenotomy Excision of Morton's or subcutaneous neuroma, glorus or small cutaneous | . 6 | 335.90 | 6 |
| N295 | nerve tumour | . 3 | 93,00 | 4 |
| E911 | Implantation of neuroma into bone or muscle - add 40% to N286, N295 | | 33.00 | 7 |
| | AUTONOMIC NERVOUS SYSTEM | | | |
| | Sympathectomy: - unilateral | | | |
| N300 | Cervica) | 6 | 300,60 | 6 |
| N301 | Cervicodorsa] | | 504.60 | 10 |
| N303 | - thoracic approach | | 371.90 | 13 |
| N304 | Lumbar | | 252.30 | 6 |
| | | | 202.00 | |

| Code | | Asst | Surg | Anaes |
|------|--|------|------------------|-------|
| | SPINAL CORD AND NERVE ROOTS | | | |
| | | | | |
| | Tumours: | | | |
| N317 | Extradural partial or total removal | . 8 | 761.00 | 10 |
| N314 | - one surgeon | 9 | 1017.40 | 13 |
| M137 | - two surgeons - thoracotomy | | 330.95 | |
| N313 | - excision | 9 | 875.70 | 13 |
| N318 | Intradural (extramedullary) partial or total removal | 8 | 964.20 | 10 |
| E914 | - three segments or moreadd | | 138.00 | |
| N319 | - Biopsy and/or decompression | 9 | 344.90 | 9 |
| N320 | - Removal | 9 | 1105.90 | 12 |
| E914 | - three segments or moreadd | | 138.00 | |
| | With operating microscope (applies to intradural or intramedullary | | | |
| E901 | tumours)add | | 185.95 | |
| | AV. malformation of cord | | | |
| | Excision or operative obliteration; with or without evacuation of | | | |
| N321 | haematoma | 9 | 1105.90 | 12 |
| E914 | - three segments or moreadd | | 138.00 | |
| E901 | With operating microscopeadd | | 185.95 | |
| Z300 | Myeloscopy (I.O.P.) | | 185.95 | |
| | | | | |
| | Decompressive Procedures | | | |
| | Applicable to all operative procedures for decompression of the spinal cord | | | |
| | and/or nerve roots, whether traumatic or non-traumatic, with the exception of tumours and arterio-venous malformations and other | | | |
| | exception of tumours and arterio-venous malformations and other | | | |
| | separately listed. | | | |
| | Posterior Spinal Decompressive Procedures | | | |
| R451 | Cervical hemilaminectomy for disc disease, with or without foraminotomy | 6 | 504,60 | 10 |
| | Lumbar hemilaminectomy for disc disease including removal of soft disc | | | |
| R457 | or osteophyte | | 368.60 | 8 |
| N185 | Posterior laminectomy one or two levels, cervical, thoracic, lumbar | . 6 | 533,30 | 9 |
| | Repeat posterior exploration or reopening of posterior exploration, more | | | |
| | than six months after original procedure, includes foraminotomy, | | | |
| N337 | discectarry or neurolysis | | 575.10 | 10 |
| E565 | Multiple levels, to R451, R457 only per additional leveladd | | 63,50 | |
| E566 | Bilateral, to R451, R457add | | 68.40 | |
| E914 | Laminectomy extending over 3 or more laminae, to N185, N337add | | 138.00 | |
| E915 | Foraminotomy, to R457, N185, per foramen decompressedadd | | 70.90 | |
| | | | | |
| | Anterior, Anterolateral or Posterolateral Spinal Decompressive Procedures | | 051 10 | |
| R447 | Simple anterior cervical discectomy | . 8 | 351.40 | 10 |
| R452 | Simple anterior lumbar discectomy | . 6 | 432.50 | 10 |
| | Anterior cervical spinal cord or nerve root decompression, including | | F00 00 | |
| N182 | removal of disc or vertebral body, single disc level | . 8 | 533.30 | 10 |
| | Anterolateral or posterolateral decompression, lumbar or thoracic spine, | | 055 00 | 10 |
| N186 | single disc level | . 9 | 955.20 | 13 |
| | For Thoracotomy or Taparotomy by separate surgeon use M137 (page 113), | | | |
| | \$312 (page 113). | | | |
| 5000 | Each additional disc level decompressed, to R447, R452, N182, N186 | | 220 m | |
| E928 | add | | 230.20 | |
| | | | | |
| | Fusions Application of the second of the sec | | | |
| | Anterior cervical interbody fusion by same surgeon, to R447, N182, per | | 70.00 | |
| E929 | disc leveladd | | 70.90 | |
| | Fusion by same surgeon, to any procedure except anterior cervical interbody | | | |
| | fusion, | | 21/ 60 | |
| E567 | - one leveladd | | 214.60 273.20 | |
| E568 | - two or more levelsadd | | 2/3.20 | |
| | | | | |

| Code | | Asst | Surg | Anaes |
|--------------|---|------|-----------------|-------|
| | SPINAL CORD AND NERVE ROOTS - Cont'd. | | | |
| | Fusion by different surgeon: | | | |
| R493 | - one level | | 274.40 | |
| R494 | - two or more levels | | 322.80 | |
| E574 | Repeat fusion, to any fusion, not to apply to N337, | | 180.20 | |
| E548 | With instrumentationadd Dural opening and repair: | | 121.85 | |
| E907 | Opening of dura (associated with any decompressive procedure)add | | 137.20 | |
| E926 | Spinal duroplasty (applies to any spinal procedure)add | | 208.90 | |
| | Other Laminectomies (uni- or bilateral) | | | |
| | Laminectomy for intradural neurolysis or unusual lesions e.g. dias- | _ | *** | |
| N336 | tematomyelia, tethered conus, intramedullary hematoma, etc | . 7 | 690.60 | 8 |
| E914 | AVM, or other decompressive laminectomy)add | | 138,00 | |
| E901 | With operating microscopeadd | | 185.95 | |
| N323 | Re-opening of laminectomy for post-operative hematoma or infection | . 7 | 322.80 | 8 |
| N192 | Re-opening of laminectomy for repair of CSF leak | . 7 | 460.40 | 8 |
| | Spinal Fractures | | | |
| Z236- | Skull calipers (I.O.P.) | | 44.20 | |
| 7241 | Halo traction (I.O.P.) | | 70.90 | |
| Z246 | Reapplication of Halo traction (I.O.P.) | | 44.20 | |
| E562 | Counter traction pins or vestadd | | 94.60 | |
| F103 | Closed reduction | . 5 | 178,60 | 5 |
| F105 | Open reduction, posterior approach | . 5 | 274.40 | 10 |
| F107 | anterior approach | | 322.80 | 10 |
| E913 | With spinal cord injury, add (when total care by operating surgeon) With irrigation, includes opening of dura, to fractures when combined with | | 137.20 | |
| E927 | decompressive proceduresadd | | 274.40 | |
| E567 | Fusion by same surgeon - one leveladd | | 214.60 | |
| E568 | - multiple levelsadd | 1 | 273.20 | |
| E929 | - anterior cervical interbody fusion, per leveladd | | 70.90 484.10 | 10 |
| R419 | Fusion of C1-2 | . 0 | 274.40 | 10 |
| R493 R494 | rusion by different surgeon - one level | | 322.80 | |
| R494 | - multiple levelsadd - anterior cervical interbody fusion, per | | 322.00 | |
| E924 | leveladd | 1 | 106.10 | |
| E548 | With instrumentationadd | | 121.85 | |
| 2010 | | | | |
| | Syringomyelia Posterior fossa craniectomy and plugging of obex (to include decompression | | | |
| N193 | of Arnold Chiari malformation if present) | | 875.70 | 15 |
| 14233 | Intracranial duraplasty (greater than 2 cm. diameter), add to any intra- | | 0.00.0 | - |
| E919 | cranial procedure | | 208.10 | |
| N194 | Syringo subarachnoid shunt | . 8 | 689.80 | 10 |
| N195 | Terminal ventriculostomy | . 8 | 689.80 | 10 |
| N196 | Syringopleural/syringoperitoneal shunt | . 9 | 805.30 | 12 |
| E901 | With operating microscope (add to N193-N196) | | 185.95 | |
| | Ablative and Stimulation Procedures | | | |
| N329 | Percutaneous cordotamy or tractotamy | . 6 | 407.10 | 8 |
| N330 | Bischoff's longitudinal myelotomy, etc.) uni- or bilateral | . 8 | 831.50 | 10 |
| N341 | Medullary spinal trigeminal tractotomy | | 875.70 | 15 |
| E901 | With operating microscope | | 185.95 | |
| Z244 | Percutaneous diagnostic stimulation of brain or spinal cord (I.O.P.) | . 6 | 283.40 | 8 |
| Z823 | Implantation or revision of stimulation pack or leads (peripheral nerve, | | | |
| | brain, spinal cord) (I_O_P_) | . 6 | 265.40 | 8 |
| N324 | Implantation of spinal cord stimulating electrode by laminectomy | . 8 | . 499.70 | 10 |

| Code | | Asst | Surg | Anaes |
|---------------|---|------|------------------|-------|
| | SPINAL CORD AND NERVE ROOTS - Cont'd. | | | |
| | Removal of any stimulation pack or electrode from peripheral nerve, brain | | | |
| N332 Note: | or spinal comd NG24, NG32 for "multiple sclerosis" are not a benefit of OHIP except for relief of intractable pain. | 6 | 195.00 | 6 |
| | Spinal intradural anterior and/or posterior rhizotomy, unilateral or | | | |
| N331 | bilateral, any number of roots | . 8 | 557.05 | 10 |
| N333 | includes use of operating microscope Percutaneous vertebral facet denervation or intercostal neurectomy (1.0.P.) | . 8 | 884.70 | 10 |
| Z810 | - one level | | 119,60 | 4 |
| E909 | - additional levels - each Percutaneous radiofrequency posterior rhizotomy for pain or spasticity | | 61.30 | |
| N340 | - one or two roots | | 234.30 | 8 |
| E910 Z817 | - three or more roots, each | | 61.80 70.90 | |
| | Meningocele and Meningomyelocele | | | |
| N334 | Repair of meningocele | | 371.90 | 9 |
| N335 | Repair of meningomyelocele - one surgeon | . 7 | 504.60 | 9 |
| N338 | - two surgeons - neurosurgeon | | 371.90 | 9 |
| N339 N197 | - reconstructive surgeon | | 300.60 716.80 | 9 |
| E901 | With operating microscope (add to M197, N335 or N338) Repair of anterior sacral meninoscele – posterior approach (to include | | 185.95 | 9 |
| N198 | release of tethered spinal cord) | | 738.90 | 9 |
| N199 | Repair of intraspinal meningocele (extradural cyst) | . 7 | 738.90 | 9 |

| | OPERATIONS ON ORGANS OF SPECIAL SENSES | | | |
|---------------|--|------|------------------|--------|
| Code | | Asst | Surg | Anaes |
| | OPERATIONS ON THE EYE | | | |
| Z850 | Examination (when sole procedure) and unlisted minor procedures under general anaesthesia (I.O.P.) | | 56.60 | 4 |
| | EYEBALL | | | |
| | Excision | | | |
| E108 | Enucleation, donor eye, post-mortem (one or both) | | 113,00 | |
| C104 | Repair | | | |
| E104 E105 | Removal of intraocular foreign body Non-magnetic - posterior segment Penetrating wound | 4 | 321.50 364.95 | 6 |
| E106 E107 | - with prolapse of intraocular tissue without prolapse of intraocular tissue | 4 | 225.70 183.10 | 6 |
| | CORNEA | | | |
| | Incision | | | |
| Z851 | Paracentesis (1.0.P.) | | 45.10 | 4 |
| | Removal embedded foreign body (I.O.P.) | | 43,10 | 7 |
| Z847 Z848` | - local anaesthetic - one foreign body | | 22.50 | |
| Z852 | - two or more foreign bodies (see Preamble para B.32 - general anaesthetic | | 45.10 | 4 |
| | Chelation of band keratopathy with EDTA (I.O.P.) | | 40.10 | • |
| Z849 Z863 | - local anaesthetic | | 22.50 | 4 |
| 2003 | | | 45.10 | 4 |
| E206 | Excision Phonorism circle (smileteral) | | 76 60 | 4 |
| E205 | Pterygium - simple (unilateral) | 4 | 76.60 208.90 | 4 |
| E207 | - with lamellar graft | 4 | 364.95 | 8 |
| E117 | Keratectony | 4 | 208.50 | 4 |
| E118 | Excision of dermoid - with partial keratectomy | | 208.50 | 4 |
| E119 | - with lamellar graft | 4 | 364.95 | 8 |
| Z871 | - local anaesthetic | | 22.50 | |
| Z853 | - general anaesthetic | | 45.10 | 4 |
| | Replacement | | | |
| | Corneal transplant | | | |
| E121 E951 | - penetrating | | 478.40 | 8 |
| E122 | - with artificial prosthesis, add | | 45.10 364.95 | 8 |
| E123 | Division of iris to cornea | | 138.85 | 4 |
| | SCLERA | | | |
| | OOLAV1 | | | |
| | Incision | | | |
| E127 E128 | Sclerotomy, posterior | 4 | 113.00 269.10 | 4 6 |
| | | | | |
| E131 | IRIS AND CILIARY BODY | 4 | 195,80 | 4 |
| E131 | Laser iridotomy Laser angle surgery | | 251.50 | 4 |
| E130 | Iridectomy - surgical - when sole procedure | 4 | 230.20 | 4 |
| E132 | Glaucoma filtering procedures | 4 | 269.10 | 6 |
| E136 E133 | - with intraocular implant of seton, add | | 63.90 156.90 | 4 |
| E135 | Ciliary body re-attachment | 4 | 434.20 | 8 |
| | | | | |
| | CRYSTALL INE LENS | | 1 | |
| | Incision | | | |
| | Needling (discission) | | | |
| E137 E139 | - primary or subsequent | 4 | 138.85 138.85 | 5 4 |
| E139 | Capsulotomy | 4 | 130.03 | 4 |

| | OPERATIONS ON ORGANS OF SPECIAL SENSES - Cont'd, | | | |
|--------------|--|------|------------------|-------|
| Code | | Asst | Surg | Anaes |
| | CRYSTALLINE LENS - Cont'd. | | | |
| Е | excision | | | |
| | Cataract (to include retrobulbar injection when administered by surgeon) | | | |
| E140 | - all types of, by any procedure | . 4 | 364.95 | 8 |
| E141 | - dislocated lens extraction | . 4 | 434.20 | 6 |
| E950 E138 | - insertion of intraocular lens, extra | | 113.00 | _ |
| 6130 | - excision of secondary membrane with comeal section following | . 4 | 230,20 | 6 |
| E143 | cataract extraction | . 4 | 225.70 | 6 |
| E144 | Removal of intraocular lens | 4 | 225.70 | 6 |
| E145 | Repositioning surgical of dislocated intraocular lens | | 113.00 | 4 |
| E146 | Insertion of secondary intraocular lens | . 4 | 251.50 | 8 |
| | VITREOUS | | | |
| E147 | Vitreous transplant, implant or anterior vitrectomy | . 4 | 225.70 | 6 |
| E148 | Vitrectary by infusion suction cutter technique | 4 | 521.00 | 8 |
| | Preretinal membrane peeling or segmentation to include posterior vitrectors | / | 02100 | |
| E142 | and coagulation | | 553.00 | |
| E938 | with transscleral retinal suturing, add | | 183.50 | |
| E1 10 | Vitreous aspiration, posterior with needle for culture and/or injection of | | 156.60 | |
| E149 E940 | medication, with or without cryopexy | , 4 | 156.50 | 5 |
| | Anterior vitrectomy when done in conjunction with another intraocular procedure, add | | 76.60 | |
| | p. 000000 09 MM 0000000000000000000000000 | | 70.00 | |
| | RETINA | | | |
| | Re-attachment of retina and choroid by diathermy, photo-coagulation or | | | |
| E151 | cryopexy as an initial procedure | . 6 | 242.90 | 6 |
| C150 | Scienal resection or buckling procedure - with or without diathermy, | | | |
| E152 | photocoagulation or cryopexy, primary or subsequent procedure | . 6 | 478.40 | 6 |
| | Secondary operation following unsuccessful operation or fresh detachment in the same eye by a different surgeon with or without diathermy, | | | |
| E153 | photocoagulation or cryopexy | 6 | 547.60 | 6 |
| E161 | Removal of scleral implant | | 138.85 | 4 |
| E154 | Photocoagulation (xenon, argon laser, etc.) - one eye | | 156.90 | 6 |
| E155 | Cryopexy - extraocular or sub-conjunctival - one eye | | 156,90 | 6 |
| | COMMONA AD MARCH CC | | | |
| | EXTRAOCULAR MUSCLES | | | |
| R | epair | | | |
| | Strabismus procedures | | | |
| E159 | - one or two muscles, one or both eyes | | 225.70 | 5 |
| E162 | - three or more muscles, one or both eyes | | 269.10 | 5 |
| E949 | - for adjustable suture, add | | 45.10 | |
| E952 | strabismus procedure (more than two previous repairs by different | | 45.10 | |
| C332 | surgeon), add | | 43.10 | |
| | OR8IT CR8IT | | | |
| | | | | |
| | Incision | | | |
| E164 | Drainage of abscess | • | 170.40 | 6 |
| | Excision | | | |
| E102 | Enucleation, with or without primary implant | . 4 | 225.70 | 4 |
| E103 | Evisceration, with or without primary implant | | 225.70 | 4 |
| E171 | Exenteration | | 255.60 | 6 |
| E941 | - with major plastic repair, add | | 255.60 | |
| E181 | Secondary orbital implant | . 4 | 320.30 | 4 |
| 53.66 | Tumour or foreign body - anterior route | 4 | 225,70 | 6 |
| E166 E167 | - moctaging exposure | 4 | 407.55 | 6 |
| E172 | - posterior exposure | | 138.85 | 4 |
| E168 | Bionsy (nosterior exposure) | | 225.70 | 4 |
| E165 | Lateral orbitotomy (Kronlein) | . 3 | 364.95 | 6 |
| E169 | Decompression - two walls | . 4 | 389.90 | 6 |
| E170 | - three walls | . 4 | 407.55 | 6 |
| | December which | | | |
| £160 | Reconstruction Dermis fat graft - immediately following enucleation | | 163.80 | |
| E160 E163 | - delayed | | 443.20 | 6 |
| E176 | Formix reconstruction | | 177.35 | 4 |
| E177 | - with mucous membrane graft | | 276.90 | 4 |
| E178 | Free mucous membrane graft - full thickness | • | 191.70 | 4 |
| E179 | - split thickness | • | 255,60 320,30 | 4 |
| E180 | Alloplastic volume replacement | • | 360+30 | ** |
| | Repair - for E173, E174, E175, see page 88. | | | |

| | OPERATIONS ON ORGANS OF SPECIAL SENSES - Cont'd. | | | |
|--------------|--|------|-----------------|-------|
| Code | | Asst | Surg | Anaes |
| | EYELIDS | | | |
| | Incision | | | |
| | Orainage of abscess (I.O.P.) | | | |
| Z854 | - local anaesthetic | | 22.50 | |
| Z855 | - general anaesthetic | | 56.50 | 4 |
| | THE RESERVE THE PARTY OF THE PA | | | |
| | Excision | | | |
| 7074 | Chalazion - single or multiple (I.O.P.) | | 20.50 | |
| Z874 Z856 | - local anaesthetic | | 22.50 56.60 | 4 |
| 7857 | Epilation – by hyfrecator, electrolysis (I.O.P.) | | 22,50 | 4 |
| Z858 | - by cryopexy | | 56.60 | 4 |
| 2000 | Verruca, papilloma, keratosis, etc. (I.O.P.) - see page | | 00,00 | |
| | Lid Tumours including Xanthelasma or Unlisted Plastic Procedures - | | | |
| | see page . | | | |
| | The second control of the control of | | | |
| | Suture | | | |
| E190 | Tarson haphy | | 95.80 | 4 |
| E191 | Double adhesion | | 138.85 | 4 |
| | Danain | | | |
| E192 | Repair | 4 | 269.10 | 4 |
| E192 | Ptosis | 4 | 338.30 | 6 |
| E194 | Distichiasis - unilateral | 4 | 208.10 | 4 |
| E195 | Trichiasis, repair by tarsal transplantation | 4 | 208.10 | 4 |
| E196 | Entropion, other than Zeigler puncture | | 225.70 | 4 |
| E945 | - repeat by second surgeon, add | | 45.10 | |
| E948 | - with mucous membrane graft, add | | 95.80 | |
| E197 | Ectropion, other than Zeigler puncture | 4 | 225.70 | 4 |
| E945 | - repeat by second surgeon, add | | 45.10 | |
| 70.00 | - with skin graft, see page 72. | | 20 50 | 4 |
| Z860 | Zeigler punctures (for entropion/ectropion) (I.O.P.) | | 22.50 113.00 | 4 |
| E199 E198 | Laceration, full thickness | | 225.70 | 4 |
| E221 | Laceration of eyelid including levator palpebrae superioris with ptosis | 4 | 283.40 | 4 |
| LZZI | Blepharoplasty - OHIP authorization necessary | - | 200810 | |
| | - excision of skin, with or without partial excision of the orbicularis | | | |
| E200 | oculi muscle - one lid | | 70.90 | 4 |
| | - same as E200 plus removal of orbital fat and/or lid fold recon- | | | |
| E201 | struction - one lid | 4 | 176.90 | 4 |
| E211 | Lid lengthening procedure | 4 | 156.50 | 4 |
| E953 | - with scleral graft, add | 4 | 69.40 | 4 |
| E222 E942 | Primary closure of full thickness lid defect | 4 | 45.95 | 4 |
| E942 | - with cantholysis, add - with releasing rotation flap including cantholysis, add | | 76.60 | |
| E223 | Tarsoconjunctival flap and skin graft (Hughes) | 4 | 416.60 | 6 |
| E224 | - second stage | | 93.00 | 4 |
| E225 | Lower or upper evelid bridge flap | 4 | 416.60 | 6 |
| E226 | - second stage | | 93.00 | 4 |
| E227 | Temporal rotation flap | 4 | 354,30 | 6 |
| E944 | - with free posterior lamellar graft, add | - | 150.70 | 0 |
| E228 | Free tarsal, scleral or cartilage graft with local skin mobilization | 6 | 460,80 | 8 |
| E229 | Free composite eyelid graft | 6 | 460.80 | 4 |
| E230 | Medial canthoplasty (skin and muscle) | 4 | 221.00 | 1 |
| E231 | Tendon repair only | 4 | 230,20 | 4 |
| E232 | Fixation to bone | 4 | 354.30 | 6 |
| £233 | - when done in conjunction with another procedure | | 131.50 | 70. |
| | Lateral canthal surgery | | | |
| E234 | Canthotomy - not chargeable with E140, E141 | | 44.30 | 4 |
| E235 | Cantholysis - when primary procedure | | 92.60 | 4 |
| E236 | Lateral canthopexy | | 175.30 | 4 |
| E930 | - when done in conjunction with another procedure | | 87.20 | |
| | | | | |

| | OPERATIONS ON ORGANS OF SPECIAL SENSES - Cont'd. | | | |
|--------------|--|-------|------------------|---------|
| Code | | st | Surg | Anaes |
| | - | ,,,,, | 3019 | 74 Idea |
| | CONJUNCTIVA | | | |
| U.V.C | . Removal of foreign body | | visit fe | es |
| | | | | |
| | Excision | | | |
| E208 | Peritomy (Gunderson conjunctival flap) | | 95,80 | 4 |
| Z861 | Biopsy (I.O.P.) | | 22.50 | 4 |
| | D | | | |
| E210 | Repair Excision and monain of conjunctival logica | | 50.00 | |
| E948 | Excision and repair of conjunctival lesion | | 69,20 95,80 | 4 |
| | | | 93,00 | 4 |
| | LACRIMAL TRACT | | | |
| | Incision | | | |
| Z862 | Dacryocystotomy - general anaesthetic (I.O.P.) | | 45.10 | 4 |
| Z917 | Three "Snip" punctum procedure (I.O.P.) | | 56.60 | 4 |
| | Excision | | | |
| E215 | Dacryocystectomy | 4 | 225,70 | 4 |
| | | | | |
| | Repair | | | |
| E216 | Lacerated canaliculus | | 100.00 | |
| E217 | - immediate repair | 4 | 182.30 | ·5 |
| E218 | Dacryocystorhinostomy | 5 | 295,30 364,95 | 5 |
| E939 | - repeat procedure by second surgeon, add | , | 75.40 | 3 |
| | - with lacrimal bypass procedure (e.g. Lester Jones) or canalicular | | | |
| E954 | reconstruction, add | | 69.40 | |
| E219 | Lacrimal bypass procedure (e.g. Lester Jones) | | 150.05 | |
| 5213 | - when sole procedure (both stages) | | 156.05 | 4 |
| | Manipulation (I.O.P.) | | | |
| Z901 | Irrigation of nasolacrimal system - unilateral or bilateral | | 17,60 | |
| | Probing and dilation of duct, initial or repeat | | | |
| Z902 | Local anaesthetic, unilateral | | 17.60 | |
| Z864 Z865 | General anaesthetic - unilateral or bilateral | | 69.40 | 4 |
| Z918 | - with insertion of inlying tube or filament | | 138,85 | 4 |
| 210 | THE THEORY OF LEADING CORES COMES CO | | 43.10 | |
| | OPERATIONS ON THE EAR | | | |
| | Preamble: | | | |
| | (1) When debridement of ears under microscopy is carried out for access | | | |
| | purposes only, no claim should be made for the debridement. If debridement of ears under microscopy is carried out because of | | | |
| | pathology, a claim should be made for this service. | | | |
| | EXTERNAL EAR | | | |
| | Endoscopy | | | |
| U.V.C | Removal of foreign body - simple | | visit fe | |
| Z366 E302 | complicated - general anaesthetic (I.O.P.) requiring post auricular or endaural incisions | | 43.40 172.85 | 4 |
| E302 | - from middle ear space | | 172.85 | 4 |
| Z906 | Removal of drainage tube(s) - general anaesthetic (I.O.P.) | | 30,30 | 4 |
| | Debridement of mastoid cavities and/or repair of small perforation under | | | |
| | microscopy but not for removal of cerumen for "access only" to the | | | |
| Z907 | tympanic membrane (I.O.P.) | | 22.50 | |
| Z908 | - under general anaesthetic (I.O.P.) - when sole procedure performed | | 43.40 | 4 |
| | Incision | | | |
| 2909 | Biopsy, ear canal (I.O.P.) | | 21.90 | |
| Z846 | - general anaesthetic (if sole procedure performed) | | 43.40 | 4 |
| | | | | |
| E317 | Incision and drainage of extensive hematoma of pinna under general | | 119.60 | 4 |
| E305 | anaesthetic | | 132.70 | 4 |
| E306 | Radical surgery for perichondritis | | 249.00 | 5 |
| ,,,,, | 3-3 | | | |
| | Excision | | | |
| Z904 | Local excision, polyp - office (I.O.P.) | | 22.50 | |
| Z905 | - hospital (I.O.P.) | | 43.40 147.45 | 4 |
| E300 E301 | Resection of pinna – with primary closure | | 210.90 | 4 |
| 5001 | - HIM! 10001 110p 000000000000000000000000000 | | | |

| | OPERATIONS ON ORGANS OF SPECIAL SENSES - Cont'd. | | | |
|--------------|---|------|------------------|--------|
| Code | | Asst | Surg | Anaes |
| | EXTERNAL EAR - Cont'd. | | | |
| | Exostosis, simple endomeatal surgery and removal and drilling out of | | | |
| E311 | exostosis | | 168.75 | 4 |
| E312 | - with multiple removal with necessary grafting | | 210.90 | 4 |
| E313 | - post auricular approach | | 253.95 | 5 |
| Z903 | Pre-auricular sinus (1.0.P.) | • | 28.30 | 5 |
| E309 | - requiring general anaesthetic | • | 177.35 | 5 |
| | Repair | | | |
| F207 | Congenital defects | - | 107 20 | - |
| E307 E308 | external - minor | | 187.20 294.90 | 5 5 |
| E310 | Otoplasty for correction of outstanding ears - unilateral | | 199.10 | 5 |
| E304 | Total ear reconstruction with cartilage graft - (Brent technique) | . 4 | 529.20 | 9 |
| Note: | E304, E307, E308 - Descriptive details of procedure (e.g. operative report | | | |
| | should be submitted with claims for professional assessment (see | 3 | | |
| | Surgical Preamble, paragraph 17). E310 - this procedure is not a benefit of OHIP for patients 18 years of age | | | |
| | or older. | | | |
| E314 | Meatoplasty or canalplasty for congenital malformation | | 253.95 | 5 |
| E955 | - with grafting of canal, add | | 172.85 | 1 |
| E956 | with tympanoplasty and/or ossiculoplasty, and/or mastoidectomy, add . | • | 341.60 | 2 |
| | MIDDLE EAR | | | |
| | Introduction (I.O.P.) | | | |
| | Eustachian catheterization | | | |
| Z910 | Unilateral - local anaesthetic | | 5.30 | |
| Z911 | Unilateral or bilateral - general anaesthetic | • | 30.30 | 4 |
| | Incision (I.O.P.) | | | |
| Z912 | Myringotomy, to include aspiration when indicated - unilateral | | 35.80 | 4 |
| | - with insertion of ventilation tube using operating microscope | | | |
| Z914 | - unilateral | | 67.20 | 4 |
| | Funicion | | | |
| | Excision Mastoidectony | | | |
| E320 | Cortical mastoidectomy | . 4 | 294.90 | 6 |
| E322 | Modified or radical mastoidectomy | . 4 | 438.30 | 7 |
| E315 | Revision mastoidectomy with revision of middle ear | . 4 | 472.70 | 7 |
| E946 E959 | - with mastoid cavity obliteration (E320, E322 or E315), add | | 90 . 90 | |
| E960 | with meatoplasty and/or canalplasty, add with ossiculoplasty (E320, E322 or E315), add | • | 72.90 | |
| 2300 | Will 03310010p1030y (2020) 2022 or 2030/5 000 000000000000000000000000000000 | | | |
| | Repair | | | _ |
| E323 | Myringoplasty | • | 178.60 | 5 7 |
| E336 E337 | Tympanoplasty - Type 1 (myringoplasty with exploration of middle ear) with ossiculoplasty | | 294,90 | 7 |
| E957 | - with mastoidectomy, add | | 118.00 | |
| E959 | with meatoplasty and/or canalplasty, add | , | 90.90 | |
| E333 | Ossiculoplasty | . 4 | 347.30 | 7 |
| E325 | Facial nerve decompression | . 4 | 548.90 843.80 | 9 |
| E326 E327 | Closure of mastoid fistula | | 215.00 | 4 |
| E328 | Tympanotomy | | 202.30 | 4 |
| E329 | Tympanic neurectomy | | 316.20 | |
| E316 | Tympanotomy with fistula repair | • | 337.50 | 6 |
| E324 | Tympanotomy with insertion of "permanent" ventilation tube | • | 223.60 | 4 |
| | INNER EAR | | | |
| F220 | Incision | | 160 60 | 7 |
| E332 | Labyrinthotomy or labyrinthectomy (including Fick procedure) | • | 468.60 | 7 |
| | Repair | | | |
| E334 | Stapes mobilization, unilateral | • | 316.20 | 6 |
| E335 | Stapedectony with prosthesis | | 468.60 | |
| E338 | Singular nerve section | . 4 | 565.20 565.20 | 9 |
| E339 E345 | Endolymphatic shunt or sac decompression | | 1054.70 | 9 |
| E343 | importar sono rescuriori | | | |

O. Reg. 745/86, s. 3.

HEALTH INSURANCE ACT

O. Reg. 746/86. General. Made—December 18th, 1986. Filed—December 19th, 1986.

REGULATION TO AMEND REGULATION 452 OF REVISED REGULATIONS OF ONTARIO, 1980 MADE UNDER THE HEALTH INSURANCE ACT

- 1. Subsection 47 (3j) of Regulation 452 of Revised Regulations of Ontario, 1980, as made by section 1 of Ontario Regulation 388/86, is revoked and the following substituted therefor:
- (3j) The amount payable by the Plan for the services prescribed in subsection (1) is, where the services are

provided to an insured person on or after the 1st day of April, 1986 up to and including the 31st day of December, 1986, the fee listed for such services in the following fee Schedule:

- 2. Oculo-Visual Re-Assessment 19.90
- 3. Partial Oculo-Visual Assessment 13.10
- (3k) The amount payable by the Plan for the services prescribed in subsection (1) is, where the services are provided to an insured person on or after the 1st day of January, 1987, the fee listed for such services in the following fee Schedule:
 - 1. Oculo-Visual Assessment \$34.70
 - 2. Oculo-Visual Re-Assessment 20.70
 - 3. Partial Oculo-Visual Assessment 13.65

O. Reg. 746/86, s. 1.

(9929)

1

ONTARIO DRUG BENEFIT ACT, 1986

O. Reg. 747/86. General. Made—December 18th, 1986. Filed—December 19th, 1986.

REGULATION TO AMEND ONTARIO REGULATION 689/86 MADE UNDER THE ONTARIO DRUG BENEFIT ACT, 1986

1.—(1) Part B of Schedule 1 to Ontario Regulation 689/86 is amended by striking out,

Phenylbutazone 100mg Tab .0077 021660 Novobutazone NOP 093041 Phenylbutazone DTC

on page 2516 under the heading "28:00 Central Nervous System Drugs" and sub-

Phenylbutazone 100mg Tab .0077

010502 Butazolidin GEI
021660 Novobutazone NOP
093041 Phenylbutazone DTC
312789 Apo-Phenylbutazone APX.

312789 Apo-Phenylbutazone

(2) Part B of the said Schedule 1 is further amended by striking out,

heading "28:08:00 Analgesics" and inserting in lieu thereof:

Glucose Oxidase Reagent Stick-20 Pk 9.5900

+980684 Glucoscan/GM

LIF

APX

O. Reg. 748/86

Glucose Oxidase Reagent Stick-50 Pk

242

+980676 Glucoscan

23.9750

on page 2536 under the heading "36:00 Diagnostic Agents" and subheading "36:26:00 Diabetes Mellitus" and inserting in lieu thereof:

| Glucose Oxidase Reagent Stick-20 Pk | +980684 Glucoscan/GM | LIF | 10.4600 |
|---|----------------------|-----|---------|
| Glucose Oxidase Reagent Stick-100 Pk | +980722 Glucoscan/GM | LIF | 47.9500 |
| Glucose Oxidase Reagent Stick-50 Pk | +980676 Glucoscan | LIF | 25.9600 |
| Glucose Oxidase Reagent Stick-100 Pk | +980676 Glucoscan | LIF | 47.9500 |

(3) Part B of the said Schedule 1 is further amended by striking out,

Octyl Dimethyl PABA & Ethyl Dihydroxypropyl PABA

.0249

+607851 Sunstop

WAM

on page 2579 under the heading "84:00 Skin and Mucous Membrane Preparations" and subheading "84:24:00 Emollients, Demulcents and Protectants".

(4) Part B of the said Schedule 1 is further amended by striking out,

 Methoxsalen
 .3500

 10mg Cap
 +007269 Oxsoralen
 ICN

 +646237 UltraMOP
 CDM

on page 2583 under the heading "84:00 Skin and Mucous Membrane Preparations" and subheading "84:36:00 Miscellaneous Skin and Mucous Membrane Agents" and inserting in lieu thereof:

 Methoxsalen 10mg Cap
 +007269 Oxsoralen
 ICN

 Methoxsalen 10 mg Cap
 +646237 UltraMOP
 CDM

- 2. A reference in this Regulation to any page number is a reference to that page (foot pagination) in *The Ontario Gazette* dated the 13th day of December, 1986.
- 3. This Regulation shall be deemed to have come into force on the 1st day of December, 1986.

(9930)

PRESCRIPTION DRUG COST REGULATION ACT, 1986

O. Reg. 748/86. General. Made—December 18th, 1986. Filed—December 19th, 1986.

REGULATION TO AMEND
ONTARIO REGULATION 690/86
MADE UNDER THE
PRESCRIPTION DRUG COST REGULATION ACT, 1986

1.—(1) Schedule 1 to Ontario Regulation 690/86 is amended by striking out,

Phenylbutazone 100mg Tab

021660 Novobutazone NOP 093041 Phenylbutazone DTC 312789 Apo-Phenylbutazone APX

on page 2612 under the heading "28:00 Central Nervous System Drugs" and subheading "28:08:00 Analgesics" and inserting in lieu thereof:

Phenylbutazone 100mg Tab

010502 Butazolidin GEI 021660 Novobutazone NOP 093041 Phenylbutazone DTC 312789 Apo-Phenylbutazone APX

(2) The said Schedule 1 is further amended by striking out,

Methoxsalen 10mg Cap

+007269 Oxsoralen +646237 UltraMOP

on page 2637 under the heading "84:00 Skin and Mucous Membrane Preparations" and subheading "84:36:00 Miscellaneous Skin and Mucous Membrane Agents".

2.—(1) Part B of Schedule 2 to the said Regulation is amended by adding,

Butazolidin

100mg Tab

GEI 010502

.1780

ICN

CDM

on page 2649 after,

Buscopan

10mg Tab

BOE 363812

.1534

(2) The said Part B of Schedule 2 is further amended by striking out,

Glucoscan Glucoscan/GM

Stick-50 Pk Stick-20 Pk

LIF 980676 23,9750 L1F 980684 9.5900

on page 2658 after.

Glucophage

500mg Tab

NRD 314552

.1368

and inserting in lieu thereof:

Glucoscan Glucoscan Glucoscan/GM Glucoscan/GM Stick-50 Pk Stick-100 Pk Stick-20 Pk Stick-100 Pk

LIF 980676 LIF 980714 LIF 980684 LIF

25,9600 47.9500 10.4600 47,9500

(3) The said Part B of Schedule 2 is further amended by striking out,

Sunstop

6% & 4% Lot

WAM 607851

980722

.0249

on page 2680.

3. A reference in this Regulation to any page number is a reference to that page (foot pagination) in *The Ontario Gazette* dated the 13th day of December, 1986.

(9931)

RESIDENTIAL RENT REGULATION ACT, 1986

O. Reg. 749/86. General. Made—December 18th, 1986. Filed—December 19th, 1986.

REGULATION MADE UNDER THE RESIDENTIAL RENT REGULATION ACT, 1986

GENERAL

1. A notice of rent increase given in compliance with subsection 60 (1) and section 99 of the *Residential Tenancies Act*, on or before the 30th day of June, 1987, shall be deemed to be and always to have been sufficient notice for the purposes of subsection 5 (1) and section 21 of the Act. O. Reg. 749/86, s. 1.

- 2. A notice of rent increase under subsection 5 (1) of the Act shall be,
 - (a) in Form 1 if the rent increase does not exceed the amount allowed under section 71 of the Act; or
 - (b) in Form 2 if the rent increase does exceed the amount allowed under section 71 of the Act. O. Reg. 749/86, s. 2.
- 3. An application under the Act, except under Part V or subsection 74 (1), shall be in Form 3. O. Reg. 749/86, s. 3.
- 4. An application under subsection 74 (1) of the Act shall be in Form 4. O. Reg. 749/86, s. 4.
- 5.—(1) An application form authorized under the *Residential Tenancies Act*, except under section 126 of that Act, may be used in place of Form 3.
- (2) An application form authorized under section 126 of the *Residential Tenancies Act* may be used in place of Form 4. O. Reg. 749/86, s. 5.

6. The Table upon which the Building Operating Cost Index is constructed in Schedule A to the Act is as follows:

TABLE

| | | Weight | Component |
|----|--|--------|--|
| 1. | Superintendent's salary and rent | 7.6 | Industrial hourly earnings composite and aggregate for hourly paid workers (Ontario) |
| 2. | Insurance | 1.6 | Homeowners' insurance, Consumer Prices and Price Indexes |
| 3. | Heating | 17.9 | Combined oil and gas, Consumer Price Index |
| 4. | Hydro | 7.4 | Electricity, Consumer Price Index |
| 5. | Water | 3.2 | Water, Consumer Price Index |
| 6. | Municipal Taxes | 34.3 | Municipal Financial Statements |
| 7. | Management and Administrative Overhead | 8.9 | Consumer Price Index |
| 8. | Interest and Bank Charges | 0.6 | Consumer Price Index |
| 9. | Bad Debts | 0.5 | Consumer Price Index |

| 10. Maintnance | | 15.6 | Homeowners' maintenance, repairs and |
|----------------------------------|-------|-------|---|
| (a) Painting and Decorating | 1.8 | | replacements, Consumer Prices and Price |
| (b) Cleaning and Janitorial | 1.3 | | Indexes |
| (c) Elevator Maintenance | 0.8 | | |
| (d) Plumbing Repairs, etc. | 2.7 | | |
| (e) General Building Maintenance | 7.7 | | |
| (f) Snow Removal | 0.4 | | |
| (g) Grounds-keeping | 0.7 | | |
| (h) Appliance Repairs | 0.2 | | |
| | | | |
| 11. Accounting and Legal | | 0.6 | Consumer Price Index |
| | | | |
| 12. Cablevision | | 0.5 | Consumer Price Index |
| | | | |
| 13. Miscellaneous | | 1.3 | Consumer Price Index |
| | | - | |
| | Total | 100.0 | |

NOTES:

- "Industrial hourly earnings composite and aggregate for hourly paid workers (Ontario)" means a calculation based on two indices of labour income as are available for specific periods in the Employment Earnings and Hours published monthly by Statistics Canada.
- "Consumer Price Index" means the All-items Index in the Consumer Price Index published monthly by Statistics Canada.
- 3. "Homeowners' Insurance, Consumer Prices and Price Indexes" means the item for Homeowners' Insurance in the Consumer Prices and Price Indexes published quarterly by Statistics Canada.
- "Combined oil and gas, Consumer Price Index" means an equal combination of the items for fuel oil and other liquid fuel and piped gas in the Consumer Price Index published monthly by Statistics Canada.
- "Electricity, Consumer Price Index" means the item for electricity in the Consumer Price Index published monthly by Statistics Canada.
- "Water, Consumer Price Index" means the item for water in the Consumer Price Index published monthly by Statistics Canada.
- "Municipal Financial Statements" means the annual percentage increase in municipal taxes for all
 municipalities in Ontario as published annually by the Ministry of Municipal Affairs in Local Government Finance in Ontario.
- 8. "Homeowners' maintenance, repairs and replacements, Consumer Prices and Price Indexes" means the item for homeowners' maintenance, repairs and replacements in the Consumer Prices and Price Indexes published quarterly by Statistics Canada. O. Reg. 749/86, s. 6.
- 7. Sections 1 to 5 of this Regulation come into force on the day that section 74 of the Act is proclaimed in force.

Form 1



Residential Rent Regulation Act, 1986 NOTICE OF RENT INCREASE

(Where no Application to the Minister of Housing is required)

(For use under Section 5 of the Act)

| (Please print or type full name of tenant and add | ress of rental unit.) | |
|---|----------------------------------|---------------------|
| To: NAME OF TENANT | | |
| ADDRESS OF UNIT | | |
| | | |
| | POSTAL CODE | |
| I hereby give you notice that the rent for the \ensuremath{abc} | ove rental unit, including al | l services |
| and facilities to which you are entitled, will be | increased to \$ | |
| per effective the d | ay of19 T | he new rent |
| (eg. month, week) consists of the current rent of \$ plu | us an increase of \$ | This |
| increase represents% of the current rent. | | |
| This does not exceed the current maximum rent | | |
| Elekteeds the turrent maximum rent by | /o • | |
| CURRENT RENT PAID | CURRENT MAXIMUM NEW RENT RENT | NEW MAXIMUM RENT |
| | | |
| Basic unit rent: \$ | \$ | . \$ |
| Separate Charges: Parking Spaces: Indoor | | |
| Outdoor | | |
| Cablevision: | | |
| Other: (please specify) | | |
| (prease specify) | | |
| TOTAL RENT: \$ | \$ | \$ |
| | | |
| Dated this day of 19 | | |
| | Name of Landlord or Agent | |
| | , | |
| | Address | |
| | | |
| Signature of Landlord or Agent | Telephone | Postal Code |
| | | |
| -1 - 1 - 1 - 1 | | |

For further information on the use of this form or about Rent Review, contact your local Rent Review Office.

O. Reg. 749/86, Form 1.

Form 2



Residential Rent Regulation Act, 1986
NOTICE OF RENT INCREASE

(Where Rent Increase is Subject to the Approval of the Minister of Housing) (For use under Section 5 of the Act)

| (Please print or type full name of tenant and ad | dress of rental u | nit.) | |
|---|------------------------|---------------|---------------------|
| To: NAME OF TENANT | | | |
| ADDRESS OF UNIT | | | |
| | | | • |
| | P | OSTAL CODE | |
| I hereby give you notice that the rent for the a | bove rental unit, | including al | 1 services |
| and facilities to which you are entitled, will b | e increased to \$_ | | |
| per effective the | day of | 19 T | he new rent |
| (eg. month, week) consists of the current rent of \$p | lus an increase o | f \$ | This |
| increase represents% of the current rent an | d represents | % of the cur | rent maximum |
| rent. | | | |
| | | | |
| . CURRENT RENT PAID | CURRENT MAXIMU RENT | M NEW RENT | NEW MAXIMUM RENT |
| Design with worth | | | |
| Basic unit rent: \$ | \$ | \$ | \$ |
| Separate Charges: Parking Spaces: Indoor | | | |
| Outdoor | | | |
| Cablevision: | | | |
| Other: | | | |
| (please specify) | | | |
| TOTAL RENT: \$ | \$ | \$ | \$ |
| | | | |
| Dated this day of 19 | | | |
| | Name of Land | lord or Agent | |
| | | | |
| | Address | | |
| | | | |
| Signature of Landlord or Agent | Telephone | | Postal Code |

For further information on the use of this form or about Rent Review, contact your local Rent Review Office.

O. Reg. 749/86, Form 2.

THE ONTARIO GAZETTE

Form 3



Residential Rent Regulation Act, 1986 APPLICATION

Please print or type

| me of Person(s) App | | | | | |
|----------------------|---------------|-----------------|------------|-----------------|---------------------------------|
| me of refsolits/ App | lying | Na | me of Othe | er Party(ies) t | o the Application |
| ndlord | Tenant | L | andlord | Tena | nt |
| Iress | | A | ddress | | |
| | Post | tal Code | | | Postal Code |
| lephone Resident | ial Busi | iness T | elephone | Residential | Business |
| above address is n | ot your maili | ing address, pl | ease provi | ide below. | |
| dress | | | | | |
| | | | | | Postal Code |
| asons for Applicati | on | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| der Requested | | | | | |
| der Requested | | | | | |
| der Requested | | | | | |
| der Requested | | | | | |
| der Requested | | | 7 | | |
| Teller | Signature (| of Person Apply | • | □ Landlord | , |
| der Requested | Signature (| of Person Apply | I | Tenant | y Authorization be attached) |

Form 4



Ministry of Housing

Residential Rent Regulation Act, 1986

(Section 74)

LANDLORD'S APPLICATION FOR WHOLE BUILDING REVIEW

For assistance in understanding and completing this form please contact your local Rent Review office.


Within ten days of making this application, you must give a copy of the application to all tenants.

Please print or type This is an application to the Minister of Housing for an Order allowing rent Name of Residential Complex increase(s) exceeding those permitted by the Act. Address Name of Landlord(s) Postal Code Total number of rental units in Residential Complex: Lot & Plan No. or Parcel No. Municipality Address Name of Landlord's Agent (if any) (Agency Authorization must be attached) Postal Code Telephone Residential Business Address Telephone Postal Code Effective date of the first increase proposed in this application: Day/Month/Year A detailed list showing the rent proposed for each rental unit lis attached or is available for examination between the hours of ____ and at and has been filed with the Minister. Signature of Landlord or Agent (Delete whichever is Date: inapplicable).

O. Reg. 749/86, Form 4.

(9932)

1



Publications Under The Regulations Act

January 10th, 1987

NIAGARA ESCARPMENT PLANNING AND DEVELOPMENT ACT

O. Reg. 750/86.

Designation of Area of Development Control.

Made—December 15th, 1986.

Filed—December 23rd, 1986.

REGULATION TO AMEND REGULATION 683 OF REVISED REGULATIONS OF ONTARIO, 1980 MADE UNDER THE NIAGARA ESCARPMENT PLANNING AND DEVELOPMENT ACT

- 1. Paragraph 35 of the Schedule to Regulation 683 of Revised Regulations of Ontario, 1980, as amended by section 5 of Ontario Regulation 740/82, is revoked and the following substituted therefor:
- 35. In the City of Thorold in The Regional Municiality of Niagara described as follows:
 - Beginning at the northwesterly angle of the City of Thorold;

Thence southerly along the westerly boundary of the said City to an angle of the said City in Lot 163 of the former Township of Thorold:

Thence easterly along the boundary of the said City to an angle in the said City in Lot 160 of the said former Township;

Thence easterly along the southerly limit of the abandoned right of way of the Canadian National Railways to the easterly limit of that Lot 160;

Thence northerly along the easterly limit of lots 160, 154 and 131 of the said former Township to the northeasterly angle of that Lot 131;

Thence northerly to the southwesterly angle of Lot 107 of the said former Township;

Thence easterly along the southerly limit of that Lot to the easterly limit of that Lot;

Thence northerly along the easterly limit of lots 107, 84 and 61 of the said former Township to a point distant 30 metres measured southerly from the northeasterly angle of that Lot 61;

Thence easterly to and along the northerly limit of a Plan deposited in the Land Registry Office for the Land Titles Division of Niagara South (No. 59) as Number 59 R 1606 to the easterly limit of Lot 59 of the said former Township;

Thence northerly along the easterly limit of lots 59 and 41 to the southerly limit of Decew Road;

Thence northwesterly along the said northerly limit to the northerly boundary of the City of Thorold;

Thence westerly along the said northerly boundary to the place of beginning.

 Beginning at the northeasterly angle of the City of Thorold;

Thence southerly along the easterly boundary of that City to the northerly limit of Regent Street East;

Thence westerly along that northerly limit to the westerly limit of Lot 13 of the former Township of Thorold;

Thence southerly along that westerly limit 100 metres to a point;

Thence due west to the westerly limit of Cemetery Road;

Thence southerly along the said westerly limit to the northerly limit of Hoover Street;

Thence westerly along the said northerly limit to the easterly limit of the right of way of the Canadian National Railways lying west of the Welland Ship Canal;

Thence northerly along the easterly limit of the said right of way to the northerly boundary of the City of Thorold;

Thence easterly along the said northerly boundary to the place of beginning.

O. Reg. 750/86

BERNARD GRANDMAÎTRE
Minister of Municipal Affairs

Dated at Toronto, this 15th day December, 1986.

(9950)

2

CANADIAN INSURANCE EXCHANGE ACT, 1986

O. Reg. 751/86. General. Made—December 19th, 1986. Filed—December 23rd, 1986.

REGULATION MADE UNDER THE CANADIAN INSURANCE EXCHANGE ACT, 1986

GENERAL

- I. The following conditions are prescribed for the purposes of subsection 21 (2) of the Act:
 - The syndicate shall provide to the Corporation for examination the application and all supporting materials and information in respect of the application to check for accuracy before forwarding it to the Superintendent.
 - Where the Corporation approves the application of the syndicate, the syndicate shall authorize the Corporation to submit the Corporation's reasons for the approval in writing to the Superintendent. O. Reg. 751/86, s. 1.
- 2.—(1) The Corporation shall report to the Superintendent forthwith with respect to any proposed examination, inquiry or investigation into the conduct, business or affairs of the Corporation, its members or underwriting managers including associates of the Corporation, its members or underwriting managers.
- (2) The Corporation shall report to the Superintendent forthwith with respect to any interim or final order and the reasons therefor in respect of any investigation made under subsection (1).
- (3) The Corporation shall report to the Superintendent any material change in or affecting,
 - (a) the business, affairs, operations, internal arrangements or financial condition of the Corporation and every member of the Corporation;
 - (b) the shareholders, partners or the participation interest in the Corporation;
 - (c) the re-insurance arrangement of a syndicate that is licensed under the Act; and

(d) anything reported or required to be reported by the Corporation under section 18 of the Act or by a syndicate under section 24 of the Act.

as soon as practicable and in any event within ten days after the change occurred.

- (4) Every syndicate shall report to the Superintendent any material change in or affecting,
 - (a) the business, affairs, operations, internal arrangements or financial condition of the syndicate;
 - (b) the shareholders, partners or the participation interest in the syndicate;
 - (c) the re-insurance arrangement of the syndicate; and
 - (d) anything reported or required to be reported by the syndicate under section 24 of the Act,

as soon as practicable and in any event within ten days after the change occurred.

- (5) Within sixty days after the Act comes into force, the Corporation shall file with the Superintendent a report that sets out as of the date of filing,
 - (a) the names and residence addresses, giving the street and number, if any, of the directors of the Corporation and the date on which each person became a director; and
 - (b) the names and residence addresses, giving the street and number, if any, of the president, secretary, treasurer and general manager of the Corporation, or persons holding offices that are equivalent thereto, and the date on which each person became an officer.
- (6) The Corporation shall file a report of every change of a matter referred to in clause (5) (a) or (b) within ten days after the change takes place that sets out the change and the date that the change took place.
- (7) For the purposes of subsection (6), the retirement of a director and the subsequent re-election of that person as a director at a meeting of members for the next ensuing term of office shall be deemed not to be a change.
- (8) The Corporation shall report to the Superintendent forthwith where the Corporation does not approve the application of a syndicate applying for a licence or a renewal thereof under section 21 of the Act or where the Corporation finds an inaccuracy in an application. O. Reg. 751/86, s. 2.
- 3.—(1) The provisions listed in Column 2 of Table 1 set out opposite the Act or regulation listed in Column 1 of Table 1 do not apply to syndicates licensed under the Act.

- (2) The provisions listed in Column 2 of Table 2 set out opposite the Act or regulation listed in Column 1 of Table 2 apply to syndicates licensed under the Act. O. Reg. 751/86, s. 3.
- **4.**—(1) The provisions listed in Column 2 of Table 3 set out opposite the Act or regulation listed in Column 1 of Table 1 do not apply to the Corporation.
- (2) The provisions listed in Column 2 of Table 4 set out opposite the Act or regulation listed in Column 1 of Table 4 apply to the Corporation. O. Reg. 751/86, 5, 4.
- 5.—(1) The board of trustees referred to in subsection 28 (3) of the Act shall be appointed by the board of directors of the Corporation and shall consist of,
 - (a) the chairman of the board of directors of the Corporation;
 - (b) two directors who are directors of the Corporation; and
 - (c) two public directors appointed under clause 6 (1) (c) of the Act.
- (2) A trustee is disqualified as a trustee if he or she has an interest, direct or indirect, in a syndicate in respect of which a claim is made against the security fund referred to in section 28 of the Act.
- (3) Where a trustee is disqualified under subsection (2) or unable to act, the board of directors of the Corporation shall appoint a new trustee to fill the vacancy.

- (4) Notwithstanding subsection (3), where the person disqualified or unable is the chairman of the board of directors of the Corporation, the board of directors of the Corporation may appoint a vice-chairman to fill the vacancy.
- (5) The board of trustees shall report at least annually to the Superintendent with respect to all matters pertaining to security funds referred to in subsection 28 (4) of the Act. O. Reg. 751/86, s. 5.
 - 6. The following fees are payable under the Act:

 - 2. Upon an application for a renewal of a licence syndicate 1,500
 - Upon an application to add a class or classes of insurance that a syndicate may undertake 1,000
 - 4. Upon an application for a change in licence of a syndicate other than a change referred to in paragraph 3 500
 - 5. For a certificate of status 100
 - 6. For a certified copy of a licence . . 50
 - 7. For copies of the contents of papers or orders on file with the Ministry 50 a page

O. Reg. 751/86, s. 6.

TABLE 1

| ltem | Act or Regulation | Provision |
|------|--|---|
| 1. | Insurance Act | Sections 20, 21 and 23 Subsections 28 (1), (2), (3), (4), (6) and (7) Sections 30, 32, 33 and 34 Subsections 35 (2), (3) and (4) Sections 36 to 78 Sections 81, 84, 90, 91 and 96 Schedule A |
| 2. | Regulation 528 of Revised Regulations of Ontario, 1980 (Agents' Licences) | All |
| 3. | Regulation 530 of Revised Regulations of Ontario, 1980 (General) | All |
| 4. | Regulation 531 of Revised Regulations of Ontario, 1980 (Life Companies Special Shares—Investment) | All |
| 5. | Regulation 532 of Revised Regulations of Ontario, 1980 (Order under Paragraph 1 of subsection 85 (2) of the Act—Rates of Interest) | All |
| 6. | Regulation 533 of Revised Regulations of Ontario, 1980 (Replacement of Life Insurance Contracts) | All |

TABLE 2

| Item | Act or Regulation | Provision |
|------|----------------------|-----------|
| 1. | Corporations Tax Act | Part IV |

O. Reg. 751/86, Table 2.

TABLE 3

| Item | Act or Regulation | Provision |
|------|-------------------|--|
| 1. | Corporations Act | Section 22 Clauses 23 (1) (h) and (m) Sections 59, 71, 80, 81 and 94 Subsection 95 (1) Section 96 Subsections 97 (1) and (3) Sections 98, 113, 119 and 125 Subsection 133 (3) Part IV Part V Subsections 277 (2) and (4) Sections 278, 284 and 286 Subsection 288 (1) Subsection 289 (1) Section 291 Subsection 304 (3) Sections 314, 316 and 335 Schedule |

O. Reg. 751/86, Table 3.

TABLE 4

| Item | Act or Regulation | Provision |
|------|-------------------------------------|---|
| 1. | Business Corporations Act, 1982 | Sections 131, 132, 149 to 154. 157, 158 and 159 |
| 2. | Ontario Regulation 446/83 (General) | Sections 39, 40 and 41 |

O. Reg. 751/86, Table 4.

(9951)

2

HIGHWAY TRAFFIC ACT

O. Reg. 752/86. Speed Limits. Made—December 15th, 1986. Filed—December 23rd, 1986.

REGULATION TO AMEND REGULATION 490 OF REVISED REGULATIONS OF ONTARIO, 1980 MADE UNDER THE HIGHWAY TRAFFIC ACT

- 1.—(1) Part 3 of Schedule 3 to Regulation 490 of Revised Regulations of Ontario, 1980 is amended by adding thereto the following paragraph:
- Middlesex and Huron— Twp. of Biddulph Town of

Exeter

- 14. That part of the King's Highway known as No. 4 lying between a point situate at its intersection with the boundary line between lots 3 and 4 in Concession III in the Township of Biddulph in the County of Middlesex and a point situate 610 metres measured southerly from its intersection with the centre line of the roadway known as Waterloo Street in the Town of Exeter in the County of Huron.
- (2) Paragraph 2 of Part 5 to the said Schedule 3 is revoked and the following substituted therefor:

Huron— Twps. of Stephen and Usborne

Huron-

- 2. That part of the King's Highway known as No. 4 in the County of Huron in the townships of Stephen and Usborne beginning at a point situate 300 metres south of its intersection with the centre line of the roadway known as Waterloo Street in the Town of Exeter and extending southerly therealong for a distance of 310 metres.
- (3) Part 6 of the said Schedule 3 is amended by adding thereto the following paragraph:
 - 5. That part of the King's Highway known as No. 4 in the County of Huron in the

Twps. of Stephen and Usborne townships of Stephen and Usborne beginning at a point situate at its intersection with the centre line of the roadway known as Waterloo Street in the Town of Exeter and extending southerly therealong for a distance of 300 metres.

EDWARD FULTON

Minister of Transportation

and Communications

Dated at Toronto, this 15th day of December, 1986.

(9952)

2

HIGHWAY TRAFFIC ACT

O. Reg. 753/86. Stop Signs at Intersections. Made—December 15th, 1986. Filed—December 23rd, 1986.

REGULATION TO AMEND REGULATION 493 OF REVISED REGULATIONS OF ONTARIO, 1980 MADE UNDER THE HIGHWAY TRAFFIC ACT

 Regulation 493 of Revised Regulations of Ontario, 1980 is amended by adding thereto the following Schedule:

Schedule 89

- Highway 41 (Boundary Road) in the City of Pembroke in the County of Renfrew at its intersection with the roadways known as Mud Lake Road and Olympic Road.
- 2. Southbound on Highway 41. O. Reg. 753/86, s. 1.

EDWARD FULTON
Minister of Transportation
and Communications

Dated at Toronto, this 15th day of December, 1986.

(9953)

2

COURTS OF JUSTICE ACT, 1984

O. Reg. 754/86.
Rules of the Provincial Court (Civil Division).
Made—October 2nd, 1986.
Approved—December 18th, 1986.
Filed—December 23rd, 1986.

REGULATION TO AMEND ONTARIO REGULATION 797/84 MADE UNDER THE COURTS OF JUSTICE ACT, 1984

- 1. The Rules of the Provincial Court (Civil Division) set out in the Schedule to Ontario Regulation 797/84, as amended by Ontario Regulation 158/85, are further amended as follows:
- 1. Rule 6.01 is amended by adding thereto the following subrule:
- (2) If the court is satisfied that the balance of convenience substantially favours holding the trial of an action at another place than those described in subrule (1), the court may order that the action be tried at that other place. O. Reg. 754/86, s. 1, par. 1.
 - 2. Subrule 7.01 (3) is revoked.
 - 3. Subrule 9.04 (5) is amended by striking out "may" in the third line and inserting in lieu thereof "shall".
 - 4. Subrule 10.01 (2) is revoked and the following substituted therefor:

Service Outside Territorial Division

- (2) Where all the defendants have been served outside the court's territorial division, the clerk shall not note any defendant in default until it is proved by an affidavit submitted to the clerk, or by evidence presented before the judge, that the action was properly brought in that territorial division. O. Reg. 754/86, s. 1, par. 4.
 - 5. Subrule 16.02 (1) is amended by striking out "have been opposed" in the second line and inserting in lieu thereof "opposed".
 - 6. Clause 18.01 (2) (b) is amended by adding at the commencement thereof "subject to subrule (2a)".
 - 7. Rule 18.01 is amended by adding thereto the following subrules:
- (2a) In the case described in clause (2) (b), if an issue as to the proper place of trial under subrule 6.01 (1) is raised in the defence, the trial judge shall consider the issue and make a finding.
- (2b) If the trial judge finds that the territorial division where the judge sits is not the proper place of trial, the action shall be tried in a place described in subclause 6.01 (a) (ii) or clause 6.01 (b) (defendant's place of residence or business, etc.), unless the trial judge orders otherwise under subrule 6.01 (2) (balance of convenience). O. Reg. 754/86, s. 1, par. 7.

8. Subrule 22.01 (1) is amended by adding at the end thereof "and shall conduct examinations under rule 21.10 (examination of debtor)".

(9954)

2

293

MUNICIPAL BOUNDARY NEGOTIATIONS ACT. 1981

O. Reg. 755/86.

Town of Ridgetown-Township of Howard Boundary.

Made-December 18th, 1986.

Filed-December 23rd, 1986.

ORDER IN COUNCIL

R.O.C. 474/86

WHEREAS The Corporation of the Town of Ridgetown and The Corporation of the Township of Howard have entered into an agreement dated the 15th day of October, 1986 for the resolution of certain boundary issues;

AND WHEREAS public notice was given by the Clerk of the Executive Council under subsection 17 (1) of the Municipal Boundary Negotiations Act, 1981 of the intention to make an Order implementing the intermunicipal agreement;

AND WHEREAS no objections to the proposed issuance of the Order were filed with the Clerk of the Executive Council within the filing period;

Now Therefore on the recommendation of the undersigned, the Lieutenant Governor, by and with the advice and concurrence of the Executive Council, orders under section 14 of the Municipal Boundary Negotiations Act, 1981 that,

- 1. On the 1st day of January, 1987, the portion of the Township of Howard described in the Schedule is annexed to the Town of Ridgetown.
- 2. All real property of The Corporation of the Township of Howard situate in the annexed area vests in The Corporation of the Town of Ridgetown on the 1st day of January, 1987.
- 3. On the 1st day of January, 1987, the by-laws of The Corporation of the Town of Ridgetown extend to the annexed area and the by-laws of The Corporation of the Township of Howard cease to apply to such area, except,
 - (a) by-laws of The Corporation of the Township of Howard.
 - (i) that were passed under section 34 of the Planning Act, 1983 or a predecessor of that section,

- (ii) that were kept in force by subsection 13 (3) of The Municipal Amendment Act, 1941, or
- (iii) that were passed under the Highway Traffic Act or the Municipal Act that regulate the use of highways by vehicles and pedestrians and that regulate the encroachment or projection of buildings or any portion thereof upon or over highways,

which shall remain in force until repealed by the council of The Corporation of the Town of Ridgetown;

- (b) by-laws of The Corporation of the Township of Howard passed under section 45, 58 or 61 of the Drainage Act or a predecessor of those sections; and
- (c) by-laws conferring rights, privileges, franchises, immunities or exemptions that could not have been lawfully repealed by the council of The Corporation of the Township of Howard.
- 4. The clerk of The Corporation of the Township of Howard shall forthwith prepare and furnish to the clerk of The Corporation of the Town of Ridgetown a special collector's roll showing all arrears of taxes or special rates assessed against the lands in the annexed area up to and including the 31st day of December, 1986 and the persons assessed therefor.
- 5.—(1) All real property taxes levied under any general or special Act and uncollected in the annexed area that are due and unpaid on the 1st day of January, 1987 shall be deemed on that date to be taxes due and payable to The Corporation of the Town of Ridgetown and may be collected by The Corporation of the Town of Ridgetown.
- (2) On or before the 31st day of March, 1987, The Corporation of the Town of Ridgetown shall pay to The Corporation of the Township of Howard an amount equal to the amount of all real property taxes that The Corporation of the Town of Ridgetown is entitled to collect in the annexed area under subsection (1) that were due but unpaid on the 1st day of January, 1987.
- 6. All business taxes levied and uncollected in the annexed area that are due and unpaid on the 31st day of December, 1986 shall continue after that date to be taxes due and payable to The Corporation of the Township of Howard and may be collected by The Corporation of the Township of Howard.

- 7. For the purposes of the assessment roll to be prepared for the Town of Ridgetown under subsection 13 (1) of the *Assessment Act* in 1986, the assessed area shall be deemed to be a part of the Town of Ridgetown.
- 8. The Corporation of the Town of Ridgetown shall pay to The Corporation of the Township of Howard, as compensation for the loss of assessment in the annexed area, the sum of \$5,000 of which,
 - (a) \$2,500 is payable within sixty days of the 1st day of January, 1987; and
 - (b) \$2,500 is payable within fourteen months of the 1st day of January, 1987.
- 9. The agreement between The Corporation of the Town of Ridgetown and The Corporation of the Township of Howard entered into on the 15th day of October, 1986 is hereby given effect. O. Reg. 755/86.

Recommended

BERNARD GRANDMAÎTRE Minister of Municipal Affairs

Concurred

JAMES BRADLEY
Chairman

Approved and Ordered December 18th, 1986.

LINCOLN M. ALEXANDER
Lieutenant Governor

Schedule

PORTION OF TOWNSHIP OF HOWARD TO BE ANNEXED TO THE TOWN OF RIDGETOWN

Beginning at the intersection of the northwesterly boundary of the Town of Ridgetown and the southwesterly limit of the northeasterly half of Lot 8 in Concession IX of the Township of Howard;

Thence northwesterly along the said southwesterly limit to the southeasterly limit of Part 2 as shown on a Plan deposited in the Land Registry Office for the Registry Division of Kent (No. 24) as Number 24 R 687;

Thence northeasterly along the southeasterly limit of the said Part to the northeasterly limit of the said Part;

Thence north 43° 12′ west along the northeasterly limit of parts 2 and 1 as shown on the said Plan 569.88 metres to an angle in the said Part 1;

Thence north 47° 02′ east along a southeasterly limit of the said Part 1 81.99 metres to the easterly angle in the said Part;

Thence north 43° 12' west along the northeasterly limit of the said Part 85.2 metres to an angle in the said Part;

Thence south 53° 55′ 50″ west along a limit of the said Part 9.6 metres to a point;

Thence north 43° 12′ west along a limit of the said Part 7.32 metres to a point;

Thence north 53° 55′ 50″ east along a limit of the said Part 5.49 metres to a point;

Thence south 58° 27' 50" west along a limit of the said Part 38.13 metres to the southeasterly limit of the road allowance between concessions VIII and IX of the Township of Howard;

Thence north 42° 39′ 30″ west 20.12 metres to the northwesterly limit of the said road allowance;

Thence northeasterly along the northwesterly limit of the said road allowance and along the diversion of the said road allowance to a point distant 215.8 metres measured southwesterly therealong from the southwesterly limit of Erie Street;

Thence northwesterly at right angles from the northwesterly limit of the said road allowance 35.13 metres to the southeasterly limit of the right of way of the Consolidated Railways;

Thence northeasterly along the southeasterly limit of the said right of way to the southwesterly boundary of the Town of Ridgetown;

Thence southerly following along the boundaries between the said Town and the Township of Howard to the place of beginning. O. Reg. 755/86, Sched.

(9955)

MUNICIPAL BOUNDARY NEGOTIATIONS ACT, 1981

O. Reg. 756/86.

Town of Forest—Township of Warwick Boundary.

Made—December 18th, 1986. Filed—December 23rd, 1986.

ORDER IN COUNCIL

R.O.C. 475/86

WHEREAS The Corporation of the Town of Forest and The Corporation of the Township of Warwick have entered into an agreement dated the 11th day of August, 1986 for the resolution of certain boundary issues;

AND WHEREAS public notice was given by the Clerk of the Executive Council under subsection 17 (1) of the Municipal Boundary Negotiations Act, 1981 of the

intention to make an Order implementing the intermunicipal agreement;

AND WHEREAS no objections to the proposed issuance of the Order were filed with the Clerk of the Executive Council within the filing period;

Now Therefore on the recommendation of the undersigned, the Lieutenant Governor, by and with the advice and concurrence of the Executive Council, orders under section 14 of the Municipal Boundary Negotiations Act, 1981 that,

- 1. On the 1st day of January, 1987, the portion of the Township of Warwick described in Schedule A is annexed to the Town of Forest.
- 2. All real property of The Corporation of the Township of Warwick situate in the annexed area vests in The Corporation of the Town of Forest on the 1st day of January, 1987.
- 3. On the 1st day of January, 1987, the by-laws of The Corporation of the Town of Forest extend to the annexed area and the by-laws of The Corporation of the Township of Warwick cease to apply to such area, except,
 - (a) by-laws of The Corporation of the Township of Warwick,
 - (i) that were passed under section 34 of the *Planning Act*, 1983 or a predecessor of that section,
 - (ii) that were kept in force by subsection 13 (3) of The Municipal Amendment Act, 1941, or
 - (iii) that were passed under the Highway Traffic Act or the Municipal Act that regulate the use of highways by vehicles and pedestrians and that regulate the encroachment or projection of buildings or any portion thereof upon or over highways,

which shall remain in force until repealed by the council of The Corporation of the Town of Forest;

- (b) by-laws of The Corporation of the Township of Warwick passed under section 45, 58 or 61 of the *Drainage Act* or a predecessor of those sections; and
- (c) by-laws conferring rights, privileges, franchises, immunities or exemptions that could not have been lawfully repealed by the council of The Corporation of the Township of Warwick.
- 4. The clerk of The Corporation of the Township of Warwick shall forthwith prepare and furnish to the clerk of The Corporation of the Town of Forest a spe-

cial collector's roll showing all arrears of taxes or special rates assessed against the lands in the annexed area up to and including the 31st day of December, 1986 and the persons assessed therefor.

- 5.—(1) All real property taxes levied under any general or special Act and uncollected in the annexed area that are due and unpaid on the 1st day of January, 1987 shall be deemed on that date to be taxes due and payable to The Corporation of the Town of Forest and may be collected by The Corporation of the Town of Forest.
- (2) On or before the 31st day of March, 1987, The Corporation of the Town of Forest shall pay to The Corporation of the Township of Warwick an amount equal to the amount of all real property taxes that The Corporation of the Town of Forest is entitled to collect in the annexed area under subsection (1) that were due but unpaid on the 1st day of January, 1987.
- 6. All business taxes levied and uncollected in the annexed area that are due and unpaid on the 31st day of December, 1986 shall continue after that date to be taxes due and payable to The Corporation of the Township of Warwick and may be collected by The Corporation of the Township of Warwick.
- 7. For the purposes of the assessment roll to be prepared for the Town of Forest under subsection 13 (1) of the *Assessment Act* in 1986, the assessed area shall be deemed to be a part of the Town of Forest.
- 8. The agreement between The Corporation of the Town of Forest and The Corporation of the Township of Warwick entered into on the 11th day of August, 1986 is hereby given effect. O. Reg. 756/86.

Recommended

BERNARD GRANDMAÎTRE Minister of Municipal Affairs

Concurred

JAMES BRADLEY
Chairman

Approved and Ordered December 18th, 1986.

LINCOLN M. ALEXANDER
Lieutenant Governor

Schedule A

AREA TO BE ANNEXED TO THE TOWN OF FOREST

That portion of the Township of Warwick described as follows:

Premising that the easterly limit of Gore Lot 2 in Concession VII North of Egremont Road of the Township of Warwick has a bearing of north 0° 15′ 30″ west and relating all bearings thereto;

Beginning at a point in the easterly limit of the said Gore Lot 2 distant 757.22 metres measured north 0° 15' 30" west therealong from the southeasterly angle of the said Gore Lot;

Thence north 89° 52' west 35.20 metres to the easterly limit of the King's Highway Number 21 as shown on a Plan registered in the Land Registry Office for the Registry Division of Lambton (No. 25) as Number 827, Plan and Profiles;

Thence north 1° 06′ 30″ east along the said easterly limit 174.97 metres to a southerly boundary of the Town of Forest;

Thence north 88° 51′ 40″ east along the said boundary 31.03 metres to an angle in the said boundary;

Thence south 0° 15′ 30″ east along a westerly boundary of the said Town being along the easterly limit of the said Gore Lot 2, 175.64 metres to the place of beginning. O. Reg. 756/86, Sched. A.

(9956)

MUNICIPAL BOUNDARY NEGOTIATIONS ACT, 1981

O. Reg. 757/86.
Town of Aylmer—Township of Malahide Boundary.
Made—December 18th, 1986.
Filed—December 23rd, 1986.

ORDER IN COUNCIL

R.O.C. 476/86

WHEREAS The Corporation of the Town of Aylmer and The Corporation of the Township of Malahide have entered into an agreement dated the 21st day of August, 1986 for the resolution of certain boundary issues;

AND WHEREAS public notice was given by the Clerk of the Executive Council under subsection 17 (1) of the Municipal Boundary Negotiations Act, 1981 of the intention to make an Order implementing the intermunicipal agreement;

AND WHEREAS no objections to the proposed issuance of the Order were filed with the Clerk of the Executive Council within the filing period;

Now Therefore on the recommendation of the undersigned, the Lieutenant Governor, by and with the advice and concurrence of the Executive Council, orders under section 14 of the Municipal Boundary Negotiations Act, 1981 that,

1. On the 1st day of January, 1987, the portion of the Township of Malahide described in the Schedule is annexed to the Town of Aylmer.

- 2. All real property of The Corporation of the Township of Malahide situate in the annexed area vests in The Corporation of the Town of Aylmer on the 1st day of January, 1987.
- 3. On the 1st day of January, 1987, the by-laws of The Corporation of the Town of Aylmer extend to the annexed area and the by-laws of The Corporation of the Township of Malahide cease to apply to such area, except,
 - (a) by-laws of The Corporation of the Township of Malahide,
 - (i) that were passed under section 34 or 41 of the *Planning Act*, 1983 or a predecessor of those sections,
 - (ii) that were kept in force by subsection 13 (3) of The Municipal Amendment Act, 1941, or
 - (iii) that were passed under the Highway Traffic Act or the Municipal Act that regulate the use of highways by vehicles and pedestrians and that regulate the encroachment or projection of buildings or any portion thereof upon or over highways,

that shall remain in force until repealed by the council of The Corporation of the Town of Aylmer;

- (b) by-laws of The Corporation of the Township of Malahide passed under section 45, 58 or 61 of the *Drainage Act* or a predecessor of those sections; and
- (c) by-laws conferring rights, privileges, franchises, immunities or exemptions that could not have been lawfully repealed by the council of The Corporation of the Township of Malahide.
- 4. The clerk of The Corporation of the Township of Malahide shall forthwith prepare and furnish to the clerk of The Corporation of the Town of Aylmer a special collector's roll showing all arrears of taxes or special rates assessed against the lands in the annexed area up to and including the 31st day of December, 1986 and the persons assessed therefor.
- 5.—(1) All real property taxes levied under any general or special Act and uncollected in the annexed area that are due and unpaid on the 1st day of January, 1987 shall be deemed on that date to be taxes due and payable to The Corporation of the Town of Aylmer and may be collected by The Corporation of the Town of Aylmer.
- (2) On or before the 31st day of March, 1987, The Corporation of the Town of Aylmer shall pay to The Corporation of the Township of Malahide an amount equal to the amount of all real property taxes that The

Corporation of the Town of Aylmer is entitled to collect in the annexed area under subsection (1) that were due but unpaid on the 1st day of January, 1987.

- 6. All business taxes levied and uncollected in the annexed area that are due and unpaid on the 31st day of December, 1986 shall continue after that date to be taxes due and payable to The Corporation of the Township of Malahide and may be collected by The Corporation of the Township of Malahide.
- 7. For the purposes of the assessment roll to be prepared for the Town of Aylmer under subsection 13 (1) of the Assessment Act in 1986, the assessed area shall be deemed to be a part of the Town of Aylmer.
- 8. The agreement between The Corporation of the Town of Aylmer and The Corporation of the Township of Malahide entered into on the 21st day of August, 1986 is hereby given effect. O. Reg. 757/86.

Recommended

BERNARD GRANDMAÎTRE
Minister of Municipal
Affairs

Concurred

JAMES BRADLEY
Chairman

Approved and Ordered December 18th, 1986.

Lincoln M. Alexander Lieutenant Governor

Schedule

AREA TO BE ANNEXED TO THE TOWN OF AYLMER

That portion of the Township of Malahide described as follows:

Beginning at the intersection of a southerly boundary of the town of Aylmer and the easterly limit of Victoria Street;

Thence easterly along the said southerly boundary 30.18 metres to a point;

Thence southerly and parallel with the easterly limit of Victoria Street 50.29 metres to a point;

Thence westerly and parallel with the said southerly boundary 30.18 metres to the easterly limit of Victoria Street;

Thence southerly along the said easterly limit 40.23 metres to the southerly limit of a Plan registered in the Registry Office for the Registry Division of Elgin (No. 11) as Number 163;

Thence westerly along the southerly limit of the said Plan to an easterly boundary of the Town of Aylmer; Thence northerly along the said easterly boundary to the southerly boundary of the said Town;

Thence easterly along the said southerly boundary to the place of beginning. O. Reg. 757/86, Sched.

(9957)

PLANNING ACT, 1983

O. Reg. 758/86.

Delegation of Authority of Minister under Section 4 of the Planning Act, 1983—Consents.

Made—December 18th, 1986. Filed—December 24th, 1986.

REGULATION TO AMEND ONTARIO REGULATION 474/83 MADE UNDER THE PLANNING ACT, 1983

1. Section 1 of Ontario Regulation 474/83, as amended by section 1 of Ontario Regulation 104/84 and section 1 of Ontario Regulation 38/86, is revoked and the following substituted therefor:

1.—(1) Subject to subsections (2) and (3) and section 2, all authority of the Minister to give consents under sections 49 and 52 of the Act is hereby delegated to the council of each of the municipalities listed in Schedule 1 in respect of land in the municipality and to the planning board of each of the planning areas listed in Schedule 2 in respect of land in the planning area, except that the authority is delegated to the planning boards of the Lakehead Rural Planning Area and the Espanola Planning Area only in respect of the land described in Schedule 2 under the names of those planning areas.

- (2) The delegation made in subsection (1) does not apply to the Minister's authority,
 - (a) under subsection 52 (11) of the Act, to change conditions at any time prior to the giving of a consent; or
 - (b) under subsection 52 (13) of the Act, to refuse to refer an application for consent to the Municipal Board because the Minister is of the opinion that the request is not made in good faith, is frivolous or vexatious, or is made only for the purpose of delay.
- (3) The delegation made in subsection (1) does not apply to an application for a consent received by the Minister,

- (a) in the case of land in the Township of Bonfield, before the 1st day of November, 1984;
- (b) in the case of land in the Township of Himsworth South, the Town of Powassan and the Town of Trout Creek, before the 1st day of February, 1986;
- (c) in the case of land in the Township of The Archipelago, before the 1st day of January, 1987; and
- (d) in all other cases, before the 1st day of August, 1983. O. Reg. 758/86, s. 1.
- Section 2 of the said Regulation is revoked and the following substituted therefor:
- 2.—(1) The delegation made in subsection 1 (1) is subject to the following conditions:
 - 1. A council or planning board in exercising the authority delegated by subsection 1 (1) shall comply with the rules of procedure contained in Schedule 3.
 - 2. A copy of the decision made in respect of each application for consent shall be sent within fifteen days of the date of the decision to the Director of the Plans Administration Branch of the Ministry of Municipal Affairs having jurisdiction in the area in which the land that is the subject of the application is situated, unless the Director has advised in writing that the Director does not wish to receive copies of such decisions.
 - 3. Where any of the authority delegated by subsection 1 (1) is in turn delegated by a council to a committee of council or an appointed officer under subsection 5 (1) of the *Planning Act*, 1983, the council shall cause to be forwarded to the Minister a certified copy of the delegating by-law within fifteen days of its passing.
- (2) The delegation of authority set out in this Order is not terminated by reason only that a council or planning board has failed to comply with a condition set out in subsection (1). O. Reg. 758/86, s. 2.
 - 3. Schedule 1 to the said Regulation, as amended by section 2 of Ontario Regulation 693/84, is further amended by adding thereto "The Township of The Archipelago".
 - 4. Schedule 2 to the said Regulation, as amended by section 2 of Ontario Regulation 104/84 and section 2 of Ontario Regulation 36/86, is revoked and the following substituted therefor:

Schedule 2

The Cochrane and Suburban Planning Area

The Geraldton and Suburban Planning Area

The Himsworth South, Powassan, Trout Creek Planning Area

The Humphrey-Rosseau-Christie Planning Area

The Kapuskasing and District Planning Area

The Kenora-Keewatin Planning Area

The Manitoulin Planning Area

The Parry Sound Area Planning Area

The Sables-Spanish Rivers Planning Area

The St. Joseph Island Planning Area

The Sault Ste. Marie North Planning Area

The Sioux Lookout Planning Area

The West Nipissing Planning Area

The Espanola Planning Area (all land in the Town of Espanola)

The Lakehead Rural Planning Area (all land in the townships of Conmee and O'Connor and in the geographic townships of Gorham and Ware)

O. Reg. 758/86, s. 4.

- 5.—(1) Section 5 of Schedule 3 to the said Regulation is amended by adding thereto the following paragraph:
 - 8. Where the land that is the subject of the application is within an area that is under the jurisdiction of a conservation authority, to its chief administrative officer, unless the officer has advised in writing that the officer does not wish to receive copies of applications.
- (2) Paragraph 6 of section 5 of the said Schedule 3 is amended by striking out "and Housing" in the third line.
- (3) Section 10 of the said Schedule 3 is amended by,
 - (a) inserting after "report" in the third line "in Form 6"; and
 - (b) by striking out "and Housing" in the seventh line.
- (4) Section 11 of the said Schedule 3 is amended by striking out "and Housing" in the fifth and sixth lines.
- 6. The said Regulation is amended by adding thereto the following Form:

THE ONTARIO GAZETTE

Form 6

Ministry of Municipal Affairs

Planning Act, 1983

Consent Activity Profile

CONSENT ACTIVITY PROFILE

| Van | ne of Cons | sent Granting Authority | | Region/District | | | ☐ Jan. | | propriete Box) une 30, 19 dec. 31, 19 |
|-----|------------|--|-----------------------|--------------------|---------------------|----------|----------|---------------|---|
| ١. | New Ap | pplications Received | | | | | | | |
| | 1. No. | of New Applications Received | New Lots | Lot Additions/A | Adjustments | Rights | of Way | Other | Total |
| | 2. No. | of New Applications which are | Resubmissions | | Total | | | | |
| | Decision | ns Made On Applications | | | | | | | |
| | 1. Tota | al No. of Decisions Made on Ap | pplications | Approved (Conc | fitionally Appro | | Refused | | Total |
| | 2. Brea | akdown of Decisions By Type | of Application | | | | | | |
| | | Type/Decis | sion | No. of New Lots | No. of Lot Adjustme | | No. o | Rights of Way | No. of Other |
| | | Approved (Conditionally A | pproved as Defined) | | | | | | |
| | | Refused | 1 | | | | | | |
| | 3. Nun | mber of Applications Outstandi | ing at the End of Rep | porting Period | | | | Total | |
| | Referra | als to the Ontario Municipa | l Board | | | | | | |
| | Number | r of Applications Referred to the | he Ontario Municipal | Board (Includes E | Both Decisions | and Cond | litions) | Total | |
| | Final A | pprovals (Deeds/Transfers | Stamped or Certif | icates (ssued) | | | | | |
| | | of Deeds/Transfers d or Certificates Issued for | New Lots | Lot Additions | | Rights | -of-Way | Other | Total |
| | Stamped | | | | | | | | |
| | Closed | Files | | | | | | | |

1658 (10/86)

O. Reg. 758/86, >


7. This Regulation comes into force on the 1st day of January, 1987.

BERNARD GRANDMAÎTRE
Minister of Municipal Affairs

Dated at Toronto, this 18th day of December, 1986.

(9958)

2



Publications Under The Regulations Act

January 17th, 1987

COMMODITY BOARDS AND MARKETING AGENCIES ACT

O. Reg. 759/86. Levies or Charges—Eggs (Overquota). Made—December 18th, 1986. Filed—December 29th, 1986.

REGULATION MADE UNDER THE COMMODITY BOARDS AND MARKETING AGENCIES ACT

LEVIES OR CHARGES—EGGS (OVERQUOTA)

1. In this Regulation,

"commodity board" means The Ontario Egg Producers' Marketing Board constituted under the Farm Products Marketing Act;

"eggs" means eggs of a domestic hen produced in Ontario other than hatching eggs. O. Reg. 759/86, s. 1.

- 2.—(1) Subject to subsection (2), the Lieutenant Governor in Council hereby grants to the commodity board, in relation to the marketing of eggs-locally within Ontario, authority to fix, impose and collect levies or charges from persons engaged in the production of eggs in Ontario and for those purposes to classify persons into groups and fix the levies or charges payable by the members of the different groups in different amounts and to use the levies or charges for the purposes of the commodity board, including the creation of reserves, the payment of expenses and losses resulting from the sale or disposal of any eggs and the equalization or adjustment among producers of eggs of moneys realized from the sale thereof during such period or periods as the commodity board may determine.
- (2) The commodity board shall fix, impose and collect levies under subsection (1) only on,
 - (a) eggs produced by a producer in excess of the production quota fixed and allotted to him or her by the commodity board under the Farm Products Marketing Act; and
 - (b) eggs produced by a producer to whom the commodity board has not fixed and allotted production quota. O. Reg. 759/86, s. 2.

3. Any person who receives eggs shall deduct from the moneys payable for the eggs any levies or charges payable to the commodity board by the person from whom he or she receives the eggs and shall forward the levies or charges to the commodity board within ten days after written request therefor has been made by the commodity board. O. Reg. 759/86, s. 3.

(9974)

3

COMMODITY BOARDS AND MARKETING AGENCIES ACT

O. Reg. 760/86. Levies or Charges—Eggs. Made—December 18th, 1986. Filed—December 29th, 1986.

REGULATION TO AMEND REGULATION 110 OF REVISED REGULATIONS OF ONTARIO, 1980 MADE UNDER THE COMMODITY BOARDS AND MARKETING AGENCIES ACT

- 1. Section 2 of Regulation 110 of Revised Regulations of Ontario, 1980, as amended by section I of Ontario Regulation 462/81 and section I of Ontario Regulation 713/83, is further amended by adding thereto the following subsection:
- (2) The grant of authority under subsection (1) does not include the authority to fix, impose and collect levies or charges granted to The Ontario Egg Producers' Marketing Board by Ontario Regulation 759/86. O. Reg. 760/86, s. 1.

(9975)

3

PLANNING ACT, 1983

O. Reg. 761/86.
Restricted Areas—Territorial District of Sudbury.
Made—December 22nd, 1986.
Filed—December 29th, 1986.

REGULATION TO AMEND ONTARIO REGULATION 834/81 MADE UNDER THE PLANNING ACT, 1983

- 1. Schedule 1 to Ontario Regulation 834/81 is amended by adding thereto the following section:
- 75. A second single dwelling and buildings and structures accessory thereto may be erected and used on the parcel of land in the geographic Township of Cleland in the Territorial District of Sudbury, being that part of Lot 6, Concession VI, shown as Parcel 45558, Sudbury East Section, in the Land Registry Office for the Land Titles Division of Sudbury (No. 53).

PAULINE MORRIS
Director
Plans Administration Branch
North and East
Ministry of Municipal Affairs

Dated at Toronto, this 22nd day of December, 1986.

(9976)

ENVIRONMENTAL ASSESSMENT ACT

O. Reg. 762/86.

Exemption—Township of South-West Oxford and the Town of Ingersoll—ING-1. Made—December 18th, 1986. Approved—December 18th, 1986. Filed—December 30th, 1986.

ORDER MADE UNDER THE ENVIRONMENTAL ASSESSMENT ACT

EXEMPTION—TOWNSHIP OF SOUTH-WEST OXFORD AND THE TOWN OF INGERSOLL—ING-1

Having received a request from the Corporations of the Township of South-West Oxford and the Town of Ingersoll that an undertaking, namely:

the activity of relocating and constructing Clark Road between Wallace Road and Ingersoll Street to facilitate the development of industrial land as the site for a new car assembly plant located in the Township of South-West Oxford and in the Town of Ingersoll, in the County of Oxford, including all necessary drainage works,

be exempt from the application of the Act pursuant to section 29; and

Having been advised by South-West Oxford and Ingersoll that if the undertaking is subject to the application of the Act, the following injury, damage or interference with the persons and property indicated will occur:

- A. South-West Oxford and Ingersoll will be interfered with if delayed in relocating the road which is required for the car assembly plant.
- B. The public will be damaged by any delay in the development of the plant, which will provide economic stimulus to the Region and Province of Ontario.

Having weighed such injury, damage or interference against the betterment of the people of the whole or any part of Ontario by the protection, conservation and wise management in Ontario of the environment which would result from the undertaking being subject to the application of the Act;

The undersigned is of the opinion that it is in the public interest to order and orders that the undertaking is exempt from the application of the Act for the following reasons:

- A. It is in the public interest that the undertaking proceed since the establishment of the assembly plant will provide manufacturing and employment opportunities for the people of Ontario.
- B. The establishment of the car assembly plant will stimulate the growth and expansion of service industries, providing further manufacturing and employment opportunities for the people of this Province.

This exemption is subject to the following terms and conditions:

- 1. The proponents shall keep local residents informed of their intent with respect to the provision of services to the car assembly plant, and where and when they consider it necessary, establish information centres for this purpose.
- This exemption shall not apply to any works for which construction has not commenced by April 30, 1990.
- 3. The proponents shall notify the Director of the Environmental Assessment Branch in writing within 30 days after construction is completed of the date on which construction was completed. O. Reg. 762/86.

JAMES BRADLEY
Minister of the Environment

3

(9977)

CORPORATIONS TAX ACT

O. Reg. 763/86. General. Made—December 18th, 1986. Filed—December 30th, 1986.

REGULATION TO AMEND REGULATION 191 OF REVISED REGULATIONS OF ONTARIO, 1980 MADE UNDER THE CORPORATIONS TAX ACT

- 1.—(1) Sub-subclause 101 (1) (g) (ii) (B) of Regulation 191 of Revised Regulations of Ontario, 1980, as made by section 1 of Ontario Regulation 254/82, is amended by striking out "1205 (a) (ii)" in the fifth line and inserting in lieu thereof "1205 (1) (a) (ii)".
- (2) Sub-subclause 101 (1) (g) (ii) (C) of the said Regulation, as made by section 1 of Ontario Regulation 254/82, is amended by striking out "1205 (a) (v)" in the fifth and sixth lines and inserting in lieu thereof "1205 (1) (a) (v)".
- (3) Sub-subclause 101 (1) (g) (ii) (D) of the said Regulation, as made by section 1 of Ontario Regulation 254/82, is revoked and the following substituted therefor:
 - (D) an expenditure incurred by the corporation that qualifies for the purposes of subparagraph 1205 (1) (a) (vi) of the regulations made under the *Income Tax Act* (Canada) other than clause (A) thereof or that portion of an expenditure incurred by the corporation that qualifies for the purposes of clause 1205 (1) (a) (vi) (A) of the regulations made under the *Income Tax Act* (Canada),
- (4) Subclause 101 (1) (g) (iii) of the said Regulation, as made by section 1 of Ontario Regulation 254/82, is amended by striking out "paragraphs 1205 (b) and (c)" in the second and third lines and inserting in lieu thereof "paragraphs 1205 (1) (b) and (c)".
- (5) Clause 101 (1) (g) of the said Regulation, as made by section 1 of Ontario

Regulation 254/82, is amended by adding thereto the following subclause immediately after subclause (iii):

- (iiia) three times the aggregate of all amounts each of which is an amount equal to the lesser of,
 - (A) the amount determined under clause 109 (1) (a), and
 - (B) the amount determined under clause 109 (1) (b),

in computing its income for a taxation year ending before the particular time,

- (6) Subclause 101 (1) (g) (viii) of the said Regulation, as made by section 1 of Ontario Regulation 254/82, is revoked and the following substituted therefor:
 - (viii) an amount described in paragraph 1205 (1) (j) of the regulations made under the *Income Tax Act* (Canada),
- (7) Clause 101 (1) (g) of the said Regulation, as made by section 1 of Ontario Regulation 254/82, is amended by adding "and" at the end of subclause (ix) and by adding thereto the following subclause:
 - (x) the amount, if any, by which,
 - (A) the aggregate of all amounts that would be determined under clauses 110 (2) (b) and (c),

exceeds,

(B) the aggregate that would be determined under clause 110 (2) (a),

in computing the supplementary depletion base at the particular time, multiplied by,

- (C) in respect of the 1984 taxation year, 1/4,
- (D) in respect of the 1985 taxation year, ½,
- (E) in respect of the 1986 taxation year, 34, and
- (F) in respect of taxation years after 1986, 1;

- (8) Subsection 101 (1) of the said Regulation, as remade by section 1 of Ontario Regulation 254/82, is amended by adding thereto the following clauses:
 - (ia) "joint exploration corporation" has the meaning given to that expression by clause 18 (14) (d) of the Act;
 - (ja) "oil or gas well" has the meaning given to that expression by clause 18 (14) (e) of the Act;
- (9) Subclause 101 (1) (n) (i) of the said Regulation, as made by section 1 of Ontario Regulation 254/82, is revoked and the following substituted therefor:
 - (i) the amount, if any, by which the aggregate of,
 - (A) the aggregate of the amounts, if any, included in computing its income for the year by virtue of subsection 59 (2.1) and paragraphs 59 (3.2) (b) and 59.1 (b) of the *Income Tax Act* (Canada), as made applicable by section 14 of the Act, and
 - (AA) the amount, if any, by which the amount included in computing its income for the year by virtue of paragraph 59 (3.2) (c) of the Income Tax Act (Canada), as made applicable by section 14 of the Act, exceeds the proceeds of disposition of properties described in clause 66 (15) (c) (ii) (A) of the Income Tax Act (Canada) that became receivable by the corporation after the 31st day of December, 1982, to the extent that such proceeds have not been deducted in determining the amount under this sub-subclause for a prior taxation year,

from the disposition of a Canadian oil and gas resource property or that would have been a Canadian oil or gas resource property if it had been acquired after 1971, exceeds,

(B) the aggregate of the amounts, if any, deducted in computing its income for the year in respect of such disposition by virtue of,

- 1. paragraph 59.1 (a) of the Income Tax Act (Canada), as made applicable by subsection 14 (1) of the Act, and
- 2. subsections 64 (1.1) and (1.2) of the Income Tax Act (Canada), as made applicable by section 16 of the Act as it then read in respect of a disposition occurring before the 13th day of November, 1981 or by virtue of subsections 16 (1) and (1a) of the Act in respect of a disposition occurring after the 12th day of November, 1981, and
- (10) Sub-subclause 101(1)(n)(ii)(C) of the said Regulation, as made by section 1 of Ontario Regulation 254/82, is revoked and the following substituted therefor:
 - (C) the processing in Canada of heavy crude oil recovered from an oil or gas well in Canada to any stage that is not beyond the crude oil stage or its equivalent, and
- (11) Subclause 101 (1) (n) (v) of the said Regulation, as made by section 1 of Ontario Regulation 254/82, is revoked and the following substituted therefor:
 - (v) amounts deducted or deductible under section 18 or 18a of the Act (other than an amount in respect of a property described in sub-subclause (i) (AA)) or subsection 17 (2) or (6) or section 29 of the Corporations Tax Application Rules, 1972, for the year, and
- (12) Sub-subclause 101 (1) (0) (i) (B) of the said Regulation, as made by section 1 of Ontario Regulation 254/82, is revoked and the following substituted therefor:
 - (B) the aggregate of the amounts, if any, deducted in computing its income for the year by virtue of,
 - 1. paragraph 59.1 (a) of the *Income Tax Act* (Canada), as made

- applicable by subsection 14 (1) of the Act, and
- 2. subsections 64 (1.1) and (1.2) of the *Income Tax Act* (Canada), as made applicable by section 16 of the Act as it then read, in respect of a disposition occurring before the 13th day of November, 1981, and by virtue of subsections 16 (1) and (1a) of the Act in respect of a disposition occurring after the 12th day of November, 1981.
- (13) Clause 101 (1) (p) of the said Regulation, as remade by section 1 of Ontario Regulation 254/82, is revoked and the following substituted therefor:
 - (p) "shareholder corporation" has the meaning given to that expression by clause 18 (14) (j) of the Act;
 - (q) "tertiary recovery equipment", "qualified tertiary oil recovery project" and "secondary recovery method" have, respectively, the meanings given to those expressions by subsection 1206 (1) of the regulations made under the *Income Tax Act* (Canada).
- (14) Clause 101 (2) (b) of the said Regulation, as made by section 1 of Ontario Regulation 254/82, is revoked and the following substituted therefor:
 - (b) the amount by which the aggregate of expenditures included under paragraphs 1205 (1) (a), (b), (c) and (d) of the regulations made under the *Income Tax Act* (Canada), incurred before the end of that taxation year exceeds three times any amount deducted under paragraph 1205 (1) (f) before the end of that taxation year.
- (15) Clauses 101 (6) (b), (d) and (e) of the said Regulation, as remade and made by section 1 of Ontario Regulation 254/82, are revoked and the following substituted therefor:
 - (b) any property acquired or disposed of by the partnership shall be deemed to have been acquired or disposed of by the corporation to the extent of its share thereof;

- (d) any amount that has become receivable by the partnership and in respect of which the consideration given by the partnership therefor was property (other than property referred to in paragraph 59 (2) (a), (c) or (d) of the Income Tax Act (Canada) as made applicable by section 14 of the Act or a share or interest therein or right thereto) or services, all or part of the original cost of which to the partnership may reasonably be regarded as primarily an exploration or development expense of the corporation, shall be deemed to be an amount receivable by the corporation to the extent of its share thereof, and the consideration so given by the partnership shall, to the extent of the corporation's share thereof, be deemed to have been given by the corporation for the amount deemed to be receivable by it:
- (e) any expenditure incurred by the partnership shall be deemed to have been incurred by the corporation to the extent of its share thereof;
- (f) any amount or expenditure deemed by clause (d) or (e) to have been receivable or incurred, as the case may be, by the corporation shall be deemed to have become receivable or been incurred, as the case may be, by it on the day the amount become receivable or the expenditure was incurred by the partnership.
- (16) Section 101 of the said Regulation, as amended by section 1 of Ontario Regulation 254/82, is further amended by adding thereto the following subsection:
- (6a) For the purposes of sections 103 and 104 and clause 101 (1) (g), where a corporation was a member of a partnership at the end of a fiscal period of the partnership, the corporation shall be deemed to receive or to become entitled to receive any amount of assistance or benefit, whether such amount is by way of a grant, subsidy, rebate, forgiveable loan, deduction from royalty or tax, rebate or royalty or tax, investment allowance or any other form of assistance or benefit, that the partnership at any time receives or becomes entitled to receive in respect of expenses incurred in the fiscal period of the partnership, to the extent of,
 - (a) where the partnership in the fiscal period receives or becomes entitled to receive the amount, the corporation's share thereof; or
 - (b) where the partnership after the fiscal period becomes entitled to receive the amount, what would have been the corporation's share thereof if the partnership had in the fiscal period received or become entitled to receive the amount,

and the time at which the corporation is deemed to receive or become entitled to receive such share of the amount shall be the time that the partnership receives or becomes entitled to receive the amount. O. Reg. 763/86, s. 1 (16).

- (17) Subsection 101 (7) of the said Regulation is revoked and the following substituted therefor:
- (7) For the purposes of this Part, where an expense incurred after the end of the corporation's last taxation year ending before the 20th day of April, 1977, that was,
 - (a) a Canadian exploration and development expense, other than the cost of a Canadian resource property acquired by a joint exploration corporation;
 - (b) a Canadian exploration expense; or
 - (c) a Canadian development expense, other than an amount referred to in subparagraph 66.2
 (5) (a) (iii) of the Income Tax Act (Canada),

has been renounced before 1982 in favour of the corporation and was deemed to be an expense of the corporation for the purposes of subsection 18 (6) or (6a) of the Act, that expense, if it is not an amount referred to in paragraph 21 (2) (b) or subsection 21 (4) of the *Income Tax Act* (Canada), shall be deemed to have been a Canadian exploration and development expense, a Canadian exploration expense or a Canadian development expense, as the case may be, incurred by the corporation.

- (7a) Where an expense incurred after the end of a corporation's last taxation year ending before the 20th day of April, 1977 that was,
 - (a) a Canadian exploration and development expense, other than the cost of a Canadian resource property acquired by a joint exploration corporation;
 - (b) a Canadian exploration expense; or
 - (c) a Canadian development expense, other than an amount referred to in subparagraph 66.2 (5) (a) (iii) of the *Income Tax Act* (Canada),

has been renounced after 1981 in favour of the corporation and was deemed to be an expense of the corporation for the purposes of subsection 18 (6) or (6a) of the Act, the expense, if it is not an amount in respect of financing, shall be deemed,

(d) to have been such an expense, for the purpose of clause (1) (g), incurred by the corporation at the time the expense was incurred by the joint exploration corporation; and

- (e) to have been such an expense, for the purposes of clauses (1) (n) and (o) and section 109, incurred by the corporation at the time it was deemed to have been incurred for the purposes of subsection 18 (6) or (6a) of the Act.
- (7b) An expense that is a Canadian exploration and development overhead expense of a joint exploration corporation that may reasonably be considered to be included in a Canadian exploration expense or Canadian development expense deemed by subsection (7a) to be an expense of a shareholder corporation of the joint exploration corporation, shall be deemed,
 - (a) to be a Canadian exploration and development overhead expense of the shareholder corporation, incurred at the time the Canadian exploration expense or Canadian development expense is deemed by subsection (7a) to have been incurred by the shareholder corporation; and
 - (b) at and after that time, not to be a Canadian exploration and development overhead expense incurred by the joint exploration corporation.

(7c) For the purposes of subsection (7b), a Canadian exploration and development overhead expense of a joint exploration corporation shall include any expense that would be a Canadian exploration and development overhead expense of the joint exploration corporation if the references to "connected with the taxpayer" in paragraph (d) of the definition of "Canadian exploration and development overhead expense" in subsection 1206 (1) of the regulations made under the *Income Tax Act* (Canada), as made applicable by clause (1) (c), were read as "connected with the shareholder corporation in favour of whom the expense was renounced by the joint exploration corporation for the purposes of subsection 18 (6a) of the Act". O. Reg. 763/86, s. 1 (17).

2.—(1) Subsection 104 (1) of the said Regulation is revoked and the following substituted therefor:

(1) For the purposes of computing the earned depletion base of a corporation, where, after the 19th day of April, 1977 and before the 13th day of November, 1981, control of the corporation is considered to have been acquired for the purposes of subsection 66 (11) of the Income Tax Act (Canada) by a person or persons who did not control the corporation at the time when it last ceased to carry on active business, the amount by which the earned depletion base of the corporation at that time exceeds the aggregate of amounts otherwise deducted under section 103 in computing its income for taxation years ending after that time and before control was so acquired, shall be deemed to have been deducted under section 103 by the corporation in computing its income for taxation years ending before such acquisition of control. O. Reg. 763/86, s. 2 (1).

- (2) Subsection 104 (2) of the said Regulation, as remade by section 3 of Ontario Regulation 254/82, is revoked and the following substituted therefor:
- (2) The rules set out in subsections 1202 (2), (3), (4), (5) and (6) of the regulations made under the *Income Tax Act* (Canada) apply for the purposes of this section in so far as they apply to income from the production of oil or gas from an oil or gas well or a petroleum deposit except that, in the application of paragraph 1202 (4) (b) of those regulations for the purposes of this section, the reference therein to Part I of the *Income Tax Act* (Canada) shall be deemed to be a reference to Part II of the Act. O. Reg. 763/86, s. 2 (2).
 - 3.—(1) Subsection 109 (1) of the said Regulation, as remade by section 5 of Ontario Regulation 254/82, is revoked and the following substituted therefor:
- (1) Subject to subsection (1a), for the purposes of clause 12 (7) (d) of the Act, there may be deducted in computing the income of a corporation for a taxation year an amount equal to 25 per cent of the amount, if any, by which.
 - (a) its resource profits from oil or gas operations for the year, within the meaning of clause 101
 (1) (n) if that clause were read without reference to subclause (i) thereof, computed as if no amounts were deducted in computing those resource profits,
 - (i) in respect of a rental or royalty paid or payable by the corporation (other than an incremental resource royalty, within the meaning assigned by the Petroleum and Gas Revenue Tax Act (Canada), an amount prescribed in section 1211 of the regulations made under the Income Tax Act (Canada) or an amount that is a production royalty) computed by reference to the amount or value of petroleum, natural gas or related hydrocarbons produced after the 31st day of December, 1981 from a property that is an oil or gas well in Canada,
 - (ii) in respect of financing, or
 - (iii) under clause 12 (7) (d) of the Act or subclause 101 (1) (n) (v),

exceeds the aggregate of,

(b) the aggregate of all amounts each of which is a Canadian exploration and development overhead expense made or incurred by the corporation in the year, other than an amount included therein,

- (i) that is in respect of financing, or
- (ii) in respect of which a person has received, is entitled to receive or at any time becomes entitled to receive,
 - (A) an incentive under the Petroleum Incentives Program Act
 (Canada), or
 - (B) a payment from the Alberta Petroleum Incentives Program Fund under the Petroleum Incentives Program Act (Alberta); and
- (c) the aggregate of all amounts each of which is an amount included in its resource profits from oil or gas operations for the year that was a rental or royalty, other than a production royalty, computed by reference to the amount or value of petroleum, natural gas or related hydrocarbons produced after the 31st day of December, 1981 from an oil or gas well in Canada.
- (1a) In respect of taxation years ending after 1983, the amount deductible under subsection (1) is reduced by the amount, if any, by which,
 - (a) the aggregate of all amounts determined under subclauses 101 (1) (g) (iv) to (x),

exceeds,

(b) 33½ per cent of the aggregate of all amounts determined under subclauses 101 (1) (g) (i) to (iiia),

in computing the corporation's earned depletion base at the end of the year. O. Reg. 763/86, s. 3 (1).

- (2) Section 109 of the said Regulation, as amended by section 5 of Ontario Regulation 254/82, is further amended by adding thereto the following subsections:
- (3) In this section, "production royalty" means an amount included in computing the income of a corporation as a rental or royalty computed by reference to the amount or value of petroleum, natural gas or related hydrocarbons produced after 1981 from an oil or gas well in Canada, if,
 - (a) the corporation has a Crown royalty in respect of,
 - (i) such production, or
 - (ii) the ownership of property to which such production relates where the Crown royalty is computed by reference to an amount of production from the property; or

- (b) the corporation would, but for an exemption or allowance (other than a rate of nil) that is provided by statute by a person referred to in subparagraph 18 (1) (m) (i), (ii) or (iii) of the Income Tax Act (Canada), as made applicable by section 12 of the Act, have a Crown royalty determined under clause (a).
- (4) For the purposes of the definition of "production royalty" in subsection (3), a "Crown royalty" of a corporation in respect of the production of petroleum, natural gas or related hydrocarbons from an oil or gas well in Canada or in respect of the ownership of a natural reservoir of gas or petroleum in Canada means an amount,
 - (a) that would be included in computing its income for a taxation year by virtue of paragraph 12 (1) (a) of the Income Tax Act (Canada), as made applicable by section 12 of the Act, in respect of such production or ownership if that paragraph were read without reference to the words "or a prescribed amount";
 - (b) that would not be deductible in computing its income for a taxation year by virtue of paragraph 18 (1) (m) of the Income Tax Act (Canada), as made applicable by section 12 of the Act, in respect of such production or ownership if that paragraph were read without reference to the words "other than a prescribed amount";
 - (c) by which its proceeds of disposition of such production are increased by virtue of subsection 69 (6) of the *Income Tax Act* (Canada), as made applicable by section 20 of the Act; or
 - (d) by which its cost of acquisition of such production is reduced by virtue of subsection69 (7) of the *Income Tax Act* (Canada), as made applicable by section 20 of the Act,

less, in respect of an amount described in clause (a) or (b), the amount of any reimbursement referred to in section 80.2 of the *Income Tax Act* (Canada) received or receivable by it in respect thereof. O. Reg. 763/86, s. 3 (2).

- 4.—(1) Subsections 201 (1a), (1b), (1c) and (1d) of the said Regulation, as made by section 1 of Ontario Regulation 756/83, are revoked and the following substituted therefor:
- (1a) In the application of section 1100 of the regulations made under the *Income Tax Act* (Canada) for the purposes of this section,
 - (a) references to "November 12, 1981" in paragraphs 1100 (1) (b), (t), (ta) and (v) and in subsections 1100 (2.1) and (2.2) shall be read as "the 24th day of October, 1985";

- (b) references to "November 13, 1981" in paragraph 1100 (1) (ta) and subsection 1100 (2.1) shall be read as "the 25th day of October, 1985";
- (c) the reference to "1983" in subsection 1100 (2.1) shall be read as "1987"; and
- (d) references to "June 1, 1982" in subsection 1100 (2.1) shall be read as "the 1st day of June, 1986". O. Reg. 763/86, s. 4 (1), part.
- (2) Clause 201 (4) (a) of the said Regulation is revoked and the following substituted therefor:
 - (a) included property acquired before the 1st day of January, 1974 in class 28 of Schedule II to the regulations made under that Act, such property shall be deemed to be property included in that class as of the 1st day of January, 1974 for the purposes of the Act, and the provisions of subsection 13 (5) of the Income Tax Act (Canada) shall apply for the purposes of the Act and this section;
- (3) Subsection 201 (5) of the said Regulation is revoked and the following substituted therefor:
- (5) In lieu of the additional allowances otherwise allowed under paragraphs 1100 (1) (w) and (x) of the regulations made under the *Income Tax Act* (Canada), a corporation may claim a deduction in computing its income for a taxation year equal to,
 - (a) such additional amount as it may claim in respect of property described in class 28 of Schedule II to those regulations acquired for the purpose of gaining or producing income from a mine, or in respect of property acquired for the purpose of gaining or producing income from a mine and for which a separate class is or would be prescribed by subsection 1101 (4a) of those regulations, if subsection 1104 (5) of those regulations were read in the manner provided under subsection (5a), not exceeding the lesser of,
 - (i) its income for the year from the mine determined before making any deduction under this clause, clause (b) or section 17, 18 or 18a of the Act or any deduction in respect of exploration and development expenses as permitted under *The Corporations Tax Application Rules*, 1972, and
 - (ii) the undepreciated capital cost to it of the property of that class as of the end of the taxation year, before making any deduction under this clause for the taxation year; and

- (b) such additional amount as it may claim in respect of property described in class 28 of Schedule II to the regulations made under the Income Tax Act (Canada) acquired for the purpose of gaining or producing income from more than one mine and for which a separate class is or would be prescribed by subsection 1101 (4b) of those regulations, if subsection 1104 (5) of those regulations were read in the manner provided under subsection (5a), not exceeding the lesser of,
 - (i) its income for the year from the mines determined before making any deduction under this clause or section 17, 18 or 18a of the Act or any deduction in respect of exploration and development expenses as permitted under The Corporations Tax Application Rules, 1972, and
 - (ii) the undepreciated capital cost to it of the property of that class as of the end of the taxation year, before making any deduction under this clause for the taxation year.
- (5a) In the application of section 1104 of the regulations made under the *Income Tax Act* (Canada) for the purposes of,
 - (a) determining if property was acquired for the purpose of gaining or producing income from a mine:
 - (b) determining if a separate class would be prescribed under subsection 1101 (4a) or (4b) of those regulations for the purposes of subsection (5); and
 - (c) determining any deduction permitted under this section,

the following rules apply:

- 1. Subparagraph 1104 (5) (a) (i) shall be read as follows:
 - (i) ore, other than tar sands ore, from a mineral resource owned by the taxpayer to any stage that is not beyond the prime metal stage or its equivalent,
- 2. Subparagraph 1104 (5) (c) (i) shall be read as follows:
 - (i) output, other than tar sands ore, from a mineral resource owned by the taxpayer that has been processed by it to any stage that is not beyond the prime metal stage or its equivalent,
- 3. Subparagraph 1104 (6) (a) (i) shall be read as follows:

- (i) ore, other than tar sands ore, from a mineral resource not owned by the taxpayer to any stage that is not beyond the prime metal stage or its equivalent,
- 4. Subparagraph 1104 (9) (f) (i) shall be read as follows:
 - (i) ore, other than tar sands ore, from a mineral resource to any stage that is not beyond the prime metal stage or its equivalent,
- 5. Subparagraphs 1104 (5) (a) (ii), (5) (c) (ii), (6) (a) (ii) and (9) (f) (ii) shall be deemed not to have been made. O. Reg. 763/86, s. 4 (3).
- (4) Subsection 201 (7) of the said Regulation is revoked and the following substituted therefor:
- (7) In addition to the deduction otherwise allowed by subsection (1), there is hereby allowed to a corporation in computing its income from a business or property, as the case may be, a deduction for each taxation year in respect of property included in class 3, 6 or 8 of Schedule II to the regulations made under the *Income Tax Act* (Canada),
 - (a) that is,
 - (i) a grain elevator situated in Ontario the principal use of which,
 - (A) is the receiving of grain directly from producers for storage or forwarding or both,
 - (B) is the receiving and storing of grain for direct manufacture or processing into other products, or
 - (C) has been certified by the Minister of Agriculture (Canada) to be the receiving of grain that has not been officially inspected or weighed,
 - (ii) an addition to a grain elevator described in subclause (i),
 - (iii) fixed machinery installed in a grain elevator or in an addition to a grain elevator in respect of which an additional amount has been or may be claimed under this subsection,
 - (iv) fixed machinery, designed for the purpose of drying grain, installed in a grain elevator described in subclause (i),

- (v) machinery designed for the purpose of drying grain on a farm in Ontario, or
- (vi) a building or other structure designed for the purpose of storing grain on a farm in Ontario;
- (b) that was acquired by the corporation after 1976; and
- (c) that was not used for any purpose before it was acquired by the corporation,

an amount not exceeding the lesser of,

- (d) where the property is included in class 3, 22 per cent of the capital cost thereof, where the property is included in class 6, 20 per cent of the capital cost thereof, or where the property is included in class 8,
 - (i) 14 per cent of the capital cost thereof in the case of property referred to in subclause (a) (iii), (iv) or (vi), and
 - (ii) 14 per cent of the lesser of \$15,000 and the capital cost thereof in the case of property described in subclause (a) (v); and
- (e) the undepreciated capital cost to it as of the end of the taxation year, before making any deduction under this subsection for the taxation year, of property of the class.
- (8) Where a taxation year is less than twelve months, the amount allowed as a deduction under subsections (5), (6) and (7) shall not exceed that proportion of the maximum amount otherwise allowable that the number of days in the taxation year is of 365. O. Reg. 763/86, s. 4 (4).
 - 5.—(1) Subsection 302 (3) of the said Regulation, as remade by section 8 of Ontario Regulation 254/82, is amended by adding "Subject to subsection (4a)" at the commencement thereof.
 - (2) Subsection 302 (4) of the said Regulation, as amended by section 2 of Ontario Regulation 756/83, is further amended by inserting after "section 320" in the first and second lines "and subject to subsection (4a)".
 - (3) Section 302 of the said Regulation, as amended by section 8 of Ontario Regulation 254/82, section 2 of Ontario Regulation 756/83 and section 1 of Ontario Regulation 191/85, is further amended by adding thereto the following subsection:

- (4a) In the application of subsections (3) and (4) and subsection 320 (3) for the purposes of this section and section 320, where,
 - (a) the destination of a shipment of merchandise to a customer to whom the merchandise is sold by a corporation is in a country other than Canada or where the customer to whom the merchandise is sold instructs that the shipment of the merchandise be made by the corporation to another person and the permanent establishment of the customer negotiating the purchase of the merchandise is situated in a country other than Canada;
 - (b) the corporation has a permanent establishment in that other country; and
 - (c) the corporation is not subject to taxation on its income or profits under the laws of that other country or its gross revenue derived from the sale is not included in the profit or other base for income or profits taxation by that other country by reason of,
 - (i) the provisions of any taxing statute of that other country, or
 - (ii) the operation of any tax treaty or convention between Canada and that other country,

the following rules apply:

- 1. Clauses (4) (a), (b) and (d) do not apply.
- That portion of clause (4) (c) immediately preceding subclause (i) shall be read as follows:
 - (c) except as provided in clause (e), where the destination of a shipment of merchandise to a customer to whom the merchandise is sold is in a jurisdiction outside Canada,
- That portion of clause (4) (e) immediately preceding subclause (i) shall be read as follows:
 - (e) where a customer to whom merchandise is sold instructs that the shipment of the merchandise be made to another person and the permanent establishment of the customer negotiating the purchase of the merchandise is situated in a jurisdiction outside Canada,
- 4. In the application of subclause (3) (a) (ii), clause (3) (b), subclauses (4) (c) (ii), (4) (e) (ii)

and 320 (3) (a) (ii) and clause 320 (3) (b), salaries and wages paid in the taxation year to employees of any permanent establishment of the corporation situated in that other country shall be deemed to be nil. O. Reg. 763/86, s. 5 (3).

- 6. Section 313 of the said Regulation is amended by striking out "or (3)" in the third line.
- Section 314 of the said Regulation is amended by striking out "or clause 2 (3) (b)" in the fourth line.
- 8. Subsection 320 (3) of the said Regulation, as remade by section 17 of Ontario Regulation 254/82, is amended by adding "Subject to subsection 302 (4a)" at the commencement thereof.
- Section 329 of the said Regulation is amended by striking out "or (3)" in the third line.
- Paragraph 26 of section 401 of the said Regulation, as made by section 26 of Ontario Regulation 254/82, is revoked.
- 11. Section 504 of the said Regulation, as remade by section 1 of Ontario Regulation 511/83, is amended by adding thereto the following subsection:
- (5) For the purposes of subsections 68 (1a), 72 (8) and (9) and 75 (6a) and clause 76 (1a) (b) of the Act, the day prescribed by regulation is,
 - (a) the day of receipt by the Ministry of the return, the payment or the amount, as the case may be; or
 - (b) in the case of an amount paid or a payment made under the Act to a bank or other financial institution authorized by the Minister to act as agent to accept receipt of amounts payable under the Act, the day of receipt by the institution. O. Reg. 763/86, s. 11.

- 12. Subsection 505 (1) of the said Regulation, as amended by section 7 of Ontario Regulation 756/83, is further amended by striking out "and clause 2 (3) (c)" in the first and second lines.
- 13. Clause 507 (3) (d) of the said Regulation is revoked and the following substituted therefor:
 - (d) "manufacturing and processing income" of a corporation means that portion of its income for the year, determined in accordance with the Act, that would qualify as "Canadian manufacturing and processing profits" for the purposes of section 125.1 of the Income Tax Act (Canada) except that, with respect to the processing of iron ore, processing from mineral resource to any stage that is not beyond the prime metal stage or its equivalent shall be deemed to be an activity listed in paragraph 125.1 (3) (b) of that Act that does not constitute manufacturing and processing;
- 14. The said Regulation is amended by adding thereto the following section:

603a. A notice of revocation of a waiver under clause 73 (7a) (a) of the Act shall be in Form 4. O. Reg. 763/86, s. 14.

15. The said Regulation is further amended by adding thereto the following Part:

PART VIII

PRESCRIBED TAX CONVENTIONS

- 701. For the purposes of subsection 29 (3) of the Act, the following Tax Treaties or Conventions are prescribed:
 - Canada-United States Income Tax Convention, 1980.
 Reg. 763/86, s. 15.

16.—(1) Form 1, as remade by section 1 of Ontario Regulation 647/84, and Form 3 of the said Regulation are revoked and the following substituted therefor:



Form 1

Notice of Objection

Corporations Tax Act

INSTRUCTIONS: Please print or type.

To be prepared in TRIPLICATE, ONE copy to be ratained and TWO copies to be sent by REGISTERED MAIL addressed to the Ministry of Revenue, Tax Appeals Branch, P.O.Box 627, 33 King Street West, Oshawe, Ontario L1H BH5.

The envelope containing this NOTICE OF OBJECTION must be postmarked within one hundred and eighty days after the day of mailing or delivery by personal service of the NOTICE OF ASSESSMENT or STATEMENT OF DISALLOWANCE OF REBATE/REFUND CLAIM to which objection is being meda.

A separate NOTICE OF OBJECTION must be filed for each NOTICE OF ASSESSMENT or each STATEMENT OF DISALLOWANCE OF REBATE/REFUND CLAIM in dispute but, if convenient, facts and reasons may be consolidated.

| ailing STREET AF | O NUMBER | | | | |
|--|--|---|---|---------------------------------|--|
| ddress | TO NOMECK | | | | |
| CITY / TO | w N | | | PROVINCE | POSTAL CODE |
| | | | | 10 m | to make the same |
| OTICE OF O | BJECTION is her | eby given to the: | | | The state of the s |
| Assessment I | Vo. | Date of Assessment | | Amount of Tex | for Period ending |
| 7 | (2.291) | | | s | |
| R Comment | | YEAR MONTH | DAY | | YEAR MONTH D |
| Statement of | Disallowance | | | Statement Date | Rebate/Refund Amount |
| ☐ of Rel | bate/Refund Claim | No. | | | \$ |
| - | | | | YEAR MONTH | DAY |
| | | Permit NumberPermit NumberPermit Number | | | ◀ Please Indicate |
| space is insuffic | | | | | of reesons for objection and relevant |
| space is insuffic] Check here if a | ient, e seperate men dditional sheets are | norendum should be | attached set | ting forth the full statement o | of reesons for objection and relevant of reesons for objection and relevant signing officer of the company. |
| space is insuffic) Check here if a | ient, e seperate men additional sheets are OBJECTION mu (Name (print) | norendum should be | etteched set | ting forth the full statement o | signing officer of the company. |
| NOTICE OF | OBJECTION mu | norendum should be attached. | e person o | ojecting or the authorized | signing officer of the company. Position or Office , |
| space is insuffic Check here if a NOTICE OF ointment of R will confirm t | OBJECTION mu Name (print) epresentative | norendum should be attached. | e person o Signeture Y's behalf | ojecting or the authorized | signing officer of the company. Position or Office , |

O. Reg. 763/86, s. 16 (1), part.



Ministry Corporations of Tax Revenue Branch Form 3

Corporations Tax Act

WAIVER OF TIME LIMIT FOR ISSUING REASSESSMENTS

For use by corporations to waive the time limit within which the Minister may assess, reassess, or make additional assessments under the Corporations Tax Act.

Two completed copies of this waiver are to be sent by REGISTERED MAIL addressed to the Minister of Revenue, Ministry of Revenue, Corporations Tax Branch, P.O. Box 622, 33 King Street West, Oshawa, Ontario L1H 8H6, within the time limit specified in clause 73(7) (c).

In order for a waiver to be valid the income tax and/or capital tax matter(s) in respect of which the time limit is waived must be specified in the space provided. The waiver will automatically apply to any matter(s) that are consequential to any specified matter(s).

This is a permanent waiver with respect to the herein specified matter(s).

A waiver which stipulates a time limit will not be accepted.

This waiver may be revoked under clause 73(7a) (a) of the <u>Corporations Tax Act.</u> by filing a "Notice of Revocation of Waiver" (Form 4).

This waiver must be signed by a signing officer with the authority to bind the corporation.

| Name of Corporation | | | | |
|-----------------------|------------------|----------------------|--|----------|
| Give full address inc | luding City, Tow | n, Municipality, Cou | inty and Province | |
| | | | | |
| | | | | |
| Account Number | | | Taxation year to which this walver applies | Month 19 |

WAIVER

The time limit referred to in subsection 73(7) of the <u>Corporations Tax Act</u>, within which the Minister may reassess or make additional assessments or assess tax, interest or penalties under the Act is hereby waived for the taxation year indicated above, in respect of:

| Signature | Position or Office | Date |
|-----------|--------------------|------|
| | | |
| | | |

O. Reg. 763/86, s. 16 (1), part.

(2) The said Regulation is further amended by adding thereto the following Form:



Form 4

Corporations Tax Act

NOTICE OF REVOCATION OF WAIVER

For use by corporations to revoke, under clause 73(7a)(a) of the <u>Corporations Tax Act</u>, a waiver (Form 3) previously filed, in respect of the time limit for issuing reassessments.

A separate Notice of Revocation must be completed for each waiver to be revoked.

Two completed copies of this notice, along with a copy of the waiver previously filed, are to be sent by REGISTERED MAIL addressed to the Minister of Revenue, Ministry of Revenue, Corporations Tax Branch, P.O. Box 622, 33 King Street West, Oshawa, Ontario L1H 8H6.

The waiver will be revoked automatically on the day that is one year after the date the Notice of Revocation is filed with the Minister of Revenue.

A copy of the notice will be returned to the corporation with the date filed with the Minister of Revenue indicated thereon.

A "Notice of Revocation of Waiver" cannot be rescinded or cancelled once it has been filed with the Minister of Revenue.

This Notice of Revocation must be signed by a signing officer with the authority to bind the corporation.

A corporation may revoke, under clause 73(7a)(b) of the <u>Corporations Tax Act</u>, the "automatic waiver" for Ontario purposes resulting from the filing of a federal waiver under subsection 152(4) of the <u>Income Tax Act</u> (Canada). To do this the corporation must file with the Minister of Revenue a copy of the federal Notice of Revocation of Waiver filed under subsection 152(4.1) of the <u>Income Tax Act</u> (Canada). Such "automatic waiver" will be revoked on the day that is one year after the date the copy of the federal Notice of Revocation of Waiver (Federal Form T652) is filed with the Minister of Revenue.

| live full address including C | City, Town, Municipality, County and Province | |
|------------------------------------|--|----------|
| | | |
| Account Number | Date on which relevant waiver (Form 3) was algned | |
| | continue of the other had undiver (Form 1) for the | |
| horoby rodulect roy | | 19 |
| hereby request rev axation year | vocation of the attached waiver (Form 3) for the | Month 19 |
| | Position or Office | |
| axation year | | Month |

O. Reg. 763/86, s. 16 (2).

0316A (86-11

- 17.—(1) Clause 101 (1) (ja) of the said Regulation, as made by subsection 1 (8) of this Regulation, shall be deemed to have come into force on the 20th day of May, 1981, and apply with respect to outlays or expenses made or incurred after the 19th day of May, 1981.
 - (2) Subsections 1 (1), (2), (3), (4), (6) and (14) of this Regulation and clause 101 (1) (jb) of the said Regulation, as made by subsection 1 (8) of this Regulation, shall be deemed to have come into force on the 1st day of January, 1981.
 - (3) Clause 101 (1) (q) of the said Regulation, as made by subsection 1 (13) of this Regulation, shall be deemed to have come into force on the 1st day of January, 1981, and applies with respect to expenses incurred after 1980.
 - (4) Subsections 1 (5) and (7) shall be deemed to have come into force on the 1st day of January, 1984, and apply with respect to all taxation years of corporations ending after the 31st day of December, 1983.
 - (5) Subclause 101 (1) (n) (i) of the said Regulation, except for sub-subclause (B) thereof, as remade by subsection 1 (9) of this Regulation, and subsection 1 (11) of this Regulation shall be deemed to have come into force on the 1st day of January, 1983, and apply to corporations with respect to taxation years commencing after the 31st day of December, 1982.
 - (6) Sub-subclause 101 (1) (n) (i) (B) of the said Regulation, as remade by subsection 1 (9) of this Regulation, and subsection 1 (12) of this Regulation shall be deemed to have come into force on the 13th day of November, 1981, and apply to corporations with respect to dispositions made after the 12th day of November, 1981.
 - (7) Subsection 1 (10) shall be deemed to have come into force on the 13th day of November, 1981, and applies to corporations with respect to taxation years commencing after the 12th day of November, 1981.

- (8) Clause 101 (1) (p) of the said Regulation, as remade by subsection 1 (13) of this Regulation, and subsections 101 (7b) and (7c) of the said Regulation, as made by subsection 1 (17) of this Regulation, shall be deemed to have come into force on the 7th day of March, 1985, and apply with respect in expenses renounced after the 6th day of March, 1985.
- (9) Subsections 1 (15) and (16) shall be deemed to have come into force on the 7th day of March, 1985, and apply with respect to fiscal periods of partnerships ending after the 6th day of March, 1985.
- (10) Subsections 101 (7) and (7a) of the said Regulation, as made by subsection 1 (17) of this Regulation, shall be deemed to have come into force on the 20th day of May, 1981, and apply with respect to expenses incurred after the 19th day of May, 1981 that are renounced in favour of a corporation.
- (11) Section 2 shall be deemed to have come into force on the 13th day of November, 1981, and applies to corporations with respect to taxation years ending after the 12th day of November, 1981.
- (12) Subsection 3 (1) shall be deemed to have come into force on the 1st day of January, 1981, and applies to corporations with respect to taxation years ending after the 31st day of December, 1980.
- (13) Subsection 3 (2) shall be deemed to have come into force on the 1st day of January, 1982.
- (14) Subsection 4 (1) of this Regulation and subsection 201 (7) of the said Regulation, as remade by subsection 4 (4) of this Regulation, shall be deemed to have come into force on the 25th day of October, 1985, and apply to corporations with respect to taxation years ending after the 24th day of October, 1985, in respect of property acquired or disposed of after the 24th day of October, 1985.
- (15) Subsection 4 (2) shall be deemed to have come into force on the 8th day of

December, 1977, and applies to corporations with respect to taxation years ending after the 7th day of December, 1977

- (16) Subsection 201 (5) of the said Regulation, as remade by subsection 4 (3) of this Regulation, and section 13 of this Regulation shall be deemed to have come into force on the 13th day of November, 1981, and apply to corporations with respect to taxation years commencing after the 12th day of November, 1981.
- (17) Subsection 201 (5a) of the said Regulation, as made by subsection 4 (3) of this Regulation, shall be deemed to have come into force on the 13th day of November, 1981, and applies with respect to taxation years commencing after the 12th day of November, 1981, and, for the purpose of determining the prescribed class in which depreciable property is included, applies only with respect to property acquired in taxation years commencing after the 12th day of November, 1981.
- (18) Subsection 201 (8) of the said Regulation, as made by subsection 4 (4) of this Regulation, shall be deemed to have come into force,
 - (a) on the 1st day of January, 1974, and applies to corporations with respect to taxation years ending after the 31st day of December, 1973, in respect of any amount allowed as a deduction under subsection 201 (5) of the said Regulation and any predecessor thereof;

ATTACHED AND ADDRESS OF THE PARTY OF THE PAR

- (b) on the 1st day of August, 1974, and applies to corporations with respect to taxation years ending after the 31st day of July, 1974, in respect of any amount allowed as a deduction under subsection 201 (6) of the said Regulation and any predecessor thereof; and
- (c) on the 1st day of January, 1977, and applies to corporations with respect to taxation years ending after the 31st day of December, 1976, in respect of any amount allowed as a deduction under subsection 201 (7) and any predecessor thereof.
- (19) Sections 5 and 8 shall be deemed to have come into force on the 1st day of January, 1986, and apply to corporations with respect to taxation years ending after the 31st day of December, 1985.
- (20) Sections 6, 7, 9, 12 and 15 shall be deemed to have come into force on the 1st day of January, 1985, and apply to corporations with respect to taxation years commencing after the 31st day of December, 1984.
- (21) Section 10 shall be deemed to have come into force on the 15th day of July, 1985.
- (22) Section 11 shall be deemed to have come into force on the 1st day of April, 1986.

(9978)

3

